<SEC-DOCUMENT>0000950170-22-002281.txt : 20220228
<SEC-HEADER>0000950170-22-002281.hdr.sgml : 20220228
<ACCEPTANCE-DATETIME>20220228160415
ACCESSION NUMBER:		0000950170-22-002281
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		105
CONFORMED PERIOD OF REPORT:	20211231
FILED AS OF DATE:		20220228
DATE AS OF CHANGE:		20220228

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Vaxcyte, Inc.
		CENTRAL INDEX KEY:			0001649094
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				464233385
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39323
		FILM NUMBER:		22689271

	BUSINESS ADDRESS:	
		STREET 1:		825 INDUSTRIAL ROAD, STE. 300
		CITY:			SAN CARLOS
		STATE:			CA
		ZIP:			94070
		BUSINESS PHONE:		650-837-0111

	MAIL ADDRESS:	
		STREET 1:		825 INDUSTRIAL ROAD, STE. 300
		CITY:			SAN CARLOS
		STATE:			CA
		ZIP:			94070

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SutroVax, Inc.
		DATE OF NAME CHANGE:	20150724
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>pcvx-20211231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="ASCII"?><!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2022-02-28T14:48:54.8136+00:00 --><!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:pcvx="http://www.vaxcyte.com/20211231" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:utr="http://www.xbrl.org/2009/utr">
 <head>
  <title>10-K</title>
  <meta http-equiv="Content-Type" content="text/html" />
 </head>
 <body>
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_30ad9e1a-2d1c-4f4e-8ca9-bfc495d5abbe" name="dei:AmendmentFlag" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f">false</ix:nonNumeric><ix:nonNumeric id="F_b0cb0a17-e593-4c86-bc0e-b70bcb38c012" name="dei:EntityCentralIndexKey" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f">0001649094</ix:nonNumeric><ix:nonNumeric id="F_dfb2b15e-0190-4335-9dd5-15ea315bbe0d" name="dei:DocumentFiscalPeriodFocus" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f">FY</ix:nonNumeric><ix:nonFraction id="F_3036f30d-a3d2-46a5-ba0d-72b7a840f4ad" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" contextRef="C_196fbfec-2db3-415e-8c1d-7ba3ff662444" unitRef="U_pure" decimals="3" scale="0">0.593</ix:nonFraction><ix:nonFraction id="F_12ca5abb-61de-41ac-ba25-bb0e431fbb88" name="us-gaap:CommitmentsAndContingencies" contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_565f8602-4d2e-4dc2-8e24-2bd920b5de6a" name="us-gaap:CommitmentsAndContingencies" contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_ced4119e-0847-4d96-a362-c9f40af1bee1" name="us-gaap:PreferredStockValue" contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_cdf000c4-3126-4076-a46e-14220371b9f3" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_a9e696e6-57cc-4729-8788-4c5e9e4ec861">P3Y</ix:nonNumeric><ix:nonFraction id="F_bc3cb20d-a774-425a-bb11-176869120719" name="us-gaap:PreferredStockValue" contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350" unitRef="U_USD" xsi:nil="true"></ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="pcvx-20211231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="C_84b31ec6-25e1-4d4b-9f94-c4046b727e6f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_faa3a312-73ee-42b0-852a-ab16d62c1cef"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bcc1b5db-4703-43c3-9272-4d0ca2f54e6a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f7ed5965-c3e7-4a8f-9810-2fb0b6527977"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pcvx:LonzaLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0a0e42fe-11ad-487e-b9de-014ca00c2d28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pcvx:SeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d1a846f2-0595-4f2b-bfde-977270efb43f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6c7d80da-3c5c-41d2-a3bf-0f29663df66e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bc281be7-82b8-4ef6-9792-0543c76c1a35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_08f2ab18-3ec2-4bf6-a856-11d6f22d4790"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9cbe4e9e-74f9-4ec8-bf47-1d291c0aaf9d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a129b41f-99aa-4150-b52d-3b8433ceb5ee"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8639465b-8e42-43a0-b445-048bbd5edbbe"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pcvx:JefferiesLimitedLiabilityCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pcvx:ATMSalesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_00eaf7db-5639-43a7-9d93-1b5cbcde71cf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8817387e-2be1-4358-95ce-a5df2bf517bf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">pcvx:SupplyAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pcvx:SutroBiopharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cb2a9833-f2d5-4d07-9f84-e6fd7b138b95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bebcd826-aabe-4884-ab32-26215b024f1a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5909cb95-2fd5-4c03-b349-88a7f48048ff"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">pcvx:CommonStockWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pcvx:SutroBiopharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ca7ed438-6716-4360-8ccd-eaaa38f9fcf2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1efdf0c7-6a07-4132-8782-b57177c53f15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_066e4651-a692-4244-9444-b8600c1c5b43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_022b1471-8226-4bef-aee0-86e11defec44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pcvx:SeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">pcvx:LicenseAmendmentATwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pcvx:SutroBiopharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-28</xbrli:startDate><xbrli:endDate>2018-05-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9ce589b3-009c-4c1f-9492-617b84d98173"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pcvx:SanCarlosMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_88219214-e682-4a47-ba69-b37e92d74db8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f2e3d587-c577-46eb-a487-767a66753618"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1db8f94d-2ec6-47be-b76a-a4960db1be21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_632492ef-57fd-48e7-acda-b7cb142000ba"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_44af597c-135d-414d-a410-f04a16cf714e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pcvx:JefferiesLimitedLiabilityCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pcvx:ATMSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_af5ccde9-e011-49f2-9896-792a8871b96a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pcvx:CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e8c80ef0-b66f-48cb-8236-662fca240430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandFourteenEquityIncentivePlanAndTwoThousandTwentyEquityIncentivePlanAndTwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_61481fb4-5a3a-40c5-abb3-1248a21e99b5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">pcvx:LicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pcvx:SutroBiopharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1217ed43-7b78-4138-a3fe-8b016f62919a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pcvx:ComputersAndComputerSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fd58b7dd-25a0-4a70-92a2-457d12426c58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pcvx:CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_93b8accf-91b3-4471-ab5d-fc8aea02adbe"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_070a9c52-605a-45b7-ac24-ad04c1d7f676"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_58ad6f5b-2983-4459-8fd3-3b4fbdef1c36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ecccdfb9-edd1-45a3-8445-0fe8b2f43253"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cf8c9eeb-5415-47f7-97f3-ce1e53cabf5b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3800b858-6c6b-4793-98cb-f7bb3ff61062"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ace47527-5c7b-43a0-97fe-7ef235c9ad0c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pcvx:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0c6ef4a7-f323-4b58-a7d5-94f0c514539b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pcvx:SharesAvailableForFutureStockOptionGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_25f1f214-138d-4f58-8434-afe2e9883750"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-14</xbrli:startDate><xbrli:endDate>2020-06-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5cd74deb-d2fe-4b8d-8171-3251599dda47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_542495c1-8a9f-4d28-9179-f5c599d02e73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2a5c2eff-6ddb-4c32-9bd6-9e0d20b2a11f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pcvx:MarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2bbf4b2d-41ff-4ec4-b597-e8a5be645bc2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a0171645-3dab-4282-933d-7e5fb2e8585a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f9848f07-54cd-412b-b65d-24c18bb6aab2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pcvx:LonzaLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e7331c69-2305-4247-a515-eb0da32be4fd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pcvx:CostReimbursementSubAwardAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7b1cec7a-d004-403e-8a42-ef595588ed48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ccf431e6-d93a-4a5a-884d-651e8f20892e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_70588bd5-1fdc-44ee-a7cf-7d459c6fc883"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3276c9c1-bce8-4e37-a494-9cd61a385e5d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e25af62d-d63b-4e1b-8b46-d08c4c227921"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-11</xbrli:startDate><xbrli:endDate>2020-06-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a1d232a3-c6a3-4bd1-9776-35c32d836d64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pcvx:CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e62d86e5-c312-474f-99a0-95ed9692529c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pcvx:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9262f685-96b6-4f7c-a6ae-83581243ab7d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">pcvx:PreferredStockWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pcvx:SutroBiopharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5c54c4ca-430a-4169-96fa-f57499d8524f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pcvx:PaloAltoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9001db26-8d96-496f-9fd0-ccbff0d80378"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandFourteenEquityIncentivePlanAndTwoThousandTwentyEquityIncentivePlanAndTwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ed58902d-2f75-4902-a5af-e641599b12d5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pcvx:CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_13251130-5d02-4a4b-82e5-dc7664b58676"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pcvx:SutroBiopharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a6bb51b5-9e65-4bc2-a156-224db74e09c4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e702b57a-b360-45bc-a12c-2341ca21e0de"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_11d04721-6c5e-451c-9f8c-b386520e079e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_448aa75e-c08c-4eb7-a778-f1a1525470d8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pcvx:LonzaLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_039297c3-6466-43f6-840d-9c5a04a312b3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pcvx:CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a7a54056-1b96-4694-a8be-248476ad36f9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pcvx:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_de000bd8-7fd0-42f8-8b81-fc098f2cc14e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4c43c843-d033-4309-afae-7cfdb2138610"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pcvx:LabEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cab820c4-1fb0-481c-b985-2ea03542a95b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">pcvx:PreferredStockWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pcvx:SutroBiopharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b2d931e6-c3f8-485c-8729-b21db15df907"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b3bc61ea-4f75-41e4-81f8-73c18aff2f6f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3e25c250-e268-4985-8e41-7be1baee8700"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c4319f5e-0947-41f2-9bc7-187004e5a87b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_39f8abfd-a954-4f03-b72e-b423c719a4a5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pcvx:SutroBiopharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_372ee990-ff50-459b-90f9-d45574ce4c70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_196fbfec-2db3-415e-8c1d-7ba3ff662444"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-05</xbrli:startDate><xbrli:endDate>2020-06-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_04acb199-245c-4c72-a959-3ad34a1f3b9f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3e0e573b-cca9-436f-b585-f3bd61467bce"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandFourteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7ac26ea9-aa26-46d1-b9ed-042601b4004d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pcvx:CostReimbursementSubAwardAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_006c2037-6bba-4d3a-bcd7-32b71e7a5475"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pcvx:SeriesDRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_77bd8890-2188-4455-95b3-5c7a4d36c588"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">pcvx:RedeemableConvertiblePreferredStockWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8f37ea4f-142c-4bc7-aa2e-4b36661b1de6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2fc259cf-825e-4ff9-9943-2f01c1a0937b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_32b0b6ee-9dc1-4ce6-9ecd-470c2a71985a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pcvx:CostReimbursementSubAwardAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ac053fdb-afd2-48a8-b734-eae8ef079868"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pcvx:HeadquartersFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-01</xbrli:startDate><xbrli:endDate>2022-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0830660e-391f-4e25-8658-4f38f275d086"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pcvx:CostReimbursementSubAwardAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b663ddb0-dc3a-4405-9809-183e08d4aa14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pcvx:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_89e8a4b5-4ab0-4668-889d-5ae7704f7e30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dc50a6ec-93a5-4d6d-8842-7d609d69c237"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_28585e6d-11c8-4ef0-bd28-a3644bbf26ac"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pcvx:NewCorporateHeadquartersFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fa60d7ee-2e38-419f-8133-f69b4b66de3f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3e34321b-16ec-44ef-ab8c-8cdab8688001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c0fb1076-a7db-464d-8c21-b64e5bc453db"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pcvx:SeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ed656fe7-27bd-4711-a1d9-07aab395e870"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_82e259ab-4adf-45bb-b0dd-9fc97b85e6bd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pcvx:LonzaLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_914c8ff3-3cf5-4419-8e2f-0309464abc71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_68dac7ff-d423-43b1-b2cb-fbeb2182a939"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_68b32ca0-daf9-4934-b4c5-74593152bb49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pcvx:ComputersAndComputerSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_68377845-3bf8-42a9-ba72-9a3b693b78a1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1e69b34d-5d84-4378-a6c6-3b4511d14d3c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5a9d30f7-2f17-4c61-b4cc-72ab32702c3f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandFourteenEquityIncentivePlanAndTwoThousandTwentyEquityIncentivePlanAndTwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e5909518-4b17-423b-8df9-fefc213da385"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">stpr:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_871fe4ad-8a52-4dc5-a523-876ef5a1de6d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_14ff4d59-3fca-47b7-aa38-4bd882e8ae38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandFourteenEquityIncentivePlanAndTwoThousandTwentyEquityIncentivePlanAndTwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_59f4b2de-1ad8-448b-acad-83f62876574d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pcvx:AdditionalFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8bc7d2ce-bbce-48ac-9b6a-f09c04733362"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dd29e038-bfb3-4788-9620-c38deb43178e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_04918cd3-bad5-49f6-b891-9bebcd71baa0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9ea862ab-153b-4f8b-bcfc-2223d2882ade"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">pcvx:SupplyAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pcvx:SutroBiopharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3d9566a8-97e9-4ae9-937d-c604f1218434"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d4cf0103-8fdd-4434-bedf-65aa2503f533"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c2d425b8-8bfe-4616-b9aa-1a6041c6bb18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pcvx:CostReimbursementSubAwardAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9fb419f9-f0a5-4dff-a890-32989d15c4e8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_432334ae-bbb2-42ed-9170-56253d99b097"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pcvx:SeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1c93f415-cf2a-4e2c-a1d1-8e49784595b5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fc0e428b-6e5e-4e81-ad32-508b6eb1375f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_922091bf-1883-4a4a-8399-cbd1c97ca12c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3fab40e5-6a35-4b2f-b816-13c7822b9afc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pcvx:SutroBiopharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_75f99d7f-d132-471c-9624-9a873477248d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pcvx:HeadquartersFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_88288d89-14d9-4c81-bcdc-77db4748e94f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-11</xbrli:startDate><xbrli:endDate>2020-06-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bef847b3-ad94-49aa-ac4c-cf8f492446d7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pcvx:MarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f112ef5d-4313-44ad-aa4e-21889fa3a7d3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pcvx:PaloAltoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e52d577e-c5ed-4801-8551-af9cd25c01fa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e95a1cc5-e02c-42d9-9f9c-6159842d1e7c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-11</xbrli:startDate><xbrli:endDate>2020-06-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_54987e17-a9c2-4890-ade9-618bd3dfc3f7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pcvx:PaloAltoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_104dc821-c967-4abc-be6e-1f58334234a8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pcvx:JefferiesLimitedLiabilityCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pcvx:ATMSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bfcc9c06-d2c1-452e-8ef8-cffaed58bf95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandFourteenEquityIncentivePlanAndTwoThousandTwentyEquityIncentivePlanAndTwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_35363580-d33d-4e25-a1e6-c5519ee4402f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pcvx:LabEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5c504db9-02bb-4fad-8cf7-b49fc071de1c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e3a2a9fa-a738-409d-96a4-c1ee8f7ecd25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201912Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a4d7b89e-0ab9-4f03-8b01-723510464ce9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a870b5f9-af49-4819-946b-a34bbe67f9e2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_17e8d504-7444-46d1-a94b-f46e5cb44fae"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_17a1e23b-77b7-43b4-b889-deab67e04a69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b350157c-7c7f-42a0-b645-149c360d1819"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0f671a12-9113-4696-9460-beb583200e4f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pcvx:LonzaLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_40beaa16-40f7-4f29-9069-2b64528824d9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2a6a1809-6c79-4e3a-9b03-3826f9729ccf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pcvx:NewCorporateHeadquartersFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d1c4c865-1394-49a2-907a-e54a6cd8c170"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_132d316b-36f4-4e18-bf45-5543bb58c44e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pcvx:MarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c1debaa3-dafc-4806-a41b-60a0b5a5aa1c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0a0e64e6-bec3-47d0-a7db-dea3ad28e107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b1ab0ed1-080d-4ff7-adaf-245dff15e8dc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pcvx:SeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d5f3d746-38cf-4e03-93db-68b59ff6ca6e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandFourteenEquityIncentivePlanAndTwoThousandTwentyEquityIncentivePlanAndTwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1d403ed3-f3ea-41fc-ab8b-8b842982729a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4ce8060d-05a1-4cdf-a58a-b689d077a297"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_52c3a991-3000-4196-9b57-c6affc82cde5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pcvx:SharesAvailableForFutureStockOptionGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1c84ebe2-ee47-4498-9c45-6e43ebdd4a7a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_34fb7648-e015-48b0-95af-d232d9d8d189"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandFourteenEquityIncentivePlanAndTwoThousandTwentyEquityIncentivePlanAndTwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_769f014e-781a-475a-bffc-269894519fd4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_afadb6ee-d738-47a2-9b09-0905934ee597"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c8d7f783-8f05-4c35-8444-31988eb17d2e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-11</xbrli:startDate><xbrli:endDate>2020-06-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3ab55850-7a59-4321-b335-f0ca2fe76524"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pcvx:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3562faed-85c8-4ea5-a88d-038f23029b7d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandFourteenEquityIncentivePlanAndTwoThousandTwentyEquityIncentivePlanAndTwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_01ab22d2-811b-4087-b1ae-4007067b9a23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4d6eec73-41eb-4eea-8812-cd5a564af773"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fe00813e-2d7b-4ece-bbe6-949a26bbf5f7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dac22bba-f4c3-4e16-abd0-7f908c3516fb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">pcvx:PreferredStockWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pcvx:SutroBiopharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9f6bf305-4c1d-45f5-96fe-42e373b0efcb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2e490417-2b25-4870-8c8f-ccac2bc83352"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7ef0af11-3445-4e12-816a-b2d4849a786e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pcvx:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c44b9b74-3efa-4a2d-b6b0-c053a39e9f18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pcvx:CostReimbursementSubAwardAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_555acc16-d9e2-4b46-9a03-aa27a3ad92e4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pcvx:AdditionalFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-01</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2bf194ae-c6b4-4264-b519-4608eda30c8d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_16333782-8505-4ca7-9e4c-1163caa27de3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-01</xbrli:startDate><xbrli:endDate>2022-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3c435103-f76a-492c-9b05-78cd97e91f32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">pcvx:SupplyAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pcvx:SutroBiopharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c8071e48-943e-4850-b4a1-a2bca3238b71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pcvx:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a9e696e6-57cc-4729-8788-4c5e9e4ec861"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b5f3713d-ecd4-4700-a7ab-db89f5c2d1ac"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fd7551c1-f7f9-4cde-a040-39d423a71993"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1a49e197-0c31-4849-ac0b-b08a2eebd593"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fddff65d-fa11-44de-96a6-5e8ce2f4167b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pcvx:PneumococcalConjugateVaccineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_efd921fe-f258-4bca-8c80-5723ef551b43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_017473b9-4a6d-4b35-bafe-2f3035074c39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pcvx:CostReimbursementSubAwardAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_83b9a259-045e-40be-a3dc-3d06c253dc05"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f77911a6-cb83-4a40-8b6c-9703e6acc5a0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pcvx:SeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pcvx:SutroBiopharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4469bcba-dbf3-41b7-810d-1333a6644626"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9ed4a1bc-93ea-4d6c-a3a2-fe0ee49c92a6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9a84ae25-675d-4a66-a9c5-6809604d88d9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_07b31212-bf35-4995-9486-d82d74f5da0e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pcvx:HeadquartersFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-01</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_56188f91-3c62-4582-88c9-91789caa7dd4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pcvx:SutroBiopharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">pcvx:PreferredStockWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6bfa48d9-3084-49f0-aff3-43a54ae90a96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6a5b5034-43db-42ae-a769-e4a78da8c922"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-02-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6da3f8ad-d2ec-440b-a451-9dbaebaea6e0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pcvx:CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3d43ebd8-c6c9-4618-9f17-19b5fc65cecf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b399954b-8b8b-4102-8291-0483e80bb7cc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">pcvx:CommonStockWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_12a75901-fd10-4da6-bb07-c58c55e98510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandFourteenEquityIncentivePlanAndTwoThousandTwentyEquityIncentivePlanAndTwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f910d477-1db3-4915-9562-49fd9c1e0523"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pcvx:SeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">pcvx:LicenseAmendmentATwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pcvx:SutroBiopharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-05-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8825ef60-997f-4d67-9024-2ab506972607"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pcvx:HeadquartersFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-07-01</xbrli:startDate><xbrli:endDate>2016-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a38e3261-0264-423e-b43f-742897fb5b71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6cff9554-4027-48fb-bcff-8e4bfb2fe23e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pcvx:AdditionalFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_decb2811-c318-46bf-b586-449b2cc7fa0b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_977bf646-5642-4ace-80e5-1617547b66ea"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_92f1ced7-c143-458c-9b8e-7abfc0c425d9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pcvx:CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bc56f763-40d5-4249-8c96-d9aa519edbb4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pcvx:HeadquartersFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6c03f021-f6d5-4fb2-b776-94bc1a86aa1d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pcvx:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_23381eb2-52cb-4648-a7ab-24309842b90d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-11</xbrli:startDate><xbrli:endDate>2020-06-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1ca103dc-5b49-40a2-af4e-c772a7562197"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pcvx:JefferiesLimitedLiabilityCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pcvx:ATMSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_61d1fa2e-cb6c-418c-bc91-f7bc598be5a9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="U_Security"><xbrli:measure>pcvx:Security</xbrli:measure></xbrli:unit><xbrli:unit id="U_RenewalOption"><xbrli:measure>pcvx:RenewalOption</xbrli:measure></xbrli:unit><xbrli:unit id="U_pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U_Lease"><xbrli:measure>pcvx:Lease</xbrli:measure></xbrli:unit><xbrli:unit id="U_UnitedStatesOfAmericaDollarsShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U_shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U_Segment"><xbrli:measure>pcvx:Segment</xbrli:measure></xbrli:unit><xbrli:unit id="U_USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_1e764aa7-2424-4823-b8e3-44b720dd76c6" fromRefs="F_cc2c63fe-9f64-413e-b88a-ea4e16e59c43 F_74662dbe-6bba-4820-bb27-5dc2f2cc22a9 F_0dab50af-8222-425f-99c5-2467c60ce49c F_49a96614-3d01-49a0-9b99-c49a73a9e61d F_9f6710a1-d9d3-4fe2-b6ef-bfe78fb4240b F_9b5f28a1-2067-4234-aaa9-854110005c43 F_ffa70a62-fef8-4aa1-ab27-93982bd1df40 F_4dc43849-1f78-43f5-a8b2-8eca8bdccb0e F_f5df6844-e104-41d9-aafd-0b5beb9fd268 F_042d310c-7a0b-4e6b-9fcb-a76480c12f1a F_3858ffdc-5880-4a92-a2d7-c0f2a030af5e F_7be159d7-162b-4aa2-bc16-756720e35f47 F_3a14c1cf-f8d3-45e2-a978-58d4d3f80e0e F_b3be9417-595c-4169-9d74-33bfdc5f467d F_177be7f4-d9df-4be9-887d-cd910eab0117 F_ad33fb03-db19-4784-8f04-ad151628c89d"></ix:relationship></ix:resources></ix:header></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="border-top:2.250pt double;padding-top:1.0pt;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:13.0pt;font-family:Times New Roman;">UNITED STATES</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:13.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:13.0pt;font-family:Times New Roman;">SECURITIES AND EXCHANGE COMMISSION</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:13.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Washington, D.C. 20549</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;"> </span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:14.0pt;font-family:Times New Roman;">FORM </span><span style="font-size:14.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6fe1e0de-8ae3-4cfb-9c22-336addd039e3" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="dei:DocumentType"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:14.0pt;font-family:Times New Roman;">10-K</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:14.0pt;font-family:Times New Roman;"> </span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(Mark One)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:4.0%;"></td>
    <td style="width:96.0%;"></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.0193750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1c1c0853-7bca-400e-ab20-ba5b3d1ec888" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">&#9746;</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:2.0pt;line-height:1.0193750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">For the fiscal year ended </span><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_757d4086-0b1c-4d31-8412-78340df3388f" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="dei:DocumentPeriodEndDate" format="ixt:datemonthdayyearen"><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bb1d181a-9089-4735-8887-953f043f4039" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="dei:CurrentFiscalYearEndDate" format="ixt:datemonthdayen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">December 31</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">, </span><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a8df000e-2314-4317-97c6-2ef349adb115" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="dei:DocumentFiscalYearFocus"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">2021</span></ix:nonNumeric></span><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"></span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">OR</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:4.0%;"></td>
    <td style="width:96.0%;"></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.0193750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7ed36dcb-a438-4200-8084-ccb7295d12e5" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:2.0pt;line-height:1.0193750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:2.0pt;line-height:1.0193750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">For the transition period from _________  to ___________</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Commission File Number </span><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_153ab1ca-effc-4e1b-b3cc-3a0550d3ffd7" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="dei:EntityFileNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">001-39323</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;"> </span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:17.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_09ac5281-5bf3-4aee-bb90-56ea10813fc3" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="dei:EntityRegistrantName"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:17.0pt;font-family:Times New Roman;">VAXCYTE, INC.</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">(Exact name of Registrant as specified in its Charter)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;"> </span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:3.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.0%;"></td>
    <td style="width:50.0%;"></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.0193750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_34e7c0c5-1ec8-4f4b-a860-499ef1d2352a" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.0193750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e013502c-3389-49f3-ac81-6231c3d0138f" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="dei:EntityTaxIdentificationNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">46-4233385</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.0193750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">(State or other jurisdiction of</span></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.0193750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">incorporation or organization)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.0193750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">(I.R.S. Employer</span></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.0193750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Identification No.)</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.0193750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c4422436-6e17-478a-87f0-2978f4769bb2" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="dei:EntityAddressAddressLine1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">825 Industrial Road</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">, </span><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a77ca57a-61d0-4d00-8ade-c74d372ae647" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="dei:EntityAddressAddressLine2"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Suite 300</span></ix:nonNumeric></span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.0193750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9809c2dd-bf98-4cda-9fd9-68a7dcaeb052" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="dei:EntityAddressCityOrTown"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">San Carlos</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">, </span><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a64575e5-8c75-46ad-b962-6da6f9db0535" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">California</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.0193750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5fedd352-eaa6-4774-99b4-e849f7402559" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="dei:EntityAddressPostalZipCode"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">94070</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.0193750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">(Address of principal executive offices)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.0193750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">(Zip Code)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Registrant&#x2019;s telephone number, including area code: (</span><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c0f1de04-2585-4438-97cf-30414d1d8bcc" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="dei:CityAreaCode"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">650</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">) </span><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0988592b-6164-480f-af9e-a59022f5e64e" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="dei:LocalPhoneNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">837-0111</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;"> </span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;">Securities registered pursuant to Section 12(b) of the Act:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:39.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:20.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:39.0%;"></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.0193750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;">Title of each class</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.0193750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.0193750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;">Trading</span></p><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.0193750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;">Symbol(s)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.0193750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.0193750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;">Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.0193750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:7.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_dc9eac62-5824-4a67-9baf-d0f0bd0a1a59" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="dei:Security12bTitle"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">Common Stock, $0.001 par value per share</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.0193750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.0193750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:7.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_56d5a922-cca5-4120-a653-2f6c99a3acd7" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="dei:TradingSymbol"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">PCVX</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.0193750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.0193750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:7.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6bb79b3a-9cf4-49ee-89d9-3e50296e4bf5" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">The Nasdaq Stock Market</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Securities registered pursuant to Section 12(g) of the Act: None</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. </span><span style="font-size:7.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9ea9f0e7-68b3-4403-a362-2174a6be28c1" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="dei:EntityWellKnownSeasonedIssuer"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">Yes</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"> &#9746; </span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"> &#9744;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act.  </span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">Yes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"> &#9744; </span><span style="font-size:7.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_49299638-868c-4e47-ad3d-358531a29fcb" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="dei:EntityVoluntaryFilers"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">No</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"> &#9746;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  </span><span style="font-size:7.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1db6262a-3b7d-43e6-bab6-457b541fcd02" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="dei:EntityCurrentReportingStatus"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">Yes</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"> &#9746; </span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"> &#9744;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files).  </span><span style="font-size:7.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3d08b6b7-f90d-4053-873a-8f0ff2bf13d2" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="dei:EntityInteractiveDataCurrent"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">Yes</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"> &#9746; </span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"> &#9744;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#x201c;large accelerated filer,&#x201d; &#x201c;accelerated filer,&#x201d; &#x201c;smaller reporting company,&#x201d; and &#x201c;emerging growth company&#x201d; in Rule 12b-2 of the Exchange Act.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:20.341%;"></td>
    <td style="width:2.004%;"></td>
    <td style="width:52.834%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:20.332%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:2.486%;"></td>
   </tr>
   <tr style="height:10.8pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.0193750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2e4ee773-a189-4401-8c32-f123f0b04684" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">Large accelerated filer</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.0193750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.0193750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#9746;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.0193750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.0193750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">Accelerated filer</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.0193750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.0193750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#9744;</span></p></td>
   </tr>
   <tr style="height:2.15pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:3.0pt;margin-top:0.0pt;line-height:1.0193750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:3.0pt;margin-top:0.0pt;line-height:1.0193750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:3.0pt;margin-top:0.0pt;line-height:1.0193750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:3.0pt;margin-top:0.0pt;line-height:1.0193750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.0193750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">Non-accelerated filer</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.0193750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.0193750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#9744;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.0193750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.0193750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">Smaller reporting company</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.0193750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.0193750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_064014b7-82ee-4619-a399-300f9744797d" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:2.15pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:3.0pt;margin-top:0.0pt;line-height:1.0193750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:3.0pt;margin-top:0.0pt;line-height:1.0193750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:3.0pt;margin-top:0.0pt;line-height:1.0193750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:3.0pt;margin-top:0.0pt;line-height:1.0193750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:3.0pt;margin-top:0.0pt;line-height:1.0193750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:3.0pt;margin-top:0.0pt;line-height:1.0193750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:3.0pt;margin-top:0.0pt;line-height:1.0193750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.0193750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">Emerging growth company</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.0193750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.0193750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d5295aa6-d629-4b1d-b2f6-f36efa7ddbe0" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.0193750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.0193750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.0193750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.0193750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  &#9744;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#x2019;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.  </span><span style="font-size:7.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_65565024-db02-437e-be01-af610657a0cb" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#9746;</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  </span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">Yes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"> &#9744; </span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"> </span><span style="font-size:7.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_084e93c6-3f76-454f-bd92-76cf6edd0deb" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="dei:EntityShellCompany" format="ixt:booleanfalse"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#9746;</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">The aggregate market value of the voting and non-voting common equity held by non-affiliates of the Registrant, based on the closing price of its Common Stock on the Nasdaq Global Select Market on June 30, 2021, the last business day of the Registrant&#x2019;s most recently completed second fiscal quarter, was approximately $</span><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_12477f24-90a4-4bf7-8d0b-952bc6eb02e0" contextRef="C_769f014e-781a-475a-bffc-269894519fd4" name="dei:EntityPublicFloat" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">788.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"> million. Shares of the Registrant&#x2019;s common stock held by each executive officer, director and holder of 10% or more of the outstanding common stock have been excluded in that such persons may be deemed to be affiliates. This calculation does not reflect a determination that certain persons are affiliates of the Registrant for any other purpose.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">The number of shares of Registrant&#x2019;s Common Stock outstanding as of February 23, 2022 was </span><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_313d726a-5d61-40f3-8a22-8a3c12839351" contextRef="C_6a5b5034-43db-42ae-a769-e4a78da8c922" name="dei:EntityCommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">56,310,751</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">DOCUMENTS INCORPORATED BY REFERENCE</span></p>
  <div><ix:nonNumeric id="F_6ed99354-2c7f-4ede-8b54-c6378f09a937" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="dei:DocumentsIncorporatedByReferenceTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">Part III incorporates information by reference from the Registrant&#x2019;s definitive proxy statement to be filed with the U.S. Securities and Exchange Commission pursuant to Regulation 14A, not later than 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K, in connection with the Registrant&#x2019;s 2022 annual meeting of stockholders.</span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:2.250pt double;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Table of Contents</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:10.0%;"></td>
    <td style="width:83.996%;"></td>
    <td style="width:6.004%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Calibri;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Page</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">PART I</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 1.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_1_business"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Business</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 1A.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_1a_risk_factors"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Risk Factors</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">45</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 1B.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_1b_unresolved_staff_comments"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Unresolved Staff Comments</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">98</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 2.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_2_properties"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Properties</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">98</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 3.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_3_legal_proceedings"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Legal Proceedings</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">98</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 4.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_4_mine_safety_disclosures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Mine Safety Disclosures</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">98</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">PART II</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 5.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_5_market_for_registrants_common_equ"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Market for Registrant&#x2019;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">99</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 6.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#reserved"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">[Reserved]</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">100</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 7.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_7_managements_discussion_analysis_f"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">101</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 7A.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_7a_quantitative_qualitative_disclos"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">118</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 8.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_8_financial_statements_supplement"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Financial Statements and Supplementary Data</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">119</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 9.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9_changes_in_disagreements_with_acc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">150</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 9A.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9a_controls_procedures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Controls and Procedures</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">150</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 9B.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9b_or_information"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Other Information</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">153</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 9C</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9c_foreign_jurisdictions"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">153</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">PART III</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 10.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_10_directors_executive_ficers_corpo"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Directors, Executive Officers and Corporate Governance</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">154</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 11.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_11_executive_compensation"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Executive Compensation</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">154</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 12.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_12_security_ownership_certain_benef"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">154</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 13.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_13_certain_relationships_related_tr"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Certain Relationships and Related Transactions, and Director Independence</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">154</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 14.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_14_principal_accounting_fees_servic"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Principal Accounting Fees and Services</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">154</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">PART IV</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 15.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_15_exhibits_financial_statement_sch"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Exhibits, Financial Statement Schedules</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">155</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 16</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_16_form_10k_summary"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Form 10-K Summary</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">155</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#signatures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Signatures</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">161</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Unless the context otherwise requires, all references in this Annual Report on Form 10-K to &#x201c;we,&#x201d; &#x201c;us,&#x201d; &#x201c;our,&#x201d; &#x201c;our company&#x201d; and &#x201c;Vaxcyte&#x201d; refer to Vaxcyte, Inc.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201c;Vaxcyte,&#x201d; &#x201c;eCRM,&#x201d; and other trademarks of ours appearing in this report are our property. This report contains additional trade names and trademarks of other companies. We do not intend our use or display of other companies&#x2019; trade names or trademarks to imply an endorsement or sponsorship of us by such companies, or any relationship with any of these companies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">i</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1260416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Special Note Regarding Forward-Looking Statements</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1260416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">This Annual Report on Form 10-K contains forward-looking statements about us and our industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this Annual Report on Form 10-K, including statements regarding our future results of operations or financial condition, business strategy and plans and objectives of management for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as &#x201c;anticipate,&#x201d; &#x201c;believe,&#x201d; &#x201c;contemplate,&#x201d; &#x201c;continue,&#x201d; &#x201c;could,&#x201d; &#x201c;estimate,&#x201d; &#x201c;expect,&#x201d; &#x201c;intend,&#x201d; &#x201c;may,&#x201d; &#x201c;plan,&#x201d; &#x201c;potential,&#x201d; &#x201c;predict,&#x201d; &#x201c;project,&#x201d; &#x201c;seek,&#x201d; &#x201c;should,&#x201d; &#x201c;target,&#x201d; &#x201c;will,&#x201d; or &#x201c;would,&#x201d; or the negative of these words or other similar terms or expressions. Forward-looking statements contained in this Annual Report on Form 10-K include, but are not limited to, statements about:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.1260416666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our expectations regarding the potential benefits, spectrum coverage and immunogenicity of our vaccine candidates;</span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.1260416666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our expectations regarding our preclinical study results potentially being predictive of clinical study results;</span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.1260416666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our belief that our pneumococcal conjugate vaccine candidates could receive regulatory approval based on a demonstration of non-inferiority to the standard of care using well-defined surrogate immune endpoints rather than requiring clinical field efficacy studies;</span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.1260416666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the timing of the initiation, progress and potential results of our preclinical studies, clinical trials and our research and development programs; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.1260416666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to advance vaccine candidates into, and successfully complete, preclinical studies and clinical trials; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.1260416666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the commercialization of our vaccine candidates, if approved;</span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.1260416666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">estimates of our future expenses, capital requirements and our needs for additional financing;</span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.1260416666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to compete effectively with existing competitors and new market entrants;</span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.1260416666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to establish and maintain intellectual property protection for our products or avoid claims of infringement;</span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.1260416666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our and our third-party manufacturers&#x2019; manufacturing capabilities and the scalable nature of our manufacturing process;</span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.1260416666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">potential effects of extensive government regulation;</span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.1260416666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the pricing, coverage and reimbursement of our vaccine candidates, if approved;</span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.1260416666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability and the ability of our third-party contract manufacturers to operate and continue operations in light of the COVID-19 pandemic;</span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.1260416666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to hire and retain key personnel;</span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.1260416666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to obtain additional financing; and</span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.1260416666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the volatility of the trading price of our common stock.</span></div></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Actual events or results may differ from those expressed in forward-looking statements. You should not rely on forward-looking statements as predictions of future events. We have based the forward-looking statements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ii</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">contained in this Annual Report on Form 10-K primarily on our current expectations and projections about future events and trends that we believe may affect our business, financial condition and operating results. The outcome of the events described in these forward-looking statements is subject to risks, uncertainties and other factors described in the section titled &#x201c;Risk Factors&#x201d; and elsewhere in this Annual Report on Form 10-K. Moreover, we operate in a very competitive and rapidly changing environment. New risks and uncertainties emerge from time to time, and it is not possible for us to predict all risks and uncertainties that could have an impact on the forward-looking statements contained in this Annual Report on Form 10-K. The results, events and circumstances reflected in the forward-looking statements may not be achieved or occur, and actual results, events or circumstances could differ materially from those described in the forward-looking statements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, statements that &#x201c;we believe&#x201d; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based on information available to us as of the date of this Annual Report on Form 10-K. While we believe that information provides a reasonable basis for these statements, that information may be limited or incomplete. Our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all relevant information. These statements are inherently uncertain, and investors are cautioned not to unduly rely on these statements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The forward-looking statements made in this Annual Report on Form 10-K relate only to events as of the date on which the statements are made. We undertake no obligation to update any forward-looking statements made in this Annual Report on Form 10-K to reflect events or circumstances after the date of this Annual Report on Form 10-K or to reflect new information or the occurrence of unanticipated events, except as required by law. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Summary of Risks Affecting Our Business</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our business is subject to numerous risks and uncertainties, including those discussed more fully in the section titled &#x201c;Risk Factors&#x201d; in this Annual Report on Form 10-K. These risks include, but are not limited to, the following:</span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are in the early stages of vaccine development and have a very limited operating history and no products approved for commercial sale, which may make it difficult for you to evaluate the success of our business to date and to assess our future viability.</span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have incurred significant net losses since inception and anticipate that we will continue to incur substantial net losses for the foreseeable future. We currently have no source of product revenue and may never achieve profitability. Our stock is a highly speculative investment.</span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We will require substantial additional funding to finance our operations, which may not be available to us on acceptable terms, or at all. If we are unable to raise additional capital when needed, we could be forced to delay, reduce or terminate certain of our development programs or other operations.</span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our approach to the discovery and development of our vaccine candidates is based on novel technologies that are unproven, which may expose us to unforeseen risks, require us to modify processes, and make it difficult to predict the time and cost of vaccine candidate development and the timing to apply for and obtain regulatory approvals.</span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our vaccine candidates are in early stages of development and may fail in development or suffer delays that materially and adversely affect their commercial viability. If we are unable to complete development of or commercialize our vaccine candidates or experience significant delays in doing so, our business would be materially harmed.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">iii</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The U.S. Food and Drug Administration, or FDA, may disagree with our regulatory plan, and we may fail to obtain regulatory approval of our vaccine candidates.</span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our business is highly dependent on the success of VAX-24, which is in the early stages of development. If we are unable to obtain approval for VAX-24 and effectively commercialize VAX-24, our business would be significantly harmed. </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our primary competitors have significantly greater resources and experience than we do, which may make it difficult for us to successfully develop our vaccine candidates, or may result in others discovering, developing or commercializing products before or more successfully than us.</span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may not be successful in our efforts to use our cell-free protein synthesis platform to expand our pipeline of vaccine candidates and develop marketable products.</span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We currently rely on third-party manufacturing and supply partners, including Lonza Ltd., or Lonza, and Sutro Biopharma, Inc., or Sutro Biopharma, to supply raw materials and components for, and manufacture of, our preclinical and clinical supplies as well as our vaccine candidates. Our inability to procure necessary raw materials or to have sufficient quantities of preclinical and clinical supplies or the inability to have our vaccine candidates manufactured, including delays or interruptions at our third-party manufacturers, or our failure to comply with applicable regulatory requirements or to supply sufficient quantities at acceptable quality levels or prices, or at all, would materially and adversely affect our business.</span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Health epidemics, including the effects of the ongoing COVID-19 pandemic, have impacted and could continue to impact our business, including in regions where we or third parties on which we rely have significant manufacturing facilities, concentrations of potential clinical trial sites or other business operations.</span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The FDA regulatory approval process is lengthy and time-consuming, and we may experience significant delays in the clinical development and regulatory approval of our vaccine candidates.</span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If we are unable to obtain and maintain patent protection for our technology and products, or if the scope of the patent protection obtained is not sufficiently broad, we may not be able to compete effectively in our markets.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">iv</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">PART I</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_1_business"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 1. Bu</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">siness.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Overview</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. We are developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. We are re-engineering the way highly complex vaccines are made through modern synthetic techniques, including advanced chemistry and the XpressCF cell-free protein synthesis platform, exclusively licensed from Sutro Biopharma, Inc. Unlike conventional cell-based approaches, our system for producing difficult-to-make proteins and antigens is intended to accelerate our ability to efficiently create and deliver high-fidelity vaccines with enhanced immunological benefits.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Vaccines are one of the most successful and cost-effective global health interventions and prevent millions of deaths worldwide each year. Routine pediatric vaccinations are estimated to prevent 20 million cases of disease each year, saving over $180 billion in direct and societal costs in the United States alone. Adult vaccination rates are lower than pediatric vaccination rates, but new technologies are driving adult vaccine development, which in turn is fueling the growth of the overall vaccine market. Given the critical role vaccines play in preventing disease from childhood to adulthood, the global vaccine market is large, durable and growing. Nonetheless, there are areas of unmet medical need, including vaccines that can provide broader protection than currently marketed vaccines and novel vaccines that target pathogens for which there are no currently approved vaccines. We are driven to eradicate or treat invasive bacterial infections, which have serious and costly health consequences when left unchecked.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We carefully select our target disease areas and vaccine candidates based on the following criteria: areas of significant unmet medical need, well-defined commercial landscape and efficient market adoption, acceptable biological risk and established clinical pathways. We are leveraging our scalable cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications using these criteria.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our pipeline includes:</span></p>
  <div style="margin-left:12.843%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.8241334603072623%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pneumococcal conjugate vaccine, or PCV, candidates that we believe are among the most broad-spectrum PCV candidates currently in development, targeting the approximately $7 billion global pneumococcal vaccine market. </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pneumococcal disease, or PD, is an infection caused by </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Streptococcus pneumoniae,</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> or</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">pneumococcus, bacteria. It can result in invasive pneumococcal disease, or IPD, including meningitis and bacteremia, and non-invasive pneumococcal disease, including pneumonia, otitis media and sinusitis.</span></div></div>
  <div style="margin-left:19.509%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.140835621373818%;">o</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our lead vaccine candidate, VAX-24, is a 24-valent, broad-spectrum investigational PCV being developed for the prevention of IPD and pneumonia. VAX-24 is intended to improve upon the standard-of-care PCV vaccines for both children and adults by covering the serotypes that are responsible for most of the residual pneumococcal disease currently in circulation. On January 6, 2022, we announced that the U.S. Food and Drug Administration, or FDA, cleared our Investigational New Drug, or IND, application for VAX-24 in adults. On February 23, 2022, we announced the initiation of our Phase 1/2 clinical proof-of-concept study of VAX-24 in adults 18 to 64 years of age. We expect to announce topline safety, tolerability and immunogenicity results from this Phase 1/2 clinical study by the end of 2022. The Phase 1 portion includes approximately 64 healthy adults 18 to 49 years of age and the Phase 2 portion includes approximately 800 healthy adults 50 to 64 years of age. Pending the successful completion of the Phase 1 portion of this study, we expect to begin enrollment in a separate Phase 2 study in healthy adults aged 65 and older and to announce topline safety, tolerability and immunogenicity results from this study in the first half of 2023. We also anticipate submitting our first VAX-24 pediatric IND </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:19.509%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;visibility:hidden;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.140835621373818%;"></span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">application to the FDA in the first half of 2023, subject to a pre-IND meeting with the FDA and successful topline results from the VAX-24 Phase 1/2 study in adults 18 to 64 years of age.</span></div></div>
  <div style="margin-left:19.509%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.140835621373818%;">o</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our second PCV candidate, VAX-XP, leverages our scalable and modular platform and builds on the technical proof-of-concept established by VAX-24 and is designed to expand the breadth of coverage to greater than 30 strains without compromising immunogenicity due to carrier suppression.</span></div></div>
  <div style="margin-left:12.843%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.8241334603072623%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">VAX-A1, a novel conjugate vaccine candidate designed to prevent Group A Strep, a pervasive disease that results in 700 million cases of illness annually, including pharyngitis, or strep throat, and certain severe invasive infections such as sepsis, necrotizing fasciitis and toxic shock syndrome. There is currently no vaccine against Group A Strep, which is one of the leading infectious disease-related causes of death and disability worldwide. We believe we have demonstrated preclinical proof of concept for VAX-A1, the data for which were published in December 2020. We nominated the final vaccine candidate for VAX-A1 in the first quarter of 2021 and initiated IND-enabling activities in the second half of 2021.</span></div></div>
  <div style="margin-left:12.843%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.8241334603072623%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis, a chronic oral inflammatory disease affecting an estimated 65 million adults in the United States. We believe we have demonstrated preclinical proof of concept, the data for which was published in February 2019. We expect to nominate a final vaccine candidate for VAX-PG by the end of 2022. Our initial goal is to develop a therapeutic vaccine to slow or stop disease progression; however, the results from clinical trials may inform the potential adoption of prophylactic immunization.</span></div></div>
  <div style="margin-left:12.843%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.8241334603072623%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have other discovery-stage programs that leverage our cell-free protein synthesis platform, which, if proven successful in preclinical studies, could also be advanced into IND-enabling activities and clinical studies. </span></div></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our modern synthetic techniques, including advanced chemistry and the XpressCF cell-free protein synthesis platform, offer several advantages over conventional cell-based protein expression methods, which we believe enable us to generate superior, novel, more broad-spectrum and/or more immunogenic vaccines. In the context of conjugate vaccines, we believe we can add more antigenic strains without compromising the overall immune response. In particular, our ability to specify the attachment point of antigens, including polysaccharides, on protein carriers represents a significant improvement over the random conjugation that occurs with conventional technologies. This site-specific conjugation is designed to ensure that B-cell and/or T-cell epitopes are optimally exposed, maximizing the immune response, whereas random conjugation blocks these critical immunogenic epitopes, which dampens the immune response and may lead to a phenomenon known as carrier suppression.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We believe this precise control of conjugation chemistry enables us to design broader-spectrum conjugate vaccine candidates using carrier-sparing conjugates that use less protein carrier without sacrificing immunogenicity. We are also able to design novel conjugate vaccine candidates using standard amounts of protein carrier to generate heightened immunogenicity. Beyond conjugate vaccines, we believe we can also design novel protein vaccine candidates based on well-appreciated but highly complex antigens that currently cannot be made using conventional technologies to address diseases for which there are no available vaccines. In addition, our platform enables us to rapidly screen vaccine candidates, requiring less effort than conventional chemistry which allows us to produce and iterate conjugate candidates, thereby dramatically accelerating the development cycle of designing, producing and testing vaccine candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Our Approach</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">To address areas of significant unmet medical need, we carefully select the disease areas we target and are developing vaccine candidates based on the following criteria:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Well-defined commercial landscape and efficient market adoption:</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> We select vaccine targets that are characterized by an established patient population and significant unmet medical need. Our lead vaccine candidate, VAX-24, is a PCV intended to improve upon the standard-of-care for both children and adults by covering the serotypes that are responsible for most of the residual pneumococcal disease currently in circulation without sacrificing immunogenicity. We believe that by providing the broadest coverage of serotypes for PCVs, as well as providing novel vaccines for diseases for which there are no currently approved vaccines, we can leverage the U.S. Centers for Disease Control, or CDC, its Advisory Committee on Immunization Practices, or ACIP, and similar international advisory body recommendations to drive rapid and significant market adoption. </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Acceptable biological risk:</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> We choose vaccine targets with well-understood mechanisms of action and strong precedents for positive preclinical study results that we believe will translate to positive clinical trial results. For example, conjugate vaccines have demonstrated effectiveness in both preclinical and clinical trials against a range of bacteria, including pneumococcus, meningococcus and Haemophilus influenza B. There is consistent evidence that antibodies directed against these bacteria are protective against their respective diseases. </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.1164583333333333;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Established clinical pathways:</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> We pursue vaccine targets that we believe have clear and established clinical development pathways in order to accelerate the potential time to market. For example, we believe that our PCVs could receive regulatory approval based on successful completion of clinical studies utilizing well-defined surrogate immune endpoints, consistent with how other PCVs have obtained regulatory approval in the past, rather than requiring clinical field efficacy studies. However, while there have been approvals granted for both PCVs and meningococcal conjugate vaccines based on surrogate immune endpoints rather than field efficacy studies, we will not be able to confirm this approach&#x2019;s applicability for our PCVs until we complete our Phase 2 clinical development program. For our novel vaccine candidates, where we believe clinical field efficacy studies will be necessary, we select disease areas with high attack rates, such as Group A Strep, which may allow for more manageable study sizes. For novel protein-based therapeutic vaccine candidates, such as our periodontitis vaccine candidate, we select disease areas where we believe clinical efficacy may be evaluated based on disease progression rather than prevention, which could allow for smaller and faster trials relative to preventative vaccines. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Our Platform</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are re-engineering the way highly complex vaccines are made through modern synthetic techniques, including advanced chemistry and the XpressCF</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications using the above criteria by taking advantage of the following:</span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.1164583333333333;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Site-Specific Conjugation. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are able to specify the attachment point of antigens, including polysaccharides, on protein carriers to ensure optimal exposure of B-cell and/or T-cell epitopes, thereby creating protein carriers designed to have enhanced potency. We believe this precise control of conjugation chemistry enables us to create broader-spectrum conjugate vaccine candidates using carrier-sparing conjugates that use less protein carrier without sacrificing immunogenicity. We are also able to design novel conjugate vaccine candidates using standard amounts of protein carrier to generate heightened immunogenicity.</span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.1164583333333333;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Production of Novel Protein Vaccines</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. We can design novel protein vaccine candidates based on well-appreciated but highly complex antigens that currently cannot be made with conventional technologies to address diseases for which there are no available vaccines, and we believe we may be able to leverage our platform to rapidly respond to new or emerging pathogens. We can design </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.1164583333333333;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;visibility:hidden;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;"></span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">and produce these &#x201c;tough-to-make&#x201d; antigens that conform to the target pathogens, thereby increasing the likelihood that the vaccine will elicit a protective immune response.</span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.1164583333333333;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Speed, Flexibility and Scalability of the Discovery Engine. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are able to rapidly screen vaccine candidates and produce conjugates, thereby accelerating the process of making and testing vaccine candidates. Because cell viability is not required for cell-free protein synthesis, we can utilize a broader range of reaction conditions as we seek to optimize proteins. This flexibility enables us to develop novel vaccine candidates unachievable with current technologies. Furthermore, we believe our platform can scale linearly from discovery to commercial scale.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Our Strategy</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our goal is to become a leader in the vaccines industry by using our cell-free protein synthesis platform to develop superior and/or novel vaccines to prevent or treat serious infectious diseases. Key elements of our strategy include:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.1164583333333333;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Advance VAX-24 through clinical development and regulatory approval.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> Our lead vaccine candidate, VAX-24, targets the pneumococcal vaccine market. We expect to advance VAX-24 along a well-understood clinical development pathway in an effort to obtain regulatory approval in adults and infants based on successful completion of clinical studies using previously established surrogate immune endpoints, potentially without the need to conduct a clinical field efficacy study, consistent with how other conjugate vaccines have obtained approval. On January 6, 2022, we announced that the FDA cleared our IND application for VAX-24. On February 23, 2022, we announced the initiation of our Phase 1/2 clinical proof-of-concept study of VAX-24 in adults 18 to 64 years of age. We expect to announce Phase 1/2 topline safety, tolerability and immunogenicity results from this study by the end of 2022. Pending the successful completion of the Phase 1 portion of this study, we expect to begin enrollment in a separate Phase 2 study in healthy adults aged 65 and older and to announce topline safety, tolerability and immunogenicity results from this study in the first half of 2023. Subject to a pre-IND  meeting with the FDA and successful topline results of the initial Phase 1/2 proof-of-concept study in adults ages 18 to 64, we anticipate submitting a pediatric IND application to the FDA for VAX-24 in the first half of 2023.  </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.1164583333333333;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Advance VAX-XP through IND-enabling activities, clinical development and regulatory approval.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> Our second PCV candidate, VAX-XP, leverages our scalable and modular platform and builds on the technical proof of concept established by VAX-24 and is designed to expand the breadth of coverage to greater than 30 strains without compromising immunogenicity due to carrier suppression. We intend to advance VAX-XP to maximize the optionality for and value of our PCV franchise.</span></div></div>
  <div style="margin-left:9.167%;display:flex;margin-top:12.0pt;line-height:1.1260416666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.669371263747757%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Establish scalable production of VAX-24 and VAX-XP.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> We believe high-quality and scalable manufacturing is critical to our long-term success. We have designed and developed a proprietary, scalable and portable manufacturing process that we believe can scale to supply clinical and commercial volumes of VAX-24 needed to serve both adult and pediatric populations. We have completed the production of Phase 1/2 clinical trial material for VAX-24 and are conducting Phase 3 optimization and commercial scale-up activities. We have access to substantial manufacturing resources through our contract manufacturer, Lonza, that we believe can facilitate an independent path to market. Moreover, our next-generation VAX-XP program will use the components and core manufacturing processes established for VAX-24. </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.1260416666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Create a long-lasting PCV franchise by offering the broadest-spectrum PCV available.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> The two leading pneumococcal vaccine franchises to date, Prevnar and Pneumovax 23, have generated over $100 billion in combined sales, have been on the market for over 40 years and 20 years, respectively, and can attribute their success to being the broadest-spectrum vaccines on the market. If approved, we believe VAX-24 may obtain an ACIP preferred recommendation and potentially replace both lesser-valent incumbents for pneumococcal disease prevention in both adult and pediatric populations because of its broader coverage. We designed VAX-24 to address the 24 pneumococcal strains covered by Prevnar and Pneumovax 23 that drive most pneumococcal disease </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.1260416666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;visibility:hidden;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;"></span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">today with the durable, boostable immune response of a conjugate vaccine. Further, we have designed VAX-XP to address these 24 strains plus additional epidemiologically significant emerging strains expected to cause increasing pneumococcal disease and antibiotic resistance in the future. With these broad-spectrum vaccine candidates, we believe we are well-positioned to obtain an ACIP preferred recommendation and potentially replace the current standard of care for pneumococcal disease prevention in both adult and pediatric populations, thereby creating a long-lasting PCV franchise.</span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.1260416666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Advance our novel vaccine candidates and leverage our platform to expand our pipeline. </span></div></div>
  <div style="margin-left:15.796%;display:flex;margin-top:12.0pt;line-height:1.1260416666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.9582442639304545%;">o</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Advance VAX-A1 through IND-enabling activities, clinical development and regulatory approval</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. VAX-A1 is designed to prevent Group A Strep, a pervasive disease that results in 700 million cases of illness each year and is one of the leading infectious disease-related causes of death and disability worldwide. Some of the most serious consequences of Group A Strep include flesh eating disease (necrotizing fasciitis) and invasive diseases such as sepsis and rheumatic heart disease. However, the majority of Group A Strep cases are pharyngitis, commonly known as strep throat. Pharyngitis is highly prevalent in school-age children and a significant source of antibiotic prescriptions, which further exacerbates the growing problem of antibiotic resistance globally. VAX-A1 is a conjugate vaccine candidate designed to confer broad protective immune responses against all subtypes of Group A Strep and be boostable to offer long-lasting protection from infection. We believe our data published in December 2020 demonstrated preclinical proof of concept for VAX-A1. We nominated the final vaccine candidate for VAX-A1 in the first quarter of 2021 and initiated IND-enabling activities in the second half of 2021. </span></div></div>
  <div style="margin-left:15.833%;display:flex;margin-top:12.0pt;line-height:1.1260416666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.9599843168937943%;">o</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Advance VAX-PG to final vaccine candidate nomination and IND-enabling activities, clinical development and regulatory approval.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">VAX-PG is our novel protein vaccine candidate which targets the keystone pathogen responsible for periodontitis, a chronic oral inflammatory disease affecting an estimated 65 million adults in the United States. Our initial goal is to develop a therapeutic vaccine to slow or stop disease progression; however, the results from clinical trials may inform the potential adoption of prophylactic immunization. We have established preclinical proof of concept for VAX-PG, and we expect to nominate a final vaccine candidate for VAX-PG by the end of 2022. </span></div></div>
  <div style="margin-left:15.833%;display:flex;margin-top:12.0pt;line-height:1.1260416666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.9599843168937943%;">o</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Leverage our platform for other discovery stage programs.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> We are also able to leverage our platform as a discovery engine given our ability to uniquely create building blocks to construct potential novel conjugate and protein vaccine candidates, and we have other discovery-stage programs which leverage this platform. </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Continue to build a robust intellectual property portfolio.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> We have developed and are continuing to develop a comprehensive intellectual property portfolio related to vaccine applications, including manufacturing, formulation and process applications as well as protection for our specific vaccine candidates. We have rights to a robust portfolio of patents and patent applications related to the XpressCF platform through our exclusive license from Sutro Biopharma. We currently have an issued U.S. patent and multiple pending patent applications in the United States and internationally that cover vaccine formulations, protein-antigen conjugates, methods of making conjugate vaccines with various protein-antigen conjugates and other processes, enhancements of immunogenicity and methods of use. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Our Pipeline</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have utilized our cell-free protein synthesis platform to generate a pipeline of vaccine candidates that we believe, if approved, may offer important advantages over existing vaccines or for which there are no vaccines available today. The following table summarizes our current pipeline:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img69628308_0.jpg" alt="img69628308_0.jpg" style="width:624px;height:241px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Global Vaccine Market (Excluding COVID-19 Vaccines)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The global vaccine market, excluding COVID-19 vaccines, was approximately $41 billion in 2021 and is expected to grow at an 10% CAGR to approximately $67 billion by 2026. The World Health Organization, or WHO, has reported that non-COVID vaccine revenues have grown at nearly twice the rate of therapeutic products over the last two decades. Conjugate vaccines, including PCVs, have historically represented the largest segment (approximately 39% in 2018) of the global non-COVID vaccine market. The Prevnar franchise, comprised of Prevnar 13 and Prevnar 20, was the highest selling vaccine product in the world in 2021, accounting for approximately 13% of global non-COVID vaccine sales.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The pediatric vaccine market is large and well-established in the United States and European Union and growing in emerging countries. The annual new birth cohort, which in the United States and Europe approached more than eight million in 2020, drives ongoing sales year after year. In the United States, once a new vaccine is approved by the FDA, the ACIP considers whether to recommend the use of the vaccine. New pediatric vaccines that receive a preferred recommendation from ACIP are nearly universally adopted by pediatricians and parents and are required by many schools, contributing to a national immunization rate for the diseases targeted by such vaccines of approximately 90%.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, the adult vaccine market is currently undergoing rapid growth. Vaccination rates among adults have historically been lower and vary by disease, though strong initiatives are underway to increase awareness and utilization. Excluding the impact of the COVID-19 pandemic, studies estimate that 40,000 to 80,000 adults in the United States die annually of vaccine-preventable diseases, and hundreds of thousands more are hospitalized. In recent years, manufacturers have started developing more vaccines for the adult market, with Pfizer&#x2019;s Prevnar 13 and Prevnar 20, Merck's Vaxneuvance and GlaxoSmithKline&#x2019;s Shingrix each representing successful examples. Prevnar 13 and Pneumovax 23 generated annual sales of over $2 billion in the adult indication, and Shingrix, a vaccine for shingles (herpes zoster) debuted with over $1 billion in sales in 2018 as it replaced Merck&#x2019;s incumbent vaccine, Zostavax, after receiving an ACIP preferred recommendation, and generated over $2.5 billion in sales in 2020.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The complex development and production processes of vaccines create a high barrier to entry and long product lifecycles. Four multinational companies&#x2014;GlaxoSmithKline, Merck, Pfizer and Sanofi&#x2014;historically comprised approximately 75% of the global vaccine market. As a result of the COVID-19 pandemic, there have been a number of new entrants into the vaccines market, including multinational companies such as Johnson &amp; Johnson, and emerging biopharmaceutical companies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Pneumococcal Disease</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pneumococcal disease is an infection caused by </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Streptococcus pneumoniae </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(pneumococcus)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">bacteria. It can result in IPD, including meningitis and bacteremia, and non-invasive pneumococcal disease, including pneumonia, otitis media and sinusitis. The global incidence of pneumococcal disease is driven by emerging serotypes not covered by currently available vaccines. In the United States, approximately 900,000 people get pneumococcal pneumonia each year, which is estimated to result in approximately 400,000 hospitalizations and 28,000 deaths. Pneumococci also cause over 50% of all cases of bacterial meningitis in the United States. Antibiotics are used to treat pneumococcal disease, but some strains of the bacteria have developed resistance to treatments. The morbidity and mortality due to pneumococcal disease are highly significant, particularly for young children and older adults, underscoring the need for a more broad-spectrum vaccine.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Evolution of Pneumococcal Vaccines</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">There are currently two types of vaccines targeting pneumococcal disease&#x2014;polysaccharide-only vaccines and polysaccharide-conjugate vaccines. Polysaccharide vaccines contain polysaccharide antigens, which induce antibodies (B-cell responses) that bind to a bacteria&#x2019;s outer coating of polysaccharides and clear the bacteria. PCVs improve on polysaccharide vaccines by attaching, or conjugating, the polysaccharide antigen to a non-disease specific protein carrier. PCVs induce both an improved B-cell response and a T-cell response, resulting in a stronger and more durable immune response and longer-lasting protection, as compared to polysaccharide vaccines, which only induce a B-cell response.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Pneumococcal Polysaccharide-Only Vaccines</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pneumovax 23, manufactured and marketed by Merck &amp; Co., Inc., is the only pneumococcal polysaccharide vaccine widely available. Pneumovax 23 is indicated for the prevention of pneumococcal disease in adults and was first approved in the United States in 1977, at which time it contained 14 different strains of pneumococcal bacteria. In 1983, it was replaced by the current version containing 23 different strains. Pneumovax 23 is routinely administered to adults to provide protection against bacteremia and generates sales of over $900 million per year.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Polysaccharide vaccines induce a B-cell response only and do not induce a T-cell dependent immune response. In the absence of immunological memory responses, the resulting antibody responses are transient and cannot be boosted. Without the ability to provide long-lasting durable immunity, polysaccharide vaccines are not effective in children below two years of age. In addition, the antibody responses primarily consist of immunoglobulin M, or IgM, antibodies that, due to their size, are restricted to blood and are unable to penetrate into lung tissue to protect against pneumonia. Therefore, polysaccharide vaccines such as Pneumovax 23 are only thought to protect against blood-borne infections, such as bacteremia. Figure 1 below illustrates polysaccharide-induced T-cell independent antibody responses.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Figure 1.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><img src="img69628308_1.jpg" alt="img69628308_1.jpg" style="width:288px;height:206px;" /><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Graphics adapted from Strugnell et al, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Understanding Modern Vaccines</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, Vol 1, Issue 1, 61-88.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Polysaccharide vaccines also interfere with optimal use of PCVs, as they create a hyporesponsive immune effect. In particular, absent T-cell inducement, polysaccharide vaccines actually clear the memory B-cells that are formed following primary immunization with a PCV, thereby eliminating the ability to boost with subsequent vaccination. This historically has been a significant drawback of vaccination in older adults, which consisted of the administration of a limited spectrum PCV followed by the administration of a polysaccharide vaccine. Despite these shortcomings, Pneumovax 23 historically has been widely used primarily to provide protection against circulating strains not contained in the currently available PCV. The current standard of care, which consists of the administration of either Prevnar 20 alone or Vaxneuvance followed by the administration of Pneumovax 23, continues to include the alternative of a polysaccharide vaccine.</span></p>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Pneumococcal Conjugate Vaccines</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">PCVs overcome the limitations of polysaccharide vaccines by conjugating the polysaccharide to a more immunogenic protein carrier containing T-cell epitopes. These T-cell epitopes provide CD4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">+</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> help, which is critical to the conversion of a traditional B-cell dependent immune response to a more robust combined B-cell and T-cell dependent immune response. The T-cell response causes immediate class switching of the B-cells from more rudimentary IgM antibodies prevalent with polysaccharide vaccines to more refined IgG antibodies. IgG antibodies are refined enough to penetrate into lung tissues to prevent pneumonia. Furthermore, as polysaccharide strands attach to multiple copies of the protein carrier, they create an inter-strand cross-linked matrix structure, which the immune system easily recognizes as foreign. The T-cell dependent immune response also generates memory B-cells that can be re-stimulated, creating a prime-boost immune response and enabling a more robust and durable immune response, enabling the use of PCVs in young children. Figure 2 below illustrates this immune response:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Figure 2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><img src="img69628308_2.jpg" alt="img69628308_2.jpg" style="width:268px;height:210px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The first PCV, Prevnar, was a 7-valent vaccine that was launched in the United States in 2000. It included purified capsular polysaccharides of seven serotypes of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">S. pneumoniae</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> (4, 6B, 9V, 14, 18C, 19F and 23F), each of which was individually conjugated to a T-cell-epitope-containing, nontoxic variant of diphtheria toxin known as CRM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:bottom;font-size:6.7pt;font-family:Times New Roman;">197</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> to produce seven separate conjugates. To obtain approval, a large field efficacy study was conducted that demonstrated the vaccine&#x2019;s efficacy in infants. Efficacy correlated with serological immune endpoints, as measured by IgG titers (a measurement of concentration), and a seroconversion threshold (or reference antibody concentration) of protection was defined. Prevnar is credited with tremendous medical and commercial success, having dramatically reduced circulating disease in children. However, after a number of years of widespread use, IPD incidence caused by strains not contained in the vaccine started to opportunistically rise, a phenomenon called serotype replacement, which led to the need for a broader-spectrum version of the vaccine.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the race to develop a broader-spectrum PCV than Prevnar, two vaccines were successfully developed: Synflorix, a 10-valent PCV from GlaxoSmithKline, and Prevnar 13, a 13-valent PCV from Wyeth (subsequently acquired by Pfizer). Based on its broader coverage of then-emerging strains, Prevnar 13 was adopted as the standard of care in the United States and Europe. Synflorix continues to be used primarily in emerging countries.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prevnar 13 contains the seven serotypes originally included in Prevnar plus six more serotypes of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">S. pneumoniae</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> (1, 3, 5, 6A, 7F and 19A) and was approved and launched in the United States in 2010. Each polysaccharide is conjugated to CRM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:bottom;font-size:6.7pt;font-family:Times New Roman;">197</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> to produce 13 individual conjugates, which are mixed into a final vaccine formulation and then adsorbed to alum. In 2010, Prevnar 13 obtained FDA approval for the prevention of IPD in infants based on non-inferior IgG antibody responses relative to Prevnar, using the surrogate immune endpoints established by the prior Prevnar field efficacy study. While Prevnar 13 failed to achieve non-inferiority on two of the common seven strains relative to Prevnar, it was granted approval across all 13 strains. Upon receipt of the ACIP preferred recommendation, Prevnar 13 replaced Prevnar in the infant market as the standard of care. This also created a &#x201c;catch-up&#x201d; population for those children previously vaccinated with Prevnar to provide protection against the incremental serotypes covered by Prevnar 13.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prevnar 13 has also received accelerated approval for the prevention of IPD and pneumonia in adults in the United States based on non-inferior opsonophagocytosis activity, or OPA, responses as compared to Pneumovax 23. To fulfill a post-marketing commitment, a large-scale field efficacy study of adults in the Netherlands was completed in 2013, which showed protection against community-acquired pneumonia and concordance between OPA and protection from community-acquired pneumonia. Thus, OPA was established as a validated surrogate immune endpoint in adults to support future regulatory approvals. Prevnar 13 subsequently received an ACIP preferred recommendation for adults 65 years and older, and the standard of care was amended to first vaccinate with Prevnar 13, and then after a waiting period, Pneumovax 23. This dual vaccine regimen provides some protection against the circulating strains over and above Prevnar 13 but we believe creates coverage gaps and patient compliance and convenience challenges.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prevnar 13 quickly became the highest selling product in the global vaccine market. However, at the time of ACIP&#x2019;s recommendation in 2014, it was determined that the recommendation would be revisited in four years to evaluate the impact of Prevnar 13 on pneumococcal disease burden in older adults. In June 2019, the ACIP downgraded its recommendation of Prevnar 13 for older adults, given the lack of disease caused by the incorporated strains, and instead began directing physicians and patients to decide whether to vaccinate on a case-by-case basis while still recommending universal vaccination with Pneumovax 23 due to its broader coverage.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> In an effort to develop even broader-spectrum PCVs than Prevnar 13, two vaccines were successfully developed for the adult population: Prevnar 20, a 20-valent PCV from Pfizer, and Vaxneuvance, a 15-valent PCV from Merck.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prevnar 20 contains the 13 serotypes included in Prevnar 13 plus seven more serotypes of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">S. pneumoniae</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> (8, 10A, 11A, 12F, 15B, 22F and 33F) and was granted regulatory approval and launched in the United States in 2021 for the prevention of IPD in adults based on non-inferior OPA responses relative to Prevnar 13 without the need for a field efficacy study. While Prevnar 20 failed to achieve non-inferiority on serotype 8 relative to Pneumovax 23, it was still granted approval across all 20 strains.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Vaxneuvance contains the 13 serotypes included in Prevnar 13 plus two more serotypes of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">S. pneumoniae</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> (22F and 33F) and was granted regulatory approval and launched in the United States in 2021 for the prevention of IPD in adults based on non-inferior OPA responses relative to Prevnar 13 without the need for a field efficacy study.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In October 2021, the ACIP voted to recommend universal vaccination for the use of either Prevnar 20 alone or Vaxneuvance with Pneumovax 23 for routine use in adults aged 65 years and older as well as for those between the ages of 19 and 64 years with certain underlying medical conditions or other risk factors.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pfizer and Merck also are developing Prevnar 20 and Vaxneuvance, respectively, for infants.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Drawbacks for Current PCVs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Routine immunization with PCVs has been effective in dramatically lowering the incidence of IPD in both adults and children in the United States and other industrialized nations. However, due to a phenomenon called serotype replacement, strains that are not covered by existing vaccines are increasing in prevalence. As published in 2020, over 71% of IPD incidence in 2017 for both children and adults was caused by strains beyond the 13 strains covered by Prevnar 13. Efforts to improve upon current standard of care vaccines center around expanding the valency of PCVs to address the strains driving residual pneumococcal disease. However, limitations due to conventional conjugation chemistry and carrier suppression have complicated those efforts, and notwithstanding the recent approvals of Prevnar 20 and Vaxneuvance, there remains a significant need for broader-spectrum PCVs, as evidenced by the fact that despite Prevnar 20&#x2019;s broader coverage, the combination of Vaxneuvance and Pneumovax 23 remains universally recommended in adults, as an alternative to Prevnar 20 alone, given its broader-spectrum coverage.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">While vaccination with current PCVs has been effective in dramatically lowering the incidence of IPD in both adults and children in the United States and other industrialized nations, current PCVs suffer from the following drawbacks.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Serotype Replacement</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Current PCVs do not address circulating strains causing the majority of pneumococcal disease. Since its introduction, there has been a decrease in the incidence of disease attributable to the serotypes covered by Prevnar 13 but an increase in incidence attributable to the incremental 11 strains that now cause most residual disease. Such change is driven by the void created when serotypes are taken out of circulation after widespread vaccination, which is a phenomenon known as serotype replacement. As a result of such change, broader-spectrum PCVs are required to maintain protection against historically pathogenic strains while expanding coverage to address current circulating and emerging strains.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">To date, the most comprehensive pneumococcal disease surveillance has been conducted by the CDC in the United States and by the National Institute of Health and Care Excellence, in the United Kingdom. As shown in Figure 3, IPD cases in adults in the United States initially declined after the introduction of Prevnar 13 but have since plateaued. As published in 2020, non-covered serotypes were responsible for over 71% of IPD incidence in 2017 for both children and adults. The rate of serotype replacement has been more pronounced in the United Kingdom. Figure 4 shows the approximate IPD incidence rates in the United Kingdom caused by the incremental 11 strains over and above those in Prevnar 13, which increased over the last three years of surveillance.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:48.244%;"></td>
    <td style="width:1.006%;"></td>
    <td style="width:0.161%;"></td>
    <td style="width:0.171%;"></td>
    <td style="width:50.418%;"></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;vertical-align:top;"><p style="text-indent:49.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Figure 3.</span></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:1.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:49.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Figure 4.</span></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:1.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">US IPD Incidence in Adults </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">&gt;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">&#160;65</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-3.9865pt;white-space:pre-wrap;font-weight:bold;font-size:5.695pt;font-family:Times New Roman;position:relative;">1</span></p></td>
    <td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">UK IPD Incidence in Adults </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">&gt;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">&#160;65</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-3.9865pt;white-space:pre-wrap;font-weight:bold;font-size:5.695pt;font-family:Times New Roman;position:relative;">2</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:1.0pt;text-align:center;"><img src="img69628308_3.jpg" alt="img69628308_3.jpg" style="width:298px;height:187px;" />&#160;</p></td>
    <td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:1.0pt;text-align:center;"><img src="img69628308_4.jpg" alt="img69628308_4.jpg" style="width:303px;height:178px;" />&#160;</p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:Times New Roman;position:relative;">1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;US CDC Active Bacterial Core Surveillance Annual Reports</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:Times New Roman;position:relative;">2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;Ladhani et al, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Lancet Infectious Disease, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2018 Apr.; 18(4):441-45 inclusive of unpublished raw data</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">While these 11 strains are covered by Pneumovax 23, that vaccine only protects against blood-borne infections and not pneumonia, leaving patients vulnerable to infection. Although Prevnar 20 and Vaxneuvance address more disease-causing strains than Prevnar 13, we believe there remains a significant need for even broader-spectrum vaccines to address a greater number of currently circulating and emerging strains.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Carrier Suppression</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Technical constraints inherent to conventional conjugation chemistry limit the coverage of current PCVs due to a phenomenon known as carrier suppression. In particular, traditional conjugation methods cannot control where conjugation of the polysaccharide occurs on the protein carrier. The protein carrier used in all versions of Prevnar is CRM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:bottom;font-size:6.7pt;font-family:Times New Roman;">197</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, a diphtheria toxin with a single point mutation rendering it non-toxic. The CRM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:bottom;font-size:6.7pt;font-family:Times New Roman;">197</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> protein contains 39 lysines, approximately 20% of which border relevant T-cell epitopes. Conventional conjugation chemistry randomly attaches the polysaccharide to any of the numerous lysines located on the protein carrier. When a polysaccharide is covalently bound to a protein carrier at a lysine residue that is co-resident with a T-cell epitope, it blocks the presentation of the T-cell epitope to the immune system, thus preventing the induction of a T-cell response. The masking of these critical epitopes prevents the conversion to a T-cell dependent immune response and negates the benefit of the protein carrier.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Meanwhile, the B-cell epitopes of both the protein carrier and the antigen are presented to the immune system, causing B-cells to the respective immunogens to compete with one another for the T-cell help engendered by unblocked T-cell epitopes. This competition for T-cell help diminishes the immune response to the polysaccharide antigen of interest, resulting in carrier suppression.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The result of carrier suppression is a decrease in the targeted immune response to the disease-specific polysaccharides, which intensifies with higher cumulative amounts of protein carrier. This phenomenon impedes the ability to expand coverage of current PCVs and has been shown consistently when broader-spectrum versions of conventional PCVs have been compared to lesser-valent versions. When Prevnar 13 was compared to Prevnar (Pfizer&#x2019;s first generation 7-valent PCV) in a well-controlled Phase 3 study in infants, the IgG antibody responses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">directed against the polysaccharides of interest for all seven of the common strains in each vaccine were lower for Prevnar 13 (Figure 5). In 2020, Pfizer presented results of a well-controlled Phase 3 study in adults, aged 60 and over, where they compared Prevnar 20 to Prevnar 13. In that study, the OPA responses directed against the polysaccharides of interest for all thirteen of the common strains in each vaccine were lower for the 20-valent development candidate (Figure 6).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:49.165%;"></td>
    <td style="width:2.013%;"></td>
    <td style="width:0.161%;"></td>
    <td style="width:48.662%;"></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;vertical-align:top;"><p style="text-indent:49.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Figure 5.</span></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:1.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:49.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Figure 6.</span></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:1.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Infant Immune Responses (IGG):</span></p><p style="text-indent:-12.0pt;padding-left:12.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Prevnar 7 vs Prevnar 13</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:bold;font-size:6.7pt;font-family:Times New Roman;position:relative;">1</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">&#160;Adult Immune Responses (OPA):</span></p><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.5pt;font-family:Times New Roman;">Prevnar 13 VS PCV20</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-3.9865pt;white-space:pre-wrap;font-weight:bold;font-size:5.695pt;font-family:Times New Roman;position:relative;">2</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:1.0pt;text-align:center;"><img src="img69628308_5.jpg" alt="img69628308_5.jpg" style="width:298px;height:119px;" />&#160;</p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:1.0pt;text-align:center;"><img src="img69628308_6.jpg" alt="img69628308_6.jpg" style="width:303px;height:122px;" />&#160;</p></td>
   </tr>
  </table>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;margin-right:66.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:2.5pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">1 </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Yeh et al, Pediatrics. 126:e493 (2010)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">2 </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prevnar 20 BLA Clinical Review Memorandum. STN: 125731/0 June 8, 2021.</span></p>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Conventional Chemistry</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The problem of carrier suppression is compounded by conventional conjugation chemistry used to make current PCVs, including Prevnar 13, Prevnar 20 and Vaxneuvance, which requires a higher amount of CRM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:bottom;font-size:6.7pt;font-family:Times New Roman;">197</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> protein carrier than polysaccharide antigen to complete the conjugation reaction, as well as long reaction times and harsh conditions that can damage the critical epitopes on the polysaccharide antigens. This results in a higher ratio of protein carrier to polysaccharide antigen in their monovalent conjugates (approximately 1.1 on average), as well as a much higher amount of cumulative protein carrier in the final formulation compared to the amount of any given polysaccharide antigen. For example, in the marketed Prevnar 13 formulation, there are 34 micrograms of the protein carrier, CRM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:bottom;font-size:6.7pt;font-family:Times New Roman;">197</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, relative to 2.2 micrograms of each polysaccharide (except serotype 6B at 4.4 micrograms), and in the marketed Prevnar 20 formulation, there are 51 micrograms of CRM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:bottom;font-size:6.7pt;font-family:Times New Roman;">197</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> relative to 2.2 micrograms of each polysaccharide (except serotype 6B at 4.4 micrograms). With substantially more protein carrier in the vaccine than polysaccharide antigen, the carrier suppression effect discussed above is exacerbated.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Our Solution</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are leveraging our cell-free protein synthesis platform to develop potentially superior conjugate vaccines for adult and pediatric indications. Our solution to the drawbacks with conventional conjugate vaccine techniques represents the first of three main applications of our platform.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Platform Application One: Creating Superior Conjugate Vaccines</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Using our cell-free protein synthesis platform, we are developing superior, novel PCVs designed to have broader-spectrum coverage in an effort to address current and future residual disease in ways that conventional technologies cannot. We are able to design our investigational PCVs using site-specific conjugation in an effort to ensure optimal exposure of targeted immunogenic T-cell epitopes on protein carriers. This enables us to create broader-spectrum conjugate vaccine candidates using carrier-sparing conjugates designed to avoid carrier suppression while maintaining protective immunogenicity.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Synthesizing proteins outside of a living host cell provides us greater freedom to design and produce specific proteins of interest under optimized conditions. We separate the precise cellular machinery required for transcription, translation and energy production&#x2014;the critical components for protein production&#x2014;into an</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Escherichia coli</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> (</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">E. coli)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-derived extract. We can then optimally express a single protein carrier by adding the plasmid-DNA encoding that protein into the extract mixture.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Site-Specific Conjugation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Within a protein carrier, we can substitute non-native amino acids, or nnAAs, for native amino acids at specific sites. These inserted nnAAs serve as conjugation anchors that permit the attachment of antigens, including polysaccharides, at a specific site on a protein carrier to ensure optimal exposure of B-cell and/or T-cell epitopes to induce the desired immune response. This precise site-specific linkage is not possible using conventional conjugation chemistry with conventional carrier proteins and affords an advantage to our conjugate vaccine candidates. Figure 7 below depicts our method of inserting nnAAs into a protein carrier, where the DNA sequence has been modified to permit nnAA incorporation into the protein at pre-selected sites using a nnAA-RNA permitting transcription and translation of the protein in the ribosome to yield the protein carrier with nnAAs site-specifically incorporated, facilitating site-specific conjugation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Figure 7.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><img src="img69628308_7.jpg" alt="img69628308_7.jpg" style="width:351px;height:208px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Most conjugate vaccines available today use a non-disease-specific protein carrier, CRM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:bottom;font-size:6.7pt;font-family:Times New Roman;">197</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, in order to leverage T-cell epitopes to induce a T-cell dependent immune response. This traditional method produces a heterogeneous mixture of conjugates with blocked and unblocked T-cell epitopes in a large immunogenic cross-linked matrix structure. In contrast, the precision and flexibility of cell-free protein expression, together with our ability to insert nnAAs, allow us to construct our proprietary enhanced protein carrier, or eCRM, with pre-determined conjugation sites. Our method produces homogenous conjugates that provide for the consistent exposure of T-cell epitopes and likewise form a large, immunogenic cross-linked matrix structure. By precisely conjugating polysaccharides to eCRM in a way that provides for optimal exposure of T-cell epitopes to the immune system, we can heighten immunogenicity attainable with conjugate vaccines.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The figures below illustrate the site-specific conjugation process. Figure 8 shows site-specific conjugation of the polysaccharide to the protein carrier, avoiding the T-cell epitopes. Figure 9 shows the inter-strand cross-linked matrix, which is the structure of each monovalent conjugate included in the final vaccine.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.0%;"></td>
    <td style="width:50.0%;"></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:21.6pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:43.2pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Figure 8.</span></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:1.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:43.2pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Figure 9.</span></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:1.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:19.45pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Precise, Site-Specific Conjugation Sites on Proprietary eCRM Protein Carrier</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Final VAX-24 Conjugates in</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:1.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Customary Matrix Form</span></p></td>
   </tr>
   <tr style="height:108.7pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </span><img src="img69628308_8.jpg" alt="img69628308_8.jpg" style="width:279px;height:117px;" />&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </span><img src="img69628308_9.jpg" alt="img69628308_9.jpg" style="width:273px;height:159px;" />&#160;</p></td>
   </tr>
  </table>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We believe consistent exposure of T-cell epitopes should translate to higher potency of the protein carrier on a weight-to-weight basis. To harness this potential potency advantage, we have elected to construct conjugates with a lower ratio of protein carrier to polysaccharide than conventional PCVs. We have observed in animal models that despite having approximately half as much protein on average in each monovalent conjugate, VAX-24 had comparable immunogenicity relative to Prevnar 13 on a strain-by-strain basis. As a result, we believe we can incorporate more monovalent conjugates to create an even more broad-spectrum vaccine with less protein carrier per conjugate in order to minimize carrier suppression.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Better Chemistry</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We also employ a rapid and less harsh chemistry method called copper-free click chemistry to site-specifically conjugate the polysaccharides to eCRM. We believe this distinctive technique is a better controlled, more efficient and faster method of conjugation relative to conventional chemistry used to make traditional PCVs. The click chemistry conjugation reaction is designed to cause less damage to the critical immunogenic epitopes on the protein carrier or the target antigen.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our PCV Franchise</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are developing broad-spectrum investigational PCVs designed to minimize carrier suppression.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">VAX-24</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our lead vaccine candidate, VAX-24, is designed to improve upon the standard of care by covering the additional strains that are responsible for the majority of residual pneumococcal disease currently in circulation. We achieved preclinical proof of concept for VAX-24 in 2017 by demonstrating that VAX-24 has the potential to protect against the pneumococcal strains collectively covered by Prevnar 13 and Pneumovax 23, which at the time we conducted our preclinical studies represented the standard of care, and showed the durable, boostable immune response of a conjugate vaccine. The incremental 11 strains covered by VAX-24 and not covered by Prevnar 13 are responsible for the majority of circulating invasive pneumococcal disease in both the United States and European Union and are associated with high case-fatality rates, antibiotic resistance and/or meningitis.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">VAX-24 includes 24 purified capsular polysaccharides of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">S.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">pneumoniae</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> (1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F and 33F), each of which is conjugated to eCRM to produce 24 monovalent conjugates. These conjugates are mixed into a final vaccine formulation and then adsorbed to alum.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As shown in Figure 10 below, there are critical differences between VAX-24 and other currently available PCVs relating to the protein carrier, particularly the use of site-specific conjugation and the milder reaction conditions. We achieve site-specific conjugation through the insertion of multiple nnAAs, which is not possible with the conventional chemistry used for making other PCVs. The click chemistry we use for site-specific conjugation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">14</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">may also minimize damage to the critical immunogenic epitopes on the protein carrier and the polysaccharides through milder and shorter reactions, while other PCVs use conventional chemistries that involve harsher and longer reaction conditions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Figure 10.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><img src="img69628308_10.jpg" alt="img69628308_10.jpg" style="width:624px;height:215px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Furthermore, VAX-24, as tested in preclinical studies, nearly doubles the serotype spectrum of coverage of Prevnar 13, yet contains a similar amount of protein carrier. We believe the resulting decreased carrier burden per conjugate of VAX-24 is critical for avoiding carrier suppression and producing broader-spectrum pneumococcal vaccines without sacrificing immunogenicity.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Where appropriate, we capitalize on the efficiencies of well-established clinical, manufacturing and regulatory precedents by leveraging conventional methods for the development of VAX-24. For example, our polysaccharide antigens are primarily made using conventional fermentation and purification techniques and activated through conventional methods. They are also labeled through conventional amination methods prior to being conjugated to eCRM. In addition, we use the same critical quality attribute assays for molecular weight and free polysaccharide that have served as the physicochemical measures of conjugates and also serve as predictors of their immunogenicity in vivo. We also use conventional IgG and OPA serological assays to gauge the immunogenicity of our conjugates, which have served as surrogate immunological endpoints in clinical studies that enabled the approval of Prevnar 13, Prevnar 20 and Vaxneuvance.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have also leveraged the same animal models that were utilized in the development of approved PCVs. In particular, our preclinical studies utilized a recognized rabbit model that Pfizer used in its development of Prevnar, Prevnar 13 and Prevnar 20, that Merck used in its development of Vaxneuvance and that GlaxoSmithKline used in its development of Synflorix. To date, the rabbit model has shown consistent immunological responsiveness across all strains for which we have tested our conjugates and has differentiated conjugated versus unconjugated polysaccharide responses (i.e., T-cell dependent versus T-cell independent responses). We believe the demonstration of conjugate-like immune responses in rabbits that resulted in killing of bacteria via OPA and induction of IgG antibody responses are key development milestones and are critical readouts for the development of PCVs. The rabbit model has also provided evidence regarding VAX-24&#x2019;s potential to generate a booster response.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We expect to pursue a well-characterized clinical development path for VAX-24, consistent with other PCV developers. We anticipate that we will be able to conduct smaller and shorter clinical trials that target immune endpoints (e.g., OPA and IgG responses) previously recognized by regulatory authorities. Pfizer applied this approach to the development of Prevnar 13 and Prevnar 20 and Merck applied it to the development of Vaxneuvance.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We conducted a pre-IND meeting with the FDA in December 2019 to obtain feedback on our VAX-24 chemistry, manufacturing and controls plan, or CMC plan, as well as our non-clinical and clinical design plans to support our IND application. On January 6, 2022, we announced that the FDA had cleared our IND application for</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">VAX-24. On February 23, 2022, we announced the initiation of our Phase 1/2 clinical proof-of-concept study in adults ages 18 to 64. We expect to announce Phase 1/2 topline safety, tolerability and immunogenicity results from this study by the end of 2022.</span></p>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Preclinical Data</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As a prerequisite for regulatory approval, we believe that any investigational PCV will have to be compared to the current standard of care, which is currently Prevnar 13 in infants, and either Prevnar 20 alone or Vaxneuvance followed by Pneumovax 23 in adults. In the case of VAX-24, we believe a successful comparison would be based on demonstrating the clinical non-inferiority of the immune response to the 20 common serotypes in Prevnar 13, and the incremental 4 common strains in Pneumovax 23. To obtain pre-clinical proof of concept on our way to the clinic, we evaluated VAX-24 compared to the then standard of care, Prevnar 13, and assessed the comparative immune responses of VAX-24 using the same rabbit model utilized by other PCV developers. We dosed rabbits in our pre-clinical studies with 0.11&#xb5;g, as measured by the amount of polysaccharide in each conjugate, for each of the 24 conjugates in VAX-24, as well as 0.11&#xb5;g for the thirteen conjugates in Prevnar 13 (except serotype 6B at 0.22&#xb5;g) and compared both PCVs immunogenically to each other and to Pneumovax 23, where each of the 23 polysaccharides were dosed at 1.1&#xb5;g. The doses are representative of body weight differences in humans versus rabbits and roughly correspond to the dose differential between PCVs and polysaccharide-only vaccines. In humans, Prevnar 13 is dosed at 2.2&#xb5;g per conjugate (except serotype 6B at 4.4&#xb5;g) or approximately one-tenth the dose of Pneumovax 23, where each polysaccharide is dosed at 25&#xb5;g. The species of rabbits used were approximately five percent of the average weight of humans in North America, thus 0.11&#xb5;g approximates to the 2.2&#xb5;g dose for PCVs and the 1.1&#xb5;g dose approximates to the 25&#xb5;g dose for Pneumovax 23.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have completed multiple pre-clinical proof-of-concept studies of VAX-24 compared to Prevnar 13 and Pneumovax 23 in rabbits. The endpoints of the studies were to measure, on a serotype-specific basis, IgG antibody responses, the surrogate endpoint for pediatrics, and OPA responses, the surrogate endpoint for adults. Initial proof of concept was obtained with research-grade raw materials and conjugates made at Vaxcyte prior to initiating technology transfer to Lonza and production scale-up. In mid-2019, conjugates were made at Vaxcyte at small-scale using optimized processes and procedures using Lonza-produced raw materials, including our proprietary eCRM carrier and all 24 polysaccharides that had already been tech transferred and scaled up. All 24 of the conjugates in VAX-24 met the critical quality attributes and the combination vaccine was administered in the rabbit model per Figures 11, 12, and 13. The chart in Figure 12 reflects the strains covered by each of VAX-24, Prevnar 13 and Pneumovax 23 in these experiments.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Figure 11.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><img src="img69628308_11.jpg" alt="img69628308_11.jpg" style="width:624px;height:125px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As reflected in Figure 12 below, VAX-24 showed comparable or superior OPA responses at 1/10th the dose of Pneumovax 23 and comparable OPA responses to an equivalent dose of Prevnar 13 on a serotype-by-serotype basis:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:9.173%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Figure 12.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><img src="img69628308_12.jpg" alt="img69628308_12.jpg" style="width:624px;height:272px;" />&#160;</p>
  <p style="text-indent:9.173%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">+/-95% confidence interval</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.173%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:9.173%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Similarly, as reflected in Figure 13 below, VAX-24 showed superior IgG antibody responses at 1/10th the dose of Pneumovax 23 and comparable IgG responses to an equivalent dose of Prevnar 13 on a serotype-by-serotype basis:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Figure 13.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.173%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><img src="img69628308_13.jpg" alt="img69628308_13.jpg" style="width:624px;height:265px;" />&#160;</p>
  <p style="text-indent:9.173%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">+/-95% confidence interval</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A critical milestone in product development is the scale-up of manufacturing to provide sufficient material for clinical evaluation and potential commercial launch. After having completed the technology transfer of the optimized processes and procedures for the production of each of the 24 conjugates in VAX-24, the conjugates were produced at Lonza at an over fifteen-fold scale increase to the prior scale at Vaxcyte. Each of the conjugates in</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">17</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">VAX-24 made at Lonza met the critical quality attributes and the combination vaccine was administered in the rabbit model. The chart in Figure 14 reflects the strains covered by each of VAX-24 and Prevnar 13 in this experiment.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Figure 14</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img69628308_14.jpg" alt="img69628308_14.jpg" style="width:624px;height:95px;" />&#160;</p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The data shown below in Figure 15 confirms that the eCRM and polysaccharide raw materials and the conjugation processes for each of the conjugates in VAX-24 all were transferred to and scaled at Lonza, and the immunogenicity remained comparable to Prevnar 13 and was consistent with prior lots of VAX-24.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Figure 15.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img69628308_15.jpg" alt="img69628308_15.jpg" style="width:624px;height:389px;" />&#160;</p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">+/-95% confidence interval</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">VAX-24 Clinical Development Plan</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">To accelerate our time to market, we intend to first pursue clinical proof of concept in the United States for adults and then pursue clinical development in the pediatric population. We believe the most expedient path to clinical proof of concept will be in the adult population where the standard of care involves the administration of a single dose and where an initial clinical trial could begin in the target population. We expect to initiate our pediatric development program in toddlers upon receipt of the Phase 2 topline safety, tolerability and immunogenicity data in adults 50 to 64 years of age and following submission and clearance of an IND application for this population. After completing such a toddler study, we would expect to commence clinical development in the infant population.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Adult Indication</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our first-in-human study is a randomized, observer-blind, dose-finding, controlled Phase 1/2 study designed to evaluate the safety, tolerability and immunogenicity of VAX-24 in healthy adults. The Phase 1 portion of the study will enroll approximately 64 healthy adults aged 18 to 49 to assess the safety and tolerability of each of three VAX-24 doses and compared to PCV20. Participants will be randomized equally in four separate arms and will be evaluated for safety 8 and 29 days after dosing. The Phase 2 portion will evaluate the safety, tolerability and immunogenicity of a single injection of VAX-24 at three dose levels compared to that of Prevnar 20 in approximately 800 healthy adults 50 to 64 years of age. Participants will be randomized equally in four separate arms and approximately 28 days after participants are dosed, samples are collected to assess immunogenicity. Topline data will be based on the results as of this one-month assessment, as well as the safety and tolerability observations throughout this period. All participants in the Phase 1/2 study will be followed for a total of 6 months after dosing to assess safety and tolerability.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">To date, our preclinical immunogenicity data suggest that VAX-24 will contain a lower overall polysaccharide to protein ratio of conjugated drug substance as compared to Prevnar 20 and depending on the dose-ranging study, the dose may contain lower cumulative protein as well. We initiated the Phase 1/2 study in February 2022 and expect to announce Phase 1/2 topline safety, tolerability and immunogenicity data by the end of 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We expect to use OPA titers as the primary immunogenicity endpoint for the VAX-24 program in adults. OPA is believed to be the primary protective mechanism against pneumococcal disease. In addition, we expect to measure IgG responses as a secondary endpoint, as such responses may serve as supportive evidence of immunogenicity for comparison. We also expect to use OPA titers and IgG concentrations as endpoints in our other planned adult studies of VAX-24. We currently believe that these endpoints, if met, will be sufficient to obtain regulatory approval of VAX-24 and do not anticipate the need for a clinical field efficacy trial. However, we have not yet obtained feedback from the FDA regarding our pivotal Phase 3 clinical development plans or the acceptability of our approach.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The FDA has previously approved pneumococcal vaccines upon the establishment of non-inferiority based on a head-to-head comparison using established surrogate immune endpoints in the target population. For adults, Prevnar 13 was approved based on the establishment of non-inferiority of OPA responses relative to Pneumovax 23, on a strain-by-strain basis, where non-inferiority was defined as greater than or equal to 0.50 of the lower limit of the two-sided 95% confidence interval of the OPA geometric mean titer ratio. Prevnar 20 and Vaxneuvance were approved based on the same non-inferiority criterion but compared with Prevnar 13 and Pneumovax 23. We have designed our Phase 1/2 study to have greater than or equal to 85% power on an individual serotype-basis taking into account the serotype with the highest variability in order to show a two-fold difference between treatment groups.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Figure 16 is a schematic of the overall study design of our planned Phase 1/2 study:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Figure 16.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><img src="img69628308_16.jpg" alt="img69628308_16.jpg" style="width:624px;height:151px;" />&#160;</p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If our Phase 2 trial is completed successfully, we expect to conduct an End-of-Phase 2 meeting with the FDA and subsequently conduct pivotal Phase 3 trials in the adult population for the purposes of evaluating</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">non-inferiority to Prevnar 20 for immunogenicity, generating a sufficient safety database in adults and establishing consistency of manufacturing through a lot-to-lot consistency study. The Phase 3 non-inferiority results would then be used to seek approval of VAX-24 in the adult population. This approach is similar to the approaches utilized by Pfizer to develop Prevnar 20 and Merck to develop Vaxneuvance, where the immunogenicity of the investigational PCVs was compared to the 13-valent Prevnar product (current standard of care at the time).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Based on Pfizer&#x2019;s experience with Prevnar 13, we believe that VAX-24, if approved, would have the potential to serve as a &#x201c;catch-up&#x201d; or booster for those who have previously received Pneumovax 23 or a lower-valent PCV. We believe a study exploring serial vaccination with Prevnar 20 and/or Pneumovax 23 followed by VAX-24 at different intervals could generate valuable data supporting a recommendation for VAX-24 vaccination in previously vaccinated adults.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">To add to the body of data in adults, we plan to conduct a separate Phase 2 study, in adults 65 and older, upon the successful completion of the Phase 1 portion of the Phase 1/2 study in adults ages 18 to 64. The topline data from this study are anticipated in the first half of 2023.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span></p>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Pediatric Indication</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are also developing VAX-24 as a pediatric vaccine. If successful, we expect the data from the adult Phase 1 and Phase 2 trials will inform the VAX-24 dose(s) to be evaluated in pediatric populations. We plan to initially evaluate VAX-24 in an age de-escalation study. The adult Phase 2 trial will provide the safety and immunogenicity data required to initiate a Phase 1 clinical study in toddlers which will examine the safety, tolerability and immunogenicity of VAX-24 in healthy toddlers aged 12 to 15 months. A dose of VAX-24 or Prevnar 13 would be administered to the 12 to 15-month age group. For trials in the United States, toddlers would be expected to have been primed with a 3-dose primary infant series of Prevnar 13. Immune response data would reveal whether the boost achieved with VAX-24 is comparable to Prevnar 13 for the common serotypes, with the remaining 11 serotypes to be assessed for a single-dose primary immune response in the toddler age group.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If our Phase 1 trial in toddlers is completed successfully, we would expect to initiate a Phase 2 study to evaluate the safety and immunogenicity of VAX-24 administered as a three-dose primary series to infants at 2, 4 and 6 months of age. We would also expect to give these infants a booster dose at 12 to 15 months for a complete four-dose series. The decision to incorporate dose-finding as part of this trial would be made based on data from ongoing or completed adult trials and the preliminary immunogenicity data generated in toddlers.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We plan to collect both IgG and OPA data to evaluate whether the immune responses observed in infants following vaccination with VAX-24 are similar to those seen with other PCVs. If dose-finding is performed in infants, the data would inform on the dose levels for each of the conjugates in the final VAX-24 infant formulation. Consistent with the approval process for Prevnar 13 in infants, we do not anticipate that a clinical field efficacy trial will be required for VAX-24 in the pediatric population. We expect the clinical development of VAX-24 to follow the same approach utilized for Prevnar 13, where vaccine effectiveness against IPD was inferred from immunologic correlates. In contrast to the adult population, VAX-24 approval in the pediatric population is expected to be based on a non-inferiority comparison of IgG responses to Prevnar 13. However, we have not yet obtained feedback from the FDA regarding our clinical development plans or the acceptability of our approach.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If our Phase 2 trials are completed successfully, we expect to conduct pivotal Phase 3 trials in the pediatric population that focus on evaluating non-inferiority to Prevnar 13 for immunogenicity and seroconversion or antibody concentration threshold; assessing U.S. routine vaccination responses following concomitant administration with VAX-24; and generating a sufficient safety database in infants. The Phase 3 non-inferiority results would then be used to seek approval of VAX-24 in the pediatric population. This approach is similar to the approach utilized to develop Prevnar 13, where the immunogenicity of Prevnar 13 was compared to the original 7-valent Prevnar product (standard of care at the time).</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">PCVs, as well as all other polysaccharide-conjugate vaccines, have historically had an excellent safety profile, especially in comparison to other vaccines such as rotavirus and diphtheria-tetanus-pertussis.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">VAX-XP</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">VAX-XP is a franchise extension of VAX-24 that, if approved, would expand strain coverage to at least 30 strains and demonstrate the scalable and modular nature of conjugate vaccines we can develop. VAX-XP includes all of the strains contained in VAX-24 plus incremental strains that were selected based on the epidemiological evidence demonstrating their role in circulating IPD and is designed to protect against these emerging strains and to help address antibiotic resistance. The serotypes in VAX-XP cover over 90% of the circulating pneumococcal disease in the United States, although we are not disclosing the specific incremental strains at this time.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have completed multiple preclinical proof-of-concept studies for VAX-XP in rabbit models compared to Prevnar 13, as well as more than 30 polysaccharides adsorbed onto alum. IgG responses in rabbits were superior to polysaccharide alone plus alum and comparable with Prevnar 13 in the common 13 strains. We recently completed the process of transferring and scaling the conjugation processes at Lonza for each of the incremental conjugates contained in VAX-XP over and above those contained in VAX-24. The data shown below in Figure 17 was generated using those conjugates produced at larger scale at Lonza and confirm that the eCRM and polysaccharide raw materials and the conjugation processes for each of the conjugates in VAX-XP demonstrate immunogenicity comparable to Prevnar 13 and superior to polysaccharide alone, consistent with prior lots of VAX-XP.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Figure 17.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><img src="img69628308_17.jpg" alt="img69628308_17.jpg" style="width:549px;height:232px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="margin-left:9.067%;text-indent:-2.943%;padding-left:2.6%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">+/-95% confidence interval</span></p>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Note: VAX-XP includes all 24 strains in VAX-24 and 7 additional pneumococcal conjugates. Serotypes A-G potential additional serotypes to be targeted by Vaxcyte under the VAX-XP program.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="margin-left:9.173%;text-indent:-2.823%;padding-left:2.507%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Platform Application Two: Novel Conjugate Vaccine Opportunities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are also developing novel conjugate vaccine candidates for other diseases for which there are no existing vaccines. By leveraging our platform, we have been able to generate novel protein carriers with site-specific incorporation of nnAAs designed to provide optimal exposure of both B-cell and T-cell epitopes on the carrier. Using these novel protein carriers, we can produce highly stable conjugate vaccine candidates through site-specific conjugation of antigens, including polysaccharides. Functionally, one significant advantage of using carriers may be the additional protective immunity that the protein itself can provide beyond the conjugated antigen itself.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Group A Strep Disease Background and Market Opportunity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Streptococcus pyogenes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> (</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">S. pyogenes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> or Group A Strep) causes a wide spectrum of both acute and chronic clinical conditions that lead to considerable burden globally. Group A Strep, a pervasive disease that results</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">in 700 million cases of illness each year, is one of the leading infectious disease-related causes of death and disability worldwide. An estimated 500,000 deaths globally result from Group A Strep, which is in line with the impact seen from the Measles, Rotavirus and Pertussis. Among older adults (&#x2265; 65 years) in the United States, rates of invasive disease and deaths caused by Group A Strep have more than doubled over the last decade. Some of the most serious consequences of Group A Strep include flesh eating disease (necrotizing fasciitis) and invasive diseases such as sepsis and rheumatic heart disease (RHD). Approximately 30 million people are currently affected by RHD worldwide. Importantly, the majority of Group A Strep infections lead to pharyngitis, commonly known as strep throat, which is highly prevalent in school-age children. In the United States, an estimated 17% of outpatient antibiotic prescriptions dispensed to children aged 3 to 9 years are for the treatment of suspected Group A Strep infections. Studies have indicated that antibiotic resistance to Group A Strep has significantly increased over the past decade, leading the CDC to categorize Group A Strep as a concerning threat. Additionally, the development of vaccines against Group A Strep has become a priority for the WHO amid recognition of the rising disease incidence globally, as well as the need to combat avoidable antibiotic consumption.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">It has been established that the repeated natural infection of children with Group A Strep results in immune responses that are protective against subsequent Group A Strep infection. We believe this observation justifies the development of a rationally designed vaccine for Group A Strep that is focused on conserved antigens expressed by all strains of the bacteria.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">VAX-A1</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have developed a conjugate vaccine candidate, VAX-A1, designed to confer broad protection against subtypes of Group A Strep by virtue of polyrhamnose, a conserved polysaccharide, conjugated to Group A Strep specific immunogenic protein carrier using our site-specific conjugation technology. The resulting conjugate is designed to ensure optimal exposure of both the B-cell and T-cell epitopes on the protein carrier to confer robust, boostable and durable protective immune responses. We believe this single conjugate could potentially cover all Group A Strep strains. The vaccine is a combination of this novel protein-polysaccharide conjugate along with two additional conserved surface proteins.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our initial preclinical proof-of-concept study was published in the journal </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Infectious Microbes &amp; Diseases</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> in December 2020. In the study, a novel protein and polysaccharide conjugate of the Group A Strep polysaccharide was constructed for inclusion in a universal subunit vaccine against infections by the pathogen. The VAX-A1 vaccine candidate, based on SpyAD-conjugated to a modified polyrhamnose backbone (lacking N-acetyl glucosamine) and including SLO and C5a peptidase, demonstrated protection from subcutaneous and systemic challenge in mice, antibody binding and opsonophagocytic killing for multiple Group A Strep M Protein Gene, or emm, types and no evidence of cross-reactivity to human heart and brain tissue antigens (Figure 18), which is a key leading indicator of vaccine safety. The study was carried out in collaboration with researchers at the Division of Host-Microbe Systems and Therapeutics, Department of Pediatrics, University of California School of Medicine and the Skaggs School of Pharmacy and Pharmaceutical Sciences at the University of California, San Diego.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Figure 18.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><img src="img69628308_18.jpg" alt="img69628308_18.jpg" style="width:409px;height:180px;" />&#160;</p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">22</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our VAX-A1 vaccine development program currently is funded in part by a grant obtained from CARB-X, a global non-profit partnership dedicated to accelerating antibacterial innovation to tackle the rising global threat of drug-resistant bacteria. The award committed initial funding of up to $1.6 million. In July 2020, the initial funding amount was amended from $1.6 million to $2.7 million and, if options to extend are exercised by CARB-X, up to $15.1 million in total funding available upon achievement of development milestones through Phase 1 human clinical trials. In April 2021, we received approval for the next phase of CARB-X development and executed the cost-reimbursement sub-award agreement with the Trustees of Boston University in August 2021. Pursuant to the agreement, the award committed additional funding of $3.2 million for IND-enabling activities and total potential funding of up to $29.7 million (including the current $3.2 million award and the prior $2.7 million award) upon the achievement of future VAX-A1 development milestones. In January 2022, CARB-X revised the parameters for the contribution of CARB-X funding and implemented maximum funding levels for all grant recipients. As a result, our total funding available upon achievement of development milestones through Phase 1 human clinical trials was revised from $29.7 million to $13.9 million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We nominated the final vaccine candidate for our VAX-A1 program in the first quarter of 2021 and initiated IND-enabling activities in the second half of 2021. Upon completion of the preclinical development program and IND-enabling activities for VAX-A1, we intend to conduct a multi-center, randomized, placebo-controlled Phase 1/2 study in adults at risk for contracting Group A Strep infections. The primary objectives of the initial clinical trial will be to evaluate safety and tolerability. Secondary exploratory endpoints will be to measure IgG immune response to the vaccine antigens and to evaluate the ability of the antibodies produced in response to vaccination to inhibit and prevent infections caused by Group A Strep.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Platform Application Three: Protein Vaccine Opportunities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We believe we can also develop novel protein vaccine candidates constructed using &#x201c;tough-to-make&#x201d; protein antigens uniquely able to be expressed using the platform. In particular, the lack of a cellular membrane in our platform allows for the exogenous addition of components to manipulate transcription, translation and folding by modification of reaction conditions. Furthermore, removal of the typical restriction to maintain cell viability also creates unique avenues for optimizing and promoting protein production for antigens that might be cytotoxic to a cell-based system or require non-physiological conditions for optimal protein folding. Thus, utilizing these advantages, we believe we can express and purify important protein targets to generate unique candidates that are beyond the scope of traditional production systems. Our therapeutic periodontitis vaccine candidate is the first example of a &#x201c;tough-to-make&#x201d; protein-based vaccine.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Periodontitis Disease Background and Market Opportunity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Periodontal disease is a highly complex, chronic oral inflammatory disease that leads to the destruction of the soft and hard tissues supporting the teeth. The subgingival niche (below the gum margin of teeth) is populated by a diverse polymicrobial plaque. It is increasingly understood that the shift from periodontal health to disease is associated with changes in the microbial composition of the subgingival plaque, including activities of bacteria such as Porphyromonas gingivalis (P. gingivalis). The development of precise approaches to control this keystone pathogen, such as a vaccine, could then positively impact the periodontal disease burden.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Those with periodontitis also have an increased risk for heart attack, stroke and other serious cardiovascular events. In addition to gum and tooth disease, periodontal inflammation and infection with P. gingivalis have been linked to atherosclerotic heart disease mediated by P. gingivalis residing in atherosclerotic plaque. While we are focused on the treatment of periodontal disease with this vaccine candidate, if P. gingivalis is found to be causative in other chronic disorders, our vaccine candidate could potentially be a highly effective treatment and allow disease intervention at a much earlier stage of the disease. For example, recent research has suggested the potential for a link between P. gingivalis and Alzheimer&#x2019;s disease.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Neither the natural host immune response nor currently available treatments are curative for periodontal disease. Existing treatment includes highly aggressive and invasive procedures, including scaling and root planing and surgical intervention, coupled with antibiotic use. Despite these types of aggressive treatments, diseased sites frequently progress, leading to tooth loss. Thus, the development of an effective vaccine for periodontitis would be highly desirable.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">23</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the United States alone, an estimated 65 million adults suffer from periodontal disease. Globally, severe periodontal disease afflicts 10% to 15% of the adult population, resulting in productivity losses estimated at nearly $54 billion in 2010.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">VAX-PG</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are developing a novel protein vaccine candidate, VAX-PG, targeting </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">P. gingivalis </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">that incorporates protein antigens that we believe are uniquely enabled with our technology. Our initial goal is to develop a therapeutic vaccine to slow or stop disease progression; however, the results from clinical trials may inform the potential adoption of prophylactic immunization.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">VAX-PG, which includes cell-free produced P. gingivalis virulence factors, including gingipains, were tested in a preclinical model that mimics periodontal disease. The results, which we believe demonstrate preclinical proof of concept, were published in the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Journal of Clinical Periodontology </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">in February 2019. The vaccine elicited protein-specific IgG response following immunization and protected mice from P. gingivalis-elicited oral bone loss. Shown in Figure 19 is the objective bone loss of VAX-PG with alum, Monophospholipid A, or no adjuvant. Immunization with all formulations of VAX-PG provided significant protection against oral bone loss compared to the no vaccine oral challenged control group (p&lt;0.01, ANOVA with Dunns multiple comparisons).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Figure 19.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><img src="img69628308_19.jpg" alt="img69628308_19.jpg" style="width:285px;height:249px;" />&#160;</p>
  <p style="margin-left:13.6%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">ABC = alveolar bone crest</span></p>
  <p style="margin-left:13.6%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">CEJ = cement-enamel junction</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">24</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Shown below in Figure 20 are pictures of representative mouse jaws from the experiment. As can be seen, the vaccinated mice had considerably less bone loss than the unvaccinated and challenged control animals.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Figure 20.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><img src="img69628308_20.jpg" alt="img69628308_20.jpg" style="width:392px;height:326px;" /><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We expect to nominate the final vaccine candidate for our VAX-PG program by the end of 2022. Upon completion of the preclinical development program and IND-enabling activities for VAX-PG, we intend to conduct a multi-center, randomized, placebo-controlled Phase 1/2 study in adults with mild to moderate chronic periodontal disease. The primary objectives of the initial clinical trial will be to evaluate safety and tolerability. Secondary exploratory endpoints will be to measure IgG immune response to the vaccine antigens and to evaluate the ability of the antibodies produced in response to vaccination to inhibit the formation of the poly-microbial biofilm, which is characteristic of periodontal disease.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Manufacturing and Supply</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have designed and developed a proprietary, scalable and portable manufacturing process for VAX-24 that we believe can scale to address clinical and commercial vaccine supply needed to serve both adult and pediatric populations. We have completed process development. technology transfer to Lonza and Phase 1/2 manufacture for the critical components of the VAX-24 conjugates. In addition, we have also completed manufacture, testing and release of the 24 drug substance conjugates and the final drug product for the VAX-24 Phase 1/2 study in adults. As we have completed clinical manufacturing, we are now progressing to commercial supply discussions. We currently do not own or operate any manufacturing facilities, but our strategic partnership with Lonza provides us with access to substantial resources to facilitate an independent supply path to the market. Lonza is a leading global contract manufacturer with deep domain expertise and experience in large and small-scale production of clinical, as well as commercial-stage products. We have entered into agreements with Lonza to secure capacity, technical expertise and resources to support the production of VAX-24 clinical material and processes that are intended to scale to commercial scale at Lonza or other commercial manufacturing sites and are progressing to commercial supply discussions with Lonza. We have also entered into agreements for eCRM and polysaccharide to support VAX-XP to IND. In addition, we have entered into an agreement with Sutro Biopharma to supply us with extract and custom reagents for use in manufacturing preclinical and certain clinical supply of vaccine compositions, and in December 2019, we exercised our right to require Sutro Biopharma to establish a second supplier for extract and custom reagents to support our anticipated clinical and commercial needs. We have completed the manufacturing process and the delivery of the clinical material to support the Phase 1/2 clinical studies of VAX-24</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">25</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">in adults. The conjugates in VAX-24 are designed to serve as the foundation for our next-generation VAX-XP program.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Process</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The manufacturing process for our VAX-24 vaccine candidate consists of four key components: a) our proprietary eCRM protein carrier; b) the 24 pneumococcal polysaccharides; c) the 24 conjugate drug substances and d) the mixture of these 24 drug substances into the final drug product.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">eCRM</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our proprietary eCRM protein carrier is produced using our cell-free protein synthesis platform. eCRM, exclusively licensed from Sutro Biopharma, contains multiple copies of non-native para azido-methyl-phenylalanine, or pAMF, amino acid. The pAMF amino acids have a specific structure that enables eCRM to participate in the site-specific click chemistry conjugation reaction with activated pneumococcal polysaccharides.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The cell-free reaction is performed in a manner analogous to traditional fermentation but without the cells. The first step in the production of eCRM is the manufacture of critical raw materials, namely </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">E. coli</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> extracts and lysates that contain the cellular machinery required for in vitro DNA transcription and translation. The eCRM protein is then manufactured by combining these </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">E. coli</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> extracts and lysates with classic media components such as amino acids, minerals and salts, with the in vitro reaction driven by the addition of plasmid DNA coding for the eCRM protein&#x2019;s amino acid sequence. This cell-free reaction takes place in a standard fermenter, followed by standard protein purification chromatographic and filtration processes. The manufacturing process has consistently yielded a product of the desired quality.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Pneumococcal Polysaccharides</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Each of the 24 pneumococcal polysaccharides are individually isolated from</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> S. pneumoniae</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> bacterial strains. Each individual </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">S. pneumoniae</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> strain is cultured in a bioreactor using a single standardized fed-batch bioreactor process and a single standardized downstream purification process. Overall, this standardized upstream and downstream process is simple and streamlined, thereby reducing manufacturing cost of goods and providing an efficient path of progression for the program from process characterization and validation through to commercialization, if our vaccine candidates are approved.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Conjugate Drug Substances</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Each of the 24 conjugate drug substances is manufactured individually, as monovalent conjugates, by conjugating each of the 24 activated pneumococcal polysaccharide strains, one at a time, to the eCRM carrier protein.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Click chemistry provides for a conjugation reaction that is quick, consistent and high-yielding, and which we optimized to be largely standardized across the various polysaccharides. Through statistical design of experiment, or DoE, studies, we have gained a significant understanding of which variables to adjust to maximize product quality and, accordingly, immunogenicity in rabbit models.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">VAX-24 PCV Drug Product</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">All 24 conjugate drug substances are mixed, formulated with appropriate excipients and adsorbed onto alum. Clinical doses are filled in vials and stored refrigerated.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Achievements to Date</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In support of our IND application submission, we completed all IND-enabling CMC deliverables. For the eCRM protein carrier, we transferred process technology to Lonza and completed the development and scale-up to clinical production scale. We completed both the engineering campaign and the GMP production campaign for</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">26</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">eCRM to provide material believed to be adequate to support our Phase 1/2 clinical study of VAX-24 in adults. For the polysaccharide antigens, we established research and GMP master cell banks for all 24 pneumococcal serotypes in VAX-24. We completed the development and GMP batches of all 24 polysaccharide antigens to enable production of GMP conjugates for VAX-24. For the 24 drug substances, we conducted extensive design-of-experiments, or DoE, studies to define and optimize conjugation process parameters based on, among other parameters, immunogenicity and stability, for all 24 serotypes and transferred this process technology to Lonza. Further, Lonza implemented the transferred processes, successfully producing all 24 conjugates at an over fifteen-fold scale-up to what was previously produced. These conjugates met the target critical quality attributes, were tested in preclinical studies and confirmed to show conjugate-like immunological responses comparable to Prevnar 13 and to the previous VAX-24 conjugates produced at smaller batches. We completed the manufacture, testing and release of the 24 GMP drug substance conjugates in VAX-24 at Lonza. For the VAX-24 drug product, we defined an optimized formulation, transferred and scaled the process, and completed manufacture, testing and release of the VAX-24 GMP drug product at three dose strengths to support the IND application submission and the Phase 1/2 clinical study in adults.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Lonza Agreements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In October 2016, we entered into a development and manufacturing services agreement, as amended, with Lonza, or the Lonza DMSA, pursuant to which Lonza is obligated to perform manufacturing process development and the manufacture of components for VAX-24, including the polysaccharide antigens, our proprietary eCRM protein carrier and conjugated drug substances.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In September 2017, we and Lonza agreed to defer the completion payments for any stage that commenced after December 31, 2019 or had not been completed by December 31, 2019 until the earlier of the completion of all IND-enabling activities or December 31, 2020. In March 2020, Lonza agreed to defer the completion payments until the earlier of the completion of all IND-enabling activities or April 30, 2021. In April 2021, Lonza further agreed to defer 50% of the completion payments until the earlier of the completion of all IND-enabling activities or December 31, 2021.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In June 2018, we entered into a letter agreement, or the Lonza Letter Agreement, with Lonza, pursuant to which we agreed to certain terms for potential future payments in shares of our common stock as partial satisfaction of future obligations to Lonza. This agreement states that the initial pre-IND cash payments would be subject to a specified dollar cap, or the &#x201c;Initial Cash Cap.&#x201d; After the Initial Cash Cap has been reached, we would have the option to make any further pre-IND payments owed to Lonza in cash, in shares of our common stock at then market prevailing prices, or a combination of both, at our election. The Initial Cash Cap had not been reached as of December 31, 2020. As such, no amount had been recorded with respect to the potential future payments above the Initial Cash Cap at December 31, 2020. In April 2021, we reached the Initial Cash Cap and notified Lonza that we would be exercising our option to issue approximately $10.0 million in shares of our common stock as payment for a portion of pre-IND payments due April 30, 2021. In June 2021, we issued 399,680 shares of our common stock to Lonza at a price of $25.02 per share to pay for $10.0 million of the pre-IND payments due April 30, 2021.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In October 2018, we entered into a second development and manufacturing services agreement with Lonza, or the Lonza 2018 DMSA, and together with the Lonza DMSA, the Lonza Agreements, pursuant to which Lonza is obligated to perform services including manufacturing process development and the manufacture and supply of VAX-24 finished drug product.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under the Lonza Agreements, we will pay Lonza agreed-upon fees for its performance of manufacturing services and reimburse Lonza for its out-of-pocket costs associated with purchasing raw materials, plus a customary handling fee. Under each Lonza Agreement, we will own all right, title and interest in and to any and all Intellectual Property (as defined in each Lonza Agreement) that Lonza and/or its affiliates, the External Laboratories (as defined in each Lonza Agreement) or other contractors or agents of Lonza develops, conceives, invents, first reduces to practice or makes, solely or jointly with us or others, in the performance of the Services (as defined in each Lonza Agreement), to the extent such Intellectual Property (the New Customer Intellectual Property) is a direct derivative of or improvement to collectively the Product, Customer Materials, Customer Information and/or Customer Background Intellectual Property (all as defined in each Lonza Agreement). Lonza shall own all right, title and interest in Intellectual Property that Lonza and/or its Affiliates, the External Laboratories or other contractors or</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">27</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">agents of Lonza, solely or jointly with Customer, develops, conceives, invents or first reduces to practice or makes in the course of performance of the Services to the extent such Intellectual Property (New General Application Intellectual Property) (i) is reasonably capable of being used/applied to other projects and/or products in Lonza's or any third party process or (ii) is an improvement of, or direct derivative of, any Lonza Background Intellectual Property. Additionally, under each Lonza Agreement, Lonza grants us a non-exclusive, world-wide, fully paid-up, irrevocable, transferable license under all New General Application Intellectual Property, with the right to grant sublicenses, to research, develop, make, have made, use, sell and import VAX-24. We also grant Lonza a non-exclusive right to use New Customer Intellectual Property during the term of the agreement solely for the purposes of fulling its obligations to us.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have the right, at our cost, to receive a technology transfer under each Lonza Agreement or have an approved third-party manufacturer receive a technology transfer of any manufacturing process developed by Lonza. For any technology transfer that includes transfer of Lonza&#x2019;s Background Intellectual Property or Lonza Confidential Information (each as defined in the applicable Lonza agreement), we will be obligated to pay Lonza reasonable royalties and/or licensing fees.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Unless earlier terminated, each Lonza Agreement will remain in place for a period of five years. Either party has the right to terminate each Lonza Agreement upon a six-month notice period, provided that Lonza may not exercise such right until a specified future date. Either party has the right to terminate each Lonza Agreement if the other party commits a material breach under the applicable agreement and does not cure such breach within a given time period, for specified bankruptcy events or if a party receives a notice from the other party or otherwise becomes aware that a debarment, suspension, exclusion, sanction or declaration of ineligibility action has been brought against the other party, and we may terminate each Lonza Agreement for an extended force majeure event.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Competition</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Historically, the global vaccine market has been highly concentrated among a small number of multinational pharmaceutical companies. Pfizer Inc., Merck, GlaxoSmithKline plc and Sanofi S.A. together controlled approximately 75% of the global vaccine market. As a result of the COVID-19 pandemic, there have been a number of new entrants to the vaccines market, including multinational companies such as Johnson &amp; Johnson, and emerging biopharmaceutical companies. Other pharmaceutical and biotechnology companies, academic institutions, governmental agencies and public and private research institutions are also working towards new solutions given the continuing global unmet medical need.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Within the current pneumococcal vaccine market, Pfizer, Merck and GlaxoSmithKline have historically  dominated, with Pfizer&#x2019;s Prevnar 13, Merck&#x2019;s Pneumovax 23 and GlaxoSmithKline&#x2019;s Synflorix totaling a combined $6.7 billion in global pneumococcal vaccine sales in 2021 (approximately 79%, 14% and 7%, of such sales for these three products, respectively). While Prevnar 13 covers fewer pneumococcal strains than Pneumovax 23, it delivers a stronger and more durable immune response than Pneumovax 23. The current standard of care is Prevnar 13 in infants and, subsequent to the FDA approvals of Prevnar 20 and Vaxneuvance in adults in 2021, either Prevnar 20 alone or Vaxneuvance followed by Pneumovax 23 in adults. If approved, we believe VAX-24 may obtain an ACIP preferred recommendation and potentially replace both incumbents for pneumococcal disease prevention in both adult and pediatric populations because of its broader coverage.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Existing vaccine makers, as well as new entrants, are competing to develop the next generation of pneumococcal vaccines. Pfizer's Prevnar 20 was approved by the FDA in June 2021 for use in adults and Merck's Vaxneuvance was approved in July 2021 for use in adults. Sanofi and SK Chemicals have partnered to develop a 21-valent PCV. Separately, Affinivax and Astellas have partnered to develop an affinity-bound pneumococcal vaccine that includes 24 pneumococcal serotypes. We believe success will ultimately be based on the combination of immunogenicity, the broadest coverage of serotypes, safety and tolerability. Convenience and pricing may also be factors. Both Pfizer and Merck are in Phase 3 development in infants, and Affinivax has completed a Phase 2 study in adults. These vaccines may obtain FDA approval and commercially launch before VAX-24. However, if approved, we believe VAX-24 should compare favorably to these PCV candidates as a 24-valent alternative, based on our unique site-specific conjugation and carrier-sparing technology. We also believe VAX-XP has the potential to compete favorably in the PCV market based on its further expanded spectrum.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">28</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The competitive landscape for vaccine development for Group A Strep was dormant for more than three decades. However, the FDA lifted a 30-year ban on Group A Strep vaccine clinical trials in 2005, and research has slowly started to resurface in academic institutions. However, we are not aware of other Group A Strep vaccines in clinical development that would cover all strains of the bacteria. Additionally, we are not aware of any other vaccines under clinical development to treat periodontitis. We believe the success of our vaccine candidates in these areas will be based on potential efficacy, safety, tolerability, convenience and pricing. We are aware of some companies developing treatments for other diseases that target the same underlying pathogens that cause Group A Strep and periodontitis. For example, Cortexyme is developing an Alzheimer&#x2019;s treatment that targets P. gingivalis.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize vaccines that are safer, more effective, more convenient, less expensive or with a more favorable label than VAX-24, VAX-XP or any other vaccine we may develop. Many of the companies against which we compete have significantly greater financial resources, and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved drugs than we do.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Intellectual Property</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have developed, and are continuing to develop, a comprehensive intellectual property portfolio related to vaccine applications, including manufacturing, formulation and process applications as well as protection for our specific vaccine candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our success depends in part on our ability to obtain and maintain proprietary protection for our vaccine candidates, technology and know-how, to operate without infringing the proprietary rights of others and to prevent others from infringing our proprietary rights. Our policy is to seek to protect our proprietary position by, among other methods, pursuing and obtaining patent protection in the United States and in jurisdictions outside of the United States related to our proprietary technology, inventions, improvements and vaccine candidates that are important to the development and implementation of our business. Our patent portfolio is intended to cover our vaccine candidates and components thereof, their methods of use and processes for their manufacture, our proprietary reagents and assays and any other inventions that are commercially important to our business. We also rely on trademarks, trade secrets and know-how to develop and maintain our proprietary position.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Generally, issued patents are granted a term of 20 years from the earliest claimed non-provisional filing date. In certain instances, patent term can be adjusted to recapture a portion of delay by the U.S. Patent and Trademark Office, or USPTO, in examining the patent application or extended to account for term effectively lost as a result of the FDA regulatory review period, or both. In addition, we cannot provide any assurance that any patents will be issued from our pending or future applications or that any issued patents will adequately protect our vaccine candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our patent portfolio as of December 31, 2021 contains approximately one issued U.S. patent, four pending U.S. patent applications and three pending patent cooperation treaty applications that are solely owned by us, as well as certain foreign counterparts of a subset of these patent applications in foreign countries, including Australia, Brazil, Canada, China, India, Israel, Japan, South Korea, Taiwan, Mexico, New Zealand, the Philippines, Singapore, South Africa and countries within the European Patent Convention and the Eurasian Patent Organization. For our pneumococcal vaccines, these applications are directed to vaccine formulations, protein-antigen conjugates, methods of making protein-antigen conjugates and the promotion of immunogenicity using the protein-antigen conjugates and vaccines. For our Group A Strep vaccine, these patent applications are directed to vaccine formulations, protein-antigen conjugates, vaccines and components thereof, as well as processes for their manufacture. For our periodontitis vaccine, the patent and applications relate to vaccine formulations, protein antigens, and methods of using the vaccine. If issued, the 20-year term expiration dates of our patents will expire between 2037 and 2041, not including any extension of the patent term that may be available in certain jurisdictions. We continue to seek to maximize the scope of our patent protection for all our programs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition to patents, we also rely upon trademarks, trade secrets, know-how and continuing technological innovation to develop and maintain our competitive position. We maintain and are seeking both registered and common law trademarks. Common law trademark protection typically continues where and for as long as the mark is used. Registered trademarks continue in each country for as long as the trademark is registered.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">29</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We believe that we have certain know-how and trade secrets relating to our technology and vaccine candidates. We rely on trade secrets to protect certain aspects of our technology related to our current and future vaccine candidates. However, trade secrets can be difficult to protect. We seek to protect our proprietary information, including trade secrets, in part, by using confidentiality agreements with our commercial partners, collaborators, employees and consultants, and invention assignment agreements with our employees. We also have confidentiality agreements or invention assignment agreements with our commercial partners and selected consultants. These agreements may be breached, and we may not have adequate remedies for any breach. In addition, our trade secrets may otherwise become known or be independently discovered by competitors. We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining the physical security of our premises and physical and electronic security of our information technology systems. To the extent that our commercial partners, collaborators, employees and consultants use intellectual property owned by others in their work for us, disputes may arise as to the rights in related or resulting know-how and inventions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Obtaining patents does not guarantee our right to practice the patented technology or commercialize the patented product. Third parties may have or obtain rights to patents that could be used to prevent or attempt to prevent us from commercializing our vaccine candidates. If third parties prepare and file patent applications in the United States or other jurisdictions that also claim technology to which we have rights, we may have to participate in interference or derivation proceedings in the USPTO or similar proceedings in other jurisdictions to determine the priority of invention.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Sutro Biopharma Agreements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Sutro Biopharma is a clinical stage, publicly traded drug discovery, development and manufacturing company using precise protein engineering and rational design (enabled by Sutro Biopharma&#x2019;s proprietary XpressCF platform technology) to advance next-generation oncology therapeutics. Following our corporate formation, Vaxcyte acquired an exclusive license to Sutro Biopharma&#x2019;s proprietary cell-free protein synthesis platform, XpressCF, for the discovery, development and sale of vaccines for the treatment or prevention of infectious diseases, excluding cancer vaccines. Under a related supply agreement with Sutro Biopharma, we have an exclusive relationship in our field to buy extract and certain custom reagents for use in manufacturing the vaccine compositions covered by the exclusive license, which we use to produce our protein carriers and certain of our antigens. Sutro Biopharma will receive a 4% royalty on aggregate worldwide net sales of our vaccine products marketed for human health and a 2% royalty on such net sales of vaccines marketed for animal health.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Amended and Restated License Agreement with Sutro Biopharma</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are party to a license agreement with Sutro Biopharma, or the Sutro Biopharma License Agreement, which was originally entered into in October 2015.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under that agreement, we received an exclusive, worldwide, royalty-bearing license under Sutro Biopharma&#x2019;s patents and know-how relating to XpressCF to research, develop, use, sell, offer for sale, export, import and otherwise exploit vaccine compositions for the treatment and prophylaxis of infectious diseases, excluding cancer vaccines, such rights being sublicenseable, and to manufacture, or have manufactured by an approved contract manufacturing organization, such vaccine compositions from extracts supplied by Sutro Biopharma pursuant to the Sutro Biopharma Supply Agreement (as described below).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In consideration of the rights granted under the Sutro Biopharma License Agreement, we are obligated to pay Sutro Biopharma a 4% royalty on worldwide aggregate annual net sales of our vaccine products for human health and a 2% royalty on such net sales of vaccine products for animal health use. Such royalty rates are subject to specified reductions, including standard reductions for third-party payments and for expiration of relevant patent claims. We are also obligated to pay Sutro Biopharma any royalties due to Stanford University (the upstream licensor of Sutro Biopharma), to the extent the royalties payable by Sutro Biopharma to Stanford University are greater than the royalties payable by us to Sutro Biopharma. Royalties are payable on a vaccine composition-by-vaccine composition and country-by-country basis until the later of expiration of the last valid claim in the licensed patents covering such vaccine composition in such country and ten years after the first commercial sale of such vaccine composition. The latest expiration date of a licensed Sutro Biopharma patent application, if issued, would be 2036, subject to any adjustment or extension of patent term that may be available in a particular country. In addition,</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we are obligated to pay Sutro Biopharma a percentage of net sublicensing revenue received in the low teen percentages. In addition, in the event we sublicense our non-manufacturing rights under the Sutro Biopharma License Agreement before a specified date, we are obligated to pay Sutro Biopharma a percentage, in the low double-digits, of the sublicensing revenue we receive under such agreement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Sutro Biopharma License Agreement will remain in effect until terminated. The agreement may be terminated by either party for the other party&#x2019;s material breach uncured within 60 days&#x2019; notice, by us at will with 60 days&#x2019; notice, or by Sutro Biopharma if we challenge Sutro Biopharma&#x2019;s patents or if we undergo a change of control with a specified competitor of Sutro Biopharma.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In connection with our formation and the entry into the Sutro License, we issued to Sutro Biopharma 1,778,304 shares of common stock, valued at a price per share of $0.002 per share.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Supply Agreement with Sutro Biopharma</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are party to a supply agreement with Sutro Biopharma, or the Sutro Biopharma Supply Agreement, which is dated May 2018 and pursuant to which we purchase from Sutro Biopharma extract and custom reagents for use in manufacturing the non-clinical and Phase 1 and Phase 2 clinical supply of vaccine compositions utilizing the technology licensed under the Sutro License at prices not to exceed a specified percentage above Sutro Biopharma&#x2019;s fully burdened manufacturing cost.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Sutro Biopharma Supply Agreement will remain in effect until the later of July 31, 2021, or the date the parties enter into and commence activities under a separate agreement for the supply of extract and custom reagents for use in manufacturing vaccine compositions for Phase 3 and commercial purposes. In February 2021, we entered into an amendment to the Sutro Biopharma Supply Agreement to extend the term to July 31, 2022. The Sutro Biopharma Supply Agreement may be terminated by either party for the other party&#x2019;s material breach uncured within 60 days&#x2019; notice, by us at will with 60 days&#x2019; notice, or by mutual agreement of the parties. In December 2019, we exercised our right to require Sutro Biopharma to establish a second supplier for extract and custom reagents to support our anticipated clinical and commercial needs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">University of California, San Diego License Agreement</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are party to a license agreement with the University of California, San Diego, or the UCSD License, dated February 2019 whereby we are the exclusive licensee of an issued U.S. patent and pending U.S. patent application related to a non-cross-reactive Group A Strep carbohydrate antigen and methods of producing the antigen. We licensed this technology for the development of our Group A Strep vaccine candidate.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Upon execution of the UCSD License, we made an upfront payment of $10,000, and each year during the term we are obligated to pay an annual license maintenance fee in the single digit thousands. We are also obligated to pay UCSD up to approximately $1 million in development and regulatory milestone payments for each licensed product under the agreement. Additionally, we are obligated to pay UCSD a fixed royalty on net sales of licensed products in the low single digits. Such royalty rate is subject standard reductions for third-party payments. Royalties are payable until expiration of the last licensed patent. Additionally, in the event we sublicense commercial rights under the UCSD License, we are obligated to pay UCSD a percentage of all sublicensing revenue received, excluding any earned royalties or reimbursements of research and development expenses, of 20% up to a maximum of $2.5 million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are obligated to use commercially reasonable efforts to diligently develop, manufacture and sell licensed products and to achieve specified research and clinical development milestone events. If we are unable to meet our diligence obligations and do not agree with UCSD to modify such obligations or do not cure such obligations, then UCSD may terminate the license or convert the license to non-exclusive.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The UCSD License will remain in effect until the expiration of the last licensed patent. The UCSD patent and patent application, if issued, would expire in 2032, subject to any adjustment or extension of patent term</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">31</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">that may be available in the United States. The UCSD License may be terminated by us at will with 90 days&#x2019; notice or by UCSD for our breach uncured within 90 days&#x2019; notice or if we challenge the licensed patents.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Other Partners</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition to those listed above, we seek to partner with various academic, governmental and public or private research institutions as needed to advance the discovery or development of our vaccine candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Coverage and Reimbursement</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Sales of our products in the United States will depend, in part, on the extent to which the costs of the products are covered by third-party payors, such as government health programs, commercial insurance and managed health care organizations. The process for determining whether a third-party payor will provide coverage for a pharmaceutical or biological product is typically separate from the process for setting the price of such a product or for establishing the reimbursement rate that the payor will pay for the product once coverage is approved. As a result, a third-party payor&#x2019;s decision to provide coverage for a pharmaceutical or biological product does not imply that the reimbursement rate will be adequate. Certain ACA marketplace and other private payor plans are required to include coverage for certain preventative services, including vaccinations recommended by the ACIP without cost share obligations (i.e., co-payments, deductibles or co-insurance) for plan members. Children through 18 years of age without other health insurance coverage may be eligible to receive such vaccinations free-of-charge through the CDC&#x2019;s Vaccines for Children program. For Medicare beneficiaries, vaccines may be covered under either the Part B program or Part D depending on several criteria, including the type of vaccine and the beneficiary&#x2019;s coverage eligibility. If our vaccine candidates, once approved, are covered only under the Part D program, physicians may be less willing to use our products because of the claims adjudication costs and time related to the claims adjudication process and collection of co-payments associated with the Part D program.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Further, no uniform policy for coverage and reimbursement exists in the United States, and coverage and reimbursement can differ significantly from payor to payor. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement rates, but also have their own methods and approval process apart from Medicare determinations. As such, one third-party payor&#x2019;s decision to cover a particular medical product or service does not ensure that other payors will also provide coverage for the medical product or service or will provide coverage at an adequate reimbursement rate. Further, coverage policies and third party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products that receives regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Government Regulation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Government authorities in the United States, at the federal, state and local level, and other countries extensively regulate, among other things, the research, development, testing, safety, effectiveness, manufacture, quality control, approval, post-approval monitoring and reporting, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, marketing and export and import of products such as those we are developing. A new biological product must be licensed by the FDA through the approval of a BLA, before it may be legally marketed in the United States.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the United States, pharmaceutical products are regulated by the FDA under the Federal Food, Drug and Cosmetic Act and other laws, including, in the case of biologics, the Public Health Service Act, or PHS Act. We expect our products to be regulated by the FDA as biologics and to be reviewed by the FDA&#x2019;s Center for Biologics Evaluation and Research.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We anticipate our vaccine candidates will require the submission of a BLA and approval by the FDA before being marketed in the United States. Failure to comply with FDA requirements, both before and after product approval, may subject us or our partners, contract manufacturers and suppliers to administrative or judicial sanctions, including FDA refusal to approve applications, warning letters, product recalls, product seizures, total or partial suspension of production or distribution, fines and/or criminal prosecution.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">32</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The steps required before a biologic may be approved for marketing of an indication in the United States generally include:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">completion of preclinical laboratory tests, animal studies, formulation studies conducted in accordance with good laboratory practices and other applicable regulations; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">submission to the FDA of an IND application, which must be active before human clinical trial commencement; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">approval by an institutional review board, or IRB, or ethics committee at each clinical site before a clinical trial is commenced; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">completion of adequate and well-controlled human clinical trials in accordance with good clinical practice, or GCP, requirements to establish that the biological product is &#x201c;safe, pure and potent,&#x201d; which is analogous to the safety and efficacy approval standard for a chemical drug product for its intended use; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">preparation and submission to the FDA of a BLA for marketing approval that includes substantive evidence of safety, purity and potency from results of nonclinical testing and clinical trials; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">a determination by the FDA within 60 days of its receipt of a BLA to file the application for review; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">satisfactory completion of an FDA pre-approval inspection of the manufacturing facility or facilities at which the product is produced to assess compliance with applicable current good manufacturing practices, or cGMPs, to assure that the facilities, methods and controls are adequate to preserve the products identify, strength, quality and purity; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">potential FDA audit of the nonclinical and clinical trial sites that generated the data in support of the BLA; and </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">FDA review of the BLA and issuance of a biologics license, which is the approval necessary to market a vaccine. </span></div></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Before conducting studies in humans, laboratory evaluation of product chemistry, toxicity and formulation, as well as animal studies to assess the potential safety and efficacy of the biologic candidate, must be conducted. Preclinical toxicology studies in animals must be conducted in compliance with FDA regulations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The results of the preclinical tests, together with manufacturing information, known as CMC, and analytical data, are submitted to the FDA as part of an IND application. Some preclinical testing may continue even after the IND application is submitted. In addition to including the results of the preclinical testing, the IND application will also include a protocol detailing, among other things, the objectives of the clinical trial, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated if the first phase or phases of the clinical trial lend themselves to an efficacy determination. The IND application will automatically become effective 30 days after receipt by the FDA unless the FDA within the 30-day time period places the IND application on clinical hold because of safety concerns about the vaccine candidate or the conduct of the trial described in the clinical protocol included in the IND application. The IND application sponsor and the FDA must resolve any outstanding concerns before clinical trials can begin. Submission of an IND application therefore may or may not result in FDA authorization to begin a clinical trial.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">All clinical trials for new drugs and biologics must be conducted under the supervision of one or more qualified principal investigators in accordance with GCPs, which include the requirement that all research subjects provide their informed consent for their participation in any clinical trial. They must be conducted under protocols detailing, among other things, the objectives of the applicable phase of the trial, dosing procedures, research subject selection, exclusion criteria and the safety and effectiveness criteria to be evaluated. Each protocol must be</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">33</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">submitted to the FDA as part of the IND application, and progress reports detailing the status of the clinical trials must be submitted to the FDA annually. Sponsors must also report to the FDA within specified timeframes, serious and unexpected adverse reactions, any clinically significant increase in the rate of a serious suspected adverse reaction over that listed in the protocol or investigator&#x2019;s brochure or any findings from other studies or animal or in vitro testing that suggest a significant risk in humans exposed to the vaccine candidate. An IRB at each institution participating in the clinical trial must review and approve the protocol before a clinical trial commences at that institution, approve the information regarding the trial and the consent form that must be provided to each research subject or the subject&#x2019;s legal representative and monitor the trial until completed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Clinical trials are typically conducted in three sequential phases, but the phases may overlap, and different trials may be initiated with the same vaccine candidate within the same phase of development in similar or differing patient populations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Phase 1: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Clinical trials may be conducted in a limited number of patients or healthy volunteers, as appropriate. The vaccine candidate is initially tested for safety and immunogenicity. </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Phase 2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">: The vaccine candidate is evaluated in a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance, optimal dosage and dosing schedule. </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Phase 3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">: Clinical trials are undertaken to further evaluate dosage, clinical efficacy, potency and safety in an expanded patient population at geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk/benefit ratio of the product and provide an adequate basis for product labeling. </span></div></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In some cases, the FDA may require, or companies may voluntarily pursue, additional clinical trials after a product is approved to gain more information about the product. These so-called Phase 4 studies may also be made a condition to approval of the BLA. These clinical trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication, particularly for long-term safety follow-up.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During all phases of clinical development, regulatory agencies require extensive monitoring and auditing of all clinical activities, clinical data and clinical trial investigators. Annual progress reports detailing the results of the clinical trials must be submitted to the FDA. Written IND application safety reports must be promptly submitted to the FDA and the investigators for serious and unexpected adverse events, any findings from other studies, tests in laboratory animals or in vitro testing that suggest a significant risk for human subjects or any clinically relevant increase in the rate of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. The sponsor must submit an IND application safety report within 15 calendar days after the sponsor determines that the information qualifies for reporting. The sponsor also must notify the FDA of any unexpected fatal or life-threatening suspected adverse reaction within seven calendar days after the sponsor&#x2019;s initial receipt of the information. Phase 1, Phase 2 and Phase 3 clinical trials may not be completed successfully within any specified period, if at all. The FDA or the sponsor or its data safety monitoring board may suspend a clinical trial at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#x2019;s requirements or if the biological product has been associated with unexpected serious harm to patients.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Assuming successful completion of all required testing in accordance with applicable regulatory requirements, the results of the preclinical studies and clinical trials, together with other detailed information, including information on the manufacture and composition of the vaccine candidate, are submitted to the FDA as part of a BLA requesting approval to market the vaccine candidate for a proposed indication or indications. The BLA must include all relevant data available from preclinical and clinical trials, including negative or ambiguous results as well as positive findings, together with detailed information relating to the product&#x2019;s CMC and proposed labeling, among other things. Under the Prescription Drug User Fee Act, the fees payable to the FDA for reviewing a BLA, as well as annual program user fees for approved products, can be substantial but are subject to certain limited deferrals, waivers and reductions that may be available. Additionally, no user fees are assessed on BLAs for</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">34</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">products designated as orphan drugs, unless the product also includes a non-orphan indication. Each BLA submitted to the FDA for approval is reviewed for administrative completeness and reviewability within 60 days following receipt by the FDA of the application. If the BLA is found complete, the FDA will file the BLA, triggering a full review of the application. The FDA may refuse to file any BLA that it deems incomplete or not properly reviewable at the time of submission. The FDA&#x2019;s established goal is to review 90% of priority BLAs within six months after the application is accepted for filing and 90% of standard BLAs within 10 months of the acceptance date, whereupon a review decision is to be made. Priority review will direct overall attention and resources to the evaluation of applications for products that, if approved, would be significant improvements in the safety or effectiveness of the treatment, diagnosis or prevention of serious conditions. In both standard and priority reviews, the review process is often significantly extended by FDA requests for additional information or clarification. The FDA reviews a BLA to determine, among other things, whether a product is safe, pure and potent and the facility in which it is manufactured, processed, packed or held meets standards designed to assure the product&#x2019;s continued safety, purity and potency. The FDA may also convene an advisory committee to provide clinical insight on application review questions. The FDA is not bound by recommendations of an advisory committee, but it considers such recommendations when making decisions regarding approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Before approving a BLA, the FDA will typically inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP and adequate to assure consistent production of the product within required specifications. Additionally, before approving a BLA, the FDA will typically inspect one or more clinical sites to assure compliance with GCP. If the FDA determines that the application, manufacturing process or manufacturing facilities are not acceptable, it will outline the deficiencies in the submission and often will request additional testing or information. Notwithstanding the submission of any requested additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">After the FDA evaluates a BLA and conducts inspections of manufacturing facilities where the investigational product and/or its drug substance will be produced, the FDA may issue an approval letter or a Complete Response Letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. A Complete Response Letter will describe all of the deficiencies that the FDA has identified in the BLA, except that where the FDA determines that the data supporting the application are inadequate to support approval, the FDA may issue the Complete Response Letter without first conducting required inspections, testing submitted product lots and/or reviewing proposed labeling. In issuing the Complete Response Letter, the FDA may recommend actions that the applicant might take to place the BLA in condition for approval, including requests for additional information or clarification. The FDA may delay or refuse approval of a BLA if applicable regulatory criteria are not satisfied, require additional testing or information and/or require post-marketing testing and surveillance to monitor the safety or efficacy of a product.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If a product is approved, the approval may impose limitations on the uses for which the product may be marketed, may require that warning statements be included in the product labeling, may require that additional studies be conducted following approval as a condition of the approval and may impose restrictions and conditions on product distribution, prescribing or dispensing in the form of a Risk Evaluation and Mitigation Strategy, or REMS, or otherwise limit the scope of any approval. A REMS is a safety strategy to manage a known or potential serious risk associated with a medicine and to enable patients to have continued access to such medicines by managing their safe use, and could include medication guides, physician communication plans or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. The FDA also may condition approval on, among other things, changes to proposed labeling or the development of adequate controls and specifications. In most cases, the FDA must approve a BLA supplement or a new BLA before a product may be marketed for other uses or before specific manufacturing or other changes may be made to the approved product. As a condition of approval, the FDA may also require one or more Phase 4 post-market studies and surveillance to further assess and monitor the product&#x2019;s safety and effectiveness after commercialization, and may limit further marketing of the product based on the results of these post-marketing studies. Also, product approvals may be withdrawn if compliance with regulatory standards is not maintained or if safety or manufacturing problems occur following initial marketing. In addition, new government requirements may be established that could delay or prevent regulatory approval of our vaccine candidates under development.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">35</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Both before and after the FDA approves a product, the manufacturer and the holder or holders of the BLA for the product are subject to comprehensive regulatory oversight. For example, quality control and manufacturing procedures must conform, on an ongoing basis, to cGMP requirements, and the FDA periodically inspects manufacturing facilities to assess compliance with cGMPs. Accordingly, manufacturers must continue to spend time, money and effort to maintain cGMP compliance.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Post-Approval Requirements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Any drug products manufactured or distributed by us or our partners pursuant to FDA approvals will be subject to pervasive and continuing regulation by the FDA, including, among other things, record-keeping requirements, reporting of adverse experiences with the drug, providing the FDA with updated safety and efficacy information, distribution requirements, complying with individual electronic records and signature requirements and complying with FDA promotion and advertising requirements. Once approval is granted, the FDA may withdraw the approval if compliance with regulatory standards is not maintained or if problems occur after the product reaches the market. After approval, most changes to the approved product, such as adding new indications, specific manufacturing changes and additional labeling claims, are subject to further FDA review and approval. Biologic manufacturers, their subcontractors and other entities involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and certain state agencies and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP regulations and other laws and regulations. Changes to the manufacturing process are strictly regulated and, depending on the significance of the change, may require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting requirements upon us and any third-party manufacturers that we may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain compliance with cGMP and other aspects of regulatory compliance.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Discovery of previously unknown problems, including adverse events of unanticipated severity or frequency, or the failure to comply with the applicable regulatory requirements may result in restrictions on the marketing of a product or withdrawal of the product from the market as well as possible civil or criminal sanctions. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or after approval, may subject an applicant or manufacturer to administrative or judicial civil or criminal sanctions and adverse publicity. FDA sanctions could include refusal to approve pending applications, withdrawal or suspension of an approval or license, clinical holds, warning or untitled letters, product recalls, product seizures, safety alerts, Dear Healthcare Provider letters, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, mandated corrective advertising or communications with doctors, debarment, restitution, disgorgement of profits, consent decrees or civil or criminal penalties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The FDA strictly regulates labeling, advertising, promotion and other types of information on products that are placed on the market and imposes requirements and restrictions on drug manufacturers, such as those related to direct-to-consumer advertising, the prohibition on promoting products for uses or inpatient populations that are not described in the product&#x2019;s approved labeling (known as &#x201c;off-label use&#x201d;), industry-sponsored scientific and educational activities and promotional activities involving the internet. Failure to comply with these requirements can result in, among other things, adverse publicity, warning letters, corrective advertising and potential civil and criminal penalties. Physicians may prescribe legally available products for uses that are not described in the product&#x2019;s labeling and that differ from those tested by us and approved by the FDA. Such off-label uses are common across medical specialties. Physicians may believe that such off-label uses are the best treatment for many patients in varied circumstances. The FDA does not regulate the behavior of physicians in their choice of treatments. The FDA does, however, restrict the manufacturer&#x2019;s communications on the subject of off-label use of their products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Disclosure of Clinical Trial Information</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Sponsors of clinical trials of FDA-regulated products, including biological products, are required to register and disclose certain clinical trial information on clinicaltrials.gov. Information related to the product, patient population, phase of the investigation, trial sites and investigators and other aspects of the clinical trial is then made public as part of the registration. Sponsors are also obligated to discuss the results of their clinical trials after</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">36</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">completion. Disclosure of the results of these trials can be delayed in certain circumstances for up to two years after the date of completion of the trial. Competitors may use this publicly available information to gain knowledge regarding the progress of development programs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Additional Controls for Biologics</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">To help reduce the increased risk of the introduction of adventitious agents, the PHS Act emphasizes the importance of manufacturing controls for products whose attributes cannot be precisely defined. The PHS Act also provides authority to the FDA to immediately suspend licenses in situations where there exists a danger to public health, to prepare or procure products in the event of shortages and critical public health needs, and to authorize the creation and enforcement of regulations to prevent the introduction or spread of communicable diseases in the United States and between states.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">After a BLA is approved, the product will also be subject to official lot release as a condition of approval. As part of the manufacturing process, the manufacturer is required to perform specific tests on each lot of the product before it is released for distribution. If the product is subject to an official release by the FDA, the manufacturer submits samples of each lot of product to the FDA together with a release protocol showing a summary of the history of the manufacture of the lot and the results of all the manufacturer&#x2019;s tests performed on the lot. The FDA may also perform specific confirmatory tests on lots of some products, such as vaccines, before releasing the lots for distribution by the manufacturer. In addition, the FDA conducts laboratory research related to the regulatory standards on the safety, purity, potency and effectiveness of biological products. As with drugs, after approval of biologics, manufacturers must address any safety issues that arise, are subject to recalls or a halt in manufacturing and are subject to periodic inspection after approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Expedited Development and Review Programs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A sponsor may seek approval of its vaccine candidate under programs designed to accelerate the FDA&#x2019;s review and approval of new drugs and biological products that meet certain criteria. Specifically, new drugs and biological products are eligible for fast track designation if they are intended to treat a serious or life-threatening disease or condition and demonstrate the potential to address unmet medical needs for the disease or condition. For a fast track product, the FDA may consider sections of the BLA for review on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the application, the FDA agrees to accept sections of the application and determines that the schedule is acceptable and the sponsor pays any required user fees upon submission of the first section of the application. A fast track designated vaccine candidate may also qualify for priority review, under which the FDA sets the target date for FDA action on the BLA at six months after the FDA accepts the application for filing. Priority review is granted when there is evidence that the proposed product would be a significant improvement in the safety or effectiveness of the treatment, diagnosis or prevention of a serious disease or condition. If criteria are not met for priority review, the application is subject to the standard FDA review period of 10 months after FDA accepts the application for filing. Priority review designation does not change the scientific/medical standard for approval or the quality of evidence necessary to support approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under the accelerated approval program, the FDA may approve a BLA on the basis of either a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity or prevalence of the condition and the availability or lack of alternative treatments. Post-marketing studies or completion of ongoing studies after marketing approval are generally required to verify the biologic&#x2019;s clinical benefit in relationship to the surrogate endpoint or ultimate outcome in relationship to the clinical benefit. In addition, the FDA currently requires as a condition for accelerated approval pre-approval of promotional materials, which could adversely impact the timing of the commercial launch of the product. FDA may withdraw approval of a drug or indication approved under accelerated approval if, for example, the confirmatory trial fails to verify the predicted clinical benefit of the product.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, a sponsor may seek FDA designation of its vaccine candidate as a breakthrough therapy if the vaccine candidate is intended to treat a serious or life-threatening disease or condition and preliminary clinical</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">37</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">evidence indicates that the therapy may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. If the FDA designates a product as a breakthrough therapy, it may take actions appropriate to expedite the development and review of the application, which may include holding meetings with the sponsor and the review team throughout the development of the therapy; providing timely advice to, and interactive communication with, the sponsor regarding the development of the drug to ensure that the development program to gather the nonclinical and clinical data necessary for approval is as efficient as practicable; involving senior managers and experienced review staff, as appropriate, in a collaborative, cross-disciplinary review; assigning a cross-disciplinary project lead for the FDA review team to facilitate an efficient review of the development program and to serve as a scientific liaison between the review team and the sponsor; and considering alternative clinical trial designs when scientifically appropriate, which may result in smaller trials or more efficient trials that require less time to complete and may minimize the number of patients exposed to a potentially less efficacious treatment. Breakthrough therapy designation comes with all of the benefits of fast track designation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Even if a drug or biologic qualifies for one or more of these programs, the FDA may later decide that the drug no longer meets the conditions for qualification or that the time period for FDA review or approval will be shortened.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Biosimilars and Exclusivity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively, ACA, includes a subtitle called the Biologics Price Competition and Innovation Act of 2009, or BPCIA, which created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an FDA-licensed reference biological product. The FDA has issued several guidance documents outlining an approach to review and approval of biosimilars. Biosimilarity, which requires that there be no clinically meaningful differences between the biological product and the reference product in terms of safety, purity and potency, can be shown through analytical studies, animal studies and a clinical trial or trials. Interchangeability requires that a product is biosimilar to the reference product and the product must demonstrate that it can be expected to produce the same clinical results as the reference product in any given patient and, for products that are administered multiple times to an individual, the biologic and the reference biologic may be alternated or switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic. However, complexities associated with the larger, and often more complex, structures of biological products, as well as the processes by which such products are manufactured, pose significant hurdles to implementation of the abbreviated approval pathway that are still being worked out by the FDA.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed. During this 12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing that applicant&#x2019;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of its product. The BPCIA also created certain exclusivity periods for biosimilars approved as interchangeable products. A biological product can also obtain pediatric market exclusivity in the United States. Pediatric exclusivity, if granted, adds six months to existing exclusivity periods and patent terms. This six-month exclusivity, which runs from the end of other exclusivity protection or patent term, may be granted based on the voluntary completion of a pediatric study in accordance with an FDA-issued &#x201c;Written Request&#x201d; for such a study.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The BPCIA is complex and continues to be interpreted and implemented by the FDA. In addition, government proposals have sought to reduce the 12-year reference product exclusivity period. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. As a result, the ultimate impact and implementation of the BPCIA are subject to significant uncertainty.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">38</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">United States Healthcare Reform</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the United States, there has been and continues to be, several legislative and regulatory changes and proposed changes regarding the healthcare system that could, among other things, prevent or delay marketing approval of vaccine candidates, restrict or regulate post-approval activities and affect the profitable sale of vaccine candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Among policymakers and payors in the United States, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives. For example, in March 2010, the ACA was passed, which substantially changed the way healthcare is financed by both the government and private insurers and significantly impacts the U.S. pharmaceutical industry. The ACA, among other things: (1) increased the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program and extended the rebate program to individuals enrolled in Medicaid managed care organizations; (2) created a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for certain drugs and biologics that are inhaled, infused, instilled, implanted or injected; (3) established an annual, nondeductible fee on any entity that manufactures or imports certain specified branded prescription drugs and biologic agents apportioned among these entities according to their market share in specific government healthcare programs; (4) expanded the eligibility criteria for Medicaid programs; (5) created a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; (6) created a new Medicare Part D coverage gap discount program, in which manufacturers must now agree to offer 70% point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#x2019;s outpatient drugs to be covered under Medicare Part D; and (7) established a Center for Medicare &amp; Medicaid Innovation at the Centers for Medicare &amp; Medicaid Services, or CMS, to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drugs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">There have been judicial and political challenges to certain aspects of the ACA. By way of example, the Tax Cuts and Jobs Act of 2017, or the Tax Act, was signed into law and included a provision repealing, effective January 1, 2019, the tax-based shared responsibility payment imposed by the ACA on specific individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#x201c;individual mandate.&#x201d; The Bipartisan Budget Act of 2018, among other things, amends the ACA, effective January 1, 2019, to close the coverage gap in most Medicare drug plans, commonly referred to as the &#x201c;donut hole.&#x201d; On June 17, 2021, the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the ACA is unconstitutional in its entirety because the &#34;individual mandate&#34; was repealed by Congress. Thus, the ACA will remain in effect in its current form. Prior to the U.S. Supreme Court ruling on January 28, 2021, President Biden issued an executive order that initiated a special enrollment period for purposes of obtaining health insurance coverage through the ACA marketplace. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. It is also unclear how the Supreme Court ruling, other such litigation and the healthcare reform measures of the Biden administration will impact the ACA and our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other legislative changes have been proposed and adopted since the ACA was enacted. For example, on August 2, 2011, the Budget Control Act of 2011 was signed into law, which, among other things, resulted in aggregate reductions of Medicare payments to providers of 2% per fiscal year, which went into effect on April 1, 2013 and, due to subsequent legislative amendments to the statute, including the Infrastructure Investment and Jobs Act, will remain in effect through 2031, with the exception of a temporary suspension from May 1, 2020 through March 31, 2022, unless additional Congressional action is taken. Under current legislation, the actual reduction in Medicare payments will vary from 1% in 2022 to up to 3% in the final fiscal year of this sequester. On January 2, 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, reduced Medicare payments to several providers, including hospitals, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">39</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Moreover, there has recently been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries, presidential executive orders and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs and reform government program reimbursement methodologies for drug products. At the federal level, the Trump administration used several means to propose or implement drug pricing reform, including through federal budget proposals, executive orders and policy initiatives. For example, on July 24, 2020 and September 13, 2020, President Trump announced several executive orders related to prescription drug pricing that seek to implement several of the administration's proposals. As a result, the FDA concurrently released a final rule and guidance in September providing pathways for states to build and submit importation plans for drugs from Canada. Further, on November 20, 2020, the Department of Health and Human Services, or HHS, finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The implementation of the rule has been delayed by the Biden administration from January 1, 2022 to January 1, 2023 in response to ongoing litigation. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers, the implementation of which have also been delayed pending review by the Biden administration until January 1, 2023. On November 20, 2020, CMS issued an interim final rule implementing President Trump&#x2019;s Most Favored Nation executive order, which would tie Medicare Part B payments for certain physician-administered drugs to the lowest price paid in other economically advanced countries, effective January 1, 2021. As a result of litigation challenging the Most Favored Nation model, on December 27, 2021, CMS published a final rule that rescinded the Most Favored Nation model interim final rule. In July 2021, the Biden administration released an executive order, &#x201c;Promoting Competition in the American Economy,&#x201d; with multiple provisions aimed at prescription drugs. In response to Biden&#x2019;s executive order, on September 9, 2021, HHS released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform and sets out a variety of potential legislative policies that Congress could pursue as well as potential administrative actions HHS can take to advance these principles. No legislation or administrative actions have been finalized to implement these principles. In addition, Congress is considering drug pricing as part of other reform initiatives. However, it is unclear whether these or similar policy initiatives will be implemented in the future. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on specific product access and marketing cost disclosure and transparency measures and, in some cases, designed to encourage importation from other countries and bulk purchasing. Further, it is possible that additional government action is taken in response to the COVID-19 pandemic.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">United States Healthcare Fraud and Abuse Laws and Compliance Requirements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Federal and state healthcare laws and regulations restrict certain business practices in the biopharmaceutical industry, including anti-kickback and false claims laws and regulations, data privacy and security laws and regulations and transparency laws and regulations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The federal Anti-Kickback Statute prohibits, among other things, individuals or entities from knowingly and willfully offering, paying, soliciting or receiving remuneration, directly or indirectly, overtly or covertly, in cash or in-kind to induce or in return for purchasing, leasing, ordering or arranging for or recommending the purchase, lease or order of any item or service reimbursable under Medicare, Medicaid or other federal healthcare programs. A person or entity does not need to have actual knowledge of this statute or specific intent to violate it in order to have committed a violation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The federal civil and criminal false claims laws, including the civil False Claims Act, and civil monetary penalties laws, prohibit, among other things, any individual or entity from knowingly presenting, or causing to be presented, a false claim for payment to the federal government or knowingly making, using or causing to be made or used a false record or statement material to a false or fraudulent claim to the federal government. Private individuals, commonly known as &#x201c;whistleblowers,&#x201d; can bring civil False Claims Act qui tam actions, on behalf of the government and such individuals and may share in amounts paid by the entity to the government in recovery or settlement. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">40</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, created additional federal civil and criminal statutes that prohibit, among other things, knowingly and willfully executing a scheme to defraud any healthcare benefit program. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. In addition, HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, and their implementing regulations, imposes specific requirements relating to the privacy, security and transmission of protected health information on HIPAA covered entities, which include certain healthcare providers, health plans and healthcare clearinghouses and their business associates and covered subcontractors who conduct certain activities for or on their behalf involving protected health information on their behalf.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The federal Physician Payments Sunshine Act requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#x2019;s Health Insurance Program, with specific exceptions, to report annually to CMS information related to payments or other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), other healthcare professionals (such as physician assistants and nurse practitioners) and teaching hospitals, and applicable manufacturers and applicable group purchasing organizations to report annually to CMS ownership and investment interests held by physicians and their immediate family members. Similar state, local and foreign healthcare laws and regulations may also restrict business practices in the pharmaceutical industry, such as state anti-kickback and false claims laws, which may apply to business practices, including but not limited to, research, distribution, sales and marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers, or by patients themselves; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#x2019;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws and regulations that require drug manufacturers to file reports relating to pricing and marketing information or which require tracking gifts and other remuneration and items of value provided to physicians, other healthcare providers and entities; state and local laws that require the registration of pharmaceutical sales representatives; and state and local laws governing the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Efforts to ensure compliance with applicable healthcare laws and regulations can involve substantial costs. Violations of healthcare laws can result in significant penalties, including the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, disgorgement, individual imprisonment, possible exclusion from participation in Medicare, Medicaid and other U.S. healthcare programs, integrity oversight and reporting obligations, contractual damages, reputational harm, diminished profits and future earnings and curtailment or restructuring of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Foreign Regulation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition to regulations in the United States, we expect to be subject to a variety of foreign regulations governing clinical trials and commercial sales and distribution of our vaccine candidates. Whether or not we obtain FDA approval for a vaccine candidate, we must obtain approval from the comparable regulatory authorities of foreign countries or economic areas, such as the European Union, before we may commence clinical trials or market products in those countries or areas. The approval process and requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary greatly from place to place, and the time may be longer or shorter than that required for FDA approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Certain countries outside of the United States have a process that requires the submission of a clinical trial application, much like an IND prior to the commencement of human clinical trials. In Europe, for example, a clinical trial application, or CTA, must be submitted to the competent national health authority and to independent ethics committees in each country in which a company intends to conduct clinical trials. Once the CTA is approved in accordance with a country&#x2019;s requirements, clinical trial development may proceed in that country. In all cases, the clinical trials must be conducted in accordance with GCPs and other applicable regulatory requirements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The requirements and process governing the conduct of clinical trials, product licensing, pricing and reimbursement vary from country to country. In all cases, the clinical trials are conducted in accordance with GCP</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">41</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under European Union regulatory systems, a company may submit marketing authorization applications either under a centralized or decentralized procedure. The centralized procedure is compulsory for medicinal products produced by biotechnology or those medicinal products containing new active substances for specific indications such as the treatment of AIDS, cancer, neurodegenerative disorders, diabetes, viral diseases and designated orphan medicines, and optional for other medicines which are highly innovative. Under the centralized procedure, a marketing application is submitted to the European Medicines Agency, or EMA, where it will be evaluated by the Committee for Medicinal Products for Human Use, and a favorable opinion typically results in the grant by the European Commission of a single marketing authorization that is valid for all European Union member states within 67 days of receipt of the opinion. The initial marketing authorization is valid for five years, but once renewed is usually valid for an unlimited period.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">To market a medicinal product in the European Economic Area, or EEA, (which is comprised of the 28 Member States of the EU plus Norway, Iceland and Liechtenstein), we must obtain a Marketing Authorization, or MA. There are two types of marketing authorizations:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Community MA, which is issued by the European Commission through the Centralized Procedure, based on the opinion of the Committee for Medicinal Products for Human Use of the EMA, and which is valid throughout the entire territory of the European Economic Area, or EEA. The Centralized Procedure is mandatory for certain types of products, such as biotechnology medicinal products, orphan medicinal products, advanced therapy products and medicinal products containing a new active substance indicated for the treatment certain diseases, such as AIDS, cancer, neurodegenerative disorders, diabetes, auto-immune and viral diseases. The Centralized Procedure is optional for products containing a new active substance not yet authorized in the EEA, or for products that constitute a significant therapeutic, scientific or technical innovation or which are in the interest of public health in the EU; and </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">National MAs, which are issued by the competent authorities of the Member States of the EEA and only cover their respective territory, are available for products not falling within the mandatory scope of the Centralized Procedure. Where a product has already been authorized for marketing in a Member State of the EEA, this National MA can be recognized in another Member State through the Mutual Recognition Procedure. If the product has not received a National MA in any Member State at the time of application, it can be approved simultaneously in the various Member States through the Decentralized Procedure. </span></div></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under the above-described procedures, before granting the MA, the EMA, or the competent authorities of the Member States of the EEA make an assessment of the risk-benefit balance of the product on the basis of scientific criteria concerning its quality, safety and efficacy.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If we fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Additional Regulation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are also subject to regulation under the Occupational Safety and Health Act, the Environmental Protection Act, the Toxic Substances Control Act, the Resource Conservation and Recovery Act and other present and potential federal, state or local regulations. These and other laws govern our use, handling and disposal of various biological and chemical substances used in, and waste generated by our operations. Our research and development involve the controlled use of hazardous materials, chemicals, bacteria and viruses. Although we believe that our safety procedures for handling and disposing of such materials comply with the standards prescribed by state and federal regulations, the risk of accidental contamination or injury from these materials cannot be</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">42</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">completely eliminated. In the event of such an accident, we could be held liable for any damages that result and any such liability could exceed our resources.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">There have been a number of federal and state proposals during the last few years regarding the pricing of pharmaceutical and biological products, government control and other changes to the healthcare system of the United States. It is uncertain what legislative proposals will be adopted or what actions federal, state or private payors for medical goods and services may take in response to any healthcare reform proposals or legislation. We cannot predict the effect medical or healthcare reforms may have on our business, and no assurance can be given that any such reforms will not have a material adverse effect.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Privacy and Data Protection Laws</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are also or may become subject to numerous data privacy and security obligations, including federal, state, local, and foreign laws, regulations, guidance, and industry standards related to data privacy, security, and the protection of health-related and other personal information. Such obligations may include, without limitation, the Federal Trade Commission Act, the California Consumer Privacy Act of 2018 (&#x201c;CCPA&#x201d;), the European Union&#x2019;s General Data Protection Regulation 2016/679 (&#x201c;EU GDPR&#x201d;), and the EU GDPR as it forms part of United Kingdom (&#x201c;UK&#x201d;) law by virtue of section 3 of the European Union (Withdrawal) Act 2018 (&#x201c;UK GDPR&#x201d;), the ePrivacy Directive. In addition, several states within the United States have enacted or proposed data privacy laws. For example, Virginia passed the Consumer Data Protection Act, and Colorado passed the Colorado Privacy Act.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">European data privacy and security laws (including the EU GDPR and UK GDPR) impose significant and complex compliance obligations on entities that are subject to those laws. For example, the EU GDPR applies to any company established in the European Economic Area (&#x201c;EEA&#x201d;) and to companies established outside the EEA that process personal data in connection with the offering of goods or services to data subjects in the EEA or the monitoring of the behavior of data subjects in the EEA. These obligations may include limiting personal data processing to only what is necessary for specified, explicit, and legitimate purposes; requiring a legal basis for personal data processing; requiring the appointment of a data protection officer in certain circumstances; increasing transparency obligations to data subjects; requiring data protection impact assessments in certain circumstances; limiting the collection and retention of personal data; increasing rights for data subjects; formalizing a heightened and codified standard of data subject consents; requiring the implementation and maintenance of technical and organizational safeguards for personal data; mandating notice of certain personal data breaches to the relevant supervisory authority(ies) and affected individuals; and mandating the appointment of representatives in the UK and/or the EU in certain circumstances. The EU GDPR allows EU member states to make new laws and regulations further limiting the processing of genetic, biometric, or health data. Failure to comply with the requirements of GDPR and the applicable national data protection laws of the EU member states may result in fines of up to &#x20ac;20,000,000 or up to 4% of the total worldwide annual turnover of the preceding financial year, whichever is higher, and other administrative penalties.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> See the section titled &#x201c;Risks Related to Government Regulation&#x201d; for additional information about the laws and regulations to which we are or may become subject to and about the risks to our business associated with such laws and regulations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Employees &amp; Human Capital</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, we had 89 full-time employees, 19 of whom have Ph.D. degrees. None of our employees are represented by labor unions or covered by collective bargaining agreements. We consider our relationship with our employees to be good.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our human capital resources objectives include, as applicable, identifying, recruiting, retaining, incentivizing and integrating our existing and additional employees. The principal purposes of our equity incentive plans are to attract, retain and motivate selected employees and directors through the granting of stock-based compensation awards.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">43</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Corporate and Other Information</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are headquartered in San Carlos, California. We were incorporated in the state of Delaware on November 27, 2013 as Sutrovax, Inc. and we changed our name to Vaxcyte, Inc. in May 2020. Our website is located at </span><span><span style="background-color:rgba(0,0,0,0);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">https://www.vaxcyte.com</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K including their exhibits, proxy and information statements, and amendments to those reports filed or furnished pursuant to Section 13(a), 14, and 15(d) of the Securities Exchange Act of 1934, as amended, or the Exchange Act, are available through the &#x201c;Investors&#x201d; portion of our website free of charge as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. Information on our website is not part of this Annual Report on Form 10-K or any of our other securities filings unless specifically incorporated herein or therein by reference. In addition, our filings with the SEC may be accessed through the SEC&#x2019;s website at </span><span><span style="background-color:rgba(0,0,0,0);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">http://www.sec.gov</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. All statements made in any of our securities filings, including all forward-looking statements or information, are made as of the date of the document in which the statement is included, and we do not assume or undertake any obligation to update any of those statements or documents unless we are required to do so by law.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">44</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_1a_risk_factors"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 1A. Ris</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">k Factors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">RISK FACTORS</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our business involves significant risks, some of which are described below. You should carefully consider the risks described below, as well as the other information in this Annual Report on Form 10-K, including &#x201c;Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations&#x201d; and the financial statements and the related notes. Many of the following risks and uncertainties are, and will be, exacerbated by the COVID-19 pandemic and any worsening of the global business and economic environment as a result. The occurrence of any of the events or developments described below could harm our business, financial condition, results of operations and growth prospects. In such an event, the market price of our common stock could decline and you may lose all or part of your investment. Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations. This Annual Report on Form 10-K also contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in the forward-looking statements as a result of factors that are described below and elsewhere in this Annual Report on Form 10-K.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Risks Related to Our Financial Position and Capital Needs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We are in the early stages of vaccine development and have a very limited operating history and no products approved for commercial sale, which may make it difficult for you to evaluate the success of our business to date and to assess our future viability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">To date, we have devoted substantially all of our resources to performing research and development, undertaking preclinical studies and enabling manufacturing activities in support of our product development efforts, acquiring and developing our technology and vaccine candidates, organizing and staffing our company, performing business planning, establishing our intellectual property portfolio and raising capital to support and expand such activities. As an organization, we have not yet demonstrated an ability to successfully complete clinical development, obtain regulatory approvals, manufacture a commercial-scale product or conduct sales and marketing activities necessary for successful commercialization or arrange for a third party to conduct these activities on our behalf. Consequently, any predictions about our future success or viability may not be as accurate as they could be if we had a longer operating history.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our current vaccine candidate pipeline includes four preclinical programs. We may encounter unforeseen expenses, difficulties, complications, delays and other known or unknown factors in achieving our business objectives, including with respect to our vaccine candidates. We will need to transition at some point from a company with a research and development focus to a company capable of supporting commercial activities. We may not be successful in such a transition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We have incurred significant net losses since inception and anticipate that we will continue to incur substantial net losses for the foreseeable future. We currently have no source of product revenue and may never achieve profitability. Our stock is a highly speculative investment.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are a clinical-stage biotechnology vaccine company that was incorporated in November 2013. Investment in clinical-stage companies and vaccine development is highly speculative because it entails substantial upfront capital expenditures and significant risk that any potential vaccine candidate will not gain regulatory approval or become commercially viable. We do not have any products approved for sale and have not generated any revenue from product sales. As a result, we are not profitable and have incurred losses in each year since inception. Our net losses were $100.1 million and $89.2 million for the years ended December 31, 2021 and 2020, respectively. As of December 31, 2021, we had an accumulated deficit of $298.6 million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We expect to continue to spend significant resources to fund research and development of, and seek regulatory approvals for, our vaccine candidates. We expect to incur substantial and increasing operating losses over the next several years as our research, development, manufacturing, preclinical testing and clinical trial activities increase. As a result, our accumulated deficit will also increase significantly. We may encounter unforeseen</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">45</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. The size of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenue. However, we do not expect to generate any revenue from commercial product sales unless and until we successfully complete development and obtain regulatory approval for one or more of our vaccine candidates, which we expect will take a number of years. Our prior losses and expected future losses have had and will continue to have an adverse effect on our stockholders&#x2019; equity and working capital. Even if we eventually generate revenue, we may never be profitable and, if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We will require substantial additional funding to finance our operations, which may not be available to us on acceptable terms, or at all. If we are unable to raise additional capital when needed, we could be forced to delay, reduce or terminate certain of our development programs or other operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, we had cash, cash equivalents and investments of $273.1 million. In the first quarter of 2022, we completed an underwritten public offering in which we issued 3,250,000 shares of common stock, which included the full exercise of the underwriters' option to purchase additional shares, and pre-funded warrants to purchase 2,500,000 shares of our common stock, and received approximately $107.6 million in net proceeds, after deducting underwriting discounts and commissions and other estimated offering expenses payable by us</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We believe our existing cash, cash equivalents and investments will fund our current operating plans through at least the next 12 months from the filing date of this Annual Report on Form 10-K. However, our operating plan may change as a result of many factors currently unknown to us, and we may need to seek additional funds sooner than planned. We will need to raise additional capital before we can progress any of our vaccine candidates into a pivotal clinical trial. We expect to finance our cash needs through public or private equity or debt financings, third-party (including government) funding and marketing and distribution arrangements, as well as other collaborations, strategic alliances and licensing arrangements or any combination of these approaches. In July 2021, we entered into the ATM Sales Agreement with Jefferies, which provides that, upon the terms and subject to the conditions and limitations set forth in the ATM Sales Agreement, we may elect to issue and sell, from time to time, shares of our common stock having an aggregate offering price of up to $150.0 million through Jefferies acting as our sales agent or principal. As of December 31, 2021, we have sold 567,045 shares of our common stock under the ATM Sales Agreement at an average price of $25.26 per share for aggregate gross proceeds of $14.3 million ($13.9 million net of commissions and offering expenses). Our ability to raise additional capital may be adversely impacted by potential worsening global economic conditions and the recent disruptions to and volatility in the credit and financial markets in the United States and worldwide, including the trading price of common stock, resulting from the ongoing COVID-19 pandemic. Our future capital requirements will depend on many factors, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the timing, scope, progress, results and costs of research and development, testing, screening, manufacturing, preclinical development and clinical trials; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the outcome, timing and cost of seeking and obtaining regulatory approvals from the U.S. Food and Drug Administration, or FDA, and comparable foreign regulatory authorities, including the potential for such authorities to require that we perform field efficacy studies for our pneumococcal conjugate vaccine, or PCV, candidates, require more studies than those that we currently expect or change their requirements regarding the data required to support a marketing application; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the cost of building a sales force in anticipation of any product commercialization; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the costs of future commercialization activities, including product manufacturing, marketing, sales, royalties and distribution, for any of our vaccine candidates for which we receive marketing approval; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to maintain existing, and establish new, strategic collaborations, licensing or other arrangements and the financial terms of any such agreements, including the timing and amount of any future milestone, royalty or other payments due under any such agreement; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">any product liability or other lawsuits related to our products;  </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">46</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the revenue, if any, received from commercial sales, or sales to foreign governments, of our vaccine candidates for which we may receive marketing approval; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the costs to establish, maintain, expand, enforce and defend the scope of our intellectual property portfolio, including the amount and timing of any payments we may be required to make, or that we may receive, in connection with licensing, preparing, filing, prosecuting, defending and enforcing of any patents or other intellectual property rights; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the expenses needed to attract, hire and retain skilled personnel; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the costs of operating as a public company; and </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the impact of the COVID-19 pandemic, which may exacerbate the magnitude of the factors discussed above. </span></div></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our ability to raise additional funds will depend on financial, economic and other factors, many of which are beyond our control. We cannot be certain that additional funding will be available on acceptable terms, or at all. We have no committed source of additional capital and if we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may have to significantly delay, scale back or discontinue the development or commercialization of our vaccine candidates or other research and development initiatives. Our license agreements may also be terminated if we are unable to meet the payment obligations or milestones under the agreements. We could be required to seek collaborators for our vaccine candidates at an earlier stage than otherwise would be desirable or on terms that are less favorable than might otherwise be available, or relinquish or license on unfavorable terms our rights to our vaccine candidates in markets where we otherwise would seek to pursue development or commercialization ourselves.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Due to the significant resources required for the development of our vaccine candidates, and depending on our ability to access capital, we must prioritize development of certain vaccine candidates. Moreover, we may expend our limited resources on vaccine candidates that do not yield a successful vaccine and fail to capitalize on vaccine candidates that may be more profitable or for which there is a greater likelihood of success.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Due to the significant resources required for the development of our vaccine candidates, we must decide which vaccine candidates to pursue and advance and the amount of resources to allocate to each. Our decisions concerning the allocation of research, development, management and financial resources toward particular vaccine candidates may not lead to the development of any viable commercial vaccines and may divert resources away from better opportunities. Similarly, our potential decisions to delay, terminate, license or collaborate with third parties in respect of certain vaccine candidates may subsequently also prove to be less than optimal and could cause us to miss valuable opportunities. If we make incorrect determinations regarding the viability or market potential of any of our vaccine candidates or misread trends in the biopharmaceutical industry, in particular for vaccines, our business could be seriously harmed. As a result, we may fail to capitalize on viable commercial products or profitable market opportunities, be required to forego or delay pursuit of opportunities with other vaccine candidates that may later prove to have greater commercial potential than those we choose to pursue or relinquish valuable rights to such vaccine candidates through collaboration, licensing or other royalty arrangements in cases in which it would have been advantageous for us to invest additional resources to retain sole development and commercialization rights.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Risks Related to Our Business and Industry</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our approach to the discovery and development of our vaccine candidates is based on novel technologies that are unproven, which may expose us to unforeseen risks, require us to modify processes, and make it difficult to predict the time and cost of vaccine candidate development and the timing to apply for and obtain regulatory approvals.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">  </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are developing a pipeline of vaccine candidates utilizing our cell-free protein synthesis platform, which is comprised of the XpressCF platform exclusively licensed from Sutro Biopharma, and our proprietary know-how for vaccine applications against infectious disease, and our future success depends on the successful</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">47</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">application of this approach to vaccine development. We are in the early stages of developing our vaccine candidates and there can be no assurance that any development problems we experience in the future will not cause significant delays or unanticipated costs, or that such development problems can be overcome. We may also experience delays in developing a sustainable, reproducible and scalable manufacturing process or transferring that process to manufacturing partners, which may prevent us from completing our clinical trials or commercializing our products on a timely or profitable basis, if at all. In addition, since we have not yet completed clinical development, we do not know the specific doses that may be effective in the clinic or, if approved, commercially. Finding a suitable dose may delay our anticipated clinical development timelines.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Furthermore, our expectations with regard to our scalability and costs of manufacturing may vary significantly as we develop our vaccine candidates and understand these critical factors. Conjugate vaccine development is highly complex, and development of broad-valency PCVs is further complicated by the number of components, analytical assays and potential for adjustments, including but not limited to changes in raw materials, composition, formulation, manufacturing methods and dosing, which could result in drug substances and/or drug product that may vary between preclinical and clinical studies over time. Over the course of the development and manufacturing of VAX-24, we have encountered process-related matters that have required us to make adjustments to our processes. We encountered such process-related matters during our drug substance manufacturing campaign for VAX-24 at Lonza. The cumulative impact of the time required to make adjustments to our processes led to a delay of our drug substance manufacturing campaign due to scheduling conflicts and capacity constraints at Lonza. There can be no assurance that we or Lonza will be able to successfully manufacture drug substances in a timely manner in the future, or at all. Such process changes and manufacturing delays have caused a change in our IND timelines in the past and future changes or delays could impact future timelines for VAX-24 or for our other product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, the preclinical and clinical trial requirements of the FDA, European Medicines Agency, or EMA, and other regulatory agencies and the criteria these regulators use to determine the safety and efficacy of a vaccine candidate are determined according to the type, complexity, novelty and intended use and market of the potential products. Approvals by the FDA and EMA for existing pneumococcal vaccines, such as Prevnar 13, Pneumovax 23, Prevnar 20 and Vaxneuvance may not be indicative of what these regulators may require for approval of our vaccine candidates. For example, we expect to use opsonophagocytic activity, or OPA, titers as the primary immunogenicity surrogate endpoint for the VAX-24 program in adults because Prevnar 13 and Prevnar 20 were approved based on the establishment of non-inferiority of serotype-specific OPA responses relative to Pneumovax 23 and Prevnar 13 respectively; however, there can be no assurance that this streamlined non-inferiority approach will be sufficient for regulatory approval or that regulators will not require field efficacy trials. Furthermore, while there have been approvals granted for both pneumococcal conjugate vaccines and meningococcal conjugate vaccines based on surrogate immune endpoints rather than field efficacy studies, we will not be able to confirm this approach&#x2019;s applicability for our vaccines until we complete our Phase 2 clinical development program. Additionally, novel aspects of our vaccine candidates and manufacturing processes may create further challenges in obtaining regulatory approval. The regulatory approval process for our novel vaccine candidates can be more complex and consequently more expensive and take longer than for other, better known or extensively studied pharmaceutical or other vaccine candidates. More generally, approvals by any regulatory agency may not be indicative of what any other regulatory agency may require for approval or what such regulatory agencies may require for approval in connection with new vaccine candidates. Moreover, our vaccine candidates may not perform successfully in clinical trials.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our vaccine candidates are in early stages of development and may fail in development or suffer delays that materially and adversely affect their commercial viability. If we are unable to complete development of or commercialize our vaccine candidates or experience significant delays in doing so, our business would be materially harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Vaccine development generally takes many years. In particular, our most advanced vaccine candidate, VAX-24, showed positive results in a preclinical proof-of-concept study in 2017. On January 6, 2022, we announced that the FDA had cleared our investigational new drug, or IND, application for VAX-24 in adults. On February 23, 2022, we announced the initiation of our Phase 1/2 clinical proof-of-concept study in adults ages 18 to 64. We expect to announce Phase 1/2 topline immunogenicity, safety and tolerability results from this study by the end of 2022. Pending the successful completion of the Phase 1 portion of this study, we expect to begin enrollment</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">48</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">in a separate Phase 2 study in healthy adults aged 65 and older and to announce topline safety, tolerability and immunogenicity results from this study in the first half of 2023. Subject to a pre-IND meeting with the FDA and the successful topline results of the initial Phase 1/2 proof-of-concept study in adults ages 18 to 64, we anticipate submitting a pediatric IND application to the FDA for VAX-24 in the first half of 2023. Our other vaccine candidates are in earlier stages of discovery and preclinical development and may never advance to clinical-stage development. Our ability to achieve and sustain profitability depends on obtaining regulatory approvals for and successfully commercializing our vaccine candidates, either alone or with third parties, and we cannot guarantee that we will ever obtain regulatory approval for any of our vaccine candidates. We have limited experience in conducting and managing the clinical trials necessary to obtain regulatory approvals, including approval by the FDA. Before obtaining regulatory approval for the commercial distribution of our vaccine candidates, we must conduct extensive preclinical studies and clinical trials to demonstrate the safety and efficacy of our vaccine candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may not have the financial resources to continue development of, or to enter into new collaborations for, a vaccine candidate if we experience any issues that delay or prevent regulatory approval of, or our ability to commercialize, vaccine candidates, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">negative or inconclusive results from our preclinical or clinical trials, leading to a decision or requirement to conduct additional preclinical studies or clinical trials or abandon a program; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">product-related adverse effects experienced by volunteers in our clinical trials; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">difficulty achieving successful development of our manufacturing processes, including process development and scale-up activities to supply products for preclinical studies, clinical trials and commercial sale, if approved; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">timely completion of our preclinical studies and clinical trials, including any field efficacy studies that may be required, which may be significantly slower or cost more than we currently anticipate and will depend substantially upon the performance of third-party contractors; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">inability of us or any third-party contract manufacturer to scale up manufacturing of our vaccine candidates to supply the needs of preclinical studies, clinical trials and commercial sales, and to manufacture such products in conformity with regulatory requirements; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">delays in submitting IND applications or compatible foreign applications or delays or failures in obtaining necessary approvals from regulators to commence a clinical trial, or suspension or termination of a clinical trial once commenced; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">conditions imposed by the FDA or similar foreign authorities regarding the scope or design of our clinical trials, including any requirements to perform field efficacy studies; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">delays in enrolling subjects in our clinical trials; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">inadequate supply or quality of vaccine candidate components or materials or other supplies necessary for conducting clinical trials; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">inability to obtain alternative sources of supply for which we have a single source for vaccine candidate components; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the availability of coverage and adequate reimbursement and pricing from third-party payors, including government authorities, pertaining to the vaccine candidate, once approved, and patients&#x2019; willingness to pay out-of-pocket if third-party payor reimbursement is limited or not available; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">greater than anticipated costs of our clinical trials, including chemistry, manufacturing and controls, or CMC, activities related to our clinical trials; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">49</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">harmful side effects or inability of our vaccine candidates to meet efficacy endpoints; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">unfavorable FDA or other regulatory agency inspection and review of one or more of our clinical trial sites or our contract manufacturers&#x2019; facilities; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">failure of our third-party contractors or investigators to comply with regulatory requirements or otherwise meet their obligations in a timely manner, or at all; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">delays and changes in regulatory requirements, policy and guidelines, including the imposition of additional regulatory oversight around clinical testing generally or with respect to our technology or vaccine candidates in particular; or </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">varying interpretations of our data by the FDA and comparable foreign regulatory authorities. </span></div></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In particular, while we believe our PCVs could receive regulatory approval based on well-defined surrogate immune endpoints, consistent with how other PCVs have obtained regulatory approval in the past, rather than requiring clinical field efficacy studies, there can be no assurance that the FDA or comparable foreign regulatory authorities will provide approvals on such basis. In addition, changes to the standard of care or the approval of new vaccines could change the threshold for achievement of non-inferiority using the established surrogate immune endpoints that our PCVs will need to meet in our clinical trials.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our inability to complete development of or commercialize our vaccine candidates, or significant delays in doing so due to one or more of these factors, could have a material and adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Moreover, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA or comparable foreign regulatory authorities. The FDA or comparable foreign regulatory authorities may conclude that a financial relationship between us and a principal investigator has created a conflict of interest or otherwise affected interpretation of the study. The FDA or comparable foreign regulatory authorities may therefore question the integrity of the data generated at the applicable clinical trial site and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of our marketing applications by the FDA or comparable foreign regulatory authorities, as the case may be, and may ultimately lead to the denial of marketing approval of one or more of our vaccine candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our business is highly dependent on the success of VAX-24, which is in the early stages of development. If we are unable to obtain approval for VAX-24 and effectively commercialize VAX-24, our business would be significantly harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our business and future success depends on our ability to obtain regulatory approval of, and then successfully commercialize, our most advanced vaccine candidate, VAX-24. VAX-24 is in the early stages of development, and to date has only completed preclinical proof-of-concept studies as compared to Prevnar 13 and polysaccharide/alum in rabbits. Although VAX-24 has produced successful results in animal studies, it may not demonstrate the same properties in humans and may interact with human biological systems in unforeseen, ineffective or harmful ways. VAX-24 will require additional clinical and non-clinical development, regulatory review and approval in multiple jurisdictions, substantial investment, access to sufficient clinical and commercial manufacturing capacity and significant marketing efforts before we can generate any revenue from product sales. We cannot provide any assurance that we will be able to successfully advance VAX-24 through the development process.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The clinical and commercial success of VAX-24 and future vaccine candidates will depend on a number of factors, including the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to raise any additional required capital on acceptable terms, or at all; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">50</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to complete IND-enabling studies and successfully submit IND or comparable applications; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the ability of third parties with whom we contract to manufacture adequate clinical study and commercial supplies of our lead vaccine candidates or any future vaccine candidates, remain in good standing with regulatory agencies and develop, validate and maintain commercially viable manufacturing processes that are compliant with current good manufacturing practices, or cGMP, and do so in a timely manner;</span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">timely completion of our preclinical studies and clinical trials, which may be significantly slower or cost more than we currently anticipate and will depend substantially upon the performance of third-party contractors; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">whether we are required by the FDA or similar foreign regulatory agencies to conduct additional clinical trials, including field efficacy studies, or other studies beyond those planned to support the approval and commercialization of our vaccine candidates or any future vaccine candidates; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">acceptance of our proposed indications and primary surrogate endpoint assessments for our PCV candidates by the FDA and similar foreign regulatory authorities; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">any changes to the required threshold for the achievement of non-inferiority using established surrogate immune endpoints that our PCVs will need to meet in our clinical trials; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities the safety, efficacy and acceptable risk to benefit profile of VAX-24 or any future vaccine candidates; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the pace and prevalence of serotype replacement following the introduction of VAX-24 or VAX-XP or other vaccines targeting pneumococcal disease; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">any vaccine-vaccine interference studies that may be required, particularly with the standard of care pediatric vaccine regimen; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the prevalence, duration and severity of potential side effects or other safety issues experienced with our vaccine candidates or future approved products, if any; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the timely receipt of necessary marketing approvals from the FDA or comparable foreign regulatory authorities; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">achieving, maintaining and, where applicable, ensuring that our third-party contractors achieve and maintain compliance with our contractual obligations and with all regulatory requirements applicable to our lead vaccine candidates or any future vaccine candidates or approved products, if any; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">obtaining and maintaining an Advisory Committee on Immunization Practices, or ACIP, preferred recommendation or comparable foreign regulatory authority&#x2019;s recommendation of our vaccine candidates and the willingness of physicians, operators of clinics and patients to utilize or adopt any of our future vaccine candidates to prevent or treat age-associated diseases; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to successfully develop a commercial strategy and thereafter commercialize our vaccine candidates or any future vaccine candidates in the United States and internationally, if approved for marketing, reimbursement, sale and distribution in such countries and territories, whether alone or in collaboration with others; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">51</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the convenience of our treatment or dosing regimen; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">acceptance by physicians, payors and patients of the benefits, safety and efficacy of our vaccine candidates or any future vaccine candidates, if approved, including relative to alternative and competing treatments; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">patient demand for our vaccine candidates, if approved; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to establish and enforce intellectual property rights in and to our vaccine candidates or any future vaccine candidates; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to avoid third-party patent interference, intellectual property challenges or intellectual property infringement claims; and </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the impact of the COVID-19 pandemic, which may exacerbate the magnitude of the factors discussed above. </span></div></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">These factors, many of which are beyond our control, could cause us to experience significant delays or an inability to obtain regulatory approvals or commercialize our vaccine candidates. Even if regulatory approvals are obtained, we may never be able to successfully commercialize any of our vaccine candidates. Accordingly, we cannot provide assurances that we will be able to generate sufficient revenue through the sale of our vaccine candidates or any future vaccine candidates to continue our business or achieve profitability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our primary competitors have significantly greater resources and experience than we do, which may make it difficult for us to successfully develop our vaccine candidates, or may result in others discovering, developing or commercializing products before or more successfully than us.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The vaccine market is intensely competitive and is dominated by a small number of multinational, globally established pharmaceutical corporations with significant resources; Pfizer, Merck, GlaxoSmithKline and Sanofi together control approximately 75% of the global vaccine market. We may also face competition from many different sources, including pharmaceutical and biotechnology companies, academic institutions, governmental agencies and public and private research institutions. For example, Sanofi and SK Chemicals have partnered to develop a PCV, and Affinivax and Astellas have partnered to develop an affinity-bound pneumococcal vaccine.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Vaccine candidates that we successfully develop and commercialize may compete with existing vaccines and new vaccines that may become available in the future. Many of our competitors have substantially greater financial, lobbying, technical, human and other resources than we do and may be better equipped to develop, manufacture and market technologically superior vaccines, including the potential that our competitors may develop chemical processes or utilize novel technologies for developing vaccines that may be superior to those we employ. In addition, many of these competitors have significantly greater experience than we have in undertaking preclinical studies and clinical trials of new products and in obtaining regulatory approvals, including for many vaccine franchises. Accordingly, our competitors may succeed in obtaining FDA approval or a preferred recommendation for their products. For example, Prevnar 13 obtained FDA approval for the prevention of invasive pneumococcal disease, or IPD, in infants based on non-inferior IgG antibody responses relative to Prevnar, using the surrogate immune endpoints established by the prior Prevnar field efficacy study. Pfizer implemented a similar approach to development of its 20-valent PCV vaccine candidate, Prevnar 20, which was approved by the FDA in June 2021 for use in adults.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Many of our competitors have established distribution channels for the commercialization of their vaccine products, whereas we have no such established channels or capabilities. In addition, many competitors have greater name recognition, more extensive collaborative relationships or the ability to leverage a broader vaccine portfolio. Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize vaccines that are safer, more effective, more convenient, less expensive or with a more favorable label than any vaccine candidates that we may develop.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">52</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As a result of these factors, our competitors may obtain regulatory approval of their products before we are able to, which may limit our ability to develop or commercialize our vaccine candidates, or achieve a competitive position in the market. This would adversely affect our ability to generate revenue. Our competitors may also develop vaccines that are safer, more effective, more widely accepted or less expensive than ours, and may also be more successful than we are in manufacturing and marketing their products. These advantages could render our vaccine candidates obsolete or non-competitive before we can recover the costs of such vaccine candidates&#x2019; development and commercialization.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller and early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific, management and commercial personnel, establishing clinical trial sites and subject enrollment for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We and our contract manufacturers may face difficulty satisfying chemistry, manufacturing and controls requirements imposed by the FDA and comparable foreign regulatory authorities. To date, no product developed using a cell-free manufacturing platform has received approval from the FDA or been commercialized.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">While we are designing and developing a manufacturing process that we believe can scale to address clinical and commercial vaccine supply, we do not own or operate any manufacturing facilities. We rely on contract manufacturing organizations, or CMOs, including our strategic partnership with our contract manufacturer, Lonza, to access resources to facilitate the development and, if approved, commercialization of VAX-24 and our other vaccine candidates. Advancing our vaccine candidates may create significant challenges, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">manufacturing our vaccine candidates to our specifications, including process development, analytical development and quality control testing, and in a timely manner to support our preclinical and clinical trials and, if approved, commercialization; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">sourcing the raw materials used to manufacture our vaccine candidates for preclinical, clinical and, if approved, commercial supplies; and </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">establishing sales and marketing capabilities upon obtaining any regulatory approval to gain market acceptance of our vaccines. </span></div></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Before we can initiate a clinical trial or commercialize any of our vaccine candidates, we must demonstrate to the FDA that the CMC for our vaccine candidates meet applicable requirements, and prior to authorization in the EU, a manufacturing authorization must be obtained from the appropriate EU regulatory authorities. Because no product manufactured on a cell-free manufacturing platform has been approved in the United States, there is no manufacturing facility that has demonstrated the ability to comply with FDA requirements, and, therefore, the timeframe for demonstrating compliance to the FDA&#x2019;s satisfaction is uncertain. Delays in establishing that our manufacturing process and the facilities we utilize for manufacturing comply with cGMP or disruptions in our manufacturing processes, implementation of novel technologies or scale-up activities, may delay or disrupt our development efforts.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Even if we obtain regulatory approval of our vaccine candidates, the products may not gain market acceptance among regulators, advisory boards, physicians, patients, third-party payors and others in the medical community necessary for commercial success.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Even if any of our vaccine candidates receive marketing approval, they may fail to receive recommendations for use by regulators or advisory boards that recommend vaccines, or gain market acceptance by physicians, patients, third-party payors and others in the medical community. If such vaccine candidates do not achieve an adequate level of acceptance, we may not generate significant product revenue and may not become</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">53</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">profitable. The degree of market acceptance of any vaccine candidate, if approved for commercial sale, will depend on a number of factors, including but not limited to:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">receiving Centers for Disease Control and Prevention, or CDC, and ACIP recommendations for use, as well as recommendations of comparable foreign regulatory and advisory bodies; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">prevalence and severity of the disease targets for which our vaccine candidates are approved; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">physicians, hospitals, third-party payors and patients considering our vaccine candidates as safe and effective; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the potential and perceived advantages of our vaccine candidates over existing vaccines, including with respect to spectrum coverage or immunogenicity; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the prevalence and severity of any side effects; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">product labeling or product insert requirements of the FDA or comparable foreign regulatory and advisory bodies; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">limitations or warnings contained in the labeling approved by the FDA or comparable foreign regulatory and advisory bodies; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the timing of market introduction of our vaccine candidates as well as competitive products; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the cost in relation to alternatives; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the availability of coverage and adequate reimbursement and pricing by third-party payors, including government authorities; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the willingness of patients to pay out-of-pocket in the absence of coverage and adequate reimbursement by third-party payors, including government authorities; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">relative convenience and ease of administration, including as compared to competitive vaccines and alternative treatments; and </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the effectiveness of our sales and marketing efforts. </span></div></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the United States, the CDC and ACIP develop vaccine recommendations for both children and adults, as do similar agencies around the world. To develop its recommendations, ACIP forms working groups that gather, analyze and prepare scientific information. The ACIP also considers many of the factors above, as well as myriad additional factors such as the value of vaccination for the target population regarding the outcomes, health economic data and implementation issues. ACIP recommendations are also made within categories, such as in an age group or a specified risk group. For example, the ACIP may determine that a preferred recommendation in a smaller child population may be more economical than recommending vaccinations for a larger adult population, which could adversely impact our market opportunity.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">New pediatric vaccines that receive an ACIP preferred recommendation are almost universally adopted, and adult vaccines that receive a preferred recommendation are widely adopted. For example, in 2014, the ACIP voted to recommend Prevnar 13 for routine use to help protect adults aged 65 years and older against pneumococcal disease, which caused Prevnar 13 to become the standard of care along with continued use of Pneumovax 23. ACIP can also modify its preferred recommendation. For instance, in June 2019, the ACIP voted to revise the pneumococcal vaccination guidelines and recommend Prevnar 13 for adults 65 and older based on the shared clinical decision making of the provider and patient, rather than a preferred use recommendation, which means the decision to vaccinate should be made at the individual level between health care providers and their patients. In</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">54</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">October 2021, the ACIP voted to recommend the use of either Pfizer&#x2019;s Prevnar 20, or PCV20, or Merck&#x2019;s Vaxneuvance, or PCV15, with Pneumovax 23 for routine use in adults aged 65 years and older as well as for those between the ages of 19 and 64 years with certain underlying medical conditions or other risk factors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If our vaccine candidates are approved but fail to receive CDC and ACIP recommendations, or recommendations of other comparable foreign regulatory and advisory bodies, or achieve market acceptance among physicians, healthcare providers, patients, third-party payors or others in the medical community, we will not be able to generate significant revenue. Even if our products achieve market acceptance, we may not be able to maintain that market acceptance over time if new products or technologies are introduced that are more favorably received than our products, are more cost effective or render our products obsolete.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We may not be successful in our efforts to use our cell-free protein synthesis platform to expand our pipeline of vaccine candidates and develop marketable products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The success of our business depends in large part upon our ability to identify, develop and commercialize products based on our cell-free protein synthesis platform. We intend to pursue clinical development of additional vaccine candidates beyond VAX-24, including VAX-XP for PCV, VAX-A1 for Group A Strep and VAX-PG for periodontitis. Our research programs may fail to identify potential vaccine candidates for clinical development for a number of reasons or we may focus our efforts and resources on potential programs or vaccine candidates that ultimately prove to be unsuccessful. In addition, we cannot provide any assurance that we will be able to successfully advance any of our existing or future vaccine candidates through the development process.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our potential vaccine candidates may be shown to have harmful side effects or may have other characteristics that may make the products unmarketable or unlikely to receive marketing approval. If any of these events occur, we may be forced to abandon our development efforts for a program or for multiple programs, which would materially harm our business and could potentially cause us to cease operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Even if we receive FDA approval to market additional vaccine candidates, we cannot provide assurance that any such vaccine candidates will be successfully commercialized, widely accepted in the marketplace or more effective than other commercially available alternatives. In addition, current PCVs do not address the majority of circulating strains causing pneumococcal disease. There has been a decrease in the incidence of disease attributable to the strains covered by existing vaccines but an increase in incidence attributable to non-covered strains that now cause most residual disease. Such change is driven by the void created when strains are taken out of circulation after widespread vaccination, which is a phenomenon known as serotype replacement. As a result of such change, broader spectrum PCVs are required to maintain protection against historically pathogenic strains while expanding coverage to current circulating and emerging strains. There can be no assurance that we will be able to develop higher-valent vaccines to address serotype replacement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, because VAX-24 is our most advanced vaccine candidate, and because our other vaccine candidates are also based on our cell-free protein synthesis platform, if VAX-24 encounters safety or efficacy problems, manufacturing problems, developmental delays, regulatory issues or other problems, our development plans and business would be significantly harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We currently rely on third-party manufacturing and supply partners, including Lonza and Sutro Biopharma, to supply raw materials and components for, and manufacture of, our preclinical and clinical supplies as well as our vaccine candidates. Our inability to procure necessary raw materials or to have sufficient quantities of preclinical and clinical supplies or the inability to have our vaccine candidates manufactured, including delays or interruptions at our third-party manufacturers, or our failure to comply with applicable regulatory requirements or to supply sufficient quantities at acceptable quality levels or prices, or at all, would materially and adversely affect our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Efficient and scalable manufacturing and supply is a vital component of our business strategy. We currently do not own or operate any manufacturing facilities. We are designing and developing a manufacturing process that we believe can scale to address clinical and commercial vaccine supply. However, our assumptions as to our ability and our CMOs&#x2019; ability to produce vaccines at the scale needed for clinical development and commercial demand, in particular for our PCVs, may prove to be wrong. If we encounter substantial problems in our</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">55</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">manufacturing processes or in our ability to scale to address commercial vaccine supply, our business would be materially adversely affected. Examples of potential issues related to our manufacturing processes or our ability to scale include difficulties with production costs, yields and quality control, including stability of the drug substance or drug product.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We rely on third-party contract manufacturers to manufacture preclinical and clinical trial product materials and supplies for our needs. There can be no assurance that our preclinical and clinical development product supplies will not be limited or interrupted or be of satisfactory quality or continue to be available on acceptable terms. Over the course of the development and manufacturing of VAX-24, we have encountered process-related matters that have required us to make adjustments to our processes. We encountered such process-related matters during our drug substance manufacturing campaign for VAX-24 at Lonza. The cumulative impact of the time required to make adjustments to our processes led to a delay of our drug substance manufacturing campaign due to scheduling conflicts and capacity constraints at Lonza. There can be no assurance that we or Lonza will be able to successfully manufacture drug substances in a timely manner in the future, or at all. Such process changes and manufacturing delays have caused a change in our IND timelines in the past and future changes or delays could impact future timelines for VAX-24 or for our other product candidates. As a third-party manufacturer, we are also subject to Lonza&#x2019;s scheduling commitments for its other clients. Scheduling conflicts with Lonza&#x2019;s other clients have contributed to manufacturing delays in the past, and there is no guarantee that future scheduling conflicts or related capacity constraints will not affect our manufacturing campaigns and related timelines. In addition, certain aspects of our manufacturing process for our clinical trial product materials and supplies were adversely affected by the COVID-19 pandemic, and could be adversely affected by the ongoing COVID-19 pandemic, earthquakes and other natural or man-made disasters, equipment failures, labor shortages, power failures and numerous other factors in the future. Please see the risk factor titled &#x201c;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our business could be adversely affected by the effects of health epidemics, including the evolving effects of the COVID-19 pandemic, in regions where we or third parties on which we rely have significant manufacturing facilities, concentrations of potential clinical trial sites or other business operations. The COVID-19 pandemic could materially affect our operations, including at our headquarters in the San Francisco Bay Area, as well as the business or operations of our contract manufacturers or other third parties with whom we conduct business</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.&#x201d;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The manufacturing process for a vaccine candidate is subject to FDA or comparable foreign regulatory authority review. Our suppliers and manufacturers must meet applicable manufacturing requirements and undergo rigorous facility and process validation tests required by regulatory authorities in order to comply with regulatory standards, such as cGMPs.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If our contract manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or comparable foreign regulatory authorities, we may not be able to rely on their manufacturing facilities for the manufacture of elements of our vaccine candidates. Moreover, we do not control the manufacturing process at our contract manufacturers and are completely dependent on them for compliance with current regulatory requirements. In the event that any of our manufacturers fails to comply with such requirements or to perform its obligations in relation to quality, timing or otherwise, or if our supply of components or other materials becomes limited or interrupted for other reasons, we may be forced to manufacture the materials ourselves or enter into an agreement with another third party, which we may not be able to do on reasonable terms, if at all. In some cases, the technical skills, raw materials or technology required to manufacture our vaccine candidates may be unique or proprietary to the original manufacturer or supplier, and we may have difficulty applying such skills or technology or sourcing such raw materials ourselves, or in transferring such skills, technology or raw materials to another third party</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> or such transfer may be subject to certain consent obligations and payment terms to Lonza. These factors would increase our reliance on such manufacturer or require us to obtain a license from such manufacturer in order to enable us, or to have another third party, manufacture our vaccine candidates. If we are required to change manufacturers for any reason, we will be required to verify that the new manufacturer maintains facilities and procedures that comply with quality standards and with all applicable regulations and guidelines, and we may be required to repeat some of the development program. The delays associated with the verification of a new manufacturer could negatively affect our ability to develop vaccine candidates in a timely manner or within budget.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We expect to continue to rely on third-party manufacturers and suppliers, including Lonza and Sutro Biopharma, if we receive regulatory approval for any PCV or any other vaccine candidates. To the extent that we</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">56</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">have existing, or enter into future, manufacturing arrangements with third parties, we will depend on these third parties to perform their obligations in a timely manner consistent with contractual and regulatory requirements, including those related to quality control and assurance. If we are unable to obtain or maintain third-party manufacturing for vaccine candidates, or to do so on commercially reasonable terms, we may not be able to develop and commercialize our vaccine candidates successfully. Our or a third party&#x2019;s failure to execute on our manufacturing requirements and comply with cGMPs could adversely affect our business in a number of ways, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">an inability to initiate or complete clinical trials of vaccine candidates under development; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">delay in submitting regulatory applications, or receiving regulatory approvals, for our vaccine candidates; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">subjecting third-party manufacturing facilities to additional inspections by regulatory authorities; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">requirements to cease distribution or to recall batches of our vaccine candidates; and </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">in the event of approval to market and commercialize a vaccine candidate, an inability to meet commercial demands for our products. </span></div></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, because VAX-24 is our most advanced vaccine candidate, and because our other vaccine candidates are also based on our cell-free protein synthesis platform, if VAX-24 encounters safety or efficacy problems, manufacturing problems, developmental delays, regulatory issues or other problems, our development plans and business would be significantly harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Additionally, we and our contract manufacturers may experience manufacturing difficulties due to limited vaccine manufacturing experience, resource constraints or as a result of labor disputes or unstable political environments. In December 2019, we exercised our right to require Sutro Biopharma to establish a second supplier for extract and custom reagents to support our anticipated clinical and commercial needs. If we or our contract manufacturers were to encounter any of these difficulties, our ability to manufacture sufficient vaccine supply for our preclinical studies and clinical trials, or to provide product for patients once approved, would be jeopardized.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our vaccine candidates may cause undesirable side effects or have other properties, including interactions with existing vaccine regimens, that could halt their clinical development, prevent their regulatory approval, limit their commercial potential or result in significant negative consequences.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Adverse effects or other undesirable or unacceptable side effects caused by our vaccine candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or other comparable foreign regulatory authorities. We have not yet initiated any clinical trials of our vaccine candidates. Results of our clinical trials could reveal a high and unacceptable severity and prevalence of side effects or unexpected characteristics. In such an event, our clinical trials could be suspended or terminated, and the FDA or comparable foreign regulatory authorities could order us to cease further development of or deny approval of our vaccine candidates. Such side effects could also affect trial recruitment or the ability of enrolled subjects to complete the clinical trial or result in potential product liability claims. A data safety monitoring board may also suspend or terminate a clinical trial at any time on various grounds, including a finding that the research volunteers are being exposed to an unacceptable health risk. Vaccine-related side effects could also affect recruitment or the ability of enrolled subjects to complete the trial or result in potential product liability claims. In addition, any vaccine to be approved in pediatric populations may need to undergo extensive vaccine-vaccine interference studies with the standard of care pediatric vaccine regimen. Further, to the extent field efficacy studies are required, prophylactic vaccines typically require clinical testing in thousands to tens of thousands of healthy volunteers to define an approvable benefit-risk profile. The need to show a high degree of safety and tolerability when dosing healthy individuals could result in rare and even spurious safety findings, negatively impacting a program prior to or after commercial launch. Any of these occurrences may harm our business, financial condition and prospects significantly.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">57</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Negative developments and negative public opinion of new technologies on which we rely may damage public perception of our vaccine candidates or adversely affect our ability to conduct our business or obtain regulatory approvals for our vaccine candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Negative developments and negative public opinion of new or existing technologies on which we rely may damage public perception of our vaccine candidates or adversely affect our ability to conduct our business or obtain regulatory approvals for our vaccine candidates. Public perception may be influenced by claims that vaccines are unsafe, and products incorporating new vaccine technology may not gain the acceptance of the public or the medical community. Adverse public attitudes may negatively impact our ability to enroll subjects in clinical trials. Moreover, our success will depend upon physicians prescribing, and their patients being willing to receive, our vaccine candidates in lieu of, or in addition to, existing, more familiar vaccines for which greater clinical data may be available. Any increase in negative perceptions of the technologies that we rely on may result in fewer physicians prescribing our products or may reduce the willingness of patients to utilize our products or participate in clinical trials for our vaccine candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We may not be able to file IND applications to commence clinical trials on the timelines we expect, and even if we are able to, the FDA may not permit us to proceed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our timing of submitting IND applications for our product candidates is dependent on preclinical and manufacturing success, and if we experience additional delays, we may fail to meet our anticipated timelines. In addition, we cannot be sure that submission of an IND application or IND application amendment will result in the FDA allowing testing and clinical trials to begin, or that, once begun, issues will not arise that suspend or terminate such clinical trials. Additionally, even if such regulatory authorities agree with the design and implementation of the clinical trials set forth in an IND or clinical trial application, we cannot guarantee that such regulatory authorities will not change their requirements in the future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We may encounter substantial delays in our clinical trials or may not be able to conduct our trials on the timelines we expect.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Clinical testing is expensive, time consuming and subject to uncertainty. We cannot guarantee that any clinical studies will be conducted as planned or completed on schedule, if at all. Even if these trials begin as planned, issues may arise that could suspend or terminate such clinical trials. A failure of one or more clinical studies can occur at any stage of testing, and our future clinical studies may not be successful. Events that may prevent successful or timely completion of clinical development include:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">inability to generate sufficient preclinical, toxicology or other in vivo or in vitro data to support the initiation of clinical trials; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">delays in sufficiently developing, characterizing or controlling a manufacturing process suitable for advanced clinical trials; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">delays in reaching a consensus with regulatory agencies on study design; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">delays in reaching agreement on acceptable terms with prospective contract research organizations, or CROs, and clinical study sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and clinical study sites; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">delays in obtaining required institutional review board, or IRB, approval at each clinical study site; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">imposition of a temporary or permanent clinical hold by regulatory agencies for a number of reasons, including after review of an IND application or amendment, or equivalent application or amendment; as a result of a new safety finding that presents unreasonable risk to clinical trial participants; a negative finding from an inspection of our clinical study operations or study sites; developments on trials conducted by competitors for related technology that raise FDA concerns </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">58</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;visibility:hidden;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;"></span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">about risk to patients of the technology broadly; or if the FDA finds that the investigational protocol or plan is clearly deficient to meet its stated objectives;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">disruptions caused by the COVID-19 pandemic may increase the likelihood that we encounter such difficulties or delays in initiating, enrolling, conducting or completing our planned clinical trials; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">delays in adding a sufficient number of trial sites and recruiting volunteers to participate in our clinical trials; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">failure by our CROs, other third parties or us, to adhere to clinical study requirements; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">failure to perform in accordance with the FDA&#x2019;s good clinical practice, or GCP, requirements or applicable regulatory guidelines in other jurisdictions; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">transfer of manufacturing processes to any new CMO or our own manufacturing facilities or any other development or commercialization partner for the manufacture of vaccine candidates; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">delays in having subjects complete participation in a study or return for post-injection follow-up; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">subjects dropping out of a study; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">occurrence of side effects associated with our vaccine candidates that are viewed to outweigh their potential benefits; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">changes in regulatory requirements and guidance that require amending or submitting new clinical protocols; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">changes in the standard of care on which a clinical development plan was based, which may require new or additional trials; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the cost of clinical trials of our vaccine candidates being greater than we anticipate; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">clinical studies of our vaccine candidates producing negative or inconclusive results, which may result in our deciding, or regulators requiring us, to conduct additional clinical studies or abandon product development programs; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">delays or failure to secure supply agreements with suitable raw material suppliers, or any failures by suppliers to meet our quantity or quality requirements for necessary raw materials; and </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">delays in manufacturing, testing, releasing, validating or importing/exporting sufficient stable quantities of our vaccine candidates for use in clinical studies or the inability to do any of the foregoing. </span></div></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Any inability to successfully complete preclinical and clinical development could result in additional costs to us or impair our ability to generate revenue. In addition, if we make manufacturing or formulation changes to our vaccine candidates, we may be required to or we may elect to conduct additional studies to bridge our modified vaccine candidates to earlier versions. Clinical trial delays could also shorten any periods during which our products have patent protection and may allow our competitors to bring products to market before we do, which could impair our ability to successfully commercialize our vaccine candidates and may harm our business and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">59</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If we encounter difficulties enrolling subjects in any clinical trials we may conduct, including any field efficacy trials that may be required, our clinical development activities could be delayed or otherwise adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may experience difficulties in enrolling subjects in any clinical trials we may conduct for a variety of reasons. The timely completion of clinical trials in accordance with their protocols depends, among other things, on our ability to enroll a sufficient number of subjects who remain in the study until its conclusion. The enrollment of subjects depends on many factors, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the eligibility and exclusion criteria defined in the protocol; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the size of the population required for analysis of the trial&#x2019;s primary endpoints; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the proximity of volunteers to study sites; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the design of the trial; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to recruit clinical trial investigators with the appropriate competencies and experience; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to obtain and maintain subject consents; </span></div></div>
  <div style="margin-left:9.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7340659340659346%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the ability to monitor volunteers adequately during and after injection; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the risk that volunteers enrolled in clinical trials will drop out of the trials before the injection of our vaccine candidates or trial completion; and</span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the risks and disruptions caused by the COVID-19 pandemic related to patient and physician investigator recruitment and retention and study site initiation and clinical trial activities.</span></div></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">To the extent we are required to conduct any field efficacy studies, enrollment of a sufficient number of subjects may require additional time and resources given widespread vaccination rates in the United States, particularly in the pediatric population. As a result, we may be required to conduct any such trials outside the United States, which could cause additional complexity and delay. Delays in enrollment may result in increased costs or may affect the timing or outcome of any clinical trials we may conduct, which could prevent completion of these trials and adversely affect our ability to advance the development of our vaccine candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Interim topline and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">From time to time, we may publish interim topline or preliminary data from our preclinical or clinical trials. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data when we publish such data. As a result, the topline results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results once additional data have been received and fully evaluated. Preliminary or topline data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we may publish. As a result, interim and preliminary data should be viewed with caution until the final data are available. Adverse differences between preliminary or interim data and final data could significantly harm our business prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular vaccine candidate and our company in general. In addition, the information we choose to publicly disclose regarding a</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">60</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is the material or otherwise appropriate information to include in our disclosure. Any information we determine not to disclose may ultimately be deemed significant by you or others with respect to future decisions, conclusions, views, activities or otherwise regarding a particular vaccine candidate or our business. If the topline data that we report differ from final results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, vaccine candidates may be harmed, which could significantly harm our business prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We may seek breakthrough therapy designation or fast track designation by the FDA for one or more of our vaccine candidates, but we may not receive such designation, and even if we do, such designation may not lead to a faster development or regulatory review or approval process and it does not increase the likelihood that our vaccine candidates will receive marketing approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may seek breakthrough therapy or fast track designation for some of our vaccine candidates. A sponsor may seek FDA designation of its vaccine candidate as a breakthrough therapy if the vaccine candidate is intended to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the therapy may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For vaccines that have been designated as breakthrough therapies, the FDA may take actions to expedite the development and review of the application, and interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A vaccine designated as a breakthrough therapy by the FDA may also be eligible for expedited review and approval. If a vaccine candidate is intended for the treatment of a serious or life-threatening condition and clinical or preclinical data demonstrate the potential to address unmet medical needs for this condition, the sponsor may apply for fast track designation. The FDA has broad discretion whether or not to grant this designation, so even if we believe a particular vaccine candidate is eligible for this designation, we cannot assure you that the FDA would decide to grant it.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Even if we obtain fast track designation for one or more of our vaccine candidates, we may not experience a faster development process, review or approval compared to non-expedited FDA review procedures. In addition, the FDA may withdraw fast track designation if it believes that the designation is no longer supported. Fast track designation alone does not guarantee qualification for the FDA&#x2019;s priority review procedures.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Whether to grant breakthrough therapy or fast track designation is within the discretion of the FDA. Accordingly, even if we believe one of our vaccine candidates meets the criteria for these designations, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of either of these designations for a vaccine candidate may not result in a faster development process, review or approval compared to vaccine candidates considered for approval under non-expedited FDA review procedures and does not assure ultimate approval by the FDA. In addition, even if one or more of our vaccine candidates qualify for either of these designations, the FDA may later decide that the vaccine candidate no longer meets the conditions for qualification.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We currently have no marketing and sales organization, and as an organization have no experience in marketing products. If we are unable to establish marketing and sales capabilities or enter into agreements with third parties to market and sell our vaccine candidates, we may not be able to generate product revenue.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We currently have no sales, marketing or distribution capabilities and as an organization have no experience in marketing products. If we develop an in-house marketing organization and sales force, we will require significant capital expenditures, management resources and time, and we will have to compete with other pharmaceutical and biotechnology companies to recruit, hire, train and retain marketing and sales personnel.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If we are unable or decide not to establish internal sales, marketing and distribution capabilities, we will pursue collaborative arrangements regarding the sales and marketing of our products; however, there can be no assurance that we will be able to establish or maintain such collaborative arrangements, or if we are able to do so, that they will have effective sales forces. Any revenue we receive will depend upon the efforts of such third parties,</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">61</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">which may not be successful. We may have little or no control over the marketing and sales efforts of such third parties and our revenue from product sales may be lower than if we had commercialized our vaccine candidates ourselves. We also face competition in our search for third parties to assist us with the sales and marketing efforts of our vaccine candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">There can be no assurance that we will be able to develop in-house sales and distribution capabilities or establish or maintain relationships with third-party collaborators to commercialize any product that receives regulatory approval in the United States or overseas. If we are unable to develop in-house sales and distribution capabilities or enter into relationships with third-party collaborators on acceptable terms or at all, we may not be able to successfully commercialize our products. If we are not successful in commercializing our products or any future products, either on our own or through arrangements with one or more third parties, we may not be able to generate any future product revenue and we would incur significant additional losses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">A variety of risks associated with potentially conducting research and clinical trials abroad and marketing our vaccine candidates internationally could materially adversely affect our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As we pursue approval and commercialization for our vaccine candidates overseas and conduct CMC and other operations overseas, we will be subject to additional risks related to operating in foreign countries, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">differing regulatory requirements in foreign countries; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">unexpected changes in tariffs, trade barriers, price and exchange controls and other regulatory requirements; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">increased difficulties in managing the logistics and transportation of storing and shipping vaccine candidates abroad; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">import and export requirements and restrictions;</span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">differing and changing data protection and privacy regimes and requirements; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">economic weakness, including inflation, or political instability in particular foreign economies and markets; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">foreign taxes, including withholding of payroll taxes; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">foreign currency fluctuations, which could result in increased operating expenses and reduced revenue, and other obligations incident to doing business in another country; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">difficulties staffing and managing foreign operations; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">workforce uncertainty in countries where labor unrest is more common than in the United States; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">differing payor reimbursement regimes, governmental payors or patient self-pay systems and price controls; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">potential liability under the U.S. Foreign Corrupt Practices Act of 1977, as amended, or comparable foreign regulations; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">62</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">challenges enforcing our contractual and intellectual property rights, especially in those foreign countries that do not respect and protect intellectual property rights to the same extent as the United States; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">business interruptions resulting from geopolitical actions, including war and terrorism. </span></div></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">These and other risks associated with our international operations and our collaborations with Lonza, based in Switzerland, may materially adversely affect our ability to attain or maintain profitable operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We are highly dependent on our key personnel, and if we are not able to retain these members of our management team or recruit and retain highly qualified personnel, we may not be able to successfully implement our business strategy.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our ability to compete in the highly competitive biotechnology and pharmaceutical industries depends upon our ability to attract and retain highly qualified managerial, scientific and medical personnel. We are highly dependent on our management, scientific and medical personnel, including our Chief Executive Officer, our President and Chief Financial Officer, our Vice President of Research and our Chief Operating Officer. The loss of the services of any of our executive officers, other key employees and other scientific and medical advisors, and our inability to find suitable replacements, could result in delays in product development and harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We conduct substantially all of our operations at our facilities in the San Francisco Bay Area. This region is headquarters to many other biopharmaceutical companies and many academic and research institutions. Competition for skilled personnel in our market is intense and may limit our ability to hire and retain highly qualified personnel on acceptable terms or at all.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">To induce valuable employees to remain at our company, in addition to salary and cash incentives, we have provided stock options that vest over time. The value to employees of stock options that vest over time may be significantly affected by movements in our stock price that are beyond our control and may at any time be insufficient to counteract more lucrative offers from other companies. Despite our efforts to retain valuable employees, members of our management and scientific and development teams may terminate their employment with us on short notice. Although we have employment agreements with our key employees, these employment agreements provide for at-will employment, which means that any of our employees could leave our employment at any time, with or without notice. We do not maintain &#x201c;key person&#x201d; insurance policies on the lives of these individuals or the lives of any of our other employees. Our success also depends on our ability to continue to attract, retain and motivate highly skilled junior, mid-level and senior managers as well as junior, mid-level and senior scientific and medical personnel.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We have grown rapidly and will need to continue to grow the size of our organization, and we may experience difficulties in managing this growth.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As our discovery, development and commercialization plans and strategies develop, we have rapidly expanded our employee base and expect to continue to add managerial, operational, sales, research and development, marketing, financial and other personnel. Current and future growth imposes significant added responsibilities on members of management, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">identifying, recruiting, integrating, maintaining and motivating additional employees; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">managing our internal development efforts effectively, including the clinical and FDA review process for our vaccine candidates, while complying with our contractual obligations to contractors and other third parties; and </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">improving our operational, financial and management controls, reporting systems and procedures. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">63</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our future financial performance and our ability to commercialize our vaccine candidates will depend, in part, on our ability to effectively manage our growth. Our management may also have to divert a disproportionate amount of its attention away from day-to-day activities in order to devote a substantial amount of time to managing these growth activities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If we are not able to effectively expand our organization by hiring new employees and expanding our groups of consultants and contractors, we may not be able to successfully implement the tasks necessary to further develop and commercialize our vaccine candidates and, accordingly, may not achieve our research, development and commercialization goals.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Obtaining and maintaining regulatory approval of our vaccine candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our vaccine candidates in other jurisdictions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Obtaining and maintaining regulatory approval of our vaccine candidates in one jurisdiction does not guarantee that we will be able to obtain or maintain regulatory approval in any other jurisdiction, while a failure or delay in obtaining regulatory approval in one jurisdiction may have a negative effect on the regulatory approval process in others. For example, even if the FDA grants marketing approval of a vaccine candidate, comparable regulatory authorities in foreign jurisdictions must also approve the manufacturing, marketing and promotion of the vaccine candidate in those countries. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from, and greater than, those in the United States, including additional preclinical studies or clinical trials as clinical studies conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside the United States, a vaccine candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we intend to charge for our products is also subject to approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may also submit marketing applications in other countries. Regulatory authorities in jurisdictions outside of the United States have requirements for approval of vaccine candidates with which we must comply prior to marketing in those jurisdictions. Obtaining foreign regulatory approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our products in certain countries. If we fail to comply with the regulatory requirements in international markets and/or receive applicable marketing approvals, our target market will be reduced and our ability to realize the full market potential of our vaccine candidates will be harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We may form or seek strategic alliances or enter into additional licensing arrangements in the future, and we may not realize the benefits of such alliances or licensing arrangements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may form or seek strategic alliances, create joint ventures or collaborations or enter into additional licensing arrangements with third parties that we believe will complement or augment our discovery, development and commercialization efforts with respect to our vaccine candidates and any future vaccine candidates that we may seek to develop. Any of these relationships may require us to incur non-recurring and other charges, increase our near and long-term expenditures, issue securities that dilute our existing stockholders or disrupt our management and business. In addition, we face significant competition in seeking appropriate strategic partners, and the negotiation process is time-consuming and complex. Moreover, we may not be successful in our efforts to establish a strategic partnership or other alternative arrangements for our vaccine candidates because they may be deemed to be at too early of a stage of development for collaborative effort, and third parties may not view our vaccine candidates as having the requisite potential to demonstrate safety and efficacy. Any delays in entering into new strategic partnership agreements related to our vaccine candidates could delay the development and commercialization of our vaccine candidates in certain geographies for certain indications, which would harm our business prospects, financial condition and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If we license products or businesses, we may not be able to realize the benefit of such transactions if we are unable to successfully integrate them with our existing operations and company culture. We cannot be certain that, following a strategic transaction or license, we will achieve the results, revenue or specific net income that justifies such transaction.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">64</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Revenue from any &#x201c;catch up&#x201d; opportunity may decline over time as more of the patient population is vaccinated.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We intend to initially seek approval of our VAX-24 vaccine candidate in adults. If approved, we believe it may have the potential to serve as a &#x201c;catch up&#x201d; or booster to those adults who have previously received Pneumovax 23 or a lower-valent PCV. Previous vaccines with a &#x201c;catch up&#x201d; opportunity have seen a high initial capture rate, but sales may decline over time as the number of individuals who remain unvaccinated with the new vaccine, and eligible for &#x201c;catch up&#x201d; opportunities, declines. Such decline could adversely affect our revenue over time.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If our security measures, or those maintained on our behalf by CROs, service providers or other third parties, are compromised now, or in the future, or the security, confidentiality, integrity or availability of our information technology, software, services, networks, communications or data is compromised, limited or fails, this could result in significant fines or other liability, interrupt our development programs, harm our reputation, or otherwise adversely affect our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the ordinary course of our business, we may collect, use, retain, safeguard, disclose, share, transfer or otherwise process proprietary, confidential and sensitive information, including personal data (including, key-coded data, health information and other special categories of personal data), intellectual property, trade secrets, and proprietary business information owned or controlled by ourselves or other parties (collectively, &#x201c;Sensitive Information&#x201d;).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may use third-party service providers and subprocessors to help us operate our business and engage in processing on our behalf. We may also share Sensitive Information with our partners or other third parties in connection with our business. Our ability to monitor these third parties&#x2019; cybersecurity practices is limited, and these third parties may not have adequate information security measures in place.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cyberattacks, malicious internet-based activity and online and offline fraud are prevalent and continue to increase. In addition to traditional computer &#x201c;hackers&#x201d;; threat actors; software bugs; malicious code (such as viruses and worms); employee error, theft or misuse; denial-of-service attacks (such as credential stuffing); advanced persistent threat intrusions; natural disasters; terrorism; war; telecommunication and electrical failures; and ransomware attacks, sophisticated nation-state and nation-state supported actors are threats to our information technology assets and data. Ransomware attacks, including those perpetrated by organized criminal threat actors, nation-states, and nation-state-supported actors, are becoming increasingly prevalent and severe and can lead to significant interruptions in our operations, loss of data and income, reputational harm and diversion of funds. Extortion payments may alleviate the negative impact of a ransomware attack, but we may be unwilling or unable to make such payments due to, for example, applicable laws or regulations prohibiting such payments. We may also be the subject of server malfunction, software or hardware failures, supply-chain cyberattacks, loss of data or other computer assets and other similar issues. Additionally, the increased usage of computers operated on home networks due to the shelter-in-place or similar restrictions related to the COVID-19 pandemic may make our systems more susceptible to security breaches. Any of the previously identified or similar threats could cause a security incident or other interruption. A security incident or other interruption could result in unauthorized, unlawful, or accidental acquisition, modification, destruction, loss, alteration, encryption, disclosure of, or access to data and could disrupt our ability (and that of third parties upon whom we rely) to provide our products or operate our business.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">While we have implemented security measures designed to protect against security incidents, there can be no assurance that these measures will be effective. We may be unable in the future to detect vulnerabilities in our information technology systems because such threats and techniques change frequently, are often sophisticated in nature and may not be detected until after a security incident has occurred. Despite our efforts to identify and remediate vulnerabilities, if any, in our information technology systems, our efforts may not be successful. Further, we may experience delays in developing and deploying remedial measures designed to address any such identified vulnerabilities.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may be required to expend significant resources, fundamentally change our business activities and practices, or modify our operations, including our clinical trial activities, or information technology in an effort to protect against security breaches and to mitigate, detect and remediate actual or potential vulnerabilities. While we have not experienced any such material system failure or security breach to date, if we (or a third party upon whom</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">65</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we rely) experience a security incident or are perceived to have experienced a security incident, we may experience adverse consequences, including interruptions in our operations, which could result in a material disruption of our development programs and our business operations. For example, the loss of clinical trial data from future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and the further development and commercialization of our vaccine candidates could be delayed. Furthermore, consequences from an actual or perceived security breach may include: government enforcement actions (for example, investigations, fines, penalties, audits, and inspections); additional reporting requirements and/or oversight; restrictions on processing data (including personal data); litigation (including class claims); indemnification obligations; negative publicity; reputational harm; monetary fund diversions; interruptions in our operations (including availability of data); financial loss; and other similar harms. Security incidents and attendant consequences may cause customers to stop using our platform/products/services, deter new customers from using our products, and negatively impact our ability to grow and operate our business.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Additionally, applicable data protection requirements, including, without limitation, laws, regulations, guidance as well as our internal and external policies and our contractual obligations, may require us to notify relevant stakeholders of security breaches, including affected individuals, partners, collaborators, regulators, law enforcement agencies, credit reporting agencies and others. Such disclosures are costly, and the disclosure or the failure to comply with such requirements could lead to litigation or other liability, fines, harm to our reputation, significant costs, or other materially adverse effects. There can be no assurance that any limitations or exclusions of liability in our contracts would be enforceable or adequate or protect us from liability or damages.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We cannot be sure that our insurance coverage, if any, will be adequate or otherwise protect us from or adequately mitigate liabilities or damages with respect to claims, costs, expenses, litigation, fines, penalties, business loss, data loss, regulatory actions or other materially adverse impacts arising out of our processing activities, privacy and security practices, or security breaches we may experience. The successful assertion of one or more large claims against use that exceeds our available insurance coverage, or results in changes to our insurance policies (including premium increases or the imposition of large excess or deductible or co-insurance requirements), could result in substantial cost increase or prevent us from obtaining insurance on acceptable terms.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our operations, and those of our CMOs, CROs and other contractors and consultants, could be subject to earthquakes, power shortages, telecommunications failures, water shortages, floods, hurricanes, typhoons, fires, extreme weather conditions, medical epidemics and other natural or man-made disasters or business interruptions, for which we are predominantly self-insured. The impact of climate change may increase these risks due to changes in weather patterns, such as increases in storm intensity, sea-level rise, melting of permafrost and temperature extremes on facilities or operations. The occurrence of any of these business disruptions could seriously harm our operations and financial condition and increase our costs and expenses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our ability to manufacture our vaccine candidates could be disrupted if our operations or those of our suppliers are affected by a man-made or natural disaster or other business interruption, including the COVID-19 pandemic. Our corporate headquarters are located in California near major earthquake faults and fire zones. The ultimate impact on us, our significant suppliers and our general infrastructure of being located near major earthquake faults and fire zones and being consolidated in certain geographical areas is unknown, but our operations and financial condition could suffer in the event of a major earthquake, fire or other natural disaster.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Health epidemics, including the effects of the ongoing COVID-19 pandemic, have impacted and could continue to impact our business, including in regions where we or third parties on which we rely have significant manufacturing facilities, concentrations of potential clinical trial sites or other business operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Health epidemics could adversely impact our business, including in regions where we have concentrations of potential clinical trial sites or other business operations, and cause significant disruption in the operations of our contract manufacturer and other third parties upon whom we rely. For example, the COVID-19</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">66</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">pandemic has presented a substantial public health and economic challenge around the world and is affecting employees, patients, communities and business operations, as well as the U.S. economy and financial markets. Our headquarters is located in the San Francisco Bay Area, and our contract manufacturer, Lonza, is located in Switzerland. </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Many geographic regions have imposed, or in the future may impose, &#x201c;shelter-in-place&#x201d; orders, quarantines or similar orders or restrictions to control the spread of COVID-19. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">At present, we have implemented work-from-home policies for all of our non-lab employees. We recently began to allow non-lab-based employees who have been fully vaccinated to return to the office on a voluntary and limited basis. The effects of these orders and our work-from-home policies may negatively impact productivity, disrupt our business and delay our clinical programs and timelines, the magnitude of which will depend, in part, on the length and severity of the restrictions and other limitations on our ability to conduct our business in the ordinary course. In connection with these measures, we may be subject to claims based upon, arising out of or related to COVID-19 and our actions and responses thereto, including any determinations that we may make to continue to operate or to re-open our facilities where permitted by applicable law. These and similar, and perhaps more severe, disruptions in our operations could negatively impact our business, financial condition, results of operations and growth prospects.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Moreover, we rely on third parties to supply raw materials and manufacture our preclinical and clinical product supplies of our vaccine candidates, and we cannot guarantee that they will continue to perform their contractual duties in a timely and satisfactory manner as a result of the COVID-19 pandemic. In addition, quarantines, shelter-in-place and similar government orders could impact personnel at third-party manufacturing facilities in the United States and other countries, or the availability or cost of materials, which would disrupt our supply chain. For example, the COVID-19 pandemic slowed raw material supply chains and travel restrictions delayed the qualification of key analytical equipment used in manufacturing and curtailed in-person CMO oversight of manufacturing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Some of our suppliers of certain materials used in the production of our vaccine candidates are located in Europe. Any manufacturing supply interruption at Lonza&#x2019;s facilities in Switzerland could adversely affect our ability to produce our vaccine candidates for use in the conduct of our preclinical studies or clinical trials. In any event, if the COVID-19 pandemic continues and persists for an extended period of time or more acutely impacts geographies with particular impact on our business, we could experience significant disruptions to our preclinical and clinical development timelines, which would adversely affect our business, financial condition, results of operations and growth prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, our planned clinical trials may be affected by the COVID-19 pandemic. Site initiation and subject enrollment may be delayed due to prioritization of hospital resources toward the COVID-19 pandemic. Some subjects may not be able to comply with clinical trial protocols if quarantines impede their movement or interrupt healthcare services. Similarly, our ability to recruit and retain subjects and principal investigators and site staff who, as healthcare providers, may have heightened exposure to COVID-19, may adversely impact our planned clinical trial operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Furthermore, while the potential economic impact brought by, and the duration of, the COVID-19 pandemic may be difficult to assess or predict, the pandemic could result in significant and prolonged disruption of global financial markets, reducing our ability to access capital, which could in the future negatively affect our liquidity. In addition, a recession or market correction resulting from the spread of COVID-19 could materially affect our business and the value of our common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">While we expect the COVID-19 pandemic to continue to adversely affect our business operations, the extent of the impact on our development and regulatory efforts and the future value of and market for our common stock will depend on future developments that are highly uncertain and cannot be predicted with confidence at this time, such as the ultimate duration of the pandemic, travel restrictions, quarantines, social distancing and business closure requirements in the United States and in other countries, and the effectiveness of actions taken globally to contain and treat COVID-19. Although some COVID-19 related restrictions have eased since March 2020, the recent surge of infections and the emergence of new strains of COVID-19 has led to a rise in hospitalization rates and concomitant new restrictions imposed by governments. In addition, to the extent the evolving effects of the COVID-19 pandemic adversely affects our business and results of operations, it may also have the effect of heightening many of the other risks and uncertainties described elsewhere in this &#x201c;Risk Factors&#x201d; section.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">67</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our vaccine candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We face an inherent risk of product liability as a result of the clinical testing of our vaccine candidates and will face an even greater risk if we commercialize any products. For example, we may be sued if our vaccine candidates cause or are perceived to cause injury or are found to be otherwise unsuitable during clinical testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability or a breach of warranties. Claims could also be asserted under state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our vaccine candidates. Even successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">decreased demand for our vaccine candidates; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">injury to our reputation; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">withdrawal of clinical trial participants; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">initiation of investigations by regulators; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">costs to defend the related litigation; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">a diversion of management&#x2019;s time and our resources; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">substantial monetary awards to trial participants or patients; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">product recalls, withdrawals or labeling, marketing or promotional restrictions; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">loss of revenue; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">exhaustion of any available insurance and our capital resources; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the inability to commercialize any vaccine candidate; and </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">a decline in our share price. </span></div></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our inability to obtain sufficient product liability insurance at an acceptable cost to protect against potential product liability claims could prevent or inhibit the commercialization of products we develop, alone or with corporate collaborators. Our insurance policies may also have various exclusions, and we may be subject to a product liability claim for which we have no coverage. Assuming we obtain clinical trial insurance for our clinical trials, we may have to pay amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts. Even if our agreements with any future corporate collaborators entitle us to indemnification against losses, such indemnification may not be available or adequate should any claim arise.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our employees, principal investigators, consultants and commercial partners may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements and insider trading.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are exposed to the risk of fraud or other misconduct by our employees, principal investigators, consultants and commercial partners. Misconduct by these parties could include intentional failures, reckless and/or negligent conduct or unauthorized activities that violate (i) the laws and regulations of the FDA and other regulatory authorities, including those laws requiring the reporting of true, complete and accurate information to such authorities, (ii) manufacturing standards, (iii) federal and state data privacy, security, fraud and abuse and other</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">68</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">healthcare laws and regulations in the United States and abroad and (iv) laws that require the true, complete and accurate reporting of financial information or data. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Such misconduct also could involve the improper use of individually identifiable information, including, without limitation, information obtained in the course of clinical trials, creating fraudulent data in our preclinical studies or clinical trials or illegal misappropriation of drug product, which could result in regulatory sanctions and cause serious harm to our reputation. It is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from government investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. Additionally, we are subject to the risk that a person or government could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us and we are not successful in defending ourselves or asserting our rights, those actions could result in significant civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from participating in government-funded healthcare programs, such as Medicare and Medicaid, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of noncompliance with these laws, contractual damages, reputational harm and the curtailment or restructuring of our operations, any of which could have a negative impact on our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Changes in tax laws or tax rulings could affect our financial position.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In December 2017, the Tax Cuts and Jobs Act, or Tax Act, was signed into law. The Tax Act, among other things, contains significant changes to corporate taxation, including (i) reduction of the corporate tax rate from a top marginal rate of 35% to a flat rate of 21%, (ii) limitation of the tax deduction for interest expense to 30% of adjusted earnings (with certain exceptions, including for certain small businesses), (iii) limitation of the deduction for post-2017 net operating losses, or NOLs, to 80% of current-year taxable income and elimination of net operating loss carrybacks for post-2017 NOLs, (iv) immediate deductions for certain new investments instead of deductions for depreciation expense over time and (v) modifying or repealing many business deductions and credits (including reducing the business tax credit for certain clinical testing expenses incurred in the testing of certain drugs for rare diseases or conditions generally referred to as &#x201c;orphan drugs&#x201d;).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In March 2020, the Coronavirus Aid, Relief, and Economic Security, or CARES, Act was signed into law. The CARES Act changed certain provisions of the Tax Act. Under the CARES Act, NOLs arising in taxable years beginning after December 31, 2017 and before January 1, 2021 may be carried back to each of the five taxable years preceding the tax year of such loss, but NOLs arising in taxable years beginning after December 31, 2020 may not be carried back. In addition, the CARES Act eliminated the limitation on the deduction of NOLs to 80% of current year taxable income for taxable years beginning before January 1, 2021, and increased the amount of interest expense that may be deducted to 50% of adjusted taxable income for taxable years beginning in 2019 or 2020. We continue to examine the impact the Tax Act may have on our business. Notwithstanding the reduction in the corporate income tax rate, the overall impact of the Tax Act is uncertain and our business, financial condition, results of operations and prospects could be adversely affected. We urge our stockholders to consult with their legal and tax advisors with respect to the Tax Act and the tax consequences of investing in our common stock.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On June 29, 2020, California Assembly Bill 85 (AB 85) was signed into law, which suspends the use of net operating losses and limits the use of research tax credits for 2020, 2021 and 2022. There may be periods during which the use of NOLs is suspended or otherwise limited, and limitation on the use of certain tax credits to offset California income and tax liabilities could accelerate or permanently increase state taxes owed. The Company continues to examine the impact this may have on our business.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On December 21, 2020, the President of the United States signed into law the &#x201c;Consolidated Appropriations Act, 2021,&#x201d; which includes further COVID-19 economic relief and extension of certain expiring tax provisions. The relief package includes a tax provision clarifying that businesses with forgiven Paycheck Protection Program, or PPP, loans can deduct regular business expenses that are paid for with the loan proceeds. Additional pandemic relief tax measures include an expansion of the employee retention credit, enhanced charitable</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">69</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">contribution deductions and a temporary full deduction for business expenses for food and beverages provided by a restaurant.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have incurred substantial losses since inception and do not expect to become profitable in the near future, if ever. As of December 31, 2021, we had federal and state NOL carryforwards of $296.7 million and $262.7 million, respectively. The federal and state loss carryforwards, except the federal loss</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">carryforward arising in tax years beginning after December 31, 2017, begin to expire in 2034 unless previously utilized. Federal NOLs arising in tax years beginning after December 31, 2017 have an indefinite carryforward period and do not expire. As of December 31, 2021, we also had federal and state research credit carryforwards of $2.2 million and $1.6 million, respectively. The federal research and development tax credit carryforwards expire beginning in 2039 unless previously utilized, and the state research and development tax credits can be carried forward indefinitely. In general, under Sections 382 and 383 of the U.S. Internal Revenue Code of 1986, as amended, a corporation that undergoes an &#x201c;ownership change&#x201d; (generally defined as a greater than 50 percentage point change (by value) in its equity ownership by certain stockholders over a rolling three-year period) is subject to limitations on its ability to utilize its pre-change NOLs to offset future taxable income. We have experienced ownership changes in the past. As a result of the ownership changes, we have determined that approximately less than $0.1 million of our federal research credits will expire unutilized, and such amounts are excluded from our research carryforwards as of December 31, 2021. We do not expect any ownership changes during the year ended December 31, 2021 to result in a limitation that would materially reduce the total amount of net operating loss carryforwards and credits that can be utilized. Subsequent ownership changes may affect the limitation in future years. As a result, if, and to the extent that we earn net taxable income, our ability to use our pre-change NOLs to offset such taxable income may be subject to limitations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our insurance policies may be inadequate and potentially expose us to unrecoverable risks.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Although we intend to maintain product liability insurance coverage, such insurance may not be adequate to cover all liabilities that we may incur. We anticipate that we will need to increase our insurance coverage each time we commence a clinical trial and if we successfully commercialize any vaccine candidate. Insurance availability, coverage terms and pricing continue to vary with market conditions. We endeavor to obtain appropriate insurance coverage for insurable risks that we identify; however, we may fail to correctly anticipate or quantify insurable risks, we may not be able to obtain appropriate insurance coverage and insurers may not respond as we intend to cover insurable events that may occur. Conditions in the insurance markets relating to nearly all areas of traditional corporate insurance change rapidly and may result in higher premium costs, higher policy deductibles and lower coverage limits. For some risks, we may not have or maintain insurance coverage because of cost or availability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Risks Related to Our Reliance on Third Parties</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We rely and will continue to rely on third parties to conduct our preclinical studies and clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval of or commercialize our vaccine candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We currently do not have the ability to independently conduct preclinical or clinical studies that comply with the regulatory requirements known as good laboratory practices and GCP. The FDA and regulatory authorities in other jurisdictions require us to comply with GCP requirements for conducting, monitoring, recording and reporting the results of clinical trials, in order to ensure that the data and results are scientifically credible and accurate and that the trial subjects are adequately informed of the potential risks of participating in clinical trials. We rely on independent investigators and collaborators, such as universities, medical institutions, CROs and strategic partners, to conduct our preclinical and clinical trials under agreements with us.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We will need to negotiate budgets and contracts with CROs and study sites, which may result in delays to our development timelines and increased costs. We will rely heavily on these third parties over the course of our clinical trials, and we control only certain aspects of their activities. Nevertheless, we are responsible for ensuring that each of our studies is conducted in accordance with applicable protocol and legal, regulatory and scientific</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">70</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">standards, and our reliance on third parties does not relieve us of our regulatory responsibilities. We and these third parties are required to comply with GCPs, which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities for vaccine candidates in clinical development. Regulatory authorities enforce these GCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any of these third parties fail to comply with applicable GCP regulations, the clinical data generated in our clinical trials may be deemed unreliable, and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. There can be no assurance that, upon inspection, such regulatory authorities will determine that any of our clinical trials comply with the GCP regulations. In addition, our clinical trials must be conducted with biologic product produced under cGMPs and will require a large number of test subjects. Our failure or any failure by these third parties to comply with these regulations or to recruit a sufficient number of subjects may require us to repeat clinical trials, which would delay the regulatory approval process. Moreover, our business may be implicated if any of these third parties violates federal or state fraud and abuse or false claims laws and regulations or healthcare privacy and security laws.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Any third parties conducting our preclinical studies and clinical trials will not be our employees and, except for remedies available to us under our agreements with such third parties, we cannot control whether or not they devote sufficient time and resources to our programs. These third parties may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials or other drug development activities, which could affect their performance on our behalf. If these third parties do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated and we may not be able to complete development of, obtain regulatory approval of or successfully commercialize our vaccine candidates. As a result, our financial results and the commercial prospects for our vaccine candidates would be harmed, our costs could increase and our ability to generate revenue could be delayed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If any of our relationships with trial sites or any CRO that we may use in the future terminate, we may not be able to enter into arrangements with alternative trial sites or CROs or do so on commercially reasonable terms. Switching or adding third parties to conduct our clinical trials involves substantial cost and requires extensive management time and focus. In addition, there is a natural transition period when a new third party commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We rely on third parties, including Sutro Biopharma and Lonza, to supply raw materials and manufacture our preclinical and clinical product supplies of our vaccine candidates, and expect to rely on third parties to supply raw materials and produce and process our vaccine candidates, if approved. The loss of these suppliers or their failure to comply with applicable regulatory requirements or provide us with sufficient quantities at acceptable quality levels or prices, or at all, would materially and adversely affect our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We do not have nor do we plan to build or acquire the infrastructure or capability internally to manufacture supplies for our vaccine candidates or the materials necessary to produce our vaccine candidates for use in the conduct of our preclinical studies or clinical trials, and we lack the internal resources and the capability to manufacture any of our vaccine candidates on a preclinical, clinical or commercial scale. We have entered into an agreement with Sutro Biopharma to supply us with extract and custom reagents for use in manufacturing non-clinical and certain clinical supply of vaccine compositions. We have engaged Lonza to perform manufacturing process development and clinical manufacture and supply of components for VAX-24, including the manufacture of polysaccharide antigens, our proprietary eCRM protein carrier and conjugated drug substances. We also engaged Lonza to perform manufacturing process development and clinical manufacture and supply of VAX-24 finished drug product. Our agreements with Lonza are denominated in Swiss Francs. Fluctuations in the exchange rate for Swiss Francs may increase our costs and affect our operating results.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We intend to engage with Lonza and other outside vendors to manufacture supplies for our vaccine candidates. Lonza is currently in the process of manufacturing our vaccine candidates on a clinical scale. We have not yet caused our vaccine candidates to be manufactured on a commercial scale and may not be able to achieve commercial scale manufacturing and may be unable to create an inventory of mass-produced product to satisfy demands for any of our vaccine candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">71</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We do not yet have sufficient information to reliably estimate the cost of the commercial manufacturing and processing of our vaccine candidates, and the actual cost to manufacture and process our vaccine candidates could materially and adversely affect the commercial viability of our vaccine candidates. As a result, we may never be able to develop a commercially viable product.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, our anticipated reliance on a limited number of third-party suppliers and manufacturers exposes us to the following risks:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may be unable to identify manufacturers on acceptable terms or at all because the number of potential manufacturers is limited and the FDA may have questions regarding any replacement contractor. This may require new testing and regulatory interactions. In addition, a new manufacturer would have to be educated in, or develop substantially equivalent processes for, production of our products after receipt of FDA questions, if any. </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our third-party suppliers and manufacturers might be unable to timely formulate and manufacture or supply raw materials for our vaccine candidates or produce the quantity and quality required to meet our clinical and commercial needs, if any. </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Contract manufacturers may not be able to execute our manufacturing procedures appropriately. </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our future contract manufacturers may not perform as agreed or may not remain in the contract manufacturing business for the time required to supply our clinical trials or to successfully produce, store and distribute our products. </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Manufacturers are subject to ongoing periodic unannounced inspection by the FDA, the Drug Enforcement Administration and corresponding state agencies to ensure strict compliance with cGMP and other government regulations and corresponding foreign standards. We do not have control over third-party manufacturers&#x2019; compliance with these regulations and standards. </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may not own, or may have to share, the intellectual property rights to any improvements made by our third-party manufacturers in the manufacturing process for our products. </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our third-party suppliers and manufacturers could breach or terminate their agreement with us. </span></div></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Each of these risks could delay our clinical trials, the approval, if any, of our vaccine candidates by the FDA or the commercialization of our vaccine candidates, or result in higher costs or deprive us of potential product revenue. In addition, we will rely on third parties to perform release tests on our vaccine candidates prior to delivery to patients. If these tests are not appropriately done and test data are not reliable, patients could be put at risk of serious harm.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If we or our third-party suppliers use hazardous, non-hazardous, biological or other materials in a manner that causes injury or violates applicable law, we may be liable for damages.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our research and development activities involve the controlled use of potentially hazardous substances, including chemical and biological materials. We and our suppliers are subject to federal, state and local laws and regulations in the United States governing the use, manufacture, storage, handling and disposal of medical and hazardous materials. Although we believe that we and our suppliers&#x2019; procedures for using, handling, storing and disposing of these materials comply with legally prescribed standards, we and our suppliers cannot completely eliminate the risk of contamination or injury resulting from medical or hazardous materials. As a result of any such contamination or injury, we may incur liability or local, city, state or federal authorities may curtail the use of these materials and interrupt our business operations. In the event of an accident, we could be held liable for damages or penalized with fines, and the liability could exceed our resources. We do not have any insurance for liabilities arising from medical or hazardous materials. Compliance with applicable environmental laws and regulations is expensive, and current or future environmental regulations may impair our research, development and production efforts, which could harm our business prospects, financial condition or results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">72</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Risks Related to Government Regulation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">The FDA regulatory approval process is lengthy and time-consuming, and we may experience significant delays in the clinical development and regulatory approval of our vaccine candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The research, testing, manufacturing, labeling, approval, selling, import, export, marketing and distribution of drug products, including biologics such as conjugate vaccines, are subject to extensive regulation by the FDA and other regulatory authorities in the United States. We expect that our vaccine candidates will be regulated by the FDA as biologics. We are not permitted to market any biological drug product in the United States until we receive approval of a Biologics License Application, or BLA, from the FDA. We have not previously submitted a BLA to the FDA, or similar approval filings to comparable foreign regulatory authorities. A BLA must include extensive preclinical and clinical data and supporting information to establish the vaccine candidate&#x2019;s safety and effectiveness for each desired indication. Further, because our vaccine candidates that are subject to regulation as biological drug products, we will need to demonstrate that they are safe, pure and potent for use in their target indications. The BLA must also include significant information regarding the CMC for the product, including with respect to chain of identity and chain of custody of the product.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical trial process. The results of preclinical studies of our vaccine candidates may not be predictive of the results of early-stage or later-stage clinical trials, and results of early clinical trials of our vaccine candidates may not be predictive of the results of later-stage clinical trials. The results of clinical trials in one set of patients or indications may not be predictive of those obtained in another. In some instances, there can be significant variability in safety or efficacy results between different clinical trials of the same vaccine candidate due to numerous factors, including changes in trial procedures set forth in protocols, differences in the size and type of the patient populations, changes in and adherence to the dosing regimen and other clinical trial protocols and the rate of dropout among clinical trial participants. Vaccine candidates in later stages of clinical trials may fail to show the desired safety and efficacy profile despite having progressed through preclinical studies and initial clinical trials. A number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or unacceptable safety issues, notwithstanding promising results in earlier trials. Most vaccine candidates that begin clinical trials are never approved by regulatory authorities for commercialization. In addition, even if such clinical trials are successfully completed, we cannot guarantee that the FDA or foreign regulatory authorities will interpret the results as we do, and more trials could be required before we submit a BLA or other marketing application.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may also experience delays in completing planned clinical trials for a variety of reasons, including delays related to:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">obtaining regulatory authorization to begin a trial, if applicable; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the availability of financial resources to commence and complete the planned trials; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">reaching agreement on acceptable terms with prospective CROs and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">obtaining approval at each clinical trial site by an independent IRB; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">recruiting suitable volunteers to participate in and complete a trial; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">clinical trial sites deviating from trial protocol or dropping out of a trial; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">addressing any safety concerns that arise during the course of a trial; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">adding new clinical trial sites; or </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">73</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">manufacturing sufficient quantities of qualified materials under cGMPs and applying them for use in clinical trials. </span></div></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We could also encounter delays if physicians encounter unresolved ethical issues associated with enrolling patients in clinical trials of our vaccine candidates in lieu of using existing vaccines that have established safety and efficacy profiles. Further, a clinical trial may be suspended or terminated by us, the IRBs for the institutions in which such trials are being conducted or by the FDA or other regulatory authorities due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a vaccine candidate, changes in governmental regulations or administrative actions, lack of adequate funding to continue the clinical trial or based on a recommendation by the data safety monitoring board. If we experience termination of, or delays in the completion of, any clinical trial of our vaccine candidates, the commercial prospects for our vaccine candidates will be harmed, and our ability to generate product revenue will be delayed. In addition, any delays in completing our clinical trials will increase our costs, slow down our product development and approval process and jeopardize our ability to commence product sales and generate revenue.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may ultimately lead to the denial of regulatory approval of our vaccine candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">The FDA may disagree with our regulatory plan, and we may fail to obtain regulatory approval of our vaccine candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The general approach for FDA approval of a new biologic or drug is for the sponsor to provide dispositive data from two Phase 3 clinical trials of the relevant biologic or drug in the relevant patient population. Phase 3 clinical trials typically involve hundreds of patients, have significant costs and are time consuming. While we have not had extensive discussions with the FDA regarding our regulatory plan, as a prerequisite for FDA approval, we believe that any new PCV, such as VAX-24, will have to be compared to the current standard of care, Prevnar 13 in infants and Prevnar 20 in adults. We believe that a successful comparison would be based on demonstrating clinical non-inferiority of the immune response to Prevnar 20 for common serotypes. In addition, we expect to use OPA titers as the primary immunogenicity surrogate endpoint for the VAX-24 program in adults because Prevnar 13 was approved based on the establishment of non-inferiority of OPA responses relative to Pneumovax 23, on a strain-by-strain basis. With the approval of Prevnar 20 in adults, if it becomes the standard of care, we would plan to demonstrate clinical non-inferiority to Prevnar 20 either along with or in lieu of Prevnar 13, but there can be no assurance that this approach would be sufficient for regulatory approval or that regulators would not require field efficacy trials. If the results are sufficiently compelling, we intend to discuss with the FDA submission of a BLA for VAX-24. However, we do not have any agreement or guidance from the FDA that our regulatory development plans will be sufficient for submission of a BLA for VAX-24.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may seek accelerated approval from the FDA for our vaccine candidates and, if granted, the FDA may require us to perform post-marketing studies as a condition of approval to verify and describe the predicted effect on irreversible morbidity or mortality or other clinical endpoint. If the results from such post-marketing studies are not positive or otherwise fail to show the predicted effect, the drug or biologic may be subject to expedited withdrawal procedures by the FDA. In addition, the standard of care may change with the approval of new products in the same disease areas that we are studying. This may result in the FDA or other regulatory agencies requesting additional studies to show that our vaccine candidate is non-inferior or superior to the new products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our clinical trial results may also not support approval. In addition, our vaccine candidates could fail to receive regulatory approval for many reasons, including the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that our vaccine candidates are safe and effective; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">74</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the results of clinical trials may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we may be unable to demonstrate that our vaccine candidates&#x2019; clinical and other benefits outweigh their safety risks; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">any changes to the required threshold for the achievement of non-inferiority using established surrogate immune endpoints that our PCVs will need to meet in our clinical trials; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">any vaccine to be approved in pediatric populations may need to undergo extensive vaccine-vaccine interference studies with the standard of care pediatric vaccine regimen; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the need to perform superiority or field efficacy trials, which can be larger, longer and more costly, if an existing vaccine is approved for a disease indication; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the data collected from clinical trials of our vaccine candidates may not be sufficient to the satisfaction of the FDA or comparable foreign regulatory authorities to support the submission of a BLA or other comparable submission in foreign jurisdictions or to obtain regulatory approval in the United States or elsewhere; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the FDA or comparable foreign regulatory authorities will inspect the commercial manufacturing facilities we may utilize and may not approve such facilities; and </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Even if we receive regulatory approval of our vaccine candidates, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense, and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our vaccine candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Any regulatory approvals that we receive for our vaccine candidates may also be subject to limitations on the approved indicated uses for which a product may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including post-marketing clinical trials, and surveillance to monitor the safety and efficacy of the vaccine candidate.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, if the FDA or a comparable foreign regulatory authority approves our vaccine candidates, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, conduct of post-marketing studies, storage, sampling, advertising, promotion, import, export and recordkeeping for our vaccine candidates will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration and continued compliance with cGMPs and GCPs for any clinical trials that we conduct post-approval. As such, we and our contract manufacturers will be subject to continual review and inspections to assess compliance with cGMP and adherence to commitments made in any BLA, other marketing application and previous responses to inspectional observations. Accordingly, we and others with whom we work must continue to expend time, money and effort in all areas of regulatory compliance, including manufacturing, production and quality control. In addition, the FDA could require us to conduct another study to obtain additional safety or biomarker information. Further, we will be required to comply with FDA promotion and advertising rules, which include, among others, standards for direct-to-consumer advertising, restrictions on promoting products for uses or in patient populations that are not described in the product&#x2019;s approved uses (known as &#x201c;off-label use&#x201d;), limitations on industry-sponsored scientific and educational activities and requirements for promotional activities involving the internet and social media. Later discovery of previously unknown problems with our vaccine candidates, including side effects of unanticipated severity or frequency, or with our third-party</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">75</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">suppliers or manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of distribution or other restrictions. Other potential consequences include, among other things:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">restrictions on the marketing or manufacturing of our vaccine candidates, withdrawal of the product from the market or voluntary or mandatory product recalls; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">fines, warning letters or holds on clinical trials; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">refusal by the FDA to approve pending applications or supplements to approved applications filed by us or suspension or revocation of regulatory approvals; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">product seizure or detention, or refusal to permit the import or export of our vaccine candidates; and </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">injunctions or the imposition of civil or criminal penalties. </span></div></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The FDA&#x2019;s and other regulatory authorities&#x2019; policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our vaccine candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. For example, certain policies of the Trump administration may impact our business and industry. Namely, the Trump administration took several executive actions, including the issuance of a number of Executive Orders, that could impose significant burdens on, or otherwise materially delay, the FDA&#x2019;s ability to engage in routine oversight activities such as implementing statutes through rulemaking, issuance of guidance and review and approval of marketing applications. It is difficult to predict how these orders will be implemented, and the extent to which they will impact the FDA&#x2019;s ability to exercise its regulatory authority. If these executive actions impose restrictions on the FDA&#x2019;s ability to engage in oversight and implementation activities in the normal course, our business may be negatively impacted. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained, and we may not achieve or sustain profitability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Any government investigation of alleged violations of law could require us to expend significant time and resources in response, and could generate negative publicity. Any failure to comply with ongoing regulatory requirements may significantly and adversely affect our ability to commercialize and generate revenue from our products. If regulatory sanctions are applied or if regulatory approval is withdrawn, the value of our company and our operating results will be adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We expect the vaccine candidates we develop will be regulated as biological products, or biologics, and therefore they may be subject to competition sooner than anticipated.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Biologics Price Competition and Innovation Act of 2009, or BPCIA, was enacted as part of the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively, ACA, to establish an abbreviated pathway for the approval of biosimilar and interchangeable biological products. The regulatory pathway establishes legal authority for the FDA to review and approve biosimilar biologics, including the possible designation of a biosimilar as &#x201c;interchangeable&#x201d; based on its similarity to an approved biologic. Under the BPCIA, an application for a biosimilar product cannot be approved by the FDA until twelve years after the reference product was approved under a BLA. The law is complex and is still being interpreted and implemented by the FDA. As a result, its ultimate impact, implementation and meaning are subject to uncertainty. While it is uncertain when such processes intended to implement the BPCIA may be fully adopted by the FDA, any such processes could have a material adverse effect on the future commercial prospects for our biological products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We believe that any of the vaccine candidates we develop that is approved in the United States as a biological product under a BLA should qualify for the 12-year period of exclusivity. However, there is a risk that</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">76</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider the subject vaccine candidates to be reference products for competing products, potentially creating the opportunity for generic competition sooner than anticipated. Moreover, the extent to which a biosimilar, once approved, will be substituted for any one of the reference products in a way that is similar to traditional generic substitution for non-biological products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our relationships with customers, physicians and third-party payors are subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, health information privacy and security laws and other healthcare laws and regulations. If we or our employees, independent contractors, consultants, commercial partners and vendors violate these laws, we could face substantial penalties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Healthcare providers, including physicians and third-party payors, in the United States and elsewhere will play a primary role in the recommendation and prescription of any vaccine candidates for which we obtain marketing approval. Our current and future arrangements with healthcare professionals, principal investigators, consultants, customers and third-party payors subject us to various federal and state fraud and abuse laws and other healthcare laws.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">These laws may constrain the business or financial arrangements and relationships through which we conduct our operations, including how we research, market, sell and distribute our vaccine candidates, if approved. Such laws include:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and willfully soliciting, offering, receiving or providing any remuneration (including any kickback, bribe or certain rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, lease, order or recommendation of, any good, facility, item or service, for which payment may be made, in whole or in part, under any U.S. federal healthcare program, such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the U.S. federal civil and criminal false claims laws, including the civil False Claims Act, which can be enforced through civil whistleblower or qui tam actions, and civil monetary penalties laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, to the U.S. federal government, claims for payment or approval that are false or fraudulent, knowingly making, using or causing to be made or used, a false record or statement material to a false or fraudulent claim, or from knowingly making a false statement to avoid, decrease or conceal an obligation to pay money to the U.S. federal government. Pharmaceutical manufacturers can cause false claims to be presented to the U.S. federal government by engaging in impermissible marketing practices, such as the off-label promotion of a product for an indication for which it has not received FDA approval. In addition, the government may assert that a claim including items and services resulting from a violation of the U.S. federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the Health Insurance Portability and Accountability Act of 1996, or HIPAA, which prohibits, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement, in connection with the delivery of, or payment for, healthcare benefits, items or services. Similar to the U.S. federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the healthcare fraud statute implemented under HIPAA or specific intent to violate it in order to have committed a violation; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, and its implementing regulations, which also impose certain obligations, including </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">77</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;visibility:hidden;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;"></span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">mandatory contractual terms, with respect to safeguarding the privacy and security of individually identifiable health information of covered entities subject to the rule, including health plans, healthcare clearinghouses and certain healthcare providers and their business associates, independent contractors of a covered entity that perform certain services involving the use or disclosure of individually identifiable health information for or on their behalf, as well as their covered subcontractors;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the Federal Food Drug or Cosmetic Act, which prohibits, among other things, the adulteration or misbranding of drugs, biologics and medical devices; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the U.S. Physician Payments Sunshine Act and its implementing regulations, which require certain manufacturers of drugs, devices, biologics and medical supplies that are reimbursable under Medicare, Medicaid or the Children&#x2019;s Health Insurance Program, with specific exceptions, to report annually to the Centers for Medicare &amp; Medicaid Services, or CMS, information related to certain payments and other transfers of value to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), other healthcare professionals (such as physician assistants and nurse practitioners), and teaching hospitals, as well as information regarding ownership and investment interests held by the physicians described above and their immediate family members; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">analogous U.S. state laws and regulations, including: state anti-kickback and false claims laws, which may apply to our business practices, including but not limited to, research, distribution, sales and marketing arrangements and claims involving healthcare items or services reimbursed by any third-party payor, including private insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#x2019;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the U.S. federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws and regulations that require drug manufacturers to file reports relating to pricing and marketing information, which require tracking gifts and other remuneration and items of value provided to healthcare professionals and entities; state and local laws requiring the registration of pharmaceutical sales representatives; and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">similar healthcare laws and regulations in the EU and other jurisdictions, including reporting requirements detailing interactions with and payments to healthcare providers; and </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">laws governing the privacy and security of certain protected information, such as the European Union&#x2019;s General Data Protection Regulation, or GDPR, and the California Consumer Privacy Act, or CCPA, which impose obligations and restrictions on the collection, use and disclosure of personal data (including health data) relating to individuals located in the European Economic Area, or EEA, and California, respectively. </span></div></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may also be subject to other laws, such as the U.S. Foreign Corrupt Practices Act of 1977, as amended, which prohibit, among other things, U.S. companies and their employees and agents from authorizing, promising, offering or providing, directly or indirectly, corrupt or improper payments or anything else of value to foreign government officials, employees of public international organizations and foreign government owned or affiliated entities, candidates for foreign political office and foreign political parties or officials thereof, as well as federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Ensuring that our internal operations and business arrangements with third parties comply with applicable healthcare laws and regulations will likely be costly. It is possible that governmental authorities will conclude that our business practices, including our relationships with physicians and other healthcare providers, some of whom are compensated in the form of stock options for consulting services provided, may not comply with</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">78</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, injunctions, damages, fines, disgorgement, imprisonment, exclusion from participating in government-funded healthcare programs, such as Medicare and Medicaid, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of noncompliance with these laws, contractual damages, reputational harm and the curtailment or restructuring of our operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Even if resolved in our favor, litigation or other legal proceedings relating to healthcare laws and regulations may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development, manufacturing, sales, marketing or distribution activities. Uncertainties resulting from the initiation and continuation of litigation or other proceedings relating to applicable healthcare laws and regulations could have an adverse effect on our ability to compete in the marketplace. In addition, if the physicians or other providers or entities with whom we expect to do business are found not to be in compliance with applicable laws, they may be subject to significant criminal, civil or administrative sanctions, including exclusions from government-funded healthcare programs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Coverage and reimbursement may be limited or unavailable in certain market segments for our vaccine candidates, which could make it difficult for us to sell our vaccine candidates, if approved, profitably.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Successful sales of our vaccine candidates, if approved, depend on the availability of coverage and adequate reimbursement from third-party payors including governmental healthcare programs, such as Medicare and Medicaid, managed care organizations and commercial payors, among others. Significant uncertainty exists as to the coverage and reimbursement status of any vaccine candidates for which we obtain regulatory approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Patients who receive vaccines generally rely on third-party payors to reimburse all or part of the associated costs. Obtaining coverage and adequate reimbursement from third-party payors is critical to new product acceptance.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Third-party payors decide which drugs and treatments they will cover and the amount of reimbursement. Reimbursement by a third-party payor may depend upon a number of factors, including, but not limited to, the third-party payor&#x2019;s determination that use of a product is:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">a covered benefit under its health plan; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">safe, effective and medically necessary; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">appropriate for the specific patient; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">cost-effective; and </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">neither experimental nor investigational. </span></div></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Obtaining coverage and reimbursement of a product from a government or other third-party payor is a time-consuming and costly process that could require us to provide to the payor supporting scientific, clinical and cost-effectiveness data for the use of our products. Even if we obtain coverage for a given product, if the resulting reimbursement rates are insufficient, hospitals may not approve our product for use in their facility or third-party payors may require co-payments that patients find unacceptably high. Patients are unlikely to use our vaccine candidates unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost of our vaccine candidates. Separate reimbursement for the product itself may or may not be available. Instead, the hospital or administering physician may be reimbursed only for administering the product. Further, from time to time, CMS revises the reimbursement systems used to reimburse health care providers, including the Medicare</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">79</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Physician Fee Schedule and Outpatient Prospective Payment System, which may result in reduced Medicare payments. In some cases, private third-party payors rely on all or portions of Medicare payment systems to determine payment rates. Changes to government healthcare programs that reduce payments under these programs may negatively impact payments from third-party payors and reduce the willingness of physicians to use our vaccine candidates. Certain ACA marketplace and other private payor plans are required to include coverage for certain preventative services, including vaccinations recommended by the ACIP without cost share obligations (i.e., co-payments, deductibles or co-insurance) for plan members. Children through 18 years of age without other health insurance coverage may be eligible to receive such vaccinations free-of-charge through the CDC&#x2019;s Vaccines for Children program. For Medicare beneficiaries, vaccines may be covered under either the Part B program or Part D depending on several criteria, including the type of vaccine and the beneficiary&#x2019;s coverage eligibility. If our vaccine candidates, once approved, are covered only under the Part D program, physicians may be less willing to use our products because of the claims adjudication costs and time related to the claims adjudication process and collection of co-payments associated with the Part D program.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the United States, no uniform policy of coverage and reimbursement for products exists among third-party payors. Therefore, coverage and reimbursement for products can differ significantly from payor to payor. Further, one payor&#x2019;s determination to provide coverage for a product does not assure that other payors will also provide coverage for the product. Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development. Further, coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We intend to seek approval to market our vaccine candidates in both the United States and in selected foreign jurisdictions. If we obtain approval in one or more foreign jurisdictions for our vaccine candidates, we will be subject to rules and regulations in those jurisdictions. In some foreign countries, particularly those in Europe, the pricing of biologics is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after obtaining marketing approval of a vaccine candidate. Some of these countries may require the completion of clinical trials that compare the cost-effectiveness of a particular vaccine candidate to currently available vaccines. Other member states allow companies to fix their own prices for medicines but monitor and control company profits. The downward pressure on health care costs has become very intense. As a result, increasingly high barriers are being erected to the entry of new products. In addition, in some countries, cross-border imports from low-priced markets exert a commercial pressure on pricing within a country.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The marketability of any vaccine candidates for which we receive regulatory approval for commercial sale may suffer if government and other third-party payors fail to provide coverage and adequate reimbursement. We expect downward pressure on pharmaceutical pricing to continue. Further, coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Healthcare legislative reform measures may have a negative impact on our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the United States and some foreign jurisdictions, there have been, and we expect there will continue to be, several legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of vaccine candidates, restrict or regulate post-approval activities and affect our ability to profitably sell any vaccine candidates for which we obtain marketing approval. In particular, there have been and continue to be a number of initiatives at the U.S. federal and state levels that seek to reduce healthcare costs and improve the quality of healthcare. For example, in March 2010, the ACA was passed, which substantially changed the way healthcare is financed by both governmental and private payors in the United States. Among the provisions of the ACA, those of greatest importance to the pharmaceutical and biotechnology industries include:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">an annual, non-deductible fee on any entity that manufactures or imports certain branded prescription drugs and biologic agents, which is apportioned among these entities according to their market share in certain government healthcare programs; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">80</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">a Medicare Part D coverage gap discount program, in which manufacturers must agree to offer point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#x2019;s outpatient drugs to be covered under Medicare Part D; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program to 23.1% and 13.0% of the average manufacturer price for branded and generic drugs, respectively; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">a methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">extension of a manufacturer&#x2019;s Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to certain individuals with income at or below 133% of the federal poverty level, thereby potentially increasing a manufacturer&#x2019;s Medicaid rebate liability; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">expansion of the entities eligible for discounts under the Public Health Service pharmaceutical pricing program; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">a requirement that certain ACA marketplace and other private payor plans include coverage for preventative services, including vaccinations recommended by the ACIP without cost share obligations (i.e., co-payments, deductibles or co-insurance) for plan members; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in and conduct comparative clinical effectiveness research, along with funding for such research; and </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">establishment of a Center for Medicare and Medicaid Innovation at the CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending. </span></div></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">There have been executive, judicial and Congressional challenges to the ACA. For example, the Tax Act included a provision that repealed, effective January 1, 2019, the tax-based shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year, which is commonly referred to as the &#x201c;individual mandate.&#x201d; On June 17, 2021, the United States Supreme Court dismissed a challenge on procedural grounds that argued the ACA is unconstitutional in its entirety because the &#x201c;individual mandate&#x201d; was repealed by Congress. Thus, the ACA will remain in effect in its current form. Moreover, prior to the United States Supreme Court ruling, on January 28, 2021, President Biden issued an executive order that initiated a special enrollment period for purposes of obtaining health insurance coverage through the ACA marketplace, which began on February 15, 2021 and remained open through August 15, 2021. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. It is possible that the ACA will be subject to judicial or Congressional challenges in the future. It is unclear how any such challenges, other litigation, and the healthcare reform measures of the Biden administration will impact the ACA.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other legislative changes have been proposed and adopted in the United States since the ACA was enacted. These changes include aggregate reductions to Medicare payments to providers of 2% per fiscal year pursuant to the Budget Control Act of 2011, which began in 2013 and, due to subsequent legislative amendments to the statute, including the BBA and the Infrastructure Investment and Jobs Act, will remain in effect through 2031 unless additional Congressional action is taken. COVID-19 pandemic relief support legislation suspended the 2% Medicare sequester from May 1, 2020 through March 31, 2022. Under the current legislation, the actual reduction in</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">81</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Medicare payments will vary from 1% in 2022 to up to 3% in the final fiscal year of this sequester. The American Taxpayer Relief Act of 2012, among other things, further reduced Medicare payments to several types of providers, including hospitals and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. In addition, Congress is considering additional healthcare reform measures as a part of the budget reconciliation process.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Additional changes that may affect our business include the expansion of new programs such as Medicare payment for performance initiatives for physicians under the Medicare Access and CHIP Reauthorization Act of 2015, or MACRA, which ended the use of the statutory formula for clinician payment and established a quality payment incentive program, also referred to as the Quality Payment Program. This program provides clinicians with two ways to participate, including through the Advanced Alternative Payment Models, or APMs, and the Merit-based Incentive Payment System, or MIPS. In November 2019, CMS issued a final rule finalizing the changes to the Quality Payment Program. At this time, the full impact of the introduction of the Medicare quality payment program on overall physician reimbursement remains unclear. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Further, in the United States there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug and biological product pricing, reduce the cost of prescription drugs and biological products under government payor programs and review the relationship between pricing and manufacturer patient programs. At the federal level, the Trump administration used several means to propose or implement drug pricing reform, including through federal budget proposals, executive orders and policy initiatives. For example, on July 24, 2020 and September 13, 2020, the Trump administration announced several executive orders related to prescription drug pricing that attempt to implement several of the administration&#x2019;s proposals The FDA concurrently released a final rule and guidance in September 2020 providing pathways for states to build and submit importation plans for drugs from Canada. Further, on November 20, 2020, the Department of Health and Human Services, or HHS, finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The implementation of the rule has been delayed by the Biden administration from January 1, 2022 to January 1, 2023 in response to ongoing litigation. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a new safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers, the implementation of which have also been delayed until January 1, 2023. On November 20, 2020, CMS issued an interim final rule implementing President Trump&#x2019;s Most Favored Nation executive order, which would tie Medicare Part B payments for certain physician-administered drugs to the lowest price paid in other economically advanced countries, effective January 1, 2021. As a result of litigation challenging the Most Favored Nation model, on December 27, 2021, CMS published a final rule that rescinded the Most Favored Nation Model interim final rule. In July 2021, the Biden administration released an executive order, &#x201c;Promoting Competition in the American Economy,&#x201d; with multiple provisions aimed at prescription drugs. In response to Biden&#x2019;s executive order, on September 9, 2021, HHS released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform and sets out a variety of potential legislative policies that Congress could pursue as well as potential administrative actions HHS can take to advance these principles. No legislation or administrative actions have been finalized to implement these principles. It is unclear whether these or similar policy initiatives will be implemented in the future. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures and, in some cases, designed to encourage importation from other countries and bulk purchasing. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine which drugs, biological products and suppliers will be included in their healthcare programs. Furthermore, there has been increased interest by third-party payors and governmental authorities in reference pricing systems and publication of discounts and list prices.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We expect that additional U.S. federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that the U.S. federal government will pay for healthcare products and services, which could result in reduced demand for our current or any future vaccine candidates or additional pricing pressures. Further, it is possible that additional governmental action is taken in response to the ongoing COVID-19 pandemic.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">82</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action in the United States or any other jurisdiction. If we or any third parties we may engage are slow or unable to adapt to changes in existing or new requirements or policies, or if we or such third parties are not able to maintain regulatory compliance, our current or any future vaccine candidates we may develop may lose any regulatory approval that may have been obtained and we may not achieve or sustain profitability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We expect that these and other healthcare reform measures that may be adopted in the future may result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for any approved product, which could have an adverse effect on demand for our vaccine candidates. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Changes in funding for the FDA and other government agencies could hinder our ability to hire and retain key leadership and other personnel, or otherwise prevent new products and services from being developed or commercialized in a timely manner, which could negatively impact our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees and statutory, regulatory and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, including for 35 days beginning on December 22, 2018, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Separately, in response to the global COVID-19 pandemic, the FDA has adopted a risk-based system for the conduct of inspections of manufacturing facilities. Additionally, the FDA is conducting voluntary remote interactive evaluations of certain drug manufacturing facilities and clinical research sites where an in-person inspection would not be prioritized, deemed mission-critical, or where direct inspection is otherwise limited by travel restrictions, but where the FDA determines that remote evaluation would still be appropriate. Regulatory authorities outside the United States may adopt similar restrictions or other policy measures in response to the COVID-19 pandemic. If a prolonged government shutdown occurs, or if global health concerns continue to prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We are subject to increasingly stringent and rapidly changing laws and regulations related to privacy and data security. The restrictions and costs imposed by these requirements, or our actual or perceived failure to comply with them, could harm our reputation, subject us to significant fines and liability, and adversely affect our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the ordinary course of business, we process personal data and other sensitive information, including proprietary and confidential business data, trade secrets, intellectual property, data we collect about trial participants in connection with clinical trials and other sensitive third-party data. We are subject to or affected by numerous evolving federal, state and foreign laws and regulations, as well as policies, contracts, industry standards and other obligations governing the collection, use, disclosure, retention and security of personal data. The global data protection landscape is rapidly evolving, and implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">83</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For example, HIPAA, as amended by HITECH, imposes requirements relating to the privacy and security of individually identifiable health information on health plans, healthcare clearinghouses and certain healthcare providers, and their respective contractors and their covered subcontractors that perform services for them involving individually identifiable health information. Additionally, certain states have adopted healthcare privacy and security laws and regulations comparable to HIPAA, some of which may be more stringent than HIPAA. In the event we fail to properly maintain the privacy and security of individually identifiable health information governed by HIPAA or comparable state laws, or we are responsible for an unauthorized disclosure or security breach of such information, we could be subject to enforcement action under HIPAA or comparable state laws, and significant civil and criminal penalties, and fines.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are also subject to a growing body of privacy, data security and data protection laws outside of the United States. For example, the EU GDPR and the UK GDPR impose strict requirements for processing the personal data of individuals located, respectively within the EEA and the United Kingdom. Under the EU GDPR, government regulators may impose temporary or definitive bans on data processing, as well as fines of up to 20 million euros or 4% of annual global revenue, whichever is greater. Further, individuals may initiate litigation related to our processing of their personal data.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, many jurisdictions have enacted data localization laws and cross-border personal data transfer laws. These laws may make it more difficult for us to transfer personal data across jurisdictions, which could impede our business. For example, absent appropriate safeguards or other circumstances, the EU GDPR generally restricts the transfer of personal data to countries outside of the EEA, such as the United States, which the European Commission does not consider to be providing an adequate level of data privacy and security. The European Commission released a set of &#x201c;Standard Contractual Clauses&#x201d; that are designed to be a valid mechanism by which entities can transfer personal data out of the EEA to jurisdictions that the European Commission has not found to provide an adequate level of protection. Currently, these Standard Contractual clauses are a valid mechanism to transfer personal data outside of the EEA. The Standard Contractual Clauses, however, require parties that rely upon that legal mechanism to comply with additional obligations, such as conducting transfer impact assessments to determine whether additional security measures are necessary to protect the at-issue personal data. Moreover, due to potential legal challenges, there exists some uncertainty regarding whether the Standard Contractual Clauses will remain a valid mechanism for transfers of personal data out of the EEA. In addition, laws in Switzerland and the UK similarly restrict transfers of personal data outside of those jurisdictions to countries such as the United States that do not provide an adequate level of personal data protection. If we cannot implement a valid compliance mechanism for cross-border privacy and security transfers, we may face increased exposure to regulatory actions, substantial fines, and injunctions against processing or transferring personal data from Europe or elsewhere. The inability to import personal data to the United States could significantly and negatively impact our business operations, including by limiting our ability to conduct clinical trial activities in Europe and elsewhere; limiting our ability to collaborate with parties that are subject to European and other data privacy and security laws; or requiring us to increase our personal data processing capabilities in Europe and/or elsewhere at significant expense. Domestic privacy and data security laws beyond HIPAA and other healthcare privacy laws are also changing rapidly and becoming more complex. For example, the CCPA imposes obligations on businesses to which it applies. These obligations include, but are not limited to, providing specific disclosures in privacy notices and affording California residents certain rights related to their personal data. The CCPA allows for statutory fines for noncompliance (up to $7,500 per violation). In addition, it is anticipated that the California Privacy Rights Act of 2020 (&#x201c;CPRA&#x201d;), effective January 1, 2023, will expand the CCPA. For example, the CPRA establishes a new California Privacy Protection Agency to implement and enforce the CCPA (as amended), which could increase the risk of an enforcement action. Other states have enacted data privacy laws. For example, Virginia passed the Consumer Data Protection Act, and Colorado passed the Colorado Privacy Act, both of which differ from the CPRA and become effective in 2023. Furthermore, several states and localities have enacted statutes banning or restricting the collection of biometric information. If we become subject to new data privacy laws, at the state level, the risk of enforcement action against us could increase because we may become subject to additional obligations, and the number of individuals or entities that can initiate actions against us may increase (including individuals, via a private right of action, and state actors).</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our obligations related to data privacy and security are quickly changing in an increasingly stringent fashion, creating some uncertainty as to the effective future legal framework. Additionally, these obligations may be subject to differing applications and interpretations, which may be inconsistent or in conflict among jurisdictions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">84</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Preparing for and complying with these obligations requires us to devote significant resources (including, without limitation, financial and time-related resources). These obligations may necessitate changes to our information technologies, systems, and practices and to those of any third parties that process personal data on our behalf. In addition, these obligations may require us to change our business model. Although we endeavor to comply with all applicable data privacy and security obligations, we may at times fail (or be perceived to have failed) to do so. Moreover, despite our efforts, our personnel or third parties upon whom we rely may fail to comply with such obligations, which could negatively impact our business operations and compliance posture. For example, any failure by a third-party processor to comply with applicable law, regulations, or contractual obligations could result in adverse effects, including inability to operate our business and proceedings against us by governmental entities or others. If we fail, or are perceived to have failed, to address or comply with data privacy and security obligations, we could face significant consequences. These consequences may include, but are not limited to, government enforcement actions (e.g., investigations, fines, penalties, audits, inspections, and similar); litigation (including class-related claims); additional reporting requirements and/or oversight; bans on processing personal data; orders to destroy or not use personal data; and imprisonment of company officials. Any of these events could have a material adverse effect on our reputation, business, or financial condition, including but not limited to: loss of customers; interruptions or stoppages in our business operations (including clinical trials); interruptions or stoppages of data collection needed to train our algorithms; inability to process personal data or to operate in certain jurisdictions; limited ability to develop or commercialize our products; expenditure of time and resources to defend any claim or inquiry; adverse publicity; or revision or restructuring of our operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Risks Related to Our Intellectual Property</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If we are unable to obtain and maintain patent protection for our technology and products, or if the scope of the patent protection obtained is not sufficiently broad, we may not be able to compete effectively in our markets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We rely upon a combination of patents, trademarks, trade secret protection and confidentiality agreements to protect the intellectual property related to our vaccine development programs and vaccine candidates. Our success depends in large part on our ability to obtain and maintain patent protection in the United States and other countries with respect to VAX-24 and any future vaccine candidates, as well as methods of making our vaccine candidates and components thereof. We seek to protect our proprietary position by filing patent applications in the United States and abroad related to our development programs and vaccine candidates. The patent prosecution process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The patents and patent applications that we own or in-license may fail to result in issued patents with claims that protect VAX-24 or any future vaccine candidate in the United States or in other foreign countries. There is no assurance that all of the potentially relevant prior art relating to our patents and patent applications has been found, which can prevent a patent from issuing from a pending patent application, or be used to invalidate a patent. Even if patents do successfully issue and even if such patents cover VAX-24 or any future vaccine candidate, third parties may challenge their validity, enforceability or scope, which may result in such patents being narrowed, invalidated or held unenforceable. Any successful opposition to these patents or any other patents owned by or licensed to us could deprive us of rights necessary for the successful commercialization of any vaccine candidates or companion diagnostic that we may develop. Further, if we encounter delays in regulatory approvals, the period of time during which we could market a vaccine candidate under patent protection could be reduced.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If the patent applications we hold or have in-licensed with respect to our development programs and vaccine candidates fail to issue, if their breadth or strength of protection is threatened, or if they fail to provide meaningful exclusivity for VAX-24 or any future vaccine candidate, it could dissuade companies from collaborating with us to develop vaccine candidates and threaten our ability to commercialize future vaccines. Any such outcome could have a materially adverse effect on our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has been and will continue to be the subject of litigation and new legislation. In addition, the laws of foreign countries may not protect our rights to the same extent as the laws of the United States. For example, many countries restrict the patentability of methods of treatment of the human body. Publications of discoveries in scientific literature often lag behind the actual discoveries, and patent applications in</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">85</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot know with certainty whether we were the first to make the inventions claimed in our owned or licensed patents or pending patent applications, or that we were the first to file for patent protection of such inventions. As a result of these and other factors, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our pending and future patent applications may not result in patents being issued which protect our technology or products, in whole or in part, or which effectively prevent others from commercializing competitive technologies and products. Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents or narrow the scope of our patent protection.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Moreover, we may be subject to a third-party pre-issuance submission of prior art to the U.S. Patent and Trademark Office, or the USPTO, or become involved in opposition, derivation, reexamination, inter partes review, post-grant review or interference proceedings challenging our patent rights or the patent rights of others. The costs of defending our patents or enforcing our proprietary rights in post-issuance administrative proceedings and litigation can be substantial and the outcome can be uncertain. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our technology or products and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future vaccine candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our owned and licensed patents may be challenged in the courts or patent offices in the United States and abroad. Such challenges may result in loss of exclusivity or freedom to operate or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and products. Generally, issued patents are granted a term of 20 years from the earliest claimed non-provisional filing date. In certain instances, patent term can be adjusted to recapture a portion of delay by the USPTO in examining the patent application (patent term adjustment) or extended to account for term effectively lost as a result of the FDA regulatory review period (patent term extension), or both. The scope of patent protection may also be limited. Without patent protection for our current or future vaccine candidates, we may be open to competition from generic versions of such products. Given the amount of time required for the development, testing and regulatory review of new vaccine candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If we fail to comply with our obligations under any license, collaboration or other agreements, we may be required to pay damages and could lose intellectual property rights that are necessary for developing and protecting our vaccine candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have licensed certain intellectual property rights related to the XpressCF platform, components of our PCV candidates, and methods of making components of VAX-24 from Sutro Biopharma and University of Georgia Research Foundation, Inc. We also license certain intellectual property rights related to a non-cross-reactive Group A Strep carbohydrate antigen and related methods of production from the Regents of the University of California. If, for any reason, these agreements are terminated or we otherwise lose those rights, it could adversely affect our business. These agreements impose, and any future collaboration agreements or license agreements we enter into are likely to impose, various development, commercialization, funding, milestone, royalty, diligence, sublicensing, insurance, patent prosecution and enforcement or other obligations on us. If we breach any material obligations, or use the intellectual property licensed to us in an unauthorized manner, we may be required to pay damages and the licensor(s) may have the right to terminate the license, which could result in us being unable to develop, manufacture and sell products that are covered by the licensed technology or enable a competitor to gain access to the licensed technology.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">86</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for noncompliance with these requirements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Periodic maintenance fees on any issued patent are due to be paid to the USPTO and other foreign patent agencies in several stages over the lifetime of the patent. The USPTO and various foreign national or international patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Noncompliance events that could result in abandonment or lapse of patent rights include, but are not limited to, failure to timely file national and regional stage patent applications based on our international patent application, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. If we or our licensors fail to maintain the patents and patent applications covering VAX-24 or any future vaccine candidate, or the XpressCF platform, our competitors might be able to enter the market, which would have an adverse effect on our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Third-party claims or litigation alleging infringement of patents or other proprietary rights, or seeking to invalidate our patents or other proprietary rights, may delay or prevent the development and commercialization of VAX-24 and any future vaccine candidate.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our commercial success depends in part on our avoiding infringement and other violations of the patents and proprietary rights of third parties. There is a substantial amount of litigation, both within and outside the United States, involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries, including patent infringement lawsuits, interferences, derivation and administrative law proceedings, inter partes review and post-grant review before the USPTO, as well as oppositions and similar processes in foreign jurisdictions. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we and our collaborators are developing vaccine candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, and as we gain greater visibility and market exposure as a public company, the risk increases that our vaccine candidates or other business activities may be subject to claims of infringement of the patent and other proprietary rights of third parties. Third parties may assert that we are infringing their patents or employing their proprietary technology without authorization.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Also, there may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our vaccine candidates. Because patent applications can take many years to issue, there may be currently pending patent applications which may later result in issued patents that our vaccine candidates may infringe.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, third parties may obtain patent rights in the future and claim that use of our technologies infringes upon rights. If any third-party patents were held by a court of competent jurisdiction to cover the manufacturing process of any of our vaccine candidates, any molecules formed during the manufacturing process or any final product itself, the holders of any such patents may be able to block our ability to commercialize such vaccine candidate unless we obtained a license under the applicable patents, or until such patents expire. Similarly, if any third-party patent were held by a court of competent jurisdiction to cover aspects of our formulations, processes for manufacture or methods of use, including combination therapy, the holders of any such patent may be able to block our ability to develop and commercialize the applicable vaccine candidate unless we obtained a license or until such patent expires. In either case, such a license may not be available on commercially reasonable terms or at all. In addition, we may be subject to claims that we are infringing other intellectual property rights, such as trademarks or copyrights, or misappropriating the trade secrets of others, and to the extent that our employees, consultants or contractors use intellectual property or proprietary information owned by others in their work for us, disputes may arise as to the rights in related or resulting know-how and inventions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Parties making claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize one or more of our vaccine candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">87</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">employee resources from our business. In the event of a successful infringement or other intellectual property claim against us, we may have to pay substantial damages, including treble damages and attorneys&#x2019; fees for willful infringement, obtain one or more licenses from third parties, pay royalties or redesign our affected products, which may be impossible or require substantial time and monetary expenditure. We cannot predict whether any such license would be available at all or whether it would be available on commercially reasonable terms.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Furthermore, as the vaccine patent landscape is crowded and highly competitive, even in the absence of litigation we may need to obtain licenses from third parties to advance our research or allow commercialization of our vaccine candidates, and we have done so from time to time. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In that event, we would be unable to further develop and commercialize one or more of our vaccine candidates, which could harm our business significantly. We cannot provide any assurances that third-party patents do not exist which might be enforced against vaccine candidates resulting in either an injunction prohibiting our sales, or, with respect to our sales, an obligation on our part to pay royalties or other forms of compensation to third parties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We may become involved in lawsuits to protect or enforce our patents, the patents of our licensors or our other intellectual property rights, which could be expensive, time consuming and unsuccessful.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Competitors may infringe or otherwise violate our patents, the patents of our licensors or our other intellectual property rights. To counter infringement or unauthorized use, we may be required to file legal claims, which can be expensive and time-consuming. In addition, in an infringement proceeding, a court may decide that a patent of ours or our licensors is not valid or is unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation or defense proceedings could put one or more of our patents at risk of being invalidated or interpreted narrowly and could put our patent applications at risk of not issuing. The initiation of a claim against a third party may also cause the third party to bring counter claims against us such as claims asserting that our patents are invalid or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, non-enablement or lack of statutory subject matter. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant material information from the USPTO, or made a materially misleading statement, during prosecution. Third parties may also raise similar validity claims before the USPTO in post-grant proceedings such as ex parte reexaminations, inter partes review or post-grant review, or oppositions or similar proceedings outside the United States, in parallel with litigation or even outside the context of litigation. The outcome following legal assertions of invalidity and unenforceability is unpredictable. We cannot be certain that there is no invalidating prior art, of which we and the patent examiner were unaware during prosecution. For the patents and patent applications that we have licensed, we may have limited or no right to participate in the defense of any licensed patents against challenge by a third party. If a defendant were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of any future patent protection on our current or future vaccine candidates. Such a loss of patent protection could harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may not be able to prevent, alone or with our licensors, misappropriation of our intellectual property rights, particularly in countries where the laws may not protect those rights as fully as in the United States. Our business could be harmed if in litigation the prevailing party does not offer us a license on commercially reasonable terms. Any litigation or other proceedings to enforce our intellectual property rights may fail, and even if successful, may result in substantial costs and distract our management and other employees.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have an adverse effect on the price of our common shares.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">88</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Changes in U.S. patent law or the patent law of other countries or jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The United States has enacted and implemented wide-ranging patent reform legislation. The U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on actions by the U.S. Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce patents that we have licensed or that we might obtain in the future. Similarly, changes in patent law and regulations in other countries or jurisdictions or changes in the governmental bodies that enforce them or changes in how the relevant governmental authority enforces patent laws or regulations may weaken our ability to obtain new patents or to enforce patents that we have licensed or that we may obtain in the future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Any trademarks we may obtain may be infringed or successfully challenged, resulting in harm to our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We expect to rely on trademarks as one means to distinguish any of our vaccine candidates that are approved for marketing from the products of our competitors. We have not yet selected trademarks for our vaccine candidates and have not yet begun the process of applying to register trademarks for our current or any future vaccine candidates. Once we select trademarks and apply to register them, our trademark applications may not be approved. Third parties may oppose our trademark applications or otherwise challenge our use of the trademarks. In the event that our trademarks are successfully challenged, we could be forced to rebrand our products, which could result in loss of brand recognition and could require us to devote resources to advertising and marketing new brands. Our competitors may infringe our trademarks, and we may not have adequate resources to enforce our trademarks.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, any proprietary name we propose to use with our current or any other vaccine candidate in the United States must be approved by the FDA, regardless of whether we have registered it, or applied to register it, as a trademark. The FDA typically conducts a review of proposed product names, including an evaluation of the potential for confusion with other product names. If the FDA objects to any of our proposed proprietary product names, we may be required to expend significant additional resources in an effort to identify a suitable proprietary product name that would qualify under applicable trademark laws, not infringe the existing rights of third parties and be acceptable to the FDA.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We may not be able to protect our intellectual property rights throughout the world, which could impair our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Filing, prosecuting and defending patents covering our current vaccine candidates and any future vaccine candidate throughout the world would be prohibitively expensive. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we may obtain patent protection, but where patent enforcement is not as strong as that in the United States. These products may compete with our products in jurisdictions where we do not have any issued or licensed patents and any future patent claims or other intellectual property rights may not be effective or sufficient to prevent them from so competing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Because we expect to rely on third parties to manufacture VAX-24 and any future vaccine candidates, and we expect to collaborate with third parties on the development of VAX-24 and any future vaccine candidates, we must, at times, share trade secrets with them. We also conduct joint research and development that may require us to share trade secrets under the terms of our research and development partnerships or similar agreements. We seek to protect our proprietary technology in part by entering into confidentiality agreements and, if applicable, material transfer agreements, consulting agreements or other similar agreements with our advisors, employees, third-party contractors and consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information, including our</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">89</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">trade secrets. Despite the contractual provisions employed when working with third parties, the need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others or are disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on our know-how and trade secrets, a competitor&#x2019;s discovery of our trade secrets or other unauthorized use or disclosure would impair our competitive position and may have an adverse effect on our business and results of operations. Further, disputes may arise under these agreements regarding inventorship or ownership of proprietary information generated during research and development.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, these agreements typically restrict the ability of our advisors, employees, third-party contractors and consultants to publish data potentially relating to our trade secrets, although our agreements may contain certain limited publication rights. Despite our efforts to protect our trade secrets, our competitors may discover our trade secrets, either through breach of our agreements with third parties, independent development or publication of information by any of our third-party collaborators. A competitor&#x2019;s discovery of our trade secrets would impair our competitive position and have an adverse impact on our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of their former employers or other third parties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We employ individuals who were previously employed at other biotechnology or pharmaceutical companies. Although we seek to protect our ownership of intellectual property rights by ensuring that our agreements with our employees, collaborators and other third parties with whom we do business include provisions requiring such parties to assign rights in inventions to us, we may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed confidential information of our employees&#x2019; former employers or other third parties. We may also be subject to claims that former employers or other third parties have an ownership interest in our patents. Litigation may be necessary to defend against these claims. There is no guarantee of success in defending these claims, and if we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Even if we are successful, litigation could result in substantial cost and be a distraction to our management and other employees.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Risks Related to Ownership of Our Common Stock</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">The price of our stock may be volatile, and the value of our common stock may decline.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The market price of our common stock may be highly volatile and could be subject to wide fluctuations in response to various factors, some of which are beyond our control, including limited trading volume. In particular, the COVID-19 pandemic has further heightened the volatility of the stock market for biopharmaceutical companies. In addition to the factors discussed in this &#x201c;Risk Factors&#x201d; section and elsewhere in this Annual Report on Form 10-K, these factors include:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the commencement, enrollment or results of our planned or future preclinical studies or clinical trials of our vaccine candidates and those of our competitors; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">regulatory or legal developments in the United States and abroad; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the success of competitive vaccines or technologies; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">developments or disputes concerning patent applications, issued patents or other proprietary rights; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the level of expenses related to our vaccine candidates or preclinical and clinical development programs; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the results of our efforts to develop additional vaccine candidates; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">90</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">actual or anticipated changes in estimates as to financial results, development timelines or recommendations or reports by securities analysts; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the level of expenses and capital investment related to manufacturing our vaccine candidates; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our inability to obtain or delays in obtaining adequate supply for any approved vaccine candidate; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">significant lawsuits, including patent or stockholder litigation; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">variations in our financial results or those of companies perceived to be similar to us; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">changes in the structure of healthcare payment systems, including coverage and adequate reimbursement for any approved vaccine; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">general economic, political and market conditions and overall fluctuations in the financial markets in the United States and abroad; and </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">investors&#x2019; general perception of us and our business. </span></div></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, the stock market in general, and the Nasdaq Global Select Market and biopharmaceutical companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies, including very recently in connection with the ongoing COVID-19 pandemic, which has resulted in decreased stock prices for many companies. Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance. In the past, securities class action litigation has often been instituted against companies following periods of volatility in the market price of a company&#x2019;s securities. You may not realize any return on your investment in us and may lose some or all of your investment. In the past, securities class action litigation has often been instituted against companies following periods of volatility in the market price of a company&#x2019;s securities. This type of litigation, if instituted, could result in substantial costs and a diversion of management&#x2019;s attention and resources, which would harm our business, operating results or financial condition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We do not intend to pay dividends on our common stock so any returns will be limited to the value of our stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. Any return to stockholders will therefore be limited to the appreciation of their stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our executive officers, directors and principal stockholders own a significant portion of our outstanding common stock. Accordingly, these stockholders have the ability to influence us through this ownership position and significantly affect the outcome of all matters requiring stockholder approval. For example, these stockholders may be able to significantly affect the outcome of elections of directors, amendments of our organizational documents or approval of any merger, sale of assets or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for our common stock that you may feel are in your best interest as one of our stockholders.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">As a public company, we are subject to more stringent federal and state law requirements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As a public company, we are subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act, the Dodd&#x2013;Frank Wall Street Reform and Consumer Protection Act, the listing requirements of The Nasdaq Stock Market LLC, or Nasdaq, and other applicable securities rules and regulations. As a public company we will incur significant legal, accounting and other expenses that we did not incur as a private company.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">91</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are also subject to more stringent state law requirements. For example, Senator Bill 826, or SB 826, generally requires public companies with principal executive offices in California to have a minimum number of females on the company&#x2019;s board of directors. By December 31, 2021, each public company with principal executive offices in California is required to have at least two females on its board of directors if the company has at least five directors, and at least three females on its board of directors if the company has at least six directors. Bill 979, or AB 979, generally requires public companies with principal executive offices in California to include specified numbers of directors from &#x201c;underrepresented communities.&#x201d; A director from an &#x201c;underrepresented community&#x201d; means a director who self-identifies as Black, African American, Hispanic, Latino, Asian, Pacific Islander, Native American, Native Hawaiian, Alaska Native, gay, lesbian, bisexual, or transgender. By December 31, 2021, each public company with principal executive offices in California is required to have at least one director from an underrepresented community. By December 31, 2022, a public company with more than four but fewer than nine directors will be required to have a minimum of two directors from underrepresented communities, and a public company with nine or more directors will need to have a minimum of three directors from underrepresented communities. Neither SB 826 nor AB 979 provide a transition period for newly listed companies.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are currently in compliance with SB 826 and AB979. If we fail to comply with either SB 826 or AB 979 in the future, we could be fined by the California Secretary of State, with a $100,000 fine for the first violation and a $300,000 fine for each subsequent violation of either law, and our reputation may be adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Future sales of a substantial number of shares of our common stock, or the perception that such sales could occur, could cause our stock price to fall.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Sales of a substantial number of shares of our common stock in the public market could occur at any time. These sales, or the public&#x2019;s perception that such sales could occur, could have an adverse effect on the market price of our common stock. Moreover, holders of up to an aggregate of 28,610,337 shares of our common stock have the right to require us to register these shares under the Securities Act of 1933, as amended, or the Securities Act, pursuant to an investors&#x2019; rights agreement. In addition, for the three months ended December 31, 2021, the average daily trading volume for our common stock on the Nasdaq Global Select Market was 154,410 shares. As a result of the low trading volume of our common stock, the trading of relatively small quantities of shares by our stockholders could disproportionately influence the market price of our common stock in either direction. The price for our shares could, for example, decline significantly in the event that a large number of shares of our common stock are sold on the market without commensurate demand, as compared to an issuer with a higher trading volume that could better absorb those sales without an adverse impact on its stock price.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Provisions in our corporate charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Provisions in our amended and restated certificate of incorporation and amended and restated bylaws may discourage, delay or prevent a merger, acquisition or other change in control of us that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares. These provisions also could limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, because our board of directors is responsible for appointing the members of our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. Among other things, these provisions:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.1020833333333333;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">establish a classified board of directors such that not all members of the board are elected at one time; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.1020833333333333;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">allow the authorized number of our directors to be changed only by resolution of our board of directors; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.1020833333333333;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">limit the manner in which stockholders can remove directors from the board; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">92</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.1020833333333333;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">establish advance notice requirements for stockholder proposals that can be acted on at stockholder meetings and nominations to our board of directors; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.1020833333333333;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">require that stockholder actions must be effected at a duly called stockholder meeting and prohibit actions by our stockholders by written consent; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.1020833333333333;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">prohibit our stockholders from calling a special meeting of our stockholders; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.1020833333333333;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">authorize our board of directors to issue preferred stock without stockholder approval, which could be used to institute a stockholder rights plan, or so-called &#x201c;poison pill,&#x201d; that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by our board of directors; and </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.1020833333333333;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">require the approval of the holders of at least 66 </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2044;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:bottom;font-size:6.7pt;font-family:Times New Roman;">3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the votes that all our stockholders would be entitled to cast to amend or repeal certain provisions of our charter or bylaws. </span></div></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, or DGCL, which prohibits a person who owns 15% or more of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired 15% or more of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner. These provisions could discourage potential acquisition proposals and could delay or prevent a change in control transaction. They could also have the effect of discouraging others from making tender offers for our common stock, including transactions that may be in your best interests. These provisions may also prevent changes in our management or limit the price that investors are willing to pay for our stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Claims for indemnification by our directors and officers may reduce our available funds to satisfy successful third-party claims against us and may reduce the amount of money available to us.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our amended and restated certificate of incorporation and amended and restated bylaws provide that we will indemnify our directors and officers, in each case, to the fullest extent permitted by Delaware law. Delaware law provides that directors of a corporation will not be personally liable for monetary damages for any breach of fiduciary duties as directors, except liability for:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">any breach of the director&#x2019;s duty of loyalty to the corporation or its stockholders; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">unlawful payments of dividends or unlawful stock repurchases or redemptions; or </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">any transaction from which the director derived an improper personal benefit. </span></div></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Such limitation of liability does not apply to liabilities arising under federal securities laws and does not affect the availability of equitable remedies such as injunctive relief or rescission.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our amended and restated bylaws provide that we are required to indemnify our directors and officers to the fullest extent permitted by Delaware law and may indemnify our other employees and agents. Our amended and restated bylaws also provide that, on satisfaction of certain conditions, we will advance expenses incurred by a director or officer in advance of the final disposition of any action or proceeding, and permit us to secure insurance on behalf of any officer, director, employee or other agent for any liability arising out of his or her actions in that capacity regardless of whether we would otherwise be permitted to indemnify him or her under the provisions of Delaware law. We have entered and expect to continue to enter into agreements to indemnify our directors and executive officers. With certain exceptions, these agreements provide for indemnification for related expenses, including attorneys&#x2019; fees, judgments, fines and settlement amounts incurred by any of these individuals in connection with any action, proceeding or investigation. We believe that these amended and restated certificate of</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">93</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">incorporation and amended and restated bylaws provisions and indemnification agreements are necessary to attract and retain qualified persons as directors and officers.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">While we maintain directors&#x2019; and officers&#x2019; liability insurance, such insurance may not be adequate to cover all liabilities that we may incur, which may reduce our available funds to satisfy third-party claims and may adversely impact our cash position.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware will, to the fullest extent permitted by applicable law, be the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders&#x2019; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware (or, in the event that the Court of Chancery does not have jurisdiction, the federal district court for the District of Delaware or other state courts of the State of Delaware), to the fullest extent permitted by applicable law, is the exclusive forum for the following types of actions or proceedings under Delaware statutory or common law:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">any derivative action or proceeding brought on our behalf; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">any action or proceeding asserting a claim of breach of a fiduciary duty owed by any of our current or former directors, officers or other employees to us or our stockholders; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">any action or proceeding asserting a claim against us or any of our current or former directors, officers or other employees, arising out of or pursuant to any provision of the DGCL, our certificate of incorporation or our bylaws; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">any action or proceeding to interpret, apply, enforce or determine the validity of our certificate of incorporation or our bylaws; and </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">any action or proceeding asserting a claim against us by any of our directors, officers or other employees governed by the internal affairs doctrine. </span></div></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">This provision would not apply to suits brought to enforce a duty or liability created by the Exchange Act. Furthermore, Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all such Securities Act actions. Accordingly, both state and federal courts have jurisdiction to entertain such claims. To prevent having to litigate claims in multiple jurisdictions and the threat of inconsistent or contrary rulings by different courts, among other considerations, our amended and restated certificate of incorporation provides that the federal district courts of the United States will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act. While the Delaware courts have determined that such choice of forum provisions are facially valid, a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum provisions. In such instance, we would expect to vigorously assert the validity and enforceability of the exclusive forum provisions of our amended and restated certificate of incorporation. This may require significant additional costs associated with resolving such action in other jurisdictions and there can be no assurance that the provisions will be enforced by a court in those other jurisdictions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">These exclusive-forum provisions may limit a stockholder&#x2019;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage these types of lawsuits. If a court were to find the exclusive-forum provision contained in our amended and restated certificate of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">General Risk Factors</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">94</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or vaccine candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may seek additional capital through a combination of public and private equity offerings, debt financings, strategic partnerships and alliances and licensing arrangements, including through the use of our &#x201c;at-the-market&#x201d; facility. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms may include liquidation or other preferences that adversely affect your rights as a stockholder. The incurrence of indebtedness would result in increased fixed payment obligations and could involve certain restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. If we raise additional funds through strategic partnerships and alliances and licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies or vaccine candidates, or grant licenses on terms unfavorable to us.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and stock price.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The global credit and financial markets have experienced extreme volatility and disruptions in the past several years, including most recently as a result of the COVID-19 pandemic. Such volatility and disruptions have caused and may continue to cause severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates and uncertainty about economic stability. There can be no assurance that further deterioration in credit and financial markets and confidence in economic conditions will not occur. Our general business strategy may be adversely affected by any such economic downturn, volatile business environment or continued unpredictable and unstable market conditions. If the current equity and credit markets deteriorate, it may make any necessary debt or equity financing more difficult, more costly and more dilutive. Failure to secure any necessary financing in a timely manner and on favorable terms could have a material adverse effect on our growth strategy, financial performance and stock price and could require us to delay or abandon clinical development plans. In addition, there is a risk that one or more of our current service providers, manufacturers and other partners may not survive an economic downturn, which could directly affect our ability to attain our operating goals on schedule and on budget.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">An active trading market for our common stock may never develop or be sustained.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our common stock is currently listed on the Nasdaq Global Select Market under the symbol &#x201c;PCVX.&#x201d; However, we cannot assure you that an active trading market for our shares will develop or be sustained. You may not be able to sell your shares quickly or at the market price if trading in shares of our common stock is not active. Further, an inactive market may also impair our ability to raise capital by selling shares of our common stock and may impair our ability to enter into strategic partnerships or acquire companies or products by using our shares of common stock as consideration.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our financial condition and results of operations may fluctuate from quarter to quarter and year to year, which makes them difficult to predict.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We expect our financial condition and results of operations to fluctuate from quarter to quarter and year to year due to a variety of factors, many of which are beyond our control. Accordingly, you should not rely upon the results of any quarterly or annual periods as indications of future operating performance.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We will incur significant increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As a public company, we will incur significant legal, accounting, investor relations and other expenses that we did not incur as a private company. In addition, the Sarbanes-Oxley Act and rules subsequently implemented by the SEC and Nasdaq have imposed various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Stockholder activism, the current political environment and the current high level of U.S. government intervention and regulatory reform</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">95</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">may also lead to substantial new regulations and disclosure obligations, which may in turn lead to additional compliance costs and impact the manner in which we operate our business in ways we do not currently anticipate. Our management and other personnel will need to devote a substantial amount of time to comply with these requirements. Moreover, these requirements will increase our legal and financial compliance costs and will make some activities more time-consuming and costly. For example, we expect that these rules and regulations may make it more difficult and more expensive for us to obtain director and officer liability insurance.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If we fail to maintain proper and effective internal control over financial reporting, our ability to produce accurate and timely financial statements could be impaired, investors may lose confidence in our financial reporting and the trading price of our common stock may decline.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to Section 404 of the Sarbanes-Oxley Act, we are required to furnish a report by management related to the internal control over financial reporting in our Form 10-K for the year ended December 31, 2021 and we will be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. The rules governing the standards that must be met for management to assess our internal control over financial reporting are complex and require significant documentation, testing and possible remediation. To comply with the Sarbanes-Oxley Act, the requirements of being a reporting company under the Exchange Act and any complex accounting rules in the future, we may need to upgrade our information technology systems, implement additional financial and management controls, reporting systems and procedures, and hire additional accounting and finance staff. We are currently in the process of hiring additional accounting and finance staff as we grow our business. If we are unable to hire the additional accounting and finance staff necessary to comply with these requirements, we may need to retain additional outside consultants. If we or, if required, our auditors, are unable to conclude that our internal control over financial reporting is effective, investors may lose confidence in our financial reporting and the trading price of our common stock may decline.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">There can be no assurance that there will not be material weaknesses in our internal control over financial reporting in the future. Any failure to maintain internal control over financial reporting could severely inhibit our ability to accurately report our financial condition, results of operations or cash flows. If we are unable to conclude that our internal control over financial reporting is effective, or if our independent registered public accounting firm determines that we have a material weakness in our internal control over financial reporting, investors may lose confidence in the accuracy and completeness of our financial reports, the market price of our common stock could decline and we could be subject to sanctions or investigations by Nasdaq, the SEC or other regulatory authorities. Failure to remedy any material weakness in our internal control over financial reporting, or to implement or maintain other effective control systems required of public companies, could also restrict our future access to the capital markets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our reported financial results may be adversely affected by changes in accounting principles generally accepted in the United States.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Generally accepted accounting principles in the United States are subject to interpretation by the Financial Accounting Standards Board, the SEC and various bodies formed to promulgate and interpret appropriate accounting principles. A change in these principles or interpretations could have a significant effect on our reported financial results, may retroactively affect previously reported results, could cause unexpected financial reporting fluctuations and may require us to make costly changes to our operational processes and accounting systems.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We designed our disclosure controls and procedures to reasonably assure that information we must disclose in reports we file or submit under the Exchange Act is accumulated and communicated to management, and recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">96</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The trading market for our common stock depends in part on the research and reports that securities or industry analysts publish about us or our business. We do not have control over these analysts. If securities or industry analysts do not publish research or reports about our business, the trading price for our stock would likely be negatively impacted. If one or more of the analysts who covers us downgrades our stock or publishes inaccurate or unfavorable research about our business, our stock price may decline. If one or more of these analysts ceases coverage of our company or fails to publish reports on us regularly, demand for our stock could decrease, which might cause our stock price and trading volume to decline.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">97</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_1b_unresolved_staff_comments"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 1B. Unresolve</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">d Staff Comments.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">None.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_2_properties"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 2. Pr</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">operties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our corporate headquarters is located at 825 Industrial Road, Suite 300, San Carlos, California 94070, where we lease and occupy 77,734 square feet of laboratory and office space. Our lease for our San Carlos headquarters expires on December 31, 2025. We use our corporate headquarters primarily for corporate research, development, regulatory, manufacturing and quality functions. We believe that our existing facilities are adequate to meet our current needs.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_3_legal_proceedings"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 3. Legal </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Proceedings.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">From time to time we may become involved in legal proceedings or be subject to claims arising in the ordinary course of our business. We are not presently a party to any legal proceedings that in the opinion of our management, if determined unfavorably to us, would have a material adverse effect on our business, financial condition, operating results or cash flows. Regardless of the outcome, litigation can, among other things, be time consuming and expensive to resolve and divert management resources.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_4_mine_safety_disclosures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 4. Mine Safe</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">ty Disclosures.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Not applicable.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">98</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">PART II</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_5_market_for_registrants_common_equ"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 5. Market for Registrant&#x2019;s Common Equity, Related Stock</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">holder Matters and Issuer Purchases of Equity Securities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Market Information for Our Common Stock</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our common stock commenced trading on the Nasdaq Global Select Market under the symbol &#x201c;PCVX&#x201d; on June 12, 2020.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Holders</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of February 23, 2022, there were approximately 21 holders of record of our common stock. The actual number of stockholders is greater than this number of record holders, and includes stockholders who are beneficial owners, but whose shares are held in street name by brokers and other nominees. This number of holders of record also does not include stockholders whose shares may be held in trust by other entities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Dividend Policy</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have not declared or paid any cash dividend on our common stock. We intend to retain any future earnings and do not expect to pay cash dividends in the foreseeable future. Payment of cash dividends, if any, in the future will be at the discretion of our board of directors and will depend on then-existing conditions, including our financial condition, operating results, contractual restrictions, capital requirements, business prospects and other factors our board of directors may deem relevant.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Securities Authorized for Issuance under Equity Compensation Plans</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Information about our equity compensation plans is incorporated herein by reference to Item 12 of Part III of this Annual Report on Form 10-K.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Stock Performance Graph</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">This performance graph shall not be deemed &#x201c;soliciting material&#x201d; or to be &#x201c;filed&#x201d; with the SEC for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities under that Section, and shall not be deemed to be incorporated by reference into any of our filings under the Securities Act, except to the extent that we specifically incorporate this information by reference therein, whether made before or after the date hereof and irrespective of any general incorporation language in any such filing.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following stock performance graph compares our cumulative total stock return relative to the cumulative total returns of the Nasdaq Composite Index and the Nasdaq Biotechnology Index for the period from June 12, 2020 (the date our common stock commenced trading on the Nasdaq Global Select Market) through December 31, 2021. The figures below assume an investment of $100 in our common stock at the closing price of $26.15 on June 12, 2020, the date of our IPO, and in each index on the same date and the reinvestment of the full amount of all dividends into shares of common stock; however, no dividends have been declared on our common</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">99</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">stock to date. The stockholder returns shown on the graph below are based on historical results and are not indicative of future performance, and we do not make or endorse any predictions as to future stockholder returns.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img69628308_21.jpg" alt="img69628308_21.jpg" style="width:531px;height:279px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Unregistered Sales of Equity Securities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">None</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Use of Proceeds from our Public Offering of Common Stock</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In June 2020, we closed our IPO of 17,968,750 shares of our common stock, including shares issued upon the exercise in full of the underwriters&#x2019; option to purchase 2,343,750 additional shares of common stock, at a public offering price of $16.00 per share. We received gross proceeds to us of $287.5 million. All of the shares issued and sold in our IPO were registered under the Securities Act pursuant to a registration statement on Form S-1 (File No. 333-238630), which was declared effective by the SEC on June 11, 2020. BofA Securities, Inc., Jefferies LLC and Evercore Group L.L.C. acted as joint book-running managers for the offering. Cantor Fitzgerald &amp; Co. and Needham &amp; Company, LLC acted as co-managers for the offering. Shares of our common stock began trading on the Nasdaq Global Select Market on June 12, 2020 and, following the sale of all the shares upon the closing of the IPO, the offer terminated.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The net proceeds to us, after deducting underwriting discounts and commissions of $20.1 million and net offering expenses of $3.4 million, were $264.0 million. No offering expenses were paid directly or indirectly to any of our directors or officers (or their associates) or persons owning ten percent or more of any class of our equity securities or to any other affiliates. There has been no material change in the planned use of proceeds from our IPO from those disclosed in the prospectus for our IPO dated as of June 11, 2020 and filed with the SEC pursuant to Rule 424(b)(4) under the Securities Act on June 15, 2020.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Issuers Purchases of Equity Securities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During the quarter ended December 31, 2021, we did not purchase any of our equity securities that are registered under Section 12 of the Exchange Act.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="reserved"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 6. </span><span id="item_6_selected_financial_data"></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">[</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Reserved]</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">100</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_7_managements_discussion_analysis_f"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 7. Management&#x2019;s Discussion and Analysis of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Financial Condition and Results of Operations.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our financial statements and related notes and other financial information included elsewhere in this Annual Report on Form 10-K. This discussion and analysis contains forward-looking statements based upon our current beliefs, plans and expectations that involve risks, uncertainties and assumptions, such as statements regarding our plans, objectives, expectations, intentions and beliefs. Our actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth under the section titled &#x201c;Risk Factors&#x201d; and elsewhere in this Annual Report on Form 10-K. You should carefully read the &#x201c;Risk Factors&#x201d; section of this Annual Report on Form 10-K to gain an understanding of the important factors that could cause actual results to differ materially from our forward-looking statements. Please also see the section titled &#x201c;Special Note Regarding Forward-Looking Statements.&#x201d;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Overview</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. We are developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. We are re-engineering the way highly complex vaccines are made through modern synthetic techniques, including advanced chemistry and the XpressCF cell-free protein synthesis platform, exclusively licensed from Sutro Biopharma, Inc. Unlike conventional cell-based approaches, our system for producing difficult-to-make proteins and antigens is intended to accelerate our ability to efficiently create and deliver high-fidelity vaccines with enhanced immunological benefits. Our pipeline includes pneumococcal conjugate vaccine, or PCV, candidates that we believe are among the most broad-spectrum PCV candidates currently in development, targeting the approximately $7 billion global pneumococcal vaccine market. Our lead vaccine candidate, VAX-24, is a 24-valent, broad-spectrum investigational PCV being developed for the prevention of invasive pneumococcal disease, or IPD, and pneumonia. On January 6, 2022, we announced that the U.S. Food and Drug Administration, or FDA, cleared our investigational new drug, or IND, application for VAX-24. On February 23, 2022, we announced the initiation of our Phase 1/2 clinical proof-of-concept study in adults aged 18 to 64. We expect to announce topline safety, tolerability and immunogenicity results from this study by the end of 2022. Pending the successful completion of the Phase 1 portion of this study, we expect to begin enrollment in a separate Phase 2 study in healthy adults aged 65 and older and to announce topline safety, tolerability and immunogenicity results from this Phase 2 study in the first half of 2023. We also anticipate submitting our first VAX-24 pediatric IND application to the FDA in the first half of 2023, subject to a pre-IND meeting with the FDA and successful topline results from the VAX-24 Phase 1/2 study in adults aged 18 to 64. Our second PCV candidate, VAX-XP, leverages our scalable and modular platform and builds on the technical proof of concept established by VAX-24 and is designed to expand the breadth of coverage to greater than 30 strains without compromising immunogenicity due to carrier suppression. In addition to our PCV franchise, we are developing a novel conjugate vaccine candidate for Group A Strep and a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Since January 1, 2021, key developments affecting our business include the following:</span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Completed the Manufacture of VAX-24 Drug Product:</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> In the fourth quarter of 2021, we completed all steps in the manufacturing process, including formulation, fill and finish, along with the testing and release, for the VAX-24 drug product. This achievement led to the submission of the VAX-24 IND application to the FDA before the end of 2021.</span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Dosed First Participants in VAX-24 Phase 1/2 Clinical Study:</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> Following the early January 2022 clearance of the VAX-24 IND application, we initiated the Phase 1/2 clinical study of VAX-24, a 24-valent PCV candidate designed to prevent IPD and pneumonia in adults. The VAX-24 clinical proof-of-concept study is a randomized, observer-blind, dose-finding, controlled study designed to evaluate the safety, tolerability and immunogenicity of VAX-24 in healthy adults. The Phase 1 portion of the study will evaluate the safety and tolerability of a single injection of VAX-24 at three dose levels and compared to Prevnar 20 in approximately 64 healthy adults 18 to 49 years of age. The Phase 2 portion will evaluate the safety, tolerability and immunogenicity of a </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">101</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;visibility:hidden;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;"></span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">single injection of VAX-24 at three dose levels and compared to Prevnar 20 in approximately 800 healthy adults 50 to 64 years of age. The prespecified immunogenicity endpoints of the Phase 2 portion of the study include an assessment of the induction of antibody responses, using immunoglobulin G (IgG) and opsonophagocytic activity (OPA), at each of the VAX-24 doses and compared to Prevnar 20 and, for the additional four serotypes contained in VAX-24 and Pneumovax 23 but not in Prevnar 20, the four-fold rise in antibody titers.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Completed Successful $115 Million Follow-On Financing:</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> In the first quarter of 2022, we completed an underwritten public offering of 3,250,000 shares of our common stock, which included the full exercise of the underwriters&#x2019; option to purchase additional shares, and pre-funded warrants to purchase 2,500,000 shares of common stock. The shares of common stock were sold at a public offering price of $20.00 per share, and the pre-funded warrants were sold at a public offering price of $19.999 per underlying share. The aggregate gross proceeds to us from the offering were $115.0 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by us, and excluding the exercise of any pre-funded warrants.</span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Advanced and Presented Preclinical Data for VAX-XP Program: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have continued to advance VAX-XP, our PCV candidate with an expanded breadth of coverage of greater than 30 strains. During IDWeek 2021, we presented findings from a preclinical study that evaluated the immunogenicity of VAX-XP, which showed VAX-XP exhibited conjugate-like immune responses for all 31 serotypes, as demonstrated by IgG immune responses 14 days after both an initial and booster dose that were superior to polysaccharide-based vaccines and comparable to Prevnar 13. Additionally, all serotypes in VAX-XP elicited a T-cell dependent immune response as demonstrated by the increase in IgG titers post-boost.</span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Initiated VAX-A1 IND-Enabling Activities.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> We continue to advance development of VAX-A1, a novel conjugate vaccine designed to prevent infections caused by Group A </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Streptococcus</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, or Strep, bacteria. Following the nomination of our final VAX-A1 vaccine candidate in the first quarter of 2021, we initiated IND-enabling studies in the second half of 2021.</span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Strengthened Leadership Team and Board of Directors with Key Appointments:</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> During 2021, we added several key leaders to our executive team and Board of Directors. In October, Harp Dhaliwal joined as Senior Vice President of Commercial Manufacturing and Supply Chain, and we appointed Dr. Carlos Paya, who serves as the Board Chair, and Dr. Michael Kamarck to our board of directors. This followed the September 2021 board appointments of Annie Drapeau and Teri Loxam. These accomplished industry leaders have deep experience across the biopharmaceutical and vaccine industries and will provide additional skills and expertise as we advance and scale our business.</span></div></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Since our inception in November 2013, we have devoted substantially all of our resources to performing research and development, undertaking preclinical studies and enabling manufacturing activities in support of our product development efforts, acquiring and developing our technology and vaccine candidates, organizing and staffing our company, performing business planning, establishing our intellectual property portfolio and raising capital to support and expand such activities. We do not have any products approved for sale and have not generated any revenue from product sales. To date, we have financed our operations primarily with proceeds from the sales of our redeemable convertible preferred stock, common stock and pre-funded warrants to purchase common stock. We will continue to require additional capital to develop our vaccine candidates and fund operations for the foreseeable future. Accordingly, until such time as we can generate significant revenue from sales of our vaccine candidates, if ever, we expect to finance our cash needs through public or private equity or debt financings, third-party (including government) funding and marketing and distribution arrangements, as well as other collaborations, strategic alliances and licensing arrangements, or any combination of these approaches.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have incurred net losses in each year since inception and expect to continue to incur net losses in the foreseeable future. Our net losses may fluctuate significantly from quarter-to-quarter and year-to-year, depending in</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">102</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">large part on the timing of our preclinical studies, clinical trials and manufacturing activities, and our expenditures on other research and development activities. Our net losses were $100.1 million and $89.2 million for the years ended December 31, 2021 and 2020, respectively. As of December 31, 2021, we had an accumulated deficit of $298.6 million and cash, cash equivalents and investments of $273.1. million, We believe our cash, cash equivalents and investments will be sufficient to fund our operating expenses and capital expenditure requirements through at least the next 12 months from the filing date of this Annual Report on Form 10-K.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We do not expect to generate any revenue from commercial product sales unless and until we successfully complete development and obtain regulatory approval for one or more of our vaccine candidates, which we expect will take a number of years. We expect our expenses will increase substantially in connection with our ongoing activities, as we:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">advance our vaccine candidates through preclinical studies and clinical trials;</span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">require the scale-up of our manufacturing capabilities; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">require the manufacture of supplies for our preclinical studies and clinical trials, in particular our PCV candidates, VAX-24 and VAX-XP; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">pursue regulatory approval of our vaccine candidates; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">hire additional personnel; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">operate as a public company; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">acquire, discover, validate and develop additional vaccine candidates; and </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">obtain, maintain, expand and protect our intellectual property portfolio. </span></div></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We rely and will continue to rely on third parties to conduct our preclinical studies and clinical trials and for manufacturing and supply of our vaccine candidates. We have no internal manufacturing capabilities, and we will continue to rely on third parties, of which the main suppliers are single-source suppliers, for our preclinical and clinical trial materials. Given our stage of development, we do not yet have a marketing or sales organization or commercial infrastructure. Accordingly, if we obtain regulatory approval for any of our vaccine candidates, we also would expect to incur significant commercialization expenses related to product sales, marketing, manufacturing and distribution.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Because of the numerous risks and uncertainties associated with vaccine development, we are unable to predict the timing or amount of increased expenses or when or if we will be able to achieve or maintain profitability. Even if we are able to generate revenue from the sale of our vaccines, we may not become profitable. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and may be forced to reduce our operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Certain Significant Relationships</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Sutro Biopharma</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Vaxcyte was formed through its relationship with Sutro Biopharma, in 2013 by our co-founders with the goal of utilizing Sutro Biopharma&#x2019;s proprietary XpressCF platform for protein synthesis in the field of vaccines addressing infectious diseases.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition to receiving funding, we entered into a license agreement with Sutro Biopharma, or the Sutro License, on August 1, 2014. The Sutro License was amended on October 12, 2015 and again on May 9, 2018 and May 29, 2018.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under this license, we received an exclusive, worldwide, royalty-bearing, sublicensable license under Sutro Biopharma&#x2019;s patents and know-how relating to cell-free expression of proteins to (i) research, develop, use,</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">103</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">sell, offer for sale, export, import and otherwise exploit specified vaccine compositions, such rights being sublicensable, for the treatment or prophylaxis of infectious diseases, excluding cancer vaccines, and (ii) manufacture, or have manufactured by an approved contract manufacturing organization, such vaccine compositions from extracts supplied by Sutro Biopharma pursuant to the Sutro Biopharma Supply Agreement (as described below). We are obligated to use commercially reasonable efforts to develop, obtain regulatory approval for and commercialize the vaccine compositions.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In consideration of the rights granted under the Sutro License, we are obligated to pay Sutro Biopharma a 4% royalty on worldwide aggregate net sales of vaccine products for human health and a 2% royalty on such net sales of vaccine products for animal health. Such royalty rates are subject to specified reductions, including standard reductions for third-party payments and for expiration of relevant patent claims. Royalties are payable on a vaccine composition-by-vaccine composition and country-by-country basis until the later of expiration of the last valid claim in the licensed patents covering such vaccine composition in such country and ten years after the first commercial sale of such vaccine composition. In addition, we are obligated to pay Sutro Biopharma a percentage in the low-double digits of any net sublicensing revenue received for sublicense agreements executed before July 2020. Our obligation to pay sublicense fees to Sutro Biopharma expired in July 2020.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In May 2018, we entered into a supply agreement, which we refer to as the Sutro Biopharma Supply Agreement, with Sutro Biopharma pursuant to which we purchase from Sutro Biopharma extract and custom reagents for use in manufacturing non-clinical and certain clinical supply of vaccine compositions utilizing the technology licensed under the Sutro License at prices not to exceed a specified percentage above Sutro Biopharma&#x2019;s fully burdened manufacturing cost. If any extracts or custom reagents do not meet the specifications and warranties provided, then we will not have an obligation to pay for the non-conforming product, and Sutro Biopharma will be obligated to replace the non-conforming product within the shortest possible time with conforming product at our cost. The term of the Sutro Biopharma Supply Agreement is from execution until the later of July 31, 2021 and the date the parties enter into and commence activities under the supply agreement unless extended through a subsequent supply agreement for the supply of extract and custom reagents for vaccine compositions for Phase 3 and commercial uses as contemplated in the Supply Agreement. In February 2021, we entered into an amendment to the Sutro Biopharma Supply Agreement and extended the term to July 31, 2022.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For additional details regarding our relationship with Sutro Biopharma, see Note 14, &#x201c;Related Party Transactions,&#x201d; to our financial statements included in Part II, Item 8 of this Annual Report on Form 10-K.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Lonza</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In October 2016, we entered into a development and manufacturing services agreement, as amended, with Lonza Ltd., or the Lonza DMSA, pursuant to which Lonza Ltd., or Lonza, is obligated to perform services including manufacturing process development and the manufacture of components for VAX-24, including the polysaccharide antigens, our proprietary eCRM protein carrier and conjugated drug substances.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In September 2017, we and Lonza agreed to defer the completion payments for any stage that commenced after December 31, 2019 or had not been completed by December 31, 2019 until the earlier of the completion of all IND-enabling activities or December 31, 2020. In March 2020, Lonza agreed to defer the completion payments until the earlier of the completion of all IND-enabling activities or April 30, 2021. In April 2021, Lonza further agreed to defer 50% of the completion payments until the earlier of the completion of all IND-enabling activities or December 31, 2021.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In June 2018, we entered into a letter agreement with Lonza, pursuant to which we agreed to certain terms for potential future payments in shares of our common stock as partial satisfaction of future obligations to Lonza. Specifically, we and Lonza agreed that the initial pre-IND cash payments made by us to Lonza would be subject to a specified dollar cap, which we refer to as the Initial Cash Cap. After the Initial Cash Cap has been reached, then at our election, we would have the option to make any further pre-IND payments owed to Lonza in cash, in shares of our common stock at then market prevailing prices, or a combination of both, provided that (i) Lonza had the right to elect to receive up to 25% of pre-IND payments in shares of our common stock, up to a maximum of $2.5 million, and (ii) we had the right to issue no more than $10.0 million of pre-IND payments in shares of our common stock. In April 2021, we reached the Initial Cash Cap and notified Lonza that we would be exercising our option to issue approximately $10.0 million in shares of our common stock as payment for a portion</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">104</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">of pre-IND payments due April 30, 2021. In June 2021, we issued 399,680 shares of our common stock to Lonza at a price of $25.02 per share to pay for $10.0 million of the pre-IND payments due April 30, 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In October 2018, we entered into a second development and manufacturing services agreement with Lonza, or the Lonza 2018 DMSA, and together with the Lonza DMSA, or the Lonza Agreements, pursuant to which Lonza is obligated to perform services including manufacturing process development and the manufacture and supply of VAX-24 finished drug product.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under the Lonza Agreements, we will pay Lonza agreed upon fees for Lonza&#x2019;s performance of manufacturing services, and we will reimburse Lonza for its out-of-pocket costs associated with purchasing raw materials, plus a customary handling fee. Each Lonza Agreement is managed by a steering committee and any dispute at the steering committee will be resolved by senior executives of the parties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For additional details regarding our relationship with Lonza, see Note 6, &#x201c;Commitments and Contingencies,&#x201d; to our financial statements included in Part II, Item 8 of this Annual Report on Form 10-K.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Impact of COVID-19</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are continuing to closely monitor the impact of the global COVID-19 pandemic on our business and are taking proactive efforts designed to protect the health and safety of our employees and to maintain business continuity. We believe that the measures we have implemented and continue to implement are appropriate, and we will continue to monitor and seek to comply with guidance from governmental authorities and adjust our activities as appropriate. Based on guidance issued by federal, state and local authorities, we transitioned to a remote work model for our non-lab based employees in March 2020, while maintaining essential in-person laboratory functions in order to advance key research and development initiatives, supported by the implementation of updated onsite safety procedures, including routine testing of employees. In 2021, we began to allow non-lab employees who have been fully vaccinated to return to the office on a voluntary and limited basis. In addition, we have recently implemented requirements for employees to obtain COVID-19 booster shots.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In particular, the COVID-19 pandemic slowed raw material supply chains and travel restrictions delayed the qualification of key analytical equipment used in manufacturing and curtailed in-person CMO oversight of manufacturing, affecting our manufacturing processes. As the pandemic continues, we could see an additional impact on our ability to advance our programs, obtain supplies from our contract manufacturers or interact with regulators, ethics committees or other important agencies due to limitations in regulatory authority, employee resources or otherwise. In any event, if the COVID-19 pandemic continues and persists for an extended period of time, we could experience significant disruptions to our development timelines, which would adversely affect our business, financial condition, results of operations and growth prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, while the potential economic impact brought by, and the duration of, the COVID-19 pandemic may be difficult to assess or predict, the pandemic could result in significant and prolonged disruption of global financial markets, reducing our ability to access capital, which could in the future negatively affect our liquidity. In addition, a recession or market correction resulting from the continued spread of COVID-19 could materially affect our business and the potential value of our common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The extent of the impact of the COVID-19 pandemic on our development and regulatory efforts, our ability to raise sufficient additional capital on acceptable terms, if at all, and the value of and market for our common stock will depend on future developments that are highly uncertain and cannot be predicted with confidence at this time, such as the ultimate duration of the pandemic, travel restrictions, quarantines, social distancing and business closure requirements in the United States and in other countries, and the effectiveness of actions taken globally to contain and treat COVID-19. For additional information about risks and uncertainties related to the COVID-19 pandemic that may impact our business, financial condition and results of operations, see the section titled &#x201c;Risk Factors.&#x201d;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">105</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Components of Results of Operations</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Operating Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Research and Development</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development expenses represent costs incurred in performing research, development and manufacturing activities in support of our own product development efforts and include personnel-related costs (such as salaries, employee benefits and stock-based compensation) for our personnel in research and development functions; costs related to acquiring, developing and manufacturing supplies for preclinical studies, clinical trials and other studies, including fees paid to contract manufacturing organizations; costs and expenses related to agreements with contract research organizations, investigative sites and consultants to conduct non-clinical and preclinical studies and clinical trials; professional and consulting services costs; research and development consumables costs; laboratory supplies and equipment costs; and facility and other allocated costs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development expenses are expensed as incurred. Non-refundable advance payments for services that will be used or rendered for future research and development activities are recorded as prepaid expenses and recognized as expenses as the related services are performed. We do not allocate our costs by vaccine candidates, as our vaccine candidates are at an early stage of development and our research and development expenses include internal costs, such as payroll and other personnel expenses, which are not tracked by vaccine candidate. In particular, with respect to internal costs, several of our departments support multiple vaccine candidate research and development programs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We expect our research and development expenses to increase substantially in absolute dollars for the foreseeable future as we advance our vaccine candidates into and through preclinical studies and clinical trials, scale up our manufacturing operations, pursue regulatory approval of our vaccine candidates and expand our pipeline of vaccine candidates. The process of conducting the necessary preclinical and clinical research and developing the necessary manufacturing capabilities to obtain regulatory approval is costly and time-consuming. The actual probability of success for our vaccine candidates may be affected by a variety of factors, including the safety and efficacy of our vaccine candidates, early clinical data, investment in our clinical programs, competition, manufacturing capability and commercial viability. We may never succeed in achieving regulatory approval for any of our vaccine candidates. As a result of the uncertainties discussed above, we are unable to determine the duration and completion costs of our research and development projects or if, when and to what extent we will generate revenue from the commercialization and sale of our vaccine candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We accrue for costs related to research and development activities based on our estimates of the services received and efforts expended pursuant to quotes and contracts with vendors, including contract manufacturing organizations, or CMOs, that conduct research and development on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to our vendors exceed the level of services provided and result in a prepayment of the research and development expense. Advance payments for goods and services to be used in future research and development activities are expensed when the activity has been performed or when the goods have been received. We make significant judgments and estimates in determining accrued research and development liabilities as of each reporting period based on the estimated time period over which services will be performed and the level of effort to be expended. If the actual timing of the performance of services or the level of effort varies from our estimate, we adjust the accrual or prepaid expense accordingly.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Although we do not expect our estimates to be materially different from amounts actually incurred, if our estimates of the status and timing of services performed differ from the actual status and timing of services performed, it could result in us reporting amounts that are too high or too low in any particular period.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our research and development costs may vary significantly based on factors such as:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the costs and timing of our chemistry, manufacturing and controls, or CMC, activities, including fulfilling GMP-related standards and compliance, and identifying and qualifying a second supplier; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">106</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the costs related to raw materials estimates from our third-party manufacturing and supply partners;</span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the cost of clinical trials of our vaccine candidates being greater than we anticipate; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">changes in the standard of care on which a clinical development plan was based, which may require new or additional trials; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the number of sites included in the trials; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the countries in which the trials are conducted; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">delays in adding a sufficient number of trial sites and recruiting suitable volunteers to participate in our clinical trials; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the number of subjects that participate in the trials; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the number of doses that subjects receive; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">subjects dropping out of a study or lost in follow-up; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">potential additional safety monitoring requested by regulatory agencies; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the duration of subject participation in the trials and follow-up; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the cost and timing of manufacturing our vaccine candidates; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the phase of development of our vaccine candidates; and </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the efficacy and safety profile of our vaccine candidates. </span></div></div>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">General and Administrative</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">General and administrative expenses consist primarily of costs and expenses related to personnel (including salaries, employee benefits and stock-based compensation) in our executive, legal, finance and accounting, human resources and other administrative functions; legal services, including relating to intellectual property and corporate matters; accounting, auditing, consulting and tax services; insurance; and facility and other allocated costs not otherwise included in research and development expenses. We expect our general and administrative expenses to increase substantially in absolute dollars for the foreseeable future as we increase our headcount to support our continued research and development activities and grow our business. We also anticipate that we will incur increased expenses as a result of operating as a public company, including expenses related to audit, legal, regulatory and tax-related services associated with maintaining compliance with SEC rules and regulations and those of any national securities exchange on which our securities are traded, additional insurance expenses, investor relations activities and other administrative and professional services.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Other Income (Expense), Net</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other income (expense), net includes interest expense incurred on our capital leases for lab equipment, interest income earned from our cash and cash equivalents, grant income, foreign currency transaction gains (losses) related to our Swiss Franc cash and liability balances and changes in the fair value of our redeemable convertible preferred stock tranche liability (see Note 2, &#x201c;Basis of Presentation and Summary of Significant Accounting Policies,&#x201d; Note 3, &#x201c;Fair Value Measurements and Fair Value of Financial Instruments,&#x201d; and Note 7, &#x201c;Redeemable Convertible Preferred Stock,&#x201d; to our financial statements included in Part II, Item 8 of this Annual Report on Form 10-K for more detail).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">107</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Grant Income</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In July 2019, we received a cost-reimbursement research award from Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator, or CARB-X, a public-private partnership funded under a Cooperative Agreement from Assistant Secretary for Preparedness and Response/Biomedical Advanced Research and Development Authority and by awards from Wellcome Trust, Germany&#x2019;s Federal Ministry of Education and Research, the United Kingdom Global Antimicrobial Resistance Innovation Fund and the Bill &amp; Melinda Gates Foundation. In connection with this funding, we entered into a cost-reimbursement sub-award agreement with the Trustees of Boston University, the administrator of the program, or the CARB-X agreement. CARB-X awarded us up to $1.6 million in initial funding to advance the development of a universal vaccine to prevent infections caused by Group A Strep Bacteria. In July 2020, the CARB-X agreement was amended with the initial funding amount increased from $1.6 million to $2.7 million. In December 2020, we reached the maximum CARB-X funding limit for this initial funding period, and subsequently submitted our funding proposal to CARB-X for the next period under our agreement. In April 2021, we received approval for the next phase of CARB-X development and executed the cost-reimbursement sub-award agreement with the Trustees of Boston University in August 2021. Pursuant to the CARB-X agreement, the award committed additional funding of $3.2 million for IND-enabling activities and total potential funding of up to $29.7 million (including the current $3.2 million award and the prior $2.7 million award) upon the achievement of future VAX-A1 development milestones. In January 2022, CARB-X revised the parameters for the contribution of CARB-X funding and implemented maximum funding levels for all grant recipients. As a result, our total funding available upon achievement of development milestones through Phase 1 human clinical trials was revised from $29.7 million to $13.9 million (inclusive of the $5.9 million awarded to date). Separately, the National Institute of Health, or NIH, awarded us up to $0.5 million in April 2021 to advance the development of a vaccine against Shigella infection. Grant income pursuant to our award agreements is recognized as we incur and pay qualifying expenses over the periods of the awards. We recognized $1.6 million, $2.5 million and $0.2 million in grant income for funding research and development under these awards during the years ended December 31, 2021, 2020 and 2019, respectively. Grant income is included as a component of Other income (expense), net in the statements of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Results of Operations</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Comparison of the Years Ended December 31, 2021 and 2020</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table summarizes our results of operations for the periods presented:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.626%;"></td>
    <td style="width:1.103%;"></td>
    <td style="width:1.371%;"></td>
    <td style="width:9.819%;"></td>
    <td style="width:0.91%;"></td>
    <td style="width:1.103%;"></td>
    <td style="width:1.371%;"></td>
    <td style="width:9.819%;"></td>
    <td style="width:0.91%;"></td>
    <td style="width:1.039%;"></td>
    <td style="width:1.371%;"></td>
    <td style="width:9.798%;"></td>
    <td style="width:0.91%;"></td>
    <td style="width:1.039%;"></td>
    <td style="width:0.803%;"></td>
    <td style="width:9.787%;"></td>
    <td style="width:3.223%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Change</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating expenses:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">78,411</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">73,564</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,847</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.6</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">General and administrative</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">25,259</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16,017</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9,242</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">57.7</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total operating expenses</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">103,670</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">89,581</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">14,089</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15.7</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Loss from operations</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(103,670</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(89,581</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(14,089</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15.7</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other income (expense), net:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Interest expense</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(7</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(7</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Interest income</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">344</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">244</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">100</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">41.0</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Grant income</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,585</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,478</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(893</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(36.0</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Realized gain on marketable securities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">*</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Foreign currency transaction gain (loss)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,669</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(2,351</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,020</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(171.0</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total other income (expense), net</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,593</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">364</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,229</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">887.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(100,077</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(89,217</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(10,860</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12.2</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;margin-right:66.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:-3.52%;padding-left:3.4%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">* not meaningful</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">108</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Operating Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Research and Development Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table summarizes our research and development expenses for the periods presented:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.749%;"></td>
    <td style="width:1.103%;"></td>
    <td style="width:1.37%;"></td>
    <td style="width:9.797%;"></td>
    <td style="width:0.814%;"></td>
    <td style="width:1.103%;"></td>
    <td style="width:1.37%;"></td>
    <td style="width:9.818%;"></td>
    <td style="width:0.814%;"></td>
    <td style="width:1.103%;"></td>
    <td style="width:1.37%;"></td>
    <td style="width:9.807%;"></td>
    <td style="width:0.921%;"></td>
    <td style="width:1.039%;"></td>
    <td style="width:0.814%;"></td>
    <td style="width:9.786%;"></td>
    <td style="width:3.223%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Change</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Product and clinical development </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:Times New Roman;position:relative;">(1)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">37,215</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">51,072</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(13,857</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(27.1</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Personnel-related</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">17,476</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9,943</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,533</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">75.8</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Professional and consulting services</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,351</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,184</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">167</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.0</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development consumables</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,848</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,288</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,560</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">199.3</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Facility related and other allocated</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8,098</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,957</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,141</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">173.9</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Laboratory supplies and equipment</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,421</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,032</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,389</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">68.4</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:Times New Roman;position:relative;">(2)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,002</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,088</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(86</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(7.9</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total research and development expenses</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">78,411</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">73,564</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,847</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.6</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;margin-right:66.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="display:flex;margin-top:2.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">(1)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Includes expenses for third-party manufacturing and outsourced contract services, including preclinical studies and outsourced assays. </span></div></div>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">(2)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Includes travel-related expenses, other miscellaneous office expenses and warrant expense. </span></div></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development expenses increased by $4.8 million, or 6.6%, in 2021 compared to 2020. The increase was primarily attributable to increases in (i) personnel-related expenses of $7.5 million related to the increase in the number of employees to support our research and development activities and higher stock-based compensation expense, (ii) facility related and other allocated expenses of $5.1 million resulting from increases in rent and lease expense as well as expenses allocated to research and development, (iii) research and development consumables of $4.6 million related to higher critical raw materials expenses and (iv) laboratory supplies and equipment expenses of $1.4 million mainly related to our VAX-24 and VAX-A1 programs. These increases were partially offset by a decrease of $13.9 million in product and clinical development expenses, which represented the net impact of a decrease in outsourced manufacturing expenses related to our VAX-24 program and an increase in such expenses related to our VAX-XP program.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">General and Administrative Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">General and administrative expenses increased by $9.2 million, or 57.7%, in 2021 compared to 2020. The increase was mainly due to increases of $7.0 million in personnel-related costs related to higher stock-based compensation expense resulting from an increase in the number of options granted during the year and growth in the number of employees in our general and administrative functions, $1.3 million in professional and consulting services related primarily to compliance activities under the Sarbanes-Oxley Act of 2002, as amended, or the Sarbanes-Oxley Act, and technology infrastructure enhancements and $1.1 million in directors and officers insurance expense as a result of operating as a public company.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Other Income (Expense), Net</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other income (expense), net increased by $3.2 million, or 887.1%, in 2021 compared to 2020. The increase was mainly due to an increase of $4.0 million in foreign currency gains resulting from the appreciation of the U.S. Dollar against the Swiss Franc in 2021 compared to 2020, partially offset by a decrease of $0.9 million in grant income for the CARB-X program.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">109</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Comparison of the Years Ended December 31, 2020 and 2019</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table summarizes our results of operations for the periods presented:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.678%;"></td>
    <td style="width:1.103%;"></td>
    <td style="width:1.371%;"></td>
    <td style="width:9.8%;"></td>
    <td style="width:0.91%;"></td>
    <td style="width:1.039%;"></td>
    <td style="width:1.371%;"></td>
    <td style="width:9.821%;"></td>
    <td style="width:0.91%;"></td>
    <td style="width:1.039%;"></td>
    <td style="width:1.371%;"></td>
    <td style="width:9.8%;"></td>
    <td style="width:0.91%;"></td>
    <td style="width:1.039%;"></td>
    <td style="width:0.803%;"></td>
    <td style="width:9.81%;"></td>
    <td style="width:3.224%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Change</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2019</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating expenses:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">73,564</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">45,607</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">27,957</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">61.3</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">General and administrative</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16,017</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8,546</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,471</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">87.4</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total operating expenses</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">89,581</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">54,153</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">35,428</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">65.4</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Loss from operations</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(89,581</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(54,153</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(35,428</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">65.4</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other income (expense), net:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Interest expense</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(7</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(40</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">33</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(82.5</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Interest income</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">244</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">632</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(388</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(61.4</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Grant income</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,478</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">237</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,241</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">*</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Foreign currency transaction gain (loss)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(2,351</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(135</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(2,216</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">*</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Change in fair value of the redeemable<br />&#160;&#160;&#160;convertible preferred stock tranche liability</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,185</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(3,185</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(100.0</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total other income (expense), net</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">364</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,879</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(3,515</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(90.6</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(89,217</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(50,274</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(38,943</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">77.5</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;margin-right:66.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:-3.52%;padding-left:3.4%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">* not meaningful</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Research and Development Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table summarizes our research and development expenses for the periods presented:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.745%;"></td>
    <td style="width:1.103%;"></td>
    <td style="width:1.37%;"></td>
    <td style="width:9.796%;"></td>
    <td style="width:0.814%;"></td>
    <td style="width:1.103%;"></td>
    <td style="width:1.37%;"></td>
    <td style="width:9.817%;"></td>
    <td style="width:0.814%;"></td>
    <td style="width:1.103%;"></td>
    <td style="width:1.37%;"></td>
    <td style="width:9.796%;"></td>
    <td style="width:0.921%;"></td>
    <td style="width:1.038%;"></td>
    <td style="width:0.814%;"></td>
    <td style="width:9.806%;"></td>
    <td style="width:3.222%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Change</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2019</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Product and clinical development </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:Times New Roman;position:relative;">(1)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">51,072</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">27,985</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">23,087</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">82.5</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Personnel-related</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9,943</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,947</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,996</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">67.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Professional and consulting services</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,184</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,669</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(485</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(10.4</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development consumables</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,288</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,474</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(186</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(7.5</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Facility related and other allocated</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,957</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,422</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">535</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">22.1</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Laboratory supplies and equipment</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,032</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,174</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">858</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">73.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:Times New Roman;position:relative;">(2)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,088</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">936</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">152</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16.2</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total research and development expenses</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">73,564</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">45,607</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">27,957</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">61.3</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;margin-right:66.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="display:flex;margin-top:2.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">(1)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Includes expenses for third-party manufacturing and outsourced contract services, including preclinical studies and outsourced assays. </span></div></div>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">(2)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Includes travel-related expenses, other miscellaneous office expenses and warrant expense. </span></div></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development expenses increased by $28.0 million, or, 61.3% in 2020 compared to 2019. The increase was primarily attributable to an increase of $23.1 million in product and clinical development expenses mainly related to our lead vaccine candidate, VAX-24, driven by increases of $18.6 million in outsourced manufacturing activities and $4.5 million in outsourced research services due to the ramp-up of the eCRM and polysaccharide GMP campaigns and conjugation and drug product activities in preparation for our anticipated IND application submission in the first quarter of 2022 and Phase 1/2 clinical study initiation thereafter. The increase in personnel-related expenses of $4.0 million was primarily related to the increase in the number of employees to support our expansion in research and development activities and higher stock-based compensation expense resulting from an increase in the number of options granted during the year and an increase in the fair value of our common stock affecting the valuation of new option grants.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">110</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">General and Administrative Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">General and administrative expenses increased by $7.5 million, or, 87.4% in 2020 compared to 2019. The increase was mainly due to increases of $3.9 million in personnel-related costs related to higher stock-based compensation expense resulting from an increase in the number of options granted during the year and an increase in the fair value of our common stock affecting the valuation of new option grants, as well as growth in the number of employees in our general and administrative functions, $1.6 million in professional and consulting services resulting from increased legal expenses and consulting costs, and $1.7 million in other expenses primarily due to an increase in directors and officers insurance expense as a result of being a public company.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Other Income (Expense), Net</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other income (expense), net decreased by $3.5 million, or, 90.6% in 2020 compared to 2019. During 2019, we recognized a $3.2 million gain resulting from a change in the fair value of the redeemable convertible preferred stock tranche liability, which was settled in December 2019, and there was no such gain recognized during 2020. Other income (expense), net also decreased due to an increase in foreign currency losses of $2.2 million resulting from the depreciation of the U.S. Dollar against the Swiss Franc. These decreases were partially offset by an increase of $2.2 million in grant income from the CARB-X program, which commenced in July 2019.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Liquidity and Capital Resources</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">From inception through December 31, 2021, we have incurred losses and negative cash flows from operations and have funded our operations primarily through the issuance of redeemable convertible preferred stock and common stock totaling approximately $583.9 million in aggregate gross proceeds and $559.1 million net of underwriting discounts, commissions and offering expenses. As of December 31, 2021, we had $69.0 million of cash and cash equivalents, $204.1 million in investments and an accumulated deficit of $298.6 million.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> On July 2, 2021, we filed a shelf registration statement on Form S-3ASR, or the Shelf Registration Statement, under which we may, from time to time, sell securities in one or more offerings of our common stock, preferred stock, debt securities or warrants. The Shelf Registration Statement became automatically effective upon the filing of the Form S-3ASR on July 2, 2021.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In July 2021, we entered into an Open Market Sales Agreement</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">SM, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">or the ATM Sales Agreement, with Jefferies LLC, which provides that, upon the terms and subject to the conditions and limitations set forth in the ATM Sales Agreement, we</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">may elect to issue and sell, from time to time, shares of our common stock having an aggregate offering price of up to $150.0 million through Jefferies acting as our sales agent or principal. Under the ATM Sales Agreement, Jefferies may sell the shares of common stock by any method permitted by law deemed to be an &#x201c;at-the-market offering&#x201d; as defined under the Securities Act of 1933, as amended, in block transactions or </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">in privately-negotiated transactions with our consent. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Jefferies will use commercially reasonable efforts to sell the shares of common stock subject to the ATM Sales Agreement from time to time, based upon our instructions (including any price, time or size limits or other customary parameters or conditions that we may impose). We will pay Jefferies a commission of up to 3.0% of the gross sales proceeds of any common stock sold through Jefferies under the ATM Sales Agreement; however, we are not obligated to make any sales of common stock. As of December 31, 2021, we have sold 567,045 shares of our common stock under the ATM Sales Agreement at an average price of $25.26 per share for aggregate gross proceeds of $14.3 million ($13.9 million net of commissions and offering expenses).</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In January 2022, we completed an underwritten public offering in which we issued 2,500,000 shares of common stock and pre-funded warrants to purchase 2,500,000 shares of our common stock, and received approximately $93.5 million in net proceeds, after deducting underwriting discounts and commissions and other estimated offering expenses payable by us. In February 2022, t</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">he underwriters exercised their option to purchase an additional 750,000 shares of common stock, and we received approximately $14.1 million in additional net proceeds after deducting underwriting discounts and commissions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">111</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Future Funding Requirements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our primary uses of cash are to fund our operations, which consist primarily of research and development expenses related to our programs, general and administrative expenses and capital expenditures. We anticipate that our operating expenses and capital expenditures will increase significantly for the foreseeable future as we continue to advance our current vaccine candidates through research, development and manufacturing, continue our research initiatives to develop new vaccine candidates, scale our laboratory and manufacturing operations and expand our corporate infrastructure, including the costs associated with being a public company. We are subject to all of the risks typically related to the development of new drug candidates, and we may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. We anticipate that we will need substantial additional funding in connection with our continuing operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We believe that our existing cash, cash equivalents and investments as of the date of this Annual Report on Form 10-K will be sufficient to fund our operating expenses and capital expenditure requirements through at least 12 months from the filing date of this Annual Report on Form 10-K. However, we will need to raise additional capital prior to commencing pivotal trials for any of our vaccine candidates. Until we can generate sufficient revenue from the commercialization of our vaccine candidates or from collaboration agreements with third parties, if ever, we expect to finance our future cash needs through public or private equity or debt financings, third-party (including government) funding and marketing and distribution arrangements, as well as other collaborations, strategic alliances and licensing arrangements, or any combination of these approaches. The sale of equity, pre-funded warrants or convertible debt securities may result in dilution to our stockholders and, in the case of preferred equity securities or convertible debt, those securities could provide for rights, preferences or privileges senior to those of our common stock. Debt financings may subject us to covenant limitations or restrictions on our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. Our ability to raise additional funds may be adversely impacted by deteriorating global economic conditions and the recent disruptions to and volatility in the credit and financial markets in the United States and worldwide resulting from the ongoing COVID-19 pandemic. There can be no assurance that we will be successful in acquiring additional funding at levels sufficient to fund our operations or on terms favorable or acceptable to us. If we are unable to obtain adequate financing when needed or on terms favorable or acceptable to us, we may be forced to delay, reduce the scope of or eliminate one or more of our research and development programs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our future capital requirements will depend on many factors, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the timing, scope, progress, results and costs of research and development, testing, screening, manufacturing, preclinical development and clinical studies and clinical trials, including any impacts related to the COVID-19 pandemic; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the outcome, timing and cost of seeking and obtaining regulatory approvals from the FDA and comparable foreign regulatory authorities, including the potential for such authorities to require that we perform field efficacy studies for our PCV candidates, require more studies than those that we currently expect or change their requirements regarding the data required to support a marketing application; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the cost of building a sales force in anticipation of any product commercialization; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the costs of future commercialization activities, including product manufacturing, marketing, sales, royalties and distribution, for any of our vaccine candidates for which we receive marketing approval; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to maintain existing, and establish new, strategic collaborations, licensing or other arrangements and the financial terms of any such agreements, including the timing and amount of any future milestone, royalty or other payments due under any such agreement; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">any product liability or other lawsuits related to our products;  </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">112</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the revenue, if any, received from commercial sales, or sales to foreign governments, of our vaccine candidates for which we may receive marketing approval; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the costs to establish, maintain, expand, enforce and defend the scope of our intellectual property portfolio, including the amount and timing of any payments we may be required to make, or that we may receive, in connection with licensing, preparing, filing, prosecuting, defending and enforcing of any patents or other intellectual property rights; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the expenses needed to attract, hire and retain skilled personnel; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the costs of operating as a public company; and </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the impact of the COVID-19 pandemic, which may exacerbate the magnitude of the factors discussed above. </span></div></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A change in the outcome of any of these or other variables could significantly change the costs and timing associated with the development of our vaccine candidates. Furthermore, our operating plans may change in the future, and we may need additional funds to meet operational needs and capital requirements associated with such change.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Cash Flows</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table summarizes our cash flows for the periods indicated:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:53.49%;"></td>
    <td style="width:1.37%;"></td>
    <td style="width:1.381%;"></td>
    <td style="width:11.796%;"></td>
    <td style="width:0.921%;"></td>
    <td style="width:1.37%;"></td>
    <td style="width:1.381%;"></td>
    <td style="width:11.785%;"></td>
    <td style="width:0.942%;"></td>
    <td style="width:1.392%;"></td>
    <td style="width:1.381%;"></td>
    <td style="width:11.85%;"></td>
    <td style="width:0.942%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2019</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(in thousands)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net cash used in operating activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(121,393</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(46,628</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(47,145</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net cash used in investing activities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(212,308</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(1,105</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(1,195</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net cash provided by financing activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">17,796</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">374,870</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">41,567</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Effect of exchange rate changes on cash and cash equivalents</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(439</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">87</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(341</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net (decrease) increase in cash and cash equivalents</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(316,344</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">327,224</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(7,114</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Cash Flows from Operating Activities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net cash used in operating activities for the year ended December 31, 2021 was $121.4 million, which primarily resulted from a net loss of $100.1 million and a net change in operating assets and liabilities of $37.0 million, partially offset by non-cash charges of $15.7 million. The net change in operating assets and liabilities of $37.0 million was primarily due to decreases in cash flows due to operating lease liabilities of $12.9 million resulting from leasehold improvements costs applied against such liabilities upon the commencement of our San Carlos office lease in December 2021; accounts payable of $12.5 million resulting primarily from the payment of deferred Lonza payables in December 2021; accrued manufacturing expenses of $8.6 million resulting from timing of payments; and prepaid and other current assets of $7.4 million related to a receivable for reimbursement of tenant improvement allowance and prepayments on various contracts, including repairs and maintenance, production of critical raw materials, research and clinical trial preparation. These changes were partially offset by increases in cash flows due to accrued expenses of $4.6 million primarily related to costs associated with the manufacture of extract in connection with our relationship with Sutro Biopharma. Non-cash charges consisted of $10.7 million in stock-based compensation expense, $1.8 million in depreciation and amortization, $1.7 million in amortization of operating lease right-of-use assets and $1.4 million in net amortization of premiums on investments.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net cash used in operating activities for the year ended December 31, 2020 was $46.6 million, which primarily resulted from a net loss of $89.2 million, partially offset by a net change in operating assets and liabilities of $35.3 million and non-cash charges of $7.3 million. The net change in operating assets and liabilities of $35.3 million was primarily due to increases in accounts payable of $26.1 million resulting from the deferral of completion</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">113</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">payments until April 2021 in accordance with our contract with Lonza, accrued manufacturing expenses of $7.2 million related to outsourced manufacturing activities and accrued expenses of $2.2 million related primarily to increases in contract research services related to the VAX-24 program. Non-cash charges primarily consisted of $5.4 million in stock-based compensation expense, $1.4 million in depreciation and amortization and $0.3 million in asset impairment charges.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net cash used in operating activities for the year ended December 31, 2019 was $47.1 million, which primarily resulted from a net loss of $50.3 million and net non-cash charges of $0.8 million, partially offset by a net change in operating assets and liabilities of $3.9 million. Non-cash charges primarily consisted of a $3.2 million decrease in the fair value of our redeemable convertible preferred stock tranche liabilities primarily related to a reduction in the time to maturity during the year and the settlement of the Series C tranche liability in December 2019, partially offset by $1.2 million of depreciation and amortization expense and $1.2 million of stock-based compensation expense. The net change in operating assets and liabilities of $3.9 million was primarily due increases of $4.7 million in accrued liabilities resulting primarily from our increased contract manufacturing activities in 2019 and $0.9 million in accounts payable resulting from timing of billings and payments, partially offset by a $1.1 million increase in prepaid expenses and other current assets, a $0.8 million decrease in accrued compensation due primarily to the timing of the payment of our annual performance bonuses and a $0.7 million in prepaid expenditures mainly related to contract manufacturing activities, contract research services and maintenance contracts.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Cash Flows from Investing Activities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash used in investing activities for the year ended December 31, 2021 was $212.3 million, which related primarily to $336.3 million in purchases of investments and $6.6 million in purchases of lab equipment and furniture and fixtures, partially offset by $100.5 million in maturities of investments and $30.1 million in sales of investments.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash used in investing activities for the years ended December 31, 2020 and 2019 was $$1.1 million and $1.2 million, respectively, which related primarily to purchases of lab equipment and leasehold improvements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Cash Flows from Financing Activities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash provided by financing activities for the year ended December 31, 2021 was $17.8 million, which primarily consisted of net proceeds from shares issued under our ATM Sales Agreement of $13.9 million, proceeds from exercises of common stock options of $3.0 million and proceeds from shares issued under our employee stock purchase plan of $0.9 million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash provided by financing activities for the year ended December 31, 2020 was $374.9 million, which primarily consisted of net proceeds of $264.0 million from our IPO and $109.9 million from the issuance of our Series D redeemable convertible preferred stock.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash provided by financing activities for the year ended December 31, 2019 was $41.6 million, which primarily consisted of net proceeds from the issuance of the second tranche of our Series C redeemable convertible preferred stock of $42.5 million, partially offset by deferred offering costs of $1.1 million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Contractual Obligations and Commitments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our material cash requirements include the following contractual and other obligations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Leases</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have operating lease agreements for our office spaces. As of December 31, 2021, we had lease payment obligations totaling $20.3 million.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">114</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Purchase Obligations</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have certain payment obligations under various license agreements. Under these agreements, we are required to make milestone payments upon successful completion and achievement of certain intellectual property, clinical, regulatory and sales milestones. The payment obligations under the license agreements are contingent upon future events such as our achievement of specified development, clinical, regulatory and commercial milestones, and we will be required to make development milestone payments and royalty payments in connection with the sale of products developed under these agreements. As the achievement and timing of these future milestone payments are not probable or estimable, such amounts have not been included in our balance sheets as of December 31, 2021 or December 31, 2020. See Note 14, &#x201c;Related Party Transactions,&#x201d; to our financial statements included in Part II, Item 8 of this Annual Report on Form 10-K.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We enter into agreements in the normal course of business with vendors for preclinical, clinical and non-clinical studies, manufacturing and supply of our preclinical and clinical materials and for other services and products used for operating purposes. These contracts are generally cancelable following a certain period after written notice, and therefore, we believe that our non-cancelable obligations under these agreements are not material.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Critical Accounting Policies and Significant Judgments and Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our management&#x2019;s discussion and analysis of our financial condition and results of operations are based on our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in our financial statements. On an ongoing basis, we evaluate our estimates and judgments, including those related to accrued expenses, stock-based compensation and leases. We base our estimates on historical experience, known trends and events and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">While our significant accounting policies are described in the notes to our financial statements included elsewhere in this Annual Report on Form 10-K, we believe that the following critical accounting policies are most important to understanding and evaluating our reported financial results:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Accrued Research and Development Expenses</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="margin-left:0.933%;text-indent:9.239%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.935%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have entered into various agreements with contract manufacturing organizations, or CMOs, and clinical research organizations, or CROs. As part of the process of preparing our financial statements, we are required to estimate our accrued research and development expenses, including accrued manufacturing expenses, as of each balance sheet date. This process involves reviewing open contracts and purchase orders, communicating with our personnel and third parties to identify services that have been performed on our behalf and estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of the actual cost. We make estimates of our accrued research and development expenses as of each balance sheet date based on facts and circumstances known to us at that time. We periodically confirm the accuracy of our estimates with the service providers and make adjustments, if necessary. The significant estimates in our accrued research and development expenses include the costs incurred for services performed by our vendors in connection with research and development activities for which we have not yet been invoiced.</span></p>
  <p style="margin-left:0.933%;text-indent:9.239%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.935%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We accrue for costs related to research and development activities based on our estimates of the services received and efforts expended pursuant to quotes and contracts with vendors, including CMOs, that conduct research, development and manufacturing on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">115</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="margin-left:0.933%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.935%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">prepayment of the research and development expense. Advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received. We make significant judgments and estimates in determining accrued research and development liabilities as of each reporting period based on the estimated time period over which services will be performed and the level of effort to be expended. If the actual timing of the performance of services or the level of effort varies from our estimate, we adjust the accrual or prepaid expense accordingly.</span></p>
  <p style="margin-left:0.933%;text-indent:9.431%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.935%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Although we do not expect our estimates to be materially different from amounts actually incurred, if our estimates of the status and timing of services performed differ from the actual status and timing of services performed, it could result in us reporting amounts that are too high or too low in any particular period. To date, there have been no material differences between our estimates of such expenses and the amounts actually incurred.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Stock-Based Compensation Expense</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="margin-left:0.933%;text-indent:9.252%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.065%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock-based compensation expense related to awards to employees is measured at the grant date based on the fair value of the award. The fair value of the award that is ultimately expected to vest is recognized as expense on a straight-line basis over the requisite service period, which is generally the vesting period, net of the impact of actual forfeitures recorded in the period in which they occur.</span></p>
  <p style="margin-left:0.8%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.0%;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="margin-left:0.8%;text-indent:9.328%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.0%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock-based compensation expense related to awards to non-employees is recognized based on the then-current fair value at each measurement date over the associated service period of the award, which is generally the vesting term, using the straight-line method. The fair value of non-employee stock options is estimated using the Black-Scholes valuation model with assumptions generally consistent with those used for employee stock options, with the exception of the expected term, which is the remaining contractual life at each measurement date. Refer to Notes 2 and 10 for more information on assumptions used in estimating stock-based compensation expense.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="margin-left:0.933%;text-indent:9.484%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:3.463%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Black-Scholes option-pricing model requires the use of subjective assumptions, such as volatility, which determine the fair value of stock-based awards. The assumptions utilized in the Black-Scholes option-pricing model are as follows:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="margin-left:10.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Expected Term</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="margin-left:0.933%;text-indent:9.265%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.204%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected term represents the period that our stock-based awards are expected to be outstanding. The expected term for employee equity instruments is calculated using the simplified method where there is insufficient historical data about exercise patterns and post-vesting employment termination behavior. The simplified method is based on the vesting period and the contractual term for each grant, or for each vesting-tranche for awards with graded vesting. The mid-point between the vesting date and the maximum contractual expiration date is used as the expected term under this method. For awards with multiple vesting-tranches, the time from grant until the mid-points for each of the tranches may be averaged to provide an overall expected term. The expected term for non-employee stock options is the remaining contractual term.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="margin-left:10.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Expected Volatility</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="margin-left:0.933%;text-indent:9.252%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.065%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected volatility is estimated from the average historical volatilities of publicly traded companies within the life sciences industry that are considered to be comparable to our business over a period approximately equal to the expected term for employees&#x2019; options and the remaining contractual life for non-employees&#x2019; options. We will continue to apply this process until a sufficient amount of historical information regarding the volatility of our own stock price becomes available.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">116</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="margin-left:10.0%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Expected Dividend</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="margin-left:0.933%;text-indent:9.431%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1979166666666667;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.935%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have not paid and do not anticipate paying any dividends in the near future. Accordingly, we have estimated the dividend yield to be zero.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="margin-left:10.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Risk-Free Interest Rate</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="margin-left:0.933%;text-indent:10.134%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1979166666666667;font-family:Times New Roman;margin-bottom:6.0pt;margin-right:9.602%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant for zero-coupon notes with remaining terms corresponding with the expected term of the option.</span></p>
  <p style="margin-left:10.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="margin-left:10.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Fair Value of Common Stock</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="margin-left:0.933%;text-indent:10.134%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1979166666666667;font-family:Times New Roman;margin-bottom:6.0pt;margin-right:9.602%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For valuations after the completion of our IPO, the fair value of each share of underlying common stock is based on the closing price of our common stock as reported on the Nasdaq Global Select Market on the date of grant.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.05pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Leases</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="margin-left:0.933%;text-indent:10.134%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1979166666666667;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:9.602%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We adopted Accounting Standards Update (&#x201c;ASU&#x201d;) 2016-02, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Leases</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> (</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Topic 842</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">) on January 1, 2021, using the modified retrospective transition approach. There was no cumulative-effect adjustment recorded to retained earnings upon adoption.</span></p>
  <p style="margin-left:0.933%;text-indent:10.134%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1979166666666667;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:9.602%;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="margin-left:0.933%;text-indent:10.134%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1979166666666667;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:9.602%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under ASC 842, we assess all arrangements that convey the right to control the use of property, plant and equipment, at inception, to determine if it is, or contains, a lease based on the unique facts and circumstances present in the arrangements. In addition, we determine whether leases meet the classification criteria of a finance or operating lease at the lease commencement date considering: (1) whether the lease transfers ownership of the underlying asset to the lessee at the end of the lease term, (2) whether the lease contains a bargain purchase option, (3) whether the lease term is for a major part of the remaining economic life of the underlying asset, (4) whether the present value of the sum of the lease payments and residual value guaranteed by the lessee equals or exceeds substantially all of the fair value of the underlying asset, and (5) whether the underlying asset is of such a specialized nature that it is expected to have no alternative use to the lessor at the end of the lease term. As of December 31, 2021, our lease population consisted only of operating real estate leases.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="margin-left:0.933%;text-indent:10.134%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1979166666666667;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:9.602%;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="margin-left:0.933%;text-indent:10.134%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1979166666666667;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:9.602%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Once a lease is identified and its classification determined, we recognize a  right-of-use, or ROU, asset and a corresponding lease liability. Lease liabilities are recorded based on the present value of lease payments over the expected least term. The corresponding ROU asset is measured from the initial lease liability, adjusted by (i) accrued or prepaid rents, (ii) remaining unamortized initial direct costs and lease incentives, and (iii) any impairments of the ROU asset.</span></p>
  <p style="margin-left:0.933%;text-indent:10.134%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1979166666666667;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:9.602%;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="margin-left:0.933%;text-indent:10.134%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1979166666666667;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:9.602%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Significant assumptions utilized in recognizing the right-of-use assets and corresponding lease liabilities included the expected lease term and the incremental borrowing rate. The expected lease term includes both contractual lease periods and, as applicable, extensions of the lease term when we have determined the exercise of the option to extend is reasonably certain to occur. The incremental borrowing rate was utilized to discount lease payments over the expected term given our operating leases do not provide an implicit rate. We estimated the incremental borrowing rate based on an analysis of corporate bond yields with a credit rating similar to us. The determination of our incremental borrowing rate requires management judgment, including development of a synthetic credit rating and cost of debt, as we currently do not carry any debt. We believe that the estimates used in determining the incremental borrowing rate are reasonable based upon current facts and circumstances.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">117</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="margin-left:0.933%;text-indent:10.134%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1979166666666667;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:9.602%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For additional details regarding the impact of adoption and disclosure, see Note 5, &#x201c;Leases,&#x201d; to our financial statements included in Part II, Item 8 of this Annual Report on Form 10-K.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Recently Adopted Accounting Pronouncements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">See Note 2, &#x201c;Basis of Presentation and Summary of Significant Accounting Policies,&#x201d; to our financial statements for additional information.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_7a_quantitative_qualitative_disclos"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 7A. Quantitative and Qualitat</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">ive Disclosures About Market Risk.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Interest Rate Risk</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our cash and cash equivalents as of December 31, 2021 and December 31, 2020 consisted of readily available checking and money market funds. As of December 31, 2021, we also invested in U.S. Treasury securities, U.S. government agency securities, corporate debt, commercial paper and asset-backed securities. Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates. However, because of the nature of the instruments in our portfolio, a sudden change in market interest rates would not be expected to have a material impact on our financial condition or results of operations. We believe that our exposure to interest rate risks is not significant and that a hypothetical 10% movement in market interest rates would not have a significant impact on the total value of our portfolio or our interest income. In addition, we do not believe that our cash and cash equivalents have significant risk of default or illiquidity.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Foreign Currency Risk</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are exposed to market risk related to changes in foreign currency exchange rates, mainly relating to our contract with Lonza, our CMO in Switzerland. We have also entered into a limited number of contracts with other parties with payments denominated in foreign currencies. Payments under these contracts are made in foreign currencies and are subject to fluctuations in foreign currency rates. We do not currently have a formal program in place to hedge foreign currency risks. However, from time to time, we buy Swiss Francs, or CHF, which is the majority of our foreign currency exposure, at market and are holding CHF in our bank accounts. As of December 31, 2021 and December 31, 2020, we had approximately $18.8 million and $4.3 million of cash and cash equivalents, respectively, held at one financial institution. As of December 31, 2021 and December 31, 2020, we had foreign currency denominated accounts payable and accrued expenses of $6.9 million and $41.2 million, respectively. To date, foreign currency transaction gains and losses have not been material to our financial statements. The following table shows the impact of a hypothetical 10% increase or decrease in current exchange rates on our net assets as of December 31, 2021 and our net loss for the three months ended December 31, 2021:</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:60.283%;"></td>
    <td style="width:1.327%;"></td>
    <td style="width:1.381%;"></td>
    <td style="width:16.23%;"></td>
    <td style="width:0.921%;"></td>
    <td style="width:1.327%;"></td>
    <td style="width:1.381%;"></td>
    <td style="width:16.23%;"></td>
    <td style="width:0.921%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Impact on Net Assets as of December 31, 2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Impact on Net Loss for Three Months Ended December 31, 2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(in thousands)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Hypothetical Change in Currency Exchange Rates</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10% increase</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,186</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">963</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10% decrease</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(1,186</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(963</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As our foreign currency risk increases in the future, we will evaluate alternative strategies, including hedging, to mitigate our foreign currency exposure.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Effects of Inflation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Inflation generally affects us by increasing our cost of labor and research and development contract costs. We do not believe inflation had a material effect on our results of operations during the periods presented.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">118</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_8_financial_statements_supplement"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 8. Fina</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">ncial Statements and Supplementary Data.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">INDEX TO FINANCIAL STATEMENTS</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:93.996%;"></td>
    <td style="width:6.004%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#report_independent_registered_public_acc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Report of Independent Registered Public Accounting Firm - PCAOB ID No. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_00963767-c9fe-4c06-8b9b-e769c7447265" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="dei:AuditorFirmId"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">34</span></ix:nonNumeric></span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">120</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#balance_sheets"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Balance Sheets</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">123</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#statementsofoperations1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Statements of Operations</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">124</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#statements_of_comprehensive_loss_"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Statements of Comprehensive Loss</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">125</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#statements_redeemable_convertible_prefer"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Statements of Redeemable Convertible Preferred Stock and Stockholders&#x2019; Equity (Deficit</span></a><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">126</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#condensed_statements_cash_flows"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Statements of Cash Flows</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">127</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#notes_to_unaudited_interim_condensed_fin"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Notes to Financial Statements</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">128</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">119</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="report_independent_registered_public_acc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Report of Independent Regist</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">ered Public Accounting Firm</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">To the stockholders and the Board of Directors of Vaxcyte, Inc.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Opinion on the Financial Statements</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have audited the accompanying balance sheets of Vaxcyte, Inc. (the &#34;Company&#34;) as of December 31, 2021 and 2020, the related statements of operations and comprehensive loss, redeemable convertible preferred stock and stockholders' equity (deficit), and cash flows, for each of the three years in the period ended December 31, 2021, and the related notes (collectively referred to as the &#34;financial statements&#34;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2021 and 2020, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2021, in conformity with accounting principles generally accepted in the United States of America.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of December 31, 2021, based on criteria established in Internal Control &#x2014; Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission and our report dated February 28, 2022, expressed an unqualified opinion on the Company's internal control over financial reporting.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Change in Accounting Principle</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As discussed in Note 2 to the financial statements, effective January 1, 2021, the Company adopted ASC No. 2016-02, Leases (Topic 842), using the modified retrospective transition approach.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Basis for Opinion</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.<br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Critical Audit Matter</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The critical audit matter communicated below is a matter arising from the current-period audit of the financial statements that was communicated or required to be communicated to the audit committee and that (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">120</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Accrued Manufacturing Expenses &#x2014; Refer to Notes 2 and 6 to the financial statements</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Critical Audit Matter Description</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company incurs research and development expenses related to the costs of research and development activities, including those performed by Lonza, a contract manufacturing organization under a development and manufacturing services agreement, to provide research and development services related to preclinical vaccine development. At the end of each period, the Company accrues for costs related to manufacturing expenses based on their estimates of the services received for each phase and efforts expended pursuant to quotes and contracts with vendors that conduct research and development on their behalf. This estimation process involves reviewing open contracts and purchase orders, communicating with Company personnel and third parties to identify services that have been performed on their behalf, and estimating the level of service performed and the associated costs incurred for the services for each phase when the Company has not yet been invoiced or otherwise notified of the actual costs. As of December 31, 2021, the Company had $4.4 million of accrued manufacturing expenses.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We identified the Company&#x2019;s accrued manufacturing expenses as a critical audit matter primarily due to judgments necessary for management to estimate the cost of services provided but not yet invoiced and the significant volume of transactions. The amount of the accrual at period end is based on the terms and conditions per the agreements and is dependent on management&#x2019;s gathering of information from various sources, including Lonza, regarding the progress of the uninvoiced services at the reporting date. Accordingly, this estimate is subjective as it involves management&#x2019;s judgment to analyze the various sources of information. This required extensive audit effort due to the volume and nature of available information from various sources, including Lonza, and required a high degree of auditor judgment when performing audit procedures to audit management&#x2019;s estimates of accrued manufacturing expenses and evaluating the results of those procedures.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">How the Critical Audit Matter Was Addressed in the Audit</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our audit procedures related to the accrued manufacturing expenses included the following, among others:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We tested the effectiveness of controls over the Company&#x2019;s accrued manufacturing expense process, including controls over the estimation of activities completed to date.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We met with internal research and development personnel and inspected Board of Directors materials to understand the status of contract manufacturing activities. We then compared this information to the judgment applied in management&#x2019;s estimate of the recorded expenses and corresponding accrual.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We evaluated the completeness of phases used by the Company by comparing to the tracker obtained from Lonza, as Lonza is the most significant contract manufacturer.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For a sample of phases, we evaluated the accrued manufacturing expenses by:</span></div></div>
  <p style="margin-left:13.6%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">o	Sending written confirmations directly to the contract manufacturing organization to confirm the total budgeted amount and percentage of completion incurred as of year-end.</span></p>
  <p style="margin-left:13.6%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">o	Inspecting the development and manufacturing services agreement and related amendments, change orders, statements of work, and agreeing key provisions of the agreements including timeline, budget, and relevant rates, to the Company&#x2019;s analysis of estimated expenses incurred to date.</span></p>
  <p style="margin-left:13.6%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">o	Obtaining invoices, if available, for each selection to substantiate when the transaction should have been recorded.</span></p>
  <p style="margin-left:13.6%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">o	Testing cash disbursements after period end to test the accuracy of the accrual.</span></p>
  <p style="margin-left:13.6%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">121</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_33a3ad8b-1f47-49ca-9f61-19d10d1b86ec" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="dei:AuditorName"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deloitte &amp; Touche LLP</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ee1e0030-22fc-4ae4-9469-f97225da9a44" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="dei:AuditorLocation"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">San Francisco, California</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">February 28, 2022</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have served as the Company's auditor since 2017.<br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">122</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">VAXCYTE, INC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="balance_sheets"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Balance S</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">heets</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">(in thousands, except share and per share data)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.513%;"></td>
    <td style="width:1.477%;"></td>
    <td style="width:1.038%;"></td>
    <td style="width:13.521%;"></td>
    <td style="width:0.707%;"></td>
    <td style="width:1.477%;"></td>
    <td style="width:1.038%;"></td>
    <td style="width:13.521%;"></td>
    <td style="width:0.707%;"></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;">December 31,</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;">2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;">2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;">Assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">Current assets:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">Cash and cash equivalents</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_1b46589b-8841-47ee-871f-232f1d62bbcd" contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">68,985</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_7da18ccf-7433-4444-935e-e81cd69d5e94" contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">386,200</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">Short-term investments</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_6d57564d-6f6b-451d-ba49-81cc0f6c40e1" contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">176,985</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">Prepaid expenses and other current assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_9742f290-5d30-4d4f-b615-441a5d2c216a" contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,378</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_bd899997-63e2-4350-9198-8136f43631d9" contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,804</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">Total current assets</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_0331d41d-2352-4f7f-8e94-35e65ec1b822" contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">256,348</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_8062c568-1e5b-4394-95d3-e5fd91599f32" contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">389,004</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">Property and equipment, net</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_4c571418-0675-4918-bf58-adf32ab12f56" contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,954</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_3e8aca73-df75-42fe-8f6f-3998c115b9e5" contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,272</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">Operating lease right-of-use assets</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_246f5cf5-b90a-402d-b359-f06e238ac28a" contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">27,958</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">Long-term investments</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_5477517d-f026-4ec3-a715-2bc4888b478a" contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350" name="us-gaap:LongTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">27,117</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">Restricted cash</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_39c8b94e-2eab-4cc8-9e22-252fe433b8ed" contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">871</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">Other assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_efc0c9d8-a6a3-442a-ad41-20a0c2120a7f" contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,089</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_a251040c-eff9-4793-bf10-78ba78ca1f71" contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3">550</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">Total noncurrent assets</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_d23f2dd5-7a3c-4dfc-9ea3-30d12a736440" contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350" name="us-gaap:AssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">67,989</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_ebe23a39-553f-4d0d-acb2-59f6e5741a8d" contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57" name="us-gaap:AssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,822</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">Total assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_964ac4a6-ab6f-4c1c-b7a3-0e33a5f4ab7f" contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">324,337</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_2ddb9ac4-f312-401a-8cc3-300e2e8fe678" contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">392,826</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;">Liabilities, Redeemable Convertible Preferred Stock and Stockholders' Equity</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">Current liabilities:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">Accounts payable</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_61a9dd07-fa0e-4ebd-b1c2-c6665bc6d578" contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,758</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_1477580e-0292-4276-801b-f236b9d792bf" contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">29,785</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">Accrued compensation</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_bc21fc04-1620-41e5-a633-752257b0ce84" contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,455</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_9ebdc8a2-2376-4bca-aaba-59ac96951d4b" contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">284</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">Accrued manufacturing expenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_856263f9-aac5-4c91-a5f3-c2e61fad6757" contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350" name="pcvx:AccruedManufacturingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,440</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_d5d00ae8-e747-410c-83ed-08b148682d15" contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57" name="pcvx:AccruedManufacturingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13,012</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">Accrued expenses (including related party accrual of $</span><span style="font-size:7.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_1031279b-b63c-4e60-a6f8-f745bd8b84d4" contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350" name="us-gaap:DueToRelatedPartiesCurrent" unitRef="U_USD" scale="3" decimals="-3">0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">&#160;and $</span><span style="font-size:7.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_8a55ffa7-4976-4062-b2eb-0b54fc886f1c" contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57" name="us-gaap:DueToRelatedPartiesCurrent" unitRef="U_USD" scale="3" decimals="-3">677</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">&#160;as of<br />&#160;&#160;&#160;December 31, 2021 and December 31, 2020, respectively)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_34365d1a-a4cf-4639-85aa-041796db63fb" contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,787</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_57b2face-9bab-4a10-a3eb-9408ea955b3f" contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,766</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">Deferred rent &#x2014; current</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_a8c3e152-503a-4479-bb86-eb9206424a7c" contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57" name="us-gaap:DeferredRentCreditCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">14</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">Operating lease liabilities &#x2014; current</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_ed5162a1-09b3-4db0-9e06-09e80457633e" contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,276</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">Total current liabilities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_e3d1db6f-3a91-48ed-ad33-a43daf52ca84" contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">28,716</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_13270f4b-a2da-4b4c-a99e-76645c4ae515" contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">46,861</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">Deferred rent &#x2014; long-term</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_1e4a9fe2-716c-4895-9b4d-566a03cdb48e" contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57" name="us-gaap:DeferredRentCreditNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">Operating lease liabilities &#x2014; long-term</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_0b0a12fd-8c70-40e3-9e0d-f44f108a1894" contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11,507</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">Other liabilities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_9fcb76a7-e28b-4a7c-8f44-cba526f0eaef" contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350" name="us-gaap:OtherLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">96</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_331c120c-8b14-4e54-805d-1a9d8a325cb2" contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57" name="us-gaap:OtherLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">112</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">Total liabilities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_33ecb619-0124-4712-bb29-9d712972aeaa" contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">40,319</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_87a412e6-9c82-4610-8543-8c128e4ad6a0" contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">46,983</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_12ca5abb-61de-41ac-ba25-bb0e431fbb88;"><span style="-sec-ix-hidden:F_565f8602-4d2e-4dc2-8e24-2bd920b5de6a;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">Commitments and contingencies (Note 6)</span></span></span></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;">Stockholders' Equity</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">Preferred stock, $</span><span style="font-size:7.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_0ccf69c7-5403-4c4f-97fe-63c6f4f06049" contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF"><ix:nonFraction id="F_2b30f4cf-04ab-44de-8d73-e39d8223d09b" contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">0.001</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">&#160;par value &#x2014; </span><span style="font-size:7.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_1839fa5a-509f-415a-8dba-ee724ad71016" contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_f7aaad76-ee24-4322-9512-ed5ea1501053" contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">10,000,000</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">&#160;authorized at December 31, 2021<br />&#160;&#160;&#160;and December 31, 2020; </span><span style="font-size:7.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_c0d73828-b884-4bd9-bc70-3476f299e5c0" contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_e9101721-d002-44fb-9188-c24398fee5cf" contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_e82e9dfc-f874-47e3-a7e9-b6ddc7a0a323" contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_a6bd096e-6966-42d4-befb-40d28677ed7d" contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">&#160;shares issued and outstanding at December 31, 2021<br />&#160;&#160;&#160;and December 31, 2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_bc3cb20d-a774-425a-bb11-176869120719;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_ced4119e-0847-4d96-a362-c9f40af1bee1;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">Common stock, $</span><span style="font-size:7.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_229d954f-1077-46f8-87d0-b45ca1ff2c8d" contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF"><ix:nonFraction id="F_c9f66b00-93cb-4643-b20e-3cb682ec357e" contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">0.001</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">&#160;par value &#x2014; </span><span style="font-size:7.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_48902fe8-a1a0-4c08-a55c-a7eda1af5e19" contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_15385dca-2d5a-47ee-ba01-23f6e0cac7b5" contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">500,000,000</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">&#160;shares authorized at December 31, 2021 <br />&#160;&#160;&#160;and December 31, 2020; </span><span style="font-size:7.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_9ab56d2a-8636-4eb3-8adf-d3404d71fa50" contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_cbdf2005-f339-4ad8-ba04-d2823868e47b" contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">53,031,978</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">&#160;and </span><span style="font-size:7.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_39564e5f-9b64-400e-bb3e-eaf41f645653" contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_b2f54f97-b4b7-4be2-824b-d9c5b88bca3f" contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">51,071,593</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">&#160;shares issued and outstanding<br />&#160;&#160;&#160;at December 31, 2021 and December 31, 2020, respectively</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_0e2ec2c8-1d09-48f3-a89c-30a49ccf3d42" contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">56</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_1f593dd8-94c9-4550-bdfb-72ddc2d47e88" contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3">54</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">Additional paid-in capital</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_f93abd5c-b1e7-45c8-bfeb-f6a748d78ee7" contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">582,844</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_9a3900b1-c3dc-431d-a817-49f447bb2d2d" contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">544,353</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">Accumulated other comprehensive loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">(</span><span style="font-size:7.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_1a4a9204-5a95-4a25-a7fe-5e389915f8fe" contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">241</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">Accumulated deficit</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">(</span><span style="font-size:7.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_68291ef0-cb3c-4ef0-bb1c-ba469dab88e0" contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">298,641</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">(</span><span style="font-size:7.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_1268865e-87d9-44ef-a174-8cba176bbf70" contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">198,564</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">Total stockholders' equity</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_d21c5bb8-5b45-4f7a-a4d9-3183a665af05" contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">284,018</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_c4ab8663-1afc-4549-b307-d8c5b98a5ad9" contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">345,843</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">Total liabilities, redeemable convertible preferred stock and stockholders' equity</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_4e50edb9-d5ed-4968-b338-23aaa217a5a4" contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">324,337</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_8c1e137b-e130-446f-a8dd-e489127c0f62" contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">392,826</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The accompanying notes are an integral part of these financial statements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">123</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">VAXCYTE, INC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="statementsofoperations1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Statements of Operations</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">(in thousands, except share and per share data)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:57.219%;"></td>
    <td style="width:1.5%;"></td>
    <td style="width:1.232%;"></td>
    <td style="width:10.701%;"></td>
    <td style="width:0.835%;"></td>
    <td style="width:1.5%;"></td>
    <td style="width:1.232%;"></td>
    <td style="width:10.701%;"></td>
    <td style="width:0.835%;"></td>
    <td style="width:1.5%;"></td>
    <td style="width:1.232%;"></td>
    <td style="width:10.679%;"></td>
    <td style="width:0.835%;"></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">2019</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Operating expenses:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Research and development (including related party expenses of $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b164fe37-39fd-4548-aac3-93cdbef88a77" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="pcvx:ResearchAndDevelopmentExpenseToRelatedParty" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,359</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">,  <br />&#160;&#160;&#160;$</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a266715a-e513-4450-b304-0957eb49d158" contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001" name="pcvx:ResearchAndDevelopmentExpenseToRelatedParty" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,331</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#160;and $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b58bc85c-b3ed-4e5e-94c0-620123908ac7" contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700" name="pcvx:ResearchAndDevelopmentExpenseToRelatedParty" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,137</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#160;in 2021, 2020 and 2019, respectively)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c82621c6-6a33-4f50-9101-8001bb98dbf1" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">78,411</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_900c83d1-2428-4030-8e37-2bd3a9617ab0" contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">73,564</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2fb046d4-84ab-433d-a1d0-a7fde59478b1" contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">45,607</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">General and administrative</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8042bfd8-3bf2-42b6-97ff-286017c5b73c" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">25,259</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b8f8f04f-83e5-427f-852a-6dd254c257c5" contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">16,017</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3e4d4db0-241c-43a3-a884-122502d8cea3" contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,546</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Total operating expenses</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6d0cda2d-036a-49cb-a3a2-098a3eb653a0" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">103,670</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c5a4ab2c-c2e4-401d-ac44-67608e4df565" contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">89,581</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_19a021eb-bf2a-42bc-86f4-c521700fa244" contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">54,153</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Loss from operations</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_770828f2-4885-4fdb-8166-42e20187d183" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">103,670</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0ef15b63-9bc3-4e12-a574-5d58dc6b6d13" contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">89,581</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8fe8f1ca-a7ef-4fe3-89ea-80a1472129f6" contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">54,153</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Other income (expense), net:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Interest expense</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_47f6ed6c-bd57-4ce6-897d-04ff3fdd3d35" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="us-gaap:InterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_05037412-cb6b-4294-9f85-309423342dc7" contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001" name="us-gaap:InterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_782aaab3-d2ff-4b2a-8248-2169a9d9f5d4" contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700" name="us-gaap:InterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">40</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Interest income</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_11a14156-97b6-4987-84ad-a095bcb37d57" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="us-gaap:InvestmentIncomeInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">344</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_04081cb2-a59f-43dc-9649-b8385dea2785" contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001" name="us-gaap:InvestmentIncomeInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">244</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7edc7922-db1e-4964-9b70-7ec2d89ed4a3" contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700" name="us-gaap:InvestmentIncomeInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">632</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Grant income</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f007c07d-9ee0-4c5f-aca1-69fa08dfc5a0" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="pcvx:GrantIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,585</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3a017cc1-44c7-45d8-9c19-90b4974fe6b7" contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001" name="pcvx:GrantIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,478</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0ad7317b-2a3b-4aa7-96d4-78372fd9c75d" contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700" name="pcvx:GrantIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">237</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Realized gains on marketable securities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_958fbe32-d579-428f-b415-09c83ff6218b" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="us-gaap:MarketableSecuritiesRealizedGainLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Foreign currency transaction gains (losses)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_764d8f7b-09b9-46e1-8a85-f462b7e5c930" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,669</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fdcf6918-234a-45f1-a94b-632ae0d0e6d8" contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">2,351</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_10123a84-b089-48a8-93ed-07620e285a0f" contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">135</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Change in fair value of the redeemable<br />&#160;&#160;&#160;convertible preferred stock tranche liability</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f883e162-3b80-43e3-83fc-e4f24581e0dc" contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700" name="pcvx:ChangeInFairValueOfRedeemableConvertiblePreferredStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,185</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Total other income (expense), net</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bf79e5ed-2287-4c1a-bbd0-dfd20c9e8750" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,593</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_aec72341-4dd9-4c72-b358-5c06b5714206" contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">364</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e62e44e4-f9d7-4cf5-852d-cb32de09b716" contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,879</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Net loss</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_378268c4-4e6b-4a6d-a6c1-06cde227a6da" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">100,077</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_eee13a05-aad5-481e-a1b2-0a0910c5d240" contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">89,217</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e8582e9e-f77a-4c86-a21c-b4b46d521285" contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">50,274</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Net loss per share, basic and diluted</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a9bda523-330c-48a7-b9c5-7f05e77562eb" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="us-gaap:EarningsPerShareBasicAndDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-">1.93</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3056c494-1897-48f3-9c41-eb965312ec56" contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001" name="us-gaap:EarningsPerShareBasicAndDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-">3.02</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c8205e43-2cc0-4eb4-9744-8947eca98054" contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700" name="us-gaap:EarningsPerShareBasicAndDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-">13.25</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Weighted-average shares outstanding, basic and diluted</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0302b519-885c-4a85-8d30-84787f65441d" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">51,922,108</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_eadcc953-b7a4-4538-9e4d-70a5bdb0ee13" contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">29,545,810</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_aafa83c9-783b-4611-a7d4-eba51e898ce6" contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">3,795,090</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The accompanying notes are an integral part of these financial statements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">124</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">VAXCYTE, INC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="statements_of_comprehensive_loss_"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Statements of Compr</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">ehensive Loss</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">(in thousands, except share and per share data)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:58.077%;"></td>
    <td style="width:1.477%;"></td>
    <td style="width:1.242%;"></td>
    <td style="width:10.224%;"></td>
    <td style="width:0.963%;"></td>
    <td style="width:1.477%;"></td>
    <td style="width:1.242%;"></td>
    <td style="width:10.213%;"></td>
    <td style="width:0.985%;"></td>
    <td style="width:1.595%;"></td>
    <td style="width:1.242%;"></td>
    <td style="width:10.277%;"></td>
    <td style="width:0.985%;"></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">2019</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Net Loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6ab94a14-1f88-4090-bed1-b305bdb9496c" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">100,077</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_292405df-dc02-4785-a542-e09bf8d914a8" contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">89,217</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_115aa1b8-b395-4f15-9a9e-ca8e9ddf1278" contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">50,274</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Other comprehensive loss:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Unrealized losses on investments</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_da5ffd8c-6e5a-48fa-bbe1-f9539af8382b" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">241</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Comprehensive Loss</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d056145a-ba8d-4920-a212-99a4409f850e" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">100,318</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c2a51c32-e5f8-41bb-a7f8-13130d39f420" contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">89,217</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_13526dfc-28ad-4ed7-ab2d-3627c3af4a48" contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">50,274</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">125</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.5pt;font-family:Times New Roman;">VAXCYTE, INC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.5pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="statements_redeemable_convertible_prefer"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.5pt;font-family:Times New Roman;">Statements of Redeemable Convertible Preferre</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.5pt;font-family:Times New Roman;">d Stock and Stockholders&#x2019; Equity (Deficit)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;font-style:italic;">(in thousands, except share data)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:14.343%;"></td>
    <td style="width:0.417%;"></td>
    <td style="width:0.322%;"></td>
    <td style="width:4.603%;"></td>
    <td style="width:0.417%;"></td>
    <td style="width:0.417%;"></td>
    <td style="width:0.644%;"></td>
    <td style="width:3.783%;"></td>
    <td style="width:0.417%;"></td>
    <td style="width:0.417%;"></td>
    <td style="width:0.322%;"></td>
    <td style="width:4.603%;"></td>
    <td style="width:0.417%;"></td>
    <td style="width:0.417%;"></td>
    <td style="width:0.644%;"></td>
    <td style="width:3.783%;"></td>
    <td style="width:0.417%;"></td>
    <td style="width:0.417%;"></td>
    <td style="width:0.322%;"></td>
    <td style="width:4.603%;"></td>
    <td style="width:0.417%;"></td>
    <td style="width:0.417%;"></td>
    <td style="width:0.644%;"></td>
    <td style="width:3.783%;"></td>
    <td style="width:0.417%;"></td>
    <td style="width:0.417%;"></td>
    <td style="width:0.322%;"></td>
    <td style="width:4.603%;"></td>
    <td style="width:0.417%;"></td>
    <td style="width:0.417%;"></td>
    <td style="width:0.644%;"></td>
    <td style="width:4.288%;"></td>
    <td style="width:0.417%;"></td>
    <td style="width:0.417%;"></td>
    <td style="width:0.417%;"></td>
    <td style="width:0.322%;"></td>
    <td style="width:4.705%;"></td>
    <td style="width:0.322%;"></td>
    <td style="width:0.417%;"></td>
    <td style="width:0.644%;"></td>
    <td style="width:3.908%;"></td>
    <td style="width:0.322%;"></td>
    <td style="width:0.417%;"></td>
    <td style="width:0.644%;"></td>
    <td style="width:5.386%;"></td>
    <td style="width:0.322%;"></td>
    <td style="width:0.417%;"></td>
    <td style="width:0.644%;"></td>
    <td style="width:5.789%;"></td>
    <td style="width:0.417%;"></td>
    <td style="width:0.578%;"></td>
    <td style="width:0.644%;"></td>
    <td style="width:6.389%;"></td>
    <td style="width:0.381%;"></td>
    <td style="width:0.717%;"></td>
    <td style="width:0.644%;"></td>
    <td style="width:5.789%;"></td>
    <td style="width:0.417%;"></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;">Series A</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;">Series B</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;">Series C</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;">Series D</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;">Accumulated</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;">Total</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;">Redeemable Convertible</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;">Redeemable Convertible</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;">Redeemable Convertible</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;">Redeemable Convertible</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;">Additional</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;">Other</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;">Stockholders&#x2019;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;">Preferred Stock</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;">Preferred Stock</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;">Preferred Stock</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;">Preferred Stock</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;">Common Stock</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;">Paid-in</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;">Accumulated</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;">Comprehensive</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;">Equity</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;">Shares</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;">Amount</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;">Shares</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;">Amount</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;">Shares</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;">Amount</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;">Shares</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;">Amount</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;">Shares</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;">Amount</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;">Capital</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;">Deficit</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;">Loss</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;">(Deficit)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;">Balance &#x2014; December 31, 2018</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3f5e4c87-a518-4bb4-88f6-7b9cb32fdf85" contextRef="C_ace47527-5c7b-43a0-97fe-7ef235c9ad0c" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">6,225,719</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ebfda047-92b9-4c4a-a2e2-f42312470b90" contextRef="C_ace47527-5c7b-43a0-97fe-7ef235c9ad0c" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">24,967</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4f7b8ec7-7c51-4f12-b923-669ef229e657" contextRef="C_e62d86e5-c312-474f-99a0-95ed9692529c" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">6,786,896</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a7cb9afd-5c5d-474e-a8fe-347095acf077" contextRef="C_e62d86e5-c312-474f-99a0-95ed9692529c" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">55,151</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_183ddd63-5e34-4e91-9f06-de5cfc753bca" contextRef="C_0a0e42fe-11ad-487e-b9de-014ca00c2d28" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,688,740</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1ec879ff-e6ab-45e5-ba4c-77a377b28e8f" contextRef="C_0a0e42fe-11ad-487e-b9de-014ca00c2d28" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">37,692</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0afced7b-fc65-40c1-9a8b-aa699722e18d" contextRef="C_dd29e038-bfb3-4788-9620-c38deb43178e" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,757,403</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_32417ec8-d3d1-462f-9081-73cc9afb0bf6" contextRef="C_dd29e038-bfb3-4788-9620-c38deb43178e" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6286cd56-108c-40e3-a2e0-2f50c8708a85" contextRef="C_7b1cec7a-d004-403e-8a42-ef595588ed48" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,339</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">(</span><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2d2cae9a-2b0a-4c1d-a409-fbec376cbe9e" contextRef="C_cb2a9833-f2d5-4d07-9f84-e6fd7b138b95" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">59,073</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">(</span><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_334dc0dc-43a8-46fc-91c4-d505ba31e6f2" contextRef="C_ecccdfb9-edd1-45a3-8445-0fe8b2f43253" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">57,728</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:8.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">Issuance of Series C redeemable<br />&#160;&#160;&#160;convertible preferred stock, net<br />&#160;&#160;&#160;of issuance costs of $</span><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_cf5a29c3-bf3a-4e29-91ef-776342faa566" contextRef="C_c0fb1076-a7db-464d-8c21-b64e5bc453db" name="pcvx:TemporaryEquityStockIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">0</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0d768f61-4a5c-4efb-8678-e4800f009da9" contextRef="C_c0fb1076-a7db-464d-8c21-b64e5bc453db" name="pcvx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,688,740</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_dbedca6e-ace8-42a9-8539-ecfa64fb3039" contextRef="C_c0fb1076-a7db-464d-8c21-b64e5bc453db" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">42,500</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:8.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">Exercise of stock options</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_13ae9837-b42d-4d18-aaf9-7bab402fc0c7" contextRef="C_08f2ab18-3ec2-4bf6-a856-11d6f22d4790" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">243,230</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c7421904-f9a8-49f2-8d15-13220f3cd0e7" contextRef="C_08f2ab18-3ec2-4bf6-a856-11d6f22d4790" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_32279676-535a-4c3f-acec-52d409752f14" contextRef="C_68dac7ff-d423-43b1-b2cb-fbeb2182a939" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">321</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b6f873f0-ae57-4267-9fa0-4f9edbe47976" contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">322</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:8.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">Issuance of common stock related<br />&#160;&#160;&#160;to early exercised stock options</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d19b1c57-b65d-4bd9-b99b-c5196c761392" contextRef="C_08f2ab18-3ec2-4bf6-a856-11d6f22d4790" name="pcvx:StockIssuedDuringPeriodSharesIssuanceOfCommonStockRelatedToEarlyExercisedStockOptions" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">59,276</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:8.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">Vesting of early exercised<br />&#160;&#160;&#160;stock options</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_424b771d-9f17-452b-a2ce-5a2db9631b6a" contextRef="C_68dac7ff-d423-43b1-b2cb-fbeb2182a939" name="pcvx:AdjustmentsToAdditionalPaidInCapitalVestingOfEarlyExercisedStockOptions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">122</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6bcee000-4003-484f-8db8-018cf63d6677" contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700" name="pcvx:AdjustmentsToAdditionalPaidInCapitalVestingOfEarlyExercisedStockOptions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">122</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:8.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">Stock-based compensation expense</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4a980031-61f1-4960-96ca-65d6d6e3ac21" contextRef="C_68dac7ff-d423-43b1-b2cb-fbeb2182a939" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,185</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a3fb83ae-d526-440c-94f6-7346fca4e3f0" contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,185</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:8.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">Net loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">(</span><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_cec7b3c4-e920-44fe-b02a-2ee4adcd8148" contextRef="C_3800b858-6c6b-4793-98cb-f7bb3ff61062" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">50,274</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">(</span><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_77bec903-c3e8-4b24-bbff-c7c3426b5532" contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">50,274</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;">Balance &#x2014; December 31, 2019</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_98039019-f3aa-4b9d-b034-31e6b7d727da" contextRef="C_3ab55850-7a59-4321-b335-f0ca2fe76524" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">6,225,719</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d496f040-6108-4ca8-bb8a-863904067dce" contextRef="C_3ab55850-7a59-4321-b335-f0ca2fe76524" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">24,967</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c126b376-551d-4296-b760-bbcb395fb78a" contextRef="C_7ef0af11-3445-4e12-816a-b2d4849a786e" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">6,786,896</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8d86f832-00c3-47e4-9616-4b3c974b95f7" contextRef="C_7ef0af11-3445-4e12-816a-b2d4849a786e" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">55,151</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_104cc953-ce3e-47dd-a4d6-681205652ecb" contextRef="C_b1ab0ed1-080d-4ff7-adaf-245dff15e8dc" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">7,377,480</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_726c9bbd-1e09-448b-bc81-155492953902" contextRef="C_b1ab0ed1-080d-4ff7-adaf-245dff15e8dc" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">80,192</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fa6d0bc6-5979-4be8-8b0b-a9d6ac262155" contextRef="C_4d6eec73-41eb-4eea-8812-cd5a564af773" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">4,059,909</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d350de91-5afb-44df-9180-5a8ab04e9128" contextRef="C_4d6eec73-41eb-4eea-8812-cd5a564af773" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_50422dab-f9f3-4b03-b57d-0fe00472c820" contextRef="C_8bc7d2ce-bbce-48ac-9b6a-f09c04733362" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,967</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">(</span><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a7564015-e7ac-4790-ac4e-b7416f5e7aab" contextRef="C_17a1e23b-77b7-43b4-b889-deab67e04a69" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">109,347</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">(</span><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5f42271f-56bf-4386-b9e8-2a90c3489c04" contextRef="C_871fe4ad-8a52-4dc5-a523-876ef5a1de6d" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">106,373</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:8.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">Issuance of Series D redeemable<br />&#160;&#160;&#160;convertible preferred stock, net<br />&#160;&#160;&#160;of issuance costs of $</span><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ab41a75d-d703-49a7-bbd0-2ec19debe15e" contextRef="C_006c2037-6bba-4d3a-bcd7-32b71e7a5475" name="pcvx:TemporaryEquityStockIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">121</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1e074a42-9c9d-4120-87ca-47f58a08d48c" contextRef="C_006c2037-6bba-4d3a-bcd7-32b71e7a5475" name="pcvx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">8,220,242</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_307b5d95-8a85-4d3c-902e-ff7dd2b65f43" contextRef="C_006c2037-6bba-4d3a-bcd7-32b71e7a5475" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">109,879</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:8.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">Conversion of preferred stock</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">(</span><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_808c79df-2655-4359-a632-b2f8ef58749f" contextRef="C_b663ddb0-dc3a-4405-9809-183e08d4aa14" name="pcvx:TemporaryEquityConversionOfPreferredStockShares" unitRef="U_shares" decimals="INF" sign="-" format="ixt:numdotdecimal">6,225,719</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">(</span><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_319ce2b3-7a00-4a8a-b91f-67257a3977d1" contextRef="C_b663ddb0-dc3a-4405-9809-183e08d4aa14" name="pcvx:TemporaryEquityConversionOfPreferredStockValue" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">24,967</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">(</span><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8203376f-1b8f-4014-87cd-d30dfd3c78fd" contextRef="C_6c03f021-f6d5-4fb2-b776-94bc1a86aa1d" name="pcvx:TemporaryEquityConversionOfPreferredStockShares" unitRef="U_shares" decimals="INF" sign="-" format="ixt:numdotdecimal">6,786,896</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">(</span><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7aa3ba47-9d81-4bfb-a5e0-744aeac0829c" contextRef="C_6c03f021-f6d5-4fb2-b776-94bc1a86aa1d" name="pcvx:TemporaryEquityConversionOfPreferredStockValue" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">55,151</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">(</span><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_416fb78b-b598-4a83-a05b-04e7bf778dfb" contextRef="C_432334ae-bbb2-42ed-9170-56253d99b097" name="pcvx:TemporaryEquityConversionOfPreferredStockShares" unitRef="U_shares" decimals="INF" sign="-" format="ixt:numdotdecimal">7,377,480</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">(</span><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_50ffa91e-1826-421e-ae2a-d6d6648ca8b2" contextRef="C_432334ae-bbb2-42ed-9170-56253d99b097" name="pcvx:TemporaryEquityConversionOfPreferredStockValue" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">80,192</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">(</span><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5d6a554b-d17a-41bd-a152-4aaa8e23c05f" contextRef="C_006c2037-6bba-4d3a-bcd7-32b71e7a5475" name="pcvx:TemporaryEquityConversionOfPreferredStockShares" unitRef="U_shares" decimals="INF" sign="-" format="ixt:numdotdecimal">8,220,242</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">(</span><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a85fb25f-3c60-430b-b888-ad64afd5dc9d" contextRef="C_006c2037-6bba-4d3a-bcd7-32b71e7a5475" name="pcvx:TemporaryEquityConversionOfPreferredStockValue" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">109,879</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c7e5338f-f377-4307-b3ae-697128efa425" contextRef="C_372ee990-ff50-459b-90f9-d45574ce4c70" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">28,610,337</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8cb2c697-68f8-4507-963a-7a695a820a48" contextRef="C_372ee990-ff50-459b-90f9-d45574ce4c70" name="pcvx:TemporaryEquityConversionOfPreferredStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">29</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_60703189-89e4-41e3-8486-4a58d391d47e" contextRef="C_c1debaa3-dafc-4806-a41b-60a0b5a5aa1c" name="pcvx:TemporaryEquityConversionOfPreferredStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">270,161</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f12a76d8-aebb-4ad3-bd2f-be0ec591e8d3" contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001" name="pcvx:TemporaryEquityConversionOfPreferredStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">270,190</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:8.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">Conversion of common<br />&#160;&#160;&#160;stock warrant</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7f3a61cd-e31c-4f26-ba1f-9b5b085fe917" contextRef="C_372ee990-ff50-459b-90f9-d45574ce4c70" name="pcvx:StockIssuedDuringPeriodSharesConversionOfCommonStockWarrant" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">30,278</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:8.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">Conversion of preferred<br />&#160;&#160;&#160;stock warrant</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_65a2bf53-6cec-41b8-8242-0e3d8d189d1b" contextRef="C_372ee990-ff50-459b-90f9-d45574ce4c70" name="pcvx:StockIssuedDuringPeriodSharesConversionOfPreferredStockWarrant" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">16,591</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:8.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">Warrant liability write-off</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b514ac26-8cc6-4701-8f57-2d3f84facedd" contextRef="C_c1debaa3-dafc-4806-a41b-60a0b5a5aa1c" name="pcvx:AdjustmentsToAdditionalPaidInCapitalWarrantLiabilityWriteOff" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">629</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6a302e72-fc6c-4a00-9c2e-052ac90834fe" contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001" name="pcvx:AdjustmentsToAdditionalPaidInCapitalWarrantLiabilityWriteOff" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">629</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:8.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">Issuance of common stock upon<br />&#160;&#160;&#160;initial public offering, net of<br />&#160;&#160;&#160;issuance costs of $</span><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f7f2031f-a90b-4757-ab19-d08d241b4f80" contextRef="C_bc281be7-82b8-4ef6-9792-0543c76c1a35" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,368</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f103b0d1-a628-427d-a900-0f44caa7df2b" contextRef="C_bc281be7-82b8-4ef6-9792-0543c76c1a35" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">17,968,750</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_53be5461-3481-47df-85d0-4d06a83384c5" contextRef="C_bc281be7-82b8-4ef6-9792-0543c76c1a35" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">18</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8428c0d1-37ff-407d-a2e2-789987305576" contextRef="C_a4d7b89e-0ab9-4f03-8b01-723510464ce9" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">263,989</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_41721498-4e02-431b-9f4f-94b6c7ded664" contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">264,007</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:8.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">Exercise of stock options</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_47ecdbe8-12b8-4aa3-9861-a32ed519316b" contextRef="C_372ee990-ff50-459b-90f9-d45574ce4c70" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">343,444</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_aa3d0c52-5955-4a2d-87eb-a5f09f93a231" contextRef="C_c1debaa3-dafc-4806-a41b-60a0b5a5aa1c" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">635</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0fadc214-c2d3-4cec-a890-c56ece87d06a" contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">635</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:8.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">Issuance of common stock related<br />&#160;&#160;&#160;to early exercised stock options</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_052e5c48-3ef7-44bd-9e2a-6579d32019d8" contextRef="C_372ee990-ff50-459b-90f9-d45574ce4c70" name="pcvx:StockIssuedDuringPeriodSharesIssuanceOfCommonStockRelatedToEarlyExercisedStockOptions" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">14,819</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:8.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">Issuance of common stock under<br />&#160;&#160;&#160;Employee Stock Purchase Plan</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c3ca576c-9a35-4169-a8cd-fb1252b201a9" contextRef="C_372ee990-ff50-459b-90f9-d45574ce4c70" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">27,465</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_54beaa39-3c19-4e61-aab0-448d9ac8f292" contextRef="C_c1debaa3-dafc-4806-a41b-60a0b5a5aa1c" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">374</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_511cf1c3-7b6e-4912-a620-8b514c76ddc7" contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">374</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:8.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">Vesting of early exercised<br />&#160;&#160;&#160;stock options</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7806dff2-9f57-42c7-bd04-10f06909deb1" contextRef="C_c1debaa3-dafc-4806-a41b-60a0b5a5aa1c" name="pcvx:AdjustmentsToAdditionalPaidInCapitalVestingOfEarlyExercisedStockOptions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">164</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f9d7f7ee-28c8-4e28-9fac-94a03adc0a34" contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001" name="pcvx:AdjustmentsToAdditionalPaidInCapitalVestingOfEarlyExercisedStockOptions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">164</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:8.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">Issuance of preferred stock</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:8.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">Stock-based compensation expense</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8ae60f65-c757-4e34-8ddf-c80c85f2f1ab" contextRef="C_c1debaa3-dafc-4806-a41b-60a0b5a5aa1c" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,434</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1259b563-040f-46bb-880b-3151d254b8fe" contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,434</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:8.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">Net loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">(</span><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1097e618-d46e-4b41-b353-c7c0682271a9" contextRef="C_b5f3713d-ecd4-4700-a7ab-db89f5c2d1ac" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">89,217</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">(</span><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_342e46d8-72e1-4ceb-8a37-125458e461fa" contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">89,217</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;">Balance &#x2014; December 31, 2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bb82fbd3-8388-455c-b978-534a125f9675" contextRef="C_b350157c-7c7f-42a0-b645-149c360d1819" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">51,071,593</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_00663899-3fc0-435a-9aab-eee48bdbd449" contextRef="C_b350157c-7c7f-42a0-b645-149c360d1819" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">54</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9f942718-5f76-44e0-b96c-97906eb6abc8" contextRef="C_914c8ff3-3cf5-4419-8e2f-0309464abc71" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">544,353</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">(</span><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_79c1c8cd-d342-4461-ad53-a99424b3e94c" contextRef="C_de000bd8-7fd0-42f8-8b81-fc098f2cc14e" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">198,564</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a4bd3f42-8d43-40a4-ae76-eef3fd522969" contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">345,843</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:8.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">Exercise of stock options</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_220a9e82-7a3e-4128-bd19-f5a832576ccf" contextRef="C_542495c1-8a9f-4d28-9179-f5c599d02e73" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">931,114</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_97c41976-dfeb-4a8a-a3c5-2ed31f641f97" contextRef="C_11d04721-6c5e-451c-9f8c-b386520e079e" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,012</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a7101494-cb67-491d-afc8-bc35d53f7250" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,012</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:8.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">Issuance of common stock to<br />&#160;&#160;&#160;Lonza Ltd.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9f604c5f-8260-440d-a2b1-6df391b22b76" contextRef="C_542495c1-8a9f-4d28-9179-f5c599d02e73" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">399,680</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d1d71218-bb46-4ac0-a0db-1255c18337a6" contextRef="C_542495c1-8a9f-4d28-9179-f5c599d02e73" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_60fb513e-db07-4b56-881d-c6a612e9c8e9" contextRef="C_11d04721-6c5e-451c-9f8c-b386520e079e" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,000</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b8a0536b-d21c-4a49-a021-dd95524fdd0e" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,001</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:8.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">Issuance of common stock in<br />&#160;&#160;&#160;connection with at-the market<br />&#160;&#160;&#160;offering, net of issuance costs<br />&#160;&#160;&#160;of $</span><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d56cde00-1542-4df0-8634-d0e8e9243cca" contextRef="C_132d316b-36f4-4e18-bf45-5543bb58c44e" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">479</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9bba787d-8bec-468f-93e0-ca8c5350ef9b" contextRef="C_2a5c2eff-6ddb-4c32-9bd6-9e0d20b2a11f" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">567,045</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a84a1354-9cf8-4fc0-b37b-67c99f434309" contextRef="C_2a5c2eff-6ddb-4c32-9bd6-9e0d20b2a11f" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8430ffa7-3e78-4430-aa84-83a4d9bfa04a" contextRef="C_bef847b3-ad94-49aa-ac4c-cf8f492446d7" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13,846</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b5a5dbb3-4270-4e87-a7bf-3a408837d2e5" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13,847</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:8.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">Issuance of common stock under<br />&#160;&#160;&#160;Employee Stock Purchase Plan</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e72b2309-2137-4dfe-8781-df6be74d0515" contextRef="C_542495c1-8a9f-4d28-9179-f5c599d02e73" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">62,546</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_57dc9bef-ac53-4282-bdc0-b6f0772715c5" contextRef="C_11d04721-6c5e-451c-9f8c-b386520e079e" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">888</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9816bb7a-2c1e-4fe0-afdb-8aa864c159b8" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">888</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:8.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">Vesting of early exercised<br />&#160;&#160;&#160;stock options</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_424ef8f6-714f-4e3e-b260-ccb2b2e1652b" contextRef="C_11d04721-6c5e-451c-9f8c-b386520e079e" name="pcvx:AdjustmentsToAdditionalPaidInCapitalVestingOfEarlyExercisedStockOptions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">16</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_529ceca8-c876-41fe-9f03-54845dca28de" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="pcvx:AdjustmentsToAdditionalPaidInCapitalVestingOfEarlyExercisedStockOptions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">16</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:8.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">Stock-based compensation expense</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_99800816-3bc1-47e8-87f5-5218b2c37e7b" contextRef="C_11d04721-6c5e-451c-9f8c-b386520e079e" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,729</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e55dafee-e0f9-42af-8edd-cb038fd8df3a" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,729</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:8.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">Unrealized losses on investment</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">(</span><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3275a663-4b43-4b41-a1f9-4b84e65950cd" contextRef="C_1d403ed3-f3ea-41fc-ab8b-8b842982729a" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">241</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">(</span><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4db89783-83e3-4940-a684-5092fd5d6df5" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">241</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:8.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">Net loss</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">(</span><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9d6b40c3-86ce-400c-a601-84e24eec2dab" contextRef="C_84b31ec6-25e1-4d4b-9f94-c4046b727e6f" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">100,077</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">(</span><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_edcf51e3-1163-41e1-b455-7b0c34cef82c" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">100,077</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;">Balance &#x2014; December 31, 2021</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d278cd81-03c6-450f-848e-4c5ebe78730e" contextRef="C_b3bc61ea-4f75-41e4-81f8-73c18aff2f6f" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">53,031,978</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b0307f50-e00a-43d2-a208-9f7a3ac2f11c" contextRef="C_b3bc61ea-4f75-41e4-81f8-73c18aff2f6f" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">56</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_09e86a14-433b-412c-89dc-64c743c9a915" contextRef="C_3d9566a8-97e9-4ae9-937d-c604f1218434" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">582,844</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">(</span><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_28a20750-f643-4ed0-b59c-e180ab13b03a" contextRef="C_a129b41f-99aa-4150-b52d-3b8433ceb5ee" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">298,641</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">(</span><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6d5bd3ea-2ffe-4832-9746-6a904a4e18a1" contextRef="C_9ed4a1bc-93ea-4d6c-a3a2-fe0ee49c92a6" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">241</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1bade322-7ee7-4ba1-a345-ceca53bf69b0" contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">284,018</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The accompanying notes are an integral part of these financial statements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">126</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">VAXCYTE, INC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="condensed_statements_cash_flows"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Statemen</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">ts of Cash Flows</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">(in thousands)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">(unaudited)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:56.959%;"></td>
    <td style="width:1.253%;"></td>
    <td style="width:1.113%;"></td>
    <td style="width:11.253%;"></td>
    <td style="width:0.739%;"></td>
    <td style="width:1.253%;"></td>
    <td style="width:1.113%;"></td>
    <td style="width:11.242%;"></td>
    <td style="width:0.739%;"></td>
    <td style="width:1.253%;"></td>
    <td style="width:1.113%;"></td>
    <td style="width:11.231%;"></td>
    <td style="width:0.739%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2019</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Cash flows from operating activities:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Net loss</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_52707c85-2bdd-42ec-bc9a-f316bd5985aa" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">100,077</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_25cf2b4c-eaba-4c63-9d5f-13c624853b8b" contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">89,217</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_60c0c6a7-052f-4d35-992f-4bb435866da3" contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">50,274</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Adjustments to reconcile net loss to net cash used in operating activities:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Depreciation and amortization</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_709c666f-121d-43eb-b1da-c4aa85a68ed5" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,800</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5857369f-c2b1-4777-9efd-5a659122aea7" contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,405</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bc06616b-e3a4-41a2-9a08-455a2bdba6fd" contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,232</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Stock-based compensation expense</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_78e0f2b9-8aec-4c2d-b28f-491832936f37" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,729</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_43c9d821-1ef9-4fe2-a66e-917f27e97edf" contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,434</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_396dc78c-d2fb-44ee-bc0f-d7aa5948805c" contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,185</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Change in fair value of redeemable convertible preferred stock warrant</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ca4d6491-c05c-4cda-804a-e4e535e74507" contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001" name="us-gaap:FairValueAdjustmentOfWarrants" unitRef="U_USD" scale="3" decimals="-3">179</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_573c18f8-d9a8-4fb1-8f5b-d78a78e16266" contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700" name="us-gaap:FairValueAdjustmentOfWarrants" unitRef="U_USD" scale="3" decimals="-3" sign="-">12</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Change in fair value of redeemable convertible preferred stock tranche<br />&#160;&#160;&#160;liabilities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_637bdc1e-5535-4486-aebc-44877411ae0e" contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700" name="pcvx:ChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,185</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Loss on disposal of assets</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_91e3144a-053b-439c-91b1-ccb7b531ab15" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="us-gaap:GainLossOnDispositionOfAssets1" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">97</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_533e6fa6-333f-4914-ad0e-a0682d343cf1" contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001" name="us-gaap:GainLossOnDispositionOfAssets1" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">34</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c41a55b7-20dd-4f2f-9767-ed353cb0629a" contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700" name="us-gaap:GainLossOnDispositionOfAssets1" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Asset impairment charges</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8d6c030c-bab6-42a5-8662-ca140f60de15" contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001" name="us-gaap:AssetImpairmentCharges" unitRef="U_USD" scale="3" decimals="-3">267</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Amortization of operating lease right-of-use assets</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8a0f51d3-cc44-4f23-9a9f-b8a12d7c3025" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,657</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Net amortization of premiums on investments</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_69963e9e-98c5-492d-9c9e-c57d662d30b6" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1,406</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Changes in operating assets and liabilities:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Prepaid expenses and other current assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d581f480-4f88-4139-a7b1-0fea6eafd04e" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,369</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_873e7c2c-321a-4f28-8619-a3fd973784fb" contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3">58</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_849a8021-966f-47c4-8afc-096cea32a606" contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,070</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Other assets</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3c09e336-d419-47f5-9870-2aa37e81893f" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,539</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fa0f166d-9896-4abe-b7c4-860b9ed09eb1" contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" unitRef="U_USD" scale="3" decimals="-3">75</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6915ecc4-a98c-421f-8cb7-d50826af3c16" contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">120</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Operating lease liabilities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c719fe0a-ad69-44a6-87d4-d80150de531d" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="pcvx:IncreaseDecreaseInOperatingLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">12,856</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Accounts payable</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_acb62528-ea5f-4c4d-bb50-82da8a0044e0" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">12,470</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_158bab57-946d-4fb7-b197-bc326244fac8" contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">26,102</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4a68493f-4c6b-48bc-8dad-59a68f947e39" contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3">868</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Accrued compensation</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3df3effa-d709-4fc8-8cc8-eb89a12c9829" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="pcvx:IncreaseDecreaseInAccruedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,170</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2a79b633-4ae2-41e2-b102-4a3e28cdac85" contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001" name="pcvx:IncreaseDecreaseInAccruedCompensation" unitRef="U_USD" scale="3" decimals="-3" sign="-">130</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_05beb491-fee5-4058-92ef-56630500466c" contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700" name="pcvx:IncreaseDecreaseInAccruedCompensation" unitRef="U_USD" scale="3" decimals="-3" sign="-">775</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Accrued manufacturing expenses</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3eb8a0ad-168a-4b3c-a691-e5390e750de9" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="pcvx:IncreaseDecreaseInAccruedManufacturingExpenses" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">8,572</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_06057de6-a869-4cea-9481-920e86c26805" contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001" name="pcvx:IncreaseDecreaseInAccruedManufacturingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,235</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bd25c2d6-2868-41c7-9a8b-5d18089829fb" contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700" name="pcvx:IncreaseDecreaseInAccruedManufacturingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,970</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Accrued expenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c181d58c-fb8c-458f-9341-07ccb6d4f926" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,631</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_67a1913e-be39-4dc2-9c54-b289a960d190" contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,207</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a4864083-3a40-4287-abdf-47e06759267b" contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">718</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Deferred rent and other long-term liabilities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_17ffd693-33ed-4599-b135-36bfc7f68e4b" contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001" name="pcvx:IncreaseDecreaseInDeferredRentAndOtherLongTermLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-">11</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8b11f050-8749-4f15-adb6-0f3841c3e068" contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700" name="pcvx:IncreaseDecreaseInDeferredRentAndOtherLongTermLiabilities" unitRef="U_USD" scale="3" decimals="-3">77</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:40.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:40.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Net cash used in operating activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_cf991aa0-87ec-4d00-b685-1a78c9bcdb18" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">121,393</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_23cf52d7-d333-481b-9152-6c0172035153" contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">46,628</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5b6ab3d2-2936-43b2-bb95-c814769aca2a" contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">47,145</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Cash flows from investing activities:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Purchases of property and equipment</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_dc50a0d3-bac5-476d-9d5e-3e25b2c02625" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,555</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_de9b4902-7e92-424e-9788-1df2b178aecd" contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,155</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5da822e3-a325-4f6c-9277-8b5ae8c719fe" contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,195</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Purchases of investments</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_dc8cae9e-0b82-4aed-8a9f-6d346031a78e" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">336,341</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Maturities of investments</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_aea719ad-4c2a-4b54-a2d9-155975ca95f5" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">100,500</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Sales of investments</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e044a594-9e53-47a2-bbfb-f47023283675" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">30,062</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Proceeds from sales of property and equipment</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f95b30bf-e4d6-46be-a87b-83d31a18da77" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">26</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5085e6f0-28d5-4f9a-b168-dc1f5ebfe8c9" contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3">50</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:40.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:40.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Net cash used in investing activities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3ee7085c-4c4c-4978-8b09-9767f99d7e14" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">212,308</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_12273721-4c69-4737-aea6-698612c38453" contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1,105</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e8c17aa4-4972-450c-ba31-f7cc128e808e" contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1,195</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Cash flows from financing activities:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Payments of capital lease obligations</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c1e2148d-41c5-49b0-b417-633718c67790" contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001" name="pcvx:PaymentsOfCapitalLeaseObligations" unitRef="U_USD" scale="3" decimals="-3">61</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_441ba825-1038-4e3a-90aa-0ff6919560eb" contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700" name="pcvx:PaymentsOfCapitalLeaseObligations" unitRef="U_USD" scale="3" decimals="-3">278</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Proceeds from initial public offering, net of underwriters' commissions and<br />&#160;&#160;&#160;discounts</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d8adc92d-4163-493a-b8b2-0f93b3c83aff" contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001" name="pcvx:ProceedsFromInitialPublicOfferingNetOfUnderwritersCommissionsAndDiscounts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">267,375</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Payment of issuance costs for initial public offering</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_df0286df-7b58-4d1b-baa6-ba8bc17d78fb" contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,368</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Proceeds from issuance of redeemable convertible preferred stock, net of<br />&#160;&#160;&#160;issuance costs</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c6a2a39b-e785-45ae-afeb-6b15007f284c" contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001" name="us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">109,879</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8155a720-b871-4d6c-a0f2-c854b114f285" contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700" name="us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">42,500</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Proceeds from exercise of common stock options</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a1294109-5878-40fb-a847-8e8316679906" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,012</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_017b7fad-77d2-4458-8eea-7f82f0ca415e" contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3">635</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_88ce900b-bf7e-4d94-8d6b-cfb62bf84934" contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3">322</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Proceeds from issuance of common stock under ATM Sales Program, net<br />&#160;&#160;&#160;of issuance costs</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_af16ff9a-ddb9-4fdd-9b74-605330d58a69" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13,896</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Proceeds from issuance of common stock related to early exercised stock<br />&#160;&#160;&#160;options</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7b363fc1-4054-4a7c-a9ca-139d74c2c9f8" contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001" name="pcvx:ProceedsFromIssuanceOfCommonStockRelatedToEarlyExercisedStockOptions" unitRef="U_USD" scale="3" decimals="-3">36</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6dbfaf5f-1b9a-4b8a-9238-85acf3f58808" contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700" name="pcvx:ProceedsFromIssuanceOfCommonStockRelatedToEarlyExercisedStockOptions" unitRef="U_USD" scale="3" decimals="-3">120</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Proceeds from issuance of common stock under the Employee Stock Purchase <br />&#160;&#160;&#160;Plan</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_33a2cc2c-e296-47fd-8439-41c6ee3f93df" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="us-gaap:ProceedsFromStockPlans" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">888</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_999756f5-4e0a-47f4-b260-a29ec5e8fc5c" contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001" name="us-gaap:ProceedsFromStockPlans" unitRef="U_USD" scale="3" decimals="-3">374</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Payments of deferred offering costs</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_83a2f0c6-880e-4416-b7a4-026dc704c8e5" contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700" name="pcvx:PaymentOfDeferredOfferingCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,097</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:40.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:40.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Net cash provided by financing activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_98173508-60dd-4dfa-9fc7-e97e1b908a48" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">17,796</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_27f243b0-6186-47d0-a901-312df8c2a686" contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">374,870</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1edd0618-e08b-41ea-aad5-e22c47d2d5ba" contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">41,567</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Effect of exchange rate changes on cash and cash equivalents</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c90c6d91-1b26-4c90-a011-e02535d56d61" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">439</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9c070cf8-ff14-46c3-8d01-d7baa069e0d5" contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3">87</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c2d8b125-e564-4fca-b9b3-a91a3bd8964d" contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" sign="-">341</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:30.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Net (decrease) increase in cash, cash equivalents and restricted cash</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d201115d-3387-4864-bc5f-a08bc5c78c79" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">316,344</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6bdc6c0a-bf14-4ffd-9906-3ec9960c40a1" contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">327,224</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e132e3fb-0905-4ab3-b257-70d4b07c4723" contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">7,114</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:30.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Cash, cash equivalents and restricted cash, beginning of period</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b252ab11-4b46-49f3-962c-87cb87f22baa" contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">386,200</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_737a565c-6a1c-4b4d-bab0-8654fd0ca5e7" contextRef="C_871fe4ad-8a52-4dc5-a523-876ef5a1de6d" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">58,976</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0edd3220-5dc7-4608-bc5c-753f96ccd41f" contextRef="C_ecccdfb9-edd1-45a3-8445-0fe8b2f43253" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">66,090</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:30.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Cash, cash equivalents and restricted cash, end of period</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_85cb7bbf-efc1-436f-b495-f8c4b67f7759" contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">69,856</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fc6ce99f-1131-4f8f-873e-e13fada124e9" contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">386,200</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0368edda-9e76-42a8-a398-d88a38c98c99" contextRef="C_871fe4ad-8a52-4dc5-a523-876ef5a1de6d" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">58,976</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Supplemental disclosure of cash flow information:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Cash paid for interest</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f0528562-d7f0-4649-9677-73c7acf0fbfe" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="us-gaap:InterestPaidNet" unitRef="U_USD" scale="3" decimals="-3">7</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bf113c8f-94af-444c-9c11-cd59f495ebdc" contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001" name="us-gaap:InterestPaidNet" unitRef="U_USD" scale="3" decimals="-3">7</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_16d03691-43c5-44bb-a1c1-62c08b5ba20b" contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700" name="us-gaap:InterestPaidNet" unitRef="U_USD" scale="3" decimals="-3">40</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Supplemental disclosures of non-cash investing and financing activities:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Purchases of property and equipment recorded in accounts payable and accrued<br />&#160;&#160;&#160;expenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b2fce3c7-c5e4-4841-aaf6-09bf417f8bde" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" unitRef="U_USD" scale="3" decimals="-3">766</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f0ef5901-68b6-4f1e-8f19-fdafbc1965b8" contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" unitRef="U_USD" scale="3" decimals="-3">494</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8985698d-b415-40eb-bb26-12ce4432c51b" contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" unitRef="U_USD" scale="3" decimals="-3">21</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Conversion of convertible preferred stock into common stock</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f936dd37-000a-4e54-a985-8c11f580e9d0" contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001" name="us-gaap:ConversionOfStockAmountConverted1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">270,190</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Stock issued for payment of accounts payable</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1e0989d9-1e5b-4517-8bd3-d50222d3aa1e" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="us-gaap:StockIssued1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,001</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Deferred offering costs included in accounts payable and accrued expenses</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d022c167-dceb-45bf-b967-1a9b67e2341f" contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001" name="pcvx:DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses" unitRef="U_USD" scale="3" decimals="-3">134</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7a6dbf0f-865c-4e3f-b684-068f0579e405" contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700" name="pcvx:DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses" unitRef="U_USD" scale="3" decimals="-3">33</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The accompanying notes are an integral part of these unaudited financial statements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">127</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">VAXCYTE, INC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="notes_to_unaudited_interim_condensed_fin"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Notes to </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Financial Statements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_85b7e3da-da55-4f96-810f-1d874a6cfc90" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" escape="true" continuedAt="F_85b7e3da-da55-4f96-810f-1d874a6cfc90_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">1. Company Organization and Nature of Business</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Vaxcyte, Inc. (&#x201c;we,&#x201d; &#x201c;us,&#x201d; &#x201c;the Company,&#x201d; or &#x201c;Vaxcyte&#x201d;), headquartered in San Carlos, California, was incorporated in the state of Delaware on November 27, 2013 as SutroVax, Inc. and we changed our name to Vaxcyte, Inc. on May 15, 2020. We are a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. We are developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. We are re-engineering the way highly complex vaccines are made through modern synthetic techniques, including advanced chemistry and the XpressCF cell-free protein synthesis platform, exclusively licensed from Sutro Biopharma, Inc. Unlike conventional cell-based approaches, our system for producing difficult-to-make proteins and antigens is intended to accelerate our ability to efficiently create and deliver high-fidelity vaccines with enhanced immunological benefits</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Our pipeline includes pneumococcal conjugate vaccine (&#x201c;PCV&#x201d;) candidates that we believe are among the most broad-spectrum PCV candidates currently in development, targeting the approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f25b15d5-e50d-496d-89a6-d18e463e8bfb" contextRef="C_fddff65d-fa11-44de-96a6-5e8ce2f4167b" name="pcvx:GlobalTargetRevenue" unitRef="U_USD" scale="9" decimals="-9">7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> billion global pneumococcal vaccine market. Our lead vaccine candidate, VAX-24, is a 24-valent broad-spectrum investigational PCV being developed for the prevention of invasive pneumococcal disease, or IPD</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, and pneumonia. On January 6, 2022, we announced that the U.S. Food and Drug Administration, or FDA, cleared our investigational new drug, or IND, application for VAX-24 in adults. On February 23, 2022, we announced the initiation of our Phase 1/2 clinical proof-of-concept study in adults 18 to 64 years of age. We expect to announce topline safety, tolerability and immunogenicity results from this study by the end of 2022. Pending the successful completion of the Phase 1 portion of this study, we expect to begin enrollment in a separate Phase 2 study in healthy adults aged 65 and older and to announce topline safety, tolerability and immunogenicity results from this study in the first half of 2023. Subject to a pre-IND meeting with the FDA and the successful topline results of the Phase 1/2 proof-of-concept study in adults 18-64 years of age, we anticipate submitting a pediatric IND application to the FDA for VAX-24 in the first half of 2023. Our second PCV candidate, VAX-XP, leverages our scalable and modular platform and builds on the technical proof of concept established by VAX-24 and is designed to expand the breadth of coverage to greater than 30 strains without compromising immunogenicity due to carrier suppression. In addition to our PCV franchise, our pipeline includes VAX-A1, a novel conjugate vaccine candidate designed to prevent Group A Strep; VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis; and other discovery-stage programs. Our primary activities since incorporation have been to perform research and development, undertake preclinical studies and conduct manufacturing activities in support of our product development efforts; organize and staff the Company; establish our intellectual property portfolio; and raise capital to support and expand such activities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Reverse Stock Split</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On June 5, 2020, we filed a certificate of amendment to our amended and restated certificate of incorporation to effect a </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fb909b60-f8ae-47f4-88dd-45e63def7a75" contextRef="C_196fbfec-2db3-415e-8c1d-7ba3ff662444" name="us-gaap:StockholdersEquityReverseStockSplit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">one-for-1.6870</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> reverse stock split of our issued and outstanding common stock, preferred stock, stock options and warrants effective on June 5, 2020. Accordingly, all share and per share amounts for all periods presented in the financial statements and notes thereto have been retroactively adjusted.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Initial Public Offering</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In June 2020, we completed an initial public offering (&#x201c;IPO&#x201d;) in which we issued and sold </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c5cc4bc7-4768-4552-a111-55ff591fc79e" contextRef="C_6c7d80da-3c5c-41d2-a3bf-0f29663df66e" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">17,968,750</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock, including shares issued upon the exercise in full of the underwriters&#x2019; option to purchase </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3ee8953a-6235-4bec-87e2-cd75fef713bf" contextRef="C_6c7d80da-3c5c-41d2-a3bf-0f29663df66e" name="pcvx:SharesIssuedUponFullExerciseOfUnderwritersOptionToPurchaseAdditionalShares" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,343,750</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> additional shares of common stock, at a public offering price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2098ce2d-144a-4dec-ac63-42dff93ee02e" contextRef="C_2fc259cf-825e-4ff9-9943-2f01c1a0937b" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">16.00</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share. We received $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8a3e1985-6858-4fab-8007-3971fd875605" contextRef="C_decb2811-c318-46bf-b586-449b2cc7fa0b" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" unitRef="U_USD" scale="6" decimals="-5">264.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in net proceeds, after deducting underwriting discounts and commissions of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_af47377e-c115-4589-ab29-406df549dd81" contextRef="C_decb2811-c318-46bf-b586-449b2cc7fa0b" name="pcvx:PaymentsOfUnderwritingDiscountsAndCommissions" unitRef="U_USD" scale="6" decimals="-5">20.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and offering expenses of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_88126e79-0b51-4ad3-863c-0e23ed5ef6ec" contextRef="C_decb2811-c318-46bf-b586-449b2cc7fa0b" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="6" decimals="-5">3.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><ix:continuation id="F_85b7e3da-da55-4f96-810f-1d874a6cfc90_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Immediately prior to the completion of our IPO, all outstanding shares of redeemable convertible preferred stock were converted into </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b22f05f9-216d-433d-b7f4-87e9da713594" contextRef="C_25f1f214-138d-4f58-8434-afe2e9883750" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">28,610,337</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock. Subsequent to the completion of the IPO, there were </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8eb80f4f-0ad8-4a1d-9f9b-9d54a44631c6" contextRef="C_2bf194ae-c6b4-4264-b519-4608eda30c8d" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of redeemable convertible preferred stock outstanding.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">128</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div><ix:nonNumeric id="F_c16bb8bb-f8b1-4c5f-a638-d91b0862f46a" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Basis of Presentation and Summary of Significant Accounting Policies</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1c83ca66-0145-4d7c-a445-57c59cf3130a" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Basis of Presentation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">These financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) and applicable rules and regulations of the Securities and Exchange Commission (&#x201c;SEC&#x201d;) regarding annual reporting. Certain changes in presentation were made in these financial statements as of and for the year ended December 31, 2019 to conform to the presentation as of and for the years ended December 31, 2021 and 2020.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_93f98c27-6bdc-4860-b0b7-d25ecfb1bde9" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="us-gaap:UseOfEstimates" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities at the date of the financial statements. On an ongoing basis, we evaluate our estimates and assumptions, including those related to stock-based compensation expense, accruals for certain research and development costs, the incremental borrowing rate, the valuation of deferred tax assets and income taxes. Management bases our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ materially from those estimates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ab916493-314f-493f-82d1-1bf3cfc232b7" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="us-gaap:ConcentrationRiskCreditRisk" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Concentration of Credit Risk and Other Risks and Uncertainties</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Financial instruments that potentially subject us to a concentration of credit risk consist primarily of cash and cash equivalents and investments. We invest in money market funds, U.S. Treasury securities, U.S. government agency securities, corporate debt, commercial paper and asset-backed securities. We maintain bank deposits in federally insured financial institutions and these deposits may exceed federally insured limits. We are exposed to credit risk in the event of a default by the financial institutions holding our cash and issuers of investments to the extent recorded on the balance sheets. Our investment policy limits investments to money market funds, certain types of debt securities issued by the U.S. Government and its agencies, corporate debt, commercial paper and asset-backed securities, and places restrictions on the credit ratings, maturities and concentration by type and issuer. We have not experienced any significant losses on our deposits of cash, cash equivalents or investments.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are subject to supplier concentration risk from our suppliers. We source our critical raw materials from a sole source supplier, Sutro Biopharma, Inc. (&#x201c;Sutro Biopharma&#x201d;). We also use one contract manufacturing organization (&#x201c;CMO&#x201d;), Lonza Ltd. (&#x201c;Lonza&#x201d;), to handle most of our manufacturing activities. If we were to experience disruptions in raw materials supplied by Sutro Biopharma, or in manufacturing activities at Lonza, we may experience significant delays in our product development timelines and may incur substantial costs to secure alternative sources of raw materials or manufacturing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our future results of operations involve a number of other risks and uncertainties. Factors that could affect our future operating results and cause actual results to vary materially from expectations include, but are not limited to: our early stages of clinical vaccine development; our ability to advance vaccine candidates into, and successfully complete, clinical trials on the timelines we project; our ability to adequately demonstrate sufficient safety and efficacy of our vaccine candidates; our ability to enroll subjects in our ongoing and future clinical trials; our ability to successfully manufacture and supply our vaccine candidates for clinical trials; our ability to obtain additional capital to finance our operations; our ability to obtain, maintain and protect our intellectual property rights; developments relating to our competitors and our industry, including competing vaccine candidates; general and market conditions; and other risks and uncertainties, including those more fully described in the &#x201c;Risk Factors&#x201d; section of this Annual Report on Form 10-K.</span></p></ix:nonNumeric></div><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">129</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_465dd04e-1bb8-4ab2-9065-2a8caf683b2a" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Segment and Geographical Information</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We operate and manage our business as </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9a1d2006-b9ef-4849-a6d2-5e0433ce2f2a" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="us-gaap:NumberOfReportableSegments" unitRef="U_Segment" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_a8d32114-e6f4-47c1-b01a-d5cb7c3c6c18" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="us-gaap:NumberOfOperatingSegments" unitRef="U_Segment" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> reportable and operating segment. Our chief executive officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance. All of our long-lived assets are based in the United States. Long-lived assets are comprised of property and equipment.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_800dc8d0-b561-475e-9fc6-134ed701314b" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Cash, Cash Equivalents and Restricted Cash</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We consider all highly liquid investments purchased with original maturities of three months or less from the date of purchase to be cash and cash equivalents. Cash equivalents consist primarily of amounts invested in money market accounts and commercial paper and are stated at their fair values. Restricted cash consists of a standby letter of credit, which was issued in the first quarter of 2021, that serves as collateral for the lease agreement for our new corporate headquarters. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_24ebce15-4e4d-4ab2-95bd-3b6f737d3b26" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" escape="true" continuedAt="F_24ebce15-4e4d-4ab2-95bd-3b6f737d3b26_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash, cash equivalents and restricted cash as reported within the statement of cash flows consisted of the following:</span></ix:nonNumeric></span></p><div style="font-size:11.0pt;font-family:Calibri;"><ix:continuation id="F_24ebce15-4e4d-4ab2-95bd-3b6f737d3b26_1"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:37.584%;"></td>
          <td style="width:6.553%;"></td>
          <td style="width:1.371%;"></td>
          <td style="width:15.494%;"></td>
          <td style="width:0.696%;"></td>
          <td style="width:2.195%;"></td>
          <td style="width:1.371%;"></td>
          <td style="width:15.376%;"></td>
          <td style="width:0.696%;"></td>
          <td style="width:2.195%;"></td>
          <td style="width:1.371%;"></td>
          <td style="width:14.402%;"></td>
          <td style="width:0.696%;"></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Years Ended December 31,</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2019</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(in thousands)</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash and cash equivalents</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_daf624a8-422d-4709-90ab-ec493f794574" contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">68,985</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_957ce9ec-3d3d-4fda-a386-a23d96a77307" contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">386,200</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_54963adf-a1f0-4e01-9f4d-19432185f05e" contextRef="C_871fe4ad-8a52-4dc5-a523-876ef5a1de6d" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">58,976</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Restricted cash</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2e828cd3-cb1c-49d9-a00a-b697a4c86ec8" contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350" name="us-gaap:RestrictedCash" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">871</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash, cash equivalents and restricted cash</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9b6e568b-eb71-49a0-a46f-f5af19bb894f" contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">69,856</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3618a345-c318-4998-b3f3-064bd57b3280" contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">386,200</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_829a5969-eba5-4dde-b397-edca191b7911" contextRef="C_871fe4ad-8a52-4dc5-a523-876ef5a1de6d" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">58,976</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
        </table></ix:continuation></div></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_78e82fc6-96c1-49bb-b6ef-c257bef163db" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="us-gaap:InvestmentPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Investments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our investments have been classified and accounted for as available-for-sale securities. Our investments consist of U.S. Treasury securities, U.S. government agency securities, corporate debt, commercial paper and asset-backed securities. These securities are recorded on the balance sheets at fair value. Unrealized gains and losses on these securities are included as a separate component of accumulated other comprehensive loss. The cost of investment securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization and accretion are included in other income (expense), net. Realized gains and losses and declines in fair value judged to be other-than-temporary, if any, are also included in other income (expense), net. We evaluate securities for other-than-temporary impairment at the balance sheet date. Declines in fair value determined to be other-than-temporary are included in other income (expense), net. We classify our investments as short or long term primarily based on the remaining contractual maturity of the securities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7f62f91f-e04e-49c0-a449-fac9737ec2e6" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="us-gaap:DeferredChargesPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Deferred Offering Costs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred offering costs consist of fees and expenses incurred in connection with the sale of our common stock in equity transactions, including legal, accounting, printing and other issuance-related costs. Prior to the completion of equity transactions, deferred offering costs are included in Other assets on the balance sheet. In connection with and as of the closing of equity transactions, these costs are reclassified to Additional paid-in capital, representing a reduction to the gross proceeds. As of December 31, 2020, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_733b290b-825e-48d5-9682-201b6239205e" contextRef="C_1e69b34d-5d84-4378-a6c6-3b4511d14d3c" name="pcvx:InitialPublicOfferingRelatedCost" unitRef="U_USD" scale="6" decimals="-5">3.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of IPO-related costs were included in the Additional paid-in capital line item on the balance sheet. As of December 31, 2021 and 2020, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_776f08a0-f2d3-46cb-88ff-d42fd1cf4d66" contextRef="C_d1a846f2-0595-4f2b-bfde-977270efb43f" name="us-gaap:DeferredOfferingCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c5822c6e-2d2c-492f-8842-f9b494dee009" contextRef="C_efd921fe-f258-4bca-8c80-5723ef551b43" name="us-gaap:DeferredOfferingCosts" unitRef="U_USD" scale="6" decimals="-5">0.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of deferred offering costs, respectively, were included in Other assets on the balance sheet.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_49979e28-49e9-484c-a643-e7a2b1a82251" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Property and Equipment, Net</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_cdf000c4-3126-4076-a46e-14220371b9f3;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">three</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> to </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_481f6030-095f-4417-925b-8ba0923f925a" contextRef="C_68377845-3bf8-42a9-ba72-9a3b693b78a1" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">five years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Leasehold improvements are amortized over the shorter of the expected life or lease term. Repairs and maintenance expenditures, which are not considered improvements and do not extend the useful life of property and equipment, are expensed as incurred. When assets are retired or otherwise disposed of, the cost and related accumulated depreciation and amortization are removed from the balance sheet and the resulting gain or loss is reflected in the statements of operations in the period realized.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">130</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_245ee8d7-d89b-4301-b3ff-8a37e9a4ae54" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="us-gaap:LesseeLeasesPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Leases</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under Financial Accounting Standards Board (FASB) Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2016-02, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Leases (Topic 842)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and its associated amendments (&#x201c;ASC 842&#x201d;), we determine if an arrangement is a lease at inception. In addition, we determine whether a lease meets the classification criteria of a finance or operating lease at the lease commencement date considering whether: (i) the lease transfers ownership of the underlying asset to the lessee at the end of the lease term; (ii) the lease grants the lessee an option to purchase the underlying asset that the lessee is reasonably certain to exercise; (iii) the lease term is for a major part of the remaining economic life of the underlying asset; (iv) the present value of the sum of the lease payments and residual value guaranteed by the lessee equals or exceeds substantially all of the fair value of the underlying asset; and (v) the underlying asset is such a specialized nature that it is expected to have no alternative use to the lessor at the end of the lease term. As of December 31, 2021, our lease population consisted of real estate operating leases. As of December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, we did </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_833db186-6396-4f00-a5fe-f207998b08c9" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="pcvx:NumberOfFinanceLease" unitRef="U_Lease" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">t have any finance leases.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating leases are included in Operating lease right-of-use (ROU) assets, Operating lease liabilities &#x2014; current and Operating lease liabilities &#x2014; long term in our balance sheet. ROU assets represent our right to use the underlying assets for the lease term and lease liabilities represent our obligation to make lease payments arising from the leases. Operating lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. In determining the present value of lease payments, if the rate implicit in the lease is not readily determinable, we use our incremental borrowing rate based on the information available at the lease commencement date. We determine the incremental borrowing rate based on an analysis of corporate bond yields with a credit rating similar to us. The determination of our incremental borrowing rate requires management judgment, including development of a synthetic credit rating and cost of debt, as we currently do not carry any debt. We believe that the estimates used in determining the incremental borrowing rate are reasonable based upon current facts and circumstances. Applying different judgment to the same facts and circumstances could yield a different incremental borrowing rate. The operating lease ROU assets also include adjustments for prepayments and accrued lease payments and exclude lease incentives. ROU assets and lease liabilities may include options to extend or terminate leases if it is reasonably certain that we will exercise such options. Lease payments which are fixed and determinable are amortized as rent and lease expense on a straight-line basis over the expected lease term. Variable lease costs, which are dependent on usage, a rate or index, including common area maintenance charges, are expensed as incurred. Lease agreements that include lease and non-lease components are accounted for as a single lease component. Lease agreements with non-cancelable terms of less than 12 months are not recorded on our balance sheets.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ef6f20e1-d123-43c7-aa33-b3a20688c208" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Impairment of Long-Lived Assets</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We review long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparing the carrying amount to the future undiscounted net cash flows which the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured as the amount by which the carrying amount of the assets exceeds the projected discounted future net cash flows generated by the assets. There were $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d62029a1-267a-4494-8d5b-dd53fb78fcaf" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="us-gaap:AssetImpairmentCharges" unitRef="U_USD" scale="6" decimals="-6" format="ixt:numdotdecimal">0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b48fa20f-838b-467a-ad92-6e030314b1b8" contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001" name="us-gaap:AssetImpairmentCharges" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_37cd30da-8004-4654-ad8c-0a926854dfc8" contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700" name="us-gaap:AssetImpairmentCharges" unitRef="U_USD" scale="6" decimals="-6" format="ixt:numdotdecimal">0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of impairments of long-lived assets during the years ended December 31, 2021, 2020 and 2019, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_da416d19-87ef-46a3-842d-c7e96121827f" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Fair Value Measurements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. The carrying amounts of our financial instruments, including cash and cash equivalents, prepaid and other current assets, accounts payable, accrued expenses, and other liabilities, approximate fair value due to their short-term maturities. Prior to their automatic conversion upon our IPO in June 2020, the redeemable convertible preferred stock tranche liability and redeemable convertible preferred stock warrant were carried at fair value (see Note 3).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">131</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_746943db-7363-4ddb-aaff-89ed369a27f2" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="us-gaap:ResearchAndDevelopmentExpensePolicy" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Research and Development</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development costs are expensed as incurred. Research and development costs include salaries, stock-based compensation and benefits for employees performing research and development activities, an allocation of facility and overhead expenses, expenses incurred under agreements with consultants, CMOs, contract research organizations (&#x201c;CROs&#x201d;) and investigative sites that conduct preclinical studies, other supplies and costs associated with product development efforts, preclinical activities and regulatory operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9c020b41-fada-4906-aeb0-2f5bf420dcef" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="pcvx:AccruedResearchAndDevelopmentPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Accrued Research and Development</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have entered into various agreements with CROs and CMOs. Our research and development accruals, which include accrued manufacturing expenses, are estimated based on the level of services performed, progress of the studies, including the phase or completion of events, and contracted costs. The estimated costs of research and development services provided, but not yet invoiced, are included in accrued expenses on the balance sheet. If the actual timing of the performance of services or the level of effort varies from the original estimates, we will adjust the accrual accordingly. Payments made to CROs or CMOs under these arrangements in advance of the performance of the related services are recorded as prepaid expenses and other current assets until the services are rendered. To date, there have been no material differences between our estimates of such expenses and the amounts actually incurred.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e4684b36-b1b3-4622-9225-24ff9a20a0e9" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="us-gaap:IncomeTaxPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Income Taxes</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We account for income taxes using the asset and liability method. We recognize deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In evaluating the ability to recover our deferred income tax assets, we consider all available positive and negative evidence, including our operating results, ongoing tax planning and forecasts of future taxable income on a jurisdiction-by-jurisdiction basis. In the event we determine that we would be able to realize our deferred income tax assets in the future in excess of their net recorded amount, we would make an adjustment to the valuation allowance that would reduce the provision for income taxes. Conversely, in the event that all or part of the net deferred tax assets are determined not to be realizable in the future, an adjustment to the valuation allowance would be charged to earnings in the period when such determination is made. As of December 31, 2021 and 2020, we have recorded a full valuation allowance on our deferred tax assets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Tax benefits related to uncertain tax positions are recognized when it is more likely than not that a tax position will be sustained during an audit. Interest and penalties related to unrecognized tax benefits are included within the provision for income tax.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_34bcb014-b196-4b41-9b73-211da5573cd1" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Stock-Based Compensation Expense</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For options granted to employees, non-employees, and directors, stock-based compensation is measured at grant date based on the fair value of the award. We determine the grant-date fair value of the options using the Black-Scholes option-pricing model. The grant-date fair value of awards is amortized over the employees&#x2019; requisite service period or the non-employees&#x2019; vesting period as the services are rendered. Forfeitures are accounted for as they occur. Additionally, our 2020 Employee Stock Purchase Plan is deemed to be a compensatory plan and is therefore included in stock-based compensation expense.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9d54dd81-4485-464e-9744-22005575a748" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Comprehensive Loss</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Comprehensive loss includes net loss and other comprehensive loss for the period. Other comprehensive loss consists of unrealized loss on investments.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">132</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bdf72b57-1cf1-4e0d-abb1-9acf0035b08e" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Foreign Currency Transactions</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Transactions denominated in foreign currencies are initially measured in U.S. dollars using the exchange rate on the date of the transaction. Foreign currency denominated monetary assets and liabilities are subsequently re-measured at the end of each reporting period using the exchange rate at that date, with the corresponding foreign currency transaction gain or loss recorded in the statements of operations and statements of cash flows. Nonmonetary assets and liabilities are not subsequently re-measured.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d3d501f8-20a3-4e93-a700-c8a9ceb946ab" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="us-gaap:EarningsPerSharePolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Net Loss Per Share</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Basic net loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common stock outstanding during the period, without consideration of potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common stock and potentially dilutive securities outstanding for the period. For purposes of the diluted net loss per share calculation, redeemable convertible preferred stock, redeemable convertible preferred stock warrant, common stock subject to repurchase, and stock options are considered to be potentially dilutive securities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Basic and diluted net loss attributable to common stockholders per share is presented in conformity with the two-class method required for participating securities as the redeemable convertible preferred stock is considered a participating security. Our participating securities do not have a contractual obligation to share in our losses. As such, the net loss was attributed entirely to common stockholders. Because we have reported a net loss for all periods presented, diluted net loss per common share is the same as basic net loss per common share for those periods.</span></p></ix:nonNumeric></div><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f5b79194-7c63-4782-83b4-44d54dfcfcdf" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" escape="true" continuedAt="F_f5b79194-7c63-4782-83b4-44d54dfcfcdf_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Recently Adopted Accounting Pronouncements</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In February 2016, the FASB issued ASU 2016-02, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Leases (Topic 842)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. ASU 2016-02 was subsequently amended by ASU 2018-01, ASU 2018-10, ASU 2018-11, ASU 2018-20, ASU 2019-01, ASU 2019-10 and ASU 2020-05, which the FASB issued in January 2018, July 2018, July 2018, December 2018, March 2019, November 2019 and June 2020, respectively (collectively, &#x201c;ASC 842&#x201d;). ASC 842 requires lessees to recognize leases on the balance sheet and disclose key information about leasing arrangements. The new standard establishes a ROU model that requires a lessee to recognize a ROU asset and a lease liability on the balance sheet for all leases with a term longer than 12 months. Under ASC 842, leases are classified as either finance leases or operating leases, with classification affecting the pattern and classification of expense recognition in the income statement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5298e60d-1557-4711-bc27-c1012fbf07ad" contextRef="C_9cbe4e9e-74f9-4ec8-bf47-1d291c0aaf9d" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption" format="ixt:booleantrue"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">early adopted</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> the new standard effective </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_50ed6908-2754-4221-8695-b32dc5b9700d" contextRef="C_9cbe4e9e-74f9-4ec8-bf47-1d291c0aaf9d" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">January 1, 2021</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> using the modified retrospective transition approach. Upon adoption on January 1, 2021, we recognized ROU assets and lease liabilities totaling $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_96b775de-97e2-407d-9bbb-ea345ad7f408" contextRef="C_a0171645-3dab-4282-933d-7e5fb2e8585a" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="6" decimals="-5">0.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8fd57376-d904-4dd8-9056-a31e260b2a69" contextRef="C_a0171645-3dab-4282-933d-7e5fb2e8585a" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="6" decimals="-5">0.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively, to reflect the present value of remaining lease payments under existing lease arrangements. The difference between the leased assets and lease liabilities represents the existing deferred rent liabilities balance resulting from historical straight-lining of operating leases for our facilities, which was reclassified upon adoption to reduce the measurement of the leased assets. The balance of our deferred rent liabilities, which was reclassified to reduce the ROU assets upon adoption, was </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_37928f93-0acb-49e9-b206-fa8043608651" contextRef="C_9cbe4e9e-74f9-4ec8-bf47-1d291c0aaf9d" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" format="ixt:booleantrue"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">immaterial</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. We applied the modified retrospective transition approach and did not recast prior periods. Although we applied this approach, we did not have a cumulative effect adjustment to the opening balance of our retained deficit upon adoption. As permitted by the standard, we elected the transition practical expedient package, which among other things, allowed the carryforward of historical lease classifications. For additional details regarding the impact of adoption and disclosure, see Note 5, &#x201c;Leases,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#34; to our financial statements included in Part II, Item 8 of this Annual Report on Form 10-K.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In December 2019, the FASB issued ASU No. 2019-12, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Income Taxes (Topic 740)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The amendments in ASU 2019-12 simplify the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The amendments also improve consistent application of and simplify U.S. GAAP or other areas of Topic 740 by clarifying and amending existing guidance. The new standard was </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ebc6cdeb-baa9-427b-b3dd-babf39e6994c" contextRef="C_e3a2a9fa-a738-409d-96a4-c1ee8f7ecd25" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" format="ixt:booleantrue"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">effective</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> for us on </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ac7ad31a-7acb-446d-9db6-0dbafa7a77b7" contextRef="C_e3a2a9fa-a738-409d-96a4-c1ee8f7ecd25" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">January 1, 2021</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and for interim periods within 2021. The adoption of ASU 2019-12 </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3c8e5344-1dc3-4585-a714-e9cc6cc5ce4d" contextRef="C_e3a2a9fa-a738-409d-96a4-c1ee8f7ecd25" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" format="ixt:booleantrue"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">did not</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> have a material impact on our financial statements.</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">133</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Recently Issued Accounting Pronouncements&#x2014;Not Yet Adopted</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In June 2016, the FASB issued ASU 2016-13, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Financial Instruments &#x2013; Credit Losses (Topic 326):</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Measurement of Credit Losses on Financial Instruments</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and has subsequently issued related amendments, collectively referred to as &#x201c;Topic 326.&#x201d; Topic 326 requires that financial assets measured at amortized cost be presented at the net amount expected to be collected. The measurement of expected credit losses is based on historical experience, current conditions and reasonable and supportable forecasts that affect collectability. Topic 326 also eliminates the concept of &#x201c;other-than-temporary&#x201d; impairment when evaluating available-for-sale debt securities and instead focuses on determining whether any impairment is a result of a credit loss or other factors. An entity will recognize an allowance for credit losses on available-for-sale debt securities rather than an other-than-temporary impairment that reduces the cost basis of the investment. Topic 326 is effective for fiscal years beginning after December 15, 2022 and interim periods within those fiscal years. Early adoption is permitted. We are currently assessing the impact of this standard to our financial statements and related disclosures.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:continuation id="F_f5b79194-7c63-4782-83b4-44d54dfcfcdf_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In November 2021, the FASB issued ASU 2021-10, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Government Assistance (Topic 832): Disclosure by Business Entities about Government Assistance, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">which </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">requires disclosures about transactions with a government entity that are accounted for by applying a grant or contribution accounting model by analogy to other accounting guidance, such as a grant model within International Accounting Standard 20, </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Accounting for Government Grants and Disclosure of Government Assistance</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, or Subtopic 958-605, </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Not-For-Profit Entities - Revenue Recognition</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The required disclosures include (i) the nature of the transactions and the related accounting policy used to account for the transactions, (ii) the financial statement line items that are affected by the transactions and (iii) the significant terms and conditions of the transactions, including commitments and contingencies. This standard is effective for annual periods beginning after December 15, 2021, with early adoption and retrospective or prospective application permitted. This standard is effective for us on January 1, 2022 and only impacts annual financial statement footnote disclosures</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. In Note 11, &#34;Funding Arrangement,&#34; to our financial statements included in Part II, Item 8 of this Annual Report on Form 10-K, we included disclosures on our cost-reimbursement research award from CARB-X. Therefore, we do not believe the adoption of this standard will have a material impact on our financial statements.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">    </span></p></ix:nonNumeric></div>
  <div><ix:nonNumeric id="F_7e140b4c-ceba-45ea-9842-41c3556e665c" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="us-gaap:FairValueDisclosuresTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">3. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Fair Value Measurements and Fair Value of Financial Instruments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Assets and liabilities recorded at fair value on a recurring basis in the balance sheets, as well as assets and liabilities measured at fair value on a non-recurring basis or disclosed at fair value, are categorized based upon the level of judgment associated with inputs used to measure their fair values. The accounting guidance for fair value provides a framework for measuring fair value and requires certain disclosures about how fair value is determined. Fair value is defined as the price that would be received</span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">upon the sale of an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. The accounting guidance also establishes a three-level valuation hierarchy that prioritizes the inputs to valuation techniques used to measure fair value based upon whether such inputs are observable or unobservable. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect market assumptions made by the reporting entity. The three-level hierarchy for the inputs to valuation techniques is briefly summarized as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Level 1&#x2014;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Level 2&#x2014;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Inputs are observable, unadjusted quoted prices in active markets for similar assets or liabilities, unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Level</span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> 3</span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Unobservable inputs that are significant to the measurement of the fair value of the assets or liabilities that are supported by little or no market data.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">134</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability. Changes in the ability to observe valuation inputs may result in a reclassification of levels of certain securities within the fair value hierarchy. We recognize transfers into and out of levels within the fair value hierarchy in the period in which the actual event or change in circumstances that caused the transfer occurs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 1 securities consist of highly liquid money market funds for which the carrying amounts approximate their fair values due to their short maturities. U.S. Treasury securities are valued using Level 1 inputs based on unadjusted, quoted prices in active markets that are observable at the measurement date for identical assets or liabilities. Level 2 securities, consisting of corporate debt, commercial paper, U.S. government agency securities and asset-backed securities, are measured based on other observable inputs, including broker or dealer quotations or alternative pricing sources. When quoted prices in active markets for identical assets or liabilities are not available, we rely on non-binding quotes from our investment managers, which are based on proprietary valuation models of independent pricing services. These models generally use inputs such as observable market data, quoted market prices for similar instruments or historical pricing trends of securities relative to our peers. To validate the fair value determinations provided by our investment managers, we review the pricing movement in the context of overall market trends and trading information from our investment managers. In addition, we assess the inputs and methods used in determining the fair value in order to determine the classification of securities in the fair value hierarchy. We had </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_49257dcd-07f8-458c-a2cb-1b0443551dad" contextRef="C_2bbf4b2d-41ff-4ec4-b597-e8a5be645bc2" name="pcvx:NumberOfSecurities" unitRef="U_Security" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_ad5b9687-c14e-4d45-8832-b1f491dc7990" contextRef="C_3276c9c1-bce8-4e37-a494-9cd61a385e5d" name="pcvx:NumberOfSecurities" unitRef="U_Security" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> Level 3 securities either as of December 31, 2021 or 2020.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">There were </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5d4088b7-50c9-4153-90ed-48cfd490678a" contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57" name="us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_29d22e4f-bbcc-4e60-992d-2bbcdcdf0397" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_b3378ec5-c6a9-49ed-a8ba-53cbd45d3895" contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57" name="us-gaap:FairValueLiabilitiesLevel2ToLevel1TransfersAmount" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_e5785dd5-4a2f-46de-bc88-a90442149640" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_bb115f7a-e52f-41f2-8e1e-2a8491954ad4" contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_c4cc334e-8430-415d-8db5-fb0bde757777" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_466e8315-a63e-4ffb-98e8-12caa931fcd1" contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_d2d4c4f6-2a50-4e68-bf13-552e8f9fc4f4" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_6f7e8b97-b976-449c-9297-3f11c161bcba" contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_cade8bb3-a476-417d-8577-30d97d5b2f1b" contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350" name="us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_8fcd926d-0d4a-4523-b669-c3ecbc639b37" contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57" name="us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_85215405-f3c9-47b5-8c89-d41a6b6dec76" contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350" name="us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_db173fdf-ce40-4371-9c64-b30d405c1b58" contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57" name="us-gaap:FairValueLiabilitiesLevel1ToLevel2TransfersAmount" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_e72f18dd-63b1-44c7-9531-6ba4599e985d" contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350" name="us-gaap:FairValueLiabilitiesLevel1ToLevel2TransfersAmount" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> transfers within the hierarchies during the years ended December 31, 2</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6702c762-8f30-43bf-8c95-b6fc445fdacf" contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350" name="us-gaap:FairValueLiabilitiesLevel2ToLevel1TransfersAmount" unitRef="U_USD" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_4f43d3dc-a230-46c6-ba56-67e0548f1bee" contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" unitRef="U_USD" decimals="INF" format="ixt:numdotdecimal">0</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21 or 2020.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">135</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We invested in money market funds as of December 31, 2020. In January 2021, we started to invest some of our funds in corporate debt, commercial paper, U.S. Treasury securities, U.S. government agency securities and asset-backed securities in addition to money market funds. </span><span style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_27b23c34-827e-486b-99eb-8700a96784d5" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" escape="true" continuedAt="F_27b23c34-827e-486b-99eb-8700a96784d5_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following tables set forth our financial instruments measured at fair value on a recurring basis by level within the fair value hierarchy at </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020: </span></ix:nonNumeric></span><span style=""></span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:continuation id="F_27b23c34-827e-486b-99eb-8700a96784d5_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:28.362%;"></td>
        <td style="width:13.565%;"></td>
        <td style="width:6.799%;"></td>
        <td style="width:1.231%;"></td>
        <td style="width:9.272%;"></td>
        <td style="width:0.6%;"></td>
        <td style="width:2.227%;"></td>
        <td style="width:1.231%;"></td>
        <td style="width:9.272%;"></td>
        <td style="width:0.6%;"></td>
        <td style="width:1.831%;"></td>
        <td style="width:1.242%;"></td>
        <td style="width:8.608%;"></td>
        <td style="width:0.835%;"></td>
        <td style="width:2.099%;"></td>
        <td style="width:1.231%;"></td>
        <td style="width:10.396%;"></td>
        <td style="width:0.6%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Fair Value<br />Hierarchy Level</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Amortized<br />Cost</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Gross <br />Unrealized Gains</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Gross <br />Unrealized Losses</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Fair<br />Value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">(in thousands)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Cash and cash equivalents:</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Cash</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Level 1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_45eabf10-2e90-4968-971c-c7decf8ee4a4" contextRef="C_4ce8060d-05a1-4cdf-a58a-b689d077a297" name="pcvx:CashAndCashEquivalentsAmortizedCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">27,834</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_25312f54-74f2-4053-9faa-697bcc9bbcb7" contextRef="C_4ce8060d-05a1-4cdf-a58a-b689d077a297" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">27,834</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Money market funds</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Level 1</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e01cb1a9-7ad9-4f18-8fa4-588d00fac51a" contextRef="C_dc50a6ec-93a5-4d6d-8842-7d609d69c237" name="pcvx:CashAndCashEquivalentsAmortizedCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">17,555</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a0dbc348-f693-4a1d-ac57-3e6e487fd46a" contextRef="C_dc50a6ec-93a5-4d6d-8842-7d609d69c237" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">17,555</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Commercial paper</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Level 2</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2570a72b-1e06-48e8-bfd4-adfebe704ba7" contextRef="C_bcc1b5db-4703-43c3-9272-4d0ca2f54e6a" name="pcvx:CashAndCashEquivalentsAmortizedCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">23,597</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9dc7e000-b5dc-4f40-8cb7-4d4f92bb74d2" contextRef="C_bcc1b5db-4703-43c3-9272-4d0ca2f54e6a" name="pcvx:CashAndCashEquivalentsGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5c2c7749-2625-4048-b74d-2e86ab3fb534" contextRef="C_bcc1b5db-4703-43c3-9272-4d0ca2f54e6a" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">23,596</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:15.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Total cash and cash equivalents</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b603efff-6333-4400-8913-5af1cdbf85a6" contextRef="C_9a84ae25-675d-4a66-a9c5-6809604d88d9" name="pcvx:CashAndCashEquivalentsAmortizedCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">68,986</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2d6ab67b-45a1-4117-90bf-dd33b8ad318a" contextRef="C_9a84ae25-675d-4a66-a9c5-6809604d88d9" name="pcvx:CashAndCashEquivalentsGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2ef31255-699e-4171-8468-a1c7db1f7a32" contextRef="C_9a84ae25-675d-4a66-a9c5-6809604d88d9" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">68,985</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Investments:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">U.S. Treasury securities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Level 1</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f2693e83-670d-4822-9be8-52ca273155dc" contextRef="C_922091bf-1883-4a4a-8399-cbd1c97ca12c" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">45,290</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4706bf8a-f7d2-4087-aa4e-02f0dfcdb941" contextRef="C_922091bf-1883-4a4a-8399-cbd1c97ca12c" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">73</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_18821bb4-e97a-4a20-9db3-443b1a837c9a" contextRef="C_922091bf-1883-4a4a-8399-cbd1c97ca12c" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">45,217</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Commercial paper</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Level 2</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_072b99b8-cfb3-43a5-86f3-7baae4651aa7" contextRef="C_a870b5f9-af49-4819-946b-a34bbe67f9e2" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">61,941</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_475eba79-c2cd-4a33-816f-32393e7703e9" contextRef="C_a870b5f9-af49-4819-946b-a34bbe67f9e2" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">22</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_25e6f27d-4bf3-4e10-bbb6-bb1499187d5f" contextRef="C_a870b5f9-af49-4819-946b-a34bbe67f9e2" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">61,919</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Corporate debt</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Level 2</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_33b2b67d-1f46-4b06-bfc2-bb2a160a47c1" contextRef="C_9fb419f9-f0a5-4dff-a890-32989d15c4e8" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">58,498</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_048885a4-28fa-4b2d-9581-5b42892eeca4" contextRef="C_9fb419f9-f0a5-4dff-a890-32989d15c4e8" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">74</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_24108b58-ad40-4afe-a58c-37d04b9ceaaf" contextRef="C_9fb419f9-f0a5-4dff-a890-32989d15c4e8" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">58,424</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Asset backed securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Level 2</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9ba34c0c-d89e-474f-9a2c-73aad69ca7d5" contextRef="C_5cd74deb-d2fe-4b8d-8171-3251599dda47" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13,899</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bf1f5128-58c5-4365-b636-bfb5eefb3baa" contextRef="C_5cd74deb-d2fe-4b8d-8171-3251599dda47" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">25</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4a805897-45b9-430b-a73c-0363f2d2c136" contextRef="C_5cd74deb-d2fe-4b8d-8171-3251599dda47" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13,874</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">U.S. government agency securities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Level 2</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a6055153-8cda-4df2-a8a8-978a14dce273" contextRef="C_0a0e64e6-bec3-47d0-a7db-dea3ad28e107" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">24,714</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4d416a35-6550-4319-bc48-ec2278be45d3" contextRef="C_0a0e64e6-bec3-47d0-a7db-dea3ad28e107" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">46</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_828ab589-39b1-43cb-97b8-956a49d34335" contextRef="C_0a0e64e6-bec3-47d0-a7db-dea3ad28e107" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">24,668</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:15.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Total investments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0013e7fe-3152-462e-af4c-134d6aa22851" contextRef="C_9a84ae25-675d-4a66-a9c5-6809604d88d9" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">204,342</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d93d43fd-42b5-4203-9bf9-7f94a97ae6ca" contextRef="C_9a84ae25-675d-4a66-a9c5-6809604d88d9" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">240</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_869a2f96-2812-45bb-b9f1-481e727fc219" contextRef="C_9a84ae25-675d-4a66-a9c5-6809604d88d9" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">204,102</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(0,0,0,0);text-indent:15.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Total assets measured at fair value</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_41eeb37e-496c-4e4a-bd31-28da587abf75" contextRef="C_9a84ae25-675d-4a66-a9c5-6809604d88d9" name="pcvx:CashAndCashEquivalentsAndInvestmentsAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">273,328</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9489485c-739d-4851-806c-4e05702f6ee1" contextRef="C_9a84ae25-675d-4a66-a9c5-6809604d88d9" name="pcvx:CashAndCashEquivalentsAndInvestmentsGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">241</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8fe98cae-6934-4b80-8e1b-1ab5ef072a9e" contextRef="C_9a84ae25-675d-4a66-a9c5-6809604d88d9" name="pcvx:CashAndCashEquivalentsAndInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">273,087</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31, 2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Fair Value<br />Hierarchy Level</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Amortized<br />Cost</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Gross <br />Unrealized Gains</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Gross <br />Unrealized Losses</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Fair<br />Value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">(in thousands)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Cash and cash equivalents:</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Cash</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Level 1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_be99b109-cbca-4d85-9b8b-5c9e479e1dca" contextRef="C_5c504db9-02bb-4fad-8cf7-b49fc071de1c" name="pcvx:CashAndCashEquivalentsAmortizedCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,788</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_041c63f1-9a43-4c7d-a1aa-976b85fcf4af" contextRef="C_5c504db9-02bb-4fad-8cf7-b49fc071de1c" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,788</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Money market funds</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Level 1</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_eb5687a5-774d-432a-857a-a7f78c81cdba" contextRef="C_1a49e197-0c31-4849-ac0b-b08a2eebd593" name="pcvx:CashAndCashEquivalentsAmortizedCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">381,412</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ba7985d0-ead5-4af5-a302-0dc45a61a27c" contextRef="C_1a49e197-0c31-4849-ac0b-b08a2eebd593" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">381,412</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Total assets measured at fair value</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d58da43f-d71c-410b-bfd4-e95396acb55e" contextRef="C_2e490417-2b25-4870-8c8f-ccac2bc83352" name="pcvx:CashAndCashEquivalentsAndInvestmentsAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">386,200</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d39994f0-1406-4abd-934f-3f88eb6c8910" contextRef="C_2e490417-2b25-4870-8c8f-ccac2bc83352" name="pcvx:CashAndCashEquivalentsAndInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">386,200</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_de086a10-7d3b-47c0-afbb-f714ec397acb" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" escape="true"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table presents the contractual maturities of our investments as of December 31, 2021 (in thousands):</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:70.292%;"></td>
        <td style="width:5.331%;"></td>
        <td style="width:1.242%;"></td>
        <td style="width:22.15%;"></td>
        <td style="width:0.985%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Fair Value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Due in less than one year</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7575df1a-d1a6-4dcd-a210-7bf172615ccc" contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">176,985</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Due in one to five years</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_73608741-fa34-4214-b97c-12fc03b14f14" contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">27,117</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a0800c1c-cd3b-420e-a9f3-379a0350a672" contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">204,102</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">136</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a3831dc8-5875-425d-bf27-65aaf68a2b80" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">4. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Balance Sheet Details</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Property and Equipment, Net</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1778444f-f35c-4eaa-9739-a47571d1ab01" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="us-gaap:PropertyPlantAndEquipmentTextBlock" escape="true"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment, net as of December 31, 2021 and 2020 consisted of the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.51%;"></td>
        <td style="width:1.478%;"></td>
        <td style="width:1.37%;"></td>
        <td style="width:12.976%;"></td>
        <td style="width:0.921%;"></td>
        <td style="width:1.478%;"></td>
        <td style="width:1.37%;"></td>
        <td style="width:12.976%;"></td>
        <td style="width:0.921%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Furniture and equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_11352b7f-7278-4cc4-9c74-755fe7920ba6" contextRef="C_fe00813e-2d7b-4ece-bbe6-949a26bbf5f7" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,619</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9acfccd3-42e3-410e-901a-f99aa2579625" contextRef="C_066e4651-a692-4244-9444-b8600c1c5b43" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">397</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Computers and computer software</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7933b44e-c979-415d-98e1-f65170ee12af" contextRef="C_68b32ca0-daf9-4934-b4c5-74593152bb49" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">430</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8f2b56bf-e929-43db-bfdb-58242946f967" contextRef="C_1217ed43-7b78-4138-a3fe-8b016f62919a" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">111</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Lab equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_14138018-b671-497e-92cb-104c6e2a7b6f" contextRef="C_4c43c843-d033-4309-afae-7cfdb2138610" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,453</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_51f1d58c-8d9e-41d9-906f-908a096e2780" contextRef="C_35363580-d33d-4e25-a1e6-c5519ee4402f" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,739</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Leasehold improvements</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e662812a-84f0-47cb-b376-496dbf9cebab" contextRef="C_fc0e428b-6e5e-4e81-ad32-508b6eb1375f" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,903</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Construction in progress</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_22789544-6d12-483d-83c6-786a0ba3557c" contextRef="C_070a9c52-605a-45b7-ac24-ad04c1d7f676" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">219</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total property and equipment</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6695cc15-56b0-4aa6-afdc-19d23772c2ce" contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11,502</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_209be3e8-09ff-48af-bc32-6e51d45bcc48" contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,369</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less: accumulated depreciation and amortization</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c18def7c-f1ae-4928-9347-2e21b54f20e0" contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,548</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7644ca06-8832-4328-8d39-b81bd1c55d8a" contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,097</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment, net</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_737313f5-9ff7-46a4-b19e-562821b3ca96" contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,954</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b6b9297a-a549-46ad-b900-f4d1bf932a6a" contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,272</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Depreciation and amortization expense for years ended December 31, 2021, 2020 and 2019 was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c996e458-bd6d-47d7-b416-fd24e0ab352d" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="us-gaap:DepreciationAndAmortization" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c92eef25-7ef2-418b-bf90-b34dc44578e5" contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001" name="us-gaap:DepreciationAndAmortization" unitRef="U_USD" scale="6" decimals="-5">1.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bfe346da-e5d4-4a96-8a09-9851999187e0" contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700" name="us-gaap:DepreciationAndAmortization" unitRef="U_USD" scale="6" decimals="-5">1.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million respectively, of which $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d38502c6-358f-4c0c-814d-2c94c6fb234e" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="pcvx:CapitalLeasesAmortizationExpense" unitRef="U_USD" decimals="0">0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ef9a25b9-233f-4de1-92fb-cb84bb7b9a21" contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001" name="pcvx:CapitalLeasesAmortizationExpense" unitRef="U_USD" decimals="0">0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fe4be491-4c43-4c85-9ef8-6330db56764d" contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700" name="pcvx:CapitalLeasesAmortizationExpense" unitRef="U_USD" scale="6" decimals="-5">0.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million related to capital lease amortization expense for the years ended December 31, 2021, 2020 and 2019, respectively.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Accrued Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b9f467e6-172f-441c-af0b-d358b4a0b6c4" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" escape="true"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued expenses as of December 31, 2021 and 2020 consisted of the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.006%;"></td>
        <td style="width:1.413%;"></td>
        <td style="width:1.381%;"></td>
        <td style="width:12.75%;"></td>
        <td style="width:0.942%;"></td>
        <td style="width:1.413%;"></td>
        <td style="width:1.381%;"></td>
        <td style="width:12.772%;"></td>
        <td style="width:0.942%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Preclinical studies</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f8cf2c2c-f7e5-4a7b-b281-891d5265952c" contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350" name="pcvx:AccruedPreclinicalStudiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,039</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_81681149-e009-45b8-aa2c-e1e804bc8d22" contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57" name="pcvx:AccruedPreclinicalStudiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,844</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Professional fees</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_84fa00f3-7ba1-4a2d-9389-42401cda96bf" contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">400</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_448b6617-5047-4a2a-b90b-0962a897b6b7" contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">490</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other accrued expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2e08bb0d-68a4-43d7-989c-6783e3e7d0a1" contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,348</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8e7e1744-4720-4af4-b3a0-f4e07f983cfa" contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">432</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:15.0pt;word-break:break-word;vertical-align:middle;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8dad6b0f-4903-48fa-8d72-ee19ff6f723f" contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,787</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_07d56c29-8a98-4b0e-a681-8f22a9ed7fa5" contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,766</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_163ca269-079c-4436-a3a6-bc2a03e659d6" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="us-gaap:LesseeOperatingLeasesTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">5. Leases</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Operating Lease Obligations</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a3f96087-f3fc-4008-ae4d-d21389cd1088" contextRef="C_bc56f763-40d5-4249-8c96-d9aa519edbb4" name="us-gaap:LesseeOperatingLeaseDescription"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In July 2016, we entered into a </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_61e12400-3ac7-4c2d-9dcb-9bac525de5fb" contextRef="C_75f99d7f-d132-471c-9624-9a873477248d" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">five-year</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> lease agreement for our previous headquarters facility located in Foster City, California. The original term of the lease was from </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1a7452be-d3b2-4fb7-92b6-4349a8df5a17" contextRef="C_8825ef60-997f-4d67-9024-2ab506972607" name="pcvx:LesseeOperatingLeaseCommencementDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">September 1, 2016</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> to </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_129950ae-89d0-4b3d-b197-a4f57ebbd429" contextRef="C_8825ef60-997f-4d67-9024-2ab506972607" name="us-gaap:LeaseExpirationDate1" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">August 31, 2021</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, with </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ed558929-761f-4d2e-af45-fb56e85e02b7" contextRef="C_8825ef60-997f-4d67-9024-2ab506972607" name="pcvx:LesseeOperatingLeaseRenewalOption" unitRef="U_RenewalOption" decimals="INF" format="ixt-sec:numwordsen">two</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cd1d95b7-2d7e-45ab-8501-68039510b45d" contextRef="C_bc56f763-40d5-4249-8c96-d9aa519edbb4" name="us-gaap:LesseeOperatingLeaseOptionToExtend"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_77213f45-a32b-4276-b8c8-aff355bec05c" contextRef="C_75f99d7f-d132-471c-9624-9a873477248d" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durmonth"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-month </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b3abd3a1-48ea-412c-90eb-682d1d7ab3c8" contextRef="C_8825ef60-997f-4d67-9024-2ab506972607" name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend" format="ixt:booleantrue"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">renewal options</span></ix:nonNumeric></span><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"></span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8aef5f14-1452-4f4a-9cc2-5dc72f7553ae" contextRef="C_59f4b2de-1ad8-448b-acad-83f62876574d" name="us-gaap:LesseeOperatingLeaseDescription"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In July 2019, we leased another facility in Foster City, California as a result of growth in personnel and lab space requirements. The original term of this lease was from </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4eed0894-2608-4301-baca-4a246254a4f7" contextRef="C_6cff9554-4027-48fb-bcff-8e4bfb2fe23e" name="pcvx:LesseeOperatingLeaseCommencementDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">July 1, 2019</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> to </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6ecb07b0-1eb6-48eb-a25c-a4eb1e5d9f45" contextRef="C_6cff9554-4027-48fb-bcff-8e4bfb2fe23e" name="us-gaap:LeaseExpirationDate1" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">October 31, 2021</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, with </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fcff5920-a357-4121-ae1f-5aeaa25ab73b" contextRef="C_59f4b2de-1ad8-448b-acad-83f62876574d" name="us-gaap:LesseeOperatingLeaseOptionToExtend"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f312a0ab-498b-4428-a541-52df4e68e1c1" contextRef="C_6cff9554-4027-48fb-bcff-8e4bfb2fe23e" name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend" format="ixt:booleanfalse"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> renewal options</span></ix:nonNumeric></span><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"></span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> In November 2020, we extended the terms of both of these leases for </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_986f27d3-0b5c-4ec0-8f10-3554675024f1" contextRef="C_07b31212-bf35-4995-9486-d82d74f5da0e" name="pcvx:LesseeOperatingLeaseExtendedLeaseTerm" format="ixt-sec:durwordsen"><ix:nonNumeric id="F_348569e9-f322-4289-8c63-9c598482165f" contextRef="C_555acc16-d9e2-4b46-9a03-aa27a3ad92e4" name="pcvx:LesseeOperatingLeaseExtendedLeaseTerm" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">six months</span></ix:nonNumeric></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> to </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8e12c82d-e5d6-47c5-9e60-297f04d383af" contextRef="C_07b31212-bf35-4995-9486-d82d74f5da0e" name="pcvx:LesseeOperatingLeaseExtendedMaturityDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">March 1, 2022</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c388a703-b757-4456-bbbe-d5e1fbe5b98c" contextRef="C_555acc16-d9e2-4b46-9a03-aa27a3ad92e4" name="pcvx:LesseeOperatingLeaseExtendedMaturityDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">April 30, 2022</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, respectively. In February 2022, we entered into an early termination agreement for one of the facilities in Foster City and terminated our lease on </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_31a1783a-796e-498a-a546-9575d8ec8c42" contextRef="C_ac053fdb-afd2-48a8-b734-eae8ef079868" name="pcvx:LeaseTerminationDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">February 12, 2022</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> instead of April 30, 2022. We also leased an office in San Diego, California with a lease term that ended on </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1073c65e-1598-42d4-b36f-a2432f07bc52" contextRef="C_fa60d7ee-2e38-419f-8133-f69b4b66de3f" name="us-gaap:LeaseExpirationDate1" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">April 30, 2021</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">137</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In January 2021, we entered into a lease agreement for our new corporate headquarters facility located in San Carlos, California and a license agreement for temporary lab and office space in Palo Alto, California. The lease term for our new corporate headquarters facility began on </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3fc1f9f9-b1e6-48da-9122-7cc6e2ba3275" contextRef="C_28585e6d-11c8-4ef0-bd28-a3644bbf26ac" name="pcvx:LesseeOperatingLeaseCommencementDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">January 22, 2021</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and expires on </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_be313428-ba89-49ba-acf6-5a9a1c2c90d8" contextRef="C_28585e6d-11c8-4ef0-bd28-a3644bbf26ac" name="us-gaap:LeaseExpirationDate1" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2025</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. We have </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4b1bf4c8-0ae1-4a4b-abfc-b9277d94e5fc" contextRef="C_28585e6d-11c8-4ef0-bd28-a3644bbf26ac" name="pcvx:NumberOfRenewalOptions" unitRef="U_RenewalOption" decimals="INF" format="ixt-sec:numwordsen">two</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_831052f3-3acd-4959-a89f-4602c1ed7388" contextRef="C_2a6a1809-6c79-4e3a-9b03-3826f9729ccf" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durmonth"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">60</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-month renewal options. The original term of the license agreement for temporary space in Palo Alto terminated when the San Carlos office leasehold improvements were completed and we moved into our new corporate headquarters. We extended the license agreement for the Palo Alto office by </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0d13eeec-e948-4595-bfb5-b9aca005b4dc" contextRef="C_28585e6d-11c8-4ef0-bd28-a3644bbf26ac" name="pcvx:LesseeOperatingLeaseExtendedLeaseTerm" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">60 days</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> to </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d8a1b460-70cb-44cc-97dd-a6a2a5be21a1" contextRef="C_f112ef5d-4313-44ad-aa4e-21889fa3a7d3" name="pcvx:LesseeOperatingLeaseExtendedMaturityDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">March 3, 2022</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> to accommodate our relocation plan. These two agreements are accounted for as a combined lease because the contracts were negotiated as a package with the same commercial objective.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We early adopted ASC 842 and its associated amendments as of January 1, 2021 using the modified retrospective transition approach by applying the new standard to all leases existing at the date of the initial adoption and not restating comparative periods. We elected the package of practical expedients permitted under the transition guidance within the new standard, which among other things, allowed us to carryforward the historical lease classification of those leases in place as of January 1, 2021. The adoption of ASC 842 resulted in an increase to total assets and liabilities due to the recording of operating lease ROU assets and operating lease liabilities of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_06117121-497a-4bd1-9bd2-d7161c91f7f6" contextRef="C_d4cf0103-8fdd-4434-bedf-65aa2503f533" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="6" decimals="-5">0.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_137d8434-8b16-42b2-9144-9e8fe109cc28" contextRef="C_d4cf0103-8fdd-4434-bedf-65aa2503f533" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="6" decimals="-5">0.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively, as of January 1, 2021. ROU assets and lease liabilities are recognized based on the present value of the fixed and in-substance fixed lease payments over the lease terms at their respective commencement dates. The ROU assets also include any initial direct costs incurred and lease payments made at or before the commencement date and are reduced by lease incentives. In determining the present value of lease payments, since the rate implicit in the lease is generally not readily determinable, we use our incremental borrowing rate, which requires management&#x2019;s judgment, including for the development of a synthetic credit rating and the cost of debt as we currently do not carry any debt. Variable lease costs, which are dependent on usage, a rate or index, including common area maintenance charges for our real estate leases, are expensed as incurred.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Upon commencement of the Palo Alto lease in March 2021, we recorded a ROU asset and lease liability of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_cbe8d816-4183-4afe-a8bc-7f4850e8da61" contextRef="C_54987e17-a9c2-4890-ade9-618bd3dfc3f7" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="6" decimals="-5">0.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c5c5e5b6-fbcc-40ec-9a55-76049cbd3aab" contextRef="C_54987e17-a9c2-4890-ade9-618bd3dfc3f7" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="6" decimals="-5">0.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively. Upon commencement of the San Carlos lease in December 2021, we recorded a ROU asset and lease liability of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c9828b3b-5301-451f-a122-58ef9eacb45b" contextRef="C_9ce589b3-009c-4c1f-9492-617b84d98173" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">28.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_68f3b6b9-eb3f-4628-be18-6c75ee54943e" contextRef="C_9ce589b3-009c-4c1f-9492-617b84d98173" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">12.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively. Because the Palo Alto and the San Carlos agreements are accounted for as a combined lease, lease payments and lease incentives are allocated between the </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_53b02333-a77d-4ce5-9a85-877c8b6f9e99" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="pcvx:NumberOfOperatingLease" unitRef="U_Lease" decimals="INF" format="ixt-sec:numwordsen">two</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> leases.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">   </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a56a8efd-6aa8-424f-9679-2fc5dc61c638" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="pcvx:ScheduleOfInformationRelatedToRightOfUseAssetsAndLeaseLiabilitiesTableTextBlock" escape="true"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Information related to our ROU assets and related lease liabilities was as follows (dollar amounts in thousands):</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:78.308%;"></td>
        <td style="width:4.176%;"></td>
        <td style="width:1.381%;"></td>
        <td style="width:13.822%;"></td>
        <td style="width:2.313%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash paid for operating lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3ca00ddf-0372-4d4f-afed-6e4207927893" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">924</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Right-of-use assets recognized in exchange for new lease obligations</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b0e6bac6-b889-4273-b777-66ec3845d122" contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">27,958</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Current operating lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_64de4bb4-1279-4ab2-ad0c-410c29d46f24" contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,276</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Non-current operating lease liabilities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4ba76bde-9150-44f2-a346-972e6180e1d1" contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11,507</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c8eb05c8-868b-4396-a546-343516136ca5" contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">16,783</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Weighted-average remaining lease term (in years)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_993810ce-9a14-4747-a51f-013dcf3cd621" contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.75</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Weighted-average discount rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ca7700d0-6610-4c75-832a-e8939e53ae00" contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">7.5</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">138</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_de82f73e-ea76-41cb-afaa-288e84ce9f95" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" escape="true"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Maturities of lease liabilities as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 were as follows:</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.289%;"></td>
        <td style="width:1.692%;"></td>
        <td style="width:1.381%;"></td>
        <td style="width:15.675%;"></td>
        <td style="width:0.964%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Years ending December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:Times New Roman;position:relative;">(1)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0f503ec8-4ea7-4f88-baba-b04d660f78b6" contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350" name="pcvx:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonthsNetOfLeaseIncentives" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">105</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2023</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fde2b0c5-88b1-471d-a978-869abbc9cf8d" contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,639</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2024</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b9922f99-677d-4a1a-af77-3608f4fcf89a" contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,805</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2025</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8b732c35-9c59-4b6b-8da2-4b67933770a4" contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,976</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Thereafter</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total future undiscounted lease payments</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_94a69d12-5a31-4f0f-beb5-48b6b16370f3" contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">20,315</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less: Imputed interest</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6e719a8a-7ff6-4204-8a4d-f6c5bbbba644" contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,532</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total lease liabilities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2006a081-83e5-4b2b-bfdd-6f73df722a8a" contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">16,783</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">_____________________________________________</span></p><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(1)	Maturities for 2022 are net of lease incentives of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e0dc4cbf-b6f1-4f4a-9c6b-48d4e7b2d911" contextRef="C_5c54c4ca-430a-4169-96fa-f57499d8524f" name="pcvx:LeasePaymentReceivableNoncurrent" unitRef="U_USD" scale="6" decimals="-5">0.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million allocated to the Palo Alto office.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Future minimum payments required under operating leases as of December 31, 2020 were as follows:</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:78.985%;"></td>
        <td style="width:1.82%;"></td>
        <td style="width:1.402%;"></td>
        <td style="width:16.679%;"></td>
        <td style="width:1.113%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Years ending December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;text-indent:13.7pt;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="margin-left:13.7pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7151987b-7e5f-4fb9-84c5-cf1fdeca442b" contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" unitRef="U_USD" scale="3" decimals="-3">742</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:13.7pt;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="margin-left:13.7pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6e459f27-72ba-4d9e-9b07-de49452229b8" contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" unitRef="U_USD" scale="3" decimals="-3">190</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total future minimum payments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="border-top:0.250pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="border-top:0.250pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_72a3a168-e976-4e8b-8ed3-5cdb150ea4b6" contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" unitRef="U_USD" scale="3" decimals="-3">932</ix:nonFraction></span></p></td>
        <td style="border-top:0.250pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Rent expense recognized under the leases was $</span><span style="font-size:10.0pt;font-family:Times New Roman;white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_36b68062-816d-4cfb-893d-f0c0f136da83" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="us-gaap:OperatingLeaseExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">3.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b72f834d-73a2-4696-b636-ff501afd4e14" contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001" name="us-gaap:OperatingLeaseExpense" unitRef="U_USD" scale="6" decimals="-5">0.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_57d97a87-5336-402b-9ee0-aaabd215fe25" contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700" name="us-gaap:OperatingLeaseExpense" unitRef="U_USD" scale="6" decimals="-5">0.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for the years ended December 31, 2021, 2020 and 2019, respectively.</span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d772575e-e963-4f56-9e5a-e9978dbe8b96" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">6. Commitments and Contingencies</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Legal Contingencies</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">From time to time, we may become involved in legal proceedings arising from the ordinary course of business. We record a liability for such matters when it is probable that future losses will be incurred and that such losses can be reasonably estimated. Significant judgment by us is required to determine both probability and the estimated amount. We do not believe that there is any litigation or asserted or unasserted claim pending that could, individually or in the aggregate, have a material adverse effect on our results of operations or financial condition.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Guarantees and Indemnifications</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the normal course of business, we enter into agreements that contain a variety of representations and provide for general indemnification. Our exposure under these agreements is unknown because it involves claims that may be made against us in the future. To date, we have not paid any claims or been required to defend any action related to our indemnification obligations. As of December 31, 2021, we did not have any material indemnification claims that were probable or reasonably possible and consequently have not recorded related liabilities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Indemnification</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">To the extent permitted under Delaware law, we have agreed to indemnify our directors and officers for certain events or occurrences while the director or officer is, or was, serving at our request in such capacity. The indemnification period covers all pertinent events and occurrences during the director&#x2019;s or officer&#x2019;s service. The maximum potential amount of future payments we could be required to make under these indemnification agreements is not specified in the agreements; however, we have director and officer insurance coverage that reduces our exposure and enables us to recover a portion of any future amounts paid. We have not incurred any material costs as a result of such indemnification and are not currently aware of any indemnification claims.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">139</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Development and Manufacturing Services Agreement</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On October 21, 2016, we entered into a development and manufacturing services agreement, as amended, with Lonza (the &#x201c;Lonza DMSA&#x201d;), pursuant to which Lonza is obligated to perform services including manufacturing process development and the manufacture of components for VAX-24, including the polysaccharide antigens, our proprietary eCRM protein carrier and conjugated drug substances.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the September 2017, we and Lonza agreed to defer the completion payments for any stage that commenced after December 31, 2019 or had not been completed by December 31, 2019 until the earlier of the completion of all Investigational New Drug (&#x201c;IND&#x201d;)-enabling activities or December 31, 2020. In March 2020, Lonza agreed to defer the completion payments until the earlier of the completion of all IND-enabling activities or April 30, 2021. In April 2021, Lonza further agreed to defer </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e6b9f14b-867d-4705-b7d6-2471b51a9990" contextRef="C_448aa75e-c08c-4eb7-a778-f1a1525470d8" name="pcvx:PercentageOfPaymentsCompletionAgreedToDefer" unitRef="U_pure" scale="-2" decimals="2">50</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the completion payments until the earlier of the completion of all IND-enabling activities or December 31, 2021. Pursuant to this agreement, all deferred completion payments were paid in December 2021.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In June 2018, we and Lonza entered into a letter agreement pursuant to which we agreed to certain terms for potential future equity payments in shares of our common stock as partial satisfaction of future obligations to Lonza. This agreement states that the initial pre-IND cash payments would be subject to a specified dollar cap (the &#x201c;Initial Cash Cap&#x201d;). After the Initial Cash Cap has been reached, we have the option to make any further pre-IND payments owed to Lonza in cash, in shares of our common stock at then market prevailing prices, or a combination of both, at our election. The Initial Cash Cap had not been reached as of December 31, 2020. As such, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_40c4c957-be74-4d9c-8e93-58dda9f75597" contextRef="C_82e259ab-4adf-45bb-b0dd-9fc97b85e6bd" name="us-gaap:GuaranteeObligationsMaximumExposure" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> amount was recorded with respect to the potential future payments above the Initial Cash Cap at December 31, 2020. In April 2021, we reached the Initial Cash Cap and notified Lonza that we would be exercising our option to issue approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1af6d13d-e575-427f-9312-bacb3e7b798c" contextRef="C_0f671a12-9113-4696-9460-beb583200e4f" name="us-gaap:GuaranteeObligationsMaximumExposure" unitRef="U_USD" scale="6" decimals="-5">10.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in shares of our common stock as payment for a portion of pre-IND payments due April 30, 2021. In June 2021, we issued </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_88fce260-5e19-4df7-b9a1-9106a324f0ae" contextRef="C_f7ed5965-c3e7-4a8f-9810-2fb0b6527977" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">399,680</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of our common stock to Lonza at a price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7cb20bed-89ad-4816-8372-d69ae86ee33e" contextRef="C_f9848f07-54cd-412b-b65d-24c18bb6aab2" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">25.02</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share to pay for $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_98230c25-8a37-43b6-a71f-ed77657f7db3" contextRef="C_f7ed5965-c3e7-4a8f-9810-2fb0b6527977" name="pcvx:DevelopmentAndManufacturingServicesAgreementPaymentsInEquity" unitRef="U_USD" scale="6" decimals="-5">10.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of the pre-IND payments due April 30, 2021.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In October 2018, we entered into a second development and manufacturing services agreement with Lonza (the &#x201c;Lonza 2018 DMSA,&#x201d; and together with the Lonza DMSA, the &#x201c;Lonza Agreements&#x201d;), pursuant to which Lonza is obligated to perform services including manufacturing process development and the manufacture and supply of VAX-24 finished drug product.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under the Lonza Agreements, we are obligated to pay Lonza agreed-upon fees for Lonza&#x2019;s performance of manufacturing services, and to reimburse Lonza for its out-of-pocket costs associated with purchasing raw materials, plus a customary handling fee. Each Lonza Agreement is managed by a steering committee and any dispute at the steering committee will be resolved by senior executives of the parties.</span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a5a020ff-4312-4c89-9427-7be12e572f94" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="pcvx:RedeemableConvertiblePreferredStockTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">7. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Redeemable Convertible Preferred Stock</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">There were </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6fd3d584-cb98-4254-acf8-55d8e403e879" contextRef="C_faa3a312-73ee-42b0-852a-ab16d62c1cef" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_3f83ad69-ee11-45f7-9d8a-683d4cd3ed7a" contextRef="C_faa3a312-73ee-42b0-852a-ab16d62c1cef" name="us-gaap:TemporaryEquitySharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of redeemable convertible preferred stock authorized or outstanding as of December 31, 2021.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In connection with our IPO in June 2020, the outstanding shares of our Series A, Series B, Series C and Series D Redeemable Convertible Preferred Stock automatically converted into </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e5c2fb22-ff0f-4cb4-a8eb-b344d29f5739" contextRef="C_632492ef-57fd-48e7-acda-b7cb142000ba" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">28,610,337</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock.</span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2fbc3798-2519-4ecf-9a22-b7e1ca28f09d" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">8. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Common Stock</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our certificate of incorporation authorizes us to issue up to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1450983e-2c39-4bb4-942a-a75179364e88" contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_93505d6b-be66-4954-89bc-7b0fbb010acf" contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">500,000,000</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock with $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3407b145-e552-4963-ab80-15f32904df29" contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF"><ix:nonFraction id="F_7637104f-7592-498e-887f-afd650da31c0" contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">0.001</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> par value per share, of which </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5f65332b-2b0e-4111-ae59-6ad83a1ed5d2" contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_0b6a6e8a-9db7-49e7-af40-785e03a55ee0" contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">53,031,978</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a07fe54d-6613-4027-853b-2ec4deecc841" contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_f31d3dec-4341-44de-bab0-af2d85a03899" contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">51,071,593</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares were issued and outstanding as of December 31, 2021 and 2020, respectively. The holders of our common stock are also entitled to receive dividends whenever funds are legally available, when and if declared by our board of directors. As of December 31, 2021 and 2020, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ba3caf66-f0d8-45c6-99e9-ff52793fda1b" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="us-gaap:CommonStockDividendsPerShareDeclared" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_7643e986-6e49-4a7f-b03f-d337279bab0c" contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001" name="us-gaap:CommonStockDividendsPerShareDeclared" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> dividends have been declared. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a84f7d47-0a55-45c2-ae70-43256e1a861b" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="us-gaap:CommonStockVotingRights"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Each share of common stock is entitled to one vote.</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">140</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In July 2021, we entered into an Open Market Sales Agreement</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">SM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> (the &#x201c;ATM Sales Agreement&#x201d;) with Jefferies LLC (&#x201c;Jefferies&#x201d;), which provides that, upon the terms and subject to the conditions and limitations set forth in the ATM Sales Agreement, we</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">may elect to issue and sell, from time to time, shares of our common stock having an aggregate offering price of up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_eb376be3-c98b-44d8-a86d-67d5a4224cb0" contextRef="C_8639465b-8e42-43a0-b445-048bbd5edbbe" name="pcvx:SaleOfCommonStockAuthorizedAmount" unitRef="U_USD" scale="6" decimals="INF">150.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million through Jefferies acting as our sales agent or principal. We are obligated to pay Jefferies a commission of up to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_17f4e97d-fc12-4ecf-be37-19d8beb6cef5" contextRef="C_1ca103dc-5b49-40a2-af4e-c772a7562197" name="pcvx:MaximumCommissionPercentageOfGrossProceedsFromCommonStockSold" unitRef="U_pure" scale="-2" decimals="INF">3.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the gross sales proceeds of any common stock sold through Jefferies under the ATM Sales Agreement; however, we are not obligated to make any sales of common stock. As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, we have sold </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_15537781-6364-4408-9b82-5c2f8ac83b2d" contextRef="C_104dc821-c967-4abc-be6e-1f58334234a8" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">567,045</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of our common stock under the ATM Sales Agreement at an average price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e35dc7dd-2929-473e-b0ff-dae70e5da5d2" contextRef="C_44af597c-135d-414d-a410-f04a16cf714e" name="us-gaap:SaleOfStockPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">25.26</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share for aggregate gross proceeds of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9d766f34-bd78-4777-b1de-6e0e758ea178" contextRef="C_104dc821-c967-4abc-be6e-1f58334234a8" name="pcvx:GrossProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">14.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million ($</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_be8b0aa5-ebca-4b77-9692-02c5fb53048a" contextRef="C_104dc821-c967-4abc-be6e-1f58334234a8" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">13.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million net of commissions and offering expenses).</span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_02a84ab9-ebdc-46b8-8581-8025f2321ee6" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="pcvx:ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock" escape="true"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Common stock reserved for future issuances under the 2020 Equity Incentive Plan (the &#x201c;2020 Plan&#x201d;) and the 2014 Equity Incentive Plan (the &#x201c;2014 Plan&#x201d;) was as follows, and excludes </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f5192ee5-5dc1-4f1c-8fb2-80830528439e" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">62,382</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares issued outside of the 2014 Plan and 2020 Plan:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.052%;"></td>
        <td style="width:1.584%;"></td>
        <td style="width:1.006%;"></td>
        <td style="width:12.877%;"></td>
        <td style="width:1.006%;"></td>
        <td style="width:1.584%;"></td>
        <td style="width:1.006%;"></td>
        <td style="width:12.877%;"></td>
        <td style="width:1.006%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Options issued and outstanding</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b926895f-4c50-433c-891f-f179d03d49e3" contextRef="C_93b8accf-91b3-4471-ab5d-fc8aea02adbe" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">5,295,007</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d1802238-16dc-422a-a749-60a9c58dd679" contextRef="C_1c93f415-cf2a-4e2c-a1d1-8e49784595b5" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">5,188,531</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Shares available for future stock option grants</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1da4a51c-0326-4929-8ae7-381289dadc20" contextRef="C_0c6ef4a7-f323-4b58-a7d5-94f0c514539b" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">6,104,756</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_46133256-79d3-4637-831e-e4f0de8e3faf" contextRef="C_52c3a991-3000-4196-9b57-c6affc82cde5" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">4,651,149</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6fdb6ca0-9e3f-47bd-918c-59d3a6b0bba6" contextRef="C_58ad6f5b-2983-4459-8fd3-3b4fbdef1c36" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">11,399,763</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_67e02c4f-0ded-4fdc-aaa9-a5222aedd925" contextRef="C_4469bcba-dbf3-41b7-810d-1333a6644626" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">9,839,680</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_747950cd-7bed-419e-9271-9cf4712aa3ca" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="pcvx:WarrantsDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">9. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Warrants</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In connection with our IPO in June 2020, our outstanding warrants were automatically net exercised for an aggregate </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_893cf8c9-f48b-4697-84ed-b5294be04a6a" contextRef="C_89e8a4b5-4ab0-4668-889d-5ae7704f7e30" name="pcvx:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRightExercised" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">46,869</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock.</span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7c007e56-5ff4-4ad6-83a3-dd7c8965bd03" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">10. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Equity Incentive Plans</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020 and 2014 Equity Incentive Plans</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In June 2020, our board of directors adopted, and our stockholders approved, the 2020 Plan, which became effective on June 11, 2020. Under the 2020 Plan, we may grant stock options, appreciation rights, restricted stock and restricted stock units to employees, consultants and directors. Stock options granted under the 2020 Plan may be either incentive stock options or nonqualified stock options. Incentive stock options may be granted only to our employees, including officers and directors who are also employees. Nonqualified stock options may be granted to our employees, officers, directors, consultants and advisors. The exercise price of stock options granted under the 2020 Plan must be at least equal to the fair market value of the common stock on the date of grant, except that an incentive stock option granted to an employee who owns more than </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_eee65416-6dd2-4f4b-a427-a31f04bd66b0" contextRef="C_e95a1cc5-e02c-42d9-9f9c-6159842d1e7c" name="pcvx:IncentiveStockOptionGrantedToEmployeesOwningPercentageOfSharesOfCommonStock" unitRef="U_pure" scale="-2" decimals="2">10</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the shares of our common stock shall have an exercise price of no less than </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fb4ac856-40e2-446e-824b-abd70d5104fa" contextRef="C_23381eb2-52cb-4648-a7ab-24309842b90d" name="pcvx:PercentageOfFairValuePerShareOnTheGrantDate" unitRef="U_pure" scale="-2" decimals="2">110</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the fair value per share on the grant date and expire </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_839cf338-5185-4ed1-81ec-44d9d1c034ad" contextRef="C_e25af62d-d63b-4e1b-8b46-d08c4c227921" name="pcvx:ExercisePriceExpireInYearsFormTheDateOfGrant" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">five years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> from the date of grant. The maximum term of stock options granted under the 2020 Plan is </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0b704b6a-dd15-441b-be16-e91c97bb0865" contextRef="C_e25af62d-d63b-4e1b-8b46-d08c4c227921" name="pcvx:StockOptionsGrantedTerm" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> years, unless subject to the provisions regarding </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6ad7ee30-b4b7-4488-89f9-46d319990ad8" contextRef="C_e25af62d-d63b-4e1b-8b46-d08c4c227921" name="pcvx:PercentageOfProvisionsSubjectToStockholders" unitRef="U_pure" scale="-2" decimals="2">10</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% stockholders. Our stock options granted to new employees generally vest over </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_54d585f0-b474-4f1e-b6c3-802bd373edad" contextRef="C_88288d89-14d9-4c81-bcdc-77db4748e94f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">four years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> at a rate of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_89b5929e-20f4-4d22-9cc1-6474de98631e" contextRef="C_88288d89-14d9-4c81-bcdc-77db4748e94f" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" unitRef="U_pure" scale="-2" decimals="2">25</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% upon the first anniversary of the vesting commencement date and monthly thereafter. Our other stock options granted to employees generally vest monthly over </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7da23cee-0ea0-4990-b229-0d798c775eaf" contextRef="C_88288d89-14d9-4c81-bcdc-77db4748e94f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">four years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> from the vesting commencement date. A total of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7f3f95a6-aa37-4608-95d4-ffeb72fb8a6e" contextRef="C_a38e3261-0264-423e-b43f-742897fb5b71" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">10,150,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock were approved to be initially reserved for issuance under the 2020 Plan. The number of shares that remained available for issuance under the 2014 Plan as of the effective date of the 2020 Plan, and shares subject to outstanding awards under the 2014 Plan as of the effective date of the 2020 Plan that are subsequently canceled, forfeited or repurchased by us, will be added to the shares reserved under the 2020 Plan. In addition, the number of shares of common stock available for issuance under the 2020 Plan is automatically increased on the first day of each calendar year during the </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2bd042df-217a-4d9e-be01-289b5fe9c564" contextRef="C_e25af62d-d63b-4e1b-8b46-d08c4c227921" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10-year</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> term of the 2020 Plan, beginning with January 1, 2021 and ending with January 1, 2030, by an amount equal to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f555a845-d0ff-4652-96fc-e62309c8fead" contextRef="C_e25af62d-d63b-4e1b-8b46-d08c4c227921" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" unitRef="U_pure" scale="-2" decimals="INF">5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the outstanding number of shares of our common stock on December 31 of the preceding calendar year or such lesser amount as determined by our board of directors. As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021, an aggregate of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_565bc5db-f11c-4988-856e-c50c9dd0df3b" contextRef="C_977bf646-5642-4ace-80e5-1617547b66ea" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">6,104,756</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock were available for issuance under the 2020 Plan. Effective January 1, 2022, the number of shares of common stock available under the 2020 Plan increased by </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0cac84ce-39ff-4010-9a82-b8f032c04ba8" contextRef="C_40beaa16-40f7-4f29-9069-2b64528824d9" name="pcvx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreaseInAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,651,598</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares pursuant to the evergreen provision of the 2020 Plan.</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">141</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our 2014 Plan permitted the granting of incentive stock options, non-statutory stock options, restricted stock and other stock-based awards. Subsequent to the adoption of the 2020 Plan, no additional equity awards can be made under the 2014 Plan. Shares reserved and remaining available for issuance under the 2014 Plan were added to the 2020 Plan reserve upon its effectiveness.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The terms of the 2014 Plan permit the exercise of options granted prior to vesting, subject to required approvals. The unvested shares are subject to our lapsing repurchase right upon termination of employment at the original purchase price. Shares purchased by employees pursuant to the early exercise of stock options are not deemed, for accounting purposes, to be issued until those shares vest according to their respective vesting schedules. Cash received for early exercised stock options is recorded as other liabilities on the balance sheet and is reclassified to common stock and additional paid-in capital as such shares vest.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c696bc1e-ee31-4428-83e9-f9163d63d926" contextRef="C_3e0e573b-cca9-436f-b585-f3bd61467bce" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,657,394</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9b608ec2-046c-4f31-ba67-1eff4bc01fe5" contextRef="C_977bf646-5642-4ace-80e5-1617547b66ea" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,637,613</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock were subject to outstanding options under the 2014 Plan and 2020 Plan, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">At December 31, 2021 and 2020, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2872a19c-3b77-4d7a-923f-b16b653a88c4" contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350" name="pcvx:EarlyExercisedStockOptions" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">7,410</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_cd323585-16d2-4c53-96ec-0b0a850e073b" contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57" name="pcvx:EarlyExercisedStockOptions" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">15,056</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares, respectively, remained subject to our right of repurchase as a result of the early exercised stock options. The remaining liabilities related to early exercised shares as of December 31, 2021 and 2020 were both less than $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_38dd75c2-430b-4a71-a7e3-8b4ffb96d17c" contextRef="C_e702b57a-b360-45bc-a12c-2341ca21e0de" name="pcvx:RemainingLiabilitiesRelatedToEarlyExercisedShares" unitRef="U_USD" scale="6" decimals="-5"><ix:nonFraction id="F_71984bcd-60e9-47c0-8a37-a14493034932" contextRef="C_afadb6ee-d738-47a2-9b09-0905934ee597" name="pcvx:RemainingLiabilitiesRelatedToEarlyExercisedShares" unitRef="U_USD" scale="6" decimals="-5">0.1</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and were recorded in other liabilities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_784d8107-4687-4f78-819c-e45d67fd5305" contextRef="C_01ab22d2-811b-4087-b1ae-4007067b9a23" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" escape="true"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Activity under our 2020 Plan and 2014 Plan, which excludes options to purchase </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1fcf3eac-a125-4ba7-9b95-b9392f143125" contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">62,382</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares granted outside of the 2020 Plan and 2014 Plan, was as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:43.015%;"></td>
        <td style="width:0.963%;"></td>
        <td style="width:0.707%;"></td>
        <td style="width:8.522%;"></td>
        <td style="width:0.91%;"></td>
        <td style="width:0.963%;"></td>
        <td style="width:0.685%;"></td>
        <td style="width:8.575%;"></td>
        <td style="width:0.91%;"></td>
        <td style="width:0.963%;"></td>
        <td style="width:1.381%;"></td>
        <td style="width:7.976%;"></td>
        <td style="width:0.685%;"></td>
        <td style="width:0.963%;"></td>
        <td style="width:0.846%;"></td>
        <td style="width:10.213%;"></td>
        <td style="width:0.685%;"></td>
        <td style="width:0.963%;"></td>
        <td style="width:1.381%;"></td>
        <td style="width:8.008%;"></td>
        <td style="width:0.685%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Options Outstanding</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Stock Option Activity</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Options<br />Available<br />for <br />Grant</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Number<br />of<br />Options</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Weighted-<br />Average<br />Exercise<br />Price Per<br />Share</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Weighted-<br />Average<br />Remaining<br />Contractual <br />Term<br />(Years)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Aggregate<br />Intrinsic<br />Value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Balances &#x2014; December 31, 2019</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d05b5c6c-e3ed-431f-961a-bbb1660ef8ca" contextRef="C_00eaf7db-5639-43a7-9d93-1b5cbcde71cf" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">835,941</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_44021f4d-9108-42e3-9987-cbc560483c2b" contextRef="C_00eaf7db-5639-43a7-9d93-1b5cbcde71cf" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,297,586</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c9f92833-55dd-4353-8ccb-00b4dbb46115" contextRef="C_00eaf7db-5639-43a7-9d93-1b5cbcde71cf" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">1.93</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Additional shares authorized</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_990bdab6-9319-4b92-b1f3-3a580804eccb" contextRef="C_fd7551c1-f7f9-4cde-a040-39d423a71993" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">5,997,435</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Options granted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_90c51d6c-8f35-4a34-b8cb-4732b498231d" contextRef="C_fd7551c1-f7f9-4cde-a040-39d423a71993" name="pcvx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantedInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,255,690</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bda00a60-73cf-4414-8787-7108f6dc15f4" contextRef="C_fd7551c1-f7f9-4cde-a040-39d423a71993" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,255,690</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b6a72018-9097-4581-a5c2-ba191742384d" contextRef="C_fd7551c1-f7f9-4cde-a040-39d423a71993" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">8.93</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Options exercised</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b12763e0-b811-4a2f-a9a1-552e3a7c1a98" contextRef="C_fd7551c1-f7f9-4cde-a040-39d423a71993" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">358,264</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1e00b13d-5ce3-41c6-81b9-89883434fc4c" contextRef="C_fd7551c1-f7f9-4cde-a040-39d423a71993" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">1.88</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Options forfeited</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_162e5147-4a78-4cca-9125-b375cd163f10" contextRef="C_fd7551c1-f7f9-4cde-a040-39d423a71993" name="pcvx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeitedInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">73,463</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_187fd4e9-2a9f-4511-b36f-409a0a0085d5" contextRef="C_fd7551c1-f7f9-4cde-a040-39d423a71993" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">73,463</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4f8f6f79-33e5-4bbc-8010-a4acb97cb919" contextRef="C_fd7551c1-f7f9-4cde-a040-39d423a71993" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">3.50</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Balances &#x2014; December 31, 2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9e4c5af5-27af-4a7c-82c8-942b63fc00b5" contextRef="C_4469bcba-dbf3-41b7-810d-1333a6644626" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">4,651,149</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5cbfb251-a2ec-428b-9517-f8b7b7585b9b" contextRef="C_4469bcba-dbf3-41b7-810d-1333a6644626" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">5,121,549</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3a2dde2c-6eaa-417e-a42d-1ef62ad5918d" contextRef="C_4469bcba-dbf3-41b7-810d-1333a6644626" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">4.99</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Additional shares authorized</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e71dfda3-c279-4e1e-a6ec-14178d63e07e" contextRef="C_01ab22d2-811b-4087-b1ae-4007067b9a23" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,553,579</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Options granted</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9d1ea714-982c-4b07-9a4e-717b4de0f75f" contextRef="C_01ab22d2-811b-4087-b1ae-4007067b9a23" name="pcvx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantedInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,616,021</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c6e94187-101e-4c51-81ad-dc0a1bfc710f" contextRef="C_01ab22d2-811b-4087-b1ae-4007067b9a23" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,616,021</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d101696e-6798-434e-84f0-32642906d45a" contextRef="C_01ab22d2-811b-4087-b1ae-4007067b9a23" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">21.83</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Options exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c693c9a5-0b1a-42f7-aee0-399c40d0de7d" contextRef="C_01ab22d2-811b-4087-b1ae-4007067b9a23" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">926,514</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a6e413cb-47b8-4bd4-b8da-c94df7112281" contextRef="C_01ab22d2-811b-4087-b1ae-4007067b9a23" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">3.25</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Options forfeited</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fd75c047-86ca-41a8-9547-20f2c6384d5c" contextRef="C_01ab22d2-811b-4087-b1ae-4007067b9a23" name="pcvx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeitedInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">516,049</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3ff2d980-68ca-49bd-aaf4-1480e5916b08" contextRef="C_01ab22d2-811b-4087-b1ae-4007067b9a23" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">516,049</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_99219f9f-b29e-4246-9dce-b0be82693d81" contextRef="C_01ab22d2-811b-4087-b1ae-4007067b9a23" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">16.70</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Balances &#x2014; December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a4ce24bd-35b0-48cb-b869-9a8627d7a0a9" contextRef="C_58ad6f5b-2983-4459-8fd3-3b4fbdef1c36" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">6,104,756</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d818b004-b9cb-4cab-80c8-d402f3fab4ea" contextRef="C_58ad6f5b-2983-4459-8fd3-3b4fbdef1c36" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">5,295,007</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_707995aa-08ce-4b0c-8ce5-bc5e823080ee" contextRef="C_58ad6f5b-2983-4459-8fd3-3b4fbdef1c36" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">9.30</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6d206f60-c7f4-4ecd-a259-ff10812c55b3" contextRef="C_01ab22d2-811b-4087-b1ae-4007067b9a23" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">7.89</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ab3cb2fc-7a05-49cc-9cc9-fb24eaf2be97" contextRef="C_58ad6f5b-2983-4459-8fd3-3b4fbdef1c36" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">78,604</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Vested and expected to vest &#x2014; December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_26b2fc59-b43f-4912-8656-08ce564b1d1b" contextRef="C_58ad6f5b-2983-4459-8fd3-3b4fbdef1c36" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">5,295,007</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_addf8c13-3d8b-4aa2-9d88-9d5f362b4ca2" contextRef="C_58ad6f5b-2983-4459-8fd3-3b4fbdef1c36" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">9.30</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b128315d-e8bb-4ae8-9338-a5fe2cdab7de" contextRef="C_01ab22d2-811b-4087-b1ae-4007067b9a23" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">7.89</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6a40e02d-b493-4879-8848-55d574a1b090" contextRef="C_58ad6f5b-2983-4459-8fd3-3b4fbdef1c36" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">78,604</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Exercisable at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b573c617-89d4-4b1e-a81f-d87d4880ac51" contextRef="C_58ad6f5b-2983-4459-8fd3-3b4fbdef1c36" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,611,523</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3e05b039-bb94-4fd2-9ea2-cae486ae0c7e" contextRef="C_58ad6f5b-2983-4459-8fd3-3b4fbdef1c36" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">4.76</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_61fbd386-9b6a-4e15-9a5f-ff424fc2b6a6" contextRef="C_01ab22d2-811b-4087-b1ae-4007067b9a23" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">7.07</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b20c43da-f5b1-41cb-ae07-d2b9313c5582" contextRef="C_58ad6f5b-2983-4459-8fd3-3b4fbdef1c36" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">50,123</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During the years ended December 31, 2021 and 2020, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_99dd6898-ae16-4042-9aea-9348c9ab7562" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="pcvx:NumberOfOptionsExercisedExcludesOptionsExercisedFromNpln" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">926,514</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0c3f46de-9fa3-4aa4-a3f7-49af52d9bcf0" contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001" name="pcvx:NumberOfOptionsExercisedExcludesOptionsExercisedFromNpln" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">358,264</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of stock options, respectively, were exercised for cash at a weighted-average price per share of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c0e580f4-1463-4c5a-9f85-a8affd1b53c0" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">3.25</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_97ae7bcf-02b3-4ddb-a9d8-256ec3b82ec6" contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">1.88</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, respectively. The weighted-average grant date fair value of options granted for the years ended December 31, 2021 and 2020 was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ccaedb14-5b69-4d3f-9d6d-6715252a5b46" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">14.65</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ca7d0811-8a34-4b10-b771-9d7bc21c4d7b" contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">9.62</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, respectively. The intrinsic value of the stock options exercised was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_586aad49-062f-4e90-8184-dd8575fa31ca" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">18.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8ef6134d-f1c5-4c19-9524-aa16a09b1b47" contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5">7.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for the years ended December 31, 2021 and 2020, respectively.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">142</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020 Employee Stock Purchase Plan</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In June 2020, our board of directors adopted, and our stockholders approved, the 2020 Employee Stock Purchase Plan (the &#x201c;2020 ESPP&#x201d;), which became effective on June 11, 2020. The 2020 ESPP permits participants to purchase common stock through payroll deductions of up to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d123efd0-e959-456f-b277-01af114c6402" contextRef="C_1efdf0c7-6a07-4132-8782-b57177c53f15" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" unitRef="U_pure" scale="-2" decimals="INF">15</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of their eligible compensation. Employees purchase shares of common stock at a price per share equal to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bcdc2fc6-0bf6-4ae1-bbd7-b29abe8cc865" contextRef="C_c8d7f783-8f05-4c35-8444-31988eb17d2e" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" unitRef="U_pure" scale="-2" decimals="2">85</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the lower of the fair market value at the start or end of the </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fc33b9e4-fc8c-4a64-8f38-09f7971ecf3c" contextRef="C_c8d7f783-8f05-4c35-8444-31988eb17d2e" name="pcvx:PurchasePeriod" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">six-month</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> purchase periods within the </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d8986d6b-383a-4cf4-9c36-958dd1ff0ad4" contextRef="C_c8d7f783-8f05-4c35-8444-31988eb17d2e" name="pcvx:OfferingPeriod" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">two-year</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> offering period. A total of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3c497adb-3fa1-4cbf-ac0f-c73f260e4cd0" contextRef="C_1efdf0c7-6a07-4132-8782-b57177c53f15" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">650,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock were approved to be initially reserved for issuance under the 2020 ESPP. In addition, the number of shares of common stock available for issuance under the 2020 ESPP is automatically increased on the first day of each calendar year during the </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8f312546-0c9d-4e62-8884-795fe73ba102" contextRef="C_c8d7f783-8f05-4c35-8444-31988eb17d2e" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10-year</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> term of the 2020 Plan, beginning with January 1, 2021 and ending with January 1, 2030, by an amount of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_11e7dd66-4249-48a9-a153-8b580db36cc0" contextRef="C_c8d7f783-8f05-4c35-8444-31988eb17d2e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" unitRef="U_pure" scale="-2" decimals="INF">1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the outstanding number of shares of our common stock on December 31 of the preceding calendar year or such lesser amount as determined by our board of directors. For the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, employees acquired </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c2a536e7-2c72-43e0-9e6c-5a196addcaac" contextRef="C_b2d931e6-c3f8-485c-8729-b21db15df907" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">62,546</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of our common stock under the 2020 ESPP and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f64278e5-9ed2-4e9f-b905-577f97bf9ea8" contextRef="C_83b9a259-045e-40be-a3dc-3d06c253dc05" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,070,704</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock remained available for issuance under the 2020 ESPP. Effective January 1, 2022, the number of shares of common stock available under the 2020 ESPP increased by </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c9c76b9c-28f3-4fe3-af9b-07fe35b7e2d0" contextRef="C_3d43ebd8-c6c9-4618-9f17-19b5fc65cecf" name="pcvx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreaseInAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">530,319</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares pursuant to the evergreen provision of the 2020 ESPP.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Stock-based Compensation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_060a8860-f7fe-4286-a0e2-c5286ece664b" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" escape="true"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We estimated the fair value of employee stock options using the Black-Scholes option-pricing model for the years ended December 31, 2021, 2020 and 2019 using the following weighted-average assumptions:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.31%;"></td>
        <td style="width:1.36%;"></td>
        <td style="width:15.203%;"></td>
        <td style="width:1.36%;"></td>
        <td style="width:15.203%;"></td>
        <td style="width:1.36%;"></td>
        <td style="width:15.203%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="5" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2019</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Fair Value Assumptions</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected volatility</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2a21d106-0c7c-4c6b-98c6-7a5fc4de33c1" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">81.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% - </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_80bc04b3-ec13-4b84-bf0d-d9b74db138dc" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">84.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ccd232b7-96a9-45f4-8568-77231343c456" contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">81.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% - </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_839dfb7f-8ac5-41ff-ad53-9ca339635549" contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">94.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4a6528ed-8875-4916-ad16-10242adeb410" contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">78.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% - </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1b17f657-f870-4ec7-860b-e52e64bc9b77" contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">80.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected dividend yield</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a2d0582e-e680-4a31-81f8-f50e69de0a35" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9f44e5af-a21d-4411-8d20-88af65a6f308" contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_43426f78-dc4f-4daa-a86f-9e815b0ee127" contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected term (in years)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_14f0837b-63d7-440a-9550-5154bea12c03" contextRef="C_a9e696e6-57cc-4729-8788-4c5e9e4ec861" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.3 </span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">- </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_83311f14-6b69-4f3f-b71a-8220038d9333" contextRef="C_68377845-3bf8-42a9-ba72-9a3b693b78a1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.5</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ae281aad-e6c5-4780-8f35-0b1dcb62171a" contextRef="C_04acb199-245c-4c72-a959-3ad34a1f3b9f" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.6</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;- </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2de4b24e-ada1-49c6-895d-5d5b5afde68c" contextRef="C_d1c4c865-1394-49a2-907a-e54a6cd8c170" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.1</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_03a72ea3-f121-4a6a-8336-bb1d3db9a14b" contextRef="C_ca7ed438-6716-4360-8ccd-eaaa38f9fcf2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.9</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;- </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a4d81b6f-55e7-4e47-8b2e-f6342a57ee8e" contextRef="C_c4319f5e-0947-41f2-9bc7-187004e5a87b" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.1</span></ix:nonNumeric></span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e32c8fb7-8790-41f0-9fd7-25e431d2c5bd" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">0.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% - </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_384282de-e9e8-4824-84f7-bee7530d7bd4" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">1.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_aeb5f4a4-09f2-4474-865e-5da86c102db0" contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">0.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% - </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_32a96c0d-e432-4078-b6d3-57502dce95a8" contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">1.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_28801f32-66e0-4d60-9f35-d5ebf0856d8c" contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">1.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% - </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d2d619fb-7414-4287-a989-18cc979b3c20" contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">2.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_79a2966e-6b64-47da-863f-7f8d425891fb" contextRef="C_b2d931e6-c3f8-485c-8729-b21db15df907" name="us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" escape="true"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We estimated the fair value of shares under the 2020 ESPP using the Black-Scholes option-pricing model for the years ended December 31, 2021, 2020 and 2019 using the following weighted-average assumptions:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:48.1%;"></td>
        <td style="width:1.381%;"></td>
        <td style="width:15.384%;"></td>
        <td style="width:1.381%;"></td>
        <td style="width:16.99%;"></td>
        <td style="width:1.381%;"></td>
        <td style="width:15.384%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="5" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2019</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Fair Value Assumptions</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected volatility</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1cef25ad-9d83-417d-87d4-35f96f084f3f" contextRef="C_b2d931e6-c3f8-485c-8729-b21db15df907" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">79.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% - </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7a8e8e99-6def-49a5-a862-5869187a723b" contextRef="C_b2d931e6-c3f8-485c-8729-b21db15df907" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">126.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_93ef16be-f09a-4701-9a48-63df2a1f8a49" contextRef="C_6bfa48d9-3084-49f0-aff3-43a54ae90a96" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">105.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% - </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_34e8b3bc-0ebb-454e-98f8-470e1ae28704" contextRef="C_6bfa48d9-3084-49f0-aff3-43a54ae90a96" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">158.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">N/A</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected dividend yield</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_577c61e9-9507-4ab3-ad13-c2c804be9c7f" contextRef="C_b2d931e6-c3f8-485c-8729-b21db15df907" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f98b5ecc-617a-4e2d-a8e8-a64d059066e6" contextRef="C_6bfa48d9-3084-49f0-aff3-43a54ae90a96" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">N/A</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected term (in years)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a38249a1-903e-497b-a2f1-7864c67739e8" contextRef="C_70588bd5-1fdc-44ee-a7cf-7d459c6fc883" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.5 </span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">- </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5b571815-6307-4ab7-a618-df764b52c234" contextRef="C_bebcd826-aabe-4884-ab32-26215b024f1a" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.0</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2c10bd3a-500c-47e9-8ff2-987741dd4834" contextRef="C_f2e3d587-c577-46eb-a487-767a66753618" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.4</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;- </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_05f695d7-7a63-4c7c-9582-ed8ed93afc09" contextRef="C_04918cd3-bad5-49f6-b891-9bebcd71baa0" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.0</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">N/A</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_808dbf57-6164-4b95-8747-8c84f6930b04" contextRef="C_b2d931e6-c3f8-485c-8729-b21db15df907" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">0.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% - </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_549ef6b4-b39f-4422-9992-2481e5e9a3e6" contextRef="C_b2d931e6-c3f8-485c-8729-b21db15df907" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">0.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f987fe71-75f1-4ef5-8ba8-4e44e6247a0a" contextRef="C_6bfa48d9-3084-49f0-aff3-43a54ae90a96" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">0.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% - </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_470eef70-7337-4754-9e14-0c27f483ad63" contextRef="C_6bfa48d9-3084-49f0-aff3-43a54ae90a96" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">0.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">N/A</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_dc3259ef-af3a-4e6c-af73-e8f193e0b24e" contextRef="C_e8c80ef0-b66f-48cb-8236-662fca240430" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" escape="true"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We recorded total stock-based compensation expense for the years ended December 31, 2021, 2020 and 2019 related to the 2014 Plan, the 2020 Plan and the 2020 ESPP in the statements of operations and allocated the amounts as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.717%;"></td>
        <td style="width:1.349%;"></td>
        <td style="width:1.381%;"></td>
        <td style="width:12.781%;"></td>
        <td style="width:0.91%;"></td>
        <td style="width:1.349%;"></td>
        <td style="width:1.381%;"></td>
        <td style="width:12.77%;"></td>
        <td style="width:0.91%;"></td>
        <td style="width:1.349%;"></td>
        <td style="width:1.381%;"></td>
        <td style="width:12.792%;"></td>
        <td style="width:0.931%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2019</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(In thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_02e6a6c7-3847-4e4b-bf5b-27102633274d" contextRef="C_3562faed-85c8-4ea5-a88d-038f23029b7d" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,954</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_85a07fe2-88c4-4db0-874f-9795016d3cbb" contextRef="C_bfcc9c06-d2c1-452e-8ef8-cffaed58bf95" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,861</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f9d2b3c1-1dda-4d41-824e-79755d150816" contextRef="C_34fb7648-e015-48b0-95af-d232d9d8d189" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3">368</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">General and administrative</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_61248c9f-2e7e-4245-a947-97dac45e0e21" contextRef="C_14ff4d59-3fca-47b7-aa38-4bd882e8ae38" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,775</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a5226ade-7817-413b-8278-aa78617f3e4f" contextRef="C_5a9d30f7-2f17-4c61-b4cc-72ab32702c3f" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,573</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c61bff5e-b5fd-4817-8ec9-029be3de4085" contextRef="C_d5f3d746-38cf-4e03-93db-68b59ff6ca6e" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3">817</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b0fcea3e-515d-44b9-bf4f-946a9faf3395" contextRef="C_e8c80ef0-b66f-48cb-8236-662fca240430" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,729</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_95ce736e-3da6-4d4d-b71d-7fcbf1be978e" contextRef="C_12a75901-fd10-4da6-bb07-c58c55e98510" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,434</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_72b7b47c-9225-43d7-bdd8-240e2f5d36c8" contextRef="C_9001db26-8d96-496f-9fd0-ccbff0d80378" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,185</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">143</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Upon our IPO, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_126dce16-5ccd-4c96-8c06-de81dcd18508" contextRef="C_61d1fa2e-cb6c-418c-bc91-f7bc598be5a9" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">362,935</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> performance-based awards vested and, as a result, we recognized $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6b368e47-f09b-4423-8f7d-32c3a5d9a1bf" contextRef="C_17e8d504-7444-46d1-a94b-f46e5cb44fae" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="6" decimals="-5">0.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of stock-based compensation expense during the three months ended June 30, 2020, which amount is included in the above table for the year ended December 31, 2020.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, there was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0745c1ff-3aab-489a-bd2e-f2897d8096fd" contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">27.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of unrecognized stock-based compensation expense related to the employee and non-employee awards, which is expected to be recognized over a weighted-average period of </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_de5c90f3-c3c4-4807-8d51-fa7725079f8b" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.5 </span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">years.</span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_921b9fb7-5e3e-49f7-a0d8-f0ed52cd45d3" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="pcvx:FundingArrangementTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">11. Funding Arrangement</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In July 2019, we received a cost-reimbursement research award from Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (&#x201c;CARB-X&#x201d;), a public-private partnership funded under a Cooperative Agreement from Assistant Secretary for Preparedness and Response/Biomedical Advanced Research and Development Authority (&#x201c;BARDA&#x201d;) and by awards from Wellcome Trust, Germany&#x2019;s Federal Ministry of Education and Research, the United Kingdom Global Antimicrobial Resistance Innovation Fund and the Bill &amp; Melinda Gates Foundation. In connection with this funding, we entered into a cost-reimbursement sub-award agreement with the Trustees of Boston University, the administrator of the program. The initial award provided the potential for funding up to </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fb8e1947-f07b-4a42-bc35-1c0fc0abaa51" contextRef="C_017473b9-4a6d-4b35-bafe-2f3035074c39" name="pcvx:FundingPeriodOfAwardToDevelopUniversalVaccineToPreventInfections" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">four years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> to develop a universal vaccine to prevent infections caused by Group A Strep bacteria, which include pharyngitis, impetigo and necrotizing fasciitis. The initial award committed initial funding of up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_20115ae5-de98-4fb3-b696-51c9d3323bc7" contextRef="C_e7331c69-2305-4247-a515-eb0da32be4fd" name="pcvx:InitialFundingCommittedByAward" unitRef="U_USD" scale="6" decimals="INF">1.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for our VAX-A1 program and, subject to a CARB-X decision to extend the options, up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c8117820-e3ef-428b-a5f0-aef42ba71c42" contextRef="C_e7331c69-2305-4247-a515-eb0da32be4fd" name="pcvx:FundingCommittedByAwardAvailableUponAchievementOfDevelopmentMilestones" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">15.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in total funding available upon achievement of development milestones over the next </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6e3c677f-98de-4dae-b2d1-2f0944d0db6a" contextRef="C_017473b9-4a6d-4b35-bafe-2f3035074c39" name="pcvx:FundingPeriodOfAwardToDevelopUniversalVaccineToPreventInfections" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">four years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Specified research expenditures are reimbursable expenses associated with agreed-upon activities needed to advance the research project supported by the grant. These expenditures can include labor, laboratory supplies, travel, consulting and third-party vendor research and development support costs.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In July 2020, the CARB-X agreement was amended with the initial funding amount increased from $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f39a1954-9e17-48fc-88f2-74aac269d924" contextRef="C_6da3f8ad-d2ec-440b-a451-9dbaebaea6e0" name="pcvx:InitialFundingCommittedByAward" unitRef="U_USD" scale="6" decimals="INF">1.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d2593e50-5a5b-457a-b304-20c496138269" contextRef="C_af5ccde9-e011-49f2-9896-792a8871b96a" name="pcvx:InitialFundingCommittedByAward" unitRef="U_USD" scale="6" decimals="INF">2.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. In December 2020, we reached the maximum CARB-X funding limit for this initial funding period, and subsequently submitted our funding proposal to CARB-X for the next period under our agreement. In April 2021, we received approval for the next phase of CARB-X development and executed the cost-reimbursement sub-award agreement with the Trustees of Boston University in August 2021. Pursuant to the agreement, the award committed additional funding of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_156b1851-faf5-4804-bacb-f1c2e0a8b427" contextRef="C_fd58b7dd-25a0-4a70-92a2-457d12426c58" name="pcvx:AdditionalFundingCommittedByAward" unitRef="U_USD" scale="6" decimals="-5">3.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for IND-enabling activities and total potential funding of up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1464ab4c-efbc-4afd-999c-2878edb0e41c" contextRef="C_a1d232a3-c6a3-4bd1-9776-35c32d836d64" name="pcvx:PotentialFundingCommittedByAward" unitRef="U_USD" scale="6" decimals="-5">29.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million (including the current $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2c291ae1-b9d2-4781-b7b1-97f831a6ca3c" contextRef="C_a1d232a3-c6a3-4bd1-9776-35c32d836d64" name="pcvx:AdditionalFundingCommittedByAward" unitRef="U_USD" scale="6" decimals="-5">3.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million award and the prior $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_917df391-8544-4b1f-a9dd-73fb30be62bb" contextRef="C_af5ccde9-e011-49f2-9896-792a8871b96a" name="pcvx:InitialFundingCommittedByAward" unitRef="U_USD" scale="6" decimals="-5">2.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million award) upon the achievement of future VAX-A1 development milestones. In January 2022, CARB-X revised the parameters for the contribution of CARB-X funding and implemented maximum funding levels for all grant recipients. As a result, our total funding available upon achievement of development milestones through Phase 1 human clinical trials was revised from $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_48c08940-318e-41b8-82c0-03cb8a3e3719" contextRef="C_a1d232a3-c6a3-4bd1-9776-35c32d836d64" name="pcvx:PotentialFundingCommittedByAward" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">29.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fdf869b7-8fc0-4afa-b6bc-b80b27a52044" contextRef="C_92f1ced7-c143-458c-9b8e-7abfc0c425d9" name="pcvx:PotentialFundingCommittedByAward" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">13.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">      </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In April 2021, we received a cost-reimbursement research award from the National Institutes of Health (&#x201c;NIH&#x201d;). In connection with this funding, we entered into a cost-reimbursement sub-award agreement with the University of Maryland, Baltimore, the administrator of the program. The award provides for potential funding up to </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8965ed5d-d188-49c8-b88e-d527d2b20855" contextRef="C_0830660e-391f-4e25-8658-4f38f275d086" name="pcvx:PotentialFundingPeriodOfAwardToDevelopVaccineToPreventInfections" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">five years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> totaling approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c845f66c-0c3b-47f7-a969-fc0b65240c73" contextRef="C_c44b9b74-3efa-4a2d-b6b0-c053a39e9f18" name="pcvx:PotentialFundingAmountOfAwardToDevelopVaccineToPreventInfections" unitRef="U_USD" scale="6" decimals="-5">0.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million to develop a vaccine to prevent infections caused by Shigella.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Income from grants is recognized in the period during which the related specified expenses are incurred, provided that the conditions under which the grants were provided have been met. We recognized $</span><span style="font-size:10.0pt;font-family:Times New Roman;white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1ecd9785-2ee2-4f2f-887b-08edf74310bb" contextRef="C_7ac26ea9-aa26-46d1-b9ed-042601b4004d" name="pcvx:GrantIncome" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_cf17e347-3476-4974-9280-ae62f3614145" contextRef="C_c2d425b8-8bfe-4616-b9aa-1a6041c6bb18" name="pcvx:GrantIncome" unitRef="U_USD" scale="6" decimals="-5">2.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_745bb124-1bf4-407f-ab28-8c56965dd16f" contextRef="C_32b0b6ee-9dc1-4ce6-9ecd-470c2a71985a" name="pcvx:GrantIncome" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of grant income and recorded the amounts in Other income (expense), net in the statement of operations during the years ended December 31, 2021, 2020, and 2019 respectively. A grant receivable of $</span><span style="font-size:10.0pt;font-family:Times New Roman;white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bb20548c-573b-42c1-9df6-bfe16bad8079" contextRef="C_ed58902d-2f75-4902-a5af-e641599b12d5" name="us-gaap:GrantsReceivable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_84c6164b-f998-40c2-a911-e673fb2ddd5c" contextRef="C_039297c3-6466-43f6-840d-9c5a04a312b3" name="us-gaap:GrantsReceivable" unitRef="U_USD" scale="6" decimals="-5">0.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million representing unreimbursed, eligible costs incurred under the CARB-X agreement was recorded and included in Prepaid expenses and other current assets in the balance sheet as of December 31, 2021 and 2020, respectively.</span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">144</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_436f57af-b31e-4845-95b3-2b7be26be64a" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="us-gaap:EarningsPerShareTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">12. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Net Loss Per Share</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_61a2170d-ea99-48bc-b55d-8a5db69e555a" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" escape="true"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table sets forth the computation of basic and diluted net loss per share and excludes shares which are legally outstanding, but subject to repurchase by us:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.198%;"></td>
        <td style="width:1.231%;"></td>
        <td style="width:1.381%;"></td>
        <td style="width:10.692%;"></td>
        <td style="width:0.92%;"></td>
        <td style="width:1.231%;"></td>
        <td style="width:1.381%;"></td>
        <td style="width:10.714%;"></td>
        <td style="width:0.942%;"></td>
        <td style="width:1.252%;"></td>
        <td style="width:1.381%;"></td>
        <td style="width:10.735%;"></td>
        <td style="width:0.942%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2019</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net loss (in thousands)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a9e1e490-cf34-4ab0-919e-50f9251b5591" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">100,077</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9eddf30b-a9b8-4138-87a2-0a134b3c40d3" contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">89,217</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_89697f9c-ee29-42d4-88fe-fcf207396690" contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">50,274</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Weighted-average shares outstanding used in computing net<br />&#160;&#160;&#160;loss per share, basic and diluted</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_56328ed3-2069-4c96-a382-0a4159f997e3" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">51,922,108</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e31f8947-01a1-4992-bca6-ca8ea5914411" contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">29,545,810</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0d7816df-40d4-4f49-995c-419051700e17" contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">3,795,090</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net loss per share, basic and diluted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6654362f-697d-424b-bafa-eac955ca66fc" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="us-gaap:EarningsPerShareBasicAndDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-">1.93</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8063f228-59e8-4414-ae99-94562e58c3b7" contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001" name="us-gaap:EarningsPerShareBasicAndDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-">3.02</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e03cbc24-19bb-4546-abae-eb6ab695ec41" contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700" name="us-gaap:EarningsPerShareBasicAndDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-">13.25</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_67689a84-1e02-47b1-ad4d-c6b2e5e51391" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" escape="true"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following potentially dilutive securities were excluded from the computation of diluted net loss per share for the period presented because including them would have been antidilutive:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.444%;"></td>
        <td style="width:1.381%;"></td>
        <td style="width:1.006%;"></td>
        <td style="width:10.767%;"></td>
        <td style="width:1.006%;"></td>
        <td style="width:1.381%;"></td>
        <td style="width:1.006%;"></td>
        <td style="width:10.767%;"></td>
        <td style="width:1.006%;"></td>
        <td style="width:1.381%;"></td>
        <td style="width:1.006%;"></td>
        <td style="width:10.842%;"></td>
        <td style="width:1.006%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2019</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock options</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c1d038fe-929d-4898-ac5f-f868b2056469" contextRef="C_1c84ebe2-ee47-4498-9c45-6e43ebdd4a7a" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">5,357,389</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d8628df8-4530-44a0-bf2f-5eba3560da55" contextRef="C_cf8c9eeb-5415-47f7-97f3-ce1e53cabf5b" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">5,188,531</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_12eb7a50-6de0-42b6-8c1e-d84d16ff0272" contextRef="C_ccf431e6-d93a-4a5a-884d-651e8f20892e" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">3,364,568</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Redeemable convertible preferred stock:</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Series A</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7e29772a-5146-4182-aee3-820bd949649d" contextRef="C_c8071e48-943e-4850-b4a1-a2bca3238b71" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">6,225,719</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Series B</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5233fd05-28a2-426c-bfe8-bc940b2868c8" contextRef="C_a7a54056-1b96-4694-a8be-248476ad36f9" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">6,786,896</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Series C</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6568d45c-8bfb-407c-872b-9c99ede0296b" contextRef="C_c0fb1076-a7db-464d-8c21-b64e5bc453db" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">7,377,480</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Common stock warrant</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_496de7fd-55c7-4bbc-98ad-fccfbe3e9509" contextRef="C_b399954b-8b8b-4102-8291-0483e80bb7cc" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">31,857</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Redeemable convertible preferred stock warrant</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_91140240-7602-49dd-85f2-9e3ee6a5c34e" contextRef="C_77bd8890-2188-4455-95b3-5c7a4d36c588" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">59,276</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_597b7a86-3e15-4bee-ae27-740820ea32ca" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">5,357,389</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fad5aa91-b578-491b-8ac3-25dcc76cd386" contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">5,188,531</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_eaedad2f-7b94-4a39-88be-e6e920671218" contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">23,845,796</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div><ix:nonNumeric id="F_8a6ec0ac-593f-4652-b9d3-65e36127889c" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="us-gaap:IncomeTaxDisclosureTextBlock" escape="true" continuedAt="F_8a6ec0ac-593f-4652-b9d3-65e36127889c_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">13. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Income Taxes</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our pre-tax book loss was derived from our business operations within the United States.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6cee82d2-43da-47c3-b4ae-edc6f3ea4cfe" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" escape="true"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A reconciliation of our effective tax rate to the statutory U.S. federal rate is as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:55.954%;"></td>
        <td style="width:1.232%;"></td>
        <td style="width:0.685%;"></td>
        <td style="width:9.552%;"></td>
        <td style="width:3.213%;"></td>
        <td style="width:1.232%;"></td>
        <td style="width:0.685%;"></td>
        <td style="width:9.552%;"></td>
        <td style="width:3.213%;"></td>
        <td style="width:1.232%;"></td>
        <td style="width:0.685%;"></td>
        <td style="width:9.552%;"></td>
        <td style="width:3.213%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:bold;font-size:6.7pt;font-family:Times New Roman;position:relative;">(1)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2019</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:bold;font-size:6.7pt;font-family:Times New Roman;position:relative;">(1)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Statutory rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f26fbaf7-614c-4dc1-baa7-77ff9fe0c309" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">21.0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_49a96614-3d01-49a0-9b99-c49a73a9e61d" contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">21.0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7be159d7-162b-4aa2-bc16-756720e35f47" contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">21.0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock-based compensation</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9432878d-85b1-4d64-83da-02ffcd8443f7" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">2.2</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3a14c1cf-f8d3-45e2-a978-58d4d3f80e0e" contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">0.8</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ad33fb03-db19-4784-8f04-ad151628c89d" contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:numdotdecimal">0.4</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Credits</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_df471d00-bf8f-4f8c-a56f-128117dc5ea0" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">1.1</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_177be7f4-d9df-4be9-887d-cd910eab0117" contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">0.6</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b3be9417-595c-4169-9d74-33bfdc5f467d" contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:numdotdecimal">0.5</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Change in fair value of tranche liability</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_01bfef4a-09e0-435e-a05d-f4f026bd6381" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="pcvx:EffectiveIncomeTaxRateReconciliationChangeInFairValueOfTrancheLiability" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">0.0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9b5f28a1-2067-4234-aaa9-854110005c43" contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001" name="pcvx:EffectiveIncomeTaxRateReconciliationChangeInFairValueOfTrancheLiability" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">0.0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_cc2c63fe-9f64-413e-b88a-ea4e16e59c43" contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700" name="pcvx:EffectiveIncomeTaxRateReconciliationChangeInFairValueOfTrancheLiability" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">1.3</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Change in valuation allowance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_356c4b35-33ac-4e1f-9e5b-d174c21331a2" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:numdotdecimal">23.0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_74662dbe-6bba-4820-bb27-5dc2f2cc22a9" contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:numdotdecimal">22.1</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9f6710a1-d9d3-4fe2-b6ef-bfe78fb4240b" contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:numdotdecimal">21.8</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Section 162(m) limitation</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_47ee4115-d7cf-4bdb-ac0b-7beb2b5ca0db" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="pcvx:Section162MLimitation" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:numdotdecimal">1.1</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_042d310c-7a0b-4e6b-9fcb-a76480c12f1a" contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001" name="pcvx:Section162MLimitation" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ffa70a62-fef8-4aa1-ab27-93982bd1df40" contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700" name="pcvx:Section162MLimitation" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">0.0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4c59c790-f2a1-42ec-886d-0ebc62ed30a5" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:numdotdecimal">0.2</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0dab50af-8222-425f-99c5-2467c60ce49c" contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:numdotdecimal">0.2</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3858ffdc-5880-4a92-a2d7-c0f2a030af5e" contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">0.4</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_af46d819-813e-427e-87a2-4217a395634c" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="3">0.0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4dc43849-1f78-43f5-a8b2-8eca8bdccb0e" contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="3">0.0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f5df6844-e104-41d9-aafd-0b5beb9fd268" contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="3">0.0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;margin-right:66.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p><div style="margin-left:3.333%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:6.667%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.8968727694042435%;">(1)</span><div style="display:inline;"><ix:footnote id="FNT_1e764aa7-2424-4823-b8e3-44b720dd76c6" xml:lang="en-US"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The 2019 and 2020 effective tax rate reconciliations have been updated to conform to the 2021 presentation.</span></ix:footnote></div></div></ix:nonNumeric></div><p style="margin-left:10.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">145</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of the assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. </span><span style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e16704f6-7df4-4b26-9d53-82e04ddee512" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" escape="true" continuedAt="F_e16704f6-7df4-4b26-9d53-82e04ddee512_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table presents significant components of our deferred tax assets as of December 31, 2021 and 2020:</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></ix:nonNumeric></span><span style=""></span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:continuation id="F_e16704f6-7df4-4b26-9d53-82e04ddee512_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.478%;"></td>
        <td style="width:1.478%;"></td>
        <td style="width:1.37%;"></td>
        <td style="width:12.998%;"></td>
        <td style="width:0.921%;"></td>
        <td style="width:1.478%;"></td>
        <td style="width:1.37%;"></td>
        <td style="width:12.987%;"></td>
        <td style="width:0.921%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">As of December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred tax assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net operating losses</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fff40e10-2ac3-49c4-a946-e0f21e343d4c" contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">85,574</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_43ce474c-b346-4f07-962c-3a3693e3b19b" contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">52,330</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Fixed assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_221949c6-b68a-4978-a407-59f7c9ba5f60" contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,700</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7a93cab8-611b-4844-a59d-13e5b792f4ce" contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">528</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accruals &amp; reserves</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_441eeba0-6a25-4f20-a3a0-42ff1d0c73af" contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,131</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2dc5a46a-8200-443b-9b6c-7c45a652beae" contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,786</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Credits</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d2a0a623-abd7-4aed-9892-4d9190f127a9" contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,865</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3a9b1b06-855f-4516-b7ec-7cb54dd1dfd1" contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,222</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Section 59(e) capitalized expenses</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_30b88749-1faf-4730-89fa-f6c2b35d1b23" contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,984</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3f8b349e-87e5-4ba0-8dd0-8793e2d3709f" contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,381</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued manufacturing expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9611fe1d-8b98-4cdb-8f1b-fa5451a15e5b" contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350" name="pcvx:DeferredTaxAssetsTaxAccruedManufacturingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,006</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_27ca5825-5537-44c4-a647-1c3a01fcf0d8" contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57" name="pcvx:DeferredTaxAssetsTaxAccruedManufacturingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,374</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Lease liability</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e5df96cb-c7c4-4ad6-aba7-8646d24754f9" contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350" name="pcvx:LeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,674</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total deferred tax assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_54ca3d5d-9b6b-4d73-9f5a-6741ec4757dc" contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">104,934</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_be5e0aef-57bf-46a7-aa5b-5ed573a25698" contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">63,621</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Deferred tax liabilities:</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ROU asset</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_585afc5a-9fe2-4a86-9929-070c555e510a" contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,349</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total deferred tax liabilities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ee7765c5-c11a-471f-857b-6186c98da97f" contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350" name="us-gaap:DeferredIncomeTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,349</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net deferred tax asset</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_de77f025-6daf-49e9-b476-aef4e3616103" contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350" name="pcvx:DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">96,585</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9683608f-d1c3-443e-9c41-84c7c9dbb6d9" contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57" name="pcvx:DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">63,621</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Valuation allowance</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b49d39ce-6c5b-4729-8d91-ff4ec26ea6ff" contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">96,585</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_064df35d-06a7-4aae-af79-088e3ec00932" contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">63,621</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net deferred taxes</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></ix:continuation></div><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">At December 31, 2021, we have net operating loss carryforwards of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bcce4b43-9110-4f14-bc4c-ba78a4e2b3e8" contextRef="C_8f37ea4f-142c-4bc7-aa2e-4b36661b1de6" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5">296.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f850ad2b-e082-44ac-a19c-d0a884e2fff5" contextRef="C_9f6bf305-4c1d-45f5-96fe-42e373b0efcb" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5">262.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million available to reduce future taxable income, if any, for federal and state income tax purposes, respectively. The federal and state net operating loss carryforwards, except the federal loss carryforward arising in tax years beginning after December 31, 2017, begin to expire in </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e586813b-ea3b-4e50-9bfc-963fe34fcd4d" contextRef="C_88219214-e682-4a47-ba69-b37e92d74db8" name="pcvx:OperatingLossCarryForwardsExpirationYear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2034</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> unless previously utilized. Federal net operating losses arising in tax years beginning after December 31, 2017 have an indefinite carryover period and do not expire.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">At December 31, 2021, we have research credit carryforwards of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f9b075df-4c7e-4457-906f-2e9abb9be331" contextRef="C_a6bb51b5-9e65-4bc2-a156-224db74e09c4" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" unitRef="U_USD" scale="6" decimals="-5">2.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4645f814-9fa7-4da4-a42a-81fe169da8c4" contextRef="C_e5909518-4b17-423b-8df9-fefc213da385" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" unitRef="U_USD" scale="6" decimals="-5">1.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million available to offset future income tax liabilities, if any, for federal and California income tax purposes, respectively. The federal research and development tax credit carryforwards expire beginning in </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e8f265f9-0dbb-4986-86ff-f4e7dc1bf4fc" contextRef="C_a6bb51b5-9e65-4bc2-a156-224db74e09c4" name="pcvx:TaxCreditCarryforwardExpirationYear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2039</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> unless previously utilized. The California tax credits can be carried forward indefinitely.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have evaluated the positive and negative evidence bearing upon the realizability of our deferred tax assets. Based on our history of operating losses, we have concluded that it is more likely than not that the benefit of our deferred tax assets will not be realized. Accordingly, we have provided a full valuation allowance for deferred tax assets as of December 31, 2021 and 2020.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Utilization of the net operating loss carryforward and research credit carryforward may be subject to an annual limitation due to the ownership percentage change limitations under Section 382 and Section 383, respectively, provided by the Internal Revenue Code of 1986, as amended (the &#x201c;Code&#x201d;), and similar state provisions. The annual limitation may result in the expiration of the net operating loss before utilization. We have experienced ownership changes in the past. As a result of the ownership changes, we have determined that approximately less than $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ae7ea1a8-053e-4225-92ee-81fa4fc7b7b9" contextRef="C_1db8f94d-2ec6-47be-b76a-a4960db1be21" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="3" decimals="-2" format="ixt:numdotdecimal">0.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of our federal research credits will expire unutilized, and such amounts are excluded from our research credit carryforwards. The Company does not expect any ownership changes during the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 to result in a limitation that would materially reduce the total amount of net operating loss carryforwards and credits that can be utilized. Subsequent ownership changes may affect the limitation in future years.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">146</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have uncertain tax benefits (&#x201c;UTBs&#x201d;) totaling $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bb6d001e-7529-40e6-95ed-04db9447dedd" contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1145a7c4-3b57-46db-9c65-667f00ef82e6" contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="6" decimals="-5">0.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million as of December 31, 2021 and 2020, respectively, which were netted against deferred tax assets subject to valuation allowance. The UTBs had no effect on the effective tax rate. We recognize interest and penalties related to UTBs, when they occur, as a component of income tax expense. To the extent accrued interest and penalties do not ultimately become payable, amounts accrued will be reduced and reflected as a reduction of the provision for income taxes in the period such determination is made. There were </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7488b4fb-1b72-4d22-a526-ce01cd10c342" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_db4f3c88-2d64-44b8-b433-b7725431e27c" contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> interest or penalties recognized for the years ended December 31, 2021 and 2020. We do not expect our UTBs to change significantly over the next 12 months.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ddc3b960-7a5a-401c-8d3c-443ecc5c9f5d" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="us-gaap:SummaryOfIncomeTaxContingenciesTextBlock" escape="true"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A reconciliation of the beginning and ending unrecognized tax benefit amount is as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.521%;"></td>
        <td style="width:1.317%;"></td>
        <td style="width:1.381%;"></td>
        <td style="width:10.716%;"></td>
        <td style="width:0.91%;"></td>
        <td style="width:1.317%;"></td>
        <td style="width:1.381%;"></td>
        <td style="width:10.716%;"></td>
        <td style="width:0.921%;"></td>
        <td style="width:1.327%;"></td>
        <td style="width:1.381%;"></td>
        <td style="width:10.17%;"></td>
        <td style="width:0.942%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2019</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Balance at the beginning of the year</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d070350a-1105-4aa8-8293-8202b8829c07" contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">393</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ca61f790-20b5-4a74-b68e-c04f594df036" contextRef="C_871fe4ad-8a52-4dc5-a523-876ef5a1de6d" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">271</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a56e0081-bf81-421c-8064-23dcd911a4be" contextRef="C_ecccdfb9-edd1-45a3-8445-0fe8b2f43253" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">408</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Additions based on tax positions related to current year</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6da28a70-9e56-478b-a188-7a07a32bf898" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">461</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_50c0c333-37a6-4c32-a877-17e9ad4d2cfc" contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">287</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f39ae2f0-ed04-42cf-b713-58fa04158fa0" contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">217</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Adjustments based on tax positions related to prior years</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_70783f66-f723-4781-8154-76aa3913ad59" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="pcvx:UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">70</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3488ff7d-3a78-459c-8c1a-d7f0ad5a88bf" contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001" name="pcvx:UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">165</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c0e93db7-c329-4555-98b2-d1bee10f7707" contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700" name="pcvx:UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">354</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Balance at end of year</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_114e3329-9aff-44ad-b02e-c3fa90ee738d" contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">924</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8cab00e0-6057-49e6-b331-275a783afc16" contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3">393</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1ee70ac2-8189-4b94-b0be-96a00317447d" contextRef="C_871fe4ad-8a52-4dc5-a523-876ef5a1de6d" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3">271</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We file U.S. federal and state tax returns. In general, the Company is no longer subject to tax examination by the Internal Revenue Service or state taxing authorities for years before 2016. Although the federal and state statutes are closed for purposes of assessing additional income tax in those prior years, the taxing authorities may still make adjustments to the net operating loss, or NOL, and credit carryforwards used in open years. Therefore, the tax statutes should be considered open as it relates to the NOL and credit carryforwards used in open years. We do not have any tax audits or other issues pending.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On March 27, 2020, the President of the United States signed into law the Coronavirus Aid, Relief, and Economic Security Act (CARES Act). The CARES Act, among other things, includes certain income tax provisions for individuals and corporations; however, these benefits do not impact our current tax provision.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></ix:nonNumeric></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><ix:continuation id="F_8a6ec0ac-593f-4652-b9d3-65e36127889c_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On December 21, 2020, the President of the United States signed into law the &#x201c;Consolidated Appropriations Act, 2021&#x201d; which includes further COVID-19 economic relief and extension of certain expiring tax provisions. The relief package includes a tax provision clarifying that businesses with forgiven Paycheck Protection Program, or PPP, loans can deduct regular business expenses that are paid for with the loan proceeds. Additional pandemic relief tax measures include an expansion of the employee retention credit, enhanced charitable contribution deductions and a temporary full deduction for business expenses for food and beverages provided by a restaurant. These benefits do not have a material impact on the current tax provision.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">147</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7fe06947-a9c6-4e88-9758-fe32e8397270" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">14. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Related Party Transactions</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have an ongoing relationship with Sutro Biopharma. In 2013, Sutro Biopharma provided support to facilitate the establishment of our Company. As of December 31, 2021 and 2020, Sutro Biopharma owned approximately </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0196f711-e855-43b3-9b56-5e2b77ed5b26" contextRef="C_3fab40e5-6a35-4b2f-b816-13c7822b9afc" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" scale="6" decimals="-5"><ix:nonFraction id="F_9c46986e-caa3-4b8e-b9c3-032b98d0f245" contextRef="C_13251130-5d02-4a4b-82e5-dc7664b58676" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" scale="6" decimals="-5">1.6</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million shares of our common stock. As of December 31, 2019, Sutro Biopharma also owned warrants to purchase </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f91b73d5-a35b-483a-9d77-844c88d7c71c" contextRef="C_39f8abfd-a954-4f03-b72e-b423c719a4a5" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">31,857</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of our common stock (the &#x201c;Common Stock Warrant&#x201d;) at an exercise price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_687a3738-b236-4327-8c69-b95964396c6b" contextRef="C_39f8abfd-a954-4f03-b72e-b423c719a4a5" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">0.79289</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8396851e-55cb-4d6a-a7de-8b2209d1dc95" contextRef="C_f77911a6-cb83-4a40-8b6c-9703e6acc5a0" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">59,276</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of our Series C redeemable convertible stock (the &#x201c;Preferred Stock Warrant&#x201d;) at an exercise price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d99b240a-e118-41df-80a9-e63adf747ab3" contextRef="C_f77911a6-cb83-4a40-8b6c-9703e6acc5a0" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">11.5215</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share. The Common Stock Warrant and the Preferred Stock Warrant were automatically net exercised pursuant to their terms for </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2a38fbb3-b86a-4c82-9bf4-5641c246f948" contextRef="C_5909cb95-2fd5-4c03-b349-88a7f48048ff" name="pcvx:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRightExercised" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">30,278</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f35ce7bc-5063-43e3-bbac-0dfb9b7f6cef" contextRef="C_56188f91-3c62-4582-88c9-91789caa7dd4" name="pcvx:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRightExercised" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">16,591</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares, respectively, of our common stock in connection with the IPO. In the agreements and amendments identified herein, we licensed certain intellectual property and acquired certain supply rights from Sutro Biopharma, including the right to use the XpressCF platform to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases. On October 12, 2015, we and Sutro Biopharma (&#x201c;the Parties&#x201d;) entered into the Sutro Biopharma License Agreement, which amended and restated an agreement dated August 1, 2014. The Sutro Biopharma License Agreement was subsequently amended on May 9, 2018 (&#x201c;License Amendment A1&#x201d;) and May 29, 2018 (&#x201c;License Amendment A2&#x201d;). In consideration for the License Amendment A2, we issued to Sutro Biopharma the Preferred Stock Warrant to purchase </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_61dcd28c-b347-403d-b070-6d8c9d55509a" contextRef="C_f910d477-1db3-4915-9562-49fd9c1e0523" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">59,276</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of Series C redeemable convertible preferred stock at a purchase price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e0eaa20f-66bb-4050-a27d-51a352578656" contextRef="C_f910d477-1db3-4915-9562-49fd9c1e0523" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="4">11.5215</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share. We also entered into a separate supply agreement with Sutro Biopharma on </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ee07acf5-55d4-4db5-b5d0-4e76e1da4466" contextRef="C_022b1471-8226-4bef-aee0-86e11defec44" name="us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">May 29, 2018</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> (the &#x201c;Sutro Biopharma Supply Agreement&#x201d;). As of June 2, 2021, Sutro Biopharma was no longer considered a related party.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under the Sutro Biopharma License Agreement, Sutro Biopharma granted us an exclusive, worldwide license to research, develop, manufacture and commercialize vaccine products addressing infectious disease, which are discovered or produced based on the use of Sutro Biopharma&#x2019;s proprietary cell-free protein expression technology, known as XpressCF, which utilizes extracts derived from strains of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">E. coli</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. In connection with the Sutro Biopharma License Agreement, under the Sutro Biopharma Supply Agreement, Sutro Biopharma has agreed to manufacture and supply extracts and reagents for us on a cost-plus basis. In consideration for the rights licensed, we are obligated to pay a </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3bc95bb2-3179-4b7f-af93-96b56dbdc192" contextRef="C_61481fb4-5a3a-40c5-abb3-1248a21e99b5" name="pcvx:PercentageOfRoyaltyPaymentOnAnnualNetSalesOfVaccineProductsForHumanHealth" unitRef="U_pure" scale="-2" decimals="2">4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% royalty on worldwide aggregate annual net sales of our vaccine products for human health and a </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4ff09cd5-ef34-4a25-830d-c58012c2e2d5" contextRef="C_61481fb4-5a3a-40c5-abb3-1248a21e99b5" name="pcvx:PercentageOfRoyaltyPaymentOnNetSalesOfVaccineCompositionsForAnimalHealth" unitRef="U_pure" scale="-2" decimals="2">2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% royalty on annual net sales of vaccine products for animal health. In License Amendment A1, the Parties amended the license agreement to remove a pre-IND regulatory meeting as a diligence milestone and to agree that certain other diligence milestones had been satisfied. In License Amendment A2, the Parties amended the license agreement to add certain terms confirming our obligation to purchase Sutro Biopharma&#x2019;s proprietary extract from </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">E. coli </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(&#x201c;Extract&#x201d;) from Sutro Biopharma. In addition, the Parties amended the license agreement to specify our rights to a transfer of certain know-how relating to the manufacture of Extract in the event of a declaration of bankruptcy by Sutro Biopharma. Finally, the Parties agreed to terms providing for injunctive relief in the event of a breach or threatened breach by the other party.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the Sutro Biopharma Supply Agreement, the Parties agreed to terms for the supply of manufactured Extract and custom reagents by Sutro Biopharma for us to use in manufacturing vaccine compositions in non-clinical research or in Phase 1 or Phase 2 clinical trials. The term of the Sutro Biopharma Supply Agreement is from execution until the later of July 31, 2021 and the date the parties enter into and commence activities under the supply agreement unless extended through a subsequent supply agreement for the supply of Extract and custom reagents for vaccine compositions for Phase 3 and commercial uses as contemplated in the Supply Agreement. In February 2021, we entered into an amendment to the Sutro Biopharma Supply Agreement and extended the term to July 31, 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We recognized expense related to the Supply Agreement of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b54dd810-adab-4668-9ea7-290cf245396d" contextRef="C_9ea862ab-153b-4f8b-bcfc-2223d2882ade" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_dc17ecb2-bc10-4344-b627-54d3e85e35a5" contextRef="C_3c435103-f76a-492c-9b05-78cd97e91f32" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_719fbab0-544d-4c00-ad07-687dc262c115" contextRef="C_8817387e-2be1-4358-95ce-a5df2bf517bf" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for the years ended December 31, 2021, 2020 and 2019, respectively. In addition, we recorded $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_aec978a5-0921-495d-a4fb-829a5e87706d" contextRef="C_dac22bba-f4c3-4e16-abd0-7f908c3516fb" name="us-gaap:FairValueAdjustmentOfWarrants" unitRef="U_USD" decimals="0">0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1b4c9b39-27aa-4459-b0df-38463fd44d64" contextRef="C_9262f685-96b6-4f7c-a6ae-83581243ab7d" name="us-gaap:FairValueAdjustmentOfWarrants" unitRef="U_USD" scale="6" decimals="-5">0.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_300dcd4f-b872-4df2-b622-9e9e4269b1c8" contextRef="C_cab820c4-1fb0-481c-b985-2ea03542a95b" name="us-gaap:FairValueAdjustmentOfWarrants" unitRef="U_USD" decimals="0">0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> in changes in the fair value of the Preferred Stock Warrant for the years ended December 31, 2021, 2020 and 2019, respectively. The expense related to the changes in the fair value of the warrant is included in research and development expenses in the statements of operations. Accrued expenses payable to Sutro Biopharma were $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ab4fb988-e410-45e5-bddd-51d726ec0abf" contextRef="C_3fab40e5-6a35-4b2f-b816-13c7822b9afc" name="us-gaap:RelatedPartyTransactionDueFromToRelatedParty" unitRef="U_USD" scale="6" decimals="-6" format="ixt:numdotdecimal">0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1591a65e-a5a1-4202-820c-123cc930bdee" contextRef="C_13251130-5d02-4a4b-82e5-dc7664b58676" name="us-gaap:RelatedPartyTransactionDueFromToRelatedParty" unitRef="U_USD" scale="6" decimals="-5">0.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and 2020, respectively.</span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">148</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_74e91e97-c26b-4ade-91ff-78d378f31634" contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f" name="us-gaap:SubsequentEventsTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">15. Subsequent Events</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In January 2022, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we completed an underwritten public offering in which we issued </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_23409a0f-1f5e-45eb-8c65-b570dc94b9c1" contextRef="C_e52d577e-c5ed-4801-8551-af9cd25c01fa" name="pcvx:StockIssuedDuringPeriodSharesOfFollowOnOffering" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,500,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of our common stock at a price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_90d0d4f2-2b06-4f10-ab84-0ba2e8f7003f" contextRef="C_ed656fe7-27bd-4711-a1d9-07aab395e870" name="pcvx:SharesIssuedPricePerShareUponFollowOnOffering" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">20.00</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share, and pre-funded warrants to purchase </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f4584993-ccf4-4413-90d3-7f84970dbbce" contextRef="C_e52d577e-c5ed-4801-8551-af9cd25c01fa" name="pcvx:SharesPreFundedWarrantsToPurchase" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,500,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of our common stock at a price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6584694a-a920-427d-b458-bc9cd2eca77f" contextRef="C_ed656fe7-27bd-4711-a1d9-07aab395e870" name="pcvx:PrefundedWarrantsPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3">19.999</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per underlying share. We received approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2801884a-e24b-4d28-bcb7-cd3201212a23" contextRef="C_e52d577e-c5ed-4801-8551-af9cd25c01fa" name="pcvx:ProceedsFromIssuanceFollowOnOffering" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">93.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in net proceeds after deducting underwriting discounts and commissions and other estimated offering expenses payable by us. In February 2022, t</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">he underwriters exercised their option to purchase an additional </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_906d7cda-7f1c-41b9-9a1d-7489dd478185" contextRef="C_16333782-8505-4ca7-9e4c-1163caa27de3" name="pcvx:SharesIssuedUponFollowOnOfferingFullExerciseOfUnderwritersOptionToPurchaseAdditionalShares" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">750,000</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock, and we received approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_247c83c4-2cf2-4152-a961-e1df95d9baca" contextRef="C_16333782-8505-4ca7-9e4c-1163caa27de3" name="pcvx:ProceedsFromIssuanceFollowOnOffering" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">14.1</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in additional net proceeds after deducting underwriting discounts and commissions.</span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">149</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_9_changes_in_disagreements_with_acc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 9. Changes in and Disagreements with Accou</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">ntants on Accounting and Financial Disclosure.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">None.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_9a_controls_procedures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 9A. Controls </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">and Procedures.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Conclusion Regarding the Effectiveness of Disclosure Controls and Procedures</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our periodic and current reports that we file with the SEC is recorded, processed, summarized and reported within the time periods specified in the SEC&#x2019;s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable and not absolute assurance of achieving the desired control objectives. In reaching a reasonable level of assurance, management necessarily is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. In addition, the design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, control may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our management, with the participation of our Chief Executive Office, or CEO, and our Chief Financial Officer, or CFO, our principal executive officer and principal financial officer, respectively, has evaluated the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act, as of December 31, 2021. Based on this evaluation, our CEO and CFO have concluded that our disclosure controls and procedures as of December 31, 2021 were effective at a reasonable assurance level.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Changes in Internal Control Over Financial Reporting</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">There have been no changes in our internal control over financial reporting during the quarter ended December 31, 2021 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Management&#x2019;s Annual Report on Internal Control over Financial Reporting</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act. Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our management assessed the effectiveness of our internal control over financial reporting as of December 31, 2021 based on the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission in its 2013 Internal Control - Integrated Framework. Based on this assessment, our management has concluded that our internal control over financial reporting was effective as of December 31, 2021. Pursuant to Section 404(c) of the Sarbanes-Oxley Act, our independent registered public accounting firm has issued an attestation report on the effectiveness of our internal control over financial reporting for the year ended December 31, 2021, which is included below.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">150</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Report of Independent Registered Public Accounting Firm</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">To the stockholders and the Board of Directors of Vaxcyte, Inc.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Opinion on Internal Control over Financial Reporting</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><br />We have audited the internal control over financial reporting of Vaxcyte, Inc. (the &#x201c;Company&#x201d;) as of December 31, 2021, based on criteria established in </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Internal Control &#x2014; Integrated Framework (2013)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2021, based on criteria established in </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Internal Control &#x2014; Integrated Framework (2013)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> issued by COSO.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the balance sheets, the related statements of operations and comprehensive loss, redeemable convertible preferred stock and stockholders' equity (deficit), and cash flows as of and for the year ended December 31, 2021, of the Company and our report dated February 28, 2022, expressed an unqualified opinion on those financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Basis for Opinion</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#x2019;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management&#x2019;s Annual Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company&#x2019;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Definition and Limitations of Internal Control over Financial Reporting</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A company&#x2019;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#x2019;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#x2019;s assets that could have a material effect on the financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">151</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Deloitte &amp; Touche LLP</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">San Francisco, California</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">   </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">February 28, 2022</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">152</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_9b_or_information"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 9B. Other</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> Information.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">None.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_9c_foreign_jurisdictions"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Not applicable.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">153</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">PART III</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_10_directors_executive_ficers_corpo"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 10. Directors, Executive Off</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">icers and Corporate Governance.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The information required by this item of Form 10-K will be included in our definitive proxy statement to be filed with the SEC in connection with the solicitation of proxies for our 2022 Annual Meeting of Stockholders, or the 2022 Proxy Statement, and is incorporated herein by reference.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_11_executive_compensation"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 11. Executiv</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">e Compensation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The information required by this item of Form 10-K will be included in our 2022 Proxy Statement to be filed with the SEC within 120 days after our fiscal year end and is incorporated herein by reference.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_12_security_ownership_certain_benef"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 12. Security Ownership of Certain Beneficial Own</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">ers and Management and Related Stockholder Matters.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The information required by this item of Form 10-K will be included in our 2022 Proxy Statement to be filed with the SEC within 120 days after our fiscal year end and is incorporated herein by reference.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_13_certain_relationships_related_tr"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 13. Certain Relationships and Related</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> Transactions, and Director Independence.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The information required by this item of Form 10-K will be included in our 2022 Proxy Statement to be filed with the SEC within 120 days after our fiscal year end and is incorporated herein by reference.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_14_principal_accounting_fees_servic"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 14. Principal Accoun</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">ting Fees and Services.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The information required by this item of Form 10-K will be included in our 2022 Proxy Statement to be filed with the SEC within 120 days after our fiscal year end and is incorporated herein by reference.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">154</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">PART IV</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_15_exhibits_financial_statement_sch"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 15. Exhibits, Financ</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">ial Statement Schedules.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">(a)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following documents are filed as part of this Annual Report on Form 10-K: </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.924082093358947%;">(1)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">All Financial Statements</span></div></div>
  <p style="margin-left:11.293%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The financial statements and Report of Independent Registered Public Accounting Firm filed as part of this Annual Report on Form 10-K are listed in the &#x201c;Index to Financial Statements&#x201d; under Part II, Item 8 of this Annual Report on Form 10-K.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:7.861%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.924082093358947%;">(2)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Financial Statement Schedules</span></div></div>
  <p style="margin-left:11.293%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">All financial statement schedules have been omitted because of the absence of conditions under which they are required or because the required information, where material, is shown in the financial statements, financial notes or supplementary financial information.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <div style="margin-left:7.861%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.924082093358947%;">(3)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exhibits</span></div></div>
  <p style="margin-left:10.84%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The list of exhibits filed with this Annual Report on Form 10-K is set forth in the Exhibit Index preceding the signature page and is incorporated herein by reference or filed with this Annual Report on Form 10-K, in each case as indicated herein (numbered in accordance with Item 601 of Regulation S-K).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_16_form_10k_summary"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 16. Form </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">10-K Summary</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">155</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Exhibit Index</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:13.47%;"></td>
    <td style="width:24.499%;"></td>
    <td style="width:16.115%;"></td>
    <td style="width:14.273%;"></td>
    <td style="width:13.942%;"></td>
    <td style="width:17.7%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="4" style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Incorporated by Reference</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Exhibit</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Description</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Schedule/Form</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">File Number</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Exhibits</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Filing Date</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:13.887%;"></td>
    <td style="width:24.775%;"></td>
    <td style="width:15.964%;"></td>
    <td style="width:13.854%;"></td>
    <td style="width:13.448%;"></td>
    <td style="width:18.073%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1649094/000119312520170425/d944845dex31.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Amended and Restated Certificate of Incorporation of Vaxcyte, Inc., as amended</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8-K</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">001-39323</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">June 16, 2020</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1649094/000119312520170425/d944845dex32.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Amended and Restated Bylaws of Vaxcyte, Inc.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8-K</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">001-39323</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">June 16, 2020</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1649094/000119312520162659/d802328dex41.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Form of common stock certificate of the Registrant</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">S-1/A</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">333-238630</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">June 8, 2020</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1649094/000156459021016110/pcvx-ex42_374.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Description of Capital Stock</span></a><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10-K</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">001-39323</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">March 29, 2021</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.3</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1649094/000119312522008768/d259937dex41.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Form of Pre-Funded Warrant</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8-K</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">001-39323</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">January 13, 2022</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1649094/000119312520150234/d802328dex101.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Amended and Restated Investors&#x2019; Rights Agreement by and among the Registrant and certain of its stockholders, dated March 20, 2020.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">S-1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">333-238630</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">May 22, 2020</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.2#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1649094/000119312520150234/d802328dex102.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Vaxcyte, Inc. Amended and Restated 2014 Equity Incentive Plan and forms of agreements thereunder.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">S-1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">333-238630</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">May 22, 2020</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.3#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1649094/000119312520162659/d802328dex103.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Vaxcyte, Inc. 2020 Equity Incentive Plan and forms of agreements thereunder.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">S-1/A</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">333-238630</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.3</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">June 8, 2020</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.4#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001649094/000119312520162659/d802328dex104.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Vaxcyte, Inc. 2020 Employee Stock Purchase Plan</span></a><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">S-1/A</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">333-238630</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.4</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">June 8, 2020</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.5</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1649094/000119312520150234/d802328dex105.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Form of Indemnification Agreement entered into by and between the Registrant and each director and executive officer.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">S-1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">333-238630</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.5</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">May 22, 2020</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.6#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1649094/000119312520150234/d802328dex106.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Executive Employment Agreement entered into by and between the Registrant and Grant Pickering, dated January 21, 2016.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">S-1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">333-238630</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.6</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">May 22, 2020</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.7#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1649094/000119312520150234/d802328dex107.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Executive Employment Agreement entered into by and between the Registrant and Jeff Fairman, dated January 21, 2016.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">S-1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">333-238630</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.7</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">May 22, 2020</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">156</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:13.887%;"></td>
    <td style="width:24.775%;"></td>
    <td style="width:15.964%;"></td>
    <td style="width:13.854%;"></td>
    <td style="width:13.448%;"></td>
    <td style="width:18.073%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="4" style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Incorporated by Reference</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Exhibit</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Description</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Schedule/Form</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">File Number</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Exhibits</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Filing Date</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.8#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1649094/000119312520150234/d802328dex108.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Offer Letter entered into by and between the Registrant and Paul Sauer, dated April 12, 2016.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">S-1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">333-238630</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.8</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">May 22, 2020</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.9#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1649094/000119312520150234/d802328dex1011.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Executive Employment Agreement entered into by and between the Registrant and Jim Wassil, dated November 15, 2019.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">S-1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">333-238630</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.11</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">May 22, 2020</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.10#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1649094/000119312520150234/d802328dex1013.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Offer Letter entered into by and between the Registrant and Andrew Guggenhime, dated April 16, 2020.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">S-1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">333-238630</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.13</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">May 22, 2020</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.11#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1649094/000119312520150234/d802328dex1014.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Form of Executive Change in Control and Severance Agreement entered into by and between the Registrant and each eligible employee.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">S-1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">333-238630</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.14</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">May 22, 2020</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.12+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1649094/000119312520150234/d802328dex1015.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Development and Manufacturing Services Agreement by and between the Registrant and Lonza Ltd, dated October 29, 2018.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">S-1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">333-238630</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.15</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">May 22, 2020</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.13+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1649094/000119312520150234/d802328dex1016.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Development and Manufacturing Services Agreement by and between the Registrant and Lonza Ltd, dated October 21, 2016, as amended.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10-Q</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">001-39323</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">November 10, 2021</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.14+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1649094/000119312520150234/d802328dex1017.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Letter Agreement by and between the Registrant and Lonza Ltd, dated June 19, 2018.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">S-1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">333-238630</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.17</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">May 22, 2020</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.15+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1649094/000119312520150234/d802328dex1018.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Amended and Restated SutroVax Agreement by and between the Registrant and Sutro Biopharma, Inc., dated October 12, 2015, as amended.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">S-1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">333-238630</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.18</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">May 22, 2020</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">157</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:13.887%;"></td>
    <td style="width:24.775%;"></td>
    <td style="width:15.964%;"></td>
    <td style="width:13.854%;"></td>
    <td style="width:13.448%;"></td>
    <td style="width:18.073%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="4" style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Incorporated by Reference</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Exhibit</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Description</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Schedule/Form</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">File Number</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Exhibits</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Filing Date</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.16+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1649094/000119312520150234/d802328dex1019.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Supply Agreement by and between the Registrant and Sutro Biopharma, Inc., dated May 29, 2018, as amended.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">S-1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">333-238630</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.19</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">May 22, 2020</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.17+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1649094/000119312520150234/d802328dex1020.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">License Agreement by and between the Registrant and The Regents of the University of California, represented by its San Diego campus, dated February 4, 2019.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">S-1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">333-238630</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.20</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">May 22, 2020</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.18</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1649094/000119312520150234/d802328dex1021.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Lease Agreement by and among the Registrant, Grey Peak Fork, LLC and Grey Peak Fork, Series A, LLC, dated July 22, 2016.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">S-1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">333-238630</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.21</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">May 22, 2020</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.19</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1649094/000119312521016229/d844599dex101.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Lease Agreement by and between the Company and ARE-San Francisco No. 63, LLC, dated as of January 21, 2021</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8-K</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">001-39323</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">January 25, 2021</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">23.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><a href="pcvx-ex23_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Consent of Independent Registered Public Accounting Firm</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">X</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">24.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><a href="#power_attorney"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Power of Attorney. Reference is made to the signature page hereto.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">X</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">31.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><a href="pcvx-ex31_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Certification of Principal Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as amended.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">X</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">158</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:13.887%;"></td>
    <td style="width:24.775%;"></td>
    <td style="width:15.964%;"></td>
    <td style="width:13.854%;"></td>
    <td style="width:13.448%;"></td>
    <td style="width:18.073%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="4" style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Incorporated by Reference</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Exhibit</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Description</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Schedule/Form</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">File Number</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Exhibits</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Filing Date</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">31.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><a href="pcvx-ex31_2.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Certification of Principal Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as amended.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">X</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">32.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><a href="pcvx-ex32_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Certification of Principal Executive Officer Pursuant to 13a-14(b) or 15d-14(b) of the Securities Exchange Act, as amended, and 18 U.S.C. Section 1350.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">X</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">32.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><a href="pcvx-ex32_2.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Certification of Principal Financial Officer Pursuant to 13a-14(b) or 15d-14(b) of the Securities Exchange Act, as amended, and 18 U.S.C. Section 1350.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">X</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">101.INS</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Inline XBRL Instance Document &#x2013; the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">X</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">101.SCH</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Inline XBRL Taxonomy Extension Schema Document</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">X</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">101.CAL</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">X</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">101.DEF</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">X</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">101.LAB</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Inline XBRL Taxonomy Extension Label Linkbase Document</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">X</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">101.PRE</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">X</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">104</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:middle;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">X</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid;margin-right:66.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"># Indicates management contract or compensatory plan or arrangement.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">+ Certain portions of this agreement have been omitted because the omitted portions are both not material and would likely cause competitive harm if publicly disclosed.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">159</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">160</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="signatures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">SIG</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">NATURES</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Annual Report on Form 10-K to be signed on its behalf by the undersigned, thereunto duly authorized</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:44.861%;"></td>
    <td style="width:5.118%;"></td>
    <td style="width:5.15%;"></td>
    <td style="width:44.872%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Vaxcyte, Inc.</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Date: February 28, 2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">By:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Grant E. Pickering</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Grant E. Pickering</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Chief Executive Officer</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="power_attorney"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">POWER OF </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">ATTORNEY</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Grant E. Pickering and Andrew Guggenhime, and each of them, as his or her true and lawful attorneys-in-fact, each with full power of substitution, for him or her in any and all capacities, to sign any amendments to this Annual Report on Form 10-K and to file the same, with exhibits thereto and other documents in connection therewith, with the SEC, hereby ratifying and confirming all that each of said attorneys-in-fact or their substitute or substitutes may do or cause to be done by virtue hereof.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Annual Report on Form 10-K has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:30.081%;"></td>
    <td style="width:1.175%;"></td>
    <td style="width:42.007%;"></td>
    <td style="width:1.175%;"></td>
    <td style="width:25.561%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Name</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.750pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Title</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.750pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.750pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Date</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:right;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.750pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Grant E. Pickering</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.750pt solid rgba(255,255,255,0.01);text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Chief Executive Officer and Director</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">February 28, 2022</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Grant E. Pickering</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">(Principal Executive)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.750pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Andrew Guggenhime</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.750pt solid rgba(255,255,255,0.01);text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;President and Chief Financial Officer</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">February 28, 2022</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Andrew Guggenhime</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">(Principal Financial and Accounting Officer)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Carlos Paya, M.D., Ph.D.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:right;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Director</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">February 28, 2022</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Carlos Paya, M.D., Ph.D.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Annie Drapeau</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Director</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">February 28, 2022</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Annie Drapeau</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Kurt von Emster</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Director</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">February 28, 2022</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Kurt von Emster</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Halley Gilbert</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Director</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">February 28, 2022</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Halley Gilbert</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Peter Hirth, Ph.D.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Director</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">February 28, 2022</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Peter Hirth, Ph.D.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Michael Kamarck, Ph.D.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Director</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">February 28, 2022</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Michael Kamarck, Ph.D.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Teri Loxam</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Director</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">February 28, 2022</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Teri Loxam</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Heath Lukatch, Ph.D.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Director</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">February 28, 2022</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Heath Lukatch, Ph.D.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">161</span></p>
  <hr style="page-break-after:always;" />
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>2
<FILENAME>pcvx-ex23_1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html>
 <head>
  <title>EX-23.1</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">									</font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3225;font-family:Times New Roman;margin-bottom:10.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Exhibit 23.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3225;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3225;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We consent to the incorporation by reference in Registration Statement No. 333-257622 on Form S-3ASR and Nos. 333-254824 and 333-239135 on Form S-8 of our reports dated February 28, 2022 relating to the financial statements of Vaxcyte, Inc. and the effectiveness of Vaxcyte, Inc.'s internal control over financial reporting, appearing in this Annual Report on Form 10-K of Vaxcyte, Inc. for the year ended December 31, 2021.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3225;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Deloitte &amp; Touche<br>San Francisco, California</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3225;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">February 28, 2022</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3225;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3225;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3225;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>pcvx-ex31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html>
 <head>
  <title>EX-31.1</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Exhibit 31.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">CERTIFICATION PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100.0%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">I, Grant E. Pickering, certify that:</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.979%;"></td>
    <td style="width:95.021%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">I have reviewed this Annual Report on Form 10-K of Vaxcyte, Inc.;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:5.182%;"></td>
    <td style="width:94.818%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:5.16%;"></td>
    <td style="width:94.84%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:5.203%;"></td>
    <td style="width:94.797%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:5.224%;"></td>
    <td style="width:5.224%;"></td>
    <td style="width:89.552%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(a)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:5.16%;"></td>
    <td style="width:5.256%;"></td>
    <td style="width:89.583%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(b)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(c)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:5.202%;"></td>
    <td style="width:5.202%;"></td>
    <td style="width:89.595%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(d)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:5.203%;"></td>
    <td style="width:94.797%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:5.182%;"></td>
    <td style="width:5.256%;"></td>
    <td style="width:89.562%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(a)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:5.182%;"></td>
    <td style="width:5.182%;"></td>
    <td style="width:89.637%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(b)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:48.996%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:3.996%;"></td>
    <td style="width:46.004%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Date: February 28, 2022</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">By:</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Grant E. Pickering</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Grant E. Pickering</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Chief Executive Officer</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>pcvx-ex31_2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html>
 <head>
  <title>EX-31.2</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Exhibit 31.2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">CERTIFICATION PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100.0%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">I, Andrew Guggenhime, certify that:</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.979%;"></td>
    <td style="width:95.021%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">I have reviewed this Annual Report on Form 10-K of Vaxcyte, Inc.;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:5.182%;"></td>
    <td style="width:94.818%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:5.16%;"></td>
    <td style="width:94.84%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:5.203%;"></td>
    <td style="width:94.797%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:5.224%;"></td>
    <td style="width:5.224%;"></td>
    <td style="width:89.552%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(a)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:5.16%;"></td>
    <td style="width:5.256%;"></td>
    <td style="width:89.583%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(b)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(c)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:5.202%;"></td>
    <td style="width:5.202%;"></td>
    <td style="width:89.595%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(d)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:5.203%;"></td>
    <td style="width:94.797%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:5.182%;"></td>
    <td style="width:5.256%;"></td>
    <td style="width:89.562%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(a)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:5.182%;"></td>
    <td style="width:5.182%;"></td>
    <td style="width:89.637%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(b)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:48.996%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:3.996%;"></td>
    <td style="width:46.004%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Date: February 28, 2022</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">By:</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Andrew Guggenhime</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Andrew Guggenhime</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">President and Chief Financial Officer</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>pcvx-ex32_1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html>
 <head>
  <title>EX-32.1</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Exhibit 32.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">CERTIFICATION PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In connection with the Annual Report of Vaxcyte, Inc. (the &#x201c;Company&#x201d;) on Form 10-K for the annual period ended December 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), I certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:</font></p>
  <div style="margin-left:4.528%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(1)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Report fully complies with the requirements of Section 13(a) or Section15(d) of the Securities Exchange Act of 1934, as amended; and</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(2)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div></div>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:48.376%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:3.996%;"></td>
    <td style="width:46.624%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Date: February 28, 2022</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">By:</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Grant E.Pickering</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Grant E. Pickering</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Chief Executive Officer</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>6
<FILENAME>pcvx-ex32_2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html>
 <head>
  <title>EX-32.2</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Exhibit 32.2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">CERTIFICATION PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In connection with the Annual Report of Vaxcyte, Inc. (the &#x201c;Company&#x201d;) on Form 10-K for the annual period ended December 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), I certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:</font></p>
  <div style="margin-left:4.528%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(1)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Report fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934; and</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(2)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div></div>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:48.376%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:3.996%;"></td>
    <td style="width:46.624%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Date: February 28, 2022</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">By:</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Andrew Guggenhime</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Andrew Guggenhime</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">President and Chief Financial Officer</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>img69628308_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img69628308_0.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" *>!LH# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MFJK)_P %15CZ?#7/_<>_^YJ^#+B\+=ZHR7)/>HY(F3HT^Q][R?\ !5((<?\
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MCV?WO_,^NH?^"BGBV8X_X171A_VTF_\ BJL7'_!0CQ9;PF3_ (1C13[;Y?\
MXJOE&QM_F'%&O2"&S(]J?U2EY_\ @4O\ROJ5&VS^]_YGT7<?\%.O%=O(5_X0
M[1FQ_P!-Y?\ &FQ_\%//%4A_Y$[1A_VWE_QKXHO9/,F;ZTV'*MUK/ZK3\_\
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M_6ODN9F7@U0N,$$TOJM+S_\  I?YB>#H]G][_P SZVF_X*?>+8LC_A"]&/\
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M6TUSC[[<(D?^\QX K+ZK3\__  *7^9R?5:=[6?WO_,^VO^'L_BWMX!T8G/\
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M]AD?S 8TZE&ZM].Q%<K>63QKDP[47IO;C'UJ'A::[_\ @4O\S*6#IKH_O?\
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M_?!_F:AX.G?K_P"!2_S,I8&E?2_WO_,^HX_^"E'BZ0<^#M'![CS9O\:T+?\
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M1?\ OY-_\57QE;S$\UH0S=Z?U6EY_P#@4O\ ,T6#H]G][_S/L%?^"B'BQO\
MF5]&_P"^YO\ XJI4_P""A/BQO^98T8?\"F_^*KY$C?YA5R-CQBJ^J4O/_P "
ME_F5]3H=G][_ ,SZMN_^"A'C*W3<GA/191_UTF'_ +-5>Q_X**>+[R38_A+1
MHO?S)C_[-7S3;OG /(J::SCCA:1!S[4_J=+S_P# I?YC^HT>S^]_YGT9J_\
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M_P"!S?\ Q5?%=O)S6S9R9QBG]5I>?_@4O\RE@Z/9_>_\S[FC_P""ASK;HS^
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MX[*33--#(4,SE<'/I6MI7AF9LW-RWEQG^#UKH-)T6.23[5*4D5>A'-6KIQ<
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M/?%+]J95 *[5X*MW_.J.T[L *&/(P><^E+'<LCC=NVYP1ZT"N:J7@W+NX)7
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MDXS7J6N>"9-8TK3[::]M[:6VD>21VR_48XQ]*2S\#:9#"K7.IS7>U=J^2@1
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MXGCG):+M&;G_ (8O];'F2QL%"@..]2)'MW!@-W?=R*]2'@?1MH!M6(_Z[/\
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M3(1GM@TOB2(AO;%<LE*.DD>?.,X*TU9G!ZE(69JPILL3707T7S-6/<1C)XK
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M.=T\'^[I>]/\%Z_Y'.:7\-]/AVRWR"YEZ[.B#_&NLM[>*UA6*&-8HU&%1%
M_"I**_+,7C\3CI<^(FW^2]%L?G^)QE?%RYJTK_E]P4445P'&%%%% !1110 5
MQGC#X1^&_&>^6ZLA;7K?\OEKA),^IXPWXBNSHK>C7JX>?/1DXOR-:=6I1ES4
MY69\G>._@KK?@OS+B%3JFF#G[1"GS(/]M>WUZ5Y_G:W/%?>+ ,"",@\$&O&O
MBE\"(-8CGU3PZBVU_P#?DLP,1R^NW^ZWMT-?H>5\3*HU1QNC_FZ?/MZ['V&
MSM2:IXG1]_\ ,^<_.9?N_P Z='?/&?O'=]:AO+>6SE>&:)H9HSM='&"I]"*K
M9(;)K] 3NKH^NOU1[UX)_P"181MQ8D<Y-6SN;IP*P_ASJB7GAPPK]^,_,M;;
M,=QKH6QZ$?A1$R[6#8R:22WWXS4Z .I+<;>E/C4R]%S[TPL93Z6'S@9'I4,V
MAP^6<\>U=%%!A2S':M567@D#Y<]:5@Y3DKC2/+7* 9'-5)+R_LWVF3S<CH1G
M%=9+#N8_* *R;U44\N!GCCK2L9M=C):Z@OF7?'Y4F.3V-5-6N-+T@QM=R21A
M_NC!(-27WE0C>Y",I_O9-=%X?\(_VW:F34(]MDPX2898^X]*G<FSEHCF$UJ.
M1FBL)+="PPK,P)'X&J%UX5OM0D\V22:ZF;N@RH_&O3-+\#^&]#!^RZ=%))G_
M %DYW&NAM9([>/"1")/2-.!5<O<M4[_$SPBX\(W%K@M!)L[X'-9DNG%)2C#;
MW7;WKZ(DM[>ZDW26JG_:8<_I6?=>#=)U,Y6-X),Y^6ER$NCV/"(X2@&5\Q?3
MN*F7*C:P93_#7IVK_#N6R#2P^5=VRC.QB585RY\-&XCS:A9"#]V-P<>U1RLS
M=-Q.=C=F;@D&K,;%D)W9/<^E:\?ANXCC9Y%D#=#&J$9_&I(_#]Z8\"W,,/4@
M\?F3187*S#MP'O%^8DJ"P&WT%;<<OV2U);(DXVCV/>HK"XTBUU9;!KN)[F92
M@2$[QN]VZ9]!3]0LFB1</YBLNT,>""#@J1ZBF-$;711N3C:>/<TYKHMD9;.<
MG)K-:1MV6&2.*7S&&=W!]: N:R7"HI56R6&>:(KQR<*VW^E9NU]F['RGWI\3
M%NG##^'^]0%S8^T910?F=AR?7VIPN"WSD [<9!K,A=Q,CX/3J*FCDS$Y#8.[
MEOZ4RKE[[<%=I ,OG(9CG%)]J=MS,V\GDKG-9ZMOV(#@]",=:3SBK9/)!]*
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M+\\I_P"!'I^&*Z.BBOK:=.%*/+!61^0U\16Q51U:\W*3ZMW844459SA1110
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M68@%U"W!:%^F?52?0U]?D.<RP-14*S_=R_!]_3O]Y])E&:/"35*J_<?X>?\
MF> 1?O&_,XZ"I+-"SIM ZYP?\\"G1PRP,T;*T<^"I4CY@.^?2M?2+$R-\J[G
M88^@/4X^G'XU^PK4_2TKAIND_:VRJ$P1G<&)YD/KC'2M S6UD.$6XN!P,<*O
MKT[_ $_.GWDWEQ_98V7:OWV08#$=%'L/U.:RI%PQ]*HTV'74[W4F^0[CT'8
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M*M4=W)W/QVM6GB*DJM1ZL****YS$**** "BBB@ HHHH **** "BBB@ HHHH
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M+!QGMUK(YK6W&;43+28YZ8YQ^%1R2/(H'W$///5C4BVV9.G/K4FW( 7@=.E
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M\J;PH+J*,1K-*V !V7Y?Z&OF^(J[P^73MO*T?OW_  N>+G57V."E;>6GW_\
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MXW$E&0GCCD_C3?M&U\2C:N>&'>J"W&THT;'('WB<$^U,61Y&+*Y!Y.T<\^E
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M]Y=29.3Z#U-=_I^BV'AY5%O&LESC!FE(9_\  ?A5S[4D,*6T,,<%O&,)&<*
M/8>M9TTI9BK889^ZI_K5))&BBHDUW=SM(-RM_P "()_2JWG%B1M^;T/6HV$8
MR 2G;YN1^!JNTR=#UZ [N:8%T70VJ&0':>H'(^M6([QXY,('=1R.1Q6/Y_\
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M[WI[PEV"JN54<XZ&K,=NVS:BE-W4FKD.F[4:*.10G\3@X#>WO3L%C.,.(UW
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M3:?>075N_ESP2++&WHRG(/YBO<?B-^T%I/BKP7>Z;I5C?6FI7RQQW$TR(J;
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M&0,C8*$# ;_QXU[F24W5S&C%=[_=K^AZN54W4QU)+O?[M3RJXUI6F.V5=@/
M' X["J\FIYX7:)"<D\DM]:P=:ANO#=T/.D,]K(V(KA,!3_LGT;_(J&'6&XV!
M6FZ;B<G\Z_=+GZSS=SI6N)9& \M8B!PS< U&UVRR+^]03?Q;E_2L*6_*J?/F
M_>*?E5?FS^-,;4594Q+MD'/S#'ZT7#F-5K]>"I6-@>-@_2JU]<1[FD#EHV/)
M4CCZCM6;=71^U@#!5SG<#D'W%59K@LWEJX";L>8?T!%*Y+D6)[C*OL8X7GKU
MJA-<1R+NW,I XXZFH+B?S)G*YC5>N?X?4TU@'DME6.2Y9NB $;N>WM[U)%QC
M7/RCKD-DCM3/WETS"-.5!;:O]T#DDU*FGSR79$J>7R20I!(QVQZ]JZ?1?"-S
M/"I=%A_BE>4\*<\ C^)A_=X [YHU8E%R,S0=+>\NXE8 $_,ZG)(4?Q'W/0"N
M\$+74J0Q(TNW. HZDG)^@_PJ[H?ARVLK<"./RH&SND_CE.>3D]![_E6I_:$<
M2B&UMP%Y 6/.3^7\R:U2.J,.5:E.'P\%&;J3RL=8TY;\35Q+.TM%/^BY(/!=
MBS'\#Q566YF(QL5".QP /I58R&3@MM;MO. ?I3+T-235!&-H4Q+V"N!GZ\<5
MFW-SN)V[0.X#%LGUR>]0R3"'(:%'8\!A\XJHUT'X5!\O93C% FR22<\CD$'E
M2,"JS7"R9#NRCLP/'Y5#-<-(20^2.[]?QJ"2Z+ A@KA>BYX%21<L-/O;"R9;
MU;^E-^V20,W+#L>,9JG(Y8C:,#LM(MP8RRM\XQR.QI"N76N'\L/U1O0]#[BN
M=\0KY;"9<_NR,8Z@=\UKP9D63U5"<GI]#44UJ+P1PJ/-+<,,9 SZ_P Z"7JB
MG;L6B!]5##W![U9D=)2 /D('3'!/M4=GIKV[;%@<;3G ()Q_>7G\<=LU8:%H
MQO3-S"01YA'R@^GL:0BMYG^Q],&EW-&RA<JX_2I%ML,OF%D5AD;!DGZ"IEM6
M4"5QL&<1JYZ_X_A0,K+D,2%(W#Y<_P Z;-O8K'C;&AP.,<^M:RZ/<22HA,LG
M'S. <GZ=P!^%,O7L/#ZA[^]M[%\95<EIC]%&?SIA8S4MI#(OEJ[D#!.W'Y>U
M(NFR!6<P/Y:_??:0%_&I/^$\\*>6 ES=;AQEXF(_(-U/UIC^._"3H5W74@ R
M(Q$0N?;+=?>EH+W>YZ]\#Y$_LG5(41X]MPK;7.3RN!_Z#7I=>-? WQ?9:MJU
M]865G<P1&W$P>0#R^&Q@8[_-GJ>E>RU^CY3-3P<+=+K\3^8>,J+HYW6[2LU\
MXK];A1117KGQ04444 >Z?"WX^:/X1\&VFDZU87MY=6$TCVDD"(ZJK XY9P0?
MG=>!T-<]\-/BSIWA#5_$^O:G:W-WKNI*QMV@13&C,S.P8LP(!;9T!X6O+**\
MQY;AW[33X]]?._\ PY]"L]QJ]C[R_=?#IY6N^[2V.W\+_%SQ+HOB+3KZ\U[5
M;ZT@G5I[::\DD62//S+M9L$XSC/?%>A6_P 9O!%E\0]5\71:5JLE[<6B10I)
M%$ LH!5V/[PXRHC&1_M>M>#4557+Z%9MM6NK::76YGALZQF&BHJ7-9\RYM;.
MUKJYZS\-?C<N@ZAX@'B>&XU73=:+2SQPJKD2G@X5F VE3C&> JUY=J'V7^T+
MG[#YOV+S6\CS\>9Y>3MW8XW8QG'>J]%=%/#4Z,Y5(*W-:_;0XJ^.KXFC"C6=
MU"]GUUU>OJ>IQ_%NUT'X2V?AGP\=1L-8:;S;N^4B(<DLVQD?=V1>0/E!J?X6
M?'*Y\,WVHIXIN]4US3;J#8$:8SNC ]A(X !!;.#V%>2T5SRR_#RA.$HWYG=O
MK?U.V&=8VG5IU83MR))+I9*VJZ^9ZM\,?&W@#P7>3W^H:/JEUJ<-[))8741&
M8X"H"*R^:%+?>SP>O6HOC%XZ\&>.P=0T;2=0M?$$UPC7%W=D!7B6,IM"B1@#
MPG11T//KY=136!IJO]8YI<WJ]NWIY">;5GA'@N2')O\ "KW[W[]+[V"BBBO0
M/#"BBB@"EK=P+/1;^=CA8K>1R?HI-?#MS?/(3\V!7VCXZC%QX1U2W:3RQ<0M
M!N_WOE_D:^;+KX1B5E6*\$:9^=V'W5[FOB>()<U2G!=%^?\ PQ^Z^'F'G]4K
MUULY)?<K_P#MQQ_A'2]7U[5 FG1M(D; RS,<1QCW/].M>T6^@V&G[&O#]MN0
M!][_ %8/T_QJI;M;:79)I>CPXM;<?,5[^K$^I[D_2H/M"KGSF4\Y$1YS]:^8
MBDC]@A%01T,FKEF&T^:G\.%P%^E5FN%ER1N5O[JDL#[XK-746;+1K&C 9(08
M/X&GV]X'8>8 I]6SG\ZLTN:&_P ^,9<AO54%5YM\;$-P0><CBH"P$9(VJP/.
MT]?>AF8LQ5]TB\C'?VH '82\\+QP5;&:J33;Q]PG;U/>B9O,BD=& 8?-MSU]
M:S9KHLQ4G:2,CG%22V6KB5HV"DY[JV>OM4,MTVU6SDYVGGM6/<7S"'=D,N[K
MGI34N59G8<8&[:*5R.8Z2"^\[ ^\NT9YYJ[X@2UOI-.LYY7$K N-O]WWK,TJ
MU#PF>1A&8N7!Z9/('X"ETO4O^$A\1/<QKF")?+C/L._XTR[Z69IQ:99Z9E8X
MRYQC+&B2^F"X7;&!TVBI[SB0BJ+$EO6F41.6D^\<GWYI H'%65M99/NPR'_@
M)IPLYEZPR?\ ?)I6)L01Q@\XQ5B-2<#M2K;R=/+8>O%3Q)V[TQDL,?( %'B2
M[_LW0Y6S@D8J[9VXX9JY'XHZCBQ6"(\^U#T0W[L6SRNZD\ZX=SW.:DB'8=*O
M:1X2U/5L,(C''_>DX%=?IW@6QM-IO;@RD=53I6*39QQBY'&0KST)K8L-/N+R
M14CC8D^U=I)#IUOM2UM8T_WN<U ;V:'<8PB@=E&#5\IKR6W8EKX8M["W\V]D
M!?&=M9&J>(8[56CM45 O&[%-U"\FN-Q+G/\ =-<S?R@QD'AN]#?8)2ML;>@^
M.C-<?8KLY#<*U=17BMX&W;E)!SP17L.FW(O-/MIP<^9&K9^HKT<#+XHGN914
MYN>#\BS1117JGT04444 >P?LP_&ZU^!OCNZU+5(+N[T6^LVMKFWLU5G+9#(X
M5F4$@@CDCAC72_%S]H#PK\4/BSX*U!M,U*V\!^'5B4:=Y$0G8!PSJ$\S9M8)
M&F-W1:^>J*P=&#G[3J<<L)2E5]NU[UK?UYGNGQR_:F\1^/OB!<:GX3U_Q#X;
MT!88X;>SAOI+9C@99W2*0KN+%N<G@+73ZQ^T?X*^)7PG\&^'/']GXAO]:T6\
MAFNKVV2.47,:,RL#(\P8L\1&21][G-?,E%+ZO3LDE:Q'U&CRQC%6Y=FMSZ*^
M*7[6ESXB^+WA?Q-X7MKBPT+PT%%EIUT$C,FX8F#!"P4,O[O@G 4$8)KE/VF?
MB9X.^+GC:W\2^%M/U/3KJX@$>I1ZA%$BR2+@(Z[';)V_*<X^ZOO7D%%.-"$&
MG'IH53P=*E*,H*SBK?+S_,]/_9P^*.E_!_XH6GB36+:\NK&*WFA:.Q1&ERZX
M! 9E'7WKGOBYXPM/B!\3/$?B*PBF@L]2O'N(H[@ 2*IZ!@"1GZ$UR-%7[.//
M[3KL;*C!576ZM6/:?V=?VDKSX'S:AI]WIRZWX9U)@UU8E@KHV-I="00<KP5/
M!P.1BO7O"O[37P)^'>N7GB#PK\/]<TW7+J)HI&0(D6TD$JJ_:&5!E5^Z@Z5\
M<45E/#TZC;?7?S.:M@*-:3D[J^]FU?U-;Q=KQ\5>+-:ULP?9CJ5[->>1OW^7
MYDC/MW8&<;L9P.E9-%%=*5E9'>DHJR"BBB@85QWCJ\$%U:QYYV$X^I_^M78U
MQ6N:3)KOB5PH)2-%3V]3_.N+&.U*W<\K,Y6P]N[1SB2S7!^12:O6=C<M,A8$
M#-=_I?@^VL8@TPRV.E6;RUMX4_=QJ"/:O%Y3Y14WNR+1\PV.#52ZN"&/:H&U
M8QML/ J"6Y6<D@\TR[Z6%:8GJ:3?5<L<^E/5LT$EE9.U6H>1Q5!#6C:#-!2-
M*SBW$<5-JFH+IUF><'%)'(MK"7<X KS[QAXD,CNJMQT%-NR*E+E1FZ]KQFN&
M :N>EU)V. <_C5&>Y:5B2>32Z=&;BX4=1FL+W.%R;9U'A^&21@[ UVT<ABA"
MD\UE:3;I:P*S=A5@W&]CS6B.B.B+\1W-5Z%!QVK,A;..:TH&'%4:(O0I[58V
MBH+=O>K6T51HC@M!8B1.<UT-U(56LS0M*D\P?*0.U=#=Z6_D].:E;&44['.S
MS%351[@XJ[>6[*2"*SI(SGI2)9&TA-,W'UI_E'TI5MV8]*1)'R:ECB+5;M=-
M>1L8K9M]$^7<W IE*+9@BW8]J<+,MU%=(+.")?F(%1M<VD3=%IV*Y3%327D_
MAJQ'H+GJN!6O'K5I'W6IUUBVD^[@FG9#Y45+/0XXV!:MM;5%CPOI65-=.QS&
M>*LV-XV</UIEJVQ7N;(K(6Q4MG_=-:C1B=,CFLFX1K:3/:@+6-&2U#+TJ33H
M623 SBC3YA<)BMRQL GS8JBTKE'4(25SCFL&XL6;I74WP&XBLJ;% 21S4VGO
MVJNUA)Z5T$QZU69ATQS4&=D8XLG'M5NSMF5L]:M?*>M2PJ W2@+&CN(LR!U(
MKE8=(DOKYCM.,]:[/3X%N/DK7M=)BM3NQ[U5KFG+S$.AZ.MC"N1VJSJN6C"
M5*^I6UOP\JBJDGB+3EDPTJY^M5H::)6+>D6/V6+<PP3S7H/@_4DOM,:,-EX'
M*$>QY'^?:O.Y-5CNH<6[!ABKO@'4SINOF&5L170V>V[J/\/QKYKB+"/%Y?)1
MWC[R^6_X7/!SS#_6,%)1WCK]W_ /5****_$#\F"BBB@ HHHH **** "BBB@
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M2H> VP 'W->LHI'KQA&)DVWPR\/6I*S&:<KP5&(T'_?(S^M78? _ANVSLM9
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M\O)^;ZT#&<?Q8^6F;AR3U]N](S)?]4RL/F4].<?6FF41\ID'..>>*@DD'8Y
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MV]#NIC,7_A"KGLM!C:/ 88))ZGFK,=MY,:/)QN^ZA'+?X"@!L,2R*TKJQ1"
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MPK.XZ$4BWB?,'SMQPS'D?2@7,:<E\N[(7)[G=UJ)KHXX7'MVK+DN!_>'J/\
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M%VGDGL"QXY)-:NAZ]?\ AS4A?6%U+:N3DB$;MZYS@CH<X[U<AT&XDRRQ,J]
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M!^-2VNF/,S,(R #C;'N8$^F<=/I563Q_%;L18Z+"H P#=.I ]\*H_G6YH?\
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MA*?)W8X4XZ=*K?:&6-BZJV,9SSF@"W/<3;5Y4Q]#C&/K4#W(4MD*ZJ?NXX_
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MPQP-K9R?PK;V]);S7WHX8Y;C9.T:$V_\+_R-"BN U3XX>%=-MY)8[F:]"3&
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M<00+]D50%Q5:[O<*4B&U>E9FYE8,#\P[U6QJK1V+&L:?Y;$KT-<U/&8F(D3
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M\/W4PT^Z:W4<?9V >-@1_=/!Q5:8%&DA<*) ^X!ONN#[_P">M$L23*A0L$V
M L.5(K(Y-=SHD^)VM1JPEL[&:2/@[H60CT. V*E/Q2U"0!I-(TTD_P!Y7X_6
MN9CC:.0,&_AVY P<>YJ6&SB;*EE1LYQG@_CV_&G=E\TNYO+\3-1:3,%EIJR-
MT<1,"OXYJ,^+?$%Z9VCN_)BCPQGMK=(ACN <9/IUJK'I3>63Y9B$G1F(;([\
M#^=;VE^&Y+A85%O<7$C2;MS<)TP#[XIZE+F?4O\ AV;5;W4K..34;L[0?/\
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MU?2G[+'[.^D>-O"OB'Q1J>E3>)1I[_9;/0[>[%J;F8*K'?*2NT890/F'\77
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M V.<@?PGTJKRO]QKS34NVJ_'<\3_ +22.0!H4CDZ?,@VGZ5(UTO_ "TCM?\
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M^T5XKAN=>L6TG6])MK:+5[>=9;=)$4Y5G4E1PYYS@$8/6L[::'/ROE36KL?
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MW ?*&R-R\$?Q#&:[*Q_8^\:7RVL<VJ:%I^L7-L;N/0[K4-M^8QU(C"$>Q.[
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MGDA!,>/XE/44XZ:%0]UM%#5ID@9H#(7DQO+#@$'TK!DU"-D=]X4(=OO73S>
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M6D+E>[=N35/RUVL!P6.>.<^U:$BLSN0"ZCC<5QGZ56XV_*O)./F.#0(@6%E
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M)!')\IXZXZU3C)63DX/O4V&S@ E\TQE]9NLG0#C::T89/,C0$;6Z!O7VK+C
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MM/''CK6/&OB2ZUW7[IK_ %:\93-<%$CW;5"+\J@*,*H' [5/JWQ6\3:G\/\
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M3_&QQ^5=KH%NL*A>HQ5)FD7?8RX[B:>\)F).36!XDTMC*64<5W%Y:P_:#L8
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MCBN!HHYK%+%M;([IM<M]O_'Q'_WV*A;7(=P GCQ_O"N+HI\[#ZY+L=VFM6P
M_P!(B_[[%6(_$5LO2ZB'U<5YY11SL?UR78](7Q);'.;N'_OX*DM]:M9FRU];
MH/\ :F4?UKS.BCVC#ZY+L>L_VAI[<?VI9C_MNO\ C4BWVDKR=5M<_P#7=?\
M&O(J*?M"OKLOY3V-=;T>'IJ%LQ_Z[+_C2SZ]HEPN'NK7/KYJ_P"->-T4>T?8
M/KTOY3V2'Q!HMJF([JU!_P"NJ_XU'-XJL/X;VW_[_+_C7C]%'M&'UZ78]5D\
M2VC-Q?0?]_5_QJM)KEGR?M\)/_75?\:\SHH]HQ?79=CT&77K;G%S"?\ MH*H
MRZ_%SB9#_P #%<912YV3]<EV.B3Q UK>K(LFX>QXK;;7K:2/S&N8]Y_AWC-<
M%12YV"Q<ET.IO-6AD?Y'3/KN%49=23RRN]2W7K6)11S"^M2[%R:\,@&#WI)+
MK=&K;LL.U5**7,3]9EV)#<,Y()(%2176,JXSQ@'TJO11S!]9?8F68M"(R>AS
MDU K'<4*Y&>#2T4<P?67V*\T)WY _(TU;5FSCY3_ +1JU12N+ZP^PRSAV[BR
MJ688&YL8]ZZ[P[::?;K'-<WD(,9!"M*N??C/6N4HJE*Q4<4X]#V6^\1::S%D
MO[1MZ!?]>IVC\ZQ)M7LF)_TRVQ[2K_C7FM%5[1FCQLGT/0&U2S\O>+JW!SA1
MY@)_G4?]J62[<SPR-WW2C_&N#HI<[%]<EV.Y;4+/.%NH0,]W'%.CU2U7"FZA
M!7D$2C!KA**.</KDNQZ9_;=C,UONN[9<#:6\Q1^=79M2T2_M4AOKNSE\E\IN
M<,.G7@\\5Y-13]HQ_79?RGK[>(M+LH0D5Y:*A&%\EDP/J.U0MXHMUP?[2M\-
MR/WP8_SX_*O)J*/:,?UV78]='BZV*@/J,&.G[N8*X_'H:</$^GS/B:ZLI=O*
MM-(C'].]>044>T8?7I]CUK4]>MEMO-M-5M\J-S6[7*Y;_=.?TXK.A\:(VUOM
M,>,=Y,?H?_KUYM11[1B^NR['K4/B^S*@F]@*]XV< _@<U8;Q1IPC+)J,3IWA
MDE4D?0YKQVBCVC']>EV/7+CQ5IN%:2Z@N8V'W?,4G\1U%1R>(](EC4+]E8@[
MLM*J8QZ8;.?K7D]%'M&'UV78]8_X26SP5CDTY5)W%6E7K^)Z_2GGQ)ITD,L+
M7%DR2_,XCN"G/<CG@_2O)**/:,7UV78]!CB\,0D2"5FP?N/>9'Y9_6K:>)M*
ML0?LL=KGN6DW8]_F//X5YG12YQ?7)=(GL-MXHM8XEEGU:W9F'$2R* ON<'.?
M:J5UXK@F.1J<2@C&=XSCZ \?F:\KHI^T97UV78]&;Q#;\,;J%EQC:TP)JLVO
MVH;(N5^F\<?E7!44N=D_7)=CTBU\56R-N:Y1).GFQR#YA_M*>&_G[UB^)H]/
MN8&U"RN;;[2HS-:+)A)E]5&<AO;O7(T4<X/&2:LT7H]01HB0HA<X!VIV'IZ5
MV.@^-K:\7[)JKE#MVK=-R' Z!^.H_O"N HI*31*Q<H]#TF^FT]>%O[5^<Y$Z
M''Y'FJLUS9K&KF^M6)[+,,_SXK@**?.5]<?\IW\-Q8LQ/VRUW <>9*./QS4D
M4U@S G4+?C^)I5S^&6XKSRBCG#ZX_P"4]/CFTR"'S)=5M509.V.16<_7;DDU
MA:E\1K>T7RM+T]K@KTFN%PN?4+U)^N*XVBCG8/&2Z(T)?'/B*67>;Z13V6.-
M5 ]AQ4;>+O$$C8.JWFW_ 'L?TJG14\S,_K4RQ-?7U\RM>7LUPW&U))2P_'G
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M_P# Q5=KN-FP)4^I85AT4N87UJ78ZFUALMI>:[AS_=\P?XU<6^L;>/$<T/\
MWV*XJBCF'];?8Z^;5HR"!/"1[,*Q+Z\20-@JWTYK+HHYA/%2?0[#P(^GV:R3
MSSV\$O;S'"G]36YJ&L6,KEEO;<D^DJ_XUYG13Y^A2QDDK6.TDOK9N1<PD_\
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M4 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M4],TO^P;ZQ>W:*R^U&8$1##*S[%RKC<I&.C$5XM12L!]1^+/VWAXF^+WP_\
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M+'"RJK'@NV",$!BN<<#P*BBP'UK=?M[0:AH[>$KOX7:--\.#8"Q_X1W[;()
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M\ ^#S.+F[M(KQ[V:Z<,&7=*Z@XW*IYR3M49P,'PRBBF 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 ?K=_PPK\#O\ H2/_ "K7W_Q^C_AA7X'?]"1_Y5K[_P"/U[U16%V!X+_P
MPK\#O^A(_P#*M??_ !^C_AA7X'?]"1_Y5K[_ ./U[U11=@>"_P##"OP._P"A
M(_\ *M??_'Z/^&%?@=_T)'_E6OO_ (_7O5%%V!X+_P ,*_ [_H2/_*M??_'Z
M/^&%?@=_T)'_ )5K[_X_7O5%%V!X+_PPK\#O^A(_\JU]_P#'Z/\ AA7X'?\
M0D?^5:^_^/U[U11=@>"_\,*_ [_H2/\ RK7W_P ?H_X85^!W_0D?^5:^_P#C
M]>]4478'@O\ PPK\#O\ H2/_ "K7W_Q^C_AA7X'?]"1_Y5K[_P"/U[U11=@>
M"_\ #"OP._Z$C_RK7W_Q^C_AA7X'?]"1_P"5:^_^/U[U11=@>"_\,*_ [_H2
M/_*M??\ Q^C_ (85^!W_ $)'_E6OO_C]>]4478'@O_#"OP._Z$C_ ,JU]_\
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M1=@>"_\ #"OP._Z$C_RK7W_Q^C_AA7X'?]"1_P"5:^_^/U[U11=@>"_\,*_
M[_H2/_*M??\ Q^C_ (85^!W_ $)'_E6OO_C]>]4478'@O_#"OP._Z$C_ ,JU
M]_\ 'Z/^&%?@=_T)'_E6OO\ X_7O5%%V!X+_ ,,*_ [_ *$C_P JU]_\?H_X
M85^!W_0D?^5:^_\ C]>]4478'@O_  PK\#O^A(_\JU]_\?H_X85^!W_0D?\
ME6OO_C]>]4478'@O_#"OP._Z$C_RK7W_ ,?H_P"&%?@=_P!"1_Y5K[_X_7O5
M%%V!X+_PPK\#O^A(_P#*M??_ !^C_AA7X'?]"1_Y5K[_ ./U[U11=@>"_P##
M"OP._P"A(_\ *M??_'Z/^&%?@=_T)'_E6OO_ (_7O5%%V!X+_P ,*_ [_H2/
M_*M??_'Z/^&%?@=_T)'_ )5K[_X_7O5%%V!X+_PPK\#O^A(_\JU]_P#'Z/\
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MK\#O^A(_\JU]_P#'Z/\ AA7X'?\ 0D?^5:^_^/U[U11=@>"_\,*_ [_H2/\
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M,G ;.!DYKU+P;\59/$OP-LOB#<:3);R2Z,VJOIJ,2Q*QERJ$CD-M^4XZ$46
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MQ+=VVG>)?&EGYUG96T,OES2J@:4)][: &'WV[CDT6 ]4HHHI %%%% !1110
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M!P*-0/6Z*X>'XU>"[BU\(7,6MI+#XN?R]%,=O*QNVQDC 3*8SSOVXZ'%=Q2
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M" :+]0/E[PW\ _&.CZ9^SBJZ#';77A.YN9-=,=Q #;+)MY)#_O,X.=FZN_\
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M@2]\+Z3'<7\^G:3I_B:Q-U%&$DLS"T=R"SA79%66([2?E(QFNCU?0?BY\/\
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MO+!UCN[>"97DMV9=RK(H.4)4@@'&0<T 7J*** "BBB@ HHHH **** "BBB@
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M1112 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\2O_\
MA=G_  TM;_9/L'_"H?LZ^9YGD;MWE'=_TV\SS.F/DVXSSFO;:*8!1112 ^1/
MA_XC\1:3X+\)Z5X>UG^PWU[X@ZSIUW="UCN&$):[<[0X(#@HK*>0& W!URK;
MNK>/-=6:]\.ZI?Q^(+CP_P#$;0].AU/4;"U:62VN'MY!N18A&LJ>8X$L:HP^
M4C##)]MT_P"$/A+2X]+2VTGRETS5)M9M!]IF/EW<OF>9)R_.?-D^4Y4;N ,#
M"W'PC\)W>H7U]+I6^ZO=4M=:N)/M,PWWEMM\B7 ? V[%^4?*<<@\U5P/GY=)
MU'1;3]IO4F\17VI"P2ZD^Q:A9V,UM<R#28W1Y4-O\VWA0H(0A1N5B23J?$/X
MI>)=/\-ZM+X6U/7&O/#7AFWU.YM]%TS3EL+1S;M,!=O=,'=65,[+4*R)GAB5
M%>UZI\(O"VLZIX@O[JQN6F\06C6.JQQ:C<Q07D30^2=\*2",OY>%#[=X &",
M5G>)/@#X%\6&?^TM'F>.YM(;&Y@M]1NK>&ZAB!$0GCCE59B@)VM(&8<8/ P7
M \ZTJUU+6OVE;/6SXBU6W$W@JVU)[&TAM&C9#<Y:U&Z OY;')SN\S+'#@8 H
M?"GXA?%/QY;^#O%4&GZU=:9K%V)-0M[E=(328+%V<;K<I+]L\R,;/]9NW$/E
M5R OMUQ\,_#UQKFBZP+6YM]2T>W%I:3VE_<0'R RL(I!'(!,F5!VR!AUXY-4
MM'^#/A'0=834;#3IX'CN7O(K/^T+EK&&=R2TL=H9# CY9CN5 06)'4T7 ^=/
M'^J^*?'WP@T/QKJ7B:5K'4/%UHB^'190"VMH8]3$4820*)O-!B!9G=E.YAL'
M!'L/[2G_ ""?A_\ ]CSH?_I6M;5U^SSX O+R6XFT)I!)>#41;&_N?LT-T)5E
M\^*#S/+BD+(,O&JDAG4DJ[ ]=XE\(Z3XPAT^+5[3[6FGWT&I6P\QT\NXA</$
M_P I&<,,X.0>X-%P/E!6N/ 'QD^)7Q1L]QM=$\3)8:_ @),VES6MMNDQW:&0
M+(,=O,^E'PRD671?V>'1@Z-XK\0E64Y!'F7_ "*^IM/\ Z!IDOB.2WTY ?$4
MIFU022/(MRQC$1RK$@ HH&% 'M7.1_L_^!;;POX>\/6NDW-AIGAZ:6XTL6.J
M7=O-:R2%S(RS1RB3YO,?.6/WJ+@<?--_PB?[37B&?P]H]SJAN_"L-YJVF:2T
M"/<70O!'!(WFR1QB3RC+RS E4[G ,7CKXG>,-7\=^'_"NCZ%XG\/R2Z9<:Q?
M0Z;_ &/+J>U)E@C0-<SO;+'EB[%2[G,8^3YJ]8\'_#_0? <5XNC630RWLOG7
M=W<7$MS<W+] TL\K-)(0.!N8X' P*9XP^'FA>.I-.FU:VN/M>G.[VE[8WL]E
M=0;UVNJ30.D@5AC<N[:VU<@[1A >/?\ "4?%"[O/A?X=UF_D\(:OK%QJ=OJ4
M\=M9W$\\$$>^&7 ,L44K( 2%+(&9OE(PHAL_BQKK^'-1T&XUS5;OQ%;^,;OP
MY97&D:=:2:IJ,,2"<;1+LM8G6-AOE=-FR-\(&967V6R^&OAO3YO#LUOIOER^
M'_/_ +.D\Z0M&TRE9G8EOWKODEGDW,68L3N)-9M_\%/!VHPW*2:7+$]QJKZX
MUQ:W]Q!<)>N@1YHYHY%>,E0%(1@N.W-/0#P#5/%/BKQYX6\*VFH7UQ8:YIGQ
M0_LB"_U&UMWNHT2WG9&F2!O(:51)MRGR':#@\YL?%3Q#KJV7C/P=K.LR>(HM
M#U_PO=6FI7,,,5P8[F\0F*40HD9*M"2"$!Q(,YZU[2/V>?A\/"Z>'3X>#Z0F
MH?VL('O+AF^U^68_/+F3<7VD\D_>^;[WS5>A^"O@Z'1;K2VTN6XM[N^AU*YE
MNK^XGN+BXA9&BDDG>0ROM,:8#,1A<8QQ1<#QC5O''B31[SQU%X?O;+1KZ;XC
MZ9HT=TFF0,/*N([57,JA5,I_>'YF;?@ !A@8M>,?BOXL^',?Q1\/C7KG7;_2
M8=(FTK4[RR@:\3[;+Y$D:QP1)'*Z%2\2^7DLVUMP %>SS?"?PK<7%W/)I6Z6
M[UBWUZ9OM$HW7T.SRI?O\;?*3Y1\IV\@Y-<M\8O@A;>.M)UF?2+6P_MS59-/
M_M!-4:1K;4;>TG$JVTF-WEJ>1O1-W/>@"/X+W/BO4_%'BVZU37/$>K>%8FMX
M-&;Q%I$&FS2,8PT[F,6T$I"N0H9E53E@ VW=7#?%SXO^)=#O?$^K>&=0UV^M
M/#NI6EG<+;Z?IZ:-$6DA$L%PTS?:I9-LAR]N55=\8QE6+=Q\)?A+>^"_&VN^
M()-(\/\ @^QOK."SC\.^%I7>T+1LS&YD)AA4RG?LXC&%4?,<\;/B/]G_ ,">
M+-3O;[5-&FGDO;A+NY@CU&ZAMIIU4*LS0)*(C( H^?;NX'- &%X;U;Q5\2O&
MGC*>S\4OX<L/#>M)I-OI,%G;SQ7*QI%++)<ET\S]YYI5?*DCVA0?F.2?'+RP
MU3PQ\(OVA=6_X2.\U?['K5_']AU6QL+BUGE$5J1/)&;8;G[;?]7@#Y,\U](Z
MQ\(/"FO>))==O-.F_M"=H&NA!?7$$%XT)S$UQ DBQ3E> #(K'"J.B@"'5?@O
MX0UJ3Q*;O3KAX?$B%-5M(]1N8[:Y)6-3(8%D$:R$11@R*H<@?>Y.2X'GOCGX
MG^*?!NI?$GP]]M2;6YX[&?P@S01[O],86H0 ##^3<*7.X$[7!.5Z>>_&:+4K
M[P]\:["76'A?2[[P^)+FSL+2*6^+0VP8SMY)9_F.X<Y7:J@[/E/TSKWP[\/>
M)O$VA^(-3TU;G5]%+M8W/F.OE[\9RJL%<94$!P=I&1@\U7U3X6^%]:C\41WN
MEK<+XF$0U4--(/M'EQB.,C#?(555P4VG(!Z\T7 \B^(/C/4?A)XZU2\>X/B2
MYT?X?:AJ2WFH65J+JXE2[C,:O+#%&1&-V"B;5P-Q!89JUX'UKXO27EE-]AU?
M5+&\TB:6:;Q,-(BMHKT1![<V_P!AE,GDN^5*R!B%*G?D'/JMC\,O#EC?17AL
MYKZ[CTZ72/.U*]GO7DM9)!(\4AF=_,!8#E\G QG'%9VC_!'P;HEK+:PZ9<75
MF]E)IJVNI:C=7L,%JZA7AACFD=8490JE8PH(4#H *+@<[\"?%VJZK)J6B^)]
M6UN3Q796UM->Z3X@TZVMI8&8R*\MO);JL4]L[H0I4N5*'<V6 'G_ (X\=^(O
M#'B+XG#P[=6.D7J^+O#VGQ7/]FPOE+B"U$GG8"M-GS&Y9MP'"LN!CW7PE\-M
M \$WU]?:9;W3ZA?*B7%]J.H7%_<NB9V)YMQ([A!DD*#C))QS4&I?"?PKK%YJ
M=U>:5YT^I7]IJEVWVB5?,N;4(L$F X VB).!@';R#DT@.6^'?B37+'XN>,/
M^K:Y=>)+:PL+'4[._OX+>*X03&1)(F\B.-& ,893L!&Y@2>*]7K%M?!VCV7B
MR_\ $T-GLUN^MHK.XNO-<[XHRQ1=I.T8+MR "<\FMJD 4444 %%%% !1110
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MR'Y5R,D9%>?7WA/QIX>TWXG^%;#PFVOP^+K^ZNK'6EO+>.T@6[C6)UNU>03
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M]P[R,H"Q[\$9!*Q8'.*K?#+2=:\+^$M?2?P'K6H>*+^-]0U2^U^ZTZ,:U=$
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M,WQ ^'&LZ19E4U7RUNM.E; \N\A82P-GM^\1<G(X)H =KWQ>\)^&]0U2QO\
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M-<^S:7)J#:3NGM)XYH[Q2P,$D+()(Y/D;Y74$Y7'WESYSX1^%?BG2_"O[/\
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M&%4 =   *8$U>/\ B+XF>)KWXQ:CX$T"\\.Z'>6>E0ZC;)X@MYII-7:0R96
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M"QGOH]3T_3[NYC"*(FC,?E0N)E<2Y9E;$8"EL;Q6+X3^'?B'3/&7BR^N=/\
M+M;[PCIFF6\GG1G?<Q)<"1,!LC!D3DX!SP3S7/\ @SX>^+_!>G_ R\N/#EUJ
M-QX:T6\TK5;*SNK;S;9YTMPK9DE5'53"0=K$\C -+0#V;QM\1_#OPY@L)?$.
MH_V>FH3FUM ())6GFV,XC545B7(1@JXRS85<LP!YB/\ :0^'L@8_VW/&(;E;
M2[\W2[N/^SY6D$:"\W1#[(&<X4S[ <$@D D2_%7PCJWB3Q7\-+S3K3[3;:/K
MYO;Y_,1?)A^RSQ[L,06^9U&%R>>F,UYQXV^$OBW5OA[\>=-LM+,E_P")M4%S
MI$8N8E^T)]GMDW9+@)\T;CYRIX]Q1H!ZSXI^,GA/P;J5[8ZE?W)N+"!;J^^P
MZ=<WB6,3!BKW+PQNL"D*S R%>%)Z FEU?XQ^$=%\06&ARZG)=:M?VL=[:VFF
MV5Q>O-;N6"S+Y,;Y3*-ENBC!) 89X6XT'Q=X(\4?$Q[#PI-XNM_%CQWEA>0W
M5M&D$GV5;<P70FE1A&IC0@QK)\KM\N1@K\)?A!J_PY\=:'YZB[TS3/ UEH3:
MD)%Q)=1W$CR*JYWA<,""1C&!G(HT B^'/[0FE?:/$>G>*]<?[=;>*]0TF";[
M!)]FMHQ=O%:PRSQQ^5&Q50!YK!FX/.03T]C\7;32?^$ZO/$^L:3#I>A:NNGQ
M?8+>Y,T>Z*)DBE5E_>S,T@P(0P(*@9.0/+-0^'?CW4O!'CKP"WA%HK?Q+XGO
M;^WU\ZA;-;V]I-?M-YLD>\2B0(H9517SN7<4(8#1UKX4^+EU#Q5K%IHXO)8O
M'MEXFLK'[5$C:A:Q6T,;A&+;4?(? D*\H.@(-/0".\_:$U*Z\3_%";1=:L[?
M2=!TW2Y+2+Q%IES"EG/+/)'/Y\2Q+<@D!<*P[HP&TY/=-^T5H=CX]\8^'=2T
M[5[.U\-VL-U+J2:3>S1NK+,TA8);D1HHA^5RQ63)V9VFO-/&WPU\=^/;KXL:
MH/"<FEGQ%I6E6NF6=Q?VSSNUO<R&02;)"B-MPV [+AE^8ME5]/L/#>KZ/\=/
M%>H3Z!-JGASQ/IFGVQOH9;<Q6K6XN0Z3QR2*Y#"5<;$<<\XYHT [)?'V@/?>
M&[--0$EQXBADN-+6.)V%Q&D:R,^0N% 5E.6(SN ')Q7G?Q\^(5_X'U_P9;SZ
M[=^$?">HR7:ZAKVGVD=S<+.D.ZWME66*51YO[PC$;.S1JJXS\W(?LN^%]4_X
M2[Q'-JKQW5AX(\[P5H=P&+&2&.=I7<Y)VL(S:Q'&?]21G@UL_&;X43^+/B5_
M:VK>$+CQ[X8NM ;2H[2RN;:.ZTJZ\XR&XA%Q)$JEU*#S%?>#$.QHZ@>B_!?4
M/%&J?"_0+OQG"\'B.6%FN5EA6&4KYC>4TD:\)(T?ELR#&UBPP,8&#8_$UM&^
M)7Q0C\1ZQ#9>%_#MEI=S$UPJ(EMYJ3&4E@-S;BB8!)YP .<' _9U\&>/?".M
M>(+CQ_;&^U/5K6S:/68;Z.=%A@0QQVLZ[48W"[W=I%5HWWGY@0 <[XC_  A\
M5>)O$'Q+OM.M(2MZ_A^^TR.YN%6'47L9'EDMWP24!(5<L,9(/0$@ ].T_P",
MOA&^35B^HSZ6^E6?]H7D&M:?<Z=-';98>?Y=Q&C-'E&&Y01D8SGBN:\;?M)>
M'O#'@:;Q'866JZL8[RUM392:5>VLJB:6-!(X>#<B[9"R,RA9&78I+'%8OB3P
M;K7Q-\977B+5? DUOI5CX;N](30]6OK:.XU62XD1I$WP23(B*D7REG4EY/X0
MNXX.H?#OQ_K/PN\:Z*MGK#Z;_:.G77AW1O$6H6MQJ21PW<=S/&UPDC*4.W9%
MYLS. GS,!BC0#W2\\=:/IO@NZ\5WTMUI^B6ML]W/+>6,\$L42 EBT#H)00 >
M"N3V'-8N@_&WP9XFU*2QT_5WDG6TDOXS+97$,=S;H<--;R/&%G0''S1%AR#W
MK"^/U]-J7[-?CRZN-.N=)GDT"[9[*\:)I8CY3<,8G=,_[K$>]<K:^'?%OQ%U
MGP;J5YX7?P]:>'-$OHO/FO8)QJ$]Q;K"BV^Q]PBPN\M*L;<H-@P<(#O],^/G
M@;6/"T_B6UUB9M BCC==2DTZZC@G+DA4@9HP)Y-P*&./<X<;2H;BKEC\9/"%
MYH^OZFVJMI]OH*J^J1ZK9SV,]HK+N1GAG1) K#.UMN&((7)! \VC^%_BBQ^
MOPKT^#2XY?$7@^?3=1N=%:XC7[2T$;++"LF?+W_.65B=NY1DCK6?\1OAAXN^
M+$WB_P 21: WA^];2M/T[3-'U2Z@,]ZUM?+?.TKPO)'&K$")!O/5V;:"*>@&
M[IWQ\M-6^-5]9P:I=0>$]-\(SZO?6M]I<UK-#*EQ'^],<L2S8\ECC VMG@$U
MZ>OQ"T![WPS:"_S<>)(9+C2D\F3_ $B-(Q*QSMPF$8'#X/..O%>2:MX+\7_$
MGXD^(-6N?#,WA;2K[P1>^';>34[RWEF%Q+*C R)!)(%7!;!5FX0YVD@'(M?
MGCCQEJGPOM-3\)7'AG3_  ]HM]I>H7\^H6LY$LUB( \212,6CW*,$E6R>44#
M) /1=6_:*\(6>AZOJ&GSWNK-96EQ=0+!IEYY-_Y+!7^SS"$I,H8C<\1<*N7/
MRJ2,[3_CJOB"U^'^J6IBT73M<\]K^SU?3+];IO+L3=%;0F)5D"X_UI&QU5MF
MYOEJIX'T7QC_ ,*GA^'&H^$1HSV?A^;1I-;:^@:RFD2+R(G@2-FE99/OGS$C
M*C/!/%4_#/A'Q3?M\#I;WPS>:,?"9FMM42\N;5R@_LMX%E3RIGW(TK!1_%W*
MJ.:- /2V^)_ARXT?PU?VFJQ31>*&6+176*1Q=.\32KE57<H"(Q8L %Q@X/%>
M:Z%^TQ%##\.;75K236KKQ/8SW<^I>&])U&2T38N5\B,P-)(#T(R&0 ,P 84O
MPK^$^O>&?B(;?4[-4\(^%!>KX9G\Y&\X7LHD/R@[@8(PT(WA>'.W<.1A^"OA
MOXO\#^&O@;=3>&[G4;SPM9WEGJNFV5U:^?"9X0JN&DE2-U#*,[7)^88!YHT
M]@'Q=\)-X4/B0:MG21?_ -EF3[/+Y@NOM'V?R?*V>9N\WY<;>GS?=YK7\-^,
M='\72:PFDW?VM](OY-+O1Y3IY5RBHSI\P&[ =3E<CGKUKP*'PE?W'[5EUX9C
M,$G@ZWGC\?30JY)BOGA:T6)NX+2J;D G&5S7OOAO5-8U.36!JVA_V*EK?R6]
MDWVM)_MML%0I<84?N]Q+#RVY&S/<4@-JBBBD 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 45QOQ@_X3'_ (5IK_\
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M2WVB27]O;QSOJ$#[9(,PQQJQ?SH",K_"<=\JP'O<,*6\211(L<:*%5$& H'
M '84^L3P3::Q8^#]%M_$-\=2UZ.SB%_=[$02W&T>80J *!NS@ =,=>M>3:AX
M?O[K]KR"XB\3:I9Q#PJ+G[+#':&,QK>1JUOEX&;RW(+,=V_+':ZC  ![I63X
M>\5:7XJ74CI=U]J&G7LNG77[MT\NXC(#I\P&<9'(R#V-?/UC\3/&G_"I=!^+
M3^)FN8]0U&V,GA,VENMG]EGN1;B"-Q'Y_GJ'5MQE(WJPV;>*Q[/Q[KOA5-6T
M7P]%>?VAXB^)6JVC7&GK:M<QPQH9G$/VIE@\Q@@4&0D %L*S;118#ZOHKYMU
MSQA\5]"\,06EW->:%<7OBS3=+TS5];M]/FO);2X8++Y\5J[0[D8L 5V%E"\
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M7;_VQJNJ75G=FWN8=?T^.RU&RD\M',%PD:)&6&_(9%"E64 L07;T"D 4444
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MO3+>UN=2NM7GC&&O;Q8EEEY)RPB1$SV^51TJ[2 **** "BBB@ HHHH ****
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MM:? WP58WL]Q!I4T:R_:"+0:A<_9(FG5EF>*V\SRHF97<%HT4_.W/S'.?/\
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M]FWEQ)+,X9A';[8 ;K"HQ+1*P !SBN]F\:Z:/!LGB:V-Q?::+<W"BUM9I)F
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MFJ_A[X]^ _%6IZ58Z3KZWKZKQ8W"6LXMKAQ'YAB6<H(C*%Y,6[>N""H((HU
MOP?"/PM#8V]JUA/<K!J4.KB>\O[BXN'NXL>5+)-)(TDA4*H =B,*%Q@ 4WQE
M\'_"?Q U+^T-;TZ:>Z:U^PRM;W]Q;"XMMQ?R9EBD431[BQV2!E^9N.3GG?BY
M\3)?AYX^^&\,^H-9Z'JEW>P7T,=MY[W)6U9H8T54:0N9=@58QN8D#!SBN@C^
M,O@Z3PG-XC_MCR],ANVT^19;6:.Z2Z#[/LQMF03"8G&(]F\@@@$$$FH%2Z^
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MV  KE-)^"_@W0O!\GA?3](-GHKW NQ%#=SK)',I4K)'-O\R-EV(%*L-H4!<
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M27,SRM>Y8^?+*SEY7)9LF1FSQG.!77T4 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MD4.DD;!E92,@@CJ"*S?^$NT+=C^VM/S]M_LW'VJ/_C[QG[/U_P!;C^#[WM2
MUJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?N9;J22-LJ2!E6!QU&>0#7IE%%( HHHH **** "BBB@ HHHH **** "BBB@
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M9]F\/^"O /\ PE>I:U->:!#'<Q^'+N[AFLK&]$>PR*RH78KERH,K(I<[0 %
M- *.G?';QC:_!_7_ (CZQ:Z+)I]O<W&GZ=I-C:W!FGF%_P#9(I9)?,?"EL@Q
M+$S' 8-SL%O3OC)X\6W\411^&KCQ3<V.A/JEA=0>&=2T2.6Z1MILS'=[C(Q!
M5U*-E@&7:" 3WUK\%_#L/PPNO 4XNK[0KF2XE<SR@3!YKE[DLKH%P4D?*D#(
MVKU(R9=/^&=Q;Z;?VU[XV\4ZM/<VZVT5Y<7<,,MH%.0\8@BC0ONP2TBN3C:<
MJ2I6@'F5Y^T3?Z?X#M[ZVU70_$^KW^N0Z'!-I>DWR-92LLC2BYT[=)<AXQ#*
M1'N5G^7A!S4>I?'SQIH_A'Q!=MH<5W>:?JNE6=CJ.H:+?Z+:ZC'=S)'(HAN,
MR1O&2RE@9!RC8.2E=O/^SYHNH6NJ2:CK.M:EKU_?6VHGQ#++#'>P3VR;+=HA
M%$D*[%+#'ED-O;=NS6AJGP=MO$7AR;2=<\2:]K;2W]KJ#7EW- L@:WE22-%2
M.)8D3<@W;8P6R<G."'H!YG\0OB+XZL_#GQ9\*WFK:1;>(-%\*G7;76-(L+B
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M9$86UJRB%WN7$4(WG]UL/S%FW?-@:$/[.&C6^H:8\?B+Q$NCZ7K!URQT$7$
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M%G8VMSI>IZ5)XFMO#UQ9V>CW\OD><ZQ[FU/(MA,K.K-!L)7E-Q89KB?^7O\
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MWFDV>D:A>%5E>)7\S4DVV]O*/,)$3HW"KSEPH/%OQG\>:=)\5=0TR'PZFC>
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M:M\?O&7ASPEXYOI])74FT;3H=0L-8N/#>HZ+:3,THC>VDANF+EUX;<CD$..
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M]SJ;72YF_P!6#BS6X\K]X%SNV@<[2=O%?=ES\)]'NOB_:_$=Y[T:Y;:0=&2
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M$S92+E H)!(R:Y/X*_#OQ]\0]!\>>!-4L;SPUX+U?20%U35/!5KH5PE]YJ8
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M02*/]9^]!8#/W./SIZ >AR>(O$.H_!O5=7UO1'\'^(?[-O))--COTNFM659
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MS'(ZYD9J[JI ****0!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M#O$7B[XZ>&_&'C[3TOEUGP?X)A\.V/D!A-)?.NZ[FC YWA PXY^=<#@5R'P
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M=>![*]\#_M">.WEOT\1^&?'<XTBXBNY$2UWW\:NRH#MW$2<MC/RKZ5ZCX?\
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M;!^9;A?7 8D8?*!^C5%%%0 4444 %%%% !1110 4444 %%%% !1110 4444
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M.6X<'-6KGX]>%6T+7[_3Y;Z^N-(L!J36+:9=Q33P,66.6)&AW21,RD>;&K(
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M2N+<):7/FACMADS\[)M^88^7<OK6U7R/XXVV]U\83X,4+HO]C>%67_A'>/\
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M!/RWM=^.WC/PQ8>*M-FM-!U/Q-H/B32M'$T<4]K9W4-Z(65BA>1XF"RD$[I
M",[6Z%V ^A:*\!U+XD?%"QU7XAZ.ESX1FN/".F1:N=1;3;I$O%EAE=+?[/\
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M0!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M:4_9)U3XM?$JU\8:/%X;U9CIZV-QI?BB:]AA4HS%94>T97)PV-I..,\YXV/
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MX/L*Z*@ HHHH ***IWVL6&ESV4%Y?6UI->R^1:QSS*C3R;2VQ 3\S;58X'.
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MCO*[3N"-P"2,<XI ;5%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %>)7_PN^)MQ^TM;^,;?QWY'P\2W5'\.^=*<D1%67R<>6<O\_F$[AG&,
M 5[;10 4444 ?/'AR:_^!FL>"=)\/>(;'Q?\-_%6J/;Z;8LJM?6 E5Y_,@GC
M.VXMPWF,Q9<HK( S"N;T7XAZE)\'O@BTOB:Z;6M2\806EV6OV-S=1K<3K+%)
M\VYU'R!E.0/E![5]$:+\-_"7AO6I]8TCPMHNEZO<!Q-?V6GPPSR;CN;=(JAC
MD@$Y/)%-C^&?@^'6)M6C\*:&FJS7"W<M\NG0B=YE;<LK/MW%PQ)#$Y!.:JX'
MS+KFNW\?@'XJ^++?QOKC^*O#?BVZM]+L$UB0PP[;T"&U:U5MLBRY*!9%;CA,
M 8K6\27S:MJGQ]N;[Q[KFE77A=OM.EVMIK4EO'8_Z!"ZR>4C#S$:1=NQ]R$[
MMJAF8GV/P9\#?#WAG5=2U:_T_3-<UJXUJ\U>UU*XTV/[19">4R"*.0[F&TL?
MF!&<DX%,TOX%>'H_&7B7Q#K=AIGB.YU/4X]3L_[0TV.1].98(8B(W?<<DP*V
MX;>@] :+@>=^%[N[^*WB?Q+;^-O$.M>&VTC0-,N8;/3-6FTD0?:+42W-VWE,
MF_;*&3]YN1/+(QR<Y/PRU3Q'\6_&7@1?%.NZU:PS^"!JMU::9>3::E[,+ORX
M[AUA92N^-@Y"E0<@?=&VOH+Q-\//"OC::VF\1>&='UZ:V!$$FIV$5RT0)!(4
MNIVY('3TK6_LBQ_M8:I]BM_[3$'V87OE+YWE;MWE[\;MN[G;G&>:5P/E.&&Y
M^&NC_M$>)_#DVJ'7M'U.3[*;C4[NYCB1K.V9IWA=W20H&9P\B,0$ ^Z,5M2?
M\)]\-=$\0:WINK:>]G'X0O;Z"PF\7W?B&XNYX45H;V(7,";57?APAV/O0;0=
MM?0R>#]!C\22>(4T33EU^2+R7U5;2,731X V&7&XK@#C..!5?PK\/_"_@7[5
M_P (WX;TCP_]JV_:/[*L8K;SMN=N_8HW8W-C/3<?6G<#Y\TS1=.T?XT_ >:U
M\3ZIKUUJ&DWUW,NIZO)?&3=9 BY42,QC$A+<)MC.WA1BNJ_:"\;ZO\*?%%GX
MBM[V[?3-4T+4-)CL?,;R5U-$\^S95SM$C[9DSU(4=<<>IZ#\,_!_A:XCN-%\
M*:'I$\<C2I+8:=# RNRE68%5!!*DJ3W!Q6KK7AW2O$D,$.KZ99ZI#;SI<PQW
MMNDRQRK]V10P.&&3AAR,TK@?-7P]\0>)[S6M ^']]XBU&^U+P3)J\^OWWVJ0
M27RHH6Q\UL[F#+=J^TD@F$$YQQD>!]#7QQJ7[.FIZWJFNW=_J/A[4&N;I=<O
M8I)'2&!@=R2C#'+;B,%P!NW!1CZKA\.:3;ZI?ZE%I=G%J.H(D=Y>);H)KE4&
M$61P,N%!( ). :S[[X=>%-3TG3M+O/#&C7>F::P:RLI]/B>&U(& 8D*[4(']
MT"G<#Y@U*&\\+^ ?BQXXTW6]9L]7TCQS</:P6^H216@'VR!75X%(24.KD'S
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M)XF63;#&QD./*&W)[Y8D<D5]XU+ ****0!1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'AOQJ\)
M6/B#XX?" W4^IQ>=/J,+?8=5NK3"I92N"OE2+M;)P67#,ORDE>*YK3M1UW3?
M!WQJ\<0:MKFKZ]H>J:U;Z/92ZA,]I:I&I* 6P;RY-I8M\ZM@* NT5]&76D6-
M]?65[<V5O<7EDSM:W$L2M) 64JQ1B,J2I(.,9!Q1I^D6.D?:18V5O9"YG>YG
M^SQ+'YLK?>D; ^9CCECR:=P/"-/\[PCXL^#TOA[Q1K&O_P#"4)*NI1ZCJL][
M%?VHL_.:\5)79(2KB,CR0B_O]N,%0///!=OKEYX#^!FJR^-_%DFH>+KK^S]8
MF?696$UNUK,VQ4)*1L/)4"9 LHRS;]YW#ZD\._#SPKX/OKF\T'PSH^B7ET,3
MW&G6$5O)*,YP[(H+<\\]ZM6_@_0;2UTJU@T33H;;2G\S3X8[2-4LVVE=T*@8
MC.UF&5QPQ'>G<#SK]G_5+QKKXBZ#<W]]J-KH/B::SL9=1NWNIDMVAAE$9ED)
M=PK.^"[$X(&>!7BNJ>#K#2/@Q^TA=P7&JO/;ZGJ=FJ76KW<\93[-;,"T<DK*
MTG/^L8%\8&['%?7.GZ+I^DS7LUC86MG->S?:+J2WA6-IY<!=[D#YFPH&3DX
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MP;>)4,TI !D? ^9B%4%CSP/2DM='T^QU"]OK:QMK>^OBAN[F*%5DN"B[4,C
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MG0E@>&\"VW_""_ #P5K.GZMJVGFX\:VUOJ$LNL730I;C6I8Y%*/(4C5E)#X
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M)P;@#[+EG8( 8F<*H4$,22!F>"_VMM(\7:_X;MA%HBZ?XBN6M;%++Q!%=:I
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MOFVZ^ _B'P+I=SXD/AWPSHPTCP7J.E7">%?-N]0U*Z>% +ER\$?FL2A.URS
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F1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>img69628308_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img69628308_1.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #9 2\# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH ANKNVL83-=W$-O$#C?*X1<_4U
M =8TQ;,7AU&T%JS;!,9UV%O3=G&:R/&UK<W>AQ1VD3RRB[A;"1E\ -U('85F
M:EX>_L^/[6+J]_M1[F6[2ZL[(RHDC #:8OF.".A/?J>@JU%-:FL81:5V=LCK
M(BNC!D895E.01ZBJMKJNG7TK16=_:W$BC+)#,KD#U(!KG[FS\0:EX/DA M+6
M6:SV?8XX2C*<?=#[\ $<8(XSC/>J4D<^HSZ"=/L+RV.GVSF5I;=X?+!CVB,%
M@-QS_=R.*%% J:?4[*[NH;&TFNKE]D$*%W;!. .IP.:?#-'<01SQ-NCD4.AQ
MC((R*\V^RZZ=&6.5-4F:ZTB<7"3>9)^]S\HP?NMCL,9JW:KJUOK>FZ)Y]TL%
MPD%ZQ,K Q(B$21>H!8+QTYQ3]GYE.BK;G>+=6[7+6RSQ&X10S1!QN4'H2.N*
M6WN(+N%9K>:.:)LX>-@RG!P>1[@BN5\70ZC9ZA;:MI5K//.]O+92+""2 P)C
M8X[!N2:Q[NUU?2;NTL=/BODCM&MD5H$G=)E_Y:,<-Y8&>H*DG.<^@H)K<4:2
MDKW/1JKRWUM!>VUG))MN+D.8DVD[@H!;GH,9'6N*8ZY_96KE1J_]K[I>!N\K
MR]ZX\O/R[MF=NSGK[5-J@U -:_V2=9-MY%]GS?-W;O*&S.[YOO9V[N<YQQBC
MD!4M=SMZ*\^DB\16MC<+9OJ3R3:1!,YE9W(GW_O F[[K;,_*N#TQSBND\,PS
MQ0W7FW]U=(T@*+<6TT1CXY ,Q+,#UZG'-)QLKW%*GRJ]S=HHHJ#(**** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ J/[/!]I^T^3']HV>7YNT;MN<[<]<9YQ4E% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !TK*@\4>'[JX6WM]=TR69CA8X[N-F)]  <UIO_ *MOH:\1T6PN-:^'D.E6
M?@T37,X=4U60Q(JGS&^?=]_Y?Z525SHHTHS3<GV_4]PHKRK^TM9\/^.-8O3<
M2WFEV$-G%J$.22%:+F91Z@@DCN":S]<U:XO=,UF5;N[N(&\2011BVF(9H2B_
M(A!'4=/<T<I:PK;6NFGXGLM%>8PV-O;>&_$5[::?XCT^>+3I54ZE<.0V5)R@
MWGD;1SVS6CXAOKJW^#<5U;W,J7#65K^]5SN.XH#SUY!/YT<I'L-4D]W8[VBO
M)G\2ZKX;\:^)-2=9[W1EN4MY;="6:*0Q@QLH[ GY3]15"VUCQ+IX\1)?7IAU
M.]O;& R9RMD)@Q.T'@;1@?6GR%K"2:O?M^-ORN>T45YQXBT,>"=*37])U/46
MN;>:,3QW-TTJW:LX4JRGC/.01BF1>(9O!MGXFTFYDDFGLV^T:9YK%FE28X1>
M>3M<XI<O8A8?F5X._P#7_!1Z517B7B'5;S2C8Z0/$ AO]&M1J%T\]Q@W=TQ#
M>5R>1@MQTY KM?$E]%J/@ZS\7Z;J'V2:TC%U"S.=D@/WH7 ZY^[Z@T<HY89K
MEUT?]+[SN**X/P;'_P )8EYXAU69FFFE\E+%9&"V2HV0A''SDC)..XK=O+98
MKJ-()YI=1>4/NWGY4SSD= ,<5G4?(9RI<LN5O4WZ*Y[6K81SK(%NEB9M\TR.
MQ"#T S6_'M\M-ARN!@YSD4HRNVNQ#C9)CJ***LD**** "BBB@ HHHH ****
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M/AU<O&H>3Y<(N&8CKD8/% '>457L+DWNGVUTT31&:)9#&QR5R,XJQ0 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 55^S"RM+@:?;Q"5B\H0_*'D/.6/N>]6J* ,+P_P")(]8,
MMG<PFRU:VXN;.0\K_M*?XE/8UNUA^(/#<.M"*Y@F:SU2VYMKR/[R'T/]Y3W!
MJMH7B26:\.BZW"MGK,8SM'^KN5_OQGO[CJ*T<5)<T?N_KH!TM%%,EE2%"[G
M%9@/J-9XWDV*P+8W<>E5PLUWRQ,<?8#J3V(/I4L,:Q2O&J@#[R\>O6@">BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MI<HO92TSR,YR^_RXQ\L:9[X0*">YR: -RBF0S1W$*30NLD4BAD=3D,#T(I]
M!1110 4444 %-=MB,Q[#/7%.J"\.+5N#SQPN[]* &V:GRC(^=SG/S8SCMR*F
ME7=$Z^H-$2A(D4    <#'Z4YF"D GDG H 2,DQJ2,'%8_B./Q#+! OAZ>SAE
M+GSGN5) 7'&/?-;55+[4[+3?)^VW44'GR"*+>V-['H!51;3T5P/.[>R\6^![
MZ\U>6"#6;>^<27JVP*NI&?F48]SV_*MNZU]-=M()K42):R('"R+M8GW%=I7
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MN 1[4Z9S*ICB&[D9.< <TR[BPPG5<D<, ,EAZ#TJQ$4:,&/&WVH 16E) :(
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A110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>img69628308_2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img69628308_2.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &E A<# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MV"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MV,D#'^-#_A4NOZ*=06*[ML+?6Q#Q-_>P<[37/BZ4G-58;K\4803=.,ENM/\
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M?YE^/^0N=]G^'^9J45E[=:_Y_;#_ , W_P#CM&W6O^?VP_\  -__ ([1[O\
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MO^?VP_\  -__ ([1MUK_ )_;#_P#?_X[1[O\R_'_ "#G?9_A_F:E%9>W6O\
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MBBB@ HHHH **** "BBB@ HHHH **** "BD5@RAE(*D9!'0TM !1110 4444
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M)F6-Y2=S=<GN:R6D=FW,YSZYKYR>:5>;W4K'JT<"IJ[9Z#%K-I*X7>R9_O#
MJY)/'$F^1U5?4FN!LIFD0JYR5[U<>9W55=RRH,*#VJX9K-1?,KLRJ83EE8ZK
M^UK+_GNOY&E75+-FP)US[\5Y_/=2M(0&**.@'%36=R[OY<ASZ&I6:U+[(T>
MM'FN>BJP89!!%+7/:)>E':WD?Y,97)Z5NK-&QPLBD^@->OA\1&M!2."<'%V)
M****Z" HHHH **** "BO)-8N=1CE\2ZA'+.HL]1PMT-2=3 @6,D+!]U^">#U
MSBNU\87LL5CI<2W,EK:WE]%!=7"-L:.-@3C=_#N(5<]MU '345Q5_>VWA*WO
MCI5[-=R9MT^Q33&9;=I'VA\L=P!S]W=SCMG-5QJVHW^IZ*E]&(I(=6:+<GR"
M5?L[MR@9MI!/0D] : .]HKS*P\3:GI/A?1S$(6M4L?/N)I%,S+\Y'S!6#*N
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M5KE58*$G%.X4445L9A1110 51U+2+/5FM3>1>8+6;SHU/3=M*\CN,,>*O44
M1I!#&$"1(NQ=J;5 VCT'H*:EG;1&4QV\2&8YDVH!O/OZU'J&HV>EVC75]<)!
M I ,CG !/ JR"&4$=#R* (!8VBR12"VA#PKMC81C*#T!["GBV@ ($,8!4J0%
M'0\D?2I:,T ( %4   #@ 4M%% !1110 4444 %%%% !1110 4444 %%%% !1
M63J/BC0M(NA;:AJUI:SD B.64*2#TXJW+J=C!IW]HS7<,=EL#^>[@)M/0YH
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M;'453G>.S*3.9U8F7Q'+9Y(2:V@,F.Z*TQ(^A)4'VS5LG J"[0'Q;</W6QA
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MCMZU'HMM/;:&(+B^_M"53\\A;A6R<X[]<]:CC\/7R>-9-7:Y0VDD95H^<G@
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M_B,C]:L0S)<0I+&<JPR*C$+WE)=E^1KA_AMYO\SPVYM;G1M4,,Z%9H'R,]&
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M_'O^56]#_P!?JW_7X/\ T3%11H?^OU;_ *_!_P"B8JVIN_-Z?JC&NDE%+O\
MHS7HHHH,@HHHH ***KW=]:V*!KJXCB#' W'&: +%%4M5@NKK3)X;*813NN%<
MD\?B.GUKDX/$FKZ#,+76[9Y8^BR_Q8]CT:E<I1;V.YHK/M-;TZ\M3<17<0C4
M9;>P4K]0>E9__"8:8^I0V<)>7S'"&4#"@GI]>:=Q<K.@HHHH$%%%% !1110
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M8((X5+%8U"@L<G '>B>WANH6BGB22-NJN,BI*X_P]<SCQ=JEI-/(Z#>45F+
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MC2SPS260:2)40$R-\P3[NX9^?';=FK":+IT=PEPEH@E2=[A6YR)'&UF^I'%
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M'%4T\=W-M8ZN^I6$<5S87*6J1QR?+*[=#D]!FBP<R.XHKCF\57@NGTR4:?\
M:YK1YK>6VN#(FY?O \9!Y!'\ZL_#V>_N?!EE-J#QO(^\AE8DD;VZY[T6!.[L
M=117E]HMC=>+/$PU+3-3U#R[P+$;=9&6,;>1\I %6O%JR6G@RWCT6V>QM[F]
MC2:*Z,B2'+ 8ZD@''//2G87-I<]&HKRR.XGT7Q;JEUJD=N;+1[!)4BAED.S.
M[[F>I)X^:NBM/&%S'?6$6IIIXBOOEC^RW&]XGQD*X_J*5@4D=C17)VGB36=0
MMQJEEI<4NEFX:(('/VAT#%"X'3&03CK@5#X/N]5N?$?B1;UXFABN0B!6;*<<
M  CIC/XT6'S'94444#"C0_\ 7:J?6\'_ *)BHJ;1$_XEPF[W#M-^!/'_ (Z!
M6M/1-_U_6ASXC[*_K^M31HHHH,0HHHH XF=O%FLW$D*+]B@5BI8?(./?[Q_#
MBJ_AR,Z'XNFL+O:TDJ;5EQU/WOUKOJQ=4\/1ZEJMI?B=H9(.I5>6P<CGMWI6
M-5-;/8VJ***9D%<_?^'I;GQ);:K!.D0C"[P026P?ZCBN@HH&FUL%%%% @HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@"M?V:WUF\!.UN&1QU1QRI_ UE6TYF5DD79/&=LL9_A;_
M  /4'TK>JA?Z=]I87$$GE72C ;JKC^ZP[C]13TDK,<9.#NBO154WGD.(KZ,V
MLI;:N\_(Y_V6Z'Z<'VJU64HN.YUQG&2O%G/7>AWUMKLNL:+/ DMP@2YM[C/E
MR8^ZV1R&'ZTRV\/7<U_<ZIJMS%)?R6[6\20@^7"ASTSR3SR:Z2BE<=D8_A;1
MY= \,6&E32I+);1[&=,X/)/&?K4>GZ%-9^*M4U=ID:.\CC14 .5VYZ_G6Y10
M%@K%\1:++K7]E>5*D?V._2Z;<#\P577 ]_FK:HH&U<YSQ+X>GU>_TZ]MS:RO
M9LQ^SWBDQ.&4C) !Y&:QI_!6JWB:Z;B[LE?4TA"K$C!8=F!CW& *[RBBXG%,
MXOQ*J:3J^C:G'<QV]W##);EYXV,,B$+E6902IRH(^AK(TCPW=^)M+UN6_FCW
M7=ZEQ;3"+Y"4Z':W)7([]17I=%%Q<NIR=AX8O!J7VN[73;5%MVA$%A  '+=6
M9BH/X"M+POI=WHFB1Z==/ X@9A&T6>5+$\Y[\UM447&E8Y&UT3Q!I&M:O>:<
MVF30ZC<B8BX>160 8_A4YJQJ^BZMKVC1VUZ]E#/'>1S PEV4HISW&<]:Z:BB
MX6.4U'P:-5U#77N;A1;:G:1VX"CYHRN3N]#R1^50:?X4OQ>63WJZ3!%:\DV5
MN \YZ#<2OR\<\5V5%%PY4<E9^'=<TRT_LFPU&WBTT3M(DVT^>B,Q<H!C:>21
MGT-:&C:+=:5K>JW!DADM;YQ*#D^8K@8P1C&/?-;M%%PL%%-=TB1GD9411DLQ
MP *@CDN-0PM@F(F&?M3CY!_NCJQ_3WJHP<MB9U(PW"9/M\XT]"<, ;AE_AC]
M,]BW0?B>U;ZJJ*%4 *!@ = *@L[.*RB*1[B6.YW8Y9V]35BM'9*R.1MR?,PH
MHHI %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 -DC2
M6-HY$5T88*L,@_A5!]"TY^D#1>T,KQ?^@D444U)K9B<4]T,_X1ZP];S_ ,#I
MO_BZ/^$>L/6\_P# Z;_XNBBJYY=Q<D>P?\(]8>MY_P"!TW_Q='_"/6'K>?\
M@=-_\7111SR[AR1[!_PCUAZWG_@=-_\ %T?\(]8>MY_X'3?_ !=%%'/+N')'
ML'_"/6'K>?\ @=-_\71_PCUAZWG_ ('3?_%T44<\NX<D>P?\(]8>MY_X'3?_
M !='_"/6'K>?^!TW_P 7111SR[AR1[!_PCUAZWG_ ('3?_%T?\(]8>MY_P"!
MTW_Q=%%'/+N')'L'_"/6'K>?^!TW_P 71_PCUAZWG_@=-_\ %T44<\NX<D>P
M?\(]8>MY_P"!TW_Q='_"/6'K>?\ @=-_\7111SR[AR1[!_PCUAZWG_@=-_\
M%T?\(]I_K>?^!TW_ ,7112YY=PY(]B:+1M/B(86J.PY#2DR$?BV:O444FV]Q
II);!1112&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>img69628308_3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img69628308_3.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 'M Q(# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M  H ?13,R_W$_P"^S_A1F7^XG_?9_P * 'T4S,O]Q/\ OL_X49E_N)_WV?\
M"@!]%,S+_<3_ +[/^%&9?[B?]]G_  H ?13,R_W$_P"^S_A1F7^XG_?9_P *
M 'T4S,O]Q/\ OL_X49E_N)_WV?\ "@!]%,S+_<3_ +[/^%&9?[B?]]G_  H
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M +[/^%&9?[B?]]G_  H ?13,R_W$_P"^S_A1F7^XG_?9_P * 'T4S,O]Q/\
MOL_X49E_N)_WV?\ "@!]%(,XY !]C2T %%%% !1110 4444 %%%% !48MX1<
M&X$,8F9=ID"C<1Z9ZXJ2B@"O;V%G:,S6UI!"S?>,<84GZXJQ110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^>+_ )C_ !H\QO\ GB_YC_&@!]%,\QO^>+_F/\:/,;_GB_YC_&@!]%,\QO\
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MP**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*\DKUOX)?\QW_MW_ /:E55^%EXC^&SUJBBBN0\P**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH ***CN-YMI?+D\N38=KA-^TXX.WO\ 3O0!
M)17)C5[U3=6\5Y*^^YMX(9;B%4ECW_>)3:O'!VDKR<]0*U]*N+G[?J-C<3M<
M?9G0I*ZJK%67.#M '!SSB@#5HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M&X2_M3,P9%7RVQN^7 '';G-=/0 44UF*]%+?3']:3S&_YXO^8_QH \H^-O\
MS O^WC_VG7DE>L_&MBW]AY1E_P"/CKC_ *9^E>35UTOA1Z>'_AH*^B/AE_R3
MS2_^VO\ Z->OG>OH7X9NP^'NE@1L?];R,?\ /5_>IK?"1BO@7J=A13/,;_GB
M_P"8_P :/,;_ )XO^8_QKF//'T4SS&_YXO\ F/\ &CS&_P">+_F/\: 'T4SS
M&_YXO^8_QH\QO^>+_F/\: 'T4SS&_P">+_F/\:/,;_GB_P"8_P : .5^)O\
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M^>+_ )C_ !H\QO\ GB_YC_&@!]%,\QO^>+_F/\:/,;_GB_YC_&@!]%,\QO\
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M^&7_ "3S2_\ MK_Z->IK?"1BO@7J=;1117,>>%%%% !1110 4444 <E\3?\
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M%/7)5UOPR_Y*'I?_ &U_]%/6LOA9U5/@?H?1%%%%<9Y(4444 %%%% !1110
M5\[_ !-_Y*'JG_;+_P!%)7T17SO\3?\ DH>J?]LO_125K1^(Z<+\;]#DJ***
MZ3T#ZUHHHKA/&"BBB@ HHHH **** "BBB@ HK&EOM1M=5M[>86TB7(F*)$C;
MHP@R"6)^;/ / Y(_%F@ZI=7^$OI(X[KRA(UK]DDA=,G&<NQW 'C('I0!N444
M4 %%%% !1110 4444 %%%% !161K-[?Z=$UW%]F-NA1?*96,DI+ $ Y 4\\<
M-4$>K78UF2VNI([:'[1Y4(DLY/WPV@C$NX)DG( QVH WJ*** "BBB@ HHHH
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M2OG>OH7XF2*WP]U0 -_RRZJ1_P M4KYZKIH_">AA?@?J%>M_!+_F._\ ;O\
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MH_\ WP?\* 'T4SS5]'_[X/\ A5.^UK3-,\O[??06GF9V>>_E[L8SC/7&1^=
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MDHL4)C4#)))RS$]:U:** "BBB@#R7XV_\P+_ +>/_:=>25ZW\;?^8%_V\?\
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MUY)772^%'IX?^&@KT7POXFU?3_#MK:VMWY<*;]J^6AQEV)Y(SU->=5U^B?\
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M-!77Z)_R"(/^!?\ H1KD*Z_1/^01!_P+_P!"-5+8N>QH4445!F>[44SSHO\
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M.FZ%;VS7"7$@+O)+']UG=V9L>V6(H U**** "BBB@ HHHH **** /)?C;_S
MO^WC_P!IUY)7K?QM_P"8%_V\?^TZ\DKKI?"CT\/_  T%=?HG_((@_P"!?^A&
MN0KK]$_Y!$'_  +_ -"-5+8N>QH4445!F>[4445RGFA1110 4444 <E\3?\
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M^(\[$_Q"]16?::K]LO)H8K*Y\N&5H7G)C"!EZ\;MWIV[UH5D<X4444 %%%%
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M\E4445W'LGHGP:_Y&^[_ .O!_P#T9'7JVJ"\;6]-FATZXFAM7=G='C .Y"O
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MJ%4?0"I*D@9Y,7_/)/\ OD4>3%_SR3_OD4^B@!GDQ?\ /)/^^11Y,7_/)/\
MOD4^B@!GDQ?\\D_[Y%<E\3(HU^'NJ%8U!_=<@?\ 35*["N2^)O\ R3S5/^V7
M_HU*J/Q(NG\:]3YWHHHKL/6/6?@HB/\ VYN56Q]GZC/_ #TKUGR8O^>2?]\B
MOGOP/K.H:1]O^PW'E>;Y>_Y%;.-V.H/J:Z__ (3+7_\ G_\ _(,?_P 37/.#
M<KG#6HRE-M'JODQ?\\D_[Y%'DQ?\\D_[Y%>5?\)EK_\ S_\ _D&/_P")KTW2
MYI+G2+*>5MTDD".[8QDE02:SE%HPG3<-RQY,7_/)/^^11Y,7_/)/^^13Z*DS
M&>3%_P \D_[Y%'DQ?\\D_P"^13Z* &>3%_SR3_OD4>3%_P \D_[Y%/HH ^2J
M***[CV38\.?\A"3_ *Y'^8KIZYCPY_R$)/\ KD?YBNGJ);F4]PKTCX?QH^@S
MED5C]J;J,_PK7F]>E?#W_D 3_P#7TW_H*5G4V.>O\!U/DQ?\\D_[Y%'DQ?\
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MYQ6K0 4444 >2_&W_F!?]O'_ +3KR2O6_C;_ ,P+_MX_]IUY)772^%'IX?\
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MH **** "BBB@!&)"DA2Q Z#J:Y>TTZ_DEUV.6RE@340WEN[QD+E2/FVL3W[
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MJOHCXF_\D\U3_ME_Z-2OG>NFC\)Z&%^!^H5O^&?^7K_@']:P*W_#/_+U_P
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ML*EJ#,9Y,7_/)/\ OD4>3%_SR3_OD4^B@!GDQ?\ /)/^^17SS\3%"_$+5 H
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M-NWS8U?;G.,C.*\LKT[2O^019?\ 7"/_ -!%29ENBBB@ KYW^)O_ "4/5/\
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M^)O_ "3S5/\ ME_Z-2JC\2+I_&O4^=Z***[#UC?\,_\ +U_P#^M=!7/^&?\
MEZ_X!_6N@J'N92W"O9]$_P"0!IW_ %ZQ?^@BO&*]GT3_ ) &G?\ 7K%_Z"*Q
MJ;'+B-D95S&HUA7TZWU"&]:\0W#$2"%XP,,QS^[/R\#OG'>NDHHK(Y0HHHH
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M_@7_ *$:T*S>YB]R:TD>&]@EC;:Z2*RGT(/%=5_PD.J_\_K_ )#_  KDX/\
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MF;M%%%<IYIK>&?\ D8;7_@?_ * :]#KSSPS_ ,C#:_\  _\ T UZ'0 4444
M<E\3?^2>:I_VR_\ 1J5\[U]$?$W_ ))YJG_;+_T:E?.]=-'X3T,+\#]0K?\
M#/\ R]?\ _K6!6_X9_Y>O^ ?UK1[&\MCH****@R-:S_X]$_'^=3U!9_\>B?C
M_.IZYI;L\^?Q,*]9KR:O6:1(4444 %?)5?6M?)5;T>IV83J%:&B?\A>#_@7_
M *":SZT-$_Y"\'_ O_036[V.Q['7T445F8E_3?\ EK^']:O51TW_ ):_A_6K
MU<\_B.&M\;"O3M*_Y!%E_P!<(_\ T$5YC7IVE?\ ((LO^N$?_H(J3,MT444
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M /CW;_>_H*SJ;'/7^ MT445@<9Z=I7_((LO^N$?_ *"*MU4TK_D$67_7"/\
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MA$NU8>[?WN/7.">PZ5T%94>AK#J,]]%?W:S3ME^(VX[*"4)"^V:U:0!1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 5YW\4O$^L>'/[)_LF\^S^?YWF?ND?=MV8^\#CJ>E>B5SOBGP9IWB[
M[)]OFNH_LN_9Y#*,[MN<Y4_W150:3U-*;BI)RV.,^&?C#7O$'B.XM-4O_M$"
M6C2*ODHF&#H,Y50>A-=MJ&JW,&K%HW"V-HT:70(')DSSGK\N5/XU4\,^ -*\
M*ZE)?6-Q>R2R0F$B=U*X)![*.?E%:K^'-,EBN5FMTFDN&=GFD13("WH<<8[>
ME.;3>@591<KQV,Z^NKA-;FC6>54%S9J%#D !BVX8]^_K6M?7,T.J:7#&^(YY
M)%D&!\P$;$?J!4?]A6QD$C2SLX:%LEAR8L[<\=\\_P!*N3V<=Q=6MP[,'MF9
MD /!)4J<_@:DS.>L-6NII[3;J/VB>2YD2>TVH?+C#,-WR@%< +U/.:<M]J$6
MA/K!OGD,4DA:W>--C(LC+@$*&!P!SD\UOV5G'86HMXF8H&9LL><LQ8_J:HIH
M$*Q"![JZEM!(9/L[% A)8MR0H8C)S@F@#6HHHI 9/B:]N-/\/75U:R>7,FS:
MV <9< \'CH:XC2_%FMW.KV4$M[NCDG1'7RD&06 (Z5Z%J>GPZKI\ME.SK')C
M)0@'@@]P?2L.U\"Z9:7D%S'/=EX9%D4,ZX)!R,_+5Q<4M3:$H*+3W+.KZ@;?
M5D@DU3[! ;5I-V$Y<, /O YXSP*6#5]286EL=/5[R2U\^0/+Y0'.,8P<$\<>
M_.*U39QG45OMS>:(C#C/RX)!_/BC[''_ &B+[<WFB'R<9^7&<_G4F)CS>*(5
MCMVB6 --;"YQ<7(B&#P%!P<MD'\NM7;?6H[J>-8HB8Y+/[4K,<'&<;2/_KTV
M+0H;9+<6MU<P/##Y(D0H2R9S@[E(Z^@'6I;C2EN)8Y3=7$<JQ&%Y$*@R*<$@
M_+@<CJ,'F@"G#KMS=?95M=/622>U^TX>?:%&<8SM.>W;\JDCUN2\%NMA:++)
M+;"Y822[ H)P%R <G.>V..M6;/2+>QD@>)Y28;?[,NXCE<YR>.O%01Z!#!'
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M,#G)..*U]+T:WTCS?L[RMYN-WF$'IGI@#UJS:6<=F)A&S'SIFF;<>A;KCVH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
4 !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>img69628308_4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img69628308_4.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &9 KD# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **:[I
M'&TDC*J*"69C@ #N34%MJ%E>.5M;RWG91DB*56('X&@"S1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 45%=7"6EI-<R!BD2-(P7J0!GBL^/Q#9R:(VJJLIA0[63:-ZG(&",
MX[COTH U:*** "BBB@ HHHH ***@DEN%O(8DMM\#*Q>;>!L(Z#;U.: )Z***
M "BHIY7AB+I!).V?N1E0?_'B!^M4K+5S?2ND>GW:K'*8I'<QX1AU!PY)_ &@
M#2HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MZ"BDY2?43G)[L9%#%!&(X8TC0=%10 /P%/HHJ2 HHHH **** "BBB@ HHHH
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MBP7.LHJO8/=26,3WL217)'[Q$.0#]:L4AA1110 4444 %%%% !1110 4444
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MR"!_#WK6HH SM)T^2R2XDN&1KFYF,TGEYV@G@ 9Z@8ZUHT44 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !4
M%W96E_ 8+RVAN(CU25 P_(U/10!PVI_"O0KJ3S].>XTRY!RK0.2H/K@_T(K,
MD?QSX(Q/--_PD&E+]_KYJ#USRP_\>%>F457.^NIHJCV>IA>'?%VD>)X-]A<8
MF R]O)Q(GX=Q[C(K=KC/$7P\L-5G_M'2Y6TO55.Y9X/E5F]P.A]QS]:RK+QO
MK'ABZ33?&EFP0G;'J,*Y5QZG'7\.?44^5/X0Y%+6)Z114%G>6VH6J7-I/'/
MXRLD;9!J>H,PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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ML=M;H$BC&%457TG2K?1]/2UMQP.7<]7;N35ZAL04444AA1110 4444 %%%%
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M<<5JTU$2.-8XU544 *JC  '8"G4 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!4
MU+3++5[&2SO[=)[=^J./U'H?<5YU-I^O_#:9[K2S)J?AXG=+;.<O".Y'I]1Q
MZCO7J%%4I6*C-K3H9.@>(]-\26(NM.G#X_UD;</&?1A_D5K5P.O^ YK>^.N>
M$IOL&I+RT"G$<WJ,=!GT/!]NM58OB=?6,:QZYX8OX)D&)'C4[2?4!@./Q/UI
M\M_A*Y.;6!Z117"6WQ<\,3X\PWEO_P!=8<_^@DUKVWC[PK=8\O6K=<_\]=T?
M_H0%)QDN@G"2Z'2453MM7TR\Q]EU&TGST\J96_D:S]<\2V^DXMX5^TW[\) G
M.">F<?RZFE8AZ;FAJ6J6FDVIN+N4(O\ "/XF/H!WKED@U3QE*)+C?9:.#E8Q
M]Z7W]_KT],U9TWPW<ZA=#4_$+^=,>8[;^%!Z$?T_/-=8    , =!1L+<KV=E
M;:?;+;VL2Q1+T _F?4U8HHI#"BBB@ HHHH S=4T#3M74_:K<>9C E3AQ^/?\
M:P/[,\0^'?FTVX_M"S7_ )=Y?O >W_UC^%=C13N%CBKKQK)<V?V2SLIXM5D;
MRQ&P^X3W'O\ 4"MSP[H*:+9DN1)>2_--+UR?0'T_G6H;>!KA;@PQF91@2%1N
M ],]:EHN(****0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "N3\8ZG?P7ND:5I^JP:2U\\K2WTL:N8TC4$A0_R[B6 YSQF
MNLJAJ>B:3K21IJNEV5^L9)1;JW24(3UQN!Q0!RW@_4K(W^JV^HW6D7&JV=T+
M?^T88XXGNT:-)%8@?Q?/M..,BNXK!B\&^$;:YBDB\-:)%.K;XF6QB5@1SE3M
MSD>U;U !1110 4444 %%%% !1110 45A:]K5[HL\,RV/GV!'[Z13\R'/^>OZ
M5HZ=JEGJML)[.82+W'=3Z$=J+ 7**** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BJ>HZI9Z5;^=>3K&O\ "O5F
M]@.]<N;W7/%9*6"-I^FG@SM]YQ[?X#\Z=@N:NL>*K/37^S0 W=Z3M$,7.#[G
M^G6L^.'QK>+YXO+2T#\B%E&5'_?)_G6SH_AZPT5,P1[YR/FF?EC_ (#Z5K47
M$<E_9_C;_H,67_? _P#C=']G^-O^@Q9?]\#_ .-UUM%%PL<E_9_C;_H,67_?
M _\ C=']G>-#PVL68'L@_P#C==;11<+'$7/A77K[/VR_L)L]=\"M_-*SG^%_
MG',DE@N?[EL%_D!7I%%/F8TVNIYNOPHM^]S;C_MVS_6J(EN_ASXB674K*.YT
M><"..\A3YH3].Q]NXZ'@BO5J@O+.WO[26UNX4F@E7:\;C((IJ7<I/7WM1;2[
MM[^TCNK29)H)5W)(AR"*FKRVYLM7^&-\][IHDOO#<KYFMV.6@SW]OKWZ'L:]
M#T?6;'7M.COM/G$L+]?53W5AV-)QMJMARC;5;%^BBBI("BBB@ HHHH ****
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M3C+)';K;-<.(G*,YW!0-P(( SGBI]8TZYU2V:VCNHH86VEMT)=LJP88.X#'
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MT5+DWNR7.3W84444B0HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\\-4_P#!5=?_ !N@#7HK(_X22Q_YX:I_X*KK_P"-T?\ "26/_/#5/_!5=?\
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M_P""JZ_^-T?\))8_\\-4_P#!5=?_ !N@#7HK(_X22Q_YX:I_X*KK_P"-T?\
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MDUMCJ-MH]FD,F70R7,B-)[X3@$^_K7:5Q3RVL4DD>EZAK MHR<BV@,D<?)R
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MK72ZRMDVF2&_E,4"D-YBDAD;/!7'.<US'G6\P"7^IZVME)P3/!L1QZ%@.E-
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MR1NX_P#UUU]8JZGI^JW=O;3)=6]Q'()HHYXC&6(!Z9Z\'I6U0 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
..%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>img69628308_5.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img69628308_5.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "K :P# 2(  A$! Q$!_\0
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M6.XQ[/N97&[=_A5 >,S_ ,(\NJ^5IK[W"A(M1WJAV%]KMY?ROQM"X.20,\T
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M)3=D$YY;&>H(XID6@Q+#=I->W=Q+=E//FD**[(O\'R*H QD' S\QYZ8N'4K
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MP!_"DH(P>A(&0".G)':UYWXMN-)OO$;07MYI=K=:>%\HWWF?,DBY. DBYY%
M'6^%HWB\,V"/!!;D1_ZFW5%2,9.% 3Y1@<''&0:UZS?#Z01Z!9);-:M L8"&
MT4K$1_L@DG'XFKMQ<):V[S2+(R(,D11M(WX*H)/X"@"6N?O/^2AZ-_V"K_\
M]&VE;%E?6^HVPN+9V:/<5.Y&1E8'!!5@""".A%8]Y_R4/1O^P5?_ /HVTH Z
M"BBB@ HHHH **** "BH;JZM[*W>XN[B*W@3&Z25PBKDX&2>!R0*SO^$J\._]
M![2__ R/_&G9C2;V->BJECJNG:GYGV"_M;OR\;_(F63;G.,X/&<'\JMTA-6"
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 1E5U*LH93U!&0:SWTL
MPL9+"9K=SR4ZHWX5HT4#3L9HU.2V8)J$!B["5/F0_P"%:"2)*@>-E93T*G(I
M2H92K $'J#6>^EB-S+8RM;2'DJ.4/U%,-&)>7US!K%C9QK%Y5RLGSMDL&5<C
MCCCIW_*LE]?U*UC^T2PP7-J)I8Q+$A3?M&. 6;'S!^>>%SQ5]YHX[F*;5=/B
M$T?$=TL8<+]#U6KD:Z?,(X8XH61$(C4*-NTC!"]NG!_^O64H2[G7"K2@DI0O
MW_'_ ('^1-9S_:+2.7<&8C#$*5&X<'@\CD'@U/3(HHX(UCBC6.-> J# 'X4^
MK6QR2LV[;!1113$>'?&7_D;[3_KP3_T9)7G=>B?&7_D;[3_KP3_T9)7G=='/
MR01[6#I>T@E>W_#G?UO>#?\ D;++_MI_Z U<B&N%8-ARIVDISQQTS_GWKKO!
MO_(V67_;3_T!JA3YDS/$T?91WO='<>._^2>>)?\ L%77_HIJZ"N5^(VFV%_X
M!UV2]LK:Y>VTZYE@::)7,3B)L,I(^4^XKJJR/),K4-?M]+NECN[>Y2W/#7>P
M>4K;6;;UW$X7J%(YZ]:IMXMMX[>5Y=.OXYH]K?9V6/>49&<,/GVXVQOU.?E(
MQG%2:KH5WJM^S2W\/V!H6A^S-;DLFY2KLKAP-Y5B 2IP.@Y;,7_",/<V=S'J
M=W!=SSK#'YGV4!4CCSC:K,V'^9_FSP6!QQR ;%G?17WFF .8XW*>81A7(Z[>
MYP>#[@CM61XECT:>6V35;^6Q8*ZQS;O+0AQM92Y&W)';.:ET3PY'HE]>30R1
M^5/@)&D6PJ S$;CD[R-V <#  '-6-:URQT:.(7J32"?<-D4)D^55+,Q _A '
M- $VE:>FG6:0Q7<]Q"%41F5PVU0,  @#C%7JYCPN=#OI9KS2M/N=-D3&^W8&
M%65U#*YB4[#D'()&X<YP<BNGH *YV]UJRTG4[[[/IEY=WKM;I*+;9F1F#!%&
M]U ( )/08(Y)KHJX;QRW]E7UEJ4'VR$71%M>36MP8LQC)7/RL-PW-@_*>OS"
M@#K=+U&'5M,M[^!)$CF7<$D #+V(."1D'(X)I]_'++8S1P('D9=H4SM#G/7Y
MU!9>.X&:YSP%K<&JZ9<6UK:Q06E@X@@$4A<;,<!B?XP.3]0>]=90!F:#87&G
M:<8;DQAVE>0(CF0(&;."[ ,Y[EF&23WZUC:]93WWCK1(K?4[O3W&F7S&6U6)
MF(\VT^4^8CC'.>F>!SUSUE<_>?\ )0]&_P"P5?\ _HVTH WHU*1JK.SD  NV
M,M[G  _(4ZBB@ HHHH **** .2^)O_)/-4_[9?\ HU*^=Z^B/B;_ ,D\U3_M
ME_Z-2OG>NFC\)Z&%^!^IZW\$O^8[_P!N_P#[4KUJO)?@E_S'?^W?_P!J5ZU6
M57XF<N(_B,****S,0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@!" 000"#U!K-GT:(OYMH[6TH.1M^[GZ5IT4!<S@^KH,-#:R8[JQ&:/MF
MHK][3,^ZS"M&BF.YG?VG,OW]-NA_N@-1_;$(^_;W4?\ O1&M&B@+H\8^)VFW
MFN^([>[TZW::%+18V.0I#!W.,$@]"*X.3P]K$?WM-N3_ +L9;^5=G\8V9?&%
MH58@_8$Y!_Z:25P<>HWT7^KO;A/]V5A_6NJ%^5'I4K\BL=N002",$=0:W?!O
M_(V67_;3_P! :L(DL2222>236[X-_P"1LLO^VG_H#5,MF1/X6=QX[_Y)YXE_
M[!5U_P"BFKH*Y7XC1W[^ ==-E<VT*+IUR9Q-;M(73RFR%(==I]R&^E=57,>>
M0R7=M#,(9;B))2AD",X#%1U;'H.YJJFO:/):/=IJUBULC!&F%RA16/0$YP#[
M5F:O:S2:_;RPZ/<31?9Y8I[B%H5+!@ !\S@G&#U'?ZU031M4NM"FLY?MR)"R
M)8K</;B904,;;R@*;-KGU; /?% '7K+&\CQK(C/'C>H8$KGD9':LK7FOT^QF
MPT>TU&1I&1C<W!B6%2IRV1&Y(/W3QW';I5\-6.J:==7T%X7>VWEDDD\O]XQ9
MOF7;\V-NW(;H1A?E  L^(KTV-O#(FHS6DQ8^7'%:&Y\XX^Z8U!<CO\I4^] $
M/A]=5%_J9U/3;.R!,0A%I*94<!,??*(3C &-O%;]9.@WVJWUO,VJ:=]C9'VQ
M-N ,RX^_LR2G/8DFM:@ K/N]&M;V<S2RWRM@#$-_/$O_ 'RC@?I6A10!'! E
MM D*&0J@P#)(SM^+,23^)IMU)/%;.]M )Y@/DC+[ 3[MV'KP?H>E356O[0WU
MC-:BYN+;S5V^=;L%D3_=)!P?>@"+2;]]2LC-+ (9%EDB95?>I*,5)5L#(XZX
M%9MY_P E#T;_ +!5_P#^C;2M;3K+^SK)+7[1).D8VH9$C7:H& H"*J@#MQ7.
MZ]I.FZSXZT2WU33[2^@73+YUCNH5E4-YMH,@,",X)&?<T =9169KDSZ9X7U*
M>SVPO;64KP[5&$*H2N!TXP..E>%?\+-\8?\ 07_\EH?_ (BKC!RV-:=&5171
M]$45Y5\,_&&O>(/$=Q::I?\ VB!+1I%7R43#!T&<JH/0FO5:4HN+LR9P<'9A
M1114D')?$W_DGFJ?]LO_ $:E?.]?1'Q-_P"2>:I_VR_]&I7SO731^$]#"_ _
M4],^$>LZ?I']L?;KCRO-\G9\C-G'F9Z ^HKTS_A,M _Y_P#_ ,@R?_$UX-X9
M_P"7K_@']:Z"E.";N*I1C*3;/<H)H[FWCGB;='(H=&QC((R#4E4-$_Y &G?]
M>L7_ *"*OUSG"]&%%<[XZU.\T;P;?W]A-Y-U%Y>Q]H;&9%!X((Z$UXS_ ,+-
M\8?]!?\ \EH?_B*N--R5T:TZ$JBNCZ(HKC/AGKNI>(/#EQ=ZI<_:)TNVC5MB
MIA0B'&% '4FNSJ6K.QG*+B[,****1(4444 %%%% !1110 45SOBGQGIWA'[)
M]OANI/M6_9Y"J<;=N<Y8?WA7._\ "Y?#O_/EJG_?J/\ ^+JE"3U2-(TIR5TC
MT2BL[0M9M_$&C6^J6B2I!/NVK* &&UBIS@D=0>]:-3L0U9V84444"/./'_C_
M %7PKKT%C8V]E)%);+,3.C%LEF'9AQ\HKE?^%R^(O^?+2_\ OU)_\71\9?\
MD;[3_KP3_P!&25YW73"$7%:'H4J4'!-H^I]%O9-2T'3KZ9466YMHYG"#"@LH
M)QGMS5ZO*-&\=:G::'I]M'!:%(;:.-2R-D@* ,_-70>'_&.HZKK=O93PVJQR
M;LE%8'A2>['TK%P:.65&2NSMZ***@Q/#OC+_ ,C?:?\ 7@G_ *,DKSNO1/C+
M_P C?:?]>"?^C)*\[KLI_"CU*/\ #1W];W@W_D;++_MI_P"@-6#6]X-_Y&RR
M_P"VG_H#5$MF9S^%G<>._P#DGGB7_L%77_HIJZ"N5^(VH0V7@'78Y4N6-QIU
MS&AAMI)0"8FY8HI"#_:; ]ZZJN8\\**YW7=1O],OQ-%,KVXLKB46WE#EXU!!
M+=3UZ#'X]LF[U#6[:TO8X-3EN_(AAN#<!(%= Z29 RH0KN6,]"VUC@DXH [B
MN6\972:<=+U'SX!-:W#O'!.DA27,;!CF-6*;1EM^TA1G/!R+7A[6Y=4GNTN8
MIH958LD3JH54#%, @D[LJ<[L<GC(Y,WB/3]+N;+[9JLTL,-HCDRQRLA"LN&'
MR\G(XQ0 WP]87D$FH:A?&T6;4)5F\FS<O$@"!0=Y"EV(&2V!V&.,G;K#\,S:
M:]G)#IMQ?.D!6-HKU94DBP.!LE 91C&..:W* "BBB@ HHJ*X29[=T@E6*4C"
MR,FX*?7&1F@"6N?O/^2AZ-_V"K__ -&VE7O#]S->>']/N;F0R32P*SN0!N)'
M)P,#\JQ=>U.#2O'6B3W$=VZ-IE\@%K:2W#9\VT/*QJQ XZXQT]10!J^*O^10
MUO\ Z\)__1;5\PU].>)G$G@S6)%# -I\Q 92IYC/4'D?0U\QUT4=F=V$^%G?
M?"*ZM[3Q7=27,\4*&Q=0TCA03OCXR:]H_MO2?^@I9?\ @0G^-?./AS_D(2?]
M<C_,5T]$X7=QUJ2E*]SW*&>&YB66"5)8VZ.C!@>W45)6%X-_Y%.R_P"VG_H;
M5NU@U9G#)6;1R7Q-_P"2>:I_VR_]&I7SO7T1\3?^2>:I_P!LO_1J5\[UT4?A
M._"_ _4W_#/_ "]?\ _K705S_AG_ )>O^ ?UKH*I[FDMSV?1/^0!IW_7K%_Z
M"*OU0T3_ ) &G?\ 7K%_Z"*OURO<\R6YR7Q-_P"2>:I_VR_]&I7SO7T1\3?^
M2>:I_P!LO_1J5\[UT4?A._"_ _4]H^$6HV-IX4NH[F\MX7-\[!9)54D;(^<$
MUWW]MZ3_ -!2R_\  A/\:\ \.?\ (/D_ZZG^0K8J90N[D5**E)NY[HCI+&LD
M;*Z, RLIR"#T(-.JAHG_ " -._Z]8O\ T$5?K XWHS&\3>)K+PKIL=]?17$D
M4DPA @4%LD$]R./E-<I_PN7P[_SY:I_WZC_^+H^,O_(H6G_7^G_HN2O#JWIT
MU)79UT:,)PNSZDT+6;?Q!HUOJEHDJ03[MJR@!AM8J<X)'4'O6C7#_#C5-.MO
M 6F13W]K%(OFY1YE4C]ZYZ$UU/\ ;>D_]!2R_P# A/\ &LI*S:.:<+2:1?HH
MHJ2#R7XV_P#,"_[>/_:=>25ZW\;?^8%_V\?^TZ\DKKI?"CT\/_#1[E\/O$VD
M:?X'TZUNKORYD\W<OEN<9D8CD#'0UU,'BS1+FXC@BO=TDC!$7RG&23@#I7B>
MB?\ ((@_X%_Z$:W]$_Y#^G?]?47_ *$*SE!7;,)T8MMGL]%%%8'&>'?&7_D;
M[3_KP3_T9)7G=>B?&7_D;[3_ *\$_P#1DE>=UV4_A1ZE'^&CM[#_ )!]M_UR
M7^0KIO!O_(V67_;3_P! :N9L/^0?;?\ 7)?Y"NF\&_\ (V67_;3_ - :HELS
M.I\+/6****YCSSP[XR_\C?:?]>"?^C)*\[KT3XR_\C?:?]>"?^C)*\[KLI_"
MCU*/\-'?UO>#?^1LLO\ MI_Z U8-;W@W_D;++_MI_P"@-42V9G/X6=QX[_Y)
MYXE_[!5U_P"BFKH*Y_QW_P D\\2_]@JZ_P#135T%<QYY3ETG3;B]2]FT^UDN
MX\;)WA4R+CIAB,C%+;:5IUG;FWM;"U@@,@E,<4*JN\$$-@#&05'/L/2J=UK\
M=K>W=N;&[DCLXA+<3IY>R-2I;H7#'A3T!J2PUN'4)5A2WN(Y@',L;A<P[6*_
M,0Q')4XP3G!]#0!<AL[6WGFG@MH8I9R#-(D85I".A8CK^-9?C!D3PAJK21-(
M@MVRJOLX]=V"5 ZD@9 &:VZP/%USC2?[.A6[>]U F&V6T"^8& W%LL0H"@9)
M)QT')(! ,?P1!'-J&J72ZE+>RQRHDEQ#>&:WGS&I&.."HXQD^O>NWKGO"EW<
MS07=M>R2B[MI0DEO+!'&8LC<,>62K @Y!!]0<$$5T- !1110 5'/;PW4#P7$
M,<T+C#QR*&5AZ$'K4E% %>SL;33X/(LK6"VASN\N&,(N?7 K'O/^2AZ-_P!@
MJ_\ _1MI705S]Y_R4/1O^P5?_P#HVTH L^*O^10UO_KPG_\ 1;5\PU]/>*O^
M10UO_KPG_P#1;5\PUT4=F=V$^%FQX<_Y"$G_ %R/\Q73US'AS_D(2?\ 7(_S
M%=/5RW-I[GK/@W_D4[+_ +:?^AM6[6%X-_Y%.R_[:?\ H;5NURRW9YL_B9R7
MQ-_Y)YJG_;+_ -&I7SO7T1\3?^2>:I_VR_\ 1J5\[UT4?A.["_ _4W_#/_+U
M_P  _K705S_AG_EZ_P" ?UKH*I[FDMSV?1/^0!IW_7K%_P"@BK]4-$_Y &G?
M]>L7_H(J_7*]SS);G)?$W_DGFJ?]LO\ T:E?.]?1'Q-_Y)YJG_;+_P!&I7SO
M711^$[\+\#]3I_#G_(/D_P"NI_D*V*Q_#G_(/D_ZZG^0K8JGN7+<]GT3_D :
M=_UZQ?\ H(J_5#1/^0!IW_7K%_Z"*OURO<\V6YYW\9?^10M/^O\ 3_T7)7AU
M>X_&7_D4+3_K_3_T7)7AU=-+X3T,-_#.OT3_ )!$'_ O_0C6A6?HG_((@_X%
M_P"A&M"A[E/<]VHHHKE/,/)?C;_S O\ MX_]IUY)7K?QM_Y@7_;Q_P"TZ\DK
MKI?"CT\/_#1U^B?\@B#_ (%_Z$:W]$_Y#^G?]?47_H0K T3_ )!$'_ O_0C6
M_HG_ "']._Z^HO\ T(4I"GU/9Z***Y3S3P[XR_\ (WVG_7@G_HR2O.Z]$^,O
M_(WVG_7@G_HR2O.Z[*?PH]2C_#1V]A_R#[;_ *Y+_(5TW@W_ )&RR_[:?^@-
M7,V'_(/MO^N2_P A73>#?^1LLO\ MI_Z U1+9F=3X6>L4445S'GGAWQE_P"1
MOM/^O!/_ $9)7G=>B?&7_D;[3_KP3_T9)7G==E/X4>I1_AH[^M[P;_R-EE_V
MT_\ 0&K!K>\&_P#(V67_ &T_] :HELS.?PLZ[XC:?#>^ ==DE>Y4V^G7,B"&
MYDB!(B;A@C ./]ELCVKJJY_QW_R3SQ+_ -@JZ_\ 135T%<QYYA7_ (<34=;A
MOI?L(2)@Q*V?[]@ 1M,I;[ISR-O(XJI9>#(+#4[*]@EA0P_-($M@I9\-G80?
MW:G=@K@Y"J,\9KJ** "LC7+;2)GM9=4EDA>(N8)([B2$@E?F 9&&<@=.^*UZ
MYWQ7H^K:S;);Z;>PP1-'(DL<R!E9CMV.05;<%PWR<;MW48H 7PO+HEQ]LGTD
MW9DD,;3F[>9G(* H?WI)P5/&*Z&LW1M&AT.WDM;4J+8ON1=@#+GKEA][ZGGU
M)K2H **** "LGQ)')+H4R)%),I>(S11@EI(1(ID4 <G*;ACOG%:U% &)X8@%
MO978AMGMK-[IWM87C,>R,@=$(!4%MQQ@=<]ZCUFQU?\ X2#3M6TJWL;DV]K<
MVTD5U=/!_K'A8,"L;YQY)&,#KUK?HH Y355\8:GH][8?V-H<?VJWDAW_ -KS
M';N4C./LW.,UYA_PIWQA_P ]-#_\#)O_ (S7O5%5&;CL:0J2A\+/$--^%GC#
M3[AI?^)')E"N/MTP[@_\\/:M3_A _&'_ #PT/_P8S?\ QBO4+C4[.UO;:SFF
M"W%T2(DVDEL#)Z#CIU.*MT_:2&ZTWU.0T:'QAI&DP6/]D:'+Y6[Y_P"UYESE
MB>GV8^M7_MGC#_H!:'_X.9O_ )%KH**@S;N[G$^)]/\ &'B/P]=:3_9>AV_G
M[/WO]K3/MVN&Z?9AGICK7G?_  IWQA_STT/_ ,#)O_C->]4V21(8GEE=4C0%
MF=C@*!U)/8549RCHBX59P5HL\6TSX8>,-.\WC0Y/,Q_R_3#&,_\ 3#WK0_X0
M/QA_SPT/_P &,W_QBO09/%>DQ6\<\CW:)('9=UC."54*6;&S.T!E^;ISUX-;
M*L&4,I!4C((/!%/GD-UIOJ<S8OXPL["VM?[%T-_)B6/=_;$PS@ 9Q]E]JG^V
M>,/^@%H?_@YF_P#D6N@HJ#(XGQ/I_C#Q'X>NM)_LO0[?S]G[W^UIGV[7#=/L
MPSTQUKSO_A3OC#_GIH?_ (&3?_&:]ZJCJ.KV6E!#>2N@<%@5B=\*,99MH.U1
MD9)P!FJC.4=$:0JS@K19Y-IOPU\8:?;M%LT.3+EL_;YAV _YX>U7/^$#\8?\
M\-#_ /!C-_\ &*]);7M/CENHY9)HFM8WFE\VVD0;$^\RDJ-X'JN>H]15FQOH
M=0M_.@6<)G'[Z!XB?P< XYZ]*?/(?MI]S!L7\86=A;6O]BZ&_DQ+'N_MB89P
M ,X^R^U3_;/&'_0"T/\ \',W_P BUT%%09'GOC/0O&'B[1X;#^S]#M/+N!-O
M_M2:3.%88Q]G'][]*X?_ (4[XP_YZ:'_ .!DW_QFO>JJWVH6VFPK+<LX#N$1
M8XFD9V()P%4$DX!/ Z U2G)*R-(U9Q5DSR:R^'7C"SLX[?R]#?9GYO[0F&<D
MG_GA[U8_X0/QA_SPT/\ \&,W_P 8KTF+7M,GLI;R*Z#01% [!&R"P4J,8SD[
MAVZ\=016E3YY#]M/N<_]L\8?] +0_P#P<S?_ "+1]L\8?] +0_\ P<S?_(M=
M!14&1YEXW\*>,/&7V'_0]#L_LOF?\Q.:3=NV_P#3N,8V_K7)?\*=\8?\]-#_
M / R;_XS7O549M8T^"[FM9;E5FA@:XD7!PD:XR2>@QD''7!!JU.25D:QK3BK
M)GE5E\.O&%G9QV_EZ&^S/S?VA,,Y)/\ SP]ZT+'P9XPL[^VNOLNAOY,JR;?[
M2F&<$'&?L_M7?KXATUK62X\V91'((FC>VD67>0"%$97>20<C _E5ZTNX;VV6
MX@9C&V0-R%2""0000"""""",\4<\A.M-]3%^V>,/^@%H?_@YF_\ D6C[9XP_
MZ 6A_P#@YF_^1:Z"BH,SR?QGX&\8>+M8AO\ [/H=IY=N(=G]HS29PS'.?LX_
MO?I7._\ "G?&'_/30_\ P,F_^,U[U6?/KFFVUQ<P2W2B2VB\V90I.Q>..!][
MD?+U^8<<C-JI)*R-8UJD59,\P@^'_C""WBB\G0VV(%S_ &A,,X&/^>%:>C>%
M?&&D:M!??8M#E\K=\G]IS+G*D=?LY]:[8^)=,%O'-YEP?,F,"QK:3&3>%W%3
M&%W#@9Y'2M2-Q)&KJ& 8 @,I4_B#R/H:3G(3JS>C9@_;/&'_ $ M#_\ !S-_
M\BT?;/&'_0"T/_P<S?\ R+7045)F>3^,_ WC#Q=K$-_]GT.T\NW$.S^T9I,X
M9CG/V<?WOTKG?^%.^,/^>FA_^!DW_P 9KWJJESJ=G:7=M:3SA9[EBL4>"2WY
M=![GBK5225D:QK5(JR9Y?_P@?C#_ )X:'_X,9O\ XQ5_1O"OC#2-6@OOL6AR
M^5N^3^TYESE2.OV<^M>A6^I6EU>W5G!,'GM=OG*%.%W9QSC!^Z>G3'-6J7/(
M3JS:M<Y#7;?Q?K?A_4M).DZ' +ZUEMC+_:TK;-Z%=V/LPSC.<9'UKKZ**DS.
M&U[27U'6;N VMP+V>:#[)?)"Q$,&T"0>9C"_\M?ER"=PZYINAV^J:?K-BCV:
M_9) YB1+-XTA1V=F(^8K$WW/E;)(( P0V>[HH **** "BBB@ HHHH **** "
MBBB@ HHHH P-0\.S7.MVVI0:E<1[;B.26(B,KM1'4!<H6ZL>,X^9CP<5OT44
M %%%% !5'6;!M4T2^L%8(UQ \:L>@)! SCMFKU% '"7?A/6+I@[&-TVS(+:3
M5K@^6'6,?ZW;N<90DH0%YKMK6.6*TACFD$DJ1JKNJ[0S <D#M]*EHH ****
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' **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>img69628308_6.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img69628308_6.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "O ;,# 2(  A$! Q$!_\0
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M -FBN.TGQ)K&IZ?IVZ*VAGORABN)+:18P#"96 C9@S$8QD, >3VQ5B+Q%>W
MF@\RRMKBRB<WTLD;ND;>9MCVJ&!(=5=@,Y^[ZT =317,6_B#4GN+07%I#!D6
MT=U V3(LDJDG:<XPIP.0<X;IBNF=E1&=CA5&2?04 +16?_;>G?\ /Q_XXW^%
M']MZ=_S\?^.-_A0!H45S>K>))[*2.6U@2>T=2H?!)\S#'H.0!A20 20QQRN"
MFK^(+JSB%U9M;26L6G27\@DC8&55P0%.?DR#W#4 =+16!=>*5MIKJ-=.N9?L
M[.,JR#>$3>Y&6[ J.<9)] 34]GXABO-6^PI;3*IWA)F*[6*A"1C.>CCJ.Q]L
M@&Q1110 4444 %%%% !1110 4444 %%0W:W+VLBV<L4-P1^[DFB,B*?=0RD_
MF*RO#U_J%W+J]IJ<EK+<:?>BW$MM"T2R*8(I0=K.Y!_>D?>/2@#4N[VTL(1-
M>74-M$3MWS2!%SZ9-1KJFGO=M:+?VK7*C)A$REP,9SMSGIS537Q=-9JEGI[7
M4LA,9=#'NA4@AF&]ER<<8SWY]#EV6EW<=\;>"WO[;3;A3]JCN7@*8\H( A0E
M]W"]3C@^U '10:A974<4EO=V\R2DB-HY P<CJ 0><8-6*XW3M&UG3M7M)XVG
M>%V;S/,,1\M"W(?&.2 IS&.H .0 :[*@ HHHH **** "BBB@ HHHH **** .
M?\/?\ASQ9_V%8_\ TBM:V[F)YK9XXY#&[#AQVK$\/?\ (<\6?]A6/_TBM:Z"
M@#&M]3FLYA:ZD-I_AF['Z_XUL @@$'(/0BH[BVBNXC%,@93^8^E8_P#I>AMW
MGLB?Q3_/Y4 ;M%8&HZ]);?Z1:F"X@6"25X@I#H$1FW%LX W!5QC^+.>*KW&O
MZG8SS)/;0RQP2-&\L2D!F\H2#C)( SSUX!/&,5#J);G5#!U)I.-M5<Z>BH;6
M9;BUBF5PX90=P4J">_!Y'T-+=.\=K*Z211LJD[Y1\B^I/(X_$55]+G/ROFY2
M6BN7_M_5##O6U@,D8B!B<,C3&1V1"N3\HX5L'/4CC%7M'UI]1NI;>951XU)
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MK=]\$T:R1O@C<I&0>?8T[-#::U9+1112$%%%% !1110 445R7Q-./AYJF/\
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M\ASQ9_V%8_\ TBM:Z"N?\/?\ASQ9_P!A6/\ ](K6N@H **** "BBB@ HHHH
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MRJ'<OR!MI]1UQ0H65HE2Q'M*BG56B/#_ (@R3R^/-6:YC$;B4* .Z!0%/XJ
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M?_7A/_Z+:O#?AJRQ>/M.ED8)'&)2[L<!1Y;#)/;D@?C7N7BK_D4-;_Z\)_\
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M8@VPGG[Q7/OQ7BVJ_P#)1[W_ +"\G_HXU[GX>_Y#GBS_ +"L?_I%:UX9JO\
MR4>]_P"PO)_Z.-:TNIO0ZGK?@W_D+R_]<#_Z$M=Q7#^#?^0O+_UP/_H2UW%9
M& 4444 %>'?&7_D;[3_KP3_T9)7N->'?&7_D;[3_ *\$_P#1DE:4OB-J'QFQ
MX5Z:)_VP_P#9:]9KR;PKTT3_ +8?^RUZS4/<RENPHKDO&_C?_A#18_\ $O\
MMANO,_Y;>7MV[?\ 9.<[OTJWX-\4_P#"7:/+?_8_LGESM#Y?F[\X53G.!_>_
M2CE=KCY'R\W0Z*O._C+_ ,BA:?\ 7^G_ *+DKT2O._C+_P BA:?]?Z?^BY*<
M/B15+XT<%X!NKBV_M#[//+%N\O=Y;E<_>ZXKV[P]+)/H5M)+(TCG=EG.2?F/
M>O"_ _\ R_\ _;/_ -FKW'PS_P B]:_\#_\ 0S3J?$QUOC8GBK_D4-;_ .O"
M?_T6U>!^#/\ D,3?]>[?^A+7OGBK_D4-;_Z\)_\ T6U>!^#/^0Q-_P!>[?\
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MZ5J$][/)/&+!/)\U?)?RY26,@CPK8&0YY8#K3;;T*<FU9COL?C#_ *#NA_\
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MOA1JVD>;]G\363>;C=YFE.>F>F)QZUU5CH_BO3[..UBU[161,X+Z/*3R2?\
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7:TZ** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>img69628308_7.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img69628308_7.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" KL$ET# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MG(:K%<AX&U3[38+:ELF-:Z^O2I3YXJ1\CBZ#H5I4WT"BBBM#G"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH *\M^(KD:U&N>/+_PKU*O*_B-_P AV/\
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M8"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 5YK\1("U^LVWHF,UZ57)
M>.;'S=(DG4988%<^)CS4V>EE-7V>+BWUT/)Z*4C!(]*2O%/T **** "BBB@
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M=7/C)1<9.+Z!1113)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MR^@#T'X+?\E,T_Z'^8KZ^KXJ^'?B&T\+>,;35;T,8(@=P4<]J]Z_X:#\*_\
M/*Y_[Y/^% 'K=%<WX3\::=XP@DEL%D54Z[Q724 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !534K1;RS>%AD$5;I#S2:NK%1DXR4D>#ZG:O:W\J,I W'%4Z
M]$\=:'N7[;$O"+SBO.R,'!KPZU-TYV/T/ 8J.)H*:"BBBLCM"BBB@ HHHH *
M*** "BBB@ HHHH *]$^'S6RVS&1E$V_C)KSNK%I>364ZS0L0PK6C4]G/F./'
M89XF@Z:=CWP$$4M<=X:\6QWJK!<-B3H">!78*P90000?2O:IU(S5XGP.)PU3
M#SY*B%HHHJSG"BBB@ HHHH @O+6*]MG@F7<C=16%'X,TN*<2K!A@<CFNDHJ)
M4XR=VC:GB:M).,)-)D<,2PQ+&HP!TJ2BBK,6[ZF1J?AZRU5]]Q'N)I-+\.6&
ME3>;;Q;7QC.:V**CV<;\UM3?ZU6Y/9\SMV"LK5= LM6</<Q[F P*U:*<HJ2L
MS.G4G3ES0=F8VF^'+'2WWV\6TYS6Q2T41BHJR'4JSJRYIN[&2QB6)HVY##!K
MGIO!FES3&1H,D^]=)12E",OB15+$5:/\.5BK8V,.GVJP0+M0=!535-!L]5.;
MB/<:U:*;BFK-:$QK5(S]HGKW,+3O"NFZ=<K<0P[9!T.:W ,4M%$8J.D4%6M4
MJOFJ.["BBBJ,P/(K"U#PKINHW+3S0YD;J<UNT5,HJ6C1I2K5*3O!V9C:9X=L
MM+D9K>/;E<'FJUUX/TR[F,LD.6/O7145/LH6M8U6,KJ7.I.Y0TO2+728#%:Q
M[%)R:O4M%6DDK(PG.4Y.4G=A24M%,DBGA2XA:*095A@BN>;P1I)?<(/UKIJ*
MB4(RW1M2Q%6EI3DT5-/L8M/MA!"N$':K=%%4DEHC*4G)\SW"BBBF(**** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M *^>_P!I+_CXT?\ W3_6OH2OGO\ :2_X^-'_ -T_UH \$KK_ (=?\C1;?]=%
MKD*Z_P"'7_(T6W_71: /LZ/_ %:_04ZFQ_ZM?H*=0!\N?M"?\CW%_P!<!_(5
MY'7KG[0G_(]Q?]<!_(5Y'0!WO@#QE'X4@GE#8FW948XK'\4>,=2\1Z@\\L[J
MN[(",0*Y^W@ENIEAA&7;H*]6\+_!74=5MUN+Z)XXG&5*D]* /)FD=_O.Q^IH
M5V7[K$?0U[MJ?P#\FU9K(RO(!P":\<U[0;SP_J,EG>1[)$."* +GASQ;J/A^
M_CGAG<KD;@S$C%?67@3Q=#XKT..Z5@7^Z1]*^+*]?^!7B"2V\2C3Y7Q;[">O
M>@#Z@H/2D4AE!'0C(H/0T ?#WC/_ )''5?\ KX:L*MWQE_R..J_]?#5A4 >E
M:3\19- \,)9V+_O73:^>U<)J&KWNHW+SSSR%FZC><4[2-'O-:NUMK2/>Y.,5
MZ_HOP&GN+57U$212$<A30!X@22<DDFGI/+$04E=2/1B*]DU_X%7MI;M)IB/*
M5&3N/:O(M1TVYTNZ:VNDV2*>E 'HGP_^*-]H-U';74I:U)Y+')KZ@TC5(=6T
M^*YA8,'4&OA$,5((ZBOH?X&>+7FA;3+B3+NX" G/% 'N]%%% 'QK\6/^2CZK
M_P!=*XJNU^+'_)1]5_ZZ5Q5 'T7\!/\ CU7Z'^5>Z5X7\!/^/5?H?Y5[I0 C
M?</TKY&^+_\ R,OXFOKEON'Z5\C?%_\ Y&7\30!YU7O?[-O_ !\:O_NC^E>"
M5[W^S=_Q\:O_ +H_I0![[>?\><O^Z:^./B?_ ,CS>?0?S-?9<L8EC9#T88->
M9Z]\$-"\0:M+J-Q=W"R2=0O3^= 'R?17IOQ,^'FF^#<_8IY9.0/G_P#UUYE0
M 45U'P^\.6WBKQ?:Z3=R.D,H.63KVKW7_AG;PW_S_77^?QH ;\!/^09>?0?T
MKV2N8\(>";'P=!)#92R2+)UWUT] !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 07-M'=0-%(,J:\D\4: ^FW;.JG8Y)KV*J6HZ=!J-LT,JCD8SCD5A7
MHJI'S/2RW'RPE2_V7N>#T5TOB#PM<:9*SQH3#G@GTKFL8KQYP<'9GW5"O"O!
M3@[H****@V"BBB@ HHHH **** "K%I9RWDPCB4EC4NG:9<:C.(X$W>M>I>&O
M#$6EPK)*N9<="*Z*-"51^1YN89C3PD.\NQYMJN@7>EE?-3@@'BLFO>KW3X+Z
M$QRHIR.N*\O\1^%)M/E:6!2T/4D]JTKX5PUCL<F6YQ'$>Y5TD<Q%*\+AD8@C
MT->@>&/&1(6VO& QPIKSUE*D@T*Q4Y4D'U%84ZLJ;NCTL7@Z6*ARS7S/H"*9
M)HPZ$$&I*\J\-^+I+%UAN&S&>,DYKTRSO(;V!9H6W(W2O7I5HU%H?#X[+ZN$
MG:6W<LT445L< 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7SW^TE_Q
M\:/_ +I_K7T)7SW^TE_Q\:/_ +I_K0!X)77_  Z_Y&BV_P"NBUR%=?\ #K_D
M:+;_ *Z+0!]G1_ZM?H*=38_]6OT%.H ^7/VA/^1[B_ZX#^0KR.O7/VA/^1[B
M_P"N _D*\CH ]!^$VAKJGBRTED7=&CX((XKZZ@@2WA6*-0JJ, "OF?X% '5<
MXY\ROIN@!:^?_P!H+18+6UM]110))I<$XKZ KQ3]HS_D6]/_ .NQH ^:Z[3X
M82M%XLC*]<5Q==C\-?\ D:HOPH ^R;8YM(3_ +"_RJ4]*AM?^/.'_KFO\JF/
M2@#X=\9_\CCJO_7PU85;OC+_ )''5?\ KX-85 'T-\"/#MN$EOI8PY= 5W#I
M7O(  P*\S^#4:+X4MF"@$Q\FO3* $(# @C(/!%?.GQV\-PV]TVIPQA!@+A1Q
M7T97E7QZBC_X0)I-HW^:.: /E6NT^%VHOI_CJPE#':&Y7/!Y%<770^"CCQ3:
M8]: /MBUF^T6L<O]\9J:J.C\Z/:_]<Q5Z@#XU^+'_)1]5_ZZ5Q5=K\6/^2CZ
MK_UTKBJ /HOX"?\ 'JOT->Z5X7\!/^/5?H:]TH 1_N'Z5\C?%_\ Y&7\37UR
MWW&^E?(_Q?\ ^1D_$T ><U[W^S;_ ,?&K_[H_I7@E>]_LV_\?&L?[H_I0!]"
M4444 ?/OQ\[_ .\*\"KWWX^=_P#>%>!4 >@_!;_DIFG_ $/\Q7U]7R#\%O\
MDING_0_S%?7U !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MGDSA>K0V['?T4R*59D#HP(/I3Z[SYMJVC"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MPKK-!^%^MZU*FV/8IZ[QB@#E=)TJYU:]2WMT9F8]AFOKGX;>$4\+Z$JE0'F
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !44UK;W&//@BEQTWH&Q^=2T4 5?[,L/^?&
MV_[]+_A3DL+.-MR6D"GU$8']*L44 %%%% $,MG:SMNFMH9&]70$_K4?]F6'_
M #XVW_?I?\*M44 0Q6EM"<Q6\49_V$ J:BB@ J.:WAN !-#'(!T#J#_.I**
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !0>E%% 'P[XR_P"1QU7_ *^#6%7W%/X,\.7$SS3:/;/(
MYRS$')-1_P#""^%_^@+:_P#?)_QH X3X'_\ (#7_ *YBO7*IV&E6.F1[+*VC
M@7IA!5R@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **R?$&O6GAW3OMMY(L<6<9:N3_
M .%N^'O^?V'\Z /0J*\]_P"%N^'O^?R'\Z/^%N^'O^?R'\Z /0J*\]_X6[X>
M_P"?R'\Z/^%N^'O^?R'\Z /0J*\]_P"%N^'O^?R'\Z/^%N^'O^?R'\Z /0J*
M\]_X6[X>_P"?R'\Z/^%N^'O^?R'\Z /0J*\]_P"%N^'O^?R'\Z/^%N^'O^?R
M'\Z /0J*\]_X6[X>_P"?R'\Z/^%N^'O^?R'\Z /0J*\]_P"%N^'O^?R'\Z/^
M%N^'O^?R'\Z /0J*\]_X6[X>_P"?R'\Z/^%N^'O^?R'\Z /0J*\]_P"%N^'O
M^?R'\Z/^%N^'O^?R'\Z /0J*\]_X6[X>_P"?R'\Z/^%N^'O^?R'\Z /0J*\]
M_P"%N^'O^?R'\Z/^%N^'O^?R'\Z /0J*\]_X6[X>_P"?R'\Z/^%N^'O^?R'\
MZ /0J*\]_P"%N^'O^?R'\ZEM_BQX;ED"OJ$*#US0!WM%<JGQ'\)R,%36("3[
MUH0>*]$N2!%?QL3TQ0!M45'%/'.NZ-@P]JDH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ K&UG0+;5+=@4"N1U YK9HJ914E9FE*K.
ME)2@[,\0UG0KC2;@JZ'R\_*Q[UDU[MJ6EV^HV[1RHI)& Q[5Y;K_ (6N-+E9
MHU9XO[U>77PSAK'8^SRW-X8A<E327YF!;W$MM*'B<J0>QKT7PUXRCE5;>\8(
M>F2:\UIR.R,&4X(K&E6E3=T=V,P-+%0Y9K7N?0*.LBAE.01D4ZO,?#/B][=E
MM[MMR_WF/2O2+:XCNH1)&P((SQ7K4JT:BNCX?&X&KA)\L]NY-1125L<0M%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HJ.:58(7D=@JJ"<DUXMK_QN@T[4GMX&8A"5/&>E 'M
MM%?/P^/>XX&\GT"5ZKX'\07?B"R>YN%(0@%,KCB@#K**** "BO/O$OQ?\/\
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M'^>M '6T444 %%%% !137=8T+,0 !GFO,M0^.?AC3KZ:TE6<O$Q5B%XR/PH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ I",@@]#2T4 <GXD\)PZA"TENH6;U->87MA/8S-'*I&#UQ7O1K#UWP[
M;ZM QV#S<8!KCQ&%4_>CN>]EF<2H-4ZNL?R/%ZNZ;J<^FW"R0OCG)J;5]&N-
M*N"CH=N>"!697EM.#\SZ].G7AIJF>O\ A[Q1!J<021L2@<ECUKI>O2O ;:YE
MM9EEB8AE.1S7I'AGQ@MTJP7;?O/7M7I8?%*7NSW/E,SR9TKU:.J[';4M-5U<
M;E((/H:=7<?.A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M81W-N^Y649/OB@"]6=K?_(*EK1K.UO\ Y!4M 'Q-XE_Y&34/^NQK*K5\2_\
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M>":^N8)5GA61#D$4 24444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%Q?++<****9(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M:^8;FVEM)VAF7:Z]17WO+$D\31N RL,$'O7R7\8?#ZZ7XMNKB)=L3MA5 X%
M'G )4@@X(Y!KZ*^!/BEKF!='EE+R#+<GG%?.E=S\*]4.E>+8Y=^T$;?SH ^Q
MJSM;_P"05+5RV?S+:)\_>0']*IZY_P @J6@#XF\2_P#(R:A_UV-4[%!)>Q*>
M035SQ+_R,FH?]=C5.P8)?1,QP W- '0^)_#<FE:?:WY4B.X/RURP)!!'6OIG
M4O#,/B+X4V<Z*&:"$NO'6OFJ>"2VF:*5"KCJ#0![[\"_%P;&C3R<(I89->^
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MV-:RB:TAD!SO16_,4 34444 %<_XW_Y$K5O^O<_TKH*YWQU(J>"]5!/)@.*
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M-::$?9HF^\.:X=I&=B6))/O3L!Z!_P )S8?\\9*/^$YL/^>,E>>T46$>A?\
M"<V'_/&2C_A.;#_GC)7GM%%@/0O^$YL/^>,E'_"<V'_/&2O/:*+ >A?\)S8?
M\\9*/^$ZL/\ GC)7GM%%@/18O&MA*X7RW'UK=M+Z&\C#QN.>V:\=%:>CZK-8
M72E6.UC@YHL!ZQ15>SN4N[99D^Z:L4AA114<\RP1&1^@H ;<745LA:1U&.Q-
M8,_C.Q@D*&-VQW%<EKVL2WUVR[CM4X&*Q22>IIV$>A?\)S8?\\9*/^$YL/\
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M6VO5!C<#/8FKU>/6=[+:3JZ,>#SS7IVBZB-1L4ES\U(9IT444 %,EE2%"SL
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M8XS4T/BBRF?: 1]37F&3ZTH9AT)_.BP'LL-S%.N8W4_0U+7E>D:U<6$Z /\
M(2 <UZ99W27=NLJ'@BD,L4444 %%%(6"CYB />@!:*IS:G;0'#2*?H:6'4;:
M?[LBCZF@"W131(C='4_0TZ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_.J=_K%EIL#37$Z!5&3AA7R8WQ7UUEQG_P ?KG=3\5:MJ;EI;R8 _P (<XH
M]2^*'Q7.H;].TN3,?*N>G%>)EBQRQ)/J:&9G8LS$D]2:=%$\TJQQC+,< 4 /
MM8&N;J*%%)+L%X]S7UM\*?"8\/\ AR,S)B=CG\#7GGPG^%TKRIJFIPE4(RN1
MD9%?0<4:PQJB  * !B@!]9VM_P#(*E^E:-9VM_\ (*EH ^)O$O\ R,FH?]=C
M656KXE_Y&34/^NQK*H ^S?A7_P DZTK_ *YUV5<;\*_^2=:5_P!<Z[*@!DL8
MEB>-APRD&OEGXS>$FTG7GNX(\6Q')QW-?5-<=\0_"Z>)/#TL(3,BY;('/ H
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MS0!]/VXQ;1#T0?RJ2D4;5 '88I: "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***0D 9)H 6BLV[UV
MQL\B67!%<]?>--@(M@K_ %H [$NJCE@/QJI)JMK$VUG&:\WO/$%Y>9RQ3/\
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M(/44E4(**** "BBB@ HHHH **** "N@\(N5U4X/\-<_75^#;%VO#.P^3;UI
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M-+7FUEXMN[;"E0P]2:Z.R\7VLH N'"L>PI6&=-15:WOK>Z7,3Y%6: "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ KQ/X\Z$TNC"_B3+EP#].*]LK#\6:+'KFASV\F/E1F&?7% 'PZ1@D'J*]
M*^#6OG3O%]M:N<0N22?Q%<)K6GS:;JD\$R%")&P#Z9J/3+Z33KZ.YB)#J>HH
M ^\(I%EB613D,,BGUS'@77HM<\.VSQL&:.,!\>M=/0 4444 ?(?QK_Y*9?\
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M#_#UC,)K;2;>*0=&4'- %K0[-+'1K6%%"XB7./7%:-(%"J% P!T%+0 4444
M-=0Z%6&0>#7RM\:] ^P^*KB_08CD(4 =.M?5=9NH^'])U;_C_L8KCG/SB@#X
M2KM/AEK9T7Q;!<,^$QMQ]:^J?^$#\+?] 2U_(_XTZ/P1X9A</'HULK#H0#_C
M0!LV<WVBSAF'\:!JGIJ(L<:HBA548 '84Z@".:9+>)I9&VHO)-?(7Q6UW^U?
M%5U"K;HHI/E-?1GQ+\1QZ'X:N4+ 2RQG9SS7Q[?7;WUW)<2?><Y.: (%4LP4
M<DU]1_ _0!9^'(=19<22 J>/:OG7PMI4VK:[:PQQEU\P;L=A7VAX>TM-'T:&
MSC "J,\4 :M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !115.[U.ULU/FRJ&]#0!<J"XO(+5=TSA17(:GXQZI
M @/^T#7+W6J75TY+S.5/:G8#MM1\7V\&1;%9*Y:^\27=X3M8Q_[IK%ZGFBBP
MB22>64_O)&;ZU'11WI@%%%% !6AHUR]OJ$6PXW, :SZO:3"TVHP[1G:X- 'K
MB\H/I2TB_<'TI:D85R/BW1VN%^U1@DH.@KKJ:\:R*5=0RGL: /%V4HQ4CD=:
M2O2=0\*6]X28R(B?05FCP$N?^/P_E3N(XBBO0(O!<,>-TP;'M5Z+PQ:1]45O
MPHN!YC7G?Q(MW%N9L?+D#-?3T>AZ>B8-K&3ZXKR#XZV5M;>'V,,*I\PZ47&?
M.%%%%(#USX61S7MG="-,[" :]'BT:^F;"0DU@?LYP12V&J^8@;#CK^%>[);0
MQG*1J#[4[@<AH7A9HY!+=*58<X-=FJJB[5&!2T4@"BBB@ ZUS6O>&TO_ -]%
MPX'0#K72T4 >3SZ%?P.P,!P.]5_[,N_^>1KUQX8Y/OH#]:9]BMO^>*T[B/)O
M[,N_^>1H_LR[_P">1KUG[%;?\\5H^Q6W_/%:+@>3?V9=_P#/(T?V9=_\\C7K
M/V*V_P">*T?8K;_GBM%P/)O[,N_^>1H_LR[_ .>1KUG[%;?\\5H^Q6W_ #Q6
MBX'DW]F7?_/(U;M?#U_<N/W#;3U->G?8K;_GBM2)$D8PBA1[47&8VAZ%'IL0
M9N7(YR*W***0!1110!'/"D\1C< J?6N$UGPI,DK26JEPW./2N_H(SUH \A?2
M;V,X:$@TW^S+O_GD:]::U@<Y:)2:3[%;?\\5IW$>3?V9=_\ /(T?V9=_\\C7
MK/V*V_YXK1]BMO\ GBM%P/)O[,N_^>1H_LR[_P">1KUG[%;?\\5H^Q6W_/%:
M+@>3?V9=_P#/(T?V9=_\\C7K/V*V_P">*T?8K;_GBM%QGDZZ5>,<"(YK:TKP
MK<SR!KA&11^M=^+2W4Y$2BI0H48' HN!7LK*.RMUB0# [U9HHI %%%% &=JV
ME1:G;LC\-C -<!?>&KVWD;RXF9 >M>H4UD5QA@"* /(CIEV#CRC2?V9=_P#/
M(UZR;.W/_+%:/L5M_P \5IW \F_LR[_YY&C^S+O_ )Y&O6?L5M_SQ6C[%;?\
M\5HN(\F_LR[_ .>1H_LR[_YY&O6?L5M_SQ6C[%;?\\5HN!Y-_9EW_P \C1_9
MEW_SR->L_8K;_GBM'V*V_P">*T7 \KBT6^F8!82:ZS0?#'V<B:Y7Y_0CI75)
M;PQG*Q@5+1<8BJ%& ,"EHHI %!&:** .7U_PVMYF6!<..P'6N-FT._A8AH"
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M;M%(!SWJS10!YQJGA:[AF9K>-G3/6L=M+O%8@Q'->O$ C!Z5";.W)R8E)IW
M\F_LR[_YY&C^S+O_ )Y&O6?L5M_SQ6C[%;?\\5HN!Y-_9EW_ ,\C1_9EW_SR
M->L_8K;_ )XK1]BMO^>*T7$>3?V9=_\ /(T?V9=_\\C7K/V*V_YXK1]BMO\
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M #Q6BX'E,>CWLK82$DUT>B^$Y#(LMT"F.<5VBVL*'*QJ*FQBBXQD<:Q($4
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4C*&4J>A&*6B@#YO\
MC?X->&_.K6T9$(4 @#O7B)!!P>HK[G\1Z+!KVD2V5P@9""0#ZXKY(\3^ M9T
MK6)8H;&::-F)4HG &: .T^"GC+^SM1&EW$F$G?[Q/ KZ81UD0.C!E/(([U\1
M6.@^(["Z2XATN[61>A\LU]5_#G6;S4]"CBO;6:&6! I,@QN- ':4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MB2N-Y'H:R/\ A.(_,SY3[?2@#M**Q-.\2VE_QQ&?]HULHZN,JP(]J '4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M* "BBB@ HHHH *\7^/?_ "+S?[XKVBO%_CW_ ,B\W^^* /FBBBB@#Z(_9O\
M^0?JW^^/Z5[O7A'[-_\ R#]6_P!\?TKW>@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M***@NKN&SA,LS;5% $S,%&20!7,ZSXHBM0T<# N..:Q-;\427.Z&W("'C<#S
M7,.[.V68D^].P%B\U":\E+R.>3TS56BBF(<DCQL"K$$>AKM_"FMM,PM96S@9
MYKAJT=%F:&_0KW(%(#UKJ**9$<Q(?]D4^D,*8\4;_>13]13Z* *G]FVV_=Y2
M9_W15A(8XQA44?04^B@ HHHH **** "BBB@ HHHH **** "BBB@ HI"0.]&X
M>HH 6BDW#U%&X>HH 6O%_CW_ ,B\W^^*]GW#U%>+_'L@^'FY'WQ0!\TT444
M?1'[-_\ R#]6_P!\?TKW>O"/V;R!I^K9/\8_I7NVX>H_.@!:*3(]11N'J* %
MHI-P]1^= (/<4 +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M-%<UHGB:*[58IV"R=!72!@PR.E(8M%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !103@9-8&M^(H=/
MB98\/(>,>E %W5-8@TZ(EG&_TKSO5M;N-1F/S%4Z8!X-5+R_FO92\CDY[&JM
M.P@-%%%, HHHH 0UN^&;)KK41QP!FJNG:/<W\B[8VV'^*O1='TB+3+=0 "_]
MZDP-)!M11Z#%.HHI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4E+10 4U
MXUD4JP!![&G44 CA/$W@X3AKBT7YQ_"HZUYS/;R6\K1R+A@<&OH \C!KE_$7
MA2#48FDA41R8[#K7!B,+S>] ^CRS.73M2K[=SR.M;2-<N=+G5E=F0'[N>*J7
M^G3Z?.T<J$ ' )[U4KSTY0?F?52C3KPL]4SVO1/$-OJT"D,!+CE1VK:KP:PU
M&?3YUDB=A@\@=Z]1\/>*[?48529ECD]":].AB5/26Y\?F>42H/VE+6/Y'444
M@Y&12UV'A!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 (RJXPPR*
MQ=4\.V]\A*J$;V'6MNB@#RK4]"N;!S\A*#H:R:]EGMHKF,K(@8>]<=K7A/EI
MK;_OA13N(XNBI9[>6W<I*A4CUJ*F 4444 .CD>)@R,5([BNR\-^(V+BWN#R>
M 2>M<74UI(8KJ-QU!S0![("",BEJEI,QN-.BD;J15VI&%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>?\
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MHHH **** "BBB@""ZM8KN%HY5!4C%>:^)?![V;M/:K^Z/\(Y->HTR2-94*N
M01CFL:M&-169W8+'U<).\=NQ\_.K(Q5@01ZT@.#Q7H_B7P:)0UQ9K\W4YKSR
M:"2"1D=2"#CD5Y%6E*F[,^XP>-I8J'-!_(Z/P]XJFTR54F8F'/(%>I6&HP7\
M"R1..1G&>:\&S6SHNOW&E3J0Y\O/(-;X?$N'NRV/.S/*(UU[2EI+\SVRBLC1
M]=M]4@4JXWXY!-:U>I&2DKH^-J4Y4Y.,U9BT4451 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%)0 M%%)0 M%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 UD5QAAD5GS:'8SONDCR:TJ* ,Z#0[&W</''
M@BM!5"C &*6B@ HHIKN$0LQX S0 ZF&6,=77\ZX_6_%;0RM%:G\ZYM]?O78L
M7IV ]5#JWW6!^AIU>8V7B>]MI!E@5[UW>DZQ#J4 *M\PZ@T@-.BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M:4*E62FKGHO@^_EOK)WE/(KI:Y#P%_R#Y?J*Z_%;T&W339YV8Q4<3-1V//\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M:ZKN6Z***W//"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?+T&:[U&#J&4Y!J1CJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^/?-TWU% '!?"O\ Y'*'_=K[#M?^/6+_ '!7QY\*_P#D<H?]VOL.U_X]8O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !7.^(M"2_A:6, 2 =:Z*@C(Q0!XQ/"]O*T;@@@XJ.N\\4:
M LB-<P+R!R*X5T*,58<BF(;1113 5&*.&4X(Y%>@>%M<%Q"MM,WS@9W'O7GU
M3VEU):3K(AQ@C-(#V2BLK1-434K-7!^;I@]:U:0PHHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L
M/Q%JRV%H4!^=Q@8K4O+I+2V>5C@*,UY?K.I/J%X[9^3/%- 9\TKS2%W.6-,H
MHIB"BB@ D@#K0!+! ]S*(XQDFO2?#VC)I]J&*C>XS67X6T/RP+F9?F!R*[$#
M P*3&%%%%( HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH *Y3QO_R#6_W:ZNJ&IZ5#JD!BFS@C'%9U
M8N4&D=.$JQI5HSELCQOP_P#\AZS_ .NE>YUREGX'T^TNXKA VZ,Y'-=76.%I
M2IIJ1WYQC:6+J1E3Z(*I:G81:A9O%*N>"1]:NTE=+5U9GDPFX24H[H\,UC39
M=-O7BD'&21QVJ#3O^/U*]AU?PW9ZNV^93N]JS(/ FG0RAP&R/>O-E@YJ?N['
MUU+/:,J-JE^:QT>G_P#(.@_W!2ZA_P >,OTJ6&(0PI&OW5&!2RQK-&8V^Z>M
M>C;2Q\GS+VG-YGA>K_\ (4G_ -ZO6?!W_(LVGTJC<^!M.N;AY6#98YZUT.FV
M,>FV,=K%G8@XS7)AZ$H3<F>WF>8T<1AX4X;K_(M4C*'4J>A&*=25VG@'F'C7
M0#:W!NH%Q%CD>]<5C!KWN^L(=0MS#,,J:YI_ .FLY.&Y/K7G5\))RO ^JR_.
MZ=.BH5[W0> O^0?+]177UG:3I$&DPM'!G!ZYK1KMI1<8),^?QM6-:O*I'9GE
MWC[_ (^5_P!ZI/AM_P A*Y_W*[#5_#%GJSAI@V0<\&C1/#5KHL[RVX;+#!R:
MY?83]MS]#UWF5%Y>\/\ :L;M%%%=Q\\<SXMT-=2L6DC7]\.AKR2>)H96C<$%
M3BOH @,I!&0:YF^\%:=>3F5E;)Y.#7%B<,YOFCN?095FT</%TZNW0XCP5_R&
M(O\ >KUZN=TOPE9:9<+-$&W Y&3715KAJ;IQLSCS7%T\564Z>U@HHHKH/+"B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH *2EHH *3&:6B@#G]?\ #4&J1,ZH!-ZUY7JND7&F7!CE0D>H
M'%>Z5FZMH]OJELT<J#GN*Y*^&535;GM9;FT\,^2>L3PRI[6\FLIUEA;#KR*U
MM>\.SZ3.?D)C/(QSQ6%7ERC*#LS[*G4IUX<T=4SU+PUXOCO%6"Y;]YTR>!79
M*RL,J01ZBOGZ*5X9%="017>^&/&6TK;7C<'A37?A\5?W9GS.9Y+RWJT%\CT6
MBHXIDF0,C @^AJ2O0/FFFM&%%%% @HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ K$\3_\ (+?_ '36W6)XF_Y!<G^Z:SJ? SHPG\>/J>,Q
M_P#'TO\ O_UKVCPU_P @E*\7C_X^E_W_ .M>T^&O^02E<&"^)GT_$/\ "B;%
M(>E%!Z5Z9\@>(>(/^0O<?[YK>\ ?\?4OU%8/B#_D+W'^^:WO '_'U)]17C4O
MXY]YC/\ D7OT1ZE7G/Q"_A_WJ]&KSGXA?P_[U>AB_P"&SYC)?][B<UX8_P"0
MJOX5[1'_ *I/]T5XQX8_Y"J_A7L\?^J3_=%98'X6=G$/\:/H/K#\6_\ (NW/
MTK;K$\6_\B[<_2NJK\#/'P?^\0]4>,2?ZP_6O7_!W_(*C_W:\@D_UA^M>O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBLK7;\66GR,#\^.* .:\6:SO<6\+=.&KCJEN)VN)VE8\L<U%5""BBB@ K?\
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M0M%%%,04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MMF8\DF,4 >4?L[1NGAS4 Z,I\X=1BO::KVEA:6"%+2WCA4\D(N,U8H ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MJX<^M=53(XQ'&JJ, #%/J1A1110 4444 %%%% !1110 4444 %%%% !1110
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MRN2,\ UR8C$*GHMSVLLRJ6)?/4TC^9[?:7 N;:.9>C+FIZYKP;??;-,QG.S
MKI:Z*<N:*9YF)I.C5E!] HHHJS **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBHY9HX4W2,
M%'J: )**H-K6G*<&Z0&I8=1M+@XBG5C[4 6J*2EH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ ILD:R(5<94]13J*
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 48HHH **** "LG6-#M]5@(=!O]36M12E%25F73
MJ2IR4H.S/%-<\/W&E7# HS1_W@.*Q:]ZU#3X-1MS#.FY37EWB3PK-ITK20KN
MCZX45Y>(PKAK'8^RRS-XUTJ=727YG-0S26\HDB8JXZ&O0/"_C#=BWO&R3P&8
M]*\[((.#P:56*$$=17/2JRINZ/2Q>"I8J'+-?,^@8I4F0/&P93W%/KRSPSXP
MDLW6WNF+QGA?:O2[2\AO(1)$X(/H:]>E6C46A\-C<!5PD[26G<L5AZ_K\&DV
MS'<&D/&T'D4:_K\&DVS?,#(>  >17DFJ:G/J=TTLSEB:RQ&(5-66YVY5E4L3
M+VE32/YAJ>ISZE<M+*Y;TS5&BBO);;=V?:PA&$5&*T.^^'M[Y>^W)Y=J]'KQ
M;PI=FVUVW)/R9Y%>S1R"6-77H1FO6P<[T[=CXK/J/)B>==1]%%)76>(+1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110!#<SK;PM(Y  %><:UXAN+V=DC<K&.,5T_C&Y:+3=J'!S
M7G1.22>]-"%9F<Y)R:GM[VXM6#12%2/2J]%,#T;PYKXOH_*E.)%&,D]:Z6O(
M-,NC:WT4@. &YKU>RN!=6B2@YW"DQEBBBBD 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 45#<7,=M&7D8 #WKF+OQE LA6$GCCD4
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110!S/C*W:33-RC)W5YT1@XKV2\MTN;=T<9&#7E&J63V5XZ,,9
M)(IH12HHHI@%=YX/U3S8C;.W"#C-<'6AHUXUI?QD' +<T@/6Z*B@F6XA613D
M&I:0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D=@B%CT
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "L+Q!K\&DVK L#*1\H/-+X@\00Z1;-\P\[&54]Z\
MDU/4YM1N6DD8X)R!FN3$8A05H[GMY5E<L3+VE32/YD>H7C7UW).P +'/%5:*
M*\EN[NS[6,5%**V04444B@HHHH *[/P%??9[IX<_ZQJXRM7P]<FVUFW?/ ;F
MM:,N6:9R8ZE[7#RAY'N%%16\HG@60?Q"I:]T_.6K.S"BBB@04444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 5QOC+3=Z&[4?=&.*[*JNH6JW=H\;#.: /'CUHJS?V[6UW(C# W'%5JH0
M4JDJ01U%)10!Z/X2U$7%BEN3ED&3725YCX8OS9W^">'P*]-4Y4'VI,8M%%%(
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *XCQGJ&[_1 >5.:[*X
M?R[>1_[HS7E.M71N]1DDSG-- 9]%%%,04Z-&D<(HR33:VO#=D;G4HV(RH/-
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 E8FO^((=(MF^8&;'"
MFK6M7\MA9-)%$9&Z8%>/:M>7=Y=-)<[NIP#V%<N)K^S5EN>SE66K$RYYOW41
MZGJ<VHW+22.2"> 3TJC117D-MN[/MX0C"*C%:!1112*"BBB@ HHHH *?#(89
M5<=13**!-7T/;?#=T+G1;<Y^;;S6Q7$> +T3020D_<6NWKW:,N:FF?G6/I>R
MQ,H^84445J<84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4'D8HHH X'QCIQCN!,@^7'-<E7JGB&S%
MWI<J@?-VKRZ9#'*R'JIQ30AE%%%,"2WD,4Z.#]TYKU71+S[;IJ2YSGBO)J[?
MP7J&[_1">%&:3 [2BBBD,**** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MCT-=/::?;V2A8$VU:I7&5;73K:T $,07Z5:HHI %%%% !1110 4444 %%%%
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M[SLNP4445N>>%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MA^749 [KB('FO0;'3X;&$)&HZ>E*X&?I/ARWL$5F4&7N:W  .@HHI#"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *3 I:*
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M>LX@HV#P:XH5L1A)69LX0JH[V*9)E#(<BI*X>VOYK9P0Q(]":Z2QUB*X4*[
M/Z5[6%S&G6TEHSCJ8>4-4:E%,+JHR3Q5=]1MHS\TF*[Y3C'=F*BWL6Z*S)-=
MLEZ2C-5G\0P@_*P(K&6+HQWDC14:CZ&Y17./XEP?E"FF_P#"3-_=6L_[0H=R
MOJU3L=+17,_\).W]U:E3Q(A'S;0:%CZ#ZA]6J=CH:*Q$\16Q'S.!5E-;L9,
M3#-:QQ5&6TD2Z-1=#2HJ"*[AE^X^:FZULI)ZHS::W%HHHJA!1110 4444 %%
M%% !1110 4444 %%%% !1110 44A. 2>@K/N=8M+<$-( 1VJ)SC!7D[%1A*6
MB1HTFX>HKD[KQ1)R(E4CUK*?6+EI-VXC\:X9YE2B[+4ZX8&I+?0]"HK-T:]:
M\M=S#E>*TJ[J<U.*DNIR3BX2<6%%%%62%%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MKS+;J>"T5K^(-'DTF_DBP3&#@-V-9%>+*+B[,_0*-6-6"G#9A1114F@4444
M%%%% !70>$5M6U;%UMVXXW>M<_4MM,T%Q'(IQA@:NG)1DFS#$TW4I2@G:Y[[
M$J)$H0 +CC%/K)\/ZDNI:8DHZCBM:O=BTU='YO4A*$W&6Z"BBBJ("BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MZ&O-/'.AF&9KZ->'.,"N'&4;KG1]%D>/<)^PF]'L<-1117EGV 4444 %%%%
M!1110!V_@+53'>"T>3;%@GGUKTT'(R.E>"6%PUM=QNIQ\P_G7N&FW*75E$Z,
M#\HSCZ5ZN#J<T>5]#XS/L+[.LJJVD7****[3P HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M,:#"K@5)17IPHP@K11S.<I;LQ=2T=)@9(@%-<S+$T+E6!&*[^LK5-+6Y0N@
M>O,QV7J:]I36ITT*]GRR.?T_4'M)1R=N>177VMRES$'4]>U<--$T+E6!&*O:
M7J+VTH4GY2<&N+ 8V5&7LY[&U:BIKFCN=E4<LR0J2[ 8]:JSZE#%;^8&!R.
M#7+WVI2W;D;CL["O6Q6/A16FK.6E0E-FI?Z]C*1 @^HK"FNI9R?,8FHU5G.%
M!)K5L=$EGPS\+Z&O#=3$8N5D=JC3I(R51G/RJ3]*MP:7<3$?(R_45U5OI5M
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 5Q?CF<^7"@!'-=I7(^.("]O"R]CDT <%1115""M;P[.8-6C<'
M%9-3V<ODW*/[T >PQ-NB5O49I]063;K*%O5!4]2,**** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0]V&Y4L=*ALU&%^;O5_I2T5[L(1@N6*/-E)R=V%%%%62%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %8/BB'S;
M G^Z,UO50UF)9-+G)ZA#B@#R.BCZT50@I5^^OUI*4=10!ZUH\IDT^+)SA0*T
M*PO"\@DT_@],5NU(PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /+_$LS2:BZL>%
M;BL2M#6V+:O<@GH]9],04444P.P\%2M]H\O^'!KNZX;P7$/-\S/.#7<TF,**
M**0!1110 4444 %%%% !1110 4444 %%%% !1110 C$*,GI7E>OW1N-1D7.0
MK8%>CZO/]GTV67.,"O*+J3S;J1_[QS30$-%%%,04444 %%%% !3D0R.%7DGI
M3:U= M#=:E%Q\H;F@#O?#MD+738VQAV7FMFF11B*,(O04^I&%%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110!G:S8)J&GO$_0 FO$KN%H+F1",
M88@?G7OC#<I4]QBO)O'.GK9ZL#&/E*Y-<.-IWCS=CZ+A_$\M5T7U.5HHHKRS
M[ **** "BBB@ J>TF:"Y1U..:@H'!!IIV=R914HM,]YTN99M.@8'/R#-7*Y7
MP-=FZTM\G.P@5U5>]3ES13/S;$TW2K2@^C"BBBK, HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@!**6H;FXCM86DD.%49H2N)M)787-Q';1-)(V
M !FO//$/B^2\<VEEAD)QGO5?Q!XBFUB[^QV9_=[N&4]:Z#PUX32S5;BZ3=(1
M]UA7I4Z4*$>>KOT1Y%6O4Q4_94-%U9D>'O#5],XFNMP0\_>-;]WH<D(S""0!
MWKIT147"J /04I (P17CXZA3Q;YI*S\CU<)%X:/+%W.">-HV*L,&H]J'[R*?
MJ*[6ZTV&Y'0*?4"N<OM*EMLL%)0=Z^<K8&OAGSPV\CTHU85%:1R6H:05N5N+
M;.[.6'3%>D>'2YT6#S#\V.>:Y+@BM&PU)[3"CE*]&CGM24%2Q&MNIQK+*=.H
MZE+2_0[&BJ=G?Q7:C:PW>E7*]6$XS7-%W1+33LPHHHJQ$;01,VYHT)]2*D
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M,DUT^DZ)Y>)9QSZ4NA:9'Y*W#<EO6N@ P,"O7P. 22J5#BQ&)=^2(BJ$7
M]J=117LG %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 56U 9L)Q_LU9J&Z&ZUD'^S0!Y#=KLN6&
M,5!5[5D*:C(I&*HU0@H[T44 >B>"Y ^GR8[-73UQ_@:0"TE3U:NPJ1A1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Y#QY8)+I+W
M&7&!77UFZW9_;=-DB_&LZD>:#1T82K[*O&?9GAA&#BBIKN/RKN5/[K$5#7A/
M<_2(NZ3"BBBD4%%%% !1110!W_P]OO+W6O\ ?:O1J\>\$RE?$5NF>":]AKV,
M)*],^%SRER8MOOJ%%%%=1XX4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4R7_ %3?2GTA&010!Y1K_P#R&)JS*V/%"A->
MN%'8UCU0@HHHH [7P21L<?[5=M7 ^#&(GQGC=7?5+&%%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !56_<I9NWI5JJFI_\>$GTH \GOVW7TS>K57J>\_X_)?\ >J"J$%%%
M% 'HG@R(_P!EB3/<\5T]<[X,_P"0&O\ O&NBJ1A1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %8GB'6X]*LV(8>81\O-6-8U:+2K1Y7Y(&<"O-&>\\
M4ZLH;<8@W&1T%=F%P_.^>?PH\_&XOV:]G#XF/TC3KCQ%JS7,N=@;)R.M>IV=
MI'9VZPQC"KT%5='TJ'2[18T4!L88UI5.*Q'M966R+P>%]C&\OB>XE+2'I52[
MU*ULXRTDJ<=LUS)-NR.N4E%79;)"C).!7,>(?%4&G1-'"P>3'53TK!UOQI+<
M,T&GAU/3UJGHOA:YU6X%S>?<)Y5AUKT*6%C!>TK:+L>76QLJC]EAU=]S#OA?
M:BLEY.'V#D9':NY^'[[K689Z8J[XBTZ"T\*W"1)@JN*QOAM+A;M6/<8_2MJM
M55L-)I62.>C0>'Q<5)W;1Z!2T45Y![PR2)95VN,BN>U/1RF9(1QZ"NDI",\'
MI7-B<+3KQM(N%24'=' ,K(V",&M+3M5>V8*Y)3TK3U/2%D!DB !KFY(VB<JP
M(Q7S=2E6P52Z.^,HU8G<P7"7$8=2/I1=#=:R#U%<IIVHO:2 $G8>HKJHIDNH
M<J001TKWL+BXXFFUU..I2=.7D<3<KMG85N^'I,DIGH*RM4A,5[)QP3Q2Z7=?
M9;G.?O<5X>'G[#%>]W.R:YZ>AVE%,BD65 RD$4^OJDTU='FA1113 **** "B
MBB@ JAJMV+:V)!^:KS'"D^@KDM:O//N"JGY:XL?B/8TG;=FU"'/(S'8NY8]S
M6_H-CG]\PY!XK&L[<W-PL8[UVMM"L$*J!VYKR<KP_M*GM);(Z<34Y8\J):6B
MBOHS@"N2U]?],8XKK:Y7Q X,Y7N#7FYHOW!T8;XS/T]]ETIQ7<)S&OT%<%;R
M+%,K,0!D=:[2"^MI8UV3QDX' :L<G4G"78K&2BI)7+=126\4OWUS4@8,,@Y%
M+7L7:.2R91?2+)\[H <]:@/A[3">;9:U:*M5)KJ0Z5-[Q1D/X9TF08:U4U'_
M ,(EHO\ SYI6W13]M4_F9/U>D_LK[C)7PUI*#"VJ@5G:KIVF64)V0*).U=#<
M3+!$78XXKB-0O'N[@LQSCBO.S#'SI0Y5+5G5AL'3G*_*K(IG&[C@5M:+IAGD
M$L@^4'H>]4-/LVO+A4 X]:[>VMUMX50#H.:\K+\*ZT_:3V._$5E!<L1S1A8-
MBC@#@5PFI#%_*/>O0*X+6/\ D)S?6NO-H_NXLRP3]YFAX78+=R9_NUUM<;X=
M_P"/IOI79#I6V6/]PD9XS^(%%%%>B<H4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Y=XK!
M_M^X..,UBUV?C#2WWFZ1<[CS@5QAX--""BBE52[  9-,#J_!@)N >VZN_KF/
M"6FM;6IDD7YB<BNGJ6,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M" 5WX%^\T?-\1QO2@_,VJ***],^1"BBB@ HHHH **** "BBB@ HHHH ****
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M^%>Z1ZR?G2O@GNF/ES!;-$;?$72RIVQRY[<?_6JE)X_C8?NDDS_NFM(?#[2
M0<R?G27GAC2["#S &SVS4SJX*G%RL]!QIYA-V;2,QM=NM3BRQ(C]",&H%4NX
M &2:3:%X4 "MS0; RRB=A\HXKXFI*6-Q-XJR?Y'T]*/U>BE)W9L:18+:VX)'
M)YK4I%   ':EKZ2E35.*C'H>=.3D[L*X+6/^0G-]:[SH*X/5SG4YOK7FYO\
MPX^IUX+XV6_#O_'VWTKLATKC?#O_ !]M]*[+M6F5_P  G&?Q HHHKTCD"BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M445V'@A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $%U=
M1VD)DD8  <9KB-3\7R2.8X5P!_$#4GC'47\PVR,1M/-<=30C7'B*]#9\U_SK
M<TCQ>?,6*X4!3_$37&4=* /9X9EFB5T.01FI*Y+P?J3S0&&1BQS@9[5UM(84
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MQTN*U4$J"WK6@JA0 !P**]+#8"G1UW9E4KRGH+1117>8!1110 4444 %%%%
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MN:]04!0 .@K@O!MMON!-C[K5WU)C"BBBD 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!#<_P"I:N(G
M_P!>_P!379Z@VRU8UQ<AS(Q]Z^?SE^]%'9A5HSH/#?\ JI?K6]7F4OB*_P!'
ME"6Z91N3\N:MP>/9>//4CU^6O>RW!57A(21Y6)S"C&M*$GJCT*DKD8?'VF8_
M?,X/TJ['XSTJ50RNV#ZBNEX:JMXA'&4);21T5%8Z^)-/89$G%2Q:[92G"R#\
MZATIK=&BK4WM(TZ*I?VK:_\ /1?SJ*77+*+[T@_.DJ<NPW5@MV:-(SJB[F8
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M-88PBC %.50HP  /:BO;PV%A0C9;G!5JRJ.[%HHHKI,@HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH \N\5?\ (P7'UK%K:\5?\C!<?6L6F(****8'6>#?^/@?[U=_
M7 >#?^/@?[U=_28PHHHI %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %5-3.+"3'I5NJFI_P#'
MA)]* /)KWF\E_P!ZH*GO?^/R7_>J"J$%%%% 'I/@S_D!K_O&NBKG?!G_ " U
M_P!XUT52,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#*\0P^?HT
MZ <D5Y7(GER,I[&O9)XA-"8SWKR7583#J,ZD8&[BFA%.BDI:8!1110 4444
M%=%X3O?L]\(LX\QJYVI[.<VUTDH/W3F@#V2BJ6EW/VK3XI,Y)'-7:D84444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7%>-+W:WV7/4 XKLIG
M$<3L3T!->4ZY>?;;]GSG:2* ,VBBBJ$%%%% !1110 4 <XHI\2&255 R<T >
M@^#;;R;!R1R3FNGJCI-N+>PB '5035ZI&%%%% !1110 4444 %%%% !1110
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M:Z_U;Y-7.M>=QS21$%'(QZ5TFDZSYA$4I ]Z]#"YFJCY:FC.>KA7%7B=!12
MY&1WI:]8Y HHHH *3%+10 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% 'EWBK_D8+CZUBUM>*O\ D8+CZUBTQ!1113 ZSP;_ ,? _P!Z
MN_K@/!O_ !\#_>KOZ3&%%%%( HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JIJ?_'A)]*MU4U/
M_CPD^E 'DU[_ ,?DO^]4%3WO_'Y+_O5!5""BBB@#TGP9_P @-?\ >-=%7.^#
M/^0&O^\:Z*I&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5YYXQ
MLQ;W4;@??Y->AUSWBNP^TV+3=XUH0'FM%!!!P:*H04444 %%%% !1110!W/@
M[4MRM!(V-HPM=E7D6DWAM+Z)\X7=S7JUI<K=VZS)C#4F,GHHHI %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%-D<1HS'H!F@#"\4:A]DL"%;YR<5YHY
MW.S'N<UN^)]2^V7[!&R@["L&FA!1113 **** "BBB@ K6\.VWVG58TQD5DUV
MO@NPR/M1&"#BD!V<2[(E7T&*?112&%%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >7>*O^1@
MN/K6+6SXJ_Y&"X^M8U,04444P.L\&_\ 'P/]ZN_K@/!O_'P/]ZN_I,84444@
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ KG_$VJBRLRBM\[<$"MFZN%MK=Y&.,#->7:WJ3:A?.X)V
M=A0!FNQ9RQ[FDHHJA!1110 4444 %%%% #X4,DJ*HSDBO5]%LQ96"H/X@#7"
M>%K W6H L/D KTM5VHJ^@Q28"T444AA1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%5[B]@MAF5]M %BBLT:[I
MY.//%78;B.X7=&V10!+1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #)(TE4
MJZAE/4&L6\\,6MTQ*A8_H*W:* .:@\(6\,FYG#CT(K=MK."U7$,:K]*L44 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!#<
MP)<0-&Z@Y&*\OUS3'T^\9<'9ZUZM6/K^E)J%F< !QSF@#RRBI;B![>9D=2"#
MWJ*J$%%%% !1110 4444 %36US):RB2-BI'I4-% 'H>@>)([I!%.P5QP,]ZZ
M=6#*".AKQB.5XG#HQ##H:[#0?%!4K!<G(/&XGI2L!W%%1PSQ3H&C<,#W%24A
MA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !0::[K&NYV 'J:Y;7O$\=NK0VQ#-_>4T :&M:]#I\#!6#2=EKSN_U&:_
MF+R,2.P-0W-U+=2EY6+'WJ&F(****8!1110 4444 %%%% !5JPM'O+I(U!()
MP3Z571&=PJC)/:O0/"VBBVA\^5<LPZ'M2 VM*T]-/LTB &X=35^BBD,****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M)$D&48,/8T .HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "@C(P:** ./\4Z'YBFYA7D=A7"LI5BI'(KVAT$BE6&0:\^\3:
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@#R[Q5_R,%Q]:Q:VO%7_(P7'UK%IB"BBBF!UG@W_CX'^]7?
MUP'@W_CX'^]7?TF,****0!1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** /+O%7_(P7'UK%K:\5?\C!<?6L6F(****8'6
M>#?^/@?[U=_7 >#?^/@?[U=_28PHHHI %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 445%<&18&,6-^.,T .$J%BNX _6G9&<9YK@+K4KU-18L"&1N@
MK=T'4Y[R[E,XQD>E '1T444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M>["C3PZYZNK['ASQ%7%R]G0TCW,;0?"5Q?R"ZO\ <%)RO.<UZ):6<-E"L42
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M]>!PLV%]ZV8+N&X&8WS7MT<52K+W6<DZ<H;HGHHHKH,PHHIDL@AB:1N%49-
M/0Y_Q=J@T_3BH.#("M>/NQ=B2223WKH_%^L&_P!0>)6S&IR*YJOHL%1]G3UW
M9\EF.(]M6=MD%%%%=AP!1110 4444 %%%% !1110 55OC((&*>E6J1U#J5/0
MT%TIJ$U)F;IUV6)1SST%:=<_'\FI[1TW5T<0!E4'N:2>AVYA2C&HI1^TKGL/
M@O\ Y%>U^E=#6+X54)X?MP.E;5?+UW>K)^9]+AE:C%>2"BBBLC<**** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \N\5?\C!<?6L6
MMKQ5_P C!<?6L6F(****8'6>#?\ CX'^]7?UP'@W_CX'^]7?TF,****0!111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %5[J\@M$W3-@58KE=?@E\Q2[,
M(C]X^E %JYB2ZN+>>WC1HV;+$CM6O%9PQ2M+&H&[L!7&627,-S$S.PMB?D.>
MHKN(6#1 @\4 24444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !534_^/"3Z5;JIJ?_
M !X2?2@#R:]_X_)?]ZH*GO?^/R7_ 'J@JA!1110!Z3X,_P"0&O\ O&NBKG?!
MG_(#7_>-=%4C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% 'EWBO\ Y&"X^M8M;7BK_D8+CZUBTQ!1113 ZSP;_P ? _WJ[^N
M\&_\? _WJ[^DQA1112 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ JIJ?_'A)]*MU4U/_ (\)/I0!Y->_\?DO^]4%3WO_ !^2_P"]
M4%4(**** /2?!G_(#7_>-=%7.^#/^0&O^\:Z*I&%%%% !1110 4444 %%%%
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M7E'5JET>YL+6%888RF..:W5FC?[KJ?QK[99A3J05.@[11\_2R]TYNI6UDQX
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "HYY1#$7(SBI*CF$;J8W(Y[9H Y]=9E-^$Y\K/+=A5W270
MW%PR?-N;J*Q+K3;L3O9Q3)Y<YSBM70M,NM.WK*ZE3TQ0!NT444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M9U]_U\8_%'PS_P (K\0-2L8TV6LK_:;; X\M^0![ Y7_ (#0![[\"/$_]N^
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ME)^@K5T"U#%I&'(/%="\2.I#*#GVKGPV6JM1YV[-FE3$<DK' ?,I[BIH;R:
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MC MG)'.:^8P,?:8I-GH5GRTS;HHHKZH\X**** "BBB@ HHHH **** "BBB@
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M+P!18/K].'\*%F4[6P2$ L Q]ZN@8'%%%,\^K5G5ES384444&84444 %%%%
M!1110 4444 %%%% !1110 4^-VC<,IP1Z4R@4 CV7PG?M>Z:-W5 !705R'@(
M$:?)GU%=?7S&)BHU9)'V>#DY4(MA1116!TA1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 <KXLU<VT/DQ-A\X.*X!W:1B
MS$DFMOQ7(QUV="> :PJ:$%/BE>%PZ,5(]*913 ]+\+ZH;^S(D/S+P/>N@K@?
M!C$3[<\%J[ZI&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %,DE2)2SM@#O52?5+>!
MF5W4$=C3+BYAN=,=\CYE.!0 L>K6TTI174KZUA:GI":AJSF*;8VW.!68DSV<
M2,+5B"V U=5I48E NBFUR,4 9FB6%S;7P69&91_&:ZFD Q2T %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 45%<7$=M$9)&  ]ZYF\\9VT;
M%(U?([T =717&1>-HMPWJY%='IVL6VHQAHS@GL3S0!H4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1152YU&VMD+23)QVW#-)M+<J,7)V2+=%<K=>.]-M6(
M*.V/[IJM_P +'TS_ )X2_P"?PK)XBDMV=D<LQ<E=4V=G17*6WCW3;APHC=<]
MR:W[74[6[4%)4Y[;JJ-6$OA9C5PE>C_$BT7**0<TM:'.%%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MLHK+9HWZ*S8-41R%;.:T$D5QE2#0<%;#U*3M-#J***9B%%%% @HHHH&%%%%
M!1110 444$X!)H J7EV+=1W.:EMI_/B#X(K'O&,U]M'W<UM01B*(**29Z&(H
M0I4(_P S)*51E@*2KVDVOVS4(X1SFB3LKLX(Q<FDCU?PG:&UTQ21C> :Z"JU
MA'Y5C#'_ '5 JS7RM67--L^VHPY*:B@HHHJ#4**** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#R[Q5_P C!<?6L6MKQ5_R
M,%Q]:Q:8@HHHI@=9X-_X^!_O5W]<!X-_X^!_O5W])C"BBBD 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !139'$
M4;.W11FL]-:MI(1(O=MN,\T :)8*,DX%()$)P&&:RM>N_(TX.C88D5F64ERF
MHQ>=<QLK+G@T :^I:F+*14"EF8< 4S3=5^UF3<I4*><]JS;SS;^_22!2KQ\!
MB.*J:6MY)<W,);@MA^.M #=3B5;F>61#<*3E=O\ #5G2KZ*[A2V^QN O\1Z5
MNPZ;#';.@7EQAJDLK)+1-J@8H ;)IT,END)4;5.0*LPQ+#&$48 J2B@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D)P,FEJM?N8[.1EZB
M@#@_$VM27%RUNC85#@US-6;]B]],QZEJK50@JYIU]+972.C$<@'Z53HH ]@T
MZ[6]M%E7TQ5NN>\'$MHBDG^(UT-2,**** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH ***1F"*6/0<F@!:*S'UZP1BK3*"/<4W_A(=/_Y[
MK^8H U:*S8M<L9G"),I)]Q6BI#*".AH 6BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH \N\5?\ (P7'UK%K:\5?\C!<?6L6F(****8'6>#?^/@?[U=_7 >#
M?^/@?[U=_28PHHHI %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MQP)'&$ & ,4RWLXK9W>,<N<FK%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^0=;_P"X*!,M4444""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 54U/_ (\)/I5NJFI_\>$GTH \FO?^/R7_
M 'J@J>]_X_)?]ZH*H04444 >D^#/^0&O^\:Z*N=\&?\ (#7_ 'C715(PHHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JCK'_(&O/^N3
M?RJ]5'6/^0->?]<F_E0!\@:]_P A:;ZG^=9M:6O?\A:;ZG^=9O:@HZ#P7_R,
MD'^>]?6NG?\ (.M_]P5\E>"_^1D@_P ]Z^M=._Y!UO\ [@H$RU1110(****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M4+Z;(O3)K=HKHI\08R/Q.YG++Z+VT.::UF3JAQ41!!P:ZED5AR*K36,4@.%
M/K7JX;B:+=JT;>ARU,M:U@SGJ*MW-D\)R.153O7TM"O3KPYZ;NCS)TY0?+)
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 454O;Z.R0O)@ =S56SU=+HL4&5SU% $5QKT<33(0-R<?6
MG/?_ &K2B2NWS%XKGKZRDN)[J>,$A#DJ.]7=$@FO$0.Q1$YV&@#+>TDM(X9"
M#RW!]:ZK3[=;A%FGB!?U-7Y+.WE14>,%5.0/2I5147:HP* *QL8S>_:#C.,8
MJW110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 54U/\ X\)/I5NJFI_\>$GTH \FO?\
MC\E_WJ@J>]_X_)?]ZH*H04444 >D^#/^0&O^\:Z*N=\&?\@-?]XUT52,****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *HZQ_P @:\_Z
MY-_*KU4=8_Y UY_UR;^5 'R!KW_(6F^I_G6;VK2U[_D+3?4_SK-[4%'0>"_^
M1D@_SWKZUT[_ )!UO_N"ODKP7_R,D'^>]?6NG?\ (.M_]P4"9:HHHH$%%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% ''>+M*>1?M$:Y)/.*X8@J<$<U[/+$LJ%'&01@UR
MVI>#XYV+6H"$^M.XC@*<B-(P5023Z5T__"#7^?\ 6QXK<TOPI#:,'G4,X[BB
MX"^%-+-G:EY!\S'(KI:15"*%48 I:0PHHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M***0D#J<4 *3@9/2J4VJ6T0XD5N<<&K$CH\;H'7)4CK7"7,<-D[P/$\DK.6#
MKR!S0!T?B&%+S364.H9AD"L2 20-#;VJF'<,-G^*M/3 FJO'(ZG$8V\UN-8V
M[S1RE/FC^[0 VTM$CM\,OS./G/K4T5M% 28UP3UJ6B@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "JFI_\>$GTJW5745+V4BCJ10!Y+>_\?DO^]4%6+X%;
MV8'J&JO5""BBB@#TGP9_R U_WC715SO@S_D!K_O&NBJ1A1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !5'6/^0->?\ 7)OY5>JCK'_(
M&O/^N3?RH ^0->_Y"TWU/\ZS>U:6O?\ (6F^I_G6;VH*.@\%_P#(R0?Y[U]:
MZ=_R#K?_ '!7R5X+_P"1D@_SWKZUT[_D'6_^X*!,M4444""BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "FLZI]Y@/K65K6MPZ7%@G+L.,=JX:[\3W]Q(V)?D[#% 'IBS
MQ,<*ZG\:DKR>+7K^%]RRUU>A>*?M3"*Y;Y_7I18#K:*0,& (Z&EH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *HZQ_R!KS_KDW\J
MO51UC_D#7G_7)OY4 ?(&O?\ (6F^I_G6;VK2U[_D+3?4_P ZS>U!1T'@O_D9
M(/\ />OK73O^0=;_ .X*^2O!?_(R0?Y[U]:Z=_R#K?\ W!0)EJBBB@04444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !124M !1110 4444 %</\1?^02_
MX5W%</\ $7_D$O\ A0!Y,/O#ZU]!:)_R!+/_ *YBOGT?>%?0.B?\@2S_ .N8
MH T**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MFO R]VKGL8Q7HG44445]$>*%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "4M%% !1110
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MU'4FY,^SH4E2IJ"Z!11169J%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% 'EOBK_D8;CZUC5M>*O\ D8+CZUBTQ!1113 ZSP;_ ,? _P!ZN_K@/!O_
M !\#_>KOZ3&%%%%( HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH 9+)Y49?&<=JYI]<GDU%0FY85.']*Z6
M0IC#D#ZFN4O=/G%Y]F@91%.<M0!HV<D5S>%P-Q!X([5MK&JL6 Y/6L31M)NM
M-=]SJ48]JW: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "F2R"*,N>@I]5-3XL)/I0!YGKEZ]UJ$H8Y56XK+J>]_X_)?]ZH*H
M04^)S'*K@D$$&F44 >J^'KQKW3%E8\YQ6M7.^#/^0&O^\:Z*I&%%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %4=8_Y UY_UR;^57JH
MZQ_R!KS_ *Y-_*@#Y U[_D+3?4_SK-[5I:]_R%IOJ?YUF]J"CH/!?_(R0?Y[
MU]:Z=_R#K?\ W!7R5X+_ .1D@_SWKZUT[_D'6_\ N"@3+5%%% @HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M=5_(=1117E'N!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MH8T/S1_*V?6I=:M+:^A,Z,PD7@;>*ET_P_;1&&X#OO SUH W.W-+2 8&*6@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JGJ?
M_'A)]*N54U/_ (\)/I0!Y->_\?DO^]4%3WO_ !^2_P"]4%4(**** /2?!G_(
M#7_>-=%7.^#/^0&O^\:Z*I&%%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "J
M6J?\>,GT-7:IZI_QXR?0U4/B1%3X&>&WG_'[-_OFH*GO/^/V;_?-05]6MCX>
M6[/=- _Y -G_ -<Q6C6=H'_(!L_^N8K1KY6I\;]3[>E_#CZ(****@T"N'^(O
M_()?\*[BN'^(O_()?\* /):N+]T53JXOW17JY7\4CQ,Z^"'J>N>"?^0?_P !
MKJJY7P3_ ,@__@-=57#B?XLCT<'_  (A1116!U!1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !39/\ 5M]#3J:_W&^E)[ >?7/_ !\R_P"\:W?#71OK6+>H$NGQW8UJ>'FQ
M-MSU-?,8/W<4KGK5M:1UE%%9'B#5$TRP=BV'9?EKZJ$7*5D>-.:A%RET,3Q=
MXE%FAM;9@9C\K#TK!\-^&IM5F%Y>;O+/(8\Y-5=$T^;Q%JS7,V=H(;ZUZG;6
MR6L"Q1J H["O1JS6&A[.'Q=3R*%.6,J>VJ?"MD):VD5I$$B0 #T%6*2EKS&V
MW=GLI)*R"BBB@84444 %17+!;:3/]TU+5'59/+LV/J"*BH^6#94%>21Y[,<R
MOS_$:ZCPJ@\DMWS7+/S(WUKL_"L>W3V+#G=7S^7J]<]C&.U$WJ***^C/%"BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "N>\0R .J9Y(K9O;H6ELTK=!7$W
MNL#4+L @#'%>5FM>,:7)U9UX6C*3YDM$,HHHKYD[ Q1110 4E+WI!0,****8
M"4M%(3@9H&%-9@HR3Q5*[U2&W4_,"P[5SU[J\MRQVDJ/:MJ=&4SNP^ JUM=D
M;%]K,<(*QD%JYZYO9;AB68@>F:KEBYR3DU<M--FN2#M.WUKMC3A35SW:6&HX
M6/,_O*B1M*X51DFMW3M&((DF!'H*TK/2XK91D!CZFKP  XKGJ8B^D3SL7F;G
M[M+88D:QKA0 *=2TE<QY-[[B&DI:2F E%%%,H2F.ZQH68X IS$ 9-8&J:CNS
M%&>.AKOR_ U,954([=3CQ^.AA*3G+?H5=4O/M4NW@JM8EQ81S#T/M5P\\FDK
M]-PV&AAZ2I06B/SJKC:U2LZS>K.<N;&2!B<?+V-5:ZMXUD4JPS6'?6+1,64?
M+6S1[.!S%5?<J;F?2T45)ZH4444P"@ DX'6BM33K+?\ O''':@QKUXT8<TA;
M"P)Q(XXK7  &!2@ # &!15I'RN)Q$Z\^:04444'.%%%(QV@DT!N<]J'_ !\M
M]:U=-'^C*?:L:[;?=/\ 6MVP&+1/I4K<]W'^[A8(LT4451X04444 %1W"[H&
M7UJ2@C(.:!Q?*TS"LSY5VR^IK=K D!BU'/;=6\K;E!%)'I9DKN$UU0M%%%,\
MP**** "BBB@ HHHH *4#) I*<F/,7ZB@#U3P#:K'I#.1\V^NOK!\)E#I(V8Q
MFMZOE\3)RJR;/L\)%1H12[!1116)TA1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 >7>*O^1@N/K6+6UXJ_Y&"X^M8M,04444P.L\&_\ 'P/]
MZN_K@/!O_'P/]ZN_I,84444@"BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "L/7KRZM(B\<0:+N36YVJE+<6T\A
MM7VLY&=IH XU=:81F&(!XW.68]C79Z=*DMHA5L\<UF:980J98Y;=06<D<=JW
M(XDB7:B@#VH ?1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 54U/\ X\)/I5NJFI_\>$GTH \FO?\ C\E_WJ@J>]_X_)?]
MZH*H04444 >D^#/^0&O^\:Z*N=\&?\@-?]XUT52,**** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *HZQ_P @:\_ZY-_*KU4=8_Y UY_U
MR;^5 'R!KW_(6F^I_G6;VK2U[_D+3?4_SK-[4%'0>"_^1D@_SWKZUT[_ )!U
MO_N"ODKP7_R,D'^>]?6NG?\ (.M_]P4"9:HHHH$%%%% !1110 4444 %%%%
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MH**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M >D^#/\ D!K_ +QKHJYWP9_R U_WC715(PHHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% &%XBT8:C;;D WKS]:\ZN+*>WD*O&PQWQ7L
M54KK2[6\SYR9SZ4[@>0X)/'6KMCIEQ>SJB(P![XXKT)?">E*VX0G/UK3M;"W
MLUVPI@47$5=&TQ--M B@ MR:TZ**0PHHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %4]4_P"/&3Z&KE4]4_X\9/H:J'Q(
MBI\#/#;S_C]F_P!\U!4]Y_Q^S?[YJ"OJX['P\MV>Z:!_R ;/_KF*T:SM _Y
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MU\UBJ7LZK2/L<#6]M14GN%%%%<QUA1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 5!=0"XA9"2,CBIZQ-8UI++]VA_
M> \Y% &#?:+>6K95AL)P.>:V=!TZ]L<";;L//O5(:K!>;)&<^<6 V]JZN,YB
M4^PH =1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% '%>)_#[N_VBW3.>6KBY$:-RK#!'6O9V57&&&0>U9EUH
M5I<MGRU4^PIW \I'-;6B:'/?SJY0^6"#FNWA\-VD3[BJM[$5JPV\, Q%&J#V
MHN EM;K;0+&O  J:BBD 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 51UC_D#7G_7)OY5>JCK'_(&O/^N3?RH ^0->_P"0M-]3_.LW
MM6EKW_(6F^I_G6;VH*.@\%_\C)!_GO7UKIW_ "#K?_<%?)7@O_D9(/\ />OK
M73O^0=;_ .X*!,M4444""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *IZI_P >,GT-7*IZI_QXR?0U4/B1
M%3X&>&WG_'[-_OFH*GO/^/V;_?-05]7'8^'ENSW30/\ D V?_7,5HUG:!_R
M;/\ ZYBM&OE:GQOU/MZ7\./H@HHHJ#0*;)_JW^AIU-D_U;_0T(&>(Z__ ,A2
M7_>-95:NO_\ (4E_WC657U=+X$?#UOXC/6_!/_(/_P" UU5<KX)_Y!__  &N
MJKYO$_Q9'UV#_@1"BBBL#J"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "DI:* (W@C?[R U"=.M&ZP*:M45+A%[H:DULRH--LU/%NE3);PQGY$ J6B
MDJ<5LAN4GNPQ1115DA1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MGT630M"4A:***\L]H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_.LWM04=!X+_ .1D@_SWKZUT[_D'6_\ N"ODKP7_ ,C)!_GO7UKIW_(.M_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JC
MJM\EA8R2,<':<5>KSOQ[JI.+1&Y1N:RK5.2#9V8##/$5XPZ'%ZK?OJ-Z\[DD
MGUJSI&F/=.)"I,8[XK-@C::=$ )W,!7K>CZ$MGHHB*C<?FKQU2E64FC[#,L7
M'!T5"&[T1A1H(T"CL*?3Y4*2L".AIE>$TT]3YJ]]0-)2FDI %9]];Y^=1S6A
M2,H88/2AFE.;A*Z,RTNO+.QNE:0((R#67=VQC;<@XI;:\,?ROTI(Z:E)5%SP
M-2BF+(K@$$4ZJ.1JPM%)5>>Z6(8SS05&+D[(?-,L2DYYK*FF,S>U-EE:5LGF
MK%M:%\.W2IW.V$(TES2W'6=MN.]AQ6AT&!0JA1@=*4U25CEJ3<W<2DI:2F0%
M9>L?\>_X5IU1U1 UJQ]!7?ELN7%0;[G)CX\V&FEV./HHHK]8/S,**** "HYX
MA-&5/>I**!QDXNZ.?C+6EYMZ+FMY&#H&'>LK5H\,C+5VP?=;(/:DCU,;:M1A
M76^S+51SQ"6,J:DHIGEQDXNZ,!XKBSD)0G\*L1:J4XD!-:S(KC!%59-/@DZK
MS2L>HL;1JJU>.O="1ZC%)[5,MU$W\8_.J+Z4I^YQ4+:3-_"P_.C47L<'/:=C
M7\Z,]'7\Z42H?XA^=8G]GW*=&%!MKI.=U%V'U&B_AJ&WO3^\*-Z_WA6)Y=WZ
MT>7=>M%Q?V?'^=&WO7^\*-Z_WA6)Y=UZT>7=>M%P_L^'\Z-F2>.-22PK&N;J
M2ZDV)G% LKF<_,U:-M8)!@D?-2U9I!8?">]?FD,L;$1*'8<FK]%%4>96K2JR
MYI!11109A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%:.CZ9)
MJ=\D"+P>^.*F4E%794(N<E%';> =+V1/<2K\V<J37?53TVS6RLHX@,$+@U<K
MYG$5?:U'(^RPM%4:2@%%%%8G0%%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% 'EWBK_ )&"X^M8M;7BK_D8+CZUBTQ!1113 ZSP;_Q\#_>KOZX#P;_Q
M\#_>KOZ3&%%%%( HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH *KW-VEJFYN<58KF?$)FADC)!:%C\P4=J ':E;VE^EO<^5G>W
M)K0MM&LHR)$B -<K'>7;7,,4 868;Y01SBNZAQY0VC H D' Q1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!4%W+Y-L[CM4]4]3_P"/"3Z4 >5:E(9=1G8GJU5:GO/^/R7_ 'J@JA!2@E2"
M.HI** /3?",K3:*K.<G=6]7.^#/^0&O^\:Z*I&%%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %4=8_Y UY_UR;^57JHZQ_R!KS_ *Y-
M_*@#Y U[_D+3?4_SK-[5I:]_R%IOJ?YUF]J"CH/!?_(R0?Y[U]:Z=_R#K?\
MW!7R5X+_ .1D@_SWKZUT[_D'6_\ N"@3+5%%% @HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MSOI4*=)6@K!11169L%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 >7>*O\ D8+CZUBUM>*O^1@N/K6+3$%%%%,#K/!O_'P/]ZN_K@/!
MO_'P/]ZN_I,84444@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MTE"S1FIS;/I."59XED0Y5NE25FZ"C1:/;HYRP7DUI5\_)6;184444@"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ IK,J#+' I3]TX]*Y35]7DANOLC94
M]=QH GU^(QWJ7WE^:B+C9ZUG6[7,MPB*K6JOSCUK3CN1J#)$LH9<<@5MBTA8
M1LZ L@P#0 ^W4I BEMQ Y/K4M(  ,"EH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "JFI_\>$GT
MJW534_\ CPD^E 'DU[_Q^2_[U05/>_\ 'Y+_ +U050@HHHH ])\&?\@-?]XU
MT5<[X,_Y :_[QKHJD84444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ K&\2R^3I+M6S7.^,O^0&WUK6@KU(HPQ+M2D_(\@F.9Y#ZL:6WB\Z=4 S
MFF/_ *QOK5W1B/[3BS7T\G:-SXV*YII'M&D1^7I-LN.B"KM06/\ QXP_[M6*
M^5D[R9]O!6BD%% HJ2@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *1ONGZ4M(>AH \7\
M46X@U1\#&XDUAUU?CI5&IIMQT-<I7U&'=Z46?%XN*C6DD>G?#V4O!,I;.T#B
MNWKSSX9YW7N?0?TKT.O!QJM79]-ESOAHL****Y3N"BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MN *^G_AKX6BT+1(YRO[Z= 7R.AH$=E9V<5C:I;PC")P*L444""BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MHHKB/1"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M****@T"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MPUXGFN[<&[A>(C^_750:C!/]V1?SKDG2E!V8.);HH!R,CI168@HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH *0L!U-+7-:W=3QW9CCF\L8SF@#H#<1B<0[AO(SBI:X6"6
M^EU))%=I"!C<*[: -Y*[SEL<T 24444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M8!XQCU-6K?X=WX;]\\9'L:;Q=%?:)6 Q#^PSB,9-68+"YN&"QPN<]P*](LO
M5HF#<+N(]#72V.D6=@,01@?6N:KF4%\"N=E'**DOC=CAM"\#/(RS7FTI_=/6
MN_L[*&QA$4"[5JP!CH*6O*K8B=9^\SW,/A*=!6@@HHHK Z0HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M!S0!%=7,=I TDC   UY/XF\2R:G.T4;?N1Q6GXU\0&:5K.!_D'.0:X?J:]O
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M>3>W7%1\GUHP>N*?"X1\D<4@&<CUJ:WNGMY P)XJVS630G+$/Z8K.;&XXZ4
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *J:G_P >$GTJW534_P#CPD^E 'DU[_Q^2_[U05/>_P#'
MY+_O5!5""BBB@#TGP9_R U_WC715SO@S_D!K_O&NBJ1A1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110!%</Y=O(_P#=&:\6\27!NM;FE/>O9-1.-.N#
M_L&O#M0):\<D\UZN5QU;/#SJ3Y8Q*U>F_#^P"Z<;EAAMQ%>9Q\RH/]H5[-X4
MC$>D*!ZUTYC.U*RZG)E%-2K<SZ&Y2T45X)].%%%% !1110 4444 '>BDI: ,
MGQ#:BYT>X!&6V<5XI/$8)FC/45[U>*'M)%/0BO$M<0)K%PHZ!J]C+)[Q/ SF
MFKQF4[9MES&P[,#7M7AR<W&CQ2$YS7B(X.17L/@=B_AJ$L<G)K3,X_NTS+)I
M?O7'R.CHHHKPSZ0**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MPQBL_5+5HIRP!V^M=-$@CC"BFS01SIM=<UQ7"QQ5174?F0,O7-=#=:*02T9
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %4]3_P"/"3Z5<JGJ
M?_'A)]* /)[S_C\E_P!ZH*GO/^/R7_>J"J$%%%% 'I/@S_D!K_O&NBKG?!G_
M " U_P!XUT52,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *NI?\
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M/-W<J6'[OO7:QQB*-4 X Q7LY9A;OVLOD<6+K67(A]%%%>Z>:%%%% !1110
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MCM4.<I.T2E&,5>0W5/#%UYLEP)4DSSA>M:?PZ,]GKS(RLI. 017.V_B;4()
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MB]X1TZY:"XO6#KU 4?XT =W2,<*3Z"N<T#QSH7B4XTVYW\9Y %=$_P#JV^E
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M&2Y:Z*]M46K$HHHKLR3#.K7Y^D3BXPS&.&P3HI^],NZ5 T^HP*HR-XS7N%E
M+>V2,=A7G/@32C+=-/(OR8RIKTT# KVLRJ\TU%=#X/**+C3<WU%HHHKS3V H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M4 07-K%=1&.10<CJ17+WO@N%V+Q2-D]A77T4 <1#X*#$>8[BNDTW1;?3D"H
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M^9/%7C6;Q0G[^ *^<[L\UW7P+\2FUUI-+E?;"06Z]Z /IJBD5@RA@<@\BEH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M)70"BBBLRQ*2EI*!A2&EI#3 .])2TE,84U@&!!IU+'&\K;4&332OHAWL95S
M48L!Q6CHEE+>RA "5'-=!I^@&7#W Q[&NAM[."U'[J-5/J*]/"97.;4YZ(SK
M8]*'(M616.GQV<8"@$^N*NT45]#"$8+EBCR)2<G=A1115B"BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@"CJFHQZ=;&1R!GIFO/=3\1W5ZYVL8QG^$U?\ &%^S
MW;6H;A#7*TT(L"^N@<B>3/UK9TGQ-<6LJK*=R^K&N>HI@>QV=W'>0+)&V<CF
MK%<7X+O&\MH6.<MQFNTJ1A1110 4444 %%%% !1110 4444 %%%% !1110 U
MT5UVL 1Z&N>U3P;INI[M\2(3W"UT=%5&<H_"P.3T_P !:78L#L63']Y:MZ_I
MD?\ 8\L-M$J#81A170TR2-9$*L,@U?MI.2DV-.Q\N_V:T'B%;>0$%7!/YUT7
MC#6&LKE+&)!L"*<5Z+XA\!1WUZMY;MLD#!CM'7%><?$'1;F&^%TZ$#:$KV*=
M:%62):<8NQS+:R&3;]EC^N*KQZE+#<K-%^[([*:T].\.&XLS=73F&$'&ZH+W
M2+>,XLKG[0?:NE.%[&5I;GJNG>.].M=-MX[NY 8H,@U3GN+;4Y'N+5Q(A.?I
M7D]Y*7V(1@H,&MWP?>SMJT-B&)2=MI]JP]A&"<D=V%QKI3U6AVH)' XIC06[
MDM) C,>I(K:U'0;FS<[49D]:R64J<$<U,91DKH^D3IU5=:D2V\$;;HX44^PJ
M2DI:HT45%62$I:GM[.>[;$,9<^U78_#VHLP!MV ]:ESBMV3*K"/Q,RZZ3PYH
MLD\ZW$BD*IR/>K^F^$@K+).QX_A(KK(+=+>,)&H 'I7'7Q2MRP/,Q>/CR\E,
MD50B@ 8%!( )/04M<YXFU8VD BB/SDX.*X80<Y61Y%*G*K-11/J?B.VL@5C<
M-(/X37,77BJZN6(50N?0T_2-!FU1O/G=@IYR:ZRVT*S@ !B1R.Y%=?[FCHU=
MGI-X;#:-<S.$6RU"_;>X9E/J:NV]H+88_BKNQ:PJA5(U7Z5R^H6S6\YST)S6
M53$.>BT1RXG&2JKE6B*E%%36S*LR[@",\U@<)#172/ID-W 'C(7Z55&A'^^:
M+CL9\%\\";5%6(]8F1LXS5Y-!4#)D-9=[8M:OW*^M '0V-^ETN,C=Z5=KB[:
MX:"4,#7802"2%6]12:!$E%%%(84444 %%%&* $I JYSBG44 %%%% !1110 4
M444 %%5KJ]CM5)9AGTKFY?'VE0SF*2>-6!QBKC2G/X4.S.K9%<88 UE7VD+)
MEX^OH*M:?J5OJ,(E@<,I&>*NU+33LQ-'%S6\L!Q(N*?:W<EM("#QZ5U,]I'.
MI#*,^M85YI#Q$F/+"BXC:LKU+I!@C=Z5:KCHII+27N".U='8:@ER@!P&]*&@
M+](>>*,X&:IW&HPP _,,BA)O8I)LP?%'A"WURW;(P^.,"O)=0^&.M0SE;:V>
M1,\$U[0?$ELK[2RBK]MJ5O=8VN,UV4\16HJUM E"^YY'X<^%$\DL<VI!X2I#
M;?6O4H?#.EPQJILX6QW*UL9S16-7$U*CU9*21##;0VR[88E1?11BIJ**P&%%
M%% !1110 4444 %%%% !1110 4444 (S!%+'H!FN<OM:A%Q^ZER1U'M71D @
M@]*Y;Q!HD3D7$<GE[F (% %FRU.WO-33[.PD.WD^AKH!TKG-/\.+:R)+%.>F
M2171J-J@9SB@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M%7NK"N\TW0K/347RH@''4BMJF,HT8\M)'FT\#B,5+VE=OY[F)X<\(Q6*)/.
M\AY (Y%=<%"C X%+17CU:LJDN:3/?HT848\L$%%)2UF:A1110 4444 %%%%
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MS@T>"O@W9^'W2:_\NYE'.X"O58T6.-8T&%48 ]J /-OC/_R)=[_N5Y#\$_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110!Y=XJ_Y&"X^M8M;7BK_D8+CZUBTQ!1113
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !114<TGE1%S
MVH Q]=UV/382JG,C#C':N$NM>OKICOER*CUFZ>XU&;<V0&XK/IB+D6JW<+92
M3!KJ=!\4N[K%=L6)XS7%4Z-S'(KCJ#FF![0K!U# \&EK'\-WAO=*61NN<5L5
M(PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBHS<0@X,T8/^\* )**B^TP?\]H_P#OH4?:8/\ GM'_ -]"@"6BHOM,
M'_/:/_OH4?:8/^>T?_?0H EHJ+[3!_SVC_[Z%'VF#_GM'_WT* ):*B^TP?\
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MM,'_ #VC_P"^A1]I@_Y[1_\ ?0H EHJ+[3!_SVC_ .^A1]I@_P">T?\ WT*
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M6BHOM,'_ #VC_P"^A1]I@_Y[1_\ ?0H EHJ+[3!_SVC_ .^A1]I@_P">T?\
MWT* ):*B^TP?\]H_^^A1]I@_Y[1_]]"@"6BHOM,'_/:/_OH4?:8/^>T?_?0H
M EHJ+[3!_P ]H_\ OH4?:8/^>T?_ 'T* ):*B^TP?\]H_P#OH4?:8/\ GM'_
M -]"@"6BHOM,'_/:/_OH4?:8/^>T?_?0H EHJ+[3!_SVC_[Z%!NK<=9XO^^Q
M0"5R6BH?M=M_S\1?]]BC[7;?\_$7_?8I717++L345#]KMO\ GXB_[[%'VNV_
MY^(O^^Q1=!R2[$U%0_:[;_GXB_[[%'VNV_Y^(O\ OL470<LNQ+BEJ'[7;?\
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M]]"C[3!_SVC_ .^A0!+147VF#_GM'_WT*/M,'_/:/_OH4 2T5%]I@_Y[1_\
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M?[2L?^?VV_[^K_C1_:5C_P _MM_W]7_&@"U157^TK'_G]MO^_J_XT?VE8_\
M/[;?]_5_QH M455_M*Q_Y_;;_OZO^-']I6/_ #^VW_?U?\: +5%5?[2L?^?V
MV_[^K_C1_:5C_P _MM_W]7_&@"U1445S!/\ ZJ:.3_<8&I: "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@#R[Q5_R,%Q]:Q:VO%7_ ",%Q]:Q:8@HHHI@=9X-_P"/@?[U
M=_7 >#?^/@?[U=_28PHHHI %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %<]XKT :[I4ML,98=ZZ&DJH3<)<R ^9M8\&:EIM]Y(A>16/!1
M<@5W7@3X=S6]S%J-YMRI#(",$5ZZ8HV.6C4_44X*%'  'M794Q\Y0Y2.17N
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !5/4_P#CPD^E7*J:G_QX
M2?2@#R:]YO)?]ZH*GO/^/R7_ 'J@JA!1110!Z3X,_P"0&O\ O&NBKG?!G_(#
M7_>-=%4C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH :_P!QOI7D6H3RC4)\2OC>?XC7KK_<;Z&O']0_Y"-Q_OFF@(O/
MF_YZO_WT://F_P">K_\ ?1J.BF(D\^;_ )ZO_P!]&CSYO^>K_P#?1J.B@"3S
MYO\ GJ__ 'T://F_YZO_ -]&HZ* )//F_P">K_\ ?1H\^;_GJ_\ WT:CHH D
M\^;_ )ZO_P!]&CSYO^>K_P#?1J.B@"3SYO\ GJ__ 'T://F_YZO_ -]&HZ*
M)//F_P">K_\ ?1H\^;_GJ_\ WT:CHH D\^;_ )ZO_P!]&CSYO^>K_P#?1J.B
M@"3SYO\ GJ__ 'T://F_YZO_ -]&HZ* )//F_P">K_\ ?1H\^;_GJ_\ WT:C
MHH D\^;_ )ZO_P!]&CSYO^>K_P#?1J.B@"3SYO\ GJ__ 'T://F_YZO_ -]&
MHZ* )//F_P">K_\ ?1H\^;_GJ_\ WT:CHH D\^;_ )ZO_P!]&CSYO^>K_P#?
M1J.B@"3SYO\ GJ__ 'T://F_YZO_ -]&HZ* )//F_P">K_\ ?1H\^;_GJ_\
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M&CSYO^>K_P#?1J.B@"3SYO\ GJ__ 'T://F_YZO_ -]&HZ* )//F_P">K_\
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M -]&CSYO^>K_ /?1J.B@"3SYO^>K_P#?1H\^;_GJ_P#WT:CHH D\^;_GJ_\
MWT://F_YZO\ ]]&HZ* )//F_YZO_ -]&CSYO^>K_ /?1J.B@"3SYO^>K_P#?
M1H\^;_GJ_P#WT:CHH D\^;_GJ_\ WT://F_YZO\ ]]&HZ* )//F_YZO_ -]&
MCSYO^>K_ /?1J.B@"3SYO^>K_P#?1H\^;_GJ_P#WT:CHH D\^;_GJ_\ WT:/
M/F_YZO\ ]]&HZ* )//F_YZO_ -]&CSYO^>K_ /?1J.B@"3SYO^>K_P#?1H\^
M;_GJ_P#WT:CHH D\^;_GJ_\ WT://F_YZO\ ]]&HZ* )//F_YZO_ -]&CSYO
M^>K_ /?1J.B@"3SYO^>K_P#?1H\^;_GJ_P#WT:CHH D\^;_GJ_\ WT://F_Y
MZO\ ]]&HZ* )//F_YZO_ -]&CSYO^>K_ /?1J.B@"3SYO^>K_P#?1H\^;_GJ
M_P#WT:CHH D\^;_GJ_\ WT://F_YZO\ ]]&HZ* )//F_YZO_ -]&CSYO^>K_
M /?1J.B@"3SYO^>K_P#?1H\^;_GJ_P#WT:CHH D\^;_GJ_\ WT:1IYMI_>OT
M_O&F4C?=/TH \P\37MTNH$+=3#KTD-8GV^\_Y^Y_^_AK3\4?\A(_C6'4E%C[
M?>?\_<__ '\-'V^\_P"?N?\ [^'_ !JO10,L?;[S_G[G_P"_A_QH^WWG_/W/
M_P!_#_C5>B@"Q]OO/^?N?_OX?\:/M]Y_S]S_ /?P_P"-5Z* +'V^\_Y^Y_\
MOX?\:/M]Y_S]S_\ ?P_XU7HH L?;[S_G[G_[^'_&C[?>?\_<_P#W\/\ C5>B
M@"Q]OO/^?N?_ +^'_&C[?>?\_<__ '\/^-5Z* +'V^\_Y^Y_^_A_QH^WWG_/
MW/\ ]_#_ (U7HH L?;[S_G[G_P"_A_QH^WWG_/W/_P!_#_C5>B@"Q]OO/^?N
M?_OX?\:/M]Y_S]S_ /?P_P"-5Z* />/@M/-,Q\R61_D_B8FO9Z\4^"/WF_ZY
MU[702%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !114%Y
M>0V%LUQ.VV->IH GHJK9ZC;7R;X) PJU0 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "JFI_P#'A)]*MU4U/_CPD^E
M'DU[_P ?DO\ O5!4][_Q^2_[U050@HHHH ])\&?\@-?]XUT5<[X,_P"0&O\
MO&NBJ1A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 -?[C?0UX_J'_(1N/]\U[ _W&^AKQ_4/^0C<?[YIH"M1113$%%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !5.][?2KE4[WM]*YL7_  F>IDW^^1*-%%%>(??A1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% #XOOBM9?NCZ5DQ??%:R_=
M'TKT\!LSY/B3XH"T445Z)\P%%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 54U/\ X\)/I5NJFI_\>$GTH \FO?\ C\E_WJ@J>]_X_)?]
MZH*H04444 >D^#/^0&O^\:Z*N=\&?\@-?]XUT52,**** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!K_<;Z&O']0_Y"-Q_O
MFO8'^XWT->/ZA_R$;C_?-- 5J***8@HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *IWO;Z5<JG>]O
MI7-B_P"$SU,F_P!\B4:***\0^_"BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** 'Q??%:R_='TK)B^^*UE^Z/I7IX#9GR?$GQ0%HHHKT3Y@**
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *1ONGZ
M4M(WW3]* /*/%'_(2/XUAUN>*/\ D)'\:PZGJ4@HHHH&%%%% !1110 4444
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M>T5P7_"TM)]5_P"^J/\ A:6D^J_]]4 =[17!?\+2TGU7_OJC_A:6D^J_]]4
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M5""BCO10!Z3X,_Y :_[QKHJYWP9_R U_WC715(PHHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &O]QOH:\?U#_D(W'^^:
M]@?[C?0UX_J'_(1N/]\TT!6HHHIB"BBB@ HHHH **** "BBB@ HHHH ****
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M0 5!<6<%TNV5,BIZ* ,L>'].!R(>:O06T5NNV-<"IJ* "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "D(R*6B@"..)8\[1@'FI*** "BBB@ HHHH ****
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MFN5M&<WS),I5L>&9)HM=M&C!($@SBL@(S' 4D^@%>@^'=.BT?2SJ5TN&=-R
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*IWO;Z5<JG>]OI7-B_X3/4R;_?(E&BBBO$/OPHHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@!\7WQ6LOW1]*R8OOBM9?NCZ5Z> V9\GQ)\4!
M:***]$^8"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "D;[I^E+2-]T_2@#RCQ1_P A(_C6'6YXH_Y"1_&L.IZE(****!A1110
M4444 %%%% !1110 4444 %%%% !1110 4444 >Z?!'[S?]<Z]KKQ3X(_>;_K
MG7M=!(4444 %%%% !1110 4444 %%%% $%W$9[9XQU->&ZS\(-4O]8N;I$7;
M(^X?-7O-% 'SQ_PI75O[B_\ ?5'_  I75O[B_P#?5?0]% 'SQ_PI75O[B_\
M?5'_  I75O[B_P#?5?0]% 'SQ_PI75O[B_\ ?5'_  I75O[B_P#?5?0]% 'S
MQ_PI75O[B_\ ?5'_  I75O[B_P#?5?0]% 'SQ_PI75O[B_\ ?5'_  I75O[B
M_P#?5?0]% 'SQ_PI75O[B_\ ?5'_  I75O[B_P#?5?0]% 'SQ_PI75O[B_\
M?5'_  I75O[B_P#?5?0]% 'SQ_PI75O[B_\ ?5'_  I75O[B_P#?5?0]% 'S
MQ_PI75O[B_\ ?5'_  I75O[B_P#?5?0]% 'SQ_PI75O[B_\ ?5'_  I75O[B
M_P#?5?0]% 'SQ_PI75O[B_\ ?5'_  I75O[B_P#?5?0]% 'SQ_PI75O[B_\
M?5'_  I75O[B_P#?5?0]% 'SQ_PI75O[B_\ ?5'_  I75O[B_P#?5?0]% 'S
MQ_PI75O[B_\ ?5'_  I75O[B_P#?5?0]% 'SQ_PI75O[B_\ ?5'_  I75O[B
M_P#?5?0]% 'SQ_PI75O[B_\ ?5'_  I75O[B_P#?5?0]% 'SQ_PI75O[B_\
M?5'_  I75O[B_P#?5?0]% 'SQ_PI75O[B_\ ?5'_  I75O[B_P#?5?0]% 'S
MQ_PI75O[B_\ ?5'_  I75O[B_P#?5?0]% 'SQ_PI75O[B_\ ?5'_  I75O[B
M_P#?5?0]% 'SQ_PI75O[B_\ ?5'_  I75O[B_P#?5?0]% 'SQ_PI75O[B_\
M?5'_  I75O[B_P#?5?0]% 'SQ_PI75O[B_\ ?5'_  I75O[B_P#?5?0]% 'S
MQ_PI75O[B_\ ?5'_  I75O[B_P#?5?0]% 'SQ_PI75O[B_\ ?5'_  I75O[B
M_P#?5?0]% 'SQ_PI75O[B_\ ?5'_  I75O[B_P#?5?0]% 'SQ_PI75O[B_\
M?5'_  I75O[B_P#?5?0]% 'SQ_PI75O[B_\ ?5'_  I75O[B_P#?5?0]% 'S
MQ_PI75O[B_\ ?5'_  I75O[B_P#?5?0]% 'SQ_PI75O[B_\ ?5'_  I75O[B
M_P#?5?0]% 'SQ_PI75O[B_\ ?5'_  I75O[B_P#?5?0]% 'SQ_PI75O[B_\
M?5'_  I75O[B_P#?5?0]% 'SQ_PI75O[B_\ ?5'_  I75O[B_P#?5?0]% 'S
MQ_PI75O[B_\ ?5'_  I75O[B_P#?5?0]% 'SQ_PI75O[B_\ ?5'_  I75O[B
M_P#?5?0]% 'SQ_PI75O[B_\ ?5'_  I75O[B_P#?5?0]% 'SQ_PI75O[B_\
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MFEI8'.%)]:UA/2S5C.4.J=S&M8FENHE4$DL/YU]/^%;1K318588)53^E>9^
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH 0@$8(R*J3Z9:S\M"F?7%7** ,Z/1K-&
MSY*'\*O1Q1Q#"(%'M3Z* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** &O]QOH:\?U#_D(W'^^:]@?[C?0UX_J'
M_(1N/]\TT!6HHHIB"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ JG>]OI5RJ=[V^E<V+_ (3/4R;_
M 'R)1HHHKQ#[\**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M ?%]\5K+]T?2LF+[XK67[H^E>G@-F?)\2?% 6BBBO1/F HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I&^Z?I2TC?=/TH \H\4
M?\A(_C6'6YXH_P"0D?QK#J>I2"BBB@84444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% 'NGP1^\W_7.O:Z\4^"/WF_ZYU[702%%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !7+?$/_D3;WZ?XUU-<M\0_P#D3;SZ
M?XT ?)]W_P ?<O\ O5#5J6&2>_>.-2SEN *[GPG\+M1UJ59+N.2WBZAB.HH&
M<-8Z=<ZE.(;6,NY. *]8\(?"">X$=QJJO">NW'%>I^'? FEZ# B^1'+(H_UA
M'-=2JA1@# H"YE:3X>T_2+=8X+>,,/XMO-:U%% @HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *0G S2U#=ML
MM96Z86@#CO%>MNLK6L+D%3S@UQK.SG+$D^]6]5E,VH2.3G/>J5,05I:7JT]A
M<JP<E?[I/%9M'>F![%97*W5JDBGJ!FK-<UX-F>73Y-Q)P<"NEJ1A1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 54N=0@M@0[@&HM5OEL[<DGDCK7C_BKQBT$C0QMO?//-
M=.'P[JEJ*2YI;'J$OB>")L%EI'U^*X@Q$P+'CBOG&XUN_GD+?:) #VS5BP\2
M7UG,&:9W /0FN]Y>K:$>T@]+'T=8Z:KCSI223S@UHM9P,FWRU'OBN&\#^+UU
M2-8)&&\^]>@ @C->95IRIRY6-JVQS&HZ>UNY91\IYJ/3[YK:4 GY2>:Z:X@6
M>(H>_>N4O+9K:8@CC/!K-,DZ@WL(A$NX8/2LBZUMF)6,#'K63YSE0NX[1VJW
M96"W6,R8IV K2W,LK'<YQZ4D4$DYPBYKHHM'BCQDAOK5V.VAC^Z@%*X6,:TT
M4DAI<CVK;B@2%0%4"I**0PJ*X*K Y;IBGLRH"6.!6%JNI!OW<9XZ'%" RKEE
M>=BG2H:*D@B:65549YJB1G4U>L].EG<$J=OK6Y;Z;"B#<@)]ZNK&B#"J *5Q
MV&00B&,*!4M%%(84444 9>O1/+ILHCSNVGI7S1XACEBUB59L[_>OJEU#J5(R
M#7">)_AM:Z[,9DF\ER>2HKOP>(C3=I"DN96/GY%+NJKU) %=3_P@7B.Z1)8[
M-Y$900:]'T3X26VG7BW,UUYX'\#"O2H84AB6-% 50!Q717S!)_N]3-0[GD/@
MGX:W%O>I>:I$R,A^XPX->MFV3[,(  % P!4])7G5:\ZLN:1HE;8\FU?PEIND
MZA<ZG-+NRV\JPXK*@\0V^HV&I0011QQI'\I7O5WXI74\)6-<['SFO--"G:/5
M((]Q$<C@..Q%>M1@YT^:3'*?+*R,T\\UTUE=Q:CH2:5(^WRR7&.Y_P BI?$^
ME6<>L3M'*L47\*CI7.;Q:R$Q/GWKJNII-&-G%V&W-K+:SF*1<'M5O3]/NGOT
MB2,EV&0/:JL<CW%Y$96+$N!S]:]NEL++3;*WO?)0.(5YQ[5%6KR67<JG!29R
M=MX=T[1[?[3?RX<_,5858/C73[9/)@$90<5Q/B#6[C4;V12["-21MSP:P\TE
M1YE>;*=7ETB>GV.J:-=WRS;HUFW9  [UROC%+EM5DFD+&!V^3)XK&L;.]N9,
MV:,S#^[7:Q:+J-_I)CN[9_,C7Y2W4FBRIRO<+N:M8\^KO?AC,)==,$ZB2()D
M*W0&L?3/!]_<W9CN87A5>23796TNE>$_NR1M.!@GO17FI1<5NQ4X.]WH>QP^
M6D86, #'05POCW6WT_3Y)$/SCH*Y@?$W$NT !>F<U5\6ZBNM^'Y+J%MRC ./
M6O/I864)IR-;I)M,\YN[V:\F>21V;<<X)Z575BK!E)!'<4AZT5[%K'(=!97H
MN]/GBN&W,B_)FL?[)( &9<*>]/M$9HI65B,"H#-(5P7./2I2UT*;NM3U'X4Z
MLRZI)8J<Q(G!KVH'(!KPWX1:9<-J\MRT9$)C^5_7K7N0X KQ,=;VNAK%W0M%
M%0W,K0P,Z+N([5Q%%;4+6WOK=T<[6Z;QU%<Y9>'Q=RS*]P^(SA35:?7I(+MI
M''W3_J_6M?P[?_:Y)G=?+W'('K0!NVEO]EMDAW%MHQD]ZGHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH ***AN+J&VC+2NJ_4T 345SLWBVUB<J%W8[
M@T^V\56L[A2-ON30!OT5'%-',@:-PP]JDH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MD_*@"I15O^S+W_GVD_*C^S+W_GVD_*@"I15O^S+W_GVD_*C^S+W_ )]I/RH
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MD_*@"I15O^S+W_GVD_*C^S+W_GVD_*@"I15O^S+W_GVD_*C^S+W_ )]I/RH
MJ45;_LR]_P"?:3\J/[,O?^?:3\J *E%6_P"S+W_GVD_*C^S+W_GVD_*@"I15
MO^S+W_GVD_*C^S+W_GVD_*@"I15O^S+W_GVD_*C^S+W_ )]I/RH J45;_LR]
M_P"?:3\J/[,O?^?:3\J *E%6_P"S+W_GVD_*C^S+W_GVD_*@"I15O^S+W_GV
MD_*C^S+W_GVD_*@"I15O^S+W_GVD_*C^S+W_ )]I/RH J45;_LR]_P"?:3\J
M/[,O?^?:3\J *E%6_P"S+W_GVD_*C^S+W_GVD_*@"I15O^S+W_GVD_*C^S+W
M_GVD_*@"I15O^S+W_GVD_*C^S+W_ )]I/RH J45;_LR]_P"?:3\J/[,O?^?:
M3\J *E%6_P"S+W_GVD_*C^S+W_GVD_*@"I15O^S+W_GVD_*C^S+W_GVD_*@"
MI15O^S+W_GVD_*C^S+W_ )]I/RH J45;_LR]_P"?:3\J/[,O?^?:3\J *E%6
M_P"S+W_GVD_*C^S+W_GVD_*@"I15O^S+W_GVD_*C^S+W_GVD_*@"I15O^S+W
M_GVD_*C^S+W_ )]I/RH J45;_LR]_P"?:3\J/[,O?^?:3\J *E%6_P"S+W_G
MVD_*C^S+W_GVD_*@"I15O^S+W_GVD_*C^S+W_GVD_*@"I2-]T_2KG]F7O_/M
M)^5(VF7VT_Z+)T]* /'?%'_(2/XUAUV'B3P[K$M^6CTZX8<\A:QO^$8US_H%
MW/\ WQ4E(R**UO\ A%]<_P"@7<_]\4?\(OKG_0+N?^^*!F316M_PB^N?] NY
M_P"^*/\ A%]<_P"@7<_]\4 9-%:W_"+ZY_T"[G_OBC_A%]<_Z!=S_P!\4 9-
M%:W_  B^N?\ 0+N?^^*/^$7US_H%W/\ WQ0!DT5K?\(OKG_0+N?^^*/^$7US
M_H%W/_?% &316M_PB^N?] NY_P"^*/\ A%]<_P"@7<_]\4 9-%:W_"+ZY_T"
M[G_OBC_A%]<_Z!=S_P!\4 9-%:W_  B^N?\ 0+N?^^*/^$7US_H%W/\ WQ0!
MDT5K?\(OKG_0+N?^^*7_ (1?7/\ H%W/_?% 'KOP1^\W_7.O:Z\?^#FF7MB3
M]JM9(?D_C&*]@H)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ K(\3:4VM:%/8J^PR?Q5KT4 >?\ AOX7Z;I+M-=I'<R$Y!(Z5WD,$=O&
M(XD"HO  J2B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ JIJ;;=-N&]$-6ZR]>F\O391G&Y3
M0!Y7-)YLA?&,TRBBJ$% ZT4J_>'UH ]&\'H4T]^,9-=)6/X=C,>GKGN!6Q4C
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BD)%59K^&#[
MSC\Z:3>P)-ENBJL%]!<#Y'4_C4K7,*?>D4?4T68[,EHJL;^T!P9T_.E^W6Q_
MY;)^='*^P^278L45&DL<GW'#?2I*1-K!12$@#FH9;J*)22PII-A8GHKF;_Q7
M:6C$/,J'T)J"S\;:?-)L,Z$G_:K7V%2U[%<K.MHJ"VNH[J,/&P(/I4S,JC+$
M"L;-:$G%^-;MH;*4_P!T'%?/E[<M=W3S-U:O?_&\*7&GR^6X8E3P*^?;B!K>
M<Q,/F%>Y@;<@5[V1%0.>.]7['2;J^<!(VV_WL<5N0^#Y%F3?<)U!Q78YQ6YC
M&G*6R+W@BRN+.9=0DE,42'H>]=5?_$3[&VR.7S,>AKFO%6H?V9:II\!V[D!)
M'TK@F8NQ8GDUA[)57S2-Y3]G[J/:='^)233@3MM&>YKN7N[/5+$3+(F=N17R
MZ&*G(ZBO3O &M27$<EO*2P0 "N7%82*CS1)53GT>YW!&#C-213R0G*,1325W
M=.*4IN&5_*O*$:MMK;( '4M[U9FUQ57Y4R:YXC!P:2BP[FB^K3,V02!2QZO,
MK98DBLVBBPB_<ZI+.,*2H[U1)+')I*DC@DE8!5)H 8 6( &36_I-AL'FN.3V
M-&GZ2$(DDP?05L@ # I-C2%'2BBBD,**** "BBB@ HHHH **** "BBB@#B_'
M'AK^U[!VC7,BJ<8%>%S:'J>FWO-K+\AX.*^IR 1BJ-QH]C=G=-"&-=N'QCIK
ME:NA22D>%2:-?:_I"$6DBS(-Q;'WJYAO#FL*Q4V$V?I7U#;:=;6B;(8PJ^E*
MUA;NVXQC-:QS%QV6@G%,\+\%> KN]ODFOH'BC'.'%=OX]C:VT0QQ\;%"C'TK
MT1$6-=JC KGO%6EB_L6!QBLUBG4JJ4MBX*VA\WPV%U?7+"&%G);M726/@.XN
M=OFRF(GL174736'A*UD=44S'YA@\U0T#Q)<:G?EG<[0W"FO2=6<E>.Q*IQ3M
M+<FO+C3_  E9)#'&DEP1@L.N:Y*Y\8ZG++NCGD1<],U4\374EQK=R';*J_ ]
M*QZTA25KO5D3J.]D=QI'C64EH;@,SN-N\FL#Q$DHU!BTAD4\[JQU8JP(ZBM6
MYE,VCH[G+[NM-04970G-R5F9.:W=%U@6\1LYUW0.<D'I6%16C2:LR$[.YT-S
MX=EN2T^G9N%;G:@^[[5#9^%M4N+I(I;66)2<%B.E=5\/K[^S]-N9F.$5^36=
MKWCF^FO&6RF:-5."?6L%.IS.*->6-N9FH_P[F6U007.68?, *GTGX37$TZ//
M<;54Y((ZUS>F>.]6M+E9)KAW0')%>[^%=>37=)BN!PS+D@]:Y<14KTHWN.T)
M;%K1=$MM%LDMX$4;>XK4I**\AMR=V4+3)7C1"9& 7U-/KG?$=W)'^X",$89+
M]A2 9?6%JVH12+;B5#RQ%;%K8V\05XXPOH/2N6:ZN;<Q+%-YJ,.2O1:Z^S8O
M:1L3DD<T 3T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110!F:]#YNDS^H7BO*74HQ4]
M17L-]'YMG(GJ*\FU&/RK^5/0TT!5HHHIB%4X8'T->E^$[@7&E$YZ-BO,Z[?P
M5<@1>1GJQ.*3 [2BBBD,**** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ KS;Q9-YE^R9^ZU>BS2>5"S^@KRC7)O/U:=\\$TT!GT444
MQ!6UX6B\W6HQCC%8M=9X,M]UR)L=#BD!WRC:H'I2T44AA1110 4444 %%%%
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MKS5;V&[EC(@4A@?6OH&VMTM8%B0845Y>858NT$:05D34445Y984444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@Y&<URRQ%3#OEW1\UC,+[*>NQXMX3^&-VUVD^IQ-$%/W2.#7L]I:QV=K'!&
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "N?\56GVBQWXSL&:Z"JNHQ^;I\R8ZKB@#QZBI[N'[/<M&1C%050@I5.
M&!]Z2B@#U'PU=_:M.S_=P*VJX?P7>[,VQ/WFS7<5(PHHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M42<WK/A6+65+*@#_ -[%<->> +RVE(W,1]*^@HK."VB^Z!@5S^IW"33_ "#
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MUOKLOV;4),3' !/ S7K2.DBAD8,IZ%3D4 .HHK%\4:E/I>CRW-N0)%4D9^E
M&U17RK)\<O%ZWS1>?#M$A7[O;->@7?QD^P>']T\@:_905*C(Z4 >RR7,,/\
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M]:?=&3CY%H ^D:*RM"UZSUZQ6YM) 5('&>:U: "BBB@ HHHH **** "BBB@
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MWZZ.R.;5":YP.;J[C51\@/%=/$GEQ!?2DQH?2T44AA3)51D.\<4^HYUWQ%:
M,6\>%9A=1NJ^3P1GK5ZPU*.['##/UKE;JVW&>&59#*[?(1G%;6B:?9JBLFX2
MI][)[T =!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 4]2LU
MO+-T(R=IQ7E5_8RV5RT<BG(KV&LW4=&MM13$@VGU YH \FHQFNUG\%*K_NBQ
M%6;+P9!&X>5FR.U.XC&\+:2]Q>I.RGRU/.:]$10BA1T%1V]M';1A(T  ]!4U
M(84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M.NW\!>![OQG>(TN\V@.UCN-<3<#=J,H]9B/UKZK^"VFQV/A1SL&YG#9QSWH
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M-05)N>0A,_K30A/2DY!]ZY23I-+T]84$C?>-:M9>CW/G0["?N"M2H*"BBB@
MHHHH JW<L%K"TLB+QWVUS[:G;6LOF6Y;$ARV16YJT$ES821Q+ER.*YM-.OHX
M\W,"JB=Q0!TFG:C%?)\F<J.<BKU4=,2%;53& ,CGBKU !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% '*?$C_D1-2_ZYU\87/\ Q\/]:^S_ (D?\B)J7_7.OC"Y_P"/A_K0!]0?
M!S3[2X\-0-+;QN?+ZD5Z9_8^G?\ /G%_WS7GGP6_Y%B#_KG7J- %'^Q]./\
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M_7[H^E<UXZ_Y%R?_ '&_E72C[HKFO'7_ "+D_P#NM_*@#XOF_P"0I)_UV/\
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M7%M',O1U#"@"6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D8[5)/84M9'
MB&_%EISL&^?TH X?Q-J'VV_PIX3(K#I\TAEE=S_$<TRJ$%%%% '8>!IG:[EC
M).T+P*[NN&\#VSI<23$':R\5W-2,**** "BBB@ HHHH **** "BBB@ HHHH
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MM,T9!YVU>\%>)9;LFTNF+,J_?8]:XJ^$T=2)\YC8J%9Q.[J6WA,\H05&HW8
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M#-&RC>64D=LU]P5R/B_P#I?BJ%FG@4W.,!SV% '@/@#XL3^&5%M<QO/$3Z\
M5ZS%\:]*>)6,:*2.F[I7G^M_ 2_AD:2UNH]G90*Y5_A)K2.5PQP>NV@#TOQ7
M\;+232IK6U@R\JX#*W2O V^TZYJI9%:265NW6O1--^".KWDR!YA&">=RUZUX
M/^$%AX?E6>[2.:9<%6'8T 6?A)X6FT/PY;RW(*3,N"A'(KL?$.C0:WI4MM.@
M<;3MSZXK550HP.E+0!\5>,_"-[X;U>5'A?RMQ8/CCK6AX(^)%]X1G4$O+; Y
M,0/!KZF\1>$],\26[1WMNLC$<$UXKXA^ ETGF7%E<1*F>$ YH VQ^T):"-,Z
M:22.?F_^O7,>,/CA-J]IY%A ]MN7!(-<Q+\(M:C?;AC[A:V])^!6JWCJTMRB
M+W#+0!YE!:W^OZB3'&\TTK<D=<U]2?"?P0?#FCI=3KMN)DPZD<BK/@OX7Z;X
M8Q+)$CW Y#CUKT&@ KF?'7_(N3_[C?RKIJR?$.E/K&ER6L;A&8$9/N* /A^;
M_D*2?]=C_P"A5]=_"G_D5A]1_*O+G_9WU5KMIO[3AP9"V,>^:]J\'>'I?#>C
MBSFE61N.10!T5<Q\0O\ D1M3_P"N5=/63XFTE]<\/W>G1N$>9-H8]J /ARZ_
MX^'^M?87PD_Y)OI?^Y_A7E$O[.NK22LPU2#GVKV[P7H$OAGPM9Z5-()'@7!9
M>AH Z"N:\<?\B[/_ +K?RKI:RO$&EOJ^ER6L;A&8$9/TH ^'Y_\ D*2_]=C_
M .A5]<?"?_D5A^%>82?L[ZJ]V\PU.'#2%L8]\U[3X-\.R^&M(^QS2K(W'*T
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 (3@$^E>>>+M2^T7GE(V4QSBNRUJ_6PL6?/)XKRJXE,T[NQSEB
M:: CHHHIB"GPQF:9(QU8XIE;WAC3OM=Z'*\(0: .W\/V7V/3(E(PX'-:U(
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M ;HZ"BF1R"1 R]*?0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M<UXQ=QI3J/NY%=+69KMD;_37A YZT >3T5)/&89WC(QM.*CJA!3HY&BD5U."
M#D4VB@#TWPSJ?VRQ1';,@'-;U>6^'M3-A?#)X<A:]/BD62,,I!!J6,?1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 48S110 FU?[H_*E
M Z"BB@ HHHH **** "D*@]A^5+10 FU1T4?E2T44 %%%% !1110 8!I-B_W1
M^5+10 F .PI:** "BBB@ HZT44 )M7^Z/RHP!T I:* "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH *3:#U _*EHH 3:H_A'Y4M%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M](M[Z!0MQ,KICC;6M63IUV(Y#9RL#(HR2#6MUH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "D(R"/6EHH \Z\6:8;:[$D:_(1DUS->LZU8+?V$D
M>W+'H:\LNH&M[AXV&-IQ30B&BBBF JDJP8=17H'A/5A/;K;.WSJ,UY]5S3;Z
M2QNUD0]2 ?I2 ]?HJKI]Y'>VJRH<C&*M4AA1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ,ED
M$43.>BC->9>(]4:^OG53F,=*[K7YVAT]]O\ $"*\K8DN23DYIH!****8@IR(
M9&"J,DTVNA\+Z6;N\69ERB'F@#K?#6FBRLED(^:1<FMVFH@C0*HX%.J1A111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !BN&\6Z/L;[3$OR@9;%=S5:]M4O+
M9X6 ^84 >.T5?U:Q>QO9$92%W?*:H50@HHHH ZGPKK/V><02MA/>O05(90PZ
M$9KQ>-S&X93@@UZ/X9UA;VU$<C?O!P :3&=%1112 **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M(SO$I;:O>O"O^%VZG::@L-U9LA5OF!;I^M 'TO17-^#O%=KXHTB*YB=1*W5
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MKH:^1?A3XOET#7TCEE(MW^4+[GBOK6WF6>WCE4Y#*&_,4 2T444 %%12W$,
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MY%2+\/Y5V- !1110 4444 %%%% !1110 44C.J*68@ =S55M4L4.&NH@?=J
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !534+)+VU>-QDXXJW10!Y+J
MFE3:?<LA4[1W K.KV"]TZWOH]LJY^E8+^#+,L=JG'UIW$>? %C@#)KJ?"VBR
M2W"W,JX0<8(K>MO"-C"X=E.1[UOQ0I"@1%  HN ]5"J%'04M%%(84444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M** "N+\<^ ;3Q=:HK(OFAMQ)KM** /#X/@3%!<QRCR_D<-U]#7LNG6K6=E'
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MJ<USA\5^)YCNS*V?1#74?"OX>Q^(]0674H9!;X[C!S7O]M\.]"M8PB0< 8Y
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@"&Z4M;.!U(KE8UV:@H;LW-=>1D8K!U*P>.7SXQWS30C=CQL&WI3JRM.
MU%6C6.3(8>M:@(/0@TABT444 %%%% !1110!6O+@00E]ZK@9Y-8]Q>17MC%+
M(1]_IWJWK&EF_A^0D,.>M<O'H]])=?9U=<H=W7B@#M[6198595P,8YJ>JFGQ
M30VH2?&\>E6Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@##UG3[R[SY,BA/0UB:=HX_M,K<<MBNMOKG[-#OR*YR;6(%*W05UF+!
M22,#% '2VEL+6'8O2K%16\RSPJZL#D#H:EH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HI"0HR>E<CK?BL0,T%L0Q
M'!]J .MWK_>'YTH93T(/XUY1)KEW(Y;>P^AJS9>)KNUD!)W#ODT[ >GT5DZ/
MK<.IQ###S<9(%:U( HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** /G[]HJ54N=.4]2AQ^M>=?"RREN?%]E+&!MCE!;->C_M$*#/IY(R=A
M_K7FWPNN7A\86**>'F - 'V11110!3U7_D#WO_7O)_Z":^%=1_Y"=W_UV?\
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MX^%6@IHOA*!-N'SGD<U\W?#;0WUOQ+$JIN$3*Y_.OL>VB6&WCC10H"@8'TH
MEKYV_: T*XGU>+4XXR8HXMI('T_PKZ)K.U?1K36K)[:YC5E;N1F@#XGT#6[G
MP]JL5];@"2,Y&ZO;]"^/,>R--395 '.U:/%GP+1YC-I)DD+<E>@!KSC4?A#X
MLL=SG3SY8[Y/^% 'OUC\9O"MXR1K</O;CE:ZVTO-'U9!,B6TF[G+JI-?%]YX
M?U?2?FGB:/'<$T[3/%6K:7.LD=W,0ISM+G% 'V]#:VT)W000H3W1 /Y5-7DW
MPL^)8\21BPO&5;A%R0*]9'(S0!XK\>O^0*_X5\Z:=_Q_1_6OHOX]?\@5_P *
M^=-._P"/Z/ZT ?;_ (8_Y%C3O^N"UK5D^&/^18T[_K@M:U !1110!Y9\=HFE
M\'PA>TI/\J^9]#?R];MSDC]ZHX_WJ^F?CI,8?!\) !S*1_*OF71%\S6[?/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?A@AN[A]C*[ -V!K["LT,=G C?>6-0?KBO-_A;\/5\,6B7<_-RRX.1SS7IU
M'B7QYN'73VA#'84!(KPGPA;Q77B6UBFQY;'G-?3WQ;\,MK?A:XD@0M.  H Y
MZ5\H'[1I6H$ M'+$V,]Q0!]P^'[6"UT6U2!%5=@Z#K6G7SWX.^. M=.CL[VW
M7,2A=[-U_6NEN?CII\,3,D,;D#@;NOZT =SXZU6/3/#-WYA ,D3*,U\674OG
MW+N1C)->@^,_B%JGC>9H[6)XHE.2BGC%>=RQ/#(4D4JW<&@#ZM^!'_).XO\
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M=^/3:;I<5I+IP?RE"@EO_KU[/X.\6#Q58FY$ BP,X!H Z:BBD9@BEF. .IH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 5D:S>-!&!')M?T]:UZS=1TR*
M[ 88$B\@GUH YMM:VB!9HB)MWS,:["UE6:!75@P/<5S=GI4=Q?RQ7L?F,H^_
MV-=':VL=I (HQA1VH GHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH ***0T 9^IZ6E_'C@-US7/66B*-5:WN&$H"Y%7M;UB:UF5(6(
M^89 ]*KIJ\#Z@I0;)" "Q- '16-I]DA,>[(SQ5JFH<HI]1FG4 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 8V
MMZ)%J4!.T>8!\IKS>]L)K&=HY%/!ZXXKV&LO5](AU&W*E1O X(]:8'E%%7]2
MTN;3YV213@=P*H4Q"4M%% #XY7A<.AP178Z#XIP5@NF)SP#Z5Q= )!R#@T@/
M:(I4F0.A!!]*?7&>$-5=P\$K9 X6NSI#"BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@"CJ6F0ZA;E'49[$"O-]7T2?3922IV
M9X->K57NK.*[B*2(#D=2* /'**Z/7/#<EB[20J6B]37.D$'!JA"4444 ;?AI
MF&HH!TW<UZA7#>#]+8LT\BX'5:[FDQA1112 **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M[](/_1\=?']>\?$/XU^&_%O@74M#L++58[JZ\O8\\480;9$<Y(D)Z*>U>#T
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MY /KYL= 'T!H>J-/<F:0;%D& G85U8Y%9.C6D"V48>%5E'4=Q6O0!\,>+/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"IJ,OE64I[[37D<\C23.S'
M)R:]?OHA+9RJ1GY3BO([N!K:Y='ZY-- 04444Q!3DD:-@R'!%-HH W=.\375
MHP$KLZ#M79:;XDM;U1O98R>Q->84J.48,IP12 ]H21)!E&!'M3J\OL/$M[:L
M TI*#M76:?XLMKD!7!4^I-%AG245#%=03 >7*K9]#4U( HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBFNP1"QZ 9H 9/<16\9>5PH]ZY?5/%\<.Z*%=Q_O UC^*-9DN+IK=&/ECG%
M<S3L(OWNKW=ZQ\R5BI[&J!HHI@%%%% !113D1I&VJI)]J &U9M+&>[D"Q1LP
M/I6QI'AF>]<-(-J^C"NZT_2+73D AC"MZTK@97A_PZMB%FDP9.H]JZ7I112&
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %?.'[2G_ ",&A?\ 7K)_Z'7T?7SA^TI_R,&A?]>LG_H= 'B]A?W6
MEW\%]93-#=0.)(I%ZJPZ&NL_X6UX\_Z&6[_[Y3_XFL;P?I%OKWC#2=)NVD6W
MN[E(9#&0&"D\X)!Y_"OHC_AG7P;_ ,_>L_\ @1'_ /&Z /";KXG^-[R(QR^)
MM0"G@^5)Y9_-<&N5FFEN)GFFD>25SEG=B2Q]237U1!^S[X(B8%_[2F [27(
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MQ1\"ZKX-UO3X=?@EFN;&:*)!%)\SE"%'*^N*^4:[S_A3'Q!_Z%V3_P "8?\
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M^OB3_P!"- 'TI^SBY;X?7ZGHNJ28_P"_45>P5X[^SA_R(.H_]A1__145>Q4
M%%%% !1110 4444 %%%% !1110 5'+-'"A:1@H'<U)5/4K5;NSDC.,D8!- %
M&/68KB2>($!1P&SUIUA9QN\C,XD#C!%<RNDW*LX@D&(OO*.]=/H:8MPQC*$C
MO0!I06\5M$(H5"H.@%2T44 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MR,&A?]>LG_H= 'G/PU_Y*7X<_P"O^+^=?:M?%7PU_P"2E^'/^O\ B_G7VK0
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M *_$_P#0* /;J*** "O@O5?^0Q>_]?$G_H1K[TKX+U7_ )#%[_U\2?\ H1H
M^DOV</\ D0=1_P"PH_\ Z*BKV*O'?V</^1!U'_L*/_Z*BKV*@ HHHH ****
M"BBB@ HHHH **** "FNN]"OK3J* *UM8PVSNZ+\S_>JR !T%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %(RJPPP!'N*6B@#)U'
M0+2_4[EVG_9&*X[4?"=U;L6@7,8[DUZ/2,H888 BBX'C,L$D+E74@CVJ.O6+
M[1+6]7#(%/J!7*ZCX.DC)-J&<>].XCD:*M76GW-FQ69-IJKTI@% ZT5I:1I<
MNHW2J%.SN: .]\,J5L!D=0*W*KV=N+:UCC ^Z,58J1A2$A5)/04M8'B?4_L-
MGA#\S<4 -U3Q/;63&.-LR#M6"WC>\\SY539]*Y:61I7+NQ)/<TRG81W-KXT#
M'_2,#Z"M6'Q7ILN!YAS]*\QI0Q7H2*+ >NQ:K:S#Y'JTLJ, 0R_G7CBW,Z])
M7'T-31ZG=Q=)G/\ P*BPSU_<I[C\Z7->70^);R( 9SCU-78O&MY'_P LD/U-
M%@/1**X6/QQ.1\\: U;A\:(P_>[5-*P'7T5FZ?K5IJ  BD!;TK2H **** "B
MBD9@JECT% "T5D7/B33K8E6F 8=JI?\ "7V/_/44 =)17-_\)?8_\]11_P )
M?8_\]10!TE%<W_PE]C_SU%'_  E]C_SU% '245S?_"7V/_/44?\ "7V/_/44
M =)17-_\)?8_\]15FV\4:;.0OGC>>U &W13(Y%D0,IR#3Z "BBB@ HHJ"XNX
M;5-\K;5H GHK F\6::APLX)J+_A+['_GJ* .DHKF_P#A+['_ )ZBC_A+['_G
MJ* .DHKF_P#A+['_ )ZBC_A+['_GJ* .DHKF_P#A+['_ )ZBC_A+['_GJ* .
MDHKG!XOL?^>HK2L];L;X@02[C0!HT4=:* "BBB@ HHS5"\UBSL<^?+M- %^B
MN<;Q=8 \2C%)_P )?8_\]10!TE%<W_PE]C_SU%'_  E]C_SU% '245S?_"7V
M/_/44?\ "7V/_/44 =)17-_\)?8_\]11_P )?8_\]10!TE%8$/BS3G;#3 5K
MVMY!>)OA?<* +%%%% !1110 44UW"*68X K(N?$VG0$J9AN':@#9HKF_^$OL
M?^>HH_X2^Q_YZB@#I**YO_A+['_GJ*/^$OL?^>HH Z2BN;_X2^Q_YZBC_A+[
M'_GJ* .DHKF_^$OL?^>HH_X2^Q_YZB@#I**Q;;Q-ITY"B8;CVK81UD4,IR#0
M ZBBB@ HHHH **KW-[!:)NF?:*R)O%FG(V$F!H WZ*YO_A+['_GJ*/\ A+['
M_GJ* .DHKF_^$OL?^>HH_P"$OL?^>HH Z2BN;_X2^Q_YZBC_ (2^Q_YZB@#I
M**YO_A+['_GJ*4>+K#/,HQ0!T=%4+/6+*^P()=QJ_0 4444 %%%!.* "BL^\
MUJRL<B>7::S#XOL,\2B@#HZ*YO\ X2^Q_P">HH_X2^Q_YZB@#I**YO\ X2^Q
M_P">HH_X2^Q_YZB@#I**YO\ X2^Q_P">HH_X2^Q_YZB@#I**YO\ X2^Q_P">
MHJ6'Q9ISMAY@* -^BH+:[ANDWPON6IZ "BBB@ HHILDBQJ68X H =16+<^)]
M.@)7SAO':JO_  E]C_SU% '245S?_"7V/_/44?\ "7V/_/44 =)17-_\)?8_
M\]11_P )?8_\]10!TE%<W_PE]C_SU%'_  E]C_SU% '245S?_"7V/_/45<MO
M$FG7)"K,-Q[4 ;%%(K!U##H>E+0 4444 %%%5KJ^M[-=TS[10!9HKGY?%NG*
M^$F!%1_\)?8_\]10!TE%<W_PE]C_ ,]11_PE]C_SU% '245S?_"7V/\ SU%'
M_"7V/_/44 =)17-_\)?8_P#/44?\)?8_\]10!TE%<ZOBZP+?-* *T[/5[.^(
M$$NXF@"_1110 4444 %%!.!FLVZUVPLV*S3;6H TJ*YP^+[#/^M%)_PE]C_S
MU% '245S?_"7V/\ SU%'_"7V/_/44 =)17-_\)?8_P#/44?\)?8_\]10!TE%
M<W_PE]C_ ,]11_PE]C_SU% '245@P^*].=@&F -;,%S%<IOB;*T 2T444 %%
M%% !13)94A0LYP!6-<>*-.A)43#<.U &Y17-_P#"7V/_ #U%'_"7V/\ SU%
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MZ=P*]O9PVR!41>.^*L444@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M]"#P:\QUSX >#]4E::Q-YI<C<[;>0-'G_=8$_@"* /++7]H7QK;Q!)8]*N6
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M3/<NI"KD' "@#J!USTH ]!4[ES2T=** /ACQ9_R.6N?]A"?_ -&-7O/[-?\
MR+>M_P#7XG_H%;.L_ +PKK&KW6HF\U2VDN96EDCBE0H&8Y.-R$CDGO78>"_
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M\72-'8+M.,UYL>M-"#.>31113 **** "BBB@ HHHH *E@N9;=@T;LN/2HJ*
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M%SQBM>O/_&<C&\9,_+QQ0!SMW?37<C-([$$]":K4450@HHHH **** "BBB@
MHHHH LVM]/:2!HY&&.P->E:!JHU*T'.60<UY975>#+AHIWC'1C28'H-%%%(8
MV1MD;-Z#->8^);Y[K46&[Y?2O3)QFWD [J:\GU>-HK]PW6F@*%%%%,04444
M%%%% !112JC.<*,F@!**NPZ3>S_<MW(]JV['P?-.P,S&,>XH H>'M.DO-0C8
M*3&IY->GPQB*)4'0"JFG:9#IT(1%&<<D=ZO5(PHHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MRH^QW/\ SP?\J (**G^QW/\ SP?\J/L=S_SP?\J (**G^QW/_/!_RH^QW/\
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M/W5%- <S14YLKD'!@?\ *C['<_\ /!_RIB(**G^QW/\ SP?\J/L=S_SP?\J
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M5/\ 8[G_ )X/^5'V.Y_YX/\ E0!!14_V.Y_YX/\ E1]CN?\ G@_Y4 045/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 -<*1ANE<IJ>AQI*TT<B
MH2<[?6KFMZT;8^0B,LA'#53@UBWO7C2:,O(.,T .TC1I[2X6<ON5SG'I75U'
M!CR$P,#%24 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?8;?^X*LT4 5OL-O_<%'V&W_ +@JS10!6^PP?W!4L<,<8PJ@?A4E% !1110
M4444 %(5!'(!I:* *YLH"<[!2?88/[@JS10!6^PV_P#<%'V&W_N"K-% %;[#
M;_W!1]AM_P"X*LT4 5OL,']P4?88/[@JS10!7%E #G8*G"JHP !2T4 %%%%
M!1110 4R2%)%PR@CZ4^B@"M]AM_[@H^PV_\ <%6:* *WV&W_ +@H^PV_]P59
MHH K?8;?^X*/L-O_ '!5FB@"M]AM_P"X*/L,']P59HH A2UAC.509^E3  =*
M** "BBB@ HHHH 0@'J*A>TA<Y9!FIZ* *WV&W_N"C[#;_P!P59HH K?8;?\
MN"C[#;_W!5FB@"M]AM_[@H^PV_\ <%6:* *WV&W_ +@H^PP?W!5FB@!B1)&,
M*H_*GT44 %%%% !1110 UD5A@@&H#8P$YV"K-% %;[#;_P!P4?8;?^X*LT4
M5OL-O_<%'V&W_N"K-% %;[#;_P!P4?8;?^X*LT4 5OL-O_<%*+* 'A!5BB@!
M%15&  *6BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "F22"-<FGUA>()[RUB,T(!C'!&.: &ZU%;75LT^PLR<?+3+308
M$2*:W0JQ&3NK#L=5NXLQ8!#G)W"NWM&=K9&?&2.U $D2E(U4]0*?110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!7N+I80<GD512
M_-Y9N45&<-C#=*9K]G/<69-ODN#GCTKE((;]V\\ADA4[6(/>@#J;?2%GMI%N
M%"ECG*UL0QB&%8U)(48&:AL4VVJ?,3D#K5F@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ K&UG59[!2%ARK?*K>]7KG4(+;(9UW#J
M*S[^5-0TV.14#9;CV- &=%?,MH(;R8Q3,V<'T-;]E:Q+:["H96Y^M<V/#D\C
MK=33M(V1\I]*ZZ)=D2+Z*!0 X *, 8%+110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !2%@",G&:;)N,;!#ANQKE+O6)DOQ"TF/+;G/>@
M"37(3!>>:Z;UE. *KP/.+A;928XU(.TUJK(-5DCY#!#D5IMI]N\WG,F7]: +
M"#"*/:G4@X'%+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !5:\O$LX3)("0/2EN;V&UC+R,,#MFJ&IW$5UI4A7/(XH CLM:%S(Y((3/&1
M5)M'@U&ZNI)%.3RAK-$6I6S0G:OE/]W [5U]@C"V5F W$<T 4=$TTV (/I6S
M1BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "FEUSMSS5
M>_<QVS,#R.:YBRU)Y+@W=RY2W4E2<T .UJ*-M5C$\CB$CG::73Y9;US @!A4
MX![XK3M;:VOKE;F-_-0<'-6K?2(K:X,J,1DYQ0!;C@1841E!VC'(J4 *,#I2
MT4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !112$A023@"@!:S+
MO5H[::2)R 5'%6IKV*+9\P.\X%87B&Q2YD0QR!9-PR!UQ0!>M;YKK32Y0,Q)
M&*SWT%Y[5N2F6SL%1V]E=1ZD(U9EA !QVKJUX0 ^E %73[46ML(PN*MT44 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5%,!)"Z@\XJOJ-
MY]BA,I!*@9.*P[#6)+B:5S*$5ONYH S;I[R/4'!5I(XCD =JV='E&I7!GEC(
MXZ&KEE:N\TTLCAUD&.*N6ME':GY!@4 6/+7.<<TZBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "HYIXX%R[ >V:DKG]?CVS1W,A;R4'S
M8- %R>\MKZRG0J651A@*P#H3SJKV_P L8['K38;LVDR+9JQ2?EMXKK[7)MD+
M 9QSB@"'3+<VUC'&>H%7*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BC.!7F/Q$^*L?A%C;V
M8CFNU(S&WI0!Z=17S=%^T/KDTRQIIEN2Q '->W^$=5U?5M+6YU6S6VD?!55[
M@T =%1139)%B0NYPHZT .HK/.LV(.#,*/[:L?^>PH T**S_[:L?^>PH_MJQ_
MY["@#0HK/_MJQ_Y["C^VK'_GL* -"BL_^VK'_GL*/[:L?^>PH T**CAGCG0/
M&V0:DH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 444R65(4W2' H R-4UE+0^4#^\/055FOQ?6963'([4NOV,%QBX+D,
M!@ 54LM$N+2XB>+=+$_+;NU &_!90R6L/R@;5X.*NH@10HZ"DC&V-1C''2GT
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M1110 4444 %%%% !1110!!>?\>4__7,_RKXV^(__ "-<W^>]?9-Y_P >4_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M#PQHLNN:U#;1*6PZE@/3- 'I7P=\ '5;M-5NXMUN.,,.,U]+PQ+!"D: !5
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MYYSBK]MXBU.R*^3.5*]* /N:.6.50T;!@>XI]?)_ACXQZ[IMQ&E]=-+;@\J
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHJA?WPMT8!@& H Q];C:&]-PZEXSP%]ZSX;J]>Z6,1O'!
MZ'I6F]W]MTZ/S)567S.C'GK6U%"DD*[QG@4 3Q?ZE,^@I](!@ #I2T %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 >+?'K4B-!:R!/W@:^::^A?CY_J3^%?/5 'O\
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MT<\4@+JH# GG-?&6JZ;/I5_);3(596(&1VS7:?#+QS+X:U>**:0_9&.6R<T
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MH **** /"OCW;R?8FFQ\F0,U\ZU];_&?2?[1\&2!%RX<'BODN5/+E=#U4D4
M?0G[/-\L6F7=L2-TDO%>\5\F_!K7UTWQ3;6LC!8I'R37UA'(LL:R(<JPR#0
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MS/\ *OC;XC_\C7-_GO0!#\/O^1KM_P#/>OLW3O\ D'6__7,5\9?#[_D:[?\
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M*3>5V1'@=Z^,Z .H\&>.+[P3>37-C#%*\J[3Y@Z?I7<?\-$>)O\ GTM?R_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"EJUA'J.G
MS6\BA@5. ?7%?&7CCP]+X=\0S02@CS&9USZ9_P#KU]M5Y9\6O ">(-.DO[=
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M_&C_ )%\_P#7,UZA7E_QH_Y%\_\ 7,T ?*%?3'P(_P"02G_7.OF>OICX$?\
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M9;?]<Q7QCX"_Y&NV_P ]Q7V=IG_(,MO^N8H MUYG\9/^1>/^X:],KS/XR?\
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M HHHH **** "BBB@ HHHH **** "HYIXX5S(P ]ZDKF?$$LV](<%4<X+]EH
MDO[:*>XAFAA617;YC[5JP:=!!.98E"Y'05R4#W5M)'$DS20J>''0UV=I)YEN
MK>M $]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^OU%?7WPG_Y%I?\ =% ^#'@D'/\ 9?ZC_"NOTG1;'1+86]C%Y<8[4 :%%%%
M'GOQ:_Y%IO\ =-?(;?>/UK[NU?1+'7+;[/?Q>9'TQ7('X,>"2?\ D%_J/\*
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MZ]M"4VNP^8XZUC^'6*>(;%E.")!BOL/7OA]X=\2S)+J=GYKIT.?_ *U9EO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 5[N[CLX6DDZ 9K)NFCOO(
MNHF0*GS$,1DT[Q';W,UL3"/E ^:N;ALKN\5!;D@P_?!.* .ZMF22%750 ?:I
MJI:8DJ64:R]0*NT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4R2*.5=LB*P]&&:?10!!]BM?^?>+_ +Y%21PQQ#$:*H_V1BGT4 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !3'BCE&)$
M5A[C-/HH @^Q6O\ S[Q?]\BI(X8XAB.-4!_NC%/HH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH 0@,,$ CT-9]KIXANII,8#'@"M&
MB@! ,=.E+110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>img69628308_8.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img69628308_8.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "E 8@# 2(  A$! Q$!_\0
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M2AD/_+O$2$_X$>K?H/:K%I9Q6:$1@EV.7D<Y9SZDU8H ;'&D48CC141> JC
M'X4ZBO)O&GC_ ,2:-K]]IT-LEK:*@6&Z>(GD@$-GH>XQ6M*C*K+EB&QZNSJN
M-S 9Z9/6G5\SZIKVJZDCW.N7ES-B3; L9"?,!DLK 8"_GG->R>%_&5B_P_@U
M>_N)%2V'D3/+RS.OTZD\5O6P<J<4[W$FF6_'.NRZ-H[*FFS7<=S%*DCQD@1
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M>M:M)JSL0U9V"BBBD(*P=*DU#5HO[2_M!X8VN&"6JQ(T?EJY7#$C=N(4\A@
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M223MQ_C6[12YF3[204445) 4444 %%%% !1110 4444 %%%% !1110 4444
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MK33\V24445F9!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>img69628308_9.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img69628308_9.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "M 2D# 2(  A$! Q$!_\0
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M%%% !1110 444A( R3@4 +14?GQ?\]$_.CSXCTD3\Z )**** "BBB@ HHHH
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M,IZ&N;UO[#XB)L;?6IXY8!NDMK25?FY &[@]#V_2M_3Y;8VL45L$18T"^4H
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M"CH>HP!G'3FNST:Y@O+-+F"=98Y%5E(CV';CC(/->;6(TO3O![0B^LXKJ_\
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M_>3Y_A3C\:EI%4*,*,"EH **** "BBB@ HHHH **** "BBB@ HHHH ****
M@$8/2H?+DC_U3#;_ '6[?C4U% #$DW':PVN.U/J.5-R[@<,O(-.C??&K8QD9
4H =1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>img69628308_10.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img69628308_10.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" (+!>P# 2(  A$! Q$!_\0
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MBBB@ HHHH **** "BBB@ HHHH **** "BBLOQ5JDNA^&-8U&!4>>SLYKB-9
M2I9$+ '!'&1ZTUKH-+F=D:E%?"?AS]L[XU^,(II=!\!Z;K<<#!97TW1[VX$9
M/(#%)C@GWKN?@K^V;K?BCXBVG@[QUX<M]%OKV06\,UK'+"8IB/E22*0LPW<
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^(OP^^'&N6^C#QCIVCI;VDGD:>+V5;= Q!Q&HW*&X!.SD<9Q6'\1/V9/"'Q
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M"MYEW136JQNOJIN,$?E7T!^U=9P:?^S7XMMK6".VMH;:!(X84"(BBXB   X
M'I6=\:/V9)OC)XH\+ZY<^*5TZXT:!(Y433?,6X97WEA^]&P$]OFQZFO1OBY\
M/_\ A:GPZUGPK]O_ ++_ +11$^U^3YWE[9%?.S<N?NXZCK7/[6%J2O\ #O\
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M+[I-*^SLR/\ [^V958^Y2M7B*4G)7ZWU3['1+'8><IQNOBNFTVMDNEG<[?\
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MOM8F-UJFGZM#IT]RP^:8HT;JS>IV2*">Y!--\<?\H_/"'_7ZO_I1/7H/Q?\
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M*6FFW;T/0****\L^<"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M[D\JWB&7?:6QSCH!GO0!:HJ.WN([JWBGB;?%(H=&P1D$9!J2@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110!Q/CS_ )&3PA_U^G^:UVU<3X\_Y&3PA_U^G^:UVU !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 5S/Q(_Y$C5?]Q?_ $-:Z:N9^)'_ ")&J_[B_P#H
M:T :WAW_ )%_3/\ KUB_] %:%9_AW_D7],_Z]8O_ $ 5H4 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MO_*9%_C75T4 <SX%U"_OK75(]0N_MLUIJ$MJ)O+6/*J%[+[DG\:Z:N4\ ?\
M,Q_]AJY_]EKJZ .?\?:I=:+X3OKVRE\FYC\O8^T-C,B@\$$=":J?\([XG_Z&
M[_RF1?XT?%+_ )$34_\ ME_Z-2NKH Y3_A'?$_\ T-W_ )3(O\:/^$=\3_\
M0W?^4R+_ !KJZ* .4_X1WQ/_ -#=_P"4R+_&C_A'?$__ $-W_E,B_P :ZNB@
M#E/^$=\3_P#0W?\ E,B_QH_X1WQ/_P!#=_Y3(O\ &NKHH Y3_A'?$_\ T-W_
M )3(O\:/^$=\3_\ 0W?^4R+_ !KJZ* .4_X1WQ/_ -#=_P"4R+_&C_A'?$__
M $-W_E,B_P :ZNB@#E/^$=\3_P#0W?\ E,B_QH_X1WQ/_P!#=_Y3(O\ &NKH
MH Y3_A'?$_\ T-W_ )3(O\:/^$=\3_\ 0W?^4R+_ !KJZ* .4_X1WQ/_ -#=
M_P"4R+_&C_A'?$__ $-W_E,B_P :ZNB@#E/^$=\3_P#0W?\ E,B_QH_X1WQ/
M_P!#=_Y3(O\ &NKHH Y3_A'?$_\ T-W_ )3(O\:/^$=\3_\ 0W?^4R+_ !KJ
MZ* .)U3P3KVM6$ME>^*O.MI,;T_LZ-<X((Y# ]0*M_\ ".^)_P#H;O\ RF1?
MXUU=% '*?\([XG_Z&[_RF1?XT?\ ".^)_P#H;O\ RF1?XUU=% '*?\([XG_Z
M&[_RF1?XT?\ ".^)_P#H;O\ RF1?XUU=% '*?\([XG_Z&[_RF1?XT?\ ".^)
M_P#H;O\ RF1?XUU=% '*?\([XG_Z&[_RF1?XT?\ ".^)_P#H;O\ RF1?XUU=
M% '*?\([XG_Z&[_RF1?XT?\ ".^)_P#H;O\ RF1?XUU=% '*?\([XG_Z&[_R
MF1?XT?\ ".^)_P#H;O\ RF1?XUU=% '*?\([XG_Z&[_RF1?XT?\ ".^)_P#H
M;O\ RF1?XUU=% '*?\([XG_Z&[_RF1?XT?\ ".^)_P#H;O\ RF1?XUU=% '*
M?\([XG_Z&[_RF1?XT?\ ".^)_P#H;O\ RF1?XUU=% '*?\([XG_Z&[_RF1?X
MT?\ ".^)_P#H;O\ RF1?XUU=% 'G_BF+Q/X:T&ZU+_A*/M/D[?W7]GQ+G+!>
MO/KZ5Z!7*?%+_D1-3_[9?^C4KJZ "BBB@ HHHH **** "BBB@ HHHH ****
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M/H **** "BBB@ HHHH ***\W^+GQG@^&NH>&_#^G:5)XF\;>*)Y;?1="AG6
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MXIW/Q6368+"TB\)^-K_PW9M9HZ;[6"&WD5Y2SMF3,S9(VK@#Y1SGK? _QB\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M5?2-9L/AG1[?Q!<:]%I5C'KEQ;I:3:FEL@N9848LD32XW%%+,0I. 6)[UI4
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M : /0/ _[5"ZA^RWXC^)_BG3X-&UGPI'J-IKFG0.6A74+)GCDCB+?-MD=5V
MG(\P*22,G(_9"^)_Q U'7O&'P\^*^L+KGC71[;3-;AOELXK42V=[:HS1A(E5
M3Y-PD\>[&2"N<UY!KW[/OQ(NOAG\//A*]O\ 8]6\<>+[WQOXUU86$E_I&EJD
MQO5LIF1HU??-]GC"B12YB<@@<CO/&W@/XJ_#[]J/X7?%;4+RQ\:VE\K>"==@
M\(>%[JT>VL9R\T-Q,&N[HF..X"LSX4*"<_>R !WA?Q!\2_B5=?'W4H/BYJOA
M?_A#/$U]INCV2:9I4FFQPPVL,Z"X\RT,SKND8,1,IV]"",U[O^SO\2[[XR?
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M]2>W<6TDJ75R6B64C:SJK*2H.0"">M>1_$CX&^,?B7JW[9VC:7I%S;7'B=-
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M>'/B5=ZSI-A<1Q:]XVF\0+!9),R!H(TU>4%VE"9S#&X B^=D)C# 'T+1110
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M\3?"OXE?LI:+=:?=7\7A7PAK5CK&IV=N\EG:W,D-J?+:4#: 7#JF[!8(2!U
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M\0/!VAO&FL:QH\]M9B5MJO*5RJ%L_*&("Y/ W9KQ?XI:YJ?[1WPC\._##2/
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M*15U2:U,G[J.>5GN(TG(R/*4AA@&@#ZI^)'C;_A7/@G5?$?]@ZYXG^P1J_\
M9/ANS^UW]SEU7;#%N7>1NR1D< GM706MQ]JM89O+DA\Q%?RY5VNN1G##L1WK
MX:^)'Q:TJV_9#^.,W@36_B-X0\6Z+9Q2WGA_QEJ=X=:T*5I0B2I-/++,$G1
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M^(GP&@NX6\OP3HDWBSQ3;S X36U:73;>%ESE)%E2^F ;G:J'H?F /N*BBB@
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M4^M?#FP_LC^U/^$P\2P^'?,^T^3]D\R&:7SL;&WX\G&WY?O9SQ@^DU\.>*_
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MFXJ#@$#BNB^)7CS3_A;\/?$GC'58;FXTS0=.GU*YBLU5IGCBC+L$#,JEB%.
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MK$)FO3_C[$EK;_LF+"BPK'XVTN-!&-H5?[.N1M&.@QQBOK*B@ HHHH ****
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M, <9KYU\8>)(?&'[&_[:.M6UI?V5K?>.)9H8=3M'M;CRR-.VLT4@#IN&& 8
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M$:5\1O#-EXMLI?!/BRXU6^@L9M&<W^GW-\=TG^E"Y"2Q(S2%4,*OAE!D.W)
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M"XMY^RKX3O?V;;#X)OJ&M#PK916<,=XL\/VXBVN8[F/+^5LR7B4'Y.A.,'D
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !117S#\8/VS
M-5^'/QBO/A[H7PTOO&FI00QRK]@OG$LNZ(2G;"D$APJGDY[$\4[7 ^GJ*^=_
M@3^V1I7Q>\;3>"]8\-:AX*\6JKM'I]\YD$A1=SIDHC*X4%L,HX!Y[5RGQ/\
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M HHHH **** "BBB@ HHHH **** "BBB@ HHKS[XQ?%2W^&^@_N2LVM72E;6
M\[?61A_='ZGCU(YL3B*6$I2KUG:*,JM6%&#J3=DC;\0?$KPQX5OULM5UFVM+
ML@'R6)9E!Z;L [?QQ70VMU#?6\=Q;31W$$BATEB8,K*>A!'45^?%]?7&IWD]
MW=S/<7,SF2260Y9F)R2:])^"OQ;U'P3K5IID\C7.AW<RQR0,<^26.-Z>G)R1
MT//?FO@<'Q<JV)]GB(<L&]&MUZ_\ ^:H9VIU>6I&T7M_P3[#HHHK]'/J@HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHKD/B=\1K+X;^'
M7OI]LUY+E+2USS*^/_01U)_J16%:M3P].56J[16[,ZE2-*#G-V2+WB;X@>'?
M!TL46LZM!8RR#<L399R/7:H) ]ZUM+U:RURQBO=/NHKRTE&4FA8,I_$5\#:]
MKM[XFU>ZU/49VN+RX?>[M^@ [ #@#L!72_#/XI:K\-M5$MLYGTZ5A]IL7/RR
M#N1_=;'0_GD5^>4>,%+$\M6G:D]GU7F_^!^)\Q3SQ.K:<;0_$^WZ*AL[J.^M
M(+F(YBF19$)'8C(_G4U?I*=U='U>X4444P"BBB@ HHHH *_//XO?%72?@O\
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MA?PS?^,-<M=)TV+S;J=L#/W47NS'L .:H6-E/J5Y#:6L+SW,SB..*,99F)P
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M444 %%%% !117S]\7/VV? ?P8\?7/A'7-/UZXU"W2)Y9[&VA>%1(H8<M*K'
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M9FX\_;Y;E<[]BYSC/2O1Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MX/#OWWN^R_S?X(XLUS#V*]A2?O/?R_X)#UY-'7@45[_^SS\'?MTD'BK6H/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MWHNO=_C\YFV8>T;P])Z=7W\@K9\(^$]0\:Z];:3IL6^XF/+'[L:CJ['L!_\
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M[<^J5^M\.9)]1A]9KK]Y+;^ZO\WU^[N?;97E_P!7C[:HO>?X+_,****^W/H
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MNWJJ^I./;U'U7##';PI%$BQQ1J%1$& H P !V%/HKU<LRJAE=)PHZM[M[O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MPA_^*H_X61X2_P"AHT7_ ,&$/_Q5<[_PSWX _P"@!_Y.7'_QRC_AGOP!_P!
M#_R<N/\ XY1RY?\ S3^Z/^8<V=?R4O\ P*?_ ,B=%_PLCPE_T-&B_P#@PA_^
M*H_X61X2_P"AHT7_ ,&$/_Q5<[_PSWX _P"@!_Y.7'_QRC_AGOP!_P! #_R<
MN/\ XY1RY?\ S3^Z/^8<V=?R4O\ P*?_ ,B=%_PLCPE_T-&B_P#@PA_^*H_X
M61X2_P"AHT7_ ,&$/_Q5<[_PSWX _P"@!_Y.7'_QRC_AGOP!_P! #_R<N/\
MXY1RY?\ S3^Z/^8<V=?R4O\ P*?_ ,B=%_PLCPE_T-&B_P#@PA_^*H_X61X2
M_P"AHT7_ ,&$/_Q5<[_PSWX _P"@!_Y.7'_QRC_AGOP!_P! #_R<N/\ XY1R
MY?\ S3^Z/^8<V=?R4O\ P*?_ ,B=%_PLCPE_T-&B_P#@PA_^*H_X61X2_P"A
MHT7_ ,&$/_Q5<[_PSWX _P"@!_Y.7'_QRC_AGOP!_P! #_R<N/\ XY1RY?\
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MSWX _P"@!_Y.7'_QRC_AGOP!_P! #_R<N/\ XY1RY?\ S3^Z/^8<V=?R4O\
MP*?_ ,B=%_PLCPE_T-&B_P#@PA_^*H_X61X2_P"AHT7_ ,&$/_Q5<[_PSWX
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MPA_^*H_X61X2_P"AHT7_ ,&$/_Q5<[_PSWX _P"@!_Y.7'_QRC_AGOP!_P!
M#_R<N/\ XY1RY?\ S3^Z/^8<V=?R4O\ P*?_ ,B=%_PLCPE_T-&B_P#@PA_^
M*H_X61X2_P"AHT7_ ,&$/_Q5<[_PSWX _P"@!_Y.7'_QRC_AGOP!_P! #_R<
MN/\ XY1RY?\ S3^Z/^8<V=?R4O\ P*?_ ,B=%_PLCPE_T-&B_P#@PA_^*H_X
M61X2_P"AHT7_ ,&$/_Q5<[_PSWX _P"@!_Y.7'_QRC_AGOP!_P! #_R<N/\
MXY1RY?\ S3^Z/^8<V=?R4O\ P*?_ ,B=%_PLCPE_T-&B_P#@PA_^*H_X61X2
M_P"AHT7_ ,&$/_Q5<[_PSWX _P"@!_Y.7'_QRC_AGOP!_P! #_R<N/\ XY1R
MY?\ S3^Z/^8<V=?R4O\ P*?_ ,B=%_PLCPE_T-&B_P#@PA_^*H_X61X2_P"A
MHT7_ ,&$/_Q5<[_PSWX _P"@!_Y.7'_QRC_AGOP!_P! #_R<N/\ XY1RY?\
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MSWX _P"@!_Y.7'_QRC_AGOP!_P! #_R<N/\ XY1RY?\ S3^Z/^8<V=?R4O\
MP*?_ ,B=%_PLCPE_T-&B_P#@PA_^*H_X61X2_P"AHT7_ ,&$/_Q5<[_PSWX
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MPA_^*H_X61X2_P"AHT7_ ,&$/_Q5<[_PSWX _P"@!_Y.7'_QRC_AGOP!_P!
M#_R<N/\ XY1RY?\ S3^Z/^8<V=?R4O\ P*?_ ,B=%_PLCPE_T-&B_P#@PA_^
M*H_X61X2_P"AHT7_ ,&$/_Q5<[_PSWX _P"@!_Y.7'_QRC_AGOP!_P! #_R<
MN/\ XY1RY?\ S3^Z/^8<V=?R4O\ P*?_ ,B=%_PLCPE_T-&B_P#@PA_^*H_X
M61X2_P"AHT7_ ,&$/_Q5<[_PSWX _P"@!_Y.7'_QRC_AGOP!_P! #_R<N/\
MXY1RY?\ S3^Z/^8<V=?R4O\ P*?_ ,B=%_PLCPE_T-&B_P#@PA_^*K2T?Q)I
M/B#S?[+U2RU+R<>9]CN$EV9SC.TG&<'KZ&N+_P"&>_ '_0 _\G+C_P".5RG[
M/6GV^D>,OB58VD?E6MK?I!#'N+;462X51DG)P .M4\/A:E&I4HRE>-MTNK2Z
M-F4<9F%'%T:&*A#EJ-J\7)O2+?5+L>X4445Y!],%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'C'[*?\ R3O4
M?^PK)_Z)AKV>O&/V4_\ DG>H_P#85D_]$PU[/7JYI_OM7U/GN'O^15A_\(44
M45Y1]"%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %>,? S_DHGQ4_["H_]'7->SUXQ\#/^2B?%3_L*C_T=<UZF%_W7$>D?_2D?
M.YA_R,,%_BG_ .D2/9Z***\L^B"BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_#'X<WOQ(\1)8V^Z*SBP]W=8XB3/ZL>@'] :^W[6VCL[6&WA7;%$@C1?10,
M?E6#X"\#Z?\ #_P[!I=@N<?//.PPTTF.6/\ 0=A@5T=?M6190LKH>_K4EO\
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M?YCJ***_4S[$**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MOBMXK7QC>:\TJW#1$B""!XA&T<>Y5 'WCPBC)Z4K@?+O[0WQ:N?VD/!7P/\
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MO-DT[1D*"[ ! 23;#"""3SNW=.E%] /IJBBBLP"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ KD=1^+7A#2=9.E7>O6L5Z&V,GS%4;T9P-JGGN1BN'_:)
M^*=YX-L;?1=*<P:A?QL\EROWHHLX^7T8D'GM@]^1\IDEB23DFOA,ZXE_L^M]
M7P\5*2WOMZ+S/G,?FWU:I[*DKM;W/T01UD171@R,,AE.01ZTZOE?X(?'1_"K
M0:#KTK2:.QVP73'+6N>Q]4_E]*^IHY$FC22-EDC<!E93D$'H0:^CRO-*.:4?
M:4M&MUU3_P NS/5P>,IXRGSPWZKL*2%!). *^4/CY\8CXPOGT+2)O^));/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *QM:\9>'_  U<06^KZYINE3S_ .JBO;N.%I.OW0Q!/0]/2N%_
M:*^-T'P/\#_VDL"WFL7CFWT^V?.PR8R7?'\*CD@<DD#C.1^9/BCQ1JOC37KO
M6=:O9=0U*Z<O+/*<D^P'0 = !P!P*^ERO)9YA%U9RY8?F>#F&:QP4E3BN:7Y
M'[$*P8 @Y!Y!%+7P)^RQ^U?)X#DMO"?B^Y>?PX[!+2_D)9K D_=;UB_]!^G
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M** "BBB@ HHHH *JZIIMOK.FW>GW:&2TNH7@F179"R,I5@&4@C@GD$$5:HH
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M\37M8A_XDMN_[F%QQ=2 _P#H /7U/'K7U8 %  & *^_X9R/G:QV)6GV5^O\
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MO^0M%%%?GQ]H%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M7E_QA^"MI\1+<WUB8[+7XUPLS<).H_A?'Z-U'3IT]0HKDQ6%HXVDZ->-XO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %>,? S_ )*)\5/^PJ/_ $=<
MU[/7C'P,_P"2B?%3_L*C_P!'7->IA?\ =<1Z1_\ 2D?.YA_R,,%_BG_Z1(]G
MHHHKRSZ(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_H<-%_[\K_\ (U'U&/\ S_A][_\ D0_M>I_T"5?NC_\ )GL]%>,?\(O\;/\
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M +\K_P#(U'_"+_&S_H<-%_[\K_\ (U'U&/\ S_A][_\ D0_M>I_T"5?NC_\
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MXQ_PB_QL_P"APT7_ +\K_P#(U'_"+_&S_H<-%_[\K_\ (U'U&/\ S_A][_\
MD0_M>I_T"5?NC_\ )GL]%>,?\(O\;/\ H<-%_P"_*_\ R-1_PB_QL_Z'#1?^
M_*__ "-1]1C_ ,_X?>__ )$/[7J?] E7[H__ "9[/17C'_"+_&S_ *'#1?\
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MM8-+:3ZGIU%%%>&?7!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MZ]9^-(_#?B:#3_/N[9KJSNM,WB-MIPR,KDG/?-<1X+\<7/A;X5^!]/TY+/\
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MIOCK6M'UG7=.\4P6!.GZ9_:R7&E[PKP@L&!5R3G*G\JYV/XP:Y9Z7::_J/\
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MU54G/ETMRV^#7FWUYNWE;2Y@QV>J:_\ %;P[*;71&L_["BN$MYK9V$4!>+S
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !6M;SOTL>FU#]L@^U"U\Z/[24\WR=XW[,XW;>N,\9KPCQ-\2]6\.:?/??\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 5YYJ/PD_M#0]:T[^U?+_ +2ULZQYGV;/
ME\H?+QOY^Y][(Z]*]#HK>E6J47>F[?\  .3$86CBERUHW6JZ]='L8&L>%?[6
M\6^'M;^U>5_9*W*^1Y>?-\U%7[V?EQMST.<]JY.3X/W:Z?<Z':^)[BV\*7$I
M=]+%JC2*C-N:-)B<JI.>QZGK7I=%:0Q5:FDHO;R7=OKUNWKN8U<OPU=RE..K
MWU:O=)/9K1J*NMG;8X.\^&MY8ZY=:EX8U]O#QO(XX[FW:S6YB<HNU64$C:V.
M_.:(_A/;VVA:-I\&H2^99:O%K-Q=3IO>[F5BSYY&W=G&>< #KUKO**?URO9+
MFV\ETT5WU^9/]FX6[?)O?J[:N[LKV5WO:USR;XA6%]J7Q@\)PZ=J3:5>?8;I
MH[D1"4#&,AD. P([9%;EO\)K>ZTG7[?6]2FU>_UO9]JOA&L)4)@QB-1D*%(!
M'6N]HJWC*G)"$-.5>5][[VO\O(RCE=!U:E6K[W.V[:V5XJ+TO:]KZVO9V. M
M?AMJMWJ6DS>(?%,VMVFERK<6UJMHL&95^X\C!B7(Z]N:U-#\!II,OBDRWC7$
M>O7#SLJ1[#"&7:5!R<GWP/I75T5G+%59*S>GDDNM^B[F]/+\-3:DHW?=MM[6
MW;?30\DE^"&JS>$G\,GQ@R:+C"0Q:;&C'!ROF,&R^"!Z9P*Z^\\&7LWCBQ\2
M6^KK:RQV:V-W;_90ZW$8D+G:2WR<GWKK**N6-KS^)KKT77?IY&5/*\)2^"+^
MS]J7V;VM=Z)7>FVIYS;_  A-CX;T&SM-;EM=7T6:>:TU.. 8_>R,SJT98Y4A
M@",\X_"KNF_#>Y6XUC4-7UR35]8U"Q;3UNOLZQ1P0D?=2,$_Q<GGG':NYHI/
M&5Y7O+?R75WWMM?6VQ4<KPD+<L-K*UW;1<JTO9M+2[U\S@[[X6_;/ASI?A7^
MT]GV%H6^U_9\[_+;=]S=QGZFNVO+.'4+.>UN(Q+;SHT4D9Z,K#!'Y&IJ*QG6
MJ5/B?5OYO<Z:6%HT;\D=TH_*-[+7U?ZGF3?!_4)M)BT"X\6W,_A:)@!I_P!E
M03&)6RL;39R5' ^[VKKX?"JV_C1]>2<*ATU-.6T6+ 4+(SA@V?\ :QC';K6]
M16D\56J:2??HEOOLMW;?<QI9?AJ+3A':V[;VO9:MZ*[LMO(P/%_A7_A*ET=?
MM7V7^S]3M]1_U>_S/*).SJ,9SUYQZ&HKOP?]J\?6'B7[7M^RV3VGV7RL[MS9
MW;L\8],5TE%9QK5(KE3TU7W[FTL+1G)SE'5M/KO';[C@X_A=Y?PKE\&?VGGS
M%D7[=]GZ;IC+]S=VSC[WO[5H^'_ YT?Q1>ZU<7YO9I+."QMX_*V"WB0?, =Q
MSN;YNV*ZNBKEBJTE)-_%=O;K:_Y(RCE^&A*$HQU@DEJ]%%-+KK:[W_1''^*O
M =QK?B.SUS3=6.D7\-G/9._D&3S(W'R]'7!1CN'OBMCPAX;A\'^&=.T:!_-C
MLXA&9"N-[=6;';+$G'O6Q142KU)P5.3T7_!_S9I#"4:=:5>,?>>^KZVOILKV
M5[=CF? G@T^!]/O;".]^U6,EW)<6L1BV&V1SGR\[CN .3G ZFL&^^%FH+-J\
M6C>)Y='TG5I7FNK$6B2D,XQ(8W)&S=]#7HE%:+%58S=2^KWT3_"UC*67X:5*
M-'E]V.UFU;RNG>WE>QP%Q\*VTV_L[[POK#^'[J&S2PDW6RW$<\2?=+*2OS#^
M]FHYOA#'-X-UG2'U:2;4M7N8[J\U2:$%G=9$< (" %PF ,\9/TKT.BJ^N5]/
M>VMT5]-5=[OT9F\KPCYO<T::M=VU5G97LFUU23.6\6Z/:KK6B>)[W4%L;30!
M<RRJ\>X.LD6S[V?EQUZ'/2N \ ^#3XT^&TNR[FTR1M<EU33[Q8]Q5ED^1]IQ
MD=:]HHIT\7.G3Y%NK6?9*[M:W=O?T)K9;2K5W5E\+3NM=6U%7O?2RBEHEWN>
M?6?PUOH_$R^(-;UU]?N([*6S>V%FL*/&P^ZH#8'\77.=W48KR'6;B/4O!;>%
M]$\4:A="618;7PS/IHCNHOWF=DTH_A7D_@.W%?3]%=%',)TWS35[6MLDK7Z6
M\^EGYG%BLDIUHN%*7*G>_P 3;YK7UYEVV?,O(X37/AS?W/C*7Q'HVO\ ]D7E
MQ MO,LMBER"%Z%"Q&TX^M4H?@_(O@SQ%H$^NR71U>]%^;V2W'F)+F-B6 ;#9
M:,'C;U->D45S+&5XI)/:W1=-M;7T.^65X24I2E%^]S7]Z5O>TEI>ROY(XN/X
M>RWFM'4M9U-=3>71I-'N46V$(E5Y-Y?ACMX^7;^.>U9'_"H=1NM-MM#U#Q9<
MWWABW9<:>;1%EDC0Y2-Y@<LHP/X1T'2O2Z*(XRM'9_@M/333Y!+*\)/XHOS]
MZ6M[73UU3ML[HYO3O!_]G^.=7\1?:_,_M"WA@^S>5CR]G?=GG/I@4>!?!_\
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8H **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>img69628308_11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img69628308_11.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %'!F # 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M+.Q.9"./0<5A^-O 'CGQ]\2O"WQ'\#7OA74- M=*C?1[7Q!]J5(S*NXSB*-
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M1(EO;JX9 Z;]LFYCE@, X Y!KM=?\3:;X7AM)=4N?LD5U<QV<3LC,#*YPH)
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MYY<)&1(_DJ^Q2.0S8!P<9P:74/B+X;TO0=/UNZU:"/2;^18K>\^9HV9@Q )
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MS2P6S,0 LLR(8XSR,[F&,\XJ;7OB)X>\-WUE9W^H>7=7T?FVL,,$DS3KD#Y
MBG<26&%')SP#7C7A&'3M+\/>)?#OBGQG>^&[MKR[6\TMOLB_:HY2WSQ>9 TD
M@=3QM))/3' KI+K2;33_ (R?#2QA62:VL]%N(X&NTQ+A(PJLP(&&QUX!SG@4
M^5!=GKUG=I?VD5Q$LJQRJ'59HGB< ^J. RGV(!K!E^(WA^'5YM--[(]Q!,EO
M/)':S/!#*Y 5))E0QHQ) PS Y('6K6H6GB.34M]EJNEV]AE?W%QIDDLN.-W[
MP7"CGG'R<>]>2ZMKL7@GQ7+=>#?$ U&YU/6-NH>#[F,&9YG8+++&"!+$ JEL
MD%",'[N!4I7!L]+U'XG>&]+U>\TJ:^DDU.S91-9VUI-/,NZ/S P2-&)4*02P
M!"Y )!(%7&\<Z%_PC]GK::@D^FWA5;:2W1I6G9LX1$4%V?@_*!N&TY'!KS71
M?&&A^$_C9\26UFYBTWS18&.]N0$C^6U4F/S#_$>H3J=IQG%9OA/Q-J/P[^&]
MA=)9QZ=#KVORM%=:HK"WTZUED)66505."!P"R@[@2P[URA<];T?QUHFN6^IS
M6EV__$L.+V&>WEAF@^7=EHG4. 5Y!QS@XS@UC2_$C1?%'A?5[K0M<FM8X+&2
MY.L+ILTL-L%4,6^9 C.H(/EYW>U><>%M6;6/'GQ+NO[2L]7230XP+S3[=H;>
M7:KKE SON ((W!B"0<5L>%8TA_91G6-%13X>O&PHP,F.4D_4DD_C1RI"N=Q_
MPL+1/#ND^&TU?6_M-UJEJKVMP+1U:^940LRQHIPS%U(CZDL  3Q6GH?C;1?$
M5K?W%G>@)8.4NUNHWMWMR!D^8D@5E&.<D <'TKS&S4-XJ^!A(!(TB[(]O]#A
MJOKV/[:^/ ,<DJ_V-:$I$VUC_HDV3GZ?H.AZ4<J"YWMG\8O"NH:A86-O>7DU
MSJ&3:*NEW>)U!Y=&\K#*.[ X YSBNLU#4;72;&>]O;B.UM(%+RS3,%1%'4DF
MO$/!>KOK7B'X>2:W<6^E)I5H\5@!:WD8U":2 1C#S01HOR<A59R3T)%=I\?-
M/O-1^&=\MI!)=K#/;W%Q;1 EI84E5G '? &<>BFDXJZ0[Z'0:-\0M"UV9H[>
MZFA=;8WO^G6<UH&@! ,JF5%#*,C)&0,CUJOI_P 4_#.I7EG;P:A(#>R-#:3S
M6DT5O<N"1MBF=!&Y.#C:QSVS7-_$#Q1IGQ'^'GB'2/"FJ0:SJ<^FM.L-BYD.
MP%<JQ7[K,#@(V&//'!QSOC#Q-HGCSX=Z#X;\.RQWNN7$UF(+&%LS6'E.AD>5
M1S&$564EL=>,T<H7/2=2^)GAS2=8O-)GOI'U2T"&:SMK2:>8*R%PP2-&++M'
M+#(7(!()&<_QAXPL[KP/9:WI?BM-$L;J:$Q:I'9?:PZLV/+\LC@D_*<C*D'.
M*SO!,:'XV?$J0JID6'2U#8Y ,,F1GWP/R%>39/\ PSJH[+XDP!Z#[5344%SZ
M.M_%&F77B*[T**YW:K:PI<36_EL-L;?=.[&TY] <U3C^('AZ70]3UG^TXTTS
M39I+>ZN)59%CD0@,OS $G) &,Y) &:X*XU:R\$_';7-2UVZBTNPU#18C:W-R
MVU)FC<!T0_Q.,CY!\V"..:\[:X,WP7UVX\B:WE;QDTBBYC=3;L9T/[Z,*7('
M0H 6R>G&*.4+GNVF_%+PYJFM3:3%<W<6H0Q&>:&[TVYM_)C SOD:2-0BX'5B
M :DL?B7X>U'4K*PCO)HY[X,;-KFRG@CN@ "3%(Z!).""-I.001FN%T/Q%)=^
M/-:\17T:QZ[%H9@L?#L4%U'+<1(S2EE:X@B+L7^7"(0!C.:Y/5/'-QXVU;X9
M7<^LZ+>RRZS#.]AI-O)YEEN!^2:4RM@\XVE$)(;&0IHY17/2O#OQ5_M?XA^(
M] FM+I;2R:T2TD32[H.6D5BYF)3"+D#:S!01D@D<UM:A\3_#6EWES;W&H.OV
M658+FX2UF>VMI&( 66=4,<9RPSN88SSBN7\.ZI9Z%\<?&]OJ5U#83:K#IK6"
M7+B,W6V.1&\O/WB&.,#FN'\(6NEZ?X1USPSXI\8WWAV[%S=QWVD,+0&X61F(
M>$/ TLF]2,%2Q)^[V%'*@NSVS6O'&C:#>6MG<W$TMY<QF:*VL;66[E:,8!?9
M$K,%R1\Q&*U[&^M]4L;>\M)5GM;B-9HI4.5=& *L/8@@UX[XXM]%\*26>HZ;
MXP?PQXATC18[:%=3C79?6JY98S'(J[W)3!,9W*3R 2!7J'@[5-1UKPKI5_JU
M@=,U*XMTDGM#D&-B.1@\C_=/(S@\BI:TN4F;-%%%2,**** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M*\FL?B_XK\2?:KKPU\/'UG1X[B2"&^?68+<S;&*EMC+D#(]332N*YZS17E__
M  G_ ,2?^B4_^7';?_$T?\)_\2?^B4_^7';?_$T^5A<]0HKR_P#X3_XD_P#1
M*?\ RX[;_P")H_X3_P")/_1*?_+CMO\ XFCE87/4**\O_P"$_P#B3_T2G_RX
M[;_XFC_A/_B3_P!$I_\ +CMO_B:.5A<]0HKR_P#X3_XD_P#1*?\ RX[;_P")
MH_X3_P")/_1*?_+CMO\ XFCE87/4**\O_P"$_P#B3_T2G_RX[;_XFC_A/_B3
M_P!$I_\ +CMO_B:.5A<]0HKR_P#X3_XD_P#1*?\ RX[;_P")H_X3_P")/_1*
M?_+CMO\ XFCE87/4**\O_P"$_P#B3_T2G_RX[;_XFC_A/_B3_P!$I_\ +CMO
M_B:.5A<]0HKR_P#X3_XD_P#1*?\ RX[;_P")H_X3_P")/_1*?_+CMO\ XFCE
M87/4**\O_P"$_P#B3_T2G_RX[;_XFC_A/_B3_P!$I_\ +CMO_B:.5A<]0HKR
M_P#X3_XD_P#1*?\ RX[;_P")H_X3_P")/_1*?_+CMO\ XFCE87/4**\O_P"$
M_P#B3_T2G_RX[;_XFC_A/_B3_P!$I_\ +CMO_B:.5A<]0HKR_P#X3_XD_P#1
M*?\ RX[;_P")H_X3_P")/_1*?_+CMO\ XFCE87/4**\O_P"$_P#B3_T2G_RX
M[;_XFC_A/_B3_P!$I_\ +CMO_B:.5A<]0HKR_P#X3_XD_P#1*?\ RX[;_P")
MH_X3_P")/_1*?_+CMO\ XFCE87/4*@OK--0L;BUD++'/&T3%#@@,"#@^O->;
M?\)_\2?^B4_^7';?_$T?\)_\2?\ HE/_ )<=M_\ $T<K"XB_!_5)/!<'@Z?Q
M+"_AF,B-DBTW9>20!RPC,WFE,] 6$8)Q[FO3H8E@B2-!M1%"J/0#I7F7_"?_
M !)_Z)3_ .7';?\ Q-'_  G_ ,2?^B4_^7';?_$TVFQ:'J%9GB72[C6_#^I:
M=:W8L+B[MW@2Z,?F>5N4C<%W#)&>.>N*X+_A/_B3_P!$I_\ +CMO_B:/^$_^
M)/\ T2G_ ,N.V_\ B:7*QW.Z\)^';?PCX:TS1K7!AL;=( P7&\@<MC)Y)R?Q
MK6KR_P#X3_XD_P#1*?\ RX[;_P")H_X3_P")/_1*?_+CMO\ XFCE871ZA17E
M_P#PG_Q)_P"B4_\ EQVW_P 31_PG_P 2?^B4_P#EQVW_ ,31RL+GJ%%>7_\
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MKHJ\O_X3_P")/_1*?_+CMO\ XFC_ (3_ .)/_1*?_+CMO_B:5F%T>H45Y?\
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ME8[GJ%8?C;PK!XX\*ZEH5S-);PWL7EF6'&Y>00>>O('%<7_PG_Q)_P"B4_\
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M\O\ ^$_^)/\ T2G_ ,N.V_\ B:/^$_\ B3_T2G_RX[;_ .)HY6%SU"BO+_\
MA/\ XD_]$I_\N.V_^)H_X3_XD_\ 1*?_ "X[;_XFCE87/4**\O\ ^$_^)/\
MT2G_ ,N.V_\ B:/^$_\ B3_T2G_RX[;_ .)HY6%SU"BO+_\ A/\ XD_]$I_\
MN.V_^)H_X3_XD_\ 1*?_ "X[;_XFCE87/4**\O\ ^$_^)/\ T2G_ ,N.V_\
MB:/^$_\ B3_T2G_RX[;_ .)HY6%SU"BO++CXC?$:UMY)I/A41'&I=B/$-N3@
M#)X"Y/X5W/@SQ1;^-?"VFZY:(T<%[")1&Y!*'H5/T((_"E9H+FU1112&%%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110!3UB\_L_2;VZ''D0/+_P!\J3_2N'_9[L_L7P;\,ICE
MX7E/N7E=L_K72_$";R/ ?B24=4TVY;\HF-9OP=A\GX5>$U]=,@;\T!_K5?9%
MU.QHHHJ1A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% "$!@01D&O,?V<28?AC!8DY^P7MW:CVQ,
MQ_\ 9J]/KS#X!_N]'\5P=H/$M_&/P93_ %JELQ=3T^BBBI&%%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M .?ZV_[_ "_XT 7**I_VSI__ #_6W_?Y?\:/[9T__G^MO^_R_P"- %RBJ?\
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ME_QH_MG3_P#G^MO^_P O^- %RBJ?]LZ?_P _UM_W^7_&C^V=/_Y_K;_O\O\
MC0!<HJG_ &SI_P#S_6W_ '^7_&C^V=/_ .?ZV_[_ "_XT 7**I_VSI__ #_6
MW_?Y?\:/[9T__G^MO^_R_P"- %RBJ?\ ;.G_ //];?\ ?Y?\:/[9T_\ Y_K;
M_O\ +_C0!<HJG_;.G_\ /];?]_E_QH_MG3_^?ZV_[_+_ (T 7**I_P!LZ?\
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MT 7**I_VSI__ #_6W_?Y?\:/[9T__G^MO^_R_P"- %RBJ?\ ;.G_ //];?\
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M^_R_XTQ%RBJ?]LZ?_P _UM_W^7_&C^V=/_Y_K;_O\O\ C2&7**I_VSI__/\
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M_?Y?\:/[9T__ )_K;_O\O^- %RBJ?]LZ?_S_ %M_W^7_ !H_MG3_ /G^MO\
MO\O^- %RBJ?]LZ?_ ,_UM_W^7_&C^V=/_P"?ZV_[_+_C0!<HJG_;.G_\_P!;
M?]_E_P :/[9T_P#Y_K;_ +_+_C0!<HJG_;.G_P#/];?]_E_QJ:WO+>\W>1/'
M-MZ^6X;'UQ0!-1110 4444 %%%% !1110 4444 %%%% !1110 4444 5=4_Y
M!EW_ -<7_P#036%X5\-:1)X7T=FTJR9FLX26-NA).P<]*W=4_P"09=_]<7_]
M!-4_"?\ R*NC?]>4/_HM:?0!_P#PB^C?] FQ_P# 9/\ "C_A%]&_Z!-C_P"
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MO^@38_\ @,G^%'_"+Z-_T";'_P !D_PK3HH S/\ A%]&_P"@38_^ R?X4?\
M"+Z-_P! FQ_\!D_PK3HH S/^$7T;_H$V/_@,G^%'_"+Z-_T";'_P&3_"M.B@
M#,_X1?1O^@38_P#@,G^%'_"+Z-_T";'_ ,!D_P *TZ* ,S_A%]&_Z!-C_P"
MR?X4?\(OHW_0)L?_  &3_"M.B@#,_P"$7T;_ *!-C_X#)_A1_P (OHW_ $";
M'_P&3_"M.B@#,_X1?1O^@38_^ R?X4?\(OHW_0)L?_ 9/\*TZ* ,S_A%]&_Z
M!-C_ . R?X4?\(OHW_0)L?\ P&3_  K3HH S/^$7T;_H$V/_ (#)_A1_PB^C
M?] FQ_\  9/\*TZ* ,S_ (1?1O\ H$V/_@,G^%'_  B^C?\ 0)L?_ 9/\*TZ
M* ,S_A%]&_Z!-C_X#)_A1_PB^C?] FQ_\!D_PK3HH S/^$7T;_H$V/\ X#)_
MA1_PB^C?] FQ_P# 9/\ "M.B@#,_X1?1O^@38_\ @,G^%'_"+Z-_T";'_P !
MD_PK3HH S/\ A%]&_P"@38_^ R?X4?\ "+Z-_P! FQ_\!D_PK3HH S/^$7T;
M_H$V/_@,G^%'_"+Z-_T";'_P&3_"M.B@#,_X1?1O^@38_P#@,G^%'_"+Z-_T
M";'_ ,!D_P *TZ* ,S_A%]&_Z!-C_P" R?X4?\(OHW_0)L?_  &3_"M.B@#,
M_P"$7T;_ *!-C_X#)_A1_P (OHW_ $";'_P&3_"M.B@#,_X1?1O^@38_^ R?
MX4?\(OHW_0)L?_ 9/\*TZ* ,S_A%]&_Z!-C_ . R?X4?\(OHW_0)L?\ P&3_
M  K3HH S/^$7T;_H$V/_ (#)_A1_PB^C?] FQ_\  9/\*TZ* ,S_ (1?1O\
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M\*TZ* ,S_A%]&_Z!-C_X#)_A1_PB^C?] FQ_\!D_PK3HH S/^$7T;_H$V/\
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M^ R?X4?\(OHW_0)L?_ 9/\*TZ* ,S_A%]&_Z!-C_ . R?X4?\(OHW_0)L?\
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MV/\ X#)_A67I^FVFF^.KA;2UAM5;38RPAC" _O7ZX%=/6!'_ ,CY-_V#8_\
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M  DFH?WH/^_1_P#BJ/\ A)-0_O0?]^C_ /%46"YUU%<C_P ))J']Z#_OT?\
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MQ_M46"YV=%<C_P ))J']Z#_OT?\ XJC_ (234/[T'_?H_P#Q5%@N==17(_\
M"2:A_>@_[]'_ .*H_P"$DU#^]!_WZ/\ \518+G745R/_  DFH?WH/^_1_P#B
MJBM?%.HSV\<A:W!89XB/_P 518+G9T5R/_"2:A_>@_[]'_XJC_A)-0_O0?\
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M*** "BBB@"KJG_(,N_\ KB__ *":\X\-_P#(NZ7_ ->L7_H KT?5/^09=_\
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M0 4444 %2^$O^1TO?^P?'_Z,>HJE\)?\CI>_]@^/_P!&/2&CNZ***DH****
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M97*^./#NH^*OL%A$MK%IJ74-S/</,PF^1]Q5$"$'.!\Q;N>*ZJGT *E\)?\
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M+CN+'Y;B\KJ^QQE-P>Z[-=TUHUYIE;5/^09=_P#7%_\ T$UYQX;_ .1=TO\
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M#&+_ .*H_P"%Q^ _^ART+_P8Q?\ Q5')+L'L:O\ *_N.QJO;_P#'S=?[R_\
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MC_A<?@/_ *'+0O\ P8Q?_%4<DNP>QJ_RO[CL:*X[_A<?@/\ Z'+0O_!C%_\
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MW/\ WX?_  H\F?\ Y];G_OP_^% #:*=Y,_\ SZW/_?A_\*/)G_Y];G_OP_\
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M *EU_K+7_KK_ .RM5FH;J&?S+7_1KC_6_P#/!_[K>U6/)G_Y];G_ +\/_A0
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MK<_]^'_PH JR?\?T'_7-_P":U8J&2&;[=!_HUQ_JW_Y8/ZK[58\F?_GUN?\
MOP_^% #:*=Y,_P#SZW/_ 'X?_"CR9_\ GUN?^_#_ .% #:*=Y,__ #ZW/_?A
M_P#"CR9_^?6Y_P"_#_X4 5--_P"0?:_]<E_D*LU#IT,W]GVO^C7!_=+T@?T'
MM5CR9_\ GUN?^_#_ .% #:*=Y,__ #ZW/_?A_P#"CR9_^?6Y_P"_#_X4 -JL
MW_(0B_ZY/_-:M^3/_P ^MS_WX?\ PJNT,W]H1?Z-<?ZI_P#E@_JOM0!-13O)
MG_Y];G_OP_\ A1Y,_P#SZW/_ 'X?_"@!M%.\F?\ Y];G_OP_^%'DS_\ /K<_
M]^'_ ,* (Y/]6WT-167_ !YP?]<U_E4\D,_EM_HUST/_ "P?_"H[*&;['!_H
MUP?W:_\ +!_3Z4 244[R9_\ GUN?^_#_ .%'DS_\^MS_ -^'_P * &T4[R9_
M^?6Y_P"_#_X4>3/_ ,^MS_WX?_"@"J?^0@O_ %R/\Q5BH3#-_:"_Z-<?ZH_\
ML']1[58\F?\ Y];G_OP_^% #:*=Y,_\ SZW/_?A_\*/)G_Y];G_OP_\ A0 V
MH[C_ (]Y?]T_RJ;R9_\ GUN?^_#_ .%1W$,WV>7_ $:X^Z?^6#^GTI -M_\
MCWB_W1_*I*;;PS?9XO\ 1KC[H_Y8/Z?2I/)G_P"?6Y_[\/\ X4P&T4[R9_\
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M ##C_P!=1_(U7JQ_S#C_ -=1_(U7I(F/4****905+:_\?4/^^O\ .HJEM?\
MCZA_WU_G0]A2V8EQ_P ?$O\ O'^=1U)<?\?$O^\?YU'0M@6P4444#"K#?\@Y
M/^NK?R%5ZL-_R#D_ZZM_(4F2^A7HHHIE!1110!/I_P#Q_6W_ %T7^8J%_O-]
M:FT__C^MO^NB_P Q4+_>;ZTNI/VA****904444 6'_Y!\/\ UU?^257JP_\
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M4 %%%% #)O\ 5/\ [IJ'3?\ D'6O_7)?Y"IIO]4_^Z:ATW_D'6O_ %R7^0H
MLT444 %%%% %0_\ (67_ *X'_P!"%6ZJ'_D++_UP/_H0JW0 4444 %0WG_'I
M/_N-_*IJAO/^/2?_ '&_E0 6?_'I!_N+_*IJAL_^/2#_ '%_E4U !1110 5@
M1_\ (^3?]@V/_P!&O6_6!'_R/DW_ &#8_P#T:] &_1110 5\G?M>?&R>WG;P
M/HMP8AM#:E-&<-SR(AZ<<GZBOK&ORZ^(&H7&I>./$%U=,S3O?S!BW7ARH_0"
MOB.*L;4PV%C1I.SJ.S?DM_O/TO@3+*6.Q\J]975))I>;V?RL_G8Z'X(_">Y^
M+GC2+35WPZ9 !+>W"C[D>>@_VCT%?<GCS7M.^"?PJNY=)M8;<VD M=+LPI*R
M7+D1PJ<<X+LNX]ADURW[)O@B+PI\*;.]:'9?ZLS7<S'J5)Q'CVVA3^-='\9M
M>U/0[7P]_96F0ZO-<:B(I;6>$2!H1$[R8)^Z=JGFO4X;RV&#P\)R7O3U?IT1
MYO&F=U,QQLZ,)?NZ;:7KLY>>NWD><:U\)K'X=_!F&2>35O$.N(!+96C2K(!J
M4Y_UJC;\Q4NW+$_(I[@5SUM\/1X!\8>'O"MO=-#JW]@1W6KW12:>/4YS<3,D
M<2Y PLQF=E++E709&*[?QA^U9X:\&_:TN=)GN38/$ MN5;;N5L'I\I&&&/3'
MK1<?M6:!%;:7>2:#?O)>MY5L%4,^\J&9<XX 1D;/OCM7VR]O;6-[GYJ_8WTE
ML8/@OP0FL>.-8\A[JZ713<:?;S79=1]KG#"^O>P49:1%0;@<@@J.G*WVDKJ5
MQ<7J07<<'BUAIFF6X221K32(%9KB[9>,/-PFTD;=P8;NE>Z3?$J74="\07UA
M9BT6'1WU.SF<JXG4IN1R,<=N#63K?QJ/@>%8]3T^^U&YN)9ECFC@$42!45@J
MG'*$;B">NTTHSJ-[%.$+;GDG]O7'CRQ\.:8(;Z&WUYIK<1B-]FE:39E5>*-B
M/FN'PC&1@!@A0."3Z!\(OA/9^)=1U#QYK4-VD=[JBWVB:?+,P2VM80$MGV\?
M?5%E"D<!P#G&:ETO]I;3]5\2:;X<T[2O/N[F/S6F9U")$4=B< ?>RN-OOFK>
MF?M 0:;INE0:A:327,]K;WDDRJH0),BN%50!PI;RQ_NY.:<O:VY8QL*/L[WD
M[E70O&FA^*_CIJFL:A?"WL=*C_L'1_/B>-)YW0RW#@LH 91$5#=""1GFK/@=
MG\*ZQ\1?%UAIEU_PC5R+6'3=.C4F2\GB\WS9D#<@2&6-03_SS)QZTM6_:0T/
M4<6Q\,_;K=)MK&]9!&, L#\RG' SGMBMW4/C8/"^L:G'J-N9;* 12Q+!@%(9
M  K'U^;(X]:SE&=K*.Z-J4Z<9J<]4G=]+^1Y1\/_ -E;5_B-\2+KXE_%K8;R
M>836GAY&WK @_P!6LK=/E 'RCOSGG%?62JL:A54*JC 4#  KS#2_CG:WGBPZ
M!<Z>]M=2745O$3("#O17';D[64_\"QVKU&N:ISW7.?19EG6)SF<95G[L%RQB
MM(Q2Z)?TWU95U3_D&7?_ %Q?_P!!-?C/??\ '[<?]=&_F:_9C5/^09=_]<7_
M /037XSWW_'[<?\ 71OYFO3RW>1Z>0?'4^7ZD-%%%>X?9!1110!8_P"8<?\
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M]_KK+_KO_P"R-5N@ HHHH **** *>E_\>[_]=YO_ $8U7*IZ7_Q[O_UWF_\
M1C5<H **** "JEY_Q]6'_75O_1;U;JI>?\?5A_UU;_T6] %NBBB@ HHHH *I
MZ5_QYC_KI)_Z&U7*IZ5_QYC_ *Z2?^AM0!<HHHH **** *EU_P ?UE_O-_Z"
M:MU4NO\ C^LO]YO_ $$U;H **** "BBB@"GI/_(/B_X%_,U<JGI/_(/B_P"!
M?S-7* "BBB@ JI<?\A"T^C_R%6ZJ7'_(0M/H_P#(4 6Z*** "BBB@ JGI/\
MR#+;_<%7*IZ3_P @RV_W!0!<HHHH **** *<W_(4M?\ KE)_-*N53F_Y"EK_
M -<I/YI5R@ HHHH **** *>C_P#()LO^N*?^@BKE4]'_ .039?\ 7%/_ $$5
M<H **** "J<G_(6@_P"N$G_H25<JG)_R%H/^N$G_ *$E %RBBB@ HHHH 9-_
MJG_W34.F_P#(.M?^N2_R%33?ZI_]TU#IO_(.M?\ KDO\A0!9HHHH **** *A
M_P"0LO\ UP/_ *$*MU4/_(67_K@?_0A5N@ HHHH *AO/^/2?_<;^535#>?\
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MY_?:)?\ GH__ 'T:_0GXQ?\ )*_%?_8-G_\ 0#7YY5TTMF8U-R3[1+_ST?\
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MJ_\ NG^51T@)/M$O_/1_^^C1]HE_YZ/_ -]&HZ*8$GVB7_GH_P#WT:/M$O\
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M -^E_P *MT4 5/[)LO\ GSM_^_2_X4?V39?\^=O_ -^E_P *MT4 5/[)LO\
MGSM_^_2_X54TG2[)M-MB;.W)V#_EDO\ A6M5/2?^09;?[@H 7^R;+_GSM_\
MOTO^%']DV7_/G;_]^E_PJW10!4_LFR_Y\[?_ +]+_A1_9-E_SYV__?I?\*MT
M4 9,VEV7]J6H^QV^/*D_Y9+ZI[5;_LFR_P"?.W_[]+_A23?\A2U_ZY2?S2KE
M %3^R;+_ )\[?_OTO^%']DV7_/G;_P#?I?\ "K=% %3^R;+_ )\[?_OTO^%'
M]DV7_/G;_P#?I?\ "K=% &3I.EV3:59DV=N3Y*?\LE_NCVJW_9-E_P ^=O\
M]^E_PI-'_P"039?]<4_]!%7* *G]DV7_ #YV_P#WZ7_"C^R;+_GSM_\ OTO^
M%6Z* *G]DV7_ #YV_P#WZ7_"JDFEV7]K0#[';X\B3_EDO]Y/:M:J<G_(6@_Z
MX2?^A)0 O]DV7_/G;_\ ?I?\*/[)LO\ GSM_^_2_X5;HH J?V39?\^=O_P!^
ME_PH_LFR_P"?.W_[]+_A5NB@"E-I5EY3_P"AV_W3_P LE_PJ'3=+LCI]J39V
MY/E+_P LE]![5H3?ZI_]TU#IO_(.M?\ KDO\A0 W^R;+_GSM_P#OTO\ A1_9
M-E_SYV__ 'Z7_"K=% %3^R;+_GSM_P#OTO\ A1_9-E_SYV__ 'Z7_"K=% &4
M=+LO[44?8[?'DG_EDO\ >'M5K^R;+_GSM_\ OTO^%!_Y"R_]<#_Z$*MT 5/[
M)LO^?.W_ ._2_P"%']DV7_/G;_\ ?I?\*MT4 5/[)LO^?.W_ ._2_P"%17FE
M67V6;_0[?[C?\LE]/I6A4-Y_QZ3_ .XW\J *MGI5E]EA_P!#M_N+_P LE]/I
M4O\ 9-E_SYV__?I?\*EL_P#CT@_W%_E4U %3^R;+_GSM_P#OTO\ A1_9-E_S
MYV__ 'Z7_"K=% %3^R;+_GSM_P#OTO\ A6-:VL-KX\G$,,<0.FQYV*%S^]?T
MKI*P(_\ D?)O^P;'_P"C7H WZ^3?B[I_C+4OVV- A\#:QI>B:R/ TS/<:M9M
M=1&+[:-RA%93NSMYSV-?659C>&=)D\11Z^VFVK:W';&S34#$OGK 6W&,/C.W
M=SCIFKC+E=SMPN(^K2E*U[IK[SXM_:,^ ]WX1^#?BK6O&/B >+/%'C+Q'H<6
MJW4%L+2W6".X6..&*,$E0%9OF)R>*R_BQ-XB^%^I?#'X2>)7NM6L+3QSI-[X
M6\0R@M]JT])2IMIF[30%T7)^\A4]J^YO$'AG2?%E@MCK6FVNJV:RI.(+R)9$
M$B,&1\$8RK $'L11KGAC2/$RV8U?3+34Q97*7EM]JA63R9D.4D3(^5AV(YK5
M5>YZE+-FHQC5CS6;?1=$E;M9*UMK'PMX#O/$%O\ $;XS+I.M?"W3;?\ X3>_
M+Q^.$9KLM\G*8<?N\8Q[AJ]7U7Q)H7A']LGP3K%]J.FZ=X?U;P)-IVG:@DJ1
MV,TZ72R&.-\[?N\@9YR*]CUC]GGX8>(-4N]3U/X?^&]0U&[D::XNKG3(9))7
M8Y+,Q7))/<UKZM\*?!FN^$[3PQJ/A71[WP[:*JVVESV4;V\ ' V(1A<>V*'4
MBQU,PHU))V>JL]NUK^>W4^(?VBM6L?&%]^T_KNBW<&JZ+!X;T/37OK2020?:
M%N0S1!QP6 (S@\9J+XL? GXC:?\ !OQ5X0UC5WE^#W@_1KC7]&NA)_I5^YA+
M6UE,<_<MW#MTY'E^VW[EM?A;X.L?!\OA2V\+Z1;^&9O]9I,=E&MM)R#EHP,$
MY .2.PK;U30]/UK1[G2=0LH+W3+F$V\UG/&'BDC(P493P5(XQ35;ELDC2.<>
MR4(TXZ1:WWT44FNST?I?YGQG\([GPW9_'S1W^([V<9D\!Z(/!TFLE1:A!;C[
M6(2_R"7S,9Q\VWVJ34OAOX3^-7[0'Q-\,>"#:?\ "(ZIX06W\0W6EA38QZR)
M]UI(I3Y#,BC<<<\'/.:^K_$GPQ\(^,O#]KH>N^&=*U?1[152WLKRT26*$* J
MA%(^7  '&.!5_P *^#]"\#:1'I7AW1['0]-C.5M-/MTAC!/4[5 &?>I]IU6Y
MC+,HW=6":G9*U]%;KZZ7MWUOT/AS1?BY/\9+CPAIWCF.6TTSX0V<^N>.?.4A
M9M2M&>"UCYX8L4:;'?=BN%\+^)O&'@/Q1HGQ[UKP)XHT^\O]7FOO$FLSK&;!
M]$N_+2&)0)"X$*B)ER@YSGM7Z'7WPQ\(ZE;ZY;W7AG2KB#79$EU6.2T0K?.F
M-K3#'SD8&-V>E;MQI=E>::^G7%I!/I\D7D/:R1JT31XQL*D8*XXQTJO:I;(W
M6;4H7C"E[KT:OT>K2]6WOT4>Q\>_M:?;?&/Q*T2W^#;7,OQ:ATB>;4-1TF9$
MC31Y(R1%.Q!!>1BIA[AOFX&#7M'[.MQ\/-0^ .D1^%;5;'PS;6[VUY:7WRW%
MO..+A+G//G;\[B>I.1P17HOACP#X;\%R7DF@:%I^CR7FS[0]E;K$TVQ=J;B!
MR%7@9Z#@5X;\7O"=U\#_ !K>_%/P[IKZIX2U8I'XX\-P1>9YJ#A=1AC[RQ_Q
M@??7GJ,UG)^TAR+\?U.=5X8JE'"1NN79]WV?W^[VVZZ>BZ->6'BOQ-IFHVAM
M=.T72%D6T7<JS7)*[20O58P,]>35/7;JWC\2:3XDBFTS5]&,T=O:V</RR1NY
M ,@ X9@?7H/2NU\.Z+X7OK2PUO1M/T]X9XUN+6\MX%&Y&7*L#C(R#5NW\'Z)
M:ZE_:$.DVD5[G=YZPJ&SZ_7WKQGA:KC9VO>_Y=/+MZ:GG^VA&6SVM;^OS+VJ
M?\@R[_ZXO_Z":_,NOTTU3_D&7?\ UQ?_ -!-?F77N4NIY=0****Z#$**** )
M/^7<_P"]_2HZD_Y=S_O?TJ.@84444""G1_ZQ?J*;3H_]8OU% PD_UC?6FTZ3
M_6-]:;0(**** "I/^7<?[Q_D*CJ3_EW'^\?Y"D,CHHHIB"BBB@"2#_71_P"\
M/YTQOO&GP?ZZ/_>'\Z8WWC0,2BBB@04444 2-_Q[I_O-_(5'4C?\>Z?[S?R%
M1T#"BBB@05);_P#'Q'_O#^=1U);_ /'Q'_O#^= R.BBB@04444 %2M_Q[Q_5
MOZ5%4K?\>\?U;^E R*BBB@04444 26_^N3ZU'4EO_KD^M1T#"BBB@04444 2
M/_J8_P :CJ1_]3'^-1T#"BBB@05);_ZT?C_*HZDM_P#6C\?Y4#(Z***!!111
M0 5]C?L<_P#)-=2_["DG_HJ*OCFOL;]CG_DFNI?]A23_ -%15E5^$TAN>\44
M45R&X4444 <=\8O^25^*_P#L&S_^@&OSRK]#?C%_R2OQ7_V#9_\ T U^>5=-
M+9F-3<****W,@HHHH DD_P!7%_N_U-1U))_JXO\ =_J:CH&%%%% @J2#[Q_W
M6_D:CJ2#[Q_W6_D:!D=%%% @HHHH *DF^['_ +O]34=23?=C_P!W^IH&1T44
M4""BBB@"2'J_^Z?Y5'4D/5_]T_RJ.@84444""BBB@"2;^#_=%1U)-_!_NBHZ
M!A1110(*DA_Y:?[IJ.I(?^6G^Z:!D=%%% @HHHH *EG^\G^X/Y5%4L_WD_W!
M_*@9%1110(**** )(ONR_P"[_45'4D7W9?\ =_J*CH **** "BBB@"2;[X_W
M5_D*CJ2;[X_W5_D*CH&%%%% @J2/_5R_[O\ 45'4D?\ JY?]W^HH&1T444""
MBBB@ J2X_P!9^ _D*CJ2X_UGX#^0H CHHHH **** /<OV/\ _DJ%W_V#)?\
MT..OLROC/]C_ /Y*A=_]@R7_ -#CK[,KDJ?$=$-@HHHK(L**** *>D_\@^+_
M (%_,U<JGI/_ "#XO^!?S-7* "BBB@ JI<?\A"T^C_R%6ZJ7'_(0M/H_\A0!
M;HHHH **** "J>D_\@RV_P!P5<JGI/\ R#+;_<% %RBBB@ HHHH IS?\A2U_
MZY2?S2KE4YO^0I:_]<I/YI5R@ HHHH **** *>C_ /()LO\ KBG_ *"*N53T
M?_D$V7_7%/\ T$5<H **** "J<G_ "%H/^N$G_H25<JG)_R%H/\ KA)_Z$E
M%RBBB@ HHHH 9-_JG_W34.F_\@ZU_P"N2_R%33?ZI_\ =-0Z;_R#K7_KDO\
M(4 6:*** "BBB@"H?^0LO_7 _P#H0JW50_\ (67_ *X'_P!"%6Z "BBB@ J&
M\_X])_\ <;^535#>?\>D_P#N-_*@ L_^/2#_ '%_E4U0V?\ QZ0?[B_RJ:@
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MG_/[\)?Y"^OX;^?\S$IT?^L7ZBMG_A'T_P">[?\ ?'_UZ5?#Z!E/GMU_N?\
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M-;D>@(LBGSVX(/W/_KTW_A'T_P">[?\ ?'_UZ/\ 6#+-_:_A+_(?U_#6^/\
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MPY9_S^_"7^0OK^&_G_,Q**V_^$?3_GNW_?'_ ->C_A'T_P">[?\ ?'_UZ/\
M6'+/^?WX2_R#Z_AOY_S,2I6_X]X_JW]*UO\ A'T_Y[M_WQ_]>G-H*&-5\]N"
M?X/I[T?ZP99_S]_"7^0_K^&_G_,PJ*V_^$?3_GNW_?'_ ->C_A'T_P">[?\
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M\-_/^9B5)-]V/_=_J:U_^$?3_GNW_?'_ ->G2: C!/W[<+C[GN?>C_6#+/\
MG[^$O\A_7\-_/^9A45M_\(^G_/=O^^/_ *]'_"/I_P ]V_[X_P#KT?ZPY9_S
M^_"7^0OK^&_G_,Q**V_^$?3_ )[M_P!\?_7H_P"$?3_GNW_?'_UZ/]8<L_Y_
M?A+_ "#Z_AOY_P S(AZO_NG^51UNQZ"BEOW[?=(^Y_\ 7IO_  CZ?\]V_P"^
M/_KT?ZP99O[7\)?Y#^OX;^?\S$HK;_X1]/\ GNW_ 'Q_]>C_ (1]/^>[?]\?
M_7H_UARS_G]^$O\ (7U_#?S_ )F)16W_ ,(^G_/=O^^/_KT?\(^G_/=O^^/_
M *]'^L.6?\_OPE_D'U_#?S_F9$W\'^Z*CK=DT!&V_OVX&/N?_7IO_"/I_P ]
MV_[X_P#KT?ZP98M'5_"7^0_K^&_G_,Q**V_^$?3_ )[M_P!\?_7H_P"$?3_G
MNW_?'_UZ/]8<L_Y_?A+_ "%]?PW\_P"9B5)#_P M/]TUK_\ "/I_SW;_ +X_
M^O3H]!1=W[]N1C[G_P!>C_6#+'M5_"7^0UC\-_/^9A45M_\ "/I_SW;_ +X_
M^O1_PCZ?\]V_[X_^O1_K#EG_ #^_"7^0OK^&_G_,Q**V_P#A'T_Y[M_WQ_\
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M;^?\S$J2/_5R_P"[_45K_P#"/I_SW;_OC_Z].70$"N//;D?W/<>]'^L&6/\
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MB_);Y\D_QM_>'M5K=?\ ]RW_ .^V_P * +E%4]U__<M_^^V_PHW7_P#<M_\
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MEH$!(')P.F3D_C0!+JG_ "#+O_KB_P#Z":_/BW_U$?\ NC^5?H/JG_(,N_\
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M% %75/\ D&7?_7%__037Y\6_^HC_ -T?RK]";^-IK&YC09=XV51ZD@U\:P_
M7QXL2*= DR% /[^+_P"+KXSB7#UL1"DJ,'*S>ROV/ S:E4JQAR1;WV.#HKO_
M /A0_CO_ * $G_?^+_XNC_A0_CO_ * $G_?^+_XNOA/[-QO_ #YE_P" L^;^
MJ8C_ )]O[F<!17?_ /"A_'?_ $ )/^_\7_Q='_"A_'?_ $ )/^_\7_Q=']FX
MW_GS+_P%A]4Q'_/M_<S@OX?QIM>@?\*'\=;<?V!)U_Y[Q?\ Q=)_PH?QW_T
M)/\ O_%_\752RW&Z?N9?^ LIX7$?\^W]S. HKO\ _A0_CO\ Z $G_?\ B_\
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M_P#\*'\=_P#0 D_[_P 7_P 71_PH?QW_ - "3_O_ !?_ !=3_9N-_P"?,O\
MP%D_5,1_S[?W,X"BN_\ ^%#^._\ H 2?]_XO_BZ/^%#^._\ H 2?]_XO_BZ/
M[-QO_/F7_@+#ZIB/^?;^YG K]X?6DKOU^ _CO</^)!)_W_B_^+H_X4/X[_Z
M$G_?^+_XNJ_LW&\J_<R_\!97U3$6_AO[F<!17?\ _"A_'?\ T )/^_\ %_\
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MNA?@1XZ5@3H$G_?^+_XNJAEN-YE^YE_X"RHX3$77[M_<S@**[_\ X4/X[_Z
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M^)!)_P!_XO\ XND_X4/X[_Z $G_?^+_XNJ_LW&\J_<R_\!?D5]4Q%OX;^YG
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M &;C?^?,O_ 63]4Q'_/M_<S@**[_ /X4/X[_ .@!)_W_ (O_ (NC_A0_CO\
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M_P#H 2?]_P"+_P"+JGEN-Y5^YE_X"ROJF(LOW;^YG 45W_\ PH?QW_T )/\
MO_%_\71_PH?QW_T )/\ O_%_\74_V;C?^?,O_ 63]4Q'_/M_<S@**[__ (4/
MX[_Z $G_ '_B_P#BZ/\ A0_CO_H 2?\ ?^+_ .+H_LW&_P#/F7_@+#ZIB/\
MGV_N9P3=OI3:] ;X#^.N/^)!)T_Y[Q?_ !=)_P *'\=_] "3_O\ Q?\ Q=5+
M+<;?^#+_ ,!94L)B+_PW]S. HKO_ /A0_CO_ * $G_?^+_XNC_A0_CO_ * $
MG_?^+_XNI_LW&_\ /F7_ ("R?JF(_P"?;^YG 4J]_I7??\*'\=_] "3_ +_Q
M?_%T#X#^.^?^)!)_W_B_^+JHY;C;_P &7_@+*CA,1?\ AO[F<!17?_\ "A_'
M?_0 D_[_ ,7_ ,71_P *'\=_] "3_O\ Q?\ Q=3_ &;C?^?,O_ 63]4Q'_/M
M_<S@**[_ /X4/X[_ .@!)_W_ (O_ (NC_A0_CO\ Z $G_?\ B_\ BZ/[-QO_
M #YE_P" L/JF(_Y]O[F<!3F[?2N]_P"%#^._^@!)_P!_XO\ XNE;X#^.N/\
MB02=/^>\7_Q=4LMQO*_W,O\ P%E?5<19_NW]S//Z*[__ (4/X[_Z $G_ '_B
M_P#BZ/\ A0_CO_H 2?\ ?^+_ .+J?[-QO_/F7_@+)^J8C_GV_N9P%%=__P *
M'\=_] "3_O\ Q?\ Q='_  H?QW_T )/^_P#%_P#%T?V;C?\ GS+_ ,!8?5,1
M_P ^W]S."7HWTIM>@+\"/'0S_P 2"3I_SWB_^+I/^%#^._\ H 2?]_XO_BZI
MY;C;+]S+_P !93PF(LOW;^YG 45W_P#PH?QW_P! "3_O_%_\71_PH?QW_P!
M"3_O_%_\74_V;C?^?,O_  %D_5,1_P ^W]S. HKO_P#A0_CO_H 2?]_XO_BZ
M/^%#^._^@!)_W_B_^+H_LW&_\^9?^ L/JF(_Y]O[F<$W7\!_*FUW[? CQT?^
M8!)_W_B_^+H_X4/X[_Z $G_?^+_XNJEEN-YG^YE_X"RI83$7?[M_<S@**[__
M (4/X[_Z $G_ '_B_P#BZ/\ A0_CO_H 2?\ ?^+_ .+J?[-QO_/F7_@+)^J8
MC_GV_N9P%.7HWT_K7>_\*'\=_P#0 D_[_P 7_P 72CX#^.N?^)!)T_Y[Q?\
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M=KC_ +]__7H_M#_IVN/^_?\ ]>@"Y4-Y_P >D_\ N-_*H?[0_P"G:X_[]_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
00 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>img69628308_12.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img69628308_12.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" )_!;@# 2(  A$! Q$!_\0
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MB&PMK:=B?F$]PT0 ]B$;/Z4 6J*R/M'B+_H%Z7_X,I/_ (Q1]H\1?] O2_\
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M*R/M'B+_ *!>E_\ @RD_^,4?:/$7_0+TO_P92?\ QB@#7HK(^T>(O^@7I?\
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M$7_0+TO_ ,&4G_QB@#7HK(^T>(O^@7I?_@RD_P#C%'VCQ%_T"]+_ /!E)_\
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MB+_H%Z7_ .#*3_XQ1]H\1?\ 0+TO_P &4G_QB@#7HK(^T>(O^@7I?_@RD_\
MC%'VCQ%_T"]+_P#!E)_\8H UZ*S[2;6'N +RQL88<'+PWKR-GM\IB4?K6A0
M4444 %%%% !164]QX@#L$TS3"N>"=1D!(^GD4W[1XB_Z!>E_^#*3_P",4 :]
M%9'VCQ%_T"]+_P#!E)_\8H^T>(O^@7I?_@RD_P#C% &O161]H\1?] O2_P#P
M92?_ !BC[1XB_P"@7I?_ (,I/_C% &O161]H\1?] O2__!E)_P#&*/M'B+_H
M%Z7_ .#*3_XQ0!KT5D?:/$7_ $"]+_\ !E)_\8H^T>(O^@7I?_@RD_\ C% &
MO161]H\1?] O2_\ P92?_&*/M'B+_H%Z7_X,I/\ XQ0!KT5D?:/$7_0+TO\
M\&4G_P 8H^T>(O\ H%Z7_P"#*3_XQ0!KT5D?:/$7_0+TO_P92?\ QBC[1XB_
MZ!>E_P#@RD_^,4 :]%9'VCQ%_P! O2__  92?_&*/M'B+_H%Z7_X,I/_ (Q0
M!KT5D?:/$7_0+TO_ ,&4G_QBC[1XB_Z!>E_^#*3_ .,4 :]%9'VCQ%_T"]+_
M /!E)_\ &*/M'B+_ *!>E_\ @RD_^,4 :]%9'VCQ%_T"]+_\&4G_ ,8H^T>(
MO^@7I?\ X,I/_C% &O161]H\1?\ 0+TO_P &4G_QBC[1XB_Z!>E_^#*3_P",
M4 :]%9'VCQ%_T"]+_P#!E)_\8H^T>(O^@7I?_@RD_P#C% &O161]H\1?] O2
M_P#P92?_ !BC[1XB_P"@7I?_ (,I/_C% &O161]H\1?] O2__!E)_P#&*/M'
MB+_H%Z7_ .#*3_XQ0!KT5D?:/$7_ $"]+_\ !E)_\8H^T>(O^@7I?_@RD_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH ***165E#*00>A!H 6BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N
M'O\ _A:?]HW/]G?\(;]A\U_L_P!H^U>9Y>3MWXXW8QG'&:[BN'O_ (O^!-,U
M&YL+S7?+NK65X9D^R3G:ZDAAD)@X(/2@#E_V<?\ DGFH?]A63_T5%7L%>/\
M[./_ "3S4/\ L*R?^BHJ]@H **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "J]C_QXP_[@JQ5>Q_X\8?\ <% %BBBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHKA[_ .+_ ($T
MS4;FPO-=\NZM97AF3[).=KJ2&&0F#@@]* .7_9Q_Y)YJ'_85D_\ 145>P5X_
M^SC_ ,D\U#_L*R?^BHJ]@H **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HIK[]A\O;N[;NE06TMQ*S%
MQ$%5BIVYSQ0!9HHHH **** "BJ5U;H;BW.7^>0AL2,,C8Q]?85<50BA5S@=,
MG- "T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %5['_CQA_W!5BJ]C_QXP_[@H L4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MBG;$?F=QDQ,!Q[D4 3T444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M)]R:\WO[7[#J-S9_:/C5<>1*\7G6[[XY-I(W(W=3C(/<4 ;'[./_ "3S4/\
ML*R?^BHJ]@KQ_P#9Q_Y)YJ'_ &%9/_145>P4 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!P?BP%M<P
M,?ZI>IQZUC2J<*<J<*!PP-;/B[_D-_\ ;)?ZU@U\OBI)59JW4XYOWF>FZ=_R
M!+3_ *]D_P#014]G_P >4'_7-?Y5Y6OQ<^PL-,_L/?Y!^S^9]KQNV_+G&SCI
MTS5FV^+6S5(M*_L3.)A;>;]K_P!K;NQL_'&:^HI4Y<D?0[XTIV6AZC69XB_Y
M -W_ +H_F*TZS/$7_(!N_P#='\Q6.(_A2]'^1E+X6>=Q_<E_W?ZBNA\&?\A*
M?_KC_45SPED48#D"MKPSJ%II][//?W<%M&8]OF3R!%)R.,D]>#7S^$:=>FE_
M6YRT]9*QVK?\A&+_ *Y/_-:L5AGQ+H)NTF&MZ:8EC92_VI-H)((&<]3@_D:T
MK+4K#4D9["]MKI4.&:"57"GT.#7T]F=MF6J***0@HHIDDL<6/,D1,]-S 9H
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M%W;&7V88-/KK+"BBB@#C/&8S?VP_Z9]_K7.R(=B<K\J\X8>IKH?&G_'];?\
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M%+XD;5NDAGFW7$K".0* <8(V@\\>]7*KV_\ K[O_ *ZC_P! 6K%?0'4%%%%
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M *[K_P"@U]C5^$]>O\#/3Z***Y3A"O+[W_D*W'_7=O\ T*O4*\OO?^0K<?\
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M"Q1110 4444 %%%% !1110 4444 %%%% &?KO_(#N_\ KG7FM>E:[_R [O\
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M:?HO_(=T_P#Z^8__ $(5]I2_AQ]$>['X%Z'U/69XB_Y -W_NC^8K3K,\1?\
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M445SG(07O_'C<?\ 7)OY5Y97J=[_ ,>-Q_UR;^5>65X>;_%#YG-7W1E>)?\
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M+6UXJ_Y#TW^ZO\A6+7R>*_CS]6<,_B9ZE8_\@^W_ .N2_P JL57L?^0?;_\
M7)?Y58KZJ'PH[5L%%%1SSQ6T#33.$C7EF/:FVDKL9'<_ZZT_ZZG_ - :K%8T
MVO:8\D#+=J0DFYOE/ VL/3U(J[::I97TACMKA9&49( (X_&H5:FW927WBYEW
M+E%%%:#"BBB@ HHHH **** ,7Q5_R I?]Y?YUY_7H'BK_D!2_P"\O\Z\_KY[
M-?XZ]#EK?$=9X)^]??1/_9JZZN1\$_>OOHG_ +-775ZF7?[M'Y_FS:E\""BB
MBNTT/.O$?_(>NOJ/Y"LJM7Q'_P AZZ^H_D*RJ^1Q'\:7J_S.&?Q,]8C_ -6G
MT%.IL?\ JT^@IU?6K8[@HHJGJFHIIEF;EXV<;@N%..M*4E"+E+9";MJ22?\
M'_!_N/\ S6K%<JWBZ!IDF^RR80%2-PYSC_"M?2-9CU=93'$T?ED [CG.:QAB
MJ,Y*,9:L2G%Z(TZ***Z"@KS'5O\ D,7O_7=_YFO3J\QU;_D,7O\ UW?^9KR<
MV^"/J85]D06W_'W#_OK_ #KU4=!7E5M_Q]P_[Z_SKU4=!4Y1M/Y"H=0HHHKV
M#H*&K:FNE68N&B,@+A=H..N?\*P3XOC:59_L;812F/,ZYP?3VJ]XP_Y R?\
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M !1110!P?B[_ )#?_;)?ZU@UO>+O^0W_ -LE_K6#7RF+_CS]3BJ?$SR_5?\
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MB[>?1/\ T-:\YKT;Q+_R+MY]$_\ 0UKSFO1R3_=WZ_HCOP'\-^O^1ZI\%/\
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MEK;@XW;>K$G( ]>O7(P_#,GBO4CXRT=M7L;C5=,N88[.ZFT^-(QD;F!11G!
MVY))'6@#T'0?$>D>)[%[W1;Y+RV20Q-(@( < $CD#LP_.M2N5^'WB5_$_AM[
MBYLXK/4+2YDL[Z"'[BSIC=M]B"#WQG&3C-=50 4444 %%%% '$_%W_DE6O\
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MW7;VSB@#0_9Q_P"2>:A_V%9/_145>N22($<%US@]Z\C_ &<?^2>:A_V%9/\
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M^_Z]9O\ T6U>5UZI??\ (+OO^O6;_P!%M7E==V1_P)>OZ([<!\#]3T#X/?\
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M_P!#6O.:]')/]W?K^B._ ?PWZ_Y'JGP4_P"/[5_^N<7\VKV&O'O@I_Q_:O\
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MO_(8O?\ KXD_]"-/T7_D.Z?_ -?,?_H0IFJ_\AB]_P"OB3_T(T_1?^0[I_\
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M@O?^/&X_ZY-_*O+*]3O?^/&X_P"N3?RKRRO#S?XH?,YJ^Z,KQ+_R+MY]$_\
M0UKSFO1O$O\ R+MY]$_]#6O.:]')/]W?K^B._ ?PWZ_Y'JGP4_X_M7_ZYQ?S
M:O8:\>^"G_']J_\ USB_FU>PUWU/B%7^-A11169D%5['_CQA_P!P58JO8_\
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MP5_J+O\ WE_E755RO@K_ %%W_O+_ "KJJ]? ?[O'^NIO2^!!11178:!1110
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M^PK)_P"BHJT]2*C6+TLI/^D/WQ_$:S/V<?\ DGFH?]A63_T5%6CJO_(8O?\
MKXD_]"->3FKM&+7<PK[(2V97U"W(4@F52><]Z]0KRRR_X_[?_KJO\Q7I=S/+
M  RPJZ9 R7P<DX]/>C*I.2FWY!0ZEBBFQEV3,B!6] V:=7K&X4444 %5X/\
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M?QHG#5[I\'?^1.G_ .OU_P#T!*\+KW3X._\ (G3_ /7Z_P#Z E?6U?A/5K_
M>@T445S'$%>3O]]OK7K%>3O]]OK7C9O]CY_H<]?H5[S_ )!E_P#]>D__ *+:
MO.]/N+&V20S+<-))&T9V;< 'CO7HEY_R#+__ *])_P#T6U>55UY)_!EZ_H=F
M!5X/U._^%/E?\)X?(W^7]F?&_&>WI7NU>"_"/_D=Q_U[2?TKWJO2J_$57^,*
M***S,3@_%W_(;_[9+_6L&M[Q=_R&_P#MDO\ 6L&OE,7_ !Y^IQ5/B9Y?JO\
MR&+W_KXD_P#0C3]%_P"0[I__ %\Q_P#H0IFJ_P#(8O?^OB3_ -"-/T7_ )#N
MG_\ 7S'_ .A"OM*7\./HCW8_ O0^IZS/$7_(!N_]T?S%:=9GB+_D W?^Z/YB
MN#$?PI>C_(\V7PL\XK"\7_\ (O\ _;PG\FK=K"\7_P#(O_\ ;PG\FKY[+O\
M>H>IAAOXL3@:]F^"W_((U3_KNO\ Z#7C->S?!;_D$:I_UW7_ -!K[&K\)Z]?
MX&>GT445RG"%>7:A_P A*Z_Z[/\ S->HUY=J'_(2NO\ KL_\S7D9O\,3"OLB
M"/\ UB_45Y%7KL?^L7ZBO(JWR+X)_(ZLOVD=;\,O^2AZ7_VU_P#13U]$5\[_
M  R_Y*'I?_;7_P!%/7T17JUOB-,1\04445D8'%^-/^/ZV_ZY'^=<S73>-/\
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MO^N)_F*ZLI-]K$7VN;:4+?=3U_W:[LL_W=>K-*/PEVBBBO0-3S_Q5_R'IO\
M=7^0K%K:\5?\AZ;_ '5_D*Q:^3Q7\>?JSAG\3/4K'_D'V_\ UR7^56*KV/\
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MF_\ PFOC;Q @_P"$8\%26D#_ ';S7)1" /7R@=Q^H)KE=*TOQ=XY\8Z]X?\
M%'BZ[MHM)$/F0Z/B&.3S%)P&P"0/]H&@#W!)8Y"X1U8HVU@ISM.,X/H<$?G3
MJP_"GA+2/!FD-IFC0R1V[RF9_,D+LSD $DGV4<# XK<H **** "BBB@ HHHH
M **** "BBB@ HHHH **** "N'O\ _A:?]HW/]G?\(;]A\U_L_P!H^U>9Y>3M
MWXXW8QG'&:[BB@#Q_P#9Q_Y)YJ'_ &%9/_145:.J_P#(8O?^OB3_ -"-9W[.
M/_)/-0_["LG_ **BK1U7_D,7O_7Q)_Z$:\C-O@CZF%?9$=E_Q_V__75?YBO2
M[W_CW'_72/\ ]#%>:67_ !_V_P#UU7^8KTN]_P"/<?\ 72/_ -#%+*/AE\@H
M;,L4445[!N%%%% '&>-/^/RU_P"N9_G7-O\ ZN/Z'^==+XTQ]MM<]/+/\ZYM
MG1D ",,#CYO_ *U?-XRWMZEW_6AR5/B9YQXI_P"1CNOHG_H"UCUL>*?^1CNO
MHG_H"UCU]5A/]WAZ+\CVJ/\ #CZ(^K-/_P"0;:_]<4_D*LU6T_\ Y!MK_P!<
M4_D*LUB<#"L3Q7_R I/]]?YUMUB>*_\ D!2?[Z_SKGQ7\"?HR9_"S@*YWQG_
M ,@>+_KN/_06KHJYWQG_ ,@>+_KN/_06KP\K_P![A\_R9CA/XT3AJ]T^#O\
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MK_D!2_[R_P Z\_KY[-?XZ]#EK?$5=3_Y!Y_ZZK_)JS&_Y!\?_75OY+6GJ?\
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M>P=!@>,/^0,G_79?Y&N$KN_&'_(&3_KLO\C7"5\YFG\?Y')6^([#P5_J+O\
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M\ZVZQ/%?_("D_P!]?YUSXK^!/T9,_A9P%<[XS_Y \7_7<?\ H+5T5<[XS_Y
M\7_7<?\ H+5X>5_[W#Y_DS'"?QHG#5[I\'?^1.G_ .OU_P#T!*\+KW3X._\
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M*PO%_P#R+_\ V\)_)JW:PO%__(O_ /;PG\FKY[+O]ZAZF&&_BQ.!KV;X+?\
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MFNYKAO&/_(8C_P"N(_F:\_,_]W^:,JWPG/5Z9HO_ "!;/_KDO\J\SKTS1?\
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MY[-?XZ]#EK?$5=3_ .0>?^NJ_P FK$K;U/\ Y!Y_ZZK_ ":L2O4R[_=H_/\
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MS_WR!0!S7PO\,7OA;P>(=4Q_:=[<27UXH.0DCX^7CC@*N<<9S7:444 %%%%
M!1110!S?C_1+SQ'X%U72+ (;JZB"QB1MJY# \GZ"KWA?3Y])\):-IMUM^T6E
MC!!+M.1N2-5.#W&16M10!RUOX,@O-2NM2\221:Q=RAX84EAQ!;0-_ D9)P2,
M;F.2>G2KWA_0I_#XFLXM0DN-* 'V2"?+R6P[H)"<L@XV@\CIDC&-NB@ KA?
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M_P CN/\ KVD_I7O5>"_"/_D=Q_U[2?TKWJO1J_$5B/C"BBBLS X/Q=_R&_\
MMDO]:P:WO%W_ "&_^V2_UK!KY3%_QY^IQ5/B9Y?JO_(8O?\ KXD_]"-/T7_D
M.Z?_ -?,?_H0IFJ_\AB]_P"OB3_T(T_1?^0[I_\ U\Q_^A"OM*7\./HCW8_
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M/@I_Q_:O_P!<XOYM7L->/?!3_C^U?_KG%_-J]AKOJ?$*O\;"BBBLS(*KV/\
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MY&N$KYS-/X_R.2M\1G:M]R'ZM_2LNM35ON0_5OZ5EU[& _W>)O2^!'KW@?\
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M6<,_B9YQXC_Y&*__ .NIJG8?\A&U_P"NJ?S%7/$?_(Q7_P#UU-4[#_D(VO\
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M $?^E6*KR_\ '[;_ $?^E6*^J.T*X;QC_P AB/\ ZXC^9KN:X;QC_P AB/\
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M_P"0;:_]<4_D*LU6T_\ Y!MK_P!<4_D*LUB<#"L3Q7_R I/]]?YUMUB>*_\
MD!2?[Z_SKGQ7\"?HR9_"S@*YWQG_ ,@>+_KN/_06KHJYWQG_ ,@>+_KN/_06
MKP\K_P![A\_R9CA/XT3AJ]T^#O\ R)T__7Z__H"5X77NGP=_Y$Z?_K]?_P!
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MY"%M_P!=5_F*74?^0E=?]=6_F:2Q_P"0A;?]=5_F*^JA\*.U;'NXZ5F>(?\
MD W?^Z/YBM,=*S/$/_(!N_\ ='\Q48C^%+T?Y"E\+/.*I:I_QYC_ 'Q_(U=J
MEJG_ !YC_?'\C7S>!_WB)R4_C1CUZ9\-_P#D"77_ %\G_P!!6O,Z],^&_P#R
M!+K_ *^3_P"@K7U)VG9UYYXG_P"1AN?^ ?\ H(KT.O//$_\ R,-S_P  _P#0
M17F9K_!7K^C,:_PF17JMM_QZQ?[@_E7E5>JVW_'K%_N#^5<^4;S^1-#J2T44
M5[9T&+XJ_P"0%+_O+_.O/Z] \5?\@*7_ 'E_G7G]?/9K_'7H<M;XBKJ?_(//
M_75?Y-6)6WJ?_(//_75?Y-6)7J9=_NT?G^;-J7P(]0^'7_(O3?\ 7RW_ *"M
M=?7(?#K_ )%Z;_KY;_T%:Z^NTT/.O$?_ "'KKZC^0K*K5\1_\AZZ^H_D*RJ^
M1Q'\:7J_S.&?Q,P[;_D)1?\ 74?SJ]X8_P"1GL/^NPJK9PR/?HZH2JRC)'0<
MU=\.PR0^*=/$B%2901D?6OKCN/9:P_%O_($/_71?ZUN5A^+?^0(?^NB_UKGQ
M?\"?H3/X6<#77^"O]7>?5?ZUR%=?X*_U=Y]5_K7@Y=_O,?G^1RTOC1T<7_'Y
M<?1?Y58JO%_Q^7'T7^56*^F.P*\QU;_D,7O_ %W?^9KTZO,=6_Y#%[_UW?\
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M_P"0/%_UW'_H+5T5<[XS_P"0/%_UW'_H+5X>5_[W#Y_DS'"?QHG#5[I\'?\
MD3I_^OU__0$KPNO=/@[_ ,B=/_U^O_Z E?6U?A/5K_ >@T445S'$%>3O]]OK
M7K%>3O\ ?;ZUXV;_ &/G^ASU^A7O/^09?_\ 7I/_ .BVKRJO5;S_ )!E_P#]
M>D__ *+:O*J[,C_@R]?T.W ? _4[OX1_\CN/^O:3^E>]5X+\(_\ D=Q_U[2?
MTKWJO1J_$5B/C"BBBLS X/Q=_P AO_MDO]:P:WO%W_(;_P"V2_UK!KY3%_QY
M^IQ5/B9Y?JO_ "&+W_KXD_\ 0C3]%_Y#NG_]?,?_ *$*9JO_ "&+W_KXD_\
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MB@ HHHH **** "BBB@ HHHH **I:OJ^GZ#I<^IZI=1VMG NZ25^@]@!R23P
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M_P!]UP%=_P##/[VJ?2+_ -GKZH[3T"N&\8_\AB/_ *XC^9KN:X;QC_R&(_\
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M_5OYUZEX#_Y%6#_??_T(U],=ATM>8ZM_R&+W_KN_\S7IU>8ZM_R&+W_KN_\
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M03A,!O*D#;?KBK%<)\-!B#4A_MI_)J[NLS$X/Q=_R&_^V2_UK!K>\7?\AO\
M[9+_ %K!KY3%_P >?J<53XF>7ZK_ ,AB]_Z^)/\ T(T_1?\ D.Z?_P!?,?\
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M_P @J'_KL/Y&N7&_[O+T(J?"SB*Y#QM]^R^C_P!*Z^N0\;??LOH_]*\C*/\
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M1HS$=<"MJL*^_P"/R3ZUQ93\<O0SH;LLS12)K.]D(5KC*GL?FKVX=*\&M/\
MC\@_ZZ+_ #KWD=*]TZ3/UW_D!W?_ %SKS6O2M=_Y =W_ -<Z\UKP<V_B1]#F
MK[HI:I_QZ#_?'\C6/6QJG_'H/]\?R-8]=V6?[NOF:4?A/2?AM_R#+W_KL/\
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M_P"\O\Z\_KY[-?XZ]#EK?$5=3_Y!Y_ZZK_)JQ*V]3_Y!Y_ZZK_)JQ*]3+O\
M=H_/\V;4O@1ZA\.O^1>F_P"OEO\ T%:Z^N0^'7_(O3?]?+?^@K77UVFAYUXC
M_P"0]=?4?R%95:OB/_D/77U'\A657R.(_C2]7^9PS^)G.2?ZQOJ:U?"__(S:
M?_UU%94G^L;ZFM7PO_R,VG_]=17UQW'M%8?BW_D"'_KHO]:W*P_%O_($/_71
M?ZUSXO\ @3]"9_"S@:SM7^Y#]6_I6C6?JI*B @X(+$'\J\'+O]XC\_R.6E\9
M2E_X\[?ZM_.O4O ?_(JP?[[_ /H1KRQKVY="K3N5/!!->I^ _P#D58/]]_\
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M5ZU;XC3$?$=M\-O^0K>?]<!_Z$*])KS;X;?\A6\_ZX#_ -"%>DUD8'&>-/\
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MM>L5Y._WV^M>-F_V/G^ASU^A7O/^09?_ /7I/_Z+:O*J]5O/^09?_P#7I/\
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M[-_):YNNDT+_ )!C?]=F_DM?85?A/7K_  &E7K_@G_D4+'_MI_Z,:O(*]?\
M!/\ R*%C_P!M/_1C5S'"=!7EVH?\A*Z_Z[/_ #->HUY=J'_(2NO^NS_S->1F
M_P ,3"OLB"/_ %B_45Y%7KL?^L7ZBO(JWR+X)_(ZLOVD7=(_Y"D/_ O_ $$U
MU-<MI'_(4A_X%_Z":ZFO5K?$:8CXCM_AK_R$;[_KDO\ .O2*\W^&O_(1OO\
MKDO\Z](K(P.+\:?\?UM_UR/\ZYFNF\:?\?UM_P!<C_.N9KY;'?[Q(XJGQL\\
M\4_\C'=?1/\ T!:QZV/%/_(QW7T3_P! 6L>OK\+_  (>B_(]RC_#CZ([Z_\
M^0A<_P#75OYFK&A?\C!IO_7U%_Z&*KW_ /R$+G_KJW\S5C0O^1@TW_KZB_\
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MXH?,YJ^Z,KQ+_P B[>?1/_0UKSFO1O$O_(NWGT3_ -#6O.:]')/]W?K^B._
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MZR?^AM70UUF@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 5P]_XG\=V^HW,-G\.OM=K'*Z0W']MP1^:@)"OM(RN1@X
M/3-=Q7#W_P 2?L.HW-G_ ,(5XRN/(E>+SK?2M\<FTD;D;=RIQD'N* .7_9Q_
MY)YJ'_85D_\ 145:.J_\AB]_Z^)/_0C6=^SC_P D\U#_ +"LG_HJ*M'5?^0Q
M>_\ 7Q)_Z$:\C-O@CZF%?9%)_P#5M]#7DU>LO_JV^AKR:MLB^&?R.K+]I&IX
M?_Y"H_ZY2?\ H)KHJYWP_P#\A4?]<I/_ $$UT5>M6^(TQ'Q';?#;_D*WG_7
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M7\/?\?D__7$_^A+6_6!X>_X_)_\ KB?_ $):WZ]&K\0Z_P 9Z'\-/^/?4?\
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MMO\ KJ?Y5X.6?[W#Y_DS'"_QHG%5UFE?\@:U_P"!_P#H1KDZZS2O^0-:_P#
M_P#T(U]=5^$]7$? 6J]G\*?\BOI__7+^M>,5[/X4_P"17T__ *Y?UKF.(UW^
MXWTKR;O7K+_<;Z5Y-WKQ<W^Q\_T.>OT(+[_D%WW_ %ZS?^BVKRNO5+[_ )!=
M]_UZS?\ HMJ\KKNR/^!+U_1';@/@?J:WA_\ X_9?^N)_]"6N@KG_  __ ,?L
MO_7$_P#H2UT%>A5^(=?XST?X:_\ (/OO^NJ_RKN*X?X:_P#(/OO^NJ_RKN*S
M,3@/%?\ R'9/]Q?Y5B5M^*_^0[)_N+_*L2OD\7_'GZLX9_$SSCQ'_P C%?\
M_74U2L?^/^V_ZZK_ #%7?$?_ ",5_P#]=35*Q_X_[;_KJO\ ,5]K3_AKT/>C
M\"]#KZW?!O\ R-MA_O-_Z U85;O@W_D;;#_>;_T!JYCSSV*N<\9?\@J'_KL/
MY&NCKG/&7_(*A_Z[#^1KEQO^[R]"*GPLXBN0\;??LOH_]*Z^N0\;??LOH_\
M2O(RC_>H_/\ (C!_QD<G7867_(.M?^N0KCZ["R_Y!UK_ -<A7U-;8]+$?"B:
MO==,_P"059_]<$_]!%>%5[KIG_(*L_\ K@G_ *"*YSC'WO\ QXW'_7)OY5Y9
M7J=[_P >-Q_UR;^5>65X>;_%#YG-7W1E>)?^1=O/HG_H:UYS7HWB7_D7;SZ)
M_P"AK7G->CDG^[OU_1'?@/X;]?\ (Z+PW_QX7_\ UUA_E)6I67X;_P"/"_\
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M?_(>NOJ/Y"LJM7Q'_P AZZ^H_D*RJ^1Q'\:7J_S.&?Q,YR3_ %C?4UJ^%_\
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MD/U;^E9=:FK?<A^K?TK+KV,!_N\3>E\"/7O _P#R*-G]9/\ T-JZ&N>\#_\
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M%0W7_'Y-_P!=&_G4VD_\AFQ_Z^(__0A6)P'N=8GBO_D!2?[Z_P ZVZQ/%?\
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M@UO>+O\ D-_]LE_K6#7RF+_CS]3BJ?$SR_5?^0Q>_P#7Q)_Z$:?HO_(=T_\
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MM>9UZ9\-_P#D"77_ %\G_P!!6OJ3M.SKSSQ/_P C#<_\ _\ 017H=>>>)_\
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M\ZVZQ/%?_("D_P!]?YUSXK^!/T9,_A9P%<[XS_Y \7_7<?\ H+5T5<[XS_Y
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M:YNNDT+_ )!C?]=F_DM?85?A/7K_  &E7K_@G_D4+'_MI_Z,:O(*]?\ !/\
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M )%?3_\ KE_6N8XC7?[C?2O)N]>LO]QOI7DW>O%S?['S_0YZ_0@OO^07??\
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M_P Z\_KT#Q5_R I?]Y?YUY_7SV:_QUZ'+6^(JZG_ ,@\_P#75?Y-6)6WJ?\
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M6M-_Z]T_E7,<1J5Y._WV^M>L5Y._WV^M>-F_V/G^ASU^A7O/^09?_P#7I/\
M^BVKRJO5;S_D&7__ %Z3_P#HMJ\JKLR/^#+U_0[<!\#]37\/?\?D_P#UQ/\
MZ$M;]8'A[_C\G_ZXG_T):WZ]&K\0Z_QGH?PT_P"/?4?]^/\ DU=Y7!_#3_CW
MU'_?C_DU=Y69B<'XN_Y#?_;)?ZU@UO>+O^0W_P!LE_K6#7RF+_CS]3BJ?$SR
M_5?^0Q>_]?$G_H1I^B_\AW3_ /KYC_\ 0A3-5_Y#%[_U\2?^A&GZ+_R'=/\
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M>B_(]RC_  X^B.^O_P#D(7/_ %U;^9JQH7_(P:;_ -?47_H8JO?_ /(0N?\
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M_OC^1KYO _[Q$Y*?QHQZ],^&_P#R!+K_ *^3_P"@K7F=>F?#?_D"77_7R?\
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M^_R__)%07NK_ !OOK22VE\':*$D&"5F3/7/_ #\5[/14-*2LR#Y^_L[XQ?\
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MR*)G!-U%GDY_Y[5ZGX3_ .2O_$3Z:;_Z(:O0*Z7)O<T<Y25FSYP_X1KXM_\
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MP;\2KZTLM4L?#MM+;SHEQ YN8@'4@,IP901D$<'!KZ*\<_\ )/O$G_8*NO\
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M%J*&.)?"UB51=HS<Q9_]'5V7PB_Y*-\3?^PH/_1MQ7L%=#DWN7*<I;L^</\
MA&OBW_T*MC_X$Q?_ !ZNL@USXXV]O'"G@W1"L:A 3,F< 8_Y^*]CHJ23QV77
MOCE+$\;>#=# =2IQ,O?_ +>*P/[.^,7_ $*>F_\ @1'_ /'Z^@:*RJ4*=7XU
M<EQ3W/G:^T+XO:A926LOA33UCDQDI<Q \$'_ )[>U<;<Z)XXM/$]IX;GT6W3
M5[R(S06_G(=Z#<2=PDVC[C=3V^E?7=>/^)/^3GO"7_8+?_T&YJZ4(TERTU9%
MPDX*T=#B++P?\6+"&6*+PO9E965FW746?ESC'[[_ &C5C_A&OBW_ -"K8_\
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M)!,B D,0>&E!'((YK0B\/?%V&9)5\*V!9&##-S%CC_MM7I?P0_Y)%HOUG_\
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MXR[3]Y>A[U]05X_H?_)T/B7_ +!2?^@V]90PU&$N:,;,E0BM4CD/^$:^+?\
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M(VN8EF0>7YB[EY,N#D#L3CO5G_A&OBW_ -"K8_\ @3%_\>KT_P +?\EB\?\
M_7/3O_1+5Z!6L(1A'EBK(:26B/$]*O\ XVZ1IT5C;^#]&:*/.#).A;DD]K@>
MM>C^";WQ9?:1/)XPTNTTZ_$Y6**U8,K1;5PQP[\YW#KVZ5TM%4,**** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_@ZVOM-0?\AO35E(4 <M/"&)3ZKD?2@#U"'7/#-OXPN=+A:VCUJZMUN9W2(
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M021@@]/H#@:SH&D^(_!.LZQ=_$.\\2WEM923I;QSK#"CA203 .1T]J ._O\
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MC-&I)8@9))]:Z^@ HHKF_'.K:]HOAB:]\.:6-2U!6 $!4OA><MM4@MCC@>M
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MK<707SKB.-0\P487<PY; Z9Z59JMIW_(,M?^N2_R%6: "BBB@ HHHH ****
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MX^I^;FL/X4>&](\2_!S2K;5K*.X1)IVC8Y5XF\UOF1A@J?<&N@/AOQMH1/\
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M)=6N;3P_X=\463V^O6>L0L9D0^3>1#(\U&QCN,CWZ#D  ^A1T%+2+]T?2EH
MY/X@>'-.\3:):6NI:O\ V4D-['<17 =%)D56"@;N,\D_A6#K7P[O+O1;J#6?
MB%JQTUH\W'GB%4V#G+' P.*J?'UUC\%Z2[D*JZS 23V&R2JGQ.U?3?$$?A*W
M@U6UNO#UQJB1ZBUM<AE/(V*Y4\+][.>F!0!3TZZT-6ATNR^,EX@B411(?*5
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M'L_A/Q'XTU6UFEC,VFW=NL?EW:#J,$9# <X]C[$]O_P@FO\ _10]<_[]Q?\
MQ- &WX3\'Z=X0LYX[-[BYN;J3S;N]NI/,FN']6;\\#W/<DGH*Y[P[X>U+19Y
MY+[Q+J&KK(H54NE0",YZC:!70T %%%% !7/>(_ WAOQ7)'-K&EQSW$0 2X1F
MCE4 Y WJ0< D\=*Z&O%/B?\ "FT;5$\6Z1I#Z@?/#ZGI49?-TK'YG380P?GD
M#KU[$, >C>'O 'AGPM<O=Z5I:1W;Y#7,KM+)@]0&<DC\,5:L?".@Z=KUWKMM
MIT0U2[8M+=,2S\]<9)VCZ8KE;;X,_#JZM8;A?#<D8E0.$ENKE'7(SAE+Y!]0
M:NV/P?\  FFZA;7]IH7EW-M*LT+_ &N<[74@J<%\'D#K0!W%%%% !1110!C:
MYXJT#PZ\46M:I;6;3J2BSMC>!P:YVV\;_#.SN#<6NJZ'!,>LD2*K'\0,UT/B
MKPKI?C#0YM*U6 /$_,<@^_"_9T/8C]>AR#6)X#\,7ND^'%TSQ'9Z?<W%I(T4
M%TL:L9X1]PMQPV.._0<DYH >_P 2/ ,DT<S^(=+:6/.QV8%DSUP<<9P/RKJK
M"_M=3L8;VRG2>VF7='*AR&'J*B_L;2_^@;9_]^%_PJU'%'#&L<2*B*,!5& /
MPH ?1110 5B^+/$EMX2\,7VN72-)';("(U."[$A57\21SVZUM5SOCKPS_P )
MAX-U'1!*(9+A 8I#T5U8,N?;(P?8F@#EHA\4HK(ZS#:^'!--B:32!$ZR,/[I
MES@R8XYXS70>%/%VE>.=/FBEM#!?VKA+W3;Q 9() >X/49'!QV['BI_"&I^(
MKVUEMO$FB?V?>6H1#.DRR171YRR8Y7IG!Z;A6=XM\#RZCJ<7B3PY<IIOB6V&
M%F(_=7*?\\Y@.H/3/4?@, $7@+Q7J7B'Q#XOL;XP^3I6I-;6PC3:0@9P,^IP
MHKNJ\T^%6AZ_I6K^+;W7M,^PRZE?_:402+(IW%R=K \@;O:O2Z "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH K:A86NJ:?<6%["LUK<(8Y8VZ,I
MZBN"@^'/B+2(!8>'_B!?V.E+PEM/917#QK_=61L%1Z>E>C44 <?HG@"#PSX=
MU"QT74[J'4[]C)/JTZK-,\A/WCG@]3@>Y/7FK_A/PC:>$[.X2*XN+R\NY3/=
MWERVZ2=SW/H/05T-% !1110!EZWX<T;Q);+;ZSIMM>QKROG)DI_NGJ/PKEE^
M#?@E%V1:?=Q1]HTU"<*/PWU@?%KX66VNI)XFTJS,VK6^)+BT&XB^1<97"G(;
M P-O)Z=<5?T?X0_#[5-'M+Y_"EQ://$KM;W%S<I)$2.58%\@@T =9X?\"^&/
M"TGFZ-HUM:S8*^=@O)@]1O8EL?C70UP4?P6^'T,J2IX?PZ,&4_;+C@C_ ('7
M>@8&* "BBLGQ)X;TSQ9HDVDZM"9;:3!^5BK(PZ,I'0C_ /7D4 65TC3DU9M6
M6QMUU%X_*:Z$8$C)Q\I;J1P/RJ[7A/@[X1:-;>(-5\/^)_#<]ZL.)K+5U>>.
M*>,_P,58*''''7KZ9/;?\*2^'G_0O?\ D[<?_'* /0**Q?#?A/1/"%G+::%9
M?9()I/-=/->3+8 SER3T K:H *Y;5_&W@RSO)=.U?6-.2>!AO@N""4;J.".M
M=37"?$;X?1>++6+4=-\NV\16)#VET0,/@YV/D$%?3/0^Q((!>_X6AX'_ .AG
MT[_OY3&^(/@/4GBMGUW2[EF=1'&Y#9;/& 1US6SINDV\FFVSZAH]A#>F-?/C
MCB5E5\<X..1FK2Z1IBL&73K0$'((@7C]* +O:BBB@"*XM;>\A,-S!%/$W5)4
M#*?P-<MJ7PN\$:J&%QX:L$+=3;H8#^<9%:GBGPMI?C#0Y=)U:(O QWHRG#1.
M 0'4^HR?;UKR/P3\(]%BU35- \5>&IKJ:U?S+754>XCAN8CT&5?:'&1QU^N"
M2 >N:UX3T3Q#I=KINJ60N+.VD62.(NRC*@@9P02,'H>#6I:6EM86D5K:01P6
M\2A8XHE"J@'8 =*X7_A27P\_Z%[_ ,G;C_XY74>&_"NB^$;"2QT.R^R6TDIF
M=/->3+D 9RY)Z*/RH V**** .0/CGP'H]Y=6XUC2K2Y$K"X1<(QD!P=V!R<^
MM._X6AX'_P"AGT__ +^5E>/OA\^L7]EXD\/Q6L7B&RE5OWP'EW4?0H_'H>OI
MD>F.QATC3VA1I=*LTD*@LGDH=I[C.* ,JS^(GA#4+V&SL_$-C-<S.$CC23)9
MCT KIJJ1Z5IT4BR1V%JCJ<JRPJ"#]<5;H **** "BBB@ HHHH *\T.M>*/&V
MM7Z^&H=(L],TJY:W2^U"$S233+]XQJ.%4>OT]P/2Z\[\/Z;XB\%^)[_3X-)&
MH^'M3OFNHKN*=5>T+XW*Z'DCCJ/ZX  [2/'VHZ9XA@\->.;&#3]0N.+._MB3
M:79_N@MRK<C@]_3(!D\9^(+K3?'_ (.TR&&U>"_FD$K2PAW7:!@H3]T\FNF\
M3>&-*\7:++I6KV_FP/\ ,K#AXV[,I[$?_6/!KRYO"'CB#QQX3340NJZ9H\[^
M7JBN/,,3 8$JDYW#'WAG.1SG)(![31110!SWB_Q3%X6TV&06<M_>W<PM[.RB
M.&FD/;/8>I[5Q]_\0M=\&6H7Q!X/BM8[A6%B=/N!(CSGD1.  5)/.?KUKH/'
M_AS4]8ATK4]#,3:KH]U]I@AF.$G&,,A/8D=#_+J+R:?'XR\.V1\3Z$;2=)A/
M]C>?<894)"L'0C/J/8\T <Q+%\3TMH]9N8?#5Y-#F4:8L+AU7NJ2D\/@?3/K
M79>%_$5KXK\.6>LV:LL5PI)1NJ,"0RGZ$$52\7ZGXDL+2"W\,:(-0N[G<GG2
M3K'':],.V>6Z]!Z'Z%W@7PQ_PA_A"RT9IA-+$&>60="[,6;'MDX'L* .CHHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** (Y+>&66.22&-Y(^49E!*_0]JDHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MZ""_]^W_ ,*\CHJ.5'-S'KG_  E^@_\ 007_ +]O_A1_PE^@_P#007_OV_\
MA7D=%'*@YCUS_A+]!_Z""_\ ?M_\*/\ A+]!_P"@@O\ W[?_  KR.BCE0<QZ
MY_PE^@_]!!?^_;_X4?\ "7Z#_P!!!?\ OV_^%>1T4<J#F/7/^$OT'_H(+_W[
M?_"C_A+]!_Z""_\ ?M_\*\CHHY4',>N?\)?H/_007_OV_P#A1_PE^@_]!!?^
M_;_X5Y'11RH.8]<_X2_0?^@@O_?M_P#"C_A+]!_Z""_]^W_PKR.BCE0<QZY_
MPE^@_P#007_OV_\ A1_PE^@_]!!?^_;_ .%>1T4<J#F/7/\ A+]!_P"@@O\
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M_ U<ABOT=M.MRKM=;=R0NC[L$XY!..Y//UK4EM$U&\LM.CD,PLX#]HGB&XD
MY*KW.,@#ZTHTN9:;_P!?\."A=>9S[12)&DC1LJ/G8Q& V.N#WIE=)XB6XETK
M39GLWMT3S%V%"/+&X!0?? _&N;J:L.27+Z"G'E=@HHHK,@ZKP9TU+_KB/ZUX
MW7LG@SIJ7_7$?UKQNOJ<I_@?UYGT>4?PG_7<*L6EA>:A(T=E:3W+J-Q6&,N0
M/7 JO72?ZKX<9C8@S:H5EQQD+&"H/J,DFO3;L>I)VV.=DC>*1XY$9)$)5E88
M*D=01ZTZ*":<2&&*23RT+OL4G:HZDXZ#D<UO>+_GNM+N7YFN-,@EF<]7?!&3
M[X J_P"%[]W\.:]8+!!'&FGR2-(B?/*VX8W,?0$@ 8'/KS4\VER7-\G-8Y*"
M":ZF6&WBDEE;[J1J68_0"HZZ_P"'FH/;^)+>SC@@_P!(9M\Q3,FT(QV@DX S
MR<#)]:S+"PM)_".L7LD8:ZMY8%C?<?E#$@\9QSCO3YM; YVDT_+\3#HKM4T#
M38XH;Z2U,D,.BI>RPB1AYTK.RC)SD#N<$=*SM4M]-F\'V6IVNGK:7+W3PR[)
M'93A<C 9C@<C]:2FF"JINQCVFDZCJ$;266GW5RBG#-#"S@'T) J.[L+S3Y%C
MO;2>V=AN"S1E"1ZX-=+IL$=Q\.KQ);N&U7^TD/F3!RO^K/'R*Q_2KNC?V7?+
MHGAF68:BINY)Y9$#HB*4($:DA6ZC<> .>])SL2ZC5]-CA:*[.TTS3KS3M1U1
M-+M%6"86MO;RWABC9B22[L\@)(7 PI&>>*>FA:1=W4=K"ML+N^LG,<,-UYHM
M[E.<!E9AM< \-D\]:?.A^V1Q-%=SH^@:2[:59WUJ9+B>RFO9V61@=I!\H#!P
M. 3T[BL^/3K#5M&L[V'3FMI6U-;-XK1V8R(R[N!(Q^88XY YYHYT'M5<Y:BN
MYN?#^G2Z7K#BWL;:>T0RPQVUT\LJ*KE<2_,R9(]"#GM69XPMM-TS4/[.L=.C
MBVQQ2-,9)&8DKDCEL8Y';/%"FF[!&JI.R.=@@FNIEAMXI)96^ZD:EF/T I]I
M975_-Y-G;37$H&[9#&7./7 KJ/AYJ#V_B2WLXX(/](9M\Q3,FT(QV@DX SR<
M#)]:YVSOI(H)K%[AX;*Y*FX\N)79MIR.I&<'MD4[N[17,[M%:>":VF>&XB>*
M5#ADD4JRGW!J.NF\8_OFTF\B+/926*1P2R']XX0D-O'9@3CC(QC!-<S3B[JX
MX2YHW-SP=_R.&E?]?"UU7C/_ )&R]_[9_P#H"URO@[_D<-*_Z^%KJO&?_(V7
MO_;/_P! 6N>K\1YV/^)&&B/)(L<:LSL0%51DDGL!2,K([(ZE64X((P0:VO"M
MXUMKMLB11,TTJ)YCKED&>=O89'&<9^E9VI_\A:\_Z[O_ .A&LS@((XI)0YCC
M=PB[WVJ3M7U/H.13*Z;1+LOX?U>U$,**EJ6+HOS2'/5C[=NU9UW9V\?AO3KM
M$Q/-)*LC;CR 1CCI1<#*HKJ=5TNPTLZA="U$J)<);PPN[;5)0.6)!!/H.>]9
MNOV]I!)8R6=OY$=Q:),R;RV&+-GD_047 IP:7J%S$)8+"ZEC;H\<+,#^(%5Y
MH9;>5HIXGBD7[R.I4CZ@UOW5O%/X8T3S+R"WQY^/-#G=\_;:I_6KB2:9J4OE
MO']KCTW2V_>99/,92,8Z' R1SZ]*5PL<C173VFC6>KII4JQ?9/M$LL<RQ,2"
M$&[(WDX...I%,>QL)K661X;*TECE0QI#?++YJ%@"I&\G('.1CZ4[A8YNBNEE
MTJR77M:MA#B&VM99(EW'Y6 !!SGGKWJQ!IVEOJ.F:<U@/]*LEEDF$K[PY0G*
M\XZCN#UI7"QR5%=)::99ZQ:6TD5LMHSWXMCY<C'*%=V3N)^88/3 YZ4P6VGW
MLFIPPV2VYLD::)P[DN$."K@GOGMC%.X6.>HKIY=)L8;B[OS#G31:+/ A=OO/
MPJD]>&W=^U6+'1+*6YM+2>VAB6:-06FF/VEF92<JBL0H&!]X?J:5PL<A174:
M5I6GW^G/=SV\B?V<6-R(BQ%PH&1@D\'CG&.#GCMSJ7+0W@N;=5B9)-\:@;@A
MSD=<YQ[T[@/N-/O;2-9+FSN(48X#21%03]2*;]AN_LGVO[+/]F_Y[>6=G7'W
MNG7BMI&DL-&U"?46S<:FH\J!OO-\V3*P[#.<'OS]:?X?NFO=5S+<.UZ\#6\$
M10+"1LP V.B^P7K@YI7 YNO:M'_Y EA_U[1_^@BO%F4JQ4\$'!KVG1_^0)8?
M]>T?_H(I2'$NT445!04444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110!S_ (R_Y%]_^NBUYU7HOC+_ )%]_P#KHM>=5X>8
M_P ;Y'G8KXPHHHK@.8LV5[+8S&2,(P92CHXRKJ>H-/GU%IQ C00K;P9VP+N"
M\]23G)S]:IT5:G)*W0KF=K%FTO'LK^.[A1-Z-N53DJ/;KG]:@D<R2,YQEB2<
M>]-HJ;NUA7=K&@VL7+:P=3 C69CDJ%^4C&",'L14L6KL5M[9%BLH8YQ,'@1F
M96P1GYFYZUE45:JS74KGD=!<:E;1Z=?PQFT:2Z8?\>T<@S\V26W]/8#CDU@
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M?59]:U!KVY2-)"BIB,$#"@ =2?2J-%-12!0BG=%W2-4GT;5(=0MUC:6'.T2
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH H:QI@U:P-JTIB!8-N"YZ5SW_  @<?_00;_OU_P#7KL**PJ8:E4?-
M-79G*E";O)''_P#"!Q_]!!O^_7_UZ/\ A X_^@@W_?K_ .O7845'U*A_+^9/
MU>GV./\ ^$#C_P"@@W_?K_Z]'_"!Q_\ 00;_ +]?_7KL**/J5#^7\P^KT^QQ
M_P#P@<?_ $$&_P"_7_UZ/^$#C_Z"#?\ ?K_Z]=A11]2H?R_F'U>GV./_ .$#
MC_Z"#?\ ?K_Z]'_"!Q_]!!O^_7_UZ["BCZE0_E_,/J]/L<?_ ,(''_T$&_[]
M?_7H_P"$#C_Z"#?]^O\ Z]=A11]2H?R_F'U>GV./_P"$#C_Z"#?]^O\ Z]'_
M  @<?_00;_OU_P#7KL**/J5#^7\P^KT^QQ__  @<?_00;_OU_P#7H_X0./\
MZ"#?]^O_ *]=A11]2H?R_F'U>GV./_X0./\ Z"#?]^O_ *]'_"!Q_P#00;_O
MU_\ 7KL**/J5#^7\P^KT^QQ__"!Q_P#00;_OU_\ 7H_X0./_ *"#?]^O_KUV
M%%'U*A_+^8?5Z?8X_P#X0./_ *"#?]^O_KT?\(''_P!!!O\ OU_]>NPHH^I4
M/Y?S#ZO3[&'H_AQ=(%SMN3+YZ;>4QCK[^]<A_P *A@_Z#,G_ (#C_P"*KTNB
MNFDO8QY8:(Z*4Y45:GH>:?\ "H8/^@S)_P" X_\ BJ/^%0P?]!F3_P !Q_\
M%5Z716OM9]S7ZS5[GFG_  J&#_H,R?\ @./_ (JC_A4,'_09D_\  <?_ !5>
MET4>UGW#ZS5[GFG_  J&#_H,R?\ @./_ (JC_A4,'_09D_\  <?_ !5>ET4>
MUGW#ZS5[GFG_  J&#_H,R?\ @./_ (JC_A4,'_09D_\  <?_ !5>ET4>UGW#
MZS5[GFG_  J&#_H,R?\ @./_ (JC_A4,'_09D_\  <?_ !5>ET4>UGW#ZS5[
MGFG_  J&#_H,R?\ @./_ (JC_A4,'_09D_\  <?_ !5>ET4>UGW#ZS5[GFG_
M  J&#_H,R?\ @./_ (JC_A4,'_09D_\  <?_ !5>ET4>UGW#ZS5[GFG_  J&
M#_H,R?\ @./_ (JC_A4,'_09D_\  <?_ !5>ET4>UGW#ZS5[GFG_  J&#_H,
MR?\ @./_ (JC_A4,'_09D_\  <?_ !5>ET4>UGW#ZS5[GFG_  J&#_H,R?\
M@./_ (JC_A4,'_09D_\  <?_ !5>ET4>UGW#ZS5[G Z1\,8M)U>UOUU5Y3;R
M!PAA W8[9W5J:QX*CU?59KYKYHC+M^01YQA0.N?:NJHJ7.3=V9SJ2J.\F</_
M ,*XB_Z";_\ ?D?XT?\ "N(O^@F__?D?XUW%%+F9G9'#_P#"N(O^@F__ 'Y'
M^-'_  KB+_H)O_WY'^-=Q11S,+(X?_A7$7_03?\ [\C_ !H_X5Q%_P!!-_\
MOR/\:[BBCF861P__  KB+_H)O_WY'^-'_"N(O^@F_P#WY'^-=Q11S,+(X?\
MX5Q%_P!!-_\ OR/\:/\ A7$7_03?_OR/\:[BBCF861P__"N(O^@F_P#WY'^-
M'_"N(O\ H)O_ -^1_C7<44<S"R.'_P"%<1?]!-_^_(_QH_X5Q%_T$W_[\C_&
MNXHHYF%D</\ \*XB_P"@F_\ WY'^-'_"N(O^@F__ 'Y'^-=Q11S,+(X?_A7$
M7_03?_OR/\:/^%<1?]!-_P#OR/\ &NXHHYF%D</_ ,*XB_Z";_\ ?D?XT?\
M"N(O^@F__?D?XUW%%',PLCA_^%<1?]!-_P#OR/\ &NRM+<6EE!;AMPBC5-V,
M9P,9J:BANX[!1112 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
5BB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>img69628308_13.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img69628308_13.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" )N!;D# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH *S9]"M+F=YGFU ,YR1'J-PB_@JN /P%:5% &1_P (W8_\]]4_\&MU
M_P#'*/\ A&['_GOJG_@UNO\ XY6O10!D?\(W8_\ /?5/_!K=?_'*/^$;L?\
MGOJG_@UNO_CE:]% &1_PC=C_ ,]]4_\ !K=?_'*/^$;L?^>^J?\ @UNO_CE:
M]% &1_PC=C_SWU3_ ,&MU_\ '*/^$;L?^>^J?^#6Z_\ CE:]% &1_P (W8_\
M]]4_\&MU_P#'*/\ A&['_GOJG_@UNO\ XY6O10!D?\(W8_\ /?5/_!K=?_'*
M/^$;L?\ GOJG_@UNO_CE:]% &1_PC=C_ ,]]4_\ !K=?_'*/^$;L?^>^J?\
M@UNO_CE:]% &1_PC=C_SWU3_ ,&MU_\ '*/^$;L?^>^J?^#6Z_\ CE:]% &1
M_P (W8_\]]4_\&MU_P#'*/\ A&['_GOJG_@UNO\ XY6O10!D?\(W8_\ /?5/
M_!K=?_'*/^$;L?\ GOJG_@UNO_CE:]% &1_PC=C_ ,]]4_\ !K=?_'*/^$;L
M?^>^J?\ @UNO_CE:]% &1_PC=C_SWU3_ ,&MU_\ '*/^$;L?^>^J?^#6Z_\
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M% &1_P (W8_\]]4_\&MU_P#'*/\ A&['_GOJG_@UNO\ XY6O10!D?\(W8_\
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MX17P[_T -+_\ X_\*UZ* ,C_ (17P[_T -+_ / ./_"C_A%?#O\ T -+_P#
M./\ PK7HH R/^$5\._\ 0 TO_P  X_\ "C_A%?#O_0 TO_P#C_PK7HH R/\
MA%?#O_0 TO\ \ X_\*/^$5\._P#0 TO_ , X_P#"M>B@#(_X17P[_P! #2__
M  #C_P */^$5\._] #2__ ./_"M>B@#(_P"$5\._] #2_P#P#C_PH_X17P[_
M - #2_\ P#C_ ,*UZ* ,C_A%?#O_ $ -+_\  ./_  H_X17P[_T -+_\ X_\
M*UZ* ,C_ (17P[_T -+_ / ./_"C_A%?#O\ T -+_P# ./\ PK7HH R/^$5\
M._\ 0 TO_P  X_\ "C_A%?#O_0 TO_P#C_PK7HH R/\ A%?#O_0 TO\ \ X_
M\*/^$5\._P#0 TO_ , X_P#"M>B@#(_X17P[_P! #2__  #C_P */^$5\._]
M #2__ ./_"M>B@#(_P"$5\._] #2_P#P#C_PH_X17P[_ - #2_\ P#C_ ,*U
MZ* ,C_A%?#O_ $ -+_\  ./_  H_X17P[_T -+_\ X_\*UZ* ,C_ (17P[_T
M -+_ / ./_"C_A%?#O\ T -+_P# ./\ PK7HH R/^$5\._\ 0 TO_P  X_\
M"C_A%?#O_0 TO_P#C_PK7HH R/\ A%?#O_0 TO\ \ X_\*/^$5\._P#0 TO_
M , X_P#"M>B@#(_X17P[_P! #2__  #C_P */^$5\._] #2__ ./_"M>B@#(
M_P"$5\._] #2_P#P#C_PH_X17P[_ - #2_\ P#C_ ,*UZ* ,C_A%?#O_ $ -
M+_\  ./_  H_X17P[_T -+_\ X_\*UZ* ,C_ (17P[_T -+_ / ./_"C_A%?
M#O\ T -+_P# ./\ PK7HH R/^$5\._\ 0 TO_P  X_\ "C_A%?#O_0 TO_P#
MC_PK7HH R/\ A%?#O_0 TO\ \ X_\*/^$5\._P#0 TO_ , X_P#"M>B@#(_X
M17P[_P! #2__  #C_P */^$5\._] #2__ ./_"M>B@#(_P"$5\._] #2_P#P
M#C_PH_X17P[_ - #2_\ P#C_ ,*UZ* ,C_A%?#O_ $ -+_\  ./_  H_X17P
M[_T -+_\ X_\*UZ* ,C_ (17P[_T -+_ / ./_"KMEIEAIJNMA8VUJKG+"")
M4#'WP.:M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 45R_BF
MY\6R7$6F>&+*UC$T>9=5NY 4MN<86/J[8Y';IFN=^"$US/X(O'O+F2YG_M2X
M#S2$EG/RY)SZF@#TJBFK+&TCQJZETQN4'E<],CM0TL:R)&SJ'?.U2>6QUP.]
M #J*Q?$U]KME81CP]I,6H7TTGE_OYQ%' ,']X_=@#CY1R<UP/PR;6D^)'C6V
MU[4OMU["MKO= 5C4E6;:B]E&<>^,T >L45YIXWO+_7_B%HW@6TU">PLIK9K[
M49;639*\8+!4##IDKS['VQ63XPT ?"RRM?%7AJ]U".WMKF-+^PEN6EBN(F."
M<,3ALX /O0!ZGJFL6.BP137\YB2640QX1G+N02% 4$DX![=J=I^J6NJ1N]J9
MBJ'!\V!XCGZ.!FN>\46L6J:[X81=:CL)4GEN;>-H=[7#"(K\N> 55R><_3@U
M+X;U;4)O$6NZ)>SI>IIODM'>(@0GS%),;@<;UP#QCAAP.X!U%%%% !1110 4
M444 %%%% !1110 4444 %%%% !02 "2< 44R6))H7BD7<CJ58>H/!H S;/7;
M:_UB:PMOWBQ1[VF!X)SC ]>O6DN-7N/[0EL[#3VNGA4&5C*(U7/09(Y-06\$
M5MXO\F"-8XUTT!548 _>&M"[5KZ*2WL]0$$R,!(T8#LO'0CM3 -+U*/5+/SX
MT9"&*.C=58=13-4U0:>8(H[=[BYN&*Q0H<%L<DY[ 50\*L8K>\L'5?,M;AD>
M1<_O"?XCGO4^KV]I?7MI;&[DMM04-);O&#D#^+V[=* &IK=S#>00:EIC6@N'
MV1R+,)%+=@<#BB[UJ[CUA].L]-%RZ1"4L9PG!..XJM->:QHDL+WT\%[9R2K$
M75-DBD]#@<&H9[>ZN/&MPMI>FT<6BDN(E?(R.,&@#7L[S5)K@)=:2MO$0<R"
MY5\?@!56'6M0NYKI;324ECMYW@+M=!<E?;;]*N6-GJ%O.SW>J&[C*X"&!4P<
MCG(_'\ZP]*_M</JYT\V6P:A-\LZMN+<=P<8Z4 ;&G:N]U?36-U:-:W42ARF\
M.&4]P14;:W-<74L.F6#7:PG;)*91&@;N 2#FJ/A\/>W%]J$TQ_M/;Y#Q%-HA
MQT&.<C(Z^U6?"#)_PCT,8XEC=UE'</N/7\,4 6;+6/M-Q+9SVKVU]&N\0.P(
M<>JMT(JC<Z_JEG) D^AJK3R".,?;%.6_[YIVHE7\8Z.L6/-2.5I>/X",#/XY
MI?$?_'_HG_7ZM #[C6M0LK-KJ\TCRXD=0^VX#D*>K<#MQQ[U?OM4M['2VOV8
M/%M#(%/W\] /K5N2-)8VC=0R."K ]P:Y/2M,=M;FT^:;S++2G$D,9[EQE<^N
MWF@#3NM:O+?^SHETP/=7JN?),^W9M .,E?0^U-?7;RSEA_M+2FMH)7$8E2<2
M!2>F0!46O_:?^$@T/[&81<?O]OG [?N#.<<],TZ?2M6U22%-3N+-;6.02&.V
M5LN1V)/2@":[UJ[CUA].L]-%RZ1"4L9PG!..XJQ9WFJ37 2ZTE;>(@YD%RKX
M_ "LB>WNKCQK<+:7IM'%HI+B)7R,CC!K9L;/4+>=GN]4-W&5P$,"I@Y'.1^/
MYT 5#KEU<7$Z:;I;7<4+F-I3.L:EAU SUJWI6JIJ:2@PO!<0/LEA?DJ?KW%9
M=O8-/YU[X?U9HHY9&+Q/%N0OGG ."M7M(U&ZN+F[L;^.-;JU*[FBSM<,,@^U
M $VL:G_95HD_D^;NE6/;NV]>_0U6OO$,6GZ[;Z=-%A)D#>?OX4DD $8Z<=<]
MZA\7_P#((A_Z^8_YU#?V,.I>+9;6=<I)I>,^A\W@CW% &OJ6H_V=]C_=>9]H
MN4M_O8V[L\].>G2KU<3->S?\2W2KYLWMIJ4 W?\ /2/G:PKMJ .>L]?U/4(/
M/M=$5XMQ4,;M1R#Z%:FC\0AM,OKAK1X[BRXEMV;H?]X=JR?#8ULZ1_H+6 @\
MU\><KELYYZ'%6KO2Y-/\.ZQ-<SB:ZN5+RLHPO'0 4 7(M5UB:W2>/1$9'4.N
M+P9((S_=I3XBB;P[+JT4#-Y7#0LVTAL@$9Q[UFM=:_8^'[>XC-DUNL*9,<;&
M1$P.<$X) I+RUMK7P!<"UF,R2*)#*1@L2XR<=O3\* -)-4UJ1%==!4JPR#]M
M7I^56)-5DM[_ $^UN;7R_M:'Y_,SLD R4Z<_6JEOINL&VB*Z^RJ4&!]DC.!B
MI?$%G+-HF]'W75H5G1\8)9>OYC- %S5M172M.>Z9/,8$*D8."[$X JA-XD2U
MUR'3;JW\KS$4F7S,A6/\/3UXS5=[F/7M8TR.,YMX8A>2C/\ $>%!^AJ&[T^'
M4_%=_:3#Y7L5PV.5.X8(H VM1U/^SY[&+R?,^U3B+.[&W/?IS3M7U(:79>>(
MC-(SK''$#@NQ/ S^=<K+?327>DZ?>_\ '[9WR(Y_OK_"P^HJ_J]]YGBBUB%K
M<W45BOFNENFXAV'RYY'08-%@-[3;]-3TZ&\C7:)%R5SG:>A'YUF6NN:C?B9[
M32$DCCE:+<UT%R1[;:J^&[OR=6OM/:WFMHY6-S;QSIL8 \,,?7^1JOH7]L"S
MOFT\V107<ORSJVXMQW!QZ4 ;NFZNUY=SV5Q:M:W<(#-&7#@J>X(K0FE2""2:
M0X2-2S'V R:Y_P ,[;R>[U*>8O?L1%-&4V>5C^$#)].OM6CKNH_V9I;S")97
M=A&B-]TD\<^U %.U\1O-/9B:P:&WO21!+YH8D^ZXXK>KAOL\GA.YCN+V,WD'
MED6Y4D+#*>2H!SC/K7;0NTD$;O&8W9060G.TXZ4,#'GUJ\&KW&GV>F"Y:!59
MF-P$X(ST(J2SUF:34ET^^L&M+AT+Q_O!(K@=>1WK+_XF/_"8ZG_9QM0WE1;_
M +0&(Q@=-M:-II5])JR:EJ=Q"\D2%(HX%(5<]3SS0 :)XBAUB>X@,7D31$X0
MMNW+G&1P.]6H=3\W7+C3?)QY,2R>9NZY[8Q_6N6TZPFDT<ZE8C%]:74C*/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MFO[\X('+-))UX]<<46"YK:+XBCUFZN(1;M#L&^(EL^:FXKNZ<<CWZU-?:O\
MV=J5M!<0;;6X.Q;G?PK]E(QQGUS7+S7BZ;<Z1=Q:;?VT5FH@GDGAVJT9X]3S
MDD_C70^*)[8:*\$L7GR7.(X(E/S,YZ$?3K_^NG8"Q<:MLU>'3;:#SYF&^8[M
MHA3U/!Y]JTZY;PGBRN+S3KU=NJ!M[NS9\U.Q!]JZFDQH****0!1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7FGP._
MY$F]_P"PK<?^RUZ7533M*L-(MVM].LX+2%G,C)"@4%CU.!W- '#>,W2S\66#
M^&"?^$RG S;QC]U-; @,UUZ(!G:WWL\+GI5CP/MN-6O9_$#R-XPC&)XIP%$$
M)/ M@"1Y)(^\,DD?,<@ =K%96L%U/=0VT,=Q<;?.E1 &DVC W'J<#@9I9+2V
MENH;F2")[B$,(I60%D#=<'J,]Z )J\S\%?\ )9OB%_VY_P#HLUZ95.WTK3[2
M_NK^WLX(KN[V_:)D0!Y=HP-Q[X% 'FOB^X@\*?&?0?%&I-Y.DWEB^G27)!V0
MRY9EW'L#D#\">QJ+XM^(=,\1^'[7PCH5];:CJNKW421QVL@E\M P8NQ7(4<#
MKVR>@)'JEW9VNH6LEK>VT-S;R##Q3('1AZ$'@U1TKPQH.A2/)I.C6%E(XPSV
M]NJ,1Z$@9Q0!/=Z1I^HV,=GJ%G!>01[2J3QAP&7HPST/O4EAIMCI5J+73[."
MT@!+>7!&$7)ZG [GUJU10!Q^M^'?&5]K$]SI/CO^R[%]OEV?]D0S^7A0#\['
M)R03STSCM7E%_P#$6XM].N9K/XS?:[J.)WAM_P#A%Q'YK@$JFXKA<G R>F:^
MAZ\G\6?\+3_X0W7/[1_X0W[#_9]Q]H^S_:O,\ORVW;,\;L9QGC- '4?"W6]1
M\1_#C2=6U:X^T7T_G>9+L5-VV9U'"@ < #@5V%>?_!+_ ))#H7_;Q_Z425Z!
M0 4444 %%%% !1110 4444 %%%% !1110!5^PQ?VH=0W/YIA\C&1MV[MWYYJ
MK=:'!<7CW<=Q=6L\@"R-;R;=X'3.0:U** *NGZ?;Z9:BWMU(7)9BQR68]23Z
MTS4M*MM42,7 </&=T<D;;60^QJ[10!D0>'K>.YBN)[J\O'B.Z,7,VX(?4# Y
MI;S08KO4&OEO+RWF9 A,$@7('X5K44 9EIHYM;E)CJ>HS;<_NYI@RG(QR,59
ML=/BL/M/E,Y^T3M.^\CAFQD#CIQ5JB@"B-*@76#J<;2),R;)%4C;(/4C'7I^
M50W&A6\MV]U!/<VDTG^L-M)M#^Y!!&:U** *-AI-MISR21^9)/+]^:5MSM^-
M.O=.AOY;625G!MI1*FTCDCUXZ5<HH *JP:?%;ZA=WB,YDNMF\$C VC QQ5JB
M@"K/I\5QJ%I>.SB2UW[ ",'<,'/%6J** ,F\T&*[U!KY;R\MYF0(3!(%R!^%
M/M-'-K<I,=3U&;;G]W-,&4Y&.1BM.B@#'E\.6S7,D]O=7EFTIW2"VEVACZXP
M:N:?IEMID3K '+2-NDDD;<[GU)JY10!3U+38=4ME@G:15619 4(!R/J#3O[/
MB_M;^TMS^=Y'D;<C;MW;L],YS[U:HH SK_1;34+VTNY=ZS6KAD9"!G!R >.F
M:T:** *>FZ=#I5F+:!G9-Q;+D$Y)SV J6]M([^RFM92PCE7:Q4\X]JGHH B@
MMT@M8[89:.-!&-W.0!CFLU?#MHFF7.G++<"VG;=MW#]WSG"\<#COFM>B@#%7
MP[M4*NLZL !@ 7 X_P#':U;:#[/;)"99)MHQOE;<S?4U+10!G:5HMKHXF%L9
M#YS L7(. .@&!T&34J:="FK2:B&?SGB$17(VX!SZ9S^-7** ,Z]T6TOM0M;Z
M3>L]LP*E"!NP<@'CI_C4MEIL-C-=31M(\ES)YDC.03[ 8 X%7** *5SID-SJ
M%K?%Y$GML[2A W ]0>.G^-+IVG0Z9%+'"SL))6E.\@\GKT'2KE% %%-)@BU9
M]2B:1)9$VR(I&Q_<C'7\:FO;*#4+22UN4WQ.,$?U%6** ,/_ (16Q? NI[R[
M55*HL\VX(/; %:UI;+:6L=NLDDBQC:&D;+$>YJ:B@"G#IT,.IW%^K.99U56!
M(V@#ICBKE%% %/3=-ATNV:"!I&5I&D)<@G)^@%0V>B6EAJ5S?6^]7N!\R9&T
M<YX&*TJ* ,*'PO%;)Y<&J:G$F2=J3 #)_P" U?M-,6V@FAENKF[24887+[^,
M8(' J]10!A#PM;+&84OM12V/_+!9_DQZ8QG%7;O1K2[TQ-/PT5NA4J(B 1CZ
M@UH44 9]UH]K>:G;7\N_SK?[H!&#W&>.QYJ2'3H8=3N+]6<RSJJL"1M '3'%
M7** ,A_#UN)Y);6YN[/S#N=+>3:K'UP0?TJWI^F6VFQNL"L6D.Z21VW.Y]2:
MN44 9VH:)::E=VUS/OWP'("D .,@X;CD9%2SZ;#<ZE;7LC2%[<,(TR-F3U.,
M=:N44 5M0L8=2L9;2?=Y<@P2O4=\BJT.BP17T5X\L\\L,0BC\U@0@QC(  Y/
MK6E10!1O-*@O+NVNR\L5Q;G*21$ D=U.0<BKU%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 023LE[!" -LBN2>_&/\:G
MJG/_ ,A6T_ZYR?\ LM7* "BBB@ HHHH **** "BBB@"MJ%C%J5A-9S,ZQRC#
M%" >O;-3QH(HDC7.%4*,^U.HH J:=IT.F0210L[*\K2G>03ENO0=*EN[6"^M
M9+:YC$D,@PRGO4U% &"/"EL8Q"^H:D]MT^SM<?(1Z8QG'XU:U'0K;4([1/-G
MMQ:G,1MV"E>,=P?2M2BG<#%'AU@0?[;U<X[&X'_Q-7_[.A_M?^T]S^=Y'V?;
MD;=N[=GIG.?>K=%*X%#4M(M]3:W>1Y(I;=]\<L1 93Z<@\4:CH]MJ3Q2R&2*
M>+[D\+;77VSZ5?HH RK?0+:&[2ZGGN;R>/\ U;7,F[9]  !5V^LX]0L9K24L
ML<J[6*'! ]JL44 16\"VUK%;H24B0(I;K@#'-0W&G0W.H6=Z[.)+3?Y8!&#N
M&#GBK=% %34].AU73Y;*=G6.3&2A /!![@^E6Z** ,_5='AU98!+-/"T#^8C
MPL%(/U(-5/\ A'&_Z#>L?^! _P#B:VZ*+@9FHZ%:ZC<)<L\\%R@VB>WDV/CT
MS26.A6UE=_:VFN;JYV[5EN9-Y4>@Z 5J447 CGB6>"2%B0LBE21UP1BL\:#:
MBPL+/S)O+LIEFC.1DLI.,\=.?:M2B@"GJFF6VKV+6ET&V,005."I'<5-:VZ6
M=G!;1EBD,:QJ6ZD 8&:FHH IPZ9#!JMSJ"M(9KA55U)&T!1QCBKE%% %+3-,
MATJV:"!I&1I&D)<@G)^@%0V6A6>GZG<W]OO62X&'3(V#G/ Q_6M.B@# @\*1
M6T?EV^JZI#'DG9'.H&3_ ,!K1LM,%I#+%)=W5VLO!^U.'P/0<#BKU%.X&#_P
MB=JL;0Q7^HQ6QS^XCN,)@]L8SC\:N76AV=SI*:: \-LA4J(B 1@Y[@UI447
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %?.&N_\ "B?^$>U/^R/^0G]DE^Q_\?W^NV'9][Y?O8Z\
M>M?1]>%^)?BGXJU'PKJ]E<?#'6;."XLIHI+F0R[859""YS"!@ YZCIU% ':?
M!+_DD.A?]O'_ *425Z!7G_P2_P"20Z%_V\?^E$E>@4 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %.?_ )"MI_US
MD_\ 9:N53G_Y"MI_USD_]EJY0 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %>3^+/B3]N\&ZY9_\(5XRM_/T^XB\ZXTK9''NC8;G;=PH
MSDGL*]8KG_'?_)//$O\ V"KK_P!%-0!S_P $O^20Z%_V\?\ I1)7H%>?_!+_
M ))#H7_;Q_Z425Z!0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% $;SPQMM>6-3Z,P%.1UD4,C!E/<'(JEJD,3PQ
MLT:,WGQ#)4$XWBKR(L:A44*HZ # H 6BBB@ HHHH ***CGE>) R023'.-L94
M$>_S$4 2456L[PWD8D%M-%&RAE:0K\P/T8G\ZLT %%%% !1110 4444 %%%%
M !1110 4444 4Y_^0K:?]<Y/_9:N53G_ .0K:?\ 7.3_ -EJY0 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %>3^+/A!X$TSP;KE_9Z%
MY=U:Z?<30O\ :YSM=8V*G!?!P0.M>L5S_CO_ ))YXE_[!5U_Z*:@#G_@E_R2
M'0O^WC_THDKT"O/_ ()?\DAT+_MX_P#2B2O0* "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **JWQN$
MMGE@E1#&C,0R;LX'U&*=:>>80\\J2%@"-J;<<?4T 6**** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@"GJ7_'O%_P!?$7_H:U<JGJ7_ ![Q?]?$
M7_H:U<H **** "BBB@ HHHH IZ5_R";3_KDO\JN53TK_ )!-I_UR7^57* "B
MBB@ HHHH **** "BBB@ HHHH **** *<_P#R%;3_ *YR?^RU<JG/_P A6T_Z
MYR?^RU<H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/8'('X$]C47Q;\0Z9XC\/VOA'0KZVU'5=7NHDCCM9!+Y:!@Q=BN0HX'7MD]
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M4M;0DN)"V4')XZUH@!5"J  . !VJI<?\A*S^DG\A5R@ HHHH **** "BBB@
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MH7% %BBBB@ HHHH IC5+8R^4!<;_ $^S2=/7[O2KE4U_Y##_ /7NO_H35<H
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M('\S0!)156RO'O$$GV9XD(RK,RG/Y&K5 !1110 4444 %%%% !1110!!>_\
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MUX&!DWB()_UH<M-^\CL****^F.P**** *>E?\@R#Z?UJY5/2O^09!]/ZU<H
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M_KE)_P"@U]S+9GNS^%GT!7+>-?\ CVM/]]OY"NIKEO&O_'M:?[[?R%>1C_\
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M &6N2KK?&W2Q_P"VG_LM<E7S&8_[S+Y?DCCJ_&SAO%SM'K<;(Q4^2.0<=S6
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M/'OB;<OKC% $E%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M,YR1_>I5^+6DV\CW+:?>E;G!4#9D;>.>?:N(\<?\>VG?[\W\DKF+C_CPL_\
M=?\ ]"->YET$\+!O^M6>AAZ494HMGTKX=UV#Q)HT6IVT4D44C,H63&1@X[?2
MM6N+^%?_ "(5G_UTE_\ 0S7:5M)6=C.:M)I!4%[_ ,>-Q_UR;^53U!>_\>-Q
M_P!<F_E43^%D/8\L[U1UO_D 7_\ UQ_J*O=ZHZW_ ,@"_P#^N/\ 45\M@_\
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M44 %%%% !1110 4444 %%%% !4%I>6M_;+<6=S#<P-]V6%PZGZ$<5)*I>%U
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MM3@[2=A.26YT]%9FG:]9ZI<-!;B4.J%SO7 QD#U]Z>\NH"^6W5[;#HS@F-N
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M?.LU_<SQ^7+*67TP*^BO ?\ R(VD?]<!_,U]-5^$[Z_PJYT5%%%8'*4-;_Y
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MQ_UR;^53U!>_\>-Q_P!<F_E6<_A9F]CRSO5'6_\ D 7_ /UQ_J*O=ZHZW_R
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M5PGA#_D-'_KDW\Q7=UU99_ ^;+H_"%%%%>B:G >*_P#D.R?[B_RK$K;\5_\
M(=D_W%_E6)7R>+_CS]6<4_B9ZCIW_(-M?^N*?R%6:K:=_P @VU_ZXI_(59KZ
MFG\".Q;!61XG_P"1?N?^ _\ H0K7K(\3_P#(OW/_  '_ -"%9XG^#/T?Y"G\
M+//*ZKP5_K[S_=7^M<K75>"O]?>?[J_UKY[ ?[S'^NARTOC1V%%%%?4'8%>=
M^)?^1@NO^ _^@BO1*\[\2_\ (P77_ ?_ $$5YF:J]%+S_1F-;X3)'2O5X?\
M41_[HKR<5ZQ#_J(_]T5GEO\ $J?UW%1W8^BBBO7-RIJ.H1:9:_:)E=DW!<(
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M'/\ D/VGU;_T$U\W1KU7*%Y/?N_(XXRE=:GHU%%%?2G8%%%% !1110 4444
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M9?\ 7M_[.U=E7&^./^/ZR_Z]O_9VKS<F_P!Y^3%@OXIRU?2?@/\ Y$;2/^N
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M."N*\9_\A&W_ .N/]37:UQ7C/_D(V_\ UQ_J:X,R_P!W?R,JWP'-5Z1X?_Y
M-I_N?U->;UZ'HMO%<>'[-95W*%R!DCN:\_*?XLO3]3*A\1KT5GZ/!''IUO*H
M.^2)2Q))SQ6A7OG4%%%% '/^,/\ D#)_UV7^35PM=UXP_P"0,G_79?Y-7"U\
MYF?\?Y')6^(Y;QQ_Q[:=_OS?R2N-KLO''_'MIW^_-_)*XVOHLL_W2']=3UL)
M_!B?0/PK_P"1"L_^NDO_ *&:[2N+^%?_ "(5G_UTE_\ 0S7:5<_B9SU/C85!
M>_\ 'C<?]<F_E4]07O\ QXW'_7)OY5G/X69O8\L[U1UO_D 7_P#UQ_J*O=ZH
MZW_R +__ *X_U%?+8/\ WB'JOS.2C_$CZH\RKT[X+?\ (9U/_KW7_P!"KS&O
M3O@M_P AG4_^O=?_ $*OM:GPL]NM\#/9Z***Y3@"O.?$?_(?NO\ >'\A7HU>
M<^(_^0_=?[P_D*\O-OX*]?T9C7^$RZ\D/6O6Z\D/6GD7_+SY?J=&7_:^7ZG2
M> /^1[TC_KL?_037TC7S=X _Y'O2/^NQ_P#037TC7L5MS;$?$@HHHK(YSDO&
MW2Q_[:?^RUR5=;XVZ6/_ &T_]EKDJ^8S'_>9?+\D<=7XV<+XQ_Y#*?\ 7%?Y
MFN>KH?&/_(93_KBO\S7/5]5@O]VAZ(]JA_"CZ'U'X>_Y%O2_^O2+_P! %:59
MOA[_ )%O2_\ KTB_] %:52]SB>X4444A%.?_ )"MI_USD_\ 9:N53G_Y"MI_
MUSD_]EJY0 5P_C+_ )"T/_7 ?^A-7<5P_C+_ )"T/_7 ?^A-7GYG_N[]495O
MA.=KTK0_^0)9_P#7,5YK7I6A_P#($L_^N8KARG^)+T,Z&[-"BBBO>.DIZM_R
M![S_ *XO_*O,:].U;_D#WG_7%_Y5YC7A9M\<?0YJ^Z-_PA_R&C_UR;^8KNZX
M3PA_R&C_ -<F_F*[NNS*_P"!\S2C\(4445Z)J<!XK_Y#LG^XO\JQ*V_%?_(=
MD_W%_E6)7R>+_CS]6<4_B9ZCIW_(-M?^N*?R%6:K:=_R#;7_ *XI_(59KZFG
M\".Q;!61XG_Y%^Y_X#_Z$*UZR/$__(OW/_ ?_0A6>)_@S]'^0I_"SSRNJ\%?
MZ^\_W5_K7*UU7@K_ %]Y_NK_ %KY[ ?[S'^NARTOC1V%%%%?4'8%>=^)?^1@
MNO\ @/\ Z"*]$KSOQ+_R,%U_P'_T$5Y>;?P5Z_HS&O\ "9->KP_ZB/\ W17E
M%>KP_P"HC_W16&4;S^7ZDT.H^BBBO;.@PO%O_($/_71?ZUP/>N^\6_\ ($/_
M %T7^M<%7@9BTL1KV_S.6K\1U_@K_5WGU7^M=77*>"O]7>?5?ZUU=>GE_P#N
MT?ZZFU+X$%%%%=AH>8:G_P A6[_Z[/\ S-,L/^0A;?\ 75?YBGZG_P A6[_Z
M[/\ S-,L/^0A;?\ 75?YBOD7_%^?ZG#]H]2[44=J*^N.X*YOQG_R#(/^NO\
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M!_\ (C:1_P!<!_,U\V5])^ _^1&TC_K@/YFOIJVQZ.(^%'14445SG&4-;_Y
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MO?\ ]G:NSKC/&_\ R$+/_KW_ /9VKS,F_P!Y^3%@OXIR]?2?@/\ Y$;2/^N
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MFWY(''/->U#I7T#BUN=4H.-KA1114D'/^,/^0,G_ %V7^35PM=UXP_Y R?\
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M6*ZJGQ,BM\;"BBBH,CS'5?\ D,7O_7=__0C5%_\ 5M]#5[5?^0Q>_P#7=_\
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M%>KP_P"HC_W16&4;S^7ZDT.H^BBBO;.@PO%O_($/_71?ZUP5=[XM_P"0(?\
MKHO]:X*OG<T_C_(Y:WQ'7^"O]7>?5?ZUU=<IX*_U=Y]5_K75UZV7_P"[1_KJ
M;4O@04445V&AYAJ?_(5N_P#KL_\ ,TRP_P"0A;?]=5_F*?J?_(5N_P#KL_\
M,TRP_P"0A;?]=5_F*^1?\7Y_J</VCU+M11VHKZX[@KF_&?\ R#(/^NO]#725
MS?C/_D&0?]=?Z&N7&_[O(BI\+.)KMO!G_(,G_P"NW_LHKB:[;P9_R#)_^NW_
M +**\7+/]X7S.>C\1TE%%%?2'6%>4S_\?$G^\:]6KRF?_CXD_P!XUXV;[0^?
MZ'/7Z%O1?^0U:?\ 745Z77FFB_\ (:M/^NHKTNKRG^'+U'0V84445ZQN<AXU
M_P!99_1OZ5RE=7XU_P!99_1OZ5RE?,9A_O,OE^1QU?C9Z#X6_P"0!!]6_P#0
MC6S6-X6_Y $'U;_T(ULU]!A?X$/1'5#X4%-E_P!4_P#NFG4V7_5/_NFMGL4>
M4'[Q^M:?AS_D/VGU;_T$UF'[Q^M:?AS_ )#]I]6_]!-?)8?^-'U7YG#'XD>C
M4445]<=P4444 %%%% !1110 4444 >6:;=0^&/CKK\.JN((_$%O!+87$G".T
M:A6CS_>SGCV'J!7H=]H>F:EJ-AJ%Y:)+=Z>S-:RDD&(MC<1@]\#KZ5%X@\/:
M3XDTQ[/6--AOH!EE208(..JL.5/;((->$Z7 =5GN;32O"?B^2VM7,,L$/B#_
M $=6'5 W0X] QQ0!W7BJYA\2_%WPGH^F,)YM&DEOK^6,Y$"X7:I/J2 ,>XKU
M&O&=!\6_\(AJ$7AG2_AC=:==7 ,B1->1AK@+U(=_]80.P8X%>B>%O&%GXH-[
M;I:W5CJ-BX2[L;M-LL1/*GC(*D<@B@#HJ*** "BBB@ HHHH **** "BBB@ H
MHHH **S=5UVPT8VZ7<DAFN6*000Q-++*0,G:B@D@#DG&!WI=)URPUN.9K*5R
M]O)Y4\4L;121/C.&1@".""..1R* -&O)_%GP@\":9X-UR_L]"\NZM=/N)H7^
MUSG:ZQL5."^#@@=:]8KG_'?_ "3SQ+_V"KK_ -%-0!S_ ,$O^20Z%_V\?^E$
ME8S_ 'V^M;/P2_Y)#H7_ &\?^E$E8S_?;ZUXV;_8^?Z'/7Z%/5?^0/>_]>\G
M_H)KSJT_X]K_ /ZX#_T8E>BZK_R![W_KWD_]!->=V]U;0P21M;.[2)L=O-QQ
MN#<#'L*Z\D_@R]3KP/P/U.[^#/\ R-5[_P!>3?\ H:5[=7B7P<*GQ;?E%*K]
MC; )SCYT[U[;7I5?B+K_ !A11169B%4],_X\S_UVE_\ 1C5!?:]8Z?<FWG9Q
M( #\JYZUG67B?38+<H[29\R1N$[%R1^AK&6(I1;3DM">>*ZFWJ'_ "#;K_KB
M_P#(U-#_ *F/_='\J^:;Z[F?Q?<XFDV&_; W'IYAI- N9SXMTQ3/(0;Z(8WG
M_GH*ZU2NKW.KV'F?35%%%9'.%<KXU_U-G_O-_2NJKE?&O^IL_P#>;^E<>8?[
MM+Y?F9U?@9Q]<;XX_P"/ZR_Z]O\ V=J[*N-\<?\ ']9?]>W_ +.U>;DW^\_)
MBP7\4Y:OI/P'_P B-I'_ %P'\S7S97TGX#_Y$;2/^N _F:^FK;'HXCX4=%11
M17.<90UO_D"7G_7(UYI7I>M_\@2\_P"N1KS2O!S;^)'T.:ONC%\5?\@";_>7
M^8KSZO0?%7_( F_WE_F*\^KU\G_W;YL]' _PCV#X*?\ 'GK'_72+^35ZK7E7
MP4_X\]8_ZZ1?R:O5:ZJGQ,BM\;"BBBH,CR_4O^0K>?\ 7=__ $(U1N/^/:7_
M '#_ "J]J7_(5O/^N[_^A&J-Q_Q[2_[A_E7R/_+[Y_J<*^(\HKM?A3_R/EM_
MURD_]!KBJ[7X4_\ (^6W_7*3_P!!K[F?PL]^I\#/H"N6\:_\>UI_OM_(5U-<
MMXU_X]K3_?;^0KR,?_N\OZZGE5?@9QU<9XW_ .0A9_\ 7O\ ^SM79UQGC?\
MY"%G_P!>_P#[.U>9DW^\_)BP7\4Y>OI/P'_R(VD?]<!_,U\V5])^ _\ D1M(
M_P"N _F:^GK;'HXCX4=%1117.<90UO\ Y EY_P!<C7FE>EZW_P @2\_ZY&O-
M*\'-OXD?0YJ^Z,CQ/_R+UU_P#_T,5YW7HGB?_D7KK_@'_H8KSNO7R?\ W;YL
M]' _POF>N_!/_5:U_O0_^SUZQ7D_P3_U6M?[T/\ [/7K%=53XF16^-A1114&
M1YCJO_(8O?\ KN__ *$:HO\ ZMOH:O:K_P AB]_Z[O\ ^A&J+_ZMOH:^1?\
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M_5:U_O0_^SUZQ7D_P3_U6M?[T/\ [/7K%=53XF16^-A1114&1YCJO_(8O?\
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M]U_O#^0KR\V_@KU_1F-?X3+KR0]:];KR0]:>1?\ +SY?J=&7_:^7ZG2> /\
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M@MTR.>>*]TKPOQ+JOA63PKJZ6_PEUFQG:RF$=W)X<BB6!MAPY<'*A3SGMC-
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M_P AH_\ 7)OYBNO;_D,1?]<'_P#0EKLRO^!\S2C\)<HHHKT34X#Q7_R'9/\
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M\&?\@R?_ *[?^RBO%RS_ 'A?,YZ/Q'24445](=85Y3/_ ,?$G^\:]6KRF?\
MX^)/]XUXV;[0^?Z'/7Z%O1?^0U:?]=17I=>::+_R&K3_ *ZBO2ZO*?X<O4=#
M9A1117K&YR'C7_66?T;^E<I75^-?]99_1OZ5RE?,9A_O,OE^1QU?C9Z#X6_Y
M $'U;_T(ULUC>%O^0!!]6_\ 0C6S7T&%_@0]$=4/A04V7_5/_NFG4V7_ %3_
M .Z:V>Q1Y0?O'ZUI^'/^0_:?5O\ T$UF'[Q^M:?AS_D/VGU;_P!!-?)8?^-'
MU7YG#'XD>C4445]<=P4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %>3^+/$_CNX\&ZY#>?#K[):R:?<)-<?VW
M!)Y2&-@S[0,M@9.!UQ7K%>3^+/B3]N\&ZY9_\(5XRM_/T^XB\ZXTK9''NC8;
MG;=PHSDGL* -CX)?\DAT+_MX_P#2B2L9_OM]:V?@E_R2'0O^WC_THDK&?[[?
M6O&S?['S_0YZ_0IZK_R![W_KWD_]!->7UZAJO_('O?\ KWD_]!->7UV9'_!E
MZ_H=N ^!^IZ/\&?^1JO?^O)O_0TKVZO$?@S_ ,C5>_\ 7DW_ *&E>W5Z-7XA
MU_C"BBBLS$X'Q9_R'&_ZYK6'6YXL_P"0XW_7-:PZ^4Q?\>?J<4_B9YCK'_(;
MO_\ KYD_]"-3^&_^1ITC_K]A_P#0Q4&L?\AN_P#^OF3_ -"-3^&_^1ITC_K]
MA_\ 0Q7VE/\ AKT/>7P?(^H:***YCS@KE?&O^IL_]YOZ5U5<KXU_U-G_ +S?
MTKCS#_=I?+\S.K\#./KC?''_ !_67_7M_P"SM795QOCC_C^LO^O;_P!G:O-R
M;_>?DQ8+^*<M7TGX#_Y$;2/^N _F:^;*^D_ ?_(C:1_UP'\S7TU;8]'$?"CH
MJ***YSC*&M_\@2\_ZY&O-*]+UO\ Y EY_P!<C7FE>#FW\2/H<U?=&+XJ_P"0
M!-_O+_,5Y]7H/BK_ ) $W^\O\Q7GU>OD_P#NWS9Z.!_A'L'P4_X\]8_ZZ1?R
M:O5:\J^"G_'GK'_72+^35ZK754^)D5OC84445!D>7ZE_R%;S_KN__H1JC<?\
M>TO^X?Y5>U+_ )"MY_UW?_T(U1N/^/:7_</\J^1_Y??/]3A7Q'E%=K\*?^1\
MMO\ KE)_Z#7%5VOPI_Y'RV_ZY2?^@U]S/X6>_4^!GT!7+>-?^/:T_P!]OY"N
MIKEO&O\ Q[6G^^W\A7D8_P#W>7]=3RJOP,XZN,\;_P#(0L_^O?\ ]G:NSKC/
M&_\ R$+/_KW_ /9VKS,F_P!Y^3%@OXIR]?2?@/\ Y$;2/^N _F:^;*^D_ ?_
M "(VD?\ 7 ?S-?3UMCT<1\*.BHHHKG.,H:W_ ,@2\_ZY&O-*]+UO_D"7G_7(
MUYI7@YM_$CZ'-7W1D>)_^1>NO^ ?^ABO.Z]$\3_\B]=?\ _]#%>=UZ^3_P"[
M?-GHX'^%\SUWX)_ZK6O]Z'_V>O3+7_C^OO\ KHO_ * M>9_!/_5:U_O0_P#L
M]>F6O_']??\ 71?_ $!:ZJGQ,BM\;+E%%%09'F.J_P#(8O?^N[_^A&J+_P"K
M;Z&KVJ_\AB]_Z[O_ .A&J+_ZMOH:^1?\7Y_J</VCR:NU^%/_ "/EM_URD_\
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MK_J;/_>;^E=57*^-?]39_P"\W]*X\P_W:7R_,SJ_ SCZXWQQ_P ?UE_U[?\
ML[5V5<;XX_X_K+_KV_\ 9VKS<F_WGY,6"_BG+5])^ _^1&TC_K@/YFOFROI/
MP'_R(VD?]<!_,U]-6V/1Q'PHZ*BBBN<XRAK?_($O/^N1KS2O2];_ .0)>?\
M7(UYI7@YM_$CZ'-7W1B^*O\ D 3?[R_S%>?5Z#XJ_P"0!-_O+_,5Y]7KY/\
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MJG/_ ,A6T_ZYR?\ LM7* "N'\9?\A:'_ *X#_P!":NXKA_&7_(6A_P"N _\
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M^'/&/_"0:B]I]@\C;$9-WG;LX(&,;1ZUU%>J;G(>-?\ 66?T;^E<I75^-?\
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M!^%?_(A6?_727_T,UVE<7\*_^1"L_P#KI+_Z&:[2KG\3.>I\;"H+W_CQN/\
MKDW\JGJ"]_X\;C_KDW\JSG\+,WL>6=ZHZW_R +__ *X_U%7N]4=;_P"0!?\
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M\8_\AE/^N*_S-<]7U6"_W:'HCVJ'\*/H?4?A[_D6]+_Z](O_ $ 5I5F^'O\
MD6]+_P"O2+_T 5I5+W.)[A1112$4Y_\ D*VG_7.3_P!EJY5.?_D*VG_7.3_V
M6KE !7#^,O\ D+0_]<!_Z$U=Q7#^,O\ D+0_]<!_Z$U>?F?^[OU1E6^$YVEN
MO%6M:?,+6UO?+AC1-J^4AQ\H/4C-)61JW_(1?_<3_P! %<.4_P 27H9T-V:7
M_"7Z[;?N8;[;&G"CR4.!^*UZZA)C4GJ0*\&G_P!>_P!:]YB_U2?[HKWCI*NK
M?\@>\_ZXO_*O,:].U;_D#WG_ %Q?^5>8UX6;?''T.:ONBKJ/_'FWU%9 _P"/
M=O\ ?'\C6OJ/_'FWU%9 GD QD8_W17;EG\#YLTH_">@_#7_CTO\ _KHG\C7=
M5POPU_X]+_\ ZZ)_(UW5>@:G >*_^0[)_N+_ "K$K;\5_P#(=D_W%_E6)7R>
M+_CS]6<4_B9@7?\ Q^3_ /71OYU/HW_(<T__ *^8_P#T(5!=_P#'Y/\ ]=&_
MG4^C?\AS3_\ KYC_ /0A7U4/A1V+8]RK(\3_ /(OW/\ P'_T(5KUD>)_^1?N
M?^ _^A"LL3_!GZ/\A3^%GGE=5X*_U]Y_NK_6N5J_8:\WA^WGN4MQ,79$VEMN
M.&.>GM7SV _WF/\ 70Y:7QH[]/\ D,S?]>\?_H3U<KS@?$*59VNO[.3+J(]O
MFGC:2<]/]K]*ZSPSKS>(+&6Y>W$)27R]H;=G@'/3WKZ@[#;KSOQ+_P C!=?\
M!_\ 017HE>=^)?\ D8+K_@/_ *"*\O-OX*]?T9C7^$R:P1_Q^G_?-;U8(_X_
M3_OFL<H^W\OU)H=2]X:_Y&73_P#KNM>U5XKX:_Y&73_^NZU[57M'087BW_D"
M'_KHO]:X*N]\6_\ ($/_ %T7^M<%7SN:?Q_D<M;XCK_!7^KO/JO]:ZNN4\%?
MZN\^J_UKJZ];+_\ =H_UU-J7P(****[#0\PU/_D*W?\ UV?^9JO#_KX_]X?S
MJQJ?_(5N_P#KL_\ ,U7A_P!?'_O#^=?(O^+\_P!3A^T<Y#_KC]&_D:VO!7_(
MW6'U?_T!JQ8?]<?HW\C6UX*_Y&ZP^K_^@-7UQW'L%<WXS_Y!D'_77^AKI*YO
MQG_R#(/^NO\ 0URXW_=Y$5/A9Q-9^HW,\,B+%-)&",D*Q%:%96J_ZV/_ ':\
M7+/]X7HSGH_$127MTH3%S,,KDXD/->N>%G:3PS8L[%F,?))R3S7CDOW8_P#=
MKV+PG_R*]A_US_K7TAUFS7E,_P#Q\2?[QKU:O*9_^/B3_>->-F^T/G^ASU^A
M!-_Q[R_[C?RK!B^[+_N?U%;TW_'O+_N-_*L&+[LO^Y_45IE/\*7J50^%G5?#
MG_D8IO\ KU;_ -"6O4:\N^'/_(Q3?]>K?^A+7J->J;'(>-?]99_1OZ5RE=7X
MU_UEG]&_I7*5\QF'^\R^7Y''5^-F[9^,+?0M/M[26TEE8J7W*P Y8TL'Q!M;
M1&C:QF8L[29##HS%L?K7'ZS_ *RV_P"N7_LS50F^^O\ N+_(5]!A?X$/1?D=
M4/A1[G8W2WUA;W:J56:-9 IZC(S4TO\ JG_W35#P_P#\B[IO_7K'_P"@BK\O
M^J?_ '36SV*/*#]X_6J]Y_QZ2?2K!^\?K5>\_P"/23Z5\GA_XT/5?F<,/B1B
MI_J9?PKLOAM_R$[S_KD/YUQJ?ZF7\*[+X;?\A.\_ZY#^=?6G<>DT444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !2*ZOG:P.#@X/0^E<QXIB\7W\\6
MG>'9;+3[66/-QJ<^9)(N2-L<?0MT.2<<^M<U\"PX\"W8EE>60:I<;I'.6<_+
MDD]R: /3:*@BO;6>ZGM8;F&2XM]OG1(X+1[AD;AU&1R,TLEW;174-M)/$EQ,
M&,43. SA>N!U..] $U('4L5# L.2,\BL;Q++XB2PCC\-6UE)>2R;&EO9"L<"
MX/SD#EN<<"O/?A?::A8?$SQQ:ZIJ<FI7L2VGFW3KMWDJS<+T &< #L* /7*;
M')'*NZ-U<9QE3FO+_'/F^*_B7HO@:2ZGATDVC7^H)!(4-PN658R1SC*\CT;/
M4#&9X[\*:=\--.M?&'A&*73I;&YB6[MXYW,=U"6VE6#$^HY]R>N" #V"YN8+
M.VEN;J:."WB4O)+*P544=22> *KZ1JUEKNE0:GITWG6DX)CDVD;@"1G!]P:+
MS3M/UFWM_MMI%=11R+/&DR[E#@'#8/&1GO7+?"+_ ))5H'_7!O\ T-J .VKG
M_'?_ "3SQ+_V"KK_ -%-705S_CO_ ))YXE_[!5U_Z*:@#G_@E_R2'0O^WC_T
MHDK&?[[?6MGX)?\ )(="_P"WC_THDK&?[[?6O&S?['S_ $.>OT*>J_\ ('O?
M^O>3_P!!->7UZAJO_('O?^O>3_T$UY?79D?\&7K^AVX#X'ZGH_P9_P"1JO?^
MO)O_ $-*]C.J:>K%3?VH(."#,O\ C7C/P=ECA\3WK2R*B_8F&6.!]]*]>:]M
M?[7C;[3#M\AAGS!C.Y:]&K\0Z_QFG14<4\4X)BE20#KL8'%25F8G ^+/^0XW
M_7-:PZW/%G_(<;_KFM8=?*8O^//U.*?Q,\QUC_D-W_\ U\R?^A&I_#?_ "-.
MD?\ 7[#_ .ABH-8_Y#=__P!?,G_H1J?PW_R-.D?]?L/_ *&*^TI_PUZ'O+X/
MD?4-%%%<QYP5ROC7_4V?^\W]*ZJN5\:_ZFS_ -YOZ5QYA_NTOE^9G5^!G'UQ
MOCC_ (_K+_KV_P#9VKLJXWQQ_P ?UE_U[?\ L[5YN3?[S\F+!?Q3EJ^CO!5Q
M';> ]':4L 8 /E0MW/H*^<:^B/!6H64/@?2XI;RW206XRK2J".O;-?35MCT<
M1\*.FMKR"[!,+,PP#DH0"#Z9'-3UE:=J>GIIMHC7ULKB% 5,J@@X''6M6N<X
MRAK?_($O/^N1KS2O2];_ .0)>?\ 7(UYI7@YM_$CZ'-7W1B^*O\ D 3?[R_S
M%>?5Z#XJ_P"0!-_O+_,5Y]7KY/\ [M\V>C@?X1[!\%/^//6/^ND7\FKU6O*?
M@LH>QUI&SAGB!P<=F[UZ'9VD2W]U@R_NG78#*Q ^4'U]ZZJGQ,BM\;-.BBBH
M,CR_4O\ D*WG_7=__0C5&X_X]I?]P_RJ]J7_ "%;S_KN_P#Z$:HW'_'M+_N'
M^5?(_P#+[Y_J<*^(\HKM?A3_ ,CY;?\ 7*3_ -!KBJ[7X4_\CY;?]<I/_0:^
MYG\+/?J? SZ KEO&O_'M:?[[?R%=37+>-?\ CVM/]]OY"O(Q_P#N\OZZGE5?
M@9QU<9XW_P"0A9_]>_\ [.U=G7&>-_\ D(6?_7O_ .SM7F9-_O/R8L%_%.7K
MZ3\!_P#(C:1_UP'\S7S97K.@^.+[2=!L+&*UMW2*!0&?=DY&?7WKZ>ML>AB/
MA1ZAI/\ R!['_KWC_P#015RO,H/'U_:+':):6Q2$"($[LD#CUKTVN<Y"AK?_
M "!+S_KD:\TKTO6_^0)>?]<C7FE>#FW\2/H<U?=&1XG_ .1>NO\ @'_H8KSN
MO1/$_P#R+UU_P#_T,5YW7KY/_NWS9Z.!_A?,WM _U,W^\/Y5L5CZ!_J9O]X?
MRK8KJJ?$R*WQL]=\#_\ (I6GUD_]#-=%7.^!_P#D4K3ZR?\ H9KHJ@R/,=5_
MY#%[_P!=W_\ 0C5%_P#5M]#5[5?^0Q>_]=W_ /0C5%_]6WT-?(O^+\_U.'[1
MY-6QX<_X_P";_K@W\Q6/6QX<_P"/^;_K@W\Q7W,_A9[]3X&=$G^JE^@_G79_
M#7_D(WW_ %R7^=<<@01L#* 6 XP>*[+X;<:E?<Y_=#^=<AYQZ/7%>,_^0C;_
M /7'^IKM:XKQG_R$;?\ ZX_U-<&9?[N_D95O@.:KSSQ3_P C%=?1/_0%KT.O
M//%/_(Q77T3_ - 6N3(_X\O3]47@/XC]#'KT"3_D*/\ ]=C_ #KS^O061FU*
M0@$@3')].:^AK=#LQ/0L^'/^1DT[_KX3^=>UUXKX>1D\2Z<&!!^T)U^M>U5@
M<IS_ (P_Y R?]=E_DU<+7=>,/^0,G_79?Y-7"U\YF?\ '^1R5OB.6\<?\>VG
M?[\W\DKC:[+QQ_Q[:=_OS?R2N-KZ++/]TA_74];"?P8GOWPQGBM_A]:232I$
MGF2#<[!1]\]S780WUI<N4@NH)6 R5CD#''X5QOPONK>'P)9K)/$C>9)PS@'[
MYKIM.O;5;,!KF$'S).#(/[YJY_$SGJ?&S3J"]_X\;C_KDW\JF!# $$$'D$5#
M>_\ 'C<?]<F_E6<_A9F]CRSO5'6_^0!?_P#7'^HJ]WJCK?\ R +_ /ZX_P!1
M7RV#_P!XAZK\SDH_Q(^J/,J].^"_.L:G_P!>Z_\ H5>8UV?P^UV70+F^N8H4
ME+HD>&)&.2?Z5]K4^%GMUO@9[?%96JZQ/BVA&V")EQ&.#NDY'Y#\JTZ\U'Q!
MNEF:Z^PP[I%$97<< +DY_P#'S^5=AX8UN37M,>[EA2)EE,>U22. #_6N4X#:
MKSGQ'_R'[K_>'\A7HU><^(_^0_=?[P_D*\O-OX*]?T9C7^$RZ\D/6O6Z\D/6
MGD7_ "\^7ZG1E_VOE^ITG@#_ )'O2/\ KL?_ $$U] WPN4GA,5V\:RR!"H13
MCY2>,CVKYZ\$3QVOC+3;B9ML43L[M@G "DD\5[;<^+]"F>W,=]D1R[W_ '+\
M#!&?N^I%>Q6W-L1\2.FC5DC"LY=AU8@ G\J=65IWB32=5N?L]E=^;+M+;?+=
M>!]0/6M6LCG.2\;=+'_MI_[+7)5UOC;I8_\ ;3_V6N2KYC,?]YE\OR1QU?C9
MPOC'_D,I_P!<5_F:YZNA\8_\AE/^N*_S-<]7U6"_W:'HCVJ'\*/H?4?A[_D6
M]+_Z](O_ $ 5I5F^'O\ D6]+_P"O2+_T 5I5+W.)[A1112$4Y_\ D*VG_7.3
M_P!EJY5.?_D*VG_7.3_V6KE !7#^,O\ D+0_]<!_Z$U=Q7#^,O\ D+0_]<!_
MZ$U>?F?^[OU1E6^$YVLC5O\ D(O_ +B?^@"M>LG5-O\ :3[\XV)T_P!T5PY3
M_$EZ&=#=E2?_ %[_ %KWF+_5)_NBO!IF1W+*&!)R<U[S%_JD_P!T5[QTE75O
M^0/>?]<7_E7F->G:M_R![S_KB_\ *O,:\+-OCCZ'-7W15U'_ (\V^HK$K;U'
M_CS;ZBL2NW+/X'S9I1^$]%^&O_'I?_\ 71/Y&NZKA?AK_P >E_\ ]=$_D:[J
MO0-3@/%?_(=D_P!Q?Y5B5M^*_P#D.R?[B_RK$KY/%_QY^K.*?Q,P+O\ X_)_
M^NC?SJ?1O^0YI_\ U\Q_^A"H+O\ X_)_^NC?SJ?1O^0YI_\ U\Q_^A"OJH?"
MCL6Q[E61XG_Y%^Y_X#_Z$*UZR/$__(OW/_ ?_0A66)_@S]'^0I_"SSRJ^I?\
M@MO^NR?R:K%5]2_Y!;?]=D_DU?/Y?_O,?G^1RTOC1C'_ (]U_P!\_P A7I/P
MW_Y EU_U\G_T%:\V/_'NO^^?Y"O2?AO_ ,@2Z_Z^3_Z"M?3G8=E7G?B7_D8+
MK_@/_H(KT2O._$O_ ",%U_P'_P!!%>7FW\%>OZ,QK_"9-8)=([EV968ACC#8
M_I6]7.S?Z^3_ 'C6.4?;^7ZDT.II^'"I\3:=M! \Y>IS7M->*^&O^1ET_P#Z
M[+7M5>T=!A>+?^0(?^NB_P!:X*N]\6_\@0_]=%_K7!5\[FG\?Y'+6^(Z_P %
M?ZN\^J_UKJZY3P5_J[SZK_6NKKULO_W:/]=3:E\""BBBNPT/,-3_ .0K=_\
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MX&?0%<MXU_X]K3_?;^0KJ:Y;QK_Q[6G^^W\A7D8__=Y?UU/*J_ SCJXSQO\
M\A"S_P"O?_V=J[.N,\;_ /(0L_\ KW_]G:O,R;_>?DQ8+^*<O78VW_'G;?\
M7%/_ $$5QU=G9A3:6^YB!Y*=!G^$5]/6V1Z&(V19D_X_7_ZZ'^=>\]J\&<HU
MSO1B=SYP1C'->\]JYSD*&M_\@2\_ZY&O-*]+UO\ Y EY_P!<C7FE>#FW\2/H
M<U?=&1XG_P"1>NO^ ?\ H8KSNO1/$_\ R+UU_P  _P#0Q7G=>OD_^[?-GHX'
M^%\S>T#_ %,W^\/Y5L5CZ!_J9O\ >'\JV*ZJGQ,BM\;/7? __(I6GUD_]#-=
M%7.^!_\ D4K3ZR?^AFNBJ#(\QU7_ )#%[_UW?_T(U1?_ %;?0U>U7_D,7O\
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MZH?"CV[P_P#\B[IO_7K'_P"@BK\O^J?_ '35#P__ ,B[IO\ UZQ_^@BK\O\
MJG_W36SV*/*#]X_6J]Y_QZ2?2K!^\?K5>\_X])/I7R>'_C0]5^9PP^)&#7;?
M#;_D)WG_ %R'\ZXFNV^&W_(3O/\ KD/YU]:=QZ31110 4444 %%%% !1110
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M16)6WJ/_ !YM]16)7;EG\#YLTH_">B_#7_CTO_\ KHG\C7=5POPU_P"/2_\
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M,1LB>/\ UB_45[[VKP*/_6+]17OO:N<Y"AK?_($O/^N1KS2O2];_ .0)>?\
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M^/&X_P"N3?RIFF?\@JS_ .N"?^@BGWO_ !XW'_7)OY5G/X69O8\L[U1UO_D
M7_\ UQ_J*O=ZHZW_ ,@"_P#^N/\ 45\M@_\ >(>J_,Y*/\2/JCS*MWP]_J[K
MZI_[-6%6[X>_U=U]4_\ 9J^UJ?"SVZWP,V:]1^'7_(NS?]?+?^@K7EU>H_#K
M_D79O^OEO_05KE. ZZO.?$?_ "'[K_>'\A7HU><^(_\ D/W7^\/Y"O+S;^"O
M7]&8U_A,NO)#UKUNO)#UIY%_R\^7ZG1E_P!KY?J:GA[_ )#,7_7.7_T6U=%7
M.^'O^0S%_P!<Y?\ T6U=%7L5MS;$?$CJ_A[_ ,C*W_7NW\Q7JE>5_#W_ )&5
MO^O=OYBO5*R.<Y+QMTL?^VG_ ++7)5UOC;I8_P#;3_V6N2KYC,?]YE\OR1QU
M?C9POC'_ )#*?]<5_F:YZNA\8_\ (93_ *XK_,USU?58+_=H>B/:H?PH^AVY
MZ+_NC^53V/\ R$+;_KJO\Q4!Z+_NC^53V/\ R$+;_KJO\Q4O<XGN>[CI10.E
M%(13G_Y"MI_USD_]EJY5.?\ Y"MI_P!<Y/\ V6KE !7#^,O^0M#_ -<!_P"A
M-7<5P_C+_D+0_P#7 ?\ H35Y^9_[N_5&5;X3G:R-6_Y"+_[B?^@"M>LC5O\
MD(O_ +B?^@"N'*?XDO0SH;LHU[[%_JD_W17@5>^Q?ZI/]T5[QTE75O\ D#WG
M_7%_Y5YC7IVK?\@>\_ZXO_*O,:\+-OCCZ'-7W15U'_CS;ZBL2MO4?^/-OJ*Q
M*[<L_@?-FE'X3T7X:_\ 'I?_ /71/Y&NZKA?AK_QZ7__ %T3^1KNJ] U. \5
M_P#(=D_W%_E6)6WXK_Y#LG^XO\JQ*^3Q?\>?JSBG\3,"[_X_)_\ KHW\ZGT;
M_D.:?_U\Q_\ H0J"[_X_)_\ KHW\ZGT;_D.:?_U\Q_\ H0KZJ'PH[%L>Y5D>
M)_\ D7[G_@/_ *$*UZR/$_\ R+]S_P !_P#0A66)_@S]'^0I_"SSRJ^I?\@M
MO^NR?R:K%5]2_P"06W_79/Y-7S^7_P"\Q^?Y'+2^-&%7IOPW_P"0)=?]?)_]
M!6O,J]-^&_\ R!+K_KY/_H*U].=AV5>=^)?^1@NO^ _^@BO1*\[\2_\ (P77
M_ ?_ $$5Y>;?P5Z_HS&O\)DUSLW^OD_WC715SLW^OD_WC6.4?;^7ZDT.II>&
MO^1ET_\ Z[+7M5>*^&O^1ET__KLM>U5[1T&%XM_Y A_ZZ+_6N"KO?%O_ "!#
M_P!=%_K7!5\[FG\?Y'+6^(SM7^Y#]6_I676IJ_W(?JW]*RZ]; ?[O'^NIM2^
M!'KG@;_D4[7_ 'G_ /0S71USG@;_ )%.U_WG_P#0S71UV&AYAJ?_ "%;O_KL
M_P#,U7A_U\?^\/YU8U/_ )"MW_UV?^9JO#_KX_\ >'\Z^1?\7Y_J</VCF#U-
M;W@K_D;K#ZO_ .@-6">IK>\%?\C=8?5__0&KZX[CV"N;\9_\@R#_ *Z_T-=)
M7-^,_P#D&0?]=?Z&N7&_[O(BI\+.)K*U7_6Q_P"[6K65JO\ K8_]VO%RS_>%
MZ,YZ/Q&?7LWA/_D5[#_KG_6O&:]F\)_\BO8?]<_ZU](=9LUY3/\ \?$G^\:]
M6KRF?_CXD_WC7C9OM#Y_H<]?H03?\>\O^XW\JYVNBF_X]Y?]QOY5SM:93_"E
MZE4/A9UWPY_Y&*;_ *]6_P#0EKU&O+OAS_R,4W_7JW_H2UZC7JFQR'C7_66?
MT;^E<I75^-?]99_1OZ5RE?,9A_O,OE^1QU?C9FZS_K+;_KE_[,U9E:>L_P"L
MMO\ KE_[,U9E?08;^!#T7Y'5#X4>W>'_ /D7=-_Z]8__ $$5?E_U3_[IJAX?
M_P"1=TW_ *]8_P#T$5?E_P!4_P#NFMGL4>4'[Q^M5[S_ (])/I5@_>/UJO>?
M\>DGTKY/#_QH>J_,X8?$C!KMOAM_R$[S_KD/YUQ-=M\-O^0G>?\ 7(?SKZT[
MCTFBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ KR?Q9\(/ FF>#=<O[/0O+NK73[B:%_M<YVNL;%3@O@X('6O6
M*X/QIXT\*W7@7Q#;V_B71IIY=,N4CCCOXF9V,3   -DDGC% $?P2_P"20Z%_
MV\?^E$E8S_?;ZUL_!+_DD.A?]O'_ *425C/]]OK7C9O]CY_H<]?H4]5_Y ][
M_P!>\G_H)KR^O4-5_P"0/>_]>\G_ *":\OKLR/\ @R]?T.W ? _4V_#G^MN_
M^N0_]"%;=8GAS_6W?_7(?^A"MNO1J_$.O\9Z-\-/^/+4/^NB?R-=S7#?#3_C
MRU#_ *Z)_(UW-9F)P/BS_D.-_P!<UK#K<\6?\AQO^N:UAU\IB_X\_4XI_$SS
M'6/^0W?_ /7S)_Z$:=HG_(?T[_KZB_\ 0A3=8_Y#=_\ ]?,G_H1IVB?\A_3O
M^OJ+_P!"%?:4_P"&O0]Y?!\CIZZ#P3_R-]C_ -M/_1;5S]=!X)_Y&^Q_[:?^
MBVKF/./7ZY7QK_J;/_>;^E=57*^-?]39_P"\W]*X\P_W:7R_,SJ_ SCZXWQQ
M_P ?UE_U[?\ L[5V5<;XX_X_K+_KV_\ 9VKS<F_WGY,6"_BG+5V-M_QYVW_7
M%/\ T$5QU=C;?\>=M_UQ3_T$5]-6V1Z&(V1/'_K%^HKWVO H_P#6+]17OM<Y
MR%#6_P#D"7G_ %R->:5Z7K?_ "!+S_KD:\TKP<V_B1]#FK[HQ?%7_( F_P!Y
M?YBO/J]!\5?\@";_ 'E_F*\^KU\G_P!V^;/1P/\ ".AT'_CSD_ZZ?T%:M96@
M_P#'G)_UT_H*U:ZJGQ,SK?&SUWP/_P BE:?63_T,UT5<[X'_ .12M/K)_P"A
MFNBJ#,\OU+_D*WG_ %W?_P!"-4;C_CVE_P!P_P JO:E_R%;S_KN__H1JC<?\
M>TO^X?Y5\C_R^^?ZG"OB/**[7X4_\CY;?]<I/_0:XJNU^%/_ "/EM_URD_\
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MK/\ ZX)_Z"*?>_\ 'C<?]<F_E6<_A9F]CRSO5'6_^0!?_P#7'^HJ]WJCK?\
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M<M;XC.U?[D/U;^E9=:FK_<A^K?TK+KUL!_N\?ZZFU+X$>N>!O^13M?\ >?\
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M/G^ASU^A!-_Q[R_[C?RKG:Z*;_CWE_W&_E7.UIE/\*7J50^%G7?#G_D8IO\
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MY&O-*\'-OXD?0YJ^Z,CQ/_R+UU_P#_T,5YW7HGB?_D7KK_@'_H8KSNO7R?\
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M_D8KKZ)_Z M>AUYYXI_Y&*Z^B?\ H"UR9'_'EZ?JB\!_$?H8]=Y=_P#'Y/\
M]=&_G7!UWEW_ ,?D_P#UT;^=?0UNAV8GH7O#G_(R:=_U\)_.O:Z\4\.?\C)I
MW_7PG\Z]KK Y3G_&'_(&3_KLO\FKA:[KQA_R!D_Z[+_)JX6OG,S_ (_R.2M\
M1RWCC_CVT[_?F_DE<;79>./^/;3O]^;^25QM?199_ND/ZZGK83^#$ZO2O^03
M;?[K?^AM5NJFE?\ ()MO]UO_ $-JMU<OB9SU/B9[KIG_ ""K/_K@G_H(I][_
M ,>-Q_UR;^5,TS_D%6?_ %P3_P!!%/O?^/&X_P"N3?RK.?PLS>QY9WJCK?\
MR +_ /ZX_P!15[O5'6_^0!?_ /7'^HKY;!_[Q#U7YG)1_B1]4>95N^'O]7=?
M5/\ V:L*MWP]_J[KZI_[-7VM3X6>W6^!FS7J/PZ_Y%V;_KY;_P!!6O+J]1^'
M7_(NS?\ 7RW_ *"M<IP'75YSXC_Y#]U_O#^0KT:O.?$?_(?NO]X?R%>7FW\%
M>OZ,QK_"9=>2'K7K=>2'K3R+_EY\OU.C+_M?+]34\/?\AF+_ *YR_P#HMJZ*
MN=\/?\AF+_KG+_Z+:NBKV*VYMB/B1U?P]_Y&5O\ KW;^8KU2O*_A[_R,K?\
M7NW\Q7JE9'.<EXVZ6/\ VT_]EKDJZWQMTL?^VG_LM<E7S&8_[S+Y?DCCJ_&S
MA?&/_(93_KBO\S7/5T/C'_D,I_UQ7^9KGJ^JP7^[0]$>U0_A1]#MST7_ '1_
M*I['_D(6W_75?YBH#T7_ '1_*I['_D(6W_75?YBI>YQ/<]W'2B@=**0BG/\
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MK\:_ZRS^C?TKE*^8S#_>9?+\CCJ_&S-UG_66W_7+_P!F:LRM/6?]9;?]<O\
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M6)H'^IF_WA_*MBKL?[/NIQ B/X@7B ]=MHP_]K4__A0>L?\ 11+[_P !7_\
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M@?C/7-BJ#KTW!.Q$X\RL7*\\\4_\C%=?1/\ T!:[+_A1>O\ _12M2_[\2?\
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M8QU.?:O3PB]A1C3>MCLHU53@HLN:5_R";;_=;_T-JMU>3X :M&@1/B%>JHZ
M6K@#_P C4[_A0>L?]%$OO_ 5_P#X]5-W=S*3NVSV73/^059_]<$_]!%/O?\
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M?^RU<KYNU/POXML/BCH_@\_$;6Y&O[5K@7OFR@Q8$AV[/-YSY77<.OM78_\
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M@#\\\CU% %3XOV%YJ?PMUFSL+2>[NI/(V0P1F1VQ/&3A1R< $_A6YX+@FM?
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M1XM](@TV"6X9NXX7''&3_.@"S\1O&'A>^^'>NVMIXCT>XN);1ECBBOHG=SZ
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M07%Y90SR!!A0S("<#TR: -:JFJ*SZ1>JJEF:!P !DD[35ND9E1&=B%51DD]
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M%M9ZC#=7UA%]^Z@3.Y /XNWR_P!0*[VLCQ%XGTCPIIZW^M736UJSB/S!#)(
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M-PRK))(4,(Y*\9Y/K[52^R7/GB#[/+YQ&1'L.[&,]/IS6G<?\BC9_P#7T_\
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MZ_Z[_P#LHKL:S>Y:V"BBBD,**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M10%V0_9;?_GWB_[X%'V6W_Y]XO\ O@5-10%V0_9;?_GWB_[X%'V6W_Y]XO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
7!1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>img69628308_14.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img69628308_14.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "8 ^D# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M*H_M*7_H&7O_ 'RG_P 55^B@"A_:4O\ T#+W_OE/_BJ/[2E_Z!E[_P!\I_\
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M_OE/_BJ/[2E_Z!E[_P!\I_\ %5?HH H?VE+_ - R]_[Y3_XJC^TI?^@9>_\
M?*?_ !57Z* *']I2_P#0,O?^^4_^*H_M*7_H&7O_ 'RG_P 55^B@"A_:4O\
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M?^NZ_P#HJ.I:8%W^TK;^])_WY?\ PI#JEH" 7D!8X&8GY/Y53JO<_P"OM/\
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M+0$ O(">@\I^?TI?[2MO[TG_ 'Y?_"LJ;_C[MOJW\JL4AEW^TK;^])_WY?\
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M+_:5M_>D_P"_+_X5E7G^KC_ZZI_Z$*L4AEW^TK;^])_WY?\ PH_M*V_O2?\
M?E_\*I44Q%Q=4M&&5>0C.,B)_P#"E_M*V_O2?]^7_P *RK+_ (]S_P!=)/\
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M>"000<@@CD&JS:39,H!CDX#+D3."P)R<D'G)]:8%P$, 000>014%A_R#[?\
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MA1],46G_ "W_ .NS4 4VOKP6\Y\I#)'<"+]VC2!5P#G Y;&>V*KPZM<SRVZ
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M_*FW-E#=E#-YAV'*[963!]>"* +%5X_^0A/_ -<T_FU6*KQ_\A"?_KFG\VH
M6]EEALII8$WRJA*+M)R?H.33;&X-Q"S-*LC*Q5L0M%@^A5B3WJ>2,2QLC%@#
MP=K%3^8Y%,M[:*U0I$I 9BQ+,6)/J2>30 R]_P!0O_76+_T-:G8,48(0&QP2
M,@'Z5!>_ZA?^NL7_ *&M6* ,674;V)6)>!A]I$"NENY_A);Y0Q)P>.#V-:\3
M%H49CEBH).TKG\#R/H:B6RMTBAB6/"0MO0;CP>>??J>M6* *]G_JG_ZZR?\
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M[-F[/;.<5)0!7LO^/<_]=)/_ $,TFH7#VEA-/&%+HN0&Z4ME_P >Y_ZZ2?\
MH9I]Q;1747E3 LF<D!BN?KCJ/:@"6F6W_(P6_P#UZS?^AQ4^F6W_ ",%O_UZ
MS?\ H<5 &W1112&%%%% !1110 4444 %%%% '+W&IVEGJ^HQSS!',RG!]/*2
MD_MW3O\ GY7\JYKQ3_R,]_\ [R?^BUK(KRZV/G3J."2T..IB91DU8[S^W=._
MY^5_*H9M9L'EMV6X4A)"S>PVL/YD5Q-.7HWT_K41S*;>R)6*D^AW7]NZ=_S\
MK^5']NZ=_P _*_E7!T4O[3G_ "H7UN78[S^W=._Y^5_*H;76;"&TAC>X4,J
M$>^*XFE?[Y^M/^TIVO9#^M2M>QW?]NZ=_P _*_E1_;NG?\_*_E7!T4O[3G_*
MA?6Y=CMAK-@+QI?M"[#&%!]P3_C4W]NZ=_S\K^5<)_ /K24Y9E-=$-XJ2Z'>
M?V[IW_/ROY5#<ZS82V[(EPI8D?S!KB:<GWJ(YE-M*R!8J3=K'=?V[IW_ #\K
M^5']NZ=_S\K^5<'12_M.?\J%];EV.\_MW3O^?E?RJ&#6;"/S=UPHW2%A]*XF
ME;M]*:S*;3=D-8J5MCN_[=T[_GY7\J/[=T[_ )^5_*N#HI?VG/\ E0OK<NQV
MTFLV#7$+BX7:A.[\1BIO[=T[_GY7\JX4?=:FTWF4TEHAO%2['>?V[IW_ #\K
M^5(^N:<48"Y7)%<)0.M)9G/^5"^MR['<6^M:?';11M<*&5 "/<"I/[=T[_GY
M7\JX1OO'ZTE.6933MRH'BI)['>?V[IW_ #\K^50IK-@+N60W"[610#[@MG^8
MKB:4_<'U-"S*;3T0UBI:Z'=_V[IW_/ROY4?V[IW_ #\K^5<'12_M.?\ *A?6
MY=CMKG6;"6)52X4D2(WX!@3^@J;^W=._Y^5_*N%7K^!_E3:?]I3Y;V0_K4K7
ML=Y_;NG?\_*_E1_;NG?\_*_E7!T4O[3G_*A?6Y=CMK?6;"*-@]PH)D=A]"Q(
MJ;^W=._Y^5_*N$;J/H*2G+,IIM60WBI)VL=Y_;NG?\_*_E4+ZS8-=12"X7:J
ML"?KC'\JXFE'W3^%$<RFWL@6*D^AW?\ ;NG?\_*_E1_;NG?\_*_E7!T4O[3G
M_*A?6Y=CN)M:T^2"1%N%+,I ^N*='K>G+$BFY7( !KAE^\/K0>II_P!I3Y;V
M0_K4K7L=W_;NG?\ /ROY4?V[IW_/ROY5P=%+^TY_RH7UN78[:/6;!;B9S<+M
M?;@_05-_;NG?\_*_E7"'[HI*<LRFGLAO%270[S^W=._Y^5_*H;C6;"01[;A3
MMD5C] :XFG+W^AHCF4V[60+%2;V.Z_MW3O\ GY7\J/[=T[_GY7\JX.BE_:<_
MY4+ZW+L=Y_;NG?\ /ROY5#;:S810;'N%!W,?S)-<32M]ZG_:4[7LA_6I6O8[
MO^W=._Y^5_*C^W=._P"?E?RK@Z*7]IS_ )4+ZW+L=LVLV!O$E^T+L$;*3[DK
M_@:F_MW3O^?E?RKA/X#]124WF4U;1#>*EV.\_MW3O^?E?RJ&ZUFPFLYXDN%+
MO&RJ/<BN)IR??7ZT1S*;DE9 L5)NUCNO[=T[_GY7\J/[=T[_ )^5_*N#HI?V
MG/\ E0OK<NQWG]NZ=_S\K^50Q:S8)-.S7"X=P5]QM _I7$TIZ+]*:S*;3T0U
MBI:Z'=_V[IW_ #\K^5']NZ=_S\K^5<'12_M.?\J%];EV.VGUFPD:$K<*0DFX
M_3!']:F_MW3O^?E?RKA%Z-]*2F\RFDG9#>*E;8[S^W=._P"?E?RH_MW3O^?E
M?RK@Z*7]IS_E0OK<NQVUKK-A%;)&]PH91R*F_MW3O^?E?RKA7^^:;3EF4TVK
M(;Q4D[6.\_MW3O\ GY7\JA_MFP^V>;]H79Y>W/OFN)I?X/QH693?1 L5)]#N
M_P"W=._Y^5_*C^W=._Y^5_*N#HI?VG/^5"^MR[';76LV$ML\:7"EF' J;^W=
M._Y^5_*N%3[XIM/^TIVO9#^M2M>QWG]NZ=_S\K^5']NZ=_S\K^5<'12_M.?\
MJ%];EV.V@UFPC:8M<* \FX?3 ']*F_MW3O\ GY7\JX1NB_2DIRS*:=K(;Q4E
MT.\_MW3O^?E?RIJZC:WEW;);2>:ZN6*J"3C::X6MSPC_ ,C'!_NO_P"@FKHX
M^=2HH-+4JGB7*2C8[#Y_^>$W_?LT?/\ \\)O^_9K9HKU#L,;Y_\ GA-_W[-5
M['>-/MAY,I_=+R$)!X%=#532O^019?\ 7"/_ -!% %'Y_P#GA-_W[-'S_P#/
M";_OV:V:* .>7?\ VA*?)E_U2<;#GJU6/G_YX3?]^S5Y/^0O/_UPC_\ 0GJW
M0!C?/_SPF_[]FJ]YO-L?W,H^=.2A'\0KH:J:E_QY'_KI'_Z&M %'Y_\ GA-_
MW[-'S_\ /";_ +]FMFB@#&^?_GA-_P!^S5>TWA)/W,I_>OT0G^(UT-5-/_U4
MW_7>3_T(T 4?G_YX3?\ ?LT?/_SPF_[]FMFB@#GI=_VRW/DR]'XV')Z58^?_
M )X3?]^S5Z?_ )"5I_NR?R%6Z ,;Y_\ GA-_W[-1S[_L\O[F8?(>L9]*W:AN
MO^/.?_KFW\J ,B#?]GB_<S'Y!TC/I4GS_P#/";_OV:T[7_CS@_ZYK_*IJ ,;
MY_\ GA-_W[-5XM_VRX/DR]$XV'(ZUT-5(/\ D)7?^['_ "- %'Y_^>$W_?LT
M?/\ \\)O^_9K9HH YZ[WE(_W,H_>IU0C^(58^?\ YX3?]^S5[4/]5#_UWC_]
M"%6Z ,;Y_P#GA-_W[-'S_P#/";_OV:V:* .>L]XMS^YE/[Q^B$_QFK'S_P#/
M";_OV:O:;_QZ'_KM+_Z,:K= &-\__/";_OV:9:[O^$@M]R.O^BS?>4C/SQ5N
M50F_Y&"S_P"O6?\ ]#BH OT444 %4-;TT:OHMW8[MC2QD(_]QQRK?@P!_"K]
M% 'F[ZG+K]K)?_9Y6N;J./2H(8]HD)(WW17<0 0-RYR.8_QJR+A&T1-(:W>'
M7;&[\K3()67S4_BC8E2PV",@.02"%8=2!7?T4 <QH%[#;Z7%;P6-S).)634G
M$D0:";(WO*2RDYR2"H.5 QV%8VE3:>]SJ%]X26S>9;/R(;2"X0RW!WC]_*"P
MZ9X+G<<G)&17H%% '*> O,33=2BEAN49-1G!:X9&=CGG)5B,YZ]O2NKHHH \
MQ\4_\C/?_P"\G_HM:R*U_%/_ ",]_P#[R?\ HM:R*^<Q7\:7J>56_B,*<O1O
MI_6FTY>C?3^M90W^_P#(B.XVBBBH)"E?[Y^M)2O]\_6K7P/Y?J5]D2BBBH)%
M_@'UI*7^ ?6DJY[HJ04Y/O4VG)]ZBG\:"/Q(;1114$A2MV^E)2MV^E6OA92V
M8E%%%02.'W6IM.'W6IM7+9?UU93V04#K10.M2MQ(5OO'ZTE*WWC]:2G/XF$M
MV%*?N#ZFDI3]P?4TX[/^NJ&MF)1114$CEZ_@?Y4VG+U_ _RIM6_@7S_0K[(4
M445!(K=1]!24K=1]!25=3XF5+=A2C[I_"DI1]T_A1#?[_P @CN)1114$BK]X
M?6@]30OWA]:#U-7]@K[(E%%%02*?NBDI3]T4E7/?[OR*EN%.7O\ 0TVG+W^A
MHI_$@CN-HHHJ"0I6^]24K?>JU\#^7ZE?9$HHHJ"1?X#]124O\!^HI*N6R*?0
M*<GWU^M-IR??7ZT4_C01^)#:***@D*4]%^E)2GHOTJX[/^NJ*6S$HHHJ"15Z
M-]*2E7HWTI*N6R*>R"BBBH)'/]\TVG/]\TVKJ?&RI?$PI?X/QI*7^#\:(=0B
M)1114$CD^^*;3D^^*;5OX%\_T*^R%%%%02*W1?I24K=%^E)5SW*EN%;GA'_D
M8X/]U_\ T$UAUN>$?^1C@_W7_P#036V$_C1+H?Q$>DT445]$>J%5-*_Y!%E_
MUPC_ /015NJFE?\ ((LO^N$?_H(H MT444 5$_Y"\_\ UPC_ /0GJW51/^0O
M/_UPC_\ 0GJW0 54U+_CR/\ UTC_ /0UJW534O\ CR/_ %TC_P#0UH MT444
M %5-/_U4W_7>3_T(U;JII_\ JIO^N\G_ *$: +=%%% %2?\ Y"5I_NR?R%6Z
MJ3_\A*T_W9/Y"K= !4-U_P ><_\ US;^535#=?\ 'G/_ -<V_E0 6O\ QYP?
M]<U_E4U0VO\ QYP?]<U_E4U !52#_D)7?^['_(U;JI!_R$KO_=C_ )&@"W11
M10!4U#_50_\ 7>/_ -"%6ZJ:A_JH?^N\?_H0JW0 4444 5--_P"/0_\ 7:7_
M -&-5NJFF_\ 'H?^NTO_ *,:K= !5";_ )&"S_Z]9_\ T.*K]4)O^1@L_P#K
MUG_]#BH OT444 %%%% !37=8T+NP51U+' %<GJ7B^2>_.E^'X%N[OD-,W^KC
M]3[X]>GUJ31])MM24W>J7LFIW"D964%8HR0&&U.G1AR?6LHU5-VAK;KT.IX;
MV<5*L^6^RZ_=T^9N)J]E*Q6"4W!'7R%,@'X@8J?[2<9^SS8_W1_C4B>6BJB;
M54# 5>*;-<0P023R.!'&I9CUP!UZ5JKF#<.B*\>K64EV+0S".Y(R(9049A[
M]?PJ[7%_$*:RN?"%^[;UGM&1H9=I4I)E<;3ZX/:NB\/2W<_AW3I;\'[4]NC2
M[A@[L=_>G;2YO.A'V"KQ>[:MZ:Z?UH>=^,+^SM?%=]'/,4<F,XV$\>6M8?\
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M6CSKC_GT;_OM:L44 5_.N/\ GT;_ +[6JMC+,(Y<6Q;]](?OC^\>*TJJ:?\
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MY!J?]=F_DM5JLM_R#4_Z[-_):K4D3$*LV'_'XO\ NM_Z":K59L/^/Q?]UO\
MT$T2V"?PLK4444R@JS=_\L/^N*U6JS=_\L/^N*TGN2]T5J***919@_X\[K_=
M7_T(56JS!_QYW7^ZO_H0JM274F.["G1_ZU/]X4VG1_ZU/]X4RF27G_']<?\
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MV[_^S5;JI_S&/^W?_P!FH MT444 5-3_ .0;/_N_UJW534_^0;/_ +O]:MT
M%%%% %2R_P!;>?\ 7<_^@K5NJEE_K;S_ *[G_P!!6K= !52[_P"/NP_Z[-_Z
M+:K=5+O_ (^[#_KLW_HMJ +=%%% !532O^019?\ 7"/_ -!%6ZJ:5_R"++_K
MA'_Z"* +=%%% %1/^0O/_P!<(_\ T)ZMU43_ )"\_P#UPC_]">K= !534O\
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MMT %4)O^1@L_^O6?_P!#BJ_5";_D8+/_ *]9_P#T.*@"_1110 4444 %%%%
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M \7]IG#D$GR_3/\ C7I=%/VL^X?6*KZGF/\ PJ-?^@H?^_='_"HU_P"@H?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
7!1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>img69628308_15.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img69628308_15.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" )3 [H# 2(  A$! Q$!_\0
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M%^OI3_M9[<GX_P# #V_D>KT5Y1Y4AB,OEMY8.TOCC/IF@0RF$RB-S$IP7"G
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M\C#:_P# _P#T UMAOXT/5?F5#XD<C\9?^1OM/^O!/_1DE>=UZ)\9?^1OM/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M5;61%4J&9LG<C'.7/?TH \<_9Q_Y*'J'_8*D_P#1L5?3]?,'[./_ "4/4/\
ML%2?^C8J^GZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JG
MJW_(&OO^O>3_ -!-7*IZM_R!K[_KWD_]!- %RBBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\O\
MB/\ &#_A7_B&WTG^POM_G6BW/F_:_*QEW7;C8W]S.<]Z]0HH ^8/V<?^2AZA
M_P!@J3_T;%7T_7S!^SC_ ,E#U#_L%2?^C8J^GZ "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ JGJW_(&OO\ KWD_]!-7*IZM_P @:^_Z]Y/_
M $$T 7**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@"%[NVCNXK1[B%;F56:.%G =PO4A>I R,_6IJ\R;2)-.^-VDW,^H7
M-[/=V5VY,Q 6) R[411P  ?J3R:[3Q%<2V=K#=6LS_;$?;!; \73'_EF1[X^
M]_#C/3()T3[_ .=@ZM=O\KFS4/VNV^V?8_M$7VKR_-\C>-^S.-VWKC/&:S/#
MTTUY;375U*_VQWVS6Q) M2/^68'MG.[^+.>F .)\/Z3)I/QLO5GU"YO[B?1!
M++/.1DDS8PJCA5    II>];^MK@_A;]/SL>B7^JZ=I:Q-J-_:V:ROLC-Q,L8
M=O09(R?:K$LT<,+S2.J1(I9G)X ')->8^)K+3]8^)FHVNMV]O<VMMX<::VCN
M$!5&+G>XST88'/45T'@FT76_A1HUIJBO+'<Z>D<H\QE9DQ@?,I!'&.AI*[C?
M^MVOT!Z2M_6R?ZFKX5\1IXITF34([62V1;F6%4ESN(1L!B" 1GKCM6Y7&ZCX
M9U/0/!.KVO@F[N%U>:4W4#WMQYQWEPS*#)N'*A@-W<Y)ZM7S5XDU+XD^$=1C
ML-<U_7+2ZDB$RI_:KR90D@'*.1U4_E3=N@'4?LX_\E#U#_L%2?\ HV*OI^OF
M#]G'_DH>H?\ 8*D_]&Q5]/T@"BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M3_\ L%1_^C9:^GZ^>/C]HU_J_C+3OL\NE1PQ:>O_ !\W]K;2%C(^?]8ZNRX
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MH5/Y$ T^BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O
M"_C9X=\+ZCXJL+W7?&<>BSFR$4=L-/>Y9E5W.\[&RH)<@9'.TX)P<>Z5Y?\
M$?P7X#\1^(;>\\4>)O[+ODM%B2'[?!!NC#N0VV123R6&>G'M0!YA^SC_ ,E#
MU#_L%2?^C8J^GZ^8/V<?^2AZA_V"I/\ T;%7T_0 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110!'<3QVL#SRDB-!EB%+8'K@<UAW/B/2I+B
MS9;K(CF+-^[?@>6X]/4BM35O^0-??]>\G_H)KS ]17'B\4Z#C97O?\#.<^4]
M/L=4L]2\S[)-YGEXW?(5QG..H]C5RN0\%HLBZBCJ&1A&&5AD$?-P:W-/L;2*
M]O7CM8$>.<!&6, J/*3@>G4_F:WH5'5IJ;ZE1=U<TZ***U**<G_(9MO^O>;_
M -"CJY5.3_D,VW_7O-_Z%'5R@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** .&\9?\AF+_KW7_T)JYW^$_C71>,O^0S%_P!>
MZ_\ H35SI P>*^?Q;7UII[WC^1RS^,\Z?_D8-0_[>?\ T!Z[KX+?\AG4_P#K
MW7_T*N!OKRZM]4O4@N9HE-Q(2J2%1G<?2O0/@W+)-KNJR2R-(YMURSG)/S>M
M?4S^ ]:I?V;^1[)6+?\ B:ST^]DM98KAGCQDHJXY /<^];5>=^)O^1BN_P#@
M'_H"UYF,KRH4N>.YP5).*NC2_P"$FL_^$?\ L/E7'F_9?)W;5VYV8]>E>#VG
M_'M?_P#7 ?\ HQ*]/_@_"O-;*W9K2Z/F0+YL05 \Z*21(IZ$Y' /6M,OQ$JW
M/S=&=&$GS*5_([_X+?\ (9U/_KW7_P!"KV:O&O@RI37-54XR(%!P01][U'6O
M9:Z:GQ!6^-GG?B;_ )&*[_X!_P"@+6.PPIK8\3?\C%=_\ _] 6LAONFOFYRE
M]=Y;Z<R_,\]O]Y\SSFUU&^:WO2U[<$K""I,K<'S$''/H37JOP<GFN-+U1YY9
M)6$R ,[%CC:?6O(;3_CVO_\ K@/_ $8E>M?!;_D$ZI_UW3_T&OJ:B]UGK5DN
M5GJ%4]6_Y U]_P!>\G_H)JY5/5O^0-??]>\G_H)KG.0N4444 %%%% !1110
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M:7JR.I5EN%!4C!!VUXQ7LOP6_P"03JG_ %W3_P!!KZRI\)Z]9>ZSU"J>K?\
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M1W6-&=V"HHRS,< #U-;%"T56BU"RGD$<-Y;R2'HJ2J2?P!JS0 4444 %%%%
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MS!>6T5S;31S02J'CDC8,KJ>001U%2T %%%% !14+W=M'=Q6CW$*W,JLT<+.
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M_D8KO_@'_H"UD'H:\C$2_P!I<;=482?OV/6Z***^D.LIV?\ Q]:A_P!? _\
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M_F0YQ6C.^HJAHU[)J&E0W4RHLC[LA 0.&([_ $J_6Z::NBPKD?&_6P_[:?\
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M6O(RR?-6VM9?JC"B[R.BKR0=!7K=>2#H*WS;X(^I5?9'1>#?^0S+_P!>[?\
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MAGMK"""YNFNIXXPLD[(%,C <L0.!GT%6*J6Y*V"BBBD,**** "BBB@ HHHH
M*^>/C]X4\0:OXRTZ_P!,T6^OK4Z>L)>T@:7:ZR.2"%!(X=>O7G&<''T/7C?Q
M9\":#XH\56M[JGCC3="G2R2);:Z";G4.YWC=(IP2Q'3^$\T <)^SC_R4/4/^
MP5)_Z-BKZ3U;_D#7W_7O)_Z":^;/V<?^2AZA_P!@J3_T;%7L&JZ[J7VJ^M?M
M/[CS)(MFQ?NY(QG&>E95:T:23EU=B924=SOZ*XK1=;U.^UBVMY[QC$Y)8"-!
MG"DXZ>U=%-:(VK1)YMR$DBE=E6YD R&3&,-Q]X\"BC6C6CSPV",E)71IT445
MJ4%%%% !1110 5Y(.@KUNO)!T%>3FWP1]3"OLC(\4?\ (OW/_ ?_ $-:\\KT
M/Q1_R+]S_P !_P#0UKSRO2RG_=(_/\SOP7\(^D_ ?_(BZ1_UP'\S6MJW_(&O
MO^O>3_T$UD^ _P#D1=(_ZX#^9K6U;_D#7W_7O)_Z":U>YA+=GF!Z]*Z+P;_R
M&9?^O=O_ $):YZHI_$\_A-1?P6\<[R'R2LA( !YSQ_NU\WE\N;$05N_Y,Y*-
MY321ZG9_\?6H?]? _P#14=7*\:/Q<U"U F73+9C=CSF!=OE(^3 _! ?QKU'P
MYJDFM>'K+4IHTCDN(]Y1,X')XYKZ5Q:W.R4)1U98U;_D#7W_ %[R?^@FO,:]
M.U;_ ) U]_U[R?\ H)KS&O#S?['S_0Y:_0YWQ@Q338&&,BX4C(!'1NQZUQ\U
M_//$(Y!#M P-L"*0,YX(&1S_ #KK_&?_ ""H?^NX_P#06KAZ]G+E_LT#TL(E
M[)'U3I/_ "!K'_KWC_\ 0153Q/\ \B[=?\ _]#6K>D_\@:Q_Z]X__0153Q/_
M ,B[=?\  /\ T-:FI\#]#D>QYY7(>-OO67_;3_V6NOKD/&WWK+_MI_[+7BY+
M_O+]'^AG@OXISVE_\A:R_P"NZ?\ H0KZJKY5TO\ Y"UE_P!=T_\ 0A7U57T=
M;='=B=T<[XS_ .01#_U\#_T%JX>NX\9_\@B'_KX'_H+5P]?,YM_&7I^K/,K_
M !'"^,O^0Q%_UP7_ -":LG2_^0M9?]=T_P#0A6MXR_Y#$7_7!?\ T)JR=+_Y
M"UE_UW3_ -"%?283_=H>B_(]>C_!7H?55<[XS_Y!$/\ U\#_ -!:NBKG?&?_
M ""(?^O@?^@M7+B?X,_1_D<$_A9P]>A^&/\ D7;7_@?_ *&U>>5S?B#Q/K>D
MWT5K8:G<6\'E;O+1N 2S9KRLGCS5))=C+"P<I-(]RTG_ ) UC_U[Q_\ H(JY
M7A?A_P 2ZW<^.+72I=3N38FZ,/DJY4; 2  1R.E>Z5[LH\ITR@X[G(^-^MA_
MVT_]EKD@1D\UUOC?K8?]M/\ V6N3KYW,9)5I)K=(XZK]X[33XP?!8F#RI)%#
M,R&.5DP<L><$9Z=ZZ*"!+="B&0@G/[R1G/YL2:P-._Y$23_KWG_FU='7NT_@
M7H=*V"N1\;];#_MI_P"RUUU<CXWZV'_;3_V6L,;_ +O/T)J?"SDZ\Y\2_P#(
MP77_  #_ - %>C5YSXE_Y&"Z_P" ?^@"N3(MY_+]2L!\3.C^$W_(]1?]<)/Y
M5[[7@7PF_P"1ZB_ZX2?RKWVO9J_$;U_C.&\9?\AF+_KW7_T)JYT]#71>,O\
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MDJ'#*8GX_2OIFTM6=A=@N[:ZW?9[B*;;C=Y;AL?7%35A:3KVF_8K&T^T_O\
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M+T_5GF5_B.%\9?\ (8B_ZX+_ .A-63I?_(6LO^NZ?^A"M;QE_P AB+_K@O\
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MQ,Z/X3?\CU%_UPD_E7OM>!?";_D>HO\ KA)_*O?:]FK\1O7^,X;QE_R&8O\
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M)\9_\@B'_KX'_H+5]#B?X,_1_D=4_A9P]=QX,_Y!$W_7P?\ T%:X>NX\&?\
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M3MP1%=P),@/4!@#BKM-IIV9*=U=!1112&%%%% !1110 4444 %<'XU^+.@^
M]9ATO5+34IIY;=;A6M8T90I9EP=SJ<Y0]O2N\K+U+PUH.LW"W&J:)IM].J!%
MDNK5)6"Y)P"P)QDDX]S0!\Z?LX_\E#U#_L%2?^C8J]0U3_D+WO\ U\2?^A&O
M+_V<?^2AZA_V"I/_ $;%7J&J?\A>]_Z^)/\ T(UYF;?P5Z_HS&O\)CZO_P @
M>\_ZX/\ ^@FN$AL+Q])FVVD[;Y8F7$9.X;7Y'J.1^==WJ_\ R![S_K@__H)K
MS&NK)_\ =OF=>"5Z;]3V7X+?\@G5/^NZ?^@UZA7E_P %O^03JG_7=/\ T&O4
M*[*GQ,57XV>;S>(=5GMY(I+O<DB%6'EH,@CGM6KH6NZE>:U;V]Q<[XGW;EV*
M,X4GL/:N7_@_"LOQ'+)#H5Q)%(T;C;AD."/F'>O H8BK*O&+EHY-''"4I34;
M]3V.3_D,VW_7O-_Z%'5ROEY-1OCI<[F]N-PFC ;S6R 5?/?V'Y5[7\*I9)O!
M222R-(YN),LYR3T[U[\H<JN=LZ3@KG;5Y(.@KUNO)!T%>-FWP1]3CK[(R/%'
M_(OW/_ ?_0UKSRO0_%'_ "+]S_P'_P!#6O/*]+*?]TC\_P SOP7\(^D_ ?\
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MWC_]!%5/$_\ R+MU_P  _P#0UJWI/_(&L?\ KWC_ /0153Q/_P B[=?\ _\
M0UJ*GP/T.1['GE<AXV^]9?\ ;3_V6NOKD/&WWK+_ +:?^RUXN2_[R_1_H9X+
M^*<]I?\ R%K+_KNG_H0KZJKY5TO_ )"UE_UW3_T(5]55]'6W1W8G='.^,_\
MD$0_]? _]!:N'KN/&?\ R"(?^O@?^@M7#U\SFW\9>GZL\RO\1POC+_D,1?\
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MR1YU3^(>8:I_R%KW_KN__H1KT3X+?\AG4_\ KW7_ -"KSO5/^0M>_P#7=_\
MT(UZ)\%O^0SJ?_7NO_H5?63^ ]BK_"/9J\[\3?\ (Q7?_ /_ $!:]$KSOQ-_
MR,5W_P  _P#0%KQLS_W=^J/-K?"9!Z&O):]:/0UY+1D?P3]4=&7[2/3_ (+?
M\AG4_P#KW7_T*O9J\9^"W_(9U/\ Z]U_]"KV:O3J?$RJWQL\[\3?\C%=_P#
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MD#,X) VH>N_/W1W)QW!!T3[_ .=@ZM?UL:M%96A7MQJ=HVH2R ).?W5L ,P
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M\4Y[2_\ D+67_7=/_0A7U57RKI?_ "%K+_KNG_H0KZJKZ.MNCNQ.Z.=\9_\
M((A_Z^!_Z"U</7<>,_\ D$0_]? _]!:N'KYG-OXR]/U9YE?XCA?&7_(8B_ZX
M+_Z$U9.E_P#(6LO^NZ?^A"M;QE_R&(O^N"_^A-63I?\ R%K+_KNG_H0KZ3"?
M[M#T7Y'KT?X*]#ZJKG?&?_((A_Z^!_Z"U=%7.^,_^01#_P!? _\ 06KEQ/\
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M7_T)JYT]#7S&,_WQ^J_)'G5/XAYAJG_(6O?^N[_^A&O1/@M_R&=3_P"O=?\
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M\#_T%J^AQ/\ !GZ/\CJG\+.'KN/!G_((F_Z^#_Z"M</7<>#/^01-_P!?!_\
M05KQ<I_C/T_5'/0^(Z*O)!T%>MUY(.@KJS;X(^I=?9'1>#?^0S+_ ->[?^A+
M7<UPW@W_ )#,O_7NW_H2UW-=.7_[M'Y_FRZ7P(\[\3?\C%=_\ _] 6L@]#6O
MXF_Y&*[_ . ?^@+60>AKQL1_O;]3GG\9ZW7(^-^MA_VT_P#9:ZZN1\;];#_M
MI_[+7N8W_=Y^ATU/A9R=>A^&/^1=M?\ @?\ Z&U>>5Z'X8_Y%VU_X'_Z&U>9
ME'QR]#&ANRWJW_(&OO\ KWD_]!->8UZ=JW_(&OO^O>3_ -!->8U>;_8^?Z#K
M]#K/!'6__P"V?_LU==7(^".M_P#]L_\ V:NNKT,%_N\/0UI_"CS#5/\ D+WO
M_7Q)_P"A&K?AG_D8K3_@?_H#54U3_D+WO_7Q)_Z$:M^&?^1BM/\ @?\ Z U>
M-3_W[_MYG.OXGS/1*X;QE_R&8O\ KW7_ -":NYKAO&7_ "&8O^O=?_0FKULP
M_P!VE\OS1O5^!G.GH:];KR0]#7K=<V4_!+U(H;,YWQG_ ,@B'_KX'_H+5P]=
MQXS_ .01#_U\#_T%JX>N7-OXR]/U9%?XCN/!G_((F_Z^#_Z"M:VK?\@:^_Z]
MY/\ T$UD^#/^01-_U\'_ -!6M;5O^0-??]>\G_H)KVL-_!AZ+\CHA\*/,:Z'
MP;_R&9?^O=O_ $):YZNA\&_\AF7_ *]V_P#0EKY[+O\ >8_/\F<M+XT=S7G?
MB;_D8KO_ (!_Z M>B5YWXF_Y&*[_ . ?^@+7KYG_ +N_5&];X2II?_(7LO\
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M\9^"W_(9U/\ Z]U_]"KV:O3J?$RJWQL\[\3?\C%=_P# /_0%K(;[IK7\3?\
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MO)_Z":]K#?P8>B_(Z(?"CS&NA\&_\AF7_KW;_P!"6N>KH?!O_(9E_P"O=O\
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M\RO\1POC+_D,1?\ 7!?_ $)JR=+_ .0M9?\ 7=/_ $(5K>,O^0Q%_P!<%_\
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MM_R&=3_Z]U_]"KZR?P'L5?X1[-7G?B;_ )&*[_X!_P"@+7HE>=^)O^1BN_\
M@'_H"UXV9_[N_5'FUOA,@]#7DM>M'H:\EHR/X)^J.C+]I'I_P6_Y#.I_]>Z_
M^A5[-7C/P6_Y#.I_]>Z_^A5[-7IU/B95;XV>=^)O^1BN_P#@'_H"UD-]TUK^
M)O\ D8KO_@'_ * M9#?=-?,U/]^_[>1Y[_B?,\EKV7X+?\@G5/\ KNG_ *#7
MC5>R_!;_ )!.J?\ 7=/_ $&OK*OPGL5_@/4*IZM_R!K[_KWD_P#035RJ>K?\
M@:^_Z]Y/_037,<1<HHHH X;QE_R&8O\ KW7_ -":N>KH?&7_ "&8O^O=?_0F
MKGJ^8S'_ 'F7R_)''5^-GIVD_P#(&L?^O>/_ -!%9/C/_D$0_P#7P/\ T%JU
MM)_Y UC_ ->\?_H(K)\9_P#((A_Z^!_Z"U?0XG^#/T?Y'5/X6</7<>#/^01-
M_P!?!_\ 05KAZ[CP9_R")O\ KX/_ *"M>+E/\9^GZHYZ'Q'15Y(.@KUNO)!T
M%=6;?!'U+K[(Z+P;_P AF7_KW;_T):[FN&\&_P#(9E_Z]V_]"6NYKIR__=H_
M/\V72^!'G?B;_D8KO_@'_H"UD'H:U_$W_(Q7?_ /_0%K(/0UXV(_WM^ISS^,
M];KD?&_6P_[:?^RUUU<CXWZV'_;3_P!EKW,;_N\_0Z:GPLY.O0_#'_(NVO\
MP/\ ]#:O/*]#\,?\B[:_\#_]#:O,RCXY>AC0W9;U;_D#7W_7O)_Z":\QKT[5
MO^0-??\ 7O)_Z":\QJ\W^Q\_T'7Z'6>".M__ -L__9JZZN1\$=;_ /[9_P#L
MU==7H8+_ '>'H:T_A1YAJG_(7O?^OB3_ -"-6_#/_(Q6G_ __0&JIJG_ "%[
MW_KXD_\ 0C5OPS_R,5I_P/\ ] :O&I_[]_V\SG7\3YGHE<-XR_Y#,7_7NO\
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M+MU_P#_T-:BI\#]#D>QYY7(>-OO67_;3_P!EKKZY#QM]ZR_[:?\ LM>+DO\
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M)JYT]#71>,O^0S%_U[K_ .A-7.GH:^8QG^^/U7Y(\ZI_$/,-4_Y"U[_UW?\
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M58)'=%$J;6^1RA..W*GW^E:5#5@/F#]G'_DH>H?]@J3_ -&Q5ZAJG_(7O?\
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M_P#7P/\ T%JY<3_!GZ/\C@G\+.'KA?&/_(8B_P"N _\ 0FKNJX7QC_R&(O\
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M_H)KF.(N4444 <-XR_Y#,7_7NO\ Z$U<]70^,O\ D,Q?]>Z_^A-7/5\QF/\
MO,OE^2..K\;/3M)_Y UC_P!>\?\ Z"*R?&?_ ""(?^O@?^@M6MI/_(&L?^O>
M/_T$5D^,_P#D$0_]? _]!:OH<3_!GZ/\CJG\+.'KN/!G_((F_P"O@_\ H*UP
M]=QX,_Y!$W_7P?\ T%:\7*?XS]/U1ST/B.BKR0=!7K=>2#H*ZLV^"/J77V1T
M7@W_ )#,O_7NW_H2UW-<-X-_Y#,O_7NW_H2UW-=.7_[M'Y_FRZ7P(\[\3?\
M(Q7?_ /_ $!:R#T-:_B;_D8KO_@'_H"UD'H:\;$?[V_4YY_&>MUR/C?K8?\
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M-_R/47_7"3^5>^UX%\)O^1ZB_P"N$G\J]]KV:OQ&]?XSAO&7_(9B_P"O=?\
MT)JYT]#71>,O^0S%_P!>Z_\ H35SIZ&OF,9_OC]5^2/.J?Q#S#5/^0M>_P#7
M=_\ T(UZ)\%O^0SJ?_7NO_H5>=ZI_P A:]_Z[O\ ^A&O1/@M_P AG4_^O=?_
M $*OK)_ >Q5_A'LU>=^)O^1BN_\ @'_H"UZ)7G?B;_D8KO\ X!_Z M>-F?\
MN[]4>;6^$R#T->2UZT>AKR6C(_@GZHZ,OVD>G_!;_D,ZG_U[K_Z%7LU>,_!;
M_D,ZG_U[K_Z%7LU>G4^)E5OC9YWXF_Y&*[_X!_Z M9#?=-:_B;_D8KO_ (!_
MZ M9#?=-?,U/]^_[>1Y[_B?,\EKV7X+?\@G5/^NZ?^@UXU7LOP6_Y!.J?]=T
M_P#0:^LJ_">Q7^ ]0JGJW_(&OO\ KWD_]!-7*IZM_P @:^_Z]Y/_ $$US'$7
M**** .&\9?\ (9B_Z]U_]":N>KH?&7_(9B_Z]U_]":N>KYC,?]YE\OR1QU?C
M9Z=I/_(&L?\ KWC_ /0163XS_P"01#_U\#_T%JUM)_Y UC_U[Q_^@BLGQG_R
M"(?^O@?^@M7T.)_@S]'^1U3^%G#UW'@S_D$3?]?!_P#05KAZ[CP9_P @B;_K
MX/\ Z"M>+E/\9^GZHYZ'Q'15Y(.@KUNO)!T%=6;?!'U+K[(Z+P;_ ,AF7_KW
M;_T):[FN&\&_\AF7_KW;_P!"6NYKIR__ ':/S_-ETO@1YWXF_P"1BN_^ ?\
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M_P"OB3_T(UYF;?P5Z_HS&O\ "8^K_P#('O/^N#_^@FO,:].U?_D#WG_7!_\
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M\!_\B+I'_7 ?S-?65MD>GB=D:VK?\@:^_P"O>3_T$UYC7IVK?\@:^_Z]Y/\
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MQOUL/^VG_LM==7(^-^MA_P!M/_9:]S&_[O/T.FI\+.3KT/PQ_P B[:_\#_\
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M_H2U\]EW^\Q^?Y,Y:7QH[FO._$W_ ",5W_P#_P! 6O1*\[\3?\C%=_\  /\
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M]&8U_A,?5_\ D#WG_7!__037F->G:O\ \@>\_P"N#_\ H)KS&NO)O]V^;.S
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MK;(]/$[(UM6_Y U]_P!>\G_H)KS&O3M6_P"0-??]>\G_ *":\QKYW-_L?/\
M0\ROT.<\9_\ (*A_Z[C_ -!:N'KN/&?_ ""H?^NX_P#06KAZ]K+O]U@>EA/X
M2/JG2?\ D#6/_7O'_P"@BJGB?_D7;K_@'_H:U;TG_D#6/_7O'_Z"*J>)_P#D
M7;K_ (!_Z&M14^!^AR/8\\KD/&WWK+_MI_[+77UR'C;[UE_VT_\ 9:\7)?\
M>7Z/]#/!?Q3GM+_Y"UE_UW3_ -"%?55?*NE_\A:R_P"NZ?\ H0KZJKZ.MNCN
MQ.Z.=\9_\@B'_KX'_H+5P]=QXS_Y!$/_ %\#_P!!:N'KYG-OXR]/U9YE?XCA
M?&7_ "&(O^N"_P#H35DZ7_R%K+_KNG_H0K6\9?\ (8B_ZX+_ .A-63I?_(6L
MO^NZ?^A"OI,)_NT/1?D>O1_@KT/JJN=\9_\ ((A_Z^!_Z"U=%7.^,_\ D$0_
M]? _]!:N7$_P9^C_ "."?PLX>N%\8_\ (8B_ZX#_ -":NZKA?&/_ "&(O^N
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MD>*/^1?N?^ _^AK7GE>A^*/^1?N?^ _^AK7GE>EE/^Z1^?YG?@OX1])^ _\
MD1=(_P"N _F:UM6_Y U]_P!>\G_H)K)\!_\ (BZ1_P!<!_,UK:M_R!K[_KWD
M_P#036KW,);L\QKG/&?_ ""8?^NX_P#06KHZYSQG_P @F'_KN/\ T%J^:RO_
M 'N'S_)G-A?XT3AZ^D_ ?_(BZ1_UP'\S7S97TGX#_P"1%TC_ *X#^9KZRMLC
MT\3LC6U;_D#7W_7O)_Z":\QKT[5O^0-??]>\G_H)KS&OG<W^Q\_T/,K]#G/&
M?_(*A_Z[C_T%JX>NX\9_\@J'_KN/_06KAZ]K+O\ =8'I83^$CZITG_D#6/\
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MW_$^9Y+7LOP6_P"03JG_ %W3_P!!KQJO9?@M_P @G5/^NZ?^@U]95^$]BO\
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M]^_[>9SK^)\ST2N&\9?\AF+_ *]U_P#0FKN:X;QE_P AF+_KW7_T)J];,/\
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M^T-V>",?ZL>M8?\ PN3_ *@/_DY_]A7A9AA:U:JI05U;R\SAJPE)W1L^,O\
MD,1?]<%_]":LG2_^0M9?]=T_]"%8&L_$'^U[Q;C^R_*VQA-OVC=W)S]T>M4[
M7QG]FNX9_L&[RI%?;YV,X.<?=KV\.U"A&$MTE^1Z5.I&-)1;UL?:M<[XS_Y!
M$/\ U\#_ -!:O(?^&FO^I1_\J7_VJL[6?VA?[7LT@_X1?RML@?=_:&[/!&/]
M6/6N>O%RI2BMVF<<E=-';UPOC'_D,1?]<!_Z$U8W_"Y/^H#_ .3G_P!A6%K/
MQ!_M:\6X_LSRMJ!-OVC=W)_NCUKBRK#U*%23J*V@81.G.\CMO G_ "/.C_\
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M[^T<XR,9_P!57+_\+D_Z@/\ Y.?_ &%7F6'J5N7V:O:_Z#JP<K6/?_!'6_\
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M@MC*FIO;"TE4Q2+<E?+<,,%3NX((XQWKF_"7@SPQX ^U_P!E2F+^U9PP^T7
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M(XQ7<^&O#[>'-/DM&UC5-4+R&3SM2N/.D7@#:#@<<=/<ULT4+16!ZNX4444
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MWD-S9R/J\<5QYL,;+M$1ZD*QY&!V%;'C'Q#X2LY(-(\2PQW*SKYIBDM3.D2
MX\Q^"$7/<U6\'^)?!\MZ=&\/V!T_S5::$"Q-O'=*.KQG #CD<^E.'3RO^O\
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MU/2C$P 6_C53)GNN">E;=<OX1\27^L7&J:9J]E!:ZIIDJ).+:4R1.'7<I4D
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
K "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>img69628308_16.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img69628308_16.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %N!>8# 2(  A$! Q$!_\0
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M\::KX?T;P['X6OO#O]C2V:[-<\3:CLCDV@!1A2&9B.20.I[5Y_KOQ8UWXD_
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@M(5B3)ZG:H S1S:/S#EV+M%%%04%%%% !1110 4444 %%%% !1110 4444
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M:A)8+=0-?1QB5[42 RJA. Q7.0"01GVH LT444 %%%% !1110 4444 %%%%
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M%G(.U<?>Y(SQTIJVEA:ZGKM%%%9%A1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %>:?'_6KO0/!-I=VE_-IS#4[59)X9C$?++_,"P(^7'7M7I=<#\:/"^I^+
M/"MG9Z5;?:KF/4K:X9/,5,(CY8Y8@<#MUJH[B>QS?Q?^)FE7&AZ1%X=\5V<M
M_)J]HKII>HH96C+X8$(V2O3/:NTU#QK>3>*KGP]H.F0ZE>V5NEQ>S7ETUM!
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MV3XDW]]K>MVNA>'VUBRT218;ZX^U"*1Y.KQP1E")&5?[S("> >]<?\)_&/\
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M:-9_\&$W_P 51_PL;Q9_T-&L_P#@PF_^*H_UJH_\^G]Z#^V:?\C/NRBOA/\
MX6-XL_Z&C6?_  83?_%5])_LUZUJ.O>!;ZXU*_NM1G74I(UENIFE8*(HCM!8
MDXR3Q[FO2R_/:>85_81@TSKPN8PQ53V:C8]9HHHKZ8]<**** "BBB@ HHHH
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MJ?"?_0/UG_OQ#_\ ':/[8P'_ #^0?7L-_.CV6BO&O^&J?"?_ $#]9_[\0_\
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M "BBB@"OJ'_(/N?^N3?R-</7<:A_R#[G_KDW\C7#U2$PHHHIDA1110 4444
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M%0O"LUF&U?P5K%C=[CF*RN8KF/'8[V\LY]MOXFCE8&9\2O\ DHGB?_L)W/\
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MB8:^HX;_ -_7HSV,I_WE>C/9:***_6#[4**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH Q_%'_(/C_ZZC^1KEZZCQ1_R
M#X_^NH_D:Y>J1+"BBBF(**** "KVCZ@;"[#$_NV^5_\ &J-% SOP0P!'(I:Q
MO#NH>?#]G<_/']WW6MFH*"BBB@ HHHH I:M_Q[K_ +_]#636MJW_ ![K_O\
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MCG8Y9@Z@\')X&/O'G!Q4G_#/OC[_ * /_DY;_P#QRC_AGWQ]_P! '_R<M_\
MXY6LGFTI<SIRZ_8T=][KEL[^:9;^NMWY'_X#WWNK6?S$O/BXNM>++C4M8\.Z
M=J>ER6OV%-,=0OD0C.SRY<%D<;C\PZY. /EVZMW\?[S_ (2'0[VPTF.UT[3+
M>2U^PW%RUPT\4FW>K2L,]$3'!P1SD<5E_P##/OC[_H _^3EO_P#'*/\ AGWQ
M]_T ?_)RW_\ CE)/-XWM"6KO\&N]][7M?IMY"3QRO:+UU^'_ ('X;&/XP\7Z
M3KEA9V&C>%[/P_:0,9&97,]Q(QS]Z9@&*\_=/^ ')UZ)_P ,^^/O^@#_ .3E
MO_\ '*/^&??'W_0!_P#)RW_^.5Q5<'CZTN>=&5_\#7X)6.>=#$U'S2IO_P !
M_P" >=T5Z)_PS[X^_P"@#_Y.6_\ \<H_X9]\??\ 0!_\G+?_ ..5E_9^-_Y\
MR_\  7_D1]5Q'_/M_<SSNBO1/^&??'W_ $ ?_)RW_P#CE;/A+]F_Q/J&M0QZ
MY:#2M-!W2R^?%(S#^ZH1CR?4U<,LQLY**HRU[II?>5'!XB32]F_N9SGPS^$F
MI_$RZD$4IT_3H^)+YH]P!]%&1N/XU)K/_!-'1=>U":^O/'^KS7,S;F=[2(_@
M.>E?8.AZ'9>'=+@T_3X%MK6%=J(H_4^IJ_7ZCE>5T\MI]YO=_HO(^QP>#AA8
M=Y/=GP^W_!+CP_\ P^/-2'UL(S_[-4;?\$MM%_A\?WX^NFH?_:E?<E%>Z>A8
M^%F_X):Z7_#\0[P?72D/_M6HV_X)9V'\/Q&N!]='4_\ M:ONVB@+'P<W_!+&
MV_A^)4H^NB _^W%1-_P2O3^'XFL/KH.?_;FOO:B@+'P*W_!*]OX?B<#]=!Q_
M[<U2NO@"W[.<@\--K@\0&Z']H_:5M/LVW=^[V;=[YQY6<Y_BZ<5^@]?*W[5/
M_)0M/_[!<?\ Z.FKY?B3_<'ZH\C-?]V?JCQJBBBOR8^*"BM:X\+:I:^&[;7I
M;7;I-S,;>*X\Q3N<9R-N=P^Z>2,<5DU<HRA;F5KZC<7'=!176>&/A5XK\8Z>
M;[2-'DN;3<5$S21Q*Q'7;O8;L'C(SS6%KF@ZAX;U*6PU2SELKN(X:.5<=R,@
M]&!QP1D'L:TE0K0@JDH-1>SL[/YENG.,5-Q=GU*%%=+X3^''B/QQ#/-HFEO>
MPP,$DD\Q(U#$9P"[ $X[#ID>HK"U#3[G2KZ>SO('MKJ%RDD4@PRL.QJ94:D8
M*I*+47L[:/T8G"<8J36C*]%=%X4^'WB'QQYW]B:7)>I#]^3<L: \<;G(&>1Q
MG-&I?#WQ%I'B*UT.\TN6WU*Z=4@C=EVREL8VOG8>H!(/!X-7]7K."J*#Y7L[
M.WWE>RJ<JERNS\CG:*[S4/@9XYTRRGN[C07$$*%W,=Q#(P ZX57)/X"L/PEX
M#UWQU)<QZ'8&^:W"M+^]2,*#G'+L.N#^57+"8B,U3E3DI/96=WZ(;H58R47!
MW?DSGZ*?+$\$CQR(T<B$JR,,%2.H([&F5R&(5C:U^RO\0OCA=+KWA/4=.M-/
MMT%C)'=WLD+F527) 5",;9%YSV-;-?5/[*W_ "3W4/\ L*2?^B8:^HX;_P!_
M7HSV,J_WE>C/B[_AW]\<(_NZWI/_  '5YA_[3H_X8+^/$?W=:L/^ ZS*/_9:
M_3:BOUFY]I8_,G_AAGX_Q_=UFV_X#KD@_I1_PQ/^T/']W6%_X#K[BOTVHHN%
MC\R?^&-?VCX_NZO)_P !\1,/_9J/^&0_VEX_NZM=?\!\2$?^SU^FU%%PL?F3
M_P ,H_M/Q_=U74?^ ^)\?^U*/^&7_P!J>/[NJ:O_ ,!\5 ?^UJ_3:BBX6/S)
M_P"&;?VKX_NZGKW_  'Q8H_]KT?\,]_M;Q_=U/Q)_P !\7H/_;BOTVHHN%C\
MR?\ A1/[7\?W=2\5_P# ?&48_P#;JC_A3'[8D?\ S$/%Q_[G&,_^W5?IM11<
M+'YD_P#"I_VQ(_\ E^\7'_N:HS_[<4?\*V_;$C_Y>_%Q_P"YBC/_ +7K]-J*
M+@?F3_P@O[8D?_+SXN/_ '&XS_[6H_X13]L2/_EOXN/_ '%(S_[4K]-J*+@?
MF3_8?[8D?_+3Q<?^WV,_^ST?8OVQ(_XO%Q_[;1G^M?IM11<#\R=W[8D?_0W'
M\(S1_:7[8D?\'BX_]N\9_P#9:_3:BBX'YD_\)!^V)'_RR\7'_MPC/_LE'_"8
M?MB1_P#+#Q<?^X1&?_:5?IM10!^9/_"?_MB1_P#+KXN/_<!C/_M&C_A9W[8D
M?_+GXN/_ '+49_\ :%?IM10!^9/_  MW]L2/_EP\7'_N4XS_ .VU'_"[/VPX
M^NG>+C_W)L9_]M:_3:B@#XE_9E^)?QW\8^/+^Q^*%IK4&@QZ;)- VI: MA&;
MD2Q!0)!"F3L:3Y<],G'''TU74>*/^0?'_P!=1_(UR],04444Q!1110 4444
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M/M#Z'F]M\8/&GA^;5I-=AT^Z33=1MK6[MX!M$:2JQ(C/4D$#KGI^-?1ND_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M&/XH_P"0?'_UU'\C7+UU'BC_ )!\?_74?R-<O5(EA1113$%%%% !1110 4*Q
M5@0<$<BBB@#L])OQ?VBN?]8O#CWJ[7&Z/J'V"[#$_NV^5O\ &NQ!# $<BI*%
MHHHI#*6K?\>Z_P"__0UQOC.WU^XT*1?#5S;6NJJZLC7:YC90>5/!ZBNRU;_C
MW7_?_H:\(_:"^(MGX?T?^PQ=7]GJ5QY4P:S9HBT.\AP) #C@'C%5%78GL02?
M'W4/!>I)IOCKP_\ V?<'D7.FS+*C#L=A;('_  (GVKT[PIXRT?QMIIOM%O4O
M8%.U]H*LC8SAE(R#7SYIOC#X7>%88Y/#^CS>(]<DF1$?549G8LP&X$J5R/8
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MT-6;/1?BT\D$C^)-#EMB59O+3.Y?8^3Z4N@^IZ;\)=:UO5;B\CU[1?[(O;=
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M;<AE ,K9<MYV<D-@]%KR&N7,YX>I.#PST44OQ>_GW,<9*E*472VL%%%%>,<
M5]4_LK?\D]U#_L*2?^B8:^5J]:^$G[2WPX^#?ARYT7QAXB_LC4I[MKR.'[#<
MS[HF1$#;HXV ^:-QC.>/I7U'#?\ OZ]&>QE/^\KT9]:45X(/V[/@:W_,\#_P
M57W_ ,8IZ_MS? ]O^9Y3\=,O1_[1K]8/M3WBBO"A^W%\$&_YGJ'_ ,%]W_\
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M5N47VCZ.T_\ X\X_Q_F:*-/_ ././\?YFBL30LU%<_\ 'O+_ +A_E4M17/\
MQ[R_[A_E0!@URNNVO@K4!+9:NNB2$3&5X;DQ!A(<98@\AC@9/4@<UT6I2>3I
M]TYE, 6)F\U1DI@'D#OBODOP/?\ PECT%$\465Y>:T)'\ZYWS[9?F.UEV,.,
M8ZC.<U<8WU);/K33I+22QA-@T+V87;$;<@QA1P N.,#&./2N!_:"O'L_A7JQ
M2]:R,ACC)523(I<;H\CID9]NQX-='\.Y-#E\&:8_AN)H=$*M]FC<L2!O;/WB
M3][=U-4OBUXE@\)^!K[49K"#4G4HD-M<H&C:1F 4L/09S^%)?$#V/"=*TWX-
M-':G_A*==BF^7$4BR9!]#MA*_D<5]9Z3_P ?#?[G]17S;J%GXN^&Z6&M^)++
MPWJ>D27$<-S:6UC&LL.\]5(C&2/J?ZU]):3_ ,?#?[G]153%$UJ***S+"BBB
M@#\\:**[GX+^&].\6?$&QTS5;;[5921RL\6]DR0A(Y4@]1ZU^#4*,L15C2CO
M)I?>?FU.#J34%N]#AJ*]CT/0_!OQ,DUC1=)\-R^&]9MK>2XM+E=0DN(Y2G!1
MPX^4$E>@)Z\C&#H:Y\+=!/P1M-<L+!H]>6RAO995F<^8I8"0[2Q4  YX Z5Z
M4<KJU(2J4Y*44F[J^MMUJD[G6L'.47*#323?7IOTW/#**^@/'7P6T73_  OX
M8L],MO)UZZU*UTZ\O/,D?YFA9I#L+;0,X; QTQ6#J ^%NC^(KWPS>Z-?1Q6@
MDMI-?%W(TOGID$^2!M^\" <8SCC'-54RFK1ERU9QCMNW:[Z;=.M]%W'+!3IN
MTY)?UMM_P#QVBMGPS86NI>,-)LI UQ8W%_#"P<;&>-I #G!^4D'L>/6O=V^'
M7AN;QX_AP?#74(=.+-&->6]N?*7]V6#C(V]>.6//KTK#"Y?4Q<>:,DM4M;[O
MT3^]V1G1PLJZO%I:VZ[_ "3/F^BN]TOX2W>O2:C<6NJZ78Z/#?-96U_JET(D
MNV!.!&0#N. #Z'/&<'%+4OA;K6CZ1KE_=FVB.C7,=O=VOF$RKOV['  P5.X8
M.<]>*P>#Q"CS\CMK^'_ 3?H9?5ZJ7-RZ''T5ZIH_PGN-)OM6L]6LK#4[F/0V
MU-8S>S0FUST)VQ_,XP?D/R^]9.A_!?7-=T>SOH[K3+6:^1Y++3[NZ$=S=JHS
MF-2,'/;)'J<#FM/[/Q.B4;O73M;0OZK5T26IP-%=O8?"+7-2C\/O"UMC69Y;
M:,.SJ;>2/.]904RI^5NF?NFH]6^%.LZ':>([F[EM(X=#FB@G;>Q\YY,;1'\O
M/#*3G'!%9?4\1R\_([?\#F_+4CZO5MS<NG_ O^1QE?5/[*W_ "3W4/\ L*2?
M^B8:^5J^J?V5O^2>ZA_V%)/_ $3#7N<-_P"_KT9Z.4_[RO1GLM%%%?K!]J%%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110!7U#_D'W/_7)OY&N'KN-
M0_Y!]S_UR;^1KAZI"9E>(/"^E>*K>.#5+-+N.-MR9)5E/?#*01^?:JD?@'0(
MM"DT==,C&G2/YC1;FR6S][=G=GWSTXZ5PGCW6(;;XBK:ZGX@U/1=*^P*X-A,
MZYDW''"@]1GMV%;5GXOTWPSX7MY]-O=2\4/?71BM5NY&,LDG *[F4%5&/3J:
M^?\ K6$G7J^TA&\;IMV;:VVWL]CR_;495)\T5IHWI?[MS?T[X?>'])6X6TTY
M8!<6[6LNV5_GC/4'YNO^UU]Z?>>!-!O]&M=*N-/66QM?]3&7?<GT;.[]:YC5
M_'EU?>'_ !+87-E/H.NV-IYPC6</\A PZ2+CD9&?J/?%;1]<O!XJ\(K/?W!M
MI- 6XG5Y6*NVPDNPSR?<\TGB,$FJ4*2:=ELEO*S337=:IB]KATU",%9Z;=W:
MUCLF\#Z$V@?V*=.C_LW<'\D%@=P.=V[.[/OG...E8%[\/;B^\0:*I%C#X<T=
MM]K"OF/.3A3M8MD;=R^O05!'\6G\F/4I=!N8O#<D_D+JAF4MW 8Q8SMR,9S^
MO%3ZQ\4DT6/Q )]._P!)TNXBA2'S^9Q)RK9V_+\H)Z&E4K994@G*R2MT:T5Y
M);:QTNNCMH$IX2:N]$O*VBU73;33HSO**Y/0_'L?B#6K&QM+7>DVGK?S3>;_
M *G)P(R,<G)'<?2NLKW*->GB(\U)W1WPJ1J*\'<****W-!4=HW5E.&4Y!KM-
M-OEO[59!][HP]#7%5HZ)J'V&Z 8_NI.&]O0TAG7T445)04444 %%%% !1110
M!Q^O_P#(6G_X#_Z"*SZT-?\ ^0M/_P !_P#016?5$E;4KJ.QT^ZN)4\R*&)I
M'4#.0 217S[:^-O$NI7D-TEKHMO;7NGW%_:V@MD956(MP[$9S\C=#^7;Z&N9
M(H;>62<JL*H6<MT"@<Y]L5\LS6OA34M:EFM/#FN)ICPS74"1W@1)XT;YBD?E
MDA>#_%QCVK6!$CZ.\#:XOB3PCI6II;+:"YA#F&,85#T('MD&MVLGPG>:=J'A
MK3;C2$$6F/ OV>,+C8N,!<>HZ?A6M6;W*.@\)_\ +U_P'^M=!7/^$_\ EZ_X
M#_6N@J64@HHHI#,_7_\ D$S_ / ?_0A7"ZIG^S+O%O\ :SY+XMS_ ,M/E/R_
MCT_&NZU__D$S_P# ?_0A7#:E;PW6GW4%RVRWDB9)&SC"D$$Y[<52)9X;\-]-
M^(5]X4M7T3Q#I5EI^7\NRD3S'MQO/R'*,1SG@D\5[5X=AU*VT6UBUBXBN]25
M<3S0KM1FR>0,#MCM7S))H_A%UFOK/PGXDO= B<AM42?"[0<%@-F,?5OKBOI#
MP/:Z;9^$M+BT>1I=,\D-;M(V6*M\W/OS6LR(AXPN]=L]'\SP[96]_J/F*/)N
M7VILYR<[AST[U2\1:AXLM[+2&T?2[.[N9,?;DFDVB+@9V_,,\[O7I7$?&#Q)
MXT\(ZS:7.GZI:V6@W;K )9H XMY,<F0["<'D\9Z&K-GHOQ:>2"1_$FARVQ*L
MWEIG<OL?)]*5M+A<]IT"S@O;QTN((YT$9(61 PSD<X-;K>'=);KI=F?K;I_A
M61X7_P"0A)_UR/\ ,5U%9,T1EGPMHK==(L#_ -NR?X4QO"&@MUT33C];2/\
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M1-.TF]N_M-CI^?LJ21H7B!Z@/C=CIP3C@>@Q[?\ \,D?]37_ .4[_P"VT?\
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M6/&6H"]UF^DOKA5V*6 55'HJJ !^ YKV_P#X9(_ZFO\ \IW_ -MH_P"&2/\
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M 4LOI>SI[]7W/K<-AH86')'YL\+/[#_P1;_F18?_  /N_P#X[3&_8;^![?\
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M3"^'_;Q3XD'U>W_^-4P_\$P? ?;Q7XB'XP?_ !NOLNB@#XQ;_@E_X'[>+?$
M^JP?_$4QO^"7_@OMXPUX?6.#_P")K[1HH$?%9_X)>^#^WC+7!_VQA_PIC?\
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M?M\35/\ W ?_ +IK[[HH"Q\ M_P2PG[?$N,_70S_ /)%-/\ P2QN^WQ)A/\
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MOJ=+2GSZZ=NB?Z,\XFT>]\*^(/!MV-*U"YM;.TD@E2V N7B9@PPS*%!QO'.
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M/ UCG_L(/_\ $4S_ (>3:W_T).G_ /@<_P#\37V</ACX.4@CPEH8/_8-A_\
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MSX5NOB GA'2;_5S?V[">^FN/*,26^S<53"@F0EH^2-HW'KC%.\1? O1=!N-
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M**_6#[4**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"OJ'_(/N?\
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M5M+@>W:+J5II=TTM[=0VD3(5#SR!%)R#C)/7@_E6S_PF&@_]!O3?_ N/_&O
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MZD_X=<^&_P#H>=4_\ X_\:_6=#[34^@_^&L?@_\ ]%!T7_O\?\*/^&L?@_\
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MP5_Z'RS_ / :X_\ C=>1?\.P? ?_ $-?B/\ .W_^-T?\.P? ?_0U^(_SM_\
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M36VIW<P*Q3LSNT:+SSC<I_#VR?0OBYX]N_"?BCPO;?;?[+TE_.O+R8K_ ,?
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M_8;4%A^]DY;V]JQ?#^G_ &JX\UQF./GZFNKJ64@HHHI#"BBB@ HHHH ****
M"BBB@#C]?_Y"T_\ P'_T$5GUH:__ ,A:?_@/_H(K/JB2&ZM(+ZW>"YACN('&
M&BE0,K?4'@U2F\,Z1<6$=C)IEHUE'()4MO)7RPPZ';C%:=%,0@ 4  8 Z"EH
MHH Z#PG_ ,O7_ ?ZUT%<_P"$_P#EZ_X#_6N@J64@HHHI#,_7_P#D$S_\!_\
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M[6SD'$?H[#U]!VKWFBBOT?!X.E@:2I4EZ^;[GU6'P\,-#D@%%%%=QTA1110
M4444 %?*W[5/_)0M/_[!<?\ Z.FKZIKY6_:I_P"2A:?_ -@N/_T=-7R_$G^X
M/U1X^:_[L_5'C5>H_">19O /Q)L5<"ZDTZ.X5<\F.,N7/T^9?SKRZM+0?$6H
M^&+YKO3+DVT[1-"QV*X9&&&4JP((/N*_,\)66'K*<MM5]Z:_4^1HU%3FI/;7
M\58]@$FG>.O#/@B>S\9V7A6;0[62VNOM%P8KF)]JC?$H(W[@O4$<'')R!!9W
M.F>./AU:^'[?Q;:Z7?Z;JLMQ)=:M*;;[6C.[+,"2<O\ -G&<@@Y(X)\4HKN_
MM*[O*FM59ZO71+OILCI^M]X[JSU>NWW;'TAJWQ"T+5+KXAO::K O_$DCLH)Y
M)1&UW*JS;C'DY;E@..OT(JII_BW2X]2^$(;6;-8+*TE%V#=(%@;R54>9S\IZ
MCGWKYZJ:ZL[BQ:-;B"2W:2-94$J%2R,,JPSU!'(/>M_[8K2?,XK?_P!OY_TL
M:?7YMW:_KFYCW/Q!XHTP^#[2WMM7M#)_PF,EP\45RN?(\V5A(0#]S[ISTZ&M
M'6/%VE7/BWXJN=:LY;:YT58+)OM2%)6^S_<CYPQW%N%[D]Z^=:MV>DWVH6]S
M/:V5Q<P6J[YY88F=8E.>7(&%'!Z^E)9M5DTE#M^$9+];_(7UV;VC_237ZGNE
MKJ.C^*;KP)XA@\6Z?H=KX?MHXKS3;B8QS(T8#.(DZN''R$CJ !\QRM9'BKQI
MI>M?#+Q?]BNH+>34/$K7$=GY@662';&?,*=<$KN/'7/I7B]%92S2<H2CRI<R
M=]^W+?RTZ$2QDG%JV^_W6/3?C_J]CK7BS2Y["]M[^-=*A222WF60!PTF5)!/
M/(X]Z[#P#I>E^%/ :WFC>)?#5OXOU*(>9=:EJ*H;*)AG8B@$[QQG('.<YQBO
M"X]-O);"6^2TG>RB<1R7*QL8T8]%+8P"?2JU3','#$3Q,J>LMO+S7^8EBG&K
M*LXZO\/0]V\*7.D:QX4T+1;GQ'I=A>>&]=-S<275R%CN81([;X6/W\D\=/4X
MR,^8_$WQ%;>+/'FLZK9;C:7$W[IF!!954*&P>F=N>?6N7HK'$8Z5>C&BXVM;
MYV5E]R^\SJ8AU*:IVV_31?@%?5/[*W_)/=0_["DG_HF&OE:OJG]E;_DGNH?]
MA23_ -$PUZO#?^_KT9VY3_O*]&>RT445^L'VH4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110!C^*/^0?'_UU'\C7+UU'
MBC_D'Q_]=1_(UR]4B6%5[K3[6^:%KFVAN&A<21-+&&,;#HRYZ'W%6**32DK,
M32>C"BBBJ **** "BBB@ KJ]!T_[':^8X_>R<GV'85C:'I_VVZ#,/W4?)]SV
M%==4LI!1112&4M6_X]U_W_Z&O*?C);Q>(O!]_H<&KZ187SF.1O[3N1&(T#@A
MN,E3G&#CK7JVK?\ 'NO^_P#T-?/WC2\T'4OC!+X?U7PY#?+<:=YL]X9Y%D9(
MT:4)M! ZH*N.XGL9]GK?Q"A\F)_B'X)F5<*2UTI=A_W[Y->]UXM\,_ _PY^(
MVA-K%EX4^Q)'<-"$FN)"VY0ISP_^T*]IHD*)YO\ %;5=(FUKPWX?U'1+?63>
M3/.[W/"VD$8!DDS_ +N>,_PG.> >9^&?Q$_MSX@V\DWAFTTRWUFTDCTR^ASY
MK00,0$89P!\IX 7H.O%=5\8O VA>*+"TO=8UH^'FLQ(@O5D5-T;C#QG/7('3
MW/!R17&> =6\'WWQ3TN#P\VH:HECIYL;>5D*VUHJJQ9\GEF<Y'0#YCUXJE;E
M$]SZ1T__ (\X_P ?YFBC3_\ CSC_ !_F:*R++-17/_'O+_N'^52U%<_\>\O^
MX?Y4 <Y=6D%];R6]S#'<02##Q2H&5AZ$'@UGS>%-%GTT:<^DV9T\2"7[+Y"B
M+<#D';C'6M6B@!$18T5$4*BC 51@ >E+110 5=TG_CX;_<_J*I5=TG_CX;_<
M_J* -:BBB@ HHHH _/&BBBOY_/S(**** "BBB@ HHHH **** "BBB@ HHHH
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MX7=\.O\ H?O"_P#X.;;_ .+K\C**/[-A_,']@TOYV?KG_P +N^'7_0_>%_\
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M /0UX/\ $'X2^)]>^(1\2Z#JFGV+?9/LH%T&9L%65N-A'(8U[QJW_'NO^_\
MT-9-4FX[":N>$^#?A3\2_ NG_P!GZ3XDT>WL6F,SQF(N2Q !Y:,GH!7NU%%#
MES;@E8^:?&'PA\5V/B2^UJ^TZ/QW9R%S'&UW()H 20N%)YQD<#<..E;7[,_B
MNRT>PF\'WZ7%EKSW4MPMO/ RY78N1G'! 0]<5[Y4$EA:S74-U);0R7,((BF9
M 73(P=K=1D>E5SW5F3RV=T=#I_\ QYQ_C_,T4:?_ ,><?X_S-%9EEFHKG_CW
ME_W#_*I:BN?^/>7_ '#_ "H P:*** "BBB@ J[I/_'PW^Y_452J[I/\ Q\-_
MN?U% &M1110 4444 ?GC1117\_GYD%%%% !1110 4444 %%%% !1110 4444
M %13?LH^+OCJPU[0=1T6TL[<?8734IYDD+K\Y("1.-N)%[YR#Q4M?5/[*W_)
M/=0_["DG_HF&OJ>&_P#?UZ,]C*O]Y7HSY-_X=S_$G_H-^%?_  +N?_D>C_AW
M/\2?^@WX5_\  NY_^1Z_1>BOUGF9]I8_.C_AW/\ $G_H-^%?_ NY_P#D>C_A
MW/\ $G_H-^%?_ NY_P#D>OT7HHYF%C\Z/^'<_P 2?^@WX5_\"[G_ .1Z/^'<
M_P 2?^@WX5_\"[G_ .1Z_1>BCF86/SH_X=S_ !)_Z#?A7_P+N?\ Y'H_X=S_
M !)_Z#?A7_P+N?\ Y'K]%Z*.9A8_.C_AW/\ $G_H-^%?_ NY_P#D>C_AW/\
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MQ:_NEC'W>K'T%=HB"-%51A5& *H:'I_V&U!8?O9.6]O:M&I904444AA1110
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M_P")MS#?7GAU]9U6^2.UB4W#Q7"W"QD([*,_O5)!88&>O2OKO_AYE\+_ /H
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M!Q7B3]D7Q9X;\1:7X?;6_#.H>(-2N5@@TJRU!VN=AC9S.R-&I6)5C?+'^[@
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M_P""8_Q/_A\0>$C];NZ'_MO6OHOP+U_]GVU?P[XCN].O;VY<WZ2:9+))&(V
MC )=$.[,3=L8(YKY?B3_ '!^J/'S7_=GZHOT445^3'Q84444 %%%% !1110
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M  #ZZEQ!*BDHT]5_>_X!^*GE)_='7/2CRD_NCKGI7[5T5/URG_SZ7]?(Z?\
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M%%% !1110!C^*/\ D'Q_]=1_(UR]=O?V$>HPB.0LJAMWRD9Z'_&J'_"+VO\
MSTF_[Z'^%,1R]%=1_P (O:_\])O^^A_A1_PB]K_STF_[Z'^%.XK'+T5U'_"+
MVO\ STF_[Z'^%'_"+VO_ #TF_P"^A_A1<+'+UI:'I_VVZ#,/W4?)]SV%:W_"
M+VO_ #TF_P"^A_A6A964=A"(HLXSDENIHN.Q8HHHJ1A1110 4444 4M6_P"/
M=?\ ?_H:R:W+NV^U1A-VW!SG&:J?V/\ ]-O_ !W_ .O0!G45H_V/_P!-O_'?
M_KT?V/\ ]-O_ !W_ .O0!G45H_V/_P!-O_'?_KT?V/\ ]-O_ !W_ .O0!9T_
M_CSC_'^9HJ2WA^SPK'G=COC'>B@"6BBB@ HHHH **** "BBB@"MJ&I6FDV<E
MW?74-E:QXWSW$@C1<D 98G R2!^-8W_"QO"?_0T:-_X,(?\ XJCQY_R [;_L
M*:;_ .EL%=%7-*5251P@TK)=+[W\UV,FY.3C%_UKYG._\+&\)_\ 0T:-_P"#
M"'_XJC_A8WA/_H:-&_\ !A#_ /%5)XD\;Z/X2N=/MM2GF2YU!G6U@M[2:XDE
M*@%@%B1CP"#5CP[XITSQ7:S3Z9<F=8)6@FCDC>*6&13RCQN RGV(%5RU]^9?
M<_\ Y(/?[K[O^"4_^%C>$_\ H:-&_P#!A#_\51_PL;PG_P!#1HW_ (,(?_BJ
MZ*BERUOYE]S_ /D@M4[K[O\ @G._\+&\)_\ 0T:-_P"#"'_XJC_A8WA/_H:-
M&_\ !A#_ /%5T5%'+6_F7W/_ .2"U3NON_X)';W,5Y;Q7%O*D\$JAXY8V#*Z
MD9# C@@CO4E<[\.?^2>^%_\ L%VO_HE:Z*M*4_:4XS?5(J$N:*EW"BBBM"PH
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MX)SO_"QO"?\ T-&C?^#"'_XJC_A8WA/_ *&C1O\ P80__%5T5%'+6_F7W/\
M^2"U3NON_P""8NG^-/#VK7D=I8Z]IE[=29V06]Y'([8!)PH;)P 3^%;5<[XH
M_P"0YX0_["DG_I%=5T5.E*4G)3Z/]$_/N.#;NI=/\@HHHK<T"BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH XC4/CC\.-)O[FQOOB!X6LKVUE:&>V
MN-:MHY(I%)#(RE\JP(((/((J#_AH'X7?]%)\(_\ @]M?_CE'P1_Y$W4?^QE\
M0?\ IXO*[Z@#@?\ AH'X7?\ 12?"/_@]M?\ XY1_PT#\+O\ HI/A'_P>VO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M6Z25@HLKD;B%).,D<^XKMZFA.,Y5'%W5_P#VU"IR4G)I]?T04445U&P4444
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M"D%4 #_+C)^88;GKP,>T_P#"[O#O_0.\7?\ A%ZQ_P#(M'_"[O#O_0.\7?\
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M^(_]!UR:\NIK_P -ZA90PQ?V7?Q;FEG@1!EY8U SDEA@5Z[4C"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BL30=5N-0U'589BI2WEV1X&.,L.?R%
M;= !1110 4444 %%%9/B367T.Q2>.-92T@3#''8G^E &M1110 4444 %%%%
M!116)XLU6XT?3HYK<J':4(=PSQ@G^E &W1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%4X]6@FU.:P4
MM]HB7>PQQCCO_P "%7* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M*YG^R/$/_06C_P"^?_K4?V3XB[:K%_WS_P#8T =-17,_V7XD_P"@I#_WS_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M(_\ B*/L'BC_ *"5K_WR/_B*Z:B@#F?L'BC_ *"5K_WR/_B*/L'BC_H)6O\
MWR/_ (BNFHH YG[!XH_Z"5K_ -\C_P"(H^P>*/\ H)6O_?(_^(KIJ* .9^P>
M*/\ H)6O_?(_^(H^P>*/^@E:_P#?(_\ B*Z:B@#F?L'BC_H)6O\ WR/_ (BC
M[!XH_P"@E:_]\C_XBNFHH YG[!XH_P"@E:_]\C_XBC[!XH_Z"5K_ -\C_P"(
MKIJ* .9^P>*/^@E:_P#?(_\ B*/L'BC_ *"5K_WR/_B*Z:B@#F?L'BC_ *"5
MK_WR/_B*/L'BC_H)6O\ WR/_ (BNFHH YG[!XH_Z"5K_ -\C_P"(H^P>*/\
MH)6O_?(_^(KIJ* .9^P>*/\ H)6O_?(_^(H^P>*/^@E:_P#?(_\ B*Z:B@#F
M?L'BC_H)6O\ WR/_ (BC[!XH_P"@E:_]\C_XBNFHH YG[!XH_P"@E:_]\C_X
MBC[!XH_Z"5K_ -\C_P"(KIJ* .9^P>*/^@E:_P#?(_\ B*/L'BC_ *"5K_WR
M/_B*Z:B@#F?L'BC_ *"5K_WR/_B*/L'BC_H)6O\ WR/_ (BNFHH YG[!XH_Z
M"5K_ -\C_P"(H^P>*/\ H)6O_?(_^(KIJ* .9^P>*/\ H)6O_?(_^(H^P>*/
M^@E:_P#?(_\ B*Z:B@#F?L'BC_H)6O\ WR/_ (BC[!XH_P"@E:_]\C_XBNFH
MH YG[!XH_P"@E:_]\C_XBC[!XH_Z"5K_ -\C_P"(KIJ* .9^P>*/^@E:_P#?
M(_\ B*/L'BC_ *"5K_WR/_B*Z:B@#F?L'BC_ *"5K_WR/_B*/L'BC_H)6O\
MWR/_ (BNFHH YG[!XH_Z"5K_ -\C_P"(H^P>*/\ H)6O_?(_^(KIJ* .9^P>
M*/\ H)6O_?(_^(H^P>*/^@E:_P#?(_\ B*Z:B@#F?L'BC_H)6O\ WR/_ (BC
M[!XH_P"@E:_]\C_XBNFHH YG[!XH_P"@E:_]\C_XBC[!XH_Z"5K_ -\C_P"(
MKIJ* .9^P>*/^@E:_P#?(_\ B*/L'BC_ *"5K_WR/_B*Z:B@#F?L'BC_ *"5
MK_WR/_B*/L'BC_H)6O\ WR/_ (BNFHH YG[!XH_Z"5K_ -\C_P"(H^P>*/\
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M4S6/%&F:#?:99WUSY%SJ<QM[1/+9O,D SC(! X[G I@9WV#Q1_T$K7_OD?\
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M_FN[:RFX>"%@FU&'8Y!.#SSS7J53+<I;!1114C"BBB@ HHHH **** "BBB@
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MB?:(VD9F<'*%&4[B""I&/SJU-\-[2\ET2>^U35-0NM*OFU".XN)4+22,",,
M@4( <!4"CCU))=T*S///AWH.MM<?$S^S/$=^FHQ:I<1P>9%:E)9_)79)(##U
MSCA=JX'2MGP[\1M3\:ZCX"M-/G:U>ZLY=0UH>2C?+'^Z,>2#M!F##C!PO;I7
M::3X'M]#\2ZGJ]E?WL*ZE+Y]UI^8VMWEVA=_*;P< =' ]JYOX4^ )O#.O>,=
M:O+(V,^K:BYMH'=',=N&9@05)"[V=V*CIQFBZ>H]3TBBBBLR@HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH ***^2/BE>3Z#^T9J7B2$,T>B-875R%_P">
M#"*-Q^.\#\:J,>83=CZWHKY&O;^7Q3^T1HOB4.)-/FU]M-M&7[K);K&"P]B9
M,YZ9)KOV^.'C/5=%UGQAHNB:0_@W2[DQF&[DD6^N(U90[*0=B\-GD<<_>QS7
M(R>8]ZK+TG13IE[J$YE$GVJ3>%VXV\L<=>?O5Y-_PN/Q7XH\=1Z%X1T_2)8+
MK1X=4@N-3,J^0'",3(4)W##;-H .Y@<X!!\_^)7Q/\3>//@JMY-%9Z8T&MOI
M>IK:R2+YS*JL@09/R?,0P8G)4$>@%!CYD?5M%?-<DWC.']H0+;V^BS>*I-!"
M2LSRK81?-DMT,A& !CKEO2O4_@S\1K[XB:#J$FJV<%IJFFWLEE<"U)\EV7!#
M*"21P<8)/3/? 3C97!,]!HKY$^(5[)XP^(WCR;5- U+Q#::$%2)K'41;#2X4
M^_*H*MN<E=V,$?>/8$?4'@G5+76O!^C7MC<W%[:S6D31W%X09W&T#,A'&_CY
ML<9S1*-D"=S;HHHJ"@HHHH **** "BBB@ HHHH **** "BBB@ HHHH *YSQI
M\/?#_P 0K6VMO$&G_P!H0V[F2)?.DCVL1@G*,#T]:Z.B@"*UM8;*VBM[>)(+
M>%!''%$H5$4# 4 <  <8%2T44 %%%% !1110 53U?2;37M+N]-OX1<65W$T$
MT1)&Y&&",@Y'!ZCD5<HH P_"'@G0_ >F-I^@Z>FGVC.96569RS'N68ECT'4U
MN444 %%%% !1110 5R\?PS\,Q^,I/%8TF,Z_)UO&D<\[0F0A;:#M &0,]?4U
MU%%, HHHI %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 5Y)_P *:\3:7XK\0ZUX>\>?V(-:N!<3V_\ 8\5QC&=HW._;
M<>@'6O6Z*:;0K7/'[K]G*QN_ >H:)+K5U-J^H7B:A=:S-$'::9<_>CSRGS-\
MN[.6SDU-HWPSU'X?^)+KQO>Z[>>*+Y-,:TN;.TTR-))U# H($1@%PJ(-N#DA
MCGYL#UJBGS,.5'AG[./PYET'4?$7B.YTV]TJ*ZGDM=+L]20QSPVGF%_F3^')
MV\>JD]""?2?B5\/[3XE>&)-)NKB6SD61;BVNH<%H9E!VO@]1R<CC()P0>1U5
M%#DV[A;2QPG@'X9S^%=<U;7]8UN3Q'XAU)4BDOFMEME6)  J+&I('09/? X'
M)/=T44F[C"BBBD 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 5Y-?_  ;\0P^.]=\3>'_&_P#8,NK%/-A_LF.YPJJ !N=_;/ '6O6:
M*:;0K7/(9/V=[*[\%Z]I5YK5S>:YK4ZW5YK<D0W-(K;D CS@(.?ESW/(X -$
M^$.I>#_$]MXQU'Q)<^)+K2].DMOL5OIB1-)$J-LBA17 4CL.<D]LUZ]13YF+
ME1X-\ ?A[):^,O$_BNXT>^T:SFFDATJRU.(QRQ1N^]SL)^7^$ ^A;D\UZ;\3
M_!=Y\0/"-QH=GK+:&MRRB>=8/-+Q#DQXW+@$XR<] 1T)KK**')MW';2QYAX)
M^$_B'PMI8T:Y\;R7.@+:/:Q6=AID5C)$6'$BS(Q8."2V3DDG)SS3/"?P7O=,
M\3:;K?B3Q9=^*Y])B:+3EN;=8_)W9W,[;F,C<\$G(QWP,>I44<S"R"BBBI&%
M%%% !1110 4444 8GBCQIHO@N&TEUF^6R2ZF$$.49RSD$]%!( QRQX'&3R*V
MZ\*\?7%CXY^(7B'2;^"]N-/TO1WT^![2PN;M$O)P&+GR4;:54(,'WK3TO7/$
M7Q ^#OA^\TS[1/J=O<Q1:O9PW9M+F=8B5EC$I(,;DA'/S+D9&>>;Y=";GL5%
M>0M/?^*O"VE2^&GUZ[L+'59(M5TJYOS:ZD%!(,(G+ DQLP;!DRP&"]4+[QP=
M:L?!&F:$WB"ZTW5+J\^U1+<+%J>( 6^S&9Y%VX8@%M^\K'C<222<H7/;:*\E
MATGQQ)X8\96%A'J6GJ[1/HW]K7\<MWL.#<1><LDA7.&5&9LKO!R,9$ N-3U[
MPEKVF>&O[<LM=L+R WNCZKJ)^T*F%9XH;LLY D4':^\XZC:#2Y1W/8:*\(\7
M>+/^*%FAT'4-?T>^M?$=M97$6H71DN;5BR@H)"[[T/WAEW!W$?=P!N6_AN6/
MXL3>'/[?UY]#.C1ZB]J^J3%VF$K19\[=YBKCYBJ,H)Z\<4^45SUNBOGRV\>:
M]?\ PW\%6+3ZE=W6H:O+IMU>6<J1W<T,+R *LC%0KL%4%]P/RL<Y-;.KR^*=
M!\+?$&7[/K&DZ*NF>?ILFI:BEQ=03A") LBS2/M.%8;FX).,=*.4+GM55K/4
MK34O/^R74-UY$K02^3('\N1?O(V#PP[@\BO([,7GA_5?ANXUG5K[_A((I8-2
M6[OI'6;=;^8K*I.V(JPX,84XR"3G-7O@CX=MK.Y\7W*2WQEA\17UNJRW\\B%
M05P61G*LW^VP+'UI<N@[GJ]%%%2,**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ KS/6_@G!KWBOQ=K%SJ>8M?TL:=]E^S\P$! L@;?\ ,08P<8'U
MKTRBFFUL+<\CTC]G^#1K?P+%!J_/AFYFNI&^R\WCR,I/\?R8V@?Q54N?V=;A
M(M4TC3/&%YIG@_4KC[1<Z*EI&[#+!F2.8G*#@ <'@ -NYS[/13YF+E1P?A_X
M4VWAOXBR>);.[$=I_9$>D0Z:(CB)$,>T^86)/$8&"._6N8D_9VCF^'NL>&7U
MYM]]K#:O%>+: "%B%&PH7.X84\[AU'I@^QT4<S'9'G'AKX4ZAI7Q B\6ZIXC
M_MG4!IWV"7_05@\P[LA_E; XP, =NM:7PQ^&_P#PKF'6X_[1_M'^TM0DOL^1
MY7E[@/D^\V<8Z\?2NUHHYFPL>3>,O@3-KWB+6=3T;Q//X=BUR 6^JVL5HLJW
M*@ '!+#82!R>2<GU(/H_AS0+3PKH-AI%@K)9V<*PQ[CEB .I/<GJ?<UI44KM
MZ!8****0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,[1O#VG^'_MWV"W\@
MWUU)>W!WLQDF?&YOF)QT' X    K)?X;^'V:Z9+2:WDN+Q]0>6VO)X9!.Z[7
M=&1P4W#@A2 >X-=/13NP.8C^&OAV#3;6QM[*2TBMI7FBEM;N:&<._P!]C,CB
M1BW?+'.!G.!A[?#GP[_8%IHRZ8L5C:2":W\F1XY89 <^8LJL) Y.<L&R<G).
M3724478CG5\ :&NG7%F;::1+B5)Y)Y;N9[EI$QL?SV<R K@8(;CMBHH?AKX=
MM]/N;1+*0"XN%NI;DW<QNFF7[K_:"_FA@. 0W )'0FNGHHNP.6'PQ\-?V4=.
M.G&2V:\6_<R7$KRR7 .1(\A;>YS_ 'B>F.E;(T"P'B ZWY'_ !-&M19F?>W^
MI#EPNW.W[Q)SC/O6A11=C.:7X<>'$\.C0AIH&F+.;I(_.DW1RER_F))NWJVX
MD@J01GBGQ^ -#72M3TY[::YM]33R[Q[J[FGFF3& IE=R^T G #8&3C&37144
M78C'F\(Z3/)HKO:;FT8YL3YC_N?DV>OS?+Q\V:33_".EZ3K5[JEG#-;75ZYE
MN$CN91!)(0H+F'=Y>\A%RVW)QUY-;-%%V,****0!1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
&1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>img69628308_17.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img69628308_17.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" )<!9@# 2(  A$! Q$!_\0
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MR/\ A%?#O_0 TO\ \ X_\*/^$5\._P#0 TO_ , X_P#"@#7HK(_X17P[_P!
M#2__  #C_P */^$5\._] #2__ ./_"@#7HK(_P"$5\._] #2_P#P#C_PH_X1
M7P[_ - #2_\ P#C_ ,* ->BLC_A%?#O_ $ -+_\  ./_  H_X17P[_T -+_\
M X_\* ->BLC_ (17P[_T -+_ / ./_"C_A%?#O\ T -+_P# ./\ PH UZ*R/
M^$5\._\ 0 TO_P  X_\ "C_A%?#O_0 TO_P#C_PH UZ*R/\ A%?#O_0 TO\
M\ X_\*/^$5\._P#0 TO_ , X_P#"@#7HK(_X17P[_P! #2__  #C_P */^$5
M\._] #2__ ./_"@#7HK(_P"$5\._] #2_P#P#C_PH_X17P[_ - #2_\ P#C_
M ,* ->BLC_A%?#O_ $ -+_\  ./_  H_X17P[_T -+_\ X_\* ->BLC_ (17
MP[_T -+_ / ./_"C_A%?#O\ T -+_P# ./\ PH UZ*R/^$5\._\ 0 TO_P
MX_\ "C_A%?#O_0 TO_P#C_PH UZ*R/\ A%?#O_0 TO\ \ X_\*/^$5\._P#0
M TO_ , X_P#"@#7HK(_X17P[_P! #2__  #C_P */^$5\._] #2__ ./_"@#
M7HK(_P"$5\._] #2_P#P#C_PH_X17P[_ - #2_\ P#C_ ,* ->BLC_A%?#O_
M $ -+_\  ./_  H_X17P[_T -+_\ X_\* ->BLC_ (17P[_T -+_ / ./_"C
M_A%?#O\ T -+_P# ./\ PH UZ*R/^$5\._\ 0 TO_P  X_\ "C_A%?#O_0 T
MO_P#C_PH UZ*R/\ A%?#O_0 TO\ \ X_\*/^$5\._P#0 TO_ , X_P#"@#7H
MK(_X17P[_P! #2__  #C_P */^$5\._] #2__ ./_"@#7HK(_P"$5\._] #2
M_P#P#C_PH_X17P[_ - #2_\ P#C_ ,* ->BLC_A%?#O_ $ -+_\  ./_  H_
MX17P[_T -+_\ X_\* ->BLC_ (17P[_T -+_ / ./_"C_A%?#O\ T -+_P#
M./\ PH UZ*R/^$5\._\ 0 TO_P  X_\ "C_A%?#O_0 TO_P#C_PH UZ*R/\
MA%?#O_0 TO\ \ X_\*/^$5\._P#0 TO_ , X_P#"@#7HK(_X17P[_P! #2__
M  #C_P */^$5\._] #2__ ./_"@#7HK(_P"$5\._] #2_P#P#C_PH_X17P[_
M - #2_\ P#C_ ,* ->BLC_A%?#O_ $ -+_\  ./_  K7H **CN+>&Z@>"XAC
MFA<8>.10RL/0@\&LS_A%?#O_ $ -+_\  ./_  H UZ*R/^$5\._] #2__ ./
M_"C_ (17P[_T -+_ / ./_"@#7HK(_X17P[_ - #2_\ P#C_ ,*/^$5\._\
M0 TO_P  X_\ "@#7HK(_X17P[_T -+_\ X_\*/\ A%?#O_0 TO\ \ X_\* -
M>BLC_A%?#O\ T -+_P# ./\ PH_X17P[_P! #2__  #C_P * ->BLC_A%?#O
M_0 TO_P#C_PH_P"$5\._] #2_P#P#C_PH UZ*R/^$5\._P#0 TO_ , X_P#"
MC_A%?#O_ $ -+_\  ./_  H UZ*R/^$5\._] #2__ ./_"C_ (17P[_T -+_
M / ./_"@#7HK(_X17P[_ - #2_\ P#C_ ,*/^$5\._\ 0 TO_P  X_\ "@#7
MHK(_X17P[_T -+_\ X_\*/\ A%?#O_0 TO\ \ X_\* ->BLC_A%?#O\ T -+
M_P# ./\ PH_X17P[_P! #2__  #C_P * ->BLC_A%?#O_0 TO_P#C_PH_P"$
M5\._] #2_P#P#C_PH UZ*R/^$5\._P#0 TO_ , X_P#"C_A%?#O_ $ -+_\
M ./_  H UZ*R/^$5\._] #2__ ./_"C_ (17P[_T -+_ / ./_"@#7HK(_X1
M7P[_ - #2_\ P#C_ ,*/^$5\._\ 0 TO_P  X_\ "@#7HK(_X17P[_T -+_\
M X_\*/\ A%?#O_0 TO\ \ X_\* ->BLC_A%?#O\ T -+_P# ./\ PH_X17P[
M_P! #2__  #C_P * ->BLC_A%?#O_0 TO_P#C_PH_P"$5\._] #2_P#P#C_P
MH UZ*R/^$5\._P#0 TO_ , X_P#"C_A%?#O_ $ -+_\  ./_  H UZ*R/^$5
M\._] #2__ ./_"C_ (17P[_T -+_ / ./_"@#7HK(_X17P[_ - #2_\ P#C_
M ,*/^$5\._\ 0 TO_P  X_\ "@#7HK(_X17P[_T -+_\ X_\*/\ A%?#O_0
MTO\ \ X_\* ->BLC_A%?#O\ T -+_P# ./\ PH_X17P[_P! #2__  #C_P *
M ->BLE?"_AY&#+H6F*P.01:1@@_E6M0 445E/X7\/R.SOH6F,S')8VD9)/KT
MH U:*R/^$5\._P#0 TO_ , X_P#"C_A%?#O_ $ -+_\  ./_  H UZ*R/^$5
M\._] #2__ ./_"C_ (17P[_T -+_ / ./_"@#7HK(_X17P[_ - #2_\ P#C_
M ,*/^$5\._\ 0 TO_P  X_\ "@#7HK(_X17P[_T -+_\ X_\*/\ A%?#O_0
MTO\ \ X_\* ->BLC_A%?#O\ T -+_P# ./\ PH_X17P[_P! #2__  #C_P *
M ->BLC_A%?#O_0 TO_P#C_PH_P"$5\._] #2_P#P#C_PH UZ*R/^$5\._P#0
M TO_ , X_P#"C_A%?#O_ $ -+_\  ./_  H UZ*R/^$5\._] #2__ ./_"C_
M (17P[_T -+_ / ./_"@#7HK(_X17P[_ - #2_\ P#C_ ,*/^$5\._\ 0 TO
M_P  X_\ "@#7HK(_X17P[_T -+_\ X_\*/\ A%?#O_0 TO\ \ X_\* ->BLC
M_A%?#O\ T -+_P# ./\ PH_X17P[_P! #2__  #C_P * ->BLC_A%?#O_0 T
MO_P#C_PH_P"$5\._] #2_P#P#C_PH UZ*R/^$5\._P#0 TO_ , X_P#"C_A%
M?#O_ $ -+_\  ./_  H UZ*R/^$5\._] #2__ ./_"C_ (17P[_T -+_ / .
M/_"@#7HK(_X17P[_ - #2_\ P#C_ ,*/^$5\._\ 0 TO_P  X_\ "@#7HK('
MA7PZ#D:#I8/_ %YQ_P"%:] !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %9'_"0
MVTFNQ:5 IE=BXDD'"HRC)7IR?7TK7K"OXTC\4Z($15!^TL=HQDE5R?K30$]U
MJ]PM]/;65A]I-NH:9FE$8&1D <')Q]*NZ?>QZC80WD(8)*NX!NHK.U"?3]3-
MWIEW/+:F##.?-$>]2#R#GD?7O3_#,LLWA^U:50" 54A=NY02%..W%'00V36;
MJ6]N+;3M.-V+<A99&F$8#=<#(.:;)XB5=!N-26U?S+>0126[MM*ON"D9P?7-
M4YH],N]3O'BO[C2[Y'V2XE">9CHVT\,#ZU2O;ZXO?!^J+/.LXAN$CCNE4 2J
M'3G'3^E.P&ZE]K32*'T6-5) +?; <#UQMI)-6O7U6[LK/3HYOLP0L[W&S.X9
M'&T^AJ& S)<1M)XHCF0,"T?EQ#</3(YJO';75QXHUK[+?O:%5@SMC5]WR'&=
MP[>WK2 TK'6#/<W-K>6_V2XMU$C+YF]2A_B#8%0Q:S?7D1N+'26EM3]QWG$;
M./4+@_J169I\+36^N6<^Y]::)XY'<_ZQ2I"%>!A>>E:FC:K8G0[;?<1Q&")8
MY4D8*491@@@].E $B:O->6$=UIEG]I)8K)')*(C&1U!X/-5K#6M3OY7":/&J
M13F"5S=CY2#AN-O.*=X9#217]YAEAN[MY8E88RO W?CBE\-_=U7_ +"4_P#,
M4 3V.M17$5U]J06D]HQ$\;/G:.S X&015=M>N!IEO>)IQS<W B@C>;:65L[6
M/'&<=/UJIXBLH)=<TG<I_P!)D,4X!P)$&& ;U&15OQ+&[V^G1PR>2YOH@KA0
M=IYP<'B@!?[:O;>ZMH]0TO[/%<2"))4G$@#GH",#&::NMZA<7EW!9Z2DRVTI
MB9VN@F3]-M2)HD\MW!/J&IS78@<21QE%10PZ$A1SBL:R$IU;6?+UE; ?:SE2
MD;;N.OS4] -V?5YK'2VN[^R\F7>$C@CE$A<GIS@8Y_E4:ZU=P75O%J.EFUCN
M'$<<BSB0;ST!P!C-17LEFNA;-4NFU"!Y1&\\:J/+)Z,=O0#CD>M49)GTJXM#
MI^M-?)-,D?V65UE)4]2&'(Q2 Z:[G^RV4]QMW>5&S[<XS@9Q6-=^)X[*+29I
MK<B*_3>[!\^2,*?3D?-[=*T]6_Y U]_U[R?^@FN>2&.XD\*0RH'C>RD5E/<&
M)*$#-^]U(6ES8Q",2"[E\L,&QMXSGIS3M5O_ .S-+GO?+\WREW;-VW/..M<M
MNGLM;TO1[@L_V>YWV\I_CB*G ^HZ5N^*O^18O_\ KF/YBBP$-SK>I6$)N+W1
MA';*1YCQW0<J"<9Q@9J6;6;HZL]A96,=P4A64NUQL!!_X":9+H-W>J(=0UF>
MXMB06B6)(]V.Q('2J;V\\_C.[2VO'M"MHGS)&K9&>F&!HT U;'59I]1DL+RS
M^S7*Q><H602*Z9QD' [U2L=<U;4;..[M]$C:*0$J3> =\?W?:H]"!BUN]AU&
M1Y-550!*Q&)(NHV   #/45G>'A/_ &#:[/$:6JX.(3'$=OS'UY]Z=@.B35)5
MU*TLKJT\EKF%G5A)N =>J=.>.<U+=:CY&IV=BD7F27&YF.['EJHZ].?2J&MQ
M,VCP7T,@N)[%EG610/W@7[W3U&>E&C,-2U.^U<',1Q;6Y_V%Y8_BW\J0$N@^
M((M<CEQ%Y$T;<QELY7H&!P..#5NQU%;R*ZD9!$MO/)"26SD(<;O:N7TZUFC\
M-6&KV2DW=H9=R#_EK%YC;E_J*C&H&?PW=QV63-J6H2QPC.#AFR2?P_G3L%SH
MM#UY-:$X\@P/&00I;.Y#]UN@]ZC76;ZXO[RVL]-CE%JX1G>YV9R,]-IK*,EY
MIFM:=>7&GK9VI063E9Q)D?PDX Q@BI+*UO;C6==-GJ#VC"9>!$CACMXSD?RH
ML!MZ9J;7TMS;SVQM[JV91)'O#C##((/?-/U34?[-MHY!%YLDLJQ1IN"@LW3)
M/05F^%V0"]2;?_::RXNS(V2Q'W2.!\N.E,\1LMS?V6EW4HM[&X#/)*<?,R\A
M03]T^]*VH&GI>IG4!<))!Y,UO*8I$#[QGKP>,TNK:C)IMM%)%;B>269(50OL
MY8X'.#7/^&=1:'46T57M&AA#GST/,YR,$<X)P>>O2M3Q.KO:6*1R&-VOH0K@
M [3NX.#UQ1;4!'UN]M)H!J.E_9X)I!$)4N!)M8],C XI]CXABO-:N],>(Q20
ML1&Q;(EQUQQP1QQS2#0YY[B&34=4FNTA<2)%Y:(NX="<#FLB#36U"?6F@;R[
MR"^\RWD]& Z?0]#3T W9=8\IM67R,_V?$)/O_P"LRA;'3CICO5>#5=9N((YH
M]#C*2*'4F]'0C(_AK(M;XZC9^)[EHS$YM0LD9'*L(V##\P:LZ<+C^SK0CQ.D
M:^4G[LQQ?*,#CGGVHL!MKJ).M)IS0X8VOV@OOS@[@NW&/?K1)J?EZY#IODY\
MV%I?,W=,'&,8_K6=<W$-KXQMYYY%CAFL6CCD8X5FWAL9Z=*:)HKWQK"]M(LJ
M06;"1D.0I+<#/K2L!:\/:\NO6TLGV<P/&P!3?NR".#G ]_RIMCXACO=7OK(0
M[(K52WGE^&P<'C' SGOVKFM,NCHNE:?J*KE;FUE@( ZR*S,GY\BK5KILD-_J
M.GIS,=)"=>KMG/ZDT[!<VXM9OKR(W%CI+2VI^X[SB-G'J%P?U(I7\0P_V?;W
MT43- \XAFW':T!)P21@]#C\Z-&U6Q.AVV^XCB,$2QRI(P4HRC!!!Z=*I:58C
M5-)U<N&6#4+B1X0PQP0,/^8S^%(#8U741IEB9Q$9I&=8XX@<%V8X S@_Y%5-
M1\01Z=JEM9/#N$@!ED#X$08[1VYY^E9FFW+ZS>Z>EQP--B,ESGIYP)09]^"W
MXU32+4-9MM4N8M-6:+46VQ2M.$*HG"?+CU&?>G8+G4ZMJ+:7;I<FW,L <"9E
M;!C4_P 6,<C\J:^K*VI6]E:1BX:1?,D</A8H^S$X.2>PK,AU]7\+132Q^==R
M#[-]G/)DE^Z01^I]C4'AZ%_#U\=+O%0-=@213KT9@.8\^W;_ .O2L!T.HWT>
MFV$MW(K,J 85>K$G  _$U4@U6Y&H06E_8?9FN QB99A("5&2#P,'%7;Z^@TZ
MRDN[EML48R<=3Z >]8NFM_:.HIJ=Y/#YRJPM;-) 3&".2?5B/RH >/$DGD+>
MMI[#3FE\L3^:-W)VAMF.F?>M^N0UN[LM1TN+5K>XD6ZB91!;.P/SAL8,?(SU
M]^E=<I)0%AM8CD9S@T,!:***0PHHHH **** "BBB@ HHHH **** "BBB@ JA
M;ZS9W6J2:?!)YDL4?F.RX*CG&,^O-7ZYVSL[>P\8?9[6%8HETT85?^NI_.F!
MI'6;+^UTTQ)/,N65F(3!"8[,>Q]JO.ZQHSNP55&23T KFWL[:R\8Z:EM"L:M
M#,[8[L>I/K6_>M EC.USG[.(V\S )^7'/3GI0P,K_A*+7RQ.;._%H3_Q]&#]
MWC.-W7./PJQ?ZY#8W,%N+:YN9)T+H+=5;('U(K*:VOK#1C-9:C!>Z8L)98+N
M(8,>.FX=>/6HKJ6XN-<T.;3D@ADDLV=$F4E%! .,#':G81OV.IM>S&,Z=?6V
M%W;YXPJGD<<$\\_I5.W\2"[MEN8-)U*2%AE66-#G_P >J[8C51(W]H/9,F/E
M^SJP.??)-<OI4VMVO@^"XLVM&@1&.WRF,BKN.2/FP2.32 Z==9L3I*ZF9L6S
M#@D<YSC;CUSQBJX\0PH4-S9WMK"Y $T\0" GID@G'XXK&FAM;72=!EMY3)8B
M[6265^Y.?F;TY_*MWQ#) GAZ^,Y!1H650>[$?+CWSB@!NI:XNF-)YMA?211K
MN::*-2@'U+"HAXB7[))=-I>HI"B"0LT2\KQR/FYZY^E1:FDD?@61)@1*MFH<
M'KG:,UJZ> VE6JL 08$!![_** ([O5K2TTT7[.9(6 \ORQDR$] !ZFH+K7%M
MKM+46%[-,T(F*PHK;021@_-UR*R])TR-/$=Y;%V>UTXK);0MRJ&0$G\L<?6I
MKP7Y\7M_9[6RO]@7=]H5B,>8W3!%%@+UOK]M.MWNAN8);6,RR0S(%?;C.1S@
M_G4,7B/SHDECT?56C=0RL(5P0>A^]4$VF745MJFHZA<1RW,EF\2K$A5$0 G
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MP8BD:Y'0N%.[^E;UZ\4?AB9IB!']D(.?=<46 LRZC!%?6=KAF>[#M&RX*X4
MG)S[UFOXG6*:*%])U19)<^6IB7+8&3CYO2J%FDD=WX32;.\6TV<]OD7'Z5HZ
MI_R,V@_[T_\ Z+H L#6H@UFDMK=0O=R-&B2( 01SD\]*6YUJ&"[:TB@N;J=
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MH$*JN[J222>@K8I,84444@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBL7Q-J&M6%A&-!TD:C?SR"-1)*(XH00?WCGKM'H.3VH VJ*\
MV^$-SJL\/BJ/6KYKV]M]<F@DER=I**JG:/X5R.!7I 922 02IP<'H: %HI,C
M<5R,@9(KR/XPZSXO3PWK/]G6_P#9>CV7E"6^,W[V[+NJ[8P.54%N2<9Q@=Z
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M4^B@"NMA9I/YZVD"S;B_F",!MQZG..IJ26WAGV>=#')L;<F]0=I]1GH:DHH
MBGMH+J+RKB&.:/.=LB!AGZ&H8=*TZVF66"PM8I%Z.D*J1VZ@5;HH KBPLQ<_
M:1:0>?G/F^6-WYXS5BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M@^QP?;C>[/\ 2#%Y6_)^[G.,=.M3T4 5WLK>2]BO'CS<1*51]QX!Z\=*G(#
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ME/DM89KF"X=,RP;O+;)^7<,&IJ* "J]K96]E:+:P1!8%SA"2W4DGK[DU8HH
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M'JV,^CRZBES/=ZO</MU2:Z39.LR]8F3_ )9A,D*@X .1G.3G?&W_ ))#KO\
MV[_^E$==S'96L5Y/>1V\27,ZJLLJH T@7.T,>^,G'UJ/4]+L=:TZ73]2M8[J
MTEQYD,@RK8(89_$ _A0!R/Q-TRYUCX0ZM9VB%YOLL<H4#)81NDA 'KA3577?
M'WAUOA3=:E'JEJWVG3FBAA$H\QI6C($>WKD$\\<8)KT)5"*%484# 'H*P8O
M_A6#51J<7A_34O0V\2K;J"&Z[AQC/OUH 9X#TVXTCP%H5A=(8[B&RC$J-U1B
M,E3[@G'X5M6MC:V/G_9H$B\^5II=H^^[=6/N<58HH \KU;0OC+-K-]+I?BS1
MH-/>XD:UBDB4LD18[%/[@\A<#J?J:Q[F;XL^%M9\.R^(/%&FW6GW^L6UC)%:
MP)N8.W(.85P-JL,@YY%>N:ZEO)X>U..\LY[VU:TE$UK;@F29"AW(@!!+$9 P
M1R>M> 7FG^%;3Q#X2DT/P+XCT&Z/B"S#76IP2I&Z;^4!>1AN)P>G13S0!]'T
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%-<,48(P5B."1G!^E5+![J0RF>:-U1V
M0!8]O0]>IH NT444 %%(3@$\\>E4[75(+RX>&..X5TX;S(64*< X)(]"* +M
M%%% !1110 4444 %%%% !1110!#!/YYF&W;Y<A3KG. .?UJ:J=A]^[_Z^&_D
M*N4 %%%% !1110 4444 %%%% !139(TEC:.10R,,,IZ$5E:'9VT"W,D4*(_V
MB5,@<[0YP/I0!KT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!#;3_:$=MNW
M;(Z=<_=8C/Z5-5/3?]1-_P!?$O\ Z&:N4 %%%% !1110 4444 %%%% '/:Y/
MIAOE@UJR M]FZ&[);[W=<J,K^=4M/<$:I'87-Q<:4MHVUIB2%DP>%)Y(Q774
M4[B."TF?15TJV6?7KZ"41C=$ERZJI] !TK4OXHK_ ,2:.$GF$4EJ[++%(48C
M (.1SS74T47"QR]K NB^)A'=M).MVNVVNIG+NA[QDD_E3M)O;?0([C3]2D^S
MLLSO'(ZG;*C'((/K[5TU%%P,+2]U_KUUJR(RVIA6WA9EVF3!R6P><9XS3;+_
M )'35/\ KWBK?HHN,P?&,,<GAN=W0%HWC*'N"7 /Z$BI_$,:1>%KV.-0J) 5
M51T '05KT47 P;?PW:3VL!N;B^N(]JMY,MRS)G'I6=K3V47BU3>WTUE']@4*
M\,A0D^8W&1VKKZ*+BL<]I][8K:W@TR\GU294WF&:=F) [ D<9S6-<2Z";9IM
M+DN++4RN4@M]X;?_ '2O3&:[JBBX6(K4S&TA-P )C&OF ?WL<_K4M%%(8444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 5[_P"V?V=<_P!G>1]N\I_L_P!HSY?F8.W?CG;G
M&<<XKQ_QA_PGG]H^#O\ A*/^$<^P_P#"2V6S^S//\SS,MC/F<;<;O?.*]@O_
M +9_9US_ &=Y'V[RG^S_ &C/E^9@[=^.=N<9QSBO'_&'_">?VCX._P"$H_X1
MS[#_ ,)+9;/[,\_S/,RV,^9QMQN]\XH ]HHHHH **** "BBB@ HHHH ****
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MJ;_T,U5U_7GT5[9$M%G,P<\R[-NW;_LG/WJPM/\ %=Q%(+==.B9KBY.TFY(
M,C\?P=LUE*O3C/D;U)<DG8[>BBBM2@HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M*>F_ZB;_ *^)?_0S5RJ>F_ZB;_KXE_\ 0S5R@ HJIJ<US;V$L]L8MT2LY$BD
M@@ G'!%26;7#VRO<M$9&Y_=J0,?B30!/1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %>_\
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M *+>N&N?^/67_</\J\3,)26)BD^B_-G/5;YT>IWG_'SIW_7P?_13U<JG>?\
M'SIW_7P?_13U<KVSH"BBB@#/UG_CQC_Z^K?_ -')6A6?K/\ QXQ_]?5O_P"C
MDK0H IZ9_P >LG_7Q-_Z-:KE4],_X]9/^OB;_P!&M5R@ HHHH IV'W[O_KX;
M^0JY5.P^_=_]?#?R%7* "BBB@ HHHH **** "BBB@#CO''_'SIO^Y-_..N<L
MO^0G8_\ 7U#_ .C%KH_''_'SIO\ N3?SCKG++_D)V/\ U]0_^C%KPL5_OT?5
M'-/^(CU2BBBO=.D**** "BBB@ HHHH **** "BBB@ HHHH *SKZ]O;:[@AAM
M+>5)VV(SW#(<A2QR AX^4]ZT:S]0_P"/_2_^OAO_ $4] &@,X&>M%%% !56[
MU&TL2HN9A'NZ9!.?RJU6?K'_ !Z0_P#7U!_Z,6@"[%*DT2R1G<C#(-/HHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** *>F_ZB;_ *^)?_0S5RJ>F_ZB
M;_KXE_\ 0S5R@"IJO_('O?\ KWD_]!-36W_'M%_N#^50ZK_R![W_ *]Y/_03
M4UM_Q[1?[@_E0!+1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !7G_Q3_P"9*_[&NQ_]GKN+
M_P"V?V=<_P!G>1]N\I_L_P!HSY?F8.W?CG;G&<<XKQ_QA_PGG]H^#O\ A*/^
M$<^P_P#"2V6S^S//\SS,MC/F<;<;O?.* /:**** "BBB@ HHHH **** "BBB
M@ HHHH ***:)$)P'4GT!H =1110 4444 %%%% !1110!5U+_ )!=W_UP?_T$
MU):?\>4'_7-?Y5'J7_(+N_\ K@__ *":DM/^/*#_ *YK_*@"&U_X_K__ *Z+
M_P"@+5RJ=K_Q_7__ %T7_P! 6KE !534M0BTNPDO)DD=$*@K& 6.6"C&2!U-
M6ZQ/%W_(M7/^_%_Z,6IF[1;$]C*7Q=:#59+K['>;&@6,#$><AF/]_P!Q72Z;
MJ$6J6$=Y"DB(Y8!9  PPQ4YP2.HKS"NST*6Y@\)VLMN\2XED4B2,MG,Q'9AC
MK7GX'&5,1)J26AE3J.3U.GHIL8D$8$K*S]RJ[0?PR?YTZO2-@HHHH **1E#*
M58 @C!![UG:=:00W5ZT<2*RS;5('0;%./SH TJ*** "BBB@ HHHH **** "B
MBB@ HHHH **** ,BQMMFKW8-Q=.L.S8KSLPY7G@GFM>L^T_Y#&H_]LO_ $&M
M"@ HHHH *\LOO^0I??\ 7U-_Z,:O4Z\LOO\ D*7W_7U-_P"C&KS,U_@KU_1F
M-?X3D?&/_'DO_71/Y/7+:7_R%K+_ *[I_P"A"NI\8_\ 'DO_ %T3^3URVE_\
MA:R_Z[I_Z$*]++O]UCZ'?A?X)]5=J*.U%,YCF?&__(+M/^OH?^BWKAKG_CUE
M_P!P_P J[GQO_P @NT_Z^A_Z+>N&N?\ CUE_W#_*O#S'_>8>B_-G-5^-'J=Y
M_P ?.G?]?!_]%/5ROG+4/&?B./4IXUUBYVPS.(P6!VX)'&?;BO7?AKJ5YJOA
M);J_N9+B=IW!>0Y.!C KWY0:5SME2<5=G84445!F8>M:MIHMQ"=0M/-2Z@W)
MYR[EVS(3D9XQ@Y],5I6VI6%Y(8[6]MIW W%8I58@>N ?>O-K[_D*7_\ U]3?
M^C&KH? __'UJ7^Y#_.2N&EC?:5W1Y=KZW[&<:EY<MCIM,_X]9/\ KXF_]&M5
MRJ>F?\>LG_7Q-_Z-:KE=QH%%%% %.P^_=_\ 7PW\A5RJ=A]^[_Z^&_D*N4 %
M%%% !1110 4444 %%%% ''>./^/G3?\ <F_G'7.67_(3L?\ KZA_]&+71^./
M^/G3?]R;^<=<Y9?\A.Q_Z^H?_1BUX6*_WZ/JCFG_ !$>J4445[ITA678O?OJ
M-S%/=0O' 5&%@VELKGKN.*U*S[/_ )"NI?[T?_H H T**** "BBB@ HHHH *
M*** "BBB@ K/U#_C_P!+_P"OAO\ T4]:%9^H?\?^E_\ 7PW_ **>@#0HHHH
M*S]8_P"/2'_KZ@_]&+6A6?K'_'I#_P!?4'_HQ: -"BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH IZ;_J)O\ KXE_]#-7*IZ;_J)O^OB7_P!#-7*
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M_'DO_71/Y/7+:7_R%K+_ *[I_P"A"O2R[_=8^AWX7^"?57:BCM13.8YGQO\
M\@NT_P"OH?\ HMZX:Y_X]9?]P_RKN?&__(+M/^OH?^BWKAKG_CUE_P!P_P J
M\/,?]YAZ+\V<U7XT>::I_P A:\_Z[O\ ^A&O<?A+_P B/'_U\2?S%>':I_R%
MKS_KN_\ Z$:]Q^$O_(CQ_P#7Q)_,5])4^%'J5OX:.YHHHKG.0\LOO^0I?_\
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M\I^S[0V/P-4]&DN;C3(+FYG$KS1K)@(%"Y'2@#0HHHH **** "BBB@ HHHH
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M*^DJ?"CU*W\-'<T445SG(>67W_(4O_\ KZF_]&-7(^,?^/)?^NB?R>NNOO\
MD*7_ /U]3?\ HQJY'QC_ ,>2_P#71/Y/7BX+_D82]698?^.9G@7_ )'C2/\
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M)]JS="U;3?[(T^W_ +0M//\ )1/+\Y=V[ &,9SG/:@#<HHHH **** "BBB@
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MCUYQXB_Y&74/]]/_ $6E8YG_ +N_5$UOA&^'O^1DT_\ WW_]%O7I->;>'O\
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M.ZNBA]%%%,#S?Q%_R,NH_P"^G_HI*Y;Q1_R+US_P#_T(5U/B+_D9=1_WT_\
M125RWBC_ )%ZY_X!_P"A"O!C_P C%>ISP_CKU.&TO_D+67_7=/\ T(5]55\J
MZ7_R%K+_ *[I_P"A"OJJOI*VZ/1Q.Z"L3Q=_R+5S_OQ?^C%K;K$\7?\ (M7/
M^_%_Z,6N:I\#]#E>QP%>=>)O^1ANO^ _^@BO1:\Z\3?\C#=?\!_]!%>7D?\
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MRU_A.1\8_P#'DO\ UT3^3URVE_\ (6LO^NZ?^A"NI\8_\>2_]=$_D]<MI?\
MR%K+_KNG_H0KTLN_W6/H=^%_@GU5VHH[44SF.9\;_P#(+M/^OH?^BWKAKG_C
MUE_W#_*NY\;_ /(+M/\ KZ'_ *+>N&N?^/67_</\J\/,?]YAZ+\V<U7XT>::
MI_R%KS_KN_\ Z$:]Q^$O_(CQ_P#7Q)_,5X=JG_(6O/\ KN__ *$:]Q^$O_(C
MQ_\ 7Q)_,5])4^%'J5OX:.YHHHKG.0\LOO\ D*7_ /U]3?\ HQJY'QC_ ,>2
M_P#71/Y/777W_(4O_P#KZF_]&-7(^,?^/)?^NB?R>O%P7_(PEZLRP_\ ',SP
M+_R/&D?]? _D:^E*^:_ O_(\:1_U\#^1KZ4KWZVYV8CX@HHHK(P*=A]^[_Z^
M&_D*N53L/OW?_7PW\A5R@#@_&/\ R,"_]>J?^AO5/P]_R,NG?[[_ /HMZN>,
M?^1@7_KU3_T-ZI^'O^1ET[_??_T6]>%4_P"1A\U^1S/^*>D4445[ITG'>./^
M/G3?]R;^<=<Y9?\ (3L?^OJ'_P!&+71^./\ CYTW_<F_G'7.67_(3L?^OJ'_
M -&+7A8K_?H^J.:?\1'JE%%%>Z=)QWCC_CYTW_<F_G'7.67_ "$['_KZA_\
M1BUT?CC_ (^=-_W)OYQUSEE_R$['_KZA_P#1BUX6*_WZ/JCFG_$1ZI1117NG
M2<SXW_Y!=I_U]#_T!ZXNNT\;_P#(+M/^OH?^@/7%U\_FO\9>GZLY:_Q'I6@_
M\B]IO_7K%_Z"*T*S]!_Y%[3?^O6+_P!!%:%?0'4%94-M /$=VPAC#"VA8$*,
M@EY<GZUJUGQ?\C#>?]>D'_H<M &A1110!0US_D7]2_Z]9?\ T UYI7I>N?\
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MBTKT>O./$7_(RZA_OI_Z+2L<S_W=^J)K?"6O!_\ R,)_Z]9/_0DKO:X+P?\
M\C"?^O63_P!"2N]J\O\ ]VC\_P V.E\""O./$7_(RZA_OI_Z+2O1Z\X\1?\
M(RZA_OI_Z+2HS/\ W=^J%6^$;X>_Y&33_P#??_T6]>DUYMX>_P"1DT__ 'W_
M /1;UZ31EG\#YL*/PA1117H&H4444 %%%% %/3?]1-_U\2_^AFKE4]-_U$W_
M %\2_P#H9JY0!YQXC_Y&6_\ ]Y/_ $6M6O!__(PG_KUD_P#0DJKXC_Y&6_\
M]Y/_ $6M6O!__(PG_KUD_P#0DKPH?\C#YO\ (YE_%.]HHHKW3I.#\8_\C G_
M %ZI_P"AO5+P_P#\C)I__71__1;U=\8_\C G_7JG_H;U2\/_ /(R:?\ ]='_
M /1;UX53_D8?-?D<S_BGI-%%%>Z=(5GZ+_R#O^VTO_HQJT*S]%_Y!W_;:7_T
M8U &A1110 5GZ;_Q\:C_ -?7_LBU'KNKMHUG%.MN)S)*(]IDV8X)SG!]*YB'
MQC-:&ZE.FQL)9#*1]I(Q\H&/N<]*RG7IPERR=F2Y).S.[HI <@&EK4H****
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M/_1;5YK6N3?[O\SJP/\ #9]4Z3_R!K'_ *]X_P#T$5<JGI/_ "!K'_KWC_\
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M\G-?X*]?T9RU_A.1\8_\>2_]=$_D]<MI?_(6LO\ KNG_ *$*ZGQC_P >2_\
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M\<S/ O\ R/&D?]? _D:^E*^:_ O_ "/&D?\ 7P/Y&OI2O?K;G9B/B"BBBLC
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M.*M5N44-<_Y%_4O^O67_ - ->:5Z7KG_ "+^I?\ 7K+_ .@&O-*\;-_L?/\
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MW?JB:WPEKP?_ ,C"?^O63_T)*[VN"\'_ /(PG_KUD_\ 0DKO:O+_ /=H_/\
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M +P(89!!'J*6FQQQQ($C140=%48 IU !7!>,?^1A7_KTC_\ 0Y*[VN"\8_\
M(PK_ ->D?_H<E<68?[M+Y?FC.K\#.1UO_D%S_P#7.3_T6U>:UZ5K?_(+G_ZY
MR?\ HMJ\UK7)O]W^9U8'^&SZITG_ ) UC_U[Q_\ H(JY5/2?^0-8_P#7O'_Z
M"*N5T&)B>+O^1:N?]^+_ -&K7 5W_B[_ )%JY_WXO_1JUP%>'FWQQ]#FK[HQ
M-4\;ZUHJKIEI)#]E*LVUXP3S(V>:Z[X;^,=8\3ZG>PZE+$T<,(91'&%Y)Q7E
MWBO_ )"B?]<S_P"C'KLO@M_R&=3_ .O=?_0J]^G%>P3\D>CR1]BG;4]FHHHJ
M#G/-_$7_ ",NH_[Z?^BDKEO%'_(O7/\ P#_T(5U/B+_D9=1_WT_]%)7+>*/^
M1>N?^ ?^A"O!C_R,5ZG/#^.O4X;2_P#D+67_ %W3_P!"%?55?*NE_P#(6LO^
MNZ?^A"OJJOI*VZ/1Q.Z"L3Q=_P BU<_[\7_HQ:VZQ/%W_(M7/^_%_P"C%KFJ
M? _0Y7L<!7G7B;_D8;K_ (#_ .@BO1:\Z\3?\C#=?\!_]!%>7D?\67H+ ?&_
M0]/^"W_()U3_ *[I_P"@UZA7E_P6_P"03JG_ %W3_P!!KU"O:J?$S:K\;"O-
M_$7_ ",NH?[Z?^BTKTBO-_$7_(RZA_OI_P"BTKS,S_W=^J.:M\)R/BG_ )!$
MW^Y_[.E<7I?_ "%K+_KNG_H0KM/%/_((F_W/_9TKB]+_ .0M9?\ 7=/_ $(5
MUY5_ND?G^9V8/^#]Y]54445J8&)XN_Y%JY_WXO\ T8M<!7?^+O\ D6KG_?B_
M]&+7 5X>;?''T.:ONCS;7?\ D+R_[D?_ * M>I_!;_D$ZI_UW3_T&O+-=_Y"
M\O\ N1_^@+7J?P6_Y!.J?]=T_P#0:^DE_#1ZE3^$OD>H4445SG(>;^(O^1EU
M#_?3_P!%I5OP?_R,+?\ 7I)_Z''53Q%_R,NH?[Z?^BTKEO$&JWVCV4=SIUS)
M;3M)Y9>/KM()(_,#\J\.DKYC;S?Y'/"/-6LCV73_ +MQ_P!?$G\ZN5\Y:=XS
M\1R:A;Q-K%SLDF4. P&<D9Z5]&U[THN.YUSIN&X5B>+?^1:N?]^+_P!&+6W6
M)XM_Y%JY_P!^+_T8M95/@?H9O8X"O+]4_P"0O>_]=W_]"->H5Y?JG_(7O?\
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M\B/'_P!?$G\Q7TE3X4>I6_AH[FBBBN<Y#RR^_P"0I?\ _7U-_P"C&KD?&/\
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M44 %%%% !1110 4444 %%%% !1110!'//#:V\MQ<2QPP1(7DDD8*J*!DDD\
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MX\E_ZZ)_)ZY;2_\ D+67_7=/_0A74^,?^/)?^NB?R>N6TO\ Y"UE_P!=T_\
M0A7I9=_NL?0[\+_!/JKM11VHIG,<SXW_ .07:?\ 7T/_ $6]<-<_\>LO^X?Y
M5W/C?_D%VG_7T/\ T6]<-<_\>LO^X?Y5X>8_[S#T7YLYJOQH\TU3_D+7G_7=
M_P#T(U[C\)?^1'C_ .OB3^8KP[5/^0M>?]=W_P#0C7N/PE_Y$>/_ *^)/YBO
MI*GPH]2M_#1W-%%%<YR'EE]_R%+_ /Z^IO\ T8U<CXQ_X\E_ZZ)_)ZZZ^_Y"
ME_\ ]?4W_HQJY'QC_P >2_\ 71/Y/7BX+_D82]698?\ CF9X%_Y'C2/^O@?R
M-?2E?-?@7_D>-(_Z^!_(U]*5[];<[,1\04445D8%.P^_=_\ 7PW\A5RJ=A]^
M[_Z^&_D*N4 <'XQ_Y&!?^O5/_0WJGX>_Y&73O]]__1;U<\8_\C O_7JG_H;U
M3\/?\C+IW^^__HMZ\*I_R,/FOR.9_P 4](HHHKW3I..\<?\ 'SIO^Y-_..N<
MLO\ D)V/_7U#_P"C%KH_''_'SIO^Y-_..N<LO^0G8_\ 7U#_ .C%KPL5_OT?
M5'-/^(CU2BBBO=.DX[QQ_P ?.F_[DW\XZYRR_P"0G8_]?4/_ *,6NC\<?\?.
MF_[DW\XZYRR_Y"=C_P!?4/\ Z,6O"Q7^_1]4<T_XB/5****]TZ3F?&__ ""[
M3_KZ'_H#UQ==IXW_ .07:?\ 7T/_ $!ZXNOG\U_C+T_5G+7^(]*T'_D7M-_Z
M]8O_ $$5H5GZ#_R+VF_]>L7_ *"*T*^@.HQ/%O\ R+5S_OQ?^C%K@*[_ ,6_
M\BU<_P"_%_Z,6N KP\V^./H<U?='I6@_\B]IO_7K%_Z"*T*S]!_Y%[3?^O6+
M_P!!%:%>X=)0US_D7]2_Z]9?_0#7FE>EZY_R+^I?]>LO_H!KS2O&S?['S_0Y
MZ_0[_P (_P#(M6_^_+_Z,:MNL3PC_P BU;_[\O\ Z,:MNO6I? O0WCL%>0V_
M_'O%_N#^5>O5Y#;_ /'O%_N#^5>9FWP1]3&OLCM_!'_(-O/^OH_^BTKIZYCP
M1_R#;S_KZ/\ Z+2NGKT,-_!AZ+\C6'PH*\LOO^0I?_\ 7U-_Z&U>IUY9??\
M(4O_ /KZF_\ 0VKBS7^"O7]&9U_A.A\#_P#'WJ/^Y#_-Z[*N-\#_ /'WJ/\
MN0_S>NRKIP7^[Q]"Z?PH*\X\1?\ (RZA_OI_Z+2O1Z\X\1?\C+J'^^G_ *+2
ML<S_ -W?JB:WPEKP?_R,)_Z]9/\ T)*[VN"\'_\ (PG_ *]9/_0DKO:O+_\
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M^./H<U?=' ^*_P#D*)_US/\ Z,>NR^"W_(9U/_KW7_T*N-\5_P#(43_KF?\
MT8]=E\%O^0SJ?_7NO_H5?0P_@1]$>G_RX1[-11161RGF_B+_ )&74?\ ?3_T
M4E<MXH_Y%ZY_X!_Z$*ZGQ%_R,NH_[Z?^BDKEO%'_ "+US_P#_P!"%>#'_D8K
MU.>'\=>IPVE_\A:R_P"NZ?\ H0KZJKY5TO\ Y"UE_P!=T_\ 0A7U57TE;='H
MXG=!6)XN_P"1:N?]^+_T8M;=8GB[_D6KG_?B_P#1BUS5/@?H<KV. KSKQ-_R
M,-U_P'_T$5Z+7G7B;_D8;K_@/_H(KR\C_BR]!8#XWZ'I_P %O^03JG_7=/\
MT&O4*\O^"W_()U3_ *[I_P"@UZA7M5/B9M5^-A7F_B+_ )&74/\ ?3_T6E>D
M5YOXB_Y&74/]]/\ T6E>9F?^[OU1S5OA.1\4_P#((F_W/_9TKB]+_P"0M9?]
M=T_]"%=IXI_Y!$W^Y_[.E<7I?_(6LO\ KNG_ *$*Z\J_W2/S_,[,'_!^\^JJ
M***U,#$\7?\ (M7/^_%_Z,6N KO_ !=_R+5S_OQ?^C%K@*\/-OCCZ'-7W1YM
MKO\ R%Y?]R/_ - 6O4_@M_R"=4_Z[I_Z#7EFN_\ (7E_W(__ $!:]3^"W_()
MU3_KNG_H-?22_AH]2I_"7R/4****YSD/-_$7_(RZA_OI_P"BTKBO&?\ R"(?
M^NX_]!:NU\1?\C+J'^^G_HM*XKQG_P @B'_KN/\ T%J\6A_R,OF_R,J/^\(Y
M+2_^0M9?]=T_]"%?55?*NE_\A:R_Z[I_Z$*^JJ^@K;H[L3N@K$\6_P#(M7/^
M_%_Z,6MNL3Q;_P BU<_[\7_HQ:YJGP/T.5[' 5Y?JG_(7O?^N[_^A&O4*\OU
M3_D+WO\ UW?_ -"->?D6]3Y?J/+]Y'K7P6_Y!.J?]=T_]!KU"O+_ (+?\@G5
M/^NZ?^@UZA7K5/B9I5^-A7EE]_R%+[_KZF_]&-7J=>67W_(4OO\ KZF_]&-7
MDYK_  5Z_HSEK_"<CXQ_X\E_ZZ)_)ZY;2_\ D+67_7=/_0A74^,?^/)?^NB?
MR>N6TO\ Y"UE_P!=T_\ 0A7I9=_NL?0[\+_!/JKM11VHIG,<SXW_ .07:?\
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M+T_5G+7^(]*T'_D7M-_Z]8O_ $$5H5GZ#_R+VF_]>L7_ *"*T*^@.HQ/%O\
MR+5S_OQ?^C%K@*[_ ,6_\BU<_P"_%_Z,6N KP\V^./H<U?='I6@_\B]IO_7K
M%_Z"*T*S]!_Y%[3?^O6+_P!!%:%>X=)0US_D7]2_Z]9?_0#7FE>EZY_R+^I?
M]>LO_H!KS2O&S?['S_0YZ_0[_P (_P#(M6_^_+_Z,:MNL3PC_P BU;_[\O\
MZ,:MNO6I? O0WCL%>0V__'O%_N#^5>O5Y#;_ /'O%_N#^5>9FWP1]3&OLCM_
M!'_(-O/^OH_^BTKIZYCP1_R#;S_KZ/\ Z+2NGKT,-_!AZ+\C6'PH*\LOO^0I
M?_\ 7U-_Z&U>IUY9??\ (4O_ /KZF_\ 0VKBS7^"O7]&9U_A.A\#_P#'WJ/^
MY#_-Z[*N-\#_ /'WJ/\ N0_S>NRKIP7^[Q]"Z?PH*\X\1?\ (RZA_OI_Z+2O
M1Z\X\1?\C+J'^^G_ *+2L<S_ -W?JB:WPEKP?_R,)_Z]9/\ T)*[VN"\'_\
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M?4/_ *&M>%BO]]CZK\SFG_$1ZI1117NG2<UXV_Y!5K_U]#_T!ZX:X_X]I?\
M</\ *NY\;?\ (*M?^OH?^@/7#7'_ ![2_P"X?Y5X>8_[S#T7YLYJOQH]=7[H
M^E+2+]T?2EKW#I,7Q9_R+5U_O1?^C%KS^O0/%G_(M77^]%_Z,6O/Z\/-OCCZ
M'-7W1Z3H/_(O:;_UZQ_^@BM&L[0?^1>TW_KUC_\ 016C7N'24-;_ .0!J/\
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M "&=3_Z]U_\ 0J^AA_ CZ(]/_EPCV:BBBLCE/-_$7_(RZC_OI_Z*2N6\4?\
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MZ^H?_1BUX6*_WZ/JCFG_ !$>J4445[ITG'>./^/G3?\ <F_G'7.67_(3L?\
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M(_#.G>)OCM:VVL:>+NQ7P]N ?<%#B=\<C'."?SKH/^%1> O^A;MO^^Y/_BJ
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MU/\ Z])?_0#6A6?KO_(O:G_UZ2_^@&L#E/-:X'Q7_P A1/\ KF?_ $8]=]7
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MNO\ Z%7T,/X$?1'I_P#+A'LU%%%9'*>;^(O^1EU'_?3_ -%)7+>*/^1>N?\
M@'_H0KJ?$7_(RZC_ +Z?^BDKEO%'_(O7/_ /_0A7@Q_Y&*]3GA_'7J<-I?\
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M/^_%_P"C%K@*[_Q=_P BU<_[\7_HQ:X"O#S;XX^AS5]T>;:[_P A>7_<C_\
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MUZR_^@&O-*\;-_L?/]#GK]#O_"/_ "+5O_OR_P#HQJVZQ/"/_(M6_P#OR_\
MHQJVZ]:E\"]#>.P5Y#;_ /'O%_N#^5>O5Y#;_P#'O%_N#^5>9FWP1]3&OLCM
M_!'_ "#;S_KZ/_HM*Z>N8\$?\@V\_P"OH_\ HM*Z>O0PW\&'HOR-8?"@KRR^
M_P"0I?\ _7U-_P"AM7J=>67W_(4O_P#KZF_]#:N+-?X*]?T9G7^$Z'P/_P ?
M>H_[D/\ -Z[*N-\#_P#'WJ/^Y#_-Z[*NG!?[O'T+I_"@KSCQ%_R,NH?[Z?\
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M&M"B@!JQHL0C"C8!M //%<C!\+/ ]MJPU.+PY:+<JVY>6,8/J(\[!^5=A10
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M]/'B.R:.6UD#,9=QPIQ*_&TL>G8<^H!W_C'_ )&%?^O2/_T.2N1UO_D%S_\
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M?]<S_P"C'KLO@M_R&=3_ .O=?_0JXWQ7_P A1/\ KF?_ $8]=E\%O^0SJ?\
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M 5X>;?''T.:ONCS;7?\ D+R_[D?_ * M>I_!;_D$ZI_UW3_T&O+-=_Y"\O\
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MD:^E*]^MN=F(^(****R,"G8??N_^OAOY"KE4[#[]W_U\-_(5<H X/QC_ ,C
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MS.ZQ, JN^1RH/]:T:IVO_'_??[Z_^@"KE>Z=)P?C'_D8$_Z]4_\ 0WJEX?\
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M/7Z'?>$?^1;@_P"NDO\ Z,:MRL/PC_R+<'_727_T8U;E>M2^"/H;QV*.M_\
M(!U'_KUE_P#037F8Z5Z9K?\ R =1_P"O67_T$UYF.E>3F_V/G^AA7Z'?>$?^
M1;@_ZZ2_^C&K<K#\(_\ (MP?]=)?_1C5N5ZU+X(^AO'8****L84444 %%%%
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M?5.D_P#(&L?^O>/_ -!%?*U?5.D_\@:Q_P"O>/\ ]!%?1UNAZ6)Z%RL_7?\
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MS_Z,>NR^"W_(9U/_ *]U_P#0JXWQ7_R%$_ZYG_T8]=E\%O\ D,ZG_P!>Z_\
MH5?0P_@1]$>G_P N$>S4445D<IYOXB_Y&74?]]/_ $4E<MXH_P"1>N?^ ?\
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M_&/_ ","_P#7JG_H;U3\/?\ (RZ=_OO_ .BWJYXQ_P"1@7_KU3_T-ZI^'O\
MD9=._P!]_P#T6]>%4_Y&'S7Y',_XIZ115*&ZNY+UX'MX55 "SK,2<'.,#:/3
MUJ[7NG2<=XX_X^=-_P!R;^<=<Y9?\A.Q_P"OJ'_T8M='XX_X^=-_W)OYQUSE
ME_R$['_KZA_]&+7A8K_?H^J.:?\ $1ZI15+[7<?;_LWV9-N-V_S?X<XSC'7V
MJ[7NG2<=XX_X^=-_W)OYQUSEE_R$['_KZA_]&+71^./^/G3?]R;^<=<Y9?\
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MGO!O_(&U#_KX;_T6E=#IW_(-M?\ KBG\A7H8;^##T7Y&L/A19KRR^_Y"E_\
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MZCX.AUSP=_8MJOB6R=;C^TXKG<^6 3:@R,@DY]O>O:*\_P#BG_S)7_8UV/\
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MG5/^NZ?^@UZA7E_P6_Y!.J?]=T_]!KU"O6J?$S2K\;"O++[_ )"E]_U]3?\
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M)H?"%%%%>F;%/3?]1-_U\2_^AFKE4]-_U$W_ %\2_P#H9JY0!YQXC_Y&6_\
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M^C%KH_''_'SIO^Y-_..N4:9[<QS1G#I(C*?0AA@UX6*_WZ/JCFG_ !$>H?\
M,9'_ %[_ /LU7*\A_P"$UUSSO.^T1^9MVY\I>G7TKTGPY>SZAH%I=7+[YI 2
MS  ?Q$=!7NG28?CC_CYTW_<F_G'7.67_ "$['_KZA_\ 1BUT?CC_ (^=-_W)
MOYQUSEE_R$['_KZA_P#1BUX6*_WZ/JCFG_$1S-Q_Q\R_[Y_G7IWP\_Y%M_\
MKX;^0KS&X_X^9?\ ?/\ .O3OAY_R+;_]?#?R%>Z=)-XW_P"07:?]?0_] >N+
MKM/&_P#R"[3_ *^A_P"@/7%U\_FO\9>GZLY:_P 1Z5H/_(O:;_UZQ?\ H(K0
MK/T'_D7M-_Z]8O\ T$5H5] =1B>+?^1:N?\ ?B_]&+7 5W_BW_D6KG_?B_\
M1BUP%>'FWQQ]#FK[H]*T'_D7M-_Z]8O_ $$5H5GZ#_R+VF_]>L7_ *"*T*]P
MZ2AKG_(OZE_UZR_^@&O-*]+US_D7]2_Z]9?_ $ UYI7C9O\ 8^?Z'/7Z'?\
MA'_D6K?_ 'Y?_1C5MUB>$?\ D6K?_?E_]&-6W7K4O@7H;QV"O(;?_CWB_P!P
M?RKUZO(;?_CWB_W!_*O,S;X(^IC7V1VG@W_D#:A_U\-_Z+2NAT[_ )!MK_UQ
M3^0KGO!O_(&U#_KX;_T6E=#IW_(-M?\ KBG\A7H8;^##T7Y&L/A19KRR^_Y"
ME_\ ]?4W_H;5ZG7EE]_R%+__ *^IO_0VKBS7^"O7]&9U_A,74^I^B_\ LU+X
M<_Y&33O^OA/YTFI]3]%_]FI?#G_(R:=_U\)_.NK!?P(>A=/X4>V5YQXB_P"1
MEU#_ 'T_]%I7H]><>(O^1EU#_?3_ -%I6&9_[N_5$UOA+7@__D83_P!>LG_H
M25WM<%X/_P"1A/\ UZR?^A)7>U>7_P"[1^?YL=+X$%><>(O^1EU#_?3_ -%I
M7H]><>(O^1EU#_?3_P!%I49G_N[]4*M\)C3SRVWES02/'*A)5T."/E;O5(>(
M=8#%AJ5R&;J?,.35F^_U(^I_]!-8E&6?[O\ -A1^$]TTMVDTBS=V+.T"%F8Y
M).T<UQWC'_D8$_Z]4_\ 0WKK](_Y MC_ ->Z?^@BN0\8_P#(P)_UZI_Z&]:9
MA_NTOE^:'5^!F/9?\A*Q_P"OJ'_T8M>J5Y79?\A*Q_Z^H?\ T8M>I>8F[;O7
M/IFL,J_@OU_1$T/A'4445Z9L4]-_U$W_ %\2_P#H9JY5/3?]1-_U\2_^AFKE
M 'G'B/\ Y&6__P!Y/_1:USVI?ZO_ ( ?YK70^(_^1EO_ />3_P!%K7/:E_J_
M^ '^:UX</^1A\W^1S+^*9D'_ !\1_P"^/YU[T.@KP6#_ (^(_P#?'\Z]Z'05
M[ATG">,?^1@3_KU3_P!#>J7A_P#Y&33_ /KH_P#Z+>KOC'_D8$_Z]4_]#>J7
MA_\ Y&33_P#KH_\ Z+>O"J?\C#YK\CF?\4[V+_D+W/\ UQB_F]7*IQ?\A>Y_
MZXQ?S>KE>Z=)QWCC_CXT[_=F_P#9*YRS_P"0E9?]?4/_ *&M='XX_P"/C3O]
MV;_V2N<L_P#D)67_ %]0_P#H:UX6*_WV/JOS.:?\1'JE%%%>Z=)S7C;_ )!5
MK_U]#_T!ZX:X_P"/:7_</\J[GQM_R"K7_KZ'_H#UPUQ_Q[2_[A_E7AYC_O,/
M1?FSFJ_&CUU?NCZ4M(OW1]*6O<.DQ?%G_(M77^]%_P"C%KS^O0/%G_(M77^]
M%_Z,6O/Z\/-OCCZ'-7W1Z3H/_(O:;_UZQ_\ H(K1K.T'_D7M-_Z]8_\ T$5H
MU[ATE#6_^0!J/_7K+_Z":\T[5Z7K?_( U'_KUE_]!->:=J\;-_L?/]#GK]#O
MO"/_ "+<'_727_T8U;E<WX;NTL_"]N[QR,OF2Y*+G'[QNM=#%)YL8?8Z9_A<
M8(KUJ7P1]#>.Q4UO_D ZC_UZR_\ H)KS,=*],UO_ ) .H_\ 7K+_ .@FO,QT
MKR<W^Q\_T,*_0V;#Q5IVG^'GTV=9_/(F4%4!7YF;'?WKH]&\4V.LW M;2.X+
MJFYBR@ #\Z\GO?\ 7?BW_H1KJ?AQ_P AJY_Z]_\ V85ZU+X(^AO'8]-HHHJQ
MA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%(2%!)( '))H 6B
ML7P[XKTGQ4E]+H]P;B&SN#;/*!\CL "2I[CGKW[<5M4 %%%8WB?Q1I/A#1GU
M36+GR8%(55 R\C'HJCN?Z D\"@#9HJ(W,26ANI'6.$)YC.YP%7&22>W%<-'\
M8O"3S(3)?QV,DGE)J4EFZVK-G&-Y'KW(Q0!WU%4M3U%=-TY[P6US=D8"0VL?
MF/(2<  =._4D #DD"L_P=KMQXE\,6^JW5JMI/++.C0*V[9LF>,#/<X49(XS0
M!NUY_P#%/_F2O^QKL?\ V>O0*\_^*?\ S)7_ &-=C_[/0 _QC_R,*_\ 7I'_
M .AR5R.M_P#(+G_ZYR?^BVKKO&/_ ",*_P#7I'_Z')7(ZW_R"Y_^N<G_ *+:
MO#E_R,5ZK\D<Z_C(\UKZITG_ ) UC_U[Q_\ H(KY6KZITG_D#6/_ %[Q_P#H
M(KZ.MT/2Q/0N5GZ[_P B]J?_ %Z2_P#H!K0K/UW_ )%[4_\ KTE_] -8'*>:
MUP/BO_D*)_US/_HQZ[ZN!\5_\A1/^N9_]&/7CY)_%EZ$8'^(=E\%O^0SJ?\
MU[K_ .A5[-7C/P6_Y#.I_P#7NO\ Z%7LU>W4^)G16^-A7!>,?^1A7_KTC_\
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MO!9OXCZY->3Z];7D.L^$&N/AGIOA=#XCL@+VUN;>1G.X_NR(U!P>N>GRCVH
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M7I_P\_Y%MO\ KX;^0K4P-'Q=_P BU<_[\7_HQ:X"N_\ %W_(M7/^_%_Z,6N
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M-_Z,:O)S7^"O7]&<M?X3D?&/_'DO_71/Y/7+:7_R%K+_ *[I_P"A"NI\8_\
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MQ_Q\Z;_N3?SCKD;C_5?\#7_T(5X>*_WZ/JOS.:?\1'/U['X._P"14L/]UO\
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M !C_ ,C"O_7I'_Z')7(ZW_R"Y_\ KG)_Z+:NN\8_\C"O_7I'_P"AR5R.M_\
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M??\ 7U-_Z,:O4Z\LOO\ D*7W_7U-_P"C&KR<U_@KU_1G+7^$Y'QC_P >2_\
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M\_SKT[X>?\BV_P#U\-_(5[ITDWC?_D%VG_7T/_0'KBZ[3QO_ ,@NT_Z^A_Z
M]<77S^:_QEZ?JSEK_$<]<?\ 'Q+_ +Y_G7I_P\_Y%M_^OAOY"O,+C_CXE_WS
M_.O3_AY_R+;_ /7PW\A7T!U&CXM_Y%JY_P!^+_T8M<!7?^+?^1:N?]^+_P!&
M+7 5X>;?''T.:ONCGIO]8/\ <7^0KO\ X:?ZC4?]Y/Y&N F_U@_W%_D*[_X:
M?ZC4?]Y/Y&O<.DZW7/\ D7]2_P"O67_T UYI7I>N?\B_J7_7K+_Z :\TKQLW
M^Q\_T.>OT,.]_P!=_P!]?^A&NJ^&_P#R&KK_ *]__9A7*WO^N_[Z_P#0C75?
M#?\ Y#5U_P!>_P#[,*]:E\"]#>.QZ97D-O\ \>\7^X/Y5Z]7D-O_ ,>\7^X/
MY5YF;?!'U,:^R,S4?]:?]\_^@K6KX%_Y&NV_W7_]!-96H_ZT_P"^?_05K5\"
M_P#(UVW^Z_\ Z":]##?P8>B_(UA\*/7*\LOO^0I?_P#7U-_Z&U>IUY9??\A2
M_P#^OJ;_ -#:N+-?X*]?T9G7^$Q=3ZGZ+_[-2^'/^1DT[_KX3^=)J?4_1?\
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M?/\ 0YZ_0P[W_7?BW_H1KJ?AQ_R&KG_KW_\ 9A7+7O\ KOQ;_P!"-=3\./\
MD-7/_7O_ .S"O6I?!'T-X['?ZW_R =1_Z]9?_037F8Z5Z9K?_(!U'_KUE_\
M037F8Z5Y.;_8^?Z&%?H8=[_KOQ;_ -"-=3\./^0U<_\ 7O\ ^S"N6O?]=^+?
M^A&NI^''_(:N?^O?_P!F%>M2^"/H;QV/3:***L84444 %%%% !1110 4444
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M_#9WU]_Q^2?A_(5WGPT_X]]1_P!^/^35P=]_Q^2?A_(5WGPT_P"/?4?]^/\
MDU=!B=!XN_Y%JY_WXO\ T:M<!7?^+O\ D6KG_?B_]&K7 5X>;?''T.:ONC@?
M%?\ R%$_ZYG_ -&/4WAG_CSU'_ME_,U#XK_Y"B?]<S_Z,>IO#/\ QYZC_P!L
MOYFOH:?\"/HCT_\ EPC7@_X^(O\ ?'\Z][KP2#_CXB_WQ_.O>ZR.4\W\1?\
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MY!$W^Y_[.E<7I?\ R%K+_KNG_H0KM/%/_((F_P!S_P!G2N+TO_D+67_7=/\
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MUZ=\//\ D6W_ .OAOY"O,;C_ (^9?]\_SKT[X>?\BV__ %\-_(5[ITDWC?\
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M %?_   _S6LR#_CXB_WQ_.M/4O\ 5_\  #_-:S(/^/B+_?'\ZO+_ /=H_/\
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M/_0WKE[[_4CZG_T$UX=3_D8?-?D<S_BF)7N6C_\ (%L?^O=/_017AM>Y:/\
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M%<#7?7W_ !^2?A_(5]'6Z'I8GH=Y\-/^/?4?]^/^35U>N_\ (O:G_P!>DO\
MZ :Y3X:?\>^H_P"_'_)JZO7?^1>U/_KTE_\ 0#6!RGFM<#XK_P"0HG_7,_\
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M^(O]\?SKWNO!(/\ CXB_WQ_.O>ZR.4\W\1?\C+J/^^G_ **2N6\4?\B]<_\
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M+_D9=0_WT_\ 1:5Q7C/_ )!$/_7<?^@M7:^(O^1EU#_?3_T6E<5XS_Y!$/\
MUW'_ *"U>+0_Y&7S?Y&5'_>$<EI?_(6LO^NZ?^A"NOG_ ./B7_?/\ZY#2_\
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M_D9=0_WT_P#1:5AF?^[OU1-;X3GM2_U?_ #_ #6LR#_CXB_WQ_.M/4O]7_P
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MO^X?Y5W/C;_D%6O_ %]#_P! >N&N/^/:7_</\J\/,?\ >8>B_-G-5^-&%/\
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MY)^'\A7 UWU]_P ?DGX?R%?1UNAZ6)Z'>?#3_CWU'_?C_DU=7KO_ "+VI_\
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M8&CXN_Y%JY_WXO\ T8M<!7?^+O\ D6KG_?B_]&+7 5X>;?''T.:ONCS;7?\
MD+R_[D?_ * M;&@_\@!_^OH_^@BL?7?^0O+_ +D?_H"UL:#_ ,@!_P#KZ/\
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MR_Z[I_Z$*]++O]UCZ'?A?X)U=>Q^#_\ D5+#_=;_ -"->.5['X/_ .14L/\
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MQN/^/F7_ 'S_ #KT[X>?\BV__7PW\A7NG23>-_\ D%VG_7T/_0'KBZ[3QO\
M\@NT_P"OH?\ H#UQ=?/YK_&7I^K.6O\ $<]<?\?$O^^?YUZ?\//^1;?_ *^&
M_D*\PN/^/B7_ 'S_ #KT_P"'G_(MO_U\-_(5] =1H^+?^1:N?]^+_P!&+7 5
MW_BW_D6KG_?B_P#1BUP%>'FWQQ]#FK[HYZ;_ %@_W%_D*[_X:?ZC4?\ >3^1
MK@)O]8/]Q?Y"N_\ AI_J-1_WD_D:]PZ3K=<_Y%_4O^O67_T UYI7I>N?\B_J
M7_7K+_Z :\TKQLW^Q\_T.>OT,.]_UW_?7_H1KJOAO_R&KK_KW_\ 9A7*WO\
MKO\ OK_T(UU7PW_Y#5U_U[_^S"O6I? O0WCL>F5Y#;_\>\7^X/Y5Z]7D-O\
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M!_Q\1_[X_G7O0Z"O!8/^/B/_ 'Q_.O>AT%>X=)PGC'_D8$_Z]4_]#>N7OO\
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M;_8^?Z&%?H8=[_KOQ;_T(UU/PX_Y#5S_ ->__LPKEKW_ %WXM_Z$:ZGX<?\
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M'\=>IPVE_P#(6LO^NZ?^A"NOG_X^)?\ ?/\ .N0TO_D+67_7=/\ T(5U\_\
MQ\2_[Y_G7TE;='HXG='I_P //^1;;_KX;^0K1\7?\BU<_P"_%_Z,6L[X>?\
M(MM_U\-_(5H^+O\ D6KG_?B_]&+7-4^!^ARO8X"O.O$W_(PW7_ ?_017HM>=
M>)O^1ANO^ _^@BO+R/\ BR]!8#XWZ&IH/_( ?_KZ/_H(KH/#G_(R:=_U\)_.
MN?T'_D /_P!?1_\ 0170>'/^1DT[_KX3^=>U/XF;5?C9[77F_B+_ )&74/\
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M_HSEK_"<CXQ_X\E_ZZ)_)ZY;2_\ D+67_7=/_0A74^,?^/)?^NB?R>N6TO\
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M?[K?^A&MRL/P?_R*EA_NM_Z$:W*R,"G8??N_^OAOY"KE4[#[]W_U\-_(5<H
MX/QC_P C O\ UZI_Z&]<O??ZD?5O_06KJ/&/_(P+_P!>J?\ H;UR]]_J1]6_
M]!:O"J?\C#YK\CF?\4Q*]STC_D#6/_7O'_Z"*\,KW/2/^0-8_P#7O'_Z"*]T
MZ3FO''_'SIO^Y-_..N1N/]5_P-?_ $(5UWCC_CYTW_<F_G'7(W'^J_X&O_H0
MKP\5_OT?5?F<T_XB.?KV/P=_R*EA_NM_Z$:\<KV/P=_R*EA_NM_Z$:]PZ3*\
M<?\ 'SIO^Y-_..N<LO\ D)V/_7U#_P"C%KH_''_'SIO^Y-_..N<LO^0G8_\
M7U#_ .C%KPL5_OT?5'-/^(CF;C_CYE_WS_.O3OAY_P BV_\ U\-_(5YC<?\
M'S+_ +Y_G7IWP\_Y%M_^OAOY"O=.DF\;_P#(+M/^OH?^@/7%UVGC?_D%VG_7
MT/\ T!ZXNOG\U_C+T_5G+7^(YZX_X^)?]\_SKT_X>?\ (MO_ -?#?R%>87'_
M !\2_P"^?YUZ?\//^1;?_KX;^0KZ ZC1\6_\BU<_[\7_ *,6N KO_%O_ "+5
MS_OQ?^C%K@*\/-OCCZ'-7W1STW^L'^XO\A7?_#3_ %&H_P"\G\C7 3?ZP?[B
M_P A7?\ PT_U&H_[R?R->X=)UNN?\B_J7_7K+_Z :\TKTO7/^1?U+_KUE_\
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M1?\ (RZA_OI_Z+2L,S_W=^J)K?"<]J7^K_X ?YK69!_Q\1?[X_G6GJ7^K_X
M?YK69!_Q\1?[X_G5Y?\ [M'Y_FQTO@1[T.@KSGQ%_P C+J'^^G_HM*]&'05Y
MSXB_Y&74/]]/_1:5&9_[N_5"K?"85]_J1]3_ .@FL2MN^_U(^I_]!-8E&6?[
MO\V%'X3W+2/^0+8_]>Z?^@BN0\8_\C G_7JG_H;UU^D?\@6Q_P"O=/\ T$5R
M'C'_ )&!/^O5/_0WK3,/]VE\OS0ZOP,YRY_X]9?]P_RKGZZ"Y_X]9?\ </\
M*N?K#*OX+]?T1-#X3V+P=_R*EC_NM_Z$:W:PO!W_ "*EC_NM_P"A&MVO3-BG
MIO\ J)O^OB7_ -#-7*IZ;_J)O^OB7_T,U<H \X\1_P#(RW_^\G_HM:Y[4O\
M5_\  #_-:Z'Q'_R,M_\ [R?^BUKGM2_U?_ #_-:\.'_(P^;_ ".9?Q3,@_X^
M(_\ ?'\Z]Z'05X+!_P ?$?\ OC^=>]#H*]PZ3A/&/_(P)_UZI_Z&]<O??ZD?
M4_\ H)KJ/&/_ ","?]>J?^AO7+WW^I'U/_H)KPZG_(P^:_(YG_%,2O<M'_Y
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M#_CXB_WQ_.O<J?$=%;XV>]UP7C'_ )&%?^O2/_T.2N]K@O&/_(PK_P!>D?\
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M#?R%>83_ /'Q+_OG^=>G_#S_ )%MO^OAOY"M3 T?%W_(M7/^_%_Z,6N KO\
MQ=_R+5S_ +\7_HQ:X"O#S;XX^AS5]T>;:[_R%Y?]R/\ ] 6MC0?^0 __ %]'
M_P!!%8^N_P#(7E_W(_\ T!:V-!_Y #_]?1_]!%?22_AH]2I_"7R.@\.?\C)I
MW_7PG\Z]KKQ3PY_R,FG?]?"?SKVNN<Y#S?Q%_P C+J'^^G_HM*XKQG_R"(?^
MNX_]!:NU\1?\C+J'^^G_ *+2N*\9_P#((A_Z[C_T%J\6A_R,OF_R,J/^\(Y+
M2_\ D+67_7=/_0A77S_\?$O^^?YUR&E_\A:R_P"NZ?\ H0KKY_\ CXE_WS_.
MOH*VZ.[$[H]/^'G_ "+;?]?#?R%:/BW_ )%JY_WXO_1BUG?#S_D6V_Z^&_D*
MT?%O_(M7/^_%_P"C%KFJ? _0Y7L<!7E^J?\ (7O?^N[_ /H1KU"O+]4_Y"][
M_P!=W_\ 0C7GY%O4^7ZCR_>1MZ%_R"?^V[_^@I7:>!?^1KMO]Q__ $$UQ>A?
M\@G_ +;O_P"@I7:>!?\ D:[;_<?_ -!->M/XF:5?C9ZW7EE]_P A2^_Z^IO_
M $8U>IUY9??\A2^_Z^IO_1C5Y.:_P5Z_HSEK_"<CXQ_X\E_ZZ)_)ZY;2_P#D
M+67_ %W3_P!"%=3XQ_X\E_ZZ)_)ZY;2_^0M9?]=T_P#0A7I9=_NL?0[\+_!.
MKKV/P?\ \BI8?[K?^A&O'*]C\'_\BI8?[K?^A&F<Q5\;_P#(+M/^OH?^BWKA
MKG_CUE_W#_*NY\;_ /(+M/\ KZ'_ *+>N&N?^/67_</\J\/,?]YAZ+\V<U7X
MT>::I_R%KS_KN_\ Z$:Z73?^1?L/^VG_ *$:YK5/^0M>?]=W_P#0C72Z;_R+
M]A_VT_\ 0C7TE3X4>I6_AHZGP+_R-=M_NO\ ^@FO7*\C\"_\C7;?[K_^@FO7
M*YSD/++[_D*7_P#U]3?^C&KD?&/_ !Y+_P!=$_D]==??\A2__P"OJ;_T8U<C
MXQ_X\E_ZZ)_)Z\7!?\C"7JS+#_QS \-_\C!:_P# O_0370USWAO_ )&"U_X%
M_P"@FNAKWZVYV8CXCV/P?_R*EA_NM_Z$:W*P_!__ "*EA_NM_P"A&MRLC IV
M'W[O_KX;^0JY5.P^_=_]?#?R%7* .#\8_P#(P+_UZI_Z&]<O??ZD?5O_ $%J
MZCQC_P C O\ UZI_Z&]<O??ZD?5O_06KPJG_ ",/FOR.9_Q3$KW/2/\ D#6/
M_7O'_P"@BO#*]STC_D#6/_7O'_Z"*]TZ3FO''_'SIO\ N3?SCKD;C_5?\#7_
M -"%==XX_P"/G3?]R;^<=<C<?ZK_ (&O_H0KP\5_OT?5?F<T_P"(CGZ]C\'?
M\BI8?[K?^A&O'*]C\'?\BI8?[K?^A&O<.DRO''_'SIO^Y-_..N<LO^0G8_\
M7U#_ .C%KH_''_'SIO\ N3?SCKG++_D)V/\ U]0_^C%KPL5_OT?5'-/^(CF;
MC_CYE_WS_.O3OAY_R+;_ /7PW\A7F-Q_Q\R_[Y_G7IWP\_Y%M_\ KX;^0KW3
MI)O&_P#R"[3_ *^A_P"@/7%UVGC?_D%VG_7T/_0'KBZ^?S7^,O3]6<M?XCGK
MC_CXE_WS_.O3_AY_R+;_ /7PW\A7F%Q_Q\2_[Y_G7I_P\_Y%M_\ KX;^0KZ
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M_P#7NG_H(KW#I.;\<?\ 'QIW^[-_[)7(W'^I_P"!+_Z$*Z[QQ_Q\:=_NS?\
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MN/\ CYE_WS_.N^^&G^IU#_>3^M>X=)UVM_\ ( U'_KUE_P#037FG:O2];_Y
M&H_]>LO_ *":\T[5XV;_ &/G^ASU^AAWO^N_%O\ T(UU/PX_Y#5S_P!>_P#[
M,*Y:]_UWXM_Z$:ZGX<?\AJY_Z]__ &85ZU+X(^AO'8[_ %O_ ) .H_\ 7K+_
M .@FO,QTKTS6_P#D ZC_ ->LO_H)KS,=*\G-_L?/]#"OT,.]_P!=^+?^A&NI
M^''_ "&KG_KW_P#9A7+7O^N_%O\ T(UU/PX_Y#5S_P!>_P#[,*]:E\$?0WCL
M>FT4458PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#SGX4
M_P#'[XZ_[&:[_F*G\5ZM?^#M>COM+^T:N^I!O,T,.SR$HG^NAX.P# ##&TY&
M/FZ]5HOAW3] DU*2P1U;4;Q[VXW.6S*_WB/0>U2VNBV%IJUYJD4)-[=A5EF=
MRS;5'"KD_*O? P,DF@#'\#-)J&C#7KG5AJ-SJ05W,+,(( ,XBC0_=VDD$D;B
M<[NP&/\ &W_DD.N_]N__ *41UV-EHUAIU]>WEG!Y,MZRO<!&(1W&1OV] Q'4
M@9.!G.*C\0Z!8>)]"N='U-'>SN-OF*CE2=K!AR/=10!R7Q7M)KWX,ZO% A9U
MMH92!_=21'8_@JDUJ:_K5@OPKO\ 5A<(;232G:-]PP^Z/"@>Y) QZFNH\B,V
M_D,@>+9L*L,@KC&#ZUQ*?"#P6EVDO]FR/ DAE2SDN9&MU<]_+)Q^'3VH F\&
MZ!%=_"WP[I^I12*R6D,R[7:.2)\!E((P589_F*Z/2M%L]'^T-;^:\US)YD\\
MTA>25@ !ECV   '05HT4 >5ZMKOQEAUF^BTOPGHT^GI<2+:RR2J&>(,=C']^
M.2N#T'T%<WKZ_&?Q'_9?VSPCI2?V;J$6H0^3<1C=)'G:&S.<KR<@8/O7O%%
M'A.I#XT:I>"ZG\(Z2KB,1X2XC P"3WG/]XUFW6B_%^[MWAD\*:>%92I*W,6>
M01_SV]Z^B**R]A3Y_:6U[BY5>_4^3+3PO\0+[6-1TFVT&W>^TWROM<7VB,>7
MYB[DY,F#D#/!..]=/+X>^+LTAD;PK8 GTN8O_CU>F>$O^2O?$7_N&?\ I.U>
M@5LY-[ERDY;GA.A_\+H\/I,EIX1TEQ,06\V>,XQGIB<>M:%WK/QPO+.>UD\'
M:($FC:-BLR9 (P<?Z1[U[-12)/G[^SOC%_T*>F_^!$?_ ,?KE_%>C_$;3M/F
MUS7/#]I:V=LJK)(D\;!=SX' E)/S.!Q7U37G_P ;?^20Z[_V[_\ H^.LJ5&G
M2=Z:L*"Y'>.AY38^#_BQI\<R1>%[-A-MW;[J(XQG&/WWO5A/#GQ<1U<>%;#*
MG(S<Q?\ QZOHZBMFV]64VV[L\?\ ^$A^.?\ T)FA_P#?Y?\ Y(K)U(?&C5+P
M74_A'25<1B/"7$8& 2>\Y_O&O=J*B<(SCRR5T2TFK,^=[K1?B_=V[PR>%-/"
MLI4E;F+/((_Y[>]<I:>%_B!?:QJ.DVV@V[WVF^5]KB^T1CR_,7<G)DP<@9X)
MQWKZSKS_ ,)?\E>^(O\ W#?_ $0U%**I1Y8:(J#<%:.AYG+X>^+LTAD;PK8
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M[B\*:>9(7#J&N8L$CU_?5U&@?\G0^*?^P4G_ *#;5[!51BH+ECL"5M$>/_\
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M# X[AACW .PM;"SL?/\ L=I!;^?*T\WDQA/,D;[SMCJQP,D\FK%%% !1110
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M2YP!\P9>".<=NE &OC P**** "J][8VFI6<EI?VL%U;28WPSQAT;!R,J>#R
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M8 500%*A0 ,<@#K7M-<]-X%\*W&L_P!KS:!8/?[MYF:$<MUW$="<\YQF@!?
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M>A4<;3UZ]!@4 1_#VZ\73Z 8?&.G):W]NWEK*)48W"@?>(4D ]NO/H*T-?\
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MRE^SW[.4-TT;J'\L?W1NX/\ L]^W.W<OBKPFNG^ KW4X+'1KJ3R+3Q$/E=(
M.(.F%EQP&)''3)YKK/B%:'0X-!\4:?;#9X>N/WL,28Q:.NR0*!Z#:<=L>U=3
MJ&GZ1XN\.M;7217NF7L092#D,I&592.AZ$$4 2:%H=AX=T>#3--B\NVA'&3E
MF)Y+,>Y)Y)K1K+\/:.= T*VTLW]S?"W4JL]R07*YX!( Z# _"M2@#A;KQSK-
MTU[<^&_"[:KI=D[1RW37:PF=D)#B%<$N%QU.,G@9K"LO$(\.7;>,+..:X\&^
M(2MS=%5S)I]P1M9V4=5. &ZX(^F>]\.:!!X4T>6QAN99;59YIT$@'[I78OM&
M.H!)Z\UYSX(\3IX?^%OA[2[&S_M76]0$SVVG1D+E6F<LSGD(@SC)ZX^N #7\
M83Z6^L>&/$^A7UO)JTM[%:H;9PQO+:0X=6"GYE4?-D_=Q7I-8NE^$_#^DWAO
M[#0M/L[UUP\D$"J1GJ 0!@?3%8NH_$[1=.N;@"RU:[L;5S'=:E:69DMH&'!#
M/GG'?:#B@!=4^(UC8W-Y%:Z/J^J6]BQ2]N[&W#Q0,/O+DD;BO\07..]<-/-J
MGPYTFZUWP<8-2\):L!<()]Y.GRO@>:< LT?J.HQV.=WHW@C1ET+PN+7[=!>V
MDDTUS!.BX#0R.77<?XCANO2N-\#^(M/\,?!K0_[0BDNY;PS1VUA OFRW&Z5R
M$53U 4\YX'Y4 =?X'\/6.D:8VH0ZA_:U]J>V>[U1F#&Y..,8X"#.%4< 5U-<
MYX4\)6GA07J:=<72V-U*)HK"5@8[4G[P3N 2>F2/U)J:I\2?#VDWL\$K7LT=
MK)Y5W=6UH\L%J_\ =DD P#R..<4 /USX@:7H=[<6OV+5-0>T :\;3[0S+:@C
M.9&X XYP,G'.,5Q=_%J/@MK[QSX(CCU?0M6C-W>6+L=RN1D3(<9V\DLO;GM]
MWM=&\.7&E:;XA?3-1@FDUB[FO[622+*1M*HP&(/SJ".OI7)7F@:M\-=,T:\T
MWQ-?7MO%<P6=QIUYL,,J2,$(B4 %6!.1R3ZD\Y .A^'VCV;VK>*9-636M5U1
M!YU^K91%S_J8A_ BGMUR.>F!VU<WH'@RP\-:WJ5_I<T\%MJ&'?3U(\A).[J,
M<$\<#C],=)0 4444 9KWVH+XBBL5TIVT]K=I'U#SEVK(& $>S[QXR<]/UQI4
M44 >8>/(=/\ #/BJW\1ZG9K<Z!JD7V'5X7A\U0Z@F"79@Y/5/;(K+\,^"/$X
M@N=9\.ZE-X4MKB026.B3@W$8C[F56)V,YYPHRHXZ]/2_%.@6_BCPS?Z-<@;+
MJ(JK$9V/U5OP(!J7P[#J5OX=T^'6'C?48X$2X:-LAG P3F@!^B?VO_9,']N?
M8_[1Q^^^Q[O*S_L[N:NS1B:"2(LZ!U*[D;:PR.H/8T^B@#Q-+[7/A$D_AZ+3
MH+V+4KK.F:O,1&AED/(NF[L!SGJ0./:3Q3X+M?!_@Z;6SXAU,^*6F$L-U%<,
M/M%T[ E$A'RD,<\8)QUXKUO5](L-=TJXTS4[9+BSN%VR1OW]QZ$=01R#7(^%
M?ALFA:E'>ZIJUSK+V(,.E"ZZ6<)[ ="_8MZ  8'% '9:>]S)IMJ]X@2Z:)3,
MB]%?'('XU9HHH \[\/:A;Z1\5?$VDZEB&^U1XKJQE?C[3$L878I]5(/'7KZ5
MU7C"\;3_  ;K-XEX;*2&SE=+@8)1@IVXSU.<#%'B7PII'BRRCM]5MRQB;?!/
M&Q26%_[R,.0>!^58,/PTMI;F!]:U_6]<MK=@T-G?W ,.X=&=54;R/]K\C0!O
M^$;J]OO!^C7>I!A>S6<3S;A@[RH))'8^U;-'2B@#RG1Y6\!^.[W_ (2YOM,F
MLRXL=??.TCM;N.D6.HQP?PKK/B)H^F:QX)U(:D4C%M ]Q#<G[T$BJ2KJ1SG/
MIUZ5MZSHVG^(-)N-,U.V2XM)UVNC?H0>Q'4&N#L/AUK,]U%I/B+6_P"TO"NG
MN'LK5A^]N>ZK<'HRIV'1NIP!B@#KO!=[>ZEX*T:\U$,+R:SC>4L,%B5'S$=L
M]?QK=I%4*H50  , #M2T >=>,M#U+1_%,/CW2+<ZI+:PF&ZTZ4[F$7=X/[KC
MG('7)]>:_AB,?$BZB\8ZS+'_ &5:RL=,TL2!EA*GF6?'!D[@=%'N>/3:X#6?
MA;:ZCKLMU9:G=:;INH'.KZ?;':E[CD'(/R$]&(ZCT))(!K^'?%[>*-8O%TRP
M+Z%; QKJ;/@7$P."L:X^9!S\V>O3-=14-K:V]C:16EI#'#;PH$CBC7:J*.
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M_>1N,'L01R"/45?C18HUC7(50 ,G/ H AL+&VTS3[>PLXA%;6T:Q1(/X548
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MRQ&1MS@UVVG:=9Z3I\%A86Z6]K @2.)!PHJ6""*V@C@@C2*&-0B(BX55'
MZ"I* "BBB@ HHHH **** "BBB@ HHHH **** "H;FT@NT G@AE*\KYL88*?7
MFIJ* .,@\*:]J&JV-QXFUVVOK33IOM%M;6EGY DE (5Y"6;[N3@#C/)S79T4
M4 >?^-O ]]XN\5Z=<QW4FGPZ?92O;7T#_O([HNFW*]UPISZY(XHT[5(?$L,W
M@?QY80)K!CR\7/E7J#I+"W'/? P00?3CT"LS5O#^EZY)92ZA:K++8SK<6T@8
MJT;@YX((...1T/>@#F$^'#R11Z=J'B?5=0T&-U<:;<^6P?:<A7DV[W0$#Y2>
MU=U110!Q7Q!\(3^,Y=#T]B\>GQ73SW4\4NR6(B)A&4]3N(_*H/#WB34M!U*#
MPKXRE4WLAVZ=J@&([]1T!_NR],@]<\9[]Y6;KN@:9XDTQM.U:U6XMF8-@DJ5
M8=&5ARI]P: +5]8VNIV,]C?0)<6LZ%)(I!D,#3K6U@L;2&TM8DAMX4$<4:#"
MHH&  /0"I54*H4= ,#FEH P_&&AS>)?"M]HT%RMLUVJQM*RYPNX%A]2 1^-<
MC<Z5>_#"ZN-6T*&6[\+RMYE]I,?+VA_BFA_V>Y3\N.GI5% '#>)O#UO\2-,T
M/4='UQK6*&8RK=VW+M$Z%753_"Q'&3TYXKJ]'T>PT#2K?3-,MDM[2!=J1K^I
M)[DGDD\DU9MK6WLK=+>U@C@@086.) JK] *EH YSQYI=_K?@G5-+TV-'NKN,
M1*';: "PW'/LN3^%<K:SWGPHGCLM0EFO/!DK!+>\?YY--8](Y,=8B>C=NA[5
MZ;45S;07EK+:W4*303(4DCD4,KJ1@@@]10!S^O:/K6LR6=UH'BV3280GSK%:
M17"3*><C=T..AY'M5_P[X>M/#>FM:6SRS/+*T]Q<3-NDGE;[SN>Y/'X "K&C
M:/9:!I-OI>G1-%:6Z[8T+L^T9SU8D]ZO4 !SCCK7EUO\-=3\,V=KK'AZ^C/B
M6 R->!@5AU-6=G*./X2,X5NV,'L1ZC10!SOAGQ/IWC+2IP(&BN(B8+_3[E?W
MD#="CJ>H///0_F*O>'] L?#.D1Z7IWG"TB9C&LLID* DG:">PS@"KT=K;PSS
M3Q01)-.099%0!I,# W'O@<<U-0 4444 (0""" 0>H-<OX-\ Z/X)@G73UDEG
MG8[KB8[G"9RL8/91Z=^M=310 UUWQLF2-P(R.HKD]"T"7PQ\-&T74)+:?[+:
MSH[0IL1T.X\@]R#S[YKKJKWUHE_I]S9R$B.XB:)B/1@0?YT >?\ AGQ-I_AK
MX9>%(+_SKFZO[>*&VM+9?,FESC.%]%4Y)Z#\JO> _AO;>$!]HNKM]1OHPT-M
M-*.+>#<2$0=B<Y)[DFG> ?AZGA.W2YU&[_M'6!"MN+EA\L$*\+%$#]U>Y[DY
M)KN* "N+M_!M_8?#W4O#=K?6TD]V]PJW$T)("32$L6&?F8*Q]LX[5VE5[ZT6
M_L+BT>6:)9HVC,D+E'4$8RK#H?>@#SJ:RUSP+JOAZW7Q%<ZII&H3KIDMI<HB
M/$2AVO$R %<;?\G!'0:5\/-*TS4(;R6^U;4FMFWVD6HWK31VQQC**>,^YR13
MM$\!V>DZC#J%WJFK:Q=VRE+674[GS?(!&#M  &XC@L03[UU= !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MB?\ "9Z3ZS_]^_\ Z]2:]XMTSPY/##?^=NE4LOEINX!QZUYO5SXN?\A73?\
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M<'D>E+=Z;?V 4WEE<VVXX'G1,F3^(]Q^='L8#^J4MCV'_A:/AWUN_P#OS_\
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M1)=QSPB>-HXSNVGCE1G!!X[]15&>TN;6417%O+#(PR$D0J2/7!HY4%V>E?\
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M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'D^K_ /(:O_\
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M)(5+*C(N&)(Z 'C/M3_#/_(N^)_^O1/_ $.N>^PW?_/K/_W[-'V&[_Y]9_\
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MEB60J>-XC*D,H/!ZXR..]4OL-W_SZS_]^S1]AN_^?6?_ +]FJMK<MK5NYO\
MC7!O[)YVSJ;6B?;E#9"R#C&!PIP!D#@>@KF:G^PW?_/K/_W[-'V&[_Y]9_\
MOV:%HK#BE%6N>DZ1_P D@?\ Z['_ -&"LSPS_P C+I__ %V%:^DP3+\)7C,3
MB3SC\I4Y_P!8.U<S]EN/^?>7_O@URRW9XE?^++U)KR":;4;TQ1.XCD=G*J3M
M&X\GT%:6A?\ (&UW_KW7_P!"K'^RW'_/O+_WP:/LMQ_S[R_]\&D9&V]G<:EX
M9TE+2,RF"69)2O\ RSW%2"WH, \GBM77HY+O^V+6R1I+K[;')+%&,N\6P '
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MB87+2>7L(Y!]ZW=2LKK2=.GTZSLKIHV(:\O&@8*^/X5XX0'OW/MUY_[+<?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
5HH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>img69628308_18.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img69628308_18.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $] L\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M'JN@^/=9UNZ>$VMZQ,81LGGUK!LOA9KMMX2\7Z8TEN9]6F\RWP_&-X//ITH
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M-'L</_S\_#_@A[*A_P _/P/1-P]11N'J*\[_ .%4V_\ T%[W_OLT?\*IM_\
MH+WO_?9H]CA_^?GX?\$/94/^?GX'HFX>HHW#U%>=_P#"J;?_ *"][_WV:/\
MA5-O_P!!>]_[[-'L</\ \_/P_P""'LJ'_/S\#T3</44;AZBO._\ A5-O_P!!
M>]_[[-'_  JFW_Z"][_WV:/8X?\ Y^?A_P $/94/^?GX'HFX>HHW#U%>=_\
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MW_OLT>QP_P#S\_#_ ((>RH?\_/P/1-P]11N'J*\[_P"%4V__ $%[W_OLT?\
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M'7MN=B2?>NMU;P-=ZAXPT;5([F!+"*.)=2A);=.T!+P;1C!PY.<XX ZTR\\
MW6HCQ8DM[';G5;R"[LIHLLT#Q*FTLI 'WDZ GCTH E7Q!XIT/5M)A\36VE26
M6J7 M$ETX2!K>9E)56#D[P<$;ACZ56L_$WC+Q!:7.M>']/TA])CFDCMK:Y=Q
M<7:QN49@X(2/)4X!!]SWJR/#_BG7-6TF;Q-<Z3%9:7<"[2+3O,9KF95(5F+@
M; ,D[1GTS52/PEXMTG3;SP]H6IZ=!HL\LK0W4GF"[M$E8LZH%^5B"S;6R",T
M 8VI>+HO#7Q/UP&#S=5U&SL+>QLFD"^9,3)PS= H)&3^6<BO4-+&HC38/[6>
MV>_VYF-JC+'N]%#$G Z9)Y]NE<?=?#Q-4UC77U&1);+4-.MK2&7<6N(WBW'S
M"2.N=K Y.2.:Z?P[#K%OH-K!KTMO/J,2[)9K<DK+C@-R!@D8)'3.<4 :E%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MW^'\[P6D$;"1?F2, ]?:O3:\Z^-?_)/+C_KHO\Z[,NG)XNGKU1$_A9T7@/\
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M*21NI(964]""*X+6)_$%GXCFTNZ?Q/'HT%M FGMH5FC_ &@A!YGFR%6*-NX
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MD8K=-&*J$Y4Y*4=&@:N>5+\$;-$")XAU-5'15. /UIW_  I2U_Z&/5/^^O\
MZ]>J4<UWO-L8]74_(CV<>QY7_P *4M?^ACU3_OK_ .O2'X*VH!_XJ/5.G][_
M .O7JO--?[I^E"S7&?S_ )?Y![./8\-^#?GP>/-=LGNYYXX(=JF1R>C=:]SK
MP[X2?\E-\2_[G_L]>XUMG;OB[^2_(5/X1:***\@T"BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M]S_V>O<:\.^$?_)3?$O^Y_[/7N->MG7^]?*/Y&=/X1:***\DT"BBB@ HHHH
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M1(3-)]\ C=MW=#QDY[59S'J-%>,'3YXO#_B:+27DN(O"FLI>:4'<OM$:*\L
M;J5PSKCWKHK'7+'4O$&N>-W?=I&C:>+:U?LY*">9A[\QK^!% &L/'D!^(/\
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MV#.H()4@@]L]CQ3['QGJ^FZ[K]CXEGTB6'2=-6^>33XW0C);*'>[<X4<>XH
MTAX\@/Q!_P"$7^Q-Y/,0O_-^7[2$$GD[<==ASG/7C%:7B7Q/!X=2TB%M->ZC
M?2&*SLH,;YF R>3PJ@<ECP!7E+:=XS_X5^+O_A&K?[<MY_PD'VW^T?WGFY\S
M_5;,_P"K_=[=W^%=7<ZQ9W?Q \%>(F<#3=2TZ>&VE<X5)G".%)Z!B 1[D$4
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MW[1#*\,A'H7C921]34:> O"\6AW.C1:/#'8W1!N$C9E:;!R-[@[FY'<UT=%
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M/^^GYBE\R/\ YZ+_ -]5QG_" /\ ]!N\_.C_ (0!_P#H-WGYTN:?8T]CAO\
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M?_?0H^T0_P#/:/\ [Z%>6_\ "EW_ .ANU7]*3_A2[_\ 0W:K^E'U?!_\_O\
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M%XXV*0 *YSQWXGTJYU3PKITT\ITVXD75KEHK>24M#&-T0*(I;#2%>H_@/TH
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MA)9)(&M5G1@;9>0"1AAZY(]0:WV^'MO;Z1I4&E:E<66I:9))-!J+*)79Y/\
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M8HKB==^*OA7P[JLFFW]Y*+F/[ZQPE@#Z9J_X7\?:!XPEFBTBYDD>$997C*T
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M<ZSVVF6D,J]'2%01^-:-% $%U9VU] 8+NWCGB/5)%# _@:H#PQH(.1H]B/\
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M[FY:1A8RF>*($;&DVE0S#')4$XYZG/4# !9M83;V<$!8L8XU0L>^!C-3444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444AX% "U5U"S^WV$
MUJ9I8/-7;YL+;77W![4D&I65S.T$%Y!+,O5$D!(JU0!XY:^'%\._&328EU34
M;_?:N=U].92O(Z$U[)7FNL_\ELT7_KT?^:UZ50 4444 %%%% !1110 4444
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M?_K5/X;\*7FC^,_$6LS31-!J<@>-%!RN !S^5=?F@#B?[7^(?_0KZ9_X,?\
MZU']K_$/_H5],_\ !C_]:NWHH \O\0^/_%_A>W@GU/PU8*D\HB3R[X-\Q_"M
MA-:^(,B*Z^%],*L,C_B8C_"NLU#2=/U5$34+*"Z6-MR":,,%/J,U;50JA5
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M$+N5U $X'X5U?AO5SKWAZRU1HO*-S'O,><[:=X@T^75O#]]I\+*LMQ$45FZ
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M2:"]@\Q0F, KC^M=+X'\)IX.\-Q:6+@W$@8O))C +$\X'84 =)1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
4% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>img69628308_19.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img69628308_19.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $W 64# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BLN^\1:7IMZMI=7028[2PVDA S;5+D#"@G@9QFKE[>V
M^G6CW5U)LA3&2 2>3@  <GDT 6**R8?$FESVM[<"X*+8C-RDL;(\0QD%E(SR
M.E6--U6WU1&>WCN550IS- \>0>F-P&: +U%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_I3)7N->'1?\?FJ_]A6^_P#2F2O3RG^,_3]4<&8_PEZ_YDU9OB+_ )%G5?\
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M &%;[_TIDKW&O#HO^/S5?^PK??\ I3)7IY3_ !GZ?JC@S'^$O7_,FK-\1?\
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MB#_<M/\ T!Z^//I2Y5/5_P#D!ZC_ ->DO_H!JY5/5_\ D!ZC_P!>DO\ Z :
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MQ5WP=;/!?Z@UFM\FC%(A!]L,F7D .]E$AW!3QUZ]J .OHHHH **** "BBB@
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M.*GHH PH?!VA6T"006DD4*#"QQW,JJH]  W%;44200I%&"$0!5!)/ ]S3Z*
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M94P9/^!D@^E;EI9VMA:I:V=O%;V\8PD4*!%4>P'%3T4 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
510 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>img69628308_20.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img69628308_20.jpg
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M-E)7U>$9*#1&1V>"M];Q*34W0T1%5EAF<G62IJ>R_\0 '0$  00# 0$
M          (#! 4!!@@'"?_$ &(1  $# @4"! (%!P8(" L$"P$" Q$$(0 %
M!A(Q05$'$R)A<8$(%#*1H14C0K'!T? 6)#,X4G8T4W*TM=+A\0DE0V)SL\+3
M%Q@U1%1C=(*2LL-55I2BHR8G-D5&9'6$A=3_V@ , P$  A$#$0 _ ._CHP8.
MC!@Z,&#HP8.C!@Z,&#HP8.C!@Z,&#HP8.C!@Z,&#HP8.C!@Z,&*#OY0B,]K>
MS8_^?ZWY_=_1WK[I*P2+=_WXU_47^",?^T#_ *MS')-30)@^6\M^8^P!_+\Q
M_9TR$+,%0@B8@CJ/B<:<(-Q\/NG]^-G&BGE]\8]_L?)\?W=21<@=R,*3]H?$
M?C_'WXRXHLCSGC@X((SG/\?V_;IPD)$#D=_O]L/XV*)Y!8\3Y\^2/;[@>_0
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MCQ[=-J:6B=P@CIA\(*TE4)$ FUPKX$#V_'[_ ,)(Q@9R<']@P?/_ '_/I$&
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M,'1@P=&#%#/\H%_Z+^SO]?5#_P#5[KSHD#DQC7]1?X(Q_P"T#_JW,<ET2'D
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M!:A$D">1;X$<:[0-J&;NME"E%HE*TE)VBP,DD1(']DGD>XQ8!'9 L:\HO9<
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M+1(M;J9F00><2&@TS!\J'$)A/%?I91D9'X6(R.0!^KCD ^.H)>0D[9  M_'
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MM!ZS/%QCHC3?T/OI,:E::J<O\'-84[;@"T#/:6FTPLA0!!+>I:O*'$@BX*D
M$0>HPOK%\3?L0D9*:#?RV0RDA1\WHK<ZV0 ^P)J;AHJEIE'_ %C,% ^X'58/
M%'03JP$:B928V_G*#-6T\V]3E$A'XV[WQN%5]!CZ5M(UYSGA-6J2E.XBGU-H
M>N=,7,,4>IGWR>P#948LGKB26ANXS83=YQ#MMO%MQK2X2_4MHLFK[-57Y1C(
M,E@-6EYA&,X,U!&#A@">)QLF6Z@T_G"D)RS.LKK7)!\FGK&5U$"YFGWA],W/
MJ0)OS?'C&LO!GQ9\/6G'M;^'.L]-4C84%9CFFGLRI\J)G_D\V^KJRUP@Q9NK
M41(F+8VNI"JH[-XR&YG[XPV203Y\_P <_P >MA@D@ 7G]A$_B!CRM2@$.%40
M H";?+]?P^6(15&[>G-NM]-+6>ZUL=)#K5ZVUQO*W&-*N"1)J0N01Q20NT/)
MOI#R1K[D 6I;*V4M$A*EDQ/<"8@< VN+<CB<:_0N!&8DD$A0*9%XXGMQ((]K
M20;VE:>J(:RBCDA=725%=2"""&4D,,$@@^P_/JC+:@DS (W<@R#)O'2/C\\;
M6!*I!Y$#[^<+&BJJRUM)+2%55P!(KCZ7(]@RD$'WSD8;/L1TRII#J8>&X@V4
MFQ'>Y^8YCOUQ+:>>IQ+9&T6(4"0?;\>_'QPB[E"E75S5-1$(/6<R%85PJL,>
M4&<X)&<'R3^9ZD-)"4[05$" -QDQ_'/ZL1UN>8HJ(2DR2=H@3UF9X^/SQCV>
MQ:;9ZFXW>M]!8AQ^7IX?4K*E4P1Z;*K-[L01Q8D\@ &/,#CM<GTLME:52 5J
M_-I$<@<]/P/2!A3#5"%*<>J%MJ!DH; !)MZ9BXB)F+8_+XUFDE'Z,I&I::"(
MAC+(9#-Q)_6,H)*<A@E <G)Q@X'2*=#C:=KJPM7,I$ #B+P3%[P)FXPBI4T7
M MELH0!!2525$ B>PD1:]Q[X1URFI742"GBCC:( 1+S,;JZ!&)61G;+K^($D
M9/M[]2/V]_\ 9VPR5H4"%()W" 1%HYDGO\^L=,,K=+';4D^82G5"LTLA7V7!
MS@+X^G!'+(\_OZ<1YD"%0.@$\R?C_'X5U0RTB5E,@S Z_N^7QOB#EC^(#MGL
M7W.5FSEUM\E1H*YWFT4&O]RZ&L*Z9VMUS?TFAMUMO:+12TLE+7U-+ M^KVN5
M#'8)FJ'J$JY*.Z0T.A9WXE930YZQD[E-45%*RXQ29YG[9/Y.R7,:T._4*"K6
MEI3>]U++A?4IYH4VTB'%M5*&>P_#7Z'&OM:^#]?XFT^9Y?E^?YK05V>^''AC
M5MH&J?$#2FGUTO\ *34&3M*JVJA+5**VF&54S67UB\X+C:DKI&:[*7LQO%IY
M5GA5XY!)'(JLC(>2NKCDKHPRI# @@CW!&,CK978*Y$$$ R.OO;GX]??',"00
M-J@4J22E22"%)4"04J2;@@@@@W!&/2,/2,)T4EE)XGQ[D8.1_P!8$C/GWQ]^
M@*3L*""9Y/SD=>GZ[],92G8OS$@R(B+1T,$VO>UAS\DGJJB_3MRIKE-3TLE7
M34<M-Z!+1B:G>1 C2NO+/RY,LT:NI_6<5YQKGG/HU"D;4TVM1"UI<]1W$7D[
M;3)@=A,V,V9JWU5,!U*1 MMM(N/5:_,_=A"SZ9I293QBS&&"QX"LRG(8+](#
M8RQ*?B/DJ"P&9BWUJ $D1U$?QR3_  <0?);M"0.O3]QD_/X=,:$T5+:S+52!
M88*=)9IG=@J)#&.4LCLV$1(N+DL6"HN6+ =1UK@%:U !(E2E$ !(N228  $W
M/ ZCIA++CKJ&6&U.N.+0A#32%...+68"$(0"5J42 E(22HFPF,-;J'N[[8]#
M\X-4;^[/V>K@4K);)=P-,5%XA\\'$MHHKE4W*-O!!#4I(9"/<8ZUVKU?I6A4
M4U>HLF96DD*;.8TJG4Q8[F6W5.".Q1R( )$8]@T_X ^.FIVFWLA\'_$?,:9Q
M(\NM1I#.V*!R18HKZJB8HE2(-J@V(/%\-8WQ)>R"WSL)]^]$UI =#$;;JFNI
MV8CZ2):6PRPD*0"'$G$C(R,@]5"_$G0<[%ZEI!<7;;JU"?\ *33*3%S)XX)Z
M8]!8^AM]*)U =:\&M1 $?9J*K(6%P>[3V;M. R."D&]QC JN_'L\UM41B@WX
MVJH'9$B5:^]1Z9ISQ7@KNU_BM<<;$$!GED^WU-@>)M'K[0[BP&M3Y5!/_G-4
MFF,D]34AD =I( Z1SC7<\^B=])?+9>K/!773@0@ C*<F7G2K3]AO)5Y@ZL_Y
M"5$F3>;N9I36.B=6PR7#1>J]-:OH%]-C5:7OMJO]*/4;"DSVFKJ8>+>ZDO@C
MV/G/6\T>89=F#1?H*^BK6]A454=4Q4IN)NMAQ8!'$\R?O\.S_26JM*5*:/5.
MFL_TU5J)2*74&39CDU02+$!C,::F=)3^EZ)%R</5;Z:)88W$[S2<RS#T?1B5
M0J$!1R8G#/C)/DJ3]\=-.)W*W V_9-OG'P^X@BM;6&T[2)CM[6^1Z7["_&,?
M4<L]=!\N9,0QY$<84##<?)Y#W\GVQ[G]W6$IV@]R<#CR?+4=I[<R?C^-S]^(
M<;D6<R"99$+>&!SGV_+P<#W'D_E^8\3&0I *HF1(OU@CK;K-NW)X&OU0!@[@
M">AZ$FTF1/0'I^O%1_=7MK2ZAT_=U6G_ %OH3E  I+.!(V"2"<'QG. ?;J2^
MRFJI=BP"H-J!)D28[=+B8]^G&,,.H:B;GVM(/L>/Q-N+XYAMRK5-I75-TMDJ
M-$JU$S1@K]/E^(5?!(P1^9 R, $$=>9+667UTY;*=JB 21"KDR!/00(,^W4X
MV!"DK2C;)D6]B.>O4 ?$<VPU55=R&X<R%QDXS@YQ@'_=YP?X=3D24"(N(O\
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M99,A!DK^K88'(Y8'F2  ?N#&J=%U*T["&U!:3<N);'QZ3UF;1[&<6=-1U.]
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M!H[)VV4"Y6O\H:AIW"E*;J"&UKF828QZWC7>L]921,7U#=I)7$4;2K\E;I
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M"\D@1*4B3R+BTUD4Z2I2O4/+(@W@VN1 _7,_BA[Y=(:G4)@IHYK,H22CBIJ
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M5YA6;@-IE,D@G<#Z8O*;1$S[#'M?-N*NQU]/+50R4E*SI'35),IC905F(G4
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MXA9-CN0)V_\ NCD7/69[@8:2XU%+*%YTY1PX!)Y@P_4>:2(V<X/U?3D+R*^
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M$W-OD(D<BUS!PM*'C=#BMW0[B .\P2;BWSP@;EH[3['U'M\8G=6,Y9$ S(2
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MZ@BW: 8 YN<-)9;0%;9*E$D@?HDP#$#H(Y-^_9]]-:Y@L<\\$U*]15)&T#I
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M(!CTP#80.HYF20/;'K64T0HD%-22O'!(5>2H0K2+RYJRK/SA5 IE# "02>
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MVOR!\<'UVJ_QRON3_JXVT/Q"^\I@"V^=_.20?_ >C?V8_P#BW]NFUM("4G:
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M2H0FZ5+2"+)FX,8Z/>FL;/@Z,&#HP8.C!@Z,&#HP8.C!@Z,&#HP8H9[D]J=
M[Z?%ZVGVUW5L/\[=#W'8EJBLL$]SO%M@FDM%GW/OE !562X6VX0Q0W6FAK'A
M@JXHJAU9*E)H998WZJT7GV;:7^CUJ#.LAJSE^:,ZK"&ZM#%,\M*:A_(Z9WT5
M++S2BIA:FPI394@$%!2H CASQ%TMD.M_I8Z7T[JFA_*V2OZ&+KM Y4UE,A:J
M2FU)64_YVBJ*9]*$52$O%"'4H<4"EU*T+6E5P^SNP>T';_9;GI[9W0ULT+9K
MU<4NUUHK947.I6NN,=+%1)5SRW2NKZAI5I88H<B4*50$J6))YVU%JO4.K:EB
MLU%FC^:U-,R:=AU]+*"TR5J<+:$L--("2M2E?9F3S&.MM(Z%TEH.CJ<OTCDE
M-DE'65":JJ9IEU#@?J$MI92ZXJI>?<*@TA*/M@0.)OAW^M>QMN#HP8.C!@Z,
M&.6#^5E9_P B7MVQ[_Y55KX_O_HDW2QTM')^'[1B%7?T:/\ +_[)QP6TXP0!
M]BH\_ES!_MR3_#J0"2/:_P!X01^K%20 ?>WW%8/Z\*RBXY&??'U?_P N5P?W
M_BS_ +.F%S!GB;?C?^/NQ%,;C'94_&#.%K0X" 1^5/XB??."1[X_+\L=-X2?
M?V^Z+?AA7TN<J%&6( 'Y>78>_@#^)'63P/A^U6(CB5*48$\]1W)ZGMA76T$>
M/OAAC]N".LGK[) ^8*0<-"Q$]")^_"MHO;]N<C]X/]G]O@],N0$WXG]<CIC+
MO]&(Z$3]Q!PMK;G(S[^GY_?TWA@\I_R/V'"VH/Q+^P #^.#T<$?Y2?\ YAC
MND^T1\R)_5A>4)/$8]R% _L /O\ LSTX5)6(29(/N+CGD=L((!L<+"W<@,8^
MQ+>W@$^/O_LSTI ($'O[>W;#S5A;W^[;^["TH/!1OOD)^S##)_C^7V_9TOB"
M/C^)_=ATD[0.A'[3^["LHS]:8]^'Y'&/JSY]O;J2.#,P2+_.^'$?9'S_ %G"
MRMQ/L "I4<L_D@/$^X]\^?\ =U);X,<0(_'#B% 3N,28%CT)'2<*VG&> 4 $
M 8 \#/@C^T'/O[]+((42(F(O/,_QQUPL.(/"NW0]>.F-_3>"%'LH 'YX]O\
M8>LP)GJ,#GV">UQ\1QA0T\:!E/D%B%&#[^^?<?8X_P#;TVZE2@ D3S-XCB.O
M6^& 1>3U/3M\!VQN8TX\<>PSY./V_P#?VZCK24*4E0 ,"POVCOT&$J4"" ?P
M/?&W@0(RX/DD9'GWQ^[']^.G/+5M(2DWN+I]O>>G6^%0 E4=B?PQLT!!SCP1
M_P .D>4YVCYC]A.$(($R>?C[^V,Z'\'_ -+_ 'C/1Y:@0"#R)(XO[\?Q'.,*
M(*AR1'0$]_;&Q3/$J54C&4S[X( S[X'LN,@><]/)5O"@.1"8B)@WN1T]CAT
M?K-^;W^6/55;B#C\_N/S/[>F'$D$DBUO?F!TP$@7./"NO5%0.L<LJ\V8+QR
M03DCW(_+!P" < G)QUL&5::SC.$E-&PZML)*U%.T) ,"=RB 5<>D'=[1B"^^
MT%IW+(!A(@*DDR;  ]")QLH*B.:..9,A'"L"W@>?."3CV_/V_NZ*S(LTH0IM
M^D<3M!0"-JY@%()V*41,3!N)OAYJI87Z4K)*8204J!D6[0;\D6]\9@(;\)!\
M9\'/CK7PVLE20D[D&%)((4.G!@_Q;G#X6E1@&3\#WB\CF>G./WI)2I)A22D^
MX(^Z>1[BV%8.L8,'1@Q\G/DGW7EC]HQ]_P#N.C!CR)R<]&#'YT8,/#VZ?](G
M8'^NG:[_ !S8.L*X/P/ZL/TO^$T__3L_]8G'6OTQC<<'1@P=&#!T8,'1@P=&
M#!T8,'1@P=&#%+FN?]-GLU_4%=/\);K==)95_5FU)_>YC_/L@QQYG7]<S2/]
MPJG_ $;J?%T?7-N.P\'1@P=&#!T8,'1@QRO_ ,K+_P"A)V[G[CNHMA!_(_T2
M;I>1TM')^'[1B%7?T:/\O_LG'!70DE1G+,2!Y/G+^0"3Y^G(_N/CJ24V$'B?
MF08^\]/NOBF+FTGTS]DS/ (^!L(^9/3"PH0N.1(#+Q#(V Q4<?J8$Y .#G((
M\GSX.8YE2HN!N@'L1,1[GMAA1N2!S)MTW V^0N./A?"SH6!1<+@,22!_J\0R
MCV _%C/L/?[]"D;4A4S)B(B.HZ]1?"/CA8TA.5 ./;&3@9#D^_VQX/Y_?I/(
M^"?N]7[OPPR>5>\D>][1^-_CA74&>3>V<L,>3DG(P,#S^SK"C&[K;\+&?B;3
M[G$<_:)[$GXQ_'M\1A6T2@ >WN/&#D9\_E@?VC/49Q6Y)$1P9GW_ -N&EN;D
M[0FP(N#/'7CK\<+>WJ3@@@9 7.?(\^X'N>C#3B]I2(_0'6.9&%M;8R7"Y/C[
MX]\#V]_]_6#Q\Q^L8 ?2;?: /PZX75O&>(SC!_O )Q^\_P#WX'GK+8]1_P I
M1^/\>TX,+.@_$X_ZB^/O[_LS_=GJ1AYK@_\ O?\ RX6= N>(]L.#[?DF<?QZ
M5$[1W$?_ )CA<6'LF?\ \Q'[<*^A!*^ 2<)C R?Q><8\^WOU+;3O*4S ))/4
M0-IN)&'$F F]H5^L86M$H4J  ,1>0 !DX&<_OZDI3MF_;I'&,J_1_P H?MPJ
M*-<%#DG)'O\ ;(&![^WC _<>EGD];G"9$%0@<6'L?]O;MA1THY\L)Y^Q R?
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M--:8H-:-1T3)%9XS1BN6C0S>DW"-:U8P\IQ)S]0E%D^ABR JP"=0*.JK'**
M-JRMQ4F 2"J4BT$2.P'$WF\NL0VW7!#:@4(#4E()C:DA0@F#!M$WF">N&*UI
MIRRU59<#0T@6WM4RBCCJ 976$2$Q,25_$R%?Q+R7'$LY'([#253J&&TN+W+
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M7^%L:"HO5=4R"0U:0AG:!GAJ895<9A9Y)9*=Q'S;BAD#/R)PH!*N2YL '$P
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ML,0^HA2/I&<@@''2DTOTI<K]#3W@WJ!L#:FJ>1JG+:U8$^IUMH-T:21<AL*
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MM;0=#ZP(VJ'\E<_A9 F3E%7Q8'B_3N+<W=.D)#)"E2" I""3<E-R-VT)G[1
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M([##LVO2UON,<L3S4R2L5!8DNC4X*J C1G]45!1< (I)D( 8D=07'W$00E1
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MI YF_O!Z=;<S(M^)2NJ(&F@>?G$CS5+D"EC<#.(H\F6/!!Y$9+> ?=1D@$F
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M@E\Y6E:BI3HOV2!,Q82"3V)F1]V))]0A9$"">X/M$=.;GVYPYMKT3JJQ6?\
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MZB6KJ*J2IJ!%-+6/'3K3R.LAD)2100)&905C9F$:L8R@G<M12" H!.T)1("
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M(D>/V8!\_OZSC(CK/R[X^R_@X\'[??\ [_V=&,8\I*@1#ZLDL#Q\>,@?<C!
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M72H^3LFDM+Z<TW:*&.FH;59J."'#&,*)423R?]P_#Y]\2=Z,8P=&#%+FN?\
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M)ZG_ .%0_6,.FUB"(/=,_>!)Q^^MCV(S^S_B3C^WI>$BQ_W?M!_5CZ6H*G.
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MW$UK1VFM$OZ-@1JJN6)N+RQIQXPAR/H$C,%8@%@"2N".0V;(<M;J"\ZZM.Q
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M'5AM) ($V_:?WXUM&Y,2"3<&?C^/XVQM8F*C!4$L<G/N"Q)P/W9P/W=/[CL
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MX9 U/35<WIDGEB,LQ*D$#&,^ 3G/N1[]:]J7(5(0MU*5*.U0$@G;!%[ @3,
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M^C==6U4KRSQJ6'J_HRV5,,=,60(Z127*5\DPE3*T:MT+D7@C4/)0<RS!Q!4
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M.2..DR/AR>AQIT[KK73,$2[*TC2@%VFRJJ P#99P54_=7!/GW\$=67\E5[
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MM!7ZISW(-+9%2JK<ZU)G.69#E%&E20JJS/-JMJ@H*<*) 3YU2^VWN4=J9DD
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M=&#!T8,4N:Y_TV>S7]05T_PENMUTEE7]6;4G][F/\^R#''F=?US-(_W"J?\
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M)2E#B7";%&Y;2)C@E&TR28 F"3QQB[9T4\XC>JH9:/!25@0#>_J2(OSQ-KS
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M(Q)#>(U4,F' /A0JH0IRV??I9=2#N'<$0+3U-K ]YF>V(ZH4K<#!,@PH2>8
MD$Q,1TCIC"_FU22G\09C,/EP2P-,0,ES"BKD$@ 9R2"1Y^V34'G; CU1$*F.
MIGB>EK?>H**00"3)%U"50;$ @ 'IUB_>"=I#:.+3R(CR556$2HF5 [QT\?IA
MH AC7T6$B+*#&?+,#YP!TT7. 8A)E*> 5&8),D$&8OT['"O,61R"5=;](%KG
MGO;GO Q[5%LFJ4>*"FED1RXD:GI@KT7UD)+&% :5VY',A<,3X(QENDAQ*2"5
M $ 1N597<$] .WQB)@Y2XM9V@),WB#Z>YO,].][1UPX!VYG;2-#>5^0K?EY)
M%KE>"H_2K(\K2K+533HRN0LHC1$9N&,#CG@(GU[^<*:]:) VP1Y?$$!*3:XG
MB]N;G&?+3)]2]T20=I ^$)[P8YO(@0"BKGHJ-H4DAH)H?60.L;3QJIB.4G 1
MT0$2$EPG ,H)4,_$LTMNJ()!6D@&)V]8E-P>EA/%I@3AHA041)]I]O:!SS&V
M;1<2<)BX:3K M.*&A,*"->0]!0WJNI1G81F1FEE4!FP$'T@KR<AC+0^D;BI8
M)D\J,0#, G; 2>.?G$8CAV3"RK;UVGU=Q!((YC@=P.V$97:'KS#3RRT$,K(L
MBA7!AGXES^L "JN,*>3N0Y#,/2*,5$A-2D*4-\ D73*DR.ADFU^!VF9C#Z7V
MU  ;Q']J),]K"UOQYO.$]/I0S.J&F^63B$<K']+^/9BRKR&>2D<^3 LQ\XZ>
M2_;[6XS/21<7$3'2+1;[U!Y*3(5T]P#\3:>.)%[]+)*[:%%7/"M-2P^K2,J\
M4@ >8@<3Z4O!0O'B)1R+$,V6'$E1)14;$JDD!0ZJL)O<>\D<">)D8>8K7  ?
M-4I/"DDF".@D1UZSWZ8DU\/K3%=2?$)[-*J*&84D/<EM&P$@CS"BZRM"3 F
M0B4KP(,CH_!'X$D*&75M>/)5H35H41O_ )/9K)$P9I'"GF=I5:TB3-@3&+W+
MZEAVJI]Y5O\ -;#8.V)*A[2;GTWD1UMC^E=U\\<;O@Z,&#HP8.C!@Z,&#HP8
M.C!@Z,&#HP8I<US_ *;/9K^H*Z?X2W6ZZ2RK^K-J3^]S'^?9!CCS.OZYFD?[
MA5/^C=3XNCZYMQV'@Z,&#HP8.C!@Z,&.8S^5,D#LX[>0<X/=%;,X'N!M1N<W
MD_8>/X^WWP?=OH_JVZLS(?VLD<!M,CZ_0GN"..G)@8KLRLR@D3#@/_Y5#'%#
MIV\4-!<H)1-(L$<8-04#JP]41QN8T+*9'4C.%;VR_#BCY[-4IM]"VVU)4N)"
M2%<28,J3$=Q!Y@F^*UUT.(VHD=8 5!-AP>I/;FY(%\3'T+K*G@5/0K7IXXU0
MM.%B#0H 0L3 @G \-P(R?*@#CU1U#"H(*0J9!22;]R 3?B)XB">;ZKF%*O>'
M%H6%(5O0II"A!!D2I((![F1%\2;L.Y%*L$L;7VKIZ9XBWR=*XA53EV8O)*LL
M@@!,:S N5("D% Y!I'J)=H:2I0@;C>181 @3$E, <F9/->V@)<*EI(DR0I,D
MR95))!YZ2;@GC#\V>_P4UEJ[K<[S3W&*D7TY+:UW@J RO#&P,48IY*.LC$S0
MR/#-605S \(9B5=HJ-YA2W4-I:*=\$.>4H7"C]HD[DG;N 4$%'4BXFV0I#:8
M;4EI/*BDA$JZF8@Q"9O)XGLM[/IV[W>V_I"VUL]5470P7ZSZ8CKJ-$85LZHM
M55P&IJ4MJ4T%/*'IZ@K4O%/'Z0S(2T-RH9;66W&BVEO<PY4*:60%(W I22A)
M7*B"%#T'K86"E;DDJ9<01N5ZVRXX@_:]))/J1,DW5,\<N+3ZPN-NIFMT=L@:
MX)# +J\LS31Q34N6>16,P*%%CD0R)ZB/X8E>+,S/U1M9\U3A*)(0.)"XM'!)
ML0+1! ,8@..^LH904  $!L$)]($$A, <F3-_<1*-U)>'U5:IH9*^9!1B6)#3
MNTDU.TC1N$A'$S$!^3/(KM$(6_$H&3(:813.[T(3*X4H6 7 *?4;#@0! ((Z
M\#++JTR%I"Y)(D2J(@ DW_'O\X\ZB?4UDHTHODG@ML<ADCGG9VJ:X*W*5)JE
M^+S.06$9 4)&0H+,.1NZ9+#R]Y5N60! 2-J>@*0!Z1U/RQ&K7)!A6T&"4A9D
M=P1(^0 %NF&2UK>+C4U:)40Q"G:(F)(Y49BG% $;D3@YY!BQ5E&<\LXZN:5I
MM(W $D&\I,$F22+7'!'(]Q.(B%%34;CN,0=Q)$'B23\"29C#)7^>C=A4<I85
MA1>(5F*^L6"!25/(MG(*X_(GED=62$J( @$D\P 2GD_+[_PQ+I5+;44[TE*Q
M,N+X(L(*OC^KJ!AP[#+2FPI+&RO5EO\ E/%3)(2HP%"#ZF#>ZX4 $^?/@Q'$
MJ\T)B$W*>@ /))L)!N>MIBV(SBU(<<#CMYN2KTD$"(),$$$6Z&??&WIZ$U7%
MX*>:1(U (F14X,3D'@0C\5(]F!X@XR!TA9BRB 28M)D6ZB1)$Q>Y'>3A"5I2
M(2J$C@)/'R%^0.?EQC75VDJRLD>6:VJI1/56:F:-?5.%$899&!#+(0"%5F/+
M !!/6 ^A(2$K!O!!!L1<@$3:+7@<DFXQ,8JU("TJ<7"@("E&.HL"?>\=(N #
MC66[2-;45#,14P>DC-/#*AXL$)*F$K)])'''DY)/X<94N*>2!$I,F$D$D\7D
M1$&>T>_;+U:A*+("H))4$@]R>!>W?M;L%Q9K+0U53##(5C,L:!@Z\_KYA297
M"YCPPR2N,\02,  0W5N)2H\PHD1U$3 '''O^NX*DV 3!-IB9/N+DD_K.'CI-
M+V*.BBYU16(F42O$K /E1A/;GD>&QQ/A@2/PDU2G72JPF3P8,7Y(XN.0>2+=
M</(J-MU 7X)],QSR+?Q,VQIX[924,LAIY7**&>&60<"H63 3TW4*?=&/CFI\
M#CG/3I4I:0"!V( %R>3-X$_+XX>%0"21VD&;"#,$<7CJ9]A&,2O CC3B_P#R
MHCU'=UY1L(V#!E*$E<C"$D9SR&, GH0),_HW  -[\@@B_6WPO>X71QL*5']/
M;$<>J1P1(O//87'S1W&.HE6F-/+4O51M&1%R>9)&?EF%2GU<_*J2>; ^#D@G
M*D$ F0G:1!( !![GC[IY[2,!5)^U,\G=)ZG]?S')XG&WFTS7PD00TE0C0*M8
M8^'(M("&,,ZLS)')&? 4^!Y+*2V50E\&Y(A1*)OP+ @@29F2>;#I8H4I Y*
M8!&\IDB\ R> 18_B<9RZ/N%$]PDN,LCK5T234I:2,/%+-)%4,/2R%9EY%&4@
M8!)!/'PGZP@I1L &Q4&QN$@CG[C(ZV,'#)42H^J0=P 3UN"# -Y(L 8/:^$=
M:[86J6BC^5,;U$<B2SR,09$;'#DN5CY8^H%L8R!Y^GJ4XOT@PJ0DB!$@1[B_
MMA!4)Y2.OJ,00?UGD^T7QKIZ!X;C4,TC5T2,2_IE@$(8 #D_!R@5F" +@D9*
MC&>EA<MI 3L)XMSWM?F+F3!G!N3$;P;7,BUQP>L\=>G PJ*"G@DJR\=$ORDP
M*LHY"2!BI".O%2[<1@E58<_;[=1UDA/VB2+S8@@&#S8>Q_?.,R"1MB# B8,D
MP"+SQ;N9'OAY]([<W2FMDUX>%X*.J@FGM-3)Z:AT12KHL<CX,_JL> =F8*I4
M("&4UU16-K6&Y"E @.) )@^Y'"8ZP)GX1C?M7M!VD*$@D)(Z6')'X#VB_P"Z
M-H;M2W":EN%#472RR%I[B[I'!<HD+*6> U#K$Y4\^:&*2-\_2RL,KBI6TI&Y
M*DH< "6P"5(GH#ME29/N/U2XDJ"@I*KDQ, [N)D\$\VC]9PKM3;85%=5&\45
M$D%-1J!'4ULB-!(9"7CB0REXY'AA)#*I8<QR8%,GJ*QF ;2&EJDJ))2@>H@<
MJ(Y 418F.L&>7_*2M14%'KZI$),  2" (M,7!^_&CO&R]WH[?;KO354E73E4
M>Y+01M4,CU*.Z"H"+]"+DIR1B"SJ%P<,%HS5LK6VL;2#"-YB0D@&"3!)YN/:
M,.>2ESTMM)"B)!0D;A D\)F-LR1TDVY#=U&A5M-S7],4,<<<[2\Y)H)SZ2,.
M2NID)0L4("^"%SYP!YL!6^:W#2[@ P"D;NAF!NYYF)]\0!3K27"M"UB1 *5$
M 29CI?Y1';&FOFVTBU$SI*DT3YDAA"$/& Y7B@1/#\1AB % ("D^Y=9K[ 24
MD6DF09CF3^N_>(QCRT] !V!3$?/C"._F=32)(&I,U/,-&1"6$<:^!SRN7D(;
M#'++['R!U,-69!D;8N2H7,F8@D)';W,7G$<LJ;!W*(O.W=;Y@\GK8?CB179!
MHZ.A[UNUBI^4"-!OMMI-QY\9(&CU5;'9S&<_1)CEC (Q[D#K7=:U6_1FJ$;N
M<BS(3$A4TCD";W D3Q>W?$_*U.?E*A -OK3&Y)M;S$\#X3P/?'>_UPGCU?!T
M8,'1@P=&#!T8,'1@P=&#!T8,'1@Q2YKG_39[-?U!73_"6ZW7265?U9M2?WN8
M_P ^R#''F=?US-(_W"J?]&ZGQ='US;CL/!T8,'1@P=&#!T8,<LG\K#U!!I_L
ML[<)9TY"M[K+;1HV 2CG:'=2;D,D '$1&2<>?((..O7?!NN30:CKW5@$*REQ
ML'J":RD5*8(O"3UB.01(Q$K&O-: !@A6X=C"5<_(XX._YY.\\!0B&-7 D-,"
MTA4 9'&,>X!!<GD&SG/W'4 SUQ:FU();0#<MV)  [1,]0#!DS$@"K^K[9-B0
MG@V%I^7PYFYP\6F=2P*(9:J1XXGXNTBMRD.0BE>$DY57P2P;@6R>2G.&ZW*A
MKVZAA/F%*2H )4I5B;#U K)!)() $*!O OAE:W@5)"D$BX#B"I!(F$J,_9Y3
M(!)%X/23VB:BFU/=[/:M+7.]5FHKC./T<E5%''325$,4DTU)/F*6F42+'EL2
MIQ@5WPC,DD2JI;=-3.5+_DHI4 %Q:5BR5%*4K!)"IW*BX,J,$$[@JN=#ZC+[
M5*4*!\LI!3Z^>QO$^F0>L7C$DJVLUS8;_ =9QU%*U!;)C';ZQ*6.GK+E%3IZ
M*50HY5:.!8O0JD9Y(A)3+%)3.P.6IV315+)-&M"PMP2X@J*DHW>HHD%))(*+
M D*W!0Q6/T^U*@M"DI62K>0"B2 +09VB()VQ$1)OA^=D.X>32=[J]07>RRWB
ML&GJ^.UT=?*[V"NN<,:-/25\=/$S!9 LLZ2Q/$%FC$0GIRX<5&<Y)];8%.U4
M>2//27%-A(>2T9 *=QB 2F1>0)A>$4Z5-OMN+/YM*1!3RHI2( E!Y[D0(N.
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M'7"T+!4I(*0204 R+GJ9$"_;\"<2.VXN]'9[/7;9:B@-?37"H2F2Y5--%/3
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M F]F]DB* H,IT4S! <K'R_FWRX)X$:EB$4*H&%'40^/>HB9_(V2\SQ6\]_\
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MS-W+JO+7*>F4U5,/4Y62\5MH>0I"MLN%)("B4E0-P"0<+.6L?64U(*DE&PA
+V[9;,@\3)ZWQ_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>img69628308_21.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img69628308_21.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %T L0# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M)7=GAO\ .:Q?"TD4NI>*I(+N[NX6@@V7%T/GD&R09Z#(XXXZ5K>$P%^'-F
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M=LT;,LC!5V'(.< 8KTRO+M.\+6EY\/X]6M+=5UB%I9XYAR7*2M\I'0\#'Y4
M=H_B..PT;2Y[^&9KV]B0K:P1[I'<J"P"^V>_2EM/$]O>1W:I8WZ7=J TEE)$
M%F(/0J,X(_&N4UF[74KGP[XDDN;RTTZ2W=);BT'S6[GUX. 3D9QVK9\,1:1/
MK=Q?6&JZCJ<_V<1//<8*!=V0H8(N3D>] "^$O$]UJ&@^?J%I>L\4<LKW31(L
M<@5R-JX/4#CH.AK5E\26</A<>(&CG^R&-9=@4>9@D <9QGGUKGO"-Y!-X3GT
M%7(U2".Y$ENRD%<NV/;^(5AWFO63_"XZ,GFMJ,4"QS0")LQ;6!)8D8 X_44
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MLVYW.S=,G^]BM.BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M9_QHVS_\](_^_9_QH EHJ+;/_P ](_\ OV?\:-L__/2/_OV?\: ):*BVS_\
M/2/_ +]G_&C;/_STC_[]G_&@"6BHML__ #TC_P"_9_QHVS_\](_^_9_QH EH
MJ+;/_P ](_\ OV?\:-L__/2/_OV?\: ):*BVS_\ /2/_ +]G_&C;/_STC_[]
MG_&@"6BHML__ #TC_P"_9_QHVS_\](_^_9_QH EHJ+;/_P ](_\ OV?\:-L_
M_/2/_OV?\: ):*BVS_\ /2/_ +]G_&C;/_STC_[]G_&@"6BHML__ #TC_P"_
M9_QHVS_\](_^_9_QH EHJ+;/_P ](_\ OV?\:-L__/2/_OV?\: ):*BVS_\
M/2/_ +]G_&C;/_STC_[]G_&@"6BHML__ #TC_P"_9_QHVS_\](_^_9_QH EH
MJ+;/_P ](_\ OV?\:-L__/2/_OV?\: ):*BVS_\ /2/_ +]G_&C;/_STC_[]
MG_&@"6BHML__ #TC_P"_9_QHVS_\](_^_9_QH EHJ+;/_P ](_\ OV?\:-L_
M_/2/_OV?\: ):*BVS_\ /2/_ +]G_&C;/_STC_[]G_&@"6BHML__ #TC_P"_
M9_QHVS_\](_^_9_QH EHJ+;/_P ](_\ OV?\:-L__/2/_OV?\: ):*BVS_\
M/2/_ +]G_&C;/_STC_[]G_&@"6BHML__ #TC_P"_9_QHVS_\](_^_9_QH EH
MJ+;/_P ](_\ OV?\:-L__/2/_OV?\: ):*BVS_\ /2/_ +]G_&C;/_STC_[]
MG_&@"6BHML__ #TC_P"_9_QHVS_\](_^_9_QH EHJ+;/_P ](_\ OV?\:-L_
M_/2/_OV?\: ):*BVS_\ /2/_ +]G_&C;/_STC_[]G_&@"6BHML__ #TC_P"_
M9_QHVS_\](_^_9_QH EHJ+;/_P ](_\ OV?\:-L__/2/_OV?\: ):*BVS_\
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M;?X4>>G]V3_OVW^% $M%1>>G]V3_ +]M_A1YZ?W9/^_;?X4 2T5%YZ?W9/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M'_+24_2,TP^-M)':X/TC'^-/ZW0_G0E@\1_(SHZ*\^_X3O4_^?>T_P"^&_\
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M(O*?_GXD_)?\*/*?_GXD_)?\*EHH B\I_P#GXD_)?\*/*?\ Y^)/R7_"I:*
M(O*?_GXD_)?\*/*?_GXD_)?\*EHH B\I_P#GXD_)?\*/*?\ Y^)/R7_"I:*
M(O*?_GXD_)?\*/*?_GXD_)?\*EHH B\I_P#GXD_)?\*/*?\ Y^)/R7_"I:*
M(O*?_GXD_)?\*/*?_GXD_)?\*EHH B\I_P#GXD_)?\*/*?\ Y^)/R7_"I:*
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M_E^1CCPOI2]+=?Q53_2GCPYIB]+:/\8D/]*U:*U]C37V5]QFZ]5_:?WG,?\
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MQ(4D D^@I:* (O-?_GWD_-?\:/-?_GWD_-?\:EHH B\U_P#GWD_-?\:/-?\
MY]Y/S7_&I:* (O-?_GWD_-?\:/-?_GWD_-?\:EHH B\U_P#GWD_-?\:/-?\
MY]Y/S7_&I:* (O-?_GWD_-?\:/-?_GWD_-?\:EHH @DN?)B>62)U1 69B5P
M/QK@[99?%WB9KJ2)VL;<CY./N]AR>IZG\:T/&>JR2R1Z)9Y:64CS0O7GHO\
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MRV&2>G:M2@"+S7_Y]Y/S7_&CS7_Y]Y/S7_&I:* (O-?_ )]Y/S7_ !H\U_\
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MT""E^S0?\\8_^^10!PVE:;KJ>:;19;8\;A("F[KC&1S_ /7K1W>+8>H\P?\
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M_4ZIQZ>:XKJ/LT'_ #QC_P"^11]F@_YXQ_\ ?(H Y?[)XJA^Y<>9_P #4_\
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M_P"- '+_ /";?]0__P C?_8U1O?%M_/,&M3]F0+@I\KY/KDBNVVS_P#/2/\
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MSC&&/H:U=L__ #TC_P"_9_QK.47%VEN:1DI*Z):*BVS_ //2/_OV?\:-L_\
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MM,'_ #VC_P"^A1]I@_Y[1_\ ?0H EHJ+[3!_SVC_ .^A1]I@_P">T?\ WT*
M):*B^TP?\]H_^^A1]I@_Y[1_]]"@"6BHOM,'_/:/_OH4?:8/^>T?_?0H EHJ
M+[3!_P ]H_\ OH4?:8/^>T?_ 'T* ):*B^TP?\]H_P#OH4?:8/\ GM'_ -]"
M@"O=:/IU[G[390R,?XM@#?F.:YC5_ B2O&VDF.$<^8LTC$=L8X)]:Z_[3!_S
MVC_[Z%'VF#_GM'_WT*UIUZD'[K,IT836J.%MO NJP[B-0AA;C'E,W/UX%3_\
M([XJ@_U.L;QZ?:'_ )$8KL_M,'_/:/\ [Z%'VF#_ )[1_P#?0K1XNH][?<9K
M"TUM?[SC/(\<6_W)?-'^]&?YUGZQJGBF&T47WF6R;QB6/Y"3@\94_7\J]#^T
MP?\ /:/_ +Z%17 L+N,1W(MID!R%DVL,^N#3CB5>\H+[A2PSM:,G]YY[X=\3
MRV6I,^IW=W- T94!G+A6R.<$^Q_.O0[/4+34(O,M+B.9>^T\CZCJ*I2Z3H,T
M31M:6(![HJJ?S'-<Y>>$1;2_:=&U,1R#D(\F"/HP_K53E1K._P +_ 4(UJ*M
M\2_$[FBN"M_%NJZ3((-7MO.4<;Q@-^!'#?YYKIK/Q/I%[%O6]BB/=)V"$?GU
M_"L9X><=;77D:PKPEI>S\S7HJI%J>GSL5AOK:1@,D),I./P-3?:8/^>T?_?0
MK)IK<U33V):*B^TP?\]H_P#OH4?:8/\ GM'_ -]"D,EHJ+[3!_SVC_[Z%'VF
M#_GM'_WT* ):*B^TP?\ /:/_ +[%<YXJ\1"RL8QIE_#]J,H#!"KD+@YXYQSB
MKITW4ERHBI-0CS,ZBBO-M.\<:C;SN]\QNXRA"QX5,-D<Y"_7\ZN-XPUR\.+/
M3D0'HVQFQ^/ K>6#J)ZV,5BZ;6ESO:J:EJ$.EV$EY.':./&0@!)R0.,D>M<9
MY?BW4/\ 6W\=NI_Z;*G_ *!S3)?!MS/$TDVLV\EQ_"'8D'ZL>?TH5"FG[\U\
M@=:;7N0?S.@L/&6FZA>QVJ)<1L^<-*%"C )Y.[VK?5U<91@P]0<UYW;>")C<
M+]KU"S6'G<8I"6Z<8R .M6V\#0*=T.M*I]T'\PU54IX>_NSM^),*E>WO1O\
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M4_\ S\2?DO\ A4M% $7E/_S\2?DO^%'E/_S\2?DO^%2T4 1>4_\ S\2?DO\
MA1Y3_P#/Q)^2_P"%2T4 1>4__/Q)^2_X4>4__/Q)^2_X5+10!%Y3_P#/Q)^2
M_P"%'E/_ ,_$GY+_ (5+10!%Y3_\_$GY+_A1Y3_\_$GY+_A4M% $7E/_ ,_$
MGY+_ (4>4_\ S\2?DO\ A4M% $7E/_S\2?DO^%'E/_S\2?DO^%2T4 1>4_\
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M?FO^-2T4 1>:_P#S[R?FO^-'FO\ \^\GYK_C4M% $7FO_P ^\GYK_C1YK_\
M/O)^:_XU+10!%YK_ //O)^:_XT>:_P#S[R?FO^-2T4 1>:__ #[R?FO^-'FO
M_P ^\GYK_C4M% $7FO\ \^\GYK_C1YK_ //O)^:_XU+10!%YK_\ /O)^:_XT
M>:__ #[R?FO^-2T4 1>:_P#S[R?FO^-'FO\ \^\GYK_C4M% $7FO_P ^\GYK
M_C1YK_\ /O)^:_XU+10!%YK_ //O)^:_XT>:_P#S[R?FO^-2T4 1>:__ #[R
M?FO^-'FO_P ^\GYK_C4M% $7FO\ \^\GYK_C1YK_ //O)^:_XU+10!%YK_\
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M7V:#_GC'_P!\BC[-!_SQC_[Y% $M%1?9H/\ GC'_ -\BC[-!_P \8_\ OD4
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M!+147V:#_GC'_P!\BC[-!_SQC_[Y% $M%1?9H/\ GC'_ -\BC[-!_P \8_\
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M/_OD4 2T5%]F@_YXQ_\ ?(H^S0?\\8_^^10!+147V:#_ )XQ_P#?(H^S0?\
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M(?\ "G;I_P#GG'_W\/\ A0!+146Z?_GG'_W\/^%&Z?\ YYQ_]_#_ (4 2T5
MDDTD:N(H\, 1F0_X4[=/_P \X_\ OX?\* ):*BW3_P#/./\ [^'_  HW3_\
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MDS,P$4?RG!_>'T!]/>G;I_\ GG'_ -_#_A0!+146Z?\ YYQ_]_#_ (4;I_\
MGG'_ -_#_A0!+14"R3,S 11_*<']X?0'T]Z=NG_YYQ_]_#_A0!+146Z?_GG'
M_P!_#_A1NG_YYQ_]_#_A0!+14"R3,S 11_*<']X?0'T]Z=NG_P"><?\ W\/^
M% $M%1;I_P#GG'_W\/\ A1NG_P"><?\ W\/^% $M%0"28R%/*CR #_K#WS[>
MU.W3_P#/./\ [^'_  H EHJ+=/\ \\X_^_A_PHW3_P#/./\ [^'_  H EHJ
M23&0IY4>0 ?]8>^?;VIVZ?\ YYQ_]_#_ (4 2T5%NG_YYQ_]_#_A1NG_ .><
M?_?P_P"% $M%0"28R%/*CR #_K#WS[>U.W3_ //./_OX?\* ):*BW3_\\X_^
M_A_PHW3_ //./_OX?\* ):*B61_-".BC()!5L],>P]:EH **** "BBB@ HHH
MH *,9ZT44 %%5;Z\6TMI&7:]P(V>*'=AI"!G '>N=MM8U*SL+35[J[AU#2[E
M5:9HH@C6I/<8/S*"<$'D?G0!UE&,]:** "BH+JZ2UB+$J92#Y<98 R,!]T>]
M<Q:ZSJEMI=MKD]U#?Z;,@:Y2*((UKGJ5Y^8*<@@\\9H ZZC&>M("" 000>A%
M+0 44R2:*(H))$0N=J!F W'T'J:Y*TUG6/[,377ECN[3+?:K*.(*]L 3G:<Y
M9EQR#U[8H ["@C(P>E,BE2>%)8F#1NH96'<'D&GT %%,DFBAV^;*B;CM7<P&
M3Z#WKE+;5M::P;6EDBNK=)'6YTY8@KP*K$':V<EP!D@]>V.* .NH(R,'I4=O
M/'=6T5Q"VZ*5 Z,.X(R#4E !13)9HH #+(D88A078#)]/K7+0:IK<UO/JT$D
M5Q'!-)'/I@C"O&JL1P^<E\ '!X.>,<4 =901D8/2H;2ZAO;.&Z@;=#,@D1O4
M$9%34 %%%<N-3UNXEOKRS-O-'9W+P/IWEXD95/W@^?O$<@8P010!U%%5[&]@
MU&QAO+9BT,RAE)&#]".QJQ0  8&!THHKF#J6MW-U?SV+6TBV-P86T]DP\B@
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MAO?WSSQZA-;1S0"WN8T4'S$!8C!/*GYV&1V-:D5O# B+%&JB-!&N!T4=!]*
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M&>1I#-++(!EY#U;'0>V.@H =I^F0::D@B,DDLK;Y9I6W/(>G)]AP!T%7***
M,#6M4U+3]8LDMH4GM7AD>2$#]XY4KD*?4 D@=\$=<54CU6T?5+/7;&0MI]\?
ML5PY4J-X/[M^<=RR9_VAZ5M:KHUIK,<*77F;8GWCRWVE@005)'\)!((J>WT^
MSM%D6WMHHED<2,J* I88P<=!T'Y4 1Z?ID&G><T;2RS3,&EFF;<[XX&3Z =!
MTJ[110!S=[XB:S\1/:7!>&&*,&*%8M\EZS?W/9?0<YZX'6$ZG VI6VN6XDB@
M=_[/U".5-C1-G]V6';#-C/H]=-+$'^=5C\Y0?+=TW;"1^!_453TW2UL;:5)I
M?M,T\IFGE= -[\<A>P 50!["@!FCZ#8Z(LOV57+RL6:21MS8R2%SV49.!_6M
M.BB@# U766LM=AMWG>.!8/.$448:2Z<OL"+GTR#QSR.0,U2EU:)M3@UF.*>V
M\AQ8ZC#<*%>-'P48@$C 8@Y!Z,:W=5TBWU:&-96>*:%M\%Q$<21-ZJ?YCH:3
M3])2R2<S327D]PP:::8+E\# &    .P% #[+2[>QN)[A6EEN)S\\LS;FP.BC
MT4>@J[110!@:])KDJSKI:^0EJGG>8P#&Y8<B-1V'&"3ZX'>H;Z\B TOQ1;,/
MLY18[D_],),8)_W6P?INKI:HZ;I<.FV+V:L9(#([JC@$(K,6VCV&>] "VFEP
M6EW/=!I);B8X:65MQ"YR$7T4>@_'-7:** .8\4Z[<:7,L,5U%9)]G>83S0F0
M2,O2,<@ ]S^&*J7&MP32VFL(DT-U9*HOH987C)MY.&8!@,JK '/^R?6NHU&Q
M34M-N+*1F1)XRA9>HSW%5K#2#;RS7%[<M?74R")Y7C51L&?E"C@#))/KGZ4
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M7<KDXR4&!^1H Z"BN5UG6[_3/%,>) =*AMHY+N/:/E#NZ^9G&?E(7(],TO\
M;=Y_8>H2),'O&U"6RLSM'!,FU/8X'//8<T =317(_P!J:M+I<*++.9;6\:UU
M*6UB6295&=KJA!!!RA.%)P3@5,;VYO;G0[>SUJ4P744[O<PQ1AI-FW&0RD*1
MD@C YSP.@ .HHKE)-:U"UL=3L'F2;4K>XCM+:<(!YC2JI1BO3(W$GH/EIPUV
M\3P^T9EC;54O5TYI'4;1(9 H<@8XVD-CCTH ZFBN?>34-)UG3()=0FOK>]9X
MF6:.,,C!"X9=BKQ\I!!S3?$.H7%KJ^EVR7EY;03I,9#:6PF<E0FWC8YQR>U
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
K!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>29
<FILENAME>pcvx-20211231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2022-02-28T14:48:59.9929+00:00 -->
<!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.vaxcyte.com/20211231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:pcvx="http://www.vaxcyte.com/20211231" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" namespace="http://fasb.org/srt/2021-01-31"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" namespace="http://fasb.org/us-gaap/2021-01-31"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" namespace="http://xbrl.sec.gov/dei/2021q4"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd" namespace="http://xbrl.sec.gov/stpr/2021"/>
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" namespace="http://www.xbrl.org/dtr/type/2020-01-21"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pcvx-20211231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Labels link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pcvx-20211231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pcvx-20211231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pcvx-20211231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:title="Calculation link" xlink:type="simple"/>
      <link:roleType roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementBalanceSheets" id="Role_StatementBalanceSheets">
        <link:definition>100010 - Statement - Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementBalanceSheetsParenthetical" id="Role_StatementBalanceSheetsParenthetical">
        <link:definition>100020 - Statement - Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfOperations" id="Role_StatementStatementsOfOperations">
        <link:definition>100030 - Statement - Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfOperationsParenthetical" id="Role_StatementStatementsOfOperationsParenthetical">
        <link:definition>100040 - Statement - Statements of Operations (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfComprehensiveLoss" id="Role_StatementStatementsOfComprehensiveLoss">
        <link:definition>100050 - Statement - Statements of Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" id="Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit">
        <link:definition>100060 - Statement - Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" id="Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical">
        <link:definition>100070 - Statement - Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited" id="Role_StatementStatementsOfCashFlowsUnaudited">
        <link:definition>100080 - Statement - Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCompanyOrganizationAndNatureOfBusiness" id="Role_DisclosureCompanyOrganizationAndNatureOfBusiness">
        <link:definition>100090 - Disclosure - Company Organization and Nature of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies" id="Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies">
        <link:definition>100100 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstruments" id="Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstruments">
        <link:definition>100110 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetails" id="Role_DisclosureBalanceSheetDetails">
        <link:definition>100120 - Disclosure - Balance Sheet Details</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureLeases" id="Role_DisclosureLeases">
        <link:definition>100130 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" id="Role_DisclosureCommitmentsAndContingencies">
        <link:definition>100140 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStock" id="Role_DisclosureRedeemableConvertiblePreferredStock">
        <link:definition>100150 - Disclosure - Redeemable Convertible Preferred Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCommonStock" id="Role_DisclosureCommonStock">
        <link:definition>100160 - Disclosure - Common Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureWarrants" id="Role_DisclosureWarrants">
        <link:definition>100170 - Disclosure - Warrants</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlans" id="Role_DisclosureEquityIncentivePlans">
        <link:definition>100180 - Disclosure - Equity Incentive Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFundingArrangement" id="Role_DisclosureFundingArrangement">
        <link:definition>100190 - Disclosure - Funding Arrangement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShare" id="Role_DisclosureNetLossPerShare">
        <link:definition>100200 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxes" id="Role_DisclosureIncomeTaxes">
        <link:definition>100210 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactions" id="Role_DisclosureRelatedPartyTransactions">
        <link:definition>100220 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureSubsequentEvents" id="Role_DisclosureSubsequentEvents">
        <link:definition>100230 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" id="Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>100240 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" id="DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>100250 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsTables" id="Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsTables">
        <link:definition>100260 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsTables" id="Role_DisclosureBalanceSheetDetailsTables">
        <link:definition>100270 - Disclosure - Balance Sheet Details (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureLeasesTables" id="Role_DisclosureLeasesTables">
        <link:definition>100280 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCommonStockTables" id="Role_DisclosureCommonStockTables">
        <link:definition>100290 - Disclosure - Common Stock (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansTables" id="Role_DisclosureEquityIncentivePlansTables">
        <link:definition>100300 - Disclosure - Equity Incentive Plans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareTables" id="Role_DisclosureNetLossPerShareTables">
        <link:definition>100310 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesTables" id="Role_DisclosureIncomeTaxesTables">
        <link:definition>100320 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCompanyOrganizationAndNatureOfBusinessAdditionalInformationDetails" id="Role_DisclosureCompanyOrganizationAndNatureOfBusinessAdditionalInformationDetails">
        <link:definition>100330 - Disclosure - Company Organization and Nature of Business - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" id="DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>100340 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfCashCashEquivalentsAndRestrictedCashDetails" id="DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfCashCashEquivalentsAndRestrictedCashDetails">
        <link:definition>100350 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Cash, Cash Equivalents And Restricted Cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsAdditionalInformationDetails" id="Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsAdditionalInformationDetails">
        <link:definition>100360 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails" id="Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails">
        <link:definition>100370 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments - Schedule of Financial Instruments Measured at Fair Value on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfContractualMaturitiesOfInvestmentsDetails" id="Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfContractualMaturitiesOfInvestmentsDetails">
        <link:definition>100380 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments - Schedule of Contractual Maturities of Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentNetDetails" id="Role_DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentNetDetails">
        <link:definition>100390 - Disclosure - Balance Sheet Details - Schedule of Property and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsAdditionalInformationDetails" id="Role_DisclosureBalanceSheetDetailsAdditionalInformationDetails">
        <link:definition>100400 - Disclosure - Balance Sheet Details - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails" id="Role_DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails">
        <link:definition>100410 - Disclosure - Balance Sheet Details - Schedule of Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" id="Role_DisclosureLeasesAdditionalInformationDetails">
        <link:definition>100420 - Disclosure - Leases - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureLeasesScheduleOfInformationRelatedToROUAssetsAndLeaseLiabilitiesDetails" id="Role_DisclosureLeasesScheduleOfInformationRelatedToROUAssetsAndLeaseLiabilitiesDetails">
        <link:definition>100430 - Disclosure - Leases - Schedule of Information Related to ROU Assets and Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails" id="Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails">
        <link:definition>100440 - Disclosure - Leases - Schedule of Maturities of Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails2" id="Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails2">
        <link:definition>100450 - Disclosure - Leases - Schedule of Maturities of Lease Liabilities (Details) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesParentheticalDetails" id="Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesParentheticalDetails">
        <link:definition>100460 - Disclosure - Leases - Schedule of Maturities of Lease Liabilities (Parenthetical) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" id="Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
        <link:definition>100470 - Disclosure - Commitments and Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails" id="Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails">
        <link:definition>100480 - Disclosure - Redeemable Convertible Preferred Stock - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails" id="Role_DisclosureCommonStockAdditionalInformationDetails">
        <link:definition>100490 - Disclosure - Common Stock - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCommonStockScheduleOfCommonStockSharesReservedForFutureIssuanceDetails" id="Role_DisclosureCommonStockScheduleOfCommonStockSharesReservedForFutureIssuanceDetails">
        <link:definition>100500 - Disclosure - Common Stock - Schedule of Common Stock Shares Reserved for Future Issuance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureWarrantsAdditionalInformationDetails" id="Role_DisclosureWarrantsAdditionalInformationDetails">
        <link:definition>100510 - Disclosure - Warrants - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails" id="Role_DisclosureEquityIncentivePlansAdditionalInformationDetails">
        <link:definition>100520 - Disclosure - Equity Incentive Plans - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfActivityUnderStockOptionPlansDetails" id="Role_DisclosureEquityIncentivePlansSummaryOfActivityUnderStockOptionPlansDetails">
        <link:definition>100530 - Disclosure - Equity Incentive Plans - Summary of Activity Under Stock Option Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfEstimatedFairValueOfEmployeeStockOptionsDetails" id="Role_DisclosureEquityIncentivePlansSummaryOfEstimatedFairValueOfEmployeeStockOptionsDetails">
        <link:definition>100540 - Disclosure - Equity Incentive Plans - Summary of Estimated Fair Value of Employee Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfEstimatedFairValueOfSharesUnderEmployeeStockPurchasePlanDetails" id="Role_DisclosureEquityIncentivePlansSummaryOfEstimatedFairValueOfSharesUnderEmployeeStockPurchasePlanDetails">
        <link:definition>100550 - Disclosure - Equity Incentive Plans - Summary of Estimated Fair Value of Shares Under Employee Stock Purchase Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfStockBasedCompensationExpenseDetails" id="Role_DisclosureEquityIncentivePlansSummaryOfStockBasedCompensationExpenseDetails">
        <link:definition>100560 - Disclosure - Equity Incentive Plans - Summary of Stock-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFundingArrangementAdditionalInformationDetails" id="Role_DisclosureFundingArrangementAdditionalInformationDetails">
        <link:definition>100570 - Disclosure - Funding Arrangement - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetails" id="Role_DisclosureNetLossPerShareScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetails">
        <link:definition>100580 - Disclosure - Net Loss Per Share - Schedule of Computation of Basic and Diluted Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails" id="Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails">
        <link:definition>100590 - Disclosure - Net Loss Per Share - Schedule of Potentially Dilutive Securities Excluded From Computation of Diluted Net Loss Per Share Attributable to Common Stockholders (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfEffectiveTaxRateDetails" id="Role_DisclosureIncomeTaxesReconciliationOfEffectiveTaxRateDetails">
        <link:definition>100600 - Disclosure - Income Taxes - Reconciliation of Effective Tax Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails" id="Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails">
        <link:definition>100610 - Disclosure - Income Taxes - Components of Deferred Tax Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" id="Role_DisclosureIncomeTaxesAdditionalInformationDetails">
        <link:definition>100620 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitDetails" id="Role_DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitDetails">
        <link:definition>100630 - Disclosure - Income Taxes - Reconciliation of Unrecognized Tax Benefit (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" id="Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails">
        <link:definition>100640 - Disclosure - Related Party Transactions - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" id="DisclosureSubsequentEventsAdditionalInformationDetails">
        <link:definition>100650 - Disclosure - Subsequent Events - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="pcvx_FundingArrangementAbstract" name="FundingArrangementAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pcvx_AccruedManufacturingExpenses" name="AccruedManufacturingExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pcvx_AccruedPreclinicalStudiesCurrent" name="AccruedPreclinicalStudiesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pcvx_AdditionalFundingCommittedByAward" name="AdditionalFundingCommittedByAward" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pcvx_AdjustmentsToAdditionalPaidInCapitalVestingOfEarlyExercisedStockOptions" name="AdjustmentsToAdditionalPaidInCapitalVestingOfEarlyExercisedStockOptions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pcvx_AdjustmentsToAdditionalPaidInCapitalWarrantLiabilityWriteOff" name="AdjustmentsToAdditionalPaidInCapitalWarrantLiabilityWriteOff" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pcvx_CapitalLeasesAmortizationExpense" name="CapitalLeasesAmortizationExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pcvx_CashAndCashEquivalentsAmortizedCost" name="CashAndCashEquivalentsAmortizedCost" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pcvx_CashAndCashEquivalentsAndInvestments" name="CashAndCashEquivalentsAndInvestments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pcvx_CashAndCashEquivalentsAndInvestmentsAmortizedCostBasis" name="CashAndCashEquivalentsAndInvestmentsAmortizedCostBasis" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pcvx_CashAndCashEquivalentsAndInvestmentsGrossUnrealizedGainBeforeTax" name="CashAndCashEquivalentsAndInvestmentsGrossUnrealizedGainBeforeTax" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pcvx_CashAndCashEquivalentsAndInvestmentsGrossUnrealizedLossBeforeTax" name="CashAndCashEquivalentsAndInvestmentsGrossUnrealizedLossBeforeTax" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pcvx_CashAndCashEquivalentsGrossUnrealizedGainBeforeTax" name="CashAndCashEquivalentsGrossUnrealizedGainBeforeTax" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pcvx_CashAndCashEquivalentsGrossUnrealizedLossBeforeTax" name="CashAndCashEquivalentsGrossUnrealizedLossBeforeTax" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pcvx_ChangeInFairValueOfRedeemableConvertiblePreferredStock" name="ChangeInFairValueOfRedeemableConvertiblePreferredStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pcvx_ChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheLiabilities" name="ChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pcvx_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRightExercised" name="ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRightExercised" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="pcvx_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses" name="DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pcvx_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance" name="DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pcvx_DeferredTaxAssetsTaxAccruedManufacturingExpenses" name="DeferredTaxAssetsTaxAccruedManufacturingExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pcvx_DevelopmentAndManufacturingServicesAgreementEquityPaymentsPercentage" name="DevelopmentAndManufacturingServicesAgreementEquityPaymentsPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pcvx_DevelopmentAndManufacturingServicesAgreementPaymentsInEquity" name="DevelopmentAndManufacturingServicesAgreementPaymentsInEquity" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pcvx_EarlyExercisedStockOptions" name="EarlyExercisedStockOptions" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="pcvx_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfTrancheLiability" name="EffectiveIncomeTaxRateReconciliationChangeInFairValueOfTrancheLiability" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pcvx_ExercisePriceExpireInYearsFormTheDateOfGrant" name="ExercisePriceExpireInYearsFormTheDateOfGrant" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pcvx_ExpenseOnIssuanceOfRedeemableConvertiblePreferredStockWarrant" name="ExpenseOnIssuanceOfRedeemableConvertiblePreferredStockWarrant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pcvx_FundingCommittedByAwardAvailableUponAchievementOfDevelopmentMilestones" name="FundingCommittedByAwardAvailableUponAchievementOfDevelopmentMilestones" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pcvx_FundingPeriodOfAwardToDevelopUniversalVaccineToPreventInfections" name="FundingPeriodOfAwardToDevelopUniversalVaccineToPreventInfections" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pcvx_GlobalTargetRevenue" name="GlobalTargetRevenue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pcvx_GrantIncome" name="GrantIncome" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pcvx_GrossProceedsFromIssuanceOfCommonStock" name="GrossProceedsFromIssuanceOfCommonStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pcvx_IncentiveStockOptionGrantedToEmployeesOwningPercentageOfSharesOfCommonStock" name="IncentiveStockOptionGrantedToEmployeesOwningPercentageOfSharesOfCommonStock" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pcvx_IncreaseDecreaseInAccruedCompensation" name="IncreaseDecreaseInAccruedCompensation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pcvx_IncreaseDecreaseInAccruedLegalSettlement" name="IncreaseDecreaseInAccruedLegalSettlement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pcvx_IncreaseDecreaseInAccruedManufacturingExpenses" name="IncreaseDecreaseInAccruedManufacturingExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pcvx_IncreaseDecreaseInDeferredRentAndOtherLongTermLiabilities" name="IncreaseDecreaseInDeferredRentAndOtherLongTermLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pcvx_IncreaseDecreaseInOperatingLeaseLiabilities" name="IncreaseDecreaseInOperatingLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pcvx_InitialFundingCommittedByAward" name="InitialFundingCommittedByAward" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pcvx_InitialPublicOfferingRelatedCost" name="InitialPublicOfferingRelatedCost" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pcvx_LeaseLiability" name="LeaseLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pcvx_LeasePaymentReceivableNoncurrent" name="LeasePaymentReceivableNoncurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pcvx_LeaseTerminationDate" name="LeaseTerminationDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pcvx_LesseeOperatingLeaseCommencementDate" name="LesseeOperatingLeaseCommencementDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pcvx_LesseeOperatingLeaseExtendedLeaseTerm" name="LesseeOperatingLeaseExtendedLeaseTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pcvx_LesseeOperatingLeaseExtendedMaturityDate" name="LesseeOperatingLeaseExtendedMaturityDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pcvx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" name="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pcvx_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonthsNetOfLeaseIncentives" name="LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonthsNetOfLeaseIncentives" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pcvx_LesseeOperatingLeaseRenewalOption" name="LesseeOperatingLeaseRenewalOption" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pcvx_LesseeOperatingLeaseRentCommencementDate" name="LesseeOperatingLeaseRentCommencementDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pcvx_MaximumCommissionPercentageOfGrossProceedsFromCommonStockSold" name="MaximumCommissionPercentageOfGrossProceedsFromCommonStockSold" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="pcvx_NumberOfFinanceLease" name="NumberOfFinanceLease" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pcvx_NumberOfOperatingLease" name="NumberOfOperatingLease" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pcvx_NumberOfOptionsExercisedExcludesOptionsExercisedFromNpln" name="NumberOfOptionsExercisedExcludesOptionsExercisedFromNpln" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pcvx_NumberOfRenewalOptions" name="NumberOfRenewalOptions" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pcvx_NumberOfSecurities" name="NumberOfSecurities" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="pcvx_OfferingPeriod" name="OfferingPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pcvx_OperatingLossCarryForwardsExpirationYear" name="OperatingLossCarryForwardsExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pcvx_PaymentOfDeferredOfferingCosts" name="PaymentOfDeferredOfferingCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pcvx_PaymentsOfCapitalLeaseObligations" name="PaymentsOfCapitalLeaseObligations" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pcvx_PaymentsOfUnderwritingDiscountsAndCommissions" name="PaymentsOfUnderwritingDiscountsAndCommissions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pcvx_PercentageOfFairValuePerShareOnTheGrantDate" name="PercentageOfFairValuePerShareOnTheGrantDate" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pcvx_PercentageOfPaymentsCompletionAgreedToDefer" name="PercentageOfPaymentsCompletionAgreedToDefer" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pcvx_PercentageOfProvisionsSubjectToStockholders" name="PercentageOfProvisionsSubjectToStockholders" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pcvx_PercentageOfRoyaltyPaymentOnAnnualNetSalesOfVaccineProductsForHumanHealth" name="PercentageOfRoyaltyPaymentOnAnnualNetSalesOfVaccineProductsForHumanHealth" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="pcvx_PercentageOfRoyaltyPaymentOnNetSalesOfVaccineCompositionsForAnimalHealth" name="PercentageOfRoyaltyPaymentOnNetSalesOfVaccineCompositionsForAnimalHealth" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="pcvx_PotentialFundingAmountOfAwardToDevelopVaccineToPreventInfections" name="PotentialFundingAmountOfAwardToDevelopVaccineToPreventInfections" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pcvx_PotentialFundingCommittedByAward" name="PotentialFundingCommittedByAward" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pcvx_PotentialFundingPeriodOfAwardToDevelopVaccineToPreventInfections" name="PotentialFundingPeriodOfAwardToDevelopVaccineToPreventInfections" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pcvx_PrefundedWarrantsPricePerShare" name="PrefundedWarrantsPricePerShare" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="pcvx_ProceedsFromInitialPublicOfferingNetOfUnderwritersCommissionsAndDiscounts" name="ProceedsFromInitialPublicOfferingNetOfUnderwritersCommissionsAndDiscounts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pcvx_ProceedsFromIssuanceFollowOnOffering" name="ProceedsFromIssuanceFollowOnOffering" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pcvx_ProceedsFromIssuanceOfCommonStockNotYetReceived" name="ProceedsFromIssuanceOfCommonStockNotYetReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pcvx_ProceedsFromIssuanceOfCommonStockRelatedToEarlyExercisedStockOptions" name="ProceedsFromIssuanceOfCommonStockRelatedToEarlyExercisedStockOptions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pcvx_PurchasePeriod" name="PurchasePeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pcvx_RemainingLiabilitiesRelatedToEarlyExercisedShares" name="RemainingLiabilitiesRelatedToEarlyExercisedShares" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pcvx_ResearchAndDevelopmentExpenseToRelatedParty" name="ResearchAndDevelopmentExpenseToRelatedParty" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pcvx_SaleOfCommonStockAuthorizedAmount" name="SaleOfCommonStockAuthorizedAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pcvx_Section162MLimitation" name="Section162MLimitation" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExercisedInPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExercisedInPeriod" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeitedInPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeitedInPeriod" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantedInPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantedInPeriod" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreaseInAvailableForGrant" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreaseInAvailableForGrant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pcvx_SharesIssuedPricePerShareUponFollowOnOffering" name="SharesIssuedPricePerShareUponFollowOnOffering" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="pcvx_SharesIssuedUponFollowOnOfferingFullExerciseOfUnderwritersOptionToPurchaseAdditionalShares" name="SharesIssuedUponFollowOnOfferingFullExerciseOfUnderwritersOptionToPurchaseAdditionalShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pcvx_SharesIssuedUponFullExerciseOfUnderwritersOptionToPurchaseAdditionalShares" name="SharesIssuedUponFullExerciseOfUnderwritersOptionToPurchaseAdditionalShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pcvx_SharesPreFundedWarrantsToPurchase" name="SharesPreFundedWarrantsToPurchase" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pcvx_StockIssuedDuringPeriodSharesConversionOfCommonStockWarrant" name="StockIssuedDuringPeriodSharesConversionOfCommonStockWarrant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pcvx_StockIssuedDuringPeriodSharesConversionOfPreferredStockWarrant" name="StockIssuedDuringPeriodSharesConversionOfPreferredStockWarrant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pcvx_StockIssuedDuringPeriodSharesIssuanceOfCommonStockRelatedToEarlyExercisedStockOptions" name="StockIssuedDuringPeriodSharesIssuanceOfCommonStockRelatedToEarlyExercisedStockOptions" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pcvx_StockIssuedDuringPeriodSharesOfFollowOnOffering" name="StockIssuedDuringPeriodSharesOfFollowOnOffering" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pcvx_StockOptionsGrantedTerm" name="StockOptionsGrantedTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pcvx_TaxCreditCarryforwardExpirationYear" name="TaxCreditCarryforwardExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pcvx_TemporaryEquityConversionOfPreferredStockShares" name="TemporaryEquityConversionOfPreferredStockShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pcvx_TemporaryEquityConversionOfPreferredStockValue" name="TemporaryEquityConversionOfPreferredStockValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pcvx_TemporaryEquityStockIssuanceCosts" name="TemporaryEquityStockIssuanceCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pcvx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" name="TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pcvx_ThresholdLimitOnEquityPayments" name="ThresholdLimitOnEquityPayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pcvx_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions" name="UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pcvx_FundingArrangementLineItems" name="FundingArrangementLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pcvx_IncomeTaxDisclosureLineItems" name="IncomeTaxDisclosureLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" name="ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pcvx_AdditionalFacilityMember" name="AdditionalFacilityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pcvx_ATMSalesAgreementMember" name="ATMSalesAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pcvx_CapitalLeasesLabEquipmentMember" name="CapitalLeasesLabEquipmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pcvx_CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorAgreementMember" name="CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pcvx_CommonStockWarrantMember" name="CommonStockWarrantMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pcvx_ComputersAndComputerSoftwareMember" name="ComputersAndComputerSoftwareMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pcvx_CostReimbursementSubAwardAgreementMember" name="CostReimbursementSubAwardAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pcvx_HeadquartersFacilityMember" name="HeadquartersFacilityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pcvx_JefferiesLimitedLiabilityCompanyMember" name="JefferiesLimitedLiabilityCompanyMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pcvx_LabEquipmentMember" name="LabEquipmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pcvx_LicenseAgreementMember" name="LicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pcvx_LicenseAmendmentATwoMember" name="LicenseAmendmentATwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pcvx_LonzaLimitedMember" name="LonzaLimitedMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pcvx_MarketOfferingMember" name="MarketOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pcvx_NewCorporateHeadquartersFacilityMember" name="NewCorporateHeadquartersFacilityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pcvx_PaloAltoMember" name="PaloAltoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pcvx_PneumococcalConjugateVaccineMember" name="PneumococcalConjugateVaccineMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pcvx_PreferredStockWarrantMember" name="PreferredStockWarrantMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pcvx_RedeemableConvertiblePreferredStockWarrantMember" name="RedeemableConvertiblePreferredStockWarrantMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pcvx_SanCarlosMember" name="SanCarlosMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pcvx_SeriesARedeemableConvertiblePreferredStockMember" name="SeriesARedeemableConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pcvx_SeriesBRedeemableConvertiblePreferredStockMember" name="SeriesBRedeemableConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pcvx_SeriesCRedeemableConvertiblePreferredStockMember" name="SeriesCRedeemableConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pcvx_SeriesDRedeemableConvertiblePreferredStockMember" name="SeriesDRedeemableConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pcvx_SharesAvailableForFutureStockOptionGrantsMember" name="SharesAvailableForFutureStockOptionGrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pcvx_SupplyAgreementMember" name="SupplyAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pcvx_SutroBiopharmaIncMember" name="SutroBiopharmaIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pcvx_TwoThousandFourteenEquityIncentivePlanAndTwoThousandTwentyEquityIncentivePlanAndTwoThousandTwentyEmployeeStockPurchasePlanMember" name="TwoThousandFourteenEquityIncentivePlanAndTwoThousandTwentyEquityIncentivePlanAndTwoThousandTwentyEmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pcvx_TwoThousandFourteenEquityIncentivePlanMember" name="TwoThousandFourteenEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pcvx_TwoThousandTwentyEmployeeStockPurchasePlanMember" name="TwoThousandTwentyEmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pcvx_TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember" name="TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pcvx_TwoThousandTwentyEquityIncentivePlanMember" name="TwoThousandTwentyEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pcvx_FundingArrangementTable" name="FundingArrangementTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pcvx_IncomeTaxDisclosureTable" name="IncomeTaxDisclosureTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsTable" name="ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pcvx_AccruedResearchAndDevelopmentPolicyTextBlock" name="AccruedResearchAndDevelopmentPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pcvx_FundingArrangementTextBlock" name="FundingArrangementTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pcvx_RedeemableConvertiblePreferredStockTextBlock" name="RedeemableConvertiblePreferredStockTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pcvx_ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock" name="ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pcvx_ScheduleOfInformationRelatedToRightOfUseAssetsAndLeaseLiabilitiesTableTextBlock" name="ScheduleOfInformationRelatedToRightOfUseAssetsAndLeaseLiabilitiesTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pcvx_WarrantsDisclosureTextBlock" name="WarrantsDisclosureTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>30
<FILENAME>pcvx-20211231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2022-02-28T14:49:03.4194+00:00 -->
<!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:href="pcvx-20211231.xsd#Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:href="pcvx-20211231.xsd#Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansTables" xlink:href="pcvx-20211231.xsd#Role_DisclosureEquityIncentivePlansTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCompanyOrganizationAndNatureOfBusinessAdditionalInformationDetails" xlink:href="pcvx-20211231.xsd#Role_DisclosureCompanyOrganizationAndNatureOfBusinessAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="pcvx-20211231.xsd#DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsAdditionalInformationDetails" xlink:href="pcvx-20211231.xsd#Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="pcvx-20211231.xsd#Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentNetDetails" xlink:href="pcvx-20211231.xsd#Role_DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentNetDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" xlink:href="pcvx-20211231.xsd#Role_DisclosureLeasesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesParentheticalDetails" xlink:href="pcvx-20211231.xsd#Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesParentheticalDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="pcvx-20211231.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails" xlink:href="pcvx-20211231.xsd#Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails" xlink:href="pcvx-20211231.xsd#Role_DisclosureCommonStockAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCommonStockScheduleOfCommonStockSharesReservedForFutureIssuanceDetails" xlink:href="pcvx-20211231.xsd#Role_DisclosureCommonStockScheduleOfCommonStockSharesReservedForFutureIssuanceDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails" xlink:href="pcvx-20211231.xsd#Role_DisclosureEquityIncentivePlansAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfActivityUnderStockOptionPlansDetails" xlink:href="pcvx-20211231.xsd#Role_DisclosureEquityIncentivePlansSummaryOfActivityUnderStockOptionPlansDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfEstimatedFairValueOfEmployeeStockOptionsDetails" xlink:href="pcvx-20211231.xsd#Role_DisclosureEquityIncentivePlansSummaryOfEstimatedFairValueOfEmployeeStockOptionsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfEstimatedFairValueOfSharesUnderEmployeeStockPurchasePlanDetails" xlink:href="pcvx-20211231.xsd#Role_DisclosureEquityIncentivePlansSummaryOfEstimatedFairValueOfSharesUnderEmployeeStockPurchasePlanDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfStockBasedCompensationExpenseDetails" xlink:href="pcvx-20211231.xsd#Role_DisclosureEquityIncentivePlansSummaryOfStockBasedCompensationExpenseDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFundingArrangementAdditionalInformationDetails" xlink:href="pcvx-20211231.xsd#Role_DisclosureFundingArrangementAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:href="pcvx-20211231.xsd#Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="pcvx-20211231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:href="pcvx-20211231.xsd#Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" xlink:href="pcvx-20211231.xsd#DisclosureSubsequentEventsAdditionalInformationDetails" xlink:type="simple"/>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_SeriesARedeemableConvertiblePreferredStockMember" xlink:label="pcvx_SeriesARedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_MarketOfferingMember" xlink:label="pcvx_MarketOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_SeriesBRedeemableConvertiblePreferredStockMember" xlink:label="pcvx_SeriesBRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_SeriesCRedeemableConvertiblePreferredStockMember" xlink:label="pcvx_SeriesCRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_SeriesDRedeemableConvertiblePreferredStockMember" xlink:label="pcvx_SeriesDRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_TemporaryEquityConversionOfPreferredStockValue" xlink:label="pcvx_TemporaryEquityConversionOfPreferredStockValue"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_TemporaryEquityConversionOfPreferredStockShares" xlink:label="pcvx_TemporaryEquityConversionOfPreferredStockShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_StockIssuedDuringPeriodSharesConversionOfCommonStockWarrant" xlink:label="pcvx_StockIssuedDuringPeriodSharesConversionOfCommonStockWarrant"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_StockIssuedDuringPeriodSharesConversionOfPreferredStockWarrant" xlink:label="pcvx_StockIssuedDuringPeriodSharesConversionOfPreferredStockWarrant"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_AdjustmentsToAdditionalPaidInCapitalWarrantLiabilityWriteOff" xlink:label="pcvx_AdjustmentsToAdditionalPaidInCapitalWarrantLiabilityWriteOff"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="pcvx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_StockIssuedDuringPeriodSharesIssuanceOfCommonStockRelatedToEarlyExercisedStockOptions" xlink:label="pcvx_StockIssuedDuringPeriodSharesIssuanceOfCommonStockRelatedToEarlyExercisedStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_AdjustmentsToAdditionalPaidInCapitalVestingOfEarlyExercisedStockOptions" xlink:label="pcvx_AdjustmentsToAdditionalPaidInCapitalVestingOfEarlyExercisedStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pcvx_SeriesARedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pcvx_MarketOfferingMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pcvx_SeriesBRedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pcvx_SeriesCRedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pcvx_SeriesDRedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pcvx_TemporaryEquityConversionOfPreferredStockValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pcvx_TemporaryEquityConversionOfPreferredStockShares" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pcvx_StockIssuedDuringPeriodSharesConversionOfCommonStockWarrant" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pcvx_StockIssuedDuringPeriodSharesConversionOfPreferredStockWarrant" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pcvx_AdjustmentsToAdditionalPaidInCapitalWarrantLiabilityWriteOff" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pcvx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pcvx_StockIssuedDuringPeriodSharesIssuanceOfCommonStockRelatedToEarlyExercisedStockOptions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pcvx_AdjustmentsToAdditionalPaidInCapitalVestingOfEarlyExercisedStockOptions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_SeriesCRedeemableConvertiblePreferredStockMember" xlink:label="pcvx_SeriesCRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_TemporaryEquityStockIssuanceCosts" xlink:label="pcvx_TemporaryEquityStockIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_MarketOfferingMember" xlink:label="pcvx_MarketOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_SeriesDRedeemableConvertiblePreferredStockMember" xlink:label="pcvx_SeriesDRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pcvx_SeriesCRedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pcvx_TemporaryEquityStockIssuanceCosts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pcvx_MarketOfferingMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pcvx_SeriesDRedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember" xlink:label="pcvx_TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_TwoThousandTwentyEmployeeStockPurchasePlanMember" xlink:label="pcvx_TwoThousandTwentyEmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_TwoThousandFourteenEquityIncentivePlanAndTwoThousandTwentyEquityIncentivePlanAndTwoThousandTwentyEmployeeStockPurchasePlanMember" xlink:label="pcvx_TwoThousandFourteenEquityIncentivePlanAndTwoThousandTwentyEquityIncentivePlanAndTwoThousandTwentyEmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="pcvx_TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="pcvx_TwoThousandTwentyEmployeeStockPurchasePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="pcvx_TwoThousandFourteenEquityIncentivePlanAndTwoThousandTwentyEquityIncentivePlanAndTwoThousandTwentyEmployeeStockPurchasePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCompanyOrganizationAndNatureOfBusinessAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:label="pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:label="pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsTable"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_GlobalTargetRevenue" xlink:label="pcvx_GlobalTargetRevenue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_PneumococcalConjugateVaccineMember" xlink:label="pcvx_PneumococcalConjugateVaccineMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_SharesIssuedUponFullExerciseOfUnderwritersOptionToPurchaseAdditionalShares" xlink:label="pcvx_SharesIssuedUponFullExerciseOfUnderwritersOptionToPurchaseAdditionalShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_PaymentsOfUnderwritingDiscountsAndCommissions" xlink:label="pcvx_PaymentsOfUnderwritingDiscountsAndCommissions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="pcvx_GlobalTargetRevenue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="pcvx_PneumococcalConjugateVaccineMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="pcvx_SharesIssuedUponFullExerciseOfUnderwritersOptionToPurchaseAdditionalShares" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="pcvx_PaymentsOfUnderwritingDiscountsAndCommissions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vaxcyte.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201912Member" xlink:label="us-gaap_AccountingStandardsUpdate201912Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember" xlink:label="us-gaap_OtherNoncurrentAssetsMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_InitialPublicOfferingRelatedCost" xlink:label="pcvx_InitialPublicOfferingRelatedCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_NumberOfFinanceLease" xlink:label="pcvx_NumberOfFinanceLease"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_NumberOfReportableSegments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_BalanceSheetLocationAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201912Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherNoncurrentAssetsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="pcvx_InitialPublicOfferingRelatedCost" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_DeferredOfferingCosts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="pcvx_NumberOfFinanceLease" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_AssetImpairmentCharges" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_OperatingLeaseLiability" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_NumberOfSecurities" xlink:label="pcvx_NumberOfSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:label="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" xlink:label="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" xlink:label="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="pcvx_NumberOfSecurities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_CashAndCashEquivalentsAmortizedCost" xlink:label="pcvx_CashAndCashEquivalentsAmortizedCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashMember" xlink:label="us-gaap_CashMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_CashAndCashEquivalentsGrossUnrealizedGainBeforeTax" xlink:label="pcvx_CashAndCashEquivalentsGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_CashAndCashEquivalentsGrossUnrealizedLossBeforeTax" xlink:label="pcvx_CashAndCashEquivalentsGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:label="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="us-gaap_AssetBackedSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_CashAndCashEquivalentsAndInvestmentsAmortizedCostBasis" xlink:label="pcvx_CashAndCashEquivalentsAndInvestmentsAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_CashAndCashEquivalentsAndInvestmentsGrossUnrealizedGainBeforeTax" xlink:label="pcvx_CashAndCashEquivalentsAndInvestmentsGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_CashAndCashEquivalentsAndInvestmentsGrossUnrealizedLossBeforeTax" xlink:label="pcvx_CashAndCashEquivalentsAndInvestmentsGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_CashAndCashEquivalentsAndInvestments" xlink:label="pcvx_CashAndCashEquivalentsAndInvestments"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="pcvx_CashAndCashEquivalentsAmortizedCost" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CashMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="pcvx_CashAndCashEquivalentsGrossUnrealizedGainBeforeTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueByAssetClassAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="pcvx_CashAndCashEquivalentsGrossUnrealizedLossBeforeTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CommercialPaperMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_AssetBackedSecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="pcvx_CashAndCashEquivalentsAndInvestmentsAmortizedCostBasis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="pcvx_CashAndCashEquivalentsAndInvestmentsGrossUnrealizedGainBeforeTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="pcvx_CashAndCashEquivalentsAndInvestmentsGrossUnrealizedLossBeforeTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="pcvx_CashAndCashEquivalentsAndInvestments" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentNetDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_ComputersAndComputerSoftwareMember" xlink:label="pcvx_ComputersAndComputerSoftwareMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_LabEquipmentMember" xlink:label="pcvx_LabEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_CapitalLeasesLabEquipmentMember" xlink:label="pcvx_CapitalLeasesLabEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="pcvx_ComputersAndComputerSoftwareMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="pcvx_LabEquipmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="pcvx_CapitalLeasesLabEquipmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_HeadquartersFacilityMember" xlink:label="pcvx_HeadquartersFacilityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_LesseeOperatingLeaseCommencementDate" xlink:label="pcvx_LesseeOperatingLeaseCommencementDate"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_AdditionalFacilityMember" xlink:label="pcvx_AdditionalFacilityMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_LeaseTerminationDate" xlink:label="pcvx_LeaseTerminationDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BuildingMember" xlink:label="us-gaap_BuildingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_NewCorporateHeadquartersFacilityMember" xlink:label="pcvx_NewCorporateHeadquartersFacilityMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_LesseeOperatingLeaseRenewalOption" xlink:label="pcvx_LesseeOperatingLeaseRenewalOption"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_PaloAltoMember" xlink:label="pcvx_PaloAltoMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_SanCarlosMember" xlink:label="pcvx_SanCarlosMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="us-gaap_LesseeOperatingLeaseDescription"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_LesseeOperatingLeaseExtendedLeaseTerm" xlink:label="pcvx_LesseeOperatingLeaseExtendedLeaseTerm"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_LesseeOperatingLeaseExtendedMaturityDate" xlink:label="pcvx_LesseeOperatingLeaseExtendedMaturityDate"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_LesseeOperatingLeaseRentCommencementDate" xlink:label="pcvx_LesseeOperatingLeaseRentCommencementDate"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_NumberOfRenewalOptions" xlink:label="pcvx_NumberOfRenewalOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_NumberOfOperatingLease" xlink:label="pcvx_NumberOfOperatingLease"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="pcvx_HeadquartersFacilityMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="pcvx_LesseeOperatingLeaseCommencementDate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="pcvx_AdditionalFacilityMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="pcvx_LeaseTerminationDate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_BuildingMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LeaseExpirationDate1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="pcvx_NewCorporateHeadquartersFacilityMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="pcvx_LesseeOperatingLeaseRenewalOption" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="pcvx_PaloAltoMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="pcvx_SanCarlosMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDescription" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="pcvx_LesseeOperatingLeaseExtendedLeaseTerm" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="pcvx_LesseeOperatingLeaseExtendedMaturityDate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="pcvx_LesseeOperatingLeaseRentCommencementDate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="pcvx_NumberOfRenewalOptions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="pcvx_NumberOfOperatingLease" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseExpense" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesParentheticalDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_LeasePaymentReceivableNoncurrent" xlink:label="pcvx_LeasePaymentReceivableNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_PaloAltoMember" xlink:label="pcvx_PaloAltoMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_default"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="pcvx_LeasePaymentReceivableNoncurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="pcvx_PaloAltoMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_PercentageOfPaymentsCompletionAgreedToDefer" xlink:label="pcvx_PercentageOfPaymentsCompletionAgreedToDefer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_LonzaLimitedMember" xlink:label="pcvx_LonzaLimitedMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_DevelopmentAndManufacturingServicesAgreementEquityPaymentsPercentage" xlink:label="pcvx_DevelopmentAndManufacturingServicesAgreementEquityPaymentsPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_DevelopmentAndManufacturingServicesAgreementPaymentsInEquity" xlink:label="pcvx_DevelopmentAndManufacturingServicesAgreementPaymentsInEquity"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_ThresholdLimitOnEquityPayments" xlink:label="pcvx_ThresholdLimitOnEquityPayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GuaranteeObligationsMaximumExposure" xlink:label="us-gaap_GuaranteeObligationsMaximumExposure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="pcvx_PercentageOfPaymentsCompletionAgreedToDefer" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="pcvx_LonzaLimitedMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="pcvx_DevelopmentAndManufacturingServicesAgreementEquityPaymentsPercentage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="pcvx_DevelopmentAndManufacturingServicesAgreementPaymentsInEquity" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="pcvx_ThresholdLimitOnEquityPayments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_GuaranteeObligationsMaximumExposure" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_JefferiesLimitedLiabilityCompanyMember" xlink:label="pcvx_JefferiesLimitedLiabilityCompanyMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_ATMSalesAgreementMember" xlink:label="pcvx_ATMSalesAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockDividendsPerShareDeclared" xlink:label="us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_SaleOfCommonStockAuthorizedAmount" xlink:label="pcvx_SaleOfCommonStockAuthorizedAmount"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_MaximumCommissionPercentageOfGrossProceedsFromCommonStockSold" xlink:label="pcvx_MaximumCommissionPercentageOfGrossProceedsFromCommonStockSold"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_GrossProceedsFromIssuanceOfCommonStock" xlink:label="pcvx_GrossProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="us-gaap_ReceivablesNetCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="pcvx_JefferiesLimitedLiabilityCompanyMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="pcvx_ATMSalesAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_BalanceSheetLocationAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockDividendsPerShareDeclared" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockVotingRights" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="pcvx_SaleOfCommonStockAuthorizedAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="pcvx_MaximumCommissionPercentageOfGrossProceedsFromCommonStockSold" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="pcvx_GrossProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ReceivablesNetCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCommonStockScheduleOfCommonStockSharesReservedForFutureIssuanceDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember" xlink:label="pcvx_TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_SharesAvailableForFutureStockOptionGrantsMember" xlink:label="pcvx_SharesAvailableForFutureStockOptionGrantsMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="pcvx_TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="pcvx_SharesAvailableForFutureStockOptionGrantsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_IncentiveStockOptionGrantedToEmployeesOwningPercentageOfSharesOfCommonStock" xlink:label="pcvx_IncentiveStockOptionGrantedToEmployeesOwningPercentageOfSharesOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_TwoThousandTwentyEquityIncentivePlanMember" xlink:label="pcvx_TwoThousandTwentyEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_PercentageOfFairValuePerShareOnTheGrantDate" xlink:label="pcvx_PercentageOfFairValuePerShareOnTheGrantDate"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_TwoThousandFourteenEquityIncentivePlanMember" xlink:label="pcvx_TwoThousandFourteenEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_ExercisePriceExpireInYearsFormTheDateOfGrant" xlink:label="pcvx_ExercisePriceExpireInYearsFormTheDateOfGrant"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_TwoThousandTwentyEmployeeStockPurchasePlanMember" xlink:label="pcvx_TwoThousandTwentyEmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_StockOptionsGrantedTerm" xlink:label="pcvx_StockOptionsGrantedTerm"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_PercentageOfProvisionsSubjectToStockholders" xlink:label="pcvx_PercentageOfProvisionsSubjectToStockholders"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreaseInAvailableForGrant" xlink:label="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreaseInAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_EarlyExercisedStockOptions" xlink:label="pcvx_EarlyExercisedStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_RemainingLiabilitiesRelatedToEarlyExercisedShares" xlink:label="pcvx_RemainingLiabilitiesRelatedToEarlyExercisedShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_NumberOfOptionsExercisedExcludesOptionsExercisedFromNpln" xlink:label="pcvx_NumberOfOptionsExercisedExcludesOptionsExercisedFromNpln"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_OfferingPeriod" xlink:label="pcvx_OfferingPeriod"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_PurchasePeriod" xlink:label="pcvx_PurchasePeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pcvx_IncentiveStockOptionGrantedToEmployeesOwningPercentageOfSharesOfCommonStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherNoncurrentLiabilitiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="pcvx_TwoThousandTwentyEquityIncentivePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pcvx_PercentageOfFairValuePerShareOnTheGrantDate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="pcvx_TwoThousandFourteenEquityIncentivePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pcvx_ExercisePriceExpireInYearsFormTheDateOfGrant" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="pcvx_TwoThousandTwentyEmployeeStockPurchasePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_BalanceSheetLocationAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pcvx_StockOptionsGrantedTerm" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pcvx_PercentageOfProvisionsSubjectToStockholders" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreaseInAvailableForGrant" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pcvx_EarlyExercisedStockOptions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pcvx_RemainingLiabilitiesRelatedToEarlyExercisedShares" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pcvx_NumberOfOptionsExercisedExcludesOptionsExercisedFromNpln" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pcvx_OfferingPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pcvx_PurchasePeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="26" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="27" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="28" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfActivityUnderStockOptionPlansDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember" xlink:label="pcvx_TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantedInPeriod" xlink:label="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExercisedInPeriod" xlink:label="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExercisedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeitedInPeriod" xlink:label="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeitedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="pcvx_TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantedInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExercisedInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeitedInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfEstimatedFairValueOfEmployeeStockOptionsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfEstimatedFairValueOfSharesUnderEmployeeStockPurchasePlanDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_TwoThousandTwentyEmployeeStockPurchasePlanMember" xlink:label="pcvx_TwoThousandTwentyEmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="pcvx_TwoThousandTwentyEmployeeStockPurchasePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfStockBasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_TwoThousandFourteenEquityIncentivePlanAndTwoThousandTwentyEquityIncentivePlanAndTwoThousandTwentyEmployeeStockPurchasePlanMember" xlink:label="pcvx_TwoThousandFourteenEquityIncentivePlanAndTwoThousandTwentyEquityIncentivePlanAndTwoThousandTwentyEmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="pcvx_TwoThousandFourteenEquityIncentivePlanAndTwoThousandTwentyEquityIncentivePlanAndTwoThousandTwentyEmployeeStockPurchasePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFundingArrangementAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_FundingArrangementLineItems" xlink:label="pcvx_FundingArrangementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_FundingArrangementTable" xlink:label="pcvx_FundingArrangementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_FundingPeriodOfAwardToDevelopUniversalVaccineToPreventInfections" xlink:label="pcvx_FundingPeriodOfAwardToDevelopUniversalVaccineToPreventInfections"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_CostReimbursementSubAwardAgreementMember" xlink:label="pcvx_CostReimbursementSubAwardAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_InitialFundingCommittedByAward" xlink:label="pcvx_InitialFundingCommittedByAward"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorAgreementMember" xlink:label="pcvx_CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_FundingCommittedByAwardAvailableUponAchievementOfDevelopmentMilestones" xlink:label="pcvx_FundingCommittedByAwardAvailableUponAchievementOfDevelopmentMilestones"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_AdditionalFundingCommittedByAward" xlink:label="pcvx_AdditionalFundingCommittedByAward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrantsReceivable" xlink:label="us-gaap_GrantsReceivable"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_PotentialFundingCommittedByAward" xlink:label="pcvx_PotentialFundingCommittedByAward"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_PotentialFundingPeriodOfAwardToDevelopVaccineToPreventInfections" xlink:label="pcvx_PotentialFundingPeriodOfAwardToDevelopVaccineToPreventInfections"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_PotentialFundingAmountOfAwardToDevelopVaccineToPreventInfections" xlink:label="pcvx_PotentialFundingAmountOfAwardToDevelopVaccineToPreventInfections"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_GrantIncome" xlink:label="pcvx_GrantIncome"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="pcvx_FundingArrangementLineItems" xlink:to="pcvx_FundingArrangementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pcvx_FundingArrangementLineItems" xlink:to="pcvx_FundingPeriodOfAwardToDevelopUniversalVaccineToPreventInfections" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="pcvx_CostReimbursementSubAwardAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="pcvx_FundingArrangementTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pcvx_FundingArrangementLineItems" xlink:to="pcvx_InitialFundingCommittedByAward" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="pcvx_CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="pcvx_FundingArrangementTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="pcvx_FundingArrangementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pcvx_FundingArrangementLineItems" xlink:to="pcvx_FundingCommittedByAwardAvailableUponAchievementOfDevelopmentMilestones" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pcvx_FundingArrangementLineItems" xlink:to="pcvx_AdditionalFundingCommittedByAward" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pcvx_FundingArrangementLineItems" xlink:to="us-gaap_GrantsReceivable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pcvx_FundingArrangementLineItems" xlink:to="pcvx_PotentialFundingCommittedByAward" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pcvx_FundingArrangementLineItems" xlink:to="pcvx_PotentialFundingPeriodOfAwardToDevelopVaccineToPreventInfections" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pcvx_FundingArrangementLineItems" xlink:to="pcvx_PotentialFundingAmountOfAwardToDevelopVaccineToPreventInfections" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pcvx_FundingArrangementLineItems" xlink:to="pcvx_GrantIncome" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_SeriesARedeemableConvertiblePreferredStockMember" xlink:label="pcvx_SeriesARedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_CommonStockWarrantMember" xlink:label="pcvx_CommonStockWarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_SeriesBRedeemableConvertiblePreferredStockMember" xlink:label="pcvx_SeriesBRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_RedeemableConvertiblePreferredStockWarrantMember" xlink:label="pcvx_RedeemableConvertiblePreferredStockWarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_SeriesCRedeemableConvertiblePreferredStockMember" xlink:label="pcvx_SeriesCRedeemableConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pcvx_SeriesARedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="pcvx_CommonStockWarrantMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pcvx_SeriesBRedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="pcvx_RedeemableConvertiblePreferredStockWarrantMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pcvx_SeriesCRedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_IncomeTaxDisclosureLineItems" xlink:label="pcvx_IncomeTaxDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_IncomeTaxDisclosureTable" xlink:label="pcvx_IncomeTaxDisclosureTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_OperatingLossCarryForwardsExpirationYear" xlink:label="pcvx_OperatingLossCarryForwardsExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_CA" xlink:label="stpr_CA"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_TaxCreditCarryforwardExpirationYear" xlink:label="pcvx_TaxCreditCarryforwardExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="pcvx_IncomeTaxDisclosureLineItems" xlink:to="pcvx_IncomeTaxDisclosureTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pcvx_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="pcvx_IncomeTaxDisclosureTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pcvx_IncomeTaxDisclosureLineItems" xlink:to="pcvx_OperatingLossCarryForwardsExpirationYear" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="pcvx_IncomeTaxDisclosureTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="pcvx_IncomeTaxDisclosureTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pcvx_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="stpr_CA" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pcvx_IncomeTaxDisclosureLineItems" xlink:to="pcvx_TaxCreditCarryforwardExpirationYear" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pcvx_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pcvx_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pcvx_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_LicenseAmendmentATwoMember" xlink:label="pcvx_LicenseAmendmentATwoMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_SeriesCRedeemableConvertiblePreferredStockMember" xlink:label="pcvx_SeriesCRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_SutroBiopharmaIncMember" xlink:label="pcvx_SutroBiopharmaIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_LicenseAgreementMember" xlink:label="pcvx_LicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_CommonStockWarrantMember" xlink:label="pcvx_CommonStockWarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_SupplyAgreementMember" xlink:label="pcvx_SupplyAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_PreferredStockWarrantMember" xlink:label="pcvx_PreferredStockWarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRightExercised" xlink:label="pcvx_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRightExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_PercentageOfRoyaltyPaymentOnAnnualNetSalesOfVaccineProductsForHumanHealth" xlink:label="pcvx_PercentageOfRoyaltyPaymentOnAnnualNetSalesOfVaccineProductsForHumanHealth"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_PercentageOfRoyaltyPaymentOnNetSalesOfVaccineCompositionsForAnimalHealth" xlink:label="pcvx_PercentageOfRoyaltyPaymentOnNetSalesOfVaccineCompositionsForAnimalHealth"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDueFromToRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionDueFromToRelatedParty"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="pcvx_LicenseAmendmentATwoMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pcvx_SeriesCRedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="pcvx_SutroBiopharmaIncMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="pcvx_LicenseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="pcvx_CommonStockWarrantMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="pcvx_SupplyAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="pcvx_PreferredStockWarrantMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="pcvx_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRightExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="pcvx_PercentageOfRoyaltyPaymentOnAnnualNetSalesOfVaccineProductsForHumanHealth" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="pcvx_PercentageOfRoyaltyPaymentOnNetSalesOfVaccineCompositionsForAnimalHealth" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionDueFromToRelatedParty" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vaxcyte.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_StockIssuedDuringPeriodSharesOfFollowOnOffering" xlink:label="pcvx_StockIssuedDuringPeriodSharesOfFollowOnOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_SharesIssuedPricePerShareUponFollowOnOffering" xlink:label="pcvx_SharesIssuedPricePerShareUponFollowOnOffering"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_SharesPreFundedWarrantsToPurchase" xlink:label="pcvx_SharesPreFundedWarrantsToPurchase"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_PrefundedWarrantsPricePerShare" xlink:label="pcvx_PrefundedWarrantsPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_ProceedsFromIssuanceFollowOnOffering" xlink:label="pcvx_ProceedsFromIssuanceFollowOnOffering"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_SharesIssuedUponFollowOnOfferingFullExerciseOfUnderwritersOptionToPurchaseAdditionalShares" xlink:label="pcvx_SharesIssuedUponFollowOnOfferingFullExerciseOfUnderwritersOptionToPurchaseAdditionalShares"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="pcvx_StockIssuedDuringPeriodSharesOfFollowOnOffering" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="pcvx_SharesIssuedPricePerShareUponFollowOnOffering" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="pcvx_SharesPreFundedWarrantsToPurchase" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="pcvx_PrefundedWarrantsPricePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="pcvx_ProceedsFromIssuanceFollowOnOffering" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="pcvx_SharesIssuedUponFollowOnOfferingFullExerciseOfUnderwritersOptionToPurchaseAdditionalShares" priority="2" use="optional"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>31
<FILENAME>pcvx-20211231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2022-02-28T14:49:02.6217+00:00 -->
<!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="us-gaap_LesseeOperatingLeaseDescription"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_TwoThousandTwentyEmployeeStockPurchasePlanMember" xlink:label="pcvx_TwoThousandTwentyEmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_InitialFundingCommittedByAward" xlink:label="pcvx_InitialFundingCommittedByAward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" xlink:label="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:label="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_ComputersAndComputerSoftwareMember" xlink:label="pcvx_ComputersAndComputerSoftwareMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_AccruedPreclinicalStudiesCurrent" xlink:label="pcvx_AccruedPreclinicalStudiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:label="us-gaap_DeferredRentCreditCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="us-gaap_InvestmentPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_AdditionalFacilityMember" xlink:label="pcvx_AdditionalFacilityMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_CommonStockWarrantMember" xlink:label="pcvx_CommonStockWarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_FundingArrangementLineItems" xlink:label="pcvx_FundingArrangementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:label="pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_StockIssuedDuringPeriodSharesIssuanceOfCommonStockRelatedToEarlyExercisedStockOptions" xlink:label="pcvx_StockIssuedDuringPeriodSharesIssuanceOfCommonStockRelatedToEarlyExercisedStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_SeriesDRedeemableConvertiblePreferredStockMember" xlink:label="pcvx_SeriesDRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="us-gaap_ReceivablesNetCurrent"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_AccruedManufacturingExpenses" xlink:label="pcvx_AccruedManufacturingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="pcvx_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeitedInPeriod" xlink:label="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeitedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_ProceedsFromIssuanceFollowOnOffering" xlink:label="pcvx_ProceedsFromIssuanceFollowOnOffering"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_CashAndCashEquivalentsAndInvestmentsAmortizedCostBasis" xlink:label="pcvx_CashAndCashEquivalentsAndInvestmentsAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_AdjustmentsToAdditionalPaidInCapitalVestingOfEarlyExercisedStockOptions" xlink:label="pcvx_AdjustmentsToAdditionalPaidInCapitalVestingOfEarlyExercisedStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GuaranteeObligationsMaximumExposure" xlink:label="us-gaap_GuaranteeObligationsMaximumExposure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_SutroBiopharmaIncMember" xlink:label="pcvx_SutroBiopharmaIncMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExercisedInPeriod" xlink:label="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExercisedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses" xlink:label="pcvx_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_PrefundedWarrantsPricePerShare" xlink:label="pcvx_PrefundedWarrantsPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_LicenseAgreementMember" xlink:label="pcvx_LicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_StockIssuedDuringPeriodSharesConversionOfPreferredStockWarrant" xlink:label="pcvx_StockIssuedDuringPeriodSharesConversionOfPreferredStockWarrant"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:label="pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_CashAndCashEquivalentsAmortizedCost" xlink:label="pcvx_CashAndCashEquivalentsAmortizedCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_SeriesCRedeemableConvertiblePreferredStockMember" xlink:label="pcvx_SeriesCRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_RedeemableConvertiblePreferredStockWarrantMember" xlink:label="pcvx_RedeemableConvertiblePreferredStockWarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashMember" xlink:label="us-gaap_CashMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_SharesIssuedPricePerShareUponFollowOnOffering" xlink:label="pcvx_SharesIssuedPricePerShareUponFollowOnOffering"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_CashAndCashEquivalentsGrossUnrealizedLossBeforeTax" xlink:label="pcvx_CashAndCashEquivalentsGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_GrantIncome" xlink:label="pcvx_GrantIncome"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_TaxCreditCarryforwardExpirationYear" xlink:label="pcvx_TaxCreditCarryforwardExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:label="pcvx_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201912Member" xlink:label="us-gaap_AccountingStandardsUpdate201912Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_PaloAltoMember" xlink:label="pcvx_PaloAltoMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_IncreaseDecreaseInAccruedCompensation" xlink:label="pcvx_IncreaseDecreaseInAccruedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_PercentageOfRoyaltyPaymentOnAnnualNetSalesOfVaccineProductsForHumanHealth" xlink:label="pcvx_PercentageOfRoyaltyPaymentOnAnnualNetSalesOfVaccineProductsForHumanHealth"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_SharesIssuedUponFollowOnOfferingFullExerciseOfUnderwritersOptionToPurchaseAdditionalShares" xlink:label="pcvx_SharesIssuedUponFollowOnOfferingFullExerciseOfUnderwritersOptionToPurchaseAdditionalShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_PaymentsOfUnderwritingDiscountsAndCommissions" xlink:label="pcvx_PaymentsOfUnderwritingDiscountsAndCommissions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_NumberOfFinanceLease" xlink:label="pcvx_NumberOfFinanceLease"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantedInPeriod" xlink:label="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_AdjustmentsToAdditionalPaidInCapitalWarrantLiabilityWriteOff" xlink:label="pcvx_AdjustmentsToAdditionalPaidInCapitalWarrantLiabilityWriteOff"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_LeasePaymentReceivableNoncurrent" xlink:label="pcvx_LeasePaymentReceivableNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_MaximumCommissionPercentageOfGrossProceedsFromCommonStockSold" xlink:label="pcvx_MaximumCommissionPercentageOfGrossProceedsFromCommonStockSold"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_ScheduleOfInformationRelatedToRightOfUseAssetsAndLeaseLiabilitiesTableTextBlock" xlink:label="pcvx_ScheduleOfInformationRelatedToRightOfUseAssetsAndLeaseLiabilitiesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_ProceedsFromIssuanceOfCommonStockRelatedToEarlyExercisedStockOptions" xlink:label="pcvx_ProceedsFromIssuanceOfCommonStockRelatedToEarlyExercisedStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BuildingMember" xlink:label="us-gaap_BuildingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_StockIssuedDuringPeriodSharesConversionOfCommonStockWarrant" xlink:label="pcvx_StockIssuedDuringPeriodSharesConversionOfCommonStockWarrant"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:label="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_FundingArrangementTable" xlink:label="pcvx_FundingArrangementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDueFromToRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionDueFromToRelatedParty"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_LesseeOperatingLeaseExtendedLeaseTerm" xlink:label="pcvx_LesseeOperatingLeaseExtendedLeaseTerm"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_ATMSalesAgreementMember" xlink:label="pcvx_ATMSalesAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_DevelopmentAndManufacturingServicesAgreementPaymentsInEquity" xlink:label="pcvx_DevelopmentAndManufacturingServicesAgreementPaymentsInEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_PercentageOfProvisionsSubjectToStockholders" xlink:label="pcvx_PercentageOfProvisionsSubjectToStockholders"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_EarlyExercisedStockOptions" xlink:label="pcvx_EarlyExercisedStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_SupplyAgreementMember" xlink:label="pcvx_SupplyAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_PreferredStockWarrantMember" xlink:label="pcvx_PreferredStockWarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_FundingCommittedByAwardAvailableUponAchievementOfDevelopmentMilestones" xlink:label="pcvx_FundingCommittedByAwardAvailableUponAchievementOfDevelopmentMilestones"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_JefferiesLimitedLiabilityCompanyMember" xlink:label="pcvx_JefferiesLimitedLiabilityCompanyMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_CashAndCashEquivalentsAndInvestments" xlink:label="pcvx_CashAndCashEquivalentsAndInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_TwoThousandFourteenEquityIncentivePlanMember" xlink:label="pcvx_TwoThousandFourteenEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_SeriesBRedeemableConvertiblePreferredStockMember" xlink:label="pcvx_SeriesBRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssued1" xlink:label="us-gaap_StockIssued1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGrossAbstract" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_PercentageOfFairValuePerShareOnTheGrantDate" xlink:label="pcvx_PercentageOfFairValuePerShareOnTheGrantDate"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_ThresholdLimitOnEquityPayments" xlink:label="pcvx_ThresholdLimitOnEquityPayments"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_GrossProceedsFromIssuanceOfCommonStock" xlink:label="pcvx_GrossProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_IncomeTaxDisclosureLineItems" xlink:label="pcvx_IncomeTaxDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrantsReceivable" xlink:label="us-gaap_GrantsReceivable"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_NumberOfRenewalOptions" xlink:label="pcvx_NumberOfRenewalOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="us-gaap_AssetBackedSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="pcvx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_DevelopmentAndManufacturingServicesAgreementEquityPaymentsPercentage" xlink:label="pcvx_DevelopmentAndManufacturingServicesAgreementEquityPaymentsPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_ExpenseOnIssuanceOfRedeemableConvertiblePreferredStockWarrant" xlink:label="pcvx_ExpenseOnIssuanceOfRedeemableConvertiblePreferredStockWarrant"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_PotentialFundingAmountOfAwardToDevelopVaccineToPreventInfections" xlink:label="pcvx_PotentialFundingAmountOfAwardToDevelopVaccineToPreventInfections"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_LicenseAmendmentATwoMember" xlink:label="pcvx_LicenseAmendmentATwoMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_LesseeOperatingLeaseCommencementDate" xlink:label="pcvx_LesseeOperatingLeaseCommencementDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockDividendsPerShareDeclared" xlink:label="us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_LonzaLimitedMember" xlink:label="pcvx_LonzaLimitedMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_SaleOfCommonStockAuthorizedAmount" xlink:label="pcvx_SaleOfCommonStockAuthorizedAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_FundingArrangementTextBlock" xlink:label="pcvx_FundingArrangementTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_PneumococcalConjugateVaccineMember" xlink:label="pcvx_PneumococcalConjugateVaccineMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember" xlink:label="pcvx_TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_TwoThousandFourteenEquityIncentivePlanAndTwoThousandTwentyEquityIncentivePlanAndTwoThousandTwentyEmployeeStockPurchasePlanMember" xlink:label="pcvx_TwoThousandFourteenEquityIncentivePlanAndTwoThousandTwentyEquityIncentivePlanAndTwoThousandTwentyEmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_NumberOfSecurities" xlink:label="pcvx_NumberOfSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_MarketOfferingMember" xlink:label="pcvx_MarketOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_LesseeOperatingLeaseRentCommencementDate" xlink:label="pcvx_LesseeOperatingLeaseRentCommencementDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_OperatingLossCarryForwardsExpirationYear" xlink:label="pcvx_OperatingLossCarryForwardsExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_PercentageOfRoyaltyPaymentOnNetSalesOfVaccineCompositionsForAnimalHealth" xlink:label="pcvx_PercentageOfRoyaltyPaymentOnNetSalesOfVaccineCompositionsForAnimalHealth"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:label="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_PurchasePeriod" xlink:label="pcvx_PurchasePeriod"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_NewCorporateHeadquartersFacilityMember" xlink:label="pcvx_NewCorporateHeadquartersFacilityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="us-gaap_DeferredChargesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_OfferingPeriod" xlink:label="pcvx_OfferingPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_FundingPeriodOfAwardToDevelopUniversalVaccineToPreventInfections" xlink:label="pcvx_FundingPeriodOfAwardToDevelopUniversalVaccineToPreventInfections"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_PaymentsOfCapitalLeaseObligations" xlink:label="pcvx_PaymentsOfCapitalLeaseObligations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_TemporaryEquityConversionOfPreferredStockShares" xlink:label="pcvx_TemporaryEquityConversionOfPreferredStockShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_CA" xlink:label="stpr_CA"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_DeferredTaxAssetsTaxAccruedManufacturingExpenses" xlink:label="pcvx_DeferredTaxAssetsTaxAccruedManufacturingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:label="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_ExercisePriceExpireInYearsFormTheDateOfGrant" xlink:label="pcvx_ExercisePriceExpireInYearsFormTheDateOfGrant"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRightExercised" xlink:label="pcvx_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRightExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_NumberOfOptionsExercisedExcludesOptionsExercisedFromNpln" xlink:label="pcvx_NumberOfOptionsExercisedExcludesOptionsExercisedFromNpln"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_InitialPublicOfferingRelatedCost" xlink:label="pcvx_InitialPublicOfferingRelatedCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_CapitalLeasesLabEquipmentMember" xlink:label="pcvx_CapitalLeasesLabEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_IncreaseDecreaseInAccruedManufacturingExpenses" xlink:label="pcvx_IncreaseDecreaseInAccruedManufacturingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonthsNetOfLeaseIncentives" xlink:label="pcvx_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonthsNetOfLeaseIncentives"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_StockIssuedDuringPeriodSharesOfFollowOnOffering" xlink:label="pcvx_StockIssuedDuringPeriodSharesOfFollowOnOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_GlobalTargetRevenue" xlink:label="pcvx_GlobalTargetRevenue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_PaymentOfDeferredOfferingCosts" xlink:label="pcvx_PaymentOfDeferredOfferingCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesRealizedGainLoss" xlink:label="us-gaap_MarketableSecuritiesRealizedGainLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_ProceedsFromIssuanceOfCommonStockNotYetReceived" xlink:label="pcvx_ProceedsFromIssuanceOfCommonStockNotYetReceived"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock" xlink:label="pcvx_ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_StockOptionsGrantedTerm" xlink:label="pcvx_StockOptionsGrantedTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_PercentageOfPaymentsCompletionAgreedToDefer" xlink:label="pcvx_PercentageOfPaymentsCompletionAgreedToDefer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember" xlink:label="us-gaap_OtherNoncurrentAssetsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_TemporaryEquityConversionOfPreferredStockValue" xlink:label="pcvx_TemporaryEquityConversionOfPreferredStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_ChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheLiabilities" xlink:label="pcvx_ChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_CostReimbursementSubAwardAgreementMember" xlink:label="pcvx_CostReimbursementSubAwardAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_LeaseLiability" xlink:label="pcvx_LeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_CashAndCashEquivalentsAndInvestmentsGrossUnrealizedGainBeforeTax" xlink:label="pcvx_CashAndCashEquivalentsAndInvestmentsGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_CashAndCashEquivalentsAndInvestmentsGrossUnrealizedLossBeforeTax" xlink:label="pcvx_CashAndCashEquivalentsAndInvestmentsGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_SharesPreFundedWarrantsToPurchase" xlink:label="pcvx_SharesPreFundedWarrantsToPurchase"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_HeadquartersFacilityMember" xlink:label="pcvx_HeadquartersFacilityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_SharesAvailableForFutureStockOptionGrantsMember" xlink:label="pcvx_SharesAvailableForFutureStockOptionGrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_TemporaryEquityStockIssuanceCosts" xlink:label="pcvx_TemporaryEquityStockIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_SharesIssuedUponFullExerciseOfUnderwritersOptionToPurchaseAdditionalShares" xlink:label="pcvx_SharesIssuedUponFullExerciseOfUnderwritersOptionToPurchaseAdditionalShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_Section162MLimitation" xlink:label="pcvx_Section162MLimitation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_IncreaseDecreaseInDeferredRentAndOtherLongTermLiabilities" xlink:label="pcvx_IncreaseDecreaseInDeferredRentAndOtherLongTermLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_PotentialFundingPeriodOfAwardToDevelopVaccineToPreventInfections" xlink:label="pcvx_PotentialFundingPeriodOfAwardToDevelopVaccineToPreventInfections"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_ChangeInFairValueOfRedeemableConvertiblePreferredStock" xlink:label="pcvx_ChangeInFairValueOfRedeemableConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_CashAndCashEquivalentsGrossUnrealizedGainBeforeTax" xlink:label="pcvx_CashAndCashEquivalentsGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_LesseeOperatingLeaseExtendedMaturityDate" xlink:label="pcvx_LesseeOperatingLeaseExtendedMaturityDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_LesseeOperatingLeaseRenewalOption" xlink:label="pcvx_LesseeOperatingLeaseRenewalOption"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_TwoThousandTwentyEquityIncentivePlanMember" xlink:label="pcvx_TwoThousandTwentyEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_PotentialFundingCommittedByAward" xlink:label="pcvx_PotentialFundingCommittedByAward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_IncreaseDecreaseInAccruedLegalSettlement" xlink:label="pcvx_IncreaseDecreaseInAccruedLegalSettlement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfTrancheLiability" xlink:label="pcvx_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfTrancheLiability"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_LabEquipmentMember" xlink:label="pcvx_LabEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_SanCarlosMember" xlink:label="pcvx_SanCarlosMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_LeaseTerminationDate" xlink:label="pcvx_LeaseTerminationDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_ResearchAndDevelopmentExpenseToRelatedParty" xlink:label="pcvx_ResearchAndDevelopmentExpenseToRelatedParty"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_AdditionalFundingCommittedByAward" xlink:label="pcvx_AdditionalFundingCommittedByAward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_IncentiveStockOptionGrantedToEmployeesOwningPercentageOfSharesOfCommonStock" xlink:label="pcvx_IncentiveStockOptionGrantedToEmployeesOwningPercentageOfSharesOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" xlink:label="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:label="pcvx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_CapitalLeasesAmortizationExpense" xlink:label="pcvx_CapitalLeasesAmortizationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreaseInAvailableForGrant" xlink:label="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreaseInAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_WarrantsDisclosureTextBlock" xlink:label="pcvx_WarrantsDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="us-gaap_LongTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_ProceedsFromInitialPublicOfferingNetOfUnderwritersCommissionsAndDiscounts" xlink:label="pcvx_ProceedsFromInitialPublicOfferingNetOfUnderwritersCommissionsAndDiscounts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_RemainingLiabilitiesRelatedToEarlyExercisedShares" xlink:label="pcvx_RemainingLiabilitiesRelatedToEarlyExercisedShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_AccruedResearchAndDevelopmentPolicyTextBlock" xlink:label="pcvx_AccruedResearchAndDevelopmentPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_NumberOfOperatingLease" xlink:label="pcvx_NumberOfOperatingLease"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_SeriesARedeemableConvertiblePreferredStockMember" xlink:label="pcvx_SeriesARedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_FundingArrangementAbstract" xlink:label="pcvx_FundingArrangementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance" xlink:label="pcvx_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorAgreementMember" xlink:label="pcvx_CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_IncomeTaxDisclosureTable" xlink:label="pcvx_IncomeTaxDisclosureTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_RedeemableConvertiblePreferredStockTextBlock" xlink:label="pcvx_RedeemableConvertiblePreferredStockTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility, Maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_TwoThousandTwentyEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020 Employee Stock Purchase Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_TwoThousandTwentyEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Employee Stock Purchase Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_TwoThousandTwentyEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty employee stock purchase plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease expiration date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Expiration Date1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting period for stock options granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_InitialFundingCommittedByAward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial funding committed by award</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_InitialFundingCommittedByAward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Initial Funding Committed By Award</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_InitialFundingCommittedByAward_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Initial funding committed by award.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment and Geographical Information</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting Policy Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value liabilities transferred into level 3</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value liabilities transferred from level 1 to level 2</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Liabilities Level1 To Level2 Transfers Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in accounting principle, accounting standards update, early adoption [true false]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change In Accounting Principle Accounting Standards Update Early Adoption</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial paper</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commercial Paper Not Included With Cash And Cash Equivalents [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating Loss Carryforwards, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ComputersAndComputerSoftwareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computers and Computer Software</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ComputersAndComputerSoftwareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Computers And Computer Software [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ComputersAndComputerSoftwareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Computers and computer software.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Liabilities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_AccruedPreclinicalStudiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preclinical studies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_AccruedPreclinicalStudiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Preclinical Studies Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_AccruedPreclinicalStudiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued preclinical studies current.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized losses on investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRentCreditCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred rent - current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRentCreditCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Rent Credit, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Class</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation By Asset Class [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income Loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employees acquired shares of common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Shares Purchased For Award</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock under the Employee Stock Purchase Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Stock Plans</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_AdditionalFacilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Facility</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_AdditionalFacilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Facility [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_AdditionalFacilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional facility.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_CommonStockWarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock Warrant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_CommonStockWarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Warrant [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_CommonStockWarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock warrant.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Prepaid Expense and Other Assets, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Prepaid Deferred Expense And Other Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of reportable segments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Reportable Segments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate number of shares available for issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Options Available for Grant, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Options Available for Grant, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_FundingArrangementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Funding Arrangement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_FundingArrangementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Funding Arrangement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_FundingArrangementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Funding arrangement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Property, Plant, and Equipment, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of property and equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Property Plant And Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Organization Consolidation And Presentation Of Financial Statements [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Organization Consolidation And Presentation Of Financial Statements [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of organization consolidation and presentation of financial statements.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, $0.001 par value - 500,000,000 shares authorized at December 31, 2021 and December 31, 2020;53,031,978 and 51,071,593 shares issued and outstanding at December 31, 2021 and December 31, 2020, respectively</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Value, Issued, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Value, Issued, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Value, Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address State Or Province</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_StockIssuedDuringPeriodSharesIssuanceOfCommonStockRelatedToEarlyExercisedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock related to early exercised stock options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_StockIssuedDuringPeriodSharesIssuanceOfCommonStockRelatedToEarlyExercisedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Issuance Of Common Stock Related To Early Exercised Stock Options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_StockIssuedDuringPeriodSharesIssuanceOfCommonStockRelatedToEarlyExercisedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period shares issuance of common stock related to early exercised stock options.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_SeriesDRedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series D Redeemable Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_SeriesDRedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series D Redeemable Convertible Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_SeriesDRedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series D redeemable convertible preferred stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reverse stock split</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Reverse Stock Split</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReceivablesNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Receivables, Net, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReceivablesNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Receivables</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReceivablesNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Receivables Net Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_AccruedManufacturingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued manufacturing expenses.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_AccruedManufacturingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Manufacturing Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_AccruedManufacturingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued manufacturing expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments based on tax positions related to prior years</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Unrecognized Tax Benefits Increases Decreases Resulting From Prior Period Tax Positions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Stock [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options Available for Grant, forfeited</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Forfeited In Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-based compensation arrangement by share-based payment award number of shares available for grant forfeited in period.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ProceedsFromIssuanceFollowOnOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds from follow on offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ProceedsFromIssuanceFollowOnOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance follow on offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ProceedsFromIssuanceFollowOnOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from issuance follow on offering.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_CashAndCashEquivalentsAndInvestmentsAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets measured at fair value, Amortized Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_CashAndCashEquivalentsAndInvestmentsAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents And Investments Amortized Cost Basis</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_CashAndCashEquivalentsAndInvestmentsAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash and cash equivalents and investments amortized cost basis.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_AdjustmentsToAdditionalPaidInCapitalVestingOfEarlyExercisedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting of early exercised stock options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_AdjustmentsToAdditionalPaidInCapitalVestingOfEarlyExercisedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Vesting Of Early Exercised Stock Options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_AdjustmentsToAdditionalPaidInCapitalVestingOfEarlyExercisedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Adjustments to additional paid In capital vesting of early exercised stock options.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GuaranteeObligationsMaximumExposure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amount recorded with respect to the potential future payments above the initial cash cap</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GuaranteeObligationsMaximumExposure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Guarantee Obligations Maximum Exposure</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized losses on investment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted-average shares outstanding used in computing net loss per share, basic and diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average shares outstanding, basic and diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number Of Share Outstanding Basic And Diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Redeemable Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Redeemable Convertible Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_SutroBiopharmaIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sutro Biopharma, Inc</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_SutroBiopharmaIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sutro Biopharma Inc [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_SutroBiopharmaIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sutro Biopharma, Inc.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExercisedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options Available for Grant, exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExercisedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Exercised In Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExercisedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-based compensation arrangement by share-based payment award number of shares available for grant exercised in period.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred offering costs included in accounts payable and accrued expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Offering Costs Included In Accounts Payable And Accrued Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred offering costs included in accounts payable and accrued expenses.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_PrefundedWarrantsPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Pre-funded warrants price per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_PrefundedWarrantsPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prefunded Warrants Price Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_PrefundedWarrantsPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Prefunded warrants price per share.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_LicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_LicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_LicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License Agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General And Administrative Expense [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of common stock to Lonza Ltd. (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of common stock issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Issued For Services</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_StockIssuedDuringPeriodSharesConversionOfPreferredStockWarrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of preferred stock warrant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_StockIssuedDuringPeriodSharesConversionOfPreferredStockWarrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Conversion Of Preferred Stock Warrant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_StockIssuedDuringPeriodSharesConversionOfPreferredStockWarrant_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period shares conversion of preferred stock warrant.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Remaining Contractual Term (Years), Exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Restricted Cash, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Organization Consolidation And Presentation Of Financial Statements [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Organization Consolidation And Presentation Of Financial Statements [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of organization consolidation and presentation of financial statements.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Related Party Transactions By Related Party [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Related Party Transactions By Related Party [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_CashAndCashEquivalentsAmortizedCost_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash and cash equivalents, Amortized Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_CashAndCashEquivalentsAmortizedCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Amortized Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_CashAndCashEquivalentsAmortizedCost_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash and cash equivalents amortized cost.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Estimated Fair Value of Employee Stock Options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. Treasury Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">U S Treasury Securities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting standard update adopted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Accounting Principle, Accounting Standards Update, Adopted [true false]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Exercise Price Per Share, Options forfeited</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies (Note 6)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_SeriesCRedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Series C Redeemable Convertible Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_SeriesCRedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series C Redeemable Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_SeriesCRedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series C Redeemable Convertible Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_SeriesCRedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series C redeemable convertible preferred stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Potentially Dilutive Securities Excluded From Computation of Diluted Net Loss Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research credit carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation Tax Credits Research</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common stock shares sold</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon initial public offering or at-the-market offering, net of issuance costs (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments, Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Debt Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_RedeemableConvertiblePreferredStockWarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Redeemable Convertible Preferred Stock Warrant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_RedeemableConvertiblePreferredStockWarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Redeemable Convertible Preferred Stock Warrant [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_RedeemableConvertiblePreferredStockWarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Redeemable convertible preferred stock warrant.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis Of Accounting Policy Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock under Employee Stock Purchase Plan (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Employee Stock Purchase Plans</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, cash equivalents and restricted cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash, cash equivalents and restricted cash, end of period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash, cash equivalents and restricted cash, beginning of period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant to purchase shares of stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting standard update material impact</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_SharesIssuedPricePerShareUponFollowOnOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock price per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_SharesIssuedPricePerShareUponFollowOnOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued Price Per Share upon follow on offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_SharesIssuedPricePerShareUponFollowOnOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Shares issued price per share upon follow on offering.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_CashAndCashEquivalentsGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Cash and cash equivalents, Gross Unrealized Losses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_CashAndCashEquivalentsGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Gross Unrealized Loss Before Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_CashAndCashEquivalentsGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash and cash equivalents gross unrealized loss before tax.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income (expense), net:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income Expense [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total noncurrent assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total noncurrent assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_GrantIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grant income</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_GrantIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Grant Income</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_GrantIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Grant income.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in investing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchases of property and equipment recorded in accounts payable and accrued expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capital Expenditures Incurred But Not Yet Paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credit Carryforward</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of outstanding number of shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Outstanding Stock Maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_TaxCreditCarryforwardExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit carry forwards expiration year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_TaxCreditCarryforwardExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward Expiration Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_TaxCreditCarryforwardExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tax credit carryforward expiration year.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credit Carryforward, Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee-related Liabilities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Employee-related Liabilities, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Estimated Fair Value of Shares Under Employee Stock Purchase Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Payment Award Employee Stock Purchase Plan Valuation Assumptions Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">General and Administrative Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General And Administrative Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Net, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Net, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property and equipment, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Shares, Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock, shares owned</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRentCreditNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred rent - long-term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRentCreditNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Rent Credit, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Income And Comprehensive Income [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Total deferred tax liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Total deferred tax liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset backed securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Investments, Amortized Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Debt Securities Amortized Cost Basis</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating lease, ROU assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">ROU assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease right-of-use assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Range [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Furniture and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Furniture And Fixtures [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Income (Loss) Available to Common Stockholders, Basic, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss (in thousands)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss Available To Common Stockholders Basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_IncreaseDecreaseInOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Operating lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_IncreaseDecreaseInOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Lease Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_IncreaseDecreaseInOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase decrease in operating lease liabilities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Liabilities, Noncurrent, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value assets transferred out of level 3</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201912Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASU 2019-12</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201912Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update 2019-12 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents, Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Fair Value Disclosure</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_PaloAltoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Palo Alto</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_PaloAltoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Palo Alto [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_PaloAltoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Palo alto.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses (including related party accrual of $0 and $677 as of December 31, 2021 and December 31, 2020, respectively)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_IncreaseDecreaseInAccruedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_IncreaseDecreaseInAccruedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accrued Compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_IncreaseDecreaseInAccruedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase decrease in accrued compensation.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expenses related to agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction Expenses From Transactions With Related Party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingenciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss Contingencies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingenciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingencies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_PercentageOfRoyaltyPaymentOnAnnualNetSalesOfVaccineProductsForHumanHealth_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of royalty payment on annual net sales of vaccine products for human health</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_PercentageOfRoyaltyPaymentOnAnnualNetSalesOfVaccineProductsForHumanHealth_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Royalty Payment On Annual Net Sales Of Vaccine Products For Human Health</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_PercentageOfRoyaltyPaymentOnAnnualNetSalesOfVaccineProductsForHumanHealth_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of royalty payment on annual net sales of vaccine products for human health.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Use Of Estimates</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities &#8212; current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Net amortization of premiums on investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions By Related Party [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosure of cash flow information:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_SharesIssuedUponFollowOnOfferingFullExerciseOfUnderwritersOptionToPurchaseAdditionalShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underwriters' option to purchase additional shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_SharesIssuedUponFollowOnOfferingFullExerciseOfUnderwritersOptionToPurchaseAdditionalShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares issued upon follow on offering full exercise of underwriters option to purchase additional shares.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_SharesIssuedUponFollowOnOfferingFullExerciseOfUnderwritersOptionToPurchaseAdditionalShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Shares issued upon follow on offering full exercise of underwriters option to purchase additional shares.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement Class Of Stock [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_PaymentsOfUnderwritingDiscountsAndCommissions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underwriting discounts and commissions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_PaymentsOfUnderwritingDiscountsAndCommissions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments Of Underwriting Discounts And Commissions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_PaymentsOfUnderwritingDiscountsAndCommissions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payments of underwriting discounts and commissions.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive securities excluded from computation of diluted net loss per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_NumberOfFinanceLease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of finance lease</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_NumberOfFinanceLease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Finance Lease</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_NumberOfFinanceLease_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of finance lease.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Options Available for Grant, granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Granted In Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-based compensation arrangement by share-based payment award number of shares available for grant granted in period.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_AdjustmentsToAdditionalPaidInCapitalWarrantLiabilityWriteOff_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant liability write-off</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_AdjustmentsToAdditionalPaidInCapitalWarrantLiabilityWriteOff_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Warrant Liability Write Off</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_AdjustmentsToAdditionalPaidInCapitalWarrantLiabilityWriteOff_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Adjustments to additional paid in capital warrant liability write off.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_LeasePaymentReceivableNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease incentives</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_LeasePaymentReceivableNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease Payment Receivable Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnDispositionOfAssets1_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Gain (Loss) on Disposition of Assets, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnDispositionOfAssets1_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Loss on disposal of assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnDispositionOfAssets1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gain Loss On Disposition Of Assets1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Paid Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_MaximumCommissionPercentageOfGrossProceedsFromCommonStockSold_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum commission percentage of gross proceeds from common stock sold</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_MaximumCommissionPercentageOfGrossProceedsFromCommonStockSold_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Commission Percentage Of Gross Proceeds From Common Stock Sold</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_MaximumCommissionPercentageOfGrossProceedsFromCommonStockSold_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum commission percentage of gross proceeds from common stock sold.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ScheduleOfInformationRelatedToRightOfUseAssetsAndLeaseLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Information Related to ROU Assets and Lease Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ScheduleOfInformationRelatedToRightOfUseAssetsAndLeaseLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Information Related To Right Of Use Assets And Lease Liabilities Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ScheduleOfInformationRelatedToRightOfUseAssetsAndLeaseLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of information related to right-of-use assets and lease liabilities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Continuing Operations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line2</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net (decrease) increase in cash, cash equivalents and restricted cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Other Operating Assets, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Other Operating Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ProceedsFromIssuanceOfCommonStockRelatedToEarlyExercisedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock related to early exercised stock options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ProceedsFromIssuanceOfCommonStockRelatedToEarlyExercisedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Common Stock Related To Early Exercised Stock Options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ProceedsFromIssuanceOfCommonStockRelatedToEarlyExercisedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from issuance of common stock related to early exercised stock options.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, existence of option to renewal</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Existence Of Option To Extend</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BuildingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Office</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BuildingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Building [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preferred stock converted into common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of preferred stock (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Conversion Of Convertible Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_StockIssuedDuringPeriodSharesConversionOfCommonStockWarrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of common stock warrant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_StockIssuedDuringPeriodSharesConversionOfCommonStockWarrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Conversion Of Common Stock Warrant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_StockIssuedDuringPeriodSharesConversionOfCommonStockWarrant_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period shares conversion of common stock warrant.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets Fair Value Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value assets transferred into level 3</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">2021</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Next Twelve Months</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value assets transferred from level 2 to level 1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets Level2 To Level1 Transfers Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Payable, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. Government Agency Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">U S Government Agencies Debt Securities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock, par value per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Par Or Stated Value Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_FundingArrangementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Funding Arrangement [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_FundingArrangementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Funding Arrangement [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_FundingArrangementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Funding arrangement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Section 59(e) Capitalized expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets In Process Research And Development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionDueFromToRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Related Party Transaction, Due from (to) Related Party, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionDueFromToRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Accrued expenses payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionDueFromToRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction Due From To Related Party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additions based on tax positions related to current year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">State And Local Jurisdiction [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_LesseeOperatingLeaseExtendedLeaseTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, extended term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_LesseeOperatingLeaseExtendedLeaseTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Extended Lease Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_LesseeOperatingLeaseExtendedLeaseTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee operating lease extended lease term.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ATMSalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ATM Sales Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ATMSalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">A T M Sales Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ATMSalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">ATM sales agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Additional Paid in Capital, Common Stock, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Additional Paid in Capital, Common Stock, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense Policy</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Domestic Country [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Continuing Operations Tax Rate Reconciliation [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Value, Issued, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Value, Issued, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Preferred Stock, Value, Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, $0.001 par value &#8212; 10,000,000 authorized at December 31, 2021 and December 31, 2020; no shares issued and outstanding at December 31, 2021 and December 31, 2020</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities &#8212; long-term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_DevelopmentAndManufacturingServicesAgreementPaymentsInEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payments in equity, amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_DevelopmentAndManufacturingServicesAgreementPaymentsInEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Development And Manufacturing Services Agreement Payments In Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_DevelopmentAndManufacturingServicesAgreementPaymentsInEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Development and manufacturing services agreement payments in equity.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Accrued Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Accrued Liabilities Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_PercentageOfProvisionsSubjectToStockholders_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of provisions subject to stockholders</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_PercentageOfProvisionsSubjectToStockholders_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Provisions Subject To Stockholders</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_PercentageOfProvisionsSubjectToStockholders_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of provisions subject to stockholders.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Option And Incentive Plans Policy</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_EarlyExercisedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Early exercised stock options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_EarlyExercisedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Early Exercised Stock Options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_EarlyExercisedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Early &#8203;exercised&#8203; stock&#8203; options.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options Issued and Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Option [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_SupplyAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supply Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_SupplyAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supply Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_SupplyAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Supply Agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Remaining Contractual Term (Years)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_PreferredStockWarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred Stock Warrant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_PreferredStockWarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Warrant [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_PreferredStockWarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Preferred stock warrant.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosures of non-cash investing and financing activities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Flow Noncash Investing And Financing Activities Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_FundingCommittedByAwardAvailableUponAchievementOfDevelopmentMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total funding committed by award, available upon achievement of development milestones</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_FundingCommittedByAwardAvailableUponAchievementOfDevelopmentMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Funding Committed By Award Available Upon Achievement Of Development Milestones</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_FundingCommittedByAwardAvailableUponAchievementOfDevelopmentMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Funding committed by award, available upon achievement of development milestones.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_JefferiesLimitedLiabilityCompanyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Jefferies LLC</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_JefferiesLimitedLiabilityCompanyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Jefferies Limited Liability Company [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_JefferiesLimitedLiabilityCompanyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Jefferies limited liability company.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Basic and Diluted, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share, basic and diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Basic And Diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_CashAndCashEquivalentsAndInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total assets measured at fair value, Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_CashAndCashEquivalentsAndInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents And Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_CashAndCashEquivalentsAndInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash and cash equivalents and investments.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeasesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leases [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_TwoThousandFourteenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2014 Equity Incentive Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_TwoThousandFourteenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Fourteen Equity Incentive Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_TwoThousandFourteenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand fourteen equity incentive plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss Contingencies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingencies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_SeriesBRedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B Redeemable Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_SeriesBRedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series B Redeemable Convertible Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_SeriesBRedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series B redeemable convertible preferred stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Vested and expected to vest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Operating Loss Carryforwards, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating losses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Operating Loss Carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssued1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock issued for payment of accounts payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssued1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Shares, Outstanding, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Shares, Outstanding, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: accumulated depreciation and amortization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation Depletion And Amortization Property Plant And Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Options, forfeited</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred tax assets:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">IPO</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">I P O [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Stock Issued Issuance Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Investments, Gross Unrealized Losses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted-Average Exercise Price Per Share, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted-Average Exercise Price Per Share, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from operating activities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Maturities of Lease Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Maturity Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Warrant purchase price per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments, Gross Unrealized Gains</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_PercentageOfFairValuePerShareOnTheGrantDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of fair value per share on the grant date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_PercentageOfFairValuePerShareOnTheGrantDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Fair Value Per Share On The Grant Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_PercentageOfFairValuePerShareOnTheGrantDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of fair value per share on the grant date.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ThresholdLimitOnEquityPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity payment, upper limit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ThresholdLimitOnEquityPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Threshold Limit On Equity Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ThresholdLimitOnEquityPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Threshold limit on equity payments.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_GrossProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate gross proceeds from issuance of common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_GrossProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gross Proceeds From Issuance Of Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_GrossProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Gross proceeds from issuance of common stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023 and 2022</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reconciliation of Effective Tax Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Effective Income Tax Rate Reconciliation Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration of Credit Risk and Other Risks and Uncertainties</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Credit Risk</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average discount rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Weighted Average Discount Rate Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_IncomeTaxDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Disclosure [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_IncomeTaxDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_IncomeTaxDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income tax disclosure.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of preferred stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Stock Issued During Period Value New Issues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Other Comprehensive Income (Loss), Net of Tax, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intrinsic value of the stock options exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of Options, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of Options, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GrantsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grant receivable on unreimbursed, eligible costs incurred</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GrantsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Grants Receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_NumberOfRenewalOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of renewal options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_NumberOfRenewalOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Renewal Options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_NumberOfRenewalOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of renewal options.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetBackedSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset backed securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetBackedSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset-backed Securities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of preferred stock, net of issuance cost (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Stock Issued During Period Shares New Issues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity stock issued during period shares new issues.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_DevelopmentAndManufacturingServicesAgreementEquityPaymentsPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payments in equity, percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_DevelopmentAndManufacturingServicesAgreementEquityPaymentsPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Development And Manufacturing Services Agreement Equity Payments Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_DevelopmentAndManufacturingServicesAgreementEquityPaymentsPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Development and manufacturing services agreement equity payments percentage.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Profit Loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommercialPaperMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial Paper</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommercialPaperMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commercial Paper [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ExpenseOnIssuanceOfRedeemableConvertiblePreferredStockWarrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expense on issuance of redeemable convertible preferred stock warrant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ExpenseOnIssuanceOfRedeemableConvertiblePreferredStockWarrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Expense On Issuance Of Redeemable Convertible Preferred Stock Warrant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ExpenseOnIssuanceOfRedeemableConvertiblePreferredStockWarrant_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Expense on issuance of redeemable convertible preferred stock warrant.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_PotentialFundingAmountOfAwardToDevelopVaccineToPreventInfections_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Potential funding amount of award to develop vaccine to prevent shingella infections</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_PotentialFundingAmountOfAwardToDevelopVaccineToPreventInfections_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Potential Funding Amount Of Award To Develop Vaccine To Prevent Infections</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_PotentialFundingAmountOfAwardToDevelopVaccineToPreventInfections_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Potential funding amount of award to develop vaccine to prevent infections.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate, Maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_LicenseAmendmentATwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License Amendment A2</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_LicenseAmendmentATwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Amendment A Two [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_LicenseAmendmentATwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License Amendment A Two.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total future undiscounted lease payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Products And Services [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Carrying Amount Attributable To Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sales of investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Sale of Debt Securities, Available-for-sale</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net proceeds from initial public offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Initial Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options Available for Grant, Additional shares authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Arrangements And Nonarrangement Transactions [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_LesseeOperatingLeaseCommencementDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, commencement date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_LesseeOperatingLeaseCommencementDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Commencement Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_LesseeOperatingLeaseCommencementDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee operating lease commencement date.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockDividendsPerShareDeclared_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, dividends, per share, declared</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockDividendsPerShareDeclared_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Dividends Per Share Declared</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_LonzaLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lonza DMSA</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_LonzaLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lonza Limited [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_LonzaLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lonza limited.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement Equity Components [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive loss:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_SaleOfCommonStockAuthorizedAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate offering price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_SaleOfCommonStockAuthorizedAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Common Stock Authorized Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_SaleOfCommonStockAuthorizedAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sale of common stock authorized amount.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Note Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_FundingArrangementTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Funding Arrangement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_FundingArrangementTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Funding Arrangement [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_FundingArrangementTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Funding arrangement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_PneumococcalConjugateVaccineMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pneumococcal Conjugate Vaccine</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_PneumococcalConjugateVaccineMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pneumococcal Conjugate Vaccine [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_PneumococcalConjugateVaccineMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Pneumococcal conjugate vaccine.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address City Or Town</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility, Minimum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective Income Tax Rate Reconciliation, Tax Credit, Percent, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Credits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Tax Credits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Details</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected term (in years)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transactions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from investing activities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020 Plan and 2014 Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Equity Incentive Plan And Two Thousand Fourteen Equity Incentive Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty equity incentive plan and two thousand fourteen equity incentive plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: Imputed interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Undiscounted Excess Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_TwoThousandFourteenEquityIncentivePlanAndTwoThousandTwentyEquityIncentivePlanAndTwoThousandTwentyEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2014 Plan, 2020 Plan and 2020 ESPP</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_TwoThousandFourteenEquityIncentivePlanAndTwoThousandTwentyEquityIncentivePlanAndTwoThousandTwentyEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Fourteen Equity Incentive Plan And Two Thousand Twenty Equity Incentive Plan And Two Thousand Twenty Employee Stock Purchase Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_TwoThousandFourteenEquityIncentivePlanAndTwoThousandTwentyEquityIncentivePlanAndTwoThousandTwentyEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand fourteen equity incentive plan and two thousand twenty equity incentive plan and two thousand twenty employee stock purchase plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201602Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASU 2016-02</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201602Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update201602 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_NumberOfSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_NumberOfSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_NumberOfSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of securities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders' equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Uncertain tax benefits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance at the beginning of the year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance at end of year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_MarketOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Market offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_MarketOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Market Offering [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_MarketOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Market offering.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for operating lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Comprehensive Loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income Policy Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Preferred Stock, Shares Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Range [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Debt Securities, Available-for-sale</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Shares Outstanding, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Shares Outstanding, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Tax Credit Carryforwards, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Credits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Credit Carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization Consolidation And Presentation Of Financial Statements [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Leases Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_LesseeOperatingLeaseRentCommencementDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, rent commencement date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_LesseeOperatingLeaseRentCommencementDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Rent Commencement Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_LesseeOperatingLeaseRentCommencementDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee, operating lease, rent commencement date.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements Fair Value Hierarchy [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Underwritten Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underwriter</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Over-Allotment Option [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Components of Deferred Tax Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Deferred Tax Assets And Liabilities Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities Current [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of Long-Lived Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment Or Disposal Of Long Lived Assets Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockVotingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, voting rights</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockVotingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Voting Rights</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated useful lives of assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Useful Life</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_OperatingLossCarryForwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss carry forwards expiration year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_OperatingLossCarryForwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carry Forwards Expiration Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_OperatingLossCarryForwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carry forwards expiration year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity incentive plan, shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement Policy Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in fair value of redeemable convertible preferred stock warrant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Adjustment Of Warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_PercentageOfRoyaltyPaymentOnNetSalesOfVaccineCompositionsForAnimalHealth_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of royalty payment on net sales of vaccine compositions for animal health</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_PercentageOfRoyaltyPaymentOnNetSalesOfVaccineCompositionsForAnimalHealth_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Royalty Payment On Net Sales Of Vaccine Compositions For Animal Health</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_PercentageOfRoyaltyPaymentOnNetSalesOfVaccineCompositionsForAnimalHealth_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of royalty payment on net sales of vaccine compositions for animal health.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reconciliation Of Unrecognized Tax Benefits Excluding Amounts Pertaining To Examined Tax Returns Roll Forward</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_PurchasePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_PurchasePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Purchase Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_PurchasePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Purchase period.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_NewCorporateHeadquartersFacilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">New Corporate Headquarters Facility</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_NewCorporateHeadquartersFacilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Corporate Headquarters Facility [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_NewCorporateHeadquartersFacilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">New Corporate Headquarters Facility.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Financial Instruments Measured at Fair Value on Recurring Basis</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets Measured On Recurring Basis [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Offering Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Charges Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Exercise Price Per Share, Options granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Stock Name Of Transaction [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_OfferingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Offering period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_OfferingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Offering Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_OfferingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Offering period.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from sales of property and equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Proceeds from Sale of Property, Plant, and Equipment, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Sale Of Property Plant And Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_FundingPeriodOfAwardToDevelopUniversalVaccineToPreventInfections_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Funding period of award to develop universal vaccine to prevent infections caused by Group A Strep bacteria</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_FundingPeriodOfAwardToDevelopUniversalVaccineToPreventInfections_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Funding Period Of Award To Develop Universal Vaccine To Prevent Infections</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_FundingPeriodOfAwardToDevelopUniversalVaccineToPreventInfections_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Funding period of award to develop universal vaccine to prevent infections.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_PaymentsOfCapitalLeaseObligations_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payments of capital lease obligations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_PaymentsOfCapitalLeaseObligations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments Of Capital Lease Obligations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_PaymentsOfCapitalLeaseObligations_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payments of capital lease obligations.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary Equity By Class Of Stock [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity By Class Of Stock [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee Lease Description [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Lease Description [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class Of Stock [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Stock [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_TemporaryEquityConversionOfPreferredStockShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of preferred stock (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_TemporaryEquityConversionOfPreferredStockShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Conversion Of Preferred Stock Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_TemporaryEquityConversionOfPreferredStockShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity conversion of preferred stock shares.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, agreement term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Term Of Contract</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon initial public offering or at-the-market offering, net of issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value New Issues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="stpr_CA_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">California</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="stpr_CA_lbl" xlink:role="http://www.xbrl.org/2003/role/label">C A</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Interest Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Interest expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DueToRelatedPartiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Due to Related Parties, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DueToRelatedPartiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related party accrual</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DueToRelatedPartiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Due To Related Parties Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock to LonzaLtd.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Issued For Services</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign currency transaction gains (losses)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Foreign Currency Transaction Gain (Loss), before Tax, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Currency Transaction Gain Loss Before Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-based Payment Arrangement, Noncash Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense And Other Assets Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Activity Under Stock Option Plans</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_DeferredTaxAssetsTaxAccruedManufacturingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued manufacturing expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_DeferredTaxAssetsTaxAccruedManufacturingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Accrued Manufacturing Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_DeferredTaxAssetsTaxAccruedManufacturingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets tax accrued manufacturing expenses.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred offering costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Offering Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Other Adjustments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant exercisable and vests immediately and expires date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Righst Date From Which Warrants Or Rights Exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Options, Exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of payroll deductions of eligible compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Maximum Employee Subscription Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 2</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level2 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reconciliation of Unrecognized Tax Benefit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Income Tax Contingencies [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Options, exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of stock options (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Stock Options Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities, redeemable convertible preferred stock and stockholders' equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities, Redeemable Convertible Preferred Stock and Stockholders' Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Cash Flows [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-in Capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security12b Title</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Comprehensive Loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income Net Of Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 3</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level3 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well-known Seasoned Issuer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ExercisePriceExpireInYearsFormTheDateOfGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise price expire in years form the date of grant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ExercisePriceExpireInYearsFormTheDateOfGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Exercise Price Expire In Years Form The Date Of Grant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ExercisePriceExpireInYearsFormTheDateOfGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Exercise price expire in years form the date of grant.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRightExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRightExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRightExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Class of warrant or right number of securities called by each warrant or right exercised.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting percentage for stock options granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Award Vesting Rights Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Fair Value Hierarchy Level [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term of plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest income</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Income Interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_NumberOfOptionsExercisedExcludesOptionsExercisedFromNpln_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of stock options (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_NumberOfOptionsExercisedExcludesOptionsExercisedFromNpln_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Options Exercised Excludes Options Exercised From NPLN</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_NumberOfOptionsExercisedExcludesOptionsExercisedFromNpln_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of options exercised, excludes options exercised from NPLN.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Property and Equipment, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_InitialPublicOfferingRelatedCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">IPO-related costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_InitialPublicOfferingRelatedCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Initial Public Offering Related Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_InitialPublicOfferingRelatedCost_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Initial public offering related cost.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level1 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_CapitalLeasesLabEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capital Leases &#8212; Lab Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_CapitalLeasesLabEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capital Leases Lab Equipment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_CapitalLeasesLabEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Capital leases &#8212; lab equipment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Four</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_IncreaseDecreaseInAccruedManufacturingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued manufacturing expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_IncreaseDecreaseInAccruedManufacturingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accrued Manufacturing Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_IncreaseDecreaseInAccruedManufacturingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase decrease in accrued manufacturing expenses.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in valuation allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Corporate Debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Corporate Debt Securities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Exercise Price Per Share, Vested and expected to vest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Options granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Options, granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonthsNetOfLeaseIncentives_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">2022</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonthsNetOfLeaseIncentives_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonthsNetOfLeaseIncentives_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Next Twelve Months Net of Lease Incentives</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonthsNetOfLeaseIncentives_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee operating lease liability payments due next twelve months net of lease incentives.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Voluntary Filers</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate, Minimum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_StockIssuedDuringPeriodSharesOfFollowOnOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_StockIssuedDuringPeriodSharesOfFollowOnOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares of follow on offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_StockIssuedDuringPeriodSharesOfFollowOnOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period, shares of follow on offering.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money Market Funds</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated By Reference [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Documents Incorporated by Reference</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_GlobalTargetRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Global target revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_GlobalTargetRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Global Target Revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_GlobalTargetRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Global target revenue.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, option to renewal, description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Option To Extend</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PerformanceSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Performance-based Awards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PerformanceSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Performance Shares [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_PaymentOfDeferredOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payments of deferred offering costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_PaymentOfDeferredOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment Of Deferred Offering Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_PaymentOfDeferredOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment of deferred offering costs.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesRealizedGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Realized gains on marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesRealizedGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Marketable Securities, Realized Gain (Loss), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesRealizedGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities Realized Gain Loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Firm ID</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Noncurrent Liabilities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ProceedsFromIssuanceOfCommonStockNotYetReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock through ATM facility not yet received</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ProceedsFromIssuanceOfCommonStockNotYetReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Common Stock Not Yet Received</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ProceedsFromIssuanceOfCommonStockNotYetReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from issuance of common stock not yet received.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Common Stock Shares Reserved for Future Issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Common Stock Shares Reserved For Future Issuance Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of common stock shares reserved for future issuance.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Exercise Price Per Share, Exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accrued Liabilities, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accrued Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_StockOptionsGrantedTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock options granted term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_StockOptionsGrantedTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Options Granted Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_StockOptionsGrantedTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock options granted term.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest or penalties recognized for the period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits Income Tax Penalties And Interest Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Minimum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Remaining Contractual Term (Years), Vested and expected to vest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement Frequency [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_PercentageOfPaymentsCompletionAgreedToDefer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of defer payments agreed for completion</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_PercentageOfPaymentsCompletionAgreedToDefer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Payments Completion Agreed To Defer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_PercentageOfPaymentsCompletionAgreedToDefer_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of payments completion agreed to defer.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of stock options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Stock Options Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Due in less than one year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Debt Maturities Within One Year Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncurrentAssetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncurrentAssetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Noncurrent Assets [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">New Accounting Pronouncements Or Change In Accounting Principle [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements Or Change In Accounting Principle [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Company Organization and Nature of Business</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization Consolidation And Presentation Of Financial Statements Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_TemporaryEquityConversionOfPreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of preferred stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_TemporaryEquityConversionOfPreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Conversion Of Preferred Stock Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_TemporaryEquityConversionOfPreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity conversion of preferred stock value.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Annual Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetImpairmentCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Asset Impairment Charges, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetImpairmentCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset impairment charges</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetImpairmentCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Impairment Charges</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assumptions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions And Methodology [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheLiabilities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Change in fair value of redeemable convertible preferred stock tranche liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change In Fair Value Of Redeemable Convertible Preferred Stock Tranche Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Change in fair value of redeemable convertible preferred stock tranche liabilities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Valuation Allowance, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Valuation allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Valuation Allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_CostReimbursementSubAwardAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cost Reimbursement Sub-Award Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_CostReimbursementSubAwardAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cost Reimbursement Sub Award Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_CostReimbursementSubAwardAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cost reimbursement sub-award agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_LeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deffered Tax Assets Lease Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_LeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_LeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease liability.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from financing activities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized stock-based compensation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_CashAndCashEquivalentsAndInvestmentsGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total assets measured at fair value, Gross Unrealized Gains</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_CashAndCashEquivalentsAndInvestmentsGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents And Investments Gross Unrealized Gain Before Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_CashAndCashEquivalentsAndInvestmentsGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash and cash equivalents and investments gross unrealized gain before tax.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_CashAndCashEquivalentsAndInvestmentsGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Total assets measured at fair value, Gross Unrealized Losses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_CashAndCashEquivalentsAndInvestmentsGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents And Investments Gross Unrealized Loss Before Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_CashAndCashEquivalentsAndInvestmentsGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash and cash equivalents and investments gross unrealized loss before tax.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign Currency Transactions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Currency Transactions And Translations Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Entity Filer Category</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Options, Vested and expected to vest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_SharesPreFundedWarrantsToPurchase_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-funded warrants to purchase shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_SharesPreFundedWarrantsToPurchase_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Pre-Funded Warrants To Purchase</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_SharesPreFundedWarrantsToPurchase_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Shares pre-funded warrants to purchase.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Construction in Progress</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Construction In Progress [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average grant date fair value of options granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Retained Earnings (Accumulated Deficit), Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Retained Earnings (Accumulated Deficit), Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Retained Earnings (Accumulated Deficit), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings Accumulated Deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Depletion and Amortization, Nonproduction, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation And Amortization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_HeadquartersFacilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Headquarters Facility</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_HeadquartersFacilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Headquarters Facility [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_HeadquartersFacilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Headquarters facility.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_SharesAvailableForFutureStockOptionGrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares Available for Future Stock Option Grants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_SharesAvailableForFutureStockOptionGrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Available For Future Stock Option Grants [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_SharesAvailableForFutureStockOptionGrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Shares available for future stock option grants.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_TemporaryEquityStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_TemporaryEquityStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Stock Issuance Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_TemporaryEquityStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity stock issuance costs.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_SharesIssuedUponFullExerciseOfUnderwritersOptionToPurchaseAdditionalShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underwriters' option to purchase additional shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_SharesIssuedUponFullExerciseOfUnderwritersOptionToPurchaseAdditionalShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued Upon Full Exercise Of Underwriters Option To Purchase Additional Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_SharesIssuedUponFullExerciseOfUnderwritersOptionToPurchaseAdditionalShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Shares issued upon full exercise of underwriters option to purchase additional shares.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares vested</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating leases, rent expense recognized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary Equity [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Contractual Maturities of Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments Classified By Contractual Maturity Date Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, par value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Par Or Stated Value Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_Section162MLimitation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Section 162(m) Limitation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_Section162MLimitation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Section 162(m) limitation.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reverse stock split, conversion ratio</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Note Stock Split Conversion Ratio1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized share-based compensation expense, expected to be recognized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accruals &amp; reserves</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Deferred Expense Reserves And Accruals</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred tax liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting standard update adoption date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change In Accounting Principle Accounting Standards Update Adoption Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold Improvements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average remaining lease term (in years)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Weighted Average Remaining Lease Term1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_IncreaseDecreaseInDeferredRentAndOtherLongTermLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred rent and other long-term liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_IncreaseDecreaseInDeferredRentAndOtherLongTermLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Deferred Rent And Other Long Term Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_IncreaseDecreaseInDeferredRentAndOtherLongTermLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase decrease in deferred rent and other long term liabilities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_PotentialFundingPeriodOfAwardToDevelopVaccineToPreventInfections_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Potential funding period of award to develop vaccine to prevent shingella infections</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_PotentialFundingPeriodOfAwardToDevelopVaccineToPreventInfections_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Potential Funding Period Of Award To Develop Vaccine To Prevent Infections</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_PotentialFundingPeriodOfAwardToDevelopVaccineToPreventInfections_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Potential funding period of award to develop vaccine to prevent infections.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee Lease Description [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Lease Description [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock price per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Public offering price per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued Price Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Standards Update</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Type Of Adoption [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Standards Update</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments For New Accounting Pronouncements [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payment of issuance costs for initial public offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Offering expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments Of Stock Issuance Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accounts Payable, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accounts Payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ChangeInFairValueOfRedeemableConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in fair value of the redeemable convertible preferred stock tranche liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ChangeInFairValueOfRedeemableConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change In Fair Value Of Redeemable Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ChangeInFairValueOfRedeemableConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Change in fair value of the redeemable convertible preferred stock tranche liability.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation and Summary of Significant Accounting Policies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis Of Presentation And Significant Accounting Policies [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_CashAndCashEquivalentsGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents, Gross Unrealized Gains</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_CashAndCashEquivalentsGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Gross Unrealized Gain Before Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_CashAndCashEquivalentsGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash and cash equivalents gross unrealized gain before tax.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Incentive Plans</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Compensation Related Costs Share Based Payments [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_LesseeOperatingLeaseExtendedMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, extended maturity date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_LesseeOperatingLeaseExtendedMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Extended Maturity Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_LesseeOperatingLeaseExtendedMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee, operating lease, extended maturity date.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_LesseeOperatingLeaseRenewalOption_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, renewal option</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_LesseeOperatingLeaseRenewalOption_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Renewal Option</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_LesseeOperatingLeaseRenewalOption_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee operating lease renewal option.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating Lease, Liability, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Gross, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Gross, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property, Plant and Equipment, Gross, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total property and equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Professional fees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Professional Fees Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Public Float</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_TwoThousandTwentyEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020 Equity Incentive Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_TwoThousandTwentyEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Equity Incentive Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_TwoThousandTwentyEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty equity incentive plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Cash, Cash Equivalents And Restricted Cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restrictions on Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_PotentialFundingCommittedByAward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Potential funding committed by award</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_PotentialFundingCommittedByAward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Potential Funding Committed By Award</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_PotentialFundingCommittedByAward_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Potential funding committed by award.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Class</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Asset Class [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of redeemable convertible preferred stock, net of issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Redeemable Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_IncreaseDecreaseInAccruedLegalSettlement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued legal settlement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_IncreaseDecreaseInAccruedLegalSettlement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accrued Legal Settlement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_IncreaseDecreaseInAccruedLegalSettlement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase decrease in accrued legal settlement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preferred stock outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Redeemable convertible preferred stock, shares outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Stockholders Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Property Plant And Equipment [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Property Plant And Equipment [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of operating segments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Operating Segments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value liabilities transferred out of level 3</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfTrancheLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in Fair Value of Tranche Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfTrancheLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Change In Fair Value Of Tranche Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfTrancheLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Effective income tax rate reconciliation change in fair value of tranche liability.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_LabEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lab Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_LabEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lab Equipment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_LabEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lab equipment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_SanCarlosMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">San Carlos</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_SanCarlosMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">San Carlos [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_SanCarlosMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">San Carlos.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment By Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_LeaseTerminationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease termination date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_LeaseTerminationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Termination Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_LeaseTerminationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease termination date.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other accrued expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fixed assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Property Plant And Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from exercise of common stock options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Stock Options Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, renewal term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Renewal Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ResearchAndDevelopmentExpenseToRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development expense to related party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ResearchAndDevelopmentExpenseToRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense To Related Party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ResearchAndDevelopmentExpenseToRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and development expense to related party.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_AdditionalFundingCommittedByAward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional funding committed by award</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_AdditionalFundingCommittedByAward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Funding Committed By Award</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_AdditionalFundingCommittedByAward_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional funding committed by award.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development (including related party expenses of $2359, $1,331 and $1,137 in 2021, 2020 and 2019, respectively)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Research and Development Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">New Accounting Pronouncements Or Change In Accounting Principle [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements Or Change In Accounting Principle [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total stock-based compensation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Allocated Share Based Compensation Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_IncentiveStockOptionGrantedToEmployeesOwningPercentageOfSharesOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Incentive stock option granted to employees owning percentage of shares of common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_IncentiveStockOptionGrantedToEmployeesOwningPercentageOfSharesOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Incentive Stock Option Granted To Employees Owning Percentage Of Shares Of Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_IncentiveStockOptionGrantedToEmployeesOwningPercentageOfSharesOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Incentive stock option granted to Employees Owning percentage of shares of common stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value liabilities transferred from level 2 to level 1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Liabilities Level2 To Level1 Transfers Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Thereafter</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due After Year Four</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee operating lease liability payments due after year four.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maturities of investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_CapitalLeasesAmortizationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capital lease amortization expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_CapitalLeasesAmortizationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Capital Leases Amortization Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Financial Position [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreaseInAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Available for issuance of shares increased</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreaseInAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Increase In Available For Grant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreaseInAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award number of shares increase in available for grant.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected dividend yield</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Depletion and Amortization, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation Depletion And Amortization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of operating right-of-use assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset, Amortization Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statutory Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders' Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_WarrantsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_WarrantsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_WarrantsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Long-term Investments, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Computation of Basic and Diluted Net Loss Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Earnings Per Share Basic And Diluted Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted-average price per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Exercise Price Per Share, Options exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Three</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Common Stock, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based Compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Shares reserved for issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock reserved for future issuances</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Capital Shares Reserved For Future Issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Measurement Frequency [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Average price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Stock Price Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ProceedsFromInitialPublicOfferingNetOfUnderwritersCommissionsAndDiscounts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from initial public offering, net of underwriters' commissions and discounts</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ProceedsFromInitialPublicOfferingNetOfUnderwritersCommissionsAndDiscounts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Initial Public Offering Net Of Underwriters Commissions And Discounts</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ProceedsFromInitialPublicOfferingNetOfUnderwritersCommissionsAndDiscounts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from initial public offering, net of underwriters' commissions and discounts.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities, Redeemable Convertible Preferred Stock and Stockholders' Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Icfr Auditor Attestation Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ICFR Auditor Attestation Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock under Employee Stock Purchase Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Employee Stock Purchase Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Repurchase Agreement Counterparty Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">ROU asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Leasing Arrangements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Due in one to five years</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Debt Maturities After One Through Five Years Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Stock By Class [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Stock By Class [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product Or Service [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of convertible preferred stock into common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Conversion Of Stock Amount Converted1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Short-term Investments, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short Term Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_RemainingLiabilitiesRelatedToEarlyExercisedShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remaining liabilities related to early exercised shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_RemainingLiabilitiesRelatedToEarlyExercisedShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Remaining Liabilities Related To Early Exercised Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_RemainingLiabilitiesRelatedToEarlyExercisedShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Remaining liabilities related to early exercised shares.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total other income (expense), net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and Cash Equivalents, at Carrying Value, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and Cash Equivalents, at Carrying Value, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash and Cash Equivalents, at Carrying Value, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents At Carrying Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recently Adopted Accounting Pronouncements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements Policy Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_AccruedResearchAndDevelopmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Research and Development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_AccruedResearchAndDevelopmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Research And Development Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_AccruedResearchAndDevelopmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued research and development.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_NumberOfOperatingLease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of operating lease</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_NumberOfOperatingLease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Operating Lease</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_NumberOfOperatingLease_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of operating lease.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research credit carryforward</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_SeriesARedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A Redeemable Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_SeriesARedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series A Redeemable Convertible Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_SeriesARedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series A redeemable convertible preferred stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Recurring</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements Recurring [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_FundingArrangementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Funding Arrangement [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_FundingArrangementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Funding arrangement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Events</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred tax asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Liabilities Net Before Valuation Allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets liabilities net before valuation allowance.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value assets transferred from level 1 to level 2</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets Level1 To Level2 Transfers Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CARB-X Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Combating antibiotic resistant bacteria biopharmaceutical accelerator agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_IncomeTaxDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Disclosure [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_IncomeTaxDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_IncomeTaxDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income tax disclosure.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property Plant And Equipment [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Assets, Noncurrent, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Type Of Arrangement [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employees purchase shares of common stock of lower of fair market value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid Expenses and Other Current Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expenses And Other Current Assets [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_RedeemableConvertiblePreferredStockTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Redeemable Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_RedeemableConvertiblePreferredStockTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Redeemable Convertible Preferred Stock [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_RedeemableConvertiblePreferredStockTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Redeemable convertible preferred stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary Sale Of Stock [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock-based Compensation Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Compensation Cost For Share Based Payment Arrangements Allocation Of Share Based Compensation Costs By Plan Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Components Of Deferred Tax Assets And Liabilities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements and Fair Value of Financial Instruments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock under ATM Sales Program, net of issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds from issuance of stock, net of commission and offering expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Common Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDescription" xlink:to="us-gaap_LesseeOperatingLeaseDescription_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_TwoThousandTwentyEmployeeStockPurchasePlanMember" xlink:to="pcvx_TwoThousandTwentyEmployeeStockPurchasePlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseExpirationDate1" xlink:to="us-gaap_LeaseExpirationDate1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_InitialFundingCommittedByAward" xlink:to="pcvx_InitialFundingCommittedByAward_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" xlink:to="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:to="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_ComputersAndComputerSoftwareMember" xlink:to="pcvx_ComputersAndComputerSoftwareMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesAuthorized" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_AccruedPreclinicalStudiesCurrent" xlink:to="pcvx_AccruedPreclinicalStudiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRentCreditCurrent" xlink:to="us-gaap_DeferredRentCreditCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentPolicyTextBlock" xlink:to="us-gaap_InvestmentPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockPlans" xlink:to="us-gaap_ProceedsFromStockPlans_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_AdditionalFacilityMember" xlink:to="pcvx_AdditionalFacilityMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_CommonStockWarrantMember" xlink:to="pcvx_CommonStockWarrantMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_FundingArrangementLineItems" xlink:to="pcvx_FundingArrangementLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_StockIssuedDuringPeriodSharesIssuanceOfCommonStockRelatedToEarlyExercisedStockOptions" xlink:to="pcvx_StockIssuedDuringPeriodSharesIssuanceOfCommonStockRelatedToEarlyExercisedStockOptions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_SeriesDRedeemableConvertiblePreferredStockMember" xlink:to="pcvx_SeriesDRedeemableConvertiblePreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesNetCurrent" xlink:to="us-gaap_ReceivablesNetCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_AccruedManufacturingExpenses" xlink:to="pcvx_AccruedManufacturingExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="pcvx_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeitedInPeriod" xlink:to="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeitedInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_ProceedsFromIssuanceFollowOnOffering" xlink:to="pcvx_ProceedsFromIssuanceFollowOnOffering_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_CashAndCashEquivalentsAndInvestmentsAmortizedCostBasis" xlink:to="pcvx_CashAndCashEquivalentsAndInvestmentsAmortizedCostBasis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_AdjustmentsToAdditionalPaidInCapitalVestingOfEarlyExercisedStockOptions" xlink:to="pcvx_AdjustmentsToAdditionalPaidInCapitalVestingOfEarlyExercisedStockOptions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GuaranteeObligationsMaximumExposure" xlink:to="us-gaap_GuaranteeObligationsMaximumExposure_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RedeemableConvertiblePreferredStockMember" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_SutroBiopharmaIncMember" xlink:to="pcvx_SutroBiopharmaIncMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExercisedInPeriod" xlink:to="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExercisedInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses" xlink:to="pcvx_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_PrefundedWarrantsPricePerShare" xlink:to="pcvx_PrefundedWarrantsPricePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_LicenseAgreementMember" xlink:to="pcvx_LicenseAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_StockIssuedDuringPeriodSharesConversionOfPreferredStockWarrant" xlink:to="pcvx_StockIssuedDuringPeriodSharesConversionOfPreferredStockWarrant_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_CashAndCashEquivalentsAmortizedCost" xlink:to="pcvx_CashAndCashEquivalentsAmortizedCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasurySecuritiesMember" xlink:to="us-gaap_USTreasurySecuritiesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_SeriesCRedeemableConvertiblePreferredStockMember" xlink:to="pcvx_SeriesCRedeemableConvertiblePreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_RedeemableConvertiblePreferredStockWarrantMember" xlink:to="pcvx_RedeemableConvertiblePreferredStockWarrantMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashMember" xlink:to="us-gaap_CashMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_SharesIssuedPricePerShareUponFollowOnOffering" xlink:to="pcvx_SharesIssuedPricePerShareUponFollowOnOffering_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_CashAndCashEquivalentsGrossUnrealizedLossBeforeTax" xlink:to="pcvx_CashAndCashEquivalentsGrossUnrealizedLossBeforeTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_GrantIncome" xlink:to="pcvx_GrantIncome_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_TaxCreditCarryforwardExpirationYear" xlink:to="pcvx_TaxCreditCarryforwardExpirationYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRentCreditNoncurrent" xlink:to="us-gaap_DeferredRentCreditNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:to="pcvx_IncreaseDecreaseInOperatingLeaseLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201912Member" xlink:to="us-gaap_AccountingStandardsUpdate201912Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_PaloAltoMember" xlink:to="pcvx_PaloAltoMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_IncreaseDecreaseInAccruedCompensation" xlink:to="pcvx_IncreaseDecreaseInAccruedCompensation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_PercentageOfRoyaltyPaymentOnAnnualNetSalesOfVaccineProductsForHumanHealth" xlink:to="pcvx_PercentageOfRoyaltyPaymentOnAnnualNetSalesOfVaccineProductsForHumanHealth_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_SharesIssuedUponFollowOnOfferingFullExerciseOfUnderwritersOptionToPurchaseAdditionalShares" xlink:to="pcvx_SharesIssuedUponFollowOnOfferingFullExerciseOfUnderwritersOptionToPurchaseAdditionalShares_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_PaymentsOfUnderwritingDiscountsAndCommissions" xlink:to="pcvx_PaymentsOfUnderwritingDiscountsAndCommissions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_NumberOfFinanceLease" xlink:to="pcvx_NumberOfFinanceLease_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantedInPeriod" xlink:to="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantedInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_AdjustmentsToAdditionalPaidInCapitalWarrantLiabilityWriteOff" xlink:to="pcvx_AdjustmentsToAdditionalPaidInCapitalWarrantLiabilityWriteOff_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_LeasePaymentReceivableNoncurrent" xlink:to="pcvx_LeasePaymentReceivableNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDispositionOfAssets1" xlink:to="us-gaap_GainLossOnDispositionOfAssets1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_MaximumCommissionPercentageOfGrossProceedsFromCommonStockSold" xlink:to="pcvx_MaximumCommissionPercentageOfGrossProceedsFromCommonStockSold_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_ScheduleOfInformationRelatedToRightOfUseAssetsAndLeaseLiabilitiesTableTextBlock" xlink:to="pcvx_ScheduleOfInformationRelatedToRightOfUseAssetsAndLeaseLiabilitiesTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_ProceedsFromIssuanceOfCommonStockRelatedToEarlyExercisedStockOptions" xlink:to="pcvx_ProceedsFromIssuanceOfCommonStockRelatedToEarlyExercisedStockOptions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BuildingMember" xlink:to="us-gaap_BuildingMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_StockIssuedDuringPeriodSharesConversionOfCommonStockWarrant" xlink:to="pcvx_StockIssuedDuringPeriodSharesConversionOfCommonStockWarrant_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:to="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_FundingArrangementTable" xlink:to="pcvx_FundingArrangementTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDueFromToRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionDueFromToRelatedParty_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_LesseeOperatingLeaseExtendedLeaseTerm" xlink:to="pcvx_LesseeOperatingLeaseExtendedLeaseTerm_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_ATMSalesAgreementMember" xlink:to="pcvx_ATMSalesAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_DevelopmentAndManufacturingServicesAgreementPaymentsInEquity" xlink:to="pcvx_DevelopmentAndManufacturingServicesAgreementPaymentsInEquity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_PercentageOfProvisionsSubjectToStockholders" xlink:to="pcvx_PercentageOfProvisionsSubjectToStockholders_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_EarlyExercisedStockOptions" xlink:to="pcvx_EarlyExercisedStockOptions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_SupplyAgreementMember" xlink:to="pcvx_SupplyAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_PreferredStockWarrantMember" xlink:to="pcvx_PreferredStockWarrantMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_FundingCommittedByAwardAvailableUponAchievementOfDevelopmentMilestones" xlink:to="pcvx_FundingCommittedByAwardAvailableUponAchievementOfDevelopmentMilestones_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_JefferiesLimitedLiabilityCompanyMember" xlink:to="pcvx_JefferiesLimitedLiabilityCompanyMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_CashAndCashEquivalentsAndInvestments" xlink:to="pcvx_CashAndCashEquivalentsAndInvestments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_TwoThousandFourteenEquityIncentivePlanMember" xlink:to="pcvx_TwoThousandFourteenEquityIncentivePlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_SeriesBRedeemableConvertiblePreferredStockMember" xlink:to="pcvx_SeriesBRedeemableConvertiblePreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssued1" xlink:to="us-gaap_StockIssued1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsGrossAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_PercentageOfFairValuePerShareOnTheGrantDate" xlink:to="pcvx_PercentageOfFairValuePerShareOnTheGrantDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_ThresholdLimitOnEquityPayments" xlink:to="pcvx_ThresholdLimitOnEquityPayments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_GrossProceedsFromIssuanceOfCommonStock" xlink:to="pcvx_GrossProceedsFromIssuanceOfCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_IncomeTaxDisclosureLineItems" xlink:to="pcvx_IncomeTaxDisclosureLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrantsReceivable" xlink:to="us-gaap_GrantsReceivable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_NumberOfRenewalOptions" xlink:to="pcvx_NumberOfRenewalOptions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetBackedSecuritiesMember" xlink:to="us-gaap_AssetBackedSecuritiesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:to="pcvx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_DevelopmentAndManufacturingServicesAgreementEquityPaymentsPercentage" xlink:to="pcvx_DevelopmentAndManufacturingServicesAgreementEquityPaymentsPercentage_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommercialPaperMember" xlink:to="us-gaap_CommercialPaperMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_ExpenseOnIssuanceOfRedeemableConvertiblePreferredStockWarrant" xlink:to="pcvx_ExpenseOnIssuanceOfRedeemableConvertiblePreferredStockWarrant_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_PotentialFundingAmountOfAwardToDevelopVaccineToPreventInfections" xlink:to="pcvx_PotentialFundingAmountOfAwardToDevelopVaccineToPreventInfections_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_LicenseAmendmentATwoMember" xlink:to="pcvx_LicenseAmendmentATwoMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:to="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_LesseeOperatingLeaseCommencementDate" xlink:to="pcvx_LesseeOperatingLeaseCommencementDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockDividendsPerShareDeclared" xlink:to="us-gaap_CommonStockDividendsPerShareDeclared_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_LonzaLimitedMember" xlink:to="pcvx_LonzaLimitedMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_SaleOfCommonStockAuthorizedAmount" xlink:to="pcvx_SaleOfCommonStockAuthorizedAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_FundingArrangementTextBlock" xlink:to="pcvx_FundingArrangementTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_PneumococcalConjugateVaccineMember" xlink:to="pcvx_PneumococcalConjugateVaccineMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember" xlink:to="pcvx_TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_TwoThousandFourteenEquityIncentivePlanAndTwoThousandTwentyEquityIncentivePlanAndTwoThousandTwentyEmployeeStockPurchasePlanMember" xlink:to="pcvx_TwoThousandFourteenEquityIncentivePlanAndTwoThousandTwentyEquityIncentivePlanAndTwoThousandTwentyEmployeeStockPurchasePlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201602Member" xlink:to="us-gaap_AccountingStandardsUpdate201602Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_NumberOfSecurities" xlink:to="pcvx_NumberOfSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_MarketOfferingMember" xlink:to="pcvx_MarketOfferingMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_LesseeOperatingLeaseRentCommencementDate" xlink:to="pcvx_LesseeOperatingLeaseRentCommencementDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchMember" xlink:to="us-gaap_ResearchMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockVotingRights" xlink:to="us-gaap_CommonStockVotingRights_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_OperatingLossCarryForwardsExpirationYear" xlink:to="pcvx_OperatingLossCarryForwardsExpirationYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_PercentageOfRoyaltyPaymentOnNetSalesOfVaccineCompositionsForAnimalHealth" xlink:to="pcvx_PercentageOfRoyaltyPaymentOnNetSalesOfVaccineCompositionsForAnimalHealth_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_PurchasePeriod" xlink:to="pcvx_PurchasePeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_NewCorporateHeadquartersFacilityMember" xlink:to="pcvx_NewCorporateHeadquartersFacilityMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredChargesPolicyTextBlock" xlink:to="us-gaap_DeferredChargesPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_OfferingPeriod" xlink:to="pcvx_OfferingPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_FundingPeriodOfAwardToDevelopUniversalVaccineToPreventInfections" xlink:to="pcvx_FundingPeriodOfAwardToDevelopUniversalVaccineToPreventInfections_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_PaymentsOfCapitalLeaseObligations" xlink:to="pcvx_PaymentsOfCapitalLeaseObligations_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_TemporaryEquityConversionOfPreferredStockShares" xlink:to="pcvx_TemporaryEquityConversionOfPreferredStockShares_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_CA" xlink:to="stpr_CA_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToRelatedPartiesCurrent" xlink:to="us-gaap_DueToRelatedPartiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_DeferredTaxAssetsTaxAccruedManufacturingExpenses" xlink:to="pcvx_DeferredTaxAssetsTaxAccruedManufacturingExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredOfferingCosts" xlink:to="us-gaap_DeferredOfferingCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:to="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:to="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_BalanceSheetLocationDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_ExercisePriceExpireInYearsFormTheDateOfGrant" xlink:to="pcvx_ExercisePriceExpireInYearsFormTheDateOfGrant_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRightExercised" xlink:to="pcvx_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRightExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_NumberOfOptionsExercisedExcludesOptionsExercisedFromNpln" xlink:to="pcvx_NumberOfOptionsExercisedExcludesOptionsExercisedFromNpln_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_InitialPublicOfferingRelatedCost" xlink:to="pcvx_InitialPublicOfferingRelatedCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_CapitalLeasesLabEquipmentMember" xlink:to="pcvx_CapitalLeasesLabEquipmentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_IncreaseDecreaseInAccruedManufacturingExpenses" xlink:to="pcvx_IncreaseDecreaseInAccruedManufacturingExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateDebtSecuritiesMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonthsNetOfLeaseIncentives" xlink:to="pcvx_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonthsNetOfLeaseIncentives_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_StockIssuedDuringPeriodSharesOfFollowOnOffering" xlink:to="pcvx_StockIssuedDuringPeriodSharesOfFollowOnOffering_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_GlobalTargetRevenue" xlink:to="pcvx_GlobalTargetRevenue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PerformanceSharesMember" xlink:to="us-gaap_PerformanceSharesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_PaymentOfDeferredOfferingCosts" xlink:to="pcvx_PaymentOfDeferredOfferingCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesRealizedGainLoss" xlink:to="us-gaap_MarketableSecuritiesRealizedGainLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncurrentLiabilitiesMember" xlink:to="us-gaap_OtherNoncurrentLiabilitiesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_ProceedsFromIssuanceOfCommonStockNotYetReceived" xlink:to="pcvx_ProceedsFromIssuanceOfCommonStockNotYetReceived_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock" xlink:to="pcvx_ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_StockOptionsGrantedTerm" xlink:to="pcvx_StockOptionsGrantedTerm_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_PercentageOfPaymentsCompletionAgreedToDefer" xlink:to="pcvx_PercentageOfPaymentsCompletionAgreedToDefer_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncurrentAssetsMember" xlink:to="us-gaap_OtherNoncurrentAssetsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_TemporaryEquityConversionOfPreferredStockValue" xlink:to="pcvx_TemporaryEquityConversionOfPreferredStockValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetImpairmentCharges" xlink:to="us-gaap_AssetImpairmentCharges_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_ChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheLiabilities" xlink:to="pcvx_ChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_CostReimbursementSubAwardAgreementMember" xlink:to="pcvx_CostReimbursementSubAwardAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_LeaseLiability" xlink:to="pcvx_LeaseLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_CashAndCashEquivalentsAndInvestmentsGrossUnrealizedGainBeforeTax" xlink:to="pcvx_CashAndCashEquivalentsAndInvestmentsGrossUnrealizedGainBeforeTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_CashAndCashEquivalentsAndInvestmentsGrossUnrealizedLossBeforeTax" xlink:to="pcvx_CashAndCashEquivalentsAndInvestmentsGrossUnrealizedLossBeforeTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_SharesPreFundedWarrantsToPurchase" xlink:to="pcvx_SharesPreFundedWarrantsToPurchase_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressMember" xlink:to="us-gaap_ConstructionInProgressMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_HeadquartersFacilityMember" xlink:to="pcvx_HeadquartersFacilityMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_SharesAvailableForFutureStockOptionGrantsMember" xlink:to="pcvx_SharesAvailableForFutureStockOptionGrantsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_TemporaryEquityStockIssuanceCosts" xlink:to="pcvx_TemporaryEquityStockIssuanceCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_SharesIssuedUponFullExerciseOfUnderwritersOptionToPurchaseAdditionalShares" xlink:to="pcvx_SharesIssuedUponFullExerciseOfUnderwritersOptionToPurchaseAdditionalShares_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="us-gaap_TemporaryEquityDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_Section162MLimitation" xlink:to="pcvx_Section162MLimitation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_IncreaseDecreaseInDeferredRentAndOtherLongTermLiabilities" xlink:to="pcvx_IncreaseDecreaseInDeferredRentAndOtherLongTermLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_PotentialFundingPeriodOfAwardToDevelopVaccineToPreventInfections" xlink:to="pcvx_PotentialFundingPeriodOfAwardToDevelopVaccineToPreventInfections_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_TypeOfAdoptionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_ChangeInFairValueOfRedeemableConvertiblePreferredStock" xlink:to="pcvx_ChangeInFairValueOfRedeemableConvertiblePreferredStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_CashAndCashEquivalentsGrossUnrealizedGainBeforeTax" xlink:to="pcvx_CashAndCashEquivalentsGrossUnrealizedGainBeforeTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_LesseeOperatingLeaseExtendedMaturityDate" xlink:to="pcvx_LesseeOperatingLeaseExtendedMaturityDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_LesseeOperatingLeaseRenewalOption" xlink:to="pcvx_LesseeOperatingLeaseRenewalOption_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_TwoThousandTwentyEquityIncentivePlanMember" xlink:to="pcvx_TwoThousandTwentyEquityIncentivePlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:to="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_PotentialFundingCommittedByAward" xlink:to="pcvx_PotentialFundingCommittedByAward_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_IncreaseDecreaseInAccruedLegalSettlement" xlink:to="pcvx_IncreaseDecreaseInAccruedLegalSettlement_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfTrancheLiability" xlink:to="pcvx_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfTrancheLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_LabEquipmentMember" xlink:to="pcvx_LabEquipmentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_SanCarlosMember" xlink:to="pcvx_SanCarlosMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_LeaseTerminationDate" xlink:to="pcvx_LeaseTerminationDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_ResearchAndDevelopmentExpenseToRelatedParty" xlink:to="pcvx_ResearchAndDevelopmentExpenseToRelatedParty_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_AdditionalFundingCommittedByAward" xlink:to="pcvx_AdditionalFundingCommittedByAward_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_IncentiveStockOptionGrantedToEmployeesOwningPercentageOfSharesOfCommonStock" xlink:to="pcvx_IncentiveStockOptionGrantedToEmployeesOwningPercentageOfSharesOfCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" xlink:to="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:to="pcvx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_CapitalLeasesAmortizationExpense" xlink:to="pcvx_CapitalLeasesAmortizationExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreaseInAvailableForGrant" xlink:to="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreaseInAvailableForGrant_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_WarrantsDisclosureTextBlock" xlink:to="pcvx_WarrantsDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermInvestments" xlink:to="us-gaap_LongTermInvestments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_ProceedsFromInitialPublicOfferingNetOfUnderwritersCommissionsAndDiscounts" xlink:to="pcvx_ProceedsFromInitialPublicOfferingNetOfUnderwritersCommissionsAndDiscounts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockAmountConverted1" xlink:to="us-gaap_ConversionOfStockAmountConverted1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_RemainingLiabilitiesRelatedToEarlyExercisedShares" xlink:to="pcvx_RemainingLiabilitiesRelatedToEarlyExercisedShares_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_AccruedResearchAndDevelopmentPolicyTextBlock" xlink:to="pcvx_AccruedResearchAndDevelopmentPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_NumberOfOperatingLease" xlink:to="pcvx_NumberOfOperatingLease_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_SeriesARedeemableConvertiblePreferredStockMember" xlink:to="pcvx_SeriesARedeemableConvertiblePreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_FundingArrangementAbstract" xlink:to="pcvx_FundingArrangementAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance" xlink:to="pcvx_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:to="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorAgreementMember" xlink:to="pcvx_CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_IncomeTaxDisclosureTable" xlink:to="pcvx_IncomeTaxDisclosureTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:to="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_RedeemableConvertiblePreferredStockTextBlock" xlink:to="pcvx_RedeemableConvertiblePreferredStockTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>32
<FILENAME>pcvx-20211231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2022-02-28T14:49:03.2596+00:00 -->
<!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:href="pcvx-20211231.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementBalanceSheets" xlink:href="pcvx-20211231.xsd#Role_StatementBalanceSheets" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementBalanceSheetsParenthetical" xlink:href="pcvx-20211231.xsd#Role_StatementBalanceSheetsParenthetical" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfOperations" xlink:href="pcvx-20211231.xsd#Role_StatementStatementsOfOperations" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfOperationsParenthetical" xlink:href="pcvx-20211231.xsd#Role_StatementStatementsOfOperationsParenthetical" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfComprehensiveLoss" xlink:href="pcvx-20211231.xsd#Role_StatementStatementsOfComprehensiveLoss" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:href="pcvx-20211231.xsd#Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:href="pcvx-20211231.xsd#Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited" xlink:href="pcvx-20211231.xsd#Role_StatementStatementsOfCashFlowsUnaudited" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCompanyOrganizationAndNatureOfBusiness" xlink:href="pcvx-20211231.xsd#Role_DisclosureCompanyOrganizationAndNatureOfBusiness" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:href="pcvx-20211231.xsd#Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstruments" xlink:href="pcvx-20211231.xsd#Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstruments" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetails" xlink:href="pcvx-20211231.xsd#Role_DisclosureBalanceSheetDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureLeases" xlink:href="pcvx-20211231.xsd#Role_DisclosureLeases" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" xlink:href="pcvx-20211231.xsd#Role_DisclosureCommitmentsAndContingencies" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStock" xlink:href="pcvx-20211231.xsd#Role_DisclosureRedeemableConvertiblePreferredStock" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCommonStock" xlink:href="pcvx-20211231.xsd#Role_DisclosureCommonStock" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureWarrants" xlink:href="pcvx-20211231.xsd#Role_DisclosureWarrants" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlans" xlink:href="pcvx-20211231.xsd#Role_DisclosureEquityIncentivePlans" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFundingArrangement" xlink:href="pcvx-20211231.xsd#Role_DisclosureFundingArrangement" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShare" xlink:href="pcvx-20211231.xsd#Role_DisclosureNetLossPerShare" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:href="pcvx-20211231.xsd#Role_DisclosureIncomeTaxes" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactions" xlink:href="pcvx-20211231.xsd#Role_DisclosureRelatedPartyTransactions" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureSubsequentEvents" xlink:href="pcvx-20211231.xsd#Role_DisclosureSubsequentEvents" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="pcvx-20211231.xsd#Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" xlink:href="pcvx-20211231.xsd#DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsTables" xlink:href="pcvx-20211231.xsd#Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsTables" xlink:href="pcvx-20211231.xsd#Role_DisclosureBalanceSheetDetailsTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureLeasesTables" xlink:href="pcvx-20211231.xsd#Role_DisclosureLeasesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCommonStockTables" xlink:href="pcvx-20211231.xsd#Role_DisclosureCommonStockTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansTables" xlink:href="pcvx-20211231.xsd#Role_DisclosureEquityIncentivePlansTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareTables" xlink:href="pcvx-20211231.xsd#Role_DisclosureNetLossPerShareTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesTables" xlink:href="pcvx-20211231.xsd#Role_DisclosureIncomeTaxesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCompanyOrganizationAndNatureOfBusinessAdditionalInformationDetails" xlink:href="pcvx-20211231.xsd#Role_DisclosureCompanyOrganizationAndNatureOfBusinessAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="pcvx-20211231.xsd#DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfCashCashEquivalentsAndRestrictedCashDetails" xlink:href="pcvx-20211231.xsd#DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfCashCashEquivalentsAndRestrictedCashDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsAdditionalInformationDetails" xlink:href="pcvx-20211231.xsd#Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="pcvx-20211231.xsd#Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfContractualMaturitiesOfInvestmentsDetails" xlink:href="pcvx-20211231.xsd#Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfContractualMaturitiesOfInvestmentsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentNetDetails" xlink:href="pcvx-20211231.xsd#Role_DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentNetDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsAdditionalInformationDetails" xlink:href="pcvx-20211231.xsd#Role_DisclosureBalanceSheetDetailsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails" xlink:href="pcvx-20211231.xsd#Role_DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" xlink:href="pcvx-20211231.xsd#Role_DisclosureLeasesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureLeasesScheduleOfInformationRelatedToROUAssetsAndLeaseLiabilitiesDetails" xlink:href="pcvx-20211231.xsd#Role_DisclosureLeasesScheduleOfInformationRelatedToROUAssetsAndLeaseLiabilitiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails" xlink:href="pcvx-20211231.xsd#Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesParentheticalDetails" xlink:href="pcvx-20211231.xsd#Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesParentheticalDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="pcvx-20211231.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails" xlink:href="pcvx-20211231.xsd#Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails" xlink:href="pcvx-20211231.xsd#Role_DisclosureCommonStockAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCommonStockScheduleOfCommonStockSharesReservedForFutureIssuanceDetails" xlink:href="pcvx-20211231.xsd#Role_DisclosureCommonStockScheduleOfCommonStockSharesReservedForFutureIssuanceDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureWarrantsAdditionalInformationDetails" xlink:href="pcvx-20211231.xsd#Role_DisclosureWarrantsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails" xlink:href="pcvx-20211231.xsd#Role_DisclosureEquityIncentivePlansAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfActivityUnderStockOptionPlansDetails" xlink:href="pcvx-20211231.xsd#Role_DisclosureEquityIncentivePlansSummaryOfActivityUnderStockOptionPlansDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfEstimatedFairValueOfEmployeeStockOptionsDetails" xlink:href="pcvx-20211231.xsd#Role_DisclosureEquityIncentivePlansSummaryOfEstimatedFairValueOfEmployeeStockOptionsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfEstimatedFairValueOfSharesUnderEmployeeStockPurchasePlanDetails" xlink:href="pcvx-20211231.xsd#Role_DisclosureEquityIncentivePlansSummaryOfEstimatedFairValueOfSharesUnderEmployeeStockPurchasePlanDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfStockBasedCompensationExpenseDetails" xlink:href="pcvx-20211231.xsd#Role_DisclosureEquityIncentivePlansSummaryOfStockBasedCompensationExpenseDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFundingArrangementAdditionalInformationDetails" xlink:href="pcvx-20211231.xsd#Role_DisclosureFundingArrangementAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetails" xlink:href="pcvx-20211231.xsd#Role_DisclosureNetLossPerShareScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:href="pcvx-20211231.xsd#Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfEffectiveTaxRateDetails" xlink:href="pcvx-20211231.xsd#Role_DisclosureIncomeTaxesReconciliationOfEffectiveTaxRateDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails" xlink:href="pcvx-20211231.xsd#Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="pcvx-20211231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitDetails" xlink:href="pcvx-20211231.xsd#Role_DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:href="pcvx-20211231.xsd#Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" xlink:href="pcvx-20211231.xsd#DisclosureSubsequentEventsAdditionalInformationDetails" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport" order="30" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="31" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="32" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="33" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="34" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="35" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorName" order="36" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorLocation" order="37" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorFirmId" order="38" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementBalanceSheets" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_AccruedManufacturingExpenses" xlink:label="pcvx_AccruedManufacturingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="us-gaap_LongTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:label="us-gaap_DeferredRentCreditCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredRentCreditNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_ShortTermInvestments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="pcvx_AccruedManufacturingExpenses" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_LongTermInvestments" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredRentCreditCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsNoncurrent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementBalanceSheetsParenthetical" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_DueToRelatedPartiesCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfOperations" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_GrantIncome" xlink:label="pcvx_GrantIncome"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesRealizedGainLoss" xlink:label="us-gaap_MarketableSecuritiesRealizedGainLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_ChangeInFairValueOfRedeemableConvertiblePreferredStock" xlink:label="pcvx_ChangeInFairValueOfRedeemableConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="pcvx_GrantIncome" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_MarketableSecuritiesRealizedGainLoss" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="pcvx_ChangeInFairValueOfRedeemableConvertiblePreferredStock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfOperationsParenthetical" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_ResearchAndDevelopmentExpenseToRelatedParty" xlink:label="pcvx_ResearchAndDevelopmentExpenseToRelatedParty"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="pcvx_ResearchAndDevelopmentExpenseToRelatedParty" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfComprehensiveLoss" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_SeriesARedeemableConvertiblePreferredStockMember" xlink:label="pcvx_SeriesARedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_SeriesBRedeemableConvertiblePreferredStockMember" xlink:label="pcvx_SeriesBRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_MarketOfferingMember" xlink:label="pcvx_MarketOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_SeriesCRedeemableConvertiblePreferredStockMember" xlink:label="pcvx_SeriesCRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_SeriesDRedeemableConvertiblePreferredStockMember" xlink:label="pcvx_SeriesDRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_TemporaryEquityConversionOfPreferredStockValue" xlink:label="pcvx_TemporaryEquityConversionOfPreferredStockValue"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_TemporaryEquityConversionOfPreferredStockShares" xlink:label="pcvx_TemporaryEquityConversionOfPreferredStockShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_StockIssuedDuringPeriodSharesConversionOfCommonStockWarrant" xlink:label="pcvx_StockIssuedDuringPeriodSharesConversionOfCommonStockWarrant"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_StockIssuedDuringPeriodSharesConversionOfPreferredStockWarrant" xlink:label="pcvx_StockIssuedDuringPeriodSharesConversionOfPreferredStockWarrant"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_AdjustmentsToAdditionalPaidInCapitalWarrantLiabilityWriteOff" xlink:label="pcvx_AdjustmentsToAdditionalPaidInCapitalWarrantLiabilityWriteOff"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="pcvx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_StockIssuedDuringPeriodSharesIssuanceOfCommonStockRelatedToEarlyExercisedStockOptions" xlink:label="pcvx_StockIssuedDuringPeriodSharesIssuanceOfCommonStockRelatedToEarlyExercisedStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_AdjustmentsToAdditionalPaidInCapitalVestingOfEarlyExercisedStockOptions" xlink:label="pcvx_AdjustmentsToAdditionalPaidInCapitalVestingOfEarlyExercisedStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_25"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_26"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_27"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_28"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pcvx_SeriesARedeemableConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pcvx_SeriesBRedeemableConvertiblePreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pcvx_MarketOfferingMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pcvx_SeriesCRedeemableConvertiblePreferredStockMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pcvx_SeriesDRedeemableConvertiblePreferredStockMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pcvx_TemporaryEquityConversionOfPreferredStockValue" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pcvx_TemporaryEquityConversionOfPreferredStockShares" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pcvx_StockIssuedDuringPeriodSharesConversionOfCommonStockWarrant" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pcvx_StockIssuedDuringPeriodSharesConversionOfPreferredStockWarrant" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pcvx_AdjustmentsToAdditionalPaidInCapitalWarrantLiabilityWriteOff" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pcvx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pcvx_StockIssuedDuringPeriodSharesIssuanceOfCommonStockRelatedToEarlyExercisedStockOptions" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pcvx_AdjustmentsToAdditionalPaidInCapitalVestingOfEarlyExercisedStockOptions" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_25" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_26" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_27" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_28" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_SeriesCRedeemableConvertiblePreferredStockMember" xlink:label="pcvx_SeriesCRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_TemporaryEquityStockIssuanceCosts" xlink:label="pcvx_TemporaryEquityStockIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_SeriesDRedeemableConvertiblePreferredStockMember" xlink:label="pcvx_SeriesDRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_MarketOfferingMember" xlink:label="pcvx_MarketOfferingMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pcvx_SeriesCRedeemableConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pcvx_TemporaryEquityStockIssuanceCosts" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pcvx_SeriesDRedeemableConvertiblePreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pcvx_MarketOfferingMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_PaymentsOfCapitalLeaseObligations" xlink:label="pcvx_PaymentsOfCapitalLeaseObligations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_ProceedsFromInitialPublicOfferingNetOfUnderwritersCommissionsAndDiscounts" xlink:label="pcvx_ProceedsFromInitialPublicOfferingNetOfUnderwritersCommissionsAndDiscounts"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_ExpenseOnIssuanceOfRedeemableConvertiblePreferredStockWarrant" xlink:label="pcvx_ExpenseOnIssuanceOfRedeemableConvertiblePreferredStockWarrant"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssued1" xlink:label="us-gaap_StockIssued1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:label="pcvx_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_ProceedsFromIssuanceOfCommonStockNotYetReceived" xlink:label="pcvx_ProceedsFromIssuanceOfCommonStockNotYetReceived"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses" xlink:label="pcvx_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_ChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheLiabilities" xlink:label="pcvx_ChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_IncreaseDecreaseInAccruedCompensation" xlink:label="pcvx_IncreaseDecreaseInAccruedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_IncreaseDecreaseInAccruedManufacturingExpenses" xlink:label="pcvx_IncreaseDecreaseInAccruedManufacturingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_ProceedsFromIssuanceOfCommonStockRelatedToEarlyExercisedStockOptions" xlink:label="pcvx_ProceedsFromIssuanceOfCommonStockRelatedToEarlyExercisedStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_IncreaseDecreaseInAccruedLegalSettlement" xlink:label="pcvx_IncreaseDecreaseInAccruedLegalSettlement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_IncreaseDecreaseInDeferredRentAndOtherLongTermLiabilities" xlink:label="pcvx_IncreaseDecreaseInDeferredRentAndOtherLongTermLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_PaymentOfDeferredOfferingCosts" xlink:label="pcvx_PaymentOfDeferredOfferingCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="pcvx_PaymentsOfCapitalLeaseObligations" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_ConversionOfStockAmountConverted1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="pcvx_ProceedsFromInitialPublicOfferingNetOfUnderwritersCommissionsAndDiscounts" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="pcvx_ExpenseOnIssuanceOfRedeemableConvertiblePreferredStockWarrant" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_StockIssued1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="pcvx_IncreaseDecreaseInOperatingLeaseLiabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="pcvx_ProceedsFromIssuanceOfCommonStockNotYetReceived" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="pcvx_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="pcvx_ChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheLiabilities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="pcvx_IncreaseDecreaseInAccruedCompensation" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnDispositionOfAssets1" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="pcvx_IncreaseDecreaseInAccruedManufacturingExpenses" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="pcvx_ProceedsFromIssuanceOfCommonStockRelatedToEarlyExercisedStockOptions" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AssetImpairmentCharges" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="pcvx_IncreaseDecreaseInAccruedLegalSettlement" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockPlans" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="pcvx_IncreaseDecreaseInDeferredRentAndOtherLongTermLiabilities" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="pcvx_PaymentOfDeferredOfferingCosts" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCompanyOrganizationAndNatureOfBusiness" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstruments" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureLeases" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStock" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_RedeemableConvertiblePreferredStockTextBlock" xlink:label="pcvx_RedeemableConvertiblePreferredStockTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="pcvx_RedeemableConvertiblePreferredStockTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCommonStock" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureWarrants" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_WarrantsDisclosureTextBlock" xlink:label="pcvx_WarrantsDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="pcvx_WarrantsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlans" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFundingArrangement" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_FundingArrangementAbstract" xlink:label="pcvx_FundingArrangementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_FundingArrangementTextBlock" xlink:label="pcvx_FundingArrangementTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pcvx_FundingArrangementAbstract" xlink:to="pcvx_FundingArrangementTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShare" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactions" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureSubsequentEvents" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="us-gaap_InvestmentPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="us-gaap_DeferredChargesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_AccruedResearchAndDevelopmentPolicyTextBlock" xlink:label="pcvx_AccruedResearchAndDevelopmentPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InvestmentPolicyTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DeferredChargesPolicyTextBlock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="pcvx_AccruedResearchAndDevelopmentPolicyTextBlock" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureLeasesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_ScheduleOfInformationRelatedToRightOfUseAssetsAndLeaseLiabilitiesTableTextBlock" xlink:label="pcvx_ScheduleOfInformationRelatedToRightOfUseAssetsAndLeaseLiabilitiesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="pcvx_ScheduleOfInformationRelatedToRightOfUseAssetsAndLeaseLiabilitiesTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCommonStockTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock" xlink:label="pcvx_ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="pcvx_ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember" xlink:label="pcvx_TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_TwoThousandTwentyEmployeeStockPurchasePlanMember" xlink:label="pcvx_TwoThousandTwentyEmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_TwoThousandFourteenEquityIncentivePlanAndTwoThousandTwentyEquityIncentivePlanAndTwoThousandTwentyEmployeeStockPurchasePlanMember" xlink:label="pcvx_TwoThousandFourteenEquityIncentivePlanAndTwoThousandTwentyEquityIncentivePlanAndTwoThousandTwentyEmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="pcvx_TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="pcvx_TwoThousandTwentyEmployeeStockPurchasePlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="pcvx_TwoThousandFourteenEquityIncentivePlanAndTwoThousandTwentyEquityIncentivePlanAndTwoThousandTwentyEmployeeStockPurchasePlanMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:label="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCompanyOrganizationAndNatureOfBusinessAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:label="pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsTable"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:label="pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_GlobalTargetRevenue" xlink:label="pcvx_GlobalTargetRevenue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_PneumococcalConjugateVaccineMember" xlink:label="pcvx_PneumococcalConjugateVaccineMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_SharesIssuedUponFullExerciseOfUnderwritersOptionToPurchaseAdditionalShares" xlink:label="pcvx_SharesIssuedUponFullExerciseOfUnderwritersOptionToPurchaseAdditionalShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_PaymentsOfUnderwritingDiscountsAndCommissions" xlink:label="pcvx_PaymentsOfUnderwritingDiscountsAndCommissions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="pcvx_GlobalTargetRevenue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="pcvx_PneumococcalConjugateVaccineMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="srt_ProductOrServiceAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="pcvx_SharesIssuedUponFullExerciseOfUnderwritersOptionToPurchaseAdditionalShares" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="pcvx_PaymentsOfUnderwritingDiscountsAndCommissions" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201912Member" xlink:label="us-gaap_AccountingStandardsUpdate201912Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember" xlink:label="us-gaap_OtherNoncurrentAssetsMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_InitialPublicOfferingRelatedCost" xlink:label="pcvx_InitialPublicOfferingRelatedCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_NumberOfFinanceLease" xlink:label="pcvx_NumberOfFinanceLease"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_NumberOfReportableSegments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201912Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherNoncurrentAssetsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="pcvx_InitialPublicOfferingRelatedCost" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_DeferredOfferingCosts" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="pcvx_NumberOfFinanceLease" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_AssetImpairmentCharges" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfCashCashEquivalentsAndRestrictedCashDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RestrictedCash" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_NumberOfSecurities" xlink:label="pcvx_NumberOfSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:label="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" xlink:label="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" xlink:label="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="pcvx_NumberOfSecurities" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_CashAndCashEquivalentsAmortizedCost" xlink:label="pcvx_CashAndCashEquivalentsAmortizedCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashMember" xlink:label="us-gaap_CashMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_CashAndCashEquivalentsGrossUnrealizedGainBeforeTax" xlink:label="pcvx_CashAndCashEquivalentsGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_CashAndCashEquivalentsGrossUnrealizedLossBeforeTax" xlink:label="pcvx_CashAndCashEquivalentsGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:label="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="us-gaap_AssetBackedSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_CashAndCashEquivalentsAndInvestmentsAmortizedCostBasis" xlink:label="pcvx_CashAndCashEquivalentsAndInvestmentsAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_CashAndCashEquivalentsAndInvestmentsGrossUnrealizedGainBeforeTax" xlink:label="pcvx_CashAndCashEquivalentsAndInvestmentsGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_CashAndCashEquivalentsAndInvestmentsGrossUnrealizedLossBeforeTax" xlink:label="pcvx_CashAndCashEquivalentsAndInvestmentsGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_CashAndCashEquivalentsAndInvestments" xlink:label="pcvx_CashAndCashEquivalentsAndInvestments"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="pcvx_CashAndCashEquivalentsAmortizedCost" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CashMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="pcvx_CashAndCashEquivalentsGrossUnrealizedGainBeforeTax" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CommercialPaperMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="pcvx_CashAndCashEquivalentsGrossUnrealizedLossBeforeTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_AssetBackedSecuritiesMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="pcvx_CashAndCashEquivalentsAndInvestmentsAmortizedCostBasis" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="pcvx_CashAndCashEquivalentsAndInvestmentsGrossUnrealizedGainBeforeTax" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="pcvx_CashAndCashEquivalentsAndInvestmentsGrossUnrealizedLossBeforeTax" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="pcvx_CashAndCashEquivalentsAndInvestments" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfContractualMaturitiesOfInvestmentsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentNetDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_ComputersAndComputerSoftwareMember" xlink:label="pcvx_ComputersAndComputerSoftwareMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_LabEquipmentMember" xlink:label="pcvx_LabEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_CapitalLeasesLabEquipmentMember" xlink:label="pcvx_CapitalLeasesLabEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="pcvx_ComputersAndComputerSoftwareMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="pcvx_LabEquipmentMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="pcvx_CapitalLeasesLabEquipmentMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_CapitalLeasesAmortizationExpense" xlink:label="pcvx_CapitalLeasesAmortizationExpense"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="pcvx_CapitalLeasesAmortizationExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_AccruedPreclinicalStudiesCurrent" xlink:label="pcvx_AccruedPreclinicalStudiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="pcvx_AccruedPreclinicalStudiesCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_HeadquartersFacilityMember" xlink:label="pcvx_HeadquartersFacilityMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_LesseeOperatingLeaseCommencementDate" xlink:label="pcvx_LesseeOperatingLeaseCommencementDate"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_AdditionalFacilityMember" xlink:label="pcvx_AdditionalFacilityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BuildingMember" xlink:label="us-gaap_BuildingMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_LeaseTerminationDate" xlink:label="pcvx_LeaseTerminationDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_NewCorporateHeadquartersFacilityMember" xlink:label="pcvx_NewCorporateHeadquartersFacilityMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_LesseeOperatingLeaseRenewalOption" xlink:label="pcvx_LesseeOperatingLeaseRenewalOption"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_PaloAltoMember" xlink:label="pcvx_PaloAltoMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_SanCarlosMember" xlink:label="pcvx_SanCarlosMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="us-gaap_LesseeOperatingLeaseDescription"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_LesseeOperatingLeaseExtendedLeaseTerm" xlink:label="pcvx_LesseeOperatingLeaseExtendedLeaseTerm"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_LesseeOperatingLeaseExtendedMaturityDate" xlink:label="pcvx_LesseeOperatingLeaseExtendedMaturityDate"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_LesseeOperatingLeaseRentCommencementDate" xlink:label="pcvx_LesseeOperatingLeaseRentCommencementDate"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_NumberOfRenewalOptions" xlink:label="pcvx_NumberOfRenewalOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_NumberOfOperatingLease" xlink:label="pcvx_NumberOfOperatingLease"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="pcvx_HeadquartersFacilityMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="pcvx_LesseeOperatingLeaseCommencementDate" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="pcvx_AdditionalFacilityMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_BuildingMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="pcvx_LeaseTerminationDate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LeaseExpirationDate1" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="pcvx_NewCorporateHeadquartersFacilityMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="pcvx_LesseeOperatingLeaseRenewalOption" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="pcvx_PaloAltoMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="pcvx_SanCarlosMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDescription" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="pcvx_LesseeOperatingLeaseExtendedLeaseTerm" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="pcvx_LesseeOperatingLeaseExtendedMaturityDate" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="pcvx_LesseeOperatingLeaseRentCommencementDate" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="pcvx_NumberOfRenewalOptions" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="pcvx_NumberOfOperatingLease" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseExpense" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureLeasesScheduleOfInformationRelatedToROUAssetsAndLeaseLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeasePayments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonthsNetOfLeaseIncentives" xlink:label="pcvx_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonthsNetOfLeaseIncentives"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:label="pcvx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="pcvx_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonthsNetOfLeaseIncentives" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="pcvx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesParentheticalDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_LeasePaymentReceivableNoncurrent" xlink:label="pcvx_LeasePaymentReceivableNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_PaloAltoMember" xlink:label="pcvx_PaloAltoMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="pcvx_LeasePaymentReceivableNoncurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="pcvx_PaloAltoMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_CounterpartyNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_LonzaLimitedMember" xlink:label="pcvx_LonzaLimitedMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_PercentageOfPaymentsCompletionAgreedToDefer" xlink:label="pcvx_PercentageOfPaymentsCompletionAgreedToDefer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_DevelopmentAndManufacturingServicesAgreementEquityPaymentsPercentage" xlink:label="pcvx_DevelopmentAndManufacturingServicesAgreementEquityPaymentsPercentage"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_DevelopmentAndManufacturingServicesAgreementPaymentsInEquity" xlink:label="pcvx_DevelopmentAndManufacturingServicesAgreementPaymentsInEquity"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_ThresholdLimitOnEquityPayments" xlink:label="pcvx_ThresholdLimitOnEquityPayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GuaranteeObligationsMaximumExposure" xlink:label="us-gaap_GuaranteeObligationsMaximumExposure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="srt_CounterpartyNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="pcvx_LonzaLimitedMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LossContingenciesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="pcvx_PercentageOfPaymentsCompletionAgreedToDefer" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="pcvx_DevelopmentAndManufacturingServicesAgreementEquityPaymentsPercentage" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="pcvx_DevelopmentAndManufacturingServicesAgreementPaymentsInEquity" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="pcvx_ThresholdLimitOnEquityPayments" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_GuaranteeObligationsMaximumExposure" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_TemporaryEquityLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_ATMSalesAgreementMember" xlink:label="pcvx_ATMSalesAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_JefferiesLimitedLiabilityCompanyMember" xlink:label="pcvx_JefferiesLimitedLiabilityCompanyMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockDividendsPerShareDeclared" xlink:label="us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_SaleOfCommonStockAuthorizedAmount" xlink:label="pcvx_SaleOfCommonStockAuthorizedAmount"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_MaximumCommissionPercentageOfGrossProceedsFromCommonStockSold" xlink:label="pcvx_MaximumCommissionPercentageOfGrossProceedsFromCommonStockSold"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_GrossProceedsFromIssuanceOfCommonStock" xlink:label="pcvx_GrossProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="us-gaap_ReceivablesNetCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="pcvx_ATMSalesAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="pcvx_JefferiesLimitedLiabilityCompanyMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_CounterpartyNameAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockDividendsPerShareDeclared" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockVotingRights" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="pcvx_SaleOfCommonStockAuthorizedAmount" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="pcvx_MaximumCommissionPercentageOfGrossProceedsFromCommonStockSold" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="pcvx_GrossProceedsFromIssuanceOfCommonStock" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ReceivablesNetCurrent" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCommonStockScheduleOfCommonStockSharesReservedForFutureIssuanceDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember" xlink:label="pcvx_TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_SharesAvailableForFutureStockOptionGrantsMember" xlink:label="pcvx_SharesAvailableForFutureStockOptionGrantsMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="pcvx_TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="pcvx_SharesAvailableForFutureStockOptionGrantsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureWarrantsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRightExercised" xlink:label="pcvx_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRightExercised"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="pcvx_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRightExercised" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_TwoThousandTwentyEquityIncentivePlanMember" xlink:label="pcvx_TwoThousandTwentyEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_IncentiveStockOptionGrantedToEmployeesOwningPercentageOfSharesOfCommonStock" xlink:label="pcvx_IncentiveStockOptionGrantedToEmployeesOwningPercentageOfSharesOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_PercentageOfFairValuePerShareOnTheGrantDate" xlink:label="pcvx_PercentageOfFairValuePerShareOnTheGrantDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_TwoThousandFourteenEquityIncentivePlanMember" xlink:label="pcvx_TwoThousandFourteenEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_TwoThousandTwentyEmployeeStockPurchasePlanMember" xlink:label="pcvx_TwoThousandTwentyEmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_ExercisePriceExpireInYearsFormTheDateOfGrant" xlink:label="pcvx_ExercisePriceExpireInYearsFormTheDateOfGrant"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_StockOptionsGrantedTerm" xlink:label="pcvx_StockOptionsGrantedTerm"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_PercentageOfProvisionsSubjectToStockholders" xlink:label="pcvx_PercentageOfProvisionsSubjectToStockholders"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreaseInAvailableForGrant" xlink:label="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreaseInAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_EarlyExercisedStockOptions" xlink:label="pcvx_EarlyExercisedStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_RemainingLiabilitiesRelatedToEarlyExercisedShares" xlink:label="pcvx_RemainingLiabilitiesRelatedToEarlyExercisedShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_NumberOfOptionsExercisedExcludesOptionsExercisedFromNpln" xlink:label="pcvx_NumberOfOptionsExercisedExcludesOptionsExercisedFromNpln"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_OfferingPeriod" xlink:label="pcvx_OfferingPeriod"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_PurchasePeriod" xlink:label="pcvx_PurchasePeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="pcvx_TwoThousandTwentyEquityIncentivePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pcvx_IncentiveStockOptionGrantedToEmployeesOwningPercentageOfSharesOfCommonStock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherNoncurrentLiabilitiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pcvx_PercentageOfFairValuePerShareOnTheGrantDate" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="pcvx_TwoThousandFourteenEquityIncentivePlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="pcvx_TwoThousandTwentyEmployeeStockPurchasePlanMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pcvx_ExercisePriceExpireInYearsFormTheDateOfGrant" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pcvx_StockOptionsGrantedTerm" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pcvx_PercentageOfProvisionsSubjectToStockholders" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreaseInAvailableForGrant" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pcvx_EarlyExercisedStockOptions" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pcvx_RemainingLiabilitiesRelatedToEarlyExercisedShares" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pcvx_NumberOfOptionsExercisedExcludesOptionsExercisedFromNpln" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pcvx_OfferingPeriod" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pcvx_PurchasePeriod" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfActivityUnderStockOptionPlansDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember" xlink:label="pcvx_TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantedInPeriod" xlink:label="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExercisedInPeriod" xlink:label="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExercisedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeitedInPeriod" xlink:label="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeitedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_5"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_10"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_17"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="pcvx_TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantedInPeriod" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExercisedInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeitedInPeriod" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_10" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_17" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfEstimatedFairValueOfEmployeeStockOptionsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfEstimatedFairValueOfSharesUnderEmployeeStockPurchasePlanDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_TwoThousandTwentyEmployeeStockPurchasePlanMember" xlink:label="pcvx_TwoThousandTwentyEmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="pcvx_TwoThousandTwentyEmployeeStockPurchasePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfStockBasedCompensationExpenseDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_TwoThousandFourteenEquityIncentivePlanAndTwoThousandTwentyEquityIncentivePlanAndTwoThousandTwentyEmployeeStockPurchasePlanMember" xlink:label="pcvx_TwoThousandFourteenEquityIncentivePlanAndTwoThousandTwentyEquityIncentivePlanAndTwoThousandTwentyEmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="pcvx_TwoThousandFourteenEquityIncentivePlanAndTwoThousandTwentyEquityIncentivePlanAndTwoThousandTwentyEmployeeStockPurchasePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFundingArrangementAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_FundingArrangementLineItems" xlink:label="pcvx_FundingArrangementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_FundingPeriodOfAwardToDevelopUniversalVaccineToPreventInfections" xlink:label="pcvx_FundingPeriodOfAwardToDevelopUniversalVaccineToPreventInfections"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_CostReimbursementSubAwardAgreementMember" xlink:label="pcvx_CostReimbursementSubAwardAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_FundingArrangementTable" xlink:label="pcvx_FundingArrangementTable"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_FundingArrangementAbstract" xlink:label="pcvx_FundingArrangementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_InitialFundingCommittedByAward" xlink:label="pcvx_InitialFundingCommittedByAward"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorAgreementMember" xlink:label="pcvx_CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_FundingCommittedByAwardAvailableUponAchievementOfDevelopmentMilestones" xlink:label="pcvx_FundingCommittedByAwardAvailableUponAchievementOfDevelopmentMilestones"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_AdditionalFundingCommittedByAward" xlink:label="pcvx_AdditionalFundingCommittedByAward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrantsReceivable" xlink:label="us-gaap_GrantsReceivable"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_PotentialFundingCommittedByAward" xlink:label="pcvx_PotentialFundingCommittedByAward"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_PotentialFundingPeriodOfAwardToDevelopVaccineToPreventInfections" xlink:label="pcvx_PotentialFundingPeriodOfAwardToDevelopVaccineToPreventInfections"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_PotentialFundingAmountOfAwardToDevelopVaccineToPreventInfections" xlink:label="pcvx_PotentialFundingAmountOfAwardToDevelopVaccineToPreventInfections"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_GrantIncome" xlink:label="pcvx_GrantIncome"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pcvx_FundingArrangementLineItems" xlink:to="pcvx_FundingPeriodOfAwardToDevelopUniversalVaccineToPreventInfections" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="pcvx_CostReimbursementSubAwardAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pcvx_FundingArrangementTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pcvx_FundingArrangementAbstract" xlink:to="pcvx_FundingArrangementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pcvx_FundingArrangementLineItems" xlink:to="pcvx_InitialFundingCommittedByAward" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pcvx_FundingArrangementTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="pcvx_CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pcvx_FundingArrangementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pcvx_FundingArrangementLineItems" xlink:to="pcvx_FundingCommittedByAwardAvailableUponAchievementOfDevelopmentMilestones" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pcvx_FundingArrangementTable" xlink:to="pcvx_FundingArrangementLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pcvx_FundingArrangementLineItems" xlink:to="pcvx_AdditionalFundingCommittedByAward" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pcvx_FundingArrangementLineItems" xlink:to="us-gaap_GrantsReceivable" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pcvx_FundingArrangementLineItems" xlink:to="pcvx_PotentialFundingCommittedByAward" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pcvx_FundingArrangementLineItems" xlink:to="pcvx_PotentialFundingPeriodOfAwardToDevelopVaccineToPreventInfections" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pcvx_FundingArrangementLineItems" xlink:to="pcvx_PotentialFundingAmountOfAwardToDevelopVaccineToPreventInfections" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pcvx_FundingArrangementLineItems" xlink:to="pcvx_GrantIncome" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_SeriesARedeemableConvertiblePreferredStockMember" xlink:label="pcvx_SeriesARedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_CommonStockWarrantMember" xlink:label="pcvx_CommonStockWarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_SeriesBRedeemableConvertiblePreferredStockMember" xlink:label="pcvx_SeriesBRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_RedeemableConvertiblePreferredStockWarrantMember" xlink:label="pcvx_RedeemableConvertiblePreferredStockWarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_SeriesCRedeemableConvertiblePreferredStockMember" xlink:label="pcvx_SeriesCRedeemableConvertiblePreferredStockMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pcvx_SeriesARedeemableConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="pcvx_CommonStockWarrantMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pcvx_SeriesBRedeemableConvertiblePreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="pcvx_RedeemableConvertiblePreferredStockWarrantMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pcvx_SeriesCRedeemableConvertiblePreferredStockMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfEffectiveTaxRateDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfTrancheLiability" xlink:label="pcvx_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfTrancheLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_Section162MLimitation" xlink:label="pcvx_Section162MLimitation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="pcvx_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfTrancheLiability" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="pcvx_Section162MLimitation" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGrossAbstract" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance" xlink:label="pcvx_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_DeferredTaxAssetsTaxAccruedManufacturingExpenses" xlink:label="pcvx_DeferredTaxAssetsTaxAccruedManufacturingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_LeaseLiability" xlink:label="pcvx_LeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsGrossAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="pcvx_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="pcvx_DeferredTaxAssetsTaxAccruedManufacturingExpenses" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="pcvx_LeaseLiability" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_IncomeTaxDisclosureTable" xlink:label="pcvx_IncomeTaxDisclosureTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_IncomeTaxDisclosureLineItems" xlink:label="pcvx_IncomeTaxDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_OperatingLossCarryForwardsExpirationYear" xlink:label="pcvx_OperatingLossCarryForwardsExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_CA" xlink:label="stpr_CA"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_TaxCreditCarryforwardExpirationYear" xlink:label="pcvx_TaxCreditCarryforwardExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="pcvx_IncomeTaxDisclosureTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pcvx_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pcvx_IncomeTaxDisclosureTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pcvx_IncomeTaxDisclosureTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pcvx_IncomeTaxDisclosureLineItems" xlink:to="pcvx_OperatingLossCarryForwardsExpirationYear" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pcvx_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="stpr_CA" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pcvx_IncomeTaxDisclosureTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pcvx_IncomeTaxDisclosureLineItems" xlink:to="pcvx_TaxCreditCarryforwardExpirationYear" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pcvx_IncomeTaxDisclosureTable" xlink:to="pcvx_IncomeTaxDisclosureLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pcvx_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pcvx_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pcvx_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:label="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="pcvx_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_3"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="pcvx_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_UnrecognizedTaxBenefits_3" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_LicenseAmendmentATwoMember" xlink:label="pcvx_LicenseAmendmentATwoMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_SeriesCRedeemableConvertiblePreferredStockMember" xlink:label="pcvx_SeriesCRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_SutroBiopharmaIncMember" xlink:label="pcvx_SutroBiopharmaIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_LicenseAgreementMember" xlink:label="pcvx_LicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_CommonStockWarrantMember" xlink:label="pcvx_CommonStockWarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_PreferredStockWarrantMember" xlink:label="pcvx_PreferredStockWarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_SupplyAgreementMember" xlink:label="pcvx_SupplyAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRightExercised" xlink:label="pcvx_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRightExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_PercentageOfRoyaltyPaymentOnAnnualNetSalesOfVaccineProductsForHumanHealth" xlink:label="pcvx_PercentageOfRoyaltyPaymentOnAnnualNetSalesOfVaccineProductsForHumanHealth"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_PercentageOfRoyaltyPaymentOnNetSalesOfVaccineCompositionsForAnimalHealth" xlink:label="pcvx_PercentageOfRoyaltyPaymentOnNetSalesOfVaccineCompositionsForAnimalHealth"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDueFromToRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionDueFromToRelatedParty"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="pcvx_LicenseAmendmentATwoMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pcvx_SeriesCRedeemableConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="pcvx_SutroBiopharmaIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="pcvx_LicenseAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="pcvx_CommonStockWarrantMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="pcvx_PreferredStockWarrantMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="pcvx_SupplyAgreementMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="pcvx_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRightExercised" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="pcvx_PercentageOfRoyaltyPaymentOnAnnualNetSalesOfVaccineProductsForHumanHealth" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="pcvx_PercentageOfRoyaltyPaymentOnNetSalesOfVaccineCompositionsForAnimalHealth" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionDueFromToRelatedParty" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_StockIssuedDuringPeriodSharesOfFollowOnOffering" xlink:label="pcvx_StockIssuedDuringPeriodSharesOfFollowOnOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_SharesIssuedPricePerShareUponFollowOnOffering" xlink:label="pcvx_SharesIssuedPricePerShareUponFollowOnOffering"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_SharesPreFundedWarrantsToPurchase" xlink:label="pcvx_SharesPreFundedWarrantsToPurchase"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_PrefundedWarrantsPricePerShare" xlink:label="pcvx_PrefundedWarrantsPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_ProceedsFromIssuanceFollowOnOffering" xlink:label="pcvx_ProceedsFromIssuanceFollowOnOffering"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_SharesIssuedUponFollowOnOfferingFullExerciseOfUnderwritersOptionToPurchaseAdditionalShares" xlink:label="pcvx_SharesIssuedUponFollowOnOfferingFullExerciseOfUnderwritersOptionToPurchaseAdditionalShares"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="pcvx_StockIssuedDuringPeriodSharesOfFollowOnOffering" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="pcvx_SharesIssuedPricePerShareUponFollowOnOffering" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="pcvx_SharesPreFundedWarrantsToPurchase" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="pcvx_PrefundedWarrantsPricePerShare" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="pcvx_ProceedsFromIssuanceFollowOnOffering" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="pcvx_SharesIssuedUponFollowOnOfferingFullExerciseOfUnderwritersOptionToPurchaseAdditionalShares" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>33
<FILENAME>pcvx-20211231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2022-02-28T14:49:03.5996+00:00 -->
<!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementBalanceSheets" xlink:href="pcvx-20211231.xsd#Role_StatementBalanceSheets" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfOperations" xlink:href="pcvx-20211231.xsd#Role_StatementStatementsOfOperations" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfComprehensiveLoss" xlink:href="pcvx-20211231.xsd#Role_StatementStatementsOfComprehensiveLoss" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited" xlink:href="pcvx-20211231.xsd#Role_StatementStatementsOfCashFlowsUnaudited" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfCashCashEquivalentsAndRestrictedCashDetails" xlink:href="pcvx-20211231.xsd#DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfCashCashEquivalentsAndRestrictedCashDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="pcvx-20211231.xsd#Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfContractualMaturitiesOfInvestmentsDetails" xlink:href="pcvx-20211231.xsd#Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfContractualMaturitiesOfInvestmentsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentNetDetails" xlink:href="pcvx-20211231.xsd#Role_DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentNetDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails" xlink:href="pcvx-20211231.xsd#Role_DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureLeasesScheduleOfInformationRelatedToROUAssetsAndLeaseLiabilitiesDetails" xlink:href="pcvx-20211231.xsd#Role_DisclosureLeasesScheduleOfInformationRelatedToROUAssetsAndLeaseLiabilitiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails" xlink:href="pcvx-20211231.xsd#Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails2" xlink:href="pcvx-20211231.xsd#Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails2" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfEffectiveTaxRateDetails" xlink:href="pcvx-20211231.xsd#Role_DisclosureIncomeTaxesReconciliationOfEffectiveTaxRateDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails" xlink:href="pcvx-20211231.xsd#Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails" xlink:type="simple"/>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementBalanceSheets">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsNoncurrent" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_DeferredRentCreditNoncurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_ShortTermInvestments" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_LongTermInvestments" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="pcvx_AccruedManufacturingExpenses" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent" order="3" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DeferredRentCreditCurrent" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent" order="4" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="5" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="us-gaap_LongTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_AccruedManufacturingExpenses" xlink:label="pcvx_AccruedManufacturingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:label="us-gaap_DeferredRentCreditCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfOperations">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_InterestExpense" order="0" weight="-1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="0" weight="-1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_InvestmentIncomeInterest" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="pcvx_GrantIncome" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_MarketableSecuritiesRealizedGainLoss" order="3" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" order="4" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="pcvx_ChangeInFairValueOfRedeemableConvertiblePreferredStock" order="5" weight="1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_GrantIncome" xlink:label="pcvx_GrantIncome"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesRealizedGainLoss" xlink:label="us-gaap_MarketableSecuritiesRealizedGainLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_ChangeInFairValueOfRedeemableConvertiblePreferredStock" xlink:label="pcvx_ChangeInFairValueOfRedeemableConvertiblePreferredStock"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfComprehensiveLoss">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" order="1" weight="1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" weight="-1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="pcvx_PaymentsOfCapitalLeaseObligations" order="0" weight="-1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" order="1" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="pcvx_ProceedsFromInitialPublicOfferingNetOfUnderwritersCommissionsAndDiscounts" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="2" weight="-1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="3" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" order="3" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="pcvx_ExpenseOnIssuanceOfRedeemableConvertiblePreferredStockWarrant" order="3" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="4" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" order="4" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="4" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="5" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="pcvx_ChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheLiabilities" order="5" weight="-1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="pcvx_ProceedsFromIssuanceOfCommonStockRelatedToEarlyExercisedStockOptions" order="6" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainLossOnDispositionOfAssets1" order="6" weight="-1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AssetImpairmentCharges" order="7" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockPlans" order="7" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" order="8" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="pcvx_PaymentOfDeferredOfferingCosts" order="8" weight="-1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="9" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="10" weight="-1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="11" weight="-1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="pcvx_IncreaseDecreaseInOperatingLeaseLiabilities" order="12" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="13" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="pcvx_IncreaseDecreaseInAccruedCompensation" order="14" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="pcvx_IncreaseDecreaseInAccruedManufacturingExpenses" order="15" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="16" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="pcvx_IncreaseDecreaseInAccruedLegalSettlement" order="17" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="pcvx_IncreaseDecreaseInDeferredRentAndOtherLongTermLiabilities" order="18" weight="1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_PaymentsOfCapitalLeaseObligations" xlink:label="pcvx_PaymentsOfCapitalLeaseObligations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_ProceedsFromInitialPublicOfferingNetOfUnderwritersCommissionsAndDiscounts" xlink:label="pcvx_ProceedsFromInitialPublicOfferingNetOfUnderwritersCommissionsAndDiscounts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_ExpenseOnIssuanceOfRedeemableConvertiblePreferredStockWarrant" xlink:label="pcvx_ExpenseOnIssuanceOfRedeemableConvertiblePreferredStockWarrant"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_ChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheLiabilities" xlink:label="pcvx_ChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_ProceedsFromIssuanceOfCommonStockRelatedToEarlyExercisedStockOptions" xlink:label="pcvx_ProceedsFromIssuanceOfCommonStockRelatedToEarlyExercisedStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_PaymentOfDeferredOfferingCosts" xlink:label="pcvx_PaymentOfDeferredOfferingCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:label="pcvx_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_IncreaseDecreaseInAccruedCompensation" xlink:label="pcvx_IncreaseDecreaseInAccruedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_IncreaseDecreaseInAccruedManufacturingExpenses" xlink:label="pcvx_IncreaseDecreaseInAccruedManufacturingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_IncreaseDecreaseInAccruedLegalSettlement" xlink:label="pcvx_IncreaseDecreaseInAccruedLegalSettlement"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_IncreaseDecreaseInDeferredRentAndOtherLongTermLiabilities" xlink:label="pcvx_IncreaseDecreaseInDeferredRentAndOtherLongTermLiabilities"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.vaxcyte.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfCashCashEquivalentsAndRestrictedCashDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_RestrictedCash" order="1" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="0" weight="-1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="pcvx_CashAndCashEquivalentsAndInvestmentsAmortizedCostBasis" xlink:to="pcvx_CashAndCashEquivalentsAndInvestmentsGrossUnrealizedGainBeforeTax" order="0" weight="-1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="pcvx_CashAndCashEquivalentsAmortizedCost" xlink:to="pcvx_CashAndCashEquivalentsGrossUnrealizedGainBeforeTax" order="0" weight="-1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="pcvx_CashAndCashEquivalentsAmortizedCost" xlink:to="pcvx_CashAndCashEquivalentsGrossUnrealizedLossBeforeTax" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="pcvx_CashAndCashEquivalentsAndInvestmentsAmortizedCostBasis" xlink:to="pcvx_CashAndCashEquivalentsAndInvestmentsGrossUnrealizedLossBeforeTax" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="pcvx_CashAndCashEquivalentsAmortizedCost" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="pcvx_CashAndCashEquivalentsAndInvestmentsAmortizedCostBasis" xlink:to="pcvx_CashAndCashEquivalentsAndInvestments" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="2" weight="1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_CashAndCashEquivalentsAndInvestmentsAmortizedCostBasis" xlink:label="pcvx_CashAndCashEquivalentsAndInvestmentsAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_CashAndCashEquivalentsAndInvestmentsGrossUnrealizedGainBeforeTax" xlink:label="pcvx_CashAndCashEquivalentsAndInvestmentsGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_CashAndCashEquivalentsAmortizedCost" xlink:label="pcvx_CashAndCashEquivalentsAmortizedCost"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_CashAndCashEquivalentsGrossUnrealizedGainBeforeTax" xlink:label="pcvx_CashAndCashEquivalentsGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_CashAndCashEquivalentsGrossUnrealizedLossBeforeTax" xlink:label="pcvx_CashAndCashEquivalentsGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_CashAndCashEquivalentsAndInvestmentsGrossUnrealizedLossBeforeTax" xlink:label="pcvx_CashAndCashEquivalentsAndInvestmentsGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_CashAndCashEquivalentsAndInvestments" xlink:label="pcvx_CashAndCashEquivalentsAndInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfContractualMaturitiesOfInvestmentsDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" order="1" weight="1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentNetDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" weight="-1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="pcvx_AccruedPreclinicalStudiesCurrent" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="2" weight="1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_AccruedPreclinicalStudiesCurrent" xlink:label="pcvx_AccruedPreclinicalStudiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureLeasesScheduleOfInformationRelatedToROUAssetsAndLeaseLiabilitiesDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" weight="1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="pcvx_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonthsNetOfLeaseIncentives" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="3" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="4" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="pcvx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" order="5" weight="1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonthsNetOfLeaseIncentives" xlink:label="pcvx_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonthsNetOfLeaseIncentives"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:label="pcvx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails2">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="1" weight="1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfEffectiveTaxRateDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="pcvx_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfTrancheLiability" order="3" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="pcvx_Section162MLimitation" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="5" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="6" weight="1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfTrancheLiability" xlink:label="pcvx_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfTrancheLiability"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_Section162MLimitation" xlink:label="pcvx_Section162MLimitation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="pcvx_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsGross" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="pcvx_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="pcvx_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="1" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="1" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="pcvx_DeferredTaxAssetsTaxAccruedManufacturingExpenses" order="5" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="pcvx_LeaseLiability" order="6" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance" xlink:label="pcvx_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_DeferredTaxAssetsTaxAccruedManufacturingExpenses" xlink:label="pcvx_DeferredTaxAssetsTaxAccruedManufacturingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20211231.xsd#pcvx_LeaseLiability" xlink:label="pcvx_LeaseLiability"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139898124044488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Feb. 23, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PCVX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">VAXCYTE, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001649094<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39323<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">46-4233385<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">825 Industrial Road<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Carlos<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94070<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">837-0111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,310,751<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 788.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">Part III incorporates information by reference from the Registrant&#8217;s definitive proxy statement to be filed with the U.S. Securities and Exchange Commission pursuant to Regulation 14A, not later than 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K, in connection with the Registrant&#8217;s 2022 annual meeting of stockholders.</span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Deloitte & Touche LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">San Francisco, California<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139898124525864">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 68,985<span></span>
</td>
<td class="nump">$ 386,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">176,985<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">10,378<span></span>
</td>
<td class="nump">2,804<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">256,348<span></span>
</td>
<td class="nump">389,004<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">7,954<span></span>
</td>
<td class="nump">3,272<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">27,958<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long-term investments</a></td>
<td class="nump">27,117<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">871<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">4,089<span></span>
</td>
<td class="nump">550<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total noncurrent assets</a></td>
<td class="nump">67,989<span></span>
</td>
<td class="nump">3,822<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">324,337<span></span>
</td>
<td class="nump">392,826<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">6,758<span></span>
</td>
<td class="nump">29,785<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation</a></td>
<td class="nump">3,455<span></span>
</td>
<td class="nump">284<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_AccruedManufacturingExpenses', window );">Accrued manufacturing expenses</a></td>
<td class="nump">4,440<span></span>
</td>
<td class="nump">13,012<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses (including related party accrual of $0 and $677 as of December 31, 2021 and December 31, 2020, respectively)</a></td>
<td class="nump">8,787<span></span>
</td>
<td class="nump">3,766<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditCurrent', window );">Deferred rent - current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities &#8212; current</a></td>
<td class="nump">5,276<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">28,716<span></span>
</td>
<td class="nump">46,861<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditNoncurrent', window );">Deferred rent - long-term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities &#8212; long-term</a></td>
<td class="nump">11,507<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">96<span></span>
</td>
<td class="nump">112<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">40,319<span></span>
</td>
<td class="nump">46,983<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 6)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value &#8212; 10,000,000 authorized at December 31, 2021 and December 31, 2020; no shares issued and outstanding at December 31, 2021 and December 31, 2020</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value - 500,000,000 shares authorized at December 31, 2021 and December 31, 2020;53,031,978 and 51,071,593 shares issued and outstanding at December 31, 2021 and December 31, 2020, respectively</a></td>
<td class="nump">56<span></span>
</td>
<td class="nump">54<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">582,844<span></span>
</td>
<td class="nump">544,353<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(241)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(298,641)<span></span>
</td>
<td class="num">(198,564)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">284,018<span></span>
</td>
<td class="nump">345,843<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, redeemable convertible preferred stock and stockholders' equity</a></td>
<td class="nump">$ 324,337<span></span>
</td>
<td class="nump">$ 392,826<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_AccruedManufacturingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued manufacturing expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_AccruedManufacturingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of rental payment required by lease over rental income recognized, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 25<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408481&amp;loc=SL77919140-209958<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123415192&amp;loc=d3e39927-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCreditCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of rental payment required by lease over rental income recognized, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 25<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408481&amp;loc=SL77919140-209958<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123415192&amp;loc=d3e39927-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCreditNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139898124478872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement Of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Related party accrual</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 677<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">53,031,978<span></span>
</td>
<td class="nump">51,071,593<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">53,031,978<span></span>
</td>
<td class="nump">51,071,593<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139898216971656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development (including related party expenses of $2359, $1,331 and $1,137 in 2021, 2020 and 2019, respectively)</a></td>
<td class="nump">$ 78,411<span></span>
</td>
<td class="nump">$ 73,564<span></span>
</td>
<td class="nump">$ 45,607<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">25,259<span></span>
</td>
<td class="nump">16,017<span></span>
</td>
<td class="nump">8,546<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">103,670<span></span>
</td>
<td class="nump">89,581<span></span>
</td>
<td class="nump">54,153<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(103,670)<span></span>
</td>
<td class="num">(89,581)<span></span>
</td>
<td class="num">(54,153)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense), net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="num">(40)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">344<span></span>
</td>
<td class="nump">244<span></span>
</td>
<td class="nump">632<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_GrantIncome', window );">Grant income</a></td>
<td class="nump">1,585<span></span>
</td>
<td class="nump">2,478<span></span>
</td>
<td class="nump">237<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesRealizedGainLoss', window );">Realized gains on marketable securities</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign currency transaction gains (losses)</a></td>
<td class="nump">1,669<span></span>
</td>
<td class="num">(2,351)<span></span>
</td>
<td class="num">(135)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_ChangeInFairValueOfRedeemableConvertiblePreferredStock', window );">Change in fair value of the redeemable convertible preferred stock tranche liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,185<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Total other income (expense), net</a></td>
<td class="nump">3,593<span></span>
</td>
<td class="nump">364<span></span>
</td>
<td class="nump">3,879<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (100,077)<span></span>
</td>
<td class="num">$ (89,217)<span></span>
</td>
<td class="num">$ (50,274)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share, basic and diluted</a></td>
<td class="num">$ (1.93)<span></span>
</td>
<td class="num">$ (3.02)<span></span>
</td>
<td class="num">$ (13.25)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average shares outstanding, basic and diluted</a></td>
<td class="nump">51,922,108<span></span>
</td>
<td class="nump">29,545,810<span></span>
</td>
<td class="nump">3,795,090<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_ChangeInFairValueOfRedeemableConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of the redeemable convertible preferred stock tranche liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_ChangeInFairValueOfRedeemableConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_GrantIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Grant income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_GrantIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=120253306&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment in marketable security, including other-than-temporary impairment (OTTI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139898131015064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Operations (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_ResearchAndDevelopmentExpenseToRelatedParty', window );">Research and development expense to related party</a></td>
<td class="nump">$ 2,359<span></span>
</td>
<td class="nump">$ 1,331<span></span>
</td>
<td class="nump">$ 1,137<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_ResearchAndDevelopmentExpenseToRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and development expense to related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_ResearchAndDevelopmentExpenseToRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139898124425432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement Of Income And Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">$ (100,077)<span></span>
</td>
<td class="num">$ (89,217)<span></span>
</td>
<td class="num">$ (50,274)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax', window );">Unrealized losses on investments</a></td>
<td class="num">(241)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive Loss</a></td>
<td class="num">$ (100,318)<span></span>
</td>
<td class="num">$ (89,217)<span></span>
</td>
<td class="num">$ (50,274)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139898120072040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th">
<div>Common Stock </div>
<div>IPO</div>
</th>
<th class="th">
<div>Common Stock </div>
<div>Market offering</div>
</th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th">
<div>Additional Paid-in Capital </div>
<div>IPO</div>
</th>
<th class="th">
<div>Additional Paid-in Capital </div>
<div>Market offering</div>
</th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th"><div>Series A Redeemable Convertible Preferred Stock</div></th>
<th class="th"><div>Series B Redeemable Convertible Preferred Stock</div></th>
<th class="th"><div>Series C Redeemable Convertible Preferred Stock</div></th>
<th class="th"><div>Series D Redeemable Convertible Preferred Stock</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2018</a></td>
<td class="num">$ (57,728)<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,339<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (59,073)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,225,719<span></span>
</td>
<td class="nump">6,786,896<span></span>
</td>
<td class="nump">3,688,740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Beginning balance at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,967<span></span>
</td>
<td class="nump">$ 55,151<span></span>
</td>
<td class="nump">$ 37,692<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,757,403<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuance of preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Issuance of preferred stock, net of issuance cost (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,688,740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">322<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">321<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">243,230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_StockIssuedDuringPeriodSharesIssuanceOfCommonStockRelatedToEarlyExercisedStockOptions', window );">Issuance of common stock related to early exercised stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,276<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_AdjustmentsToAdditionalPaidInCapitalVestingOfEarlyExercisedStockOptions', window );">Vesting of early exercised stock options</a></td>
<td class="nump">122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">1,185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">(50,274)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(50,274)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2019</a></td>
<td class="num">(106,373)<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,967<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(109,347)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending balance, shares at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,225,719<span></span>
</td>
<td class="nump">6,786,896<span></span>
</td>
<td class="nump">7,377,480<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ending balance at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,967<span></span>
</td>
<td class="nump">$ 55,151<span></span>
</td>
<td class="nump">$ 80,192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,059,909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_TemporaryEquityConversionOfPreferredStockValue', window );">Conversion of preferred stock</a></td>
<td class="nump">270,190<span></span>
</td>
<td class="nump">$ 29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">270,161<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (24,967)<span></span>
</td>
<td class="num">$ (55,151)<span></span>
</td>
<td class="num">$ (80,192)<span></span>
</td>
<td class="num">$ (109,879)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_TemporaryEquityConversionOfPreferredStockShares', window );">Conversion of preferred stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,225,719)<span></span>
</td>
<td class="num">(6,786,896)<span></span>
</td>
<td class="num">(7,377,480)<span></span>
</td>
<td class="num">(8,220,242)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of preferred stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,610,337<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_StockIssuedDuringPeriodSharesConversionOfCommonStockWarrant', window );">Conversion of common stock warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,278<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_StockIssuedDuringPeriodSharesConversionOfPreferredStockWarrant', window );">Conversion of preferred stock warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,591<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_AdjustmentsToAdditionalPaidInCapitalWarrantLiabilityWriteOff', window );">Warrant liability write-off</a></td>
<td class="nump">629<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">629<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock upon initial public offering or at-the-market offering, net of issuance costs</a></td>
<td class="nump">264,007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 263,989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock upon initial public offering or at-the-market offering, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,968,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under Employee Stock Purchase Plan</a></td>
<td class="nump">374<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">374<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under Employee Stock Purchase Plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,465<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuance of preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 109,879<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Issuance of preferred stock, net of issuance cost (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,220,242<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">635<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">635<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">343,444<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_StockIssuedDuringPeriodSharesIssuanceOfCommonStockRelatedToEarlyExercisedStockOptions', window );">Issuance of common stock related to early exercised stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,819<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_AdjustmentsToAdditionalPaidInCapitalVestingOfEarlyExercisedStockOptions', window );">Vesting of early exercised stock options</a></td>
<td class="nump">164<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">164<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">5,434<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,434<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">(89,217)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(89,217)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2020</a></td>
<td class="nump">345,843<span></span>
</td>
<td class="nump">$ 54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">544,353<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(198,564)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,071,593<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock upon initial public offering or at-the-market offering, net of issuance costs</a></td>
<td class="nump">13,847<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,846<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock upon initial public offering or at-the-market offering, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">567,045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under Employee Stock Purchase Plan</a></td>
<td class="nump">888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under Employee Stock Purchase Plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,546<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">3,012<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,012<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">931,114<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of common stock to LonzaLtd.</a></td>
<td class="nump">10,001<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock to Lonza Ltd. (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">399,680<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized losses on investment</a></td>
<td class="num">(241)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (241)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_AdjustmentsToAdditionalPaidInCapitalVestingOfEarlyExercisedStockOptions', window );">Vesting of early exercised stock options</a></td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">10,729<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,729<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">(100,077)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(100,077)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2021</a></td>
<td class="nump">$ 284,018<span></span>
</td>
<td class="nump">$ 56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 582,844<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (298,641)<span></span>
</td>
<td class="num">$ (241)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,031,978<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_AdjustmentsToAdditionalPaidInCapitalVestingOfEarlyExercisedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments to additional paid In capital vesting of early exercised stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_AdjustmentsToAdditionalPaidInCapitalVestingOfEarlyExercisedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_AdjustmentsToAdditionalPaidInCapitalWarrantLiabilityWriteOff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments to additional paid in capital warrant liability write off.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_AdjustmentsToAdditionalPaidInCapitalWarrantLiabilityWriteOff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_StockIssuedDuringPeriodSharesConversionOfCommonStockWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares conversion of common stock warrant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_StockIssuedDuringPeriodSharesConversionOfCommonStockWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_StockIssuedDuringPeriodSharesConversionOfPreferredStockWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares conversion of preferred stock warrant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_StockIssuedDuringPeriodSharesConversionOfPreferredStockWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_StockIssuedDuringPeriodSharesIssuanceOfCommonStockRelatedToEarlyExercisedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares issuance of common stock related to early exercised stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_StockIssuedDuringPeriodSharesIssuanceOfCommonStockRelatedToEarlyExercisedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_TemporaryEquityConversionOfPreferredStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity conversion of preferred stock shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_TemporaryEquityConversionOfPreferredStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_TemporaryEquityConversionOfPreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity conversion of preferred stock value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_TemporaryEquityConversionOfPreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity stock issued during period shares new issues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139898124752024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pcvx_MarketOfferingMember', window );">Market offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance costs</a></td>
<td class="nump">$ 479<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=pcvx_SeriesCRedeemableConvertiblePreferredStockMember', window );">Series C Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_TemporaryEquityStockIssuanceCosts', window );">Issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=pcvx_SeriesDRedeemableConvertiblePreferredStockMember', window );">Series D Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_TemporaryEquityStockIssuanceCosts', window );">Issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_TemporaryEquityStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity stock issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_TemporaryEquityStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=pcvx_MarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=pcvx_MarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=pcvx_SeriesCRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=pcvx_SeriesCRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=pcvx_SeriesDRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=pcvx_SeriesDRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139898125442696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Cash Flows (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (100,077)<span></span>
</td>
<td class="num">$ (89,217)<span></span>
</td>
<td class="num">$ (50,274)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">1,800<span></span>
</td>
<td class="nump">1,405<span></span>
</td>
<td class="nump">1,232<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">10,729<span></span>
</td>
<td class="nump">5,434<span></span>
</td>
<td class="nump">1,185<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of redeemable convertible preferred stock warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">179<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_ChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheLiabilities', window );">Change in fair value of redeemable convertible preferred stock tranche liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,185)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Loss on disposal of assets</a></td>
<td class="nump">97<span></span>
</td>
<td class="nump">34<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset impairment charges</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">267<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of operating right-of-use assets</a></td>
<td class="nump">1,657<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Net amortization of premiums on investments</a></td>
<td class="nump">1,406<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(7,369)<span></span>
</td>
<td class="num">(58)<span></span>
</td>
<td class="num">(1,070)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="num">(3,539)<span></span>
</td>
<td class="num">(75)<span></span>
</td>
<td class="nump">120<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_IncreaseDecreaseInOperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="num">(12,856)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(12,470)<span></span>
</td>
<td class="nump">26,102<span></span>
</td>
<td class="nump">868<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_IncreaseDecreaseInAccruedCompensation', window );">Accrued compensation</a></td>
<td class="nump">3,170<span></span>
</td>
<td class="num">(130)<span></span>
</td>
<td class="num">(775)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_IncreaseDecreaseInAccruedManufacturingExpenses', window );">Accrued manufacturing expenses</a></td>
<td class="num">(8,572)<span></span>
</td>
<td class="nump">7,235<span></span>
</td>
<td class="nump">3,970<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">4,631<span></span>
</td>
<td class="nump">2,207<span></span>
</td>
<td class="nump">718<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_IncreaseDecreaseInDeferredRentAndOtherLongTermLiabilities', window );">Deferred rent and other long-term liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11)<span></span>
</td>
<td class="nump">77<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(121,393)<span></span>
</td>
<td class="num">(46,628)<span></span>
</td>
<td class="num">(47,145)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(6,555)<span></span>
</td>
<td class="num">(1,155)<span></span>
</td>
<td class="num">(1,195)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of investments</a></td>
<td class="num">(336,341)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities', window );">Maturities of investments</a></td>
<td class="nump">100,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt', window );">Sales of investments</a></td>
<td class="nump">30,062<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sales of property and equipment</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(212,308)<span></span>
</td>
<td class="num">(1,105)<span></span>
</td>
<td class="num">(1,195)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_PaymentsOfCapitalLeaseObligations', window );">Payments of capital lease obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(61)<span></span>
</td>
<td class="num">(278)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_ProceedsFromInitialPublicOfferingNetOfUnderwritersCommissionsAndDiscounts', window );">Proceeds from initial public offering, net of underwriters' commissions and discounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">267,375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of issuance costs for initial public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,368)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock', window );">Proceeds from issuance of redeemable convertible preferred stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">109,879<span></span>
</td>
<td class="nump">42,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of common stock options</a></td>
<td class="nump">3,012<span></span>
</td>
<td class="nump">635<span></span>
</td>
<td class="nump">322<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock under ATM Sales Program, net of issuance costs</a></td>
<td class="nump">13,896<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_ProceedsFromIssuanceOfCommonStockRelatedToEarlyExercisedStockOptions', window );">Proceeds from issuance of common stock related to early exercised stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36<span></span>
</td>
<td class="nump">120<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from issuance of common stock under the Employee Stock Purchase Plan</a></td>
<td class="nump">888<span></span>
</td>
<td class="nump">374<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_PaymentOfDeferredOfferingCosts', window );">Payments of deferred offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,097)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">17,796<span></span>
</td>
<td class="nump">374,870<span></span>
</td>
<td class="nump">41,567<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="num">(439)<span></span>
</td>
<td class="nump">87<span></span>
</td>
<td class="num">(341)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net (decrease) increase in cash, cash equivalents and restricted cash</a></td>
<td class="num">(316,344)<span></span>
</td>
<td class="nump">327,224<span></span>
</td>
<td class="num">(7,114)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, beginning of period</a></td>
<td class="nump">386,200<span></span>
</td>
<td class="nump">58,976<span></span>
</td>
<td class="nump">66,090<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, end of period</a></td>
<td class="nump">69,856<span></span>
</td>
<td class="nump">386,200<span></span>
</td>
<td class="nump">58,976<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosures of non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchases of property and equipment recorded in accounts payable and accrued expenses</a></td>
<td class="nump">766<span></span>
</td>
<td class="nump">494<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Conversion of convertible preferred stock into common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">270,190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Stock issued for payment of accounts payable</a></td>
<td class="nump">$ 10,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses', window );">Deferred offering costs included in accounts payable and accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 134<span></span>
</td>
<td class="nump">$ 33<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_ChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of redeemable convertible preferred stock tranche liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_ChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred offering costs included in accounts payable and accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_IncreaseDecreaseInAccruedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in accrued compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_IncreaseDecreaseInAccruedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_IncreaseDecreaseInAccruedManufacturingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in accrued manufacturing expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_IncreaseDecreaseInAccruedManufacturingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_IncreaseDecreaseInDeferredRentAndOtherLongTermLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in deferred rent and other long term liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_IncreaseDecreaseInDeferredRentAndOtherLongTermLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_IncreaseDecreaseInOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in operating lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_IncreaseDecreaseInOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_PaymentOfDeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment of deferred offering costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_PaymentOfDeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_PaymentsOfCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_PaymentsOfCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_ProceedsFromInitialPublicOfferingNetOfUnderwritersCommissionsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from initial public offering, net of underwriters' commissions and discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_ProceedsFromInitialPublicOfferingNetOfUnderwritersCommissionsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_ProceedsFromIssuanceOfCommonStockRelatedToEarlyExercisedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of common stock related to early exercised stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_ProceedsFromIssuanceOfCommonStockRelatedToEarlyExercisedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of callable preferred stock which is identified as being convertible to another type of financial security at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3151-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139898130295160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Company Organization and Nature of Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Company Organization and Nature of Business</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">1. Company Organization and Nature of Business</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Vaxcyte, Inc. (&#8220;we,&#8221; &#8220;us,&#8221; &#8220;the Company,&#8221; or &#8220;Vaxcyte&#8221;), headquartered in San Carlos, California, was incorporated in the state of Delaware on November 27, 2013 as SutroVax, Inc. and we changed our name to Vaxcyte, Inc. on May 15, 2020. We are a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. We are developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. We are re-engineering the way highly complex vaccines are made through modern synthetic techniques, including advanced chemistry and the XpressCF cell-free protein synthesis platform, exclusively licensed from Sutro Biopharma, Inc. Unlike conventional cell-based approaches, our system for producing difficult-to-make proteins and antigens is intended to accelerate our ability to efficiently create and deliver high-fidelity vaccines with enhanced immunological benefits</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Our pipeline includes pneumococcal conjugate vaccine (&#8220;PCV&#8221;) candidates that we believe are among the most broad-spectrum PCV candidates currently in development, targeting the approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> billion global pneumococcal vaccine market. Our lead vaccine candidate, VAX-24, is a 24-valent broad-spectrum investigational PCV being developed for the prevention of invasive pneumococcal disease, or IPD</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, and pneumonia. On January 6, 2022, we announced that the U.S. Food and Drug Administration, or FDA, cleared our investigational new drug, or IND, application for VAX-24 in adults. On February 23, 2022, we announced the initiation of our Phase 1/2 clinical proof-of-concept study in adults 18 to 64 years of age. We expect to announce topline safety, tolerability and immunogenicity results from this study by the end of 2022. Pending the successful completion of the Phase 1 portion of this study, we expect to begin enrollment in a separate Phase 2 study in healthy adults aged 65 and older and to announce topline safety, tolerability and immunogenicity results from this study in the first half of 2023. Subject to a pre-IND meeting with the FDA and the successful topline results of the Phase 1/2 proof-of-concept study in adults 18-64 years of age, we anticipate submitting a pediatric IND application to the FDA for VAX-24 in the first half of 2023. Our second PCV candidate, VAX-XP, leverages our scalable and modular platform and builds on the technical proof of concept established by VAX-24 and is designed to expand the breadth of coverage to greater than 30 strains without compromising immunogenicity due to carrier suppression. In addition to our PCV franchise, our pipeline includes VAX-A1, a novel conjugate vaccine candidate designed to prevent Group A Strep; VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis; and other discovery-stage programs. Our primary activities since incorporation have been to perform research and development, undertake preclinical studies and conduct manufacturing activities in support of our product development efforts; organize and staff the Company; establish our intellectual property portfolio; and raise capital to support and expand such activities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Reverse Stock Split</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On June 5, 2020, we filed a certificate of amendment to our amended and restated certificate of incorporation to effect a </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">one-for-1.6870</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> reverse stock split of our issued and outstanding common stock, preferred stock, stock options and warrants effective on June 5, 2020. Accordingly, all share and per share amounts for all periods presented in the financial statements and notes thereto have been retroactively adjusted.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Initial Public Offering</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In June 2020, we completed an initial public offering (&#8220;IPO&#8221;) in which we issued and sold </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">17,968,750</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock, including shares issued upon the exercise in full of the underwriters&#8217; option to purchase </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,343,750</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> additional shares of common stock, at a public offering price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share. We received $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">264.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in net proceeds, after deducting underwriting discounts and commissions of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and offering expenses of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Immediately prior to the completion of our IPO, all outstanding shares of redeemable convertible preferred stock were converted into </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">28,610,337</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock. Subsequent to the completion of the IPO, there were </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of redeemable convertible preferred stock outstanding.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139898127695384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Basis of Presentation and Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Basis of Presentation and Summary of Significant Accounting Policies</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Basis of Presentation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">These financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and applicable rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;) regarding annual reporting. Certain changes in presentation were made in these financial statements as of and for the year ended December 31, 2019 to conform to the presentation as of and for the years ended December 31, 2021 and 2020.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities at the date of the financial statements. On an ongoing basis, we evaluate our estimates and assumptions, including those related to stock-based compensation expense, accruals for certain research and development costs, the incremental borrowing rate, the valuation of deferred tax assets and income taxes. Management bases our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ materially from those estimates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Concentration of Credit Risk and Other Risks and Uncertainties</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Financial instruments that potentially subject us to a concentration of credit risk consist primarily of cash and cash equivalents and investments. We invest in money market funds, U.S. Treasury securities, U.S. government agency securities, corporate debt, commercial paper and asset-backed securities. We maintain bank deposits in federally insured financial institutions and these deposits may exceed federally insured limits. We are exposed to credit risk in the event of a default by the financial institutions holding our cash and issuers of investments to the extent recorded on the balance sheets. Our investment policy limits investments to money market funds, certain types of debt securities issued by the U.S. Government and its agencies, corporate debt, commercial paper and asset-backed securities, and places restrictions on the credit ratings, maturities and concentration by type and issuer. We have not experienced any significant losses on our deposits of cash, cash equivalents or investments.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are subject to supplier concentration risk from our suppliers. We source our critical raw materials from a sole source supplier, Sutro Biopharma, Inc. (&#8220;Sutro Biopharma&#8221;). We also use one contract manufacturing organization (&#8220;CMO&#8221;), Lonza Ltd. (&#8220;Lonza&#8221;), to handle most of our manufacturing activities. If we were to experience disruptions in raw materials supplied by Sutro Biopharma, or in manufacturing activities at Lonza, we may experience significant delays in our product development timelines and may incur substantial costs to secure alternative sources of raw materials or manufacturing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our future results of operations involve a number of other risks and uncertainties. Factors that could affect our future operating results and cause actual results to vary materially from expectations include, but are not limited to: our early stages of clinical vaccine development; our ability to advance vaccine candidates into, and successfully complete, clinical trials on the timelines we project; our ability to adequately demonstrate sufficient safety and efficacy of our vaccine candidates; our ability to enroll subjects in our ongoing and future clinical trials; our ability to successfully manufacture and supply our vaccine candidates for clinical trials; our ability to obtain additional capital to finance our operations; our ability to obtain, maintain and protect our intellectual property rights; developments relating to our competitors and our industry, including competing vaccine candidates; general and market conditions; and other risks and uncertainties, including those more fully described in the &#8220;Risk Factors&#8221; section of this Annual Report on Form 10-K.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Segment and Geographical Information</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We operate and manage our business as </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">one</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> reportable and operating segment. Our chief executive officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance. All of our long-lived assets are based in the United States. Long-lived assets are comprised of property and equipment.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Cash, Cash Equivalents and Restricted Cash</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We consider all highly liquid investments purchased with original maturities of three months or less from the date of purchase to be cash and cash equivalents. Cash equivalents consist primarily of amounts invested in money market accounts and commercial paper and are stated at their fair values. Restricted cash consists of a standby letter of credit, which was issued in the first quarter of 2021, that serves as collateral for the lease agreement for our new corporate headquarters. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash, cash equivalents and restricted cash as reported within the statement of cash flows consisted of the following:</span></span></p><div style="font-size:11.0pt;font-family:Calibri;"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:37.584%;"/>
          <td style="width:6.553%;"/>
          <td style="width:1.371%;"/>
          <td style="width:15.494%;"/>
          <td style="width:0.696%;"/>
          <td style="width:2.195%;"/>
          <td style="width:1.371%;"/>
          <td style="width:15.376%;"/>
          <td style="width:0.696%;"/>
          <td style="width:2.195%;"/>
          <td style="width:1.371%;"/>
          <td style="width:14.402%;"/>
          <td style="width:0.696%;"/>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Years Ended December 31,</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2019</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(in thousands)</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash and cash equivalents</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">68,985</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">386,200</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">58,976</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Restricted cash</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">871</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash, cash equivalents and restricted cash</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">69,856</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">386,200</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">58,976</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
        </table></div></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Investments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our investments have been classified and accounted for as available-for-sale securities. Our investments consist of U.S. Treasury securities, U.S. government agency securities, corporate debt, commercial paper and asset-backed securities. These securities are recorded on the balance sheets at fair value. Unrealized gains and losses on these securities are included as a separate component of accumulated other comprehensive loss. The cost of investment securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization and accretion are included in other income (expense), net. Realized gains and losses and declines in fair value judged to be other-than-temporary, if any, are also included in other income (expense), net. We evaluate securities for other-than-temporary impairment at the balance sheet date. Declines in fair value determined to be other-than-temporary are included in other income (expense), net. We classify our investments as short or long term primarily based on the remaining contractual maturity of the securities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Deferred Offering Costs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred offering costs consist of fees and expenses incurred in connection with the sale of our common stock in equity transactions, including legal, accounting, printing and other issuance-related costs. Prior to the completion of equity transactions, deferred offering costs are included in Other assets on the balance sheet. In connection with and as of the closing of equity transactions, these costs are reclassified to Additional paid-in capital, representing a reduction to the gross proceeds. As of December 31, 2020, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of IPO-related costs were included in the Additional paid-in capital line item on the balance sheet. As of December 31, 2021 and 2020, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of deferred offering costs, respectively, were included in Other assets on the balance sheet.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Property and Equipment, Net</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_cdf000c4-3126-4076-a46e-14220371b9f3;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">three</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> to </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">five years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Leasehold improvements are amortized over the shorter of the expected life or lease term. Repairs and maintenance expenditures, which are not considered improvements and do not extend the useful life of property and equipment, are expensed as incurred. When assets are retired or otherwise disposed of, the cost and related accumulated depreciation and amortization are removed from the balance sheet and the resulting gain or loss is reflected in the statements of operations in the period realized.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Leases</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under Financial Accounting Standards Board (FASB) Accounting Standards Update (&#8220;ASU&#8221;) No. 2016-02, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Leases (Topic 842)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and its associated amendments (&#8220;ASC 842&#8221;), we determine if an arrangement is a lease at inception. In addition, we determine whether a lease meets the classification criteria of a finance or operating lease at the lease commencement date considering whether: (i) the lease transfers ownership of the underlying asset to the lessee at the end of the lease term; (ii) the lease grants the lessee an option to purchase the underlying asset that the lessee is reasonably certain to exercise; (iii) the lease term is for a major part of the remaining economic life of the underlying asset; (iv) the present value of the sum of the lease payments and residual value guaranteed by the lessee equals or exceeds substantially all of the fair value of the underlying asset; and (v) the underlying asset is such a specialized nature that it is expected to have no alternative use to the lessor at the end of the lease term. As of December 31, 2021, our lease population consisted of real estate operating leases. As of December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, we did </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">t have any finance leases.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating leases are included in Operating lease right-of-use (ROU) assets, Operating lease liabilities &#8212; current and Operating lease liabilities &#8212; long term in our balance sheet. ROU assets represent our right to use the underlying assets for the lease term and lease liabilities represent our obligation to make lease payments arising from the leases. Operating lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. In determining the present value of lease payments, if the rate implicit in the lease is not readily determinable, we use our incremental borrowing rate based on the information available at the lease commencement date. We determine the incremental borrowing rate based on an analysis of corporate bond yields with a credit rating similar to us. The determination of our incremental borrowing rate requires management judgment, including development of a synthetic credit rating and cost of debt, as we currently do not carry any debt. We believe that the estimates used in determining the incremental borrowing rate are reasonable based upon current facts and circumstances. Applying different judgment to the same facts and circumstances could yield a different incremental borrowing rate. The operating lease ROU assets also include adjustments for prepayments and accrued lease payments and exclude lease incentives. ROU assets and lease liabilities may include options to extend or terminate leases if it is reasonably certain that we will exercise such options. Lease payments which are fixed and determinable are amortized as rent and lease expense on a straight-line basis over the expected lease term. Variable lease costs, which are dependent on usage, a rate or index, including common area maintenance charges, are expensed as incurred. Lease agreements that include lease and non-lease components are accounted for as a single lease component. Lease agreements with non-cancelable terms of less than 12 months are not recorded on our balance sheets.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Impairment of Long-Lived Assets</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We review long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparing the carrying amount to the future undiscounted net cash flows which the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured as the amount by which the carrying amount of the assets exceeds the projected discounted future net cash flows generated by the assets. There were $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of impairments of long-lived assets during the years ended December 31, 2021, 2020 and 2019, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Fair Value Measurements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. The carrying amounts of our financial instruments, including cash and cash equivalents, prepaid and other current assets, accounts payable, accrued expenses, and other liabilities, approximate fair value due to their short-term maturities. Prior to their automatic conversion upon our IPO in June 2020, the redeemable convertible preferred stock tranche liability and redeemable convertible preferred stock warrant were carried at fair value (see Note 3).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Research and Development</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development costs are expensed as incurred. Research and development costs include salaries, stock-based compensation and benefits for employees performing research and development activities, an allocation of facility and overhead expenses, expenses incurred under agreements with consultants, CMOs, contract research organizations (&#8220;CROs&#8221;) and investigative sites that conduct preclinical studies, other supplies and costs associated with product development efforts, preclinical activities and regulatory operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Accrued Research and Development</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have entered into various agreements with CROs and CMOs. Our research and development accruals, which include accrued manufacturing expenses, are estimated based on the level of services performed, progress of the studies, including the phase or completion of events, and contracted costs. The estimated costs of research and development services provided, but not yet invoiced, are included in accrued expenses on the balance sheet. If the actual timing of the performance of services or the level of effort varies from the original estimates, we will adjust the accrual accordingly. Payments made to CROs or CMOs under these arrangements in advance of the performance of the related services are recorded as prepaid expenses and other current assets until the services are rendered. To date, there have been no material differences between our estimates of such expenses and the amounts actually incurred.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Income Taxes</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We account for income taxes using the asset and liability method. We recognize deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In evaluating the ability to recover our deferred income tax assets, we consider all available positive and negative evidence, including our operating results, ongoing tax planning and forecasts of future taxable income on a jurisdiction-by-jurisdiction basis. In the event we determine that we would be able to realize our deferred income tax assets in the future in excess of their net recorded amount, we would make an adjustment to the valuation allowance that would reduce the provision for income taxes. Conversely, in the event that all or part of the net deferred tax assets are determined not to be realizable in the future, an adjustment to the valuation allowance would be charged to earnings in the period when such determination is made. As of December 31, 2021 and 2020, we have recorded a full valuation allowance on our deferred tax assets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Tax benefits related to uncertain tax positions are recognized when it is more likely than not that a tax position will be sustained during an audit. Interest and penalties related to unrecognized tax benefits are included within the provision for income tax.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Stock-Based Compensation Expense</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For options granted to employees, non-employees, and directors, stock-based compensation is measured at grant date based on the fair value of the award. We determine the grant-date fair value of the options using the Black-Scholes option-pricing model. The grant-date fair value of awards is amortized over the employees&#8217; requisite service period or the non-employees&#8217; vesting period as the services are rendered. Forfeitures are accounted for as they occur. Additionally, our 2020 Employee Stock Purchase Plan is deemed to be a compensatory plan and is therefore included in stock-based compensation expense.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Comprehensive Loss</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Comprehensive loss includes net loss and other comprehensive loss for the period. Other comprehensive loss consists of unrealized loss on investments.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Foreign Currency Transactions</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Transactions denominated in foreign currencies are initially measured in U.S. dollars using the exchange rate on the date of the transaction. Foreign currency denominated monetary assets and liabilities are subsequently re-measured at the end of each reporting period using the exchange rate at that date, with the corresponding foreign currency transaction gain or loss recorded in the statements of operations and statements of cash flows. Nonmonetary assets and liabilities are not subsequently re-measured.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Net Loss Per Share</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Basic net loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common stock outstanding during the period, without consideration of potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common stock and potentially dilutive securities outstanding for the period. For purposes of the diluted net loss per share calculation, redeemable convertible preferred stock, redeemable convertible preferred stock warrant, common stock subject to repurchase, and stock options are considered to be potentially dilutive securities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Basic and diluted net loss attributable to common stockholders per share is presented in conformity with the two-class method required for participating securities as the redeemable convertible preferred stock is considered a participating security. Our participating securities do not have a contractual obligation to share in our losses. As such, the net loss was attributed entirely to common stockholders. Because we have reported a net loss for all periods presented, diluted net loss per common share is the same as basic net loss per common share for those periods.</span></p></div><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Recently Adopted Accounting Pronouncements</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In February 2016, the FASB issued ASU 2016-02, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Leases (Topic 842)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. ASU 2016-02 was subsequently amended by ASU 2018-01, ASU 2018-10, ASU 2018-11, ASU 2018-20, ASU 2019-01, ASU 2019-10 and ASU 2020-05, which the FASB issued in January 2018, July 2018, July 2018, December 2018, March 2019, November 2019 and June 2020, respectively (collectively, &#8220;ASC 842&#8221;). ASC 842 requires lessees to recognize leases on the balance sheet and disclose key information about leasing arrangements. The new standard establishes a ROU model that requires a lessee to recognize a ROU asset and a lease liability on the balance sheet for all leases with a term longer than 12 months. Under ASC 842, leases are classified as either finance leases or operating leases, with classification affecting the pattern and classification of expense recognition in the income statement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">early adopted</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> the new standard effective </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">January 1, 2021</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> using the modified retrospective transition approach. Upon adoption on January 1, 2021, we recognized ROU assets and lease liabilities totaling $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively, to reflect the present value of remaining lease payments under existing lease arrangements. The difference between the leased assets and lease liabilities represents the existing deferred rent liabilities balance resulting from historical straight-lining of operating leases for our facilities, which was reclassified upon adoption to reduce the measurement of the leased assets. The balance of our deferred rent liabilities, which was reclassified to reduce the ROU assets upon adoption, was </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">immaterial</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. We applied the modified retrospective transition approach and did not recast prior periods. Although we applied this approach, we did not have a cumulative effect adjustment to the opening balance of our retained deficit upon adoption. As permitted by the standard, we elected the transition practical expedient package, which among other things, allowed the carryforward of historical lease classifications. For additional details regarding the impact of adoption and disclosure, see Note 5, &#8220;Leases,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">" to our financial statements included in Part II, Item 8 of this Annual Report on Form 10-K.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In December 2019, the FASB issued ASU No. 2019-12, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Income Taxes (Topic 740)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The amendments in ASU 2019-12 simplify the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The amendments also improve consistent application of and simplify U.S. GAAP or other areas of Topic 740 by clarifying and amending existing guidance. The new standard was </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">effective</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> for us on </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">January 1, 2021</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and for interim periods within 2021. The adoption of ASU 2019-12 </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">did not</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> have a material impact on our financial statements.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Recently Issued Accounting Pronouncements&#8212;Not Yet Adopted</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In June 2016, the FASB issued ASU 2016-13, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Financial Instruments &#8211; Credit Losses (Topic 326):</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Measurement of Credit Losses on Financial Instruments</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and has subsequently issued related amendments, collectively referred to as &#8220;Topic 326.&#8221; Topic 326 requires that financial assets measured at amortized cost be presented at the net amount expected to be collected. The measurement of expected credit losses is based on historical experience, current conditions and reasonable and supportable forecasts that affect collectability. Topic 326 also eliminates the concept of &#8220;other-than-temporary&#8221; impairment when evaluating available-for-sale debt securities and instead focuses on determining whether any impairment is a result of a credit loss or other factors. An entity will recognize an allowance for credit losses on available-for-sale debt securities rather than an other-than-temporary impairment that reduces the cost basis of the investment. Topic 326 is effective for fiscal years beginning after December 15, 2022 and interim periods within those fiscal years. Early adoption is permitted. We are currently assessing the impact of this standard to our financial statements and related disclosures.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In November 2021, the FASB issued ASU 2021-10, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Government Assistance (Topic 832): Disclosure by Business Entities about Government Assistance, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">which </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">requires disclosures about transactions with a government entity that are accounted for by applying a grant or contribution accounting model by analogy to other accounting guidance, such as a grant model within International Accounting Standard 20, </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Accounting for Government Grants and Disclosure of Government Assistance</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, or Subtopic 958-605, </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Not-For-Profit Entities - Revenue Recognition</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The required disclosures include (i) the nature of the transactions and the related accounting policy used to account for the transactions, (ii) the financial statement line items that are affected by the transactions and (iii) the significant terms and conditions of the transactions, including commitments and contingencies. This standard is effective for annual periods beginning after December 15, 2021, with early adoption and retrospective or prospective application permitted. This standard is effective for us on January 1, 2022 and only impacts annual financial statement footnote disclosures</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. In Note 11, "Funding Arrangement," to our financial statements included in Part II, Item 8 of this Annual Report on Form 10-K, we included disclosures on our cost-reimbursement research award from CARB-X. Therefore, we do not believe the adoption of this standard will have a material impact on our financial statements.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">    </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139898130315624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements and Fair Value of Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements and Fair Value of Financial Instruments</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">3. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Fair Value Measurements and Fair Value of Financial Instruments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Assets and liabilities recorded at fair value on a recurring basis in the balance sheets, as well as assets and liabilities measured at fair value on a non-recurring basis or disclosed at fair value, are categorized based upon the level of judgment associated with inputs used to measure their fair values. The accounting guidance for fair value provides a framework for measuring fair value and requires certain disclosures about how fair value is determined. Fair value is defined as the price that would be received</span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">upon the sale of an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. The accounting guidance also establishes a three-level valuation hierarchy that prioritizes the inputs to valuation techniques used to measure fair value based upon whether such inputs are observable or unobservable. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect market assumptions made by the reporting entity. The three-level hierarchy for the inputs to valuation techniques is briefly summarized as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Level 1&#8212;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Level 2&#8212;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Inputs are observable, unadjusted quoted prices in active markets for similar assets or liabilities, unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Level</span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> 3</span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Unobservable inputs that are significant to the measurement of the fair value of the assets or liabilities that are supported by little or no market data.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability. Changes in the ability to observe valuation inputs may result in a reclassification of levels of certain securities within the fair value hierarchy. We recognize transfers into and out of levels within the fair value hierarchy in the period in which the actual event or change in circumstances that caused the transfer occurs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 1 securities consist of highly liquid money market funds for which the carrying amounts approximate their fair values due to their short maturities. U.S. Treasury securities are valued using Level 1 inputs based on unadjusted, quoted prices in active markets that are observable at the measurement date for identical assets or liabilities. Level 2 securities, consisting of corporate debt, commercial paper, U.S. government agency securities and asset-backed securities, are measured based on other observable inputs, including broker or dealer quotations or alternative pricing sources. When quoted prices in active markets for identical assets or liabilities are not available, we rely on non-binding quotes from our investment managers, which are based on proprietary valuation models of independent pricing services. These models generally use inputs such as observable market data, quoted market prices for similar instruments or historical pricing trends of securities relative to our peers. To validate the fair value determinations provided by our investment managers, we review the pricing movement in the context of overall market trends and trading information from our investment managers. In addition, we assess the inputs and methods used in determining the fair value in order to determine the classification of securities in the fair value hierarchy. We had </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> Level 3 securities either as of December 31, 2021 or 2020.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">There were </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> transfers within the hierarchies during the years ended December 31, 2</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21 or 2020.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We invested in money market funds as of December 31, 2020. In January 2021, we started to invest some of our funds in corporate debt, commercial paper, U.S. Treasury securities, U.S. government agency securities and asset-backed securities in addition to money market funds. </span><span style="font-size:12.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following tables set forth our financial instruments measured at fair value on a recurring basis by level within the fair value hierarchy at </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020: </span></span><span style=""/></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:28.362%;"/>
        <td style="width:13.565%;"/>
        <td style="width:6.799%;"/>
        <td style="width:1.231%;"/>
        <td style="width:9.272%;"/>
        <td style="width:0.6%;"/>
        <td style="width:2.227%;"/>
        <td style="width:1.231%;"/>
        <td style="width:9.272%;"/>
        <td style="width:0.6%;"/>
        <td style="width:1.831%;"/>
        <td style="width:1.242%;"/>
        <td style="width:8.608%;"/>
        <td style="width:0.835%;"/>
        <td style="width:2.099%;"/>
        <td style="width:1.231%;"/>
        <td style="width:10.396%;"/>
        <td style="width:0.6%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Fair Value<br/>Hierarchy Level</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Amortized<br/>Cost</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Gross <br/>Unrealized Gains</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Gross <br/>Unrealized Losses</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Fair<br/>Value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">(in thousands)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Cash and cash equivalents:</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Cash</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Level 1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">27,834</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">27,834</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Money market funds</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Level 1</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">17,555</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">17,555</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Commercial paper</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Level 2</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">23,597</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">23,596</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:15.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Total cash and cash equivalents</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">68,986</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">68,985</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Investments:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">U.S. Treasury securities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Level 1</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">45,290</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">73</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">45,217</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Commercial paper</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Level 2</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">61,941</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">22</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">61,919</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Corporate debt</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Level 2</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">58,498</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">74</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">58,424</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Asset backed securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Level 2</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">13,899</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">25</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">13,874</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">U.S. government agency securities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Level 2</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">24,714</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">46</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">24,668</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:15.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Total investments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">204,342</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">240</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">204,102</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(0,0,0,0);text-indent:15.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Total assets measured at fair value</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">273,328</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">241</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">273,087</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31, 2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Fair Value<br/>Hierarchy Level</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Amortized<br/>Cost</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Gross <br/>Unrealized Gains</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Gross <br/>Unrealized Losses</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Fair<br/>Value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">(in thousands)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Cash and cash equivalents:</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Cash</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Level 1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">4,788</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">4,788</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Money market funds</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Level 1</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">381,412</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">381,412</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Total assets measured at fair value</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">386,200</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">386,200</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table presents the contractual maturities of our investments as of December 31, 2021 (in thousands):</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:70.292%;"/>
        <td style="width:5.331%;"/>
        <td style="width:1.242%;"/>
        <td style="width:22.15%;"/>
        <td style="width:0.985%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Fair Value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Due in less than one year</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">176,985</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Due in one to five years</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">27,117</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">204,102</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139898127664968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Details<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Balance Sheet Details</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">4. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Balance Sheet Details</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Property and Equipment, Net</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment, net as of December 31, 2021 and 2020 consisted of the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.51%;"/>
        <td style="width:1.478%;"/>
        <td style="width:1.37%;"/>
        <td style="width:12.976%;"/>
        <td style="width:0.921%;"/>
        <td style="width:1.478%;"/>
        <td style="width:1.37%;"/>
        <td style="width:12.976%;"/>
        <td style="width:0.921%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Furniture and equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,619</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">397</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Computers and computer software</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">430</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">111</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Lab equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9,453</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,739</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Leasehold improvements</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,903</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Construction in progress</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">219</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total property and equipment</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11,502</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,369</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less: accumulated depreciation and amortization</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,548</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,097</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment, net</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,954</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,272</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Depreciation and amortization expense for years ended December 31, 2021, 2020 and 2019 was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million respectively, of which $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million related to capital lease amortization expense for the years ended December 31, 2021, 2020 and 2019, respectively.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Accrued Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued expenses as of December 31, 2021 and 2020 consisted of the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.006%;"/>
        <td style="width:1.413%;"/>
        <td style="width:1.381%;"/>
        <td style="width:12.75%;"/>
        <td style="width:0.942%;"/>
        <td style="width:1.413%;"/>
        <td style="width:1.381%;"/>
        <td style="width:12.772%;"/>
        <td style="width:0.942%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Preclinical studies</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,039</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,844</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Professional fees</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">400</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">490</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other accrued expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,348</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">432</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:15.0pt;word-break:break-word;vertical-align:middle;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8,787</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,766</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI http://asc.fasb.org/topic&amp;trid=2122208<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139898130369864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">5. Leases</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Operating Lease Obligations</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In July 2016, we entered into a </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">five-year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> lease agreement for our previous headquarters facility located in Foster City, California. The original term of the lease was from </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">September 1, 2016</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> to </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">August 31, 2021</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, with </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">two</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-month </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">renewal options</span></span><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"/></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In July 2019, we leased another facility in Foster City, California as a result of growth in personnel and lab space requirements. The original term of this lease was from </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">July 1, 2019</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> to </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">October 31, 2021</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, with </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> renewal options</span></span><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"/></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> In November 2020, we extended the terms of both of these leases for </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">six months</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> to </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">March 1, 2022</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">April 30, 2022</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, respectively. In February 2022, we entered into an early termination agreement for one of the facilities in Foster City and terminated our lease on </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">February 12, 2022</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> instead of April 30, 2022. We also leased an office in San Diego, California with a lease term that ended on </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">April 30, 2021</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In January 2021, we entered into a lease agreement for our new corporate headquarters facility located in San Carlos, California and a license agreement for temporary lab and office space in Palo Alto, California. The lease term for our new corporate headquarters facility began on </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">January 22, 2021</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and expires on </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2025</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. We have </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">two</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">60</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-month renewal options. The original term of the license agreement for temporary space in Palo Alto terminated when the San Carlos office leasehold improvements were completed and we moved into our new corporate headquarters. We extended the license agreement for the Palo Alto office by </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">60 days</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> to </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">March 3, 2022</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> to accommodate our relocation plan. These two agreements are accounted for as a combined lease because the contracts were negotiated as a package with the same commercial objective.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We early adopted ASC 842 and its associated amendments as of January 1, 2021 using the modified retrospective transition approach by applying the new standard to all leases existing at the date of the initial adoption and not restating comparative periods. We elected the package of practical expedients permitted under the transition guidance within the new standard, which among other things, allowed us to carryforward the historical lease classification of those leases in place as of January 1, 2021. The adoption of ASC 842 resulted in an increase to total assets and liabilities due to the recording of operating lease ROU assets and operating lease liabilities of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively, as of January 1, 2021. ROU assets and lease liabilities are recognized based on the present value of the fixed and in-substance fixed lease payments over the lease terms at their respective commencement dates. The ROU assets also include any initial direct costs incurred and lease payments made at or before the commencement date and are reduced by lease incentives. In determining the present value of lease payments, since the rate implicit in the lease is generally not readily determinable, we use our incremental borrowing rate, which requires management&#8217;s judgment, including for the development of a synthetic credit rating and the cost of debt as we currently do not carry any debt. Variable lease costs, which are dependent on usage, a rate or index, including common area maintenance charges for our real estate leases, are expensed as incurred.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Upon commencement of the Palo Alto lease in March 2021, we recorded a ROU asset and lease liability of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively. Upon commencement of the San Carlos lease in December 2021, we recorded a ROU asset and lease liability of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">28.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively. Because the Palo Alto and the San Carlos agreements are accounted for as a combined lease, lease payments and lease incentives are allocated between the </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">two</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> leases.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">   </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Information related to our ROU assets and related lease liabilities was as follows (dollar amounts in thousands):</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:78.308%;"/>
        <td style="width:4.176%;"/>
        <td style="width:1.381%;"/>
        <td style="width:13.822%;"/>
        <td style="width:2.313%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash paid for operating lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">924</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Right-of-use assets recognized in exchange for new lease obligations</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">27,958</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Current operating lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,276</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Non-current operating lease liabilities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11,507</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16,783</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Weighted-average remaining lease term (in years)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.75</span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Weighted-average discount rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.5</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
      </table></div><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Maturities of lease liabilities as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 were as follows:</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.289%;"/>
        <td style="width:1.692%;"/>
        <td style="width:1.381%;"/>
        <td style="width:15.675%;"/>
        <td style="width:0.964%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Years ending December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:Times New Roman;position:relative;">(1)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">105</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2023</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,639</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2024</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,805</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2025</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,976</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Thereafter</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total future undiscounted lease payments</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20,315</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less: Imputed interest</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,532</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total lease liabilities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16,783</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">_____________________________________________</span></p><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(1)	Maturities for 2022 are net of lease incentives of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million allocated to the Palo Alto office.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Future minimum payments required under operating leases as of December 31, 2020 were as follows:</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:78.985%;"/>
        <td style="width:1.82%;"/>
        <td style="width:1.402%;"/>
        <td style="width:16.679%;"/>
        <td style="width:1.113%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Years ending December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;text-indent:13.7pt;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="margin-left:13.7pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">742</span></p></td>
        <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:13.7pt;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="margin-left:13.7pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">190</span></p></td>
        <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total future minimum payments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="border-top:0.250pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="border-top:0.250pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">932</span></p></td>
        <td style="border-top:0.250pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
       </tr>
      </table></div><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Rent expense recognized under the leases was $</span><span style="font-size:10.0pt;font-family:Times New Roman;white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for the years ended December 31, 2021, 2020 and 2019, respectively.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139898130157800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">6. Commitments and Contingencies</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Legal Contingencies</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">From time to time, we may become involved in legal proceedings arising from the ordinary course of business. We record a liability for such matters when it is probable that future losses will be incurred and that such losses can be reasonably estimated. Significant judgment by us is required to determine both probability and the estimated amount. We do not believe that there is any litigation or asserted or unasserted claim pending that could, individually or in the aggregate, have a material adverse effect on our results of operations or financial condition.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Guarantees and Indemnifications</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the normal course of business, we enter into agreements that contain a variety of representations and provide for general indemnification. Our exposure under these agreements is unknown because it involves claims that may be made against us in the future. To date, we have not paid any claims or been required to defend any action related to our indemnification obligations. As of December 31, 2021, we did not have any material indemnification claims that were probable or reasonably possible and consequently have not recorded related liabilities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Indemnification</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">To the extent permitted under Delaware law, we have agreed to indemnify our directors and officers for certain events or occurrences while the director or officer is, or was, serving at our request in such capacity. The indemnification period covers all pertinent events and occurrences during the director&#8217;s or officer&#8217;s service. The maximum potential amount of future payments we could be required to make under these indemnification agreements is not specified in the agreements; however, we have director and officer insurance coverage that reduces our exposure and enables us to recover a portion of any future amounts paid. We have not incurred any material costs as a result of such indemnification and are not currently aware of any indemnification claims.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Development and Manufacturing Services Agreement</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On October 21, 2016, we entered into a development and manufacturing services agreement, as amended, with Lonza (the &#8220;Lonza DMSA&#8221;), pursuant to which Lonza is obligated to perform services including manufacturing process development and the manufacture of components for VAX-24, including the polysaccharide antigens, our proprietary eCRM protein carrier and conjugated drug substances.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the September 2017, we and Lonza agreed to defer the completion payments for any stage that commenced after December 31, 2019 or had not been completed by December 31, 2019 until the earlier of the completion of all Investigational New Drug (&#8220;IND&#8221;)-enabling activities or December 31, 2020. In March 2020, Lonza agreed to defer the completion payments until the earlier of the completion of all IND-enabling activities or April 30, 2021. In April 2021, Lonza further agreed to defer </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">50</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the completion payments until the earlier of the completion of all IND-enabling activities or December 31, 2021. Pursuant to this agreement, all deferred completion payments were paid in December 2021.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In June 2018, we and Lonza entered into a letter agreement pursuant to which we agreed to certain terms for potential future equity payments in shares of our common stock as partial satisfaction of future obligations to Lonza. This agreement states that the initial pre-IND cash payments would be subject to a specified dollar cap (the &#8220;Initial Cash Cap&#8221;). After the Initial Cash Cap has been reached, we have the option to make any further pre-IND payments owed to Lonza in cash, in shares of our common stock at then market prevailing prices, or a combination of both, at our election. The Initial Cash Cap had not been reached as of December 31, 2020. As such, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> amount was recorded with respect to the potential future payments above the Initial Cash Cap at December 31, 2020. In April 2021, we reached the Initial Cash Cap and notified Lonza that we would be exercising our option to issue approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in shares of our common stock as payment for a portion of pre-IND payments due April 30, 2021. In June 2021, we issued </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">399,680</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of our common stock to Lonza at a price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">25.02</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share to pay for $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of the pre-IND payments due April 30, 2021.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In October 2018, we entered into a second development and manufacturing services agreement with Lonza (the &#8220;Lonza 2018 DMSA,&#8221; and together with the Lonza DMSA, the &#8220;Lonza Agreements&#8221;), pursuant to which Lonza is obligated to perform services including manufacturing process development and the manufacture and supply of VAX-24 finished drug product.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under the Lonza Agreements, we are obligated to pay Lonza agreed-upon fees for Lonza&#8217;s performance of manufacturing services, and to reimburse Lonza for its out-of-pocket costs associated with purchasing raw materials, plus a customary handling fee. Each Lonza Agreement is managed by a steering committee and any dispute at the steering committee will be resolved by senior executives of the parties.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139898130272536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Redeemable Convertible Preferred Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityDisclosureAbstract', window );"><strong>Temporary Equity Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_RedeemableConvertiblePreferredStockTextBlock', window );">Redeemable Convertible Preferred Stock</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">7. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Redeemable Convertible Preferred Stock</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">There were </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of redeemable convertible preferred stock authorized or outstanding as of December 31, 2021.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In connection with our IPO in June 2020, the outstanding shares of our Series A, Series B, Series C and Series D Redeemable Convertible Preferred Stock automatically converted into </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">28,610,337</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_RedeemableConvertiblePreferredStockTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Redeemable convertible preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_RedeemableConvertiblePreferredStockTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139898130270856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Common Stock</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">8. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Common Stock</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our certificate of incorporation authorizes us to issue up to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">500,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock with $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.001</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> par value per share, of which </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">53,031,978</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">51,071,593</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares were issued and outstanding as of December 31, 2021 and 2020, respectively. The holders of our common stock are also entitled to receive dividends whenever funds are legally available, when and if declared by our board of directors. As of December 31, 2021 and 2020, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> dividends have been declared. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Each share of common stock is entitled to one vote.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In July 2021, we entered into an Open Market Sales Agreement</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">SM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> (the &#8220;ATM Sales Agreement&#8221;) with Jefferies LLC (&#8220;Jefferies&#8221;), which provides that, upon the terms and subject to the conditions and limitations set forth in the ATM Sales Agreement, we</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">may elect to issue and sell, from time to time, shares of our common stock having an aggregate offering price of up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">150.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million through Jefferies acting as our sales agent or principal. We are obligated to pay Jefferies a commission of up to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the gross sales proceeds of any common stock sold through Jefferies under the ATM Sales Agreement; however, we are not obligated to make any sales of common stock. As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, we have sold </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">567,045</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of our common stock under the ATM Sales Agreement at an average price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">25.26</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share for aggregate gross proceeds of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">14.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million ($</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million net of commissions and offering expenses).</span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Common stock reserved for future issuances under the 2020 Equity Incentive Plan (the &#8220;2020 Plan&#8221;) and the 2014 Equity Incentive Plan (the &#8220;2014 Plan&#8221;) was as follows, and excludes </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">62,382</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares issued outside of the 2014 Plan and 2020 Plan:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.052%;"/>
        <td style="width:1.584%;"/>
        <td style="width:1.006%;"/>
        <td style="width:12.877%;"/>
        <td style="width:1.006%;"/>
        <td style="width:1.584%;"/>
        <td style="width:1.006%;"/>
        <td style="width:12.877%;"/>
        <td style="width:1.006%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Options issued and outstanding</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,295,007</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,188,531</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Shares available for future stock option grants</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,104,756</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,651,149</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11,399,763</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9,839,680</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139898127697368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_WarrantsDisclosureTextBlock', window );">Warrants</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">9. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Warrants</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In connection with our IPO in June 2020, our outstanding warrants were automatically net exercised for an aggregate </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">46,869</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_WarrantsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_WarrantsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139898130286472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Equity Incentive Plans</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">10. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Equity Incentive Plans</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020 and 2014 Equity Incentive Plans</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In June 2020, our board of directors adopted, and our stockholders approved, the 2020 Plan, which became effective on June 11, 2020. Under the 2020 Plan, we may grant stock options, appreciation rights, restricted stock and restricted stock units to employees, consultants and directors. Stock options granted under the 2020 Plan may be either incentive stock options or nonqualified stock options. Incentive stock options may be granted only to our employees, including officers and directors who are also employees. Nonqualified stock options may be granted to our employees, officers, directors, consultants and advisors. The exercise price of stock options granted under the 2020 Plan must be at least equal to the fair market value of the common stock on the date of grant, except that an incentive stock option granted to an employee who owns more than </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the shares of our common stock shall have an exercise price of no less than </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">110</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the fair value per share on the grant date and expire </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">five years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> from the date of grant. The maximum term of stock options granted under the 2020 Plan is </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> years, unless subject to the provisions regarding </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% stockholders. Our stock options granted to new employees generally vest over </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">four years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> at a rate of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">25</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% upon the first anniversary of the vesting commencement date and monthly thereafter. Our other stock options granted to employees generally vest monthly over </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">four years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> from the vesting commencement date. A total of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,150,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock were approved to be initially reserved for issuance under the 2020 Plan. The number of shares that remained available for issuance under the 2014 Plan as of the effective date of the 2020 Plan, and shares subject to outstanding awards under the 2014 Plan as of the effective date of the 2020 Plan that are subsequently canceled, forfeited or repurchased by us, will be added to the shares reserved under the 2020 Plan. In addition, the number of shares of common stock available for issuance under the 2020 Plan is automatically increased on the first day of each calendar year during the </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10-year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> term of the 2020 Plan, beginning with January 1, 2021 and ending with January 1, 2030, by an amount equal to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the outstanding number of shares of our common stock on December 31 of the preceding calendar year or such lesser amount as determined by our board of directors. As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021, an aggregate of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,104,756</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock were available for issuance under the 2020 Plan. Effective January 1, 2022, the number of shares of common stock available under the 2020 Plan increased by </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,651,598</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares pursuant to the evergreen provision of the 2020 Plan.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our 2014 Plan permitted the granting of incentive stock options, non-statutory stock options, restricted stock and other stock-based awards. Subsequent to the adoption of the 2020 Plan, no additional equity awards can be made under the 2014 Plan. Shares reserved and remaining available for issuance under the 2014 Plan were added to the 2020 Plan reserve upon its effectiveness.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The terms of the 2014 Plan permit the exercise of options granted prior to vesting, subject to required approvals. The unvested shares are subject to our lapsing repurchase right upon termination of employment at the original purchase price. Shares purchased by employees pursuant to the early exercise of stock options are not deemed, for accounting purposes, to be issued until those shares vest according to their respective vesting schedules. Cash received for early exercised stock options is recorded as other liabilities on the balance sheet and is reclassified to common stock and additional paid-in capital as such shares vest.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,657,394</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,637,613</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock were subject to outstanding options under the 2014 Plan and 2020 Plan, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">At December 31, 2021 and 2020, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,410</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15,056</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares, respectively, remained subject to our right of repurchase as a result of the early exercised stock options. The remaining liabilities related to early exercised shares as of December 31, 2021 and 2020 were both less than $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and were recorded in other liabilities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Activity under our 2020 Plan and 2014 Plan, which excludes options to purchase </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">62,382</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares granted outside of the 2020 Plan and 2014 Plan, was as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:43.015%;"/>
        <td style="width:0.963%;"/>
        <td style="width:0.707%;"/>
        <td style="width:8.522%;"/>
        <td style="width:0.91%;"/>
        <td style="width:0.963%;"/>
        <td style="width:0.685%;"/>
        <td style="width:8.575%;"/>
        <td style="width:0.91%;"/>
        <td style="width:0.963%;"/>
        <td style="width:1.381%;"/>
        <td style="width:7.976%;"/>
        <td style="width:0.685%;"/>
        <td style="width:0.963%;"/>
        <td style="width:0.846%;"/>
        <td style="width:10.213%;"/>
        <td style="width:0.685%;"/>
        <td style="width:0.963%;"/>
        <td style="width:1.381%;"/>
        <td style="width:8.008%;"/>
        <td style="width:0.685%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Options Outstanding</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Stock Option Activity</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Options<br/>Available<br/>for <br/>Grant</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Number<br/>of<br/>Options</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Weighted-<br/>Average<br/>Exercise<br/>Price Per<br/>Share</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Weighted-<br/>Average<br/>Remaining<br/>Contractual <br/>Term<br/>(Years)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Aggregate<br/>Intrinsic<br/>Value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Balances &#8212; December 31, 2019</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">835,941</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">3,297,586</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1.93</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Additional shares authorized</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">5,997,435</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Options granted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">2,255,690</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">2,255,690</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">8.93</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Options exercised</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">358,264</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1.88</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Options forfeited</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">73,463</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">73,463</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">3.50</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Balances &#8212; December 31, 2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">4,651,149</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">5,121,549</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">4.99</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Additional shares authorized</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">2,553,579</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Options granted</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1,616,021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1,616,021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">21.83</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Options exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">926,514</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">3.25</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Options forfeited</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">516,049</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">516,049</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">16.70</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Balances &#8212; December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">6,104,756</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">5,295,007</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">9.30</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">7.89</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">78,604</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Vested and expected to vest &#8212; December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">5,295,007</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">9.30</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">7.89</span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">78,604</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Exercisable at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">2,611,523</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">4.76</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">7.07</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">50,123</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During the years ended December 31, 2021 and 2020, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">926,514</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">358,264</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of stock options, respectively, were exercised for cash at a weighted-average price per share of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.25</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.88</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, respectively. The weighted-average grant date fair value of options granted for the years ended December 31, 2021 and 2020 was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">14.65</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9.62</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, respectively. The intrinsic value of the stock options exercised was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for the years ended December 31, 2021 and 2020, respectively.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020 Employee Stock Purchase Plan</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In June 2020, our board of directors adopted, and our stockholders approved, the 2020 Employee Stock Purchase Plan (the &#8220;2020 ESPP&#8221;), which became effective on June 11, 2020. The 2020 ESPP permits participants to purchase common stock through payroll deductions of up to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of their eligible compensation. Employees purchase shares of common stock at a price per share equal to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">85</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the lower of the fair market value at the start or end of the </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">six-month</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> purchase periods within the </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">two-year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> offering period. A total of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">650,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock were approved to be initially reserved for issuance under the 2020 ESPP. In addition, the number of shares of common stock available for issuance under the 2020 ESPP is automatically increased on the first day of each calendar year during the </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10-year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> term of the 2020 Plan, beginning with January 1, 2021 and ending with January 1, 2030, by an amount of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the outstanding number of shares of our common stock on December 31 of the preceding calendar year or such lesser amount as determined by our board of directors. For the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, employees acquired </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">62,546</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of our common stock under the 2020 ESPP and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,070,704</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock remained available for issuance under the 2020 ESPP. Effective January 1, 2022, the number of shares of common stock available under the 2020 ESPP increased by </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">530,319</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares pursuant to the evergreen provision of the 2020 ESPP.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Stock-based Compensation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We estimated the fair value of employee stock options using the Black-Scholes option-pricing model for the years ended December 31, 2021, 2020 and 2019 using the following weighted-average assumptions:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.31%;"/>
        <td style="width:1.36%;"/>
        <td style="width:15.203%;"/>
        <td style="width:1.36%;"/>
        <td style="width:15.203%;"/>
        <td style="width:1.36%;"/>
        <td style="width:15.203%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="5" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2019</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Fair Value Assumptions</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected volatility</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">81.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% - </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">84.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">81.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% - </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">94.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">78.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% - </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">80.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected dividend yield</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected term (in years)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.3 </span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">- </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.5</span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.6</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;- </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.1</span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.9</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;- </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.1</span></span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% - </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% - </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% - </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We estimated the fair value of shares under the 2020 ESPP using the Black-Scholes option-pricing model for the years ended December 31, 2021, 2020 and 2019 using the following weighted-average assumptions:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:48.1%;"/>
        <td style="width:1.381%;"/>
        <td style="width:15.384%;"/>
        <td style="width:1.381%;"/>
        <td style="width:16.99%;"/>
        <td style="width:1.381%;"/>
        <td style="width:15.384%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="5" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2019</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Fair Value Assumptions</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected volatility</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">79.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% - </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">126.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">105.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% - </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">158.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">N/A</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected dividend yield</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">N/A</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected term (in years)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.5 </span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">- </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.0</span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.4</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;- </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.0</span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">N/A</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% - </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% - </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">N/A</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We recorded total stock-based compensation expense for the years ended December 31, 2021, 2020 and 2019 related to the 2014 Plan, the 2020 Plan and the 2020 ESPP in the statements of operations and allocated the amounts as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.717%;"/>
        <td style="width:1.349%;"/>
        <td style="width:1.381%;"/>
        <td style="width:12.781%;"/>
        <td style="width:0.91%;"/>
        <td style="width:1.349%;"/>
        <td style="width:1.381%;"/>
        <td style="width:12.77%;"/>
        <td style="width:0.91%;"/>
        <td style="width:1.349%;"/>
        <td style="width:1.381%;"/>
        <td style="width:12.792%;"/>
        <td style="width:0.931%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2019</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(In thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,954</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,861</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">368</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">General and administrative</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,775</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,573</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">817</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,729</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,434</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,185</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Upon our IPO, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">362,935</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> performance-based awards vested and, as a result, we recognized $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of stock-based compensation expense during the three months ended June 30, 2020, which amount is included in the above table for the year ended December 31, 2020.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, there was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">27.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of unrecognized stock-based compensation expense related to the employee and non-employee awards, which is expected to be recognized over a weighted-average period of </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.5 </span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">years.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139898130379544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Funding Arrangement<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_FundingArrangementAbstract', window );"><strong>Funding Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_FundingArrangementTextBlock', window );">Funding Arrangement</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">11. Funding Arrangement</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In July 2019, we received a cost-reimbursement research award from Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (&#8220;CARB-X&#8221;), a public-private partnership funded under a Cooperative Agreement from Assistant Secretary for Preparedness and Response/Biomedical Advanced Research and Development Authority (&#8220;BARDA&#8221;) and by awards from Wellcome Trust, Germany&#8217;s Federal Ministry of Education and Research, the United Kingdom Global Antimicrobial Resistance Innovation Fund and the Bill &amp; Melinda Gates Foundation. In connection with this funding, we entered into a cost-reimbursement sub-award agreement with the Trustees of Boston University, the administrator of the program. The initial award provided the potential for funding up to </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">four years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> to develop a universal vaccine to prevent infections caused by Group A Strep bacteria, which include pharyngitis, impetigo and necrotizing fasciitis. The initial award committed initial funding of up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for our VAX-A1 program and, subject to a CARB-X decision to extend the options, up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in total funding available upon achievement of development milestones over the next </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">four years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Specified research expenditures are reimbursable expenses associated with agreed-upon activities needed to advance the research project supported by the grant. These expenditures can include labor, laboratory supplies, travel, consulting and third-party vendor research and development support costs.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In July 2020, the CARB-X agreement was amended with the initial funding amount increased from $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. In December 2020, we reached the maximum CARB-X funding limit for this initial funding period, and subsequently submitted our funding proposal to CARB-X for the next period under our agreement. In April 2021, we received approval for the next phase of CARB-X development and executed the cost-reimbursement sub-award agreement with the Trustees of Boston University in August 2021. Pursuant to the agreement, the award committed additional funding of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for IND-enabling activities and total potential funding of up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">29.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million (including the current $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million award and the prior $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million award) upon the achievement of future VAX-A1 development milestones. In January 2022, CARB-X revised the parameters for the contribution of CARB-X funding and implemented maximum funding levels for all grant recipients. As a result, our total funding available upon achievement of development milestones through Phase 1 human clinical trials was revised from $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">29.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">      </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In April 2021, we received a cost-reimbursement research award from the National Institutes of Health (&#8220;NIH&#8221;). In connection with this funding, we entered into a cost-reimbursement sub-award agreement with the University of Maryland, Baltimore, the administrator of the program. The award provides for potential funding up to </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">five years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> totaling approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million to develop a vaccine to prevent infections caused by Shigella.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Income from grants is recognized in the period during which the related specified expenses are incurred, provided that the conditions under which the grants were provided have been met. We recognized $</span><span style="font-size:10.0pt;font-family:Times New Roman;white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of grant income and recorded the amounts in Other income (expense), net in the statement of operations during the years ended December 31, 2021, 2020, and 2019 respectively. A grant receivable of $</span><span style="font-size:10.0pt;font-family:Times New Roman;white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million representing unreimbursed, eligible costs incurred under the CARB-X agreement was recorded and included in Prepaid expenses and other current assets in the balance sheet as of December 31, 2021 and 2020, respectively.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_FundingArrangementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Funding arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_FundingArrangementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_FundingArrangementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Funding arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_FundingArrangementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139898130175736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">12. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Net Loss Per Share</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table sets forth the computation of basic and diluted net loss per share and excludes shares which are legally outstanding, but subject to repurchase by us:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.198%;"/>
        <td style="width:1.231%;"/>
        <td style="width:1.381%;"/>
        <td style="width:10.692%;"/>
        <td style="width:0.92%;"/>
        <td style="width:1.231%;"/>
        <td style="width:1.381%;"/>
        <td style="width:10.714%;"/>
        <td style="width:0.942%;"/>
        <td style="width:1.252%;"/>
        <td style="width:1.381%;"/>
        <td style="width:10.735%;"/>
        <td style="width:0.942%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2019</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net loss (in thousands)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">100,077</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">89,217</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">50,274</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Weighted-average shares outstanding used in computing net<br/>&#160;&#160;&#160;loss per share, basic and diluted</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">51,922,108</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">29,545,810</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,795,090</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net loss per share, basic and diluted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.93</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.02</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13.25</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
      </table></div><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following potentially dilutive securities were excluded from the computation of diluted net loss per share for the period presented because including them would have been antidilutive:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.444%;"/>
        <td style="width:1.381%;"/>
        <td style="width:1.006%;"/>
        <td style="width:10.767%;"/>
        <td style="width:1.006%;"/>
        <td style="width:1.381%;"/>
        <td style="width:1.006%;"/>
        <td style="width:10.767%;"/>
        <td style="width:1.006%;"/>
        <td style="width:1.381%;"/>
        <td style="width:1.006%;"/>
        <td style="width:10.842%;"/>
        <td style="width:1.006%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2019</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock options</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,357,389</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,188,531</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,364,568</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Redeemable convertible preferred stock:</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Series A</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,225,719</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Series B</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,786,896</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Series C</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,377,480</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Common stock warrant</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">31,857</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Redeemable convertible preferred stock warrant</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">59,276</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,357,389</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,188,531</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">23,845,796</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139898130137432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">13. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Income Taxes</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our pre-tax book loss was derived from our business operations within the United States.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A reconciliation of our effective tax rate to the statutory U.S. federal rate is as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:55.954%;"/>
        <td style="width:1.232%;"/>
        <td style="width:0.685%;"/>
        <td style="width:9.552%;"/>
        <td style="width:3.213%;"/>
        <td style="width:1.232%;"/>
        <td style="width:0.685%;"/>
        <td style="width:9.552%;"/>
        <td style="width:3.213%;"/>
        <td style="width:1.232%;"/>
        <td style="width:0.685%;"/>
        <td style="width:9.552%;"/>
        <td style="width:3.213%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:bold;font-size:6.7pt;font-family:Times New Roman;position:relative;">(1)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2019</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:bold;font-size:6.7pt;font-family:Times New Roman;position:relative;">(1)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Statutory rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock-based compensation</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.2</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.8</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.4</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Credits</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.6</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.5</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Change in fair value of tranche liability</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.0</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.0</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.3</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Change in valuation allowance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">23.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">22.1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21.8</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Section 162(m) limitation</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.1</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.1</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.0</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.2</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.2</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.4</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.0</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.0</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.0</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;margin-right:66.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p><div style="margin-left:3.333%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:6.667%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.8968727694042435%;">(1)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The 2019 and 2020 effective tax rate reconciliations have been updated to conform to the 2021 presentation.</span></div></div></div><p style="margin-left:10.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of the assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. </span><span style="font-size:12.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table presents significant components of our deferred tax assets as of December 31, 2021 and 2020:</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></span><span style=""/></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.478%;"/>
        <td style="width:1.478%;"/>
        <td style="width:1.37%;"/>
        <td style="width:12.998%;"/>
        <td style="width:0.921%;"/>
        <td style="width:1.478%;"/>
        <td style="width:1.37%;"/>
        <td style="width:12.987%;"/>
        <td style="width:0.921%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">As of December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred tax assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net operating losses</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">85,574</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">52,330</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Fixed assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,700</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">528</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accruals &amp; reserves</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,131</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,786</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Credits</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,865</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,222</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Section 59(e) capitalized expenses</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,984</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,381</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued manufacturing expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,006</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,374</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Lease liability</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,674</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total deferred tax assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">104,934</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">63,621</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Deferred tax liabilities:</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ROU asset</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8,349</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total deferred tax liabilities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8,349</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net deferred tax asset</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">96,585</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">63,621</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Valuation allowance</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">96,585</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">63,621</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net deferred taxes</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></div><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">At December 31, 2021, we have net operating loss carryforwards of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">296.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">262.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million available to reduce future taxable income, if any, for federal and state income tax purposes, respectively. The federal and state net operating loss carryforwards, except the federal loss carryforward arising in tax years beginning after December 31, 2017, begin to expire in </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2034</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> unless previously utilized. Federal net operating losses arising in tax years beginning after December 31, 2017 have an indefinite carryover period and do not expire.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">At December 31, 2021, we have research credit carryforwards of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million available to offset future income tax liabilities, if any, for federal and California income tax purposes, respectively. The federal research and development tax credit carryforwards expire beginning in </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2039</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> unless previously utilized. The California tax credits can be carried forward indefinitely.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have evaluated the positive and negative evidence bearing upon the realizability of our deferred tax assets. Based on our history of operating losses, we have concluded that it is more likely than not that the benefit of our deferred tax assets will not be realized. Accordingly, we have provided a full valuation allowance for deferred tax assets as of December 31, 2021 and 2020.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Utilization of the net operating loss carryforward and research credit carryforward may be subject to an annual limitation due to the ownership percentage change limitations under Section 382 and Section 383, respectively, provided by the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;), and similar state provisions. The annual limitation may result in the expiration of the net operating loss before utilization. We have experienced ownership changes in the past. As a result of the ownership changes, we have determined that approximately less than $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of our federal research credits will expire unutilized, and such amounts are excluded from our research credit carryforwards. The Company does not expect any ownership changes during the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 to result in a limitation that would materially reduce the total amount of net operating loss carryforwards and credits that can be utilized. Subsequent ownership changes may affect the limitation in future years.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have uncertain tax benefits (&#8220;UTBs&#8221;) totaling $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million as of December 31, 2021 and 2020, respectively, which were netted against deferred tax assets subject to valuation allowance. The UTBs had no effect on the effective tax rate. We recognize interest and penalties related to UTBs, when they occur, as a component of income tax expense. To the extent accrued interest and penalties do not ultimately become payable, amounts accrued will be reduced and reflected as a reduction of the provision for income taxes in the period such determination is made. There were </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> interest or penalties recognized for the years ended December 31, 2021 and 2020. We do not expect our UTBs to change significantly over the next 12 months.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A reconciliation of the beginning and ending unrecognized tax benefit amount is as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.521%;"/>
        <td style="width:1.317%;"/>
        <td style="width:1.381%;"/>
        <td style="width:10.716%;"/>
        <td style="width:0.91%;"/>
        <td style="width:1.317%;"/>
        <td style="width:1.381%;"/>
        <td style="width:10.716%;"/>
        <td style="width:0.921%;"/>
        <td style="width:1.327%;"/>
        <td style="width:1.381%;"/>
        <td style="width:10.17%;"/>
        <td style="width:0.942%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2019</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Balance at the beginning of the year</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">393</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">271</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">408</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Additions based on tax positions related to current year</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">461</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">287</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">217</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Adjustments based on tax positions related to prior years</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">70</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">165</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">354</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Balance at end of year</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">924</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">393</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">271</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We file U.S. federal and state tax returns. In general, the Company is no longer subject to tax examination by the Internal Revenue Service or state taxing authorities for years before 2016. Although the federal and state statutes are closed for purposes of assessing additional income tax in those prior years, the taxing authorities may still make adjustments to the net operating loss, or NOL, and credit carryforwards used in open years. Therefore, the tax statutes should be considered open as it relates to the NOL and credit carryforwards used in open years. We do not have any tax audits or other issues pending.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On March 27, 2020, the President of the United States signed into law the Coronavirus Aid, Relief, and Economic Security Act (CARES Act). The CARES Act, among other things, includes certain income tax provisions for individuals and corporations; however, these benefits do not impact our current tax provision.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On December 21, 2020, the President of the United States signed into law the &#8220;Consolidated Appropriations Act, 2021&#8221; which includes further COVID-19 economic relief and extension of certain expiring tax provisions. The relief package includes a tax provision clarifying that businesses with forgiven Paycheck Protection Program, or PPP, loans can deduct regular business expenses that are paid for with the loan proceeds. Additional pandemic relief tax measures include an expansion of the employee retention credit, enhanced charitable contribution deductions and a temporary full deduction for business expenses for food and beverages provided by a restaurant. These benefits do not have a material impact on the current tax provision.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139898130276504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">14. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Related Party Transactions</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have an ongoing relationship with Sutro Biopharma. In 2013, Sutro Biopharma provided support to facilitate the establishment of our Company. As of December 31, 2021 and 2020, Sutro Biopharma owned approximately </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million shares of our common stock. As of December 31, 2019, Sutro Biopharma also owned warrants to purchase </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">31,857</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of our common stock (the &#8220;Common Stock Warrant&#8221;) at an exercise price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.79289</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">59,276</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of our Series C redeemable convertible stock (the &#8220;Preferred Stock Warrant&#8221;) at an exercise price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11.5215</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share. The Common Stock Warrant and the Preferred Stock Warrant were automatically net exercised pursuant to their terms for </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30,278</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16,591</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares, respectively, of our common stock in connection with the IPO. In the agreements and amendments identified herein, we licensed certain intellectual property and acquired certain supply rights from Sutro Biopharma, including the right to use the XpressCF platform to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases. On October 12, 2015, we and Sutro Biopharma (&#8220;the Parties&#8221;) entered into the Sutro Biopharma License Agreement, which amended and restated an agreement dated August 1, 2014. The Sutro Biopharma License Agreement was subsequently amended on May 9, 2018 (&#8220;License Amendment A1&#8221;) and May 29, 2018 (&#8220;License Amendment A2&#8221;). In consideration for the License Amendment A2, we issued to Sutro Biopharma the Preferred Stock Warrant to purchase </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">59,276</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of Series C redeemable convertible preferred stock at a purchase price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11.5215</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share. We also entered into a separate supply agreement with Sutro Biopharma on </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">May 29, 2018</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> (the &#8220;Sutro Biopharma Supply Agreement&#8221;). As of June 2, 2021, Sutro Biopharma was no longer considered a related party.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under the Sutro Biopharma License Agreement, Sutro Biopharma granted us an exclusive, worldwide license to research, develop, manufacture and commercialize vaccine products addressing infectious disease, which are discovered or produced based on the use of Sutro Biopharma&#8217;s proprietary cell-free protein expression technology, known as XpressCF, which utilizes extracts derived from strains of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">E. coli</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. In connection with the Sutro Biopharma License Agreement, under the Sutro Biopharma Supply Agreement, Sutro Biopharma has agreed to manufacture and supply extracts and reagents for us on a cost-plus basis. In consideration for the rights licensed, we are obligated to pay a </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% royalty on worldwide aggregate annual net sales of our vaccine products for human health and a </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% royalty on annual net sales of vaccine products for animal health. In License Amendment A1, the Parties amended the license agreement to remove a pre-IND regulatory meeting as a diligence milestone and to agree that certain other diligence milestones had been satisfied. In License Amendment A2, the Parties amended the license agreement to add certain terms confirming our obligation to purchase Sutro Biopharma&#8217;s proprietary extract from </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">E. coli </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(&#8220;Extract&#8221;) from Sutro Biopharma. In addition, the Parties amended the license agreement to specify our rights to a transfer of certain know-how relating to the manufacture of Extract in the event of a declaration of bankruptcy by Sutro Biopharma. Finally, the Parties agreed to terms providing for injunctive relief in the event of a breach or threatened breach by the other party.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the Sutro Biopharma Supply Agreement, the Parties agreed to terms for the supply of manufactured Extract and custom reagents by Sutro Biopharma for us to use in manufacturing vaccine compositions in non-clinical research or in Phase 1 or Phase 2 clinical trials. The term of the Sutro Biopharma Supply Agreement is from execution until the later of July 31, 2021 and the date the parties enter into and commence activities under the supply agreement unless extended through a subsequent supply agreement for the supply of Extract and custom reagents for vaccine compositions for Phase 3 and commercial uses as contemplated in the Supply Agreement. In February 2021, we entered into an amendment to the Sutro Biopharma Supply Agreement and extended the term to July 31, 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We recognized expense related to the Supply Agreement of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for the years ended December 31, 2021, 2020 and 2019, respectively. In addition, we recorded $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> in changes in the fair value of the Preferred Stock Warrant for the years ended December 31, 2021, 2020 and 2019, respectively. The expense related to the changes in the fair value of the warrant is included in research and development expenses in the statements of operations. Accrued expenses payable to Sutro Biopharma were $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and 2020, respectively.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139898130307016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">15. Subsequent Events</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In January 2022, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we completed an underwritten public offering in which we issued </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,500,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of our common stock at a price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share, and pre-funded warrants to purchase </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,500,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of our common stock at a price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19.999</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per underlying share. We received approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">93.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in net proceeds after deducting underwriting discounts and commissions and other estimated offering expenses payable by us. In February 2022, t</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">he underwriters exercised their option to purchase an additional </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">750,000</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock, and we received approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">14.1</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in additional net proceeds after deducting underwriting discounts and commissions.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139898119947240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Basis of Presentation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">These financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and applicable rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;) regarding annual reporting. Certain changes in presentation were made in these financial statements as of and for the year ended December 31, 2019 to conform to the presentation as of and for the years ended December 31, 2021 and 2020.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities at the date of the financial statements. On an ongoing basis, we evaluate our estimates and assumptions, including those related to stock-based compensation expense, accruals for certain research and development costs, the incremental borrowing rate, the valuation of deferred tax assets and income taxes. Management bases our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ materially from those estimates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk and Other Risks and Uncertainties</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Concentration of Credit Risk and Other Risks and Uncertainties</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Financial instruments that potentially subject us to a concentration of credit risk consist primarily of cash and cash equivalents and investments. We invest in money market funds, U.S. Treasury securities, U.S. government agency securities, corporate debt, commercial paper and asset-backed securities. We maintain bank deposits in federally insured financial institutions and these deposits may exceed federally insured limits. We are exposed to credit risk in the event of a default by the financial institutions holding our cash and issuers of investments to the extent recorded on the balance sheets. Our investment policy limits investments to money market funds, certain types of debt securities issued by the U.S. Government and its agencies, corporate debt, commercial paper and asset-backed securities, and places restrictions on the credit ratings, maturities and concentration by type and issuer. We have not experienced any significant losses on our deposits of cash, cash equivalents or investments.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are subject to supplier concentration risk from our suppliers. We source our critical raw materials from a sole source supplier, Sutro Biopharma, Inc. (&#8220;Sutro Biopharma&#8221;). We also use one contract manufacturing organization (&#8220;CMO&#8221;), Lonza Ltd. (&#8220;Lonza&#8221;), to handle most of our manufacturing activities. If we were to experience disruptions in raw materials supplied by Sutro Biopharma, or in manufacturing activities at Lonza, we may experience significant delays in our product development timelines and may incur substantial costs to secure alternative sources of raw materials or manufacturing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our future results of operations involve a number of other risks and uncertainties. Factors that could affect our future operating results and cause actual results to vary materially from expectations include, but are not limited to: our early stages of clinical vaccine development; our ability to advance vaccine candidates into, and successfully complete, clinical trials on the timelines we project; our ability to adequately demonstrate sufficient safety and efficacy of our vaccine candidates; our ability to enroll subjects in our ongoing and future clinical trials; our ability to successfully manufacture and supply our vaccine candidates for clinical trials; our ability to obtain additional capital to finance our operations; our ability to obtain, maintain and protect our intellectual property rights; developments relating to our competitors and our industry, including competing vaccine candidates; general and market conditions; and other risks and uncertainties, including those more fully described in the &#8220;Risk Factors&#8221; section of this Annual Report on Form 10-K.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment and Geographical Information</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Segment and Geographical Information</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We operate and manage our business as </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">one</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> reportable and operating segment. Our chief executive officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance. All of our long-lived assets are based in the United States. Long-lived assets are comprised of property and equipment.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Cash, Cash Equivalents and Restricted Cash</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We consider all highly liquid investments purchased with original maturities of three months or less from the date of purchase to be cash and cash equivalents. Cash equivalents consist primarily of amounts invested in money market accounts and commercial paper and are stated at their fair values. Restricted cash consists of a standby letter of credit, which was issued in the first quarter of 2021, that serves as collateral for the lease agreement for our new corporate headquarters. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash, cash equivalents and restricted cash as reported within the statement of cash flows consisted of the following:</span></span></p><div style="font-size:11.0pt;font-family:Calibri;"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:37.584%;"/>
          <td style="width:6.553%;"/>
          <td style="width:1.371%;"/>
          <td style="width:15.494%;"/>
          <td style="width:0.696%;"/>
          <td style="width:2.195%;"/>
          <td style="width:1.371%;"/>
          <td style="width:15.376%;"/>
          <td style="width:0.696%;"/>
          <td style="width:2.195%;"/>
          <td style="width:1.371%;"/>
          <td style="width:14.402%;"/>
          <td style="width:0.696%;"/>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Years Ended December 31,</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2019</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(in thousands)</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash and cash equivalents</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">68,985</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">386,200</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">58,976</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Restricted cash</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">871</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash, cash equivalents and restricted cash</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">69,856</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">386,200</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">58,976</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
        </table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investments</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Investments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our investments have been classified and accounted for as available-for-sale securities. Our investments consist of U.S. Treasury securities, U.S. government agency securities, corporate debt, commercial paper and asset-backed securities. These securities are recorded on the balance sheets at fair value. Unrealized gains and losses on these securities are included as a separate component of accumulated other comprehensive loss. The cost of investment securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization and accretion are included in other income (expense), net. Realized gains and losses and declines in fair value judged to be other-than-temporary, if any, are also included in other income (expense), net. We evaluate securities for other-than-temporary impairment at the balance sheet date. Declines in fair value determined to be other-than-temporary are included in other income (expense), net. We classify our investments as short or long term primarily based on the remaining contractual maturity of the securities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredChargesPolicyTextBlock', window );">Deferred Offering Costs</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Deferred Offering Costs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred offering costs consist of fees and expenses incurred in connection with the sale of our common stock in equity transactions, including legal, accounting, printing and other issuance-related costs. Prior to the completion of equity transactions, deferred offering costs are included in Other assets on the balance sheet. In connection with and as of the closing of equity transactions, these costs are reclassified to Additional paid-in capital, representing a reduction to the gross proceeds. As of December 31, 2020, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of IPO-related costs were included in the Additional paid-in capital line item on the balance sheet. As of December 31, 2021 and 2020, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of deferred offering costs, respectively, were included in Other assets on the balance sheet.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Property and Equipment, Net</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_cdf000c4-3126-4076-a46e-14220371b9f3;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">three</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> to </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">five years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Leasehold improvements are amortized over the shorter of the expected life or lease term. Repairs and maintenance expenditures, which are not considered improvements and do not extend the useful life of property and equipment, are expensed as incurred. When assets are retired or otherwise disposed of, the cost and related accumulated depreciation and amortization are removed from the balance sheet and the resulting gain or loss is reflected in the statements of operations in the period realized.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Leases</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under Financial Accounting Standards Board (FASB) Accounting Standards Update (&#8220;ASU&#8221;) No. 2016-02, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Leases (Topic 842)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and its associated amendments (&#8220;ASC 842&#8221;), we determine if an arrangement is a lease at inception. In addition, we determine whether a lease meets the classification criteria of a finance or operating lease at the lease commencement date considering whether: (i) the lease transfers ownership of the underlying asset to the lessee at the end of the lease term; (ii) the lease grants the lessee an option to purchase the underlying asset that the lessee is reasonably certain to exercise; (iii) the lease term is for a major part of the remaining economic life of the underlying asset; (iv) the present value of the sum of the lease payments and residual value guaranteed by the lessee equals or exceeds substantially all of the fair value of the underlying asset; and (v) the underlying asset is such a specialized nature that it is expected to have no alternative use to the lessor at the end of the lease term. As of December 31, 2021, our lease population consisted of real estate operating leases. As of December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, we did </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">t have any finance leases.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating leases are included in Operating lease right-of-use (ROU) assets, Operating lease liabilities &#8212; current and Operating lease liabilities &#8212; long term in our balance sheet. ROU assets represent our right to use the underlying assets for the lease term and lease liabilities represent our obligation to make lease payments arising from the leases. Operating lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. In determining the present value of lease payments, if the rate implicit in the lease is not readily determinable, we use our incremental borrowing rate based on the information available at the lease commencement date. We determine the incremental borrowing rate based on an analysis of corporate bond yields with a credit rating similar to us. The determination of our incremental borrowing rate requires management judgment, including development of a synthetic credit rating and cost of debt, as we currently do not carry any debt. We believe that the estimates used in determining the incremental borrowing rate are reasonable based upon current facts and circumstances. Applying different judgment to the same facts and circumstances could yield a different incremental borrowing rate. The operating lease ROU assets also include adjustments for prepayments and accrued lease payments and exclude lease incentives. ROU assets and lease liabilities may include options to extend or terminate leases if it is reasonably certain that we will exercise such options. Lease payments which are fixed and determinable are amortized as rent and lease expense on a straight-line basis over the expected lease term. Variable lease costs, which are dependent on usage, a rate or index, including common area maintenance charges, are expensed as incurred. Lease agreements that include lease and non-lease components are accounted for as a single lease component. Lease agreements with non-cancelable terms of less than 12 months are not recorded on our balance sheets.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Impairment of Long-Lived Assets</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We review long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparing the carrying amount to the future undiscounted net cash flows which the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured as the amount by which the carrying amount of the assets exceeds the projected discounted future net cash flows generated by the assets. There were $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of impairments of long-lived assets during the years ended December 31, 2021, 2020 and 2019, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Fair Value Measurements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. The carrying amounts of our financial instruments, including cash and cash equivalents, prepaid and other current assets, accounts payable, accrued expenses, and other liabilities, approximate fair value due to their short-term maturities. Prior to their automatic conversion upon our IPO in June 2020, the redeemable convertible preferred stock tranche liability and redeemable convertible preferred stock warrant were carried at fair value (see Note 3).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Research and Development</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development costs are expensed as incurred. Research and development costs include salaries, stock-based compensation and benefits for employees performing research and development activities, an allocation of facility and overhead expenses, expenses incurred under agreements with consultants, CMOs, contract research organizations (&#8220;CROs&#8221;) and investigative sites that conduct preclinical studies, other supplies and costs associated with product development efforts, preclinical activities and regulatory operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_AccruedResearchAndDevelopmentPolicyTextBlock', window );">Accrued Research and Development</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Accrued Research and Development</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have entered into various agreements with CROs and CMOs. Our research and development accruals, which include accrued manufacturing expenses, are estimated based on the level of services performed, progress of the studies, including the phase or completion of events, and contracted costs. The estimated costs of research and development services provided, but not yet invoiced, are included in accrued expenses on the balance sheet. If the actual timing of the performance of services or the level of effort varies from the original estimates, we will adjust the accrual accordingly. Payments made to CROs or CMOs under these arrangements in advance of the performance of the related services are recorded as prepaid expenses and other current assets until the services are rendered. To date, there have been no material differences between our estimates of such expenses and the amounts actually incurred.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Income Taxes</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We account for income taxes using the asset and liability method. We recognize deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In evaluating the ability to recover our deferred income tax assets, we consider all available positive and negative evidence, including our operating results, ongoing tax planning and forecasts of future taxable income on a jurisdiction-by-jurisdiction basis. In the event we determine that we would be able to realize our deferred income tax assets in the future in excess of their net recorded amount, we would make an adjustment to the valuation allowance that would reduce the provision for income taxes. Conversely, in the event that all or part of the net deferred tax assets are determined not to be realizable in the future, an adjustment to the valuation allowance would be charged to earnings in the period when such determination is made. As of December 31, 2021 and 2020, we have recorded a full valuation allowance on our deferred tax assets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Tax benefits related to uncertain tax positions are recognized when it is more likely than not that a tax position will be sustained during an audit. Interest and penalties related to unrecognized tax benefits are included within the provision for income tax.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation Expense</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Stock-Based Compensation Expense</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For options granted to employees, non-employees, and directors, stock-based compensation is measured at grant date based on the fair value of the award. We determine the grant-date fair value of the options using the Black-Scholes option-pricing model. The grant-date fair value of awards is amortized over the employees&#8217; requisite service period or the non-employees&#8217; vesting period as the services are rendered. Forfeitures are accounted for as they occur. Additionally, our 2020 Employee Stock Purchase Plan is deemed to be a compensatory plan and is therefore included in stock-based compensation expense.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Comprehensive Loss</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Comprehensive loss includes net loss and other comprehensive loss for the period. Other comprehensive loss consists of unrealized loss on investments.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Transactions</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Foreign Currency Transactions</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Transactions denominated in foreign currencies are initially measured in U.S. dollars using the exchange rate on the date of the transaction. Foreign currency denominated monetary assets and liabilities are subsequently re-measured at the end of each reporting period using the exchange rate at that date, with the corresponding foreign currency transaction gain or loss recorded in the statements of operations and statements of cash flows. Nonmonetary assets and liabilities are not subsequently re-measured.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Net Loss Per Share</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Basic net loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common stock outstanding during the period, without consideration of potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common stock and potentially dilutive securities outstanding for the period. For purposes of the diluted net loss per share calculation, redeemable convertible preferred stock, redeemable convertible preferred stock warrant, common stock subject to repurchase, and stock options are considered to be potentially dilutive securities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Basic and diluted net loss attributable to common stockholders per share is presented in conformity with the two-class method required for participating securities as the redeemable convertible preferred stock is considered a participating security. Our participating securities do not have a contractual obligation to share in our losses. As such, the net loss was attributed entirely to common stockholders. Because we have reported a net loss for all periods presented, diluted net loss per common share is the same as basic net loss per common share for those periods.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Recently Adopted Accounting Pronouncements</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In February 2016, the FASB issued ASU 2016-02, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Leases (Topic 842)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. ASU 2016-02 was subsequently amended by ASU 2018-01, ASU 2018-10, ASU 2018-11, ASU 2018-20, ASU 2019-01, ASU 2019-10 and ASU 2020-05, which the FASB issued in January 2018, July 2018, July 2018, December 2018, March 2019, November 2019 and June 2020, respectively (collectively, &#8220;ASC 842&#8221;). ASC 842 requires lessees to recognize leases on the balance sheet and disclose key information about leasing arrangements. The new standard establishes a ROU model that requires a lessee to recognize a ROU asset and a lease liability on the balance sheet for all leases with a term longer than 12 months. Under ASC 842, leases are classified as either finance leases or operating leases, with classification affecting the pattern and classification of expense recognition in the income statement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">early adopted</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> the new standard effective </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">January 1, 2021</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> using the modified retrospective transition approach. Upon adoption on January 1, 2021, we recognized ROU assets and lease liabilities totaling $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively, to reflect the present value of remaining lease payments under existing lease arrangements. The difference between the leased assets and lease liabilities represents the existing deferred rent liabilities balance resulting from historical straight-lining of operating leases for our facilities, which was reclassified upon adoption to reduce the measurement of the leased assets. The balance of our deferred rent liabilities, which was reclassified to reduce the ROU assets upon adoption, was </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">immaterial</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. We applied the modified retrospective transition approach and did not recast prior periods. Although we applied this approach, we did not have a cumulative effect adjustment to the opening balance of our retained deficit upon adoption. As permitted by the standard, we elected the transition practical expedient package, which among other things, allowed the carryforward of historical lease classifications. For additional details regarding the impact of adoption and disclosure, see Note 5, &#8220;Leases,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">" to our financial statements included in Part II, Item 8 of this Annual Report on Form 10-K.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In December 2019, the FASB issued ASU No. 2019-12, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Income Taxes (Topic 740)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The amendments in ASU 2019-12 simplify the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The amendments also improve consistent application of and simplify U.S. GAAP or other areas of Topic 740 by clarifying and amending existing guidance. The new standard was </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">effective</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> for us on </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">January 1, 2021</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and for interim periods within 2021. The adoption of ASU 2019-12 </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">did not</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> have a material impact on our financial statements.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Recently Issued Accounting Pronouncements&#8212;Not Yet Adopted</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In June 2016, the FASB issued ASU 2016-13, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Financial Instruments &#8211; Credit Losses (Topic 326):</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Measurement of Credit Losses on Financial Instruments</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and has subsequently issued related amendments, collectively referred to as &#8220;Topic 326.&#8221; Topic 326 requires that financial assets measured at amortized cost be presented at the net amount expected to be collected. The measurement of expected credit losses is based on historical experience, current conditions and reasonable and supportable forecasts that affect collectability. Topic 326 also eliminates the concept of &#8220;other-than-temporary&#8221; impairment when evaluating available-for-sale debt securities and instead focuses on determining whether any impairment is a result of a credit loss or other factors. An entity will recognize an allowance for credit losses on available-for-sale debt securities rather than an other-than-temporary impairment that reduces the cost basis of the investment. Topic 326 is effective for fiscal years beginning after December 15, 2022 and interim periods within those fiscal years. Early adoption is permitted. We are currently assessing the impact of this standard to our financial statements and related disclosures.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In November 2021, the FASB issued ASU 2021-10, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Government Assistance (Topic 832): Disclosure by Business Entities about Government Assistance, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">which </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">requires disclosures about transactions with a government entity that are accounted for by applying a grant or contribution accounting model by analogy to other accounting guidance, such as a grant model within International Accounting Standard 20, </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Accounting for Government Grants and Disclosure of Government Assistance</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, or Subtopic 958-605, </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Not-For-Profit Entities - Revenue Recognition</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The required disclosures include (i) the nature of the transactions and the related accounting policy used to account for the transactions, (ii) the financial statement line items that are affected by the transactions and (iii) the significant terms and conditions of the transactions, including commitments and contingencies. This standard is effective for annual periods beginning after December 15, 2021, with early adoption and retrospective or prospective application permitted. This standard is effective for us on January 1, 2022 and only impacts annual financial statement footnote disclosures</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. In Note 11, "Funding Arrangement," to our financial statements included in Part II, Item 8 of this Annual Report on Form 10-K, we included disclosures on our cost-reimbursement research award from CARB-X. Therefore, we do not believe the adoption of this standard will have a material impact on our financial statements.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_AccruedResearchAndDevelopmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_AccruedResearchAndDevelopmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123345438&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredChargesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for deferral and amortization of significant deferred charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredChargesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI http://asc.fasb.org/topic&amp;trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139898130330040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Schedule of Cash, Cash Equivalents And Restricted Cash</a></td>
<td class="text"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash, cash equivalents and restricted cash as reported within the statement of cash flows consisted of the following:</span><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:37.584%;"/>
          <td style="width:6.553%;"/>
          <td style="width:1.371%;"/>
          <td style="width:15.494%;"/>
          <td style="width:0.696%;"/>
          <td style="width:2.195%;"/>
          <td style="width:1.371%;"/>
          <td style="width:15.376%;"/>
          <td style="width:0.696%;"/>
          <td style="width:2.195%;"/>
          <td style="width:1.371%;"/>
          <td style="width:14.402%;"/>
          <td style="width:0.696%;"/>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Years Ended December 31,</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2019</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(in thousands)</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash and cash equivalents</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">68,985</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">386,200</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">58,976</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Restricted cash</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">871</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash, cash equivalents and restricted cash</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">69,856</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">386,200</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">58,976</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
        </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139898130172584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements and Fair Value of Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Schedule of Financial Instruments Measured at Fair Value on Recurring Basis</a></td>
<td class="text"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following tables set forth our financial instruments measured at fair value on a recurring basis by level within the fair value hierarchy at </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020: </span><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:28.362%;"/>
        <td style="width:13.565%;"/>
        <td style="width:6.799%;"/>
        <td style="width:1.231%;"/>
        <td style="width:9.272%;"/>
        <td style="width:0.6%;"/>
        <td style="width:2.227%;"/>
        <td style="width:1.231%;"/>
        <td style="width:9.272%;"/>
        <td style="width:0.6%;"/>
        <td style="width:1.831%;"/>
        <td style="width:1.242%;"/>
        <td style="width:8.608%;"/>
        <td style="width:0.835%;"/>
        <td style="width:2.099%;"/>
        <td style="width:1.231%;"/>
        <td style="width:10.396%;"/>
        <td style="width:0.6%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Fair Value<br/>Hierarchy Level</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Amortized<br/>Cost</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Gross <br/>Unrealized Gains</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Gross <br/>Unrealized Losses</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Fair<br/>Value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">(in thousands)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Cash and cash equivalents:</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Cash</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Level 1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">27,834</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">27,834</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Money market funds</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Level 1</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">17,555</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">17,555</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Commercial paper</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Level 2</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">23,597</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">23,596</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:15.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Total cash and cash equivalents</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">68,986</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">68,985</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Investments:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">U.S. Treasury securities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Level 1</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">45,290</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">73</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">45,217</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Commercial paper</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Level 2</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">61,941</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">22</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">61,919</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Corporate debt</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Level 2</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">58,498</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">74</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">58,424</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Asset backed securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Level 2</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">13,899</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">25</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">13,874</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">U.S. government agency securities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Level 2</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">24,714</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">46</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">24,668</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:15.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Total investments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">204,342</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">240</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">204,102</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(0,0,0,0);text-indent:15.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Total assets measured at fair value</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">273,328</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">241</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">273,087</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31, 2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Fair Value<br/>Hierarchy Level</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Amortized<br/>Cost</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Gross <br/>Unrealized Gains</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Gross <br/>Unrealized Losses</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Fair<br/>Value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">(in thousands)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Cash and cash equivalents:</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Cash</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Level 1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">4,788</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">4,788</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Money market funds</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Level 1</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">381,412</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">381,412</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Total assets measured at fair value</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">386,200</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">386,200</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Schedule of Contractual Maturities of Investments</a></td>
<td class="text"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table presents the contractual maturities of our investments as of December 31, 2021 (in thousands):</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:70.292%;"/>
        <td style="width:5.331%;"/>
        <td style="width:1.242%;"/>
        <td style="width:22.15%;"/>
        <td style="width:0.985%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Fair Value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Due in less than one year</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">176,985</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Due in one to five years</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">27,117</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">204,102</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139898130157240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Details (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment, Net</a></td>
<td class="text"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment, net as of December 31, 2021 and 2020 consisted of the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.51%;"/>
        <td style="width:1.478%;"/>
        <td style="width:1.37%;"/>
        <td style="width:12.976%;"/>
        <td style="width:0.921%;"/>
        <td style="width:1.478%;"/>
        <td style="width:1.37%;"/>
        <td style="width:12.976%;"/>
        <td style="width:0.921%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Furniture and equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,619</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">397</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Computers and computer software</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">430</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">111</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Lab equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9,453</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,739</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Leasehold improvements</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,903</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Construction in progress</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">219</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total property and equipment</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11,502</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,369</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less: accumulated depreciation and amortization</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,548</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,097</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment, net</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,954</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,272</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued expenses as of December 31, 2021 and 2020 consisted of the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.006%;"/>
        <td style="width:1.413%;"/>
        <td style="width:1.381%;"/>
        <td style="width:12.75%;"/>
        <td style="width:0.942%;"/>
        <td style="width:1.413%;"/>
        <td style="width:1.381%;"/>
        <td style="width:12.772%;"/>
        <td style="width:0.942%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Preclinical studies</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,039</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,844</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Professional fees</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">400</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">490</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other accrued expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,348</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">432</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:15.0pt;word-break:break-word;vertical-align:middle;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8,787</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,766</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139898124779736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_ScheduleOfInformationRelatedToRightOfUseAssetsAndLeaseLiabilitiesTableTextBlock', window );">Schedule of Information Related to ROU Assets and Lease Liabilities</a></td>
<td class="text"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Information related to our ROU assets and related lease liabilities was as follows (dollar amounts in thousands):</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:78.308%;"/>
        <td style="width:4.176%;"/>
        <td style="width:1.381%;"/>
        <td style="width:13.822%;"/>
        <td style="width:2.313%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash paid for operating lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">924</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Right-of-use assets recognized in exchange for new lease obligations</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">27,958</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Current operating lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,276</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Non-current operating lease liabilities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11,507</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16,783</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Weighted-average remaining lease term (in years)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.75</span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Weighted-average discount rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.5</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Maturities of Lease Liabilities</a></td>
<td class="text"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Maturities of lease liabilities as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 were as follows:</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.289%;"/>
        <td style="width:1.692%;"/>
        <td style="width:1.381%;"/>
        <td style="width:15.675%;"/>
        <td style="width:0.964%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Years ending December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:Times New Roman;position:relative;">(1)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">105</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2023</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,639</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2024</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,805</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2025</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,976</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Thereafter</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total future undiscounted lease payments</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20,315</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less: Imputed interest</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,532</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total lease liabilities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16,783</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">_____________________________________________</span></p><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(1)	Maturities for 2022 are net of lease incentives of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million allocated to the Palo Alto office.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Future minimum payments required under operating leases as of December 31, 2020 were as follows:</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:78.985%;"/>
        <td style="width:1.82%;"/>
        <td style="width:1.402%;"/>
        <td style="width:16.679%;"/>
        <td style="width:1.113%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Years ending December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;text-indent:13.7pt;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="margin-left:13.7pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">742</span></p></td>
        <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:13.7pt;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="margin-left:13.7pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">190</span></p></td>
        <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total future minimum payments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="border-top:0.250pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="border-top:0.250pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">932</span></p></td>
        <td style="border-top:0.250pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_ScheduleOfInformationRelatedToRightOfUseAssetsAndLeaseLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of information related to right-of-use assets and lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_ScheduleOfInformationRelatedToRightOfUseAssetsAndLeaseLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139898130305304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock', window );">Schedule of Common Stock Shares Reserved for Future Issuance</a></td>
<td class="text"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Common stock reserved for future issuances under the 2020 Equity Incentive Plan (the &#8220;2020 Plan&#8221;) and the 2014 Equity Incentive Plan (the &#8220;2014 Plan&#8221;) was as follows, and excludes </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">62,382</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares issued outside of the 2014 Plan and 2020 Plan:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.052%;"/>
        <td style="width:1.584%;"/>
        <td style="width:1.006%;"/>
        <td style="width:12.877%;"/>
        <td style="width:1.006%;"/>
        <td style="width:1.584%;"/>
        <td style="width:1.006%;"/>
        <td style="width:12.877%;"/>
        <td style="width:1.006%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Options issued and outstanding</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,295,007</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,188,531</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Shares available for future stock option grants</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,104,756</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,651,149</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11,399,763</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9,839,680</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of common stock shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139898125372040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary of Estimated Fair Value of Employee Stock Options</a></td>
<td class="text"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We estimated the fair value of employee stock options using the Black-Scholes option-pricing model for the years ended December 31, 2021, 2020 and 2019 using the following weighted-average assumptions:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.31%;"/>
        <td style="width:1.36%;"/>
        <td style="width:15.203%;"/>
        <td style="width:1.36%;"/>
        <td style="width:15.203%;"/>
        <td style="width:1.36%;"/>
        <td style="width:15.203%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="5" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2019</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Fair Value Assumptions</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected volatility</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">81.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% - </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">84.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">81.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% - </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">94.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">78.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% - </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">80.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected dividend yield</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected term (in years)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.3 </span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">- </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.5</span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.6</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;- </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.1</span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.9</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;- </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.1</span></span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% - </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% - </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% - </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pcvx_TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember', window );">2020 Plan and 2014 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Activity Under Stock Option Plans</a></td>
<td class="text"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Activity under our 2020 Plan and 2014 Plan, which excludes options to purchase </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">62,382</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares granted outside of the 2020 Plan and 2014 Plan, was as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:43.015%;"/>
        <td style="width:0.963%;"/>
        <td style="width:0.707%;"/>
        <td style="width:8.522%;"/>
        <td style="width:0.91%;"/>
        <td style="width:0.963%;"/>
        <td style="width:0.685%;"/>
        <td style="width:8.575%;"/>
        <td style="width:0.91%;"/>
        <td style="width:0.963%;"/>
        <td style="width:1.381%;"/>
        <td style="width:7.976%;"/>
        <td style="width:0.685%;"/>
        <td style="width:0.963%;"/>
        <td style="width:0.846%;"/>
        <td style="width:10.213%;"/>
        <td style="width:0.685%;"/>
        <td style="width:0.963%;"/>
        <td style="width:1.381%;"/>
        <td style="width:8.008%;"/>
        <td style="width:0.685%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Options Outstanding</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Stock Option Activity</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Options<br/>Available<br/>for <br/>Grant</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Number<br/>of<br/>Options</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Weighted-<br/>Average<br/>Exercise<br/>Price Per<br/>Share</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Weighted-<br/>Average<br/>Remaining<br/>Contractual <br/>Term<br/>(Years)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Aggregate<br/>Intrinsic<br/>Value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Balances &#8212; December 31, 2019</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">835,941</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">3,297,586</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1.93</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Additional shares authorized</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">5,997,435</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Options granted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">2,255,690</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">2,255,690</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">8.93</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Options exercised</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">358,264</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1.88</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Options forfeited</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">73,463</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">73,463</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">3.50</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Balances &#8212; December 31, 2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">4,651,149</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">5,121,549</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">4.99</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Additional shares authorized</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">2,553,579</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Options granted</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1,616,021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1,616,021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">21.83</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Options exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">926,514</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">3.25</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Options forfeited</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">516,049</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">516,049</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">16.70</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Balances &#8212; December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">6,104,756</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">5,295,007</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">9.30</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">7.89</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">78,604</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Vested and expected to vest &#8212; December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">5,295,007</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">9.30</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">7.89</span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">78,604</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Exercisable at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">2,611,523</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">4.76</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">7.07</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">50,123</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pcvx_TwoThousandTwentyEmployeeStockPurchasePlanMember', window );">2020 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock', window );">Summary of Estimated Fair Value of Shares Under Employee Stock Purchase Plan</a></td>
<td class="text"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We estimated the fair value of shares under the 2020 ESPP using the Black-Scholes option-pricing model for the years ended December 31, 2021, 2020 and 2019 using the following weighted-average assumptions:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:48.1%;"/>
        <td style="width:1.381%;"/>
        <td style="width:15.384%;"/>
        <td style="width:1.381%;"/>
        <td style="width:16.99%;"/>
        <td style="width:1.381%;"/>
        <td style="width:15.384%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="5" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2019</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Fair Value Assumptions</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected volatility</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">79.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% - </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">126.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">105.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% - </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">158.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">N/A</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected dividend yield</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">N/A</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected term (in years)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.5 </span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">- </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.0</span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.4</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;- </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.0</span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">N/A</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% - </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% - </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">N/A</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pcvx_TwoThousandFourteenEquityIncentivePlanAndTwoThousandTwentyEquityIncentivePlanAndTwoThousandTwentyEmployeeStockPurchasePlanMember', window );">2014 Plan, 2020 Plan and 2020 ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Summary of Stock-based Compensation Expense</a></td>
<td class="text"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We recorded total stock-based compensation expense for the years ended December 31, 2021, 2020 and 2019 related to the 2014 Plan, the 2020 Plan and the 2020 ESPP in the statements of operations and allocated the amounts as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.717%;"/>
        <td style="width:1.349%;"/>
        <td style="width:1.381%;"/>
        <td style="width:12.781%;"/>
        <td style="width:0.91%;"/>
        <td style="width:1.349%;"/>
        <td style="width:1.381%;"/>
        <td style="width:12.77%;"/>
        <td style="width:0.91%;"/>
        <td style="width:1.349%;"/>
        <td style="width:1.381%;"/>
        <td style="width:12.792%;"/>
        <td style="width:0.931%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2019</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(In thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,954</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,861</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">368</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">General and administrative</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,775</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,573</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">817</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,729</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,434</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,185</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pcvx_TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pcvx_TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pcvx_TwoThousandTwentyEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pcvx_TwoThousandTwentyEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pcvx_TwoThousandFourteenEquityIncentivePlanAndTwoThousandTwentyEquityIncentivePlanAndTwoThousandTwentyEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pcvx_TwoThousandFourteenEquityIncentivePlanAndTwoThousandTwentyEquityIncentivePlanAndTwoThousandTwentyEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139898124446136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Computation of Basic and Diluted Net Loss Per Share</a></td>
<td class="text"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table sets forth the computation of basic and diluted net loss per share and excludes shares which are legally outstanding, but subject to repurchase by us:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.198%;"/>
        <td style="width:1.231%;"/>
        <td style="width:1.381%;"/>
        <td style="width:10.692%;"/>
        <td style="width:0.92%;"/>
        <td style="width:1.231%;"/>
        <td style="width:1.381%;"/>
        <td style="width:10.714%;"/>
        <td style="width:0.942%;"/>
        <td style="width:1.252%;"/>
        <td style="width:1.381%;"/>
        <td style="width:10.735%;"/>
        <td style="width:0.942%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2019</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net loss (in thousands)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">100,077</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">89,217</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">50,274</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Weighted-average shares outstanding used in computing net<br/>&#160;&#160;&#160;loss per share, basic and diluted</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">51,922,108</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">29,545,810</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,795,090</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net loss per share, basic and diluted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.93</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.02</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13.25</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Potentially Dilutive Securities Excluded From Computation of Diluted Net Loss Per Share</a></td>
<td class="text"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following potentially dilutive securities were excluded from the computation of diluted net loss per share for the period presented because including them would have been antidilutive:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.444%;"/>
        <td style="width:1.381%;"/>
        <td style="width:1.006%;"/>
        <td style="width:10.767%;"/>
        <td style="width:1.006%;"/>
        <td style="width:1.381%;"/>
        <td style="width:1.006%;"/>
        <td style="width:10.767%;"/>
        <td style="width:1.006%;"/>
        <td style="width:1.381%;"/>
        <td style="width:1.006%;"/>
        <td style="width:10.842%;"/>
        <td style="width:1.006%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2019</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock options</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,357,389</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,188,531</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,364,568</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Redeemable convertible preferred stock:</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Series A</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,225,719</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Series B</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,786,896</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Series C</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,377,480</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Common stock warrant</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">31,857</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Redeemable convertible preferred stock warrant</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">59,276</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,357,389</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,188,531</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">23,845,796</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139898124498648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation of Effective Tax Rate</a></td>
<td class="text"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A reconciliation of our effective tax rate to the statutory U.S. federal rate is as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:55.954%;"/>
        <td style="width:1.232%;"/>
        <td style="width:0.685%;"/>
        <td style="width:9.552%;"/>
        <td style="width:3.213%;"/>
        <td style="width:1.232%;"/>
        <td style="width:0.685%;"/>
        <td style="width:9.552%;"/>
        <td style="width:3.213%;"/>
        <td style="width:1.232%;"/>
        <td style="width:0.685%;"/>
        <td style="width:9.552%;"/>
        <td style="width:3.213%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:bold;font-size:6.7pt;font-family:Times New Roman;position:relative;">(1)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2019</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:bold;font-size:6.7pt;font-family:Times New Roman;position:relative;">(1)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Statutory rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock-based compensation</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.2</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.8</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.4</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Credits</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.6</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.5</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Change in fair value of tranche liability</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.0</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.0</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.3</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Change in valuation allowance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">23.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">22.1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21.8</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Section 162(m) limitation</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.1</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.1</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.0</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.2</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.2</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.4</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.0</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.0</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.0</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;margin-right:66.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p><div style="margin-left:3.333%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:6.667%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.8968727694042435%;">(1)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The 2019 and 2020 effective tax rate reconciliations have been updated to conform to the 2021 presentation.</span></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Components of Deferred Tax Assets</a></td>
<td class="text"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table presents significant components of our deferred tax assets as of December 31, 2021 and 2020:</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.478%;"/>
        <td style="width:1.478%;"/>
        <td style="width:1.37%;"/>
        <td style="width:12.998%;"/>
        <td style="width:0.921%;"/>
        <td style="width:1.478%;"/>
        <td style="width:1.37%;"/>
        <td style="width:12.987%;"/>
        <td style="width:0.921%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">As of December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred tax assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net operating losses</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">85,574</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">52,330</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Fixed assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,700</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">528</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accruals &amp; reserves</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,131</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,786</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Credits</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,865</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,222</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Section 59(e) capitalized expenses</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,984</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,381</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued manufacturing expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,006</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,374</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Lease liability</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,674</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total deferred tax assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">104,934</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">63,621</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Deferred tax liabilities:</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ROU asset</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8,349</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total deferred tax liabilities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8,349</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net deferred tax asset</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">96,585</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">63,621</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Valuation allowance</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">96,585</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">63,621</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net deferred taxes</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock', window );">Reconciliation of Unrecognized Tax Benefit</a></td>
<td class="text"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A reconciliation of the beginning and ending unrecognized tax benefit amount is as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.521%;"/>
        <td style="width:1.317%;"/>
        <td style="width:1.381%;"/>
        <td style="width:10.716%;"/>
        <td style="width:0.91%;"/>
        <td style="width:1.317%;"/>
        <td style="width:1.381%;"/>
        <td style="width:10.716%;"/>
        <td style="width:0.921%;"/>
        <td style="width:1.327%;"/>
        <td style="width:1.381%;"/>
        <td style="width:10.17%;"/>
        <td style="width:0.942%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2019</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Balance at the beginning of the year</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">393</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">271</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">408</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Additions based on tax positions related to current year</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">461</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">287</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">217</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Adjustments based on tax positions related to prior years</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">70</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">165</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">354</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Balance at end of year</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">924</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">393</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">271</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfIncomeTaxContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139898124090024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Company Organization and Nature of Business - Additional Information (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 15, 2020 </div>
<div>shares</div>
</th>
<th class="th"><div>Jun. 05, 2020</div></th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 17, 2020 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Schedule Of Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">one-for-1.6870<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split, conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.593<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Net proceeds from initial public offering | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 264,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_PaymentsOfUnderwritingDiscountsAndCommissions', window );">Underwriting discounts and commissions | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Offering expenses | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember', window );">Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Schedule Of Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of preferred stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,610,337<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Redeemable convertible preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Schedule Of Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of preferred stock (in shares)</a></td>
<td class="nump">28,610,337<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,610,337<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">Initial Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Schedule Of Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock shares sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,968,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_SharesIssuedUponFullExerciseOfUnderwritersOptionToPurchaseAdditionalShares', window );">Underwriters' option to purchase additional shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,343,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Public offering price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">Initial Public Offering | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Schedule Of Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock shares sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,968,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=pcvx_PneumococcalConjugateVaccineMember', window );">Pneumococcal Conjugate Vaccine</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Schedule Of Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_GlobalTargetRevenue', window );">Global target revenue | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_GlobalTargetRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Global target revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_GlobalTargetRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_PaymentsOfUnderwritingDiscountsAndCommissions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments of underwriting discounts and commissions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_PaymentsOfUnderwritingDiscountsAndCommissions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of organization consolidation and presentation of financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_SharesIssuedUponFullExerciseOfUnderwritersOptionToPurchaseAdditionalShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares issued upon full exercise of underwriters option to purchase additional shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_SharesIssuedUponFullExerciseOfUnderwritersOptionToPurchaseAdditionalShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pcvx_PneumococcalConjugateVaccineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pcvx_PneumococcalConjugateVaccineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139898124918520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>Segment </div>
<div>Lease</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 01, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements Or Change In Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | Segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | Segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_NumberOfFinanceLease', window );">Number of finance lease | Lease</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset impairment charges</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 267<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">ROU assets</a></td>
<td class="nump">27,958<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liabilities</a></td>
<td class="nump">$ 16,783<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements Or Change In Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of assets</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements Or Change In Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of assets</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">ASU 2016-02</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements Or Change In Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption', window );">Change in accounting principle, accounting standards update, early adoption [true false]</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate', window );">Accounting standard update adoption date</a></td>
<td class="text">Jan.  01,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect', window );">Accounting standard update material impact</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">ROU assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201912Member', window );">ASU 2019-12</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements Or Change In Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted', window );">Accounting standard update adopted</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate', window );">Accounting standard update adoption date</a></td>
<td class="text">Jan.  01,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect', window );">Accounting standard update material impact</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid-in Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements Or Change In Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_InitialPublicOfferingRelatedCost', window );">IPO-related costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember', window );">Other Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements Or Change In Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Deferred offering costs</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_InitialPublicOfferingRelatedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial public offering related cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_InitialPublicOfferingRelatedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_NumberOfFinanceLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_NumberOfFinanceLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether accounting standards update was adopted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 65<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121483254&amp;loc=SL120254523-199619<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S65<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124359872&amp;loc=SL124427846-239511<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL122642865-165497<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL122642865-165497<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL120254526-165497<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL120254526-165497<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120254519-210437<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123341672&amp;loc=SL120154346-209984<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122150657&amp;loc=SL122150809-237846<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120320025-210437<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120320025-210437<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)<br><br>Reference 32: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 33: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date accounting standards update was adopted, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S65<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124359872&amp;loc=SL124427846-239511<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL122642865-165497<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL120254526-165497<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120320025-210437<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120320025-210437<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL122642865-165497<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122150657&amp;loc=SL122150809-237846<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123341672&amp;loc=SL120154346-209984<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 65<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121483254&amp;loc=SL120254523-199619<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120254519-210437<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL120254526-165497<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 35: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether accounting standards update was early adopted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL120254526-165497<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL122642865-165497<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123877278&amp;loc=SL120174030-210619<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S65<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124359872&amp;loc=SL124427846-239511<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL120254526-165497<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120320025-210437<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120254519-210437<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 65<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121483254&amp;loc=SL120254523-199619<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123341672&amp;loc=SL120154346-209984<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether effect from applying amendment to accounting standards is immaterial.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=122038215&amp;loc=d3e31010-122693<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -URI http://asc.fasb.org/extlink&amp;oid=122040515&amp;loc=d3e105025-122735<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201912Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201912Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139898119962056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Cash, Cash Equivalents And Restricted Cash (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 68,985<span></span>
</td>
<td class="nump">$ 386,200<span></span>
</td>
<td class="nump">$ 58,976<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted Cash</a></td>
<td class="nump">871<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash</a></td>
<td class="nump">$ 69,856<span></span>
</td>
<td class="nump">$ 386,200<span></span>
</td>
<td class="nump">$ 58,976<span></span>
</td>
<td class="nump">$ 66,090<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139898124504584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements and Fair Value of Financial Instruments - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>Security</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>Security</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount', window );">Fair value assets transferred from level 1 to level 2</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount', window );">Fair value assets transferred from level 2 to level 1</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount', window );">Fair value liabilities transferred from level 1 to level 2</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount', window );">Fair value liabilities transferred from level 2 to level 1</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3', window );">Fair value assets transferred into level 3</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3', window );">Fair value assets transferred out of level 3</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3', window );">Fair value liabilities transferred into level 3</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3', window );">Fair value liabilities transferred out of level 3</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_NumberOfSecurities', window );">Number of securities | Security</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_NumberOfSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_NumberOfSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of assets measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of assets measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of liabilities measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of liabilities measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of financial instrument classified as a liability into level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of financial instrument classified as a liability out of level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfer of financial instrument classified as an asset into level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of financial instrument classified as an asset out of level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139898125739560">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements and Fair Value of Financial Instruments - Schedule of Financial Instruments Measured at Fair Value on Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments, Fair Value</a></td>
<td class="nump">$ 204,102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_CashAndCashEquivalentsAmortizedCost', window );">Cash and cash equivalents, Amortized Cost</a></td>
<td class="nump">68,986<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_CashAndCashEquivalentsGrossUnrealizedLossBeforeTax', window );">Cash and cash equivalents, Gross Unrealized Losses</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents, Fair Value</a></td>
<td class="nump">68,985<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Investments, Amortized Cost</a></td>
<td class="nump">204,342<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Investments, Gross Unrealized Losses</a></td>
<td class="num">(240)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments, Fair Value</a></td>
<td class="nump">204,102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_CashAndCashEquivalentsAndInvestmentsAmortizedCostBasis', window );">Total assets measured at fair value, Amortized Cost</a></td>
<td class="nump">273,328<span></span>
</td>
<td class="nump">$ 386,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_CashAndCashEquivalentsAndInvestmentsGrossUnrealizedLossBeforeTax', window );">Total assets measured at fair value, Gross Unrealized Losses</a></td>
<td class="num">(241)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_CashAndCashEquivalentsAndInvestments', window );">Total assets measured at fair value, Fair Value</a></td>
<td class="nump">273,087<span></span>
</td>
<td class="nump">386,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Cash | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_CashAndCashEquivalentsAmortizedCost', window );">Cash and cash equivalents, Amortized Cost</a></td>
<td class="nump">27,834<span></span>
</td>
<td class="nump">4,788<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents, Fair Value</a></td>
<td class="nump">27,834<span></span>
</td>
<td class="nump">4,788<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Money Market Funds | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_CashAndCashEquivalentsAmortizedCost', window );">Cash and cash equivalents, Amortized Cost</a></td>
<td class="nump">17,555<span></span>
</td>
<td class="nump">381,412<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents, Fair Value</a></td>
<td class="nump">17,555<span></span>
</td>
<td class="nump">$ 381,412<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Commercial Paper | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_CashAndCashEquivalentsAmortizedCost', window );">Cash and cash equivalents, Amortized Cost</a></td>
<td class="nump">23,597<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_CashAndCashEquivalentsGrossUnrealizedLossBeforeTax', window );">Cash and cash equivalents, Gross Unrealized Losses</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents, Fair Value</a></td>
<td class="nump">23,596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | U.S. Treasury Securities | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Investments, Amortized Cost</a></td>
<td class="nump">45,290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Investments, Gross Unrealized Losses</a></td>
<td class="num">(73)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments, Fair Value</a></td>
<td class="nump">45,217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Commercial paper | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Investments, Amortized Cost</a></td>
<td class="nump">61,941<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Investments, Gross Unrealized Losses</a></td>
<td class="num">(22)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments, Fair Value</a></td>
<td class="nump">61,919<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Corporate Debt | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Investments, Amortized Cost</a></td>
<td class="nump">58,498<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Investments, Gross Unrealized Losses</a></td>
<td class="num">(74)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments, Fair Value</a></td>
<td class="nump">58,424<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Asset backed securities | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Investments, Amortized Cost</a></td>
<td class="nump">13,899<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Investments, Gross Unrealized Losses</a></td>
<td class="num">(25)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments, Fair Value</a></td>
<td class="nump">13,874<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | U.S. Government Agency Securities | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Investments, Amortized Cost</a></td>
<td class="nump">24,714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Investments, Gross Unrealized Losses</a></td>
<td class="num">(46)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments, Fair Value</a></td>
<td class="nump">$ 24,668<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_CashAndCashEquivalentsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash and cash equivalents amortized cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_CashAndCashEquivalentsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_CashAndCashEquivalentsAndInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash and cash equivalents and investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_CashAndCashEquivalentsAndInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_CashAndCashEquivalentsAndInvestmentsAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash and cash equivalents and investments amortized cost basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_CashAndCashEquivalentsAndInvestmentsAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_CashAndCashEquivalentsAndInvestmentsGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash and cash equivalents and investments gross unrealized loss before tax.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_CashAndCashEquivalentsAndInvestmentsGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_CashAndCashEquivalentsGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash and cash equivalents gross unrealized loss before tax.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_CashAndCashEquivalentsGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139898207323352">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements and Fair Value of Financial Instruments - Schedule of Contractual Maturities of Investments (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Due in less than one year</a></td>
<td class="nump">$ 176,985<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Due in one to five years</a></td>
<td class="nump">27,117<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total</a></td>
<td class="nump">$ 204,102<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=SL120269850-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139898125888120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Details - Schedule of Property and Equipment, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 11,502<span></span>
</td>
<td class="nump">$ 7,369<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation and amortization</a></td>
<td class="num">(3,548)<span></span>
</td>
<td class="num">(4,097)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">7,954<span></span>
</td>
<td class="nump">3,272<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">1,619<span></span>
</td>
<td class="nump">397<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pcvx_ComputersAndComputerSoftwareMember', window );">Computers and Computer Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">430<span></span>
</td>
<td class="nump">111<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pcvx_LabEquipmentMember', window );">Lab Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 9,453<span></span>
</td>
<td class="nump">4,739<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,903<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in Progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 219<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pcvx_ComputersAndComputerSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=pcvx_ComputersAndComputerSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pcvx_LabEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=pcvx_LabEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139898124436696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Details - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property Plant And Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">$ 1,800,000<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_CapitalLeasesAmortizationExpense', window );">Capital lease amortization expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_CapitalLeasesAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Capital Leases Amortization Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_CapitalLeasesAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139898280928408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Details - Schedule of Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Liabilities Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_AccruedPreclinicalStudiesCurrent', window );">Preclinical studies</a></td>
<td class="nump">$ 5,039<span></span>
</td>
<td class="nump">$ 2,844<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees</a></td>
<td class="nump">400<span></span>
</td>
<td class="nump">490<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued expenses</a></td>
<td class="nump">3,348<span></span>
</td>
<td class="nump">432<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 8,787<span></span>
</td>
<td class="nump">$ 3,766<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_AccruedPreclinicalStudiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued preclinical studies current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_AccruedPreclinicalStudiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139898120300040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 28, 2022</div></th>
<th class="th">
<div>Jan. 31, 2021 </div>
<div>RenewalOption</div>
</th>
<th class="th"><div>Nov. 30, 2020</div></th>
<th class="th"><div>Jul. 31, 2019</div></th>
<th class="th">
<div>Jul. 31, 2016 </div>
<div>RenewalOption</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>Lease</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 01, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease, ROU assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,958<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,783<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_NumberOfOperatingLease', window );">Number of operating lease | Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating leases, rent expense recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,200<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">ASU 2016-02</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease, ROU assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pcvx_HeadquartersFacilityMember', window );">Headquarters Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease, agreement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_LesseeOperatingLeaseCommencementDate', window );">Operating lease, commencement date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Sep.  01,  2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Aug. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_LesseeOperatingLeaseRenewalOption', window );">Operating lease, renewal option | RenewalOption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease, renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToExtend', window );">Operating lease, option to renewal, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30-month renewal options<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend', window );">Operating lease, existence of option to renewal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDescription', window );">Operating lease, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">In July 2016, we entered into a five-year lease agreement for our previous headquarters facility located in Foster City, California. The original term of the lease was from September 1, 2016 to August 31, 2021, with two 30-month renewal options.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_LesseeOperatingLeaseExtendedLeaseTerm', window );">Operating lease, extended term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_LesseeOperatingLeaseExtendedMaturityDate', window );">Operating lease, extended maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar.  01,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pcvx_HeadquartersFacilityMember', window );">Headquarters Facility | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_LeaseTerminationDate', window );">Lease termination date</a></td>
<td class="text">Feb. 12,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pcvx_AdditionalFacilityMember', window );">Additional Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_LesseeOperatingLeaseCommencementDate', window );">Operating lease, commencement date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul.  01,  2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Oct. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToExtend', window );">Operating lease, option to renewal, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">no renewal options<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend', window );">Operating lease, existence of option to renewal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDescription', window );">Operating lease, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">In July 2019, we leased another facility in Foster City, California as a result of growth in personnel and lab space requirements. The original term of this lease was from July 1, 2019 to October 31, 2021, with no renewal options.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_LesseeOperatingLeaseExtendedLeaseTerm', window );">Operating lease, extended term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_LesseeOperatingLeaseExtendedMaturityDate', window );">Operating lease, extended maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Apr. 30,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Office</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Apr. 30,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pcvx_NewCorporateHeadquartersFacilityMember', window );">New Corporate Headquarters Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_LesseeOperatingLeaseCommencementDate', window );">Operating lease, commencement date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan. 22,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease, renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_LesseeOperatingLeaseExtendedLeaseTerm', window );">Operating lease, extended term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_NumberOfRenewalOptions', window );">Number of renewal options | RenewalOption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pcvx_PaloAltoMember', window );">Palo Alto</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_LesseeOperatingLeaseExtendedMaturityDate', window );">Operating lease, extended maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar.  03,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease, ROU assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pcvx_SanCarlosMember', window );">San Carlos</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease, ROU assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_LeaseTerminationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease termination date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_LeaseTerminationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_LesseeOperatingLeaseCommencementDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease commencement date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_LesseeOperatingLeaseCommencementDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_LesseeOperatingLeaseExtendedLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease extended lease term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_LesseeOperatingLeaseExtendedLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_LesseeOperatingLeaseExtendedMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, operating lease, extended maturity date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_LesseeOperatingLeaseExtendedMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_LesseeOperatingLeaseRenewalOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease renewal option.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_LesseeOperatingLeaseRenewalOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_NumberOfOperatingLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_NumberOfOperatingLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_NumberOfRenewalOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of renewal options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_NumberOfRenewalOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date which lease or group of leases is set to expire, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of lessee's operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether lessee has option to extend operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pcvx_HeadquartersFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=pcvx_HeadquartersFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pcvx_AdditionalFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=pcvx_AdditionalFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pcvx_NewCorporateHeadquartersFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=pcvx_NewCorporateHeadquartersFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pcvx_PaloAltoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=pcvx_PaloAltoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pcvx_SanCarlosMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=pcvx_SanCarlosMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139898125399064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Schedule of Information Related to ROU Assets and Lease Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for operating lease liabilities</a></td>
<td class="nump">$ 924<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">27,958<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities &#8212; current</a></td>
<td class="nump">5,276<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities &#8212; long-term</a></td>
<td class="nump">11,507<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating Lease, Liability, Total</a></td>
<td class="nump">$ 16,783<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term (in years)</a></td>
<td class="text">3 years 9 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139898123935624">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Maturities of Lease Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 742<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonthsNetOfLeaseIncentives', window );">2022</a></td>
<td class="num">$ (105)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2023 and 2022</a></td>
<td class="nump">6,639<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">190<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2024</a></td>
<td class="nump">6,805<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2025</a></td>
<td class="nump">6,976<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future undiscounted lease payments</a></td>
<td class="nump">20,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 932<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Imputed interest</a></td>
<td class="num">(3,532)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liabilities</a></td>
<td class="nump">$ 16,783<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonthsNetOfLeaseIncentives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease liability payments due next twelve months net of lease incentives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonthsNetOfLeaseIncentives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139898124779736">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Maturities of Lease Liabilities (Parenthetical) (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pcvx_PaloAltoMember', window );">Palo Alto</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_LeasePaymentReceivableNoncurrent', window );">Lease incentives</a></td>
<td class="nump">$ 0.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_LeasePaymentReceivableNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease Payment Receivable Noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_LeasePaymentReceivableNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=pcvx_PaloAltoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=pcvx_PaloAltoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139898124490232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Details) - Lonza DMSA - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Apr. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_PercentageOfPaymentsCompletionAgreedToDefer', window );">Percentage of defer payments agreed for completion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_DevelopmentAndManufacturingServicesAgreementPaymentsInEquity', window );">Payments in equity, amount</a></td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GuaranteeObligationsMaximumExposure', window );">Amount recorded with respect to the potential future payments above the initial cash cap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Number of common stock issued</a></td>
<td class="nump">399,680<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Public offering price per share</a></td>
<td class="nump">$ 25.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_DevelopmentAndManufacturingServicesAgreementPaymentsInEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Development and manufacturing services agreement payments in equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_DevelopmentAndManufacturingServicesAgreementPaymentsInEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_PercentageOfPaymentsCompletionAgreedToDefer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of payments completion agreed to defer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_PercentageOfPaymentsCompletionAgreedToDefer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GuaranteeObligationsMaximumExposure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum potential amount of future payments (undiscounted) the guarantor could be required to make under the guarantee or each group of similar guarantees before reduction for potential recoveries under recourse or collateralization provisions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124440162&amp;loc=d3e12069-110248<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GuaranteeObligationsMaximumExposure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=pcvx_LonzaLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=pcvx_LonzaLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139898125630648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Redeemable Convertible Preferred Stock - Additional Information (Details) - Redeemable Convertible Preferred Stock - shares<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 17, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Preferred stock outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Preferred stock authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Preferred stock converted into common stock</a></td>
<td class="nump">28,610,337<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139898123901224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jul. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value per share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">53,031,978<span></span>
</td>
<td class="nump">51,071,593<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">53,031,978<span></span>
</td>
<td class="nump">51,071,593<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Common stock, dividends, per share, declared</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockVotingRights', window );">Common stock, voting rights</a></td>
<td class="text">Each share of common stock is entitled to one vote.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of stock, net of commission and offering expenses</a></td>
<td class="nump">$ 13,896,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Equity incentive plan, shares issued</a></td>
<td class="nump">62,382<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=pcvx_ATMSalesAgreementMember', window );">ATM Sales Agreement | Jefferies LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_MaximumCommissionPercentageOfGrossProceedsFromCommonStockSold', window );">Maximum commission percentage of gross proceeds from common stock sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock shares sold</a></td>
<td class="nump">567,045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Average price</a></td>
<td class="nump">$ 25.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_GrossProceedsFromIssuanceOfCommonStock', window );">Aggregate gross proceeds from issuance of common stock</a></td>
<td class="nump">$ 14,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of stock, net of commission and offering expenses</a></td>
<td class="nump">$ 13,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=pcvx_ATMSalesAgreementMember', window );">ATM Sales Agreement | Maximum | Jefferies LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_SaleOfCommonStockAuthorizedAmount', window );">Aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_GrossProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross proceeds from issuance of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_GrossProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_MaximumCommissionPercentageOfGrossProceedsFromCommonStockSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum commission percentage of gross proceeds from common stock sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_MaximumCommissionPercentageOfGrossProceedsFromCommonStockSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_SaleOfCommonStockAuthorizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale of common stock authorized amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_SaleOfCommonStockAuthorizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockVotingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockVotingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=pcvx_ATMSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=pcvx_ATMSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=pcvx_JefferiesLimitedLiabilityCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=pcvx_JefferiesLimitedLiabilityCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139898124843944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Common Stock - Schedule of Common Stock Shares Reserved for Future Issuance (Details) - 2020 Plan and 2014 Plan - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuances</a></td>
<td class="nump">11,399,763<span></span>
</td>
<td class="nump">9,839,680<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pcvx_TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember', window );">Options Issued and Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuances</a></td>
<td class="nump">5,295,007<span></span>
</td>
<td class="nump">5,188,531<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pcvx_TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember', window );">Shares Available for Future Stock Option Grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuances</a></td>
<td class="nump">6,104,756<span></span>
</td>
<td class="nump">4,651,149<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pcvx_TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pcvx_TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=pcvx_SharesAvailableForFutureStockOptionGrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=pcvx_SharesAvailableForFutureStockOptionGrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139898130377320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Warrants - Additional Information (Details)<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRightExercised', window );">Warrant exercised</a></td>
<td class="nump">46,869<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRightExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right number of securities called by each warrant or right exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRightExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139898120828680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2022</div></th>
<th class="th"><div>Jun. 11, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage for stock options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period for stock options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_EarlyExercisedStockOptions', window );">Early exercised stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,410<span></span>
</td>
<td class="nump">15,056<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,382<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_NumberOfOptionsExercisedExcludesOptionsExercisedFromNpln', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">926,514<span></span>
</td>
<td class="nump">358,264<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted-average price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.25<span></span>
</td>
<td class="nump">$ 1.88<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value of options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.65<span></span>
</td>
<td class="nump">$ 9.62<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of the stock options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.9<span></span>
</td>
<td class="nump">$ 7.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized share-based compensation expense, expected to be recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance-based Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance-based Awards | IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number of shares vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">362,935<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pcvx_TwoThousandTwentyEquityIncentivePlanMember', window );">2020 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_ExercisePriceExpireInYearsFormTheDateOfGrant', window );">Exercise price expire in years form the date of grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_StockOptionsGrantedTerm', window );">Stock options granted term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_PercentageOfProvisionsSubjectToStockholders', window );">Percentage of provisions subject to stockholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Term of plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Percentage of outstanding number of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Aggregate number of shares available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,104,756<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,637,613<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pcvx_TwoThousandTwentyEquityIncentivePlanMember', window );">2020 Equity Incentive Plan | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreaseInAvailableForGrant', window );">Available for issuance of shares increased</a></td>
<td class="nump">2,651,598<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pcvx_TwoThousandFourteenEquityIncentivePlanMember', window );">2014 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,657,394<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pcvx_TwoThousandTwentyEmployeeStockPurchasePlanMember', window );">2020 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">650,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Term of plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Percentage of outstanding number of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Aggregate number of shares available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,070,704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Employees purchase shares of common stock of lower of fair market value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_OfferingPeriod', window );">Offering period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_PurchasePeriod', window );">Purchase period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate', window );">Percentage of payroll deductions of eligible compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward', window );">Employees acquired shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,546<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pcvx_TwoThousandTwentyEmployeeStockPurchasePlanMember', window );">2020 Employee Stock Purchase Plan | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreaseInAvailableForGrant', window );">Available for issuance of shares increased</a></td>
<td class="nump">530,319<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | 2020 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_IncentiveStockOptionGrantedToEmployeesOwningPercentageOfSharesOfCommonStock', window );">Incentive stock option granted to employees owning percentage of shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Other Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_RemainingLiabilitiesRelatedToEarlyExercisedShares', window );">Remaining liabilities related to early exercised shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | 2020 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_PercentageOfFairValuePerShareOnTheGrantDate', window );">Percentage of fair value per share on the grant date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_EarlyExercisedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Early &#8203;exercised&#8203; stock&#8203; options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_EarlyExercisedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_ExercisePriceExpireInYearsFormTheDateOfGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price expire in years form the date of grant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_ExercisePriceExpireInYearsFormTheDateOfGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_IncentiveStockOptionGrantedToEmployeesOwningPercentageOfSharesOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Incentive stock option granted to Employees Owning percentage of shares of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_IncentiveStockOptionGrantedToEmployeesOwningPercentageOfSharesOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_NumberOfOptionsExercisedExcludesOptionsExercisedFromNpln">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options exercised, excludes options exercised from NPLN.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_NumberOfOptionsExercisedExcludesOptionsExercisedFromNpln</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_OfferingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Offering period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_OfferingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_PercentageOfFairValuePerShareOnTheGrantDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of fair value per share on the grant date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_PercentageOfFairValuePerShareOnTheGrantDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_PercentageOfProvisionsSubjectToStockholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of provisions subject to stockholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_PercentageOfProvisionsSubjectToStockholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_PurchasePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_PurchasePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_RemainingLiabilitiesRelatedToEarlyExercisedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining liabilities related to early exercised shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_RemainingLiabilitiesRelatedToEarlyExercisedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreaseInAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award number of shares increase in available for grant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreaseInAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_StockOptionsGrantedTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock options granted term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_StockOptionsGrantedTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares purchased for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pcvx_TwoThousandTwentyEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pcvx_TwoThousandTwentyEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pcvx_TwoThousandFourteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pcvx_TwoThousandFourteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pcvx_TwoThousandTwentyEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pcvx_TwoThousandTwentyEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139898121747832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans - Summary of Activity Under Stock Option Plans (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options, granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,382<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price Per Share, Options exercised</a></td>
<td class="nump">$ 3.25<span></span>
</td>
<td class="nump">$ 1.88<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pcvx_TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember', window );">2020 Plan and 2014 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Options Available for Grant, Beginning Balance</a></td>
<td class="nump">4,651,149<span></span>
</td>
<td class="nump">835,941<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Options Available for Grant, Additional shares authorized</a></td>
<td class="nump">2,553,579<span></span>
</td>
<td class="nump">5,997,435<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantedInPeriod', window );">Options Available for Grant, granted</a></td>
<td class="num">(1,616,021)<span></span>
</td>
<td class="num">(2,255,690)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeitedInPeriod', window );">Options Available for Grant, forfeited</a></td>
<td class="nump">516,049<span></span>
</td>
<td class="nump">73,463<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Options Available for Grant, Ending Balance</a></td>
<td class="nump">6,104,756<span></span>
</td>
<td class="nump">4,651,149<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Beginning Balance</a></td>
<td class="nump">5,121,549<span></span>
</td>
<td class="nump">3,297,586<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options, granted</a></td>
<td class="nump">1,616,021<span></span>
</td>
<td class="nump">2,255,690<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Options, exercised</a></td>
<td class="num">(926,514)<span></span>
</td>
<td class="num">(358,264)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Options, forfeited</a></td>
<td class="num">(516,049)<span></span>
</td>
<td class="num">(73,463)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Ending Balance</a></td>
<td class="nump">5,295,007<span></span>
</td>
<td class="nump">5,121,549<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of Options, Vested and expected to vest</a></td>
<td class="nump">5,295,007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Options, Exercisable</a></td>
<td class="nump">2,611,523<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price Per Share, Beginning Balance</a></td>
<td class="nump">$ 4.99<span></span>
</td>
<td class="nump">$ 1.93<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price Per Share, Options granted</a></td>
<td class="nump">21.83<span></span>
</td>
<td class="nump">8.93<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price Per Share, Options exercised</a></td>
<td class="nump">3.25<span></span>
</td>
<td class="nump">1.88<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price Per Share, Options forfeited</a></td>
<td class="nump">16.70<span></span>
</td>
<td class="nump">3.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price Per Share, Ending Balance</a></td>
<td class="nump">9.30<span></span>
</td>
<td class="nump">$ 4.99<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price Per Share, Vested and expected to vest</a></td>
<td class="nump">9.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price Per Share, Exercisable</a></td>
<td class="nump">$ 4.76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-Average Remaining Contractual Term (Years)</a></td>
<td class="text">7 years 10 months 20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted-Average Remaining Contractual Term (Years), Vested and expected to vest</a></td>
<td class="text">7 years 10 months 20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-Average Remaining Contractual Term (Years), Exercisable</a></td>
<td class="text">7 years 25 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value</a></td>
<td class="nump">$ 78,604<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Vested and expected to vest</a></td>
<td class="nump">78,604<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable</a></td>
<td class="nump">$ 50,123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by share-based payment award number of shares available for grant forfeited in period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by share-based payment award number of shares available for grant granted in period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pcvx_TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pcvx_TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139898125679400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans - Summary of Estimated Fair Value of Employee Stock Options (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Fair Value Assumptions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, Minimum</a></td>
<td class="nump">81.00%<span></span>
</td>
<td class="nump">81.20%<span></span>
</td>
<td class="nump">78.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, Maximum</a></td>
<td class="nump">84.10%<span></span>
</td>
<td class="nump">94.10%<span></span>
</td>
<td class="nump">80.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, Minimum</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="nump">0.30%<span></span>
</td>
<td class="nump">1.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, Maximum</a></td>
<td class="nump">1.30%<span></span>
</td>
<td class="nump">1.40%<span></span>
</td>
<td class="nump">2.40%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Fair Value Assumptions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years 3 months 18 days<span></span>
</td>
<td class="text">5 years 7 months 6 days<span></span>
</td>
<td class="text">5 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Fair Value Assumptions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139898125721176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans - Summary of Estimated Fair Value of Shares Under Employee Stock Purchase Plan (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Fair Value Assumptions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, Minimum</a></td>
<td class="nump">81.00%<span></span>
</td>
<td class="nump">81.20%<span></span>
</td>
<td class="nump">78.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, Maximum</a></td>
<td class="nump">84.10%<span></span>
</td>
<td class="nump">94.10%<span></span>
</td>
<td class="nump">80.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, Minimum</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="nump">0.30%<span></span>
</td>
<td class="nump">1.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, Maximum</a></td>
<td class="nump">1.30%<span></span>
</td>
<td class="nump">1.40%<span></span>
</td>
<td class="nump">2.40%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Fair Value Assumptions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years 3 months 18 days<span></span>
</td>
<td class="text">5 years 7 months 6 days<span></span>
</td>
<td class="text">5 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Fair Value Assumptions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pcvx_TwoThousandTwentyEmployeeStockPurchasePlanMember', window );">2020 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Fair Value Assumptions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, Minimum</a></td>
<td class="nump">79.60%<span></span>
</td>
<td class="nump">105.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, Maximum</a></td>
<td class="nump">126.30%<span></span>
</td>
<td class="nump">158.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, Minimum</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, Maximum</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="nump">0.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pcvx_TwoThousandTwentyEmployeeStockPurchasePlanMember', window );">2020 Employee Stock Purchase Plan | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Fair Value Assumptions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pcvx_TwoThousandTwentyEmployeeStockPurchasePlanMember', window );">2020 Employee Stock Purchase Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Fair Value Assumptions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pcvx_TwoThousandTwentyEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pcvx_TwoThousandTwentyEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139898124997208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans - Summary of Stock-based Compensation Expense (Details) - 2014 Plan, 2020 Plan and 2020 ESPP - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 10,729<span></span>
</td>
<td class="nump">$ 5,434<span></span>
</td>
<td class="nump">$ 1,185<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pcvx_TwoThousandFourteenEquityIncentivePlanAndTwoThousandTwentyEquityIncentivePlanAndTwoThousandTwentyEmployeeStockPurchasePlanMember', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">3,954<span></span>
</td>
<td class="nump">1,861<span></span>
</td>
<td class="nump">368<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pcvx_TwoThousandFourteenEquityIncentivePlanAndTwoThousandTwentyEquityIncentivePlanAndTwoThousandTwentyEmployeeStockPurchasePlanMember', window );">General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 6,775<span></span>
</td>
<td class="nump">$ 3,573<span></span>
</td>
<td class="nump">$ 817<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pcvx_TwoThousandFourteenEquityIncentivePlanAndTwoThousandTwentyEquityIncentivePlanAndTwoThousandTwentyEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pcvx_TwoThousandFourteenEquityIncentivePlanAndTwoThousandTwentyEquityIncentivePlanAndTwoThousandTwentyEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139898120656344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Funding Arrangement - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2021</div></th>
<th class="th"><div>Jul. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jan. 31, 2022</div></th>
<th class="th"><div>Aug. 04, 2021</div></th>
<th class="th"><div>Jul. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_FundingArrangementLineItems', window );"><strong>Funding Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_GrantIncome', window );">Grant income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,585,000<span></span>
</td>
<td class="nump">$ 2,478,000<span></span>
</td>
<td class="nump">$ 237,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=pcvx_CostReimbursementSubAwardAgreementMember', window );">Cost Reimbursement Sub-Award Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_FundingArrangementLineItems', window );"><strong>Funding Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_FundingPeriodOfAwardToDevelopUniversalVaccineToPreventInfections', window );">Funding period of award to develop universal vaccine to prevent infections caused by Group A Strep bacteria</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_PotentialFundingAmountOfAwardToDevelopVaccineToPreventInfections', window );">Potential funding amount of award to develop vaccine to prevent shingella infections</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_GrantIncome', window );">Grant income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600,000<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=pcvx_CostReimbursementSubAwardAgreementMember', window );">Cost Reimbursement Sub-Award Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_FundingArrangementLineItems', window );"><strong>Funding Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_InitialFundingCommittedByAward', window );">Initial funding committed by award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_FundingCommittedByAwardAvailableUponAchievementOfDevelopmentMilestones', window );">Total funding committed by award, available upon achievement of development milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_PotentialFundingPeriodOfAwardToDevelopVaccineToPreventInfections', window );">Potential funding period of award to develop vaccine to prevent shingella infections</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=pcvx_CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorAgreementMember', window );">CARB-X Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_FundingArrangementLineItems', window );"><strong>Funding Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_AdditionalFundingCommittedByAward', window );">Additional funding committed by award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrantsReceivable', window );">Grant receivable on unreimbursed, eligible costs incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=pcvx_CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorAgreementMember', window );">CARB-X Agreement | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_FundingArrangementLineItems', window );"><strong>Funding Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_PotentialFundingCommittedByAward', window );">Potential funding committed by award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=pcvx_CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorAgreementMember', window );">CARB-X Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_FundingArrangementLineItems', window );"><strong>Funding Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_InitialFundingCommittedByAward', window );">Initial funding committed by award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,700,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_AdditionalFundingCommittedByAward', window );">Additional funding committed by award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_PotentialFundingCommittedByAward', window );">Potential funding committed by award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=pcvx_CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorAgreementMember', window );">CARB-X Agreement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_FundingArrangementLineItems', window );"><strong>Funding Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_InitialFundingCommittedByAward', window );">Initial funding committed by award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_AdditionalFundingCommittedByAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional funding committed by award.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_AdditionalFundingCommittedByAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_FundingArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Funding arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_FundingArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_FundingCommittedByAwardAvailableUponAchievementOfDevelopmentMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Funding committed by award, available upon achievement of development milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_FundingCommittedByAwardAvailableUponAchievementOfDevelopmentMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_FundingPeriodOfAwardToDevelopUniversalVaccineToPreventInfections">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Funding period of award to develop universal vaccine to prevent infections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_FundingPeriodOfAwardToDevelopUniversalVaccineToPreventInfections</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_GrantIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Grant income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_GrantIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_InitialFundingCommittedByAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial funding committed by award.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_InitialFundingCommittedByAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_PotentialFundingAmountOfAwardToDevelopVaccineToPreventInfections">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential funding amount of award to develop vaccine to prevent infections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_PotentialFundingAmountOfAwardToDevelopVaccineToPreventInfections</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_PotentialFundingCommittedByAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential funding committed by award.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_PotentialFundingCommittedByAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_PotentialFundingPeriodOfAwardToDevelopVaccineToPreventInfections">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential funding period of award to develop vaccine to prevent infections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_PotentialFundingPeriodOfAwardToDevelopVaccineToPreventInfections</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrantsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrantsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=pcvx_CostReimbursementSubAwardAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=pcvx_CostReimbursementSubAwardAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=pcvx_CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=pcvx_CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139898120018664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Schedule of Computation of Basic and Diluted Net Loss Per Share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss (in thousands)</a></td>
<td class="num">$ (100,077)<span></span>
</td>
<td class="num">$ (89,217)<span></span>
</td>
<td class="num">$ (50,274)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average shares outstanding used in computing net loss per share, basic and diluted</a></td>
<td class="nump">51,922,108<span></span>
</td>
<td class="nump">29,545,810<span></span>
</td>
<td class="nump">3,795,090<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share, basic and diluted</a></td>
<td class="num">$ (1.93)<span></span>
</td>
<td class="num">$ (3.02)<span></span>
</td>
<td class="num">$ (13.25)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139898120801112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Schedule of Potentially Dilutive Securities Excluded From Computation of Diluted Net Loss Per Share Attributable to Common Stockholders (Details) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted net loss per share</a></td>
<td class="nump">5,357,389<span></span>
</td>
<td class="nump">5,188,531<span></span>
</td>
<td class="nump">23,845,796<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Options Issued and Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted net loss per share</a></td>
<td class="nump">5,357,389<span></span>
</td>
<td class="nump">5,188,531<span></span>
</td>
<td class="nump">3,364,568<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=pcvx_CommonStockWarrantMember', window );">Common Stock Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted net loss per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,857<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=pcvx_RedeemableConvertiblePreferredStockWarrantMember', window );">Redeemable Convertible Preferred Stock Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted net loss per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,276<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=pcvx_SeriesARedeemableConvertiblePreferredStockMember', window );">Series A Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted net loss per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,225,719<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=pcvx_SeriesBRedeemableConvertiblePreferredStockMember', window );">Series B Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted net loss per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,786,896<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=pcvx_SeriesCRedeemableConvertiblePreferredStockMember', window );">Series C Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted net loss per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,377,480<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=pcvx_CommonStockWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=pcvx_CommonStockWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=pcvx_RedeemableConvertiblePreferredStockWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=pcvx_RedeemableConvertiblePreferredStockWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=pcvx_SeriesARedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=pcvx_SeriesARedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=pcvx_SeriesBRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=pcvx_SeriesBRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=pcvx_SeriesCRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=pcvx_SeriesCRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139898125812504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of Effective Tax Rate (Details)<br></strong></div></th>
<th class="th" colspan="5">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><sup>[1]</sup></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><sup>[1]</sup></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Effective Income Tax Rate Continuing Operations Tax Rate Reconciliation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory Rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td colspan="2" class="nump">21.00%<span></span>
</td>
<td colspan="2" class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock-based Compensation</a></td>
<td class="nump">2.20%<span></span>
</td>
<td colspan="2" class="nump">0.80%<span></span>
</td>
<td colspan="2" class="num">(0.40%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">Credits</a></td>
<td class="nump">1.10%<span></span>
</td>
<td colspan="2" class="nump">0.60%<span></span>
</td>
<td colspan="2" class="num">(0.50%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfTrancheLiability', window );">Change in Fair Value of Tranche Liability</a></td>
<td class="nump">0.00%<span></span>
</td>
<td colspan="2" class="nump">0.00%<span></span>
</td>
<td colspan="2" class="nump">1.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(23.00%)<span></span>
</td>
<td colspan="2" class="num">(22.10%)<span></span>
</td>
<td colspan="2" class="num">(21.80%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_Section162MLimitation', window );">Section 162(m) Limitation</a></td>
<td class="num">(1.10%)<span></span>
</td>
<td colspan="2" class="num">(0.10%)<span></span>
</td>
<td colspan="2" class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="num">(0.20%)<span></span>
</td>
<td colspan="2" class="num">(0.20%)<span></span>
</td>
<td colspan="2" class="nump">0.40%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Total</a></td>
<td class="nump">0.00%<span></span>
</td>
<td colspan="2" class="nump">0.00%<span></span>
</td>
<td colspan="2" class="nump">0.00%<span></span>
</td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The 2019 and 2020 effective tax rate reconciliations have been updated to conform to the 2021 presentation.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfTrancheLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation change in fair value of tranche liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfTrancheLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_Section162MLimitation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Section 162(m) limitation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_Section162MLimitation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139898121781144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Components of Deferred Tax Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGrossAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating losses</a></td>
<td class="nump">$ 85,574<span></span>
</td>
<td class="nump">$ 52,330<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">Fixed assets</a></td>
<td class="nump">1,700<span></span>
</td>
<td class="nump">528<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals', window );">Accruals &amp; reserves</a></td>
<td class="nump">4,131<span></span>
</td>
<td class="nump">2,786<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Credits</a></td>
<td class="nump">2,865<span></span>
</td>
<td class="nump">1,222<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Section 59(e) Capitalized expenses</a></td>
<td class="nump">2,984<span></span>
</td>
<td class="nump">3,381<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_DeferredTaxAssetsTaxAccruedManufacturingExpenses', window );">Accrued manufacturing expenses</a></td>
<td class="nump">1,006<span></span>
</td>
<td class="nump">3,374<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_LeaseLiability', window );">Lease Liability</a></td>
<td class="nump">6,674<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total</a></td>
<td class="nump">104,934<span></span>
</td>
<td class="nump">63,621<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements', window );">ROU asset</a></td>
<td class="num">(8,349)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(8,349)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance', window );">Net deferred tax asset</a></td>
<td class="nump">96,585<span></span>
</td>
<td class="nump">63,621<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">$ (96,585)<span></span>
</td>
<td class="num">$ (63,621)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets liabilities net before valuation allowance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_DeferredTaxAssetsTaxAccruedManufacturingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets tax accrued manufacturing expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_DeferredTaxAssetsTaxAccruedManufacturingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_LeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_LeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGrossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGrossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139898120783720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Uncertain tax benefits</a></td>
<td class="nump">$ 924,000<span></span>
</td>
<td class="nump">$ 393,000<span></span>
</td>
<td class="nump">$ 271,000<span></span>
</td>
<td class="nump">$ 408,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense', window );">Interest or penalties recognized for the period</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">296,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Research credit carryforwards</a></td>
<td class="nump">$ 2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_TaxCreditCarryforwardExpirationYear', window );">Tax credit carry forwards expiration year</a></td>
<td class="text">2039<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | Research | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Research credit carryforward</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 262,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_OperatingLossCarryForwardsExpirationYear', window );">Operating loss carry forwards expiration year</a></td>
<td class="text">2034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=stpr_CA', window );">California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Research credit carryforwards</a></td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_IncomeTaxDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income tax disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_IncomeTaxDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_OperatingLossCarryForwardsExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating loss carry forwards expiration year</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_OperatingLossCarryForwardsExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_TaxCreditCarryforwardExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax credit carryforward expiration year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_TaxCreditCarryforwardExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=stpr_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=stpr_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139898127171160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of Unrecognized Tax Benefit (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Reconciliation Of Unrecognized Tax Benefits Excluding Amounts Pertaining To Examined Tax Returns Roll Forward</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at the beginning of the year</a></td>
<td class="nump">$ 393<span></span>
</td>
<td class="nump">$ 271<span></span>
</td>
<td class="nump">$ 408<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Additions based on tax positions related to current year</a></td>
<td class="nump">461<span></span>
</td>
<td class="nump">287<span></span>
</td>
<td class="nump">217<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions', window );">Adjustments based on tax positions related to prior years</a></td>
<td class="nump">70<span></span>
</td>
<td class="num">(165)<span></span>
</td>
<td class="num">(354)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at end of year</a></td>
<td class="nump">$ 924<span></span>
</td>
<td class="nump">$ 393<span></span>
</td>
<td class="nump">$ 271<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized Tax Benefits Increases Decreases Resulting From Prior Period Tax Positions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139898120760264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 29, 2018</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares owned</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,031,978<span></span>
</td>
<td class="nump">51,071,593<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRightExercised', window );">Warrant exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,869<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of redeemable convertible preferred stock warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 179,000<span></span>
</td>
<td class="num">$ (12,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pcvx_SutroBiopharmaIncMember', window );">Sutro Biopharma, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares owned</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600,000<span></span>
</td>
<td class="nump">1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDueFromToRelatedParty', window );">Accrued expenses payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pcvx_SutroBiopharmaIncMember', window );">Sutro Biopharma, Inc | License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_PercentageOfRoyaltyPaymentOnAnnualNetSalesOfVaccineProductsForHumanHealth', window );">Percentage of royalty payment on annual net sales of vaccine products for human health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_PercentageOfRoyaltyPaymentOnNetSalesOfVaccineCompositionsForAnimalHealth', window );">Percentage of royalty payment on net sales of vaccine compositions for animal health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pcvx_SutroBiopharmaIncMember', window );">Sutro Biopharma, Inc | Supply Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Expenses related to agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400,000<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pcvx_SutroBiopharmaIncMember', window );">Sutro Biopharma, Inc | Series C Redeemable Convertible Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Warrant to purchase shares of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,276<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant purchase price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.5215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pcvx_SutroBiopharmaIncMember', window );">Sutro Biopharma, Inc | Series C Redeemable Convertible Stock | License Amendment A2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Warrant to purchase shares of stock</a></td>
<td class="nump">59,276<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant purchase price per share</a></td>
<td class="nump">$ 11.5215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable', window );">Warrant exercisable and vests immediately and expires date</a></td>
<td class="text">May 29,  2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pcvx_SutroBiopharmaIncMember', window );">Sutro Biopharma, Inc | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Warrant to purchase shares of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant purchase price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.79289<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pcvx_SutroBiopharmaIncMember', window );">Sutro Biopharma, Inc | Common Stock Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRightExercised', window );">Warrant exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,278<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pcvx_SutroBiopharmaIncMember', window );">Sutro Biopharma, Inc | Preferred Stock Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRightExercised', window );">Warrant exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,591<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of redeemable convertible preferred stock warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRightExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right number of securities called by each warrant or right exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRightExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_PercentageOfRoyaltyPaymentOnAnnualNetSalesOfVaccineProductsForHumanHealth">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of royalty payment on annual net sales of vaccine products for human health.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_PercentageOfRoyaltyPaymentOnAnnualNetSalesOfVaccineProductsForHumanHealth</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_PercentageOfRoyaltyPaymentOnNetSalesOfVaccineCompositionsForAnimalHealth">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of royalty payment on net sales of vaccine compositions for animal health.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_PercentageOfRoyaltyPaymentOnNetSalesOfVaccineCompositionsForAnimalHealth</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date the warrants or rights are exercisable, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionDueFromToRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Receivables to be collected from (obligations owed to) related parties, net as of the balance sheet date where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionDueFromToRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pcvx_SutroBiopharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pcvx_SutroBiopharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=pcvx_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=pcvx_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=pcvx_SupplyAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=pcvx_SupplyAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=pcvx_SeriesCRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=pcvx_SeriesCRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=pcvx_LicenseAmendmentATwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=pcvx_LicenseAmendmentATwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=pcvx_CommonStockWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=pcvx_CommonStockWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=pcvx_PreferredStockWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=pcvx_PreferredStockWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139898124457944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events - Additional Information (Details) - Subsequent Event - Underwritten Public Offering - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 28, 2022</div></th>
<th class="th"><div>Jan. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_StockIssuedDuringPeriodSharesOfFollowOnOffering', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_SharesIssuedPricePerShareUponFollowOnOffering', window );">Common stock price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_SharesPreFundedWarrantsToPurchase', window );">Pre-funded warrants to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_PrefundedWarrantsPricePerShare', window );">Pre-funded warrants price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19.999<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_ProceedsFromIssuanceFollowOnOffering', window );">Net proceeds from follow on offering</a></td>
<td class="nump">$ 14.1<span></span>
</td>
<td class="nump">$ 93.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcvx_SharesIssuedUponFollowOnOfferingFullExerciseOfUnderwritersOptionToPurchaseAdditionalShares', window );">Underwriters' option to purchase additional shares</a></td>
<td class="nump">750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_PrefundedWarrantsPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prefunded warrants price per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_PrefundedWarrantsPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_ProceedsFromIssuanceFollowOnOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance follow on offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_ProceedsFromIssuanceFollowOnOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_SharesIssuedPricePerShareUponFollowOnOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares issued price per share upon follow on offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_SharesIssuedPricePerShareUponFollowOnOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_SharesIssuedUponFollowOnOfferingFullExerciseOfUnderwritersOptionToPurchaseAdditionalShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares issued upon follow on offering full exercise of underwriters option to purchase additional shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_SharesIssuedUponFollowOnOfferingFullExerciseOfUnderwritersOptionToPurchaseAdditionalShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_SharesPreFundedWarrantsToPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares pre-funded warrants to purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_SharesPreFundedWarrantsToPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_StockIssuedDuringPeriodSharesOfFollowOnOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period, shares of follow on offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_StockIssuedDuringPeriodSharesOfFollowOnOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>pcvx-20211231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:pcvx="http://www.vaxcyte.com/20211231"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2021"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="pcvx-20211231.xsd" xlink:type="simple"/>
    <context id="C_84b31ec6-25e1-4d4b-9f94-c4046b727e6f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_faa3a312-73ee-42b0-852a-ab16d62c1cef">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_bcc1b5db-4703-43c3-9272-4d0ca2f54e6a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_f7ed5965-c3e7-4a8f-9810-2fb0b6527977">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pcvx:LonzaLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_0a0e42fe-11ad-487e-b9de-014ca00c2d28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pcvx:SeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_d1a846f2-0595-4f2b-bfde-977270efb43f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_6c7d80da-3c5c-41d2-a3bf-0f29663df66e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_bc281be7-82b8-4ef6-9792-0543c76c1a35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_08f2ab18-3ec2-4bf6-a856-11d6f22d4790">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_9cbe4e9e-74f9-4ec8-bf47-1d291c0aaf9d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_a129b41f-99aa-4150-b52d-3b8433ceb5ee">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_8639465b-8e42-43a0-b445-048bbd5edbbe">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pcvx:JefferiesLimitedLiabilityCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pcvx:ATMSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-31</instant>
        </period>
    </context>
    <context id="C_00eaf7db-5639-43a7-9d93-1b5cbcde71cf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_8817387e-2be1-4358-95ce-a5df2bf517bf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">pcvx:SupplyAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pcvx:SutroBiopharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_cb2a9833-f2d5-4d07-9f84-e6fd7b138b95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_bebcd826-aabe-4884-ab32-26215b024f1a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_5909cb95-2fd5-4c03-b349-88a7f48048ff">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pcvx:SutroBiopharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">pcvx:CommonStockWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_ca7ed438-6716-4360-8ccd-eaaa38f9fcf2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_1efdf0c7-6a07-4132-8782-b57177c53f15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-11</instant>
        </period>
    </context>
    <context id="C_066e4651-a692-4244-9444-b8600c1c5b43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_022b1471-8226-4bef-aee0-86e11defec44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">pcvx:LicenseAmendmentATwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pcvx:SutroBiopharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pcvx:SeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-28</startDate>
            <endDate>2018-05-29</endDate>
        </period>
    </context>
    <context id="C_9ce589b3-009c-4c1f-9492-617b84d98173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pcvx:SanCarlosMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_88219214-e682-4a47-ba69-b37e92d74db8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_f2e3d587-c577-46eb-a487-767a66753618">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_1db8f94d-2ec6-47be-b76a-a4960db1be21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_632492ef-57fd-48e7-acda-b7cb142000ba">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_44af597c-135d-414d-a410-f04a16cf714e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pcvx:JefferiesLimitedLiabilityCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pcvx:ATMSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_af5ccde9-e011-49f2-9896-792a8871b96a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pcvx:CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="C_e8c80ef0-b66f-48cb-8236-662fca240430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandFourteenEquityIncentivePlanAndTwoThousandTwentyEquityIncentivePlanAndTwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_61481fb4-5a3a-40c5-abb3-1248a21e99b5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">pcvx:LicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pcvx:SutroBiopharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_1217ed43-7b78-4138-a3fe-8b016f62919a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pcvx:ComputersAndComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_fd58b7dd-25a0-4a70-92a2-457d12426c58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pcvx:CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-04</instant>
        </period>
    </context>
    <context id="C_93b8accf-91b3-4471-ab5d-fc8aea02adbe">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_070a9c52-605a-45b7-ac24-ad04c1d7f676">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_58ad6f5b-2983-4459-8fd3-3b4fbdef1c36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_ecccdfb9-edd1-45a3-8445-0fe8b2f43253">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_cf8c9eeb-5415-47f7-97f3-ce1e53cabf5b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_3800b858-6c6b-4793-98cb-f7bb3ff61062">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_ace47527-5c7b-43a0-97fe-7ef235c9ad0c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pcvx:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_0c6ef4a7-f323-4b58-a7d5-94f0c514539b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pcvx:SharesAvailableForFutureStockOptionGrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_25f1f214-138d-4f58-8434-afe2e9883750">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-14</startDate>
            <endDate>2020-06-15</endDate>
        </period>
    </context>
    <context id="C_5cd74deb-d2fe-4b8d-8171-3251599dda47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_542495c1-8a9f-4d28-9179-f5c599d02e73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_2a5c2eff-6ddb-4c32-9bd6-9e0d20b2a11f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pcvx:MarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_2bbf4b2d-41ff-4ec4-b597-e8a5be645bc2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_a0171645-3dab-4282-933d-7e5fb2e8585a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="C_f9848f07-54cd-412b-b65d-24c18bb6aab2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pcvx:LonzaLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_e7331c69-2305-4247-a515-eb0da32be4fd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pcvx:CostReimbursementSubAwardAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-31</instant>
        </period>
    </context>
    <context id="C_7b1cec7a-d004-403e-8a42-ef595588ed48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_ccf431e6-d93a-4a5a-884d-651e8f20892e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_70588bd5-1fdc-44ee-a7cf-7d459c6fc883">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_3276c9c1-bce8-4e37-a494-9cd61a385e5d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_e25af62d-d63b-4e1b-8b46-d08c4c227921">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-11</startDate>
            <endDate>2020-06-11</endDate>
        </period>
    </context>
    <context id="C_a1d232a3-c6a3-4bd1-9776-35c32d836d64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pcvx:CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-04</instant>
        </period>
    </context>
    <context id="C_e62d86e5-c312-474f-99a0-95ed9692529c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pcvx:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_9262f685-96b6-4f7c-a6ae-83581243ab7d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pcvx:SutroBiopharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">pcvx:PreferredStockWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_5c54c4ca-430a-4169-96fa-f57499d8524f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pcvx:PaloAltoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_9001db26-8d96-496f-9fd0-ccbff0d80378">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandFourteenEquityIncentivePlanAndTwoThousandTwentyEquityIncentivePlanAndTwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_ed58902d-2f75-4902-a5af-e641599b12d5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pcvx:CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_13251130-5d02-4a4b-82e5-dc7664b58676">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pcvx:SutroBiopharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_a6bb51b5-9e65-4bc2-a156-224db74e09c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_e702b57a-b360-45bc-a12c-2341ca21e0de">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_11d04721-6c5e-451c-9f8c-b386520e079e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_448aa75e-c08c-4eb7-a778-f1a1525470d8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pcvx:LonzaLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="C_039297c3-6466-43f6-840d-9c5a04a312b3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pcvx:CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_a7a54056-1b96-4694-a8be-248476ad36f9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pcvx:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_de000bd8-7fd0-42f8-8b81-fc098f2cc14e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_4c43c843-d033-4309-afae-7cfdb2138610">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pcvx:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_cab820c4-1fb0-481c-b985-2ea03542a95b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pcvx:SutroBiopharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">pcvx:PreferredStockWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_b2d931e6-c3f8-485c-8729-b21db15df907">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_b3bc61ea-4f75-41e4-81f8-73c18aff2f6f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_3e25c250-e268-4985-8e41-7be1baee8700">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_c4319f5e-0947-41f2-9bc7-187004e5a87b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_39f8abfd-a954-4f03-b72e-b423c719a4a5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pcvx:SutroBiopharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_372ee990-ff50-459b-90f9-d45574ce4c70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_196fbfec-2db3-415e-8c1d-7ba3ff662444">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
        </entity>
        <period>
            <startDate>2020-06-05</startDate>
            <endDate>2020-06-05</endDate>
        </period>
    </context>
    <context id="C_04acb199-245c-4c72-a959-3ad34a1f3b9f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_3e0e573b-cca9-436f-b585-f3bd61467bce">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandFourteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_7ac26ea9-aa26-46d1-b9ed-042601b4004d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pcvx:CostReimbursementSubAwardAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_006c2037-6bba-4d3a-bcd7-32b71e7a5475">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pcvx:SeriesDRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_77bd8890-2188-4455-95b3-5c7a4d36c588">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">pcvx:RedeemableConvertiblePreferredStockWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_8f37ea4f-142c-4bc7-aa2e-4b36661b1de6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_2fc259cf-825e-4ff9-9943-2f01c1a0937b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="C_32b0b6ee-9dc1-4ce6-9ecd-470c2a71985a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pcvx:CostReimbursementSubAwardAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_ac053fdb-afd2-48a8-b734-eae8ef079868">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pcvx:HeadquartersFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2022-02-28</endDate>
        </period>
    </context>
    <context id="C_0830660e-391f-4e25-8658-4f38f275d086">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pcvx:CostReimbursementSubAwardAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="C_b663ddb0-dc3a-4405-9809-183e08d4aa14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pcvx:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_89e8a4b5-4ab0-4668-889d-5ae7704f7e30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="C_dc50a6ec-93a5-4d6d-8842-7d609d69c237">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_28585e6d-11c8-4ef0-bd28-a3644bbf26ac">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pcvx:NewCorporateHeadquartersFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="C_fa60d7ee-2e38-419f-8133-f69b4b66de3f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_3e34321b-16ec-44ef-ab8c-8cdab8688001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_c0fb1076-a7db-464d-8c21-b64e5bc453db">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pcvx:SeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_ed656fe7-27bd-4711-a1d9-07aab395e870">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-31</instant>
        </period>
    </context>
    <context id="C_82e259ab-4adf-45bb-b0dd-9fc97b85e6bd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pcvx:LonzaLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_914c8ff3-3cf5-4419-8e2f-0309464abc71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_68dac7ff-d423-43b1-b2cb-fbeb2182a939">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_68b32ca0-daf9-4934-b4c5-74593152bb49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pcvx:ComputersAndComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_68377845-3bf8-42a9-ba72-9a3b693b78a1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_1e69b34d-5d84-4378-a6c6-3b4511d14d3c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_5a9d30f7-2f17-4c61-b4cc-72ab32702c3f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandFourteenEquityIncentivePlanAndTwoThousandTwentyEquityIncentivePlanAndTwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_e5909518-4b17-423b-8df9-fefc213da385">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">stpr:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_871fe4ad-8a52-4dc5-a523-876ef5a1de6d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_14ff4d59-3fca-47b7-aa38-4bd882e8ae38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandFourteenEquityIncentivePlanAndTwoThousandTwentyEquityIncentivePlanAndTwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_59f4b2de-1ad8-448b-acad-83f62876574d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pcvx:AdditionalFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_8bc7d2ce-bbce-48ac-9b6a-f09c04733362">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_dd29e038-bfb3-4788-9620-c38deb43178e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_04918cd3-bad5-49f6-b891-9bebcd71baa0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_9ea862ab-153b-4f8b-bcfc-2223d2882ade">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">pcvx:SupplyAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pcvx:SutroBiopharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_3d9566a8-97e9-4ae9-937d-c604f1218434">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_d4cf0103-8fdd-4434-bedf-65aa2503f533">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="C_c2d425b8-8bfe-4616-b9aa-1a6041c6bb18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pcvx:CostReimbursementSubAwardAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_9fb419f9-f0a5-4dff-a890-32989d15c4e8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_432334ae-bbb2-42ed-9170-56253d99b097">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pcvx:SeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_1c93f415-cf2a-4e2c-a1d1-8e49784595b5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_fc0e428b-6e5e-4e81-ad32-508b6eb1375f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_922091bf-1883-4a4a-8399-cbd1c97ca12c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_3fab40e5-6a35-4b2f-b816-13c7822b9afc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pcvx:SutroBiopharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_75f99d7f-d132-471c-9624-9a873477248d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pcvx:HeadquartersFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-07-31</instant>
        </period>
    </context>
    <context id="C_88288d89-14d9-4c81-bcdc-77db4748e94f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
        </entity>
        <period>
            <startDate>2020-06-11</startDate>
            <endDate>2020-06-11</endDate>
        </period>
    </context>
    <context id="C_bef847b3-ad94-49aa-ac4c-cf8f492446d7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pcvx:MarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_f112ef5d-4313-44ad-aa4e-21889fa3a7d3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pcvx:PaloAltoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="C_e52d577e-c5ed-4801-8551-af9cd25c01fa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="C_e95a1cc5-e02c-42d9-9f9c-6159842d1e7c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-11</startDate>
            <endDate>2020-06-11</endDate>
        </period>
    </context>
    <context id="C_54987e17-a9c2-4890-ade9-618bd3dfc3f7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pcvx:PaloAltoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_104dc821-c967-4abc-be6e-1f58334234a8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pcvx:JefferiesLimitedLiabilityCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pcvx:ATMSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_bfcc9c06-d2c1-452e-8ef8-cffaed58bf95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandFourteenEquityIncentivePlanAndTwoThousandTwentyEquityIncentivePlanAndTwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_35363580-d33d-4e25-a1e6-c5519ee4402f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pcvx:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_5c504db9-02bb-4fad-8cf7-b49fc071de1c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_e3a2a9fa-a738-409d-96a4-c1ee8f7ecd25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201912Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_a4d7b89e-0ab9-4f03-8b01-723510464ce9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_a870b5f9-af49-4819-946b-a34bbe67f9e2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_17e8d504-7444-46d1-a94b-f46e5cb44fae">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_17a1e23b-77b7-43b4-b889-deab67e04a69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_b350157c-7c7f-42a0-b645-149c360d1819">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0f671a12-9113-4696-9460-beb583200e4f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pcvx:LonzaLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="C_40beaa16-40f7-4f29-9069-2b64528824d9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-01</endDate>
        </period>
    </context>
    <context id="C_2a6a1809-6c79-4e3a-9b03-3826f9729ccf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pcvx:NewCorporateHeadquartersFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-31</instant>
        </period>
    </context>
    <context id="C_d1c4c865-1394-49a2-907a-e54a6cd8c170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_132d316b-36f4-4e18-bf45-5543bb58c44e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pcvx:MarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_c1debaa3-dafc-4806-a41b-60a0b5a5aa1c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0a0e64e6-bec3-47d0-a7db-dea3ad28e107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_b1ab0ed1-080d-4ff7-adaf-245dff15e8dc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pcvx:SeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_d5f3d746-38cf-4e03-93db-68b59ff6ca6e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandFourteenEquityIncentivePlanAndTwoThousandTwentyEquityIncentivePlanAndTwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_1d403ed3-f3ea-41fc-ab8b-8b842982729a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_4ce8060d-05a1-4cdf-a58a-b689d077a297">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_52c3a991-3000-4196-9b57-c6affc82cde5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pcvx:SharesAvailableForFutureStockOptionGrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_1c84ebe2-ee47-4498-9c45-6e43ebdd4a7a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_34fb7648-e015-48b0-95af-d232d9d8d189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandFourteenEquityIncentivePlanAndTwoThousandTwentyEquityIncentivePlanAndTwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_769f014e-781a-475a-bffc-269894519fd4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_afadb6ee-d738-47a2-9b09-0905934ee597">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_c8d7f783-8f05-4c35-8444-31988eb17d2e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-11</startDate>
            <endDate>2020-06-11</endDate>
        </period>
    </context>
    <context id="C_3ab55850-7a59-4321-b335-f0ca2fe76524">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pcvx:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_3562faed-85c8-4ea5-a88d-038f23029b7d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandFourteenEquityIncentivePlanAndTwoThousandTwentyEquityIncentivePlanAndTwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_01ab22d2-811b-4087-b1ae-4007067b9a23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_4d6eec73-41eb-4eea-8812-cd5a564af773">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_fe00813e-2d7b-4ece-bbe6-949a26bbf5f7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_dac22bba-f4c3-4e16-abd0-7f908c3516fb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pcvx:SutroBiopharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">pcvx:PreferredStockWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_9f6bf305-4c1d-45f5-96fe-42e373b0efcb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_2e490417-2b25-4870-8c8f-ccac2bc83352">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_7ef0af11-3445-4e12-816a-b2d4849a786e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pcvx:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_c44b9b74-3efa-4a2d-b6b0-c053a39e9f18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pcvx:CostReimbursementSubAwardAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="C_555acc16-d9e2-4b46-9a03-aa27a3ad92e4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pcvx:AdditionalFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="C_2bf194ae-c6b4-4264-b519-4608eda30c8d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-17</instant>
        </period>
    </context>
    <context id="C_16333782-8505-4ca7-9e4c-1163caa27de3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2022-02-28</endDate>
        </period>
    </context>
    <context id="C_3c435103-f76a-492c-9b05-78cd97e91f32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">pcvx:SupplyAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pcvx:SutroBiopharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_c8071e48-943e-4850-b4a1-a2bca3238b71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pcvx:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_a9e696e6-57cc-4729-8788-4c5e9e4ec861">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_b5f3713d-ecd4-4700-a7ab-db89f5c2d1ac">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_fd7551c1-f7f9-4cde-a040-39d423a71993">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_1a49e197-0c31-4849-ac0b-b08a2eebd593">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_fddff65d-fa11-44de-96a6-5e8ce2f4167b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pcvx:PneumococcalConjugateVaccineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_efd921fe-f258-4bca-8c80-5723ef551b43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_017473b9-4a6d-4b35-bafe-2f3035074c39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pcvx:CostReimbursementSubAwardAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-07-31</endDate>
        </period>
    </context>
    <context id="C_83b9a259-045e-40be-a3dc-3d06c253dc05">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_f77911a6-cb83-4a40-8b6c-9703e6acc5a0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pcvx:SutroBiopharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pcvx:SeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_4469bcba-dbf3-41b7-810d-1333a6644626">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_9ed4a1bc-93ea-4d6c-a3a2-fe0ee49c92a6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_9a84ae25-675d-4a66-a9c5-6809604d88d9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_07b31212-bf35-4995-9486-d82d74f5da0e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pcvx:HeadquartersFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="C_56188f91-3c62-4582-88c9-91789caa7dd4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pcvx:SutroBiopharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">pcvx:PreferredStockWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_6bfa48d9-3084-49f0-aff3-43a54ae90a96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_6a5b5034-43db-42ae-a769-e4a78da8c922">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
        </entity>
        <period>
            <instant>2022-02-23</instant>
        </period>
    </context>
    <context id="C_6da3f8ad-d2ec-440b-a451-9dbaebaea6e0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pcvx:CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="C_3d43ebd8-c6c9-4618-9f17-19b5fc65cecf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-01</endDate>
        </period>
    </context>
    <context id="C_b399954b-8b8b-4102-8291-0483e80bb7cc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">pcvx:CommonStockWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_12a75901-fd10-4da6-bb07-c58c55e98510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandFourteenEquityIncentivePlanAndTwoThousandTwentyEquityIncentivePlanAndTwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_f910d477-1db3-4915-9562-49fd9c1e0523">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">pcvx:LicenseAmendmentATwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pcvx:SutroBiopharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pcvx:SeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-29</instant>
        </period>
    </context>
    <context id="C_8825ef60-997f-4d67-9024-2ab506972607">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pcvx:HeadquartersFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-01</startDate>
            <endDate>2016-07-31</endDate>
        </period>
    </context>
    <context id="C_a38e3261-0264-423e-b43f-742897fb5b71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-11</instant>
        </period>
    </context>
    <context id="C_6cff9554-4027-48fb-bcff-8e4bfb2fe23e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pcvx:AdditionalFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-07-31</endDate>
        </period>
    </context>
    <context id="C_decb2811-c318-46bf-b586-449b2cc7fa0b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_977bf646-5642-4ace-80e5-1617547b66ea">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_92f1ced7-c143-458c-9b8e-7abfc0c425d9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pcvx:CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-31</instant>
        </period>
    </context>
    <context id="C_bc56f763-40d5-4249-8c96-d9aa519edbb4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pcvx:HeadquartersFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_6c03f021-f6d5-4fb2-b776-94bc1a86aa1d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pcvx:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_23381eb2-52cb-4648-a7ab-24309842b90d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-11</startDate>
            <endDate>2020-06-11</endDate>
        </period>
    </context>
    <context id="C_1ca103dc-5b49-40a2-af4e-c772a7562197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pcvx:JefferiesLimitedLiabilityCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pcvx:ATMSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-31</instant>
        </period>
    </context>
    <context id="C_61d1fa2e-cb6c-418c-bc91-f7bc598be5a9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <unit id="U_Security">
        <measure>pcvx:Security</measure>
    </unit>
    <unit id="U_RenewalOption">
        <measure>pcvx:RenewalOption</measure>
    </unit>
    <unit id="U_pure">
        <measure>pure</measure>
    </unit>
    <unit id="U_Lease">
        <measure>pcvx:Lease</measure>
    </unit>
    <unit id="U_UnitedStatesOfAmericaDollarsShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_shares">
        <measure>shares</measure>
    </unit>
    <unit id="U_Segment">
        <measure>pcvx:Segment</measure>
    </unit>
    <unit id="U_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      id="F_30ad9e1a-2d1c-4f4e-8ca9-bfc495d5abbe">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      id="F_b0cb0a17-e593-4c86-bc0e-b70bcb38c012">0001649094</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      id="F_dfb2b15e-0190-4335-9dd5-15ea315bbe0d">FY</dei:DocumentFiscalPeriodFocus>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="C_196fbfec-2db3-415e-8c1d-7ba3ff662444"
      decimals="3"
      id="F_3036f30d-a3d2-46a5-ba0d-72b7a840f4ad"
      unitRef="U_pure">0.593</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57"
      id="F_12ca5abb-61de-41ac-ba25-bb0e431fbb88"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350"
      id="F_565f8602-4d2e-4dc2-8e24-2bd920b5de6a"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57"
      id="F_ced4119e-0847-4d96-a362-c9f40af1bee1"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_a9e696e6-57cc-4729-8788-4c5e9e4ec861"
      id="F_cdf000c4-3126-4076-a46e-14220371b9f3">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PreferredStockValue
      contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350"
      id="F_bc3cb20d-a774-425a-bb11-176869120719"
      unitRef="U_USD"
      xsi:nil="true"/>
    <dei:DocumentType
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      id="F_6fe1e0de-8ae3-4cfb-9c22-336addd039e3">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      id="F_1c1c0853-7bca-400e-ab20-ba5b3d1ec888">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      id="F_757d4086-0b1c-4d31-8412-78340df3388f">2021-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      id="F_bb1d181a-9089-4735-8887-953f043f4039">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      id="F_a8df000e-2314-4317-97c6-2ef349adb115">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      id="F_7ed36dcb-a438-4200-8084-ccb7295d12e5">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      id="F_153ab1ca-effc-4e1b-b3cc-3a0550d3ffd7">001-39323</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      id="F_09ac5281-5bf3-4aee-bb90-56ea10813fc3">VAXCYTE, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      id="F_34e7c0c5-1ec8-4f4b-a860-499ef1d2352a">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      id="F_e013502c-3389-49f3-ac81-6231c3d0138f">46-4233385</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      id="F_c4422436-6e17-478a-87f0-2978f4769bb2">825 Industrial Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      id="F_a77ca57a-61d0-4d00-8ade-c74d372ae647">Suite 300</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      id="F_9809c2dd-bf98-4cda-9fd9-68a7dcaeb052">San Carlos</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      id="F_a64575e5-8c75-46ad-b962-6da6f9db0535">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      id="F_5fedd352-eaa6-4774-99b4-e849f7402559">94070</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      id="F_c0f1de04-2585-4438-97cf-30414d1d8bcc">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      id="F_0988592b-6164-480f-af9e-a59022f5e64e">837-0111</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      id="F_dc9eac62-5824-4a67-9baf-d0f0bd0a1a59">Common Stock, $0.001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      id="F_56d5a922-cca5-4120-a653-2f6c99a3acd7">PCVX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      id="F_6bb79b3a-9cf4-49ee-89d9-3e50296e4bf5">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      id="F_9ea9f0e7-68b3-4403-a362-2174a6be28c1">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      id="F_49299638-868c-4e47-ad3d-358531a29fcb">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      id="F_1db6262a-3b7d-43e6-bab6-457b541fcd02">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      id="F_3d08b6b7-f90d-4053-873a-8f0ff2bf13d2">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      id="F_2e4ee773-a189-4401-8c32-f123f0b04684">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      id="F_064014b7-82ee-4619-a399-300f9744797d">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      id="F_d5295aa6-d629-4b1d-b2f6-f36efa7ddbe0">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      id="F_65565024-db02-437e-be01-af610657a0cb">true</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      id="F_084e93c6-3f76-454f-bd92-76cf6edd0deb">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="C_769f014e-781a-475a-bffc-269894519fd4"
      decimals="-5"
      id="F_12477f24-90a4-4bf7-8d0b-952bc6eb02e0"
      unitRef="U_USD">788600000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_6a5b5034-43db-42ae-a769-e4a78da8c922"
      decimals="INF"
      id="F_313d726a-5d61-40f3-8a22-8a3c12839351"
      unitRef="U_shares">56310751</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      id="F_6ed99354-2c7f-4ede-8b54-c6378f09a937">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"&gt;Part III incorporates information by reference from the Registrant&#x2019;s definitive proxy statement to be filed with the U.S. Securities and Exchange Commission pursuant to Regulation 14A, not later than 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K, in connection with the Registrant&#x2019;s 2022 annual meeting of stockholders.&lt;/span&gt;&lt;/p&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      id="F_00963767-c9fe-4c06-8b9b-e769c7447265">34</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      id="F_33a3ad8b-1f47-49ca-9f61-19d10d1b86ec">Deloitte &amp; Touche LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      id="F_ee1e0030-22fc-4ae4-9469-f97225da9a44">San Francisco, California</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350"
      decimals="-3"
      id="F_1b46589b-8841-47ee-871f-232f1d62bbcd"
      unitRef="U_USD">68985000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57"
      decimals="-3"
      id="F_7da18ccf-7433-4444-935e-e81cd69d5e94"
      unitRef="U_USD">386200000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350"
      decimals="-3"
      id="F_6d57564d-6f6b-451d-ba49-81cc0f6c40e1"
      unitRef="U_USD">176985000</us-gaap:ShortTermInvestments>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350"
      decimals="-3"
      id="F_9742f290-5d30-4d4f-b615-441a5d2c216a"
      unitRef="U_USD">10378000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57"
      decimals="-3"
      id="F_bd899997-63e2-4350-9198-8136f43631d9"
      unitRef="U_USD">2804000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350"
      decimals="-3"
      id="F_0331d41d-2352-4f7f-8e94-35e65ec1b822"
      unitRef="U_USD">256348000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57"
      decimals="-3"
      id="F_8062c568-1e5b-4394-95d3-e5fd91599f32"
      unitRef="U_USD">389004000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350"
      decimals="-3"
      id="F_4c571418-0675-4918-bf58-adf32ab12f56"
      unitRef="U_USD">7954000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57"
      decimals="-3"
      id="F_3e8aca73-df75-42fe-8f6f-3998c115b9e5"
      unitRef="U_USD">3272000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350"
      decimals="-3"
      id="F_246f5cf5-b90a-402d-b359-f06e238ac28a"
      unitRef="U_USD">27958000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:LongTermInvestments
      contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350"
      decimals="-3"
      id="F_5477517d-f026-4ec3-a715-2bc4888b478a"
      unitRef="U_USD">27117000</us-gaap:LongTermInvestments>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350"
      decimals="-3"
      id="F_39c8b94e-2eab-4cc8-9e22-252fe433b8ed"
      unitRef="U_USD">871000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350"
      decimals="-3"
      id="F_efc0c9d8-a6a3-442a-ad41-20a0c2120a7f"
      unitRef="U_USD">4089000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57"
      decimals="-3"
      id="F_a251040c-eff9-4793-bf10-78ba78ca1f71"
      unitRef="U_USD">550000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350"
      decimals="-3"
      id="F_d23f2dd5-7a3c-4dfc-9ea3-30d12a736440"
      unitRef="U_USD">67989000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57"
      decimals="-3"
      id="F_ebe23a39-553f-4d0d-acb2-59f6e5741a8d"
      unitRef="U_USD">3822000</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350"
      decimals="-3"
      id="F_964ac4a6-ab6f-4c1c-b7a3-0e33a5f4ab7f"
      unitRef="U_USD">324337000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57"
      decimals="-3"
      id="F_2ddb9ac4-f312-401a-8cc3-300e2e8fe678"
      unitRef="U_USD">392826000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350"
      decimals="-3"
      id="F_61a9dd07-fa0e-4ebd-b1c2-c6665bc6d578"
      unitRef="U_USD">6758000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57"
      decimals="-3"
      id="F_1477580e-0292-4276-801b-f236b9d792bf"
      unitRef="U_USD">29785000</us-gaap:AccountsPayableCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350"
      decimals="-3"
      id="F_bc21fc04-1620-41e5-a633-752257b0ce84"
      unitRef="U_USD">3455000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57"
      decimals="-3"
      id="F_9ebdc8a2-2376-4bca-aaba-59ac96951d4b"
      unitRef="U_USD">284000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <pcvx:AccruedManufacturingExpenses
      contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350"
      decimals="-3"
      id="F_856263f9-aac5-4c91-a5f3-c2e61fad6757"
      unitRef="U_USD">4440000</pcvx:AccruedManufacturingExpenses>
    <pcvx:AccruedManufacturingExpenses
      contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57"
      decimals="-3"
      id="F_d5d00ae8-e747-410c-83ed-08b148682d15"
      unitRef="U_USD">13012000</pcvx:AccruedManufacturingExpenses>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350"
      decimals="-3"
      id="F_1031279b-b63c-4e60-a6f8-f745bd8b84d4"
      unitRef="U_USD">0</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57"
      decimals="-3"
      id="F_8a55ffa7-4976-4062-b2eb-0b54fc886f1c"
      unitRef="U_USD">677000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350"
      decimals="-3"
      id="F_34365d1a-a4cf-4639-85aa-041796db63fb"
      unitRef="U_USD">8787000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57"
      decimals="-3"
      id="F_57b2face-9bab-4a10-a3eb-9408ea955b3f"
      unitRef="U_USD">3766000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DeferredRentCreditCurrent
      contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57"
      decimals="-3"
      id="F_a8c3e152-503a-4479-bb86-eb9206424a7c"
      unitRef="U_USD">14000</us-gaap:DeferredRentCreditCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350"
      decimals="-3"
      id="F_ed5162a1-09b3-4db0-9e06-09e80457633e"
      unitRef="U_USD">5276000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350"
      decimals="-3"
      id="F_e3d1db6f-3a91-48ed-ad33-a43daf52ca84"
      unitRef="U_USD">28716000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57"
      decimals="-3"
      id="F_13270f4b-a2da-4b4c-a99e-76645c4ae515"
      unitRef="U_USD">46861000</us-gaap:LiabilitiesCurrent>
    <us-gaap:DeferredRentCreditNoncurrent
      contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57"
      decimals="-3"
      id="F_1e4a9fe2-716c-4895-9b4d-566a03cdb48e"
      unitRef="U_USD">10000</us-gaap:DeferredRentCreditNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350"
      decimals="-3"
      id="F_0b0a12fd-8c70-40e3-9e0d-f44f108a1894"
      unitRef="U_USD">11507000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350"
      decimals="-3"
      id="F_9fcb76a7-e28b-4a7c-8f44-cba526f0eaef"
      unitRef="U_USD">96000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57"
      decimals="-3"
      id="F_331c120c-8b14-4e54-805d-1a9d8a325cb2"
      unitRef="U_USD">112000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350"
      decimals="-3"
      id="F_33ecb619-0124-4712-bb29-9d712972aeaa"
      unitRef="U_USD">40319000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57"
      decimals="-3"
      id="F_87a412e6-9c82-4610-8543-8c128e4ad6a0"
      unitRef="U_USD">46983000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350"
      decimals="INF"
      id="F_0ccf69c7-5403-4c4f-97fe-63c6f4f06049"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57"
      decimals="INF"
      id="F_2b30f4cf-04ab-44de-8d73-e39d8223d09b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350"
      decimals="INF"
      id="F_1839fa5a-509f-415a-8dba-ee724ad71016"
      unitRef="U_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57"
      decimals="INF"
      id="F_f7aaad76-ee24-4322-9512-ed5ea1501053"
      unitRef="U_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350"
      decimals="INF"
      id="F_c0d73828-b884-4bd9-bc70-3476f299e5c0"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57"
      decimals="INF"
      id="F_e9101721-d002-44fb-9188-c24398fee5cf"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350"
      decimals="INF"
      id="F_e82e9dfc-f874-47e3-a7e9-b6ddc7a0a323"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57"
      decimals="INF"
      id="F_a6bd096e-6966-42d4-befb-40d28677ed7d"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350"
      decimals="INF"
      id="F_229d954f-1077-46f8-87d0-b45ca1ff2c8d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57"
      decimals="INF"
      id="F_c9f66b00-93cb-4643-b20e-3cb682ec357e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350"
      decimals="INF"
      id="F_48902fe8-a1a0-4c08-a55c-a7eda1af5e19"
      unitRef="U_shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57"
      decimals="INF"
      id="F_15385dca-2d5a-47ee-ba01-23f6e0cac7b5"
      unitRef="U_shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350"
      decimals="INF"
      id="F_9ab56d2a-8636-4eb3-8adf-d3404d71fa50"
      unitRef="U_shares">53031978</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350"
      decimals="INF"
      id="F_cbdf2005-f339-4ad8-ba04-d2823868e47b"
      unitRef="U_shares">53031978</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57"
      decimals="INF"
      id="F_39564e5f-9b64-400e-bb3e-eaf41f645653"
      unitRef="U_shares">51071593</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57"
      decimals="INF"
      id="F_b2f54f97-b4b7-4be2-824b-d9c5b88bca3f"
      unitRef="U_shares">51071593</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350"
      decimals="-3"
      id="F_0e2ec2c8-1d09-48f3-a89c-30a49ccf3d42"
      unitRef="U_USD">56000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57"
      decimals="-3"
      id="F_1f593dd8-94c9-4550-bdfb-72ddc2d47e88"
      unitRef="U_USD">54000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350"
      decimals="-3"
      id="F_f93abd5c-b1e7-45c8-bfeb-f6a748d78ee7"
      unitRef="U_USD">582844000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57"
      decimals="-3"
      id="F_9a3900b1-c3dc-431d-a817-49f447bb2d2d"
      unitRef="U_USD">544353000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350"
      decimals="-3"
      id="F_1a4a9204-5a95-4a25-a7fe-5e389915f8fe"
      unitRef="U_USD">-241000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350"
      decimals="-3"
      id="F_68291ef0-cb3c-4ef0-bb1c-ba469dab88e0"
      unitRef="U_USD">-298641000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57"
      decimals="-3"
      id="F_1268865e-87d9-44ef-a174-8cba176bbf70"
      unitRef="U_USD">-198564000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350"
      decimals="-3"
      id="F_d21c5bb8-5b45-4f7a-a4d9-3183a665af05"
      unitRef="U_USD">284018000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57"
      decimals="-3"
      id="F_c4ab8663-1afc-4549-b307-d8c5b98a5ad9"
      unitRef="U_USD">345843000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350"
      decimals="-3"
      id="F_4e50edb9-d5ed-4968-b338-23aaa217a5a4"
      unitRef="U_USD">324337000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57"
      decimals="-3"
      id="F_8c1e137b-e130-446f-a8dd-e489127c0f62"
      unitRef="U_USD">392826000</us-gaap:LiabilitiesAndStockholdersEquity>
    <pcvx:ResearchAndDevelopmentExpenseToRelatedParty
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      decimals="-3"
      id="F_b164fe37-39fd-4548-aac3-93cdbef88a77"
      unitRef="U_USD">2359000</pcvx:ResearchAndDevelopmentExpenseToRelatedParty>
    <pcvx:ResearchAndDevelopmentExpenseToRelatedParty
      contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001"
      decimals="-3"
      id="F_a266715a-e513-4450-b304-0957eb49d158"
      unitRef="U_USD">1331000</pcvx:ResearchAndDevelopmentExpenseToRelatedParty>
    <pcvx:ResearchAndDevelopmentExpenseToRelatedParty
      contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700"
      decimals="-3"
      id="F_b58bc85c-b3ed-4e5e-94c0-620123908ac7"
      unitRef="U_USD">1137000</pcvx:ResearchAndDevelopmentExpenseToRelatedParty>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      decimals="-3"
      id="F_c82621c6-6a33-4f50-9101-8001bb98dbf1"
      unitRef="U_USD">78411000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001"
      decimals="-3"
      id="F_900c83d1-2428-4030-8e37-2bd3a9617ab0"
      unitRef="U_USD">73564000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700"
      decimals="-3"
      id="F_2fb046d4-84ab-433d-a1d0-a7fde59478b1"
      unitRef="U_USD">45607000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      decimals="-3"
      id="F_8042bfd8-3bf2-42b6-97ff-286017c5b73c"
      unitRef="U_USD">25259000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001"
      decimals="-3"
      id="F_b8f8f04f-83e5-427f-852a-6dd254c257c5"
      unitRef="U_USD">16017000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700"
      decimals="-3"
      id="F_3e4d4db0-241c-43a3-a884-122502d8cea3"
      unitRef="U_USD">8546000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      decimals="-3"
      id="F_6d0cda2d-036a-49cb-a3a2-098a3eb653a0"
      unitRef="U_USD">103670000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001"
      decimals="-3"
      id="F_c5a4ab2c-c2e4-401d-ac44-67608e4df565"
      unitRef="U_USD">89581000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700"
      decimals="-3"
      id="F_19a021eb-bf2a-42bc-86f4-c521700fa244"
      unitRef="U_USD">54153000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      decimals="-3"
      id="F_770828f2-4885-4fdb-8166-42e20187d183"
      unitRef="U_USD">-103670000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001"
      decimals="-3"
      id="F_0ef15b63-9bc3-4e12-a574-5d58dc6b6d13"
      unitRef="U_USD">-89581000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700"
      decimals="-3"
      id="F_8fe8f1ca-a7ef-4fe3-89ea-80a1472129f6"
      unitRef="U_USD">-54153000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      decimals="-3"
      id="F_47f6ed6c-bd57-4ce6-897d-04ff3fdd3d35"
      unitRef="U_USD">7000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001"
      decimals="-3"
      id="F_05037412-cb6b-4294-9f85-309423342dc7"
      unitRef="U_USD">7000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700"
      decimals="-3"
      id="F_782aaab3-d2ff-4b2a-8248-2169a9d9f5d4"
      unitRef="U_USD">40000</us-gaap:InterestExpense>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      decimals="-3"
      id="F_11a14156-97b6-4987-84ad-a095bcb37d57"
      unitRef="U_USD">344000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001"
      decimals="-3"
      id="F_04081cb2-a59f-43dc-9649-b8385dea2785"
      unitRef="U_USD">244000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700"
      decimals="-3"
      id="F_7edc7922-db1e-4964-9b70-7ec2d89ed4a3"
      unitRef="U_USD">632000</us-gaap:InvestmentIncomeInterest>
    <pcvx:GrantIncome
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      decimals="-3"
      id="F_f007c07d-9ee0-4c5f-aca1-69fa08dfc5a0"
      unitRef="U_USD">1585000</pcvx:GrantIncome>
    <pcvx:GrantIncome
      contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001"
      decimals="-3"
      id="F_3a017cc1-44c7-45d8-9c19-90b4974fe6b7"
      unitRef="U_USD">2478000</pcvx:GrantIncome>
    <pcvx:GrantIncome
      contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700"
      decimals="-3"
      id="F_0ad7317b-2a3b-4aa7-96d4-78372fd9c75d"
      unitRef="U_USD">237000</pcvx:GrantIncome>
    <us-gaap:MarketableSecuritiesRealizedGainLoss
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      decimals="-3"
      id="F_958fbe32-d579-428f-b415-09c83ff6218b"
      unitRef="U_USD">2000</us-gaap:MarketableSecuritiesRealizedGainLoss>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      decimals="-3"
      id="F_764d8f7b-09b9-46e1-8a85-f462b7e5c930"
      unitRef="U_USD">1669000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001"
      decimals="-3"
      id="F_fdcf6918-234a-45f1-a94b-632ae0d0e6d8"
      unitRef="U_USD">-2351000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700"
      decimals="-3"
      id="F_10123a84-b089-48a8-93ed-07620e285a0f"
      unitRef="U_USD">-135000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <pcvx:ChangeInFairValueOfRedeemableConvertiblePreferredStock
      contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700"
      decimals="-3"
      id="F_f883e162-3b80-43e3-83fc-e4f24581e0dc"
      unitRef="U_USD">3185000</pcvx:ChangeInFairValueOfRedeemableConvertiblePreferredStock>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      decimals="-3"
      id="F_bf79e5ed-2287-4c1a-bbd0-dfd20c9e8750"
      unitRef="U_USD">3593000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001"
      decimals="-3"
      id="F_aec72341-4dd9-4c72-b358-5c06b5714206"
      unitRef="U_USD">364000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700"
      decimals="-3"
      id="F_e62e44e4-f9d7-4cf5-852d-cb32de09b716"
      unitRef="U_USD">3879000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      decimals="-3"
      id="F_378268c4-4e6b-4a6d-a6c1-06cde227a6da"
      unitRef="U_USD">-100077000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001"
      decimals="-3"
      id="F_eee13a05-aad5-481e-a1b2-0a0910c5d240"
      unitRef="U_USD">-89217000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700"
      decimals="-3"
      id="F_e8582e9e-f77a-4c86-a21c-b4b46d521285"
      unitRef="U_USD">-50274000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      decimals="2"
      id="F_a9bda523-330c-48a7-b9c5-7f05e77562eb"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.93</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001"
      decimals="2"
      id="F_3056c494-1897-48f3-9c41-eb965312ec56"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-3.02</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700"
      decimals="2"
      id="F_c8205e43-2cc0-4eb4-9744-8947eca98054"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-13.25</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      decimals="0"
      id="F_0302b519-885c-4a85-8d30-84787f65441d"
      unitRef="U_shares">51922108</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001"
      decimals="0"
      id="F_eadcc953-b7a4-4538-9e4d-70a5bdb0ee13"
      unitRef="U_shares">29545810</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700"
      decimals="0"
      id="F_aafa83c9-783b-4611-a7d4-eba51e898ce6"
      unitRef="U_shares">3795090</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:NetIncomeLoss
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      decimals="-3"
      id="F_6ab94a14-1f88-4090-bed1-b305bdb9496c"
      unitRef="U_USD">-100077000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001"
      decimals="-3"
      id="F_292405df-dc02-4785-a542-e09bf8d914a8"
      unitRef="U_USD">-89217000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700"
      decimals="-3"
      id="F_115aa1b8-b395-4f15-9a9e-ca8e9ddf1278"
      unitRef="U_USD">-50274000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      decimals="-3"
      id="F_da5ffd8c-6e5a-48fa-bbe1-f9539af8382b"
      unitRef="U_USD">-241000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      decimals="-3"
      id="F_d056145a-ba8d-4920-a212-99a4409f850e"
      unitRef="U_USD">-100318000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001"
      decimals="-3"
      id="F_c2a51c32-e5f8-41bb-a7f8-13130d39f420"
      unitRef="U_USD">-89217000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700"
      decimals="-3"
      id="F_13526dfc-28ad-4ed7-ab2d-3627c3af4a48"
      unitRef="U_USD">-50274000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_ace47527-5c7b-43a0-97fe-7ef235c9ad0c"
      decimals="INF"
      id="F_3f5e4c87-a518-4bb4-88f6-7b9cb32fdf85"
      unitRef="U_shares">6225719</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_ace47527-5c7b-43a0-97fe-7ef235c9ad0c"
      decimals="-3"
      id="F_ebfda047-92b9-4c4a-a2e2-f42312470b90"
      unitRef="U_USD">24967000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_e62d86e5-c312-474f-99a0-95ed9692529c"
      decimals="INF"
      id="F_4f7b8ec7-7c51-4f12-b923-669ef229e657"
      unitRef="U_shares">6786896</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_e62d86e5-c312-474f-99a0-95ed9692529c"
      decimals="-3"
      id="F_a7cb9afd-5c5d-474e-a8fe-347095acf077"
      unitRef="U_USD">55151000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_0a0e42fe-11ad-487e-b9de-014ca00c2d28"
      decimals="INF"
      id="F_183ddd63-5e34-4e91-9f06-de5cfc753bca"
      unitRef="U_shares">3688740</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_0a0e42fe-11ad-487e-b9de-014ca00c2d28"
      decimals="-3"
      id="F_1ec879ff-e6ab-45e5-ba4c-77a377b28e8f"
      unitRef="U_USD">37692000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="C_dd29e038-bfb3-4788-9620-c38deb43178e"
      decimals="INF"
      id="F_0afced7b-fc65-40c1-9a8b-aa699722e18d"
      unitRef="U_shares">3757403</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_dd29e038-bfb3-4788-9620-c38deb43178e"
      decimals="-3"
      id="F_32417ec8-d3d1-462f-9081-73cc9afb0bf6"
      unitRef="U_USD">6000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_7b1cec7a-d004-403e-8a42-ef595588ed48"
      decimals="-3"
      id="F_6286cd56-108c-40e3-a2e0-2f50c8708a85"
      unitRef="U_USD">1339000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_cb2a9833-f2d5-4d07-9f84-e6fd7b138b95"
      decimals="-3"
      id="F_2d2cae9a-2b0a-4c1d-a409-fbec376cbe9e"
      unitRef="U_USD">-59073000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_ecccdfb9-edd1-45a3-8445-0fe8b2f43253"
      decimals="-3"
      id="F_334dc0dc-43a8-46fc-91c4-d505ba31e6f2"
      unitRef="U_USD">-57728000</us-gaap:StockholdersEquity>
    <pcvx:TemporaryEquityStockIssuanceCosts
      contextRef="C_c0fb1076-a7db-464d-8c21-b64e5bc453db"
      decimals="-3"
      id="F_cf5a29c3-bf3a-4e29-91ef-776342faa566"
      unitRef="U_USD">0</pcvx:TemporaryEquityStockIssuanceCosts>
    <pcvx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="C_c0fb1076-a7db-464d-8c21-b64e5bc453db"
      decimals="INF"
      id="F_0d768f61-4a5c-4efb-8678-e4800f009da9"
      unitRef="U_shares">3688740</pcvx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="C_c0fb1076-a7db-464d-8c21-b64e5bc453db"
      decimals="-3"
      id="F_dbedca6e-ace8-42a9-8539-ecfa64fb3039"
      unitRef="U_USD">42500000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_08f2ab18-3ec2-4bf6-a856-11d6f22d4790"
      decimals="INF"
      id="F_13ae9837-b42d-4d18-aaf9-7bab402fc0c7"
      unitRef="U_shares">243230</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_08f2ab18-3ec2-4bf6-a856-11d6f22d4790"
      decimals="-3"
      id="F_c7421904-f9a8-49f2-8d15-13220f3cd0e7"
      unitRef="U_USD">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_68dac7ff-d423-43b1-b2cb-fbeb2182a939"
      decimals="-3"
      id="F_32279676-535a-4c3f-acec-52d409752f14"
      unitRef="U_USD">321000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700"
      decimals="-3"
      id="F_b6f873f0-ae57-4267-9fa0-4f9edbe47976"
      unitRef="U_USD">322000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <pcvx:StockIssuedDuringPeriodSharesIssuanceOfCommonStockRelatedToEarlyExercisedStockOptions
      contextRef="C_08f2ab18-3ec2-4bf6-a856-11d6f22d4790"
      decimals="INF"
      id="F_d19b1c57-b65d-4bd9-b99b-c5196c761392"
      unitRef="U_shares">59276</pcvx:StockIssuedDuringPeriodSharesIssuanceOfCommonStockRelatedToEarlyExercisedStockOptions>
    <pcvx:AdjustmentsToAdditionalPaidInCapitalVestingOfEarlyExercisedStockOptions
      contextRef="C_68dac7ff-d423-43b1-b2cb-fbeb2182a939"
      decimals="-3"
      id="F_424b771d-9f17-452b-a2ce-5a2db9631b6a"
      unitRef="U_USD">122000</pcvx:AdjustmentsToAdditionalPaidInCapitalVestingOfEarlyExercisedStockOptions>
    <pcvx:AdjustmentsToAdditionalPaidInCapitalVestingOfEarlyExercisedStockOptions
      contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700"
      decimals="-3"
      id="F_6bcee000-4003-484f-8db8-018cf63d6677"
      unitRef="U_USD">122000</pcvx:AdjustmentsToAdditionalPaidInCapitalVestingOfEarlyExercisedStockOptions>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_68dac7ff-d423-43b1-b2cb-fbeb2182a939"
      decimals="-3"
      id="F_4a980031-61f1-4960-96ca-65d6d6e3ac21"
      unitRef="U_USD">1185000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700"
      decimals="-3"
      id="F_a3fb83ae-d526-440c-94f6-7346fca4e3f0"
      unitRef="U_USD">1185000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="C_3800b858-6c6b-4793-98cb-f7bb3ff61062"
      decimals="-3"
      id="F_cec7b3c4-e920-44fe-b02a-2ee4adcd8148"
      unitRef="U_USD">-50274000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700"
      decimals="-3"
      id="F_77bec903-c3e8-4b24-bbff-c7c3426b5532"
      unitRef="U_USD">-50274000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_3ab55850-7a59-4321-b335-f0ca2fe76524"
      decimals="INF"
      id="F_98039019-f3aa-4b9d-b034-31e6b7d727da"
      unitRef="U_shares">6225719</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_3ab55850-7a59-4321-b335-f0ca2fe76524"
      decimals="-3"
      id="F_d496f040-6108-4ca8-bb8a-863904067dce"
      unitRef="U_USD">24967000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_7ef0af11-3445-4e12-816a-b2d4849a786e"
      decimals="INF"
      id="F_c126b376-551d-4296-b760-bbcb395fb78a"
      unitRef="U_shares">6786896</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_7ef0af11-3445-4e12-816a-b2d4849a786e"
      decimals="-3"
      id="F_8d86f832-00c3-47e4-9616-4b3c974b95f7"
      unitRef="U_USD">55151000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_b1ab0ed1-080d-4ff7-adaf-245dff15e8dc"
      decimals="INF"
      id="F_104cc953-ce3e-47dd-a4d6-681205652ecb"
      unitRef="U_shares">7377480</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_b1ab0ed1-080d-4ff7-adaf-245dff15e8dc"
      decimals="-3"
      id="F_726c9bbd-1e09-448b-bc81-155492953902"
      unitRef="U_USD">80192000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="C_4d6eec73-41eb-4eea-8812-cd5a564af773"
      decimals="INF"
      id="F_fa6d0bc6-5979-4be8-8b0b-a9d6ac262155"
      unitRef="U_shares">4059909</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_4d6eec73-41eb-4eea-8812-cd5a564af773"
      decimals="-3"
      id="F_d350de91-5afb-44df-9180-5a8ab04e9128"
      unitRef="U_USD">7000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_8bc7d2ce-bbce-48ac-9b6a-f09c04733362"
      decimals="-3"
      id="F_50422dab-f9f3-4b03-b57d-0fe00472c820"
      unitRef="U_USD">2967000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_17a1e23b-77b7-43b4-b889-deab67e04a69"
      decimals="-3"
      id="F_a7564015-e7ac-4790-ac4e-b7416f5e7aab"
      unitRef="U_USD">-109347000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_871fe4ad-8a52-4dc5-a523-876ef5a1de6d"
      decimals="-3"
      id="F_5f42271f-56bf-4386-b9e8-2a90c3489c04"
      unitRef="U_USD">-106373000</us-gaap:StockholdersEquity>
    <pcvx:TemporaryEquityStockIssuanceCosts
      contextRef="C_006c2037-6bba-4d3a-bcd7-32b71e7a5475"
      decimals="-3"
      id="F_ab41a75d-d703-49a7-bbd0-2ec19debe15e"
      unitRef="U_USD">121000</pcvx:TemporaryEquityStockIssuanceCosts>
    <pcvx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="C_006c2037-6bba-4d3a-bcd7-32b71e7a5475"
      decimals="INF"
      id="F_1e074a42-9c9d-4120-87ca-47f58a08d48c"
      unitRef="U_shares">8220242</pcvx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="C_006c2037-6bba-4d3a-bcd7-32b71e7a5475"
      decimals="-3"
      id="F_307b5d95-8a85-4d3c-902e-ff7dd2b65f43"
      unitRef="U_USD">109879000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <pcvx:TemporaryEquityConversionOfPreferredStockShares
      contextRef="C_b663ddb0-dc3a-4405-9809-183e08d4aa14"
      decimals="INF"
      id="F_808c79df-2655-4359-a632-b2f8ef58749f"
      unitRef="U_shares">-6225719</pcvx:TemporaryEquityConversionOfPreferredStockShares>
    <pcvx:TemporaryEquityConversionOfPreferredStockValue
      contextRef="C_b663ddb0-dc3a-4405-9809-183e08d4aa14"
      decimals="-3"
      id="F_319ce2b3-7a00-4a8a-b91f-67257a3977d1"
      unitRef="U_USD">-24967000</pcvx:TemporaryEquityConversionOfPreferredStockValue>
    <pcvx:TemporaryEquityConversionOfPreferredStockShares
      contextRef="C_6c03f021-f6d5-4fb2-b776-94bc1a86aa1d"
      decimals="INF"
      id="F_8203376f-1b8f-4014-87cd-d30dfd3c78fd"
      unitRef="U_shares">-6786896</pcvx:TemporaryEquityConversionOfPreferredStockShares>
    <pcvx:TemporaryEquityConversionOfPreferredStockValue
      contextRef="C_6c03f021-f6d5-4fb2-b776-94bc1a86aa1d"
      decimals="-3"
      id="F_7aa3ba47-9d81-4bfb-a5e0-744aeac0829c"
      unitRef="U_USD">-55151000</pcvx:TemporaryEquityConversionOfPreferredStockValue>
    <pcvx:TemporaryEquityConversionOfPreferredStockShares
      contextRef="C_432334ae-bbb2-42ed-9170-56253d99b097"
      decimals="INF"
      id="F_416fb78b-b598-4a83-a05b-04e7bf778dfb"
      unitRef="U_shares">-7377480</pcvx:TemporaryEquityConversionOfPreferredStockShares>
    <pcvx:TemporaryEquityConversionOfPreferredStockValue
      contextRef="C_432334ae-bbb2-42ed-9170-56253d99b097"
      decimals="-3"
      id="F_50ffa91e-1826-421e-ae2a-d6d6648ca8b2"
      unitRef="U_USD">-80192000</pcvx:TemporaryEquityConversionOfPreferredStockValue>
    <pcvx:TemporaryEquityConversionOfPreferredStockShares
      contextRef="C_006c2037-6bba-4d3a-bcd7-32b71e7a5475"
      decimals="INF"
      id="F_5d6a554b-d17a-41bd-a152-4aaa8e23c05f"
      unitRef="U_shares">-8220242</pcvx:TemporaryEquityConversionOfPreferredStockShares>
    <pcvx:TemporaryEquityConversionOfPreferredStockValue
      contextRef="C_006c2037-6bba-4d3a-bcd7-32b71e7a5475"
      decimals="-3"
      id="F_a85fb25f-3c60-430b-b888-ad64afd5dc9d"
      unitRef="U_USD">-109879000</pcvx:TemporaryEquityConversionOfPreferredStockValue>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="C_372ee990-ff50-459b-90f9-d45574ce4c70"
      decimals="INF"
      id="F_c7e5338f-f377-4307-b3ae-697128efa425"
      unitRef="U_shares">28610337</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <pcvx:TemporaryEquityConversionOfPreferredStockValue
      contextRef="C_372ee990-ff50-459b-90f9-d45574ce4c70"
      decimals="-3"
      id="F_8cb2c697-68f8-4507-963a-7a695a820a48"
      unitRef="U_USD">29000</pcvx:TemporaryEquityConversionOfPreferredStockValue>
    <pcvx:TemporaryEquityConversionOfPreferredStockValue
      contextRef="C_c1debaa3-dafc-4806-a41b-60a0b5a5aa1c"
      decimals="-3"
      id="F_60703189-89e4-41e3-8486-4a58d391d47e"
      unitRef="U_USD">270161000</pcvx:TemporaryEquityConversionOfPreferredStockValue>
    <pcvx:TemporaryEquityConversionOfPreferredStockValue
      contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001"
      decimals="-3"
      id="F_f12a76d8-aebb-4ad3-bd2f-be0ec591e8d3"
      unitRef="U_USD">270190000</pcvx:TemporaryEquityConversionOfPreferredStockValue>
    <pcvx:StockIssuedDuringPeriodSharesConversionOfCommonStockWarrant
      contextRef="C_372ee990-ff50-459b-90f9-d45574ce4c70"
      decimals="INF"
      id="F_7f3a61cd-e31c-4f26-ba1f-9b5b085fe917"
      unitRef="U_shares">30278</pcvx:StockIssuedDuringPeriodSharesConversionOfCommonStockWarrant>
    <pcvx:StockIssuedDuringPeriodSharesConversionOfPreferredStockWarrant
      contextRef="C_372ee990-ff50-459b-90f9-d45574ce4c70"
      decimals="INF"
      id="F_65a2bf53-6cec-41b8-8242-0e3d8d189d1b"
      unitRef="U_shares">16591</pcvx:StockIssuedDuringPeriodSharesConversionOfPreferredStockWarrant>
    <pcvx:AdjustmentsToAdditionalPaidInCapitalWarrantLiabilityWriteOff
      contextRef="C_c1debaa3-dafc-4806-a41b-60a0b5a5aa1c"
      decimals="-3"
      id="F_b514ac26-8cc6-4701-8f57-2d3f84facedd"
      unitRef="U_USD">629000</pcvx:AdjustmentsToAdditionalPaidInCapitalWarrantLiabilityWriteOff>
    <pcvx:AdjustmentsToAdditionalPaidInCapitalWarrantLiabilityWriteOff
      contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001"
      decimals="-3"
      id="F_6a302e72-fc6c-4a00-9c2e-052ac90834fe"
      unitRef="U_USD">629000</pcvx:AdjustmentsToAdditionalPaidInCapitalWarrantLiabilityWriteOff>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="C_bc281be7-82b8-4ef6-9792-0543c76c1a35"
      decimals="-3"
      id="F_f7f2031f-a90b-4757-ab19-d08d241b4f80"
      unitRef="U_USD">3368000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_bc281be7-82b8-4ef6-9792-0543c76c1a35"
      decimals="INF"
      id="F_f103b0d1-a628-427d-a900-0f44caa7df2b"
      unitRef="U_shares">17968750</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_bc281be7-82b8-4ef6-9792-0543c76c1a35"
      decimals="-3"
      id="F_53be5461-3481-47df-85d0-4d06a83384c5"
      unitRef="U_USD">18000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_a4d7b89e-0ab9-4f03-8b01-723510464ce9"
      decimals="-3"
      id="F_8428c0d1-37ff-407d-a2e2-789987305576"
      unitRef="U_USD">263989000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001"
      decimals="-3"
      id="F_41721498-4e02-431b-9f4f-94b6c7ded664"
      unitRef="U_USD">264007000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_372ee990-ff50-459b-90f9-d45574ce4c70"
      decimals="INF"
      id="F_47ecdbe8-12b8-4aa3-9861-a32ed519316b"
      unitRef="U_shares">343444</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_c1debaa3-dafc-4806-a41b-60a0b5a5aa1c"
      decimals="-3"
      id="F_aa3d0c52-5955-4a2d-87eb-a5f09f93a231"
      unitRef="U_USD">635000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001"
      decimals="-3"
      id="F_0fadc214-c2d3-4cec-a890-c56ece87d06a"
      unitRef="U_USD">635000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <pcvx:StockIssuedDuringPeriodSharesIssuanceOfCommonStockRelatedToEarlyExercisedStockOptions
      contextRef="C_372ee990-ff50-459b-90f9-d45574ce4c70"
      decimals="INF"
      id="F_052e5c48-3ef7-44bd-9e2a-6579d32019d8"
      unitRef="U_shares">14819</pcvx:StockIssuedDuringPeriodSharesIssuanceOfCommonStockRelatedToEarlyExercisedStockOptions>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_372ee990-ff50-459b-90f9-d45574ce4c70"
      decimals="INF"
      id="F_c3ca576c-9a35-4169-a8cd-fb1252b201a9"
      unitRef="U_shares">27465</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_c1debaa3-dafc-4806-a41b-60a0b5a5aa1c"
      decimals="-3"
      id="F_54beaa39-3c19-4e61-aab0-448d9ac8f292"
      unitRef="U_USD">374000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001"
      decimals="-3"
      id="F_511cf1c3-7b6e-4912-a620-8b514c76ddc7"
      unitRef="U_USD">374000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <pcvx:AdjustmentsToAdditionalPaidInCapitalVestingOfEarlyExercisedStockOptions
      contextRef="C_c1debaa3-dafc-4806-a41b-60a0b5a5aa1c"
      decimals="-3"
      id="F_7806dff2-9f57-42c7-bd04-10f06909deb1"
      unitRef="U_USD">164000</pcvx:AdjustmentsToAdditionalPaidInCapitalVestingOfEarlyExercisedStockOptions>
    <pcvx:AdjustmentsToAdditionalPaidInCapitalVestingOfEarlyExercisedStockOptions
      contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001"
      decimals="-3"
      id="F_f9d7f7ee-28c8-4e28-9fac-94a03adc0a34"
      unitRef="U_USD">164000</pcvx:AdjustmentsToAdditionalPaidInCapitalVestingOfEarlyExercisedStockOptions>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_c1debaa3-dafc-4806-a41b-60a0b5a5aa1c"
      decimals="-3"
      id="F_8ae60f65-c757-4e34-8ddf-c80c85f2f1ab"
      unitRef="U_USD">5434000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001"
      decimals="-3"
      id="F_1259b563-040f-46bb-880b-3151d254b8fe"
      unitRef="U_USD">5434000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="C_b5f3713d-ecd4-4700-a7ab-db89f5c2d1ac"
      decimals="-3"
      id="F_1097e618-d46e-4b41-b353-c7c0682271a9"
      unitRef="U_USD">-89217000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001"
      decimals="-3"
      id="F_342e46d8-72e1-4ceb-8a37-125458e461fa"
      unitRef="U_USD">-89217000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_b350157c-7c7f-42a0-b645-149c360d1819"
      decimals="INF"
      id="F_bb82fbd3-8388-455c-b978-534a125f9675"
      unitRef="U_shares">51071593</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_b350157c-7c7f-42a0-b645-149c360d1819"
      decimals="-3"
      id="F_00663899-3fc0-435a-9aab-eee48bdbd449"
      unitRef="U_USD">54000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_914c8ff3-3cf5-4419-8e2f-0309464abc71"
      decimals="-3"
      id="F_9f942718-5f76-44e0-b96c-97906eb6abc8"
      unitRef="U_USD">544353000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_de000bd8-7fd0-42f8-8b81-fc098f2cc14e"
      decimals="-3"
      id="F_79c1c8cd-d342-4461-ad53-a99424b3e94c"
      unitRef="U_USD">-198564000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57"
      decimals="-3"
      id="F_a4bd3f42-8d43-40a4-ae76-eef3fd522969"
      unitRef="U_USD">345843000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_542495c1-8a9f-4d28-9179-f5c599d02e73"
      decimals="INF"
      id="F_220a9e82-7a3e-4128-bd19-f5a832576ccf"
      unitRef="U_shares">931114</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_11d04721-6c5e-451c-9f8c-b386520e079e"
      decimals="-3"
      id="F_97c41976-dfeb-4a8a-a3c5-2ed31f641f97"
      unitRef="U_USD">3012000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      decimals="-3"
      id="F_a7101494-cb67-491d-afc8-bc35d53f7250"
      unitRef="U_USD">3012000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="C_542495c1-8a9f-4d28-9179-f5c599d02e73"
      decimals="INF"
      id="F_9f604c5f-8260-440d-a2b1-6df391b22b76"
      unitRef="U_shares">399680</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="C_542495c1-8a9f-4d28-9179-f5c599d02e73"
      decimals="-3"
      id="F_d1d71218-bb46-4ac0-a0db-1255c18337a6"
      unitRef="U_USD">1000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="C_11d04721-6c5e-451c-9f8c-b386520e079e"
      decimals="-3"
      id="F_60fb513e-db07-4b56-881d-c6a612e9c8e9"
      unitRef="U_USD">10000000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      decimals="-3"
      id="F_b8a0536b-d21c-4a49-a021-dd95524fdd0e"
      unitRef="U_USD">10001000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="C_132d316b-36f4-4e18-bf45-5543bb58c44e"
      decimals="-3"
      id="F_d56cde00-1542-4df0-8634-d0e8e9243cca"
      unitRef="U_USD">479000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_2a5c2eff-6ddb-4c32-9bd6-9e0d20b2a11f"
      decimals="INF"
      id="F_9bba787d-8bec-468f-93e0-ca8c5350ef9b"
      unitRef="U_shares">567045</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_2a5c2eff-6ddb-4c32-9bd6-9e0d20b2a11f"
      decimals="-3"
      id="F_a84a1354-9cf8-4fc0-b37b-67c99f434309"
      unitRef="U_USD">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_bef847b3-ad94-49aa-ac4c-cf8f492446d7"
      decimals="-3"
      id="F_8430ffa7-3e78-4430-aa84-83a4d9bfa04a"
      unitRef="U_USD">13846000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      decimals="-3"
      id="F_b5a5dbb3-4270-4e87-a7bf-3a408837d2e5"
      unitRef="U_USD">13847000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_542495c1-8a9f-4d28-9179-f5c599d02e73"
      decimals="INF"
      id="F_e72b2309-2137-4dfe-8781-df6be74d0515"
      unitRef="U_shares">62546</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_11d04721-6c5e-451c-9f8c-b386520e079e"
      decimals="-3"
      id="F_57dc9bef-ac53-4282-bdc0-b6f0772715c5"
      unitRef="U_USD">888000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      decimals="-3"
      id="F_9816bb7a-2c1e-4fe0-afdb-8aa864c159b8"
      unitRef="U_USD">888000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <pcvx:AdjustmentsToAdditionalPaidInCapitalVestingOfEarlyExercisedStockOptions
      contextRef="C_11d04721-6c5e-451c-9f8c-b386520e079e"
      decimals="-3"
      id="F_424ef8f6-714f-4e3e-b260-ccb2b2e1652b"
      unitRef="U_USD">16000</pcvx:AdjustmentsToAdditionalPaidInCapitalVestingOfEarlyExercisedStockOptions>
    <pcvx:AdjustmentsToAdditionalPaidInCapitalVestingOfEarlyExercisedStockOptions
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      decimals="-3"
      id="F_529ceca8-c876-41fe-9f03-54845dca28de"
      unitRef="U_USD">16000</pcvx:AdjustmentsToAdditionalPaidInCapitalVestingOfEarlyExercisedStockOptions>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_11d04721-6c5e-451c-9f8c-b386520e079e"
      decimals="-3"
      id="F_99800816-3bc1-47e8-87f5-5218b2c37e7b"
      unitRef="U_USD">10729000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      decimals="-3"
      id="F_e55dafee-e0f9-42af-8edd-cb038fd8df3a"
      unitRef="U_USD">10729000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_1d403ed3-f3ea-41fc-ab8b-8b842982729a"
      decimals="-3"
      id="F_3275a663-4b43-4b41-a1f9-4b84e65950cd"
      unitRef="U_USD">-241000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      decimals="-3"
      id="F_4db89783-83e3-4940-a684-5092fd5d6df5"
      unitRef="U_USD">-241000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="C_84b31ec6-25e1-4d4b-9f94-c4046b727e6f"
      decimals="-3"
      id="F_9d6b40c3-86ce-400c-a601-84e24eec2dab"
      unitRef="U_USD">-100077000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      decimals="-3"
      id="F_edcf51e3-1163-41e1-b455-7b0c34cef82c"
      unitRef="U_USD">-100077000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_b3bc61ea-4f75-41e4-81f8-73c18aff2f6f"
      decimals="INF"
      id="F_d278cd81-03c6-450f-848e-4c5ebe78730e"
      unitRef="U_shares">53031978</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_b3bc61ea-4f75-41e4-81f8-73c18aff2f6f"
      decimals="-3"
      id="F_b0307f50-e00a-43d2-a208-9f7a3ac2f11c"
      unitRef="U_USD">56000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_3d9566a8-97e9-4ae9-937d-c604f1218434"
      decimals="-3"
      id="F_09e86a14-433b-412c-89dc-64c743c9a915"
      unitRef="U_USD">582844000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_a129b41f-99aa-4150-b52d-3b8433ceb5ee"
      decimals="-3"
      id="F_28a20750-f643-4ed0-b59c-e180ab13b03a"
      unitRef="U_USD">-298641000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_9ed4a1bc-93ea-4d6c-a3a2-fe0ee49c92a6"
      decimals="-3"
      id="F_6d5bd3ea-2ffe-4832-9746-6a904a4e18a1"
      unitRef="U_USD">-241000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350"
      decimals="-3"
      id="F_1bade322-7ee7-4ba1-a345-ceca53bf69b0"
      unitRef="U_USD">284018000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      decimals="-3"
      id="F_52707c85-2bdd-42ec-bc9a-f316bd5985aa"
      unitRef="U_USD">-100077000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001"
      decimals="-3"
      id="F_25cf2b4c-eaba-4c63-9d5f-13c624853b8b"
      unitRef="U_USD">-89217000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700"
      decimals="-3"
      id="F_60c0c6a7-052f-4d35-992f-4bb435866da3"
      unitRef="U_USD">-50274000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      decimals="-3"
      id="F_709c666f-121d-43eb-b1da-c4aa85a68ed5"
      unitRef="U_USD">1800000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001"
      decimals="-3"
      id="F_5857369f-c2b1-4777-9efd-5a659122aea7"
      unitRef="U_USD">1405000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700"
      decimals="-3"
      id="F_bc06616b-e3a4-41a2-9a08-455a2bdba6fd"
      unitRef="U_USD">1232000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      decimals="-3"
      id="F_78e0f2b9-8aec-4c2d-b28f-491832936f37"
      unitRef="U_USD">10729000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001"
      decimals="-3"
      id="F_43c9d821-1ef9-4fe2-a66e-917f27e97edf"
      unitRef="U_USD">5434000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700"
      decimals="-3"
      id="F_396dc78c-d2fb-44ee-bc0f-d7aa5948805c"
      unitRef="U_USD">1185000</us-gaap:ShareBasedCompensation>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001"
      decimals="-3"
      id="F_ca4d6491-c05c-4cda-804a-e4e535e74507"
      unitRef="U_USD">179000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700"
      decimals="-3"
      id="F_573c18f8-d9a8-4fb1-8f5b-d78a78e16266"
      unitRef="U_USD">-12000</us-gaap:FairValueAdjustmentOfWarrants>
    <pcvx:ChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheLiabilities
      contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700"
      decimals="-3"
      id="F_637bdc1e-5535-4486-aebc-44877411ae0e"
      unitRef="U_USD">3185000</pcvx:ChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheLiabilities>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      decimals="-3"
      id="F_91e3144a-053b-439c-91b1-ccb7b531ab15"
      unitRef="U_USD">-97000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001"
      decimals="-3"
      id="F_533e6fa6-333f-4914-ad0e-a0682d343cf1"
      unitRef="U_USD">-34000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700"
      decimals="-3"
      id="F_c41a55b7-20dd-4f2f-9767-ed353cb0629a"
      unitRef="U_USD">-1000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:AssetImpairmentCharges
      contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001"
      decimals="-3"
      id="F_8d6c030c-bab6-42a5-8662-ca140f60de15"
      unitRef="U_USD">267000</us-gaap:AssetImpairmentCharges>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      decimals="-3"
      id="F_8a0f51d3-cc44-4f23-9a9f-b8a12d7c3025"
      unitRef="U_USD">1657000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      decimals="-3"
      id="F_69963e9e-98c5-492d-9c9e-c57d662d30b6"
      unitRef="U_USD">-1406000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      decimals="-3"
      id="F_d581f480-4f88-4139-a7b1-0fea6eafd04e"
      unitRef="U_USD">7369000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001"
      decimals="-3"
      id="F_873e7c2c-321a-4f28-8619-a3fd973784fb"
      unitRef="U_USD">58000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700"
      decimals="-3"
      id="F_849a8021-966f-47c4-8afc-096cea32a606"
      unitRef="U_USD">1070000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      decimals="-3"
      id="F_3c09e336-d419-47f5-9870-2aa37e81893f"
      unitRef="U_USD">3539000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001"
      decimals="-3"
      id="F_fa0f166d-9896-4abe-b7c4-860b9ed09eb1"
      unitRef="U_USD">75000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700"
      decimals="-3"
      id="F_6915ecc4-a98c-421f-8cb7-d50826af3c16"
      unitRef="U_USD">-120000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <pcvx:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      decimals="-3"
      id="F_c719fe0a-ad69-44a6-87d4-d80150de531d"
      unitRef="U_USD">12856000</pcvx:IncreaseDecreaseInOperatingLeaseLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      decimals="-3"
      id="F_acb62528-ea5f-4c4d-bb50-82da8a0044e0"
      unitRef="U_USD">-12470000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001"
      decimals="-3"
      id="F_158bab57-946d-4fb7-b197-bc326244fac8"
      unitRef="U_USD">26102000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700"
      decimals="-3"
      id="F_4a68493f-4c6b-48bc-8dad-59a68f947e39"
      unitRef="U_USD">868000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <pcvx:IncreaseDecreaseInAccruedCompensation
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      decimals="-3"
      id="F_3df3effa-d709-4fc8-8cc8-eb89a12c9829"
      unitRef="U_USD">3170000</pcvx:IncreaseDecreaseInAccruedCompensation>
    <pcvx:IncreaseDecreaseInAccruedCompensation
      contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001"
      decimals="-3"
      id="F_2a79b633-4ae2-41e2-b102-4a3e28cdac85"
      unitRef="U_USD">-130000</pcvx:IncreaseDecreaseInAccruedCompensation>
    <pcvx:IncreaseDecreaseInAccruedCompensation
      contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700"
      decimals="-3"
      id="F_05beb491-fee5-4058-92ef-56630500466c"
      unitRef="U_USD">-775000</pcvx:IncreaseDecreaseInAccruedCompensation>
    <pcvx:IncreaseDecreaseInAccruedManufacturingExpenses
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      decimals="-3"
      id="F_3eb8a0ad-168a-4b3c-a691-e5390e750de9"
      unitRef="U_USD">-8572000</pcvx:IncreaseDecreaseInAccruedManufacturingExpenses>
    <pcvx:IncreaseDecreaseInAccruedManufacturingExpenses
      contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001"
      decimals="-3"
      id="F_06057de6-a869-4cea-9481-920e86c26805"
      unitRef="U_USD">7235000</pcvx:IncreaseDecreaseInAccruedManufacturingExpenses>
    <pcvx:IncreaseDecreaseInAccruedManufacturingExpenses
      contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700"
      decimals="-3"
      id="F_bd25c2d6-2868-41c7-9a8b-5d18089829fb"
      unitRef="U_USD">3970000</pcvx:IncreaseDecreaseInAccruedManufacturingExpenses>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      decimals="-3"
      id="F_c181d58c-fb8c-458f-9341-07ccb6d4f926"
      unitRef="U_USD">4631000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001"
      decimals="-3"
      id="F_67a1913e-be39-4dc2-9c54-b289a960d190"
      unitRef="U_USD">2207000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700"
      decimals="-3"
      id="F_a4864083-3a40-4287-abdf-47e06759267b"
      unitRef="U_USD">718000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <pcvx:IncreaseDecreaseInDeferredRentAndOtherLongTermLiabilities
      contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001"
      decimals="-3"
      id="F_17ffd693-33ed-4599-b135-36bfc7f68e4b"
      unitRef="U_USD">-11000</pcvx:IncreaseDecreaseInDeferredRentAndOtherLongTermLiabilities>
    <pcvx:IncreaseDecreaseInDeferredRentAndOtherLongTermLiabilities
      contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700"
      decimals="-3"
      id="F_8b11f050-8749-4f15-adb6-0f3841c3e068"
      unitRef="U_USD">77000</pcvx:IncreaseDecreaseInDeferredRentAndOtherLongTermLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      decimals="-3"
      id="F_cf991aa0-87ec-4d00-b685-1a78c9bcdb18"
      unitRef="U_USD">-121393000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001"
      decimals="-3"
      id="F_23cf52d7-d333-481b-9152-6c0172035153"
      unitRef="U_USD">-46628000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700"
      decimals="-3"
      id="F_5b6ab3d2-2936-43b2-bb95-c814769aca2a"
      unitRef="U_USD">-47145000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      decimals="-3"
      id="F_dc50a0d3-bac5-476d-9d5e-3e25b2c02625"
      unitRef="U_USD">6555000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001"
      decimals="-3"
      id="F_de9b4902-7e92-424e-9788-1df2b178aecd"
      unitRef="U_USD">1155000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700"
      decimals="-3"
      id="F_5da822e3-a325-4f6c-9277-8b5ae8c719fe"
      unitRef="U_USD">1195000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      decimals="-3"
      id="F_dc8cae9e-0b82-4aed-8a9f-6d346031a78e"
      unitRef="U_USD">336341000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      decimals="-3"
      id="F_aea719ad-4c2a-4b54-a2d9-155975ca95f5"
      unitRef="U_USD">100500000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      decimals="-3"
      id="F_e044a594-9e53-47a2-bbfb-f47023283675"
      unitRef="U_USD">30062000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      decimals="-3"
      id="F_f95b30bf-e4d6-46be-a87b-83d31a18da77"
      unitRef="U_USD">26000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001"
      decimals="-3"
      id="F_5085e6f0-28d5-4f9a-b168-dc1f5ebfe8c9"
      unitRef="U_USD">50000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      decimals="-3"
      id="F_3ee7085c-4c4c-4978-8b09-9767f99d7e14"
      unitRef="U_USD">-212308000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001"
      decimals="-3"
      id="F_12273721-4c69-4737-aea6-698612c38453"
      unitRef="U_USD">-1105000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700"
      decimals="-3"
      id="F_e8c17aa4-4972-450c-ba31-f7cc128e808e"
      unitRef="U_USD">-1195000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <pcvx:PaymentsOfCapitalLeaseObligations
      contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001"
      decimals="-3"
      id="F_c1e2148d-41c5-49b0-b417-633718c67790"
      unitRef="U_USD">61000</pcvx:PaymentsOfCapitalLeaseObligations>
    <pcvx:PaymentsOfCapitalLeaseObligations
      contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700"
      decimals="-3"
      id="F_441ba825-1038-4e3a-90aa-0ff6919560eb"
      unitRef="U_USD">278000</pcvx:PaymentsOfCapitalLeaseObligations>
    <pcvx:ProceedsFromInitialPublicOfferingNetOfUnderwritersCommissionsAndDiscounts
      contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001"
      decimals="-3"
      id="F_d8adc92d-4163-493a-b8b2-0f93b3c83aff"
      unitRef="U_USD">267375000</pcvx:ProceedsFromInitialPublicOfferingNetOfUnderwritersCommissionsAndDiscounts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001"
      decimals="-3"
      id="F_df0286df-7b58-4d1b-baa6-ba8bc17d78fb"
      unitRef="U_USD">3368000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
      contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001"
      decimals="-3"
      id="F_c6a2a39b-e785-45ae-afeb-6b15007f284c"
      unitRef="U_USD">109879000</us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock>
    <us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
      contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700"
      decimals="-3"
      id="F_8155a720-b871-4d6c-a0f2-c854b114f285"
      unitRef="U_USD">42500000</us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      decimals="-3"
      id="F_a1294109-5878-40fb-a847-8e8316679906"
      unitRef="U_USD">3012000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001"
      decimals="-3"
      id="F_017b7fad-77d2-4458-8eea-7f82f0ca415e"
      unitRef="U_USD">635000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700"
      decimals="-3"
      id="F_88ce900b-bf7e-4d94-8d6b-cfb62bf84934"
      unitRef="U_USD">322000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      decimals="-3"
      id="F_af16ff9a-ddb9-4fdd-9b74-605330d58a69"
      unitRef="U_USD">13896000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <pcvx:ProceedsFromIssuanceOfCommonStockRelatedToEarlyExercisedStockOptions
      contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001"
      decimals="-3"
      id="F_7b363fc1-4054-4a7c-a9ca-139d74c2c9f8"
      unitRef="U_USD">36000</pcvx:ProceedsFromIssuanceOfCommonStockRelatedToEarlyExercisedStockOptions>
    <pcvx:ProceedsFromIssuanceOfCommonStockRelatedToEarlyExercisedStockOptions
      contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700"
      decimals="-3"
      id="F_6dbfaf5f-1b9a-4b8a-9238-85acf3f58808"
      unitRef="U_USD">120000</pcvx:ProceedsFromIssuanceOfCommonStockRelatedToEarlyExercisedStockOptions>
    <us-gaap:ProceedsFromStockPlans
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      decimals="-3"
      id="F_33a2cc2c-e296-47fd-8439-41c6ee3f93df"
      unitRef="U_USD">888000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001"
      decimals="-3"
      id="F_999756f5-4e0a-47f4-b260-a29ec5e8fc5c"
      unitRef="U_USD">374000</us-gaap:ProceedsFromStockPlans>
    <pcvx:PaymentOfDeferredOfferingCosts
      contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700"
      decimals="-3"
      id="F_83a2f0c6-880e-4416-b7a4-026dc704c8e5"
      unitRef="U_USD">1097000</pcvx:PaymentOfDeferredOfferingCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      decimals="-3"
      id="F_98173508-60dd-4dfa-9fc7-e97e1b908a48"
      unitRef="U_USD">17796000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001"
      decimals="-3"
      id="F_27f243b0-6186-47d0-a901-312df8c2a686"
      unitRef="U_USD">374870000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700"
      decimals="-3"
      id="F_1edd0618-e08b-41ea-aad5-e22c47d2d5ba"
      unitRef="U_USD">41567000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      decimals="-3"
      id="F_c90c6d91-1b26-4c90-a011-e02535d56d61"
      unitRef="U_USD">-439000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001"
      decimals="-3"
      id="F_9c070cf8-ff14-46c3-8d01-d7baa069e0d5"
      unitRef="U_USD">87000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700"
      decimals="-3"
      id="F_c2d8b125-e564-4fca-b9b3-a91a3bd8964d"
      unitRef="U_USD">-341000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      decimals="-3"
      id="F_d201115d-3387-4864-bc5f-a08bc5c78c79"
      unitRef="U_USD">-316344000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001"
      decimals="-3"
      id="F_6bdc6c0a-bf14-4ffd-9906-3ec9960c40a1"
      unitRef="U_USD">327224000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700"
      decimals="-3"
      id="F_e132e3fb-0905-4ab3-b257-70d4b07c4723"
      unitRef="U_USD">-7114000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57"
      decimals="-3"
      id="F_b252ab11-4b46-49f3-962c-87cb87f22baa"
      unitRef="U_USD">386200000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_871fe4ad-8a52-4dc5-a523-876ef5a1de6d"
      decimals="-3"
      id="F_737a565c-6a1c-4b4d-bab0-8654fd0ca5e7"
      unitRef="U_USD">58976000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_ecccdfb9-edd1-45a3-8445-0fe8b2f43253"
      decimals="-3"
      id="F_0edd3220-5dc7-4608-bc5c-753f96ccd41f"
      unitRef="U_USD">66090000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350"
      decimals="-3"
      id="F_85cb7bbf-efc1-436f-b495-f8c4b67f7759"
      unitRef="U_USD">69856000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57"
      decimals="-3"
      id="F_fc6ce99f-1131-4f8f-873e-e13fada124e9"
      unitRef="U_USD">386200000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_871fe4ad-8a52-4dc5-a523-876ef5a1de6d"
      decimals="-3"
      id="F_0368edda-9e76-42a8-a398-d88a38c98c99"
      unitRef="U_USD">58976000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      decimals="-3"
      id="F_f0528562-d7f0-4649-9677-73c7acf0fbfe"
      unitRef="U_USD">7000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001"
      decimals="-3"
      id="F_bf113c8f-94af-444c-9c11-cd59f495ebdc"
      unitRef="U_USD">7000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700"
      decimals="-3"
      id="F_16d03691-43c5-44bb-a1c1-62c08b5ba20b"
      unitRef="U_USD">40000</us-gaap:InterestPaidNet>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      decimals="-3"
      id="F_b2fce3c7-c5e4-4841-aaf6-09bf417f8bde"
      unitRef="U_USD">766000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001"
      decimals="-3"
      id="F_f0ef5901-68b6-4f1e-8f19-fdafbc1965b8"
      unitRef="U_USD">494000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700"
      decimals="-3"
      id="F_8985698d-b415-40eb-bb26-12ce4432c51b"
      unitRef="U_USD">21000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001"
      decimals="-3"
      id="F_f936dd37-000a-4e54-a985-8c11f580e9d0"
      unitRef="U_USD">270190000</us-gaap:ConversionOfStockAmountConverted1>
    <us-gaap:StockIssued1
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      decimals="-3"
      id="F_1e0989d9-1e5b-4517-8bd3-d50222d3aa1e"
      unitRef="U_USD">10001000</us-gaap:StockIssued1>
    <pcvx:DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses
      contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001"
      decimals="-3"
      id="F_d022c167-dceb-45bf-b967-1a9b67e2341f"
      unitRef="U_USD">134000</pcvx:DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses>
    <pcvx:DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses
      contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700"
      decimals="-3"
      id="F_7a6dbf0f-865c-4e3f-b684-068f0579e405"
      unitRef="U_USD">33000</pcvx:DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      id="F_85b7e3da-da55-4f96-810f-1d874a6cfc90">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;1. Company Organization and Nature of Business&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Vaxcyte, Inc. (&#x201c;we,&#x201d; &#x201c;us,&#x201d; &#x201c;the Company,&#x201d; or &#x201c;Vaxcyte&#x201d;), headquartered in San Carlos, California, was incorporated in the state of Delaware on November 27, 2013 as SutroVax, Inc. and we changed our name to Vaxcyte, Inc. on May 15, 2020. We are a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. We are developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. We are re-engineering the way highly complex vaccines are made through modern synthetic techniques, including advanced chemistry and the XpressCF cell-free protein synthesis platform, exclusively licensed from Sutro Biopharma, Inc. Unlike conventional cell-based approaches, our system for producing difficult-to-make proteins and antigens is intended to accelerate our ability to efficiently create and deliver high-fidelity vaccines with enhanced immunological benefits&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. Our pipeline includes pneumococcal conjugate vaccine (&#x201c;PCV&#x201d;) candidates that we believe are among the most broad-spectrum PCV candidates currently in development, targeting the approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; billion global pneumococcal vaccine market. Our lead vaccine candidate, VAX-24, is a 24-valent broad-spectrum investigational PCV being developed for the prevention of invasive pneumococcal disease, or IPD&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, and pneumonia. On January 6, 2022, we announced that the U.S. Food and Drug Administration, or FDA, cleared our investigational new drug, or IND, application for VAX-24 in adults. On February 23, 2022, we announced the initiation of our Phase 1/2 clinical proof-of-concept study in adults 18 to 64 years of age. We expect to announce topline safety, tolerability and immunogenicity results from this study by the end of 2022. Pending the successful completion of the Phase 1 portion of this study, we expect to begin enrollment in a separate Phase 2 study in healthy adults aged 65 and older and to announce topline safety, tolerability and immunogenicity results from this study in the first half of 2023. Subject to a pre-IND meeting with the FDA and the successful topline results of the Phase 1/2 proof-of-concept study in adults 18-64 years of age, we anticipate submitting a pediatric IND application to the FDA for VAX-24 in the first half of 2023. Our second PCV candidate, VAX-XP, leverages our scalable and modular platform and builds on the technical proof of concept established by VAX-24 and is designed to expand the breadth of coverage to greater than 30 strains without compromising immunogenicity due to carrier suppression. In addition to our PCV franchise, our pipeline includes VAX-A1, a novel conjugate vaccine candidate designed to prevent Group A Strep; VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis; and other discovery-stage programs. Our primary activities since incorporation have been to perform research and development, undertake preclinical studies and conduct manufacturing activities in support of our product development efforts; organize and staff the Company; establish our intellectual property portfolio; and raise capital to support and expand such activities.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Reverse Stock Split&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;On June 5, 2020, we filed a certificate of amendment to our amended and restated certificate of incorporation to effect a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;one-for-1.6870&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; reverse stock split of our issued and outstanding common stock, preferred stock, stock options and warrants effective on June 5, 2020. Accordingly, all share and per share amounts for all periods presented in the financial statements and notes thereto have been retroactively adjusted.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Initial Public Offering&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In June 2020, we completed an initial public offering (&#x201c;IPO&#x201d;) in which we issued and sold &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;17,968,750&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of common stock, including shares issued upon the exercise in full of the underwriters&#x2019; option to purchase &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,343,750&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; additional shares of common stock, at a public offering price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;16.00&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; per share. We received $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;264.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million in net proceeds, after deducting underwriting discounts and commissions of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;20.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and offering expenses of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Immediately prior to the completion of our IPO, all outstanding shares of redeemable convertible preferred stock were converted into &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;28,610,337&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of common stock. Subsequent to the completion of the IPO, there were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of redeemable convertible preferred stock outstanding.&lt;/span&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <pcvx:GlobalTargetRevenue
      contextRef="C_fddff65d-fa11-44de-96a6-5e8ce2f4167b"
      decimals="-9"
      id="F_f25b15d5-e50d-496d-89a6-d18e463e8bfb"
      unitRef="U_USD">7000000000</pcvx:GlobalTargetRevenue>
    <us-gaap:StockholdersEquityReverseStockSplit
      contextRef="C_196fbfec-2db3-415e-8c1d-7ba3ff662444"
      id="F_fb909b60-f8ae-47f4-88dd-45e63def7a75">one-for-1.6870</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_6c7d80da-3c5c-41d2-a3bf-0f29663df66e"
      decimals="INF"
      id="F_c5cc4bc7-4768-4552-a111-55ff591fc79e"
      unitRef="U_shares">17968750</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <pcvx:SharesIssuedUponFullExerciseOfUnderwritersOptionToPurchaseAdditionalShares
      contextRef="C_6c7d80da-3c5c-41d2-a3bf-0f29663df66e"
      decimals="INF"
      id="F_3ee8953a-6235-4bec-87e2-cd75fef713bf"
      unitRef="U_shares">2343750</pcvx:SharesIssuedUponFullExerciseOfUnderwritersOptionToPurchaseAdditionalShares>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_2fc259cf-825e-4ff9-9943-2f01c1a0937b"
      decimals="INF"
      id="F_2098ce2d-144a-4dec-ac63-42dff93ee02e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">16.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="C_decb2811-c318-46bf-b586-449b2cc7fa0b"
      decimals="-5"
      id="F_8a3e1985-6858-4fab-8007-3971fd875605"
      unitRef="U_USD">264000000.0</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <pcvx:PaymentsOfUnderwritingDiscountsAndCommissions
      contextRef="C_decb2811-c318-46bf-b586-449b2cc7fa0b"
      decimals="-5"
      id="F_af47377e-c115-4589-ab29-406df549dd81"
      unitRef="U_USD">20100000</pcvx:PaymentsOfUnderwritingDiscountsAndCommissions>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_decb2811-c318-46bf-b586-449b2cc7fa0b"
      decimals="-5"
      id="F_88126e79-0b51-4ad3-863c-0e23ed5ef6ec"
      unitRef="U_USD">3400000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="C_25f1f214-138d-4f58-8434-afe2e9883750"
      decimals="INF"
      id="F_b22f05f9-216d-433d-b7f4-87e9da713594"
      unitRef="U_shares">28610337</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_2bf194ae-c6b4-4264-b519-4608eda30c8d"
      decimals="INF"
      id="F_8eb80f4f-0ad8-4a1d-9f9b-9d54a44631c6"
      unitRef="U_shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      id="F_c16bb8bb-f8b1-4c5f-a638-d91b0862f46a">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Basis of Presentation and Summary of Significant Accounting Policies&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Basis of Presentation&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;These financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) and applicable rules and regulations of the Securities and Exchange Commission (&#x201c;SEC&#x201d;) regarding annual reporting. Certain changes in presentation were made in these financial statements as of and for the year ended December 31, 2019 to conform to the presentation as of and for the years ended December 31, 2021 and 2020.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Use of Estimates&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities at the date of the financial statements. On an ongoing basis, we evaluate our estimates and assumptions, including those related to stock-based compensation expense, accruals for certain research and development costs, the incremental borrowing rate, the valuation of deferred tax assets and income taxes. Management bases our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ materially from those estimates.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Concentration of Credit Risk and Other Risks and Uncertainties&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Financial instruments that potentially subject us to a concentration of credit risk consist primarily of cash and cash equivalents and investments. We invest in money market funds, U.S. Treasury securities, U.S. government agency securities, corporate debt, commercial paper and asset-backed securities. We maintain bank deposits in federally insured financial institutions and these deposits may exceed federally insured limits. We are exposed to credit risk in the event of a default by the financial institutions holding our cash and issuers of investments to the extent recorded on the balance sheets. Our investment policy limits investments to money market funds, certain types of debt securities issued by the U.S. Government and its agencies, corporate debt, commercial paper and asset-backed securities, and places restrictions on the credit ratings, maturities and concentration by type and issuer. We have not experienced any significant losses on our deposits of cash, cash equivalents or investments.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;We are subject to supplier concentration risk from our suppliers. We source our critical raw materials from a sole source supplier, Sutro Biopharma, Inc. (&#x201c;Sutro Biopharma&#x201d;). We also use one contract manufacturing organization (&#x201c;CMO&#x201d;), Lonza Ltd. (&#x201c;Lonza&#x201d;), to handle most of our manufacturing activities. If we were to experience disruptions in raw materials supplied by Sutro Biopharma, or in manufacturing activities at Lonza, we may experience significant delays in our product development timelines and may incur substantial costs to secure alternative sources of raw materials or manufacturing.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Our future results of operations involve a number of other risks and uncertainties. Factors that could affect our future operating results and cause actual results to vary materially from expectations include, but are not limited to: our early stages of clinical vaccine development; our ability to advance vaccine candidates into, and successfully complete, clinical trials on the timelines we project; our ability to adequately demonstrate sufficient safety and efficacy of our vaccine candidates; our ability to enroll subjects in our ongoing and future clinical trials; our ability to successfully manufacture and supply our vaccine candidates for clinical trials; our ability to obtain additional capital to finance our operations; our ability to obtain, maintain and protect our intellectual property rights; developments relating to our competitors and our industry, including competing vaccine candidates; general and market conditions; and other risks and uncertainties, including those more fully described in the &#x201c;Risk Factors&#x201d; section of this Annual Report on Form 10-K.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Segment and Geographical Information&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;We operate and manage our business as &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;one&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; reportable and operating segment. Our chief executive officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance. All of our long-lived assets are based in the United States. Long-lived assets are comprised of property and equipment.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Cash, Cash Equivalents and Restricted Cash&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;We consider all highly liquid investments purchased with original maturities of three months or less from the date of purchase to be cash and cash equivalents. Cash equivalents consist primarily of amounts invested in money market accounts and commercial paper and are stated at their fair values. Restricted cash consists of a standby letter of credit, which was issued in the first quarter of 2021, that serves as collateral for the lease agreement for our new corporate headquarters. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Cash, cash equivalents and restricted cash as reported within the statement of cash flows consisted of the following:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11.0pt;font-family:Calibri;"&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:37.584%;"/&gt;
          &lt;td style="width:6.553%;"/&gt;
          &lt;td style="width:1.371%;"/&gt;
          &lt;td style="width:15.494%;"/&gt;
          &lt;td style="width:0.696%;"/&gt;
          &lt;td style="width:2.195%;"/&gt;
          &lt;td style="width:1.371%;"/&gt;
          &lt;td style="width:15.376%;"/&gt;
          &lt;td style="width:0.696%;"/&gt;
          &lt;td style="width:2.195%;"/&gt;
          &lt;td style="width:1.371%;"/&gt;
          &lt;td style="width:14.402%;"/&gt;
          &lt;td style="width:0.696%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2019&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;68,985&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;386,200&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;58,976&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Restricted cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;871&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Cash, cash equivalents and restricted cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;69,856&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;386,200&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;58,976&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Investments&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Our investments have been classified and accounted for as available-for-sale securities. Our investments consist of U.S. Treasury securities, U.S. government agency securities, corporate debt, commercial paper and asset-backed securities. These securities are recorded on the balance sheets at fair value. Unrealized gains and losses on these securities are included as a separate component of accumulated other comprehensive loss. The cost of investment securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization and accretion are included in other income (expense), net. Realized gains and losses and declines in fair value judged to be other-than-temporary, if any, are also included in other income (expense), net. We evaluate securities for other-than-temporary impairment at the balance sheet date. Declines in fair value determined to be other-than-temporary are included in other income (expense), net. We classify our investments as short or long term primarily based on the remaining contractual maturity of the securities.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Deferred Offering Costs&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Deferred offering costs consist of fees and expenses incurred in connection with the sale of our common stock in equity transactions, including legal, accounting, printing and other issuance-related costs. Prior to the completion of equity transactions, deferred offering costs are included in Other assets on the balance sheet. In connection with and as of the closing of equity transactions, these costs are reclassified to Additional paid-in capital, representing a reduction to the gross proceeds. As of December 31, 2020, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million of IPO-related costs were included in the Additional paid-in capital line item on the balance sheet. As of December 31, 2021 and 2020, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million of deferred offering costs, respectively, were included in Other assets on the balance sheet.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Property and Equipment, Net&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Property and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_cdf000c4-3126-4076-a46e-14220371b9f3;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;three&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. Leasehold improvements are amortized over the shorter of the expected life or lease term. Repairs and maintenance expenditures, which are not considered improvements and do not extend the useful life of property and equipment, are expensed as incurred. When assets are retired or otherwise disposed of, the cost and related accumulated depreciation and amortization are removed from the balance sheet and the resulting gain or loss is reflected in the statements of operations in the period realized.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Under Financial Accounting Standards Board (FASB) Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2016-02, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Leases (Topic 842)&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; and its associated amendments (&#x201c;ASC 842&#x201d;), we determine if an arrangement is a lease at inception. In addition, we determine whether a lease meets the classification criteria of a finance or operating lease at the lease commencement date considering whether: (i) the lease transfers ownership of the underlying asset to the lessee at the end of the lease term; (ii) the lease grants the lessee an option to purchase the underlying asset that the lessee is reasonably certain to exercise; (iii) the lease term is for a major part of the remaining economic life of the underlying asset; (iv) the present value of the sum of the lease payments and residual value guaranteed by the lessee equals or exceeds substantially all of the fair value of the underlying asset; and (v) the underlying asset is such a specialized nature that it is expected to have no alternative use to the lessor at the end of the lease term. As of December 31, 2021, our lease population consisted of real estate operating leases. As of December 31, 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, we did &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;t have any finance leases.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Operating leases are included in Operating lease right-of-use (ROU) assets, Operating lease liabilities &#x2014; current and Operating lease liabilities &#x2014; long term in our balance sheet. ROU assets represent our right to use the underlying assets for the lease term and lease liabilities represent our obligation to make lease payments arising from the leases. Operating lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. In determining the present value of lease payments, if the rate implicit in the lease is not readily determinable, we use our incremental borrowing rate based on the information available at the lease commencement date. We determine the incremental borrowing rate based on an analysis of corporate bond yields with a credit rating similar to us. The determination of our incremental borrowing rate requires management judgment, including development of a synthetic credit rating and cost of debt, as we currently do not carry any debt. We believe that the estimates used in determining the incremental borrowing rate are reasonable based upon current facts and circumstances. Applying different judgment to the same facts and circumstances could yield a different incremental borrowing rate. The operating lease ROU assets also include adjustments for prepayments and accrued lease payments and exclude lease incentives. ROU assets and lease liabilities may include options to extend or terminate leases if it is reasonably certain that we will exercise such options. Lease payments which are fixed and determinable are amortized as rent and lease expense on a straight-line basis over the expected lease term. Variable lease costs, which are dependent on usage, a rate or index, including common area maintenance charges, are expensed as incurred. Lease agreements that include lease and non-lease components are accounted for as a single lease component. Lease agreements with non-cancelable terms of less than 12 months are not recorded on our balance sheets.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;We review long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparing the carrying amount to the future undiscounted net cash flows which the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured as the amount by which the carrying amount of the assets exceeds the projected discounted future net cash flows generated by the assets. There were $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; of impairments of long-lived assets during the years ended December 31, 2021, 2020 and 2019, respectively.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Fair Value Measurements&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. The carrying amounts of our financial instruments, including cash and cash equivalents, prepaid and other current assets, accounts payable, accrued expenses, and other liabilities, approximate fair value due to their short-term maturities. Prior to their automatic conversion upon our IPO in June 2020, the redeemable convertible preferred stock tranche liability and redeemable convertible preferred stock warrant were carried at fair value (see Note 3).&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Research and Development&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Research and development costs are expensed as incurred. Research and development costs include salaries, stock-based compensation and benefits for employees performing research and development activities, an allocation of facility and overhead expenses, expenses incurred under agreements with consultants, CMOs, contract research organizations (&#x201c;CROs&#x201d;) and investigative sites that conduct preclinical studies, other supplies and costs associated with product development efforts, preclinical activities and regulatory operations.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Accrued Research and Development&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;We have entered into various agreements with CROs and CMOs. Our research and development accruals, which include accrued manufacturing expenses, are estimated based on the level of services performed, progress of the studies, including the phase or completion of events, and contracted costs. The estimated costs of research and development services provided, but not yet invoiced, are included in accrued expenses on the balance sheet. If the actual timing of the performance of services or the level of effort varies from the original estimates, we will adjust the accrual accordingly. Payments made to CROs or CMOs under these arrangements in advance of the performance of the related services are recorded as prepaid expenses and other current assets until the services are rendered. To date, there have been no material differences between our estimates of such expenses and the amounts actually incurred.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;We account for income taxes using the asset and liability method. We recognize deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In evaluating the ability to recover our deferred income tax assets, we consider all available positive and negative evidence, including our operating results, ongoing tax planning and forecasts of future taxable income on a jurisdiction-by-jurisdiction basis. In the event we determine that we would be able to realize our deferred income tax assets in the future in excess of their net recorded amount, we would make an adjustment to the valuation allowance that would reduce the provision for income taxes. Conversely, in the event that all or part of the net deferred tax assets are determined not to be realizable in the future, an adjustment to the valuation allowance would be charged to earnings in the period when such determination is made. As of December 31, 2021 and 2020, we have recorded a full valuation allowance on our deferred tax assets.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Tax benefits related to uncertain tax positions are recognized when it is more likely than not that a tax position will be sustained during an audit. Interest and penalties related to unrecognized tax benefits are included within the provision for income tax.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Stock-Based Compensation Expense&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;For options granted to employees, non-employees, and directors, stock-based compensation is measured at grant date based on the fair value of the award. We determine the grant-date fair value of the options using the Black-Scholes option-pricing model. The grant-date fair value of awards is amortized over the employees&#x2019; requisite service period or the non-employees&#x2019; vesting period as the services are rendered. Forfeitures are accounted for as they occur. Additionally, our 2020 Employee Stock Purchase Plan is deemed to be a compensatory plan and is therefore included in stock-based compensation expense.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Comprehensive Loss&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Comprehensive loss includes net loss and other comprehensive loss for the period. Other comprehensive loss consists of unrealized loss on investments.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Foreign Currency Transactions&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Transactions denominated in foreign currencies are initially measured in U.S. dollars using the exchange rate on the date of the transaction. Foreign currency denominated monetary assets and liabilities are subsequently re-measured at the end of each reporting period using the exchange rate at that date, with the corresponding foreign currency transaction gain or loss recorded in the statements of operations and statements of cash flows. Nonmonetary assets and liabilities are not subsequently re-measured.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Net Loss Per Share&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Basic net loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common stock outstanding during the period, without consideration of potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common stock and potentially dilutive securities outstanding for the period. For purposes of the diluted net loss per share calculation, redeemable convertible preferred stock, redeemable convertible preferred stock warrant, common stock subject to repurchase, and stock options are considered to be potentially dilutive securities.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Basic and diluted net loss attributable to common stockholders per share is presented in conformity with the two-class method required for participating securities as the redeemable convertible preferred stock is considered a participating security. Our participating securities do not have a contractual obligation to share in our losses. As such, the net loss was attributed entirely to common stockholders. Because we have reported a net loss for all periods presented, diluted net loss per common share is the same as basic net loss per common share for those periods.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In February 2016, the FASB issued ASU 2016-02, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Leases (Topic 842)&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. ASU 2016-02 was subsequently amended by ASU 2018-01, ASU 2018-10, ASU 2018-11, ASU 2018-20, ASU 2019-01, ASU 2019-10 and ASU 2020-05, which the FASB issued in January 2018, July 2018, July 2018, December 2018, March 2019, November 2019 and June 2020, respectively (collectively, &#x201c;ASC 842&#x201d;). ASC 842 requires lessees to recognize leases on the balance sheet and disclose key information about leasing arrangements. The new standard establishes a ROU model that requires a lessee to recognize a ROU asset and a lease liability on the balance sheet for all leases with a term longer than 12 months. Under ASC 842, leases are classified as either finance leases or operating leases, with classification affecting the pattern and classification of expense recognition in the income statement.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;We &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;early adopted&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; the new standard effective &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;January 1, 2021&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; using the modified retrospective transition approach. Upon adoption on January 1, 2021, we recognized ROU assets and lease liabilities totaling $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, respectively, to reflect the present value of remaining lease payments under existing lease arrangements. The difference between the leased assets and lease liabilities represents the existing deferred rent liabilities balance resulting from historical straight-lining of operating leases for our facilities, which was reclassified upon adoption to reduce the measurement of the leased assets. The balance of our deferred rent liabilities, which was reclassified to reduce the ROU assets upon adoption, was &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;immaterial&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. We applied the modified retrospective transition approach and did not recast prior periods. Although we applied this approach, we did not have a cumulative effect adjustment to the opening balance of our retained deficit upon adoption. As permitted by the standard, we elected the transition practical expedient package, which among other things, allowed the carryforward of historical lease classifications. For additional details regarding the impact of adoption and disclosure, see Note 5, &#x201c;Leases,&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;" to our financial statements included in Part II, Item 8 of this Annual Report on Form 10-K.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In December 2019, the FASB issued ASU No. 2019-12, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Income Taxes (Topic 740)&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. The amendments in ASU 2019-12 simplify the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The amendments also improve consistent application of and simplify U.S. GAAP or other areas of Topic 740 by clarifying and amending existing guidance. The new standard was &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;effective&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; for us on &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;January 1, 2021&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; and for interim periods within 2021. The adoption of ASU 2019-12 &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;did not&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; have a material impact on our financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Recently Issued Accounting Pronouncements&#x2014;Not Yet Adopted&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In June 2016, the FASB issued ASU 2016-13, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Financial Instruments &#x2013; Credit Losses (Topic 326):&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Measurement of Credit Losses on Financial Instruments&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; and has subsequently issued related amendments, collectively referred to as &#x201c;Topic 326.&#x201d; Topic 326 requires that financial assets measured at amortized cost be presented at the net amount expected to be collected. The measurement of expected credit losses is based on historical experience, current conditions and reasonable and supportable forecasts that affect collectability. Topic 326 also eliminates the concept of &#x201c;other-than-temporary&#x201d; impairment when evaluating available-for-sale debt securities and instead focuses on determining whether any impairment is a result of a credit loss or other factors. An entity will recognize an allowance for credit losses on available-for-sale debt securities rather than an other-than-temporary impairment that reduces the cost basis of the investment. Topic 326 is effective for fiscal years beginning after December 15, 2022 and interim periods within those fiscal years. Early adoption is permitted. We are currently assessing the impact of this standard to our financial statements and related disclosures.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In November 2021, the FASB issued ASU 2021-10, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Government Assistance (Topic 832): Disclosure by Business Entities about Government Assistance, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;which &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;requires disclosures about transactions with a government entity that are accounted for by applying a grant or contribution accounting model by analogy to other accounting guidance, such as a grant model within International Accounting Standard 20, &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Accounting for Government Grants and Disclosure of Government Assistance&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, or Subtopic 958-605, &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Not-For-Profit Entities - Revenue Recognition&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. The required disclosures include (i) the nature of the transactions and the related accounting policy used to account for the transactions, (ii) the financial statement line items that are affected by the transactions and (iii) the significant terms and conditions of the transactions, including commitments and contingencies. This standard is effective for annual periods beginning after December 15, 2021, with early adoption and retrospective or prospective application permitted. This standard is effective for us on January 1, 2022 and only impacts annual financial statement footnote disclosures&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. In Note 11, "Funding Arrangement," to our financial statements included in Part II, Item 8 of this Annual Report on Form 10-K, we included disclosures on our cost-reimbursement research award from CARB-X. Therefore, we do not believe the adoption of this standard will have a material impact on our financial statements.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;    &lt;/span&gt;&lt;/p&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      id="F_1c83ca66-0145-4d7c-a445-57c59cf3130a">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Basis of Presentation&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;These financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) and applicable rules and regulations of the Securities and Exchange Commission (&#x201c;SEC&#x201d;) regarding annual reporting. Certain changes in presentation were made in these financial statements as of and for the year ended December 31, 2019 to conform to the presentation as of and for the years ended December 31, 2021 and 2020.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      id="F_93f98c27-6bdc-4860-b0b7-d25ecfb1bde9">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Use of Estimates&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities at the date of the financial statements. On an ongoing basis, we evaluate our estimates and assumptions, including those related to stock-based compensation expense, accruals for certain research and development costs, the incremental borrowing rate, the valuation of deferred tax assets and income taxes. Management bases our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ materially from those estimates.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      id="F_ab916493-314f-493f-82d1-1bf3cfc232b7">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Concentration of Credit Risk and Other Risks and Uncertainties&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Financial instruments that potentially subject us to a concentration of credit risk consist primarily of cash and cash equivalents and investments. We invest in money market funds, U.S. Treasury securities, U.S. government agency securities, corporate debt, commercial paper and asset-backed securities. We maintain bank deposits in federally insured financial institutions and these deposits may exceed federally insured limits. We are exposed to credit risk in the event of a default by the financial institutions holding our cash and issuers of investments to the extent recorded on the balance sheets. Our investment policy limits investments to money market funds, certain types of debt securities issued by the U.S. Government and its agencies, corporate debt, commercial paper and asset-backed securities, and places restrictions on the credit ratings, maturities and concentration by type and issuer. We have not experienced any significant losses on our deposits of cash, cash equivalents or investments.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;We are subject to supplier concentration risk from our suppliers. We source our critical raw materials from a sole source supplier, Sutro Biopharma, Inc. (&#x201c;Sutro Biopharma&#x201d;). We also use one contract manufacturing organization (&#x201c;CMO&#x201d;), Lonza Ltd. (&#x201c;Lonza&#x201d;), to handle most of our manufacturing activities. If we were to experience disruptions in raw materials supplied by Sutro Biopharma, or in manufacturing activities at Lonza, we may experience significant delays in our product development timelines and may incur substantial costs to secure alternative sources of raw materials or manufacturing.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Our future results of operations involve a number of other risks and uncertainties. Factors that could affect our future operating results and cause actual results to vary materially from expectations include, but are not limited to: our early stages of clinical vaccine development; our ability to advance vaccine candidates into, and successfully complete, clinical trials on the timelines we project; our ability to adequately demonstrate sufficient safety and efficacy of our vaccine candidates; our ability to enroll subjects in our ongoing and future clinical trials; our ability to successfully manufacture and supply our vaccine candidates for clinical trials; our ability to obtain additional capital to finance our operations; our ability to obtain, maintain and protect our intellectual property rights; developments relating to our competitors and our industry, including competing vaccine candidates; general and market conditions; and other risks and uncertainties, including those more fully described in the &#x201c;Risk Factors&#x201d; section of this Annual Report on Form 10-K.&lt;/span&gt;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      id="F_465dd04e-1bb8-4ab2-9065-2a8caf683b2a">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Segment and Geographical Information&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;We operate and manage our business as &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;one&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; reportable and operating segment. Our chief executive officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance. All of our long-lived assets are based in the United States. Long-lived assets are comprised of property and equipment.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      decimals="INF"
      id="F_9a1d2006-b9ef-4849-a6d2-5e0433ce2f2a"
      unitRef="U_Segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:NumberOfOperatingSegments
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      decimals="INF"
      id="F_a8d32114-e6f4-47c1-b01a-d5cb7c3c6c18"
      unitRef="U_Segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      id="F_800dc8d0-b561-475e-9fc6-134ed701314b">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Cash, Cash Equivalents and Restricted Cash&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;We consider all highly liquid investments purchased with original maturities of three months or less from the date of purchase to be cash and cash equivalents. Cash equivalents consist primarily of amounts invested in money market accounts and commercial paper and are stated at their fair values. Restricted cash consists of a standby letter of credit, which was issued in the first quarter of 2021, that serves as collateral for the lease agreement for our new corporate headquarters. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Cash, cash equivalents and restricted cash as reported within the statement of cash flows consisted of the following:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11.0pt;font-family:Calibri;"&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:37.584%;"/&gt;
          &lt;td style="width:6.553%;"/&gt;
          &lt;td style="width:1.371%;"/&gt;
          &lt;td style="width:15.494%;"/&gt;
          &lt;td style="width:0.696%;"/&gt;
          &lt;td style="width:2.195%;"/&gt;
          &lt;td style="width:1.371%;"/&gt;
          &lt;td style="width:15.376%;"/&gt;
          &lt;td style="width:0.696%;"/&gt;
          &lt;td style="width:2.195%;"/&gt;
          &lt;td style="width:1.371%;"/&gt;
          &lt;td style="width:14.402%;"/&gt;
          &lt;td style="width:0.696%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2019&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;68,985&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;386,200&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;58,976&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Restricted cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;871&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Cash, cash equivalents and restricted cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;69,856&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;386,200&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;58,976&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      id="F_24ebce15-4e4d-4ab2-95bd-3b6f737d3b26">&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Cash, cash equivalents and restricted cash as reported within the statement of cash flows consisted of the following:&lt;/span&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:37.584%;"/&gt;
          &lt;td style="width:6.553%;"/&gt;
          &lt;td style="width:1.371%;"/&gt;
          &lt;td style="width:15.494%;"/&gt;
          &lt;td style="width:0.696%;"/&gt;
          &lt;td style="width:2.195%;"/&gt;
          &lt;td style="width:1.371%;"/&gt;
          &lt;td style="width:15.376%;"/&gt;
          &lt;td style="width:0.696%;"/&gt;
          &lt;td style="width:2.195%;"/&gt;
          &lt;td style="width:1.371%;"/&gt;
          &lt;td style="width:14.402%;"/&gt;
          &lt;td style="width:0.696%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2019&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;68,985&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;386,200&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;58,976&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Restricted cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;871&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Cash, cash equivalents and restricted cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;69,856&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;386,200&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;58,976&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350"
      decimals="-3"
      id="F_daf624a8-422d-4709-90ab-ec493f794574"
      unitRef="U_USD">68985000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57"
      decimals="-3"
      id="F_957ce9ec-3d3d-4fda-a386-a23d96a77307"
      unitRef="U_USD">386200000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_871fe4ad-8a52-4dc5-a523-876ef5a1de6d"
      decimals="-3"
      id="F_54963adf-a1f0-4e01-9f4d-19432185f05e"
      unitRef="U_USD">58976000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash
      contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350"
      decimals="-3"
      id="F_2e828cd3-cb1c-49d9-a00a-b697a4c86ec8"
      unitRef="U_USD">871000</us-gaap:RestrictedCash>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350"
      decimals="-3"
      id="F_9b6e568b-eb71-49a0-a46f-f5af19bb894f"
      unitRef="U_USD">69856000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57"
      decimals="-3"
      id="F_3618a345-c318-4998-b3f3-064bd57b3280"
      unitRef="U_USD">386200000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_871fe4ad-8a52-4dc5-a523-876ef5a1de6d"
      decimals="-3"
      id="F_829a5969-eba5-4dde-b397-edca191b7911"
      unitRef="U_USD">58976000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InvestmentPolicyTextBlock
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      id="F_78e82fc6-96c1-49bb-b6ef-c257bef163db">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Investments&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Our investments have been classified and accounted for as available-for-sale securities. Our investments consist of U.S. Treasury securities, U.S. government agency securities, corporate debt, commercial paper and asset-backed securities. These securities are recorded on the balance sheets at fair value. Unrealized gains and losses on these securities are included as a separate component of accumulated other comprehensive loss. The cost of investment securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization and accretion are included in other income (expense), net. Realized gains and losses and declines in fair value judged to be other-than-temporary, if any, are also included in other income (expense), net. We evaluate securities for other-than-temporary impairment at the balance sheet date. Declines in fair value determined to be other-than-temporary are included in other income (expense), net. We classify our investments as short or long term primarily based on the remaining contractual maturity of the securities.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:DeferredChargesPolicyTextBlock
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      id="F_7f62f91f-e04e-49c0-a449-fac9737ec2e6">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Deferred Offering Costs&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Deferred offering costs consist of fees and expenses incurred in connection with the sale of our common stock in equity transactions, including legal, accounting, printing and other issuance-related costs. Prior to the completion of equity transactions, deferred offering costs are included in Other assets on the balance sheet. In connection with and as of the closing of equity transactions, these costs are reclassified to Additional paid-in capital, representing a reduction to the gross proceeds. As of December 31, 2020, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million of IPO-related costs were included in the Additional paid-in capital line item on the balance sheet. As of December 31, 2021 and 2020, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million of deferred offering costs, respectively, were included in Other assets on the balance sheet.&lt;/span&gt;&lt;/p&gt;</us-gaap:DeferredChargesPolicyTextBlock>
    <pcvx:InitialPublicOfferingRelatedCost
      contextRef="C_1e69b34d-5d84-4378-a6c6-3b4511d14d3c"
      decimals="-5"
      id="F_733b290b-825e-48d5-9682-201b6239205e"
      unitRef="U_USD">3400000</pcvx:InitialPublicOfferingRelatedCost>
    <us-gaap:DeferredOfferingCosts
      contextRef="C_d1a846f2-0595-4f2b-bfde-977270efb43f"
      decimals="-5"
      id="F_776f08a0-f2d3-46cb-88ff-d42fd1cf4d66"
      unitRef="U_USD">500000</us-gaap:DeferredOfferingCosts>
    <us-gaap:DeferredOfferingCosts
      contextRef="C_efd921fe-f258-4bca-8c80-5723ef551b43"
      decimals="-5"
      id="F_c5822c6e-2d2c-492f-8842-f9b494dee009"
      unitRef="U_USD">100000</us-gaap:DeferredOfferingCosts>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      id="F_49979e28-49e9-484c-a643-e7a2b1a82251">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Property and Equipment, Net&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Property and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_cdf000c4-3126-4076-a46e-14220371b9f3;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;three&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. Leasehold improvements are amortized over the shorter of the expected life or lease term. Repairs and maintenance expenditures, which are not considered improvements and do not extend the useful life of property and equipment, are expensed as incurred. When assets are retired or otherwise disposed of, the cost and related accumulated depreciation and amortization are removed from the balance sheet and the resulting gain or loss is reflected in the statements of operations in the period realized.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_68377845-3bf8-42a9-ba72-9a3b693b78a1"
      id="F_481f6030-095f-4417-925b-8ba0923f925a">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      id="F_245ee8d7-d89b-4301-b3ff-8a37e9a4ae54">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Under Financial Accounting Standards Board (FASB) Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2016-02, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Leases (Topic 842)&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; and its associated amendments (&#x201c;ASC 842&#x201d;), we determine if an arrangement is a lease at inception. In addition, we determine whether a lease meets the classification criteria of a finance or operating lease at the lease commencement date considering whether: (i) the lease transfers ownership of the underlying asset to the lessee at the end of the lease term; (ii) the lease grants the lessee an option to purchase the underlying asset that the lessee is reasonably certain to exercise; (iii) the lease term is for a major part of the remaining economic life of the underlying asset; (iv) the present value of the sum of the lease payments and residual value guaranteed by the lessee equals or exceeds substantially all of the fair value of the underlying asset; and (v) the underlying asset is such a specialized nature that it is expected to have no alternative use to the lessor at the end of the lease term. As of December 31, 2021, our lease population consisted of real estate operating leases. As of December 31, 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, we did &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;t have any finance leases.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Operating leases are included in Operating lease right-of-use (ROU) assets, Operating lease liabilities &#x2014; current and Operating lease liabilities &#x2014; long term in our balance sheet. ROU assets represent our right to use the underlying assets for the lease term and lease liabilities represent our obligation to make lease payments arising from the leases. Operating lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. In determining the present value of lease payments, if the rate implicit in the lease is not readily determinable, we use our incremental borrowing rate based on the information available at the lease commencement date. We determine the incremental borrowing rate based on an analysis of corporate bond yields with a credit rating similar to us. The determination of our incremental borrowing rate requires management judgment, including development of a synthetic credit rating and cost of debt, as we currently do not carry any debt. We believe that the estimates used in determining the incremental borrowing rate are reasonable based upon current facts and circumstances. Applying different judgment to the same facts and circumstances could yield a different incremental borrowing rate. The operating lease ROU assets also include adjustments for prepayments and accrued lease payments and exclude lease incentives. ROU assets and lease liabilities may include options to extend or terminate leases if it is reasonably certain that we will exercise such options. Lease payments which are fixed and determinable are amortized as rent and lease expense on a straight-line basis over the expected lease term. Variable lease costs, which are dependent on usage, a rate or index, including common area maintenance charges, are expensed as incurred. Lease agreements that include lease and non-lease components are accounted for as a single lease component. Lease agreements with non-cancelable terms of less than 12 months are not recorded on our balance sheets.&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <pcvx:NumberOfFinanceLease
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      decimals="INF"
      id="F_833db186-6396-4f00-a5fe-f207998b08c9"
      unitRef="U_Lease">0</pcvx:NumberOfFinanceLease>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      id="F_ef6f20e1-d123-43c7-aa33-b3a20688c208">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;We review long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparing the carrying amount to the future undiscounted net cash flows which the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured as the amount by which the carrying amount of the assets exceeds the projected discounted future net cash flows generated by the assets. There were $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; of impairments of long-lived assets during the years ended December 31, 2021, 2020 and 2019, respectively.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:AssetImpairmentCharges
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      decimals="-6"
      id="F_d62029a1-267a-4494-8d5b-dd53fb78fcaf"
      unitRef="U_USD">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001"
      decimals="-5"
      id="F_b48fa20f-838b-467a-ad92-6e030314b1b8"
      unitRef="U_USD">300000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700"
      decimals="-6"
      id="F_37cd30da-8004-4654-ad8c-0a926854dfc8"
      unitRef="U_USD">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      id="F_da416d19-87ef-46a3-842d-c7e96121827f">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Fair Value Measurements&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. The carrying amounts of our financial instruments, including cash and cash equivalents, prepaid and other current assets, accounts payable, accrued expenses, and other liabilities, approximate fair value due to their short-term maturities. Prior to their automatic conversion upon our IPO in June 2020, the redeemable convertible preferred stock tranche liability and redeemable convertible preferred stock warrant were carried at fair value (see Note 3).&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      id="F_746943db-7363-4ddb-aaff-89ed369a27f2">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Research and Development&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Research and development costs are expensed as incurred. Research and development costs include salaries, stock-based compensation and benefits for employees performing research and development activities, an allocation of facility and overhead expenses, expenses incurred under agreements with consultants, CMOs, contract research organizations (&#x201c;CROs&#x201d;) and investigative sites that conduct preclinical studies, other supplies and costs associated with product development efforts, preclinical activities and regulatory operations.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <pcvx:AccruedResearchAndDevelopmentPolicyTextBlock
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      id="F_9c020b41-fada-4906-aeb0-2f5bf420dcef">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Accrued Research and Development&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;We have entered into various agreements with CROs and CMOs. Our research and development accruals, which include accrued manufacturing expenses, are estimated based on the level of services performed, progress of the studies, including the phase or completion of events, and contracted costs. The estimated costs of research and development services provided, but not yet invoiced, are included in accrued expenses on the balance sheet. If the actual timing of the performance of services or the level of effort varies from the original estimates, we will adjust the accrual accordingly. Payments made to CROs or CMOs under these arrangements in advance of the performance of the related services are recorded as prepaid expenses and other current assets until the services are rendered. To date, there have been no material differences between our estimates of such expenses and the amounts actually incurred.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;</pcvx:AccruedResearchAndDevelopmentPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      id="F_e4684b36-b1b3-4622-9225-24ff9a20a0e9">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;We account for income taxes using the asset and liability method. We recognize deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In evaluating the ability to recover our deferred income tax assets, we consider all available positive and negative evidence, including our operating results, ongoing tax planning and forecasts of future taxable income on a jurisdiction-by-jurisdiction basis. In the event we determine that we would be able to realize our deferred income tax assets in the future in excess of their net recorded amount, we would make an adjustment to the valuation allowance that would reduce the provision for income taxes. Conversely, in the event that all or part of the net deferred tax assets are determined not to be realizable in the future, an adjustment to the valuation allowance would be charged to earnings in the period when such determination is made. As of December 31, 2021 and 2020, we have recorded a full valuation allowance on our deferred tax assets.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Tax benefits related to uncertain tax positions are recognized when it is more likely than not that a tax position will be sustained during an audit. Interest and penalties related to unrecognized tax benefits are included within the provision for income tax.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      id="F_34bcb014-b196-4b41-9b73-211da5573cd1">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Stock-Based Compensation Expense&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;For options granted to employees, non-employees, and directors, stock-based compensation is measured at grant date based on the fair value of the award. We determine the grant-date fair value of the options using the Black-Scholes option-pricing model. The grant-date fair value of awards is amortized over the employees&#x2019; requisite service period or the non-employees&#x2019; vesting period as the services are rendered. Forfeitures are accounted for as they occur. Additionally, our 2020 Employee Stock Purchase Plan is deemed to be a compensatory plan and is therefore included in stock-based compensation expense.&lt;/span&gt;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      id="F_9d54dd81-4485-464e-9744-22005575a748">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Comprehensive Loss&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Comprehensive loss includes net loss and other comprehensive loss for the period. Other comprehensive loss consists of unrealized loss on investments.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      id="F_bdf72b57-1cf1-4e0d-abb1-9acf0035b08e">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Foreign Currency Transactions&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Transactions denominated in foreign currencies are initially measured in U.S. dollars using the exchange rate on the date of the transaction. Foreign currency denominated monetary assets and liabilities are subsequently re-measured at the end of each reporting period using the exchange rate at that date, with the corresponding foreign currency transaction gain or loss recorded in the statements of operations and statements of cash flows. Nonmonetary assets and liabilities are not subsequently re-measured.&lt;/span&gt;&lt;/p&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      id="F_d3d501f8-20a3-4e93-a700-c8a9ceb946ab">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Net Loss Per Share&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Basic net loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common stock outstanding during the period, without consideration of potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common stock and potentially dilutive securities outstanding for the period. For purposes of the diluted net loss per share calculation, redeemable convertible preferred stock, redeemable convertible preferred stock warrant, common stock subject to repurchase, and stock options are considered to be potentially dilutive securities.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Basic and diluted net loss attributable to common stockholders per share is presented in conformity with the two-class method required for participating securities as the redeemable convertible preferred stock is considered a participating security. Our participating securities do not have a contractual obligation to share in our losses. As such, the net loss was attributed entirely to common stockholders. Because we have reported a net loss for all periods presented, diluted net loss per common share is the same as basic net loss per common share for those periods.&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      id="F_f5b79194-7c63-4782-83b4-44d54dfcfcdf">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In February 2016, the FASB issued ASU 2016-02, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Leases (Topic 842)&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. ASU 2016-02 was subsequently amended by ASU 2018-01, ASU 2018-10, ASU 2018-11, ASU 2018-20, ASU 2019-01, ASU 2019-10 and ASU 2020-05, which the FASB issued in January 2018, July 2018, July 2018, December 2018, March 2019, November 2019 and June 2020, respectively (collectively, &#x201c;ASC 842&#x201d;). ASC 842 requires lessees to recognize leases on the balance sheet and disclose key information about leasing arrangements. The new standard establishes a ROU model that requires a lessee to recognize a ROU asset and a lease liability on the balance sheet for all leases with a term longer than 12 months. Under ASC 842, leases are classified as either finance leases or operating leases, with classification affecting the pattern and classification of expense recognition in the income statement.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;We &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;early adopted&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; the new standard effective &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;January 1, 2021&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; using the modified retrospective transition approach. Upon adoption on January 1, 2021, we recognized ROU assets and lease liabilities totaling $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, respectively, to reflect the present value of remaining lease payments under existing lease arrangements. The difference between the leased assets and lease liabilities represents the existing deferred rent liabilities balance resulting from historical straight-lining of operating leases for our facilities, which was reclassified upon adoption to reduce the measurement of the leased assets. The balance of our deferred rent liabilities, which was reclassified to reduce the ROU assets upon adoption, was &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;immaterial&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. We applied the modified retrospective transition approach and did not recast prior periods. Although we applied this approach, we did not have a cumulative effect adjustment to the opening balance of our retained deficit upon adoption. As permitted by the standard, we elected the transition practical expedient package, which among other things, allowed the carryforward of historical lease classifications. For additional details regarding the impact of adoption and disclosure, see Note 5, &#x201c;Leases,&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;" to our financial statements included in Part II, Item 8 of this Annual Report on Form 10-K.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In December 2019, the FASB issued ASU No. 2019-12, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Income Taxes (Topic 740)&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. The amendments in ASU 2019-12 simplify the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The amendments also improve consistent application of and simplify U.S. GAAP or other areas of Topic 740 by clarifying and amending existing guidance. The new standard was &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;effective&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; for us on &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;January 1, 2021&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; and for interim periods within 2021. The adoption of ASU 2019-12 &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;did not&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; have a material impact on our financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Recently Issued Accounting Pronouncements&#x2014;Not Yet Adopted&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In June 2016, the FASB issued ASU 2016-13, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Financial Instruments &#x2013; Credit Losses (Topic 326):&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Measurement of Credit Losses on Financial Instruments&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; and has subsequently issued related amendments, collectively referred to as &#x201c;Topic 326.&#x201d; Topic 326 requires that financial assets measured at amortized cost be presented at the net amount expected to be collected. The measurement of expected credit losses is based on historical experience, current conditions and reasonable and supportable forecasts that affect collectability. Topic 326 also eliminates the concept of &#x201c;other-than-temporary&#x201d; impairment when evaluating available-for-sale debt securities and instead focuses on determining whether any impairment is a result of a credit loss or other factors. An entity will recognize an allowance for credit losses on available-for-sale debt securities rather than an other-than-temporary impairment that reduces the cost basis of the investment. Topic 326 is effective for fiscal years beginning after December 15, 2022 and interim periods within those fiscal years. Early adoption is permitted. We are currently assessing the impact of this standard to our financial statements and related disclosures.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In November 2021, the FASB issued ASU 2021-10, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Government Assistance (Topic 832): Disclosure by Business Entities about Government Assistance, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;which &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;requires disclosures about transactions with a government entity that are accounted for by applying a grant or contribution accounting model by analogy to other accounting guidance, such as a grant model within International Accounting Standard 20, &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Accounting for Government Grants and Disclosure of Government Assistance&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, or Subtopic 958-605, &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Not-For-Profit Entities - Revenue Recognition&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. The required disclosures include (i) the nature of the transactions and the related accounting policy used to account for the transactions, (ii) the financial statement line items that are affected by the transactions and (iii) the significant terms and conditions of the transactions, including commitments and contingencies. This standard is effective for annual periods beginning after December 15, 2021, with early adoption and retrospective or prospective application permitted. This standard is effective for us on January 1, 2022 and only impacts annual financial statement footnote disclosures&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. In Note 11, "Funding Arrangement," to our financial statements included in Part II, Item 8 of this Annual Report on Form 10-K, we included disclosures on our cost-reimbursement research award from CARB-X. Therefore, we do not believe the adoption of this standard will have a material impact on our financial statements.&lt;/span&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption
      contextRef="C_9cbe4e9e-74f9-4ec8-bf47-1d291c0aaf9d"
      id="F_5298e60d-1557-4711-bc27-c1012fbf07ad">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate
      contextRef="C_9cbe4e9e-74f9-4ec8-bf47-1d291c0aaf9d"
      id="F_50ed6908-2754-4221-8695-b32dc5b9700d">2021-01-01</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_a0171645-3dab-4282-933d-7e5fb2e8585a"
      decimals="-5"
      id="F_96b775de-97e2-407d-9bbb-ea345ad7f408"
      unitRef="U_USD">900000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_a0171645-3dab-4282-933d-7e5fb2e8585a"
      decimals="-5"
      id="F_8fd57376-d904-4dd8-9056-a31e260b2a69"
      unitRef="U_USD">900000</us-gaap:OperatingLeaseLiability>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect
      contextRef="C_9cbe4e9e-74f9-4ec8-bf47-1d291c0aaf9d"
      id="F_37928f93-0acb-49e9-b206-fa8043608651">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted
      contextRef="C_e3a2a9fa-a738-409d-96a4-c1ee8f7ecd25"
      id="F_ebc6cdeb-baa9-427b-b3dd-babf39e6994c">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate
      contextRef="C_e3a2a9fa-a738-409d-96a4-c1ee8f7ecd25"
      id="F_ac7ad31a-7acb-446d-9db6-0dbafa7a77b7">2021-01-01</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect
      contextRef="C_e3a2a9fa-a738-409d-96a4-c1ee8f7ecd25"
      id="F_3c8e5344-1dc3-4585-a714-e9cc6cc5ce4d">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      id="F_7e140b4c-ceba-45ea-9842-41c3556e665c">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;3. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Fair Value Measurements and Fair Value of Financial Instruments&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Assets and liabilities recorded at fair value on a recurring basis in the balance sheets, as well as assets and liabilities measured at fair value on a non-recurring basis or disclosed at fair value, are categorized based upon the level of judgment associated with inputs used to measure their fair values. The accounting guidance for fair value provides a framework for measuring fair value and requires certain disclosures about how fair value is determined. Fair value is defined as the price that would be received&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;upon the sale of an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. The accounting guidance also establishes a three-level valuation hierarchy that prioritizes the inputs to valuation techniques used to measure fair value based upon whether such inputs are observable or unobservable. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect market assumptions made by the reporting entity. The three-level hierarchy for the inputs to valuation techniques is briefly summarized as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Level 1&#x2014;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Level 2&#x2014;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Inputs are observable, unadjusted quoted prices in active markets for similar assets or liabilities, unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Level&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; 3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Unobservable inputs that are significant to the measurement of the fair value of the assets or liabilities that are supported by little or no market data.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability. Changes in the ability to observe valuation inputs may result in a reclassification of levels of certain securities within the fair value hierarchy. We recognize transfers into and out of levels within the fair value hierarchy in the period in which the actual event or change in circumstances that caused the transfer occurs.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Level 1 securities consist of highly liquid money market funds for which the carrying amounts approximate their fair values due to their short maturities. U.S. Treasury securities are valued using Level 1 inputs based on unadjusted, quoted prices in active markets that are observable at the measurement date for identical assets or liabilities. Level 2 securities, consisting of corporate debt, commercial paper, U.S. government agency securities and asset-backed securities, are measured based on other observable inputs, including broker or dealer quotations or alternative pricing sources. When quoted prices in active markets for identical assets or liabilities are not available, we rely on non-binding quotes from our investment managers, which are based on proprietary valuation models of independent pricing services. These models generally use inputs such as observable market data, quoted market prices for similar instruments or historical pricing trends of securities relative to our peers. To validate the fair value determinations provided by our investment managers, we review the pricing movement in the context of overall market trends and trading information from our investment managers. In addition, we assess the inputs and methods used in determining the fair value in order to determine the classification of securities in the fair value hierarchy. We had &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; Level 3 securities either as of December 31, 2021 or 2020.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;There were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; transfers within the hierarchies during the years ended December 31, 2&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;21 or 2020.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;We invested in money market funds as of December 31, 2020. In January 2021, we started to invest some of our funds in corporate debt, commercial paper, U.S. Treasury securities, U.S. government agency securities and asset-backed securities in addition to money market funds. &lt;/span&gt;&lt;span style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following tables set forth our financial instruments measured at fair value on a recurring basis by level within the fair value hierarchy at &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021 and 2020: &lt;/span&gt;&lt;/span&gt;&lt;span style=""/&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:28.362%;"/&gt;
        &lt;td style="width:13.565%;"/&gt;
        &lt;td style="width:6.799%;"/&gt;
        &lt;td style="width:1.231%;"/&gt;
        &lt;td style="width:9.272%;"/&gt;
        &lt;td style="width:0.6%;"/&gt;
        &lt;td style="width:2.227%;"/&gt;
        &lt;td style="width:1.231%;"/&gt;
        &lt;td style="width:9.272%;"/&gt;
        &lt;td style="width:0.6%;"/&gt;
        &lt;td style="width:1.831%;"/&gt;
        &lt;td style="width:1.242%;"/&gt;
        &lt;td style="width:8.608%;"/&gt;
        &lt;td style="width:0.835%;"/&gt;
        &lt;td style="width:2.099%;"/&gt;
        &lt;td style="width:1.231%;"/&gt;
        &lt;td style="width:10.396%;"/&gt;
        &lt;td style="width:0.6%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;"&gt;Fair Value&lt;br/&gt;Hierarchy Level&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;"&gt;Gross &lt;br/&gt;Unrealized Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;"&gt;Gross &lt;br/&gt;Unrealized Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;"&gt;Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Cash and cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;27,834&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;27,834&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;17,555&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;17,555&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;23,597&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;23,596&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:15.0pt;word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="margin-left:15.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Total cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;68,986&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;68,985&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Investments:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;45,290&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;73&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;45,217&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;61,941&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;22&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;61,919&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Corporate debt&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;58,498&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;74&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;58,424&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Asset backed securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;13,899&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;13,874&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;U.S. government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;24,714&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;46&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;24,668&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:15.0pt;word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="margin-left:15.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Total investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;204,342&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;240&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;204,102&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:15.0pt;word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="margin-left:15.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;273,328&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;241&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;273,087&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;"&gt;Fair Value&lt;br/&gt;Hierarchy Level&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;"&gt;Gross &lt;br/&gt;Unrealized Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;"&gt;Gross &lt;br/&gt;Unrealized Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;"&gt;Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Cash and cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;4,788&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;4,788&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;381,412&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;381,412&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;386,200&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;386,200&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following table presents the contractual maturities of our investments as of December 31, 2021 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:70.292%;"/&gt;
        &lt;td style="width:5.331%;"/&gt;
        &lt;td style="width:1.242%;"/&gt;
        &lt;td style="width:22.15%;"/&gt;
        &lt;td style="width:0.985%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Due in less than one year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;176,985&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Due in one to five years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;27,117&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;204,102&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <pcvx:NumberOfSecurities
      contextRef="C_2bbf4b2d-41ff-4ec4-b597-e8a5be645bc2"
      decimals="INF"
      id="F_49257dcd-07f8-458c-a2cb-1b0443551dad"
      unitRef="U_Security">0</pcvx:NumberOfSecurities>
    <pcvx:NumberOfSecurities
      contextRef="C_3276c9c1-bce8-4e37-a494-9cd61a385e5d"
      decimals="INF"
      id="F_ad5b9687-c14e-4d45-8832-b1f491dc7990"
      unitRef="U_Security">0</pcvx:NumberOfSecurities>
    <us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount
      contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57"
      decimals="INF"
      id="F_5d4088b7-50c9-4153-90ed-48cfd490678a"
      unitRef="U_USD">0</us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      decimals="INF"
      id="F_29d22e4f-bbcc-4e60-992d-2bbcdcdf0397"
      unitRef="U_USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3>
    <us-gaap:FairValueLiabilitiesLevel2ToLevel1TransfersAmount
      contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57"
      decimals="INF"
      id="F_b3378ec5-c6a9-49ed-a8ba-53cbd45d3895"
      unitRef="U_USD">0</us-gaap:FairValueLiabilitiesLevel2ToLevel1TransfersAmount>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      decimals="INF"
      id="F_e5785dd5-4a2f-46de-bc88-a90442149640"
      unitRef="U_USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
      contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001"
      decimals="INF"
      id="F_bb115f7a-e52f-41f2-8e1e-2a8491954ad4"
      unitRef="U_USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      decimals="INF"
      id="F_c4cc334e-8430-415d-8db5-fb0bde757777"
      unitRef="U_USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
      contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001"
      decimals="INF"
      id="F_466e8315-a63e-4ffb-98e8-12caa931fcd1"
      unitRef="U_USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      decimals="INF"
      id="F_d2d4c4f6-2a50-4e68-bf13-552e8f9fc4f4"
      unitRef="U_USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
      contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001"
      decimals="INF"
      id="F_6f7e8b97-b976-449c-9297-3f11c161bcba"
      unitRef="U_USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3>
    <us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount
      contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350"
      decimals="INF"
      id="F_cade8bb3-a476-417d-8577-30d97d5b2f1b"
      unitRef="U_USD">0</us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount>
    <us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount
      contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57"
      decimals="INF"
      id="F_8fcd926d-0d4a-4523-b669-c3ecbc639b37"
      unitRef="U_USD">0</us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount>
    <us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount
      contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350"
      decimals="INF"
      id="F_85215405-f3c9-47b5-8c89-d41a6b6dec76"
      unitRef="U_USD">0</us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount>
    <us-gaap:FairValueLiabilitiesLevel1ToLevel2TransfersAmount
      contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57"
      decimals="INF"
      id="F_db173fdf-ce40-4371-9c64-b30d405c1b58"
      unitRef="U_USD">0</us-gaap:FairValueLiabilitiesLevel1ToLevel2TransfersAmount>
    <us-gaap:FairValueLiabilitiesLevel1ToLevel2TransfersAmount
      contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350"
      decimals="INF"
      id="F_e72f18dd-63b1-44c7-9531-6ba4599e985d"
      unitRef="U_USD">0</us-gaap:FairValueLiabilitiesLevel1ToLevel2TransfersAmount>
    <us-gaap:FairValueLiabilitiesLevel2ToLevel1TransfersAmount
      contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350"
      decimals="INF"
      id="F_6702c762-8f30-43bf-8c95-b6fc445fdacf"
      unitRef="U_USD">0</us-gaap:FairValueLiabilitiesLevel2ToLevel1TransfersAmount>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
      contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001"
      decimals="INF"
      id="F_4f43d3dc-a230-46c6-ba56-67e0548f1bee"
      unitRef="U_USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      id="F_27b23c34-827e-486b-99eb-8700a96784d5">&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following tables set forth our financial instruments measured at fair value on a recurring basis by level within the fair value hierarchy at &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021 and 2020: &lt;/span&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:28.362%;"/&gt;
        &lt;td style="width:13.565%;"/&gt;
        &lt;td style="width:6.799%;"/&gt;
        &lt;td style="width:1.231%;"/&gt;
        &lt;td style="width:9.272%;"/&gt;
        &lt;td style="width:0.6%;"/&gt;
        &lt;td style="width:2.227%;"/&gt;
        &lt;td style="width:1.231%;"/&gt;
        &lt;td style="width:9.272%;"/&gt;
        &lt;td style="width:0.6%;"/&gt;
        &lt;td style="width:1.831%;"/&gt;
        &lt;td style="width:1.242%;"/&gt;
        &lt;td style="width:8.608%;"/&gt;
        &lt;td style="width:0.835%;"/&gt;
        &lt;td style="width:2.099%;"/&gt;
        &lt;td style="width:1.231%;"/&gt;
        &lt;td style="width:10.396%;"/&gt;
        &lt;td style="width:0.6%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;"&gt;Fair Value&lt;br/&gt;Hierarchy Level&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;"&gt;Gross &lt;br/&gt;Unrealized Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;"&gt;Gross &lt;br/&gt;Unrealized Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;"&gt;Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Cash and cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;27,834&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;27,834&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;17,555&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;17,555&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;23,597&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;23,596&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:15.0pt;word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="margin-left:15.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Total cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;68,986&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;68,985&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Investments:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;45,290&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;73&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;45,217&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;61,941&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;22&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;61,919&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Corporate debt&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;58,498&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;74&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;58,424&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Asset backed securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;13,899&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;13,874&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;U.S. government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;24,714&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;46&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;24,668&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:15.0pt;word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="margin-left:15.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Total investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;204,342&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;240&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;204,102&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:15.0pt;word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="margin-left:15.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;273,328&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;241&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;273,087&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;"&gt;Fair Value&lt;br/&gt;Hierarchy Level&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;"&gt;Gross &lt;br/&gt;Unrealized Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;"&gt;Gross &lt;br/&gt;Unrealized Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;"&gt;Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Cash and cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;4,788&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;4,788&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;381,412&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;381,412&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;386,200&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;386,200&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <pcvx:CashAndCashEquivalentsAmortizedCost
      contextRef="C_4ce8060d-05a1-4cdf-a58a-b689d077a297"
      decimals="-3"
      id="F_45eabf10-2e90-4968-971c-c7decf8ee4a4"
      unitRef="U_USD">27834000</pcvx:CashAndCashEquivalentsAmortizedCost>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_4ce8060d-05a1-4cdf-a58a-b689d077a297"
      decimals="-3"
      id="F_25312f54-74f2-4053-9faa-697bcc9bbcb7"
      unitRef="U_USD">27834000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <pcvx:CashAndCashEquivalentsAmortizedCost
      contextRef="C_dc50a6ec-93a5-4d6d-8842-7d609d69c237"
      decimals="-3"
      id="F_e01cb1a9-7ad9-4f18-8fa4-588d00fac51a"
      unitRef="U_USD">17555000</pcvx:CashAndCashEquivalentsAmortizedCost>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_dc50a6ec-93a5-4d6d-8842-7d609d69c237"
      decimals="-3"
      id="F_a0dbc348-f693-4a1d-ac57-3e6e487fd46a"
      unitRef="U_USD">17555000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <pcvx:CashAndCashEquivalentsAmortizedCost
      contextRef="C_bcc1b5db-4703-43c3-9272-4d0ca2f54e6a"
      decimals="-3"
      id="F_2570a72b-1e06-48e8-bfd4-adfebe704ba7"
      unitRef="U_USD">23597000</pcvx:CashAndCashEquivalentsAmortizedCost>
    <pcvx:CashAndCashEquivalentsGrossUnrealizedLossBeforeTax
      contextRef="C_bcc1b5db-4703-43c3-9272-4d0ca2f54e6a"
      decimals="-3"
      id="F_9dc7e000-b5dc-4f40-8cb7-4d4f92bb74d2"
      unitRef="U_USD">1000</pcvx:CashAndCashEquivalentsGrossUnrealizedLossBeforeTax>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_bcc1b5db-4703-43c3-9272-4d0ca2f54e6a"
      decimals="-3"
      id="F_5c2c7749-2625-4048-b74d-2e86ab3fb534"
      unitRef="U_USD">23596000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <pcvx:CashAndCashEquivalentsAmortizedCost
      contextRef="C_9a84ae25-675d-4a66-a9c5-6809604d88d9"
      decimals="-3"
      id="F_b603efff-6333-4400-8913-5af1cdbf85a6"
      unitRef="U_USD">68986000</pcvx:CashAndCashEquivalentsAmortizedCost>
    <pcvx:CashAndCashEquivalentsGrossUnrealizedLossBeforeTax
      contextRef="C_9a84ae25-675d-4a66-a9c5-6809604d88d9"
      decimals="-3"
      id="F_2d6ab67b-45a1-4117-90bf-dd33b8ad318a"
      unitRef="U_USD">1000</pcvx:CashAndCashEquivalentsGrossUnrealizedLossBeforeTax>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_9a84ae25-675d-4a66-a9c5-6809604d88d9"
      decimals="-3"
      id="F_2ef31255-699e-4171-8468-a1c7db1f7a32"
      unitRef="U_USD">68985000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_922091bf-1883-4a4a-8399-cbd1c97ca12c"
      decimals="-3"
      id="F_f2693e83-670d-4822-9be8-52ca273155dc"
      unitRef="U_USD">45290000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_922091bf-1883-4a4a-8399-cbd1c97ca12c"
      decimals="-3"
      id="F_4706bf8a-f7d2-4087-aa4e-02f0dfcdb941"
      unitRef="U_USD">73000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_922091bf-1883-4a4a-8399-cbd1c97ca12c"
      decimals="-3"
      id="F_18821bb4-e97a-4a20-9db3-443b1a837c9a"
      unitRef="U_USD">45217000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_a870b5f9-af49-4819-946b-a34bbe67f9e2"
      decimals="-3"
      id="F_072b99b8-cfb3-43a5-86f3-7baae4651aa7"
      unitRef="U_USD">61941000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_a870b5f9-af49-4819-946b-a34bbe67f9e2"
      decimals="-3"
      id="F_475eba79-c2cd-4a33-816f-32393e7703e9"
      unitRef="U_USD">22000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_a870b5f9-af49-4819-946b-a34bbe67f9e2"
      decimals="-3"
      id="F_25e6f27d-4bf3-4e10-bbb6-bb1499187d5f"
      unitRef="U_USD">61919000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_9fb419f9-f0a5-4dff-a890-32989d15c4e8"
      decimals="-3"
      id="F_33b2b67d-1f46-4b06-bfc2-bb2a160a47c1"
      unitRef="U_USD">58498000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_9fb419f9-f0a5-4dff-a890-32989d15c4e8"
      decimals="-3"
      id="F_048885a4-28fa-4b2d-9581-5b42892eeca4"
      unitRef="U_USD">74000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_9fb419f9-f0a5-4dff-a890-32989d15c4e8"
      decimals="-3"
      id="F_24108b58-ad40-4afe-a58c-37d04b9ceaaf"
      unitRef="U_USD">58424000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_5cd74deb-d2fe-4b8d-8171-3251599dda47"
      decimals="-3"
      id="F_9ba34c0c-d89e-474f-9a2c-73aad69ca7d5"
      unitRef="U_USD">13899000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_5cd74deb-d2fe-4b8d-8171-3251599dda47"
      decimals="-3"
      id="F_bf1f5128-58c5-4365-b636-bfb5eefb3baa"
      unitRef="U_USD">25000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_5cd74deb-d2fe-4b8d-8171-3251599dda47"
      decimals="-3"
      id="F_4a805897-45b9-430b-a73c-0363f2d2c136"
      unitRef="U_USD">13874000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0a0e64e6-bec3-47d0-a7db-dea3ad28e107"
      decimals="-3"
      id="F_a6055153-8cda-4df2-a8a8-978a14dce273"
      unitRef="U_USD">24714000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_0a0e64e6-bec3-47d0-a7db-dea3ad28e107"
      decimals="-3"
      id="F_4d416a35-6550-4319-bc48-ec2278be45d3"
      unitRef="U_USD">46000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0a0e64e6-bec3-47d0-a7db-dea3ad28e107"
      decimals="-3"
      id="F_828ab589-39b1-43cb-97b8-956a49d34335"
      unitRef="U_USD">24668000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_9a84ae25-675d-4a66-a9c5-6809604d88d9"
      decimals="-3"
      id="F_0013e7fe-3152-462e-af4c-134d6aa22851"
      unitRef="U_USD">204342000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_9a84ae25-675d-4a66-a9c5-6809604d88d9"
      decimals="-3"
      id="F_d93d43fd-42b5-4203-9bf9-7f94a97ae6ca"
      unitRef="U_USD">240000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_9a84ae25-675d-4a66-a9c5-6809604d88d9"
      decimals="-3"
      id="F_869a2f96-2812-45bb-b9f1-481e727fc219"
      unitRef="U_USD">204102000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <pcvx:CashAndCashEquivalentsAndInvestmentsAmortizedCostBasis
      contextRef="C_9a84ae25-675d-4a66-a9c5-6809604d88d9"
      decimals="-3"
      id="F_41eeb37e-496c-4e4a-bd31-28da587abf75"
      unitRef="U_USD">273328000</pcvx:CashAndCashEquivalentsAndInvestmentsAmortizedCostBasis>
    <pcvx:CashAndCashEquivalentsAndInvestmentsGrossUnrealizedLossBeforeTax
      contextRef="C_9a84ae25-675d-4a66-a9c5-6809604d88d9"
      decimals="-3"
      id="F_9489485c-739d-4851-806c-4e05702f6ee1"
      unitRef="U_USD">241000</pcvx:CashAndCashEquivalentsAndInvestmentsGrossUnrealizedLossBeforeTax>
    <pcvx:CashAndCashEquivalentsAndInvestments
      contextRef="C_9a84ae25-675d-4a66-a9c5-6809604d88d9"
      decimals="-3"
      id="F_8fe98cae-6934-4b80-8e1b-1ab5ef072a9e"
      unitRef="U_USD">273087000</pcvx:CashAndCashEquivalentsAndInvestments>
    <pcvx:CashAndCashEquivalentsAmortizedCost
      contextRef="C_5c504db9-02bb-4fad-8cf7-b49fc071de1c"
      decimals="-3"
      id="F_be99b109-cbca-4d85-9b8b-5c9e479e1dca"
      unitRef="U_USD">4788000</pcvx:CashAndCashEquivalentsAmortizedCost>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_5c504db9-02bb-4fad-8cf7-b49fc071de1c"
      decimals="-3"
      id="F_041c63f1-9a43-4c7d-a1aa-976b85fcf4af"
      unitRef="U_USD">4788000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <pcvx:CashAndCashEquivalentsAmortizedCost
      contextRef="C_1a49e197-0c31-4849-ac0b-b08a2eebd593"
      decimals="-3"
      id="F_eb5687a5-774d-432a-857a-a7f78c81cdba"
      unitRef="U_USD">381412000</pcvx:CashAndCashEquivalentsAmortizedCost>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_1a49e197-0c31-4849-ac0b-b08a2eebd593"
      decimals="-3"
      id="F_ba7985d0-ead5-4af5-a302-0dc45a61a27c"
      unitRef="U_USD">381412000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <pcvx:CashAndCashEquivalentsAndInvestmentsAmortizedCostBasis
      contextRef="C_2e490417-2b25-4870-8c8f-ccac2bc83352"
      decimals="-3"
      id="F_d58da43f-d71c-410b-bfd4-e95396acb55e"
      unitRef="U_USD">386200000</pcvx:CashAndCashEquivalentsAndInvestmentsAmortizedCostBasis>
    <pcvx:CashAndCashEquivalentsAndInvestments
      contextRef="C_2e490417-2b25-4870-8c8f-ccac2bc83352"
      decimals="-3"
      id="F_d39994f0-1406-4abd-934f-3f88eb6c8910"
      unitRef="U_USD">386200000</pcvx:CashAndCashEquivalentsAndInvestments>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      id="F_de086a10-7d3b-47c0-afbb-f714ec397acb">&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following table presents the contractual maturities of our investments as of December 31, 2021 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:70.292%;"/&gt;
        &lt;td style="width:5.331%;"/&gt;
        &lt;td style="width:1.242%;"/&gt;
        &lt;td style="width:22.15%;"/&gt;
        &lt;td style="width:0.985%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Due in less than one year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;176,985&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Due in one to five years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;27,117&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;204,102&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350"
      decimals="-3"
      id="F_7575df1a-d1a6-4dcd-a210-7bf172615ccc"
      unitRef="U_USD">176985000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350"
      decimals="-3"
      id="F_73608741-fa34-4214-b97c-12fc03b14f14"
      unitRef="U_USD">27117000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350"
      decimals="-3"
      id="F_a0800c1c-cd3b-420e-a9f3-379a0350a672"
      unitRef="U_USD">204102000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      id="F_a3831dc8-5875-425d-bf27-65aaf68a2b80">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;4. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Balance Sheet Details&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Property and Equipment, Net&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Property and equipment, net as of December 31, 2021 and 2020 consisted of the following:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.51%;"/&gt;
        &lt;td style="width:1.478%;"/&gt;
        &lt;td style="width:1.37%;"/&gt;
        &lt;td style="width:12.976%;"/&gt;
        &lt;td style="width:0.921%;"/&gt;
        &lt;td style="width:1.478%;"/&gt;
        &lt;td style="width:1.37%;"/&gt;
        &lt;td style="width:12.976%;"/&gt;
        &lt;td style="width:0.921%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Furniture and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,619&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;397&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Computers and computer software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;430&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;111&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Lab equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;9,453&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,739&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,903&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Construction in progress&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;219&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;11,502&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,369&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Less: accumulated depreciation and amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,548&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,097&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,954&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,272&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Depreciation and amortization expense for years ended December 31, 2021, 2020 and 2019 was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million respectively, of which $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million related to capital lease amortization expense for the years ended December 31, 2021, 2020 and 2019, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Accrued Expenses&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Accrued expenses as of December 31, 2021 and 2020 consisted of the following:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.006%;"/&gt;
        &lt;td style="width:1.413%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:12.75%;"/&gt;
        &lt;td style="width:0.942%;"/&gt;
        &lt;td style="width:1.413%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:12.772%;"/&gt;
        &lt;td style="width:0.942%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Preclinical studies&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,039&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,844&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Professional fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;400&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;490&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Other accrued expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,348&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;432&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:15.0pt;word-break:break-word;vertical-align:middle;"&gt;&lt;p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8,787&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,766&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      id="F_1778444f-f35c-4eaa-9739-a47571d1ab01">&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Property and equipment, net as of December 31, 2021 and 2020 consisted of the following:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.51%;"/&gt;
        &lt;td style="width:1.478%;"/&gt;
        &lt;td style="width:1.37%;"/&gt;
        &lt;td style="width:12.976%;"/&gt;
        &lt;td style="width:0.921%;"/&gt;
        &lt;td style="width:1.478%;"/&gt;
        &lt;td style="width:1.37%;"/&gt;
        &lt;td style="width:12.976%;"/&gt;
        &lt;td style="width:0.921%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Furniture and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,619&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;397&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Computers and computer software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;430&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;111&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Lab equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;9,453&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,739&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,903&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Construction in progress&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;219&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;11,502&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,369&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Less: accumulated depreciation and amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,548&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,097&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,954&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,272&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_fe00813e-2d7b-4ece-bbe6-949a26bbf5f7"
      decimals="-3"
      id="F_11352b7f-7278-4cc4-9c74-755fe7920ba6"
      unitRef="U_USD">1619000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_066e4651-a692-4244-9444-b8600c1c5b43"
      decimals="-3"
      id="F_9acfccd3-42e3-410e-901a-f99aa2579625"
      unitRef="U_USD">397000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_68b32ca0-daf9-4934-b4c5-74593152bb49"
      decimals="-3"
      id="F_7933b44e-c979-415d-98e1-f65170ee12af"
      unitRef="U_USD">430000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_1217ed43-7b78-4138-a3fe-8b016f62919a"
      decimals="-3"
      id="F_8f2b56bf-e929-43db-bfdb-58242946f967"
      unitRef="U_USD">111000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_4c43c843-d033-4309-afae-7cfdb2138610"
      decimals="-3"
      id="F_14138018-b671-497e-92cb-104c6e2a7b6f"
      unitRef="U_USD">9453000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_35363580-d33d-4e25-a1e6-c5519ee4402f"
      decimals="-3"
      id="F_51f1d58c-8d9e-41d9-906f-908a096e2780"
      unitRef="U_USD">4739000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_fc0e428b-6e5e-4e81-ad32-508b6eb1375f"
      decimals="-3"
      id="F_e662812a-84f0-47cb-b376-496dbf9cebab"
      unitRef="U_USD">1903000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_070a9c52-605a-45b7-ac24-ad04c1d7f676"
      decimals="-3"
      id="F_22789544-6d12-483d-83c6-786a0ba3557c"
      unitRef="U_USD">219000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350"
      decimals="-3"
      id="F_6695cc15-56b0-4aa6-afdc-19d23772c2ce"
      unitRef="U_USD">11502000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57"
      decimals="-3"
      id="F_209be3e8-09ff-48af-bc32-6e51d45bcc48"
      unitRef="U_USD">7369000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350"
      decimals="-3"
      id="F_c18def7c-f1ae-4928-9347-2e21b54f20e0"
      unitRef="U_USD">3548000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57"
      decimals="-3"
      id="F_7644ca06-8832-4328-8d39-b81bd1c55d8a"
      unitRef="U_USD">4097000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350"
      decimals="-3"
      id="F_737313f5-9ff7-46a4-b19e-562821b3ca96"
      unitRef="U_USD">7954000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57"
      decimals="-3"
      id="F_b6b9297a-a549-46ad-b900-f4d1bf932a6a"
      unitRef="U_USD">3272000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      decimals="-5"
      id="F_c996e458-bd6d-47d7-b416-fd24e0ab352d"
      unitRef="U_USD">1800000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001"
      decimals="-5"
      id="F_c92eef25-7ef2-418b-bf90-b34dc44578e5"
      unitRef="U_USD">1400000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700"
      decimals="-5"
      id="F_bfe346da-e5d4-4a96-8a09-9851999187e0"
      unitRef="U_USD">1200000</us-gaap:DepreciationAndAmortization>
    <pcvx:CapitalLeasesAmortizationExpense
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      decimals="0"
      id="F_d38502c6-358f-4c0c-814d-2c94c6fb234e"
      unitRef="U_USD">0</pcvx:CapitalLeasesAmortizationExpense>
    <pcvx:CapitalLeasesAmortizationExpense
      contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001"
      decimals="0"
      id="F_ef9a25b9-233f-4de1-92fb-cb84bb7b9a21"
      unitRef="U_USD">0</pcvx:CapitalLeasesAmortizationExpense>
    <pcvx:CapitalLeasesAmortizationExpense
      contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700"
      decimals="-5"
      id="F_fe4be491-4c43-4c85-9ef8-6330db56764d"
      unitRef="U_USD">200000</pcvx:CapitalLeasesAmortizationExpense>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      id="F_b9f467e6-172f-441c-af0b-d358b4a0b6c4">&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Accrued expenses as of December 31, 2021 and 2020 consisted of the following:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.006%;"/&gt;
        &lt;td style="width:1.413%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:12.75%;"/&gt;
        &lt;td style="width:0.942%;"/&gt;
        &lt;td style="width:1.413%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:12.772%;"/&gt;
        &lt;td style="width:0.942%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Preclinical studies&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,039&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,844&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Professional fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;400&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;490&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Other accrued expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,348&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;432&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:15.0pt;word-break:break-word;vertical-align:middle;"&gt;&lt;p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8,787&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,766&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <pcvx:AccruedPreclinicalStudiesCurrent
      contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350"
      decimals="-3"
      id="F_f8cf2c2c-f7e5-4a7b-b281-891d5265952c"
      unitRef="U_USD">5039000</pcvx:AccruedPreclinicalStudiesCurrent>
    <pcvx:AccruedPreclinicalStudiesCurrent
      contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57"
      decimals="-3"
      id="F_81681149-e009-45b8-aa2c-e1e804bc8d22"
      unitRef="U_USD">2844000</pcvx:AccruedPreclinicalStudiesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350"
      decimals="-3"
      id="F_84fa00f3-7ba1-4a2d-9389-42401cda96bf"
      unitRef="U_USD">400000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57"
      decimals="-3"
      id="F_448b6617-5047-4a2a-b90b-0962a897b6b7"
      unitRef="U_USD">490000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350"
      decimals="-3"
      id="F_2e08bb0d-68a4-43d7-989c-6783e3e7d0a1"
      unitRef="U_USD">3348000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57"
      decimals="-3"
      id="F_8e7e1744-4720-4af4-b3a0-f4e07f983cfa"
      unitRef="U_USD">432000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350"
      decimals="-3"
      id="F_8dad6b0f-4903-48fa-8d72-ee19ff6f723f"
      unitRef="U_USD">8787000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57"
      decimals="-3"
      id="F_07d56c29-8a98-4b0e-a681-8f22a9ed7fa5"
      unitRef="U_USD">3766000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      id="F_163ca269-079c-4436-a3a6-bc2a03e659d6">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;5. Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Operating Lease Obligations&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In July 2016, we entered into a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;five-year&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; lease agreement for our previous headquarters facility located in Foster City, California. The original term of the lease was from &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;September 1, 2016&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;August 31, 2021&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, with &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;two&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;30&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;-month &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;renewal options&lt;/span&gt;&lt;/span&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"/&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;.&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In July 2019, we leased another facility in Foster City, California as a result of growth in personnel and lab space requirements. The original term of this lease was from &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;July 1, 2019&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;October 31, 2021&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, with &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; renewal options&lt;/span&gt;&lt;/span&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"/&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;.&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; In November 2020, we extended the terms of both of these leases for &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;six months&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;March 1, 2022&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;April 30, 2022&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, respectively. In February 2022, we entered into an early termination agreement for one of the facilities in Foster City and terminated our lease on &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;February 12, 2022&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; instead of April 30, 2022. We also leased an office in San Diego, California with a lease term that ended on &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;April 30, 2021&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In January 2021, we entered into a lease agreement for our new corporate headquarters facility located in San Carlos, California and a license agreement for temporary lab and office space in Palo Alto, California. The lease term for our new corporate headquarters facility began on &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;January 22, 2021&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; and expires on &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. We have &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;two&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;60&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;-month renewal options. The original term of the license agreement for temporary space in Palo Alto terminated when the San Carlos office leasehold improvements were completed and we moved into our new corporate headquarters. We extended the license agreement for the Palo Alto office by &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;60 days&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;March 3, 2022&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; to accommodate our relocation plan. These two agreements are accounted for as a combined lease because the contracts were negotiated as a package with the same commercial objective.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;We early adopted ASC 842 and its associated amendments as of January 1, 2021 using the modified retrospective transition approach by applying the new standard to all leases existing at the date of the initial adoption and not restating comparative periods. We elected the package of practical expedients permitted under the transition guidance within the new standard, which among other things, allowed us to carryforward the historical lease classification of those leases in place as of January 1, 2021. The adoption of ASC 842 resulted in an increase to total assets and liabilities due to the recording of operating lease ROU assets and operating lease liabilities of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, respectively, as of January 1, 2021. ROU assets and lease liabilities are recognized based on the present value of the fixed and in-substance fixed lease payments over the lease terms at their respective commencement dates. The ROU assets also include any initial direct costs incurred and lease payments made at or before the commencement date and are reduced by lease incentives. In determining the present value of lease payments, since the rate implicit in the lease is generally not readily determinable, we use our incremental borrowing rate, which requires management&#x2019;s judgment, including for the development of a synthetic credit rating and the cost of debt as we currently do not carry any debt. Variable lease costs, which are dependent on usage, a rate or index, including common area maintenance charges for our real estate leases, are expensed as incurred.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Upon commencement of the Palo Alto lease in March 2021, we recorded a ROU asset and lease liability of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, respectively. Upon commencement of the San Carlos lease in December 2021, we recorded a ROU asset and lease liability of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;28.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;12.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, respectively. Because the Palo Alto and the San Carlos agreements are accounted for as a combined lease, lease payments and lease incentives are allocated between the &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;two&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; leases.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;   &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Information related to our ROU assets and related lease liabilities was as follows (dollar amounts in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:78.308%;"/&gt;
        &lt;td style="width:4.176%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:13.822%;"/&gt;
        &lt;td style="width:2.313%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Cash paid for operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;924&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Right-of-use assets recognized in exchange for new lease obligations&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;27,958&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Current operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,276&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Non-current operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;11,507&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;16,783&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Weighted-average remaining lease term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3.75&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Maturities of lease liabilities as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021 were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.289%;"/&gt;
        &lt;td style="width:1.692%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:15.675%;"/&gt;
        &lt;td style="width:0.964%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Years ending December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:Times New Roman;position:relative;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;105&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,639&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,805&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,976&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total future undiscounted lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;20,315&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Less: Imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,532&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;16,783&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"&gt;_____________________________________________&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(1)	Maturities for 2022 are net of lease incentives of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million allocated to the Palo Alto office.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Future minimum payments required under operating leases as of December 31, 2020 were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:78.985%;"/&gt;
        &lt;td style="width:1.82%;"/&gt;
        &lt;td style="width:1.402%;"/&gt;
        &lt;td style="width:16.679%;"/&gt;
        &lt;td style="width:1.113%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Years ending December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);padding-top:0.010in;text-indent:13.7pt;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"&gt;&lt;p style="margin-left:13.7pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;742&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:13.7pt;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"&gt;&lt;p style="margin-left:13.7pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;190&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total future minimum payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.250pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);padding-right:0.010in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.250pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);padding-right:0.010in;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;932&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.250pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);padding-right:0.010in;"&gt;&lt;p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Rent expense recognized under the leases was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million for the years ended December 31, 2021, 2020 and 2019, respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseDescription
      contextRef="C_bc56f763-40d5-4249-8c96-d9aa519edbb4"
      id="F_a3f96087-f3fc-4008-ae4d-d21389cd1088">In July 2016, we entered into a five-year lease agreement for our previous headquarters facility located in Foster City, California. The original term of the lease was from September 1, 2016 to August 31, 2021, with two 30-month renewal options.</us-gaap:LesseeOperatingLeaseDescription>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="C_75f99d7f-d132-471c-9624-9a873477248d"
      id="F_61e12400-3ac7-4c2d-9dcb-9bac525de5fb">P5Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <pcvx:LesseeOperatingLeaseCommencementDate
      contextRef="C_8825ef60-997f-4d67-9024-2ab506972607"
      id="F_1a7452be-d3b2-4fb7-92b6-4349a8df5a17">2016-09-01</pcvx:LesseeOperatingLeaseCommencementDate>
    <us-gaap:LeaseExpirationDate1
      contextRef="C_8825ef60-997f-4d67-9024-2ab506972607"
      id="F_129950ae-89d0-4b3d-b197-a4f57ebbd429">2021-08-31</us-gaap:LeaseExpirationDate1>
    <pcvx:LesseeOperatingLeaseRenewalOption
      contextRef="C_8825ef60-997f-4d67-9024-2ab506972607"
      decimals="INF"
      id="F_ed558929-761f-4d2e-af45-fb56e85e02b7"
      unitRef="U_RenewalOption">2</pcvx:LesseeOperatingLeaseRenewalOption>
    <us-gaap:LesseeOperatingLeaseOptionToExtend
      contextRef="C_bc56f763-40d5-4249-8c96-d9aa519edbb4"
      id="F_cd1d95b7-2d7e-45ab-8501-68039510b45d">30-month renewal options</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="C_75f99d7f-d132-471c-9624-9a873477248d"
      id="F_77213f45-a32b-4276-b8c8-aff355bec05c">P30M</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend
      contextRef="C_8825ef60-997f-4d67-9024-2ab506972607"
      id="F_b3abd3a1-48ea-412c-90eb-682d1d7ab3c8">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend>
    <us-gaap:LesseeOperatingLeaseDescription
      contextRef="C_59f4b2de-1ad8-448b-acad-83f62876574d"
      id="F_8aef5f14-1452-4f4a-9cc2-5dc72f7553ae">In July 2019, we leased another facility in Foster City, California as a result of growth in personnel and lab space requirements. The original term of this lease was from July 1, 2019 to October 31, 2021, with no renewal options.</us-gaap:LesseeOperatingLeaseDescription>
    <pcvx:LesseeOperatingLeaseCommencementDate
      contextRef="C_6cff9554-4027-48fb-bcff-8e4bfb2fe23e"
      id="F_4eed0894-2608-4301-baca-4a246254a4f7">2019-07-01</pcvx:LesseeOperatingLeaseCommencementDate>
    <us-gaap:LeaseExpirationDate1
      contextRef="C_6cff9554-4027-48fb-bcff-8e4bfb2fe23e"
      id="F_6ecb07b0-1eb6-48eb-a25c-a4eb1e5d9f45">2021-10-31</us-gaap:LeaseExpirationDate1>
    <us-gaap:LesseeOperatingLeaseOptionToExtend
      contextRef="C_59f4b2de-1ad8-448b-acad-83f62876574d"
      id="F_fcff5920-a357-4121-ae1f-5aeaa25ab73b">no renewal options</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend
      contextRef="C_6cff9554-4027-48fb-bcff-8e4bfb2fe23e"
      id="F_f312a0ab-498b-4428-a541-52df4e68e1c1">false</us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend>
    <pcvx:LesseeOperatingLeaseExtendedLeaseTerm
      contextRef="C_07b31212-bf35-4995-9486-d82d74f5da0e"
      id="F_986f27d3-0b5c-4ec0-8f10-3554675024f1">P6M</pcvx:LesseeOperatingLeaseExtendedLeaseTerm>
    <pcvx:LesseeOperatingLeaseExtendedLeaseTerm
      contextRef="C_555acc16-d9e2-4b46-9a03-aa27a3ad92e4"
      id="F_348569e9-f322-4289-8c63-9c598482165f">P6M</pcvx:LesseeOperatingLeaseExtendedLeaseTerm>
    <pcvx:LesseeOperatingLeaseExtendedMaturityDate
      contextRef="C_07b31212-bf35-4995-9486-d82d74f5da0e"
      id="F_8e12c82d-e5d6-47c5-9e60-297f04d383af">2022-03-01</pcvx:LesseeOperatingLeaseExtendedMaturityDate>
    <pcvx:LesseeOperatingLeaseExtendedMaturityDate
      contextRef="C_555acc16-d9e2-4b46-9a03-aa27a3ad92e4"
      id="F_c388a703-b757-4456-bbbe-d5e1fbe5b98c">2022-04-30</pcvx:LesseeOperatingLeaseExtendedMaturityDate>
    <pcvx:LeaseTerminationDate
      contextRef="C_ac053fdb-afd2-48a8-b734-eae8ef079868"
      id="F_31a1783a-796e-498a-a546-9575d8ec8c42">2022-02-12</pcvx:LeaseTerminationDate>
    <us-gaap:LeaseExpirationDate1
      contextRef="C_fa60d7ee-2e38-419f-8133-f69b4b66de3f"
      id="F_1073c65e-1598-42d4-b36f-a2432f07bc52">2021-04-30</us-gaap:LeaseExpirationDate1>
    <pcvx:LesseeOperatingLeaseCommencementDate
      contextRef="C_28585e6d-11c8-4ef0-bd28-a3644bbf26ac"
      id="F_3fc1f9f9-b1e6-48da-9122-7cc6e2ba3275">2021-01-22</pcvx:LesseeOperatingLeaseCommencementDate>
    <us-gaap:LeaseExpirationDate1
      contextRef="C_28585e6d-11c8-4ef0-bd28-a3644bbf26ac"
      id="F_be313428-ba89-49ba-acf6-5a9a1c2c90d8">2025-12-31</us-gaap:LeaseExpirationDate1>
    <pcvx:NumberOfRenewalOptions
      contextRef="C_28585e6d-11c8-4ef0-bd28-a3644bbf26ac"
      decimals="INF"
      id="F_4b1bf4c8-0ae1-4a4b-abfc-b9277d94e5fc"
      unitRef="U_RenewalOption">2</pcvx:NumberOfRenewalOptions>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="C_2a6a1809-6c79-4e3a-9b03-3826f9729ccf"
      id="F_831052f3-3acd-4959-a89f-4602c1ed7388">P60M</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <pcvx:LesseeOperatingLeaseExtendedLeaseTerm
      contextRef="C_28585e6d-11c8-4ef0-bd28-a3644bbf26ac"
      id="F_0d13eeec-e948-4595-bfb5-b9aca005b4dc">P60D</pcvx:LesseeOperatingLeaseExtendedLeaseTerm>
    <pcvx:LesseeOperatingLeaseExtendedMaturityDate
      contextRef="C_f112ef5d-4313-44ad-aa4e-21889fa3a7d3"
      id="F_d8a1b460-70cb-44cc-97dd-a6a2a5be21a1">2022-03-03</pcvx:LesseeOperatingLeaseExtendedMaturityDate>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_d4cf0103-8fdd-4434-bedf-65aa2503f533"
      decimals="-5"
      id="F_06117121-497a-4bd1-9bd2-d7161c91f7f6"
      unitRef="U_USD">900000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_d4cf0103-8fdd-4434-bedf-65aa2503f533"
      decimals="-5"
      id="F_137d8434-8b16-42b2-9144-9e8fe109cc28"
      unitRef="U_USD">900000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_54987e17-a9c2-4890-ade9-618bd3dfc3f7"
      decimals="-5"
      id="F_cbe8d816-4183-4afe-a8bc-7f4850e8da61"
      unitRef="U_USD">300000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_54987e17-a9c2-4890-ade9-618bd3dfc3f7"
      decimals="-5"
      id="F_c5c5e5b6-fbcc-40ec-9a55-76049cbd3aab"
      unitRef="U_USD">300000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_9ce589b3-009c-4c1f-9492-617b84d98173"
      decimals="-5"
      id="F_c9828b3b-5301-451f-a122-58ef9eacb45b"
      unitRef="U_USD">28400000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_9ce589b3-009c-4c1f-9492-617b84d98173"
      decimals="-5"
      id="F_68f3b6b9-eb3f-4628-be18-6c75ee54943e"
      unitRef="U_USD">12900000</us-gaap:OperatingLeaseLiability>
    <pcvx:NumberOfOperatingLease
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      decimals="INF"
      id="F_53b02333-a77d-4ce5-9a85-877c8b6f9e99"
      unitRef="U_Lease">2</pcvx:NumberOfOperatingLease>
    <pcvx:ScheduleOfInformationRelatedToRightOfUseAssetsAndLeaseLiabilitiesTableTextBlock
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      id="F_a56a8efd-6aa8-424f-9679-2fc5dc61c638">&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Information related to our ROU assets and related lease liabilities was as follows (dollar amounts in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:78.308%;"/&gt;
        &lt;td style="width:4.176%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:13.822%;"/&gt;
        &lt;td style="width:2.313%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Cash paid for operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;924&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Right-of-use assets recognized in exchange for new lease obligations&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;27,958&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Current operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,276&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Non-current operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;11,507&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;16,783&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Weighted-average remaining lease term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3.75&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</pcvx:ScheduleOfInformationRelatedToRightOfUseAssetsAndLeaseLiabilitiesTableTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      decimals="-3"
      id="F_3ca00ddf-0372-4d4f-afed-6e4207927893"
      unitRef="U_USD">924000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350"
      decimals="-3"
      id="F_b0e6bac6-b889-4273-b777-66ec3845d122"
      unitRef="U_USD">27958000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350"
      decimals="-3"
      id="F_64de4bb4-1279-4ab2-ad0c-410c29d46f24"
      unitRef="U_USD">5276000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350"
      decimals="-3"
      id="F_4ba76bde-9150-44f2-a346-972e6180e1d1"
      unitRef="U_USD">11507000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350"
      decimals="-3"
      id="F_c8eb05c8-868b-4396-a546-343516136ca5"
      unitRef="U_USD">16783000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350"
      id="F_993810ce-9a14-4747-a51f-013dcf3cd621">P3Y9M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350"
      decimals="3"
      id="F_ca7700d0-6610-4c75-832a-e8939e53ae00"
      unitRef="U_pure">0.075</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      id="F_de82f73e-ea76-41cb-afaa-288e84ce9f95">&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Maturities of lease liabilities as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021 were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.289%;"/&gt;
        &lt;td style="width:1.692%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:15.675%;"/&gt;
        &lt;td style="width:0.964%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Years ending December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:Times New Roman;position:relative;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;105&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,639&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,805&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,976&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total future undiscounted lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;20,315&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Less: Imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,532&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;16,783&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"&gt;_____________________________________________&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(1)	Maturities for 2022 are net of lease incentives of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million allocated to the Palo Alto office.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Future minimum payments required under operating leases as of December 31, 2020 were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:78.985%;"/&gt;
        &lt;td style="width:1.82%;"/&gt;
        &lt;td style="width:1.402%;"/&gt;
        &lt;td style="width:16.679%;"/&gt;
        &lt;td style="width:1.113%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Years ending December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);padding-top:0.010in;text-indent:13.7pt;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"&gt;&lt;p style="margin-left:13.7pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;742&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:13.7pt;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"&gt;&lt;p style="margin-left:13.7pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;190&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total future minimum payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.250pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);padding-right:0.010in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.250pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);padding-right:0.010in;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;932&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.250pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);padding-right:0.010in;"&gt;&lt;p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <pcvx:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonthsNetOfLeaseIncentives
      contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350"
      decimals="-3"
      id="F_0f503ec8-4ea7-4f88-baba-b04d660f78b6"
      unitRef="U_USD">105000</pcvx:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonthsNetOfLeaseIncentives>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350"
      decimals="-3"
      id="F_fde2b0c5-88b1-471d-a978-869abbc9cf8d"
      unitRef="U_USD">6639000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350"
      decimals="-3"
      id="F_b9922f99-677d-4a1a-af77-3608f4fcf89a"
      unitRef="U_USD">6805000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350"
      decimals="-3"
      id="F_8b732c35-9c59-4b6b-8da2-4b67933770a4"
      unitRef="U_USD">6976000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350"
      decimals="-3"
      id="F_94a69d12-5a31-4f0f-beb5-48b6b16370f3"
      unitRef="U_USD">20315000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350"
      decimals="-3"
      id="F_6e719a8a-7ff6-4204-8a4d-f6c5bbbba644"
      unitRef="U_USD">3532000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350"
      decimals="-3"
      id="F_2006a081-83e5-4b2b-bfdd-6f73df722a8a"
      unitRef="U_USD">16783000</us-gaap:OperatingLeaseLiability>
    <pcvx:LeasePaymentReceivableNoncurrent
      contextRef="C_5c54c4ca-430a-4169-96fa-f57499d8524f"
      decimals="-5"
      id="F_e0dc4cbf-b6f1-4f4a-9c6b-48d4e7b2d911"
      unitRef="U_USD">900000</pcvx:LeasePaymentReceivableNoncurrent>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57"
      decimals="-3"
      id="F_7151987b-7e5f-4fb9-84c5-cf1fdeca442b"
      unitRef="U_USD">742000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57"
      decimals="-3"
      id="F_6e459f27-72ba-4d9e-9b07-de49452229b8"
      unitRef="U_USD">190000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57"
      decimals="-3"
      id="F_72a3a168-e976-4e8b-8ed3-5cdb150ea4b6"
      unitRef="U_USD">932000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      decimals="-5"
      id="F_36b68062-816d-4cfb-893d-f0c0f136da83"
      unitRef="U_USD">3200000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001"
      decimals="-5"
      id="F_b72f834d-73a2-4696-b636-ff501afd4e14"
      unitRef="U_USD">700000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700"
      decimals="-5"
      id="F_57d97a87-5336-402b-9ee0-aaabd215fe25"
      unitRef="U_USD">600000</us-gaap:OperatingLeaseExpense>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      id="F_d772575e-e963-4f56-9e5a-e9978dbe8b96">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;6. Commitments and Contingencies&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Legal Contingencies&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;From time to time, we may become involved in legal proceedings arising from the ordinary course of business. We record a liability for such matters when it is probable that future losses will be incurred and that such losses can be reasonably estimated. Significant judgment by us is required to determine both probability and the estimated amount. We do not believe that there is any litigation or asserted or unasserted claim pending that could, individually or in the aggregate, have a material adverse effect on our results of operations or financial condition.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Guarantees and Indemnifications&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In the normal course of business, we enter into agreements that contain a variety of representations and provide for general indemnification. Our exposure under these agreements is unknown because it involves claims that may be made against us in the future. To date, we have not paid any claims or been required to defend any action related to our indemnification obligations. As of December 31, 2021, we did not have any material indemnification claims that were probable or reasonably possible and consequently have not recorded related liabilities.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Indemnification&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;To the extent permitted under Delaware law, we have agreed to indemnify our directors and officers for certain events or occurrences while the director or officer is, or was, serving at our request in such capacity. The indemnification period covers all pertinent events and occurrences during the director&#x2019;s or officer&#x2019;s service. The maximum potential amount of future payments we could be required to make under these indemnification agreements is not specified in the agreements; however, we have director and officer insurance coverage that reduces our exposure and enables us to recover a portion of any future amounts paid. We have not incurred any material costs as a result of such indemnification and are not currently aware of any indemnification claims.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Development and Manufacturing Services Agreement&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;On October 21, 2016, we entered into a development and manufacturing services agreement, as amended, with Lonza (the &#x201c;Lonza DMSA&#x201d;), pursuant to which Lonza is obligated to perform services including manufacturing process development and the manufacture of components for VAX-24, including the polysaccharide antigens, our proprietary eCRM protein carrier and conjugated drug substances.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In the September 2017, we and Lonza agreed to defer the completion payments for any stage that commenced after December 31, 2019 or had not been completed by December 31, 2019 until the earlier of the completion of all Investigational New Drug (&#x201c;IND&#x201d;)-enabling activities or December 31, 2020. In March 2020, Lonza agreed to defer the completion payments until the earlier of the completion of all IND-enabling activities or April 30, 2021. In April 2021, Lonza further agreed to defer &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;50&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% of the completion payments until the earlier of the completion of all IND-enabling activities or December 31, 2021. Pursuant to this agreement, all deferred completion payments were paid in December 2021.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In June 2018, we and Lonza entered into a letter agreement pursuant to which we agreed to certain terms for potential future equity payments in shares of our common stock as partial satisfaction of future obligations to Lonza. This agreement states that the initial pre-IND cash payments would be subject to a specified dollar cap (the &#x201c;Initial Cash Cap&#x201d;). After the Initial Cash Cap has been reached, we have the option to make any further pre-IND payments owed to Lonza in cash, in shares of our common stock at then market prevailing prices, or a combination of both, at our election. The Initial Cash Cap had not been reached as of December 31, 2020. As such, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; amount was recorded with respect to the potential future payments above the Initial Cash Cap at December 31, 2020. In April 2021, we reached the Initial Cash Cap and notified Lonza that we would be exercising our option to issue approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million in shares of our common stock as payment for a portion of pre-IND payments due April 30, 2021. In June 2021, we issued &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;399,680&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of our common stock to Lonza at a price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;25.02&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; per share to pay for $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million of the pre-IND payments due April 30, 2021.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In October 2018, we entered into a second development and manufacturing services agreement with Lonza (the &#x201c;Lonza 2018 DMSA,&#x201d; and together with the Lonza DMSA, the &#x201c;Lonza Agreements&#x201d;), pursuant to which Lonza is obligated to perform services including manufacturing process development and the manufacture and supply of VAX-24 finished drug product.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Under the Lonza Agreements, we are obligated to pay Lonza agreed-upon fees for Lonza&#x2019;s performance of manufacturing services, and to reimburse Lonza for its out-of-pocket costs associated with purchasing raw materials, plus a customary handling fee. Each Lonza Agreement is managed by a steering committee and any dispute at the steering committee will be resolved by senior executives of the parties.&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <pcvx:PercentageOfPaymentsCompletionAgreedToDefer
      contextRef="C_448aa75e-c08c-4eb7-a778-f1a1525470d8"
      decimals="2"
      id="F_e6b9f14b-867d-4705-b7d6-2471b51a9990"
      unitRef="U_pure">0.50</pcvx:PercentageOfPaymentsCompletionAgreedToDefer>
    <us-gaap:GuaranteeObligationsMaximumExposure
      contextRef="C_82e259ab-4adf-45bb-b0dd-9fc97b85e6bd"
      decimals="INF"
      id="F_40c4c957-be74-4d9c-8e93-58dda9f75597"
      unitRef="U_USD">0</us-gaap:GuaranteeObligationsMaximumExposure>
    <us-gaap:GuaranteeObligationsMaximumExposure
      contextRef="C_0f671a12-9113-4696-9460-beb583200e4f"
      decimals="-5"
      id="F_1af6d13d-e575-427f-9312-bacb3e7b798c"
      unitRef="U_USD">10000000.0</us-gaap:GuaranteeObligationsMaximumExposure>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="C_f7ed5965-c3e7-4a8f-9810-2fb0b6527977"
      decimals="INF"
      id="F_88fce260-5e19-4df7-b9a1-9106a324f0ae"
      unitRef="U_shares">399680</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_f9848f07-54cd-412b-b65d-24c18bb6aab2"
      decimals="2"
      id="F_7cb20bed-89ad-4816-8372-d69ae86ee33e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">25.02</us-gaap:SharesIssuedPricePerShare>
    <pcvx:DevelopmentAndManufacturingServicesAgreementPaymentsInEquity
      contextRef="C_f7ed5965-c3e7-4a8f-9810-2fb0b6527977"
      decimals="-5"
      id="F_98230c25-8a37-43b6-a71f-ed77657f7db3"
      unitRef="U_USD">10000000.0</pcvx:DevelopmentAndManufacturingServicesAgreementPaymentsInEquity>
    <pcvx:RedeemableConvertiblePreferredStockTextBlock
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      id="F_a5a020ff-4312-4c89-9427-7be12e572f94">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;7. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Redeemable Convertible Preferred Stock&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;There were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of redeemable convertible preferred stock authorized or outstanding as of December 31, 2021.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In connection with our IPO in June 2020, the outstanding shares of our Series A, Series B, Series C and Series D Redeemable Convertible Preferred Stock automatically converted into &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;28,610,337&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of common stock.&lt;/span&gt;&lt;/p&gt;</pcvx:RedeemableConvertiblePreferredStockTextBlock>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_faa3a312-73ee-42b0-852a-ab16d62c1cef"
      decimals="INF"
      id="F_6fd3d584-cb98-4254-acf8-55d8e403e879"
      unitRef="U_shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="C_faa3a312-73ee-42b0-852a-ab16d62c1cef"
      decimals="INF"
      id="F_3f83ad69-ee11-45f7-9d8a-683d4cd3ed7a"
      unitRef="U_shares">0</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="C_632492ef-57fd-48e7-acda-b7cb142000ba"
      decimals="INF"
      id="F_e5c2fb22-ff0f-4cb4-a8eb-b344d29f5739"
      unitRef="U_shares">28610337</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      id="F_2fbc3798-2519-4ecf-9a22-b7e1ca28f09d">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;8. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Common Stock&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Our certificate of incorporation authorizes us to issue up to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;500,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of common stock with $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.001&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; par value per share, of which &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;53,031,978&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;51,071,593&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares were issued and outstanding as of December 31, 2021 and 2020, respectively. The holders of our common stock are also entitled to receive dividends whenever funds are legally available, when and if declared by our board of directors. As of December 31, 2021 and 2020, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; dividends have been declared. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Each share of common stock is entitled to one vote.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In July 2021, we entered into an Open Market Sales Agreement&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;"&gt;SM&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; (the &#x201c;ATM Sales Agreement&#x201d;) with Jefferies LLC (&#x201c;Jefferies&#x201d;), which provides that, upon the terms and subject to the conditions and limitations set forth in the ATM Sales Agreement, we&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;may elect to issue and sell, from time to time, shares of our common stock having an aggregate offering price of up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;150.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million through Jefferies acting as our sales agent or principal. We are obligated to pay Jefferies a commission of up to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% of the gross sales proceeds of any common stock sold through Jefferies under the ATM Sales Agreement; however, we are not obligated to make any sales of common stock. As of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, we have sold &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;567,045&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of our common stock under the ATM Sales Agreement at an average price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;25.26&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; per share for aggregate gross proceeds of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;14.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million ($&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;13.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million net of commissions and offering expenses).&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Common stock reserved for future issuances under the 2020 Equity Incentive Plan (the &#x201c;2020 Plan&#x201d;) and the 2014 Equity Incentive Plan (the &#x201c;2014 Plan&#x201d;) was as follows, and excludes &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;62,382&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares issued outside of the 2014 Plan and 2020 Plan:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.052%;"/&gt;
        &lt;td style="width:1.584%;"/&gt;
        &lt;td style="width:1.006%;"/&gt;
        &lt;td style="width:12.877%;"/&gt;
        &lt;td style="width:1.006%;"/&gt;
        &lt;td style="width:1.584%;"/&gt;
        &lt;td style="width:1.006%;"/&gt;
        &lt;td style="width:12.877%;"/&gt;
        &lt;td style="width:1.006%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Options issued and outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,295,007&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,188,531&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Shares available for future stock option grants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,104,756&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,651,149&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;11,399,763&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;9,839,680&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350"
      decimals="INF"
      id="F_1450983e-2c39-4bb4-942a-a75179364e88"
      unitRef="U_shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57"
      decimals="INF"
      id="F_93505d6b-be66-4954-89bc-7b0fbb010acf"
      unitRef="U_shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350"
      decimals="INF"
      id="F_3407b145-e552-4963-ab80-15f32904df29"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57"
      decimals="INF"
      id="F_7637104f-7592-498e-887f-afd650da31c0"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350"
      decimals="INF"
      id="F_5f65332b-2b0e-4111-ae59-6ad83a1ed5d2"
      unitRef="U_shares">53031978</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350"
      decimals="INF"
      id="F_0b6a6e8a-9db7-49e7-af40-785e03a55ee0"
      unitRef="U_shares">53031978</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57"
      decimals="INF"
      id="F_a07fe54d-6613-4027-853b-2ec4deecc841"
      unitRef="U_shares">51071593</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57"
      decimals="INF"
      id="F_f31d3dec-4341-44de-bab0-af2d85a03899"
      unitRef="U_shares">51071593</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      decimals="INF"
      id="F_ba3caf66-f0d8-45c6-99e9-ff52793fda1b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001"
      decimals="INF"
      id="F_7643e986-6e49-4a7f-b03f-d337279bab0c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockVotingRights
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      id="F_a84f7d47-0a55-45c2-ae70-43256e1a861b">Each share of common stock is entitled to one vote.</us-gaap:CommonStockVotingRights>
    <pcvx:SaleOfCommonStockAuthorizedAmount
      contextRef="C_8639465b-8e42-43a0-b445-048bbd5edbbe"
      decimals="INF"
      id="F_eb376be3-c98b-44d8-a86d-67d5a4224cb0"
      unitRef="U_USD">150000000.0</pcvx:SaleOfCommonStockAuthorizedAmount>
    <pcvx:MaximumCommissionPercentageOfGrossProceedsFromCommonStockSold
      contextRef="C_1ca103dc-5b49-40a2-af4e-c772a7562197"
      decimals="INF"
      id="F_17f4e97d-fc12-4ecf-be37-19d8beb6cef5"
      unitRef="U_pure">0.030</pcvx:MaximumCommissionPercentageOfGrossProceedsFromCommonStockSold>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_104dc821-c967-4abc-be6e-1f58334234a8"
      decimals="INF"
      id="F_15537781-6364-4408-9b82-5c2f8ac83b2d"
      unitRef="U_shares">567045</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_44af597c-135d-414d-a410-f04a16cf714e"
      decimals="INF"
      id="F_e35dc7dd-2929-473e-b0ff-dae70e5da5d2"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">25.26</us-gaap:SaleOfStockPricePerShare>
    <pcvx:GrossProceedsFromIssuanceOfCommonStock
      contextRef="C_104dc821-c967-4abc-be6e-1f58334234a8"
      decimals="-5"
      id="F_9d766f34-bd78-4777-b1de-6e0e758ea178"
      unitRef="U_USD">14300000</pcvx:GrossProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_104dc821-c967-4abc-be6e-1f58334234a8"
      decimals="-5"
      id="F_be8b0aa5-ebca-4b77-9692-02c5fb53048a"
      unitRef="U_USD">13900000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <pcvx:ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      id="F_02a84ab9-ebdc-46b8-8581-8025f2321ee6">&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Common stock reserved for future issuances under the 2020 Equity Incentive Plan (the &#x201c;2020 Plan&#x201d;) and the 2014 Equity Incentive Plan (the &#x201c;2014 Plan&#x201d;) was as follows, and excludes &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;62,382&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares issued outside of the 2014 Plan and 2020 Plan:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.052%;"/&gt;
        &lt;td style="width:1.584%;"/&gt;
        &lt;td style="width:1.006%;"/&gt;
        &lt;td style="width:12.877%;"/&gt;
        &lt;td style="width:1.006%;"/&gt;
        &lt;td style="width:1.584%;"/&gt;
        &lt;td style="width:1.006%;"/&gt;
        &lt;td style="width:12.877%;"/&gt;
        &lt;td style="width:1.006%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Options issued and outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,295,007&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,188,531&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Shares available for future stock option grants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,104,756&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,651,149&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;11,399,763&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;9,839,680&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</pcvx:ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      decimals="INF"
      id="F_f5192ee5-5dc1-4f1c-8fb2-80830528439e"
      unitRef="U_shares">62382</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_93b8accf-91b3-4471-ab5d-fc8aea02adbe"
      decimals="0"
      id="F_b926895f-4c50-433c-891f-f179d03d49e3"
      unitRef="U_shares">5295007</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_1c93f415-cf2a-4e2c-a1d1-8e49784595b5"
      decimals="INF"
      id="F_d1802238-16dc-422a-a749-60a9c58dd679"
      unitRef="U_shares">5188531</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0c6ef4a7-f323-4b58-a7d5-94f0c514539b"
      decimals="0"
      id="F_1da4a51c-0326-4929-8ae7-381289dadc20"
      unitRef="U_shares">6104756</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_52c3a991-3000-4196-9b57-c6affc82cde5"
      decimals="INF"
      id="F_46133256-79d3-4637-831e-e4f0de8e3faf"
      unitRef="U_shares">4651149</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_58ad6f5b-2983-4459-8fd3-3b4fbdef1c36"
      decimals="0"
      id="F_6fdb6ca0-9e3f-47bd-918c-59d3a6b0bba6"
      unitRef="U_shares">11399763</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_4469bcba-dbf3-41b7-810d-1333a6644626"
      decimals="INF"
      id="F_67e02c4f-0ded-4fdc-aaa9-a5222aedd925"
      unitRef="U_shares">9839680</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <pcvx:WarrantsDisclosureTextBlock
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      id="F_747950cd-7bed-419e-9271-9cf4712aa3ca">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;9. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Warrants&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In connection with our IPO in June 2020, our outstanding warrants were automatically net exercised for an aggregate &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;46,869&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of common stock.&lt;/span&gt;&lt;/p&gt;</pcvx:WarrantsDisclosureTextBlock>
    <pcvx:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRightExercised
      contextRef="C_89e8a4b5-4ab0-4668-889d-5ae7704f7e30"
      decimals="INF"
      id="F_893cf8c9-f48b-4697-84ed-b5294be04a6a"
      unitRef="U_shares">46869</pcvx:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRightExercised>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      id="F_7c007e56-5ff4-4ad6-83a3-dd7c8965bd03">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;10. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Equity Incentive Plans&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2020 and 2014 Equity Incentive Plans&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In June 2020, our board of directors adopted, and our stockholders approved, the 2020 Plan, which became effective on June 11, 2020. Under the 2020 Plan, we may grant stock options, appreciation rights, restricted stock and restricted stock units to employees, consultants and directors. Stock options granted under the 2020 Plan may be either incentive stock options or nonqualified stock options. Incentive stock options may be granted only to our employees, including officers and directors who are also employees. Nonqualified stock options may be granted to our employees, officers, directors, consultants and advisors. The exercise price of stock options granted under the 2020 Plan must be at least equal to the fair market value of the common stock on the date of grant, except that an incentive stock option granted to an employee who owns more than &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% of the shares of our common stock shall have an exercise price of no less than &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;110&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% of the fair value per share on the grant date and expire &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; from the date of grant. The maximum term of stock options granted under the 2020 Plan is &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; years, unless subject to the provisions regarding &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% stockholders. Our stock options granted to new employees generally vest over &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;four years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; at a rate of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;25&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% upon the first anniversary of the vesting commencement date and monthly thereafter. Our other stock options granted to employees generally vest monthly over &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;four years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; from the vesting commencement date. A total of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10,150,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of common stock were approved to be initially reserved for issuance under the 2020 Plan. The number of shares that remained available for issuance under the 2014 Plan as of the effective date of the 2020 Plan, and shares subject to outstanding awards under the 2014 Plan as of the effective date of the 2020 Plan that are subsequently canceled, forfeited or repurchased by us, will be added to the shares reserved under the 2020 Plan. In addition, the number of shares of common stock available for issuance under the 2020 Plan is automatically increased on the first day of each calendar year during the &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10-year&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; term of the 2020 Plan, beginning with January 1, 2021 and ending with January 1, 2030, by an amount equal to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% of the outstanding number of shares of our common stock on December 31 of the preceding calendar year or such lesser amount as determined by our board of directors. As of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021, an aggregate of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,104,756&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of common stock were available for issuance under the 2020 Plan. Effective January 1, 2022, the number of shares of common stock available under the 2020 Plan increased by &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,651,598&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares pursuant to the evergreen provision of the 2020 Plan.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Our 2014 Plan permitted the granting of incentive stock options, non-statutory stock options, restricted stock and other stock-based awards. Subsequent to the adoption of the 2020 Plan, no additional equity awards can be made under the 2014 Plan. Shares reserved and remaining available for issuance under the 2014 Plan were added to the 2020 Plan reserve upon its effectiveness.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The terms of the 2014 Plan permit the exercise of options granted prior to vesting, subject to required approvals. The unvested shares are subject to our lapsing repurchase right upon termination of employment at the original purchase price. Shares purchased by employees pursuant to the early exercise of stock options are not deemed, for accounting purposes, to be issued until those shares vest according to their respective vesting schedules. Cash received for early exercised stock options is recorded as other liabilities on the balance sheet and is reclassified to common stock and additional paid-in capital as such shares vest.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;As of December 31, 2021, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,657,394&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,637,613&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of common stock were subject to outstanding options under the 2014 Plan and 2020 Plan, respectively.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;At December 31, 2021 and 2020, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,410&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;15,056&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares, respectively, remained subject to our right of repurchase as a result of the early exercised stock options. The remaining liabilities related to early exercised shares as of December 31, 2021 and 2020 were both less than $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and were recorded in other liabilities.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Activity under our 2020 Plan and 2014 Plan, which excludes options to purchase &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;62,382&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares granted outside of the 2020 Plan and 2014 Plan, was as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:43.015%;"/&gt;
        &lt;td style="width:0.963%;"/&gt;
        &lt;td style="width:0.707%;"/&gt;
        &lt;td style="width:8.522%;"/&gt;
        &lt;td style="width:0.91%;"/&gt;
        &lt;td style="width:0.963%;"/&gt;
        &lt;td style="width:0.685%;"/&gt;
        &lt;td style="width:8.575%;"/&gt;
        &lt;td style="width:0.91%;"/&gt;
        &lt;td style="width:0.963%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:7.976%;"/&gt;
        &lt;td style="width:0.685%;"/&gt;
        &lt;td style="width:0.963%;"/&gt;
        &lt;td style="width:0.846%;"/&gt;
        &lt;td style="width:10.213%;"/&gt;
        &lt;td style="width:0.685%;"/&gt;
        &lt;td style="width:0.963%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:8.008%;"/&gt;
        &lt;td style="width:0.685%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Options Outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Stock Option Activity&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Options&lt;br/&gt;Available&lt;br/&gt;for &lt;br/&gt;Grant&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Number&lt;br/&gt;of&lt;br/&gt;Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price Per&lt;br/&gt;Share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual &lt;br/&gt;Term&lt;br/&gt;(Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Balances &#x2014; December 31, 2019&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;835,941&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;3,297,586&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;1.93&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Additional shares authorized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;5,997,435&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Options granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;2,255,690&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;2,255,690&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;8.93&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Options exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;358,264&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;1.88&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Options forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;73,463&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;73,463&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;3.50&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Balances &#x2014; December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;4,651,149&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;5,121,549&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;4.99&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Additional shares authorized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;2,553,579&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Options granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;1,616,021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;1,616,021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;21.83&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Options exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;926,514&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;3.25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Options forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;516,049&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;516,049&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;16.70&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Balances &#x2014; December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;6,104,756&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;5,295,007&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;9.30&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;7.89&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;78,604&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Vested and expected to vest &#x2014; December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;5,295,007&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;9.30&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;7.89&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;78,604&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Exercisable at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;2,611,523&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;4.76&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;7.07&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;50,123&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;During the years ended December 31, 2021 and 2020, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;926,514&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;358,264&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of stock options, respectively, were exercised for cash at a weighted-average price per share of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3.25&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.88&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, respectively. The weighted-average grant date fair value of options granted for the years ended December 31, 2021 and 2020 was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;14.65&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;9.62&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, respectively. The intrinsic value of the stock options exercised was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;18.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million for the years ended December 31, 2021 and 2020, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2020 Employee Stock Purchase Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In June 2020, our board of directors adopted, and our stockholders approved, the 2020 Employee Stock Purchase Plan (the &#x201c;2020 ESPP&#x201d;), which became effective on June 11, 2020. The 2020 ESPP permits participants to purchase common stock through payroll deductions of up to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;15&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% of their eligible compensation. Employees purchase shares of common stock at a price per share equal to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;85&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% of the lower of the fair market value at the start or end of the &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;six-month&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; purchase periods within the &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;two-year&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; offering period. A total of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;650,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of common stock were approved to be initially reserved for issuance under the 2020 ESPP. In addition, the number of shares of common stock available for issuance under the 2020 ESPP is automatically increased on the first day of each calendar year during the &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10-year&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; term of the 2020 Plan, beginning with January 1, 2021 and ending with January 1, 2030, by an amount of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% of the outstanding number of shares of our common stock on December 31 of the preceding calendar year or such lesser amount as determined by our board of directors. For the year ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, employees acquired &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;62,546&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of our common stock under the 2020 ESPP and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,070,704&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of common stock remained available for issuance under the 2020 ESPP. Effective January 1, 2022, the number of shares of common stock available under the 2020 ESPP increased by &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;530,319&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares pursuant to the evergreen provision of the 2020 ESPP.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Stock-based Compensation&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;We estimated the fair value of employee stock options using the Black-Scholes option-pricing model for the years ended December 31, 2021, 2020 and 2019 using the following weighted-average assumptions:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.31%;"/&gt;
        &lt;td style="width:1.36%;"/&gt;
        &lt;td style="width:15.203%;"/&gt;
        &lt;td style="width:1.36%;"/&gt;
        &lt;td style="width:15.203%;"/&gt;
        &lt;td style="width:1.36%;"/&gt;
        &lt;td style="width:15.203%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="5" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2019&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Fair Value Assumptions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;81.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;84.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;81.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;94.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;78.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;80.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.3 &lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;- &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.5&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.6&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;- &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.9&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;- &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;We estimated the fair value of shares under the 2020 ESPP using the Black-Scholes option-pricing model for the years ended December 31, 2021, 2020 and 2019 using the following weighted-average assumptions:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:48.1%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:15.384%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:16.99%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:15.384%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="5" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2019&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Fair Value Assumptions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;79.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;126.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;105.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;158.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;N/A&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;N/A&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.5 &lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;- &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.0&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.4&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;- &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.0&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;N/A&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;N/A&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;We recorded total stock-based compensation expense for the years ended December 31, 2021, 2020 and 2019 related to the 2014 Plan, the 2020 Plan and the 2020 ESPP in the statements of operations and allocated the amounts as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.717%;"/&gt;
        &lt;td style="width:1.349%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:12.781%;"/&gt;
        &lt;td style="width:0.91%;"/&gt;
        &lt;td style="width:1.349%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:12.77%;"/&gt;
        &lt;td style="width:0.91%;"/&gt;
        &lt;td style="width:1.349%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:12.792%;"/&gt;
        &lt;td style="width:0.931%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2019&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,954&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,861&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;368&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,775&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,573&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;817&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10,729&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,434&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,185&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Upon our IPO, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;362,935&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; performance-based awards vested and, as a result, we recognized $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million of stock-based compensation expense during the three months ended June 30, 2020, which amount is included in the above table for the year ended December 31, 2020.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;As of December 31, 2021, there was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;27.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million of unrecognized stock-based compensation expense related to the employee and non-employee awards, which is expected to be recognized over a weighted-average period of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.5 &lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;years.&lt;/span&gt;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <pcvx:IncentiveStockOptionGrantedToEmployeesOwningPercentageOfSharesOfCommonStock
      contextRef="C_e95a1cc5-e02c-42d9-9f9c-6159842d1e7c"
      decimals="2"
      id="F_eee65416-6dd2-4f4b-a427-a31f04bd66b0"
      unitRef="U_pure">0.10</pcvx:IncentiveStockOptionGrantedToEmployeesOwningPercentageOfSharesOfCommonStock>
    <pcvx:PercentageOfFairValuePerShareOnTheGrantDate
      contextRef="C_23381eb2-52cb-4648-a7ab-24309842b90d"
      decimals="2"
      id="F_fb4ac856-40e2-446e-824b-abd70d5104fa"
      unitRef="U_pure">1.10</pcvx:PercentageOfFairValuePerShareOnTheGrantDate>
    <pcvx:ExercisePriceExpireInYearsFormTheDateOfGrant
      contextRef="C_e25af62d-d63b-4e1b-8b46-d08c4c227921"
      id="F_839cf338-5185-4ed1-81ec-44d9d1c034ad">P5Y</pcvx:ExercisePriceExpireInYearsFormTheDateOfGrant>
    <pcvx:StockOptionsGrantedTerm
      contextRef="C_e25af62d-d63b-4e1b-8b46-d08c4c227921"
      id="F_0b704b6a-dd15-441b-be16-e91c97bb0865">P10Y</pcvx:StockOptionsGrantedTerm>
    <pcvx:PercentageOfProvisionsSubjectToStockholders
      contextRef="C_e25af62d-d63b-4e1b-8b46-d08c4c227921"
      decimals="2"
      id="F_6ad7ee30-b4b7-4488-89f9-46d319990ad8"
      unitRef="U_pure">0.10</pcvx:PercentageOfProvisionsSubjectToStockholders>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_88288d89-14d9-4c81-bcdc-77db4748e94f"
      id="F_54d585f0-b474-4f1e-b6c3-802bd373edad">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="C_88288d89-14d9-4c81-bcdc-77db4748e94f"
      decimals="2"
      id="F_89b5929e-20f4-4d22-9cc1-6474de98631e"
      unitRef="U_pure">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_88288d89-14d9-4c81-bcdc-77db4748e94f"
      id="F_7da23cee-0ea0-4990-b229-0d798c775eaf">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_a38e3261-0264-423e-b43f-742897fb5b71"
      decimals="INF"
      id="F_7f3f95a6-aa37-4608-95d4-ffeb72fb8a6e"
      unitRef="U_shares">10150000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="C_e25af62d-d63b-4e1b-8b46-d08c4c227921"
      id="F_2bd042df-217a-4d9e-be01-289b5fe9c564">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="C_e25af62d-d63b-4e1b-8b46-d08c4c227921"
      decimals="INF"
      id="F_f555a845-d0ff-4652-96fc-e62309c8fead"
      unitRef="U_pure">0.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_977bf646-5642-4ace-80e5-1617547b66ea"
      decimals="INF"
      id="F_565bc5db-f11c-4988-856e-c50c9dd0df3b"
      unitRef="U_shares">6104756</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <pcvx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreaseInAvailableForGrant
      contextRef="C_40beaa16-40f7-4f29-9069-2b64528824d9"
      decimals="INF"
      id="F_0cac84ce-39ff-4010-9a82-b8f032c04ba8"
      unitRef="U_shares">2651598</pcvx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreaseInAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_3e0e573b-cca9-436f-b585-f3bd61467bce"
      decimals="INF"
      id="F_c696bc1e-ee31-4428-83e9-f9163d63d926"
      unitRef="U_shares">3657394</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_977bf646-5642-4ace-80e5-1617547b66ea"
      decimals="INF"
      id="F_9b608ec2-046c-4f31-ba67-1eff4bc01fe5"
      unitRef="U_shares">1637613</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <pcvx:EarlyExercisedStockOptions
      contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350"
      decimals="INF"
      id="F_2872a19c-3b77-4d7a-923f-b16b653a88c4"
      unitRef="U_shares">7410</pcvx:EarlyExercisedStockOptions>
    <pcvx:EarlyExercisedStockOptions
      contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57"
      decimals="INF"
      id="F_cd323585-16d2-4c53-96ec-0b0a850e073b"
      unitRef="U_shares">15056</pcvx:EarlyExercisedStockOptions>
    <pcvx:RemainingLiabilitiesRelatedToEarlyExercisedShares
      contextRef="C_e702b57a-b360-45bc-a12c-2341ca21e0de"
      decimals="-5"
      id="F_38dd75c2-430b-4a71-a7e3-8b4ffb96d17c"
      unitRef="U_USD">100000</pcvx:RemainingLiabilitiesRelatedToEarlyExercisedShares>
    <pcvx:RemainingLiabilitiesRelatedToEarlyExercisedShares
      contextRef="C_afadb6ee-d738-47a2-9b09-0905934ee597"
      decimals="-5"
      id="F_71984bcd-60e9-47c0-8a37-a14493034932"
      unitRef="U_USD">100000</pcvx:RemainingLiabilitiesRelatedToEarlyExercisedShares>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="C_01ab22d2-811b-4087-b1ae-4007067b9a23"
      id="F_784d8107-4687-4f78-819c-e45d67fd5305">&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Activity under our 2020 Plan and 2014 Plan, which excludes options to purchase &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;62,382&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares granted outside of the 2020 Plan and 2014 Plan, was as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:43.015%;"/&gt;
        &lt;td style="width:0.963%;"/&gt;
        &lt;td style="width:0.707%;"/&gt;
        &lt;td style="width:8.522%;"/&gt;
        &lt;td style="width:0.91%;"/&gt;
        &lt;td style="width:0.963%;"/&gt;
        &lt;td style="width:0.685%;"/&gt;
        &lt;td style="width:8.575%;"/&gt;
        &lt;td style="width:0.91%;"/&gt;
        &lt;td style="width:0.963%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:7.976%;"/&gt;
        &lt;td style="width:0.685%;"/&gt;
        &lt;td style="width:0.963%;"/&gt;
        &lt;td style="width:0.846%;"/&gt;
        &lt;td style="width:10.213%;"/&gt;
        &lt;td style="width:0.685%;"/&gt;
        &lt;td style="width:0.963%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:8.008%;"/&gt;
        &lt;td style="width:0.685%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Options Outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Stock Option Activity&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Options&lt;br/&gt;Available&lt;br/&gt;for &lt;br/&gt;Grant&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Number&lt;br/&gt;of&lt;br/&gt;Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price Per&lt;br/&gt;Share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual &lt;br/&gt;Term&lt;br/&gt;(Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Balances &#x2014; December 31, 2019&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;835,941&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;3,297,586&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;1.93&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Additional shares authorized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;5,997,435&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Options granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;2,255,690&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;2,255,690&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;8.93&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Options exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;358,264&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;1.88&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Options forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;73,463&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;73,463&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;3.50&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Balances &#x2014; December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;4,651,149&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;5,121,549&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;4.99&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Additional shares authorized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;2,553,579&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Options granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;1,616,021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;1,616,021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;21.83&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Options exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;926,514&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;3.25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Options forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;516,049&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;516,049&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;16.70&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Balances &#x2014; December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;6,104,756&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;5,295,007&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;9.30&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;7.89&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;78,604&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Vested and expected to vest &#x2014; December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;5,295,007&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;9.30&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;7.89&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;78,604&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Exercisable at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;2,611,523&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;4.76&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;7.07&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;50,123&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001"
      decimals="INF"
      id="F_1fcf3eac-a125-4ba7-9b95-b9392f143125"
      unitRef="U_shares">62382</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_00eaf7db-5639-43a7-9d93-1b5cbcde71cf"
      decimals="INF"
      id="F_d05b5c6c-e3ed-431f-961a-bbb1660ef8ca"
      unitRef="U_shares">835941</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_00eaf7db-5639-43a7-9d93-1b5cbcde71cf"
      decimals="INF"
      id="F_44021f4d-9108-42e3-9987-cbc560483c2b"
      unitRef="U_shares">3297586</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_00eaf7db-5639-43a7-9d93-1b5cbcde71cf"
      decimals="2"
      id="F_c9f92833-55dd-4353-8ccb-00b4dbb46115"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="C_fd7551c1-f7f9-4cde-a040-39d423a71993"
      decimals="INF"
      id="F_990bdab6-9319-4b92-b1f3-3a580804eccb"
      unitRef="U_shares">5997435</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <pcvx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantedInPeriod
      contextRef="C_fd7551c1-f7f9-4cde-a040-39d423a71993"
      decimals="INF"
      id="F_90c51d6c-8f35-4a34-b8cb-4732b498231d"
      unitRef="U_shares">2255690</pcvx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_fd7551c1-f7f9-4cde-a040-39d423a71993"
      decimals="INF"
      id="F_bda00a60-73cf-4414-8787-7108f6dc15f4"
      unitRef="U_shares">2255690</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_fd7551c1-f7f9-4cde-a040-39d423a71993"
      decimals="2"
      id="F_b6a72018-9097-4581-a5c2-ba191742384d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">8.93</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_fd7551c1-f7f9-4cde-a040-39d423a71993"
      decimals="INF"
      id="F_b12763e0-b811-4a2f-a9a1-552e3a7c1a98"
      unitRef="U_shares">358264</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_fd7551c1-f7f9-4cde-a040-39d423a71993"
      decimals="2"
      id="F_1e00b13d-5ce3-41c6-81b9-89883434fc4c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.88</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <pcvx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeitedInPeriod
      contextRef="C_fd7551c1-f7f9-4cde-a040-39d423a71993"
      decimals="INF"
      id="F_162e5147-4a78-4cca-9125-b375cd163f10"
      unitRef="U_shares">73463</pcvx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_fd7551c1-f7f9-4cde-a040-39d423a71993"
      decimals="INF"
      id="F_187fd4e9-2a9f-4511-b36f-409a0a0085d5"
      unitRef="U_shares">73463</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_fd7551c1-f7f9-4cde-a040-39d423a71993"
      decimals="2"
      id="F_4f8f6f79-33e5-4bbc-8010-a4acb97cb919"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.50</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_4469bcba-dbf3-41b7-810d-1333a6644626"
      decimals="INF"
      id="F_9e4c5af5-27af-4a7c-82c8-942b63fc00b5"
      unitRef="U_shares">4651149</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_4469bcba-dbf3-41b7-810d-1333a6644626"
      decimals="INF"
      id="F_5cbfb251-a2ec-428b-9517-f8b7b7585b9b"
      unitRef="U_shares">5121549</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_4469bcba-dbf3-41b7-810d-1333a6644626"
      decimals="2"
      id="F_3a2dde2c-6eaa-417e-a42d-1ef62ad5918d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">4.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="C_01ab22d2-811b-4087-b1ae-4007067b9a23"
      decimals="INF"
      id="F_e71dfda3-c279-4e1e-a6ec-14178d63e07e"
      unitRef="U_shares">2553579</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <pcvx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantedInPeriod
      contextRef="C_01ab22d2-811b-4087-b1ae-4007067b9a23"
      decimals="INF"
      id="F_9d1ea714-982c-4b07-9a4e-717b4de0f75f"
      unitRef="U_shares">1616021</pcvx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_01ab22d2-811b-4087-b1ae-4007067b9a23"
      decimals="INF"
      id="F_c6e94187-101e-4c51-81ad-dc0a1bfc710f"
      unitRef="U_shares">1616021</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_01ab22d2-811b-4087-b1ae-4007067b9a23"
      decimals="2"
      id="F_d101696e-6798-434e-84f0-32642906d45a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">21.83</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_01ab22d2-811b-4087-b1ae-4007067b9a23"
      decimals="INF"
      id="F_c693c9a5-0b1a-42f7-aee0-399c40d0de7d"
      unitRef="U_shares">926514</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_01ab22d2-811b-4087-b1ae-4007067b9a23"
      decimals="2"
      id="F_a6e413cb-47b8-4bd4-b8da-c94df7112281"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.25</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <pcvx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeitedInPeriod
      contextRef="C_01ab22d2-811b-4087-b1ae-4007067b9a23"
      decimals="INF"
      id="F_fd75c047-86ca-41a8-9547-20f2c6384d5c"
      unitRef="U_shares">516049</pcvx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_01ab22d2-811b-4087-b1ae-4007067b9a23"
      decimals="INF"
      id="F_3ff2d980-68ca-49bd-aaf4-1480e5916b08"
      unitRef="U_shares">516049</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_01ab22d2-811b-4087-b1ae-4007067b9a23"
      decimals="2"
      id="F_99219f9f-b29e-4246-9dce-b0be82693d81"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">16.70</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_58ad6f5b-2983-4459-8fd3-3b4fbdef1c36"
      decimals="INF"
      id="F_a4ce24bd-35b0-48cb-b869-9a8627d7a0a9"
      unitRef="U_shares">6104756</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_58ad6f5b-2983-4459-8fd3-3b4fbdef1c36"
      decimals="INF"
      id="F_d818b004-b9cb-4cab-80c8-d402f3fab4ea"
      unitRef="U_shares">5295007</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_58ad6f5b-2983-4459-8fd3-3b4fbdef1c36"
      decimals="2"
      id="F_707995aa-08ce-4b0c-8ce5-bc5e823080ee"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">9.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_01ab22d2-811b-4087-b1ae-4007067b9a23"
      id="F_6d206f60-c7f4-4ecd-a259-ff10812c55b3">P7Y10M20D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_58ad6f5b-2983-4459-8fd3-3b4fbdef1c36"
      decimals="-3"
      id="F_ab3cb2fc-7a05-49cc-9cc9-fb24eaf2be97"
      unitRef="U_USD">78604000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="C_58ad6f5b-2983-4459-8fd3-3b4fbdef1c36"
      decimals="INF"
      id="F_26b2fc59-b43f-4912-8656-08ce564b1d1b"
      unitRef="U_shares">5295007</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="C_58ad6f5b-2983-4459-8fd3-3b4fbdef1c36"
      decimals="2"
      id="F_addf8c13-3d8b-4aa2-9d88-9d5f362b4ca2"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">9.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="C_01ab22d2-811b-4087-b1ae-4007067b9a23"
      id="F_b128315d-e8bb-4ae8-9338-a5fe2cdab7de">P7Y10M20D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="C_58ad6f5b-2983-4459-8fd3-3b4fbdef1c36"
      decimals="-3"
      id="F_6a40e02d-b493-4879-8848-55d574a1b090"
      unitRef="U_USD">78604000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_58ad6f5b-2983-4459-8fd3-3b4fbdef1c36"
      decimals="INF"
      id="F_b573c617-89d4-4b1e-a81f-d87d4880ac51"
      unitRef="U_shares">2611523</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_58ad6f5b-2983-4459-8fd3-3b4fbdef1c36"
      decimals="2"
      id="F_3e05b039-bb94-4fd2-9ea2-cae486ae0c7e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">4.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_01ab22d2-811b-4087-b1ae-4007067b9a23"
      id="F_61fbd386-9b6a-4e15-9a5f-ff424fc2b6a6">P7Y25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="C_58ad6f5b-2983-4459-8fd3-3b4fbdef1c36"
      decimals="-3"
      id="F_b20c43da-f5b1-41cb-ae07-d2b9313c5582"
      unitRef="U_USD">50123000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <pcvx:NumberOfOptionsExercisedExcludesOptionsExercisedFromNpln
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      decimals="INF"
      id="F_99dd6898-ae16-4042-9aea-9348c9ab7562"
      unitRef="U_shares">926514</pcvx:NumberOfOptionsExercisedExcludesOptionsExercisedFromNpln>
    <pcvx:NumberOfOptionsExercisedExcludesOptionsExercisedFromNpln
      contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001"
      decimals="INF"
      id="F_0c3f46de-9fa3-4aa4-a3f7-49af52d9bcf0"
      unitRef="U_shares">358264</pcvx:NumberOfOptionsExercisedExcludesOptionsExercisedFromNpln>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      decimals="2"
      id="F_c0e580f4-1463-4c5a-9f85-a8affd1b53c0"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.25</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001"
      decimals="2"
      id="F_97ae7bcf-02b3-4ddb-a9d8-256ec3b82ec6"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.88</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      decimals="2"
      id="F_ccaedb14-5b69-4d3f-9d6d-6715252a5b46"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">14.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001"
      decimals="2"
      id="F_ca7d0811-8a34-4b10-b771-9d7bc21c4d7b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">9.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      decimals="-5"
      id="F_586aad49-062f-4e90-8184-dd8575fa31ca"
      unitRef="U_USD">18900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001"
      decimals="-5"
      id="F_8ef6134d-f1c5-4c19-9524-aa16a09b1b47"
      unitRef="U_USD">7800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate
      contextRef="C_1efdf0c7-6a07-4132-8782-b57177c53f15"
      decimals="INF"
      id="F_d123efd0-e959-456f-b277-01af114c6402"
      unitRef="U_pure">0.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="C_c8d7f783-8f05-4c35-8444-31988eb17d2e"
      decimals="2"
      id="F_bcdc2fc6-0bf6-4ae1-bbd7-b29abe8cc865"
      unitRef="U_pure">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <pcvx:PurchasePeriod
      contextRef="C_c8d7f783-8f05-4c35-8444-31988eb17d2e"
      id="F_fc33b9e4-fc8c-4a64-8f38-09f7971ecf3c">P6M</pcvx:PurchasePeriod>
    <pcvx:OfferingPeriod
      contextRef="C_c8d7f783-8f05-4c35-8444-31988eb17d2e"
      id="F_d8986d6b-383a-4cf4-9c36-958dd1ff0ad4">P2Y</pcvx:OfferingPeriod>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_1efdf0c7-6a07-4132-8782-b57177c53f15"
      decimals="INF"
      id="F_3c497adb-3fa1-4cbf-ac0f-c73f260e4cd0"
      unitRef="U_shares">650000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="C_c8d7f783-8f05-4c35-8444-31988eb17d2e"
      id="F_8f312546-0c9d-4e62-8884-795fe73ba102">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="C_c8d7f783-8f05-4c35-8444-31988eb17d2e"
      decimals="INF"
      id="F_11e7dd66-4249-48a9-a153-8b580db36cc0"
      unitRef="U_pure">0.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward
      contextRef="C_b2d931e6-c3f8-485c-8729-b21db15df907"
      decimals="INF"
      id="F_c2a536e7-2c72-43e0-9e6c-5a196addcaac"
      unitRef="U_shares">62546</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_83b9a259-045e-40be-a3dc-3d06c253dc05"
      decimals="INF"
      id="F_f64278e5-9ed2-4e9f-b905-577f97bf9ea8"
      unitRef="U_shares">1070704</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <pcvx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreaseInAvailableForGrant
      contextRef="C_3d43ebd8-c6c9-4618-9f17-19b5fc65cecf"
      decimals="INF"
      id="F_c9c76b9c-28f3-4fe3-af9b-07fe35b7e2d0"
      unitRef="U_shares">530319</pcvx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreaseInAvailableForGrant>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      id="F_060a8860-f7fe-4286-a0e2-c5286ece664b">&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;We estimated the fair value of employee stock options using the Black-Scholes option-pricing model for the years ended December 31, 2021, 2020 and 2019 using the following weighted-average assumptions:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.31%;"/&gt;
        &lt;td style="width:1.36%;"/&gt;
        &lt;td style="width:15.203%;"/&gt;
        &lt;td style="width:1.36%;"/&gt;
        &lt;td style="width:15.203%;"/&gt;
        &lt;td style="width:1.36%;"/&gt;
        &lt;td style="width:15.203%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="5" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2019&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Fair Value Assumptions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;81.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;84.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;81.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;94.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;78.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;80.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.3 &lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;- &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.5&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.6&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;- &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.9&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;- &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      decimals="3"
      id="F_2a21d106-0c7c-4c6b-98c6-7a5fc4de33c1"
      unitRef="U_pure">0.810</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      decimals="3"
      id="F_80bc04b3-ec13-4b84-bf0d-d9b74db138dc"
      unitRef="U_pure">0.841</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001"
      decimals="3"
      id="F_ccd232b7-96a9-45f4-8568-77231343c456"
      unitRef="U_pure">0.812</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001"
      decimals="3"
      id="F_839dfb7f-8ac5-41ff-ad53-9ca339635549"
      unitRef="U_pure">0.941</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700"
      decimals="3"
      id="F_4a6528ed-8875-4916-ad16-10242adeb410"
      unitRef="U_pure">0.784</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700"
      decimals="3"
      id="F_1b17f657-f870-4ec7-860b-e52e64bc9b77"
      unitRef="U_pure">0.804</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      decimals="2"
      id="F_a2d0582e-e680-4a31-81f8-f50e69de0a35"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001"
      decimals="2"
      id="F_9f44e5af-a21d-4411-8d20-88af65a6f308"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700"
      decimals="2"
      id="F_43426f78-dc4f-4daa-a86f-9e815b0ee127"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_a9e696e6-57cc-4729-8788-4c5e9e4ec861"
      id="F_14f0837b-63d7-440a-9550-5154bea12c03">P5Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_68377845-3bf8-42a9-ba72-9a3b693b78a1"
      id="F_83311f14-6b69-4f3f-b71a-8220038d9333">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_04acb199-245c-4c72-a959-3ad34a1f3b9f"
      id="F_ae281aad-e6c5-4780-8f35-0b1dcb62171a">P5Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_d1c4c865-1394-49a2-907a-e54a6cd8c170"
      id="F_2de4b24e-ada1-49c6-895d-5d5b5afde68c">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_ca7ed438-6716-4360-8ccd-eaaa38f9fcf2"
      id="F_03a72ea3-f121-4a6a-8336-bb1d3db9a14b">P5Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_c4319f5e-0947-41f2-9bc7-187004e5a87b"
      id="F_a4d81b6f-55e7-4e47-8b2e-f6342a57ee8e">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      decimals="INF"
      id="F_e32c8fb7-8790-41f0-9fd7-25e431d2c5bd"
      unitRef="U_pure">0.005</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      decimals="INF"
      id="F_384282de-e9e8-4824-84f7-bee7530d7bd4"
      unitRef="U_pure">0.013</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001"
      decimals="INF"
      id="F_aeb5f4a4-09f2-4474-865e-5da86c102db0"
      unitRef="U_pure">0.003</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001"
      decimals="INF"
      id="F_32a96c0d-e432-4078-b6d3-57502dce95a8"
      unitRef="U_pure">0.014</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700"
      decimals="INF"
      id="F_28801f32-66e0-4d60-9f35-d5ebf0856d8c"
      unitRef="U_pure">0.016</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700"
      decimals="INF"
      id="F_d2d619fb-7414-4287-a989-18cc979b3c20"
      unitRef="U_pure">0.024</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock
      contextRef="C_b2d931e6-c3f8-485c-8729-b21db15df907"
      id="F_79a2966e-6b64-47da-863f-7f8d425891fb">&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;We estimated the fair value of shares under the 2020 ESPP using the Black-Scholes option-pricing model for the years ended December 31, 2021, 2020 and 2019 using the following weighted-average assumptions:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:48.1%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:15.384%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:16.99%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:15.384%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="5" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2019&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Fair Value Assumptions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;79.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;126.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;105.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;158.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;N/A&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;N/A&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.5 &lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;- &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.0&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.4&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;- &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.0&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;N/A&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;N/A&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_b2d931e6-c3f8-485c-8729-b21db15df907"
      decimals="3"
      id="F_1cef25ad-9d83-417d-87d4-35f96f084f3f"
      unitRef="U_pure">0.796</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_b2d931e6-c3f8-485c-8729-b21db15df907"
      decimals="3"
      id="F_7a8e8e99-6def-49a5-a862-5869187a723b"
      unitRef="U_pure">1.263</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_6bfa48d9-3084-49f0-aff3-43a54ae90a96"
      decimals="3"
      id="F_93ef16be-f09a-4701-9a48-63df2a1f8a49"
      unitRef="U_pure">1.058</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_6bfa48d9-3084-49f0-aff3-43a54ae90a96"
      decimals="3"
      id="F_34e8b3bc-0ebb-454e-98f8-470e1ae28704"
      unitRef="U_pure">1.582</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_b2d931e6-c3f8-485c-8729-b21db15df907"
      decimals="2"
      id="F_577c61e9-9507-4ab3-ad13-c2c804be9c7f"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_6bfa48d9-3084-49f0-aff3-43a54ae90a96"
      decimals="2"
      id="F_f98b5ecc-617a-4e2d-a8e8-a64d059066e6"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_70588bd5-1fdc-44ee-a7cf-7d459c6fc883"
      id="F_a38249a1-903e-497b-a2f1-7864c67739e8">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_bebcd826-aabe-4884-ab32-26215b024f1a"
      id="F_5b571815-6307-4ab7-a618-df764b52c234">P2Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_f2e3d587-c577-46eb-a487-767a66753618"
      id="F_2c10bd3a-500c-47e9-8ff2-987741dd4834">P0Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_04918cd3-bad5-49f6-b891-9bebcd71baa0"
      id="F_05f695d7-7a63-4c7c-9582-ed8ed93afc09">P2Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_b2d931e6-c3f8-485c-8729-b21db15df907"
      decimals="3"
      id="F_808dbf57-6164-4b95-8747-8c84f6930b04"
      unitRef="U_pure">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_b2d931e6-c3f8-485c-8729-b21db15df907"
      decimals="3"
      id="F_549ef6b4-b39f-4422-9992-2481e5e9a3e6"
      unitRef="U_pure">0.005</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_6bfa48d9-3084-49f0-aff3-43a54ae90a96"
      decimals="3"
      id="F_f987fe71-75f1-4ef5-8ba8-4e44e6247a0a"
      unitRef="U_pure">0.001</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_6bfa48d9-3084-49f0-aff3-43a54ae90a96"
      decimals="3"
      id="F_470eef70-7337-4754-9e14-0c27f483ad63"
      unitRef="U_pure">0.002</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
      contextRef="C_e8c80ef0-b66f-48cb-8236-662fca240430"
      id="F_dc3259ef-af3a-4e6c-af73-e8f193e0b24e">&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;We recorded total stock-based compensation expense for the years ended December 31, 2021, 2020 and 2019 related to the 2014 Plan, the 2020 Plan and the 2020 ESPP in the statements of operations and allocated the amounts as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.717%;"/&gt;
        &lt;td style="width:1.349%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:12.781%;"/&gt;
        &lt;td style="width:0.91%;"/&gt;
        &lt;td style="width:1.349%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:12.77%;"/&gt;
        &lt;td style="width:0.91%;"/&gt;
        &lt;td style="width:1.349%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:12.792%;"/&gt;
        &lt;td style="width:0.931%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2019&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,954&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,861&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;368&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,775&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,573&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;817&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10,729&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,434&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,185&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_3562faed-85c8-4ea5-a88d-038f23029b7d"
      decimals="-3"
      id="F_02e6a6c7-3847-4e4b-bf5b-27102633274d"
      unitRef="U_USD">3954000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_bfcc9c06-d2c1-452e-8ef8-cffaed58bf95"
      decimals="-3"
      id="F_85a07fe2-88c4-4db0-874f-9795016d3cbb"
      unitRef="U_USD">1861000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_34fb7648-e015-48b0-95af-d232d9d8d189"
      decimals="-3"
      id="F_f9d2b3c1-1dda-4d41-824e-79755d150816"
      unitRef="U_USD">368000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_14ff4d59-3fca-47b7-aa38-4bd882e8ae38"
      decimals="-3"
      id="F_61248c9f-2e7e-4245-a947-97dac45e0e21"
      unitRef="U_USD">6775000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_5a9d30f7-2f17-4c61-b4cc-72ab32702c3f"
      decimals="-3"
      id="F_a5226ade-7817-413b-8278-aa78617f3e4f"
      unitRef="U_USD">3573000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_d5f3d746-38cf-4e03-93db-68b59ff6ca6e"
      decimals="-3"
      id="F_c61bff5e-b5fd-4817-8ec9-029be3de4085"
      unitRef="U_USD">817000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_e8c80ef0-b66f-48cb-8236-662fca240430"
      decimals="-3"
      id="F_b0fcea3e-515d-44b9-bf4f-946a9faf3395"
      unitRef="U_USD">10729000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_12a75901-fd10-4da6-bb07-c58c55e98510"
      decimals="-3"
      id="F_95ce736e-3da6-4d4d-b71d-7fcbf1be978e"
      unitRef="U_USD">5434000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_9001db26-8d96-496f-9fd0-ccbff0d80378"
      decimals="-3"
      id="F_72b7b47c-9225-43d7-bdd8-240e2f5d36c8"
      unitRef="U_USD">1185000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="C_61d1fa2e-cb6c-418c-bc91-f7bc598be5a9"
      decimals="INF"
      id="F_126dce16-5ccd-4c96-8c06-de81dcd18508"
      unitRef="U_shares">362935</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_17e8d504-7444-46d1-a94b-f46e5cb44fae"
      decimals="-5"
      id="F_6b368e47-f09b-4423-8f7d-32c3a5d9a1bf"
      unitRef="U_USD">300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350"
      decimals="-5"
      id="F_0745c1ff-3aab-489a-bd2e-f2897d8096fd"
      unitRef="U_USD">27500000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      id="F_de5c90f3-c3c4-4807-8d51-fa7725079f8b">P2Y6M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <pcvx:FundingArrangementTextBlock
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      id="F_921b9fb7-5e3e-49f7-a0d8-f0ed52cd45d3">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;11. Funding Arrangement&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In July 2019, we received a cost-reimbursement research award from Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (&#x201c;CARB-X&#x201d;), a public-private partnership funded under a Cooperative Agreement from Assistant Secretary for Preparedness and Response/Biomedical Advanced Research and Development Authority (&#x201c;BARDA&#x201d;) and by awards from Wellcome Trust, Germany&#x2019;s Federal Ministry of Education and Research, the United Kingdom Global Antimicrobial Resistance Innovation Fund and the Bill &amp;amp; Melinda Gates Foundation. In connection with this funding, we entered into a cost-reimbursement sub-award agreement with the Trustees of Boston University, the administrator of the program. The initial award provided the potential for funding up to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;four years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; to develop a universal vaccine to prevent infections caused by Group A Strep bacteria, which include pharyngitis, impetigo and necrotizing fasciitis. The initial award committed initial funding of up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million for our VAX-A1 program and, subject to a CARB-X decision to extend the options, up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;15.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million in total funding available upon achievement of development milestones over the next &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;four years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. Specified research expenditures are reimbursable expenses associated with agreed-upon activities needed to advance the research project supported by the grant. These expenditures can include labor, laboratory supplies, travel, consulting and third-party vendor research and development support costs.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In July 2020, the CARB-X agreement was amended with the initial funding amount increased from $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million. In December 2020, we reached the maximum CARB-X funding limit for this initial funding period, and subsequently submitted our funding proposal to CARB-X for the next period under our agreement. In April 2021, we received approval for the next phase of CARB-X development and executed the cost-reimbursement sub-award agreement with the Trustees of Boston University in August 2021. Pursuant to the agreement, the award committed additional funding of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million for IND-enabling activities and total potential funding of up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;29.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million (including the current $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million award and the prior $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million award) upon the achievement of future VAX-A1 development milestones. In January 2022, CARB-X revised the parameters for the contribution of CARB-X funding and implemented maximum funding levels for all grant recipients. As a result, our total funding available upon achievement of development milestones through Phase 1 human clinical trials was revised from $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;29.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;13.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;      &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In April 2021, we received a cost-reimbursement research award from the National Institutes of Health (&#x201c;NIH&#x201d;). In connection with this funding, we entered into a cost-reimbursement sub-award agreement with the University of Maryland, Baltimore, the administrator of the program. The award provides for potential funding up to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; totaling approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million to develop a vaccine to prevent infections caused by Shigella.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Income from grants is recognized in the period during which the related specified expenses are incurred, provided that the conditions under which the grants were provided have been met. We recognized $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million of grant income and recorded the amounts in Other income (expense), net in the statement of operations during the years ended December 31, 2021, 2020, and 2019 respectively. A grant receivable of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million representing unreimbursed, eligible costs incurred under the CARB-X agreement was recorded and included in Prepaid expenses and other current assets in the balance sheet as of December 31, 2021 and 2020, respectively.&lt;/span&gt;&lt;/p&gt;</pcvx:FundingArrangementTextBlock>
    <pcvx:FundingPeriodOfAwardToDevelopUniversalVaccineToPreventInfections
      contextRef="C_017473b9-4a6d-4b35-bafe-2f3035074c39"
      id="F_fb8e1947-f07b-4a42-bc35-1c0fc0abaa51">P4Y</pcvx:FundingPeriodOfAwardToDevelopUniversalVaccineToPreventInfections>
    <pcvx:InitialFundingCommittedByAward
      contextRef="C_e7331c69-2305-4247-a515-eb0da32be4fd"
      decimals="INF"
      id="F_20115ae5-de98-4fb3-b696-51c9d3323bc7"
      unitRef="U_USD">1600000</pcvx:InitialFundingCommittedByAward>
    <pcvx:FundingCommittedByAwardAvailableUponAchievementOfDevelopmentMilestones
      contextRef="C_e7331c69-2305-4247-a515-eb0da32be4fd"
      decimals="-5"
      id="F_c8117820-e3ef-428b-a5f0-aef42ba71c42"
      unitRef="U_USD">15100000</pcvx:FundingCommittedByAwardAvailableUponAchievementOfDevelopmentMilestones>
    <pcvx:FundingPeriodOfAwardToDevelopUniversalVaccineToPreventInfections
      contextRef="C_017473b9-4a6d-4b35-bafe-2f3035074c39"
      id="F_6e3c677f-98de-4dae-b2d1-2f0944d0db6a">P4Y</pcvx:FundingPeriodOfAwardToDevelopUniversalVaccineToPreventInfections>
    <pcvx:InitialFundingCommittedByAward
      contextRef="C_6da3f8ad-d2ec-440b-a451-9dbaebaea6e0"
      decimals="INF"
      id="F_f39a1954-9e17-48fc-88f2-74aac269d924"
      unitRef="U_USD">1600000</pcvx:InitialFundingCommittedByAward>
    <pcvx:InitialFundingCommittedByAward
      contextRef="C_af5ccde9-e011-49f2-9896-792a8871b96a"
      decimals="INF"
      id="F_d2593e50-5a5b-457a-b304-20c496138269"
      unitRef="U_USD">2700000</pcvx:InitialFundingCommittedByAward>
    <pcvx:AdditionalFundingCommittedByAward
      contextRef="C_fd58b7dd-25a0-4a70-92a2-457d12426c58"
      decimals="-5"
      id="F_156b1851-faf5-4804-bacb-f1c2e0a8b427"
      unitRef="U_USD">3200000</pcvx:AdditionalFundingCommittedByAward>
    <pcvx:PotentialFundingCommittedByAward
      contextRef="C_a1d232a3-c6a3-4bd1-9776-35c32d836d64"
      decimals="-5"
      id="F_1464ab4c-efbc-4afd-999c-2878edb0e41c"
      unitRef="U_USD">29700000</pcvx:PotentialFundingCommittedByAward>
    <pcvx:AdditionalFundingCommittedByAward
      contextRef="C_a1d232a3-c6a3-4bd1-9776-35c32d836d64"
      decimals="-5"
      id="F_2c291ae1-b9d2-4781-b7b1-97f831a6ca3c"
      unitRef="U_USD">3200000</pcvx:AdditionalFundingCommittedByAward>
    <pcvx:InitialFundingCommittedByAward
      contextRef="C_af5ccde9-e011-49f2-9896-792a8871b96a"
      decimals="-5"
      id="F_917df391-8544-4b1f-a9dd-73fb30be62bb"
      unitRef="U_USD">2700000</pcvx:InitialFundingCommittedByAward>
    <pcvx:PotentialFundingCommittedByAward
      contextRef="C_a1d232a3-c6a3-4bd1-9776-35c32d836d64"
      decimals="-5"
      id="F_48c08940-318e-41b8-82c0-03cb8a3e3719"
      unitRef="U_USD">29700000</pcvx:PotentialFundingCommittedByAward>
    <pcvx:PotentialFundingCommittedByAward
      contextRef="C_92f1ced7-c143-458c-9b8e-7abfc0c425d9"
      decimals="-5"
      id="F_fdf869b7-8fc0-4afa-b6bc-b80b27a52044"
      unitRef="U_USD">13900000</pcvx:PotentialFundingCommittedByAward>
    <pcvx:PotentialFundingPeriodOfAwardToDevelopVaccineToPreventInfections
      contextRef="C_0830660e-391f-4e25-8658-4f38f275d086"
      id="F_8965ed5d-d188-49c8-b88e-d527d2b20855">P5Y</pcvx:PotentialFundingPeriodOfAwardToDevelopVaccineToPreventInfections>
    <pcvx:PotentialFundingAmountOfAwardToDevelopVaccineToPreventInfections
      contextRef="C_c44b9b74-3efa-4a2d-b6b0-c053a39e9f18"
      decimals="-5"
      id="F_c845f66c-0c3b-47f7-a969-fc0b65240c73"
      unitRef="U_USD">500000</pcvx:PotentialFundingAmountOfAwardToDevelopVaccineToPreventInfections>
    <pcvx:GrantIncome
      contextRef="C_7ac26ea9-aa26-46d1-b9ed-042601b4004d"
      decimals="-5"
      id="F_1ecd9785-2ee2-4f2f-887b-08edf74310bb"
      unitRef="U_USD">1600000</pcvx:GrantIncome>
    <pcvx:GrantIncome
      contextRef="C_c2d425b8-8bfe-4616-b9aa-1a6041c6bb18"
      decimals="-5"
      id="F_cf17e347-3476-4974-9280-ae62f3614145"
      unitRef="U_USD">2500000</pcvx:GrantIncome>
    <pcvx:GrantIncome
      contextRef="C_32b0b6ee-9dc1-4ce6-9ecd-470c2a71985a"
      decimals="-5"
      id="F_745bb124-1bf4-407f-ab28-8c56965dd16f"
      unitRef="U_USD">200000</pcvx:GrantIncome>
    <us-gaap:GrantsReceivable
      contextRef="C_ed58902d-2f75-4902-a5af-e641599b12d5"
      decimals="-5"
      id="F_bb20548c-573b-42c1-9df6-bfe16bad8079"
      unitRef="U_USD">1200000</us-gaap:GrantsReceivable>
    <us-gaap:GrantsReceivable
      contextRef="C_039297c3-6466-43f6-840d-9c5a04a312b3"
      decimals="-5"
      id="F_84c6164b-f998-40c2-a911-e673fb2ddd5c"
      unitRef="U_USD">300000</us-gaap:GrantsReceivable>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      id="F_436f57af-b31e-4845-95b3-2b7be26be64a">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;12. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Net Loss Per Share&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following table sets forth the computation of basic and diluted net loss per share and excludes shares which are legally outstanding, but subject to repurchase by us:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.198%;"/&gt;
        &lt;td style="width:1.231%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:10.692%;"/&gt;
        &lt;td style="width:0.92%;"/&gt;
        &lt;td style="width:1.231%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:10.714%;"/&gt;
        &lt;td style="width:0.942%;"/&gt;
        &lt;td style="width:1.252%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:10.735%;"/&gt;
        &lt;td style="width:0.942%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2019&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Net loss (in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;100,077&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;89,217&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;50,274&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Weighted-average shares outstanding used in computing net&lt;br/&gt;&#160;&#160;&#160;loss per share, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;51,922,108&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;29,545,810&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,795,090&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Net loss per share, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.93&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3.02&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;13.25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following potentially dilutive securities were excluded from the computation of diluted net loss per share for the period presented because including them would have been antidilutive:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.444%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:1.006%;"/&gt;
        &lt;td style="width:10.767%;"/&gt;
        &lt;td style="width:1.006%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:1.006%;"/&gt;
        &lt;td style="width:10.767%;"/&gt;
        &lt;td style="width:1.006%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:1.006%;"/&gt;
        &lt;td style="width:10.842%;"/&gt;
        &lt;td style="width:1.006%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2019&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,357,389&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,188,531&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,364,568&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Redeemable convertible preferred stock:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Series A&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,225,719&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Series B&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,786,896&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Series C&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,377,480&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Common stock warrant&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;31,857&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Redeemable convertible preferred stock warrant&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;59,276&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,357,389&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,188,531&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;23,845,796&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      id="F_61a2170d-ea99-48bc-b55d-8a5db69e555a">&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following table sets forth the computation of basic and diluted net loss per share and excludes shares which are legally outstanding, but subject to repurchase by us:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.198%;"/&gt;
        &lt;td style="width:1.231%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:10.692%;"/&gt;
        &lt;td style="width:0.92%;"/&gt;
        &lt;td style="width:1.231%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:10.714%;"/&gt;
        &lt;td style="width:0.942%;"/&gt;
        &lt;td style="width:1.252%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:10.735%;"/&gt;
        &lt;td style="width:0.942%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2019&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Net loss (in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;100,077&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;89,217&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;50,274&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Weighted-average shares outstanding used in computing net&lt;br/&gt;&#160;&#160;&#160;loss per share, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;51,922,108&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;29,545,810&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,795,090&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Net loss per share, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.93&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3.02&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;13.25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      decimals="-3"
      id="F_a9e1e490-cf34-4ab0-919e-50f9251b5591"
      unitRef="U_USD">-100077000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001"
      decimals="-3"
      id="F_9eddf30b-a9b8-4138-87a2-0a134b3c40d3"
      unitRef="U_USD">-89217000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700"
      decimals="-3"
      id="F_89697f9c-ee29-42d4-88fe-fcf207396690"
      unitRef="U_USD">-50274000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      decimals="0"
      id="F_56328ed3-2069-4c96-a382-0a4159f997e3"
      unitRef="U_shares">51922108</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001"
      decimals="0"
      id="F_e31f8947-01a1-4992-bca6-ca8ea5914411"
      unitRef="U_shares">29545810</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700"
      decimals="0"
      id="F_0d7816df-40d4-4f49-995c-419051700e17"
      unitRef="U_shares">3795090</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      decimals="2"
      id="F_6654362f-697d-424b-bafa-eac955ca66fc"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.93</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001"
      decimals="2"
      id="F_8063f228-59e8-4414-ae99-94562e58c3b7"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-3.02</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700"
      decimals="2"
      id="F_e03cbc24-19bb-4546-abae-eb6ab695ec41"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-13.25</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      id="F_67689a84-1e02-47b1-ad4d-c6b2e5e51391">&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following potentially dilutive securities were excluded from the computation of diluted net loss per share for the period presented because including them would have been antidilutive:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.444%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:1.006%;"/&gt;
        &lt;td style="width:10.767%;"/&gt;
        &lt;td style="width:1.006%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:1.006%;"/&gt;
        &lt;td style="width:10.767%;"/&gt;
        &lt;td style="width:1.006%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:1.006%;"/&gt;
        &lt;td style="width:10.842%;"/&gt;
        &lt;td style="width:1.006%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2019&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,357,389&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,188,531&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,364,568&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Redeemable convertible preferred stock:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Series A&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,225,719&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Series B&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,786,896&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Series C&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,377,480&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Common stock warrant&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;31,857&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Redeemable convertible preferred stock warrant&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;59,276&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,357,389&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,188,531&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;23,845,796&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_1c84ebe2-ee47-4498-9c45-6e43ebdd4a7a"
      decimals="0"
      id="F_c1d038fe-929d-4898-ac5f-f868b2056469"
      unitRef="U_shares">5357389</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_cf8c9eeb-5415-47f7-97f3-ce1e53cabf5b"
      decimals="0"
      id="F_d8628df8-4530-44a0-bf2f-5eba3560da55"
      unitRef="U_shares">5188531</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_ccf431e6-d93a-4a5a-884d-651e8f20892e"
      decimals="0"
      id="F_12eb7a50-6de0-42b6-8c1e-d84d16ff0272"
      unitRef="U_shares">3364568</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_c8071e48-943e-4850-b4a1-a2bca3238b71"
      decimals="0"
      id="F_7e29772a-5146-4182-aee3-820bd949649d"
      unitRef="U_shares">6225719</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_a7a54056-1b96-4694-a8be-248476ad36f9"
      decimals="0"
      id="F_5233fd05-28a2-426c-bfe8-bc940b2868c8"
      unitRef="U_shares">6786896</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_c0fb1076-a7db-464d-8c21-b64e5bc453db"
      decimals="0"
      id="F_6568d45c-8bfb-407c-872b-9c99ede0296b"
      unitRef="U_shares">7377480</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_b399954b-8b8b-4102-8291-0483e80bb7cc"
      decimals="0"
      id="F_496de7fd-55c7-4bbc-98ad-fccfbe3e9509"
      unitRef="U_shares">31857</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_77bd8890-2188-4455-95b3-5c7a4d36c588"
      decimals="0"
      id="F_91140240-7602-49dd-85f2-9e3ee6a5c34e"
      unitRef="U_shares">59276</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      decimals="0"
      id="F_597b7a86-3e15-4bee-ae27-740820ea32ca"
      unitRef="U_shares">5357389</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001"
      decimals="0"
      id="F_fad5aa91-b578-491b-8ac3-25dcc76cd386"
      unitRef="U_shares">5188531</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700"
      decimals="0"
      id="F_eaedad2f-7b94-4a39-88be-e6e920671218"
      unitRef="U_shares">23845796</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      id="F_8a6ec0ac-593f-4652-b9d3-65e36127889c">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;13. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Our pre-tax book loss was derived from our business operations within the United States.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;A reconciliation of our effective tax rate to the statutory U.S. federal rate is as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:55.954%;"/&gt;
        &lt;td style="width:1.232%;"/&gt;
        &lt;td style="width:0.685%;"/&gt;
        &lt;td style="width:9.552%;"/&gt;
        &lt;td style="width:3.213%;"/&gt;
        &lt;td style="width:1.232%;"/&gt;
        &lt;td style="width:0.685%;"/&gt;
        &lt;td style="width:9.552%;"/&gt;
        &lt;td style="width:3.213%;"/&gt;
        &lt;td style="width:1.232%;"/&gt;
        &lt;td style="width:0.685%;"/&gt;
        &lt;td style="width:9.552%;"/&gt;
        &lt;td style="width:3.213%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:bold;font-size:6.7pt;font-family:Times New Roman;position:relative;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2019&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:bold;font-size:6.7pt;font-family:Times New Roman;position:relative;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Statutory rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Change in fair value of tranche liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;23.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;22.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;21.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Section 162(m) limitation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;margin-right:66.667%;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:3.333%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:6.667%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.8968727694042435%;"&gt;(1)&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The 2019 and 2020 effective tax rate reconciliations have been updated to conform to the 2021 presentation.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-left:10.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of the assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. &lt;/span&gt;&lt;span style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following table presents significant components of our deferred tax assets as of December 31, 2021 and 2020:&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/span&gt;&lt;span style=""/&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.478%;"/&gt;
        &lt;td style="width:1.478%;"/&gt;
        &lt;td style="width:1.37%;"/&gt;
        &lt;td style="width:12.998%;"/&gt;
        &lt;td style="width:0.921%;"/&gt;
        &lt;td style="width:1.478%;"/&gt;
        &lt;td style="width:1.37%;"/&gt;
        &lt;td style="width:12.987%;"/&gt;
        &lt;td style="width:0.921%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Net operating losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;85,574&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;52,330&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Fixed assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,700&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;528&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Accruals &amp;amp; reserves&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,131&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,786&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,865&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,222&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Section 59(e) capitalized expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,984&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,381&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Accrued manufacturing expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,006&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,374&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,674&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;104,934&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;63,621&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;ROU asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8,349&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8,349&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Net deferred tax asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;96,585&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;63,621&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;96,585&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;63,621&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Net deferred taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;At December 31, 2021, we have net operating loss carryforwards of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;296.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;262.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million available to reduce future taxable income, if any, for federal and state income tax purposes, respectively. The federal and state net operating loss carryforwards, except the federal loss carryforward arising in tax years beginning after December 31, 2017, begin to expire in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2034&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; unless previously utilized. Federal net operating losses arising in tax years beginning after December 31, 2017 have an indefinite carryover period and do not expire.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;At December 31, 2021, we have research credit carryforwards of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million available to offset future income tax liabilities, if any, for federal and California income tax purposes, respectively. The federal research and development tax credit carryforwards expire beginning in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2039&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; unless previously utilized. The California tax credits can be carried forward indefinitely.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;We have evaluated the positive and negative evidence bearing upon the realizability of our deferred tax assets. Based on our history of operating losses, we have concluded that it is more likely than not that the benefit of our deferred tax assets will not be realized. Accordingly, we have provided a full valuation allowance for deferred tax assets as of December 31, 2021 and 2020.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Utilization of the net operating loss carryforward and research credit carryforward may be subject to an annual limitation due to the ownership percentage change limitations under Section 382 and Section 383, respectively, provided by the Internal Revenue Code of 1986, as amended (the &#x201c;Code&#x201d;), and similar state provisions. The annual limitation may result in the expiration of the net operating loss before utilization. We have experienced ownership changes in the past. As a result of the ownership changes, we have determined that approximately less than $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million of our federal research credits will expire unutilized, and such amounts are excluded from our research credit carryforwards. The Company does not expect any ownership changes during the year ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021 to result in a limitation that would materially reduce the total amount of net operating loss carryforwards and credits that can be utilized. Subsequent ownership changes may affect the limitation in future years.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;We have uncertain tax benefits (&#x201c;UTBs&#x201d;) totaling $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million as of December 31, 2021 and 2020, respectively, which were netted against deferred tax assets subject to valuation allowance. The UTBs had no effect on the effective tax rate. We recognize interest and penalties related to UTBs, when they occur, as a component of income tax expense. To the extent accrued interest and penalties do not ultimately become payable, amounts accrued will be reduced and reflected as a reduction of the provision for income taxes in the period such determination is made. There were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; interest or penalties recognized for the years ended December 31, 2021 and 2020. We do not expect our UTBs to change significantly over the next 12 months.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;A reconciliation of the beginning and ending unrecognized tax benefit amount is as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.521%;"/&gt;
        &lt;td style="width:1.317%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:10.716%;"/&gt;
        &lt;td style="width:0.91%;"/&gt;
        &lt;td style="width:1.317%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:10.716%;"/&gt;
        &lt;td style="width:0.921%;"/&gt;
        &lt;td style="width:1.327%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:10.17%;"/&gt;
        &lt;td style="width:0.942%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2019&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Balance at the beginning of the year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;393&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;271&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;408&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Additions based on tax positions related to current year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;461&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;287&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;217&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Adjustments based on tax positions related to prior years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;70&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;165&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;354&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Balance at end of year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;924&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;393&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;271&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;We file U.S. federal and state tax returns. In general, the Company is no longer subject to tax examination by the Internal Revenue Service or state taxing authorities for years before 2016. Although the federal and state statutes are closed for purposes of assessing additional income tax in those prior years, the taxing authorities may still make adjustments to the net operating loss, or NOL, and credit carryforwards used in open years. Therefore, the tax statutes should be considered open as it relates to the NOL and credit carryforwards used in open years. We do not have any tax audits or other issues pending.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;On March 27, 2020, the President of the United States signed into law the Coronavirus Aid, Relief, and Economic Security Act (CARES Act). The CARES Act, among other things, includes certain income tax provisions for individuals and corporations; however, these benefits do not impact our current tax provision.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;On December 21, 2020, the President of the United States signed into law the &#x201c;Consolidated Appropriations Act, 2021&#x201d; which includes further COVID-19 economic relief and extension of certain expiring tax provisions. The relief package includes a tax provision clarifying that businesses with forgiven Paycheck Protection Program, or PPP, loans can deduct regular business expenses that are paid for with the loan proceeds. Additional pandemic relief tax measures include an expansion of the employee retention credit, enhanced charitable contribution deductions and a temporary full deduction for business expenses for food and beverages provided by a restaurant. These benefits do not have a material impact on the current tax provision.&lt;/span&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      id="F_6cee82d2-43da-47c3-b4ae-edc6f3ea4cfe">&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;A reconciliation of our effective tax rate to the statutory U.S. federal rate is as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:55.954%;"/&gt;
        &lt;td style="width:1.232%;"/&gt;
        &lt;td style="width:0.685%;"/&gt;
        &lt;td style="width:9.552%;"/&gt;
        &lt;td style="width:3.213%;"/&gt;
        &lt;td style="width:1.232%;"/&gt;
        &lt;td style="width:0.685%;"/&gt;
        &lt;td style="width:9.552%;"/&gt;
        &lt;td style="width:3.213%;"/&gt;
        &lt;td style="width:1.232%;"/&gt;
        &lt;td style="width:0.685%;"/&gt;
        &lt;td style="width:9.552%;"/&gt;
        &lt;td style="width:3.213%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:bold;font-size:6.7pt;font-family:Times New Roman;position:relative;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2019&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:bold;font-size:6.7pt;font-family:Times New Roman;position:relative;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Statutory rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Change in fair value of tranche liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;23.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;22.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;21.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Section 162(m) limitation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;margin-right:66.667%;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:3.333%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:6.667%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.8968727694042435%;"&gt;(1)&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The 2019 and 2020 effective tax rate reconciliations have been updated to conform to the 2021 presentation.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      decimals="3"
      id="F_f26fbaf7-614c-4dc1-baa7-77ff9fe0c309"
      unitRef="U_pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001"
      decimals="INF"
      id="F_49a96614-3d01-49a0-9b99-c49a73a9e61d"
      unitRef="U_pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700"
      decimals="INF"
      id="F_7be159d7-162b-4aa2-bc16-756720e35f47"
      unitRef="U_pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      decimals="3"
      id="F_9432878d-85b1-4d64-83da-02ffcd8443f7"
      unitRef="U_pure">0.022</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001"
      decimals="3"
      id="F_3a14c1cf-f8d3-45e2-a978-58d4d3f80e0e"
      unitRef="U_pure">0.008</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700"
      decimals="3"
      id="F_ad33fb03-db19-4784-8f04-ad151628c89d"
      unitRef="U_pure">-0.004</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      decimals="3"
      id="F_df471d00-bf8f-4f8c-a56f-128117dc5ea0"
      unitRef="U_pure">0.011</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001"
      decimals="3"
      id="F_177be7f4-d9df-4be9-887d-cd910eab0117"
      unitRef="U_pure">0.006</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700"
      decimals="3"
      id="F_b3be9417-595c-4169-9d74-33bfdc5f467d"
      unitRef="U_pure">-0.005</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <pcvx:EffectiveIncomeTaxRateReconciliationChangeInFairValueOfTrancheLiability
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      decimals="3"
      id="F_01bfef4a-09e0-435e-a05d-f4f026bd6381"
      unitRef="U_pure">0.000</pcvx:EffectiveIncomeTaxRateReconciliationChangeInFairValueOfTrancheLiability>
    <pcvx:EffectiveIncomeTaxRateReconciliationChangeInFairValueOfTrancheLiability
      contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001"
      decimals="3"
      id="F_9b5f28a1-2067-4234-aaa9-854110005c43"
      unitRef="U_pure">0.000</pcvx:EffectiveIncomeTaxRateReconciliationChangeInFairValueOfTrancheLiability>
    <pcvx:EffectiveIncomeTaxRateReconciliationChangeInFairValueOfTrancheLiability
      contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700"
      decimals="3"
      id="F_cc2c63fe-9f64-413e-b88a-ea4e16e59c43"
      unitRef="U_pure">0.013</pcvx:EffectiveIncomeTaxRateReconciliationChangeInFairValueOfTrancheLiability>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      decimals="3"
      id="F_356c4b35-33ac-4e1f-9e5b-d174c21331a2"
      unitRef="U_pure">-0.230</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001"
      decimals="3"
      id="F_74662dbe-6bba-4820-bb27-5dc2f2cc22a9"
      unitRef="U_pure">-0.221</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700"
      decimals="3"
      id="F_9f6710a1-d9d3-4fe2-b6ef-bfe78fb4240b"
      unitRef="U_pure">-0.218</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <pcvx:Section162MLimitation
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      decimals="3"
      id="F_47ee4115-d7cf-4bdb-ac0b-7beb2b5ca0db"
      unitRef="U_pure">-0.011</pcvx:Section162MLimitation>
    <pcvx:Section162MLimitation
      contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001"
      decimals="3"
      id="F_042d310c-7a0b-4e6b-9fcb-a76480c12f1a"
      unitRef="U_pure">-0.001</pcvx:Section162MLimitation>
    <pcvx:Section162MLimitation
      contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700"
      decimals="3"
      id="F_ffa70a62-fef8-4aa1-ab27-93982bd1df40"
      unitRef="U_pure">0.000</pcvx:Section162MLimitation>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      decimals="3"
      id="F_4c59c790-f2a1-42ec-886d-0ebc62ed30a5"
      unitRef="U_pure">-0.002</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001"
      decimals="3"
      id="F_0dab50af-8222-425f-99c5-2467c60ce49c"
      unitRef="U_pure">-0.002</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700"
      decimals="3"
      id="F_3858ffdc-5880-4a92-a2d7-c0f2a030af5e"
      unitRef="U_pure">0.004</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      decimals="3"
      id="F_af46d819-813e-427e-87a2-4217a395634c"
      unitRef="U_pure">0.000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001"
      decimals="3"
      id="F_4dc43849-1f78-43f5-a8b2-8eca8bdccb0e"
      unitRef="U_pure">0.000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700"
      decimals="3"
      id="F_f5df6844-e104-41d9-aafd-0b5beb9fd268"
      unitRef="U_pure">0.000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      id="F_e16704f6-7df4-4b26-9d53-82e04ddee512">&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following table presents significant components of our deferred tax assets as of December 31, 2021 and 2020:&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.478%;"/&gt;
        &lt;td style="width:1.478%;"/&gt;
        &lt;td style="width:1.37%;"/&gt;
        &lt;td style="width:12.998%;"/&gt;
        &lt;td style="width:0.921%;"/&gt;
        &lt;td style="width:1.478%;"/&gt;
        &lt;td style="width:1.37%;"/&gt;
        &lt;td style="width:12.987%;"/&gt;
        &lt;td style="width:0.921%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Net operating losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;85,574&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;52,330&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Fixed assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,700&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;528&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Accruals &amp;amp; reserves&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,131&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,786&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,865&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,222&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Section 59(e) capitalized expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,984&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,381&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Accrued manufacturing expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,006&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,374&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,674&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;104,934&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;63,621&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;ROU asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8,349&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8,349&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Net deferred tax asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;96,585&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;63,621&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;96,585&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;63,621&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Net deferred taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350"
      decimals="-3"
      id="F_fff40e10-2ac3-49c4-a946-e0f21e343d4c"
      unitRef="U_USD">85574000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57"
      decimals="-3"
      id="F_43ce474c-b346-4f07-962c-3a3693e3b19b"
      unitRef="U_USD">52330000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350"
      decimals="-3"
      id="F_221949c6-b68a-4978-a407-59f7c9ba5f60"
      unitRef="U_USD">1700000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57"
      decimals="-3"
      id="F_7a93cab8-611b-4844-a59d-13e5b792f4ce"
      unitRef="U_USD">528000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350"
      decimals="-3"
      id="F_441eeba0-6a25-4f20-a3a0-42ff1d0c73af"
      unitRef="U_USD">4131000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57"
      decimals="-3"
      id="F_2dc5a46a-8200-443b-9b6c-7c45a652beae"
      unitRef="U_USD">2786000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350"
      decimals="-3"
      id="F_d2a0a623-abd7-4aed-9892-4d9190f127a9"
      unitRef="U_USD">2865000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57"
      decimals="-3"
      id="F_3a9b1b06-855f-4516-b7ec-7cb54dd1dfd1"
      unitRef="U_USD">1222000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350"
      decimals="-3"
      id="F_30b88749-1faf-4730-89fa-f6c2b35d1b23"
      unitRef="U_USD">2984000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57"
      decimals="-3"
      id="F_3f8b349e-87e5-4ba0-8dd0-8793e2d3709f"
      unitRef="U_USD">3381000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <pcvx:DeferredTaxAssetsTaxAccruedManufacturingExpenses
      contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350"
      decimals="-3"
      id="F_9611fe1d-8b98-4cdb-8f1b-fa5451a15e5b"
      unitRef="U_USD">1006000</pcvx:DeferredTaxAssetsTaxAccruedManufacturingExpenses>
    <pcvx:DeferredTaxAssetsTaxAccruedManufacturingExpenses
      contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57"
      decimals="-3"
      id="F_27ca5825-5537-44c4-a647-1c3a01fcf0d8"
      unitRef="U_USD">3374000</pcvx:DeferredTaxAssetsTaxAccruedManufacturingExpenses>
    <pcvx:LeaseLiability
      contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350"
      decimals="-3"
      id="F_e5df96cb-c7c4-4ad6-aba7-8646d24754f9"
      unitRef="U_USD">6674000</pcvx:LeaseLiability>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350"
      decimals="-3"
      id="F_54ca3d5d-9b6b-4d73-9f5a-6741ec4757dc"
      unitRef="U_USD">104934000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57"
      decimals="-3"
      id="F_be5e0aef-57bf-46a7-aa5b-5ed573a25698"
      unitRef="U_USD">63621000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350"
      decimals="-3"
      id="F_585afc5a-9fe2-4a86-9929-070c555e510a"
      unitRef="U_USD">8349000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350"
      decimals="-3"
      id="F_ee7765c5-c11a-471f-857b-6186c98da97f"
      unitRef="U_USD">8349000</us-gaap:DeferredIncomeTaxLiabilities>
    <pcvx:DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance
      contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350"
      decimals="-3"
      id="F_de77f025-6daf-49e9-b476-aef4e3616103"
      unitRef="U_USD">96585000</pcvx:DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance>
    <pcvx:DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance
      contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57"
      decimals="-3"
      id="F_9683608f-d1c3-443e-9c41-84c7c9dbb6d9"
      unitRef="U_USD">63621000</pcvx:DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350"
      decimals="-3"
      id="F_b49d39ce-6c5b-4729-8d91-ff4ec26ea6ff"
      unitRef="U_USD">96585000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57"
      decimals="-3"
      id="F_064df35d-06a7-4aae-af79-088e3ec00932"
      unitRef="U_USD">63621000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_8f37ea4f-142c-4bc7-aa2e-4b36661b1de6"
      decimals="-5"
      id="F_bcce4b43-9110-4f14-bc4c-ba78a4e2b3e8"
      unitRef="U_USD">296700000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_9f6bf305-4c1d-45f5-96fe-42e373b0efcb"
      decimals="-5"
      id="F_f850ad2b-e082-44ac-a19c-d0a884e2fff5"
      unitRef="U_USD">262700000</us-gaap:OperatingLossCarryforwards>
    <pcvx:OperatingLossCarryForwardsExpirationYear
      contextRef="C_88219214-e682-4a47-ba69-b37e92d74db8"
      id="F_e586813b-ea3b-4e50-9bfc-963fe34fcd4d">2034</pcvx:OperatingLossCarryForwardsExpirationYear>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="C_a6bb51b5-9e65-4bc2-a156-224db74e09c4"
      decimals="-5"
      id="F_f9b075df-4c7e-4457-906f-2e9abb9be331"
      unitRef="U_USD">2200000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="C_e5909518-4b17-423b-8df9-fefc213da385"
      decimals="-5"
      id="F_4645f814-9fa7-4da4-a42a-81fe169da8c4"
      unitRef="U_USD">1600000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <pcvx:TaxCreditCarryforwardExpirationYear
      contextRef="C_a6bb51b5-9e65-4bc2-a156-224db74e09c4"
      id="F_e8f265f9-0dbb-4986-86ff-f4e7dc1bf4fc">2039</pcvx:TaxCreditCarryforwardExpirationYear>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_1db8f94d-2ec6-47be-b76a-a4960db1be21"
      decimals="-2"
      id="F_ae7ea1a8-053e-4225-92ee-81fa4fc7b7b9"
      unitRef="U_USD">100</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350"
      decimals="-5"
      id="F_bb6d001e-7529-40e6-95ed-04db9447dedd"
      unitRef="U_USD">900000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57"
      decimals="-5"
      id="F_1145a7c4-3b57-46db-9c65-667f00ef82e6"
      unitRef="U_USD">400000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      decimals="INF"
      id="F_7488b4fb-1b72-4d22-a526-ce01cd10c342"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001"
      decimals="INF"
      id="F_db4f3c88-2d64-44b8-b433-b7725431e27c"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:SummaryOfIncomeTaxContingenciesTextBlock
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      id="F_ddc3b960-7a5a-401c-8d3c-443ecc5c9f5d">&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;A reconciliation of the beginning and ending unrecognized tax benefit amount is as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.521%;"/&gt;
        &lt;td style="width:1.317%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:10.716%;"/&gt;
        &lt;td style="width:0.91%;"/&gt;
        &lt;td style="width:1.317%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:10.716%;"/&gt;
        &lt;td style="width:0.921%;"/&gt;
        &lt;td style="width:1.327%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:10.17%;"/&gt;
        &lt;td style="width:0.942%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2019&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Balance at the beginning of the year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;393&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;271&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;408&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Additions based on tax positions related to current year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;461&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;287&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;217&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Adjustments based on tax positions related to prior years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;70&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;165&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;354&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Balance at end of year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;924&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;393&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;271&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:SummaryOfIncomeTaxContingenciesTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57"
      decimals="-3"
      id="F_d070350a-1105-4aa8-8293-8202b8829c07"
      unitRef="U_USD">393000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_871fe4ad-8a52-4dc5-a523-876ef5a1de6d"
      decimals="-3"
      id="F_ca61f790-20b5-4a74-b68e-c04f594df036"
      unitRef="U_USD">271000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_ecccdfb9-edd1-45a3-8445-0fe8b2f43253"
      decimals="-3"
      id="F_a56e0081-bf81-421c-8064-23dcd911a4be"
      unitRef="U_USD">408000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      decimals="-3"
      id="F_6da28a70-9e56-478b-a188-7a07a32bf898"
      unitRef="U_USD">461000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001"
      decimals="-3"
      id="F_50c0c333-37a6-4c32-a877-17e9ad4d2cfc"
      unitRef="U_USD">287000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700"
      decimals="-3"
      id="F_f39ae2f0-ed04-42cf-b713-58fa04158fa0"
      unitRef="U_USD">217000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <pcvx:UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      decimals="-3"
      id="F_70783f66-f723-4781-8154-76aa3913ad59"
      unitRef="U_USD">70000</pcvx:UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions>
    <pcvx:UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="C_3e34321b-16ec-44ef-ab8c-8cdab8688001"
      decimals="-3"
      id="F_3488ff7d-3a78-459c-8c1a-d7f0ad5a88bf"
      unitRef="U_USD">-165000</pcvx:UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions>
    <pcvx:UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="C_3e25c250-e268-4985-8e41-7be1baee8700"
      decimals="-3"
      id="F_c0e93db7-c329-4555-98b2-d1bee10f7707"
      unitRef="U_USD">-354000</pcvx:UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350"
      decimals="-3"
      id="F_114e3329-9aff-44ad-b02e-c3fa90ee738d"
      unitRef="U_USD">924000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57"
      decimals="-3"
      id="F_8cab00e0-6057-49e6-b331-275a783afc16"
      unitRef="U_USD">393000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_871fe4ad-8a52-4dc5-a523-876ef5a1de6d"
      decimals="-3"
      id="F_1ee70ac2-8189-4b94-b0be-96a00317447d"
      unitRef="U_USD">271000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      id="F_7fe06947-a9c6-4e88-9758-fe32e8397270">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;14. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Related Party Transactions&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;We have an ongoing relationship with Sutro Biopharma. In 2013, Sutro Biopharma provided support to facilitate the establishment of our Company. As of December 31, 2021 and 2020, Sutro Biopharma owned approximately &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million shares of our common stock. As of December 31, 2019, Sutro Biopharma also owned warrants to purchase &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;31,857&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of our common stock (the &#x201c;Common Stock Warrant&#x201d;) at an exercise price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.79289&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; per share and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;59,276&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of our Series C redeemable convertible stock (the &#x201c;Preferred Stock Warrant&#x201d;) at an exercise price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;11.5215&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; per share. The Common Stock Warrant and the Preferred Stock Warrant were automatically net exercised pursuant to their terms for &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;30,278&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;16,591&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares, respectively, of our common stock in connection with the IPO. In the agreements and amendments identified herein, we licensed certain intellectual property and acquired certain supply rights from Sutro Biopharma, including the right to use the XpressCF platform to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases. On October 12, 2015, we and Sutro Biopharma (&#x201c;the Parties&#x201d;) entered into the Sutro Biopharma License Agreement, which amended and restated an agreement dated August 1, 2014. The Sutro Biopharma License Agreement was subsequently amended on May 9, 2018 (&#x201c;License Amendment A1&#x201d;) and May 29, 2018 (&#x201c;License Amendment A2&#x201d;). In consideration for the License Amendment A2, we issued to Sutro Biopharma the Preferred Stock Warrant to purchase &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;59,276&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of Series C redeemable convertible preferred stock at a purchase price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;11.5215&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; per share. We also entered into a separate supply agreement with Sutro Biopharma on &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;May 29, 2018&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; (the &#x201c;Sutro Biopharma Supply Agreement&#x201d;). As of June 2, 2021, Sutro Biopharma was no longer considered a related party.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Under the Sutro Biopharma License Agreement, Sutro Biopharma granted us an exclusive, worldwide license to research, develop, manufacture and commercialize vaccine products addressing infectious disease, which are discovered or produced based on the use of Sutro Biopharma&#x2019;s proprietary cell-free protein expression technology, known as XpressCF, which utilizes extracts derived from strains of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;E. coli&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. In connection with the Sutro Biopharma License Agreement, under the Sutro Biopharma Supply Agreement, Sutro Biopharma has agreed to manufacture and supply extracts and reagents for us on a cost-plus basis. In consideration for the rights licensed, we are obligated to pay a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% royalty on worldwide aggregate annual net sales of our vaccine products for human health and a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% royalty on annual net sales of vaccine products for animal health. In License Amendment A1, the Parties amended the license agreement to remove a pre-IND regulatory meeting as a diligence milestone and to agree that certain other diligence milestones had been satisfied. In License Amendment A2, the Parties amended the license agreement to add certain terms confirming our obligation to purchase Sutro Biopharma&#x2019;s proprietary extract from &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;E. coli &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&#x201c;Extract&#x201d;) from Sutro Biopharma. In addition, the Parties amended the license agreement to specify our rights to a transfer of certain know-how relating to the manufacture of Extract in the event of a declaration of bankruptcy by Sutro Biopharma. Finally, the Parties agreed to terms providing for injunctive relief in the event of a breach or threatened breach by the other party.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In the Sutro Biopharma Supply Agreement, the Parties agreed to terms for the supply of manufactured Extract and custom reagents by Sutro Biopharma for us to use in manufacturing vaccine compositions in non-clinical research or in Phase 1 or Phase 2 clinical trials. The term of the Sutro Biopharma Supply Agreement is from execution until the later of July 31, 2021 and the date the parties enter into and commence activities under the supply agreement unless extended through a subsequent supply agreement for the supply of Extract and custom reagents for vaccine compositions for Phase 3 and commercial uses as contemplated in the Supply Agreement. In February 2021, we entered into an amendment to the Sutro Biopharma Supply Agreement and extended the term to July 31, 2022.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;We recognized expense related to the Supply Agreement of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million for the years ended December 31, 2021, 2020 and 2019, respectively. In addition, we recorded $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; in changes in the fair value of the Preferred Stock Warrant for the years ended December 31, 2021, 2020 and 2019, respectively. The expense related to the changes in the fair value of the warrant is included in research and development expenses in the statements of operations. Accrued expenses payable to Sutro Biopharma were $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; and 2020, respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_3fab40e5-6a35-4b2f-b816-13c7822b9afc"
      decimals="-5"
      id="F_0196f711-e855-43b3-9b56-5e2b77ed5b26"
      unitRef="U_shares">1600000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_13251130-5d02-4a4b-82e5-dc7664b58676"
      decimals="-5"
      id="F_9c46986e-caa3-4b8e-b9c3-032b98d0f245"
      unitRef="U_shares">1600000</us-gaap:CommonStockSharesIssued>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="C_39f8abfd-a954-4f03-b72e-b423c719a4a5"
      decimals="INF"
      id="F_f91b73d5-a35b-483a-9d77-844c88d7c71c"
      unitRef="U_shares">31857</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_39f8abfd-a954-4f03-b72e-b423c719a4a5"
      decimals="INF"
      id="F_687a3738-b236-4327-8c69-b95964396c6b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.79289</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="C_f77911a6-cb83-4a40-8b6c-9703e6acc5a0"
      decimals="INF"
      id="F_8396851e-55cb-4d6a-a7de-8b2209d1dc95"
      unitRef="U_shares">59276</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_f77911a6-cb83-4a40-8b6c-9703e6acc5a0"
      decimals="INF"
      id="F_d99b240a-e118-41df-80a9-e63adf747ab3"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">11.5215</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <pcvx:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRightExercised
      contextRef="C_5909cb95-2fd5-4c03-b349-88a7f48048ff"
      decimals="INF"
      id="F_2a38fbb3-b86a-4c82-9bf4-5641c246f948"
      unitRef="U_shares">30278</pcvx:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRightExercised>
    <pcvx:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRightExercised
      contextRef="C_56188f91-3c62-4582-88c9-91789caa7dd4"
      decimals="INF"
      id="F_f35ce7bc-5063-43e3-bbac-0dfb9b7f6cef"
      unitRef="U_shares">16591</pcvx:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRightExercised>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="C_f910d477-1db3-4915-9562-49fd9c1e0523"
      decimals="INF"
      id="F_61dcd28c-b347-403d-b070-6d8c9d55509a"
      unitRef="U_shares">59276</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_f910d477-1db3-4915-9562-49fd9c1e0523"
      decimals="4"
      id="F_e0eaa20f-66bb-4050-a27d-51a352578656"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">11.5215</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
      contextRef="C_022b1471-8226-4bef-aee0-86e11defec44"
      id="F_ee07acf5-55d4-4db5-b5d0-4e76e1da4466">2018-05-29</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
    <pcvx:PercentageOfRoyaltyPaymentOnAnnualNetSalesOfVaccineProductsForHumanHealth
      contextRef="C_61481fb4-5a3a-40c5-abb3-1248a21e99b5"
      decimals="2"
      id="F_3bc95bb2-3179-4b7f-af93-96b56dbdc192"
      unitRef="U_pure">0.04</pcvx:PercentageOfRoyaltyPaymentOnAnnualNetSalesOfVaccineProductsForHumanHealth>
    <pcvx:PercentageOfRoyaltyPaymentOnNetSalesOfVaccineCompositionsForAnimalHealth
      contextRef="C_61481fb4-5a3a-40c5-abb3-1248a21e99b5"
      decimals="2"
      id="F_4ff09cd5-ef34-4a25-830d-c58012c2e2d5"
      unitRef="U_pure">0.02</pcvx:PercentageOfRoyaltyPaymentOnNetSalesOfVaccineCompositionsForAnimalHealth>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="C_9ea862ab-153b-4f8b-bcfc-2223d2882ade"
      decimals="-5"
      id="F_b54dd810-adab-4668-9ea7-290cf245396d"
      unitRef="U_USD">2400000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="C_3c435103-f76a-492c-9b05-78cd97e91f32"
      decimals="-5"
      id="F_dc17ecb2-bc10-4344-b627-54d3e85e35a5"
      unitRef="U_USD">1200000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="C_8817387e-2be1-4358-95ce-a5df2bf517bf"
      decimals="-5"
      id="F_719fbab0-544d-4c00-ad07-687dc262c115"
      unitRef="U_USD">1100000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="C_dac22bba-f4c3-4e16-abd0-7f908c3516fb"
      decimals="0"
      id="F_aec978a5-0921-495d-a4fb-829a5e87706d"
      unitRef="U_USD">0</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="C_9262f685-96b6-4f7c-a6ae-83581243ab7d"
      decimals="-5"
      id="F_1b4c9b39-27aa-4459-b0df-38463fd44d64"
      unitRef="U_USD">200000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="C_cab820c4-1fb0-481c-b985-2ea03542a95b"
      decimals="0"
      id="F_300dcd4f-b872-4df2-b622-9e9e4269b1c8"
      unitRef="U_USD">0</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:RelatedPartyTransactionDueFromToRelatedParty
      contextRef="C_3fab40e5-6a35-4b2f-b816-13c7822b9afc"
      decimals="-6"
      id="F_ab4fb988-e410-45e5-bddd-51d726ec0abf"
      unitRef="U_USD">0</us-gaap:RelatedPartyTransactionDueFromToRelatedParty>
    <us-gaap:RelatedPartyTransactionDueFromToRelatedParty
      contextRef="C_13251130-5d02-4a4b-82e5-dc7664b58676"
      decimals="-5"
      id="F_1591a65e-a5a1-4202-820c-123cc930bdee"
      unitRef="U_USD">700000</us-gaap:RelatedPartyTransactionDueFromToRelatedParty>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f"
      id="F_74e91e97-c26b-4ade-91ff-78d378f31634">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;15. Subsequent Events&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In January 2022, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;we completed an underwritten public offering in which we issued &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,500,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of our common stock at a price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;20.00&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; per share, and pre-funded warrants to purchase &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,500,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of our common stock at a price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;19.999&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; per underlying share. We received approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;93.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million in net proceeds after deducting underwriting discounts and commissions and other estimated offering expenses payable by us. In February 2022, t&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;he underwriters exercised their option to purchase an additional &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;750,000&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of common stock, and we received approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;14.1&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million in additional net proceeds after deducting underwriting discounts and commissions.&lt;/span&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <pcvx:StockIssuedDuringPeriodSharesOfFollowOnOffering
      contextRef="C_e52d577e-c5ed-4801-8551-af9cd25c01fa"
      decimals="INF"
      id="F_23409a0f-1f5e-45eb-8c65-b570dc94b9c1"
      unitRef="U_shares">2500000</pcvx:StockIssuedDuringPeriodSharesOfFollowOnOffering>
    <pcvx:SharesIssuedPricePerShareUponFollowOnOffering
      contextRef="C_ed656fe7-27bd-4711-a1d9-07aab395e870"
      decimals="2"
      id="F_90d0d4f2-2b06-4f10-ab84-0ba2e8f7003f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">20.00</pcvx:SharesIssuedPricePerShareUponFollowOnOffering>
    <pcvx:SharesPreFundedWarrantsToPurchase
      contextRef="C_e52d577e-c5ed-4801-8551-af9cd25c01fa"
      decimals="INF"
      id="F_f4584993-ccf4-4413-90d3-7f84970dbbce"
      unitRef="U_shares">2500000</pcvx:SharesPreFundedWarrantsToPurchase>
    <pcvx:PrefundedWarrantsPricePerShare
      contextRef="C_ed656fe7-27bd-4711-a1d9-07aab395e870"
      decimals="3"
      id="F_6584694a-a920-427d-b458-bc9cd2eca77f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">19.999</pcvx:PrefundedWarrantsPricePerShare>
    <pcvx:ProceedsFromIssuanceFollowOnOffering
      contextRef="C_e52d577e-c5ed-4801-8551-af9cd25c01fa"
      decimals="-5"
      id="F_2801884a-e24b-4d28-bcb7-cd3201212a23"
      unitRef="U_USD">93500000</pcvx:ProceedsFromIssuanceFollowOnOffering>
    <pcvx:SharesIssuedUponFollowOnOfferingFullExerciseOfUnderwritersOptionToPurchaseAdditionalShares
      contextRef="C_16333782-8505-4ca7-9e4c-1163caa27de3"
      decimals="INF"
      id="F_906d7cda-7f1c-41b9-9a1d-7489dd478185"
      unitRef="U_shares">750000</pcvx:SharesIssuedUponFollowOnOfferingFullExerciseOfUnderwritersOptionToPurchaseAdditionalShares>
    <pcvx:ProceedsFromIssuanceFollowOnOffering
      contextRef="C_16333782-8505-4ca7-9e4c-1163caa27de3"
      decimals="-5"
      id="F_247c83c4-2cf2-4152-a961-e1df95d9baca"
      unitRef="U_USD">14100000</pcvx:ProceedsFromIssuanceFollowOnOffering>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#F_042d310c-7a0b-4e6b-9fcb-a76480c12f1a"
          xlink:label="F_042d310c-7a0b-4e6b-9fcb-a76480c12f1a"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_3858ffdc-5880-4a92-a2d7-c0f2a030af5e"
          xlink:label="F_3858ffdc-5880-4a92-a2d7-c0f2a030af5e"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_177be7f4-d9df-4be9-887d-cd910eab0117"
          xlink:label="F_177be7f4-d9df-4be9-887d-cd910eab0117"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_49a96614-3d01-49a0-9b99-c49a73a9e61d"
          xlink:label="F_49a96614-3d01-49a0-9b99-c49a73a9e61d"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_3a14c1cf-f8d3-45e2-a978-58d4d3f80e0e"
          xlink:label="F_3a14c1cf-f8d3-45e2-a978-58d4d3f80e0e"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_b3be9417-595c-4169-9d74-33bfdc5f467d"
          xlink:label="F_b3be9417-595c-4169-9d74-33bfdc5f467d"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_cc2c63fe-9f64-413e-b88a-ea4e16e59c43"
          xlink:label="F_cc2c63fe-9f64-413e-b88a-ea4e16e59c43"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_ad33fb03-db19-4784-8f04-ad151628c89d"
          xlink:label="F_ad33fb03-db19-4784-8f04-ad151628c89d"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_7be159d7-162b-4aa2-bc16-756720e35f47"
          xlink:label="F_7be159d7-162b-4aa2-bc16-756720e35f47"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_74662dbe-6bba-4820-bb27-5dc2f2cc22a9"
          xlink:label="F_74662dbe-6bba-4820-bb27-5dc2f2cc22a9"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_4dc43849-1f78-43f5-a8b2-8eca8bdccb0e"
          xlink:label="F_4dc43849-1f78-43f5-a8b2-8eca8bdccb0e"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_f5df6844-e104-41d9-aafd-0b5beb9fd268"
          xlink:label="F_f5df6844-e104-41d9-aafd-0b5beb9fd268"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_9f6710a1-d9d3-4fe2-b6ef-bfe78fb4240b"
          xlink:label="F_9f6710a1-d9d3-4fe2-b6ef-bfe78fb4240b"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_9b5f28a1-2067-4234-aaa9-854110005c43"
          xlink:label="F_9b5f28a1-2067-4234-aaa9-854110005c43"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_ffa70a62-fef8-4aa1-ab27-93982bd1df40"
          xlink:label="F_ffa70a62-fef8-4aa1-ab27-93982bd1df40"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_0dab50af-8222-425f-99c5-2467c60ce49c"
          xlink:label="F_0dab50af-8222-425f-99c5-2467c60ce49c"
          xlink:type="locator"/>
        <link:footnote id="FNT_1e764aa7-2424-4823-b8e3-44b720dd76c6" xlink:label="FNT_1e764aa7-2424-4823-b8e3-44b720dd76c6" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The 2019 and 2020 effective tax rate reconciliations have been updated to conform to the 2021 presentation.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_042d310c-7a0b-4e6b-9fcb-a76480c12f1a"
          xlink:to="FNT_1e764aa7-2424-4823-b8e3-44b720dd76c6"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_3858ffdc-5880-4a92-a2d7-c0f2a030af5e"
          xlink:to="FNT_1e764aa7-2424-4823-b8e3-44b720dd76c6"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_177be7f4-d9df-4be9-887d-cd910eab0117"
          xlink:to="FNT_1e764aa7-2424-4823-b8e3-44b720dd76c6"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_49a96614-3d01-49a0-9b99-c49a73a9e61d"
          xlink:to="FNT_1e764aa7-2424-4823-b8e3-44b720dd76c6"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_3a14c1cf-f8d3-45e2-a978-58d4d3f80e0e"
          xlink:to="FNT_1e764aa7-2424-4823-b8e3-44b720dd76c6"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_b3be9417-595c-4169-9d74-33bfdc5f467d"
          xlink:to="FNT_1e764aa7-2424-4823-b8e3-44b720dd76c6"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_cc2c63fe-9f64-413e-b88a-ea4e16e59c43"
          xlink:to="FNT_1e764aa7-2424-4823-b8e3-44b720dd76c6"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_ad33fb03-db19-4784-8f04-ad151628c89d"
          xlink:to="FNT_1e764aa7-2424-4823-b8e3-44b720dd76c6"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_7be159d7-162b-4aa2-bc16-756720e35f47"
          xlink:to="FNT_1e764aa7-2424-4823-b8e3-44b720dd76c6"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_74662dbe-6bba-4820-bb27-5dc2f2cc22a9"
          xlink:to="FNT_1e764aa7-2424-4823-b8e3-44b720dd76c6"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_4dc43849-1f78-43f5-a8b2-8eca8bdccb0e"
          xlink:to="FNT_1e764aa7-2424-4823-b8e3-44b720dd76c6"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_f5df6844-e104-41d9-aafd-0b5beb9fd268"
          xlink:to="FNT_1e764aa7-2424-4823-b8e3-44b720dd76c6"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_9f6710a1-d9d3-4fe2-b6ef-bfe78fb4240b"
          xlink:to="FNT_1e764aa7-2424-4823-b8e3-44b720dd76c6"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_9b5f28a1-2067-4234-aaa9-854110005c43"
          xlink:to="FNT_1e764aa7-2424-4823-b8e3-44b720dd76c6"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_ffa70a62-fef8-4aa1-ab27-93982bd1df40"
          xlink:to="FNT_1e764aa7-2424-4823-b8e3-44b720dd76c6"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_0dab50af-8222-425f-99c5-2467c60ce49c"
          xlink:to="FNT_1e764aa7-2424-4823-b8e3-44b720dd76c6"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>100
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MP\P+\/M&"'VZ,0/4YY/W?P-02P,$%     @ >X!<5/F-,<E,!@  @QD  !@
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M[(KAW<!AM>:(:6NGE4:*V/]\E'#<[UYHXKK4B;N<^T@W"7SL(9PN[3[2BY+
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M.[^Z", T,Z/9D*Y]%RTT<4_Z9<%C%HUSX/.EUK3;N #=X$Z? 5!+ P04
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M4Z^7<0[)%?'==\1S/+<CH-GKX4X'?/YJN'O3DXW?2N$;/O]_4I#[C-RRA%=
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M*;W+/EY^6;6D:J+%RA;IN=!8\NTPPS8.TAS _50(O9T8 \T?@_ _4$L#!!0
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M^$,NI/@TA^<JB>(M5B2;H*N;08$L2:3C?2Y4%B$)N2TV/%=I;LE][YCE1>O
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M10%F<@B$[(1]EPQ-\-_L]0C]OU<P10/P[[\:B2$0S-%**6!<;VK@1GIO$"N
M)\6&Z>54 T65ZPI:FD OEB5K().<KR1.UMAW#:=B;._'TK#R:, B2QG@J\F(
MQZ<GA%YAZ0#D:EK,H\,I) J0UG$>0!(1%3FSO+(:@RY2SC&92HC("%YM2H(5
MY! Z<:,"46<: -_E 4'K=J\J2\L@VV_U!>2%9N)6.=?(^E*0\89C)%I]8JDV
MX%Q.4BNA/[Z'B#7F+@'=&PJ&=7#G)6(R'K2C=>4NIGVPTTIN2,"$"'-5MW=A
M/T0@>5U$,><VOOWJ[YP">WV0 ON*4V!(?W%N[:M'/$?;.Z+'/?[J\FC\^J?L
M^8O9RQ?/Z(^G+Y[/SD]/Z:]G]-4WS[\:[\^+;\[8_IV=?^?__]4?8 --]7+V
MXMGSB:G([$6U&,9=:9JVJ$EO"19R5%%Z$322(20NY[=Y5<,*SNF+N<N!W)/P
M=SRP%WQB\_]C4"X)ZB0LS!E;WA>;0I^B)BW(SA'E=?4[/;\FKZ9)G1!G=5,S
M*/XKF6_T(R='Q1J2FFL,7A3]MI=4GOA0-I9F@ZH8;0JFX 4PNAY&V\- ET#(
M;[T+6[5%ZOGWD'^A(;=5OW5^5ZT)6;O*J9GA5"O;Q3VYSQZ9P724X9N#!0*?
M,?&:ZGNDF4<*DAK3P0P=XYWD'@M!G$B1!)YSDBTD\7CX.=F99DX:#5E@ (/L
M-?T_MQKU?3%%OR:9UX2-;)8FILJJ[8XH$_'L#N6%G<0"]F)J)24!;KNE'^Y;
MS1_C*%R@J.I>05U4.A(WMV% )"X\P^R)[Q$'KF)/<D%[(AA0(N4^^L>]MX^I
M-OWDT[SOD('$FY<<^(7O6_^]!(2)#5B9<=Z=HT@M"]&#C0(\]M8\,2R,PA$H
M/?W&Z6X\#VL("&WSQN7%09Z\)H!4SY+BTHRK2YV/()2_Y-^PCW.?4&>B%]FU
MK>"Z))VE49-JS.2\Y9'5CW?UG<];P\A,F9X%6>H#5HAY\[N!"@4G,8[0(M8H
MSD^F+IIU6M)%#%=(JLLY>"]A"]"GEHB83?01J0#0H:Q86U)<@#BD(I&:9JK&
MM:+3&5S0XNML6]6ULNWJ^MV0R9(*29F#"8X3ET&W,L*;VR.,FZ8EUJU U.GB
M62 *W^.;LY3,(QL)SC@$]V25Z_WLD/8OV-CK%/J^]M!WEOU"!N1Z$A:/$!XH
MF0D\31U'B3TC9QC-=&*WH;#)SY5C:>[Q7N\D(L,4-D<\.6<6;PT!&V+ K19+
M?#D!;QB*VC(@_""-OK86Z[6"ISD"OO4U18H-  &12X8QM32X6BO8;J'7)'.R
M!1.,*0EE\)Y3W2LC&)VA.%DVN!<89Y^:0K@L@3=;&9(FBO>=Q[0^#^,#"#,F
M!PZIU10K#21EP;#NE3D>P\Q\\AVFC?756S>RU^30TY (7I2%3/W-7>4X#RB)
M^W8U4[OC.@5ZLM-?O.LZR;9%*!9"F:'/\C5/26I!%.">Q6LXAA36K&IA^QA0
M'^;DI+Q,&M."7/'WNNF.X!-BM5A,2IH+;A"$Y+9TV:N6_I<]>G-Q\^KQ]!,?
M=QR,^7SLQ<W'4'W_I5T ES^?GY[/_*R//K2[JLA>?'W^..;ZG6O!-*X/T_;*
M8N*(EW@\YGCO$N\M<(,X:U'$9_4$[/*Q#<I1Z%-@G;N*2:'1('<;(Y9"W]LR
MW!2S+D:ZD!U$TAS)18G50C+))JF#,',,L1@9TX-,7BEX4R0=+^CDWV:/JL?)
M2^P^5ES.N2,E=IMJYQ6/2Z8U%S99?+T?@!$R86[HB;X0%?,[FF4PS9JFT;7Z
MUTG<=MZ]Q ![<MY-6">_RN*IE=U]K 0AL8[(P!F>?KA,X"#-EN1D*7Y#UB2W
MG2<]8B&*#9IV2[+C-7Z*)$QP^SAMJU"\YT%3OQTR99?OMVGL5I4])WKQSIK"
M7N*.B=4J72<RK9(GE_*?2W/N*!Q+OH:CV @YCY*,J1\IU0<\KC XC&0&5U<I
M:&]RSICR!E3\4+#&7 +ABM0@V]]+EL2O NR^1TZ..NZ99*&$=^U.^W2&T3M,
M#1P4)VF&BG$4G9QEHI-5"<([60**:%[)_.OO1@,>HKF1*G)2=MZNYN# H_?O
M/CX.[G'\:-H1X$-^]A::L_R2YR.ZUPSY"' 0 =[I!%S'SS&=V*+^B+JY4>:&
M)^&X[8"8X<CMLJ[6N5=I;MT9"[^M&'<$KW2$VRGU!VTW&L"O&Y;0!RS@(. Y
M4-41>0&!I )*YMQ;< ^9'AB'@U,V*J" ( 9:Z#KO)^59TJ2T!<3/@/0*"RC7
M,#FX.]:%,UQ:FB<.B9H'F,.A9/1.]S?]Q.G@!PFB[[4?,.9GEBUMU;XR-1DJ
M"5V&=>_,502V<RO")ZF-L' ?83VPZ*D^,=^2DT: :0%3$I[[AA;8D5T?TB0)
M5HE1)<&4<_U+]1%[(Y"0FWS85. QYIUV&T7_%'N9>DV4CT7GGJ6)8(>&)>%W
MOX/54]N  I:FA-,>)K)U*&;QLKDU*&6*-\:.(,^Q ;0LREN'UI PR'%J9??&
M<"15VR0GH_DI43*N5Z!=,'&(W*1FRBE?29Z/AU"UX0X$A""+ QMQ8)VT5,VO
MM[Y3K/78'C9.1<_;(>BM>+DI>(%-1A&?XL4 -,1GZN *>2/],>Q859\UK9IJ
M^B@ XDRVN@!9C084K'6C0$V*/S%."T%28KK^1O:6Y_$&@(/92!6%$>CW;+A^
MUCO2IQGB?O:G7"PTGT>5PJV$%_D@UB+D9M?<!',T!GH[K %H-=YOCF+9!CZY
MF0=K):E2#1,/LM$9/$FR-GU\8BZV11BY +EB&<$@)Z;;,35-=G;NZT"Q02_F
MB0]<++HZ8F:01N("V%LN@%V(6/YJM*(W44[#,I+,(J'SQF SN46+,5_2,#S4
M5MH8! J)W0D-B%)8DM9>!7;0 BQF*6Z3Y@ #$#GK!ZE&DS!M.4$O*!3\S*VW
M6N/QU:9H(9X A":2@1A1(8[E%A&VF"L(,N(QI*0.8%"N5HI T^IAB-0E>RH<
M,Z6VJ$;^^7[/@ O2]>02>"CQM+I(U03G$F(][!:GSPT1B+[C:I4#HT7[-04\
M+\.QS;3:!O2G[#23I-13GX*:^:P4Y_K#VD1,#P2H[,/VW-NZ+4DY382=O1PF
ML] >0X'#WQC(_"S\DCG?Q(""6%F:%>>P<\^+JE#QNV/7(;PWE;;>.E/740(Y
MU*KX!Q]M(@2N@NA)?[1E&)KF,VG8[@ZE*:V*(F C*+7C4%)%?QN)5E!S(9',
M+(V).%B74;1;.GU/:I@;OY(D9Q]!S[C;>(HDX47/?HIY)  CLB&L6>LZ0^%S
M'O^LICIO!Y;X6,5Q)JZU*I,T=X@L-!H)M67R4X(WO?OUJ?E9\G;B4&?H5+;M
M9X8X@R)'[V,^^HJS=W,.&F*I?9A4IZ?ROFL!5POH.)DA[H)@L ,&7%V_ PO_
MVI.CD^RMQ.@EF70VW_)25^%O6K&F;:4\  $J-B81,(FYO^CE.T[Q=**CV)]*
M8HQDM8\0FO_2$@N>/N8R>VRE_RE!G>_O[;&_QU<^\*)WFHZ<D>5=.7H(  ,L
MR1:M*G4XAF*1=H]*C/9]:)?(]'RQFW#&4JR-)7K$(R\B<^%(4,!/).BPS",=
M^&._#!/?U\AIT$N7/[_CBJ_V;0;*TI;-F+&[?/_.#4[Y2"6,8U#T'5:="6U_
M#;<U(FOJV[I<1[H$2K7A7GHM70@(!OE")G6J.=*LB(VJ=V'HM TSGC-J<= J
MI$W1V2]:=U2"?,\O_2W)ZD9Z#_D0Q)B/8 :/ !Y*-?Z>C94S(1X+!IBN% V;
M2A.K8-."P"#^K#$\Y *M(%41)0R^FAA'U+I0-@BL3WO#2!<Y ]C:<<WM5BR;
M-DJS:,1BW8=!D4(VCG-#1]8>Z;/M+6&+4GHT@9#V2(,UMRW]7,X.\CUC(WFL
M@J< 0HJI1)=6ZS1%[INM!JP*Z1;EH0@5;[5)NI%""U,(,V<A()$(2Z?FW=6C
M=@#)Y&ZN?4S")\U(CEA>:&*(2SP< ^ <<]R,/7VCZ?0:Q"Y+52*L9]!CD;O@
MDP9'KJ:<4X:T?ZUEY\%@#:- VNZ6O3P[!&N2[I6F#1VY(8#%ZQY"C(X:*=8\
M. 3F/;'L7[U/[/*5E.,_X"P3]YJ+'Q4DGYQS2FIKXOC3#-9>*VP+"0X4KAX]
M/Y6&LSXK%]"S@D^\ BM*,$"6''1&C%_DT;C>.GE,#[/0B-;0X$U:\[^'- DF
M#U%3Q\?J_&:$O3@Z-^\"3;/TATV/S"<<IO!3H@B0JYW/T!TTSP[.2-+7$?&G
MPC$.1BQ",&<XZ9>T2_)6QJY=#:/TA(5R)TI  %IWHU[%F)?C4QG5K<:\1AV6
M@3TBNE*[F#00Q^;T66B'QG0[LC]-Z(UNB;I<C6 4$)Y52>1DPF]DVUTIIU3F
MR_T\_2SL9R9TX=#0W3!5J+D0#YDEIFY]]>\!U@3Y$_JP:Y^+Z!\JRP%5M""L
MD[,X(:>6@4A"6LE'I/%0(M#*'5NI)$SAE@;CP[E;Z;T=ZR\?G&,YJ+E1.F&"
M'-]#U658/0*YDRH\U LXF7 PD?BDNY+P8O;ERPJ\E_0+RR\).R1A7)-%<D'L
MW3#=6HD[^)+NB3NUM7%3N(=[DK)P^.B (0M8SPA)DX.LH6E<1)KU@X_##;/]
MO!))T7$?>5U],MQUD#?"7=Z@P1CB'Y=(U3E,@ !>3\L0T:1EW'8#A*4%=_((
M>:WEC82^A(HN7<0 )R0-J,<$;)'=,%Y_Q4;R,L7KKS7=]X8KO<( +ISJ[GKT
M/N-L5O*104Y%%*)C_IZ 8) 4Z63LB3K)83$QI[BHG*@7\ CS<A0/ZDM^"=$?
MOJIS(NRFV+0X@R^_SWV@O&U+4PN@.SHLTR$MCX=](X$A7"/[YCLI%B ,\&C"
M*X0ZAP$7_4L<0N Z GE4,QY'X CMU,I(E\ETFI+>)=1?$(98).U-,"Q0$<[,
MO%8*1"ZR:U\*OR:[+KD7\HX^ 9;'#44\ =NOYP0%$<'^#_S\0R?$%RR"L>OT
M+?H_+@\:4?V8CFT=?Y. N,/'O?\5+BZT16KBP;0MO8^=MOP;)#8]FTC<-M6Z
MR2X9-!;[[$/2^S;\0(ZTE=P^<V&E;PK<+&*;;J6E]* 6]# W)9=H9+>I\!I_
M&80DR!7=)*?_D\Q5I+7PM*84H=>_X\;/XW@*I7Z&=*A!63-/%3>IIYN<S'JX
M;L)+[3&J<S61@J%#JR79=&0%<; 'U=DQZ6E*;M G%+S!0SU"?.1J\&-,ERZR
M7]KF2S@" W^,*PONI&/AO29!N]G@!=Q94D2!W9G82,J_HR$NKPMMJEKB9#U!
M,,^Y*.A=9RL*$CW(29M1T=2&YAE-]-[Q14&FG.=(K1/7XS'%00MKVW=\ H-K
M=C&1*[LG&X/+!3Q\C+W<R<'[LJKEI-&@0Q=?:AH^+#JNUK?__3/7RC[U?KH'
M_!B;CC>C TX"XH\NT^\H)]2_+.OWI<_Y[.!LN,#DK#0IHIIO/8 IN[V+8.:@
MI/'@EHH4BXL?K?I+=FL@ -JY$)JN![>QL V[:^?<C.8[0;7@+@XM9+OU^%L\
M\^#^2(:V<BD;\NEA]Y+$.CJEEN6E@6?0P3[L0]&U-WJLS?GF(*D1#(0?AYX\
M2Y'I:="H6>^/<)9VQL@)X0B._?4S<4S& 76MTISLP&Q:B,<&*M3NB;;E _9,
M- >'+'4VKO*)K;PH6[Y'*;W;R;9-VVM'B$.X]\8L;0\KC'9*80Y:,OU)L(N;
MC_<V6B[2)YB; W/-39=B?/2Y%_-3"C7"A[/3]$/ZRWG\Y67ZSDMZAU5#/I^?
MSD^?S9)@/Z4>!86\\<M[,<O^VM<3?X8H2#[^S%E$J9S]@E9A_>DE3YM4*-*R
M6O8(Y^!BQ_ATBRG8Q5_$KA9I_',^RR#)(6U.F,HWJEG@BXM,]LGLAXU ?$,-
M7N=P)TGL"<S&"3RG';;<2$>*0\.B5H;F"@;D@A<"@;GO31Q0F,=F#.GG&'5C
M[*>)][JA"]2>(2X=H=[)L#XMS"^TF5C9-DM;\]+3:RXC3 Z\.6SJFVB@=0J"
M1OVW<D% \,HYSD@*SAX]" "F09MR0^(LWY3%05\ /G+VB$_]YZJ.W<$VR-1D
M3;RP^F \8CK:&%FI-9UMO=@)3!,"N%!'R) XAIH:SZ9'B$?#<FB?Q+8/=M5T
M;4<8G2A![?KEP8&*E[&:/3PUP0+#/>73/72Q W?4!23):?.Y<FGC\X$P'\DS
M\N/E_4L*;8Q.(;-.%3(8G*).W_!R'/OG.4N?7%^5=NMH"6 L>^$DK-;2JGA4
MX8Y[@1*9[@?;R+P,J:RTE)UVV)9IWT$@66O,1]=VE(3AI(F<#&B;R='A;4C&
MR[TL>I')'Y->M6ZE;\;)Y1PU@(CW;Q<UD/)Z RF.DR _H&,D[;X1+,A!"LZY
M2KKX,.6&FU'ENK8!VXAFS2&9%7=U#A;/P&*'_$B7=']XW99+W_1410@89<D[
M@)=P[UG)%VGL\N(3]V1IQ]86+;\2<2/+A'N$..FFHW$W 8D44B0@-Q%&[9$:
MV"Z)I]/[*TJLK7;);8:^R::0EB(O?HG3X9QE*(@_"Z[NK5K7$W\=Q9$K 6.B
MXAKYU*NK67:%4UXOONBB!X(LJ;M^.0U9]'P(887SV;"*H^#EFZ]/ 5X^</TG
M' PAFB+*.$?S*HG7:N]K;!Y%'91_EGLY?<.-&IK41'X[=B!RYDPOUDANO:3G
M CT'U$@_I1Q7"FWP*)S)S9;>&W'0X2F-UROZLT;<O,=15)B)N[W02K#:^R("
M3RNE7[6$Z[XJY8Z( ]P =8]."]SHW82?\=4)OM+$5ML B#5EBF=TT<%9K08;
M,%+B8&"\@#9'Y2R!P5<J%L=0L+;7DS1G?R>$XE'S56A&N1<7GSV=)2>=KI)K
M\WC<L^_\%7QOY0BTRM_3\^>/OTW;KY++^MZ&@^;3 X.MFS'25KK"T;$@1K,L
M!:99B,MPL8_SNAN(6OC+5\(W$0@R+(S,5E>0)JEBAI;[JY<FB3XUAX501AOO
MTC(<BAI")I=\#UU<>%A[N?5$>>5B'GOR)LE9J#?'2VRT12/T7?O;@?R5+[&B
MEMXVJO3%=J[ (594@[N>FEP:4(S<G+9CTI7'4\? /;=';:%I)7+B#H;QO7?2
M"$/&(8>^%;U*3]J('LZA-8/3[=PD)XA&>N83[D8+LI)[><C5-1PA<_:@KM-H
M("T&\55*@UU*3R@<7P8AI8T/ /+FP9/Y&J4 GGB6NR[6D06-^U1RNEW5V'JM
MR+&1T$A/Y=*L*RVNKG D-7B;LV=LULZ5W9,F34+Q=+Q%]CJB?RW(!+@0[MZ+
M1P^@5<X=>F)VC,$"W^=ATQ.DT65+<3<)9^4FERFK=G[&87ER=>*%@^_AS?7!
M_]-SLE\_Q?MSR:6\\I<HO8:,L&!R-#HYD(<XP;HDI/I[5M/LOD:*R<4A*HGA
M?M5A(6;)EZSJ&2<M>W&?42/)'KE"/K@$"7SQ$L&B=BU7=8G&Q(>\2YSYKN4P
MLKRN0L"E1:FW3A]^S3BW,<03"9/^+ <GN3=L<$'Q]([PO8 W_;+CC7GY[,7\
M.3(BY,_FA)OFY.Q6I(EA3^;D&6]-0Q'8^R1\%9L;,G_I9OA6,7^(5 \('E9
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MZ8!I_P'(7UC5NH\N*V6MJMW/4G",$[0!ZVN%22]<D(+^*]SU?P%02P,$%
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MGY.]8&3K9M-&&IQT;EGC7PM0U@#W*RG-0; '#']65G\#4$L#!!0    ( 'N
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M=V]R:W-H965T<R]S:&5E=#$V+GAM;*U4VV[;, S]%<+/0>PXZ65%$B"7#NN
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MP"6"I4S9W=Q<B#S3[4REM:Y1 (-#V.!"OXV%C=3)I<X1!1M-!8JT#D][TIY
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M3X"SK):G(AJ-02D:1?@WQ=441T1(^'QU]E[;3Y<KF)E*!T5S+_?#AS^*F(,
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M:]!)K4KP)=4ZV346@B)!@7#@OG[HH:?'LY<E5!0^DD!Z+HG=@=@W9W%E5?$
MJG/\#*0L23.6Y#-:Q7G.TB2FN";3"4NG^>@>2Z0!XTJW4"UES=9N340WJ#49
M,@[L:K0B!R@@U_##=SF/^4_'[Y1QGK+,F1U$;LZ(9/F4Y;/I0>3VA0@1S#(V
MR:/1K6H:"JLW"SNA-87@A3@YG:?9-Y)_%26E&LZFHT_*"GDV3#QA.55B-IO"
MN><I/'GP&]1;/]8,4>E;.[S]Q]/CY+P>!L87\6'L?A!Z6U.R)&Y(-1IG:0!Z
M&&7#QJK.CX^ULC2,_+*BZ8_:"=#]1E$I[S?.P/'_Q/(_4$L#!!0    ( 'N
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M-V5I =[#++ZYH0W:S]+O_P=02P,$%     @ >X!<5+=SRCZE"   S!<  !D
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MQX/8 +N'8&N^KYW: )3S3\Q'(!A:@.\SBV&Z?2 %_07^Y9]02P,$%     @
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MI1Z=<5VL@M@)0H&Y=0R,7L]XCD(X(I+QM.,,AI ..%[OV:]\[I1+Q@R>*_'
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M ](0R)%ZF%)O&JU>.#4EBBT!%]-P3MTAA&MTREO2-"./'+$PP$I+A*2TI0E
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MPD"&829Z>)LV1=W1>[1\,T('#21A6=!V&#=K8"JU=<4"J2.6$Q;,BB;K=G1
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M;A$G[IF. 6*.I))Y=8- 4QO[?ONN@8TJGEU9UID7O*HH6'*H1TP/POP$"B]
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MHF$\0."I50D91,\X*X3WH3'@MC5I9=/L*)U4DIU;SJ+L\(S3PZWS6O6XR08
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MZ=D4GS44'G/ZP/WBE(BJ -F-NC/,=0,W41*=P4OT+EHDNOY&\I;7<0* /?X
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M,%-OG?KB=.DG?:T=[@U_S'%1@R$#U&=:N_V%")K5/_T-4$L#!!0    ( 'N
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MEL:T7Y;T783:"=!]H93=;)R![9?6[#M02P,$%     @ >X!<5(%G\MKI @
M. 8  !D   !X;"]W;W)K<VAE971S+W-H965T,S N>&ULC97K;]HP$,"_\U><
M,FEJI:AY\2X@E3ZT?JB&2K=]F/;!) >)ZMC4=DK[W^_LA(Q*!4U"X+/O?O>P
M[YCLI'K6.:*!MY(+/?5R8[;C(-!ICB73%W*+@D[64I7,D*@V@=XJ9)DS*GD0
MAV$_*%DAO-G$[2W4;"(KPPN!"P6Z*DNFWN?(Y6[J1=Y^X['8Y,9N!+/)EFUP
MB>;'=J%("EI*5I0H="$%*%Q/O:MH/.]:?:?PL\"=/EB#S60EY;,5[K.I%]J
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MT"#11>9*W'IVCJQI&^&X0^\%RQ4E:-_,H="Q#\AI=KYO[21HT99@\886A=A
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M/A F0)\7G*NWC1E^W=<T_0=02P,$%     @ >X!<5"\E7?A$ P  A0P  !D
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M=L"4S>@J5O=\\P\K)N1G^28\EOE?L"G&>ATP64G%DR)8*TBB=/N?_BD*L1,
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M1B,-EE]6=).!<0ET7FJ-;X&;KOYNS'X!4$L#!!0    ( 'N 7%1<5@;:< ,
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M4+L)]'RIE'T:N 7J+YOI3U!+ P04    " ![@%Q498PKX,P"  !G"   &0
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M.X,T?&%9T6T'ZQ/HO#0&3X&?P.'_D?T%4$L#!!0    ( 'N 7%3B_?^F'P,
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M)KY_S.@21^T,Z/U*41O5"^>@^5LP_0502P,$%     @ >X!<5*'$:TV* @
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M7;3XX@!FN"M#@+H-_=EI=-T.P]H]+S ^P:U76N,I\"V?'FS^%U!+ P04
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MN]P\4I&E1RJ#*@:2::;5N5$@Z)Z&=$,C.-"N.$_'+Z6;PF5U*3E]W+*2C)Y
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M0BIT _7]E'.Y_:#?>"E?NKKX#U!+ P04    " ![@%Q40X. 4*<%   C&0
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M%D2;IER$JI1 <B<J6!A'T3 L".7!;.+Z;N1L(E::40XW$JE541"YN0 FUM,
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M7<IFF*E&"[@.4,\7C,G]1+^@;MV&_P%02P,$%     @ >X!<5!6M%9KF!
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MN$^"5- _H+\86< N4Z^VE+A-!VV[X'/8W(UA+W+N@5&3D-&5"?D-N3B<+J2
MU@?R83T+W.:Z8:3CL?U()9?(4->4C9Q?(K'>1Z[R&#?9&+M/A+KUPH.P6]Y
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M4-8 WZ^E-*\#VV=U??7\7U!+ P04    " ![@%Q4L5J8T:D#  #>#0  &0
M 'AL+W=O<FMS:&5E=',O<VAE970V,BYX;6RU5TUOXS80_2N$T,,NT$8BY<_
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M7)"8_DQ8Q&B+H.GY\*@%/CL;3H<M\)OSX0-/,N*ZDG'!%W^SDF0F3)(IL]%
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M20:8X=).\Y I0Y+V6=@+5B-+5!*!].N[DAV78*"\@+0Z9[5G5]*ZMY'J11<
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M965T<R]S:&5E=#8T+GAM;+586V_;-A1^[GX%86Q "Z2Q2%FV520&$B=!,[1
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M,9O3,E'W8O65-0$%VEXDDJ+Z1:M&UNNAJ"R42!ME0)#RK/ZGSTTB.@I@QZY
M&@7R6F&P0\%O%/Q]%0:-PF!?A:!1"/95&#8*53'[=;*J3%]112=G4JR0U-)@
M35]4Y:JT(<$\TYTU4Q+><M!3DWN64,5B=$>E>D%_2)H5M*IY@3ZCBSCF^IHF
MZ#:KNUAWP\<KIBA/BD\@\F-VA3[^^NFLKP",-MF/&L>7M6.RP_%W^H)(>(*(
MA\<6[:E;^XI%I\C'6IU@B_K5_NJ>1?UZ;W4<6M1OW.J_EQFH>S;O?2A?6T/2
MUI!4]OQ#:XC^^@:BZ%:QM/C;X<AO'?F5H\$.1U.1IF 5FC+Z>8**!96L0&*5
ML=A6P=I64-G2!+><!+[GXW $]5YV:V41Q-X(!Z'?"F[ ';1P!TZX#U1"+A1B
MSTQ&O+"BO!EL.1\,Q\/0[CEH/0?N1"UH]L00S]"<<HF6-"D9$G.@XIC!RO"8
M,!2);,FDXOH:UH0YD_"R3BU:U<!M?5W['77@XE'H>=YF2J^WQ3YCTA7;"&O8
MAC5TAC4KE13HDHL<2I_2$V"%R-%6H];LZ+C].VX=C?_'_AUO=08>>MY6KJ_>
MEML &[9@0R?8BRB2)62%/<,440#0G+[HSK%!#;?*_1KDML3(@1%[9OGP#FX)
M]"_ZQB,-&ET\26AX]KJ7-YUUUBI\W$;!AE(Q<<9U!Y0!L&&XJKY;\4(3< DE
MT,$@/1)E60GK8@;#7T$3W4=S^,ZC2./(I8C+2!4(UDRT*%.:H04# POK0N<&
M,CCUO-]<(1GRQF[V?C,D:RR12'-1\'HDT/'0C*<0N",@-PSR5D"&WK&;WW?T
MWJS,\^1EO]8SA(Z#([>>(5GL9MGK]0<O&Y]*(&H/IDGX<.OC)@,;4S6"&U1%
M+(+7%HL8N_C"4#T>O:MF3'*(>(KNS0HY[:R0,TW9KNR:)0"/CUQ(0^#8S>#K
M^0/JEY<R6L &J%UTYO4J9)T]P^UY*"2CH3WUQ% U<5/U&DZ+)9? TBAGLD9E
MP]*8Q&2C$TX#@H,=< R9$WRT3NBN,/!5Q!6#71#7+-T9IH\\31/#R,1-A>]K
MD$MB&9@=#6+XE.PW+Q_0()>-R0,:Q% N<0_1K\;WJA-H%J,E*V!IY6G*8@Z5
M JK73V%,XCIQ,3RR G4[:[:COWSXL+TAW<1O>)P</BU#XS9#Z%N,1@REDB./
MS\20)W$/T.]D-+(](OMX'(QV=(@A6+(?P1[$:+5)['>'Y=-12,8[]GR^(5C_
M7;-PM^#HP;:UV_1G&-0_\CCL&U+TW5/H/EOIZ\;&1ID]TMGN;SKOG#JX:7)'
M7N_:7?/>J354Z ^.G%I#<_Y!-+<CM8%EDQF$>$=J#4?Y;HXZVD'%U-\>(5^/
MHQ81ZS3J-%4'WN^<@.H3\>]4/G'8L"1L#CKP?4/F9'W(7-\HD5>'HH]"*9%6
ME["CB9G4 O!^+H1:W^ASUO:H?_(?4$L#!!0    ( 'N 7%0V:@O0"0,  "D(
M   9    >&PO=V]R:W-H965T<R]S:&5E=#8U+GAM;)56;6_3,!#^*Z<("9"@
M:=/7H+;2VH$88E!M&GQ ?'"32V/-L8/MK./?<W:RT&UI!?V0^.6>Q\_=.7>=
M[Y6^-3FBA?M"2+,(<FO+=V%HDAP+9GJJ1$D[F=(%LS35N]"4&EGJ084(HWY_
M$A:,RV Y]VL;O9RKR@HN<:/!5$7!].\5"K5?!(/@8>&*[W+K%L+EO&0[O$9[
M4VXTS<*6)>4%2L.5!(W9(C@;O%O'SMX;?..X-P=C<)YLE;IUDXMT$?2=(!28
M6,? Z'6':Q3"$9&,7PUGT![I@(?C!_8/WG?R9<L,KI7XSE.;+X)9 "EFK!+V
M2NT_8N//V/$E2AC_A'UCVP\@J8Q510,F!067]9O=-W$X !!/-R!J -%3P.@(
M8-@ AM[16IEWZYQ9MIQKM0?MK(G-#7QL/)J\X=)E\=IJVN6$L\OK:FOP5X72
MPOL[>AIX"V=IREV,F8 +65\4%_%7YV@9%^8UF3R%T=*-3%'O-;<6)6RJK> )
M?,TRU%SNW/;U.;QZ\1I>0 @F9QH-<$D@;LT;6J3Q)1>"SC'ST))C3EZ8-$ZL
M:B>B(TX,X%))FQMX3QK2Q_B0 M)&)7J(RBHZ2?@!MSV(9F\@ZD=1AY[U:?@G
M)GLP''3!'\D9MDD:>K[A/R8)?GPF"[BP6)B?)_A'+?_(\X^.\3?Y,*9Z&K[:
MW1H^]G!7%^Z6T;CO?O/PKN/<<7ON^.2Y:U44=+'HDB>W4&J>()2HZ^O1):-F
MFQ[*.*)@TBJ8G%2PT?@VJ]RM@3W3FKD/P"HH*YWD5!R:F]JE9?)_(9FV@J;_
M+>@?(E.3S@[4#.)>',?=8F:MF-E),5^HBY1:)8BI@4RK C(EJ.X#)4TUGW;7
MUUJS3@[5C'J#5DLM^;E1/.R-NP7'K>#XI."V!J$V+T&5OFX=YI/]+6U'4[N*
MGZ5V.N[(;'A0=0O4.]^,#"2JDK8N->UJV^_.?)E_LKZB/EBWK;\T=1.]9'K'
MI0&!&5'V>U,2I>O&5$^L*GUMWRI+G<(/<^KEJ)T![6=*V8>).Z#]=[#\ U!+
M P04    " ![@%Q4[13:;T0#   :%0  #0   'AL+W-T>6QE<RYX;6S=6&UO
MVC 0_BN1.TV=-#5 VD!60-J0*DW:IDKMAWVK#'' DF-GCNF@OWZ^.(27^BCK
MAQ66"&+?XWON.?N2&/JE60IV-V/,!(M<R') 9L84G\*PG,Q83LL+53!ID4SI
MG!K;U=.P+#2C:0E.N0@[K58<YI1+,NS+>7Z3FS*8J+DT ])M3(&[?$T'I!U?
MDL#1C53*!N3A_/VON3+7[P)W/?MX=M:Z:#U\N-Y%SFOH PF]Q%<'$*.T&&E\
MD-K6/KTME+Q[&/D^;HRZMTV]J?-E7<F!2>_/&J/OM@ZE?X'?!0CKLAOV,R77
MU1<19[ *:,Z"1RH&9$0%'VL.7AG-N5@Z<P<,$R64#HPM>RNI#9;RR<%MUX,[
MHN;)N52ZBNTBN.]Q/7P'6/5 (!>B$=@ASC#L%]08IN6-[52#*^,S**C;]\O"
M*IQJNFQWKLC:H;K8(&.E4Z:;,&VR,@W[@F4@1_/I#*Y&%2& QJC<-E).ITK2
M2L/*HVY8V@D3X@X>%S^S+>Y%MK&VU<K*IFD%U4U'XSK O\GFN#=I+U_%&Q3\
M49DO<YN.K/I0+^Q6LXPOJOXB:P1@[&V<G1:%6'X6?"ISYI(_.."P3U=^P4QI
M_F2C0:E,K(%I$CPR;?ADT_);T^*>+<RJG!89KKES@IK_[3Q/F62:BDW1MO:/
M>99?K3CJOI7DZJFR*]BKL=X#'+O(JU,0&9^"R).HR=[QBXR2X]=8[QZ/7&3W
MS9[L>T6&]4YH8[NUM=EJK %L:@?D!VRCQ3IH,)YS8;BL>S.>IDP^VW-9>D/'
M]H??%K\=G[*,SH6Y;\ !6;>_LY3/\Z09=0L348]:M[]!>NVXV5';6%RF;,'2
M4=W5TW'5#&S#1JT/<-A%;JK#CV ^#O,C@&%Q, 68C_/"XOQ/^?30?!R&:>MY
MD1[JTT-]G)</&54G%L?OD]C#GVF21%$<8S,Z&GD5C+!YBV/X^-DP;>"!Q8%(
M?S?7^&KC%;*_#K UW5<A6*9X)6*9XG,-B'_>P"-)_*N-Q0$/;!6PVH'X_CA0
M4WZ?*()5Q;1A=S".) F&0"WZ:S2.D=F)X?2O#W:71%&2^!' _ JB"$/@;L01
M3 %HP) HJMZ#.^^C</6>"M?_A@[_ %!+ P04    " ![@%Q4EXJ[',     3
M @  "P   %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">, ?0(8@S9?$6!/D!5J(/
MV!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]$%)I6M6X 4BV)8]ISI%"
MKM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D5XA<UYVE/=LO3T%O@*\Z3'%"
M:4A+,P[PS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A(E@6FD7)TZ(=I7\=Q_:0
MT^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0    ( 'N 7%1R
M_S^,_@0  !,K   /    >&PO=V]R:V)O;VLN>&ULQ9I;4]LX%(#_BB9/W0<V
M\;4M0YCI%MAEIH4,8=G''6$K1(,MI9(,+;]^C^RF2)"<V9=CGD)LH7P^NGQ'
MDH\>M;F_U?J>?6\;9>>3M7.;P^G45FO1<ON[W@@%=U;:M-S!5W,WM1LC>&W7
M0KBVF::S63EMN523XZ-M70LS#;]H)RHGM8*+_L*-%(_V^;[_RAZDE;>RD>['
M?-+_W8@):Z62K7P2]7PRFS"[UH]_:2.?M'*\659&-\U\D@PW;H1QLGIU>>DA
MK_FM[:\X?GO% 60^*6=0X4H:Z_H2??T<&!\$%!Z^=4Z?R<8)<\*=^-/H;B/5
MG:\&GF(:/$8?A^WG$,1#\W_"J%<K68D3776M4&Z(HQ&-!U1V+3=VPA1OQ7RR
M+<*XJMFI<A D=JZ&JJ"L?U+XZ?-Z>&H'N$$,S:&$&^:\[L'I(/_@#5>58'T\
M;<"4(DSIF$SLW8(;^(>UZ'O*;P%CAC!FM(Q+_[N^C&5ZQ2XWP@QE KH<H<O?
MANYG+ /( H$LQH3\K%N8G]9"61C-[(L.(UDBD.68D%>B%E E$ "O>A F@'R/
M0+Y_0\A_TP#R P+Y8=3FYG;-SAK]"'WR;\6[.H#\B$!^I(7TO9"K'^S2W'$E
MG_H"_?Q]P5UG1#AGS[!)>T8]0UK9AW%AA(6BSYS+KFUYB(FZA5@N9UP:=L.;
M3K"O@EL(X-#^'A3NA9B8;I(Q?<-.A..R":>?!/-,0BR:+Q X$=%@7DF(Q0+C
MHY7NN15A@G&07PE5R1@2\TI"+)97L[3S 'ZLK(2)!S%FEH18+3Z6,&J73E?W
M(1,FDH38)/]P8[B*$L$$<T9"+(W3;]V0-E=0SB<&"QBJ$1TFBX38%F>=JJ'W
MLT\^:'?]Y!9FT)@A4F)#7$"]D$19MA &)C8>=?L4DT)*+ 5H2]T*=LV_1S-&
MBBXXB UPY2^*FD%V#+WM&EK3\NIE/I]B&DBIUQO=K17?.K^</'T0\0A-,2.D
MQ$9 4Y$H]TPQ)Z3$3L QLQ 3<T)*[ 0T8XJCB6DB)=;$SHR)O;OVSK7A"CW%
MY)$2RV-(G79B8=9(Z=<8O[R_"R[#O)$1>V.W<'=B8A+)B"7R6F\[$3&G9,1.
M"3VW$P[=O2+6";K.C>:9#)-+]J9RR4-,3"[9F\JE"#$QN61O*I?0@1DFEXQ8
M+CAFU.B873)BN^"84:-CMLF(;;-;U0=L"77771/N5V/>R<EWM'9C?JIK"85#
M3,P[^9C')2^C&<V;.>:>G-@]/S.?7^%3O-ES])1C%LI'V=MZ[HS"SZ'/G"$F
M>IA";*&=F%_]AC#$-EK$YIB%<F(+H9AQW\0LE(^P[;5W"Y$=A)B8A7)B"Z&;
MB'$T,0OEQ!:*%A.OQWN(B5DH'W/-$_=0?RL\D,0L5!!;:+O]N6?F##$Q"Q7$
M%MJS2-M"AYB8A0IB"^W%[ ^IPKY98!8JB"V$8D8CO< L5!!;",<,L_<"/=0G
MMA".&6;O!6:A@GHM]'KK/AST(29FH8+80COV.<+9,\3$+%006PC%C(<09J&"
MV$+1ELP!NQ*5AJRCD<-Z/8QFB5FH)+;0"TR_5Z/5]L6)D_ @I\0L5(YXD(.G
M'B5FH7+,?;B7C1[US1*S4$ELH?U'4'UL0TS,0B7UFV4OSZ'BE@\Q,0N5O86F
M?6%[?%2+E52BOH"?L'"]XDVU,,Q_#"^'Y(4_YUUU3?,9KEVJ+YK7VW<ZM^^C
M'O\'4$L#!!0    ( 'N 7%2U<6!\%@(  *HF   :    >&PO7W)E;',O=V]R
M:V)O;VLN>&UL+G)E;'/-V3MNVT 4A>&M"%R 1_<UM@/+51JW@3= R*,'+(D$
MAT'LW4>0"^D0*=(8/!4Q)'CY-_Q #)]^E4,[[KM3W>W[NO@X'DYUU>S&L?^1
M4EWORK&M=UU?3N<KFVXXMN-Y.6Q3WZ[?VVU)NESF--S.:)Z?;F<N7C_[\C\3
MN\UFORX_N_7O8SF-_QB<_G3#>]V5,C:+UW;8EG'5I(_#]71-EX/<G2<WBY>W
M53.\O$F3Y@Y2"-+Y@PR";/X@AR"?/R@@*.8/RA"4YP^ZAZ#[^8,>(.AA_J!'
M"'J</TB6*..2(&F"-8'6@EP+@=>"8 N!V()D"X'9@F@+@=J"; N!VX)P"X'<
M@G0+@=V"> N!WHIZ*X'>BGHK@=XZ^=@FT%M1;R706U%O)=!;46\ET%M1;R70
M6U%O)=!;46\ET%M1;R70VU!O(]#;4&\CT-M0;R/0VR:;)01Z&^IM!'H;ZFT$
M>AOJ;01Z&^IM!'H;ZFT$>AOJ;01Z.^KM!'H[ZNT$>COJ[01Z.^KM!'K[9+.;
M0&]'O9U ;T>]G4!O1[V=0&]'O9U ;T>]G4#O0+V#0.] O8- [T"]@T#O0+V#
M0.] O8- [YC\K"30.U#O(- [4.\@T#M0[R#0.U#O(- [H]Z90.^,>F<"O3/J
MG0GTSJAW)M [H]Z90.^,>N?OU+N.GX=2KSU?:WS^=U(]GN\MU\=?EE\G)R_4
M!>=T6U&?_P)02P,$%     @ >X!<5-(T9!3L 0  !R8  !,   !;0V]N=&5N
M=%]4>7!E<UTN>&ULS=I=3\(P% ;@OT)V:UCIU_R(<*/>JA?^@;H=9&%;F[8@
M_'N[ 28:)1I,?&]8H.UYSWJ2YXKKIZVC,-JT31>FV2)&=\58*!?4FI!;1UU:
MF5O?FIB^^A?F3+DT+\3$9%*PTG:1NCB.?8UL=GU+<[-JXNANDWX.M>VFF:<F
M9*.;W<8^:YH9YYJZ-#&MLW57?4H9[Q/R='+8$Q:U"V=I0\:^3.A7O@_8GWM8
MD_=U1:-'X^.]:=,NMFE8B-N&0GZ\Q!<]VOF\+JFRY:I-1_+@/)DJ+(ABV^2[
MHF?'DV.Z8=I]\I/SAS+' M/.1V]=2!/S]/NXPTCZTV.7"I&/]?%7?$],I4]^
M/^JG75'UP^QTO:_6+X=Y!#8\3K_CCS-^K__+/@1('Q*D#P72AP;IHP#IXQRD
MCPN0/BY!^N 3E$901.4HI'(44SD*JAQ%58["*D=QE:/ RE%D%2BR"A19!8JL
M D56@2*K0)%5H,@J4&05*+(*%%DEBJP215:)(JM$D56BR"I19)4HLDH4626*
MK!)%5H4BJT*15:'(JE!D52BR*A19%8JL"D56A2*K0I%5H\BJ4635*+)J%%DU
MBJP:15:-(JM&D56CR*I19"U09"U09"U09"U09"U09"W^4]9G:Y=_'#\\\];4
MW2&?#?__FKT!4$L! A0#%     @ >X!<5 =!36*!    L0   !
M     ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " ![@%Q4_<A;
MVNX    K @  $0              @ &O    9&]C4')O<',O8V]R92YX;6Q0
M2P$"% ,4    " ![@%Q4F5R<(Q &  "<)P  $P              @ ', 0
M>&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( 'N 7%3=QE"Y&0<  *L<
M   8              " @0T(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q0
M2P$"% ,4    " ![@%Q4^8TQR4P&  "#&0  &               @(%<#P
M>&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ >X!<5."QB8KF
M @  Z D  !@              ("!WA4  'AL+W=O<FMS:&5E=',O<VAE970S
M+GAM;%!+ 0(4 Q0    ( 'N 7%18MT#9W@0  *L0   8              "
M@?H8  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4    " ![@%Q4
MP]^DLF8"  #$!0  &               @($.'@  >&PO=V]R:W-H965T<R]S
M:&5E=#4N>&UL4$L! A0#%     @ >X!<5!!HFD6I @  90<  !@
M     ("!JB   'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    (
M 'N 7%0B1]Q"D0@  /(N   8              " @8DC  !X;"]W;W)K<VAE
M971S+W-H965T-RYX;6Q02P$"% ,4    " ![@%Q4J$),&+T"   D"   &
M            @(%0+   >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#
M%     @ >X!<5+\VE@=#"0   BD  !@              ("!0R\  'AL+W=O
M<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( 'N 7%1FDI0?R D  )(6
M   9              " @;PX  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL
M4$L! A0#%     @ >X!<5!H44M^>(   D&0  !D              ("!NT(
M 'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4    " ![@%Q4]Z@[
MV+4)  "1&P  &0              @(&08P  >&PO=V]R:W-H965T<R]S:&5E
M=#$R+GAM;%!+ 0(4 Q0    ( 'N 7%0JAND6SP,  +@(   9
M  " @7QM  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @
M>X!<5,?V>58O"0  #!@  !D              ("!@G$  'AL+W=O<FMS:&5E
M=',O<VAE970Q-"YX;6Q02P$"% ,4    " ![@%Q4XCCNB'<)  !_&   &0
M            @('H>@  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4
M Q0    ( 'N 7%2R@QF5B (  .<%   9              " @9:$  !X;"]W
M;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%     @ >X!<5'D24?,S!0
MS@L  !D              ("!58<  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX
M;6Q02P$"% ,4    " ![@%Q4W>4#034"  #!!   &0              @(&_
MC   >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( 'N 7%2E
M3TU;O P  !LH   9              " @2N/  !X;"]W;W)K<VAE971S+W-H
M965T,3DN>&UL4$L! A0#%     @ >X!<5(GMY__5!P  +A,  !D
M     ("!'IP  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( 'N 7%0@"763""(  #EO   9              "
M@4W   !X;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @ >X!<
M5#1_2+O# @  !@8  !D              ("!C.(  'AL+W=O<FMS:&5E=',O
M<VAE970R-BYX;6Q02P$"% ,4    " ![@%Q4-^W>%%D$   U"P  &0
M        @(&&Y0  >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0
M   ( 'N 7%0R(>*=B@,   0(   9              " @1;J  !X;"]W;W)K
M<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @ >X!<5/1@;@_I P  =0D
M !D              ("!U^T  'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q0
M2P$"% ,4    " ![@%Q4@6?RVND"   X!@  &0              @('W\0
M>&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( 'N 7%0I.W"V
MY 4  '<0   9              " @1?U  !X;"]W;W)K<VAE971S+W-H965T
M,S$N>&UL4$L! A0#%     @ >X!<5%!74$\!!   40D  !D
M ("!,OL  'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4    " ![
M@%Q4% K 5A<%   ?#   &0              @(%J_P  >&PO=V]R:W-H965T
M<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( 'N 7%33/1E[R 0  !T3   9
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M970S."YX;6Q02P$"% ,4    " ![@%Q4;[DQQU8"   G!0  &0
M    @('6&@$ >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    (
M 'N 7%1<5@;:< ,   ,-   9              " @6,= 0!X;"]W;W)K<VAE
M971S+W-H965T-# N>&UL4$L! A0#%     @ >X!<5*#X,+V  @  G@8  !D
M             ("!"B$! 'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"
M% ,4    " ![@%Q4S >7[X "  !=!@  &0              @('!(P$ >&PO
M=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    ( 'N 7%2*CF&)5@<
M *\E   9              " @7@F 0!X;"]W;W)K<VAE971S+W-H965T-#,N
M>&UL4$L! A0#%     @ >X!<5%[FYGXI P  Y0@  !D              ("!
M!2X! 'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6Q02P$"% ,4    " ![@%Q4
M98PKX,P"  !G"   &0              @(%E,0$ >&PO=V]R:W-H965T<R]S
M:&5E=#0U+GAM;%!+ 0(4 Q0    ( 'N 7%18R'5A% (  $L$   9
M      " @6@T 0!X;"]W;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#%
M  @ >X!<5.+]_Z8? P  (@@  !D              ("!LS8! 'AL+W=O<FMS
M:&5E=',O<VAE970T-RYX;6Q02P$"% ,4    " ![@%Q4H<1K38H"  "\!@
M&0              @($).@$ >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+
M 0(4 Q0    ( 'N 7%0,SZK32 0  *$/   9              " @<H\ 0!X
M;"]W;W)K<VAE971S+W-H965T-#DN>&UL4$L! A0#%     @ >X!<5%B[+^BF
M @  R@<  !D              ("!24$! 'AL+W=O<FMS:&5E=',O<VAE970U
M,"YX;6Q02P$"% ,4    " ![@%Q4FQWW9-L!  "\ P  &0
M@($F1 $ >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0    ( 'N
M7%1"YAMK<P<  ( E   9              " @3A& 0!X;"]W;W)K<VAE971S
M+W-H965T-3(N>&UL4$L! A0#%     @ >X!<5$.#@%"G!0  (QD  !D
M         ("!XDT! 'AL+W=O<FMS:&5E=',O<VAE970U,RYX;6Q02P$"% ,4
M    " ![@%Q4A6)M#F0#  #1#0  &0              @(' 4P$ >&PO=V]R
M:W-H965T<R]S:&5E=#4T+GAM;%!+ 0(4 Q0    ( 'N 7%1S4_VH/@0   86
M   9              " @5M7 0!X;"]W;W)K<VAE971S+W-H965T-34N>&UL
M4$L! A0#%     @ >X!<5'\HYAX9 P  Q@D  !D              ("!T%L!
M 'AL+W=O<FMS:&5E=',O<VAE970U-BYX;6Q02P$"% ,4    " ![@%Q4%:T5
MFN8$  "W%0  &0              @($@7P$ >&PO=V]R:W-H965T<R]S:&5E
M=#4W+GAM;%!+ 0(4 Q0    ( 'N 7%3(L,VY^ (  /$'   9
M  " @3UD 0!X;"]W;W)K<VAE971S+W-H965T-3@N>&UL4$L! A0#%     @
M>X!<5&&;N"S) P  9!$  !D              ("!;&<! 'AL+W=O<FMS:&5E
M=',O<VAE970U.2YX;6Q02P$"% ,4    " ![@%Q4A^L)\C,$  "^$   &0
M            @(%L:P$ >&PO=V]R:W-H965T<R]S:&5E=#8P+GAM;%!+ 0(4
M Q0    ( 'N 7%0H><MZ< ,  &,+   9              " @=9O 0!X;"]W
M;W)K<VAE971S+W-H965T-C$N>&UL4$L! A0#%     @ >X!<5+%:F-&I P
MW@T  !D              ("!?7,! 'AL+W=O<FMS:&5E=',O<VAE970V,BYX
M;6Q02P$"% ,4    " ![@%Q4BC&CH10#  "V"   &0              @(%=
M=P$ >&PO=V]R:W-H965T<R]S:&5E=#8S+GAM;%!+ 0(4 Q0    ( 'N 7%33
MAS5U2P4  /87   9              " @:AZ 0!X;"]W;W)K<VAE971S+W-H
M965T-C0N>&UL4$L! A0#%     @ >X!<5#9J"] ) P  *0@  !D
M     ("!*H ! 'AL+W=O<FMS:&5E=',O<VAE970V-2YX;6Q02P$"% ,4
M" ![@%Q4[13:;T0#   :%0  #0              @ %J@P$ >&PO<W1Y;&5S
M+GAM;%!+ 0(4 Q0    ( 'N 7%27BKL<P    !,"   +              "
M =F& 0!?<F5L<R\N<F5L<U!+ 0(4 Q0    ( 'N 7%1R_S^,_@0  !,K   /
M              "  <*' 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " ![
M@%Q4M7%@?!8"  "J)@  &@              @ 'MC $ >&PO7W)E;',O=V]R
M:V)O;VLN>&UL+G)E;'-02P$"% ,4    " ![@%Q4TC1D%.P!   ')@  $P
M            @ $[CP$ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     20!)
+ /83  !8D0$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>202</ContextCount>
  <ElementCount>483</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>73</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="pcvx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="pcvx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementBalanceSheets</Role>
      <ShortName>Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="pcvx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100020 - Statement - Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementBalanceSheetsParenthetical</Role>
      <ShortName>Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="pcvx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100030 - Statement - Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfOperations</Role>
      <ShortName>Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="pcvx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100040 - Statement - Statements of Operations (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfOperationsParenthetical</Role>
      <ShortName>Statements of Operations (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="pcvx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100050 - Statement - Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfComprehensiveLoss</Role>
      <ShortName>Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="pcvx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100060 - Statement - Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit</Role>
      <ShortName>Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="pcvx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100070 - Statement - Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical</Role>
      <ShortName>Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="pcvx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100080 - Statement - Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited</Role>
      <ShortName>Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="pcvx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>100090 - Disclosure - Company Organization and Nature of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCompanyOrganizationAndNatureOfBusiness</Role>
      <ShortName>Company Organization and Nature of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="pcvx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>100100 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="pcvx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>100110 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstruments</Role>
      <ShortName>Fair Value Measurements and Fair Value of Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="pcvx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>100120 - Disclosure - Balance Sheet Details</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetails</Role>
      <ShortName>Balance Sheet Details</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="pcvx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>100130 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureLeases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="pcvx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>100140 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="pcvx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>100150 - Disclosure - Redeemable Convertible Preferred Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStock</Role>
      <ShortName>Redeemable Convertible Preferred Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="pcvx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>100160 - Disclosure - Common Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCommonStock</Role>
      <ShortName>Common Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="pcvx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>100170 - Disclosure - Warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureWarrants</Role>
      <ShortName>Warrants</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="pcvx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>100180 - Disclosure - Equity Incentive Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlans</Role>
      <ShortName>Equity Incentive Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="pcvx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>100190 - Disclosure - Funding Arrangement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFundingArrangement</Role>
      <ShortName>Funding Arrangement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="pcvx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>100200 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="pcvx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>100210 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="pcvx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>100220 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="pcvx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>100230 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="pcvx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>100240 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="pcvx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>100250 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="pcvx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>100260 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsTables</Role>
      <ShortName>Fair Value Measurements and Fair Value of Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstruments</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="pcvx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>100270 - Disclosure - Balance Sheet Details (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsTables</Role>
      <ShortName>Balance Sheet Details (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetails</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="pcvx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>100280 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureLeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureLeases</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="pcvx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>100290 - Disclosure - Common Stock (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCommonStockTables</Role>
      <ShortName>Common Stock (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCommonStock</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="pcvx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>100300 - Disclosure - Equity Incentive Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansTables</Role>
      <ShortName>Equity Incentive Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlans</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="pcvx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>100310 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShare</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="pcvx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>100320 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxes</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="pcvx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>100330 - Disclosure - Company Organization and Nature of Business - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCompanyOrganizationAndNatureOfBusinessAdditionalInformationDetails</Role>
      <ShortName>Company Organization and Nature of Business - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="pcvx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>100340 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="pcvx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>100350 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Cash, Cash Equivalents And Restricted Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfCashCashEquivalentsAndRestrictedCashDetails</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Cash, Cash Equivalents And Restricted Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="pcvx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>100360 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsAdditionalInformationDetails</Role>
      <ShortName>Fair Value Measurements and Fair Value of Financial Instruments - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="pcvx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>100370 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments - Schedule of Financial Instruments Measured at Fair Value on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements and Fair Value of Financial Instruments - Schedule of Financial Instruments Measured at Fair Value on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="pcvx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>100380 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments - Schedule of Contractual Maturities of Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfContractualMaturitiesOfInvestmentsDetails</Role>
      <ShortName>Fair Value Measurements and Fair Value of Financial Instruments - Schedule of Contractual Maturities of Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="pcvx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>100390 - Disclosure - Balance Sheet Details - Schedule of Property and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentNetDetails</Role>
      <ShortName>Balance Sheet Details - Schedule of Property and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="pcvx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>100400 - Disclosure - Balance Sheet Details - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsAdditionalInformationDetails</Role>
      <ShortName>Balance Sheet Details - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="pcvx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>100410 - Disclosure - Balance Sheet Details - Schedule of Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails</Role>
      <ShortName>Balance Sheet Details - Schedule of Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="pcvx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>100420 - Disclosure - Leases - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails</Role>
      <ShortName>Leases - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="pcvx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>100430 - Disclosure - Leases - Schedule of Information Related to ROU Assets and Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureLeasesScheduleOfInformationRelatedToROUAssetsAndLeaseLiabilitiesDetails</Role>
      <ShortName>Leases - Schedule of Information Related to ROU Assets and Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="pcvx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>100440 - Disclosure - Leases - Schedule of Maturities of Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails</Role>
      <ShortName>Leases - Schedule of Maturities of Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="pcvx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>100460 - Disclosure - Leases - Schedule of Maturities of Lease Liabilities (Parenthetical) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesParentheticalDetails</Role>
      <ShortName>Leases - Schedule of Maturities of Lease Liabilities (Parenthetical) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="pcvx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>100470 - Disclosure - Commitments and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="pcvx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>100480 - Disclosure - Redeemable Convertible Preferred Stock - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails</Role>
      <ShortName>Redeemable Convertible Preferred Stock - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="pcvx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>100490 - Disclosure - Common Stock - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails</Role>
      <ShortName>Common Stock - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="pcvx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>100500 - Disclosure - Common Stock - Schedule of Common Stock Shares Reserved for Future Issuance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCommonStockScheduleOfCommonStockSharesReservedForFutureIssuanceDetails</Role>
      <ShortName>Common Stock - Schedule of Common Stock Shares Reserved for Future Issuance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="pcvx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>100510 - Disclosure - Warrants - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureWarrantsAdditionalInformationDetails</Role>
      <ShortName>Warrants - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="pcvx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>100520 - Disclosure - Equity Incentive Plans - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails</Role>
      <ShortName>Equity Incentive Plans - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="pcvx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>100530 - Disclosure - Equity Incentive Plans - Summary of Activity Under Stock Option Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfActivityUnderStockOptionPlansDetails</Role>
      <ShortName>Equity Incentive Plans - Summary of Activity Under Stock Option Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="pcvx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>100540 - Disclosure - Equity Incentive Plans - Summary of Estimated Fair Value of Employee Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfEstimatedFairValueOfEmployeeStockOptionsDetails</Role>
      <ShortName>Equity Incentive Plans - Summary of Estimated Fair Value of Employee Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="pcvx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>100550 - Disclosure - Equity Incentive Plans - Summary of Estimated Fair Value of Shares Under Employee Stock Purchase Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfEstimatedFairValueOfSharesUnderEmployeeStockPurchasePlanDetails</Role>
      <ShortName>Equity Incentive Plans - Summary of Estimated Fair Value of Shares Under Employee Stock Purchase Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="pcvx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>100560 - Disclosure - Equity Incentive Plans - Summary of Stock-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfStockBasedCompensationExpenseDetails</Role>
      <ShortName>Equity Incentive Plans - Summary of Stock-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="pcvx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>100570 - Disclosure - Funding Arrangement - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFundingArrangementAdditionalInformationDetails</Role>
      <ShortName>Funding Arrangement - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="pcvx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>100580 - Disclosure - Net Loss Per Share - Schedule of Computation of Basic and Diluted Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetails</Role>
      <ShortName>Net Loss Per Share - Schedule of Computation of Basic and Diluted Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="pcvx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>100590 - Disclosure - Net Loss Per Share - Schedule of Potentially Dilutive Securities Excluded From Computation of Diluted Net Loss Per Share Attributable to Common Stockholders (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails</Role>
      <ShortName>Net Loss Per Share - Schedule of Potentially Dilutive Securities Excluded From Computation of Diluted Net Loss Per Share Attributable to Common Stockholders (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="pcvx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>100600 - Disclosure - Income Taxes - Reconciliation of Effective Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfEffectiveTaxRateDetails</Role>
      <ShortName>Income Taxes - Reconciliation of Effective Tax Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="pcvx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>100610 - Disclosure - Income Taxes - Components of Deferred Tax Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails</Role>
      <ShortName>Income Taxes - Components of Deferred Tax Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="pcvx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>100620 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="pcvx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>100630 - Disclosure - Income Taxes - Reconciliation of Unrecognized Tax Benefit (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitDetails</Role>
      <ShortName>Income Taxes - Reconciliation of Unrecognized Tax Benefit (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="pcvx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>100640 - Disclosure - Related Party Transactions - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails</Role>
      <ShortName>Related Party Transactions - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="pcvx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>100650 - Disclosure - Subsequent Events - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails</Role>
      <ShortName>Subsequent Events - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="pcvx-20211231.htm">pcvx-20211231.htm</File>
    <File>pcvx-20211231.xsd</File>
    <File>pcvx-20211231_cal.xml</File>
    <File>pcvx-20211231_def.xml</File>
    <File>pcvx-20211231_lab.xml</File>
    <File>pcvx-20211231_pre.xml</File>
    <File>pcvx-ex23_1.htm</File>
    <File>pcvx-ex31_1.htm</File>
    <File>pcvx-ex31_2.htm</File>
    <File>pcvx-ex32_1.htm</File>
    <File>pcvx-ex32_2.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img69628308_0.jpg</File>
    <File>img69628308_1.jpg</File>
    <File>img69628308_10.jpg</File>
    <File>img69628308_11.jpg</File>
    <File>img69628308_12.jpg</File>
    <File>img69628308_13.jpg</File>
    <File>img69628308_14.jpg</File>
    <File>img69628308_15.jpg</File>
    <File>img69628308_16.jpg</File>
    <File>img69628308_17.jpg</File>
    <File>img69628308_18.jpg</File>
    <File>img69628308_19.jpg</File>
    <File>img69628308_2.jpg</File>
    <File>img69628308_20.jpg</File>
    <File>img69628308_21.jpg</File>
    <File>img69628308_3.jpg</File>
    <File>img69628308_4.jpg</File>
    <File>img69628308_5.jpg</File>
    <File>img69628308_6.jpg</File>
    <File>img69628308_7.jpg</File>
    <File>img69628308_8.jpg</File>
    <File>img69628308_9.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="667">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="38">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>106
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "pcvx-20211231.htm": {
   "axisCustom": 0,
   "axisStandard": 22,
   "contextCount": 202,
   "dts": {
    "calculationLink": {
     "local": [
      "pcvx-20211231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "pcvx-20211231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "pcvx-20211231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "pcvx-20211231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "pcvx-20211231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "pcvx-20211231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd",
      "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd"
     ]
    }
   },
   "elementCount": 603,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 6,
    "http://xbrl.sec.gov/dei/2021q4": 3,
    "total": 9
   },
   "keyCustom": 93,
   "keyStandard": 390,
   "memberCustom": 31,
   "memberStandard": 38,
   "nsprefix": "pcvx",
   "nsuri": "http://www.vaxcyte.com/20211231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100090 - Disclosure - Company Organization and Nature of Business",
     "role": "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCompanyOrganizationAndNatureOfBusiness",
     "shortName": "Company Organization and Nature of Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100100 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies",
     "role": "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100110 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments",
     "role": "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstruments",
     "shortName": "Fair Value Measurements and Fair Value of Financial Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100120 - Disclosure - Balance Sheet Details",
     "role": "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetails",
     "shortName": "Balance Sheet Details",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100130 - Disclosure - Leases",
     "role": "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureLeases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100140 - Disclosure - Commitments and Contingencies",
     "role": "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pcvx:RedeemableConvertiblePreferredStockTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100150 - Disclosure - Redeemable Convertible Preferred Stock",
     "role": "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStock",
     "shortName": "Redeemable Convertible Preferred Stock",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pcvx:RedeemableConvertiblePreferredStockTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100160 - Disclosure - Common Stock",
     "role": "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCommonStock",
     "shortName": "Common Stock",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pcvx:WarrantsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100170 - Disclosure - Warrants",
     "role": "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureWarrants",
     "shortName": "Warrants",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pcvx:WarrantsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100180 - Disclosure - Equity Incentive Plans",
     "role": "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlans",
     "shortName": "Equity Incentive Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100010 - Statement - Balance Sheets",
     "role": "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementBalanceSheets",
     "shortName": "Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pcvx:FundingArrangementTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100190 - Disclosure - Funding Arrangement",
     "role": "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFundingArrangement",
     "shortName": "Funding Arrangement",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pcvx:FundingArrangementTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100200 - Disclosure - Net Loss Per Share",
     "role": "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShare",
     "shortName": "Net Loss Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100210 - Disclosure - Income Taxes",
     "role": "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100220 - Disclosure - Related Party Transactions",
     "role": "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactions",
     "shortName": "Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100230 - Disclosure - Subsequent Events",
     "role": "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureSubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100240 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "div",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100250 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)",
     "role": "http://www.vaxcyte.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "div",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100260 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments (Tables)",
     "role": "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsTables",
     "shortName": "Fair Value Measurements and Fair Value of Financial Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100270 - Disclosure - Balance Sheet Details (Tables)",
     "role": "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsTables",
     "shortName": "Balance Sheet Details (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pcvx:ScheduleOfInformationRelatedToRightOfUseAssetsAndLeaseLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100280 - Disclosure - Leases (Tables)",
     "role": "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureLeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pcvx:ScheduleOfInformationRelatedToRightOfUseAssetsAndLeaseLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DueToRelatedPartiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100020 - Statement - Balance Sheets (Parenthetical)",
     "role": "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementBalanceSheetsParenthetical",
     "shortName": "Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DueToRelatedPartiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pcvx:ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100290 - Disclosure - Common Stock (Tables)",
     "role": "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCommonStockTables",
     "shortName": "Common Stock (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pcvx:ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100300 - Disclosure - Equity Incentive Plans (Tables)",
     "role": "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansTables",
     "shortName": "Equity Incentive Plans (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100310 - Disclosure - Net Loss Per Share (Tables)",
     "role": "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareTables",
     "shortName": "Net Loss Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100320 - Disclosure - Income Taxes (Tables)",
     "role": "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_196fbfec-2db3-415e-8c1d-7ba3ff662444",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityReverseStockSplit",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100330 - Disclosure - Company Organization and Nature of Business - Additional Information (Details)",
     "role": "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCompanyOrganizationAndNatureOfBusinessAdditionalInformationDetails",
     "shortName": "Company Organization and Nature of Business - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_196fbfec-2db3-415e-8c1d-7ba3ff662444",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityReverseStockSplit",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "div",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfReportableSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_Segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100340 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)",
     "role": "http://www.vaxcyte.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "div",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfReportableSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_Segment",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100350 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Cash, Cash Equivalents And Restricted Cash (Details)",
     "role": "http://www.vaxcyte.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfCashCashEquivalentsAndRestrictedCashDetails",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Cash, Cash Equivalents And Restricted Cash (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "div",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_871fe4ad-8a52-4dc5-a523-876ef5a1de6d",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3",
       "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3",
       "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3",
       "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3",
       "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3",
       "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3",
       "us-gaap:FairValueLiabilitiesLevel2ToLevel1TransfersAmount",
       "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3",
       "us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount",
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100360 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments - Additional Information (Details)",
     "role": "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsAdditionalInformationDetails",
     "shortName": "Fair Value Measurements and Fair Value of Financial Instruments - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3",
       "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3",
       "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3",
       "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3",
       "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3",
       "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3",
       "us-gaap:FairValueLiabilitiesLevel2ToLevel1TransfersAmount",
       "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3",
       "us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount",
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100370 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments - Schedule of Financial Instruments Measured at Fair Value on Recurring Basis (Details)",
     "role": "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails",
     "shortName": "Fair Value Measurements and Fair Value of Financial Instruments - Schedule of Financial Instruments Measured at Fair Value on Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_9a84ae25-675d-4a66-a9c5-6809604d88d9",
      "decimals": "-3",
      "lang": null,
      "name": "pcvx:CashAndCashEquivalentsAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100380 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments - Schedule of Contractual Maturities of Investments (Details)",
     "role": "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfContractualMaturitiesOfInvestmentsDetails",
     "shortName": "Fair Value Measurements and Fair Value of Financial Instruments - Schedule of Contractual Maturities of Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100030 - Statement - Statements of Operations",
     "role": "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfOperations",
     "shortName": "Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100390 - Disclosure - Balance Sheet Details - Schedule of Property and Equipment, Net (Details)",
     "role": "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentNetDetails",
     "shortName": "Balance Sheet Details - Schedule of Property and Equipment, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100400 - Disclosure - Balance Sheet Details - Additional Information (Details)",
     "role": "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsAdditionalInformationDetails",
     "shortName": "Balance Sheet Details - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "pcvx:AccruedPreclinicalStudiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100410 - Disclosure - Balance Sheet Details - Schedule of Accrued Expenses (Details)",
     "role": "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails",
     "shortName": "Balance Sheet Details - Schedule of Accrued Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "pcvx:AccruedPreclinicalStudiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100420 - Disclosure - Leases - Additional Information (Details)",
     "role": "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
     "shortName": "Leases - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f",
      "decimals": "INF",
      "lang": null,
      "name": "pcvx:NumberOfOperatingLease",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_Lease",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "pcvx:ScheduleOfInformationRelatedToRightOfUseAssetsAndLeaseLiabilitiesTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100430 - Disclosure - Leases - Schedule of Information Related to ROU Assets and Lease Liabilities (Details)",
     "role": "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureLeasesScheduleOfInformationRelatedToROUAssetsAndLeaseLiabilitiesDetails",
     "shortName": "Leases - Schedule of Information Related to ROU Assets and Lease Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "pcvx:ScheduleOfInformationRelatedToRightOfUseAssetsAndLeaseLiabilitiesTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100440 - Disclosure - Leases - Schedule of Maturities of Lease Liabilities (Details)",
     "role": "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails",
     "shortName": "Leases - Schedule of Maturities of Lease Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_5c54c4ca-430a-4169-96fa-f57499d8524f",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "pcvx:LeasePaymentReceivableNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100460 - Disclosure - Leases - Schedule of Maturities of Lease Liabilities (Parenthetical) (Details)",
     "role": "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesParentheticalDetails",
     "shortName": "Leases - Schedule of Maturities of Lease Liabilities (Parenthetical) (Details)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_5c54c4ca-430a-4169-96fa-f57499d8524f",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "pcvx:LeasePaymentReceivableNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_448aa75e-c08c-4eb7-a778-f1a1525470d8",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "pcvx:PercentageOfPaymentsCompletionAgreedToDefer",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100470 - Disclosure - Commitments and Contingencies - Additional Information (Details)",
     "role": "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
     "shortName": "Commitments and Contingencies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_448aa75e-c08c-4eb7-a778-f1a1525470d8",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "pcvx:PercentageOfPaymentsCompletionAgreedToDefer",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "pcvx:RedeemableConvertiblePreferredStockTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_faa3a312-73ee-42b0-852a-ab16d62c1cef",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:TemporaryEquitySharesOutstanding",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100480 - Disclosure - Redeemable Convertible Preferred Stock - Additional Information (Details)",
     "role": "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails",
     "shortName": "Redeemable Convertible Preferred Stock - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:TemporaryEquitySharesOutstanding",
       "span",
       "p",
       "pcvx:RedeemableConvertiblePreferredStockTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_faa3a312-73ee-42b0-852a-ab16d62c1cef",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:TemporaryEquitySharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100490 - Disclosure - Common Stock - Additional Information (Details)",
     "role": "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
     "shortName": "Common Stock - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:CommonStockDividendsPerShareDeclared",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "pcvx:ResearchAndDevelopmentExpenseToRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100040 - Statement - Statements of Operations (Parenthetical)",
     "role": "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfOperationsParenthetical",
     "shortName": "Statements of Operations (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "pcvx:ResearchAndDevelopmentExpenseToRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "pcvx:ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_58ad6f5b-2983-4459-8fd3-3b4fbdef1c36",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100500 - Disclosure - Common Stock - Schedule of Common Stock Shares Reserved for Future Issuance (Details)",
     "role": "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCommonStockScheduleOfCommonStockSharesReservedForFutureIssuanceDetails",
     "shortName": "Common Stock - Schedule of Common Stock Shares Reserved for Future Issuance (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "pcvx:ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_58ad6f5b-2983-4459-8fd3-3b4fbdef1c36",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "pcvx:WarrantsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_89e8a4b5-4ab0-4668-889d-5ae7704f7e30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "pcvx:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRightExercised",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100510 - Disclosure - Warrants - Additional Information (Details)",
     "role": "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureWarrantsAdditionalInformationDetails",
     "shortName": "Warrants - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_88288d89-14d9-4c81-bcdc-77db4748e94f",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100520 - Disclosure - Equity Incentive Plans - Additional Information (Details)",
     "role": "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails",
     "shortName": "Equity Incentive Plans - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_88288d89-14d9-4c81-bcdc-77db4748e94f",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_3e34321b-16ec-44ef-ab8c-8cdab8688001",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100530 - Disclosure - Equity Incentive Plans - Summary of Activity Under Stock Option Plans (Details)",
     "role": "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfActivityUnderStockOptionPlansDetails",
     "shortName": "Equity Incentive Plans - Summary of Activity Under Stock Option Plans (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_00eaf7db-5639-43a7-9d93-1b5cbcde71cf",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "reportCount": 1,
      "unitRef": "U_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100540 - Disclosure - Equity Incentive Plans - Summary of Estimated Fair Value of Employee Stock Options (Details)",
     "role": "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfEstimatedFairValueOfEmployeeStockOptionsDetails",
     "shortName": "Equity Incentive Plans - Summary of Estimated Fair Value of Employee Stock Options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "reportCount": 1,
      "unitRef": "U_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100550 - Disclosure - Equity Incentive Plans - Summary of Estimated Fair Value of Shares Under Employee Stock Purchase Plan (Details)",
     "role": "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfEstimatedFairValueOfSharesUnderEmployeeStockPurchasePlanDetails",
     "shortName": "Equity Incentive Plans - Summary of Estimated Fair Value of Shares Under Employee Stock Purchase Plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_b2d931e6-c3f8-485c-8729-b21db15df907",
      "decimals": "3",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_e8c80ef0-b66f-48cb-8236-662fca240430",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100560 - Disclosure - Equity Incentive Plans - Summary of Stock-based Compensation Expense (Details)",
     "role": "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfStockBasedCompensationExpenseDetails",
     "shortName": "Equity Incentive Plans - Summary of Stock-based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_e8c80ef0-b66f-48cb-8236-662fca240430",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "pcvx:GrantIncome",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100570 - Disclosure - Funding Arrangement - Additional Information (Details)",
     "role": "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFundingArrangementAdditionalInformationDetails",
     "shortName": "Funding Arrangement - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "pcvx:FundingArrangementTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_017473b9-4a6d-4b35-bafe-2f3035074c39",
      "decimals": null,
      "lang": "en-US",
      "name": "pcvx:FundingPeriodOfAwardToDevelopUniversalVaccineToPreventInfections",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100580 - Disclosure - Net Loss Per Share - Schedule of Computation of Basic and Diluted Net Loss Per Share (Details)",
     "role": "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetails",
     "shortName": "Net Loss Per Share - Schedule of Computation of Basic and Diluted Net Loss Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100590 - Disclosure - Net Loss Per Share - Schedule of Potentially Dilutive Securities Excluded From Computation of Diluted Net Loss Per Share Attributable to Common Stockholders (Details)",
     "role": "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
     "shortName": "Net Loss Per Share - Schedule of Potentially Dilutive Securities Excluded From Computation of Diluted Net Loss Per Share Attributable to Common Stockholders (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100050 - Statement - Statements of Comprehensive Loss",
     "role": "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfComprehensiveLoss",
     "shortName": "Statements of Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100600 - Disclosure - Income Taxes - Reconciliation of Effective Tax Rate (Details)",
     "role": "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfEffectiveTaxRateDetails",
     "shortName": "Income Taxes - Reconciliation of Effective Tax Rate (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100610 - Disclosure - Income Taxes - Components of Deferred Tax Assets (Details)",
     "role": "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails",
     "shortName": "Income Taxes - Components of Deferred Tax Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:SummaryOfIncomeTaxContingenciesTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100620 - Disclosure - Income Taxes - Additional Information (Details)",
     "role": "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails",
     "shortName": "Income Taxes - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:SummaryOfIncomeTaxContingenciesTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_2e7b2f0a-90ff-4e7f-9d0e-7d2dbddf1e57",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100630 - Disclosure - Income Taxes - Reconciliation of Unrecognized Tax Benefit (Details)",
     "role": "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitDetails",
     "shortName": "Income Taxes - Reconciliation of Unrecognized Tax Benefit (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:SummaryOfIncomeTaxContingenciesTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_d1956d9f-c83b-4c84-91c2-a5e67cbf3350",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100640 - Disclosure - Related Party Transactions - Additional Information (Details)",
     "role": "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
     "shortName": "Related Party Transactions - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_3fab40e5-6a35-4b2f-b816-13c7822b9afc",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_e52d577e-c5ed-4801-8551-af9cd25c01fa",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "pcvx:StockIssuedDuringPeriodSharesOfFollowOnOffering",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100650 - Disclosure - Subsequent Events - Additional Information (Details)",
     "role": "http://www.vaxcyte.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
     "shortName": "Subsequent Events - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_e52d577e-c5ed-4801-8551-af9cd25c01fa",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "pcvx:StockIssuedDuringPeriodSharesOfFollowOnOffering",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_ecccdfb9-edd1-45a3-8445-0fe8b2f43253",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100060 - Statement - Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit)",
     "role": "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit",
     "shortName": "Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_ecccdfb9-edd1-45a3-8445-0fe8b2f43253",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_132d316b-36f4-4e18-bf45-5543bb58c44e",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100070 - Statement - Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)",
     "role": "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical",
     "shortName": "Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_132d316b-36f4-4e18-bf45-5543bb58c44e",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100080 - Statement - Statements of Cash Flows (Unaudited)",
     "role": "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited",
     "shortName": "Statements of Cash Flows (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20211231.htm",
      "contextRef": "C_cf53865a-9e8d-45e9-a4c2-e3c937a8cf6f",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 73,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r564",
      "r565",
      "r566"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r564",
      "r565",
      "r566"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r564",
      "r565",
      "r566"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r564",
      "r565",
      "r566"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "verboseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated By Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address Address Line1",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address Address Line2",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address City Or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address State Or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "verboseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r569"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r570"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r564",
      "r565",
      "r566"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Icfr Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security12b Title",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "pcvx_ATMSalesAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ATM sales agreement.",
        "label": "A T M Sales Agreement [Member]",
        "terseLabel": "ATM Sales Agreement"
       }
      }
     },
     "localname": "ATMSalesAgreementMember",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pcvx_AccruedManufacturingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued manufacturing expenses.",
        "label": "Accrued Manufacturing Expenses",
        "terseLabel": "Accrued manufacturing expenses"
       }
      }
     },
     "localname": "AccruedManufacturingExpenses",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcvx_AccruedPreclinicalStudiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued preclinical studies current.",
        "label": "Accrued Preclinical Studies Current",
        "terseLabel": "Preclinical studies"
       }
      }
     },
     "localname": "AccruedPreclinicalStudiesCurrent",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcvx_AccruedResearchAndDevelopmentPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued research and development.",
        "label": "Accrued Research And Development Policy [Text Block]",
        "terseLabel": "Accrued Research and Development"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentPolicyTextBlock",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "pcvx_AdditionalFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional facility.",
        "label": "Additional Facility [Member]",
        "terseLabel": "Additional Facility"
       }
      }
     },
     "localname": "AdditionalFacilityMember",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pcvx_AdditionalFundingCommittedByAward": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional funding committed by award.",
        "label": "Additional Funding Committed By Award",
        "terseLabel": "Additional funding committed by award"
       }
      }
     },
     "localname": "AdditionalFundingCommittedByAward",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFundingArrangementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcvx_AdjustmentsToAdditionalPaidInCapitalVestingOfEarlyExercisedStockOptions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments to additional paid In capital vesting of early exercised stock options.",
        "label": "Adjustments To Additional Paid In Capital Vesting Of Early Exercised Stock Options",
        "terseLabel": "Vesting of early exercised stock options"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalVestingOfEarlyExercisedStockOptions",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcvx_AdjustmentsToAdditionalPaidInCapitalWarrantLiabilityWriteOff": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments to additional paid in capital warrant liability write off.",
        "label": "Adjustments To Additional Paid In Capital Warrant Liability Write Off",
        "terseLabel": "Warrant liability write-off"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantLiabilityWriteOff",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcvx_CapitalLeasesAmortizationExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Capital Leases Amortization Expense",
        "label": "Capital lease amortization expense"
       }
      }
     },
     "localname": "CapitalLeasesAmortizationExpense",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcvx_CapitalLeasesLabEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Capital leases \u2014 lab equipment.",
        "label": "Capital Leases Lab Equipment [Member]",
        "terseLabel": "Capital Leases \u2014 Lab Equipment"
       }
      }
     },
     "localname": "CapitalLeasesLabEquipmentMember",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pcvx_CashAndCashEquivalentsAmortizedCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash and cash equivalents amortized cost.",
        "label": "Cash And Cash Equivalents Amortized Cost",
        "totalLabel": "Cash and cash equivalents, Amortized Cost"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAmortizedCost",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcvx_CashAndCashEquivalentsAndInvestments": {
     "auth_ref": [],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails": {
       "order": 2.0,
       "parentTag": "pcvx_CashAndCashEquivalentsAndInvestmentsAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash and cash equivalents and investments.",
        "label": "Cash And Cash Equivalents And Investments",
        "terseLabel": "Total assets measured at fair value, Fair Value"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAndInvestments",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcvx_CashAndCashEquivalentsAndInvestmentsAmortizedCostBasis": {
     "auth_ref": [],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash and cash equivalents and investments amortized cost basis.",
        "label": "Cash And Cash Equivalents And Investments Amortized Cost Basis",
        "totalLabel": "Total assets measured at fair value, Amortized Cost"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAndInvestmentsAmortizedCostBasis",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcvx_CashAndCashEquivalentsAndInvestmentsGrossUnrealizedGainBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails": {
       "order": 0.0,
       "parentTag": "pcvx_CashAndCashEquivalentsAndInvestmentsAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash and cash equivalents and investments gross unrealized gain before tax.",
        "label": "Cash And Cash Equivalents And Investments Gross Unrealized Gain Before Tax",
        "terseLabel": "Total assets measured at fair value, Gross Unrealized Gains"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAndInvestmentsGrossUnrealizedGainBeforeTax",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcvx_CashAndCashEquivalentsAndInvestmentsGrossUnrealizedLossBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "pcvx_CashAndCashEquivalentsAndInvestmentsAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash and cash equivalents and investments gross unrealized loss before tax.",
        "label": "Cash And Cash Equivalents And Investments Gross Unrealized Loss Before Tax",
        "negatedLabel": "Total assets measured at fair value, Gross Unrealized Losses"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAndInvestmentsGrossUnrealizedLossBeforeTax",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcvx_CashAndCashEquivalentsGrossUnrealizedGainBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails": {
       "order": 0.0,
       "parentTag": "pcvx_CashAndCashEquivalentsAmortizedCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash and cash equivalents gross unrealized gain before tax.",
        "label": "Cash And Cash Equivalents Gross Unrealized Gain Before Tax",
        "terseLabel": "Cash and cash equivalents, Gross Unrealized Gains"
       }
      }
     },
     "localname": "CashAndCashEquivalentsGrossUnrealizedGainBeforeTax",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcvx_CashAndCashEquivalentsGrossUnrealizedLossBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "pcvx_CashAndCashEquivalentsAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash and cash equivalents gross unrealized loss before tax.",
        "label": "Cash And Cash Equivalents Gross Unrealized Loss Before Tax",
        "negatedLabel": "Cash and cash equivalents, Gross Unrealized Losses"
       }
      }
     },
     "localname": "CashAndCashEquivalentsGrossUnrealizedLossBeforeTax",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcvx_ChangeInFairValueOfRedeemableConvertiblePreferredStock": {
     "auth_ref": [],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfOperations": {
       "order": 5.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in fair value of the redeemable convertible preferred stock tranche liability.",
        "label": "Change In Fair Value Of Redeemable Convertible Preferred Stock",
        "terseLabel": "Change in fair value of the redeemable convertible preferred stock tranche liability"
       }
      }
     },
     "localname": "ChangeInFairValueOfRedeemableConvertiblePreferredStock",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcvx_ChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in fair value of redeemable convertible preferred stock tranche liabilities.",
        "label": "Change In Fair Value Of Redeemable Convertible Preferred Stock Tranche Liabilities",
        "negatedLabel": "Change in fair value of redeemable convertible preferred stock tranche liabilities"
       }
      }
     },
     "localname": "ChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheLiabilities",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcvx_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRightExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of warrant or right number of securities called by each warrant or right exercised.",
        "label": "Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right Exercised",
        "terseLabel": "Warrant exercised"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRightExercised",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureWarrantsAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "pcvx_CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Combating antibiotic resistant bacteria biopharmaceutical accelerator agreement.",
        "label": "Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator Agreement [Member]",
        "terseLabel": "CARB-X Agreement"
       }
      }
     },
     "localname": "CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorAgreementMember",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFundingArrangementAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pcvx_CommonStockWarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock warrant.",
        "label": "Common Stock Warrant [Member]",
        "terseLabel": "Common Stock Warrant"
       }
      }
     },
     "localname": "CommonStockWarrantMember",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pcvx_ComputersAndComputerSoftwareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Computers and computer software.",
        "label": "Computers And Computer Software [Member]",
        "terseLabel": "Computers and Computer Software"
       }
      }
     },
     "localname": "ComputersAndComputerSoftwareMember",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pcvx_CostReimbursementSubAwardAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost reimbursement sub-award agreement.",
        "label": "Cost Reimbursement Sub Award Agreement [Member]",
        "terseLabel": "Cost Reimbursement Sub-Award Agreement"
       }
      }
     },
     "localname": "CostReimbursementSubAwardAgreementMember",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFundingArrangementAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pcvx_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred offering costs included in accounts payable and accrued expenses.",
        "label": "Deferred Offering Costs Included In Accounts Payable And Accrued Expenses",
        "terseLabel": "Deferred offering costs included in accounts payable and accrued expenses"
       }
      }
     },
     "localname": "DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcvx_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance": {
     "auth_ref": [],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets liabilities net before valuation allowance.",
        "label": "Deferred Tax Assets Liabilities Net Before Valuation Allowance",
        "totalLabel": "Net deferred tax asset"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcvx_DeferredTaxAssetsTaxAccruedManufacturingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets tax accrued manufacturing expenses.",
        "label": "Deferred Tax Assets Tax Accrued Manufacturing Expenses",
        "terseLabel": "Accrued manufacturing expenses"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxAccruedManufacturingExpenses",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcvx_DevelopmentAndManufacturingServicesAgreementEquityPaymentsPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development and manufacturing services agreement equity payments percentage.",
        "label": "Development And Manufacturing Services Agreement Equity Payments Percentage",
        "terseLabel": "Payments in equity, percentage"
       }
      }
     },
     "localname": "DevelopmentAndManufacturingServicesAgreementEquityPaymentsPercentage",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pcvx_DevelopmentAndManufacturingServicesAgreementPaymentsInEquity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development and manufacturing services agreement payments in equity.",
        "label": "Development And Manufacturing Services Agreement Payments In Equity",
        "terseLabel": "Payments in equity, amount"
       }
      }
     },
     "localname": "DevelopmentAndManufacturingServicesAgreementPaymentsInEquity",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcvx_EarlyExercisedStockOptions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Early \u200bexercised\u200b stock\u200b options.",
        "label": "Early Exercised Stock Options",
        "terseLabel": "Early exercised stock options"
       }
      }
     },
     "localname": "EarlyExercisedStockOptions",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "pcvx_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfTrancheLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfEffectiveTaxRateDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective income tax rate reconciliation change in fair value of tranche liability.",
        "label": "Effective Income Tax Rate Reconciliation Change In Fair Value Of Tranche Liability",
        "terseLabel": "Change in Fair Value of Tranche Liability"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInFairValueOfTrancheLiability",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pcvx_ExercisePriceExpireInYearsFormTheDateOfGrant": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price expire in years form the date of grant.",
        "label": "Exercise Price Expire In Years Form The Date Of Grant",
        "terseLabel": "Exercise price expire in years form the date of grant"
       }
      }
     },
     "localname": "ExercisePriceExpireInYearsFormTheDateOfGrant",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "pcvx_ExpenseOnIssuanceOfRedeemableConvertiblePreferredStockWarrant": {
     "auth_ref": [],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expense on issuance of redeemable convertible preferred stock warrant.",
        "label": "Expense On Issuance Of Redeemable Convertible Preferred Stock Warrant",
        "terseLabel": "Expense on issuance of redeemable convertible preferred stock warrant"
       }
      }
     },
     "localname": "ExpenseOnIssuanceOfRedeemableConvertiblePreferredStockWarrant",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcvx_FundingArrangementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Funding arrangement.",
        "label": "Funding Arrangement [Abstract]"
       }
      }
     },
     "localname": "FundingArrangementAbstract",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "xbrltype": "stringItemType"
    },
    "pcvx_FundingArrangementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Funding arrangement.",
        "label": "Funding Arrangement [Line Items]",
        "terseLabel": "Funding Arrangement [Line Items]"
       }
      }
     },
     "localname": "FundingArrangementLineItems",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFundingArrangementAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pcvx_FundingArrangementTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Funding arrangement.",
        "label": "Funding Arrangement [Table]",
        "terseLabel": "Funding Arrangement [Table]"
       }
      }
     },
     "localname": "FundingArrangementTable",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFundingArrangementAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pcvx_FundingArrangementTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Funding arrangement.",
        "label": "Funding Arrangement [Text Block]",
        "terseLabel": "Funding Arrangement"
       }
      }
     },
     "localname": "FundingArrangementTextBlock",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFundingArrangement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "pcvx_FundingCommittedByAwardAvailableUponAchievementOfDevelopmentMilestones": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Funding committed by award, available upon achievement of development milestones.",
        "label": "Funding Committed By Award Available Upon Achievement Of Development Milestones",
        "terseLabel": "Total funding committed by award, available upon achievement of development milestones"
       }
      }
     },
     "localname": "FundingCommittedByAwardAvailableUponAchievementOfDevelopmentMilestones",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFundingArrangementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcvx_FundingPeriodOfAwardToDevelopUniversalVaccineToPreventInfections": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Funding period of award to develop universal vaccine to prevent infections.",
        "label": "Funding Period Of Award To Develop Universal Vaccine To Prevent Infections",
        "terseLabel": "Funding period of award to develop universal vaccine to prevent infections caused by Group A Strep bacteria"
       }
      }
     },
     "localname": "FundingPeriodOfAwardToDevelopUniversalVaccineToPreventInfections",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFundingArrangementAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "pcvx_GlobalTargetRevenue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Global target revenue.",
        "label": "Global Target Revenue",
        "terseLabel": "Global target revenue"
       }
      }
     },
     "localname": "GlobalTargetRevenue",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCompanyOrganizationAndNatureOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcvx_GrantIncome": {
     "auth_ref": [],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Grant income.",
        "label": "Grant Income",
        "terseLabel": "Grant income"
       }
      }
     },
     "localname": "GrantIncome",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFundingArrangementAdditionalInformationDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcvx_GrossProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross proceeds from issuance of common stock.",
        "label": "Gross Proceeds From Issuance Of Common Stock",
        "terseLabel": "Aggregate gross proceeds from issuance of common stock"
       }
      }
     },
     "localname": "GrossProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcvx_HeadquartersFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Headquarters facility.",
        "label": "Headquarters Facility [Member]",
        "terseLabel": "Headquarters Facility"
       }
      }
     },
     "localname": "HeadquartersFacilityMember",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pcvx_IncentiveStockOptionGrantedToEmployeesOwningPercentageOfSharesOfCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incentive stock option granted to Employees Owning percentage of shares of common stock.",
        "label": "Incentive Stock Option Granted To Employees Owning Percentage Of Shares Of Common Stock",
        "terseLabel": "Incentive stock option granted to employees owning percentage of shares of common stock"
       }
      }
     },
     "localname": "IncentiveStockOptionGrantedToEmployeesOwningPercentageOfSharesOfCommonStock",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pcvx_IncomeTaxDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax disclosure.",
        "label": "Income Tax Disclosure [Line Items]",
        "terseLabel": "Income Tax Disclosure [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureLineItems",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pcvx_IncomeTaxDisclosureTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax disclosure.",
        "label": "Income Tax Disclosure [Table]",
        "terseLabel": "Income Tax Disclosure [Table]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTable",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pcvx_IncreaseDecreaseInAccruedCompensation": {
     "auth_ref": [],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease in accrued compensation.",
        "label": "Increase Decrease In Accrued Compensation",
        "terseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedCompensation",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcvx_IncreaseDecreaseInAccruedLegalSettlement": {
     "auth_ref": [],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease in accrued legal settlement.",
        "label": "Increase Decrease In Accrued Legal Settlement",
        "terseLabel": "Accrued legal settlement"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLegalSettlement",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcvx_IncreaseDecreaseInAccruedManufacturingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease in accrued manufacturing expenses.",
        "label": "Increase Decrease In Accrued Manufacturing Expenses",
        "terseLabel": "Accrued manufacturing expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedManufacturingExpenses",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcvx_IncreaseDecreaseInDeferredRentAndOtherLongTermLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease in deferred rent and other long term liabilities.",
        "label": "Increase Decrease In Deferred Rent And Other Long Term Liabilities",
        "terseLabel": "Deferred rent and other long-term liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredRentAndOtherLongTermLiabilities",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcvx_IncreaseDecreaseInOperatingLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease in operating lease liabilities.",
        "label": "Increase Decrease In Operating Lease Liabilities",
        "negatedLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiabilities",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcvx_InitialFundingCommittedByAward": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial funding committed by award.",
        "label": "Initial Funding Committed By Award",
        "terseLabel": "Initial funding committed by award"
       }
      }
     },
     "localname": "InitialFundingCommittedByAward",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFundingArrangementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcvx_InitialPublicOfferingRelatedCost": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial public offering related cost.",
        "label": "Initial Public Offering Related Cost",
        "terseLabel": "IPO-related costs"
       }
      }
     },
     "localname": "InitialPublicOfferingRelatedCost",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcvx_JefferiesLimitedLiabilityCompanyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Jefferies limited liability company.",
        "label": "Jefferies Limited Liability Company [Member]",
        "terseLabel": "Jefferies LLC"
       }
      }
     },
     "localname": "JefferiesLimitedLiabilityCompanyMember",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pcvx_LabEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lab equipment.",
        "label": "Lab Equipment [Member]",
        "terseLabel": "Lab Equipment"
       }
      }
     },
     "localname": "LabEquipmentMember",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pcvx_LeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease liability.",
        "label": "Deffered Tax Assets Lease Liability",
        "terseLabel": "Lease Liability"
       }
      }
     },
     "localname": "LeaseLiability",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcvx_LeasePaymentReceivableNoncurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease Payment Receivable Noncurrent",
        "label": "Lease incentives"
       }
      }
     },
     "localname": "LeasePaymentReceivableNoncurrent",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesParentheticalDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcvx_LeaseTerminationDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease termination date.",
        "label": "Lease Termination Date",
        "terseLabel": "Lease termination date"
       }
      }
     },
     "localname": "LeaseTerminationDate",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "pcvx_LesseeOperatingLeaseCommencementDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating lease commencement date.",
        "label": "Lessee Operating Lease Commencement Date",
        "terseLabel": "Operating lease, commencement date"
       }
      }
     },
     "localname": "LesseeOperatingLeaseCommencementDate",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "pcvx_LesseeOperatingLeaseExtendedLeaseTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating lease extended lease term.",
        "label": "Lessee Operating Lease Extended Lease Term",
        "terseLabel": "Operating lease, extended term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseExtendedLeaseTerm",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "pcvx_LesseeOperatingLeaseExtendedMaturityDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, operating lease, extended maturity date.",
        "label": "Lessee Operating Lease Extended Maturity Date",
        "terseLabel": "Operating lease, extended maturity date"
       }
      }
     },
     "localname": "LesseeOperatingLeaseExtendedMaturityDate",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "pcvx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating lease liability payments due after year four.",
        "label": "Lessee Operating Lease Liability Payments Due After Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcvx_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonthsNetOfLeaseIncentives": {
     "auth_ref": [],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating lease liability payments due next twelve months net of lease incentives.",
        "label": "Lessee Operating Lease Liability Payments Due Next Twelve Months Net of Lease Incentives",
        "negatedLabel": "2022",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonthsNetOfLeaseIncentives",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcvx_LesseeOperatingLeaseRenewalOption": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating lease renewal option.",
        "label": "Lessee Operating Lease Renewal Option",
        "terseLabel": "Operating lease, renewal option"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalOption",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "pcvx_LesseeOperatingLeaseRentCommencementDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, operating lease, rent commencement date.",
        "label": "Lessee Operating Lease Rent Commencement Date",
        "terseLabel": "Operating lease, rent commencement date"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRentCommencementDate",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "pcvx_LicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement.",
        "label": "License Agreement [Member]",
        "terseLabel": "License Agreement"
       }
      }
     },
     "localname": "LicenseAgreementMember",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pcvx_LicenseAmendmentATwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Amendment A Two.",
        "label": "License Amendment A Two [Member]",
        "terseLabel": "License Amendment A2"
       }
      }
     },
     "localname": "LicenseAmendmentATwoMember",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pcvx_LonzaLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lonza limited.",
        "label": "Lonza Limited [Member]",
        "terseLabel": "Lonza DMSA"
       }
      }
     },
     "localname": "LonzaLimitedMember",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pcvx_MarketOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Market offering.",
        "label": "Market Offering [Member]",
        "terseLabel": "Market offering"
       }
      }
     },
     "localname": "MarketOfferingMember",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "pcvx_MaximumCommissionPercentageOfGrossProceedsFromCommonStockSold": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum commission percentage of gross proceeds from common stock sold.",
        "label": "Maximum Commission Percentage Of Gross Proceeds From Common Stock Sold",
        "terseLabel": "Maximum commission percentage of gross proceeds from common stock sold"
       }
      }
     },
     "localname": "MaximumCommissionPercentageOfGrossProceedsFromCommonStockSold",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pcvx_NewCorporateHeadquartersFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "New Corporate Headquarters Facility.",
        "label": "New Corporate Headquarters Facility [Member]",
        "terseLabel": "New Corporate Headquarters Facility"
       }
      }
     },
     "localname": "NewCorporateHeadquartersFacilityMember",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pcvx_NumberOfFinanceLease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of finance lease.",
        "label": "Number Of Finance Lease",
        "terseLabel": "Number of finance lease"
       }
      }
     },
     "localname": "NumberOfFinanceLease",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "pcvx_NumberOfOperatingLease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating lease.",
        "label": "Number Of Operating Lease",
        "terseLabel": "Number of operating lease"
       }
      }
     },
     "localname": "NumberOfOperatingLease",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "pcvx_NumberOfOptionsExercisedExcludesOptionsExercisedFromNpln": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options exercised, excludes options exercised from NPLN.",
        "label": "Number Of Options Exercised Excludes Options Exercised From NPLN",
        "terseLabel": "Exercise of stock options (in shares)"
       }
      }
     },
     "localname": "NumberOfOptionsExercisedExcludesOptionsExercisedFromNpln",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "pcvx_NumberOfRenewalOptions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of renewal options.",
        "label": "Number Of Renewal Options",
        "terseLabel": "Number of renewal options"
       }
      }
     },
     "localname": "NumberOfRenewalOptions",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "pcvx_NumberOfSecurities": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities.",
        "label": "Number Of Securities",
        "verboseLabel": "Number of securities"
       }
      }
     },
     "localname": "NumberOfSecurities",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "pcvx_OfferingPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Offering period.",
        "label": "Offering Period",
        "terseLabel": "Offering period"
       }
      }
     },
     "localname": "OfferingPeriod",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "pcvx_OperatingLossCarryForwardsExpirationYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating loss carry forwards expiration year",
        "label": "Operating Loss Carry Forwards Expiration Year",
        "terseLabel": "Operating loss carry forwards expiration year"
       }
      }
     },
     "localname": "OperatingLossCarryForwardsExpirationYear",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearItemType"
    },
    "pcvx_PaloAltoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Palo alto.",
        "label": "Palo Alto [Member]",
        "terseLabel": "Palo Alto"
       }
      }
     },
     "localname": "PaloAltoMember",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesParentheticalDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pcvx_PaymentOfDeferredOfferingCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment of deferred offering costs.",
        "label": "Payment Of Deferred Offering Costs",
        "negatedLabel": "Payments of deferred offering costs"
       }
      }
     },
     "localname": "PaymentOfDeferredOfferingCosts",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcvx_PaymentsOfCapitalLeaseObligations": {
     "auth_ref": [],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments of capital lease obligations.",
        "label": "Payments Of Capital Lease Obligations",
        "negatedLabel": "Payments of capital lease obligations"
       }
      }
     },
     "localname": "PaymentsOfCapitalLeaseObligations",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcvx_PaymentsOfUnderwritingDiscountsAndCommissions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments of underwriting discounts and commissions.",
        "label": "Payments Of Underwriting Discounts And Commissions",
        "terseLabel": "Underwriting discounts and commissions"
       }
      }
     },
     "localname": "PaymentsOfUnderwritingDiscountsAndCommissions",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCompanyOrganizationAndNatureOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcvx_PercentageOfFairValuePerShareOnTheGrantDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of fair value per share on the grant date.",
        "label": "Percentage Of Fair Value Per Share On The Grant Date",
        "terseLabel": "Percentage of fair value per share on the grant date"
       }
      }
     },
     "localname": "PercentageOfFairValuePerShareOnTheGrantDate",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pcvx_PercentageOfPaymentsCompletionAgreedToDefer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of payments completion agreed to defer.",
        "label": "Percentage Of Payments Completion Agreed To Defer",
        "terseLabel": "Percentage of defer payments agreed for completion"
       }
      }
     },
     "localname": "PercentageOfPaymentsCompletionAgreedToDefer",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pcvx_PercentageOfProvisionsSubjectToStockholders": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of provisions subject to stockholders.",
        "label": "Percentage Of Provisions Subject To Stockholders",
        "terseLabel": "Percentage of provisions subject to stockholders"
       }
      }
     },
     "localname": "PercentageOfProvisionsSubjectToStockholders",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pcvx_PercentageOfRoyaltyPaymentOnAnnualNetSalesOfVaccineProductsForHumanHealth": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of royalty payment on annual net sales of vaccine products for human health.",
        "label": "Percentage Of Royalty Payment On Annual Net Sales Of Vaccine Products For Human Health",
        "terseLabel": "Percentage of royalty payment on annual net sales of vaccine products for human health"
       }
      }
     },
     "localname": "PercentageOfRoyaltyPaymentOnAnnualNetSalesOfVaccineProductsForHumanHealth",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pcvx_PercentageOfRoyaltyPaymentOnNetSalesOfVaccineCompositionsForAnimalHealth": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of royalty payment on net sales of vaccine compositions for animal health.",
        "label": "Percentage Of Royalty Payment On Net Sales Of Vaccine Compositions For Animal Health",
        "terseLabel": "Percentage of royalty payment on net sales of vaccine compositions for animal health"
       }
      }
     },
     "localname": "PercentageOfRoyaltyPaymentOnNetSalesOfVaccineCompositionsForAnimalHealth",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pcvx_PneumococcalConjugateVaccineMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pneumococcal conjugate vaccine.",
        "label": "Pneumococcal Conjugate Vaccine [Member]",
        "terseLabel": "Pneumococcal Conjugate Vaccine"
       }
      }
     },
     "localname": "PneumococcalConjugateVaccineMember",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCompanyOrganizationAndNatureOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pcvx_PotentialFundingAmountOfAwardToDevelopVaccineToPreventInfections": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential funding amount of award to develop vaccine to prevent infections.",
        "label": "Potential Funding Amount Of Award To Develop Vaccine To Prevent Infections",
        "terseLabel": "Potential funding amount of award to develop vaccine to prevent shingella infections"
       }
      }
     },
     "localname": "PotentialFundingAmountOfAwardToDevelopVaccineToPreventInfections",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFundingArrangementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcvx_PotentialFundingCommittedByAward": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential funding committed by award.",
        "label": "Potential Funding Committed By Award",
        "terseLabel": "Potential funding committed by award"
       }
      }
     },
     "localname": "PotentialFundingCommittedByAward",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFundingArrangementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcvx_PotentialFundingPeriodOfAwardToDevelopVaccineToPreventInfections": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential funding period of award to develop vaccine to prevent infections.",
        "label": "Potential Funding Period Of Award To Develop Vaccine To Prevent Infections",
        "terseLabel": "Potential funding period of award to develop vaccine to prevent shingella infections"
       }
      }
     },
     "localname": "PotentialFundingPeriodOfAwardToDevelopVaccineToPreventInfections",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFundingArrangementAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "pcvx_PreferredStockWarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock warrant.",
        "label": "Preferred Stock Warrant [Member]",
        "terseLabel": "Preferred Stock Warrant"
       }
      }
     },
     "localname": "PreferredStockWarrantMember",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pcvx_PrefundedWarrantsPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prefunded warrants price per share.",
        "label": "Prefunded Warrants Price Per Share",
        "verboseLabel": "Pre-funded warrants price per share"
       }
      }
     },
     "localname": "PrefundedWarrantsPricePerShare",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "pcvx_ProceedsFromInitialPublicOfferingNetOfUnderwritersCommissionsAndDiscounts": {
     "auth_ref": [],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from initial public offering, net of underwriters' commissions and discounts.",
        "label": "Proceeds From Initial Public Offering Net Of Underwriters Commissions And Discounts",
        "terseLabel": "Proceeds from initial public offering, net of underwriters' commissions and discounts"
       }
      }
     },
     "localname": "ProceedsFromInitialPublicOfferingNetOfUnderwritersCommissionsAndDiscounts",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcvx_ProceedsFromIssuanceFollowOnOffering": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from issuance follow on offering.",
        "label": "Proceeds from Issuance follow on offering",
        "terseLabel": "Net proceeds from follow on offering"
       }
      }
     },
     "localname": "ProceedsFromIssuanceFollowOnOffering",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcvx_ProceedsFromIssuanceOfCommonStockNotYetReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from issuance of common stock not yet received.",
        "label": "Proceeds From Issuance Of Common Stock Not Yet Received",
        "terseLabel": "Proceeds from issuance of common stock through ATM facility not yet received"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStockNotYetReceived",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcvx_ProceedsFromIssuanceOfCommonStockRelatedToEarlyExercisedStockOptions": {
     "auth_ref": [],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from issuance of common stock related to early exercised stock options.",
        "label": "Proceeds From Issuance Of Common Stock Related To Early Exercised Stock Options",
        "terseLabel": "Proceeds from issuance of common stock related to early exercised stock options"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStockRelatedToEarlyExercisedStockOptions",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcvx_PurchasePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase period.",
        "label": "Purchase Period",
        "terseLabel": "Purchase period"
       }
      }
     },
     "localname": "PurchasePeriod",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "pcvx_RedeemableConvertiblePreferredStockTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Redeemable convertible preferred stock.",
        "label": "Redeemable Convertible Preferred Stock [Text Block]",
        "terseLabel": "Redeemable Convertible Preferred Stock"
       }
      }
     },
     "localname": "RedeemableConvertiblePreferredStockTextBlock",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStock"
     ],
     "xbrltype": "textBlockItemType"
    },
    "pcvx_RedeemableConvertiblePreferredStockWarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Redeemable convertible preferred stock warrant.",
        "label": "Redeemable Convertible Preferred Stock Warrant [Member]",
        "terseLabel": "Redeemable Convertible Preferred Stock Warrant"
       }
      }
     },
     "localname": "RedeemableConvertiblePreferredStockWarrantMember",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pcvx_RemainingLiabilitiesRelatedToEarlyExercisedShares": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining liabilities related to early exercised shares.",
        "label": "Remaining Liabilities Related To Early Exercised Shares",
        "terseLabel": "Remaining liabilities related to early exercised shares"
       }
      }
     },
     "localname": "RemainingLiabilitiesRelatedToEarlyExercisedShares",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcvx_ResearchAndDevelopmentExpenseToRelatedParty": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development expense to related party.",
        "label": "Research And Development Expense To Related Party",
        "terseLabel": "Research and development expense to related party"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseToRelatedParty",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfOperationsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcvx_SaleOfCommonStockAuthorizedAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of common stock authorized amount.",
        "label": "Sale Of Common Stock Authorized Amount",
        "terseLabel": "Aggregate offering price"
       }
      }
     },
     "localname": "SaleOfCommonStockAuthorizedAmount",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcvx_SanCarlosMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "San Carlos.",
        "label": "San Carlos [Member]",
        "terseLabel": "San Carlos"
       }
      }
     },
     "localname": "SanCarlosMember",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pcvx_ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of common stock shares reserved for future issuance.",
        "label": "Schedule Of Common Stock Shares Reserved For Future Issuance Table [Text Block]",
        "terseLabel": "Schedule of Common Stock Shares Reserved for Future Issuance"
       }
      }
     },
     "localname": "ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCommonStockTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "pcvx_ScheduleOfInformationRelatedToRightOfUseAssetsAndLeaseLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information related to right-of-use assets and lease liabilities.",
        "label": "Schedule Of Information Related To Right Of Use Assets And Lease Liabilities Table [Text Block]",
        "terseLabel": "Schedule of Information Related to ROU Assets and Lease Liabilities"
       }
      }
     },
     "localname": "ScheduleOfInformationRelatedToRightOfUseAssetsAndLeaseLiabilitiesTableTextBlock",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of organization consolidation and presentation of financial statements.",
        "label": "Schedule Of Organization Consolidation And Presentation Of Financial Statements [Line Items]",
        "terseLabel": "Schedule Of Organization Consolidation And Presentation Of Financial Statements [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsLineItems",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCompanyOrganizationAndNatureOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of organization consolidation and presentation of financial statements.",
        "label": "Schedule Of Organization Consolidation And Presentation Of Financial Statements [Table]",
        "terseLabel": "Schedule Of Organization Consolidation And Presentation Of Financial Statements [Table]"
       }
      }
     },
     "localname": "ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsTable",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCompanyOrganizationAndNatureOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pcvx_Section162MLimitation": {
     "auth_ref": [],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfEffectiveTaxRateDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Section 162(m) limitation.",
        "label": "Section 162(m) Limitation"
       }
      }
     },
     "localname": "Section162MLimitation",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pcvx_SeriesARedeemableConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A redeemable convertible preferred stock.",
        "label": "Series A Redeemable Convertible Preferred Stock [Member]",
        "terseLabel": "Series A Redeemable Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesARedeemableConvertiblePreferredStockMember",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "pcvx_SeriesBRedeemableConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series B redeemable convertible preferred stock.",
        "label": "Series B Redeemable Convertible Preferred Stock [Member]",
        "terseLabel": "Series B Redeemable Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesBRedeemableConvertiblePreferredStockMember",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "pcvx_SeriesCRedeemableConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series C redeemable convertible preferred stock.",
        "label": "Series C Redeemable Convertible Preferred Stock [Member]",
        "terseLabel": "Series C Redeemable Convertible Preferred Stock",
        "verboseLabel": "Series C Redeemable Convertible Stock"
       }
      }
     },
     "localname": "SeriesCRedeemableConvertiblePreferredStockMember",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "pcvx_SeriesDRedeemableConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series D redeemable convertible preferred stock.",
        "label": "Series D Redeemable Convertible Preferred Stock [Member]",
        "terseLabel": "Series D Redeemable Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesDRedeemableConvertiblePreferredStockMember",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExercisedInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based compensation arrangement by share-based payment award number of shares available for grant exercised in period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Exercised In Period",
        "terseLabel": "Options Available for Grant, exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExercisedInPeriod",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfActivityUnderStockOptionPlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeitedInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based compensation arrangement by share-based payment award number of shares available for grant forfeited in period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Forfeited In Period",
        "terseLabel": "Options Available for Grant, forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeitedInPeriod",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfActivityUnderStockOptionPlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantedInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based compensation arrangement by share-based payment award number of shares available for grant granted in period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Granted In Period",
        "negatedLabel": "Options Available for Grant, granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantedInPeriod",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfActivityUnderStockOptionPlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreaseInAvailableForGrant": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award number of shares increase in available for grant.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Increase In Available For Grant",
        "terseLabel": "Available for issuance of shares increased"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreaseInAvailableForGrant",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "pcvx_SharesAvailableForFutureStockOptionGrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares available for future stock option grants.",
        "label": "Shares Available For Future Stock Option Grants [Member]",
        "terseLabel": "Shares Available for Future Stock Option Grants"
       }
      }
     },
     "localname": "SharesAvailableForFutureStockOptionGrantsMember",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCommonStockScheduleOfCommonStockSharesReservedForFutureIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pcvx_SharesIssuedPricePerShareUponFollowOnOffering": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares issued price per share upon follow on offering.",
        "label": "Shares Issued Price Per Share upon follow on offering",
        "terseLabel": "Common stock price per share"
       }
      }
     },
     "localname": "SharesIssuedPricePerShareUponFollowOnOffering",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "pcvx_SharesIssuedUponFollowOnOfferingFullExerciseOfUnderwritersOptionToPurchaseAdditionalShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares issued upon follow on offering full exercise of underwriters option to purchase additional shares.",
        "label": "Shares issued upon follow on offering full exercise of underwriters option to purchase additional shares.",
        "terseLabel": "Underwriters' option to purchase additional shares"
       }
      }
     },
     "localname": "SharesIssuedUponFollowOnOfferingFullExerciseOfUnderwritersOptionToPurchaseAdditionalShares",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "pcvx_SharesIssuedUponFullExerciseOfUnderwritersOptionToPurchaseAdditionalShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares issued upon full exercise of underwriters option to purchase additional shares.",
        "label": "Shares Issued Upon Full Exercise Of Underwriters Option To Purchase Additional Shares",
        "terseLabel": "Underwriters' option to purchase additional shares"
       }
      }
     },
     "localname": "SharesIssuedUponFullExerciseOfUnderwritersOptionToPurchaseAdditionalShares",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCompanyOrganizationAndNatureOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "pcvx_SharesPreFundedWarrantsToPurchase": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares pre-funded warrants to purchase.",
        "label": "Shares Pre-Funded Warrants To Purchase",
        "terseLabel": "Pre-funded warrants to purchase shares"
       }
      }
     },
     "localname": "SharesPreFundedWarrantsToPurchase",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "pcvx_StockIssuedDuringPeriodSharesConversionOfCommonStockWarrant": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period shares conversion of common stock warrant.",
        "label": "Stock Issued During Period Shares Conversion Of Common Stock Warrant",
        "terseLabel": "Conversion of common stock warrant"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfCommonStockWarrant",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "pcvx_StockIssuedDuringPeriodSharesConversionOfPreferredStockWarrant": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period shares conversion of preferred stock warrant.",
        "label": "Stock Issued During Period Shares Conversion Of Preferred Stock Warrant",
        "terseLabel": "Conversion of preferred stock warrant"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfPreferredStockWarrant",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "pcvx_StockIssuedDuringPeriodSharesIssuanceOfCommonStockRelatedToEarlyExercisedStockOptions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period shares issuance of common stock related to early exercised stock options.",
        "label": "Stock Issued During Period Shares Issuance Of Common Stock Related To Early Exercised Stock Options",
        "terseLabel": "Issuance of common stock related to early exercised stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesIssuanceOfCommonStockRelatedToEarlyExercisedStockOptions",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "pcvx_StockIssuedDuringPeriodSharesOfFollowOnOffering": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period, shares of follow on offering.",
        "label": "Stock Issued During Period, Shares of follow on offering",
        "terseLabel": "Shares issued"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesOfFollowOnOffering",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "pcvx_StockOptionsGrantedTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock options granted term.",
        "label": "Stock Options Granted Term",
        "terseLabel": "Stock options granted term"
       }
      }
     },
     "localname": "StockOptionsGrantedTerm",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "pcvx_SupplyAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supply Agreement.",
        "label": "Supply Agreement [Member]",
        "terseLabel": "Supply Agreement"
       }
      }
     },
     "localname": "SupplyAgreementMember",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pcvx_SutroBiopharmaIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sutro Biopharma, Inc.",
        "label": "Sutro Biopharma Inc [Member]",
        "terseLabel": "Sutro Biopharma, Inc"
       }
      }
     },
     "localname": "SutroBiopharmaIncMember",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pcvx_TaxCreditCarryforwardExpirationYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax credit carryforward expiration year.",
        "label": "Tax Credit Carryforward Expiration Year",
        "terseLabel": "Tax credit carry forwards expiration year"
       }
      }
     },
     "localname": "TaxCreditCarryforwardExpirationYear",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearItemType"
    },
    "pcvx_TemporaryEquityConversionOfPreferredStockShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity conversion of preferred stock shares.",
        "label": "Temporary Equity Conversion Of Preferred Stock Shares",
        "terseLabel": "Conversion of preferred stock (in shares)"
       }
      }
     },
     "localname": "TemporaryEquityConversionOfPreferredStockShares",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "pcvx_TemporaryEquityConversionOfPreferredStockValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity conversion of preferred stock value.",
        "label": "Temporary Equity Conversion Of Preferred Stock Value",
        "terseLabel": "Conversion of preferred stock"
       }
      }
     },
     "localname": "TemporaryEquityConversionOfPreferredStockValue",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcvx_TemporaryEquityStockIssuanceCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity stock issuance costs.",
        "label": "Temporary Equity Stock Issuance Costs",
        "terseLabel": "Issuance costs"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuanceCosts",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcvx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity stock issued during period shares new issues.",
        "label": "Temporary Equity Stock Issued During Period Shares New Issues",
        "terseLabel": "Issuance of preferred stock, net of issuance cost (in shares)"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "pcvx_ThresholdLimitOnEquityPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold limit on equity payments.",
        "label": "Threshold Limit On Equity Payments",
        "terseLabel": "Equity payment, upper limit"
       }
      }
     },
     "localname": "ThresholdLimitOnEquityPayments",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcvx_TwoThousandFourteenEquityIncentivePlanAndTwoThousandTwentyEquityIncentivePlanAndTwoThousandTwentyEmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand fourteen equity incentive plan and two thousand twenty equity incentive plan and two thousand twenty employee stock purchase plan.",
        "label": "Two Thousand Fourteen Equity Incentive Plan And Two Thousand Twenty Equity Incentive Plan And Two Thousand Twenty Employee Stock Purchase Plan [Member]",
        "terseLabel": "2014 Plan, 2020 Plan and 2020 ESPP"
       }
      }
     },
     "localname": "TwoThousandFourteenEquityIncentivePlanAndTwoThousandTwentyEquityIncentivePlanAndTwoThousandTwentyEmployeeStockPurchasePlanMember",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfStockBasedCompensationExpenseDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansTables"
     ],
     "xbrltype": "domainItemType"
    },
    "pcvx_TwoThousandFourteenEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand fourteen equity incentive plan.",
        "label": "Two Thousand Fourteen Equity Incentive Plan [Member]",
        "terseLabel": "2014 Equity Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandFourteenEquityIncentivePlanMember",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pcvx_TwoThousandTwentyEmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand twenty employee stock purchase plan.",
        "label": "Two Thousand Twenty Employee Stock Purchase Plan [Member]",
        "terseLabel": "2020 Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "TwoThousandTwentyEmployeeStockPurchasePlanMember",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfEstimatedFairValueOfSharesUnderEmployeeStockPurchasePlanDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansTables"
     ],
     "xbrltype": "domainItemType"
    },
    "pcvx_TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand twenty equity incentive plan and two thousand fourteen equity incentive plan.",
        "label": "Two Thousand Twenty Equity Incentive Plan And Two Thousand Fourteen Equity Incentive Plan [Member]",
        "terseLabel": "2020 Plan and 2014 Plan"
       }
      }
     },
     "localname": "TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCommonStockScheduleOfCommonStockSharesReservedForFutureIssuanceDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfActivityUnderStockOptionPlansDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansTables"
     ],
     "xbrltype": "domainItemType"
    },
    "pcvx_TwoThousandTwentyEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand twenty equity incentive plan.",
        "label": "Two Thousand Twenty Equity Incentive Plan [Member]",
        "terseLabel": "2020 Equity Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandTwentyEquityIncentivePlanMember",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pcvx_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrecognized Tax Benefits Increases Decreases Resulting From Prior Period Tax Positions",
        "label": "Adjustments based on tax positions related to prior years"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcvx_WarrantsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants.",
        "label": "Warrants Disclosure [Text Block]",
        "terseLabel": "Warrants"
       }
      }
     },
     "localname": "WarrantsDisclosureTextBlock",
     "nsuri": "http://www.vaxcyte.com/20211231",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureWarrants"
     ],
     "xbrltype": "textBlockItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r61",
      "r63",
      "r114",
      "r115",
      "r252",
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesParentheticalDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r251",
      "r264",
      "r301",
      "r302",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r535",
      "r537",
      "r557",
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfEstimatedFairValueOfEmployeeStockOptionsDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfEstimatedFairValueOfSharesUnderEmployeeStockPurchasePlanDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFundingArrangementAdditionalInformationDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r251",
      "r264",
      "r301",
      "r302",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r535",
      "r537",
      "r557",
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]",
        "verboseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfEstimatedFairValueOfEmployeeStockOptionsDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfEstimatedFairValueOfSharesUnderEmployeeStockPurchasePlanDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFundingArrangementAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r181",
      "r289",
      "r290",
      "r488",
      "r534",
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product Or Service [Axis]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCompanyOrganizationAndNatureOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r181",
      "r289",
      "r290",
      "r488",
      "r534",
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Products And Services [Domain]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCompanyOrganizationAndNatureOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r251",
      "r264",
      "r291",
      "r301",
      "r302",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r535",
      "r537",
      "r557",
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfEstimatedFairValueOfEmployeeStockOptionsDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfEstimatedFairValueOfSharesUnderEmployeeStockPurchasePlanDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFundingArrangementAdditionalInformationDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r251",
      "r264",
      "r291",
      "r301",
      "r302",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r535",
      "r537",
      "r557",
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Member]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfEstimatedFairValueOfEmployeeStockOptionsDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfEstimatedFairValueOfSharesUnderEmployeeStockPurchasePlanDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFundingArrangementAdditionalInformationDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r62",
      "r63",
      "r114",
      "r115",
      "r252",
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repurchase Agreement Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesParentheticalDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_CA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "C A",
        "terseLabel": "California"
       }
      }
     },
     "localname": "CA",
     "nsuri": "http://xbrl.sec.gov/stpr/2021",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate201602Member": {
     "auth_ref": [
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).",
        "label": "Accounting Standards Update201602 [Member]",
        "terseLabel": "ASU 2016-02"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201602Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingStandardsUpdate201912Member": {
     "auth_ref": [
      "r371",
      "r372",
      "r373",
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2019-12 Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes.",
        "label": "Accounting Standards Update 2019-12 [Member]",
        "terseLabel": "ASU 2019-12"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201912Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r49",
      "r473"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable",
        "totalLabel": "Accounts Payable, Current, Total"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedLabel": "Net amortization of premiums on investments"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities Current",
        "terseLabel": "Accrued expenses (including related party accrual of $0 and $677 as of December 31, 2021 and December 31, 2020, respectively)",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities Current [Abstract]"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r11",
      "r12",
      "r51"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees Current",
        "terseLabel": "Professional fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r47",
      "r217"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation Depletion And Amortization Property Plant And Equipment",
        "negatedLabel": "Less: accumulated depreciation and amortization",
        "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance",
        "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance",
        "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r36",
      "r67",
      "r68",
      "r69",
      "r525",
      "r545",
      "r549"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss",
        "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r66",
      "r69",
      "r76",
      "r77",
      "r78",
      "r117",
      "r118",
      "r119",
      "r388",
      "r540",
      "r541",
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "Accumulated Other Comprehensive Income [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid In Capital Common Stock",
        "periodEndLabel": "Additional Paid in Capital, Common Stock, Ending Balance",
        "periodStartLabel": "Additional Paid in Capital, Common Stock, Beginning Balance",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r117",
      "r118",
      "r119",
      "r337",
      "r338",
      "r339",
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid In Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r122",
      "r123",
      "r124",
      "r125",
      "r135",
      "r184",
      "r185",
      "r204",
      "r205",
      "r206",
      "r207",
      "r209",
      "r210",
      "r237",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r371",
      "r372",
      "r373",
      "r374",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r420",
      "r421",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r462",
      "r489",
      "r490",
      "r491",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by amendment to accounting standards.",
        "label": "Adjustments For New Accounting Pronouncements [Axis]",
        "terseLabel": "Accounting Standards Update"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r303",
      "r305",
      "r343",
      "r344"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value",
        "terseLabel": "Stock-based compensation expense",
        "totalLabel": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "auth_ref": [
      "r278",
      "r285"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.",
        "label": "Adjustments To Additional Paid In Capital Stock Issued Issuance Costs",
        "terseLabel": "Issuance costs"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r305",
      "r329",
      "r342"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Allocated Share Based Compensation Expense",
        "terseLabel": "Stock-based compensation expense",
        "verboseLabel": "Total stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r146"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount",
        "terseLabel": "Antidilutive securities excluded from computation of diluted net loss per share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r146"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r146"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Arrangements And Nonarrangement Transactions [Member]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFundingArrangementAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetBackedSecuritiesMember": {
     "auth_ref": [
      "r196",
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans.",
        "label": "Asset-backed Securities [Member]",
        "terseLabel": "Asset backed securities"
       }
      }
     },
     "localname": "AssetBackedSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetImpairmentCharges": {
     "auth_ref": [
      "r99",
      "r214"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.",
        "label": "Asset Impairment Charges",
        "terseLabel": "Asset impairment charges",
        "totalLabel": "Asset Impairment Charges, Total"
       }
      }
     },
     "localname": "AssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r110",
      "r167",
      "r175",
      "r179",
      "r199",
      "r238",
      "r239",
      "r240",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r249",
      "r250",
      "r384",
      "r389",
      "r419",
      "r471",
      "r473",
      "r505",
      "r523"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r8",
      "r9",
      "r60",
      "r110",
      "r199",
      "r238",
      "r239",
      "r240",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r249",
      "r250",
      "r384",
      "r389",
      "r419",
      "r471",
      "r473"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsNoncurrent": {
     "auth_ref": [
      "r16",
      "r17",
      "r18",
      "r19",
      "r20",
      "r21",
      "r22",
      "r23",
      "r110",
      "r199",
      "r238",
      "r239",
      "r240",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r249",
      "r250",
      "r384",
      "r389",
      "r419",
      "r471"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.",
        "label": "Assets Noncurrent",
        "terseLabel": "Total noncurrent assets",
        "totalLabel": "Total noncurrent assets"
       }
      }
     },
     "localname": "AssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r191"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax",
        "terseLabel": "Investments, Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r192"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax",
        "negatedLabel": "Investments, Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r189",
      "r211"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Available For Sale Debt Securities Amortized Cost Basis",
        "terseLabel": "Asset backed securities",
        "totalLabel": "Investments, Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "auth_ref": [
      "r193",
      "r195",
      "r518"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfContractualMaturitiesOfInvestmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Available For Sale Securities Debt Maturities After One Through Five Years Fair Value",
        "terseLabel": "Due in one to five years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfContractualMaturitiesOfInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r193",
      "r194",
      "r517"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfContractualMaturitiesOfInvestmentsDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Available For Sale Securities Debt Maturities Within One Year Fair Value",
        "terseLabel": "Due in less than one year"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfContractualMaturitiesOfInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r187",
      "r190",
      "r211",
      "r510"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfContractualMaturitiesOfInvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Available For Sale Securities Debt Securities",
        "terseLabel": "Investments, Fair Value",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfContractualMaturitiesOfInvestmentsDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r306",
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCommonStockScheduleOfCommonStockSharesReservedForFutureIssuanceDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r394",
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis Of Accounting Policy Policy [Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Basis Of Presentation And Significant Accounting Policies [Text Block]",
        "terseLabel": "Basis of Presentation and Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BuildingMember": {
     "auth_ref": [
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities.",
        "label": "Building [Member]",
        "terseLabel": "Office"
       }
      }
     },
     "localname": "BuildingMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r104",
      "r105",
      "r106"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred But Not Yet Paid",
        "terseLabel": "Purchases of property and equipment recorded in accounts payable and accrued expenses"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r7",
      "r43",
      "r101"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfCashCashEquivalentsAndRestrictedCashDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      },
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash And Cash Equivalents At Carrying Value",
        "periodEndLabel": "Cash and Cash Equivalents, at Carrying Value, Ending Balance",
        "periodStartLabel": "Cash and Cash Equivalents, at Carrying Value, Beginning Balance",
        "terseLabel": "Cash and cash equivalents",
        "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfCashCashEquivalentsAndRestrictedCashDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails": {
       "order": 2.0,
       "parentTag": "pcvx_CashAndCashEquivalentsAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash And Cash Equivalents Fair Value Disclosure",
        "terseLabel": "Cash and cash equivalents, Fair Value"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r15",
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash And Cash Equivalents Policy [Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r95",
      "r101",
      "r107"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfCashCashEquivalentsAndRestrictedCashDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash, end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of period",
        "totalLabel": "Cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfCashCashEquivalentsAndRestrictedCashDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r95",
      "r433"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect",
        "totalLabel": "Net (decrease) increase in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow Noncash Investing And Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental disclosures of non-cash investing and financing activities:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashMember": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits.",
        "label": "Cash [Member]",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "CashMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted": {
     "auth_ref": [
      "r0",
      "r1",
      "r117",
      "r118",
      "r121",
      "r184",
      "r185",
      "r200",
      "r201",
      "r202",
      "r204",
      "r205",
      "r237",
      "r333",
      "r334",
      "r335",
      "r371",
      "r396",
      "r397",
      "r398",
      "r420",
      "r422",
      "r423",
      "r424",
      "r427",
      "r428",
      "r446",
      "r462",
      "r489",
      "r490",
      "r538",
      "r539",
      "r572"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether accounting standards update was adopted.",
        "label": "Change in Accounting Principle, Accounting Standards Update, Adopted [true false]",
        "terseLabel": "Accounting standard update adopted"
       }
      }
     },
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate": {
     "auth_ref": [
      "r0",
      "r1",
      "r117",
      "r118",
      "r129",
      "r184",
      "r185",
      "r200",
      "r201",
      "r202",
      "r204",
      "r205",
      "r237",
      "r333",
      "r334",
      "r335",
      "r371",
      "r396",
      "r397",
      "r398",
      "r399",
      "r402",
      "r420",
      "r422",
      "r423",
      "r424",
      "r427",
      "r428",
      "r446",
      "r462",
      "r489",
      "r490",
      "r538",
      "r539",
      "r572"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date accounting standards update was adopted, in YYYY-MM-DD format.",
        "label": "Change In Accounting Principle Accounting Standards Update Adoption Date",
        "terseLabel": "Accounting standard update adoption date"
       }
      }
     },
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption": {
     "auth_ref": [
      "r4",
      "r121",
      "r185",
      "r200",
      "r203",
      "r206",
      "r237",
      "r336",
      "r372",
      "r396",
      "r399",
      "r402",
      "r421",
      "r422",
      "r425",
      "r426",
      "r428",
      "r446",
      "r491",
      "r538",
      "r539",
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether accounting standards update was early adopted.",
        "label": "Change In Accounting Principle Accounting Standards Update Early Adoption",
        "terseLabel": "Change in accounting principle, accounting standards update, early adoption [true false]"
       }
      }
     },
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect": {
     "auth_ref": [
      "r122",
      "r134",
      "r186",
      "r208",
      "r340",
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether effect from applying amendment to accounting standards is immaterial.",
        "label": "Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]",
        "terseLabel": "Accounting standard update material impact"
       }
      }
     },
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r108",
      "r110",
      "r138",
      "r139",
      "r140",
      "r143",
      "r145",
      "r152",
      "r153",
      "r154",
      "r199",
      "r238",
      "r243",
      "r244",
      "r245",
      "r249",
      "r250",
      "r262",
      "r263",
      "r267",
      "r271",
      "r419",
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class Of Stock [Domain]",
        "terseLabel": "Class of Stock"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCompanyOrganizationAndNatureOfBusinessAdditionalInformationDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class Of Stock [Line Items]",
        "terseLabel": "Class Of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCommonStockScheduleOfCommonStockSharesReservedForFutureIssuanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable": {
     "auth_ref": [
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date the warrants or rights are exercisable, in YYYY-MM-DD format.",
        "label": "Class Of Warrant Or Righst Date From Which Warrants Or Rights Exercisable",
        "terseLabel": "Warrant exercisable and vests immediately and expires date"
       }
      }
     },
     "localname": "ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1",
        "verboseLabel": "Warrant purchase price per share"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.",
        "label": "Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right",
        "terseLabel": "Warrant to purchase shares of stock"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial Paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember": {
     "auth_ref": [
      "r292",
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds that is excluded from cash and cash equivalents.",
        "label": "Commercial Paper Not Included With Cash And Cash Equivalents [Member]",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperNotIncludedWithCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r54",
      "r225",
      "r511",
      "r530"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments And Contingencies",
        "terseLabel": "Commitments and contingencies (Note 6)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments And Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r222",
      "r223",
      "r224",
      "r232",
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments And Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r56"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock Capital Shares Reserved For Future Issuance",
        "terseLabel": "Common stock reserved for future issuances",
        "verboseLabel": "Shares reserved for issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCommonStockScheduleOfCommonStockSharesReservedForFutureIssuanceDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockDividendsPerShareDeclared": {
     "auth_ref": [
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.",
        "label": "Common Stock Dividends Per Share Declared",
        "terseLabel": "Common stock, dividends, per share, declared"
       }
      }
     },
     "localname": "CommonStockDividendsPerShareDeclared",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r117",
      "r118",
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCompanyOrganizationAndNatureOfBusinessAdditionalInformationDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r32"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock Par Or Stated Value Per Share",
        "terseLabel": "Common stock, par value",
        "verboseLabel": "Common stock, par value per share"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r32"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r32"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock Shares Issued",
        "terseLabel": "Common stock, shares issued",
        "totalLabel": "Common Stock, Shares, Issued, Total",
        "verboseLabel": "Common stock, shares owned"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r32",
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock Shares Outstanding",
        "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance",
        "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance",
        "terseLabel": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r32",
      "r473"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock Value",
        "periodEndLabel": "Common Stock, Value, Issued, Ending Balance",
        "periodStartLabel": "Common Stock, Value, Issued, Beginning Balance",
        "terseLabel": "Common stock, $0.001 par value - 500,000,000 shares authorized at December 31, 2021 and December 31, 2020;53,031,978 and 51,071,593 shares issued and outstanding at December 31, 2021 and December 31, 2020, respectively",
        "totalLabel": "Common Stock, Value, Issued, Total"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStockVotingRights": {
     "auth_ref": [
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.",
        "label": "Common Stock Voting Rights",
        "terseLabel": "Common stock, voting rights"
       }
      }
     },
     "localname": "CommonStockVotingRights",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components Of Deferred Tax Assets And Liabilities [Abstract]"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r71",
      "r73",
      "r74",
      "r81",
      "r513",
      "r532"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income Net Of Tax",
        "totalLabel": "Comprehensive Loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income Policy Policy [Text Block]",
        "terseLabel": "Comprehensive Loss"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r157",
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk Credit Risk",
        "terseLabel": "Concentration of Credit Risk and Other Risks and Uncertainties"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction In Progress [Member]",
        "terseLabel": "Construction in Progress"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConversionOfStockAmountConverted1": {
     "auth_ref": [
      "r104",
      "r105",
      "r106"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion Of Stock Amount Converted1",
        "terseLabel": "Conversion of convertible preferred stock into common stock"
       }
      }
     },
     "localname": "ConversionOfStockAmountConverted1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r292",
      "r300",
      "r550"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate Debt"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DeferredChargesPolicyTextBlock": {
     "auth_ref": [
      "r48"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges.",
        "label": "Deferred Charges Policy [Text Block]",
        "terseLabel": "Deferred Offering Costs"
       }
      }
     },
     "localname": "DeferredChargesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r26",
      "r27",
      "r360",
      "r506",
      "r521"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "pcvx_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedLabel": "Total deferred tax liabilities",
        "negatedTotalLabel": "Total deferred tax liabilities",
        "totalLabel": "Total deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredOfferingCosts": {
     "auth_ref": [
      "r59",
      "r212"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.",
        "label": "Deferred Offering Costs",
        "terseLabel": "Deferred offering costs"
       }
      }
     },
     "localname": "DeferredOfferingCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRentCreditCurrent": {
     "auth_ref": [
      "r25",
      "r444",
      "r461"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of rental payment required by lease over rental income recognized, classified as current.",
        "label": "Deferred Rent Credit, Current",
        "terseLabel": "Deferred rent - current"
       }
      }
     },
     "localname": "DeferredRentCreditCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRentCreditNoncurrent": {
     "auth_ref": [
      "r28",
      "r444",
      "r461"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of rental payment required by lease over rental income recognized, classified as noncurrent.",
        "label": "Deferred Rent Credit, Noncurrent",
        "terseLabel": "Deferred rent - long-term"
       }
      }
     },
     "localname": "DeferredRentCreditNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r361"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails": {
       "order": 0.0,
       "parentTag": "pcvx_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets Gross",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGrossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsGrossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "auth_ref": [
      "r368",
      "r369"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.",
        "label": "Deferred Tax Assets In Process Research And Development",
        "terseLabel": "Section 59(e) Capitalized expenses"
       }
      }
     },
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r363"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred taxes"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r368",
      "r369"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets Operating Loss Carryforwards",
        "terseLabel": "Net operating losses",
        "totalLabel": "Deferred Tax Assets, Operating Loss Carryforwards, Total"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": {
     "auth_ref": [],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Assets Property Plant And Equipment",
        "terseLabel": "Fixed assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "auth_ref": [
      "r366",
      "r368",
      "r369"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.",
        "label": "Deferred Tax Assets Tax Credit Carryforwards",
        "terseLabel": "Credits",
        "totalLabel": "Deferred Tax Assets, Tax Credit Carryforwards, Total"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals": {
     "auth_ref": [
      "r368",
      "r369"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.",
        "label": "Deferred Tax Assets Tax Deferred Expense Reserves And Accruals",
        "terseLabel": "Accruals &amp; reserves",
        "totalLabel": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Total"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r362"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets Valuation Allowance",
        "negatedLabel": "Valuation allowance",
        "totalLabel": "Deferred Tax Assets, Valuation Allowance, Total"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": {
     "auth_ref": [
      "r368",
      "r369"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.",
        "label": "Deferred Tax Liabilities, Leasing Arrangements",
        "negatedLabel": "ROU asset"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesLeasingArrangements",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r99",
      "r215"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation And Amortization",
        "terseLabel": "Depreciation and amortization expense",
        "totalLabel": "Depreciation, Depletion and Amortization, Nonproduction, Total"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r99",
      "r166"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation Depletion And Amortization",
        "terseLabel": "Depreciation and amortization",
        "totalLabel": "Depreciation, Depletion and Amortization, Total"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Disclosure Of Compensation Related Costs Share Based Payments [Text Block]",
        "terseLabel": "Equity Incentive Plans"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Country [Member]",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrent": {
     "auth_ref": [
      "r49",
      "r112",
      "r241",
      "r243",
      "r244",
      "r248",
      "r249",
      "r250",
      "r466"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Due To Related Parties Current",
        "terseLabel": "Related party accrual",
        "totalLabel": "Due to Related Parties, Current, Total"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r144"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share Basic And Diluted",
        "terseLabel": "Net loss per share, basic and diluted",
        "totalLabel": "Earnings Per Share, Basic and Diluted, Total"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r146",
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share Policy [Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r146",
      "r147",
      "r148",
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r433"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents",
        "terseLabel": "Effect of exchange rate changes on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r350"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfEffectiveTaxRateDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Continuing Operations",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Continuing Operations Tax Rate Reconciliation [Abstract]"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r111",
      "r350",
      "r377"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfEffectiveTaxRateDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate",
        "terseLabel": "Statutory Rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r350",
      "r377"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfEffectiveTaxRateDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "auth_ref": [
      "r350",
      "r377"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfEffectiveTaxRateDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost",
        "terseLabel": "Stock-based Compensation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r350",
      "r377"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfEffectiveTaxRateDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation Other Adjustments",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": {
     "auth_ref": [
      "r350",
      "r377"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfEffectiveTaxRateDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.",
        "label": "Effective Income Tax Rate Reconciliation Tax Credits",
        "terseLabel": "Credits",
        "totalLabel": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent, Total"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued compensation",
        "totalLabel": "Employee-related Liabilities, Current, Total"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r330"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized",
        "terseLabel": "Unrecognized stock-based compensation expense",
        "totalLabel": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1",
        "terseLabel": "Unrecognized share-based compensation expense, expected to be recognized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Options Issued and Outstanding"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCommonStockScheduleOfCommonStockSharesReservedForFutureIssuanceDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r2",
      "r76",
      "r77",
      "r78",
      "r117",
      "r118",
      "r119",
      "r123",
      "r131",
      "r133",
      "r151",
      "r207",
      "r278",
      "r285",
      "r337",
      "r338",
      "r339",
      "r373",
      "r374",
      "r405",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r540",
      "r541",
      "r542",
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCompanyOrganizationAndNatureOfBusinessAdditionalInformationDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "auth_ref": [
      "r99",
      "r257"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.",
        "label": "Fair Value Adjustment Of Warrants",
        "terseLabel": "Change in fair value of redeemable convertible preferred stock warrant"
       }
      }
     },
     "localname": "FairValueAdjustmentOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsAdditionalInformationDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "auth_ref": [
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Table]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsAdditionalInformationDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount": {
     "auth_ref": [
      "r410"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of assets measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.",
        "label": "Fair Value Assets Level1 To Level2 Transfers Amount",
        "terseLabel": "Fair value assets transferred from level 1 to level 2"
       }
      }
     },
     "localname": "FairValueAssetsLevel1ToLevel2TransfersAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount": {
     "auth_ref": [
      "r410"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of assets measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.",
        "label": "Fair Value Assets Level2 To Level1 Transfers Amount",
        "terseLabel": "Fair value assets transferred from level 2 to level 1"
       }
      }
     },
     "localname": "FairValueAssetsLevel2ToLevel1TransfersAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r408",
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Fair Value Assets Measured On Recurring Basis [Text Block]",
        "terseLabel": "Schedule of Financial Instruments Measured at Fair Value on Recurring Basis"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation By Asset Class [Domain]",
        "terseLabel": "Asset Class"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r408",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Fair Value By Asset Class [Axis]",
        "terseLabel": "Asset Class"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r253",
      "r255",
      "r256",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r300",
      "r409",
      "r477",
      "r478",
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value By Fair Value Hierarchy Level [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsAdditionalInformationDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r408",
      "r409",
      "r412",
      "r413",
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Fair Value By Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements and Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r253",
      "r292",
      "r293",
      "r298",
      "r300",
      "r409",
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value Inputs Level1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r253",
      "r255",
      "r256",
      "r292",
      "r293",
      "r298",
      "r300",
      "r409",
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value Inputs Level2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r253",
      "r255",
      "r256",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r300",
      "r409",
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value Inputs Level3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount": {
     "auth_ref": [
      "r410"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of liabilities measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.",
        "label": "Fair Value Liabilities Level1 To Level2 Transfers Amount",
        "terseLabel": "Fair value liabilities transferred from level 1 to level 2"
       }
      }
     },
     "localname": "FairValueLiabilitiesLevel1ToLevel2TransfersAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount": {
     "auth_ref": [
      "r410"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of liabilities measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.",
        "label": "Fair Value Liabilities Level2 To Level1 Transfers Amount",
        "terseLabel": "Fair value liabilities transferred from level 2 to level 1"
       }
      }
     },
     "localname": "FairValueLiabilitiesLevel2ToLevel1TransfersAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Fair Value Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement Policy Policy [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3": {
     "auth_ref": [
      "r415"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of financial instrument classified as a liability into level 3 of the fair value hierarchy.",
        "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3",
        "terseLabel": "Fair value liabilities transferred into level 3"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3": {
     "auth_ref": [
      "r415"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of financial instrument classified as a liability out of level 3 of the fair value hierarchy.",
        "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3",
        "terseLabel": "Fair value liabilities transferred out of level 3"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3": {
     "auth_ref": [
      "r415"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfer of financial instrument classified as an asset into level 3 of the fair value hierarchy.",
        "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3",
        "terseLabel": "Fair value assets transferred into level 3"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3": {
     "auth_ref": [
      "r415"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of financial instrument classified as an asset out of level 3 of the fair value hierarchy.",
        "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3",
        "terseLabel": "Fair value assets transferred out of level 3"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r253",
      "r255",
      "r256",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r300",
      "r477",
      "r478",
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Measurements Fair Value Hierarchy [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsAdditionalInformationDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r416",
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value Measurements Recurring [Member]",
        "terseLabel": "Fair Value, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "auth_ref": [
      "r429",
      "r430",
      "r431",
      "r432"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain Loss Before Tax",
        "terseLabel": "Foreign currency transaction gains (losses)",
        "totalLabel": "Foreign Currency Transaction Gain (Loss), before Tax, Total"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions And Translations Policy [Text Block]",
        "terseLabel": "Foreign Currency Transactions"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture And Fixtures [Member]",
        "terseLabel": "Furniture and Equipment"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnDispositionOfAssets1": {
     "auth_ref": [
      "r99"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.",
        "label": "Gain Loss On Disposition Of Assets1",
        "negatedLabel": "Loss on disposal of assets",
        "totalLabel": "Gain (Loss) on Disposition of Assets, Total"
       }
      }
     },
     "localname": "GainLossOnDispositionOfAssets1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General And Administrative Expense",
        "terseLabel": "General and administrative",
        "totalLabel": "General and Administrative Expense, Total"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r82"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General And Administrative Expense [Member]",
        "terseLabel": "General and Administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GrantsReceivable": {
     "auth_ref": [
      "r59"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants.",
        "label": "Grants Receivable",
        "terseLabel": "Grant receivable on unreimbursed, eligible costs incurred"
       }
      }
     },
     "localname": "GrantsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFundingArrangementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GuaranteeObligationsMaximumExposure": {
     "auth_ref": [
      "r235"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum potential amount of future payments (undiscounted) the guarantor could be required to make under the guarantee or each group of similar guarantees before reduction for potential recoveries under recourse or collateralization provisions.",
        "label": "Guarantee Obligations Maximum Exposure",
        "terseLabel": "Amount recorded with respect to the potential future payments above the initial cash cap"
       }
      }
     },
     "localname": "GuaranteeObligationsMaximumExposure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "I P O [Member]",
        "terseLabel": "Initial Public Offering",
        "verboseLabel": "IPO"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCompanyOrganizationAndNatureOfBusinessAdditionalInformationDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r213",
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment Or Disposal Of Long Lived Assets Policy [Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r219",
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r111",
      "r351",
      "r358",
      "r365",
      "r376",
      "r378",
      "r379",
      "r380",
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r75",
      "r348",
      "r349",
      "r358",
      "r359",
      "r364",
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax Policy [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r350"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Income Tax Reconciliation Tax Credits Research",
        "terseLabel": "Research credit carryforwards"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r98"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase Decrease In Accounts Payable",
        "terseLabel": "Accounts payable",
        "totalLabel": "Increase (Decrease) in Accounts Payable, Total"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r98"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase Decrease In Accrued Liabilities",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Increase (Decrease) in Accrued Liabilities, Total"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase Decrease In Operating Liabilities [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r98"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase Decrease In Other Operating Assets",
        "negatedLabel": "Other assets",
        "totalLabel": "Increase (Decrease) in Other Operating Assets, Total"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r98"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase Decrease In Prepaid Deferred Expense And Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets",
        "totalLabel": "Increase (Decrease) in Prepaid Expense and Other Assets, Total"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r79",
      "r165",
      "r442",
      "r443",
      "r514"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfOperations": {
       "order": 0.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense",
        "totalLabel": "Interest Expense, Total"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r93",
      "r96",
      "r103"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid Net",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r84",
      "r164"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "auth_ref": [
      "r198",
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment in financial asset.",
        "label": "Investment Policy [Text Block]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.",
        "label": "Investments Classified By Contractual Maturity Date Table [Text Block]",
        "terseLabel": "Schedule of Contractual Maturities of Investments"
       }
      }
     },
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseExpirationDate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-DD format.",
        "label": "Lease Expiration Date1",
        "terseLabel": "Lease expiration date"
       }
      }
     },
     "localname": "LeaseExpirationDate1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold Improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee Lease Description [Line Items]",
        "terseLabel": "Lessee Lease Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesParentheticalDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee Lease Description [Table]",
        "terseLabel": "Lessee Lease Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesParentheticalDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee Leases Policy [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseDescription": {
     "auth_ref": [
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of lessee's operating lease.",
        "label": "Lessee Operating Lease Description",
        "terseLabel": "Operating lease, description"
       }
      }
     },
     "localname": "LesseeOperatingLeaseDescription",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": {
     "auth_ref": [
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether lessee has option to extend operating lease.",
        "label": "Lessee Operating Lease Existence Of Option To Extend",
        "terseLabel": "Operating lease, existence of option to renewal"
       }
      }
     },
     "localname": "LesseeOperatingLeaseExistenceOfOptionToExtend",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee Operating Lease Liability Maturity Table [Text Block]",
        "terseLabel": "Schedule of Maturities of Lease Liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r458"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee Operating Lease Liability Payments Due",
        "totalLabel": "Total future undiscounted lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r458"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due Next Twelve Months",
        "negatedLabel": "2021",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r458"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r458"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r458"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due Year Two",
        "terseLabel": "2023 and 2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r458"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails2": {
       "order": 0.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee Operating Lease Liability Undiscounted Excess Amount",
        "negatedLabel": "Less: Imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseOptionToExtend": {
     "auth_ref": [
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.",
        "label": "Lessee Operating Lease Option To Extend",
        "terseLabel": "Operating lease, option to renewal, description"
       }
      }
     },
     "localname": "LesseeOperatingLeaseOptionToExtend",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee Operating Lease Renewal Term",
        "terseLabel": "Operating lease, renewal term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee Operating Lease Term Of Contract",
        "terseLabel": "Operating lease, agreement term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureLeases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r50",
      "r110",
      "r176",
      "r199",
      "r238",
      "r239",
      "r240",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r249",
      "r250",
      "r385",
      "r389",
      "r390",
      "r419",
      "r471",
      "r472"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r39",
      "r110",
      "r199",
      "r419",
      "r473",
      "r507",
      "r527"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities And Stockholders Equity",
        "terseLabel": "Liabilities, Redeemable Convertible Preferred Stock and Stockholders' Equity",
        "totalLabel": "Total liabilities, redeemable convertible preferred stock and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities, Redeemable Convertible Preferred Stock and Stockholders' Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r52",
      "r110",
      "r199",
      "r238",
      "r239",
      "r240",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r249",
      "r250",
      "r385",
      "r389",
      "r390",
      "r419",
      "r471",
      "r472",
      "r473"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermInvestments": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).",
        "label": "Long Term Investments",
        "terseLabel": "Long-term investments",
        "totalLabel": "Long-term Investments, Total"
       }
      }
     },
     "localname": "LongTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r233",
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MarketableSecuritiesRealizedGainLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized gain (loss) on investment in marketable security, including other-than-temporary impairment (OTTI).",
        "label": "Marketable Securities Realized Gain Loss",
        "terseLabel": "Realized gains on marketable securities",
        "totalLabel": "Marketable Securities, Realized Gain (Loss), Total"
       }
      }
     },
     "localname": "MarketableSecuritiesRealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money Market Funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided By Used In Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided By Used In Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r95",
      "r97",
      "r100"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided By Used In Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r5",
      "r70",
      "r72",
      "r78",
      "r80",
      "r100",
      "r110",
      "r122",
      "r127",
      "r128",
      "r129",
      "r130",
      "r132",
      "r133",
      "r141",
      "r167",
      "r174",
      "r177",
      "r178",
      "r180",
      "r199",
      "r238",
      "r239",
      "r240",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r249",
      "r250",
      "r407",
      "r419",
      "r512",
      "r531"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfComprehensiveLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income Loss",
        "terseLabel": "Net Loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfComprehensiveLoss",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfOperations",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r127",
      "r128",
      "r129",
      "r130",
      "r136",
      "r137",
      "r142",
      "r145",
      "r167",
      "r174",
      "r177",
      "r178",
      "r180"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income Loss Available To Common Stockholders Basic",
        "terseLabel": "Net loss (in thousands)",
        "totalLabel": "Net Income (Loss) Available to Common Stockholders, Basic, Total"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "New Accounting Pronouncements Or Change In Accounting Principle [Line Items]",
        "terseLabel": "New Accounting Pronouncements Or Change In Accounting Principle [Line Items]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r120",
      "r122",
      "r123",
      "r124",
      "r125",
      "r126",
      "r129",
      "r135",
      "r149",
      "r184",
      "r185",
      "r204",
      "r205",
      "r206",
      "r207",
      "r209",
      "r210",
      "r237",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r371",
      "r372",
      "r373",
      "r374",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r420",
      "r421",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r462",
      "r489",
      "r490",
      "r491",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.",
        "label": "New Accounting Pronouncements Or Change In Accounting Principle [Table]",
        "terseLabel": "New Accounting Pronouncements Or Change In Accounting Principle [Table]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements Policy Policy [Text Block]",
        "terseLabel": "Recently Adopted Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number Of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfReportableSegments": {
     "auth_ref": [
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number Of Reportable Segments",
        "terseLabel": "Number of reportable segments"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfOperations": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r167",
      "r174",
      "r177",
      "r178",
      "r180"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfOperations": {
       "order": 0.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income Loss",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r449"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease Expense",
        "terseLabel": "Operating leases, rent expense recognized"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r448"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureLeasesScheduleOfInformationRelatedToROUAssetsAndLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails2": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease Liability",
        "terseLabel": "Lease liabilities",
        "totalLabel": "Operating Lease, Liability, Total",
        "verboseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureLeasesScheduleOfInformationRelatedToROUAssetsAndLeaseLiabilitiesDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r448"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureLeasesScheduleOfInformationRelatedToROUAssetsAndLeaseLiabilitiesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease Liability Current",
        "terseLabel": "Operating lease liabilities \u2014 current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureLeasesScheduleOfInformationRelatedToROUAssetsAndLeaseLiabilitiesDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r448"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureLeasesScheduleOfInformationRelatedToROUAssetsAndLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease Liability Noncurrent",
        "terseLabel": "Operating lease liabilities \u2014 long-term"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureLeasesScheduleOfInformationRelatedToROUAssetsAndLeaseLiabilitiesDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r450",
      "r455"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease Payments",
        "terseLabel": "Cash paid for operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureLeasesScheduleOfInformationRelatedToROUAssetsAndLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r447"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating lease, ROU assets",
        "terseLabel": "Operating lease right-of-use assets",
        "verboseLabel": "ROU assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureLeasesScheduleOfInformationRelatedToROUAssetsAndLeaseLiabilitiesDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "auth_ref": [
      "r99"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for right-of-use asset from operating lease.",
        "label": "Operating Lease, Right-of-Use Asset, Amortization Expense",
        "terseLabel": "Amortization of operating right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r457",
      "r459"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease Weighted Average Discount Rate Percent",
        "terseLabel": "Weighted-average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureLeasesScheduleOfInformationRelatedToROUAssetsAndLeaseLiabilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r456",
      "r459"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease Weighted Average Remaining Lease Term1",
        "terseLabel": "Weighted-average remaining lease term (in years)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureLeasesScheduleOfInformationRelatedToROUAssetsAndLeaseLiabilitiesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r366"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards",
        "totalLabel": "Operating Loss Carryforwards, Total"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization Consolidation And Presentation Of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r6",
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization Consolidation And Presentation Of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Company Organization and Nature of Business"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCompanyOrganizationAndNatureOfBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r11",
      "r12",
      "r13",
      "r51"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities Current",
        "terseLabel": "Other accrued expenses"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets Noncurrent",
        "terseLabel": "Other assets",
        "totalLabel": "Other Assets, Noncurrent, Total"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent [Abstract]",
        "terseLabel": "Other comprehensive loss:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax": {
     "auth_ref": [
      "r65",
      "r67",
      "r197"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax",
        "terseLabel": "Unrealized losses on investments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r65",
      "r67"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Unrealized losses on investment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other liabilities",
        "totalLabel": "Other Liabilities, Noncurrent, Total"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent assets.",
        "label": "Other Noncurrent Assets [Member]",
        "terseLabel": "Other Assets"
       }
      }
     },
     "localname": "OtherNoncurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNoncurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.",
        "label": "Other Noncurrent Liabilities [Member]",
        "terseLabel": "Other Liabilities"
       }
      }
     },
     "localname": "OtherNoncurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income Expense",
        "totalLabel": "Total other income (expense), net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Nonoperating Income Expense [Abstract]",
        "terseLabel": "Other income (expense), net:"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over-Allotment Option [Member]",
        "terseLabel": "Underwriter",
        "verboseLabel": "Underwritten Public Offering"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments Of Stock Issuance Costs",
        "negatedLabel": "Payment of issuance costs for initial public offering",
        "terseLabel": "Offering expenses"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCompanyOrganizationAndNatureOfBusinessAdditionalInformationDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r86",
      "r89",
      "r188"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-sale",
        "negatedLabel": "Purchases of investments"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments To Acquire Property Plant And Equipment",
        "negatedLabel": "Purchases of property and equipment",
        "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]",
        "terseLabel": "Performance-based Awards"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r306",
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCommonStockScheduleOfCommonStockSharesReservedForFutureIssuanceDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfActivityUnderStockOptionPlansDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfEstimatedFairValueOfSharesUnderEmployeeStockPurchasePlanDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfStockBasedCompensationExpenseDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCommonStockScheduleOfCommonStockSharesReservedForFutureIssuanceDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfActivityUnderStockOptionPlansDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfEstimatedFairValueOfSharesUnderEmployeeStockPurchasePlanDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfStockBasedCompensationExpenseDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r31",
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock Par Or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r31"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r31",
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock Shares Issued",
        "terseLabel": "Preferred stock, shares issued",
        "totalLabel": "Preferred Stock, Shares Issued, Total"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r31"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock Shares Outstanding",
        "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance",
        "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance",
        "terseLabel": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r31",
      "r473"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock Value",
        "periodEndLabel": "Preferred Stock, Value, Issued, Ending Balance",
        "periodStartLabel": "Preferred Stock, Value, Issued, Beginning Balance",
        "terseLabel": "Preferred stock, $0.001 par value \u2014 10,000,000 authorized at December 31, 2021 and December 31, 2020; no shares issued and outstanding at December 31, 2021 and December 31, 2020",
        "totalLabel": "Preferred Stock, Value, Issued, Total"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r8",
      "r41",
      "r42"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense And Other Assets Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets.",
        "label": "Prepaid Expenses And Other Current Assets [Member]",
        "terseLabel": "Prepaid Expenses and Other Current Assets"
       }
      }
     },
     "localname": "PrepaidExpensesAndOtherCurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r91"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceeds From Issuance Initial Public Offering",
        "verboseLabel": "Net proceeds from initial public offering"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCompanyOrganizationAndNatureOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds From Issuance Of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock under ATM Sales Program, net of issuance costs",
        "verboseLabel": "Proceeds from issuance of stock, net of commission and offering expenses"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from issuance of callable preferred stock which is identified as being convertible to another type of financial security at the option of the issuer or the holder.",
        "label": "Proceeds From Issuance Of Redeemable Convertible Preferred Stock",
        "terseLabel": "Proceeds from issuance of redeemable convertible preferred stock, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r86",
      "r87",
      "r188"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale",
        "terseLabel": "Maturities of investments"
       }
      }
     },
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r86",
      "r87",
      "r188"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale of Debt Securities, Available-for-sale",
        "terseLabel": "Sales of investments"
       }
      }
     },
     "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.",
        "label": "Proceeds From Sale Of Property Plant And Equipment",
        "terseLabel": "Proceeds from sales of property and equipment",
        "totalLabel": "Proceeds from Sale of Property, Plant, and Equipment, Total"
       }
      }
     },
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r91",
      "r332"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds From Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of common stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockPlans": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period.",
        "label": "Proceeds From Stock Plans",
        "terseLabel": "Proceeds from issuance of common stock under the Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "ProceedsFromStockPlans",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r5",
      "r70",
      "r72",
      "r78",
      "r94",
      "r110",
      "r122",
      "r132",
      "r133",
      "r167",
      "r174",
      "r177",
      "r178",
      "r180",
      "r199",
      "r238",
      "r239",
      "r240",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r249",
      "r250",
      "r383",
      "r386",
      "r387",
      "r391",
      "r392",
      "r407",
      "r419",
      "r515"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Profit Loss",
        "terseLabel": "Net loss",
        "totalLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property Plant And Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r47",
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Property Plant And Equipment By Type [Axis]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentNetDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r46",
      "r216"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentNetDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property Plant And Equipment Gross",
        "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance",
        "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance",
        "terseLabel": "Total property and equipment",
        "totalLabel": "Property, Plant and Equipment, Gross, Total"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property Plant And Equipment [Line Items]",
        "terseLabel": "Property Plant And Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r19",
      "r20",
      "r218",
      "r473",
      "r519",
      "r529"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property Plant And Equipment Net",
        "periodEndLabel": "Property, Plant and Equipment, Net, Ending Balance",
        "periodStartLabel": "Property, Plant and Equipment, Net, Beginning Balance",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentNetDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r45",
      "r218",
      "r555",
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property Plant And Equipment Policy [Text Block]",
        "terseLabel": "Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r19",
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property Plant And Equipment [Text Block]",
        "terseLabel": "Schedule of Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r19",
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Property Plant And Equipment Type [Domain]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentNetDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Estimated useful lives of assets"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ReceivablesNetCurrent": {
     "auth_ref": [
      "r33",
      "r40",
      "r473",
      "r528",
      "r551"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.",
        "label": "Receivables Net Current",
        "terseLabel": "Receivables",
        "totalLabel": "Receivables, Net, Current, Total"
       }
      }
     },
     "localname": "ReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Reconciliation Of Unrecognized Tax Benefits Excluding Amounts Pertaining To Examined Tax Returns Roll Forward"
       }
      }
     },
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RedeemableConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of type or class of redeemable convertible preferred stock. Convertible redeemable preferred stock possess conversion and redemption features. The stock has redemption features that are outside the control of the issuer.",
        "label": "Redeemable Convertible Preferred Stock [Member]",
        "terseLabel": "Redeemable Convertible Preferred Stock"
       }
      }
     },
     "localname": "RedeemableConvertiblePreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCompanyOrganizationAndNatureOfBusinessAdditionalInformationDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r299",
      "r465",
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r299",
      "r465",
      "r466",
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]",
        "terseLabel": "Related Party Transaction"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]",
        "terseLabel": "Related Party Transaction"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionDueFromToRelatedParty": {
     "auth_ref": [
      "r112",
      "r241",
      "r243",
      "r244",
      "r248",
      "r249",
      "r250",
      "r466"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Receivables to be collected from (obligations owed to) related parties, net as of the balance sheet date where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth.",
        "label": "Related Party Transaction Due From To Related Party",
        "totalLabel": "Related Party Transaction, Due from (to) Related Party, Total",
        "verboseLabel": "Accrued expenses payable"
       }
      }
     },
     "localname": "RelatedPartyTransactionDueFromToRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": {
     "auth_ref": [
      "r465"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.",
        "label": "Related Party Transaction Expenses From Transactions With Related Party",
        "terseLabel": "Expenses related to agreement"
       }
      }
     },
     "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r299",
      "r465",
      "r468",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party Transactions By Related Party [Axis]",
        "terseLabel": "Related Party"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r463",
      "r464",
      "r466",
      "r469",
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r346",
      "r487",
      "r559"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfOperations": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research And Development Expense",
        "terseLabel": "Research and development (including related party expenses of $2359, $1,331 and $1,137 in 2021, 2020 and 2019, respectively)",
        "totalLabel": "Research and Development Expense, Total"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research And Development Expense [Member]",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research And Development Expense Policy",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchMember": {
     "auth_ref": [
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.",
        "label": "Research [Member]",
        "terseLabel": "Research"
       }
      }
     },
     "localname": "ResearchMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCash": {
     "auth_ref": [
      "r107",
      "r504",
      "r524"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfCashCashEquivalentsAndRestrictedCashDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash",
        "totalLabel": "Restricted Cash, Total"
       }
      }
     },
     "localname": "RestrictedCash",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfCashCashEquivalentsAndRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r10",
      "r23",
      "r107",
      "r552"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash Noncurrent",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r35",
      "r285",
      "r340",
      "r473",
      "r526",
      "r544",
      "r549"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings Accumulated Deficit",
        "periodEndLabel": "Retained Earnings (Accumulated Deficit), Ending Balance",
        "periodStartLabel": "Retained Earnings (Accumulated Deficit), Beginning Balance",
        "terseLabel": "Accumulated deficit",
        "totalLabel": "Retained Earnings (Accumulated Deficit), Total"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r2",
      "r117",
      "r118",
      "r119",
      "r123",
      "r131",
      "r133",
      "r207",
      "r337",
      "r338",
      "r339",
      "r373",
      "r374",
      "r405",
      "r540",
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale Of Stock Name Of Transaction [Domain]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCompanyOrganizationAndNatureOfBusinessAdditionalInformationDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale Of Stock Price Per Share",
        "terseLabel": "Average price"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule Of Accrued Liabilities Table [Text Block]",
        "terseLabel": "Schedule of Accrued Expenses"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r146"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]",
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r146"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]",
        "terseLabel": "Schedule of Potentially Dilutive Securities Excluded From Computation of Diluted Net Loss Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "auth_ref": [
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.",
        "label": "Schedule Of Compensation Cost For Share Based Payment Arrangements Allocation Of Share Based Compensation Costs By Plan Table [Text Block]",
        "terseLabel": "Summary of Stock-based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule Of Deferred Tax Assets And Liabilities Table [Text Block]",
        "terseLabel": "Components of Deferred Tax Assets"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r145"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule Of Earnings Per Share Basic And Diluted Table [Text Block]",
        "terseLabel": "Schedule of Computation of Basic and Diluted Net Loss Per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule Of Effective Income Tax Rate Reconciliation Table [Text Block]",
        "terseLabel": "Reconciliation of Effective Tax Rate"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r47",
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Schedule Of Property Plant And Equipment [Table]",
        "terseLabel": "Schedule Of Property Plant And Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r467",
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule Of Related Party Transactions By Related Party [Table]",
        "terseLabel": "Schedule Of Related Party Transactions By Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": {
     "auth_ref": [
      "r15",
      "r107",
      "r504",
      "r524"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.",
        "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of Cash, Cash Equivalents And Restricted Cash"
       }
      }
     },
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r306",
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfActivityUnderStockOptionPlansDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfEstimatedFairValueOfEmployeeStockOptionsDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfEstimatedFairValueOfSharesUnderEmployeeStockPurchasePlanDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r311",
      "r317",
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]",
        "terseLabel": "Summary of Activity Under Stock Option Plans"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule Of Share Based Payment Award Employee Stock Purchase Plan Valuation Assumptions Table [Text Block]",
        "terseLabel": "Summary of Estimated Fair Value of Shares Under Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]",
        "terseLabel": "Summary of Estimated Fair Value of Employee Stock Options"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r55",
      "r108",
      "r152",
      "r153",
      "r258",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r267",
      "r271",
      "r276",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule Of Stock By Class [Table]",
        "terseLabel": "Schedule Of Stock By Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCommonStockScheduleOfCommonStockSharesReservedForFutureIssuanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r182"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting Policy Policy [Text Block]",
        "terseLabel": "Segment and Geographical Information"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r98"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share Based Compensation",
        "terseLabel": "Stock-based compensation expense",
        "totalLabel": "Share-based Payment Arrangement, Noncash Expense, Total"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1",
        "terseLabel": "Vesting period for stock options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions And Methodology [Abstract]",
        "terseLabel": "Fair Value Assumptions"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfEstimatedFairValueOfEmployeeStockOptionsDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfEstimatedFairValueOfSharesUnderEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfEstimatedFairValueOfEmployeeStockOptionsDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfEstimatedFairValueOfSharesUnderEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfEstimatedFairValueOfEmployeeStockOptionsDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfEstimatedFairValueOfSharesUnderEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum",
        "terseLabel": "Expected volatility, Maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfEstimatedFairValueOfEmployeeStockOptionsDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfEstimatedFairValueOfSharesUnderEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum",
        "terseLabel": "Expected volatility, Minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfEstimatedFairValueOfEmployeeStockOptionsDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfEstimatedFairValueOfSharesUnderEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfEstimatedFairValueOfSharesUnderEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum",
        "terseLabel": "Risk-free interest rate, Maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfEstimatedFairValueOfEmployeeStockOptionsDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfEstimatedFairValueOfSharesUnderEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum",
        "terseLabel": "Risk-free interest rate, Minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfEstimatedFairValueOfEmployeeStockOptionsDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfEstimatedFairValueOfSharesUnderEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]",
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfActivityUnderStockOptionPlansDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfEstimatedFairValueOfEmployeeStockOptionsDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfEstimatedFairValueOfSharesUnderEmployeeStockPurchasePlanDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": {
     "auth_ref": [
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Maximum Employee Subscription Rate",
        "terseLabel": "Percentage of payroll deductions of eligible compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized",
        "terseLabel": "Options Available for Grant, Additional shares authorized"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfActivityUnderStockOptionPlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant",
        "periodEndLabel": "Options Available for Grant, Ending Balance",
        "periodStartLabel": "Options Available for Grant, Beginning Balance",
        "terseLabel": "Aggregate number of shares available for issuance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfActivityUnderStockOptionPlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number",
        "terseLabel": "Number of Options, Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfActivityUnderStockOptionPlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price",
        "terseLabel": "Weighted-Average Exercise Price Per Share, Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfActivityUnderStockOptionPlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r319"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value",
        "terseLabel": "Intrinsic value of the stock options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period",
        "negatedLabel": "Number of Options, forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfActivityUnderStockOptionPlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross",
        "terseLabel": "Number of Options, granted",
        "verboseLabel": "Options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfActivityUnderStockOptionPlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant date fair value of options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r331"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfActivityUnderStockOptionPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r313",
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number",
        "periodEndLabel": "Number of Options, Ending Balance",
        "periodStartLabel": "Number of Options, Beginning Balance",
        "terseLabel": "Number of shares outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfActivityUnderStockOptionPlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price",
        "periodEndLabel": "Weighted-Average Exercise Price Per Share, Ending Balance",
        "periodStartLabel": "Weighted-Average Exercise Price Per Share, Beginning Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfActivityUnderStockOptionPlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r320"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfActivityUnderStockOptionPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number",
        "terseLabel": "Number of Options, Vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfActivityUnderStockOptionPlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price",
        "terseLabel": "Weighted-Average Exercise Price Per Share, Vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfActivityUnderStockOptionPlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Outstanding Stock Maximum",
        "terseLabel": "Percentage of outstanding number of shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "auth_ref": [
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued under share-based payment arrangement.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period",
        "terseLabel": "Equity incentive plan, shares issued"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward": {
     "auth_ref": [
      "r304",
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares purchased for issuance under share-based payment arrangement.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Shares Purchased For Award",
        "terseLabel": "Employees acquired shares of common stock"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r304",
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCommonStockScheduleOfCommonStockSharesReservedForFutureIssuanceDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted-Average Exercise Price Per Share, Options exercised",
        "verboseLabel": "Weighted-average price per share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfActivityUnderStockOptionPlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted-Average Exercise Price Per Share, Options forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfActivityUnderStockOptionPlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted-Average Exercise Price Per Share, Options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfActivityUnderStockOptionPlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r306",
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share Based Compensation Option And Incentive Plans Policy",
        "terseLabel": "Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Award Vesting Rights Percentage",
        "terseLabel": "Vesting percentage for stock options granted"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period",
        "terseLabel": "Term of plan"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r323",
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfEstimatedFairValueOfEmployeeStockOptionsDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfEstimatedFairValueOfSharesUnderEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r331"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1",
        "terseLabel": "Aggregate Intrinsic Value, Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfActivityUnderStockOptionPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1",
        "terseLabel": "Weighted-Average Remaining Contractual Term (Years), Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfActivityUnderStockOptionPlansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2",
        "terseLabel": "Weighted-Average Remaining Contractual Term (Years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfActivityUnderStockOptionPlansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1",
        "terseLabel": "Weighted-Average Remaining Contractual Term (Years), Vested and expected to vest"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfActivityUnderStockOptionPlansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options vested.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares",
        "terseLabel": "Number of shares vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent",
        "terseLabel": "Employees purchase shares of common stock of lower of fair market value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued Price Per Share",
        "terseLabel": "Public offering price per share",
        "verboseLabel": "Common stock price per share"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCompanyOrganizationAndNatureOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares Outstanding",
        "periodEndLabel": "Ending balance, shares",
        "periodStartLabel": "Beginning balance, shares"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r24",
      "r508",
      "r509",
      "r522"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Short Term Investments",
        "terseLabel": "Short-term investments",
        "totalLabel": "Short-term Investments, Total"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State And Local Jurisdiction [Member]",
        "terseLabel": "State"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r30",
      "r31",
      "r32",
      "r108",
      "r110",
      "r138",
      "r139",
      "r140",
      "r143",
      "r145",
      "r152",
      "r153",
      "r154",
      "r199",
      "r238",
      "r243",
      "r244",
      "r245",
      "r249",
      "r250",
      "r262",
      "r263",
      "r267",
      "r271",
      "r278",
      "r419",
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Statement Class Of Stock [Axis]",
        "terseLabel": "Class of Stock"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCompanyOrganizationAndNatureOfBusinessAdditionalInformationDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r2",
      "r58",
      "r76",
      "r77",
      "r78",
      "r117",
      "r118",
      "r119",
      "r123",
      "r131",
      "r133",
      "r151",
      "r207",
      "r278",
      "r285",
      "r337",
      "r338",
      "r339",
      "r373",
      "r374",
      "r405",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r540",
      "r541",
      "r542",
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Statement Equity Components [Axis]",
        "terseLabel": "Equity Components"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCompanyOrganizationAndNatureOfBusinessAdditionalInformationDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansTables",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Income And Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Stockholders Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r117",
      "r118",
      "r119",
      "r151",
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansTables",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssued1": {
     "auth_ref": [
      "r104",
      "r105",
      "r106"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of stock issued in noncash financing activities.",
        "label": "Stock Issued1",
        "terseLabel": "Stock issued for payment of accounts payable"
       }
      }
     },
     "localname": "StockIssued1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r57",
      "r254",
      "r278",
      "r279",
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period Shares Conversion Of Convertible Securities",
        "terseLabel": "Conversion of preferred stock (in shares)",
        "verboseLabel": "Preferred stock converted into common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCompanyOrganizationAndNatureOfBusinessAdditionalInformationDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r31",
      "r32",
      "r278",
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period Shares Employee Stock Purchase Plans",
        "terseLabel": "Issuance of common stock under Employee Stock Purchase Plan (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.",
        "label": "Stock Issued During Period Shares Issued For Services",
        "terseLabel": "Number of common stock issued",
        "verboseLabel": "Issuance of common stock to Lonza Ltd. (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r31",
      "r32",
      "r278",
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Common stock shares sold",
        "terseLabel": "Issuance of common stock upon initial public offering or at-the-market offering, net of issuance costs (in shares)",
        "verboseLabel": "Shares issued"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCompanyOrganizationAndNatureOfBusinessAdditionalInformationDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r31",
      "r32",
      "r278",
      "r285",
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Stock Issued During Period Shares Stock Options Exercised",
        "negatedLabel": "Number of Options, exercised",
        "terseLabel": "Exercise of stock options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfActivityUnderStockOptionPlansDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r31",
      "r32",
      "r278",
      "r285"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period Value Employee Stock Purchase Plan",
        "terseLabel": "Issuance of common stock under Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.",
        "label": "Stock Issued During Period Value Issued For Services",
        "terseLabel": "Issuance of common stock to LonzaLtd."
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r31",
      "r32",
      "r278",
      "r285"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period Value New Issues",
        "terseLabel": "Issuance of common stock upon initial public offering or at-the-market offering, net of issuance costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r58",
      "r278",
      "r285"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period Value Stock Options Exercised",
        "terseLabel": "Exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r32",
      "r37",
      "r38",
      "r110",
      "r183",
      "r199",
      "r419",
      "r473"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders Equity",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementBalanceSheets",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders Equity [Abstract]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r109",
      "r263",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r277",
      "r285",
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders Equity Note Disclosure [Text Block]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCommonStock"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "auth_ref": [
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.",
        "label": "Stockholders Equity Note Stock Split Conversion Ratio1",
        "terseLabel": "Reverse stock split, conversion ratio"
       }
      }
     },
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCompanyOrganizationAndNatureOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_StockholdersEquityReverseStockSplit": {
     "auth_ref": [
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.",
        "label": "Stockholders Equity Reverse Stock Split",
        "terseLabel": "Reverse stock split"
       }
      }
     },
     "localname": "StockholdersEquityReverseStockSplit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCompanyOrganizationAndNatureOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r440",
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFundingArrangementAdditionalInformationDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r440",
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r440",
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFundingArrangementAdditionalInformationDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r440",
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFundingArrangementAdditionalInformationDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r474",
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureSubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Subsidiary Sale Of Stock [Axis]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCompanyOrganizationAndNatureOfBusinessAdditionalInformationDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SummaryOfIncomeTaxContingenciesTextBlock": {
     "auth_ref": [
      "r353",
      "r357",
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.",
        "label": "Summary Of Income Tax Contingencies [Text Block]",
        "terseLabel": "Reconciliation of Unrecognized Tax Benefit"
       }
      }
     },
     "localname": "SummaryOfIncomeTaxContingenciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "auth_ref": [
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "terseLabel": "Balance Sheet Details"
       }
      }
     },
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetails"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r366"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward Amount",
        "terseLabel": "Research credit carryforward"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]",
        "terseLabel": "Tax Credit Carryforward"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward.",
        "label": "Tax Credit Carryforward Name [Domain]",
        "terseLabel": "Tax Credit Carryforward, Name"
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TemporaryEquityByClassOfStockTable": {
     "auth_ref": [
      "r14",
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table of capital stock that is classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer. This table may include a description by series, value, shares authorized, shares issued and outstanding, redemption price per share and subscription receivable.",
        "label": "Temporary Equity By Class Of Stock [Table]",
        "terseLabel": "Temporary Equity By Class Of Stock [Table]"
       }
      }
     },
     "localname": "TemporaryEquityByClassOfStockTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "auth_ref": [
      "r238",
      "r243",
      "r244",
      "r245",
      "r249",
      "r250"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity Carrying Amount Attributable To Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity Disclosure [Abstract]"
       }
      }
     },
     "localname": "TemporaryEquityDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Temporary Equity [Line Items]",
        "terseLabel": "Temporary Equity [Line Items]"
       }
      }
     },
     "localname": "TemporaryEquityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquitySharesAuthorized": {
     "auth_ref": [
      "r29"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity Shares Authorized",
        "terseLabel": "Preferred stock authorized"
       }
      }
     },
     "localname": "TemporaryEquitySharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "auth_ref": [
      "r29"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity Shares Outstanding",
        "periodEndLabel": "Ending balance, shares",
        "periodStartLabel": "Beginning balance, shares",
        "terseLabel": "Redeemable convertible preferred stock, shares outstanding",
        "verboseLabel": "Preferred stock outstanding"
       }
      }
     },
     "localname": "TemporaryEquitySharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCompanyOrganizationAndNatureOfBusinessAdditionalInformationDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of new stock classified as temporary equity issued during the period.",
        "label": "Temporary Equity Stock Issued During Period Value New Issues",
        "terseLabel": "Issuance of preferred stock"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r122",
      "r123",
      "r124",
      "r125",
      "r135",
      "r184",
      "r185",
      "r204",
      "r205",
      "r206",
      "r207",
      "r209",
      "r210",
      "r237",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r371",
      "r372",
      "r373",
      "r374",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r420",
      "r421",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r462",
      "r489",
      "r490",
      "r491",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to accounting standards.",
        "label": "Type Of Adoption [Member]",
        "terseLabel": "Accounting Standards Update"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Type Of Arrangement [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFundingArrangementAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "auth_ref": [
      "r113",
      "r292",
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).",
        "label": "U S Government Agencies Debt Securities [Member]",
        "terseLabel": "U.S. Government Agency Securities"
       }
      }
     },
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r113",
      "r292",
      "r300",
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "U S Treasury Securities [Member]",
        "terseLabel": "U.S. Treasury Securities"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r347",
      "r355"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Balance at end of year",
        "periodStartLabel": "Balance at the beginning of the year",
        "terseLabel": "Uncertain tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": {
     "auth_ref": [
      "r352"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits Income Tax Penalties And Interest Expense",
        "terseLabel": "Interest or penalties recognized for the period",
        "totalLabel": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense, Total"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r356"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions",
        "terseLabel": "Additions based on tax positions related to current year"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r155",
      "r156",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use Of Estimates",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number Of Share Outstanding Basic And Diluted",
        "terseLabel": "Weighted-average shares outstanding, basic and diluted",
        "verboseLabel": "Weighted-average shares outstanding used in computing net loss per share, basic and diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetails",
      "http://www.vaxcyte.com/20211231/taxonomy/role/Role_StatementStatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 8
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31010-122693"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1377-109256"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(27)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(10))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(11))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)(1)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27357-111563"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL120254519-210437"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL120320025-210437"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL120320025-210437"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL120320025-210437"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.A)",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=122040515&loc=d3e105025-122735"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2420-110228"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12069-110248"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S65",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359872&loc=SL124427846-239511"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.C)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121483254&loc=SL120254523-199619"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28228-110885"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123602790&loc=d3e30226-110892"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "http://asc.fasb.org/topic&trid=2175825"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=123415192&loc=d3e39927-112707"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123341672&loc=SL77916155-209984"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123341672&loc=SL120154346-209984"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918666-209980"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408481&loc=SL77919140-209958"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-06(3))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e604059-122996"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=123877278&loc=SL120174030-210619"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r560": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r561": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r562": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r563": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r564": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r565": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r566": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r567": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r568": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r569": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r570": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r571": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "848"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "210",
   "URI": "http://asc.fasb.org/topic&trid=2122208"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3151-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>107
<FILENAME>0000950170-22-002281-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-22-002281-xbrl.zip
M4$L#!!0    ( 'R 7%11L0'A$FH# )N6 P 1    :6UG-CDV,C@S,#A?,"YJ
M<&?LNV545&_8/CJ(B(* *"$2HX*"=(?$6'1W@TAW2L.(* @"(UT"(M+=#0+2
MW1U#A\ ,.< P\]^@_M[WP_EPSOEVUCKC[+58>_9^]G/7=5_7O9?8">P"Z):,
MA+0$" <'!_0%^ ?"3H->@G"O7+GX I^KP!?O.A[>U:MX!/CXUZ[?)+AYDY"
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MS"N8#_,'EQ+$<O\ZZGWSX.^+1698@+TQ()6WX*)WH=/2C6U10$5(U6E.-R<
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M/,('PICG/L.[&V_/YY='Q-K8)9M3O_'SD<:"A-(/=7PO/0_+&?9DN'#]E#*
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M?['>O9_ 'Y<510\PRO=QZ&>C[!2"#;26S"0:UO'OR$>A+3_K=,F$,Q%C032
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MD63BV+^3 \Z8:[#)B\&!U^$:FFRZM>(#M)4Z[6G*XOXJ>"P5@##_1:#LXP6
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MSIBX."%,PZAC$$93SSPDX#V2G]I+Z-TA"=?Q5/QPR&9ES][59QVS6ZR /W)
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M> ?WA0GS'7G4WH$FY^R@Q&D!N/(FFU:I09Z5[Q5C?(;3UH*X4K0Q<=6<Y7V
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M[W7+=.^S&U)5LVPHOFU;)S(9-COVE]:4<:#F+<U5("GCN!F,>G!9R^XCP$"
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MPX:KD\W4+_@E9/B&4X8A'H]'KI/=$QDY+4=94.@_@OGI6UBQ!^T@G;%W799
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MK \/87LLB3',>9%SA0E.P(HA02:6E;2EQA:AY&.VAC%'H=F#FF+=N_ $I)D
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M.=;O?J;".>XG[1;4%9 ]5"R<*\T Q,F-YEY&FXHS_TI&/L4Y*,(I\A$CK>:
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M.N#-5C017/[,Z?KG:54?=H0H^@SIMYF*5K3UV3"IS*VOC$9D/,5*/.9S;TE
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MHMI#RYEUAE?;J@+3GHI4(WT\U38O@/-WF?@Y'GHZ9_@O@!"?\#%J"2!.\0O
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MXYR:)U'W=;0YQ-441?%]#]VD1C+;V +*.J 0N@@6X)8DFO':6P2:ZKZBUVK
MH[[EQA.K':Q?1VLKD>(\8O7TICSU8W-,'?ICMQ0)8BRVZ_0(="FJ#AYW_=X\
ML9&JD_0J-YR(I35<R*0EO(TC$=?-L^.X3<-;^?WIELAYDHCHXL3"S;FO?A.U
MQH2VV(<SF3/<+"SP4H:P"G,*RZ8K2V$K!Y2PQ3![LA1S7+W@..5Q.:QCKGW6
MA9/#,7;W!0!K[@S]#%/B^/^7T@4#M!+D(N%%H5PZD0!"G.<<^_S%EI[I(6SF
MF>2-9DB?.'[^W+:7O,FX98D?*=I-U*U61D2?>D?O^:P^_I4@,=Y&U>!L08,E
M;&O"T]W7$&J]@1=);J!N;]9C@Q_,.M[60)69T%'U+@=7VPC_*/-RC]ZKF.QS
MA>K9>23G%?W?U'5@9Q4MUV.]B<#]W([KP1B^ZG31E?GE"LJKH"&.B2[C7(N^
M,Q^]"].$E8YK?R=^4CPC)L$"S3]\@$@_/)B6K2QK%Z#56J99YFL[)1<SL\K<
M^UG-\.[A0LP?.!?8-]=PR+@MS0Q[ZOW!X>=FQE?)67W4$8:5W9SA?VN%WC40
M!N2?T;B)\PN*#ESQ5MH+LNYE,K[+4G<2[G]L)W=R>UKHVY-0&" =I73NP.DO
MVTJNE36^O2JFC=M:\^\J6-?0'YK4AR8OMWRAJB%7*$%AQ"8O L9H$GWK?G75
MEX\]V%05%YFN(IRHNSY%$A,)70H-R<>6TL+:9:J2&^X2+598,?A&$?L9GUE!
M&A";6\E3.3"F5J/G:$8JGB%+O++U$Z68![UZ).0U$<E5#VB&M3OZB-1,=+_=
MD%,AY:.\D>- J>IB']].S.+GCLMM_SK.0]N"4$2W+I?',M7AOR=I51"Y=UC0
M5HOR[>RPD#ZL;9$78U*"(KEWHO^RK_@*ANZB#<_%^P#=A2ZN,F.ZD84,EM&9
M,]@7\UQ%I(GLM-$VNI]V1[1+25(<.4:+DRG?2IMV&'X\VR<+X]@R%ZA,LE%K
MRNBOA"^W#,!#O(4=%^G['O2M/)K9:>%(7.72BK_#WF5;9CHQK7X;CY8BM7UO
M O25'X%;(1BT)Z+?*GCE=KZF$GW*9?$B8V$#&=G2ACO')/+67 /(W1%V2,NB
M)26;XR\./L58\2,17XWP?&?R(43;@J7XEM#VA;C+[6J3*4B5)C1#Q;476F@2
MKWW$1I$4$S1$,L"[T_JY<>;Q:PF75"QK8T9)2VO-[NH2/BIG=S;#19Y>42]Z
MA/2Z8FFDZC:HH<.R#0<.]V_I(D"KL>]:(R?G1>U%GNCS+[4F%]&EU[50%+_^
MK9I %6'\5MRIV4O=[G #JQ&7<\:JIV,G%!;++.?LLLK%EPO2,!UY'4%HI>?'
MO:W4FJ 97]Q!PGND7DH6NGM?0A*L%8&L5Y4D+![_OZBJTUA00Y29_Q6/_\8+
M#_9]A\PZ54J3J3,<NGT8IN4>9I6>E7Q)&,:[[D97QYM$GS<EH[_DR#/E0BXR
M%Z1;5?(8%=-CLA6<E/0-,65WHIDI%UA8())QD+SVZ4)T#P7[JL1)-O(*OW'Q
MRPASZ':W@F?HW!3K<!D&85)^^UPX!P;AO&4M*Z:_5FJU):$S6C?1Q;]U*>EL
M..V!9+TEAJE@N84>;]))X9Z:]'HRFV?V8_$YHEA]6^1C=0I!5ORS)G:JUPO
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M]\B.E,A\B\:O*=&#B,I9\T@L>TX-X]I?-(,5)_IN:2Z@C4\@1#U"J_Z*L.=
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MB9_SQ<H]K-^^D"D"%>E> %##J-F&9*3%)C;YK=LF-H57:B*Y0!J3CFI5NGG
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MD)*_<AP_)@7,F7O]'>$)?09_T[QS[_R"\WP-?5L"CZ";_(!N@W?W0^J'\RZ
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M&(.YCN]CV)6^$;9=-^#$#$1Y]".SJ(>7;=L1Z_[ [RM 1*-YC/$F.5\?F+T
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M ++NGZ?=:'HGB;X@6/A_Q9J\:R6^BM8M/@L<*C2APJL3\HR.2"%W5WG[27Q
M\%W'PI\.MX4UC3M1<^(X]9.G6]TC3)O2>23>@)9/G?G(X+8KJ?&GQ:O_ !Q<
M:5K/@/XQ>&?"NCS6ZB[TS6A;K<Q/N)9@LB,Q;! V\#Y<@G-3S2MH9*I4M>.E
MV_ZV9X#X=_9;O_$-QXVT<ZW%;^+O#9+#1EM]ZWD94,CI*7& W3[O&5SC/$%U
M^S]I7@:X^'K^,O%2Z3>^()1-/IC:8\_V2(*64.5?)+-Y<9&T8+L<D(<^@?#+
MQMHWA7QE\0_B;XA\;V/B/4[-&L-/1&2UGU1PB#>+9<$)\L:@@$<,Q^[FN?\
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M)GN2#@"O5_CA^SSXL_9Y\1:=HWB&>RN_[0M1=PWFDRO) _S%2"S1H=RX!QC
M#+BK^O?L\^(O"?P9\/\ Q(U:YL+?2-;N/L]I8/+*UXY/F$.4\O:%(C+9W]"O
M<XK X4T[,\NCMS(P+X+CC@8K3BM1Y"_+R"6(]0*LPV(5DW1Y##CM^%:,5F8T
MW*,+T([@^HJTC91*,=JEO)"\BYA;.\]BOI4$EH4W)C:&*[)/[H)ZUT$]H[21
M.R!8>%+;<JV.OXUI^ /#%AXJ\8:?IFHZ[:^&M,N[CRKC5+[!AMH^H9\LHQD
M<D#GJ*935AOB3]I#Q'K_ ,((_A7]ETU/"]I?&ZCNHXY/MCMYC.0SF3:1N=N
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M 1+<1=,KY((;W(.1G\*BUQXFL;6XMWDF6']VF]0& 4=3COZ5T]]X?G*G:%E
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M[&UDL+?[-$MC&Z*5SG)W.V3^5>>^']/E\0ZYINE0SPVTU]<QVJ37+%8HV=@
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MW7B+RE:\DT"" 6]J6&5WJZEN00< DX(.!D5H:#^TQI?Q _:"^&&G:?IY\/\
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MW>/<'0E&'#H0P^M0X96 9LB@"T&&[GCVQ4PD$<GRGCKCK5.,E9.3@^]38;.
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M&\)Q0V^AH(=/LM)1;2-A)_K%C?< Y!P6'/%7_A'\4#I_["OBG6?^$2\+W/\
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M0\3^&?AM8Z!IWAY+I?[.M[YWGO&FB:,F6Y="S;0P*@J<?,,\\+X:_:0;0?\
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MQ(%90V8T4]'88SCFO'M,TVXN+H%(SC/6NRM_#\KQC<<?6E&*WL*--7O;4T?
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M6@M'L8^QASMJ:.!E7<1BMC^R0\>0P/\ NFIX],EDPI3*COFBP<IEPQ.JGY<
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M1N+T0QFZ.Y)+YLK3QE1:;YP<<@M?Z'BZ<O8F5)IY>0RJII(Y]].X;EZ^-H=
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M.WC=]9-0IIREOM],1]ND('6CX[J?,H^;_.4RED8^-N2QJT:]^_Y;3''U*0D
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M*H)2^9;Q@YD4 =/9F9IB-*"1'5G1IE&=;*YZ!VS3139:27#Z3C0C%PG01>_
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M*$H(;X<;1H'":I,9=DW@ER="'IP9YY<]L;^/K)UX%Z#T/3"0T8M)3)?7]^B
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MA]AR#'M9_5N[+<->HT1.K=\9L?MPBA )XEQK<H]Y G3+'Y,-GH66^XS#WY$
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M"::;[\[3B5?;P[+TU'Y9;JG1&]CI[MJUR.L76<SKS]+M$[+6F\1SN&#==>=
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M Q,<:RY(U"ZB2\I0G6@(DBC:2]XW [>?M5BH4^RW,Q["M9R>W0"<Y1@LJ>L
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MH)8_(86FN/T2G(H6]L4U^V01Y@!>/&JZN#3F,<4[HM9A_COQ1[!GSLCZQV>
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M73-5Z:>G1 +2^X<];B,F;^_>:$<%,PT%&0X-TU/OSJ]28DHC&]>B[ZAKT=E
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M]/AMO"ON4'VC4C<40Z*#B1;<@^+UYFX KE%29[7S2+H](#*LNUS8$&6^>:9
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M<HM58YYAOVEOPIG(9.JW!3(Z# B%^RY0IG][5;>WY/BV4+?YGOMQ@@S'\W?
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M#V+TB2)4A 2GQED?&0_W4M)FPC"6*O_\.O<D__/K3QI8C9&ER,64T;!WY;L
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M-!LSR3\T]V8#<U%")VI#2:5G%%9WS1MK1C)W(>3GT,1.>_JA+6+H<&MMRN=
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MFHB?F61MX4U+\; T?^.^$P/Y-@<7VZO]UQR)0NJI;YG^#];>,BJJ-WP7'D1
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M[+B#[V?"QW,9TY25;-(#Y-QY-'#)M)^_MK+T\'A^G+D8B@C2D'\EQ]3P/SH
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M-)1^5 (>,BZ2'L=)[+_5(_JUPHY[@QX>"_H'H#P5\!6LKRB%-4-?]^&Y49Q
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MMW*HV\U::CM=,90+<W20<.&_(!=7Y%:">WZ.6M5K/+DO\#<'6LWP!5#5$Y!
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M>*S*R6\HJR=!@'\1F\9-.M(!$% "=:\YQ]Y8K5F%K!(];M>AV^YJGC)U*(%
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M J,+<A%#FR_83/N3"CDM*S>"A-[N;;8/X'YA A65SZRQHD$06AM>!\YT2:.
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MV6:] EQ>04EQD9?21YJ2?PZGMLL,/ST/TV8F[PW7']QNX5"%9%W*7$\TG_=
MB7&-N%V3COE8L+LR@WT#:]_BR#&U!9A0GNY%IF40S7E\@'\>6,; /.(##MC+
MR0>E!3(Q^C VL*ZG:A)\&6HE.7JWS_8QJ%-A?WU]L]7<Y"JJ%D8+]D EI 2@
M2:$XE?G!YG2A^AN XV+Z)Q4*&HES*_?O[.TRG(\%O0A';@"VR%@E18QT,M;[
MLD_?KR!!2O&!I^&TSDS=>W)CQ:G?4Z+I$D[A^GZAP; O;@G9X;^NESZ=F]-
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MQM%QG$?"Z=E66"M7'IBI1UJ)<U*H+Q5FQ93LXF3M>X=?LW^+#Z8[DW%L?^M
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M+1E/GZW<>[H&SW*5O5UZ@&?";I_5:RQ-9%F&#LE.J-[$2<4^M-9D4/C/14U
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MG9W +:)<6,&Q?3Z:#OE O_.(S8EL1/_TJWFU9';6T,&N]9:']MD:OWW! ]\
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M!VXXW0"60B7(4O&-"S8]$ $D *<?KCT)<*5TTLCO+;V4Y$$+.Q3&(TK.Z"Q
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M9WU"GQ8.F!OQK0V_%=&/K@T]@3Z;<H5<BEU'NCZO*0XE$J%P[TGH\*/#3SO
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MKQ8Z&'%PHX,-+@.[""AY9;A\;,H18EF?^&#OPI[]46ZOA8H<"/:N&8X&G'W
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MD'ZX5W[@7]+N&UR&#=!VRBI>$+)*5E&UL/#E*"3Q6([L=L,_ZE:6KXSHS=2
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M6-G$/DE0?6 \NB)[\O\9@OP_!>7E[/\"4$L#!!0    ( 'R 7%2;,N+5<A<
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MP:;G7F8?O_;4'[>TQA0NCU@4[;;G-[UF@N@DU(_+;4;S&3_6<1![*J8<Z'#
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M:2"4R?M@+6CDCSU]UCP6R7H5/P!U2B"1=1I]7)QG\#5/GXTUT0D#*VB_F_:
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M?7I+@.2N2Z3U2)AWRN%TJ,@3Z0I$VB__GQX1_2^<O;3&YKI./$*6Z$]F4 2
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MY,6:=D+0DYC\@WZ?/QYK<9Y#3GGTUTE2_&" U+0QESNE%E&-<8VZ6\8OZ\U
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MIXH2 9"<^I?N@F;-NUGI)8$V[-%1ER'Y6\V+_\FW"/\/8#7>E_2'7MKVC)D
M4+78K<K$)A, O.I5>!0!L./Z@&WY2MDF0Y\2 '5FW2=$%DSY:RM_F$_&SW_'
M$0 /F H?D#(:_$/!4=XO_H=.&G3A0  4&[:W;ZK<@7Z-J20 %L4OV=)F)_YO
M#QBYY'K-(_S O':27L<%XWS@NV=E'J+VO9_=1W\2X83%L1H0O:N!],<;\1(
M;$I0 N#^]F5D3?>IR]X.\0<"X)U_'P%P(@O=O"^.*<;3K3 0 !-+!,"'K]T#
M[>VW_^GQ[_:(ZD9SP2I_+/RPPA:/ID_BOEI>*),-K.>QYX776/_MVK6UL8!-
MT!HG!G1)L_+G:1S.Z9_V?Z\=99=J,PDQ+URPV<]'/IM?#CFYX/>TLP_@B,\K
M"?2I1;;IT4&_GJUQ7T (@,E'[>T D0\8WZW*RZZ"W7;WPLO<TY6F@)0_5.(_
M3%X@0I0OYDVMRJ.[-X+029=PZ$[A W(<'UR( "CL( #N)$,3N-&)V'Q\Y!&N
M3 TO/3MY=?+_T_[_)_NSF4[FNKW3^PM+V*I1V(<7TQ<*TN/R>^S*:GX?],EO
M>:S9TELL]I/8B"XPNM Q7\A(AI(!]@VAO8HHZ#E[]W$F,W;>5 W@E?^O=B/U
M3^O_UZS>*J0SXD<UOIJ_J;I;1ITKM%T$C^>4/D4<P#?R!]I=-I6(" !)[LO(
M6NBIQ546SL><5OH6877/3X=M!;= XG:'-/%?"] /.2D^_<UN((97E0^#$0'0
M8GLN+5)50&OTM]DGZ6]S_=[./SW^_1Y"QFC=KAHS;8<@5)T"\JF'WL'.O!Q/
MHBKQ#"6, +A^%'-5A;H3 ,/VMNO6UHQ$P__ZV$_^T^$_[K"-OQ/7AV>;<&\6
MQSY1F=XXO)P_A6CG?+;I/#\W+3"]@]'&/];1PR] =V9J:_]#@D]>CYL ^-9&
M +RH\KC,:F^W?S\HLR+!=/K9X8=DF +=D=[?\7#NOPU:HS[;8V6L!GX%=*)_
M5;'<!M3^[3<?)P:.^>-CQS*1?5YM^^'(4.Z_2Q% S@@ FHR2EB14]PT-]-$@
M U:Q%UFSG%H-3KGN\T>T1J=ZV?K;%E.GK XU6,S\EM!S(0\2TXZ=]MFD&"E7
M&LNG[8D7.MVPQ+VY/88/64+Z7_>"PDKH?A=0-?TE%Y_9QOIV8]4[):OV\'I(
M:./!5L>QO]LOI291F)S<F$0.VS:<$J=) $3TH)-ZN63Q8_BAJY(M_&FXX04P
M?SN ZR79PI:;]?<QR2;'"7URU__]XZ0;^70ALBZ!W/UNP+7R\$YI-Y0'RQZ;
M%?)@_].>1]GWA5W,5][[2KLD/\>FVGF+!@)3OK6RARJ[QQXGW<3N#RKXARO)
M!DZ 05^0E^/1HB>'C^;[+1JU':4[GDXV+.BPJ/)/A98Q)=_(_0Z>P17G3T-?
MZP&60R;R;F$MO5'<--_'2WM</MN.U"U&=G:G._.F]+R04X&\CJ4D$\T 5"@_
M4%Z.W?#MCN<B1H_'W>T4K<(N(MI-8XXL^)LG/9I=P1Z.SNRO']YRI.U?W-0G
M%WJ;M5\!*.H$X9GGXY1LU\<Y=D"T.(IR;.)(3P:=\WD:OKFN)7V>N>9&YFI3
M@MLK^M?J\<QIA89';]/8]Z>EDZ*76=&=3DIJ=<XA[&TRXI5:KE6V/23UEF63
M=VLR!OK$"G/H"SYO)S_@%&!*6!-G P<-(N\&#D9*+TGV!3ZN'N(J+%G6\'4_
M**<F2:XW?+@:CS&W8<+VK((X76'M0I&=;FLK-_9EA,=]RYTMFKM&^]NK2.SX
M/=L<B**-WM_3Y'0BKBUJ ]+AGJ.9PW$Z#FNC00-XCDDEU4 ^F7;=TBK+Q:7Q
M+7G-T\<_.6'WA._1:O)X6_DU8])M =A45 (!$->IL^KJ009V&1L($G$-UNS_
MA.RLE[A30<&BP9W+&Q'N3A7_6XKH@-%TJ)N" ' 69\498T%%8"1B<.6ZVE9E
MA7.,9_&/I@D:+L4HMU.CIV(;]Y<;/IC-#%X7JTGC"56)Q(SWCQ-#Q(.D,!D)
M2LIK@EVT;J96L\\;)-\-'.>YUAYV9,CMM@9.D)NKW;^3 DXQR[5/^.+@*T\-
MY G_8;3SUZ^)B#^@R7'?H*=L5[%AP;6JZ$IU_*V(GQ:,5(S^YE7T->I3ZU=0
MA,K_%%KJ9+%MF#Q@9'M4) Y4[FP(SAY8OIUG&<S\*-(W5'NS,, Q[QGY,"SA
MC<V#6H17A,9+QM! -::M+/^^)":L.^=5$$391C1!*<#0I]/V,QOS)] ;G+IC
M4G&9AB]$FYN^7H3X+C!&/X*;FPEW"Y3@WF#S41[D/>MNS*LX!K#A%B.\N;X+
M(Y2,HHJ[3^QA><L%36%.81]1^R'_@X0Z/P (+FJM(\&]1,/Z@.]:0/12"8^U
MUK2[E)LE_'F0=C%,\6\'0IX]JJV6[#%4-"6]$,5/ZUVH.6>=G29%"*!U.TJR
M1:*FA+J8=>=,TRN]G=^8J6?[5\G="6\N?I'R\ MYFX$:(^#?!O@L3D5VOP83
MN[Y6]Q9RQPZE'*0WN3[7;-GE;18L-CQWQT&BA[[3;Q[(7]>B/IA^0]CKCZ(3
M\7>G6O?Y >U2[$T0'7A,T98D6A1WJ"5-\XC/XZ4&37;\.XGM]]O.//&?<BH\
M(O&WP;(#-FR=F)MO44M *_1E\GMK%Z1[*4U_"2FCTMM-=>$.XTAYI6L4J% %
M%Y$L]%'?.#FVPRQ?:Z+3M'#?HJ:K2;;1;!<9+SG.V5E1QU@=W1^FH'"_GN7Y
MWD.>V/+5I/@5(%[0Q@H)!@VJL&.LEYI>FJ]._ X*&HRA^/+*+#<V'I/Z@#.!
M:<.VD0#HO[1$Y8[WV\\]_]P4UQLBTXU>RC8O+KLPNP5+MC$<6TB5E-%$MA)O
M<FS7H$$#X@"<;GM["]H_44D6-1)G3&^E6K@W=U9'F1HZQNLG3+$N&*I(*1*.
M\1\<CP0!?Y=/X@PP[+TA[+/K:LD'TL%><W.^SUB?20SQ/+^^P>%M? +B<K'A
MP79S)N:CQ$GV;,C;T7T*_6G-";^T:T;Y4]]G/#2)=WLYB6X0%[A A2KSQFZ\
M#KD'!AIC2I:!#1A8E#O.DDI!NZ"GZL'9SE=9.2?B/Z$5)#F)Y!8>.#$0@ #H
M];C*VHXX(2[VJY".@&9<?2( 3IN[3R,/LT\O\Z&9N?DR,B?;I0 _1M,4I^Z;
MS0G:IT48#82S6[6IZA1.PJY&]4UR-]+"N58P838[9"KT<2O1PR&EK-_M_W+M
M^G\ZY2;_W[\P^I^-D-<+L#Y1V5/'RP)?&G&#Z9]*UY1\49HXM9+ON_%9VZ>6
M-O=7AIP#^ ^O?>41>]15_X5:E0SINFO+M8+C"V9>TPLW[9'MOOFR8TKIB!K[
M;/AV;4W)=%&8^,E0<4>6R%/> .$4W>7GDG3<*X&G("J<$+H\W(<S2&U*ZAUL
MZO?BXJB&84N*LZ!ES,^/S0C.@SYR?EPQI>07IF\Z%^(XN50$GFYR;?+H!*LD
M1(QTRK!XU09U#'8@KIV+<%_+=91X#[@]Q?3'-.G#<^(U H!^CUF& /B<=&A;
M.%BV O9X,J'T0KDVM6!YA$$ER7W*;/34^-@^15HM18OEKKNQAYST4?<-%3:L
M]VK2(?>%BBU84E>'V7!>6EE;8^[W]>_-<\W$9IU]*T]U+RJ5OAOJW3<<;67(
MTPDB 37 >A<]HD*$T7=5F#0[15!QR0'59@*'7R^L>E[:WOO*OUP-B1YA>F[^
M]M70*Z$FC"PB'PA&]'&QS$L'@PX#RR-K2[JFRG^5Z#4^Q4CI+IJ$P0V^O^CA
MV&;="E611^<CNBEQ+[&V%ZK@LT&TAO>Z"/<-<&2/TD-/B=@SQ-R<8G^3#(R5
MYG5TOCSE ZCTV<]G/%LX65C2 !YX&:_"N3\E!2>;@XC[5KI8*$5$M#1Z.CL0
M+UKJ$ETSFX<TLE@*X_5_E(@&FZ/$%_+7NF-Q6I]<+<JC\H(2S(M3C1IUU/=$
M00;@ 7KM*OX/EC\4UMX<JW^CO#5FXGF5#4XA:+)2]!%B^7KVP\6KX::]S-D9
M(3WLDPUT?9ATY_#GU$-/AE")+GMJXX84U1L/E,@N$ K^O5 D,PH4#@$ZDD6L
MUIBN18QU58*#=.+57CA7E*PX1H(+K#2H1J^_EYGE<ER837R2:B,JU NB!4-/
M)2YSE9Q+'_J68K>VC=";'>"&L9]FOQU@';Q(5Y\.FJUJE:?C;'TLO-1NQ$QG
M^>_P%%C9'@O_:#>I4;%7'C<2VKOPA5#O8&@%$?>'(M>VC8 ?=Z'"D5XW.,2$
M6>'$V)OK:V>1G72"41V]>/:LL?4G]1=6ZP='+CTUXYG=00?"M)S1<G\:'W#=
M*0#+JF*5+[R=++C#3CH\:)S@O&C1S8&J\MT=WK!C%/+X%DU?K%Q :)Z^P^L.
M<GE!^*=:]_VU\:@Z.,\N7BY?;P451Z/B)H:\&'O_NB5M<B-IA.;S9C(MJB3^
MC8;TU/^ZR+01Q62O)H6KR( 13U- C+9@/10TL@8^^:(:;&=D&?QL#.FX>]?V
M7OJR1G1"0Z%1RX,2=\B%CE>(/%9CU2,6^ I_'VT;U6DQ]["_RC7+F+D,@%UF
M&%5?['#9YO1+>@+ AO>!&""F&,E5T#N]N&9%$/T2%KH>F5%@ :[2@UF"I2]<
M@[[WVE0[?[#^-O9._8E[S&>=H)4PO;2+8)R>QA\N6Y*=!O6:'E]FYB=F@:'@
M\9J@'#PQ>G0NIF1G&NROE:$QQ;6L(ZN7,B (:W"2V)"22%MD32)^H2^S:L=$
M'@UGPVH,L&TEU[@N,TU*=]EIO-<IVV-+S*7I[X^+I.5BY=16[TFS%'XX'#ZC
M3]X')0_AO*HL8 ?;&->'<SC/U=QKXP;STEB( U?76D"MQX&8RJ38J[S]BR?\
M2QPB),D=CZ_Q:IR%V5_:.@KU=5/OJG!,04"E8-N!+.O:;%>299Y9G([W"V]_
MW@&FS1L:+]Z4R,@2;WMWP(RZ4-QAW4 E:Y23DE8M%HA0F(]^+O&QV4U5 Y;W
M4Y+U6Y"#CYA,GCJ0LZJQ /@!+H^[,W'2VAF,J5KSZ"?'>JQS*K!&=@38^=,L
M)U186508T18["^[@-O4GR0P3$^Z\9&U5HEF)]TF*SF\&'I2C;&/8K!/CJO=M
M:#J[FZ<]9M/EI!TOI)*+1$[>^']$'+,(JKPI@S?/P<EQ<ABA..9^!1B" *#:
MRQ,TY\WTK5JZB72=P$30?<Y\#]<7/I3_BI28:NV.AA+9HK@/2==LF5U:VF5J
M5O>!M"X68L4E>YY_1KWFZ;_L*)7%#V!0@F,H^4'RS^3?NMGS36[@%^=5B(/>
M/F]73^)<=.Y^8QOGCY^26'V[)5H9-]HS]@;XC5;9;WY-E "(;0:^S>-KPV:O
M4GD L7YX]B1*(#76PEI&>]^_(5D%X78W*P<QG/+]YNUH+3.BG3+X>W3=.RGN
M:TY^Y^*133J*"*1TFQUM;JF%AJL'ZZN[_7;QI*POM;YLI+A2]7:3AG"!F?L8
M]N'L:.Y("*AFK#9ES^)9DH>;-V\'V9LI7K);T21A 3SZY!$AW^C!+_=[H)R+
M@Z[E[.-8'=]ZU";F1M+PS6$L[!=N)>.@=T*M$=3QG59NU-&I^]@SOT7V,D[E
M2F1/^_X.9D !PVV!.'-4G"W]?AX9>KD1I6C$"IO]3<.['-3ZU*U=.56!V;KF
M:\_JL8B#$G?!8*6K0IA3EHOMOH$&6;E/2W*,1W&"N9W6(FNRB?4,&3^@C[8L
M5(5SKGN3.[_1]#)2B9, *+TWWPAA2!E;/ZVZ+)JVU8<\:G"^XP(KQC_O?FG$
MG=H13I'SXVAQX-C?VV:/  !VB@I%G8R2XJ1+5*+*E.Z;.2>\H&MI<M*\UV3@
MAHRX3OKD;=/;>!,@!X0;S=VW>RB$20J#***&:IA2EG6\M6!=3B;1=V\,)S31
MDSW8?_N G8L!?S57WIFJ7[W978#P=-WUJI<9EZF-!U"'X_FA8Z7NU.$%F/M*
MAKM$OZL1;PQ/#&_,3;D)4F.#T((W ,[_AXSX5_B3A/I]$D)TV0R_@879MB8.
M]IZW1%6"+9#GJ^_":'2U>/-NYXY33O/K5E",L'SE^'WNU?C[BN!NB/!D[4F"
MAT[CG%1VGX35][T;_.BG49\ZW2D_G_*&*KF>CD^_PLP?[&+XOIPSS4AB$0;H
MP]'-O 3&_=.1BI?VORC5<K^5I"7QV/G$EA\! CVB5MB5Z"KPX^WB?3X8THCN
M< :-V)]N6J771'P?4^Y@=W:^%.IULK@-@&NSOZQ00AC07>(,/7#@A!(_K)1F
M:B?0_N8CK\SOML,F2S!O.V59;HNA&9#C2D0[+$8 PW2$L+UN PXSAT\+UG@6
M(+NF1P@ 9>HRY?YNY)@3\5HU-@FQ@M8C *(( )J30\%SO9L0JSGWXJ9)48O;
M/]>G:MW+NEI%MMK5@=_1Y=ZWR=Y0L AVR>@QNT"IN]V 47B^3FQ '40%G930
MY(L6[9FKE=I.J"L45WZKUV ]ILID^LY]\3V"=9#K")U_:HCU1UOV(2/KUQ+$
MS)XY4[?[Y0?<;FN96$ $%U_(R8FZ-*9_BTUH;N$!D%[K$N]389Q4LO9P)NLH
MWCV?D<F06%X<K+ HV:?I<Y3X]K8'N:>K2JMA]X"MZ7]3##*M=K.HD&*-4.4)
MM9TF:^.<2S@5;/U:E4!+1I\*)SQZU(-81(>:+:%J4[!%[*:MV(/2/CM:,M?E
MJ@0,K <:M<(@O@K'1+U5DD1U+(([/[K[=G$M'VNN#RDRE:K?\M+ZLLX_0=X'
MRV?H],4$(4 -IVTH'5/5SPFX%Y7F6BA1;>V@7'8#."P6W%0UT**UMN6H#F[Y
MROC$)"->-' ^#LZXE\?<B<6@+J&#(1RSG5HU$*64%?T))>5BE<PVWL0#RQ4]
MC@P8[8%&+F7;ESY[8/OLR<_F-6N&OCRN[ >S3<$@XXGRZ(=B&4$NJ99:+ -T
M1<^-*[ZLQK\1$4& *'!TJ[G$^A.=RJM'P!T%P>*.PW;WS-(>-S?O-AG93#8>
MT^'0\C?R'#X%P,2KD;G@IH+VB(=P+'ZWZ(J*/)(ZHEX!9U;_:COXZ=B<;9 V
MOGP+-\2FVRVBHOYCOA(_F=[^>(6> 'C5BA.\.]]_ US*/TT -%[ST"$Q?RK>
M<KAJR7C,N![_,?305F,7*9A;O-/2KAP149.>ZNK>\M[,LK>^AUJX\"9_/,VG
MMP_T"YX3Q6YW M'0+U!JQX[\GF4*]-&[K0X3[1@I9<'EH3(3_@IO>K%5"CGR
M,AT A!OEZ( 5NE"-*Q8&.\.52#'L [K,3^[OYKN()_UQA$7NR:2/L]850IVT
MK>][Q*\T^H0PW1Q!52@].E:]S&/P<N)^D6,3O/R>X=0!_Q,5ZAU[#M1!)T84
M]7\:+-]I#XX/;/Z6D15K:3'(TIFG1L7?2$K\S<]$W[Q!4Y\"U: $1$=]R:=V
MZ,SH6::\ZN1&)R5,O'!7WYRU=^-?^BC+X5BF5P,(\46L!S,,YA%A\]&>@A,^
MW73@?)0##HW-M\;0IKKRW_)5XPUPX]JQB4N[T63 V^M/1$%=&&U;%,([5(6X
M< %?XE0:53J[2;2=]]TE;[6QI:U\8+ZLN? \TFV^S(.+.D-)<);HD-LXX*>=
M9=[VF?3U 61ZH9\O621^;3-ORQIT4)UJS9.ET]9N<C=YHX+$=!(.Q'H4@556
M-%)$1(*Z/'0F:T[$#_?C?&1_(7O)OB\_EV42S5C,[?B88S]!GAHRU(U^JW-Q
M!W<S1?P@YBZ^Y]5<0L!F.O[[[17GV[9X&_B$.\SM#XQ5>7^+ $#RK=-A(R[$
M=A4(@$@(PQJ4 J><.N!'C#A+V7<E^^2^/JN1R6\!\2OC3\L4R_Q@Y4&QI4C]
MT^(B2ALKB28 5#'Q>-'I3IJU#B#3.'_*2"UR]R9F1?/8\=NK7'UYT=36U#%=
ME^I\HA!6[>J]P Z< CI[#YG-W-WM1CLS[C=@\B'3_OA,_CZOBEE^IDE[J!/Q
M,$2$ +A#@GU+ +PD2[U*7ADF)PFO$&NY7"M]S&PG%B;Q@9O][18ZE:4-5)DO
MU.\F2[7^,-"6H-0E>ADTE_9W*4^F#6B3:?^HW5IM]IHH=^]<"\Q& I/>0?:V
M5/I<$HE,-TUQK4PS-Y^Z7>SWO9I*PF B1=FKD^^T AN$XK[!'64CBR[+$.RN
MP0+[/%V!10AA#='+[ 'TD@:%5^4VR7N%G\]I>[O,],FMUT!1*C)H>%NYC37.
M? YB^;*^*3 RNVY7P2G1J@Y(C+1<[!3C ,)?&49DO$+5PN]<@&#]'@DKE$>=
M-MVLTC62-M;>QDU-GU,UIARFPBQMM1D-1E@:+2,?)4>X-58=:SYW7502P(P_
MQ0PTE^]FZ47@7C=:\6E[R]2LN1X*4C%2Y4YI!W#<WO8TIJ!('GI]^+UV?S6_
M8;XO!@Z$<,'1<S6K'MQ6V!J(:K6.1\DB%F1(X;V]QZ#$T@&^.<LT._,GZ7Y1
M>/ISH@+@ S3H4+\]Z@"& L7@[TRO3C;G4VI4(%VS?&@MF&;N9JZGR,5!%NU]
MK4-SDN[=X8_/25J@0D'[:#1L,%&(\=CSWOT\Z<G#IE%W]LW&V!EMQR"7^,EW
M,29ZJ6]2!SM8>6J];1[6A8QWTXO!67%*V">G!(#=;*<GZF*%'3O_[":][2Z;
M1<G []=E]DZS9Z.GX-X8QK:8KSQ>BN/L8""J#G&$3%KS[W=[=#PXT)(QO$PQ
M_QP=%?&SA@LYX/5+U?.>:T>17>*JB.3:HS#OLP8 YQKT!D0;F^:+.3,,1VU5
MK4&QJDHZP64[IUIESH;.]0B::LF"UE^BU&,=)<_[GI9[/+H^&M1]<(01NU@7
M^K)"C%TQK$_2F9%>$J9:C#-3O3ZE;ONQ#*7YR,N4/X=N:-^& 6U[ZC$-<5CW
M2#RS49R$:*8K1"6)O6K^W#KK*\(I:]1TH5Q/>QHC;+GT^!NKMH+"9\-RGN?!
MC@X.'F4+/<[.),]:TC'5^CV4))J3ZDPF&G_]Y95//P""P8SR8\LOM"#\6$?F
MT5*G>#QH_@,')'U\8Q>3KW^F.QX^?[#-VC-P=%B# ?9!*:]"?C<C.*/7HLHI
MZ[)F+).FZ_PAXRC]:,7B0T%Z8Q_^09&D3%W)O()GW <)GE<5OH@)-@.3;K"E
MND[C5NTC[_W>QY5Z<?'^.84 \WU,SR^B[=CF"PC6Z!EF\$I$'#*K3C73N!JU
M=TQ!.D3%6 5:?:T-)W\4#<CB*JK[$M]JK;,64 9FQ$)<T8ZGT5C+-:H5CA7<
M0_19$K-!2_J*36-][(5N^M3W'U31;&/+I.!LX<0&/C>!ZR]2:/N/#L/77#G%
M;!EDHSJUA!!F=6IQN$>)5!X';Q;[U/7+/'V>T^??_<8CL7&3VFB[%H'H!BAQ
MKW%J&\R>C+@]6N\S31<M%X/5N3*W]V]VDGL>H[*.G6WX[R[&J@^SA.IJDD"R
MT4FK*^^:],(5/'K'8T+(L8V5X*P>4'U=D[6X(88CBZNL@P#PORNI\:;=2Y7W
M?ILIN)=SN.?)!/D47O2R7,J6!O<\?\TW*1*BA4IB%\RX67\SMQCQ^J:K8P!=
MCK821CV;&BK[\2OM":5YMIL]V AE^@XBCE%=/RVL!.?WZ_>O)9=9[7_&QAX*
M3$DUN0+EH8W%C\R)^5[IJUL\/-Z.GT>71TA; A>#!K*&IL0+T3@X^=1!S6\A
MF*<;?Z6OEX7 AX3JO>J2"GE 6.!\,DX3R[[.'1,(.\PM=@Y4&VT>C)E^X$:+
M.B>+G#<*"E:@QVB('&J0KDM(T#1KOXCN*0#Z3(-<1(5UM'MW:[&2_7":R4XC
MGW0+KJXZ"V1IZ6%?_A[O'::^U,7.X@_,=&HY;G*O12TQ0H<BQ3OP^QCRJ*9N
M*FQQ_^%:201.M0(<,L9:<Y(OX1_Q7FF(?^HZ 0"V:]$JH=08:8U0<<#H]?FO
M-*U$XAA6<\E[N$0FZC;F3KKL+#/ZV$CG<EV++!=^]"L-G<84:]8*W"WBM_1+
M]3-OH-,VSB.=:<Y?.$.5#V33:/3 !3$,V$9;/3JPU_[CJ;(.V SU*>:1FWV;
MFH2%E!<B;%Z<GO3-1<M&*/&I(K:K>O2"':> N5GJC$J*7N:=M>]*E&X:7=J<
M9)Z7NV]EI9G\N(HM>'=3K9?$T*I(UK8*/[6RF$^-O_T#"T5P\=9CNL-OI="H
M(F Q+V%S]%UMZ:Q#KN%N_);7/S"FG0GGB'!_P'KT@K 6^5=4[>O"X%QQ6ACF
M=ZC49S.BG>85SFS$>UEC21ZG'94OG>XB[U!1F/&R4M-':,E&;.JX06C00G&^
MXRSX&5/99WC1SO#^0)M,CR)7%:DIU+2[KW(+\SWW!8X;18!^]6DVA4H]"56&
M!USA5Z$DIXV[$1C1&801T9R76LQLRA5G>S>Q,(R_U=FF9GSSV:FWXL\4=2N^
M0;K+U3\/:& 3$';,\D@?] ;[E_/Y2&D"X!JV5D=IKR70/YJT.&[?)'4D>2UK
M"@7^6,RTQ/IF5:%EJ5SZ^+1PM2MH$%H?U6M-.]Z;)PJ]@9/HFA!O7J&YC#U3
M[^[0UD2*?*QVYQZB__K)YC%80%ZBXMF/86 S1 "=C\@U0D7D=16 O5$FRXTE
MWZTT;G:M.W<^^&S._^UM08)TP$._#X+>U.Z N&U[P7M?N!]-_JL;(D8"F3PQ
MFVES_X6U-PV',OS__D>$LF7?C1#)EFR%1I(MB<@>4W;&F)1E9"Q9QDX40DBV
MK)-UQ##994GVD&5F4/89,J9FC+_O@_]QW,?O][OO!_=Q/[B>7L=Y7N=G>;^N
M\_R<G^O?!;S<HMX_,[T9!\)8D/O;2(^6&0Z+."G2YE@L2259-K['=M)^P?1R
MO1F:VSQ(01+T,*#7W>WB%VMT1A\@5&5[BVH"G^U;%E4OQM<Z^]/.D31[;*8P
MW)XS ;?)9D]>_);Z^5'$0G.\^%V.IR3Q*D>80 ?UOL\+6!\7#TUW B&.'Q.
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MP^<D&S\*P=J>@H0W0%*S>G[+G/"B'3 WY@$N#,:ZZ1A)DY'0)/YTO&W\=%8
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M+P& N2V0 .TLC"GB&YV+\J*-7OO!-\^\E&>LUANM(-Z%7?SUR/R@>D *,Z;
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M1R :) T3&*(H^EZ!7]RJ51A/]YPP3HN3R+PAV(K=$<@$2,3>,;M)%_]V,70
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M9&5:6-"9>:ON1><XJ!9N95:4OVW/*J-43>+,U0:(HFJ/F/"ER30;&[=["W(
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M>U)+<,VF+)=,CPVG5 ?OUXYK\L_Q%V)&XU_JWTB]\KYXW#M:NMB8]=FFWI2
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M?ZCL9OV12W0F&0R#I(-Z0$QXJYC5FYF[D6C&<Y/[UQ-=OHUA7OJ<XR]HW;6
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MB\ED[;)HKX%7QQW^U>-?"O0G.-* +3K<OX%WZ0#>9UL$(O>1!>V;H_R[-ZF
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ME[/$[NWM,8*&G8L_&M/[/NH1C']=E&V;Y(R!QB+8' B)WUR"F\QN%C,[7\3
M;02 AC.#;EN( .6!G)1'J_/N!)--4N*&#;Z\=00Y'2! TTU11A+"ED0.=5>G
M\Y=#9GE*I.*CP84[.M]>16^HGEDTIP).(W6H;KEE49#?SH732+W9?<*T'$T"
M'T].D^V4D,V5^POSST5]WL=1 :'P2_FG+_ JTTS\RM";A@]NR--<I'!W7>D
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MBO+;D%CKX ,2[B\E7+7J9JOYJ%9:_E)M9=9>\9U#<A+(9EO:>8L*H/$5@^"
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M:)!CGL!;Z/Z/<Q.=?%+X\%Q,G#_&:/2+I&S$14ZPH,X4JS<-%?#-3VYO:CP
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MJ\>'+J6@.DH#/.W00U@=<UUO#*CB#@5/IN/+P[$1:B^O0:0*MX61<UI4P*U
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MW"6V5$]U- (N(<A4RS2L2"V9CQM:[NO@X_T.NLWPX4YAOZ9'#(3R0):\M=5
M-C.QP*#3$C;5]KW9X4Y+3F  \.1LXY 2W"Z^O#-8#.)X>SE[#__9#2R89<]'
ML\IGL]I[GXC-7I4LJ3>_[0R:8CP);%'V)B;::5JX1/3!F+MX:QU,2)E3/L3
MMR/EVT\GCH86*O/='8HWDK+%./Y"6ZE'&27O3WV#X3N#=;A/NJI-KZ)Y-H2W
M3DIO,_7DK(7/&(,)1&O8*5D9[88\9MY:G/5*:/,ES6%BQ_>C;KZO3 ,]' V*
MJ;*-[X!&N.V SA\=:'3C:-D.UA8O  &5,2%^]\LPN#"'9;WI4@EQDIZU7>6U
M.J'EK)]F !X_$D^XN7)VU,.P&P\DQ[@#MZZ#C%(R[<!"-F*]5*.'UFI$?+!
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M<0=19+E-QNQ'N^5O%)7;W0.27<S!KSCD7X[?\_#=M;1?3;2(^"P@W^W</J-
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M87&&=MJ07B7! W8<UTU[*@/C>/;CVC5H=,;I82E).Q/G"!3D@3HSWLV/T?^
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MJF+F.#@PH]I_6QW"\JTUIV* BAZN3/5Q+4<6)5[@A_4+FF.*&>@VLQ!E\]D
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MZY!CLA>G?,<#;U?8AQ0,V7N]&]@ [,42.9P7H=Q%0^U''&M-8;^<A=P]R=L
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MZEG;%'Q03P?.E[+@CYNZ9)5PC'Y&.-:?PDPUDB0B@47P636Z4-/SX1%M.!+
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ML )DW!.HV/Q/R3K5%Q^-6CLEOU9(DHSH[21-H=).<LN.<7HV/Y=%="_L,S?
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ML[T* ?I1R[>^-!)(DX]$H#/#E)  =F,X$GB21 ?'5#@J>LR"SHL@]*)"^ J
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M\#]P-9 P,RPW$\446E9WT8D,0=#,6%6Z[U4N>C46Y&GS24LUIK DMYO<=6<
MLPIUS[H.83'E:5W&#%S?V-'>QY*O_E0UP%]N+V* 5ZHHVWQ></II)9GN"DNB
M].OB,1\AJXCH$*<VNI 9XYH8EN$P[EC63=N+((++C6M4(4$"'U%+3;'^9.$P
MUL<%U^^+5HF'LTX%^P1RHUM7+(BAL?X+ S0+INCT:,4W45A]P[&S1:Y^[4C
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M<S@S<^>?AC)\T6!.(%WN%0?/1[E2JRME32].,XXL["CDY5EW, YGO"CPC>H
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MSVA 0D^DWZ18D9H+ ZE"F4+3+1XGSFI-SPY&NE=6*8N\C,[I)JF\3^&M\-+
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M\[(W>C;9O37E\]M];MF*W@YH8 K6(-1:0X@7>1?]?)N]3+48M+8SM;-TB5/
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M-Y GC2TP@6M4D<MFSRV(0[^] 4*XS>S2.'LD>YDAR@IZIKKP*1QM,'5\>TU
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M$$%<041P!2"D(2"B(< W 1"PG\0$OWR __@0$!*=(3Y+0GJ.C!Q\H/0\0$A
M1$1XAHB8^,P9\*XW>!\X0T-\X?*-VV=IU4U(KCC0";^,^$S*<:?P*[U&WR:G
MR!-'OW-D#(P7F9BO7N/BYN$5%;LI+B$I)7]705'IGO)]32UM'?@C73U3LZ?F
M%L\LK9R<75ZXNKE[O'KM'Q#XYFU09-3[Z)C8#Q_C4E+3TC,RL[)SBHI+2LO*
M*RJK&AJ;FEM:V]H[OO</# ZA?_P<GIJ>F9V;7UA<6M[:WMG=VS\X/#H^C8L
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MS:J$LJK!-(N'+CI^IN=<NN4>C[GW/.0-B(S1<(OA<3X38?/:=K^,X/4#Q&O
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M#-,SU.2E_H3W<0]V0Z%J)P]CB4=/U-H3_$E888?:604F"=-<E"UN]/*-J&T
MA%AG/" "YT?,= BE>XJ:S3T4V%>ZZW(/U#@ZJ7^I0+U!(-; \C:;CUOI4%M>
M25\KOG&)@#<2H?=0^7G#?#0<%)DQT+U!2XX!_HQW2O1SU96+N>!MBN_@G'1"
MCI=+>'AL&N9 Y_GA%#687*NP8<F.M@N69WP)[2M7M#YMR<63"5<K1Z[.G/L1
MJ;23!Z$'1_H%[(#Q2$<&Y8:H@D:[11>3?4F(+ MKE<EIO^F1IL'?FY9]8"A/
M<<P<U(B[O3^QUXYXEV4C^-A0ZJ?>LZ\T@K<=%GELGC]FN-EA'G(]5%$\9!=I
M)5"1X2P07**N<)V,.T<O*9,J^GGQPR+A8EL"@$N"JY(M6CC2;SZFX?EPD2:8
ML& ?"I2.@@H->C!78\Y.PN8,ULB+6>"2W=[6I@\&'P^FN+,KTW'8RCTF.J+5
M;:2Y;Q<C7'TAP>AM;%9*T(]/I^B:@];H(=L(483SHFXZ13I@K;K@M:"NM#MY
MEGQ\\=.YU)V;/CO/-_8]-+-R-!MQT><O?".*:;MP7DJ->)B'SE:MDHOH4D*<
MWC_MY'FM8B_H6<;2-H<N?C0(03/A@7-RZ4+\?7-R3X^D=W&E:&O4-A$X904N
M"S2[B -$%I(#HI?&VZPP(D]69'6_U71J[/F!)BJ2)>!.,)-)J4.WTB%:U0#Z
M"C$K((YU@'Z#.QCJ>LU)G6L?BU4N9[T3Q%W0?^L_*]?D1*HX%Z=976Y<.+-0
MJI^S#2;_'*H/E0X\%"EYWN(Y'?.'YP@B[UTQ;#:L;*%7AJ8+D[^O. F^)JM+
M2B\&+P('[NYQ\L(MAK\H<DB^]A>Y%$^ZL+X@=M6\I\"R4.9=[?>W=-%\)9L(
MWH\/KQ\FOA[6C\FG0!(J\\<?9$F,A&@'M96BG9L#+JH.OR7T'RG9P^0:O>D6
M/C3\*KH/CF"6R;\"[0:R>. MQM4N:[318G-E[45AQQ)EZ_XHS5'6.;*3>QVS
MCR=WNUSI&R<PRB=4J4Z@QB&%AQ3(O#42DIJX/W$I7IDEHMPQDXFDXK^E.+4&
MBC#MY^8B%^NZ_ #3G;#7R9MB5KE(S.NGX/PK8X;S_KJE()G>.*+$ R-7<:6O
M],<%\<"["6R1\<HCL>T/J)F>@>GL+9&N]76%LG*O^7&F\&$(VS,9K]8,TFP;
MI,_(M("<8GD E_BS;WU^XA=F"I1S])"8 "'$RC0,2]J_:WQ$M80']G8@N-=\
MJTM"8ZU];*OPBN2(/5ESMV#<+7'$>O@\W\/BTR/V["RH Z4=^L8W.+I:R*Q[
M$:C1Z'\+VSIK)FXH'/C@B1ML=G#GI^O)@.R#ZQ/-;[\U9QHE4KDPN#)9O_E
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M)R'FLM?F-K+QTQMR#(]XCZA56CBB>843EI0Z%I]"8]Y(P4]"P50O]9HS5L2
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MNS0\\WX.S[%7ZI=V]"J]0[9H=!UYKRBB([RYZ=D1OD1O"G6+%JWXAWI'XYL
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MTVV]E0U24RY&9^G9BN?'/9VZZ[>IYU!E3XD1UUO[5P[I/@UO&CV<5?/PM'[
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M-0HTTK^^T?6D2=ST9YKM9YT*#.84$\?>;"989""= _,C_-J:.9/1W!Y*;;J
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M=UB!0DDMX6RT(UJ"TF%Y!R:;@>_(E$9++1\B"51)UGROGB2%Y4,REJ2AB;V
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M8 O43GM9 \<Y75PQ( -^[[BRORMT?5&<BZ=<8F;MS4BBF+^:_-$S[:*RMH7
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M&7UK)X=[S1_X@5Q]YW5VT;-TGN%;<TD82[:H2@&WDU3P<2-AIKNEQIU2C?X
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M5 R\\G-3G>?4GF3KU^I) Z0X ]7AIC-!:EM=5[?8B3Z52ZOZ)R5@R<!ORKK
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M#M<[E/@IK%DX%,OYU_:5L7&'X.T/X)>[$43K(<8(Q4\5V*3/^7@[>CV\/9W
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M,PNLW\\L[)3?O_E--U.%I2H8Y5"/GDC )Y=5 ^R"=^[0TN*;JLDQ-<V"+)2
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MLQV;FG<%$UI"3(&/ ;-!*T^%G[S^;$D=_O>T:O.B1#"K &Q^8(T2V2P&<'T
MKP_]#CIR]K=,,"HL<3['H?:+$S!<Q8#I_[ZQM"=:.<K*C]7Z[)"[D0X"ZZ]\
MHH\#=OEDN8_U):8[_RN*[Q*C#.B[;X P  ?L7\YJ2 KE=04 G-#YZ^6_20FM
M? =RD@?H,HY-F#2,'X/RKM"L[<_ .ZJN_NV"FM5P3+UU)Z8@VZ0)6!L&G&@
MK2A"YY]EC0-_XNX<)G3RZ@(,)<0#8X(?X%N<:C&X)0/'YCL]RT,!1G'UL+D?
MNG5%[1G4 RRU1PKVBG,^)CFDS7M<@--!P/ G ST"43.1:QN$8P 0!$D/.)6P
MW(+[F,PE#$6,2:UL]P/[HL'E3.8.]!RT!89)ZG LZ7#J=$XJ[)%O 0#LVZ'I
MNRG>\1^"1$YMATW[JF'V,,K?!C*_.M&4O2U[8B14!0,:NPIZSVY"%'?1U &*
M!NO_QCV!Z'NB\J9+]4>#]A:&!A'_5E>32P]P)(^U[UB#9965F_0E0,9] -=M
M"0U_IC)^3+VH6H'R9SI1>/J/OHULZ#0:6![8)KG]7WUQI_ (Y%U%[ 0^O26X
M/[IN@0HLIE_C1[_L]]*L!O9=2'']X2S@[:C+@H5W6/ZNLIDOZM 60<"]GIM>
M^E.5C.\O"7$'9>?<]\#_R0+O3\3OG\VU#G ]UM.]:']\H)1/-.KA7DS_KJ3J
MB8[NL9,#I4*A%7!(-RV2>!(.V1#D.)D/CYR$(]<Q;3 ?CT W6)4PU2XYB()>
MC(-L(?K9U?M5E>9$NOP_V_J-P;Z_-WW7J$+7.]=,XJ7A.T[[R85;_ZK8Y\^L
M>(GIN0,TF'%_D.(1HJVKPWO9+!WE=@<#B/8&*X/")P;B$7NXAS:0.9T-0=5R
MF_?[?\C4.ZD $/:R$'Q_3L=4A\@,);U_J7]7@NT16@3W8'J/NCDG\/>WN<L%
MAZ,N[<PHII23V?#27V5 $TR !?&#SXCP'V2AO)X-#/[Q?K!U"AX,5GG1.65
ME_Q#MF)Q_'./&L9C?#==LO+@[UX1(.TRF)O&;'OXYY_C=W<M3R3$TP15#%]#
M?]9L)O^8N*<$T'9R6<S 8$[,P&" %3U""S=C;F"ODOB@0?X^E)KSEW;N6=M?
M^SOVPPJ7?VGIGO^ENV.3&S(!@W2_&T0^\/L])PY0[H-XY%[DX29JB2#9$057
M,K+E<+!'2XH(H:M)]P:+57V1QZ\*_Y]L\N!FKS*M@6ZPU*(/,/F2RH@3E]7O
ME@4U_BV=3TP&?%#Q1)='3/(D9EQ5%/H$QN8\CK^7:7%PCTEY5L"/U[2XS!JC
MH"&MFE/<13]SX -IOS5X[-RB7T7PIZXS#)Y$V+_@[R6>[Q./_JU7+AW@%'#=
M>44D9]&;=S?9<U,=TZ!%'?Q"%]0F1'%D1/[)<_^3Y_XGS_U/GON?//<_>>Y_
M\MS_Y+G_R7/_D^?^)\_][^2Y*SVF(/XN3_G<<]F]4D:,!?7=C59Y9=,W9J*)
M/[XFTYO8)EZ8M]3QFLA(+5VG]S&,DXI0YVDS=*3UY^;TE6&,2XD"C2:]O#-O
ME'#:;[92=8H0(L.WXT3ILVJK+;F@UO05SX+H[,7PUNE<L36/GM(CD$=Y1!DT
M$_D)?!Y2-+J2FW#%18 SF7W[ZBTG=M6@,R"G'/)9'>8^6PB9RWV?FG+S#,M4
MM>&OKB6*905F!1];3I'#?=:8P"OT\M8H":+D];2#^P,YPG<R(?.JE,:F4,,,
M+<<QC8_@2DD&U@#2[>;;/*<6G;Q3]5,UHK,./N0DCE"Z9)-1B("VF3Y>BC*(
MSEK8;^"23=<1MPHI"U)@RU=L5G[:1R>%.U#62?),X36:T._9@RL6J1(,+ 9J
M73?VO8PYD;TW2R00P2K29&>O=YNEEC4[WLO/#%LKV#K]4D@0("S"T/]&EDE]
MO" 8%=8NCJ[+A\Y_R)(Z@2$WN'^2.,#KJXR+Z\AA5!)_B#<]]Y_\,:4^8Q(
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M7 \!H)A.GZT(6*[;;*Z\Y]N&!<-FB$MZ&X%^"F@CL%>$-<._;IPBR?MV9-W
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M]I.$1$*F1E'&\9]Q39BO!9UI4@!M9;K1(3J;".WO%O?90,_-1_)=\":Y#S'
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M^=VB'%_&ZFTIO7@V&=EI,<!("K:6]>'/=ES$C# 3?X0<_3#$6SA&U!U.]0H
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M27@1!"0K03)(D"0@43(BDD1RSB#)!0')25P$"2+L"@@*DI><TR))PH(L&5E
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M9QI]3LNM-2V3O-ZH,1_#]WWB7KUAF=M*"P8@7#Z_Z-J;5\%R9=M:)N!&Z+=
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M%*EY.-^1SU!)=X.%R]2'>KDM2K""Q(Z6O.EPXJ 80P^_E"0)O!_WY-T"PSO
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MC2?0QJ0V;!34OD>'N&&#1>4,Z]U$"X(7-YJOSED6+;Y3U26EQO[;&)[W*R5
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MYI'K(.DU#I'YFWN_0OLMLK\OL-?_I<C^&MB_Q34!D./C@9N'3P5 @!,45WH
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M%"#\_&@2BGD$)7.:X=/=L7LUE[B(CR@RTPBW6CQ7-)>^)%N83$-D)/1VU&W
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M_;0!&V\;$8^]A@-*B=CIF,3&PK-B_6[E)\1ENY!U7J$.E: .LCB2.9 G>K?
MY?YNFU70Z^H]K<OER.Y$&V?IT1QWB+A%Y;!OHI<@7_+3[2ID&,QLN73SXM?!
MOLQ'@GYV[NR@)TI^GZR# U)6S1B8#LWB0V]OSY]'F]UHW,@."SP4P7O4;SUR
M1")S;DEEQ=]ZE['L>N":4:%FKJ79,X0X(L$S6-5;D?-2I4O?G,2&CT<^Y)*I
MO?XZ([+,H_Q]KZ\R_^"NVX97 ;\]V2=?3M]X<>4-S:H#F>^)-BZOY!D]]L^.
M!S4KG#Z]*DY<9!<-GN%D;VXWO.;%9BW0=>"WE[B(,BI/[A+),^83.R-Q2Q8L
M-:9]+<>21]4\[:B_(3Y ;)LU>RLS6\$SU$"]BD?+(_F-_X/12^PM%_.LIR<S
MZSOFSG_0]NU%"X>Y#)4PKY<^.TJ2D[E(]HZ?^N6!9P.*(72L8\)ZT\.H>553
MEDIPNMP=K7D-WTK6=>4HJ;17L/#!W8H^KS?V[9C$P(2$6;/S^[3V_)8"!1]+
M)CI^<H:%424&;JJ ,]Y%1D;[ZUXV.GZ(..HU@$ B$)WL)QXF*<S(!D@F8+\>
MO_YM_;N5<LV]O.BJON&!R+[T'Z.$R-%]DG(%>ZQUHGGP SE'P3:YLG":G[OG
M4*.")F6YT>>"C91M<J^^\TB/Q"CO^AJITA<Y4311/WD/X6_WET#G?&=(N%6?
MT!.3_>'ALP8;PI*ZB^POM:0,3JHKCOTS' A;&!T**4:K9IO@)ZKM+!8(<?X-
M$WLSRREOOZ/\RZEEGU??\GR4E;K:(2E:L^!5@%#Q\4H_R*R4LZ"BK.W_&9EM
MC0,L 9,4P_&\N]GFC:L]S;[9'@1J&YXRYT;A;LS76A-/$OP6D".!3B^?]B?4
MO94;'1X"TD.Y_I&!+V".<'BAH<_Q5:;%?_OR3UL<@+=CM%3_>J;5<=O&Y!$/
M79RLD'"D=\>>9NSW07?&1E),9AJI#3LG$$&<:5>05(8,2I]J^I'_D$.GF?6.
M!7YDRS 5\_N\6R4V)[HMCQ5XV8(E.2BPL^K%.=9WLWYJ>CFKAMZ(B<C^SO*9
M)F9>X(QH&H98@O<508,;UO64OJGJ33QBY\/KX-@;8%Z(2-6)L1Y!(GM'^U[Q
M>>2*2Y,%V1H>\8:-H)*KQ^RROVCH>CA%L#';QH]<D&1%C:H5E&'8QK,J1M+K
M7M/P/:J*O%0**Y5**= ?<S0W! V%Q\+XQ/CJI]A'::'7*=H#M1J@[3F;X6PA
M X;4'\C\RK2("P4U_/(MF_/#Q?JUS3]?@B>;9E/-.?)&A$P>9 9JC2Y6AB\C
MS$Q&7SW#=C-L,W]FXI4[M6:Y3OE=M+H;\Z4SR:1P]@Z*JE]=WH(!.5IW5%:>
MF<5H6 6[+7G%A75ZS9/NV]$EVZT*EW&S2=GES? 9O3LZ[S=Z/&G>LTSLH+4)
ML\KX7#KM?<\]4\/>?&%IK8SV;->VK\FD8GE?5IH8*=NBS>S31B2!<DG@(]@L
M['5RIV8H3!Y3?%PN>2_]'O^:*CY1C/Z8J*R$Q7T1]^@QJA1II'H5<XU+0DA;
M$&2>*5JN1(T/2K(#=UX_?5IP&@/9#9O=9DWA6'H5"@0CC$:W'YK"OX\^\JQM
M<2KGGFZ3;YLZ,'Y18,:DKTD;*I-OHQX&&_V^<3%[';)/5(P#BCQQP"&5Q4IQ
M5D<R:^C0F-NE^N^,2%)9_95'LD(2Z+4+YYZ?@T.\\OC?B>U6FKQ4"[PS1?M2
MBUCN<+TLZ>D$;8(3Y0('8V+F0C%^59MDEF<Y'1+-Z$ZN>D7$9-3  V\L;@'1
M4O%!MC:>P4:W(]-T084/;VZ1D_H907P]V^7Q]9-K1G#[<[<WX?>3K2X>S6&X
MNW,V@P(<\ S5EC!E6A#U;H0(#B@V/_5O&GO,J.*:$XTD5\ >4S)YM4+O9FU>
ME'&Z73O4ED^F<JS:-I^LK')_,)5B1/0S_\Y04U=GT>UQF38%5B6E]>CV3+%N
M\SC+>W8GQY1/7#NL[MA<X7V%('B9X_1\#CXV]7-#R'3C^SV"H*O.7%[TQ,'H
M]7($JC ESVP=E:'@'*]0^VW!LB"6_D8\6O89ON.*4\E$K]CTC!EMFTLB^1@-
M(E2I*"3_Z/%3$XN.JUU77*NF^USZIS%06ST<\,%R%N,"PQ @V%+%@VKOD! P
M*5Y60)61T(^J?;LG8B?*)<BG@7\_];HC8$N/'*81#>^?%#F'%GR168O3K.H3
MPFN#,2P5E<S_+.,7[1,Y[_9*'L$!_>(3KBGS.&"S,/XN> >B+SC JABVQA8<
MD.%2:!7^:%7KQU!0MWQN3]N22C/Y;ZRX$J-O*0=J(:CTN\NUUG6_@H^:^8$#
M%I[@@(M9WS )#OAGND[GJH\$2U],FHEY:Z(3FNR],ULH^53UN I&0&*4E!G
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MHTK=DHEXU4.!II"F/7/.>*)OWUH^<]K?!SIQ0,#HN::@0VH"O6.AXY!N,*T
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M=XWE;B[C/L' ]80R@QT8XB<(0>W8CD,\.R8;I1>21O1$27\G*ACIVQVG3&S
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M#U*\-1('O(P_&NDJ:NB3JH&3P#IHX)LEL!L6-U_Z7P:GR0M#/,4JUH85G>*
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MA(^Z2FJ$EYRP\O$I1QV(!.;1=>]9]"O0KD85B<CFM?3 PUE44(E']1POK/Y
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MRHO_D2N]1)2,4>TVDEG#A'XIA:*7[F9PV^;F@+\!7K:2*!6;DNJH+O4#GC"
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MFU6T[>^IS&\EL;"JK@?7)$6MCEH0XAM'4!3-/K<=CK"/KMVE6-)1UY]5J!/
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M1Y+)633T'?GASH&8F&]1#J?X#*6D1;!LF5]95;K$HW^$5:V&*C&C+T(/!?-
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MXKG7]2%F&9XWFWH.B[GQB*FV]3>4E>88SP?I_S;,_Q,-<]$L5B&\NQ3<TRD
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M^A%@)?(Q1&5;\T/R&$)]?A:$)F1%3R79$IL.E)9X=9>"[5F_?3\A$:0&#!W
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M:'L^.C3)YR:;>KZ!PA8$M]>$/*R#VV  ]V>8JZ*O=R*C5.HO9;^WMKLJ6T$
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M.7SFP4EDRL*:TT4NTF7^ZMO8?'(3=PREZ]TC[1L%Y07S$D"P5#=,/L:49S'
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M\WWW_-W':'G&USMK*?BE_;I4?NCSA:Z&VC&'JLB>C ))!/_]D3EYB&;QFV,
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M=2=-.B")G*N%D4G!MD53\#7C:.1N)*K%LP?0E2?<1#1?EFM[!%@S^WF[V*L
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MA"Z=^38K-1/87O^SR*6N?K1L&LJ/C"LZ1UL_ZW#RX<?0(]DGJ)&4/T>;4(3
M[]VJ0@@%<Z[/NF4F*%;*P2,4^(I"? "7Y5DAIBC_68W7-9S9*4):PW6=SE?D
MYX\2-?:5'\0]!6I_Q>**,<0/3" C.J8"Z\N]PC&</@I8>(\HERV!EJ8.K "!
MGGRMADY= Z1Q8N%^)'"]%K>H0 EAE(9.:3G-VV/ =_?P@7T%TV*M@^0[DT6^
MO<OZ*;]G']6(3;4&T<!/XQ:)*8UCHSH%B\Y' /H.,9Q)'VX8R4P882<HU%NT
M)G' ==U&!CSW&/DF9OUUX&A;8,,T/,/&5:,YJ$5$U4(A8\H<P?]:DOL*4S<#
MSE6<5)R.MH&2F@?P5>5+JT^T5VFLT316'^^OY%(>.CFBN639Q\"(#Y?+0JT<
MF(ORHJNJ[A'E95[W[_-7^MTHL-7.[Z2F6,&$8"K:]5!WK3F"]!5E<IP%=\S)
M>95&G3VO3\K&(JF1/M[&TZGPD=JG-3^>H#IGWMET1T;0'P."N:NE,L;> ^G'
MSXDX5*[JD;R&>(&T2RLK8:](UFPG<6QQ'S,[/W;0H1=>]Y4\&3/XV\+8,U+E
M<0L  ZJZ4P(^[;D\)7!^@&<B:_7X-5;+^BC/J->0S'86DI?5<%G/!!T*J<9_
M!;(#13[S*"GK6XQ$S7[; 5VSK&/0D8W8CF)_U=)PU2TL]<)),DYA3W8@_D^Q
MF]MAI)C00BL,B/'$(R"0]>0$DCL].^S5 ,=P>TEZ8S>#>D76I_UHLBR=E42O
MB?#N[.H\%Y72QQJ=X487 /#K/];UHH+16HQ!3E[XRAZR*1"/=*N" G(9U[EP
MQY$JD=]-2BA@JQ8D/_3Y**V&.[LE<Z(CLRE31,'Y2U&HX)A]DP0/25<-V;@[
M+.>GF.KVAJ)-20)-BHJ"E*N&=JREWFE_&\.IW TOX6.@D"U<;JC'5]370)#)
M#Y6"\%8H#SZ#70SY+&Q6Z8<XR2BVX-0X/O?:Q0[5/P');@UR?RA%9@9Q>0KM
M!HX1#R5<M+=23G]4<<D;&LGNTHIA9R!&1/34E+W<OJ]"\+!.?[V+2O2+E^.
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M!^L2PR.C$V/Z]26CNM)BG'M&(4UW#D@E2<W=_2RJC*CZ&^S//:Y^[4+Z;L[
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M$3/_=OI-]IZ&,-V/%H 3 QTRH#S$YE8@,;=FR=W;+V&[UI?*/,ZY)R[EQB!
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M:UNI/WD:#F9^6/9/9.! @IJ!EUU3)YN;9MYM5^^C<\7O+P@WOXAT;KNAP6*
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MUP8P)SURJ\ #<-YI.'9F7?^'5E',[)YT]8"1UB,"KO<*//6B@0,RPDR(? L
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M[@5U_=96'G6U% ^D&\.P/EC'T$Q8T< *FV&N3_JOIF*09J][>$"NBFUW=7>
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MW@B]W?LSLJX!KHZ&#X3<940]$"8WBE];2D")/G3$#"O2I.:ON:K-DBW>*?W
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M;0D5]B[TDP5S)2PX9']WS_Y_+*83=3<0RM@.[D4<@:&ES%JFR;]Z[EPQ^DI
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MM6;#=NA0H,]B"\B2)B(894F!4.YAY+L8,OM>LQAFU,9%S+@ /,QYAP+=3:9
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MI+6^0<Q3S2^K\<?%!,*KA4-D"I62D!Y:G?Q9X/U"ZYA&,A_!',>&B+,N!G2
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M(R.:6UF2SUZ49N%*/KH"*'L9-!?.>/*MX"5A5+N1<V+TZXLSI:<:S>Y^"MY
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M=8TA,T]]X[+@3\S:ZG2D[+)!]8L6%F\<'&\DN/_62AMHMA.R$1G'7;I_.?\
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M%763K:%WG=V[;\0B:/3))2\?K:_[*"%-TUGQ[(_^T2T1&X@#]+,B.[LNV=B
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MVB'/_HGE-5TZ_S Q*B50X*NX;+$TI"TS.>)SK35J&+Q]+-6+D#>ZAX\I@E
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M-7$0\#J.Z__8<!3I1^Y.;(.;FXY@U6-_=MKP2"5F?;9%^N(+SQ3\FL=%OFU
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MO!H:Z58^7@T2#@/$-5=/ZGC3$:P^$(HD5F;'=J@6O#P,!7:1=7T^T;OE4?-
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MT$^()7K]'D@+@;7"1X?T/5 ?"O=:#H@T$A=;;@Y13SOW4KY7ZNN_H*-Y5:"
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M193?4W1,/ZBRKDBW,2H<5I>@TO>Q;>,.4^)%+ 8?*-Q:CH3R']QG&C$SPWP
MIAI,]WTAS^=DC[IVM#C-W-JUEWE],N=+R7(5<-KP&7?MTWMGPIF+VSB A)5F
M#YLVN_J-HL[F(F&*(.JGJOHC[A; ^^5,J:]"2C+L67X$C3"&B_MF% +Z.6:
M=]:FZE09]!D8=%4!_Q/3LPG)- L_S?I14!:]R7S[4!_K?O$=AYYCR'NE&XB]
M8#LV8'NTE@[BW%6O7V2HGRU!D^S>;NFSL_NKB1&GCVY]'RKVZ>AJ&799 ;&@
MPBZ-"Y!,G]T7RS%I6,4C.G[,+!94D_[<8\?8"U)>.^]-V)K)BET4DA2NJKTT
MFCK:V(]/+UF46+N<&M!YDK3K_FS]A8V+UR(5\5E'M'QGTPP[96;F6Z6VU8U
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M0W_(^.X"\X1U79D;0;04^=-U[3+;Z[%BGOLRYT:*0L65C--3]I8*#>-*HO[
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M$[S0'V_/?8PM%OT !^AZ\V\J^'\E_N\JX6#="JX0"*DW*U;]WEY52=_7[AC
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MT8T4558$4UCZ)\!3W_"FEXM!I9/-GF 4O3/P--?O%2.//^5R U57*U9P_#A
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M]>!LF*0ENKUF !P[90UL7V381VN"OIF?/S/V3GP<_M7Q]<1J]B K$<6[KZ&
M$\J!]95T<O _* 7"(?X!>$[-C4ZOPM/Z3WD<$W8=HTF0,\<)#%,,QHM,Y&U2
MNM7\1N!\GR4)"K^27FTH*< 4?;?P#M,= T18J#@^T5BG>?^>K7+B58N(ZU6%
M6&638;1Q+6)^=W"I2 ?U<+>$ENBT\7G]$:>6_V6NBCIE%)5, 3ZV_5DMN$T)
M=8E]!SR7!>$)Y*W9>VM1C+)B%JG1J8W8D])2"P_JTUG!_(9[HU:-D\+^3U'E
M8*2XP\UD[K+IF<Z[H :;7_7[B<ZJ"E'^#21"Z['(!ZIAS1>@4%@3WK,<6ZQ%
M$OD@,SJ@(XF[ [1NS2_E4FW1$@>Q39MX3TQ,QM,HU]A_&!HQ\\F9WO(\@5O"
M\JUGIN[V\S1F[ /;,O<6SO!!4E+L"U+KT3 (QB+B?XLBD&T,.L$^SV6VQ2<N
MOM\>>8OU03)G[),[S@_9)CO";TO=IKJ7DMN5M<5&D66FK43VI6:.M:^&^^Y+
M:ADL;_IJHO3_IB72'),I\7H)ED^KS&9582>5DYM,G68I\;-HH-*LU?>N!]Q[
MU[VH(V#:%I+ZM!;3'0Z,I3/>(=DB!F=OSVN\5@A+30^AU(9R2@UYVV]#X5 G
MZQI!,^+3ZK>VI*Q=IGO_./A_'@4AAP=2[3*U%>OG9@[S?E5>0P:\486CZ39[
M)?-8M?ZN3@R-=]!*NV$@:2@W;3>9UM;)+7Y]USHO'S^5X^.NB1\5W!$%7)%^
M.=YIJK$=; $=HU;$"7#H:HRG[&NJKPA7;Y;+KG0.?<C_>CXF%6<ZWG*3<]TY
ME?1:V$D>P-HE8VOGS[FQA(M^12;H]GI4=>UDI)B4J'5;K6=>;H_#*<,HI\HY
M3=3NX5J+C4LUNJWD">#<<WL>#:['A]:P!PT_1JQAHQ5]/J*!;2ZNDY0*>HX+
M4&&*XX==I$1N\1VO<( _]<'OI2P >88!@ ]=%W& &#T=Z>@],OL#A$/#&6PO
M,,V'3,&U(>MD$H\<WZ/>6J/:.BZ>U+RP?9'M;3G8=AIW-_Z+^: ++P=FZS.)
M\. \<(E4P#(<!Z"X7#FX ."C^EH3#L"1_><@9&[@['TQLI'!:H6F#"0SWLB@
MT%;O%P+]9>O@G<\\X^;_KLM23@.EL?Y]^ +@5?5Q%^ZC/<ROHUKAX7^4*X??
MGFYJOPB%4?BN?1VI&/+2N@UAB&J[+*2-%1@;;Q/I''@D% 7;3[7RT6U9YALY
M!>W;RB(&X?QY2/%M988\G='L9:WU6&?2836U%=18ZB":7EUU$D966JH +NIW
MDW"R]=.(79+=LGJ^Z<N9$N9>+8E1(JZ$A7AF"6)T"HI.+F*,DD;[[,[2YK&1
MW9<<7%0LQEZ)\Q#J*C3="AXVMZWT:P2\Y05>2JDM(K0<F5'^X$"E6GMN3(&5
MJZ[EUJ8QRJ1I*;G6"H%^4,]M<8L:.YX_BR6S?8$&TI:03JKC01*L:']&D)R;
M5!I-USF+"KSY2*F6!WCIHHN_;P"&+3M0EP1#,#6E#?E?1?RO+2(>G6*YPYLQ
M[AS@O7Z]6M25Q?+TX#;M$FH:]F^8[-.DBLM[\XMUTU5^&UR&;I#EK8[ X,G>
M19@.^I,H$-N"9[*;6T5KJ$1,RT5V=S]X'E*H8!\A6-H3&W%-V'2E=2:W-'0/
MMN7HN24MP>Y=HM AGV[+Z^1%7>O#RV&H;9XM:/;%]"*ZH\N=P<@$'AMB*8R,
MR0151'-II6EW/.SG<Q&FG70Z9?_AW3TH%5+R1BXL].366RDMV;<ERS)OULR]
M>'F.G[NTL)*606^J5/ 4/J)4W=W=Q;ZJ=8O2G[. Z(4PCJ!TX%T?T2X41V]2
MS1;:"(D2=.[R/FVW!=0!GLA3?>'*^@&C5-IXU)@Y<$A:61O2J\D03%$LS_9%
MMX!%*"%2UT_^#88E78"E0"I;>-B".42)VSNLB\OKE#_EYO:#L]6YLJ\*+C7=
MK*LNZ<,%_HI(IOAE80NJ(ZWD1;U:#PU>3XN?R9WW&CVYOM)1DP8;G?@.7,L*
M7O.3EP]8\Q-*+S0O&>S>>%-R]!3%NI(AWNM7%TW<3O/-Z^[< UZ '-R@!_BN
M&$CF36V!'$NYN^E)<@YMK6AJT&@-3G?=E5O"&KBVON25>J*_FG-JZ!7XT2G$
MN$>U9?Y< I(%$=$ABN7X.-S]H8B7@I$WG[?LN]'UCX;W8)?":!44W+WV[,,)
MI]RH3I6R-9^7UT^5=8.;/01/HQSC?0:MS:3^+7B/^1-XCVR"+RYR\%[6+N )
M!,'X.O?EDUC4\Z986LR\?1N6L+@7>&J*N9?59%)SF@P4!\-# X%=9QYI(!15
M#0\6'VGIL4-(S/P+\)+<901>+C(D]A<$96TUHP2L*^K!UXBDI\:DQJ)L@#.6
M^!P+<+._QF\P]7U,U[GL'*^2(OM2!U^AA3J6<-D?O/<("$_! >R]L?L%13A
ML[\^*7:B=-1>L-H8C:\MU!%3M')9F]GPN^*7L9A2=;3$XAZ(>WX,K?D[RY<:
M4_VOTB'TEU;XJF\S_J[H%0L.,%L(A#\.G,(3E%\/.KJP&RR#V'FC+1B#N4B@
M#0[0FH<IP_/AE -F[LO4;+R'J:.%0;-TP',_)-XM:B(D\*ZX<SP3(4:ZKH/F
M::KD Q\>+>-IL$OU('8B&TNK\UL6])<<C4'LV%_:P?T%. 7^+3F*U[=H#;Q4
MY'Z)UX*]C=?AR(J%73C^I@H"7GOAW!C*+D34,";W\J4ZFDL,>'K B@-,._Q-
M'Q_W[UKZ\+7,X6/)36[$Y[_8T4>-K^B#&O@T*3!-]SY>&P*"_4M^:60LIAFO
M3RT69;+XN^C&[X:YCMGB &]^FTSPN^_)O4[;8['F"N;@_6=1>)8%XT;4 =_*
M7&PMB '/^#O!IQ--VOE?J</!KZW"P9QHZY6^2^X(IM0Q-@K?MXGW9Y+?5=*F
MQ8LHWX]3^2+/II.B*.[2Q:UMI+L<>T[:A0-8J!]*]8W2Z*HRM/]M_UG+P?4T
MA4PH8 T(@7E.3))Y7'D4)M0FU6HX&29%S6_]=F,UT&AJQ%I=6Y5!_]/O GKC
M32OSX$5LZ$\',T,<(!9/S< 7;#U_IR:44"!6804-_I(5_;<O[T3&C(#(@]N7
M8>?Z,,9!M%\?%H[5)UB'T-H@;>0<ZU#:Q70>^!4ST#GK3EY<(&Q-3CT*>]NA
MD371\F>L1MH3@_CA2L!((1VY4.)H<-02TNI^#UL_.V]A[9V9WC:>X#%:*WY+
M*V\C]80CC9' FPZ&J81UP=:@E_MI9@="C2?=JU%[&PNPT%KC<&YU?_') P7=
M)6U>@Z9DUI+];-OXO;'"@%, P)<&0#K'IA-N*8E?S$E;SE);F\7RHHJ=6[NN
MC4@0FT.4TR&Y\O"B-UW-M?<1>,[H[O&QF/+.]5F*!Q)^R11@MG[4<+%=JG3;
MO/))@.*)MM)K#;ZJ&.THKSLME%-!!&@AI:$++I C,K@SDSO-,-$B3*=66UJW
M$E97]<Z1-J>P_>.@GC)AB6^@U+'3WW8-& \](5DHZD<(%#(9XE;@'<]3]XZ3
MZV+KY9T:>?W>*W13>U,K'$=6QG_;<#"0=V?0MA?,*A?YS=G0R*P(X7,TNON_
M>O?F2N,?2>^?*;#^AU8\!];XP\_O";*_;7._J"6(W<^!-S10>IQLG(Q[@Y]>
M&E1]VA#OZAK3_QD/_2?_.8"@:^>/C!=*"<:JC/[E_(+6Y.1A"(/NX]\;+*3*
M<."Y[U_.,4PWA2'_>@ BDH.?R=>_7/SIG&.:S]C:UE-?E?W+YR6 7(+#SS^2
MXU;['A!_BG>*X\_A;RX2OORCU5B3PH?E_4WPKQ5?/,BLJT9@9+O6X>O,:5?.
M"\,H='5T3WCS9$HUAD\<++RT8&,B.4>.3M9T:JA.9:Q:H^\HFK)T7IEQ/6S9
MXL;E@]$],5'>IO.J-D(G,:X[.?LM;SUV)G/]P&U] 7*3+7(*<MJCEEM; .,2
MUFNLLK*..38V&Q$CFJ(?C;;=]755E=6Z0O MO2Z <07^,M(U;_KCG5XOOB/T
M6,\S$#I8/>5\'&"J;YD:P^QC]5WJG^7IX4=0Z+Y@:9J_Q:6F=]I]I&'9=[.I
MK=O$&:L3R(JX7N-"V:=/^ AEN)+B?Y_^+@]>D&XNGBV#L/)64DK7FUN?B-:5
M\G8GVX5&VE6=<>L/6PG_/C0NQ[Z_D,:@TOYV:/R'8KK8G\_EFZJM9J:<#O:5
M"K(:#7_O\"!M,83'H$ND]%]?RNB '%,/-QVT+Z(]8T\2">8Q+1AHZ#YV93M5
M> V$LH<P@8> :CA $SWX7XYR37X?Y;)CT=K_\E* R1W.Q3GN_Z?BOUS%+")V
M3Q/L GU _;&X^,5HCKRI Y_'F\&SF(VW$=4N5%=<==?M,<.Z_7=&[*P02C%9
M6;#:T(L9X4@?PS=\3WMN<(22?F,4#;CA-<[U ^_TS7\/76N@F3SL(R8(#O"\
M&@<X=A\_T?:'7NKC:<[O*+#+S(V-26VT"@?.<1<J^$]BIB^R._.S(M#IJ.P%
M!8FL&>]8N,X[R=F5R/^/M?>.:^K+VD>C@B@(*-);4$ $1*1W BI-!)3>HR(B
M1$!Z)PH"BA3I" @(TDM$2I"22!>0WB2A)?022*@!0G+CS'UGON_,G?O^WL^]
M?Y%S.+NML];:S[/W7NOHQU_\=D_!=:H^&3?P8I[7J\_Y5X/Y=T>"\AB)Y\MJ
MSF_?[0YG+\;$,KQ0&XO.C,J=TP!%M:.)]\X(Q=$7&[NQRDO:#4,UZQW-^L)7
MV6?.B[ 4,WU9F%N.6:X-1,:J@YX?=897H)W7*XR\2FQ.4JX@+8T9G@I$BGY-
M%5HF5F<K<7:$Q &Y(E+$^R8[A$LM?,/!GH%ED&G!Z0+[F,];*K(5=60<4CJ^
M0T415H!G-7:17N5G=!63O'8H$) ?_:!<3ZPI34!;C0HI;9<[MYC7N-6K"NQ<
MK$^ZWCHBOED)9F-'T34><6R^++I[ J\\]02%QH&1ZF+^92UUUWIUQX7J:OHQ
M#-J)I=EZ*#[#J40CSKXGD)DKHTU&Q<W[94%R)R/+!TGROF%ZJ/R\2KW6F%/9
MM &6Y<_X:T4GU0-LAJQL#LLG(!UR(?W*8ZNF;\IS9.!Y\ &PA*S:/,8.D8D!
MGUF11UQ)U'^KJE=<T1>FPQ#@.W%.0SMA[+5*=-?K#:].W1WWV&S.,565^6N9
ME@@X CF:S^$V/O3MZM,4E,QOUQ_+BF?D/F)RHLGB^-#,?481BT34@(<'@Q;O
M9[UU>&#6A9W7G7IJZ^*VA$@X%F*C$F)C\GWT2<WTPLGG@V^;2D)5"SDEB@"F
ME$)!OLB*\%A:CCX>F[U&1+/UB#ZJPZS=N$336&_:YFC6OF[$(%YK0GV,"GL7
M,<BO;L<BZ$+RT+97[(S#8>@SE9"9YOUC"R-,? VTE1F//#;R0T,Q D95AQ3
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M7 43Z@K-TJOVS6AR>HJ&?'J!%W\+;W[RA)O_TF7ZSAN7&_Y3O9.*-]Z.BY=
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M19DN?6+L";>8<+F;9V@\-=;$1T+//S\@\Q.ZWKEN9;,.>J]<@X\C!AENKR@
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MV1.TGZ(:B@+3VI"=>D&DLU3*/^]]"I=L\5X2]Q%OAUP*J2(]SH+BE /)ORF
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M&CKG.9T6)Q#,,V(1:3M3)^/1W7CY\2L?N2G'TBZW(\VI(H?HS]GF1_$*/>U
MF@>%&: ;X*6(QES<W)CL+N;!M)]+L<M#<.H>#T?YZ V]PV':(I=%/HH)EIJ=
M?4?J\OYL?O:X'[L#@N-U[D?[>=VU!\C)BGM]I1[RFCF+YVTSCR;^$B2P*A Y
ML\'/3WS^X6'TT7;[.HS!/VU <*@/9,T]0)Z6*?YR:TRVF5V?5A%[WQ>UEVU/
MPROY;/C+M#-%OG,+D14Y2=V+9P>^GY#.3@WY^&$_9?A&:\@9U-S&!N_?9*CZ
M]?I+=/F.P7]SC/%_,? ?VPLB/EM!+,4@^$P5W#E^^*-[$E2 WYSZ,:R+F5]P
M%BEP@ 5:&Q.WO9T'ARR "URQ8?K@XNY>PN+B;R&\?S9+723]:.UX]V/TCNQH
MSEPU\?P)VM<6%4];.<[>E"@?X*'736RZK-SR_+&$35RX)9>_7MFZ82?=9>Z*
M%IO>Z]< )H :F#]K_3^FBZY?"GVXI_#=/?ZHC1V_*%>,6H,^%7UE^W2M^^B/
M:;7JK$D9F:)9'LZ],R(V"@N28M\/ E1"\VR#+69?@JWOM$U"&6TN<YC9G+3V
M*H'>3=2HC+*$"TR*F5GROY0]V(;F5#7>A@3VA"(.SG_(7U^\)O<(:7M-H^XH
M]*S\RPM/OXO42VG1: P2W:8@( IP5$KWN":'+&&+6[BF78+5-XJ F-?@1!;$
M&486JOR"K>S3V2(2.>R?-!*&';QE;GA^LI&XYV(N]JS-P#@7[N$\VTAN>465
M,9'9EQ_&6'#DL]>Z\CWQX#KACC&:9YM?U"E 7+0YWYF]IX)V ]G9Z)??]?&:
MEE-R-@7?U@3?V;N[25B>*@Y]^.@,GS#$8&9G$Z51  <1U_KQ&'(E=%8D.]L[
M[E=+SH;<))*8_@R4F87QS= ]L77T=;N_*;--!_>'WE,<JAFU>R9%"-R2R=WD
M<-NYU-C)*/[PT4O' PUO^:>[\FY+;Z54$F3P5O AU)9<Z+*14$WR"O_MV1=G
MK.XU Q9"[(JEFF1VDT;$YO$AQ"H11K1%B^8W?5D8?#45E[^E*)-I&/QJ/-ID
M1]&J:DTPWSM'.7O<-KYX\?AT9U4<=E2OX6-33)2_-X>_O>[V]$V"3WD\(V:5
MT3?GFX48MK?\9%(8@V_N_@$#2T=PZ_0H&5$ -.XW<1]; Q)]E=X*%!=-(&IZ
M#X7,:GO[3I$[6VHI@.0LR&19[+PR:LIVJEK?>1XJX(\6"<UR>PP S2?]']$H
M-N9JY<'';3[8]&%,V[/J6Z9*/&^W<')%ZTL^\52@<8'? 'L5\= F^W-TDT"0
M\AL(H<O'PO:.V,%VR%"RM!:.;"GD[D@\PF,4ZDVV^N2E';)52_WU;;]TN-*-
MIXG>JC:N:V<?'HAFB@ ?-PC7&RJE?XQUD!992K[F9N9ODI-@<.PHKV7PQ79Y
M[^%^)*YC L3 ;P-!$(; [L,7Q$^/OXE'2#C-/"YWN$/N:BGM[!_8#=(=1)4&
M1]L1QD(7= [9"73E\PE'A!P5>AK35JM%\V++[K;HG2"]FD!.=;JRM;9'BQ\J
M/QL!L+,SZPI:OA=^&HPJ4:(<?!WG3^51  P>@1\4WT)(H&7BMR#?:\Q6]Y!2
MLL&E02%3@H.."7+!OVR<JO31Y.4-NIMBPLN5XL&T6Z.?/^Y;_FE(?(9@K>-6
MM]"= M1#NC\]K?_L@<KXRU)E@ZJ  0Y).B2-)%  \+WB>$^N[P)_SF"&G2C
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M4]?&7IWMAI![4#:IUX)G*0!SJ=EI>[LF/^B JZ;O_8GK&]7CN+*7*@>BKU.
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MVPEN;NB4C?BH.$>NE%V7;NIU.OQ#ENW#^3(MJ)6X"SM>A9O,HZ>/].JK,*L
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M845 PJ5N;?G?)0G+@/P9[M&-][G[#IKG B'%U?!-1?:TK"E&8-P-"F&:KR@
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M9 S4[WQX@?AEX6F*R.\'E-$3AFDP]7E4%Q)OB"SC1ZQO38&"W>40"#[L="C
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M=<N=YD53'(U9PQH2L\8EJTX^/GAZ:H^J:,V!"6&'!.=;Z^R/!2DQ^B-N##!
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ML+EHI=;4M!:GW/*Q%XVCT9=\-#0<MVMP "ZFPTE.1>++69TJJ]UW0?A57R*
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M-5S3PL;4!,(L_DPYUOX)C!\<4YY_]63K3QCWY?;(R@5#SF;P:@\&7.$4.UR
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M($S@%1X@6VP U'*V7)]G/[I-FQKG'O%)QR[*]*VUJFYC$#ZQ=+IT+W\/<79
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MRY_ND!>K?=V^]<C.>4)W[O.%O.@R6^9L%@20[*C^TA88*C2'-N><9:7/_<'
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M-;+ISN)T[6/81)CA=O86FI_O?5C8.M<L<&'S_4 #-6:Q@-D$14GP,9+/(0O
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MG'<\"I-5>2193?D16?W5Y.Q7D[-_:Y.S@LJTW.A#Z8\-3.Y<.VJ+JB91O'P
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M7FS?.MYA=G>DSM?.D+%;9\+S8RJ=HCB:\R'PJ9,BS[KP .(>XL!VUC!*,4F
MA28Q7:@<S&D,-0)JF64DE]=,"TWIO[GKW?SY(9=?D^RE0@.KG3 'TLO[#%-)
M-]4R[58LV=*-ZDO8.=WM?Z\);<^N:$V;-3Z:&WJ+5\U^R9XV66P0XI7;/E P
M-/@<UUXX]S1:[7,]\%<+B%\M(/Y&"XB0!DR/"'BS$P&C:"\_%Y,-'MZ$S&Q&
M<PJ,OJ5P>\%CI"KW^J7F*PQ.__@MEQTQ064/G,$MH>NL'T9=Q8/%_0Y82X@0
M.SC1 #/HBV>"^W^*;?R?*T3O/T.Y[\E=A&9L2'<O9QO8_8A7.%M(.>"BX&(
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MJ5ADT_*.=(K&W?AUWZQZDMN$C1Z=1K(P UZ"A@(4$VPUQ\%D.(,1I*C'0'$
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M*Z61NTB8=DVX(AJ:?TKZ0+:\+PSC?+N@3#M#KOEM,N=_P+T]RJ3)L5N0!@Q
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ML84ZTHG%'30Y,DJBM<Z.G Z/ESKS65V2>\K*YVKX@9<N7,H>L-?)OM<:'R_
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M+;@(:\"<\?9>@:T[%CA'?8Z__$[&)B&@/VRDNINU$<UHV&[?/IS=MR:G(?)
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MNNO9%-,Y(]$$H225B>#CT+ !^59V"RW&&^BF-HY[$&?\ZV=\SKUTTNIT=0X
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M")#NO3B"W]*?;L_:?]5>*?IM2WI(D\$'.[L7AK,%5#?[7@ZXHFTM(@ASMO(
M.SW]>+4J0QCD<&O:ZQZ"64_I+Y758<2G&(H_B4H,D#6EGUMPX)'+:;-\PSCO
M6/58^8IA Z]/SX6#M@_31$4^/K)-#FU^U$Z;(U9=>;.C2E@N],#\$>VC(W0Y
M-X\4<'&= ];MA?PI[P\Q^F=C-A(I5)KT['G*Z6AP&2] 19U@>!6S EZ\,P0.
M8<>BLO-:.'S8$]FBYUE>M;A/XII=I:6N:Q(_\TT'<G&T/>Q=W*AM:.'XZ99[
M1U,W00B!0PDW<35,3 ACTE3:&BH(2,Y=[?>^_/$<)>A $<@J'O-D/M#3V9D!
MW?U,P52WW_M71@:U>!V7Z'4145%XEG?C09\#KV:G9XB-1G5ZVM.'&L^(KRAN
MV"F)"G%DTONQS%YI,]76O*YVVLWHCG+!I-2SE6^VOHAX4.MVC&E62'-I:A>=
M].B^2,TA+T\*PF4*+T_<\EC:A?V$(B7JVP'LE;L4E8WFPA7M28<+K]R-[26M
M]<4C^RFGI@Y_=9YZ_-)^J7'@@%9NRD2S"PQT(/6!KOX'];,Q[N_),ZH"/GVA
M]*9@8<$3I-JYM#*[ALJGAK1<;P6E;#D[.<LN)M^.;[:!#0>J^.K&Q"^V\FG)
M=X-1DNEV1L*]Z.DE*^\G7%<YZ:>J!6?JQ<[AQ*9_2DWA>0OXK=K2#X9>BD#D
M$]-*:?4Y(CN<>(N5U2OA((^7J]R_"0-^?,P0:%##HD2R0X$0!Q&<U_S:9!'O
M#>I#DE0X%RY1T=F&=:HJ28%,Q2E;1"7?0SR+"TX]AXRV,3*')U90L8I"G%1,
MIBNYA49[M//3M\/U$:UA9T,[( *H^P]KY N=O9HA3A9\"><(707(UW9HL><
M5/)VRZ*19"F%-"3^\K7[P<C2QP/*Q4%XEVX>U0L@9EH<SJTN:A4]V>=MHJ0E
MH]0P:0P_PL.6<E #!\?ZX0""]X!DGW?7QDS)!K>1M(WQ_3-2S_L?G!YV$SG:
ME5IW[;"0:%C!(N+6A8_GE$' LB("Q6Q!%>*+LQO=OE'0#)$DJ\;DA2D-F>"R
MJ0#N*=&4:F_J<PRE]FT5\C:592HHFP_0BI+VKO?4"^KNY6\M#?12I7).? CY
M6.9F_D2 GS_.-%RB0D$QK*Y]^,[9L.[S]S-AW.06!'J/2;)E1Y]<K5R,W\Z)
MDB4KQ*D+6Z+2V]9%)XB?\7[6;NR@>:BTW&>/5/:$2W::0>!13J)U.IX%>!E(
MS3;;_F\?HOQL$.W15\6; OVS8^:):Y<_7Q)EN,P:ASS<%F/72W=B1*7;Y'VZ
MBO][!AZ81;@9%XPZ>+X(3='"!Y]Z48M7[2!YZLW[IR=*]0[YN'D179W2V  P
MDW!Y:JP!]?T<GWB+X#9_/0O?P*I1()NT QWCL\V"/2UX&+:*^[2;(JMY 3(C
MOD2J5:9W__Z\:8^N4<_UL)8#Z1\@ZIS>:6]'C=Q2V]^U95[4U*@B67D5=+IH
M/*FC+<]*@^8D/I3;B!HR0V.((#2*U2ZN/>320?6\7];OR7.O(T1FE^CD98QB
MB4^B)N3?EJHKO-"XGFGSX89P&\U]:(;TI',,V[%[9>:31\MD(F02H+X:#?:Z
MAXYKC'/1>+-H/=,Y.NKN,;18$G?*<L6I[HC!0;1WM+TD<J/+.W>BC1K]NDQE
M".X?%7;:.< KNZ=GQKS!S@>-,;S>K=D13S9+UZC:.+FEI@G\%W8V9TE$D)%O
M;G],$?,=T!*##@<E/E+GJU]G[5!S]WQJG&[8!1]Z 7OS&'V_Q^ FU.K4XY%(
MVH4(O,9QV\PO8YP6-A:%4PI3&DGMQHG3%'5OZOBUA$1)$&+EMF97T&>0FF&D
M2..8?KE"LD>*4/_W F&/*<Z>L@LN9[R3PR6(7R>+TW O/9U00*F93XZ!"(49
MDG +++&=YXM<NWTML*..-,?O-H%KVGSKU4-ZM#W(^A+#M'QIJO3\1PZ/>J[?
MR^&E -W[+L(#LY5HH"\R]3GH9&5[!6$MS.ZVC'QJPI3I/?(4=LA=XL$ZD906
MX++CX\>MU,7?BD?&:9[-?W]46U:S]]PFB,%X<=CC >J+?J+!\I( -6^.O9_V
MF+G0QBA1TE!U5<,(Y($#I04C7S=$F[S97B+.$*'N%WS_DU6 B-[I.:TZKKIW
ME,F"]==#ANT5+B+AI48,I4WV.0^CB9=NK&V""-AS+;@9C$KC69P(0>:F71-H
M]ME#XH=GDUJ$;WTY'F"9_C(!HL?B]IB ^8B:#$O8$:*>NYDN-!I ZCAP-?+9
M01EJ@@MQP"8MPBN9-7%=F*$TC#>"WG?IQSW1KGW)JL;HU""W0*\@.H(D^Y 1
M*4EY4U[B<])*5.<@42R((%SWT@E%*;X2WL<?.^ZXX.@)BJ<=*$=%5V@S9/A,
M2/N6W32T?>LXJG648.SQ)F@J]+'29*DRI;U"_R:(2-J[GY"*KY;7*SDATGXJ
M;8  2>]0=>O2<B(Q 11^!>GKUE-,SYT13"A_)%C(J/O[L):,76 !]X%Y 6.<
ML(U']26H1=BA<6I.S\63G$M6F8=2U36N=805WZ])N[()LHBL7RM"GSJ!4BI5
M9R\LA<2E&5T&UG/I<V/_DZZ'QXF[6<^#(BU*[#L#/N3+IS(AAU]PI)-_7M6*
M;(DZ=!;Q4O2+OV\^(GM]0A[ ^Q%SP@/=3D(*N*@UV5FWS+;@TB]Q=ZIGZR&,
M![\1>H_#GBG ]1 9T' :V1AUZ-M26X[H#[7Q"LD=[9J&;7ZFK)U.LP]H*&]$
M\9[- 1&9A]('P#S(K5;IWY%[VXF%I<>\LA.[WIO+PR/"EF<_6N8C4TCWI1'I
M ^<H9!K1:"CS?6H1912K1ZY$Z)I#=72($F0:ZL/SS8_ U],JC*,QG:9+H,S7
M!L;K5\:K[O36(>=CG XK[?&5*A8&?FZ'#2)@(R8FF)P<%0A)&%-IKW5K=SE!
MW2[B;GB 3KK!W+^G*7J6B2($[F8IYT#=IS(WW'0E(T@'Q_36$4J+U:4)[5MG
MJ%OHJ9'#OKTKO+#CA@%2T+D>J<'WY_'/F3%IICE_<_83JE,XXR1<Z&[K1KZ4
M _<P?OI"LWEFFGY<H.^#JM_GKV(2!$<</./J/,OHU#=!4DC#G";C=KJK71TQ
M:1"O3B$_8LYPQ<"*&'-X3'V_#B5,#Y71QBY0&MQ6^*AY,>F(]=.JHPXQCH_]
M)'3]S)=]+O;$-]GC0/03RA(>A23')/5\*4L=/^$A![OU-.*<WD15!%%F.JFR
M7<*:'$NF7,+KNY!GHJ^O^%!\M3^9IA]?)&IW\[ 61*<I3^0A1SID-.GTPV_N
M]1P]7<JT*4N@D$KJ5QZ.3%#K6TV3Z93)O2&,!*/9:J?KGESC(GA/XN_?HL+I
MS:%34B#4**H*,^(K]S2"\"7.25'Y?<_ULV^*#CW.'R#LZ!G6.@AXE>8RU]*"
M@V_ZLYH>,QGR<3(E4@08W\J8\L/WCKH>UO$J[!P.N<@=>]G#!<\@,3>(2VF$
MZ-N6;V=89ZX)1^(O/:,S'3:^R27$-(*+:+*@$Z@(X4@Z'(-.B9T(N8CK\'66
MTCAZP(?B0H\O2_M'J%G;B-*L_-L!!V;>%_((WG3J4#;4&650>9'>L&ZPSG4<
M;6<@L5"YX?G,XIV<1@LOQ"["DD[,*:S+HPWD)$FPJ"USQNDB'^?3G!OO,R]6
M?)B@6++ZVJC5_5WMS2DW. '^_9,^:Q)E-LC\E@*Z47-ME/!P\RWDP]A3$$@\
MU=NU"S)&B?5.<A$+HBY<-FL=W=0MZ3!/6PV4^EKQ:MV'X+GJQR86HZ*#V3)F
M)5^%Z#4>^)A7,+Q3(!RE",-#I&FPON[G+SBW=FM<^([1K"0'O?*Y_*/'GG:D
MX!'S'NB"<I;D.'K&\-7&S#^R%GY&02$<ZD.7_,V'AM$[@N$E$6A==@P2CHQU
M2Q(];6)C&-NEF>[5_"8R/6CY["<Q99'>T#"%"0 P@E@YM6</>WH^#AA>B=%C
M?1KI<=0KX.N(7]R+*E%JSU)QED_(3BZ'>&,.CN0[,>GOWDO+3E,2^+V8%&+J
M)1K.SF6M(::#IEYK27J?UYQ.3%3%E=W,.64EEV&PY.HUVWS:652_S8G'TB(5
M]5K%Z#3<0H<<Y2C!EZ?N=83?*^,H4:B+=YI]B6#1N"#O@LV,.",T3(NGG)E=
M</2K5S>#CR3ZU:DO\SU@1[8!/&[A^_/S%CEP9SY"G=)V'R W/\:W]);I4X7)
M(][>^'0*]K6NHIF5[UF4 PP>\JY1#/2CZMKP!"U>^E.-,_>=^30(&*^G7+V]
M]$4%-&A1)4C)=!/W0^/V,=F!MS8.L",IL>T=8PJF^J:%4Q3WE!6-G(.JPS18
M?(15@H $42K3,VE*5 D&EQ(MADQ (T-H?=F][D\YOJDC$N[/DH.1C!50S?:4
MTFFO2I^JT34B(&&^'R9QH/C,XD,F?Y0MWN*%83TD_=,PH:Q9\^*F<:4S'U<\
MSY\\W*XE\_ "J7Y'9\.1<,_I1;D-<OPD?05?A?Q MK8JSC=#7N\B0HE,O=;:
MWI'>Q&7IAQWK?$2=7_C4PD'%B.=.>B8$QBUXXD'8"6N;QTE.-J/F7_B^&(00
MNZU+]5+E*<''Y2VSE8?S6KRKGFNHM=P]?//2K<A+.+1.PH@TA)B LSVK:>(F
M"%(;<4<,/37\T,VLRYJD(70^]*$311%"^%V/\P+$^RZX8S!=^F56R4D??#M_
M%X?:.ZWK:GU31_I%'#344CZ'2 3Y& 9IT&=-BJVJE-F(NR89.-(@UI4_H*J2
MIBSQDRYKO,\JN![3E0!BQ!N\Z\[ 4=?IJPFZ/ZX$;2XIN*":-=M<T;<A?^LQ
M'TNZ3__AAT(D-<UWQ7#.5U -A#Y&A9>@P6UIP2DMB?;@Q"MNLD9BH4WJ6I+G
MQLZD&M]T#'K6-ZHJ?T4F0X >-,L??38F/ZB)C'^MZN)5ISF22D'<0_9)H2$+
M,%PH[ ZR*J^9PU(BSB!E2MCP+7,_V8B%L2T9K9&8[0(EZ0&&D@XXA4($I;U>
M[-FDC5P;R+D@RLYS#%!W)IP.N+A+&M\FB IE5SQ#:EL72Y86X%U#WV;=L='_
M\1C^-#1)M3#-!\U*D?W,>$@Z0%#.:3K!RT_8CYO532"^3^$%M5M[UO<'_91)
M3>6+GE6T*?%*. +(Z;62"*:P#TX<J)SNGO+N(Q @N&M+65L_[)]7".ER=>6U
M61'>!!VO]H/EUS[A)R=W%&I+A*,9OICV51UDRDE.,,D1="6K_UZJR08/#+ E
M6JDD:X7&7J,'%9A0C^)4?IY778,H*#W]X/U4Z0*GQ)D 8LIZ\94N9+BGB;T0
M'.IR;KUPDK6J;:X6Q[[QZL!R@D^-W]'5AD/=%)[E*J]XVJ$!(]<+T[QQ_1V,
MDVB;&)8&RAM[(A>2DA14@&S[?G9+\D"Z\^ =MX!0CF%!4%B/4IF<*<S0D"]/
M5>"BY-F:E2>)/J25WUCPPV)!"+&!>H(;_5-G:J[1*Z8*(&MLDTO)G679$GQ&
MG%OT0D"-L_+N%,_6>1S>5PX1EL)R@A0N5A(-FOI*@Q!>)8?$>84M/WC&U,:@
MNG&&QE>34@S(*Z.-S)F_'J.J#N74MCF%HY7D$VV'K!YF9]'."I@H.5')V+PH
M,Y3$TW2^?MF!(389]T8MN 01HE.JL:%=6K;A_;&=M8L9+55-RWINS$.R/JL6
MQ%/2IBW4E*Z<VKHH)G*GB3^ DYJ'L"FL6EFZ;:J^+8<0HI[2P%O%1WA9^NIM
M]P/'<W,#W945:RZ*@LZWER<91AI2",?,<[=W,*^HW4[!GW!N2[%\QP^F;$?!
ME)HL*0GX7\WJ5##W7#Q[B9)DL826OO0F+CM<>ZSP^/M,Y'"D;@+*6AUW*N<Z
MHO&"A[]0]=0]2N=6!<'$"8U\2'G869TCJ":#M$@]ZBJQF#QW^<]FC@\>$W?=
MO1\W(C3FQ:D\8*DZ:^WL1W9B$V1XM6CD710Y&SA(M>UT@SC3^"OA&UEY&DED
MK?UM4Z"#W?;SU&"K<FXNF0;G2W23BC*'9$FOQE.?4U:FQ,.]=)A[>KJ[N Z2
MFQV #[V9%U#Y35FQ)?!Z=FY&T\)2=D'NU:1>B6%-^2^7Z+@KG%B#4;Y]$^$G
M4-H\L?ZF?*&SW3%O^77SCYH/"8Y*$H6A(@C"2;[7SRH4-6H;] ^W2)HOO="P
M&^P@BH@SRT4(7<Q4#'40IJYXH=HJ?N$ZFHS?#&55_47/2%?.^<E]7%92R<\/
M)+IE8@=BH^%/T:>_WTC60+FLE;3;7?25_^QRJ#/7\=;\?;KO=QUO7BJBG;_-
MSBNF4WY3P6HY/@8Z4++L>\]2#EI>\Q)T7$N8[,'=)[;T1;0W#T^=:#<ALK^C
MA2_;"I]9^)Y(;3<!R74%?V>J_/;%]U3FLGF=^9CO]8 KS_D#9&Y['WCX4! /
M]]8-/:A>";DC17-(=U>8W9NWM;EYKX<UWBBHZJU[/JKS7Q>9Y9$*J1/Y/IB>
MF8-O>>@6Y>O/)U\/TEF%RV]X@W3+^B<X&2"9CN2O;OBAK-#5.JD]J2\%;M#$
MP=A@%L:]FZ#4GDP1:\[G><PY,">XI2";!21>](4""7%0$TC0]0.YYA-*_XKK
M89!$E+N!A2 O ZGA4HF^9S+8CD#62UUXTN\<O:MAQ6,[5:4XPU69%WG";0A9
MLNDW=L<? *##/^@!8^2H!.D!9O?(;U!K&=?KS??FIB)I[P^]#I.[."T[&-*8
M6$AL,'*I(2DM%69NS][RL=Y,PBR[]P1HE N,UQ)!1#Y1(5S;K-V),BF>^CAF
M)=]88X& ''OGY]=/]H6#@DZ>&TJ5R,IYW)=(*].+;2!DX$O!:59S"V5SYO G
MTFU6BJWR(.,LQK&PY9*00_2DC4,I'L-J1BHVL1*G&')4[ZU)"SO)3M3:U+N(
MRH<QH#3ZICC*Z]=4-5H.U1O%2E\>4M=GJ[,YZBI8->&;#.);UQ4/7JWP$%6(
MU-&H2I"S(_M(HT_P?]K[KJBHEFWMA2A!DH#DG$0EJ-#D)"HYH^0D0<DY-<D6
M$)"<03)*SIDF(UG)T 3)221#DYHF=?_H.6=O]QA[__?E/IUQ'VJ,50\U:]:W
MOC7KFZO6JK+GRA9T?9GW0X.!7V6NRU/)9.,-*1P5"[;?!G&)#QY/$K'>NA^=
MGGD+"QM&%II_H3SBLI7REK/&NI%&Z]&<E6;":P4+2H>GXAX]/IG+;RE>(,--
M39T]R$HCBS83$)SJB-WN65'5A^=],=++K9T4@GOZH$.K#$*7E!+WMFX"A7;=
M<@H<]GGE#(Y%CSR@2F93.,Q-:&Y]'F<D\0F\KN;<A:(V1HFOG_33(HA'R'46
M\GZIX:A4X#.*&7;Q"&[]%#4<HE!OCS\RH_VXQ09*D^-$_.(80T5H\<T+C$DD
M0\>$L/2'Z7?"08@:1%ZM5[/:AT?U@BN4BXR#9#* UG/]M0!1-LLE2<]DUZ[1
M;W/R=T+:-;%$U-_ E1=)/,TBQY*3\SHSB"P%JMHX# ?HBM,UYL9KLOIN%*$!
M-SG@LVB$4!<@H8_TS5EWAY*WFHSS85=CE-&H5/-RY;,(1==A1CCP. X^TC>X
MT(WTFS[O$<>)$#-Z,IXEX)[ W>-43T7*U.UVH/# SLMG?E(:OMH=GXL,.!J0
MQLV>X/[16A,C6QE=7?B0TO\PGZ4LQTDK&:L$/JDX4@9:(#4RG.EROI'6G>91
MWG%?M@TG^/$-;=+HK^+9AU&$04N(R->(DN4D/K.)&@,U[+0W)7%20V<?@N#,
MZ7-.0AN^,UH"F6">C@[=^1Q(SH H^70@W=$QRQ<YD88P!Q5:0@E%E[A?RBWY
M9-H/&<)!-II6C8!:,J@>)EI]H<2@'VH"?QU2F:1^H?:8WGCEB\M5VH\L7.CT
M3$N>7:?.-C(>7P)[CQ-F?F";\H\=%ZOD>- ACK,OZ+>F ]_-$0C@*F4ET5Z/
M]7>DC*R/UTX+6TN]VQLA?'34>GN=''47/H *=\+JRP\I(DZ+'->#,U(G=I1O
M:J+H8$L3] )CIKXD2UDV@0X/E2TPSM@1K0A%AID,4]1(SUY+3V/OT+E(?5&5
M]!T_V5!A;/7&Z-KR+YM$IBJ?WHHJ/:@9>B<G$?0)EMD<JMXPF%34_\SB5=0!
M=THCQJ!GE" BMDL<KP8.\<^=&'KORKN<\$&!8$P+7WS$91OWV3OO[$=#E.QT
MX#*]\:-0 G?Y.AB?B%E=59U!I?3E9<]'.DE:?_W(@#<T=P(*9+P*K2:%^[[Y
M$\9Q-^BT>V$,MYK,O\7P[0+<=+UFO^9.-R]?;["(ZP\=,:+U18XGW\TD$H$C
M/MIG>VOL\\<6F-#LJ"TW5,0CSQ45* U"?%[X]QBVQ(^#V_>KT0#6ED PV"8[
M<%!+P==/S2^M;NAY*K[:LM%-2WK.RH@%#2BGB2U<A>9V @7JX.%W>NQ5[8<7
MH-J$']@3-9?V^K70E\-3"[.8A$LC:1K2!Q+3%^& /5)Z$W'>=L8WGTUI.&!.
M.E#W<N\^+JN;^'B5C/Q=S%X7#[W/;T2:K[+)^A;8G2IN3M>3P5$1O;H-<N$P
M!\C-+7%FB[/7%8MILE92+.3#8IT"['N2S 7W-V6$AO(,XZ'%Z].0]Z"4<-[G
MM0JA<I/666_>T7>Z8M6)$ 7I]I^H68HS3Z"!ZB:.O#HO#DV&YOK=(@=/GCSC
MD894C!!@JXG"RZL S"'=-/84[VOQBH<"/CF;3+^,S?&%M5OTB_L!J@ F0#A6
MC;%FR#-\S,70]1!Y(@L5SJXM_V!7O:'\@]@=+-&PDNH[R3Z9C*(,\Y9M".T6
M[J]  Z]T>WL41SM]$TCRDLQ[L)077=1VP4?3BWP9 ;4-$8U<XPEYKKD;#;Z#
M97DS= 5>$9)?))C$*".RAF-DL5J#O WG[TX\H% L?_!1#Y-ZTP9)08KI5U$J
M;D9[,;4%XQM[P5];B^"/UM5]2LL/SY1=#G<KO+L(8$L^5\6F66G%UK?>R=NB
MEFIO*[/D?E7)ZSW<XIEU;]&< >PDD<CW27_>6V$?OP(<W%K%-,*FPOM83ODT
MEU+<+"]\)+![6%!P;6%\*VGR@L*RQ-K3#7JC?]JMQ&R%PFW1+H;S8J1.E"?C
M31P&S.7G3YE#+>P#=#E# ?:N1*?7V@J+#$E/5'>8!>RE" 95R$;!6<KC-25T
M-M6V:J"]:D&]T!SU44Y6NGDU6FQ10.6QW%8(;,QE2\Q(.4-EC&MT>=1EBE.9
MAQ*2?EGT'HIT+MY0"Z4C[?',B8@0)(^\[BQJ/:6N2:4JXOCXMC>5B3??/HLZ
MO#O(BZ_;U]XDD>*1,LH86N^VR.%*$T?.,I9\=-8#7PMT6<"S[!Y2EA$W33)/
M-U_@/* OW9E-_O8_[+WTOU2BXPUN"@=J4C*&^=VSR"2DE@A<46BHL\='!JD/
M%^^F-B$TEX68OVZ:$N;UL<_ PAP-E(.S=) 0N2"E"JU;4K&))H/;<IS]/44D
M<NSSU?^V68\&;H,%Y/?-'OI4*]U8+3I-@$Z4K0[9S1<N#']_PZ@E*04X-6CY
MOX:.<]5P61NV3)3:G.!).@33.NQ2<M4 L^?@6>>QHP'7%_]>A5&;</&B@\C6
MCQYSN*8/KO++AI_ZB>$(,B(8-3;O7FL.B/-T2[-]1=J[/]-=P2&_.OOV48+I
M5_%CDW]]'74-[\NKNLIT2F[#"<M;A<HA5%FL#I\?,D;OZ<\'+]'T&9B(F1I-
MYDP<XX&3:;2LS?P$B2OJWAD6STAK9V22C8_\=4&([ULA[PW.QZQW-WT*QE2Q
MP\"Z,YT+^"XT8L]50ZQ+;JZ#IM-B2LU&ISYD/ (VWQ(W>]U2*7'S; D2>,]'
M(-!-3SQA:]RJ8'JMC_6-#87FMKN-S2UIFBC)Q1^-/!C7;^&(218;$2*UE.#0
MF:S1=R-Z!H/FYX^\NW!9HJG1  Y[JM<9 -R0($):G4WJU$T>[TB+7)I82%5Z
M$'LXS#PA7([VDQ,2C>F,]861P4:D +)N[Z?PN!;>T&>C4]J6&Q!$:+UI%$MW
MT6U?^?.$EQQ5G]X*$N!UZD8&U(A \)#=D$>Y]@\4QK^T&Q)^94)1>;J>SZ^5
M0M][\Y5LN3NQM89RNUQR@YN*0F5M3;FE<4381#\*;?GOA'R;!'$)="8K3K\N
ML4KDC[G\;O?0ZY8,8Z2:UHI4"%^X$]EC3';1FT!@>_>,(FQGFW.96$]/NN*9
M/U)#&BCZ":G'P$D'E9TKUW,#Z%A7V?OL5@%-@1$F^A=>9,]XN-^\:D^]?)-Y
MQG<;HP=IWV7:*7VEUCM)+-\PU8:5C%=^>5$9'2E,3ALGM!@A0[6MU(S7QD]-
M__$R\V0Z/<^SXL.GNK'2L %\<ZH7BQBI^*EF*R7V*7K.;MS]Q#[93&%*Y?8X
MRFYKI;R#]ZV G^NZ:W9-$LX/(H^N\N(>42/SP'8].>,HD@5>#@[VEV#&#)4R
MRO#*!Q%5^E0D@EGP+[PD2(9]N"S[.L;W],#&Z<4+!?@6BD2%NJ-P*/\K>0+"
MVM;'G(JI](F0J_I<U%HJQ,7S.\"#1\"P+#;0765> (X8G1#@?S<SU]Q$D=^T
M*N/21QP-%>2;L9QV38_-:S,VMDM E#/*+DNVAR3@,-?Z"3*&,P?RX;P/#="@
M!8#U^_*_7/Z[<I\F199[&'<Q4+VI+(7R9=YD<G((L,((SVW.MZH5H+\S:5M6
M MIH&;&UM33_CLL&!'C@OCZO%\0,.W V^/D"* ,Y\_EDGGO?,,V9;BS96]@G
MKLS6!Q-U(/)I \HQYY G7L\2 MI19R#I$/"]\#"^9HTEVJ1_JI4OK(#G..2-
M?TOR:&68@U<3CDHLE7O%_=&JLL]4>%9/EK)(>G'-#T=P)7KX))/06)Q6-%HF
MSXJ>?=R5 $M B]IV**$-D1K@P;_G<ITH+GU\3DT*<#2ZY<TD$;8Z?(1X0)]!
M!AMR%57?3F!F-J92>5X7V9L)/PGFX\)6]V]OX8E7V@ZR2RO$>+\WYH)]7GGT
M1<RYV^LD/J5TG=H\&-0-J['6J*M]3> G'V\\$A]TWZ<M$T]K@K\A+0PA,,S6
M5;RN+IM-A4\@/#&!1R-KRV4B:[LD2:N6V?[)]RUP="U'X^9'F<</A7(R\24H
M+9S!B>W0:1 %A\VD545U<7W[[HV@L;<R*_KA@_%>\/;-%<WACPE[[0?0))_L
MGKYIAN5D!H17W$7=QL8+56R"97LBO0M9&$A,1F:2>N+N:YZ2.2CWB#"9Z_,+
M3ADJ,:'EAF8&F?)A4)$/KV*M@I<LA95T:P%[/7N,"NMXBK6>%X<+M.:*#)(!
M$:PWBZY<RR1T[DDV0$$7TYXKP$QE&AK#GGV<L0#*9YVWZR4"G&JKYKWOIHMP
M/=$I$Z7BN YM@J0K\47*?N_1#EZ?:Z ?WZ@A&ZBF2*B<GGL2*\GSQ^=/8E*
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M+2+:2J $Y-9#V7MO17R-]7FU"L;4AG"8<,!\09$UA5NO^H2!\MK  0:ER&/
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M;SRR%<%>RDM\NFY@?9W.>G1-W%K?ZIF4=@NPX?F<>I^^'0UJ1U"G7](O@)7
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MMX"%[<KQFCUJR21?LR/[)R$[#'^[>'3 Y3#*O9VI@;KI? LP7IE>_6I?,X'
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M&K1EF)79NLSM.><GQ7.S$+_A/2VT,3!)R[,Y.Z-Y;I/$B_'CG4-70L+H3("
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M/U@HT9HE^CPE1U-MU\!5'<M>0FQ(-3ROIC9DB6JS7)'\[GZ/G$?NKL<Q7I7
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MUX^3Z;WD3+M#,:)X_-U:<=&,+S-9!%X/$>GUV5%\"/YE49#F0T([!,'&?.^
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M@2AM(V41#X3H4_='DDOW@P'_KS8%I&2P)6O*$-GGKIY"\53QM[+Q@*7SJ;T
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M>@_)$XF$*Z0% "1)PUKR>[NAI9<LHQJ#*$;3DDI59+'1MRCA\+?V U_:>S'
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M0!/];YE3TBX]VI0N+4=]@S+H961[0VU"G,<WH BS :16VGZ>;F/>,$IDDR1
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M+R^%'.%)PL'"=V:IKR+ @<UFTAZ(,E04BMKUS2=+#9X/24Z?*QA"?^ J$G\
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M+Y,@?%H^ !/!_]P!#F1AG)TR-6TZ'_8[.[6IUX;G-K0DW)8U"4 UI3 R49
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M\"^JSSVG*LC]4 J)\,WUTV&_T;L.4&+033F=]&%+\P:4.1*"-#^&-%L@=>Y
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MQ,K3#R42!/*O5-\'<:>V DG37"!Y29U 4JU_5RGXSXH!9O8_ %!+ P04
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MF4VK,0#$_'P]F/OZ'R^.^1_^\\'\+XSYX^;[93(/$, 8MGDU"2*U#.]\;RC
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M7^; OPWMG>] +I$GR4_6).&G\XK-F]D.*V8;55IV 8:2-)%$TRIAZ9DN^/$
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M=C;)?3>$C7OX61+TOXM<@(X8.''[MFAKM+23L^;,@F)2>I1"^DI9H!,H\'Z
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MSZ4]31+$E_*.IA.PO7B^163['>4ZK]!I86+Y'9<C"8W=48XY#7^XZJ.XX"7
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MUZTQ)+MU&AV+(,&P,7 MF8X5Z=/ 0D>J%&$5<+4J@Y,!8V"$&JA<SDT6^ S
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M_/?NU'<QCFTS*YQRI>V7<,3&$X$&K<PFM7F 4)_!0<>!?P?U?Z&\X[/_19-
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M(K/O/W5M0!@2SY<[9N3M*Q,(EV[>,CP&12 JG+-F7_]R!] ]P,\W) $A@$3
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M9R%P8N8UB9I1ICZH/3^BT/ABWL9MVV8/'GE5X-^[$;&_B',9#X/#^Z<;TI=
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MX'!W=.[9K)"'GLZU8Q\WK!S>Y2DY_L/G1'>8D2\=+VNI-\57IOST:4MHC?;
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MTC1Q;Y$W=^3(7K+/_,XZ)'_O&KI_S>P'8:^M@3#O=Q$3U6ZM+7H72%Q+B*-
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M)="5/9768^5_B1\Y[9Z+S."-EIAPNR\%F[2LY)8^AP&9%( -UH,.B^?B8B?
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M$@339-UX\A1?Z2D@_%,\<CC 6<'C<<='ZG8Z\KNEA'&OV9"$5SRFT(/E&-\
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MSX<:490]$QC;6VUHO$VP@KQ](_$X-<U"1-F(;7 ; GK>K!4HDS2R\^F@^3Y
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M23;"&\=NY'O$ORJ T' FE\$G+M%]ANZI<@\EZ!_D3/ACKY7V>,&UGR%O=.9
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MGV- (I*BME2XM'2&$"N@JP<Z<11RU6,2R1NQ,R**@XV(>[\]B]48+S>SG\#
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M;6HPO+"0%Y6L5%%:2)(F;$?UDR> ?>8Q;]6[@<8K.VP+]R10& @"[6RO^>.
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M*;/#293;JBJ5E:5FN-9TH'>L$.6XY1QWC2])GC<4K9^-]VS9%V4&87X(K,V
MUIE"/71,=OVDAIWMJCY71'+>:QB(F/!IX6M_=-%7<>&LBC(XKK5G7>80#.*C
M*(\B9&M"UG']P0,F*1@_9U%)O(F- C4]0?F(H2W7B&$R(2LDR68.C;V>N%P]
M_Q@B9I8\.8+R)X=* Z9TI^RK8C\&Z_8E0,2+1G,QC[813J.RT5D]Q074^ESK
M3(2&'D:=T[XUSR>8X4GAWH++^BQ+G%Y]:,-RB9>N\J=L41,F9BA=+GP?;9CB
MR5'VSD\5S2.$I.YVY#?,$BHC2'6;_K5/GU9L,N:>GS>S(V(:_43L[88CKGRF
M?W?IL =%D_6KUQJ%Q>C")/]14;\TSK4UVGHZIC:@8MWLH4JG$$3]T=.)Q>C'
MV"%J-?ZF@Y8LR!DPXB.*5N*GA[9EZ-"84$^B_PY5.*5TD-HRH^0[@>];)D,.
M3"=>[M :.;UWRM7N\T^PGY]DI[WZE+!BH13)4/M=1_S]]M_&V/:/[FW-L-5/
MV(-?Z'5)V25&@%0ALW8S1K)_)#I,5 XGSZ]=">H_0CJEH^B)=KZUQ7?:*^25
M-S\ )K-EOMX!+I\T"2X1]=8A/_.!X1H-?E?B>E#0J6S43.&U24=DZ(M&5YL-
M=K=S,G7R6MP\_JP' ,>R?M8N7XL9L\'4_,V]GZFAED)7;>\F=R5,E)BXW#T0
M<_DD%$6N]/7JDGF,)'OP"/1QT;CEL'3Y?4%A$96M;;UL,5J"-9YU4D:)?%'U
M^T&M73OG-B?'$(A\WD5N>&(*';?)0P)O@AWL*4 YR*9>;X@G.OM%4:?HETFI
MO-*O(0[@-IMQ#@5AD!3'OC([\PLF(OCKVO,6!=-(J;81 UU6?<2 U^1B1ET\
M<1?[>Q&J JT!:G:>GCW>6BB?\LNQ?-5,:1UDR>CIUXZ-_3^CB1#(XEK*&U@$
M59H.L4X9NWTBECP -YA?D\)(X=7V=%$<YDL1Z/DHZZ?S(79FJ)H5LU+24'IV
M-]W+1JD1.->>_<5[][(?D9A\._/BI17#F!^;AD.Q<XT5(O=?".:(V$1"H70L
MM"C-UVYH=C5CCZQ2='(P(ETG35CLO96R:*@2(8/2C_#MA1CMY'O-*HTA_6'5
MK3 98CX!SF:9.#.&P,6 Y=1STB3'JKUZD3U2/=12XZ;^"]JWKZ6W^"Q]?O .
M47W&HL0>'/GV$G_O0C@K64C18S27VS(E9<?33(DLE(D $]R\8SYA6?Y\-+E\
MTH!;YO'L:W*+%0IS+&8./XT39I'^_J.8%]+132W[680LH7D.]8CK3RPV*N>O
MT<J-%=5//]3R.F(,,:5N$=@QU;+#A-H2V29E[-"%-[#\4E%BO/DG-$).PK[I
M%=H&)2,<\1B%4 WA7A0'"[82V:/#<75IM&-':7&PRC4.@CB-N\_R9?XYMRHA
MNR$%9^3\V'C<(#*=<)Z_@DBE3,5?J?Q>+W>QB)*GL@@,A&LDGV$YY7=E8]5'
M2"D8,K#0>KFC ;*1RS JTR1@.FY2("@GNL^O_:?&PKDS&GF1X[9#]3G#P?<^
MX04RG5R*-X4\F@\R5N>&<QX6JP(=DGG].6VKB(_=MT.?./+\ ="O%TH$Q,[;
MP%6/$@7A6(@K%(TF-<<8_R1/N_Z\H[RE,FY P98F?1+.+AI_1"-9IKXDTT(5
MJ%.VV_13QNCQ<"(8-II86;DY&A<=88*W(>&^7F@4X*^>S'DO-8S F:%.F_PT
M)YHC_A3G1Z!$ ]NA3>M<:MURMWPB\^2,$^1)XE6'5NV%Z#:\12KP0%_)J6J%
M34=7H/2.G3]D!K7,J*RL<F[_+6?V R&6$I25DYIS""LQ[U4)'0MT3"B@C$[-
M0JB0:T>)68[!VGQK<8ZW>>[M_DLMJ_3L/53>2UV<C=Q)[!6BJU&M0^>(M72S
M#'23LYC&XLL]J+0DG;Z:@" *D6KAX-X+JO%,]%T/W8:R\>WXN8'X:*LT67]P
M"N9CWTWO/DYC#EDT_9%B==534=$J*'8#S2_3(7>T&?[2OIY]D65?_G;-7_PK
M[6+[. :A0&0]\:S*P%G]^%M<:BI"XNV6@ER3K)^O1(<"Z-YP& A=84HN[5K'
M,3WK"U;N^&&>,+30(SN&3(LUN8.5,C;)9=*/&KN5-#MI_II6-NBUN!3*QY3I
M /4G6CJ\PMEXB$P_\(4 S;5YH)RLE"SDP 7*+$NE?.'17'8AB*:%DICA@E*+
MDS\64'F<@AM#NF*:LGT5-[:&X-.(B M&4GAX^!R.4;HT^B^HT:)?Y:Z4O=8.
MYSSS+M^)I-&R(O]J^53W"'#)]FAW7$VB0S%??LS=%?_@'EZ .[JJMO$ H#C-
M,N)X+X35N8/8=)Y2G7V3  $2<M&?'+N-27-.M*[0HH-^(KWM.3_&V0XXO<"D
MS5)1);+1N$:CB<.W<MWPHD!DJ*P1EAJ)'<WD:!#I<%0*5#1'4NM+?.X[JPSU
MK]W8D74*.0B>/0 9X9F'AUW3H.E[V\MX'WB[:,G;'Y^V26<H#\=JI+<22'W%
M/^>H97(17V%E+J^['\BEULG#Y'@M]]6-@I)+P]7/_AS_[JQ)ZR=[DV:8\6S"
MEVU_G"[!=6$W#_7HVF+RXC*@,&3]HW6378#U<Y'R)N.O.Z1$?0ZQ"NK<TKYF
MR:7#6^1^<F!+J1#:.1T'K"O-&+;0H&(4)%1<+JJGHR"-G#"O8C,)]M?@ <#I
MLA;>URK3P5II'_G->;B3)4?+V2OQAAR*^!Q,U*\US\BW.0#OY+>4@LGQ66ZI
M<@H5H,V5;X\XEZ+[++>_A+"\T:E\@G-+>R+,/+#3?2L)V7PJUMYYQ!'R$NXX
M=JQW'54;1>G8D'523P$8JZ 9W1"UO@XQ-8K)8535Z;<KT:_6]TB6!PV-_OPZ
M3M]&!)!G#FHY2D6W$SX "# * *7I%E)WY<G1@1XV(LD/E.T?2P_L,%)>J[$>
M;K%3S=T-DB<<:?TD0H/Y73BB*E2E)&>;I-_0N]ND'SYA-(.22F%%3"E<$/5$
M7 W5M55-WF?%E? [QQFP*;K8Y*Z4'AF*5RG]H[/EXJK3>S ]?_YPUTAKO^#J
M4^T<AA[B/E7CS[Q.#04 \)&<2S*2JP&)]?+Z7LD4%]&T*=0%)6>7PG_??LVU
MVXE(\PD.''3RWB%8$/;XOON.Q46FX!*?[R1-5->[Q-(5]Z635Y+D[H@/C?97
MA>[!IQ*WUZES98.*8[]VN2E!_]FNWFET;E=*>XQZQ_&*W$3?1VSU&6GP0L/D
M"N8]49(WWA^^DUNX_?>%X;U.S9E#]:VJ&FH&+<B/>6\OB'^P-'VRP#BV^"$3
M\O74^>HO)8?M8\.4C *4\F/>:KY$T>[O<DZGW^>Z.6T9\3MD5N;C%/#GEE60
M'N&6C"$?\9%& $R;"W%HQ+][X5=/M>@49\\L)K -DO_5*9'HL%/]B"FP=*'Z
M-M.VE((G),:>7!$-%$QH:/U>?[/DU+(JFOEZ;R7(H<Z$9MJKV6YX+;LHO[E=
MVLL.*M)-+:-?G"H1K#ALX27==M9VJ6%S;;7#_>>V^#-W8%F2CN8WA]>Z\74T
MQ2/14- A"2S)E33,4:S8*S5USO,<X6<@,_)GWQ@<HJ9W;_([H-B>:MY3I"$8
M_W0178/%7!@FUELPRRCJ^']*Y?\^ +@Z6U<W;UX<ZEJ>7SK>%+U=_/"JK#4B
M=^K)P6SV0@E_PQ.^%_Q+1WC[:GJH?>2+([1X]JYMXVRZ:4E,H0R8.4UI2F4?
M@KO6=-1GW$2S"-3.1R-PEZ(X*RX&F/76&!['W-S+GKYH]7]\F[ 8<H0\G6"[
M\&(;<03 @E0TQF5S@M[I\=>5NQ%YQBY-)5RM_=$RBZ"6&R#9J/HYMK)QH CX
M39:X6+-P>W+;0\#D&A!U*AR?CL4.A3 5$603C%<'JM!=GQMN3P]<Z-Q7:UV8
M(91/FOX6M@SL>_M6K&5LRGUCJ+PUNI3[&R/'*FF,#@::7Z9Q%@V\[MV-7*TN
MATB]88Y@FE3%M@S(V9B'*YR4_LT55UQ9=A#RB32[G5J\I=\*NGET?-/F.>IQ
M>'_<>==>LRC\;(JTHXP 0W?1-'\K*ZXS>6O3P3$%F/*VJ# 4["* .:'8/C:Z
MY1,T)5QX4EC1$4)8[\P#+;N;.N@D4FPYKWIRF7X51/_;18ACWL39]'V)!!U]
M-A <OKJW/\R]' NHA]RVQ.N7[I;^%,\\.WQ/9F:()>O7_"OAW+6X\&_G+:3P
M-F#:?N[:8U?M<* CR#J.Z?>!U.S:;Z96\J2,'0+O/RD!^;*]@6M_!#!Y?YO?
M*6]O[GO+899DW^U]:F'ZN%WP7F4;TJD7GP7$ZNFW>T-\[UY&P9AZLW8F4%OT
MM_J=XBN]H>7^,F=YIMO,I5\WV 'UP7?M,G&!B%&YLY2@WV+WQ=14;Z@9'P#;
M<*NCEWI >2M.3=O'CNL))5#?FZ UF:=NM)_<0S(B-!X RAV G%\!\[KP=]HW
M9TD)LAOGPL!UIMM7$R\'Z'.<..1DZ_S\$Q9=/Z<;R/^+K[.(8?!^H)'*<XTR
M\'HE*<=U,3$,ZP'P]9!80$%64Z0:I1KG\V>7<ZE(%$L;%W+PIY$FJZ<^6$.Q
M^@'PXI\[?X*B>M"9&[IKI#%&K<$S3L%K][F3.+_<#HL&:O_,S(@LI,O?^HUW
M,-BW5*K.G'[8#(^%_DJ<IOLKRQ9PV$SJ?:F=M1[L*,DS[Y_PS.(HJ/5&4L<N
MUV(D4Z.DS;OGOA5Q+_'&/>BMV.]W2C>3SEA-:]J4O];^DJCXB@_)78E(!]D8
MZO*%LF"O+]Z&G'2?+U:?#-\DW5>)3MPJW@R;DKA\NMU"!?UF_'"7]@#86%LJ
MGIO"AK\-#M ==T#&SP]6ENV?=FQ=,JZ4T$'NF3]MM%3?_GWS.8Y^_LR[^5]D
M5Q*7EWOYX=!?S^T.Z-^L=3SS$"C7>LQ%R$#N,J"W*4OV /#O05%+K04,,6,[
M9LC=+7H?3X52X"E+TQ')3DAT2F>)_$O7%":95Q93L<9K!1^R FXN?=Z)GJ]!
M!Y*NGT 29.7X9*9$BW\3C#T JFDU+0RAM]?YDWNJG;?+ULIK'[WYSAGV.RBV
M+,[XT?=KM]D_%Y,F JMGXWB$*F@>8_S\=-9NLRQ+ AF6Z'?]GN=<B*(? +\>
M &HO[=I*ZM5O-KE'>2"M^SFG.@,/@,<#M!3>2RL%@MMMWWO$LZR_%9YD)3P
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MUHS7W>;$()#+9<'?"?Y+Z^ F@%U-J="5AWDJ5_S(5=J%2\;\]BIES5L3&7B
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MRLU2X%[7#F]4.)PA_59!)4XLK?\!V&.N&<Z=IHLVR6CQY_SJ+YF<U0DUH7=
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M'FV)6U*>^Q1HE<%L(%>0<5+[*4[NB)'S)F'7U%=154@!ZRN;K2<-8.+95TX
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M1^O,GF>(#N9_ '1!U3\ 4Z%;6KFZYZKPLT^8*(RGS<<LN\@$.S@MLRVMTS^
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M.43U\?-%70-W2WHUIYSOV !2B ;>/\#H:P5_>->=W".'G-PIB:2?L5:9>)7
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M>4^-T/OPH4Y3!KDQ)1N8DOX&EM-C;HXA(I: >Z'30S#]L8Y=%@<8,:- QS^
MM5SF[UEIMB2]J(HUV[4&:5-KA[EAUD3R\JR>[1UA$&>1YPH5I &W/@OC"TAV
M(>4&[7-+-.M!0KA!]':QYI:,)_JQ :%&E)>E]A4:-K7<U'+=)E"79U))H$-9
M!<MALH.7K^HGY011F0A%(V4E2%IECK4#E2X_YP#BI8=L]0_0ZGN%",[,A18'
MU0^-(W?AX _X*2U =4P@7( VE',5_]K8S#D$5;DH3DDE<1#$L%J@O?3I=/6P
M[@\N6P,E/YCV)=G\L,8DY>@DA[7![>R;7T6L>IDW/'6NGT1.<>8F9/Q:)>NG
M/TDN>@A]G?#1;A5&B.ONT*78MV0ZK'28G>\%(,#F;[M:FCAJ1!:-KFN25W6;
M]J'ESL'!)\CH/JU&;K$Q:$VPYU<(Z/S22J=PIPU_"M$>8Y#%^JQ)\LNY&:_1
M$)E"#G.-1U':J@NSG;2:L8L$HV]C[9^V$_H0VC1#"H;,:]5\A>$<2J$)/8:O
MHK78@AQ&C@SV+)=+[J(YF*OY7KKB& )9K+QN90K</.U5JGP@4J6A\%45XHI=
M'<>\6JUVO !S"^7$#;346H, =I6&%Y\"V A.H.FF%,$0*9P:O-Y@342XT4X$
MGHRS)0<FLHWS),=F0P@+2_ V#F@):UF8ZLT<<[R57=SP"[C<$KUXHQX;_7^<
M)V##KC&7HBL1;*#-KKJ:CS1=-S/57H2^':>NJ_B.SXHOX'<?FA.*$9$5'SE6
M-;:WM+QPGO=[FX3+.5XBS6S3&K[HD\&P,]#8<+V:>HTVV^-$%F(@QXC(]X[*
M!A (/XZ"#5M!DHUH:SYNSW>C<:L2#>=,FA_:UO/N'-03V/@' .FW4:92:.XM
M(/+(\\5Q$GL"$SC\E#;TL7[)'&K+(P[V:T?98Q*RVC/A/]S;97:HI,I!&MR:
M?G@BBA%!=L$3WFZI_ ZZKXW&EVANFV,*-=$8(FEI&=V:!N3:ZN2!/W_/3_3H
MP=S5ZP_*>BW+VA<M>/Y0(UW,'.H:2*=MJYCK?K'&T5K,MM(Q*0%, 1=K<-^K
MHH7\->'*D]3A]Q0E+KS(?+L&<48R5;62>5-V<7R_YM>YDOQ0QSG$9V2[1NSK
M2D%4@P;2#+P<&L+T(.TY@"UZ@3RM+J[0VGGA5]QM1?9[>B=$'7*35W_8<I @
MUS"IC8#I^'(63\T;^>#ZR,28TX<VY$K$MBP9(>.K3GX>HXHK]%W<^=ZW+YK4
MP;A*73:5:A>"]_-J:@+L4FQBBLKAI-K>Y%-3$5XI/5P<)W<9W!-,4]RDE/E<
MPVZ28.(?D_KF#L#,03/RE?4WDDPGK[QN<G_97[W[A6CTA0KN0:630V'ZXU4$
M]=.\B^9&^VJ_E2Q]]RC3*$LY\2-Z&>G=QW;TK7F2**]3C4J1<QJNO'95638F
M4RU?SGJ51OTSBOW?1'9SX4)F6UX@=3;<V33Y"?( @P81KK2?1]Y')*L+3.N?
MLB+A6P.O##5-M#GE5;**RBG0W%$#P)/=Q>/O+<N><%/7K4O;<6"*_7M'(&\T
M4TUAQN4C>VK&]L"AM1V+U^Z1,J_L%^#1J_0@^B!,%A7KRD0N4:4I70^+NNI%
MX@Q;T.< [(LDA;[[O^I:S@<Q%3T')NY@F6@"ERQ>4G)HPD*LNJTTN_=[DZ<J
M.F"X/(W>;V,K#</,?5,>@WN"=.Q+L,29_'UBI&[7,2P7,K?X,!KN :;LHDY3
M<B3TD0!L7[O>5RSTI!"H1OX#G&-JRT @FI.78K?@3\MHFRCLE^+8_H2@P=#"
M&;' O/70.AJF4G+5Q;9O='V]WT['V)#(JEZY[1D32S";?[/PD3"SG%3^6G>1
M<)6;L?GBT$F=JEM-@ />0U4 )1DCHYB[3!X2:<^#(\<W\JD^O*5)I,>HW),'
M)<WYIO9\-T&NE?>-7G][I:=9)6N^(ZG=# +QKBS!#Z[HM4>:I\&A''PRKG0P
M1W.Y5'!RJ(SZ7'#@KI<KJ9BS4(D@%$E&^K4*3S-K4EUJM_)5*J_$.!@I9>BI
M:Y_W&H%)39B6+IAJ-K^/];ZGZ[*PHWRJ:E59.>#8?59<RIJ?G9"Q!#5":IIE
MUW<;J0Y9Y]=!'PTA1BC#F\;""9_ N^5@-?3%<R<#)W2OV*SF%F5991ORFK=(
M5H/>QV(^1^XNUH\5]F8W:D>PI3RO<>-TS1)F25;-'1I?3/ +-BU&'--$]21P
MF*!$'S;ZF<K$$#;->&YN%M5CKK5D6)[(7_525G?7DDI:J<Y\HN5AJ6-07*)B
MC0C[0BRPUPQ6) ]]*^=<VFOY&P:L?1.N I-#ZG6=#(0.+SV-&18N=52!OR[*
M >#F,%<VDBLPO(+,G[KOAZXTZ^!N+:LN4 JQFCQ ,7B(.0#:[N2\R:%72U_.
MGKQCE$3\R2&8U^6,"1+?2.@/"I[MKV*$?-1'MZ5CCDE36<<V, -G&7[R5TA,
MN)C5U9<BE36X IEJ?+D#NIELR2%%O0,_N"/DU5A^4<9TI*_:?A9PU>[8@D@"
MJQ\J9W:" [^,!@@BT)8E?QGG#" *B(Z>C5U%ZD.36MC>+>/KL#K[E%COMDNR
MZ>:O%D4W5ON(VSHMX$52RS1_LT' 57F%Y[#;_6U AE#5C4^=2[YNXQ2=ANF"
M=)_2L([3M&&;D5E5;8!JSZ^O!.]K2W$0J\]RCRQQS387N(;\Y)XMBD\;/G(\
ML$RX'#R0+E(U<1;-D5_H6@PBFDZ&I1IKO^47KO%5.:-A=[%+D&PS$@3D#_A
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M(T L.X0$=?#ZKD52V]Q-A-=C!GV2F)6X\H (=$C#0(4Q\1$+AW.(D8\HR5)
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MVY"X472XCVW\\S8[M6@3SVLVQ?SXT=F^>15N:'ER4!5+E\-M6U\CVOKW4#[
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MFDW]3OD;D0Z9]YGOQ/(]WZ7[WH2KFEQE_NNW"=XWZ\B@ZY1F?24[H/LRXQG
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M.Q5&:Y\SG#8T#B_GM&^H:.M]]"RXFXSP-?W;V]L28(;IM+6L@D!R:G0%B:_
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MP[7M?*=J/;\P)<[9.3B+<7'+Z>24@2]Y=(60"V//_(.#1]\AQ<E(,T^O]+F
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MK4#IK["*6'.DNX;SK0T_6+BO-D $!>V&0#NU81Z+[32*WW<-M&S*4I<)]/3
M=K?,=;G6J&(JH>]D8>DQW5A]FG\39+. C67-B1_SH[+S=;(H .3 ,?4+QG?H
M*M1#/'W:$]"T"E)V5JCU6Q8_.*."YUNAW&+!7E+[=J=NKFNG4[V2N,+]:DYE
MDD\0W"J6M)88R]-]JAF5 \\?**27NHDP5Q.G7 9F5  = 'W-(D63$BL0^IG8
MH$\2Q%LFB_9 \8H5=M0J[.VRZWY)K.'N5[>XW*K2YHO>*@DLR$UFEK4&#>C?
M,H=@,\E'3YOB&&_8+1;^X%]G<E*!RM[3^2+:/HW ) -]T:8QIU*-<@#14YX^
M+Q)6A94-E7G[6D[E69R-R]!X]H;,I';2EK'CQ#+(\"P#]QZ !&H8<*I(JY.C
M#^S5G(!.$786:67'T,?KB">/$0/2_&6&3NNML'54A^+&L362#QZ*>+0&!H=W
M-Y+3ECJ<*>N.ZA=9&-[+*.)=I')+OB(#%94),BKP\TW&1_?@>>LI#FZR$\EG
M+20&<0Q4:4P,V6*2/H'N2$E=.?@6EP<*(#WZUXF9O=@;.85E*\5AK.EHE40F
MK3#'ADK5S1!B"57X[S]%6..8T39_?S&)XFDQ6U!(*>O4M72T^A6%*@@8+\C>
M*G_6EI/1*HA1B$@#H&W1/D+T6-+<M"'QZ-\QJXKL;;U9&+E%[!LZ-L[RU4A?
MBR^-D[@*U-N()%EZS780)-F,CUVM%(T:&8!A#'&3B?+?C!>I_![T9M$Z$9\$
M]9LHU4;,LWQ27K\H:#3L#.R;62WZ+GO7D^I/O)@>8&L2#E].LF:(E[,G/4KH
M%I//[E*]ILVS0GEG3P!3\-3,K.' >7O'H2(AD_9.I#%<0#Y?WM&B(I=UD3Z>
M&FVS/OAA)/*<=GGK8E9UR>^,):L3LED6U2@FPL%YZF!OH5%;>U1C;Y'WF4LF
M=NY=D])WJ]5:[>\:XBBN,5 P& +@C)!]PX18F0\1&O<J]?X:0S?/7Y9S>'N<
M'Q'ZNV]YNPGNT;I%.T_S?F'Q^_EKOCMP95LL(&<_AY_"$"H7-#!&$O_[$ WC
M6$<W5A"<V?.9V,3D$UJPD_:&*H[,!AA_SWVQX3?W1^+N#UU"M1I_HB5"^J8_
MFNK/5"VV4X;],%*]4H_+ S%"\[3U VR5AA/ULD XRG3UF/(QEECT.JMS7WC
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M2I5!C"W\*DPZ%?'!U=JZ'$.6R\O[ I?80]K/0]I?ZT(<0(RE;GB7BFBD9L\
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M!#W9?GD:"7F\I_O]#]"_V^ #PQ:791$G5-Z]&HHA=)\5?OC&#[T<\5IX-4,
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M/>>^9W5\;O>#'81BWS7,3'9,774ST""ZE7T-5Q2O5;(&9^FG>$>%KW?!J_\
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M _$M0E?"I>BWVIXE3:JDSP2:9L,NT;8U596$_%Q-Q<(LWP[)069U:47_&XD
M%L6NM5P\E=:5 AB;#<2C0+AH,.*14T&4U@:98AX:JB*!4'U'8*!!2(*3S.G$
MS]J\+IQ\7K$) R^,#,NG0MPKZ@MGY;5Y25% BWNZM+ZI4A9.R5K(4SM?"@=M
M_>;7+;%XJ.6/,C>XO[W*#\@T(%OS;UEBD"&NH]/KCEK.WNPN";<GT8IJUBE*
M][)EDR/HF-#TJ[)ZL:T"75H2:7EL8NT/A;_D9)XTW'2,J=HYCE'1DE#A+^_$
M'U2!")5%SG%6R)QV#A2K5]L,+S+(P]"+4F]71T$E(6&0P)ZR,K8(%6C:73"=
M[XC#0 ^@Z+]6TT(Q;9\5A-K:WX0ZQ93<*]<Q@@!"!I^4?Y1]^^&[%WD;?5M3
M1PT9=O-)&2%_UZX)A?<.0JU7N.#RG5!#;_"LZ(R!87UW&*#2^\6BC:@T0<\E
M_C0,6R0W'QKO_TIB(3"9JU8.=^ >58"?L)ED\1FKKM-Q]T.[E8N"NQ4'ZRI*
M2C1._$,<+]U*3D>3VX=>E+-5SZRP04-K5KE/MWHPK/\ @W_F(N%59:.8R]54
M[FJ1L3=5.@*3ZQ.S\!L,3<Z-Q UKMLME_0+U[+)PFX)W88%NV(4E1HGE^[EA
M#6.KI&1+MG_+B,7\M"(V6VU'R),;91)VU4.9;N2FQYN!T6W#B63RE]U]^9@2
M02#X#<.J/4R38EB[E@YA=^RJI*S/YTI!#*$&0P]HF]\Q=^LOVO#N3WZK7P@E
M')&2B C_:.KN>A/G_Z=,T-F)?T++(@OU7_K/8Z 7^K:6H$H&DOKR$\MI^%RY
M4N*%K:>[%CHN7U<_(\PC/MLTR$Z1=,3VSYKK?]!P?":)>O%PU9M8>88+LKX_
MI_V]>UA]-W'L:X+(PX%]0G='0L:/1#Z#X=4ZF5=O+K_TPE[)N7FW-!8MO)T9
MUI'R2R9D0IXQOENT2XE.I]@)<TZNAZF-S<5RZ4C45EO.P?= B%69#:*)"8K[
MK^8ZYN9B.R(>M363?28"TRJ5E43.QB_V#!X)"!SAL7&A1^:(0QKC9*$U"E)'
MQ\MZL%6_H5+\=&$;E6YO.AZ8GI7Z/D*>F?AL.F"5(=5)$&9$7=Q6"DZ/<JR=
M*-SQZ^OE:<OX[A-:R]J+/7[6O+HXKFK+O*F#'B@1^&2_JV&8'K9+IQY13#\F
M%K*=TNJ"R)HWQE,\[MI"H=%$R$1TM@;(]=N;<F-?2O"=]T_T@3*M*.6S4!C"
MQY\A SAP+0 H:N0O*$*D^\G46)]8'$*M?1AB"GD^/I'&9CT3,\E[M: .BE(A
MH4N_#P, W _G\.HQ+1UK(7"D:X.8:KK+T)^S9%;V40HUN"H42-^J496[MQ;_
M\^F3U(*#M0$/ OQR,J[7G<UYDN_6_S$FQ7CBQY]W=Y1$>3:_T\4RIA+2<1+"
MDMT9X^CJ,4XECS_8).7Q;I[JZ=2<\0N&C_-'G_6N6&]>59WSKU[,8G=K=B]-
M6@U,76HB7A7J4%5@7EG8+^ KCVB7YA\5+\T6F%4C7(N09%*:HO$W!?HB32_[
M']!83YSKMJ5)+L[7)TH?"6N:O7$)M;XG8U).F+<I+3.Q"DW1LQ;6\V+S7##:
MI9GOJY7ML$QI3UYTGVSN26%T;!WVF#5+LMZ&CWJT%AJ-&IO9NN;\O7>(V0MT
M3BS!\&4%8"UF=S/2]/9O)4,D#=)G#O2XJO%5$KI-;PAA6IF55SI>9/E(%<_O
MH]V[M>[KVU-=#.V%(HJ'.=NQKM:3M]%?=/_:5UVD>-5*22Y/$>8[4TR]WBR9
M>-A2O_8['"NOJJD<7WBN(]02$0?%8.82W>6UEG'E7EW!EFI.'"^?>PA>!1>7
MOCUP7V5*+V9H^2$X::W9UM;V&S5D;&5]SK1RN%_25MJ",6!T_^";T:.%S6,
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MP:TJ-*W#?:6@9Y=UL_I[;U8+KI]M?GI\WX)GIUFE>9Z'A\7<"4XP88DPA'-
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ME%DM9[!CB&OB)T4WP+JC8VU].X.F7\L\<QV5IHEC"3>]XOI0VJ^"NQ&];YX
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MAT3<R<PH6\"<0T':K3>CHY:*GI<+ N62;(FE7-'&?9@<YO,KD;=U*8:4RX8
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M&J1\JYIDZ2<>5V (VFAWVZ-1H^R\;MCF1-0(\)>_ATR;LM<3BG-&__ <VB'
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MV"YZK<7STFE@K.UJ)=QZ$$2Q]Y"C[SC&.?AEO=C'<6&@1)-0(F-_W'/>Z2,
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MA(-[@R3%^2U\<1XM26=,CDO^^![&*42+K0 UA4/\AC.Q!IM#Z(Y*+!"IFXL
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M8Q]52"R _5C-7@ I![RC4I .$M+595M?VQ8TW476 _R4:*S@] YR7XF20SX
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MTYK735)I'4,.FKI1ZWHK)15LEPFMM/=!)1+9+]?8I*58*E$9ZF2DG]56'R_
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MBSDDLS%F.2,@''0GZ1&I4A,9#D,I! )%?-__ /+@1:(%HPA6G:!2BK\XF2#
M4(!'%B"(]C[XU$?\F*[7HA)Z?<=W$(T@8-(%VYYCD,-@G2!!!\^""//C'3H^
MD;J: #D.0J X!^OQ[6^MQ;IA2L@HU)()7N,0N$[A>>HZBWL,;>S_ ,FB[8[*
MZ/2]Q'<"Q1V?$L>W3!F8(,L?YH G'#P,X +   XZ0OZ1.I'"2K(<BDB+',!W
M_P#ZOW^/OAM_3E&^V&RX\B 0%)\N;QS*"#Q\+\1A=T_\G?[<X!(#OOO;,7&
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M=]\:6=_\,_^W[NE5:U77WF?7]JI]3G5#9Z KP%,Y*5DI  X> .!@'P Z#T@
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MJV]H[^CLZN[I[>L?&Y^8G)J>F9U;75O?V-S:WMG=.SD].[^XO+J^N?U%+C@
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MQ"_)U[OR(2)\H+RX>E1^KVM7Y>-YNP3CBKI61LUB]2W:T[2[U>#;1&!WNEO
MRY+7;1]IW:=ZEK5DBM(LP?([E=ANMY/,6JFEP$--B=#E "PQ+A!RZBU*E[<)
MDP2(44CHYP6_JSM/41)-*;5GY6[4<ZVV3E(Y$W=XKM3O@"GNJ/N:,%0F3:^N
MY=ND"YDBN/)3JE<8+FHCE02B?G*D)S [^8YN,C="HF#/-8G ;EXP%KNV'J&@
M5*_]A):<H/*$MZ!TKY.:.Z:XUN8'*8?RDZN#GA*WR:WRV877WN3CD!&<5Z/?
MOJZIQ.Q5Q(B276\?IV-D+G?S.BWJ=CB:Y,^RSB,%6.?#TX9Y F)\],MX<D==
M!#5+/-9(X]5$)=B#M;&X#/(MQT)MLLAV?/O3U:HGCVK?K#7JD7%)N]8WQ!PR
M$J+,>#S)8QF662?CT'*QE9J6NO:W]<J7>5.=\,H"6S4[ &)DV^36EHZN(-%Y
MK&TP9$L6E.5^N4(T5$P2+Q3F)TM#CTB*-B4=<G1PH81FZ385V?*X[&"6A!#"
ME%-@S;9$-5'B8FL,!5Z%P&<.SPT_)U_!N@JT%0P6;M0@_&X81$Z.:!2ZXT]Q
M.9N/,&X]>+">X@V_1!7;*9#\HI#.=-EUB(2S][O6FU[^-L*R5V5LXTVLEA['
M$&'=L44M[0\YJ?P?Z?KEEAG),!$HX@#7R#6^G]RV;%[7;ZWG9Z)*BK$.HQ?R
M6>#OS%OE])1PYI>D70M,?!-<T[GC55_B&V.*9_'1G)2JZ30:R&UWM-#&;)V.
M*\8LCNF%BIWIU5^LK.!$)[N6I*%)9BN5+!AJ6S5$Y(%F.Y6$NY\@+49E!+ I
M2C<#[.^;E%SR+41\,RP]1W"=^J\4L%F<D)QX2S&5^78$B"<3.N,=KO7=_;/2
M?@;Q)!BI;!E%(1-U>UR4>K6_B%)8Y3_'<^*1H:G'UJN(TF*;N810:;LE7L3>
MLPEP>I3D=\'W<,,_&]33QM:.]N-[D 1<;\M"6;B#?ZXDHM:;-8;U/1$C=%H4
MT3?GY\]N.K%-";#LWAJ&\+-/#BK?$$7A]?1K\?<M<(1-O2O$#+_GB>[]ED!T
M<!I26QQY7=K$ =G<AOA5P8%E3M!KRIR=K6JN-&M=5U_%7ZF\=\"4^$X9V5TG
MV[I* P7>YVW<V8D,/5NX,;2^ R76]QP__#016FO0LX$"[>,M^Y$_JZ# :)?+
M9T!%$O>_L\%]3;<$S7BR$+NE;=](CGRMM',3?/$J[<BX:N=_> M9Q)OSQM:-
MK/BJYH?^0"0;$9V&6U];&SU]*M.DTVOZ">X".ST)KR1FRU(TI]<*7,5>-*HH
M&]'UP\^1^?8<NT4%!%,4VX?=5QI::@)TP),]+(7%]^M^2D*CMRGOW09,KZ8&
M7)==$9B",7\X)VZXZ"41VGFKX.WW;"WI=;-BM9SO&;=_@@+-9]NY#@KFG?@@
MC"6+*[2T^3$K!E5LZ<2AYB=UA^H,=XO/,;GA=G%59&;G7*,PC:4LX"SR:T:@
M@##,PJWF]Q;SH/OS2,A#VDGZX[\ ?P'^ OR_ \BEC,)I_AQYJ44Q,;X#9(8P
MP%K'%!O[ 8\!;9=KD;7PC/\J%MHWAI^R)JE[''Z"V\)^+QA*!3L]NS/,\@UZ
MD,[::8)X:[55><,X;"BJ\!&[FS&<LH"5V"[:VYI\%O;JN!9X0?EE2ET6R\T&
MYO<VY2053C*4ZWFX<+,JDC1/"V6'D=.' %8\@M2TQ5C(0^VURG;>E2F,35L(
M+MS_IN'7>C.487U<W(YEFN^,D-=#MB[8R72^?_E)8UW@^8BR$!Q<0B7G0I;Y
M*45&[/6KO3X 6P9P>59GB.->N+>LKEU5='[ZTL2W2XODU+D/N88)P7R-':ON
MQ9BLM97'G(E1W:7*]$E)D1**190XOKL=FV%CG<M]P%H#%;&ZP9Y@RX!:JE.1
MANZ3@7I0X(5\B99\HEY?9R5MEW,5/(%%#^"YU4!\5GLF1+:&Q<U,8SE^$I!M
MYA7A%3&Y).F!>$);3N"^\$@3JP;EODCH);;WR6RB<I)UC%YFUY^)BC=L)R\I
M^;OD'KL/LZ"C>? 'X*_AOX;_YX<Y:+5H@8Z'39J;?\U6Q25*+P52AIJ&"EZ+
M77H@EM-2LQ:N8#5NB2NAN=.33Q;I3"<.XNN&YWR.TJ_4[Z71P6=?+'HJ@Q0!
MMZKT:IUTG=J/^;6[$W-]:3;!U3?6#:L$6:Q7"OZU]$QR,7R",KL*AJ@Z69\C
MO+(KN5@.3(E>O5HGI&=N)%)V;"0B$YAL+-$7\[0Y^%EJ;ZZ.23W_$_ZYIQU;
M/Z># QQ]2!%[\(%QJNA4+?AMB*,]ZXS&:5;4BM']?!TMO"@E^3E<K22N,MP_
M:_J8X1<D\PI6A =E;%02=L6:_')AAW;N(+F#([O5;Y7Q>Z[SI-9U4.#C5%TX
M?+<2]K[SWNW[-P<_ON5W,"F9W<(],!>A?;97U:-)P%XH412LR W/-+Q.I7%T
MR^^W77-*$TRP62'G:MN?:C3@ZKBU^PQ76_M(!0JPFMXDG1U<:]QYZ7G)#+J.
M2C[!B2E/5TG3?Q*?6TJMYJK+UC660<C<;.B0&<*<O)!5M.NP=_LN/M8Q5:4Q
MRY6G_UI+/4EN@G;4A2(!X^7+5 1/'TP8U>G2M?I(@ATIR(2A;L&=/@*]O9;*
M@[2* ?>SQ$NU60C:=LFCM*J@_1-I)4DC=ST#XJZ/"5R8U>U %-C=U?[DJN2V
MW<$A-I3W_<1:=D (0P$#0V8(\'^G930V!G1/'MH9FC*&#P4XQD8L;<5:,I=G
MSU<\RZPX$)+(,5RDJZZ>NDD3U!IXDXR6FC6JF<.@R*456J^6QR>HH#<!(Y,)
M'\*0#A_"U'PQ-JL]XM2&A6MS)]N]]L@QS5,AN[0[UJZW7-)Q]/KR12IW?,=
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M-%A<AI/_WC416UODM7QOJO"4_V9#Q?\&1RFARU,=["H+VX8[8EYT =8>95!
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M_OBFV1Q[$QB+49]-5B*NWAZE,=O,3+8X<"ZUZ@[E8.8E[W3:3@SB<G CW8T
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MT*K\]BL#@)Y0#9@0'GP-:,IDA*^V9&[M:>;JXQ<Z77^6R1E_V*'M_KGRX.H
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M6:19)*0QZ#_>$*4E_JYQ6G;UN[ENA63EJ"\/ AM1:G4**7EM]1\9+H]!NR4
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M'<" EG]M7U/BXCO43 2B/S*KO1-ITX<SCI!E>,I$&E#?5<ZK>1.-4IR;B2
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M\^6HJX=G"PF]-M+XO5>@)JFE]E0J0M*"-,=56+FBL&TA1,T_:)(C$=8 DO&
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M6(0%/#DQ_ZR++38YC$W$D"&T7#=A_YG+]B\@I)RY1$N%"F#@;=[K&>$8*VG
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M\7$*7N"ZS+E_$PP<'!Q\/'P* @(*SM,TISG_\A^Z$B#&QEB G(!@G &.$&-
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MUQJQJM+$L<U+C[M03<!RD!C^,0-OL:%3'CURX8$WK&8TY1XMSF?943O939_
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MK=Q-3*ZP3,:F<+/.$9EXJLXZBN99M,"*)L%^*Z%;>.WH3I2B4SNL%5SF"F_
M2>)@54$5T0."Z#X7575ZXVE;D$_-':!3O=,QJ]@/4:!!Q%&-LV6U0\>)L9!X
M:. JMV)?\;PQN,['C$H5;JS%@Z0D!0VXX0I.PZ=28<-7B^4N@^R(GV-[-F:K
M+:'E*0H$[>M?T-6W 8'?KL42JOS24-1^$E(W3&0ODG,.6O*9?L<T=*W[1T[,
M0 /X:*"Q%PG9Z3EJA3!":<$_T_?DN5 WZL6"=H8?J+ILA?2]K[W9B0;$3 <S
M854==15D.01G'JXMR^U:J%?8::]U0Y?B-#H&HUU19T'R\XH<"?K+M,*4.!H
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MBNC)10.!UY"P5W+R/U#/M]HL[D8D".TB_V:G*'Q]>-L, 5,KOVWW[1\::X@
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M3A?R0BMW-HHJ!,;VL1/"O#%>4LSVB)IK>IJA:IO+_Q9<N9^6_@-02P,$%
M  @ ?(!<5(Q0JKOR.   XDD  !$   !I;6<V.38R.#,P.%\T+FIP9^UZ=51<
M7[9F$5P"P=TAN$OP A(L! @NA;L$=P@2"(3@3G!W"BTHW((3K+#@[NX.P^\W
M\WI6S^KW7G>_F36SUO2I]?U1ZYZJN_>]^WQ[?_N<I]]/RX!7[Z7EI %P+P
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M UTNKY#X9DD#^OWE:&,B"\$NO"KPD8F,933C^Q6)_6\DSP9%]\W6N'$3/S8
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M44<:D%@_ 2R3M7EM-#JIUX;LSZ9''16HT0MV5*]+UG=G>TZL,L^]#1WX;Q^
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MREB#RLN)J2)_Y_0M&8>1]9A,)AL)/G/RWI=(QA?E7SQ%#\(+/#5,\(YPADL
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MWX0);2V=G5$4-BK97/)X)]_"%M%7X2^%.R7*Q1; P_;E(\):&X1S2S?>FHH
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M=8\Y!ZM*7H^4$U=,7]^]37:YO>0=V6V8'-O&^=4)-3KYZB?&0F+F^OLAEWB
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M2MZS+L$#KLN970C[]RW)!"PK=DZF.D!]CE7C)#=\"X$1Z0?!'H]V;:P:M#'
MDB8%IL3U80L[+2 /=ZY"9[RLQ411*.QWZ;O7T,@UES%<_T%(>*8N#B837*J;
MJZUB=TZ3GM!4]T R.T+WX\?VDSD1]_*4!A_-GU><.D,4X7B@84#B6"H:ILRO
MY&4*0?*]H@(XK5F()L'TF+5&]>QW AYT&:<[_"]4Q]YDH3-E80_T'!>EGN5@
MV.J8H<OLUE<G:4SA=5.5%\4*BI>' PJRVCH2>)WO4*G-8XX=X$3<^4:G^=C#
MO&V\+5XFG[ET-6@W0_U2,"RH<"<]=R8TY?^Q%/XO_&\!Y=/,?P-02P,$%
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MQ<"K?DQB[C:"_8B1;X7IY+=I?[/L?V=8X/^79?]AV+_LF@5P49 0SD,A!$#
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M;0CVS(V$84!C"Q:;BK?NO>$ X]F/]DOL)C@P\LH(32'YUW7.J_':Y,G14?8
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M9_XN[#1G,$6:2#A@6@('H)1VB!V]^G,27[U:<4/,WWY[G $'9&K?=IJH^)3
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M>:>:)8U/(UDG(3&YWRV@,5E]&TZ(/JAVTW C?.?28D\'-K-&<(MD"[X61CQ
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M[@ T JG8C/(V= B/^C&AJ?,H!A$][PK#R>_0_HCL_RRPP/]/D?U/8/^,:Q;
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MUS/ 2[1<D^Z$\* U&8>[;W:UCTE@K)>\06;18OH\SUC.3<N8)[UQ3X)2B7!
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M- K:]3LE_KEYY_C$HL)S<1+HB,<S.-#&NW2;H"_=_9U2?4LO20.*/Q.^7B_
M(/-ASH-H(<+KJLMW;V)/6&=B2J92?C"[<ZZ76Y*"_T:@DJOU9K] _!&S4G$
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M.Y\:][82?RG'5OG??!T%/O/_ %!+ P04    " !\@%Q4V%(D^;,U P!4(P8
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M C'IQD5#$-XU /\"'N@"'J8% &/K>0[OUP_P^P</'T1PCI"(F(24#'M!Q7D
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MYGZZC,PYJUE'>S<NZYYY=^S34T)L!29#2LW:\4UT$*^O/WS7 2>D/Y1>4,$
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MV)=&:]_?3DV"PW9:GW7/4ZRR*9P]Y\KO]P&!6\&[O%-GD Y!#'!$)HL^\,(
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M*V95&GQ/798&;V_[CX3&X4Q,"@;X1CNKA;<B=:YQ(<<: \B<MOKZ&E\YI<,
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M8T'WI%W"68[V8L!%\$].<EFN)6LQ)A:V7J.4XR<26M3'AB6Y@]E<YU^%S9Y
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M2 ?-)PF4G3+7=6&BZ<,KX+%G,A67@!+W0C%Y1M/^"2I:[7?<R81/\)B1BMH
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M"$G+3)K6<V)C!S&,I?TXQ(21'CG_M*M=9HNC=&<FZ$M59950$AI+H8T#;T8
M1\Y7!RP>M&_>OO?9+.*B[U4-IT761&I92/W>'? '?@>$-HLSSN+HKIRIY%'B
MBN6X1(>SHA<USJM7X.-AV=EW\3;WVS"U9<F2?:1X'L539/!9-FOX>DS9=V9C
M=].3?;5TC2(Z"9F"'4DCA0.5%0:*TA_OU+UE,JFBU"H: Y6D.C\3-+FASVJZ
M+IR?HX'#Q::/?9LS]6,0HPP)H5S)]_L1_H$V@A8O 7(ALOB.-U:SXLMZJ<8^
MGV#:.7<VC>O+HZ9-IBA#N1 IA+[/P^9MPS.U'3 _@ -WM5J44I !+@NAA66P
M/3RMI/^\::0J<4-!X'$ZYPIZ.NPQ4F-V7$@:QAG%3!](C&G4W ZXW6UNQ+H3
MEBZ=HT SF7V%6)H/IIECF2(/L0_&1/=FM_@WB(3_!C(R4_ ,(*UC$P5X#UBC
MJ>YM@M7R5YT$#%H9.$BP CHQZUMR+'0-&C)?#?;ZA/,Q5T/F8B4=JC>6Q@MV
M8'&Z;3OQ<=/S\N:/(TLTL<I?(0-;N=?LN*7\T_HII>56;,#JZ:QRO:>Z&KGS
MM_JP[/OE=_I#;S[7<ZLX1M%_1^UKAT@)MB[Z!D]IUN:86;](@\: .A/&)Q5'
MH?J.O%.![1[OD_GCG]>.IC1(9ZDH3WYMMR.N4R0C2L)7 /OL;?)\:X'*Z?[J
MG.<?^!WPZ/X]>4G V&+B:D,J.7M>J9=KW26@-EC$<RS#+G<)N($V>#7W.BB_
MA-IFS9IA=.84?=#;Z:T('7ITO\%;2V! +A O5!0GE6BDHNMY=1B6JOG-:_IS
MQL\\_!W E#L;=?DV @OF75>4L0S2VP;6(AGPKK.?TP%XWX^0_MYI$W_@_QXN
MET!HXH1U]E; ?#UZM1+96I]PC2S9)[5H,1HO22R&G+0<<4E:N?%!>[9R<A_V
MQQ[[[8#F,$\NXMHHD0Q6-956FCD%%86]V":-J9UFV?D#:A$@,J??M5;NUYD/
M?P=42FTP'/%Y44*Y?IHUND>?$+ (V,NEXAHWEY&"D!$BZ.GHH $.5Y<0D2'/
MF>6.3O%(LH[OW2BGSFX!9:S0OP@*T" *I=$J([?*@TPRGJ9#3RZ!N<K7"SOP
M@,V%2*R)DD"CZ3JOV4J?L/.U$9AQKQQ&F\?&FC*Z-]"4<O6W.=GX2&Q=#%76
M^V66(_A^-A[1&SLQW!_L=\6;GR_K./@<<;:*-J(R%AX#J"CL7_>BN+#'U%QM
M.L=',QKYP;H*=[SW>HX','(R\"A3L=:^OV?$?\3AJ4A6=.\CFWHO ?1>AQ]]
MIGH3=\0'P0.4J4GDKC9=\*S_CPG+=WV,HTJ77QW$ %IN8-IQ&Z]5LFBL$6WA
MYUWG^<2@HYSO+4ZV7/(CA6/*MW.T17%WLF1_/Y\!]%2<ILQ[=A<<,6^(&2RA
MKP/K&UFNVS-C])625L7F6]2*U(S)K>7>XG*>T,ZQ$S\+CVB=9O_P)%;U!3/5
MWE77V(#TJV>XC(K\Y!TN,,R^EZLUYQVQ F]6>OKIQI#N\H&UMR,$N;L9#-SD
M=.7WA4NA78.(20_5J^P+GOQ7QLI=(Z.B:D0>9/*K18>.OBM3D53Y'3)?8H R
M%=E?QO4/_ D8.J .LN>:[A/4H=LU,GL0.2CPV4^BI-)ZM].70UR=M8DL\SO'
M9=6^?M3KC,$#K!O%W1N%[Q>)ZNWJ27!(6G@)+,\8UCMR@A.]$<KK,PX^)Q0.
M+F%O@[<M,\B?:M4[N2J6$&0"[#-<Z_AT/*N_M[?W!_X/$#J )DE.4Z:,IM*'
MHW1#:O9Z*XB)!*W=8OHZY](F&N-)?(L5[KIXQ;'Q/DPUZYOA%O0.%FZ6L\"S
M=7A(F<,L'&() 16(,RAS";.[_G,&O> N:-4:$L^X(^?S[M9XI^M4!AT-/N!^
M;][@I@>63GRW WNWW<F8I ?I;F,SYOR7]4.;5^\_X &;A@*E,<^R<_AX@)CO
M<=3'N<2;"G9Z%1\UF)Y[%$([@9*F#4-I]QL[HN.WD]5J0\[-"(D8UL1HLN>$
MT44)5A\<LJ:0P:\LQ$_]1CW)D;AK\*U"DW.7QG&YAGU)R.H2H!N[!!Q+"S8Q
M!\>]H7'T;$=\=Y%RY83;GN53SM)M?BJOQ;GQ5SEZGOID>P3=[\S4*ZU*EAF)
M*6'5:#"*WUO32F!R*CGD^UKC;_&*2%;F2)=#4&KTAGJQ[$AH9:89O#C>8A6I
M^R:6GZ_'WF3CZ"XD2RCR? X,L9J'K#1^4:*LAPP*J:#:X 2[57X)O$D^PSV!
M8]ZQ5=,T'5HL,^\G?,AD]Y4SX9,);J5J2KQ>)YLYPUUEMGBO,[^42\!:=>82
MZ(QIE-LZ9?FL=U2Q+Y2ONGO[0.!U3K:WA\518)VA@.&5:J/RSU?M!(H_%W(A
M+ +D=38C6=@?1>_%[YX7C!2]/[*Z&I@K*=YND#[]+/)%J$""GU(12[,('>F#
M#1,.DP%3ED+':IANHB3?/L/\/6=SH[P:6RP^*9'1I9I+( AF68[Y6.CY$4S%
M"V%YP#M_P8*2(-]#P6Z!<0%D/-IE_BA3ART_*63V]-BJ('%)"+H&>;-#>N:W
M= +=V-4;L!Q62'(T!E$]&7$4N@0Z*/I&7Z_3"]U$%+TBO&G(N-H[PRJTK^LI
M<@E$Q%P"KM5\+[.J0LL@B>G,=1.CS'D\[Q'O/6E>%Y?8086S)4;31U^J/I5:
MF"CGZ*QC*7KPUA,TN6CU%K/>D5S3+'9DD2A^NW7L,')?Q)2[J>XVY*[_-UG]
MP%"$[,$!C>P%Q<:&+]+O".NT;!<_SS+--D?*.:=#;C5SSM)UZT@UG%_I:CUD
M*+_+'70)W IJG(:!"W:B; .R%5T427:OB>N)I4$Y"G8?_0_?3G.%G>RZE'B1
M4EO2C1#EL*Q*??E5/M#8H J?E$7O#&%0;F!\XL/<6:<*;AU%XU@9NE&+PT2[
MUHJ)PEK\5/TCE>\!-9Q"HY4QZ-'*DDA:73S226$F]7#<T52)I. @DB Q]ZLY
M')?SB6TV7S]HW9-V5YTB@3VJ^(9Q)%A43<] 'G+_$^4;]14_N3 7-4_)A;T)
MYZJ-C-JD\S?FD. =>.BS:HW*.NO" ;?X30T_5KH=R%BV*B]HWEV$!5<-7T0N
M2)<UK8R_Y7_AG3T_D%);+:_G&/L9  G;BO"-7/1E\[!ZVD($HA=#(@?]4S;&
MPGA'5HH:;EG<^RKP.))$D^ZYZH3[HQ'&:HU$>J*D#)PESMNT*@W7<Y@^,*=6
M^11FFTWZ9H,63UUKOYY:??M*NG,,^N;6'C._/L3O0RNPG%TDW2R04E=R[^:G
M4#0#!]>#E7Z2_N!V97L.N0^K)"J2.I]_+ !%PC8P9(<78V7VQ;K]=#LS7=Y&
M\$KP#HD%+F%@EK2I'UJ_W.ZQ;M1I8Q6N>5/99JG%0M0>D7T)Z);SB%)-S8 +
M2.4IMOC(0&WCYE%@W?[[Z(\-+'!EPS*_V=X("XO?9P#GF5>F(LKO?Z5:8'V$
MLWHTP<$MWD ZH:[VZI.1KL,WR2E]I,4;^^79(W%)$C6Z/UNS8.2'^<EM+*2G
MX :)5&3&A$2XH)8E6&-WY>+Q%Z\-&%(9ZWWR!&D[7>2AF^'IHI<_RQG/7:C7
MRC3\XIAV#JQ X?(6)WG:6E3WT))R-L&U*)FZ^]/=WI3=+5;TMW_YGXH1A_Z[
M_#8-N ;U%RH7H.I+  ?-:R5C%+PR2Y4C:FMB50B(*IZGW)WJGU0%@2?5O?Q=
MO?P]65:3Z!\'HXR"[ 6=&'J#V^[=%@^G1SY%DOEDUTW>13<5W6E5J1F"$9LQ
M/G_.W\37!WC,8S/0^0KG0OH:;B!'SV0S.J\L>J22<G*#H\6(OO)#)W2PU!^U
M[H#VPS_N+K35>.8*ERGKD81+J<121PPUA-2C3 5EQ,GB3'<#W:[T6>#6);#Q
M\1(0  YZ:"=NM-UV]-VB- E$!JDD+QF*(:W ?H9#1C7!S2_$]*C#W/GH'4.K
M:%G7(? + N3.FM:"0DWTXGMOR@AQ,5K%P2<!SY.8XKACC-Z8'P!:T6>*R.A\
MI(AM'%%+TW41FTM@#*8-2Q011IGC80])0']'JR/YNG-@&]&7*8E7#$91&E)>
ML6Y?[SSWIT*88#8(?K]_D2%&= O^Q;%Q=X/TU->;Z4>"X'UD\BZ[%58K\=JT
MWM>;K8'D[:Z\2RT3NO*"5%?TXY&7P'Q PTEGR)VFERVT''V ?>/.0 /;)9#\
M<VQ=#5L)H:2>]VI.;R.#F2>T7P-:GX>=7\R+XNEMH!&^Y0#U+UWPVC51[ X(
MR9(L=0?<$CB)!TY5H85&UF\UN>0";Z6KG6C$_QOX.K\M. C;23LZ%? ('D:5
M5^LWA@TTQ-)@2:,T&-B'/]O2CK(U9T4%]UKVFU*6(G//I81HWN>I*V,5F@LD
MN(:5%AO5$;[3#',1B<S[E#W%\4J0NY]W+=[C3.MP@_Z!+'DNN>W_EA'\ _\&
M8 _/SI$V>OGY&UISAQEZ17EA9]9C%TREK?BYN^Z23O:*<+.+@#P+U]!X_QZ9
MQ84L]C!![$:"CVXW AX2/Q"\80 .G$\6$,=#7MFYQMLR'#GQ$"_[BE,*H:D4
M@4_,(H6#,=+UV]>UP8#%O#W(LS<M_V)K<70+7^N&)_/6Y9#=YR)'T#<((?WF
MS.MX83W7)$J"7R;;&9IIO3T#[YC![67O/'WR]:XU?U,*80QK[IU;$+=@>B/?
M4/4+$@F\Z&Z&8'G^U:N 0R.A$/?=("&)5PTZ9J"=E:&&YJ$R9%F? *6,-R[%
M G3_$GB=1!@A,2C9.QCQP('@/C]HK>PWV]+68EOP.L:L/"T?A?_I*=9K[F/E
MG4O )3!W)8E2>:*OBH&NW@HY(_[@"',/-"_119V/U2I-,55YBO@F$!OJ-&9U
M(X<11KZIS\/&'A,O$G&_O0<W]/6)GEI/'5-11:(S?62CXQ?E:[-:!>WL?10U
M";X<;>5A#PQ85)\WMR0$%&TWZR*K_2V97U:1?\IK&;7Q_"Q%_IF ]VF)>L.+
M%:CH(@%B4;-Q[\8EX..EB^A'_>VBWNC:]%I$\1WZ13E?_SS#DY#S"=-*\YD]
M K_S9JG42X!&]9QUN'&1&NO4-TSB0LCD1"O]4.G=)?"VD;L-(7J,)W^!<,)/
M8\Z>/752"0R3MQ: $^9108@O@7IP^9PUX\Y439*X[K[UH%I"M,A'WD)V'C;U
M\#58UYZ@[/+0=NOS=$SR$ZWB58$RUTQ?&>RI85 K<E*,ZPG\#:R[DU+:HF\G
MJVK"9#V]<JN?3)A;DDT Q,]47%)F]&Y.P\*+^*+ %36B^5:I,-)=T3-_O77(
M.+%&_*0KE6_U.4?'F1+*]]4\B9^DW&'P"XS-_\1=^]V37T1Y\AMO_OR43GC&
MX^+R]G3D7.G.[M&9.^QT9!M](G.\)GB$>G!6S=WC$J!%R:B+M)6>6*;]IH4#
M)_8@^1"NX3")X$_TDHN6&9D"!-&Z++[5@>8)>6]^-NTAL(48M^M26#AR=J7(
M5+\\XEU2ED<Y]]C=]RM%GPPR[B!>5;"'IL8_/6;:99AJ[NJS]KKN.8L*YVH,
M"==WU^-P9L.:T*#+#73GS1>;#O"HV)N#\R9E2_)4J;<'^YTY+B2(O.K!]6")
M6=@QGN0%PA4AA8M\\57\8J\>-:.*6EO^F7T+XH\(!9H9]4JS10T\:?QP2;-!
MV8S1]]:Y[+;+(1^%(."=OHZW'/?3>71.IT?[X0U3XZUNU\+5\; [>9?!S#LQ
M%:KDFS%USQ>]159A=XG\;8[22Q#'+VPHQK+U9#U-&:C";@0\$J=N=Q(AV_4)
M*BR?M!E_!\=1_W[R!UW\B@.H3S$CMS9]K-V(;=ZHA\?M[$9FVS.9278+W3TE
M N=2#Q&3<,?[TL/1X%23''$/G$]X/J7\G1:(57B81M9*ZT+I>I4L)&]+#Q71
MV/7_CX4/F%_FT.Z-YM*@7K=HVWUXYKMX"=B/]$W<CA_(0G&JAY@S3(J3!,PL
MVVX6<OJB<K_-K^<"X2Q0,=[J^@!BZV&[M?Y59_(538_^]8Y*S^<>3*]HH9#Q
MGK&5%$-D=\MX=SM[-4A5E'KBHW<[@"@B$N+/^_RPO"!AA+2&&@'=CL-2WU*R
M"'X&L3)V=5'$F%VN10A#.W5+1TA<;F :?]$,<Y9*_A$4,;YJPD!-U2\\^,H6
MCMB70!OI<E&!R"WUP2WGXR3UG:0S@_D^UU2W NVU+Z?J\R)?1T_VDX,,6R\0
MYKKIV03/;4V09O.0/%O')]]NG\EF&L@OM=H73,>^V%<O*S$8[KX1N@_FR)SV
M")CM"=UM-ZBN'D&,?R3NVA@V*])>T N?2)IZXDN4NZLKK"=8?>9@%@62DJ(I
MOYT<5F#ZAK.4'6=_=\[RR9YEQEG^@_7NY1:#CU*#E2]1ADQ7H,R^D[5I1+\X
MKB&[9M*@U?'#G'7/.KO%WEU<9Z@;QTB ]&U*FI5,UQ'BX#D=K70\Z&:JCH:6
MB!M7DSR66NQZ4EM,3)GF2A+OI 6W*QX\$MFO^K F54.4E0PF"X>]51H&2_%]
MQ8'NFAMLW?G$6&)Z4=X<EIOF*_(V< <>771"[>5=MBVP:!#;I2JIL=L0;WEW
M=)"KX!KO5V=IQ5.". QF7*.\NV1KS_;EXXQZ4F:55SWGIQ[Q1YRQV7DDAM]H
M/HGX@N )K0!-QB,.'"(QV+J$-YK2'<MJ\/B>\WYKH!BY>207B,69W\<)4ICM
MGL=[4 *CR1HE40'[[*/)RDL"&HTU-QVMN.U!\[KEPP86-_B%7O'!I';'LA?-
MMRT* VTBP7:9$^6'Z53:7_7A[T.3>6*($..@JW*A)<0;QS3^<PI4=\+N+/4G
M5!=A&91!%#2=N^<D;,"#69/G'Y0".)_FS<)Q%Z98C.1C%DMZGL&(I$9B:ZB.
M7PCW4#*Q9 0BL=1I>0LBO/.;8(]@> /;\3TJP3YS[U[4EP[-O;(<4^?'+&L>
M60[D6+4SK3(T,9RXG:$D2:)E-/<?.TM:G<G'-XPN@:+&.7#^?XK->N)F=L\)
MSQUH/S<,[-">A;SQJFKL;KA;@8IC5KTV4BX<#@.]+X%%?;_S]@OU[T?I2-"4
MU(931SE-RM^+ZY!B\>Y&1)1]*4LF7[^I?-XU@P%"S 2=*1BEK;TE[K$-8;^C
M(;L.66B\N>ZGN\L[M7<)]&CV :ZBWU 4RBG"5"L>IW:=[&##4"'<M\$3B38W
MOKG-/,HDL:1PDR2RW>.JV'4P*IP)ZSRWM5HRO.Z<?B%QY(48OP02/1K=4%3V
MD!;QJ3'677P^XIAPZA* FU[8HTTCL9I#YKT "QC%5K4.((8EO/'YU:VJ 80+
MPW&4-BWY%K['M5,!P)TW!^,2$ Y$%!"&3@.G0MD:'Y5B?/<L:3]["T:\OA#T
MTQTR+DE267GDX[JGX!KK+CIWV].+$%)QA+UDK-53Y H])6VYN%6Y>S,2?Y&S
M-M%6W3$%O^9X>&'FS./AB-:@PSZLLQ%Y8I630H U9W@6KGP)U!H:3:"$*3#<
MPD'N__HS( [E/Q%PS!L&D4KNM/<^]]YO>P3OJDA%&%B0V.HLO\%!)(<W,#U\
MN_-%XHY0X*TF4=TE3Y"S!P)&E!X4$D3&OY )N%F=W0H2(>M\.N"[DR_*\,7+
MW[W>AB1.()*@5H>Q?Q&R!:_4X9S ,])Y<!&[Y]0^@T]-VK979GS$:$IG$RU&
M,[/CU99;X&RBJF,G4#&0<0A:X]V+:$Y&4;\),H[#7.]Z,4MT!V2]*H.X+>JN
M%#D)</)[[\[_ULC,'2_<3)=J9427-$CS%O)2+HGKGHO2X.AWS09GPLP&UQ_T
M:HB]L4M"+%<Z1DT\&>S.E!%Z\>['-<:@ZA2(K?D1&MD2V>Q*N=$  8$9QKAE
M$4.-OTE8:79J;K[W3D?-4QLK;O=Z3$B]%$$JROF._/'>GS_P_S<\$B-G0?=F
MJ'I/YY]A"V#P+C?<&J.X6(K4.WJZPV'<[CHW/59<*?&)>B-$*&'X^TW2[ZZ2
M:$P]:)$_S0A3?Z-XK5,.V!9B+JC0H?/6@J[F925:<'Y+#W)0\=-<_Y>3$T&@
M-@X;C+:%6S'0."AP+#B_[3O9>C(7C[V/X?NMF^_*OB)2=/9PS&'5*BNHO$PI
M\(J-H3AROR72.?U1%-QL7SOTWD&N.VA.1H@M\X.9AKC[S4X[,6JJZYEUU_",
ML?T ]9C?,!_"-NGA)? &XE5K8/#G1QVM"TI!V^VC=ZY)-G.H8.'&ANC)&G@)
M3#YW"1P3ZJ!(0.Y(8+GIC!-1%8$L/CA7U&H_H9@9?V]L.(T7!>DM*,H:OMN:
MR]I<[/D>YN! S'"+BL@/K+>@ $P8\(ZP!460H6>3RLW4!;LP\\H*\1HD=:HX
MY';F.YO5$$4VT_J[9.9TY$8<1NSG'DR!Y?D4JEEZ^!>F\\<KSF4>YK^HSM,X
M#.=$[+Q[Z*]!7^%&,Y6-"LA$9LZ;Y7.\.D,;Y10$+\1WO*K8' B1>V_7P(WC
M(@P7AN[]1*,H?F43/1W= !/R[_3!ANK>:J&$S;@$MK4*D((7DA^4,EV02O,?
MU[G[CP0\\_=X$)1\VY8T;*1"5%JA&[HOX\%I7>)-_)CU'=56I*L<.>,\)3G[
MTHRG6E+L$4*O*J5CHQ<:8%I1AKC<[I3SA")?)Q3'W:ENK.E'0$DI<H6#>9,M
MA29,UARZ2Z/83C*/)I=E^;O(>)O9ZT:.P:LGNGQ,\B3KK>8T$;-WC[%Z$" X
M_-;WIT_?G[(#+RA$1+DO =?DW*7I[]LDL:CG3.1+KWD3FXLER85MY+'A49Y2
MP,P><?4E8%NE=?KI0/42B)0X.%=Z8H*7J?3H'MA\P1*W*[9H3BEFUP?\7H,7
MEW6[$"4< Q:M[E:AK'I81$+3LR7_@JR*=1=1?X?*X;NQU!&Q2=+U]IY\D:]>
M#CWGO\JM[UF9*9]I6,HU&]4TG_R@]$@ HM<MR]?$N]R1'DK-3VL@Q&D!#V!_
MV]OXYRC+A="W<?$>*:K71\=]+\AG=[%.NP]0<[&6$/N?7>5CYW\FNV#VU43[
M*30*BB8HF-[OKC [BZ&ORXI1- I:V6ME)%"59&\M@:602["I#< 9YI6P);UN
M*+S,BPJ7113A2=V\."#,ZN'.IE0M.MART;!<]:2O&LHV?!]_9YWC_E8WA/^)
M;>H5FOE\>%+&[%:E2+QU-OAF5(UIU1K%:$,V>JG -L/6<CE'2UF][H)\E<XM
MVQ2J77!VBG,\OBI(\VEI.(&2+H+UF88"S4K'LLZ3G?ZDI)*S<"CTR6[[;8<D
MUO_)RH@F2S!*9TE93K,J-FZT70)[N%Y'"I)*/HED2@N=([LO3E<V#"X!GS*^
MY5#P$^_#YB)\3%.,T?QQ(;;K@5*2-.5+<W29@A\W]GL?YQIMTF3-YV@ >&@:
MO)38Y;B: 9)7:'6K95RU"H8L>I$YGSKT>^Q:>/6,(#E]Q >:=%HV._,KME,,
ME4^>TK9470+7O;K "^?[>M, 2OMR1=+JH#2;EH15O:1E/9,>D>L:*Z+7&P//
MUP\L?HF@G.8; _H_?/*:GK>.VR7/?HPA^ [G4(G K'AM3,:1D"MTN:ZR=?":
M P]6"69]Z:T@9:]2CF2,*]O,K@D205%+&4E^N_IOP^R#7@PMU4Q@I,S"];0]
M;Z,4VG9ES2 VRMI)" ]?5H((BW24YG[!L[?L+J#-!NIW\JD3B>.6"?"@3Q?%
MYQ#X&?4E0)=S"4P5X=THFQ#Y$/0T$;OGHX#<DZ$14MN@V\_?)!C)PA16W=TU
MIB*;D*?J7Q7B*Q\1<+S=6?*SH$B3#@TOOUGO<KBI*/LQ:>2<5-N2V8KW/N6(
M5H0 U,$EL^2HC&LXW??0'EYOU798=:/'E^=BW4?6!OWKH\&'=/!XKQ8/N_.5
M](L;&\G;PDX>KV(+W&<.F>\<E?0C?=L+$+(^IP6=H"%G7,T]YJAIB40DKOYT
M>;Z717>1>-=&/"S3@#<K'2]E%O-3$7;?(QB/HTA2$8W&CN?GK,.S".>TW+6W
MSPY;^)M/6XJT2A-'^[UC])_/GUQ]('6-\I[P58&2.GE/3OOL-P\(Y53?LM>R
MASU4M<#-74ZZ/1)VD6,]?BVV4 EM+8SW2RW'16%^>.)93S#M::^"U>H%:[2L
M=R?-7%(5C"9A8=-EV6.:!5_EZ7G8U:+.$DVEH)>:1_+OB.)PVZT;=Y*^HD*+
M-=A"]11.R3-\)WF0G%SG9]5/)?;+67&=3#Q*YM;*.]V0D3.BO)#"^X(OEB47
MX_=.3Y/+IX5FC1TLD:)J#RB2;^\5X^IKNR;$"D6D].[T$[T>=>M1^\)FGN-$
M7[S%K9 8ZKA7O)XC<Y8_+H(7!3W6TD8VSX<8O-B;%A9OD>9@#W<&1N\B#6@X
M+H&4D(O&!3%:O4%#1J^6U5W#\RN&B$N XML%M;L\'#'U7&\:S!-<A4<!G!#7
MY2]TG@47HQC,< >F 6-'HMB-_J4H8O*,%6/)NYV90""@S]&Q\4:=N#%ZJZ4'
MITT.!@"GIG!YR_IC]^PH@N",O'RTK&I+6SI.V>5$&2O9JV5\5_K\2M;9&N5\
M/U1NUL(. P%#4:0_OOD:2/IADYYC4% O^WD8X*R8.U]OJLVR61G!*E(^XHS5
MI.P<M?S0#1E]Y0;YND<>/+2!R$*$XO]C[RV@XEJ7M.$F! E!0D(3( 02W(,U
M[J1Q=]>@G>!." F>QH)+D. TTHT[!(= \,8EN+M;R-<Y,_?.G?EGYI[OWIG)
M_>8_:_&PUN[5:_?>KU354U5OU3MX0"B-V(OMQQB.38\/\%;?P<#"#8%$["Q8
MCF*45N?>DOYBPYFE[\1TNFS'X/;--T^-[WM83ETW&8EWTR=O,-RZ^^W\ +5C
MX8K7A8L$1+[=;_9NZD6/$-5[ODN=2S>UO(>(D)]Y"$^O/E^B^&'_6^&]4V?4
MUK)'$25X:Z.5P3#56$5M40[Z?39^!-WW%)0$TD>*;I4@()\(H->N"Y[7_ CE
M1\][[[R6<FP!3EQ3'(Q83T5.V*54<)K>>] ZCKC6V'_QAFIPN58#4]^%I0FE
MD.B:E*/YCXN?H\<FTPU09WPB:'B:S+]T_WE+[#%5D\?/4AF4BB? J>LG!^UZ
MG>'XZ<[TEQJ0>$MA"/3\K.]GE,W!^&<9?Z?@[U-7^.,WPF8_  XHJOW_^4SE
M=F7,HJ*B2RK.YG[3"-EJ96&W".]YB([-K18:E-@*>/+6&GT-062K7.01M+GE
M]@/ <<B\_NQ=&ODK47FR&#:\=H\-8R[))U 7)S[UY!/6ATO U<@<2?.[,C"2
MYEMO16 (FO/9!<0.)<''?.VSC$X9\GEMM!^ N].HT4R+'E647V+MS[,\':>
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M/B]M#WW+D>*LI:F)2000AD&0.5+<8\&=YAPGI6H-<ZE^T?'0B<5?[\-#H?4
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M7 8[QC[M*6D)<:D,L1U?X#0H5_@2"XR]\I[="6R\-C)LM0.V;J5AM'B^K"K
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MR)!2O_5&_DX@U,3T&C:]Z*M<JV*_E;GUJX M:7CGBO6<M6-66*3Q:+H;L$V
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MC#[,X6M@M7OPE)D'L?<=<P@9]T0(;=X9]6/0\=]O@'=>2:CCL<]I;I*MB<=
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MV-\U]N3S3WJA_&AZY0K/<K\VIU!01]O#W50"*(=V_ZN:WMC<EAR$.67)E,;
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M#$"U8U>WLL0%MO#GOLYD-7;@0^3[A._M)>_#667'/U) _$9&_:29D7TIR@"
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M&P)<BWTA(R5!7*B,0XF&D7'FXUPSZ:<$1=HZ1QP !U<&'J_T?Q9]WM\@\TJ
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M^]D\#]8GE'77\A:7!CZS::[0ESZS+Q\J@F76\"6=7#CZ4N>?-DU\^E75R,]
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M+7K,N2-MM69,'_9X-\*_:9R:?=C'Q[2;ZH5$HK^NNM&C+9"32JIS_6&L-"2
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MPI8 )]R O!'@ZJ*!]RH\ZR<7)%J/.*U8QYHE.&PAO?U8&/_W$G#^]T&-T97
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M)$4X<T^M!$IRAFS=>I])SZ;VJ]++4N8NCJ&OS+H6P^,[0YEM/2;,@]BS1&)
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M)P:$)(('5IV0V#A%R'.MEI$0W[.RA]-"#55 G#=.3?'%(]G+3D@123A;- @
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MP"-^*(#I@08P18IHO=A\-<R"84N%X@L_(1[9$*+[Z,W-J/(N%/5*$65P)YS
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MG'9:"O@L_21X&KN!/23^!-FO(7:-%MS(;P+]71,._U'V<Y]R507% T7Z%3&
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M@[X=',3QD@<S/5@\J/A&>D)P9R10SHDD-;KD:SV&7UX>564[6)5[459APHY
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M5%D?>G%J+W\<:Y@&H\E=PCB*$H]Z$ZR3RC57O@K#:B.*G6O?4SJEIH^%+H<
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M*P<!&U$LJQ;J8+3Y;(DP[LO!>WMU"5FNZ^TJ:]@UC)0KC?.?S77]LY:6._W
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MR7F6H^=-=_;1$CIQ8D^^3Z(K^AV+HMUN>J"?EPQR;)KAE3#<GXZT_>7$*/<
MC)^53GRZ YK/A:P?2.3>"4!*6J/:"M@)V?W%\T?4#-I--(SXG4)4FV=3I $O
M;5]3EXV8LIIK,KJI&;U"'2NOO+#T'$30_9(=JG^=454)7V:.U"3$:P>/AK3V
MQ6Y'4FK=2''#?/C.O[IHG2SR $^\$+5K'/RR/ 7%N<#,"[L;4+6']WV\0:'(
MMOT#S6.]\-7^!)E-(_;/$3>V6:@/%.<_3JH64A/5FPS*?LJM#]P VSN8]K7.
M)!VR\$^QMZ:4&<XP$HP6R@QI6\H+;'H;73N40-<.)85\FWM)_!^MHR O(%,G
M>HC>-"=YO?M&UT4X$N*_M :'\]$]]K][E1[^Q:M4,B^4RJFNM!%>0E^R\1?2
M!E\?)9LZ]FMULDGXK ]<BX0JK[1WV$_+EI=0:G\<&GO0J!Y7C1 Q3=)Z*_QP
M )-GW)UGR+\7F["%R)>VLR;GJ"F>S\.U;F34EHJS:?OQTKF-MU"44Y\LVSI1
MI*C1+#Q^6QJF%3%'H20.3'[ED,U=["OX(E#YC3J_ZL0ZCA&:X&%$BJSU:A2R
MR6+@>OZ)(7*6]?.B;8/D%?MQW(;),WU2-V>XE0"_!4E3J:AZAL:G/&IUTKL$
M!& SJ%@2"*IG(3T.[N'1'H Q[/O9/TA<QIN&BRGDJ;&<7C&5YP@_(F0G/T03
M>]J"-K1B\+Z\=]F#[Q6&4L]:1K3A,6HW!+?(E#M42N@_>IM [>Y-A1OT2XKY
M@WM)Q[=JEA@5A<-"F['E&2:I]\WT=3<?$!EH(STI]/?GH38?H_W3QZE-@Y6\
MY5*#(6&V1EWZKJ(%K)EUYJO/_@&XU_\+;HG9T#;GF?[0S!VTRZ5L))7(@#Z#
M*[-M&]@JTQ"4X" +=+_0A?MDYF;"'U2\K5C<;OKD5GNGRU)Z%03[2'^;N) 0
MWO[P&3B_BC=#\+8A)1:IV&%F.4:1I#+I$PW;<AET87THGJU*[F"!B<F56$W:
MDH<]I7<BBCT7X;;4$>$>B4&$[LMOR)>A(HC'^2N(4CW:U6W/ZY.4]8L5<4I;
MLL(1)4IT$+2?NR@> !N@/L":X_)7K_7[H2%R$ZHU-N\A#5)U<CV%6\ZGTS@L
MO.;!X%A#HQ+[E:^+?D3@+FK,J9$D'+)C([Z0<7+A$>SJI'0 "[K>?[!P7;$B
M=N-^\22(3\'$G*$**'ZZ/-F?7J GNECU$SERR'8VP>;%9_0WKN3_&.6 N.NF
M<B>3SOLR2BPEA&N0O+E.V;2B%_,(+G5 K)7EH]OL?3_DC@1H:R*=W5/C!QOG
MJ"R7;R) ZAT+M*?CC\UM%IE5-(R^S5&D/5&($+0R>V-05;.?A<.:PL]=#M*.
M>^@N=N(#+$X@*Z?5BD?[HV;\4\AP8!' 947>@GX%86F\ST6+Y=^P=2>C&7C<
M#TP-Q4C>?\V[+U,8):FA9N &4LYMZ3O59!O2"KA>!/3ATQ_0[_C#ZFK9UPW#
M=RAZJ6 [<F<Y=%?RH"4)C30Q_G\J(X$H]$8<.."A"[=X)2P/"A.GDDF,0=S[
M1'1*JK75AE(JT1F2#%A#_KS?ZQ*$D/HY=+G+M"IZ:ZX'K7'>(4)%IG,_$4*6
M7CJ\X5L'Q6?6/5JK(7G$6+0 PBLN^Z>_O_\C4&#KMSO',E0\JJ1R(<9XJHH;
M:_0;.1/_\5>Z=CT#QHH]Y$-VE03!EP#/<6F#'[_-@A7(_!%N6> _&ZO7+H@L
M^WUID+_$TW\V]:6G]UO7LOS?F+$G^P>=L9=KQU=)[^74KD^2A#*D;:<M*8%J
M;]>"4LT74E1G;.GYG] :W .]+]0+WQ(_Z&E_(MR^ H&NLS9JY&1&P5L@;K;5
M97Y-4XJV>G >@[;B?>U/7[\D#'#( 2"DI"CS1O)7$YN$;_V* / -4'.[EAN[
M?J9$(F=S@69<ZN;5*SDO_IN=\B\^('K$+.@M&_LM8RF#L8SO'Q6K%5LK:+VQ
M#"% I$A9[DX9>SG;J!:BNL6OJ3[LPCNJ*^I8N\2O_\NOPLI,S.G2JV7A2T#9
MSB6@RXEF!VUZ"4A=V"M.X6OZ"?/&W1N<=K73.@3RM8S&E%DTXSZ[NQL*OQ%^
M]TH8@[#S?@L0BSY*<W0%#5/TL>:L;0,BXT"6MX\'.W120E"@B554E\YZ^4)W
M]8IVM_5H(M]@*M\E "\UZQ(@QO@KWV_NX8C?RMNT>&].8.7/>.6V)Q,'WF4=
M6V*/O,3\Y5"!(_ #<6RI,)DRG39RR=$-2_@*.BQ?5W?3S?03<9Z$]383)[$V
MV]3?&(S);KJ#5ZA%!EJ47]$IY>$*':+EBLXM.]WN",B1OJ2&9MW1'<K[T!V>
M7JCNM.X)L5G5+K8HD&+>9+6+ACPVVWO,%$4ZU:()^+[\.1HI]+5Z[[Y#\H]1
MZA,+H9KR2-/!8-M6EXL'M6<RT?A6<0JKH*6"]A@'EBFU-'$PU]QU%_<_[N7\
M8P.(YM1:?I#M$GG':=R]UYZ/C93L^[B;;DUJ<J4:B=H^EI&E>>#/P97(U=4,
M[?C)36<@)>K^;>8B)8)F.IF;9J6'MY4% F<_F\FWR\!<L_H9X<J]_)A\>P=Z
MR52,<A/5D(,X2 /(NMJB65D5 &<M^.<#8']#2M2DL1GBQ3HF?65 [T<X(^J[
MN22,]38+'VN5/6RNENT11OO1]D@4ABXF-C.T]>T\T<WHI8&S<$J#;A1)9J,'
M8S_G?A&_"HTY-[4):F;&1[2DP[P$7Z3F5.)UM)HHYU"<S]Q:?W'(>]1_>\A7
MK4&:E^4!K>ELVHM]<IO)Z^<7\'MP98MYD">W <<"U1)EEOB5,\,UZ@3$V:6*
M'+[+V!C\\+)_#5\=R[:"4"9K,7PSD#_"QC=Y%$OST>T1?Z0^4]%B=+E#NE$I
MEM*91<.O0[T><H-2YW[%\_!+P/Z FON30E.2R(R"V':6&4=;A2_65F5^<3&X
M2!TE<[.Y]['2G?F)\F<CQKS@U:+8HEMSYF "8X,GTW>D!^]W0QO"I.QJT(SS
M68+W[Z) Q!2=KW]N:HPU>9!Q2#\"GP8)^3W(!+?V/-D?T&C)@W&#X:XGB5G#
M+SRL'0G4'$\CR'R =RKB[_GTX*A7C\1P/S.-4-MS0 J9311RV^B()@=N24^,
M4=R1G2T$G="G/YSM[',?*RZ.^9K'@E-OV^+$J/B6-'<@.IB%?)U+#O0<-"A!
M-;O$1>\RC76JG3(N^_VLOVR]I#T9UW:EM3DU[+F)K;?(KE6)FAP> WW"9^NS
MW\/6'P#L[E]:1#_/&]O)BA0VZLQS:Z8IXLD(H=$Y;XG_Q=KGA3HRLPV"%^N2
M=]J@)?GF_]G&_X,RM[##T@I+RRF>L?*-R.- PF%K/@*?'^VDQ:RM"C8\[2Z]
MX/[0<=Z93D+VKGOO2:DQWDT-#[CN9N$@F_@X(@):#M " L.]G@,%?(JU-^]6
MHP*5=D:G!2N&!%1CD^\;;:X.J9;)V+K8G2K?UO),>"ZLM::NY1 001+E$.G<
MZ 5&&C]ALAPT_8]N^,HI8R<L^8)\XKHP5*UDK!U#@2X5T#R<MK[A^YJ!:MW8
MZ[4M_8)5L94^IJ<2#UYLB^X3ARJ+1N?Q/B\--G#&L0^3TY'I\R\EQ'Y*5*G^
MGCYA^NGBZ4BY/X#[?U=._]WP3^L<"]W^45904ZO,T\ ;)O3"$X;U>YOO$16_
M]&O:#;GP[-7[1O*+LG+L3OZ70%>"V'7H2H5Z..3-3=@ W]>&.<_FJR3.G/=8
M BSE8L5/_:*A[AEF?D25A--XQA>UM4SI(+Y>3*S*)R4]<NM#OJRK))TO:&SK
MLX 43KF3%Y]/ 8XGDACOB.C8B/L2T$^6=PD(6L#]M8.HDT@.-6S*8TSU5\4=
M^$Q]7. V(R-J;;\L;'+[ *U#!>K\?-]3:I,$6^/#+2LCOA'MH@':/_-9%KUZ
MT+VXQC5:9O CO&'QUC>]L8!ZN2Q"10S;$X8.9N%4J?6VA-G'(FY/^1#FEU=_
M76PX&'HQ' 8^V'./Z(^ +R-DRVWNG\"42A<R\6M5KSAS>_B3[5'XB:YH9]HK
M'.ML8E76?-;_:DWQ+U=X<=*M6F.W_E)SH!VEP:9X!PXQ-(Z,E\GYZ#0PSF:L
M%N*!)/$QXF('9T>O?2.R>'RS2U_TZ7PM;+\_V&O&.TWR'#2PT=A6J&TU;-%W
M;/TI$PZ*V_[3G5A_!W ??I5K87; HDR#[9]]\%E[1P4:=M-7P4S6'&'#]T$?
M/3#);0O1QGP?!Q?SLA/"?^ZU(3Q@"!)0!<![M*;PY5PZ=KT><(ENM$&T*DY-
MFH_[ZGFEFUVO..2^[F(EX<(4C [BVHBO+^*24C*MEA._(Q*#H%X!%]HLL_"V
M21A+Z@*G%1]T!>EH<^;IB)>_?;-W./_YB*YWU)H=:%Q7L2\!$NU*8?.&*<YX
MGUQOPCX-7&XJ<U-T[J*25<8@E=SN!JE(R6?9B5O)9"+XRKO3-9]?I2.1QIHW
M6RRS#1Y@I!6L+/WFK]D#ADJ*$/7S<\X/SG ^!%NJR>]5AS$XZXW;G'1Q2^/\
MC;GZ;!V1Q4.JMH6C\-)8>GWKV.UBQ2DX*U]<<N5U(8<.!5\@%"I84:Y@81;!
M2.,T%<WMU )E4NQRZ47B[3-5:C"<Q$#V0Z:Z)->K=X/W;W[KRAREG[XR9#![
MNU$%K,;YN/C1D$>6'WZ(&%P"K(<S$E%SB&J#E<#M7^?4I/M=G*YN>Z/FW0)1
M%1D2,*?WU_66O#_(8XJE==$ENDKHS.4+"A@5 SG9+66=) [@'\">8:WC +SP
MAM"$'WU"3K>*MUB:G'OI.R4$B.;H:\_#S@=/U/UQ)96_2]O;)7PJLN8&M"K]
MI\LQC%@Q3G)4*C*XN^GXB* ]W2:=*P)@/D\46K&C,+99S%*#F#V.\@;G).U)
MQLQ(J"%V* (9>OKI/W&X=*"U<4+"LWIIDT](0IPL\FQ>[*TG_.R)D7&6=8;>
M/6L]S3[*>9Y<4&B!M:4+\]W%Q!+U//_55*."?ZR@0G)%4F\-$MKOWSI K;%J
MU"%+TD1M.P[1(35;;<5(UFI"PX=,45*&=I714D=)K]W>6>0VSZ7<-U,+R ^0
M]GH,]W&!(<(_32D&W:I+&OAY2!'95L/D1;UQ9Y'O?%SC>.1P/S)JH=>(8#6P
M-XX#B_0([839Y<PHCY1/9F/GJYK/^?Q ,Q7Q3D^?HASS;%BKO$X(_I)E@+OP
MZYM529068IJ<Y/]J*_(@(U[OYYTB(&ZF>Y^>2#V]FY>;)'G?F1?0*^!=E:[>
M]\5\MN#CZBN.Y#PA=NL;Y>1#O3Q.*2D"H[K%]H>&QJZ?8@3,F4N"T_*>I=E4
MF#!PAE-C1FUNLTP&*D8<8&DK#JHWK98"'C&.;?W)E83_:= \E+!C/(5TO2QY
MQ\#N/8 ;]7LY*A>E)UZ1Q68:9#E?QGY%RY4C"&/8L4;F_<5I?N\?1L]U"Y0.
M)3"3"O="1_[N*ZS1OE; \ZRO+W@CN:%+Z% C\L1GXTR^2<':HA+QA_:.:0_J
M.*FK,^O6/R!N,CF*(  G#G#$^I2B:$BP13/ZIJ8F,=-OM,G=F,B'3Z >)4W[
MHID@X.0 I3PUI5@]AA=L6'7C<]HQ=,ZZG/.!<-?%J2O.G@CY37<M=R>=*60=
M UXR?LF?W&8$4;0,WBY/U#@L1J"]\?NA]()*N2>0X42.6+Y":FNAU#O<+=OB
MI,/%%O>F0:FC7%G87[\IH'CVDU^[:7U&ZF;-&RXPS!PD/K#1ZB'2!+I7J^#8
M&MM]XHF]*,(R-/1IM1;2M$FS"<DK4 ^_#MS1?ULHEY=Q>DH@S2Q;3$9=#BA7
M?PD;&OA/'RPE!^)SME$I[3H2$9_8A^%.RFR5+U]D9Y%,+LZR)2L5"-QUCP'A
M%QDKKACU,KM4O\L#='Y!%^12ZS#Z*-FXC#B+\\UM2ACP?9;8 4YKB\X1,+S*
M;J4CW2>I83_IT:PNJ/!UQZ>,N[8.H5SR_LS'\_>",J;MN.P%X!R)R^&%ZBL1
MD\,J>^I7;T 61_QI[U7&8%#>VJ@2M??-7NQES-P'BQ>!FJ@M8:Z @E:^IM$]
M?>I?<^2#RY'+,T CBNSW6*FV?DBU5M:J6FYD=N8;'"9.)FQ\*44Y&W^/;.0/
M^1>F\HIRGNEFY I6R4$5*PA??@AB6@'N^<"5O0GY0]J A55>@:L77TW#H'1B
M\<<F]=2SIR>P4?PMJS<LX5EW,3W?)L#7S =QMIDH$LG$#C&N:W@XMQ^>JN.^
M/G3L1W\E=XSE?-8H!XHZ($'F!KK=MF?#VV-;=*K--['EL\KNA*7@VH^;LW_5
M:"/1&XZ$1#MG0RA2P(S=S!X0;*K>+*MD(AC7X,2JZ2[[04J:>7IF:?HH[+8G
M, /8XD*8D>L24$%23//NP: T,>7<OW+LKN4%Z;]&'-9H[F[[#(IYG0743NW3
MA,24>V@#_$A PX4K3H,8=U]+72X[D2OJ4]7_],\^"==@8[-!-AW2^PL_)CM&
MB-\:1#R3\32 C5/-O0)"M?N.M D#1JQPZUV-[_T2=4&O[8:![ZZ?A;)@'&%%
M@B*X@2V$M4S[PJVP),_A>/Z$S<+R7]&Y:,_3+G?K2'U*RO!Q'L8I@5)":+6#
M_O9/8#O?([.6Q50;")R;74XBLQYO(!R2:;9>69UU'N;&=%P!%V"*)'[3ZCW>
M_(.0B&@MYQD/XSJ!KVUN<[>W=R^/10RQU5-NA?!Q&$#-GQO7U,B([\'266D6
M,8;71]KV2$^SDV9V KH<X3P$55+70:J34N=\+K*XBY3[/I[J^:,)X393E,AK
M025IEY>%;2BY]SDKSBL^BK!D^93H=+6AKP9-\:TGL>3K\T7II?P3%1]M+E3%
M45KUDI2)94VQ3-_L0K-BGO+6\O97HZ*MGH]\$2=Z?#X\\VSE*=*&2RZD&S%*
M,)*/N\\>.C)$1QDK[*Y,42RR$,-IA%4G#XD+5(.4]/!&G 9.\?U"!7ZV/>:I
M>O_21%LJVQ,^KOE4_:G\%N)DT#+FAU(TDH.<+BA?#(R>7M.+4UHN>?9-0*]J
MY4U8V-+T\!3SH>R(;F99N>+2B&N>@V2'$V(039>3DM24M%= 6$*3HM503U)"
MTM'K51GZRX,JKBB,Y8<XR):?26T54EXKSK<UL$(1LJ)C1+?[7,] U,S$D@$T
MK1W>N_M0P^;UTZ1>?>\3]*!%_#LSOK$L&ODYFWT/T=)I#AZWD<<991[SA6?Y
M!(^PU[3+T\B-IKKR&;"IO5#J\!TMYDR/ZL/]+L?2W(Y,V.LL+Y*,FX_P-]6E
M.G"3-<<TRA1_*OH=@H8]])IW* E\18N*6F1XL=8,Y]>X.3<,4%*"ID/U,.=E
MN%7SO/49>6GN1"J!A:(3!=:&1N9-4FRXARU[SXT_NXGV/Q"$AB[/PC3"'.=&
MG"(/FV8\750K7<YBRTK0FCGEUI< +\G3 =Q8Z4SC%V?J#Z"% W4<]M-*KMF"
M&:AB^SFI^ C)?)OIFQ#\=*POR$SXT[][C["305<URU_S\%::-,!G9A?:9(^T
MC<BCOT_5O,/3ZA7AZ[M A<_I\CQ5,%P,'F(I"SMYHC7,/ 0FXUA1+V51M29G
MNVX2X+,6WZ%1_*@S8EX6).^Q!@?\N'CH^7R])FF$Z9GZ3&.[N;%,.WDKZ7,
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MFEZ$&*C<+!V0FMEXFK9@^))+9%;<0FO*1.=G!W!<R@+;:%64R?@S;_#G4I@
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MK!RG>F,)2%7M-699RF- T8]^=<!LE8;)T-F^K&;]C!5G2B+&#7@(EC#(>]E
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M-YH^6"Z9F!<*),1F.?IUYU:JQ=16^6D/%R1='O)%&7-_&.$0/2,HL/^L&0J
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MOP6K5FPXL(!0-[OZG\EHDL/LM8'_S<<:YO2VT"STDHCL/P)$0(-V.7SZS>\
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MX_/%W^&EA[ITO81(V(O,,>\X[X \F:51/#F@X%VYB%GRKU*7\6+N_^5FH-]
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M,/-N#640XI647^A,9#61^NNGF%^!OV1',_B;'8X[0&2/WUP^F_?\Q4W"CZV
M_-^B!Z%G_S4W6MW\ []N7+\Y_F&ML']F! C(C\XK\L,?SVZ?"M+L)YVA_RT]
MXOL&S,^$F?YR2OF/D.<]O0EF2]UWS'$QO0.\'])DN@/XA,C"6. /KP]^QP%
ME$/??S.%5IC^F1EY>> F'ODH'$K]I.U-C]9^.0GX#5'-FU<:(W^R3QU%$OEU
MR]_R!QND_849Y17(L_R.!+?>?V5!C9H+D7..5^O&2.G'_Y H\NC=5T\01W-*
M\".L:E"JXYAW6!&2Y >XCX'1[@#82@JG)M=;D1?Z^JJ%=X!Y+92Y84.2&PX.
MYG&__4+)11L;B:([@*\:NK?,:Y.#JJIT[3M <_X=(# G^PK^XU2*:A?XU:]U
M9,07?'N5=4L<'[/UY7P< *WZH^X_ZOY_L&XDQR'^[?/I^;R+"9._O.3K862[
MN*#&P?A L0RT=GGM,SY*P\^9HN[G3&%K$(3_>D?DD;J:FG8#E>*^\B<E"*_L
M7)'VSX7TJX/@3LS=^^[U,+Z9A>[.IBR%0^+DXN<E$#>*<K*IW&:!DG"2]OKX
M0#9$7)LLR@8+,+)\ TY_$-PQ#1FF*CF*^WA@[M+A%9>6!?%[&#UG_I%F+^4;
MW?A_Q@KJM'2MHZRBT+T8[N*VE;3V,2FN@)0B(>DXM(EG;4*CY-%+: <?71S1
M'8#MQ8\V\,D/ZK4S-U6..-5#@@XNP1L2AYU.0\H'I5OY-OJN7F[YX8#[$4[;
MX*W_:4R+WXO'9/?!_,4&EU!1_TM(;J%^''R*EM9WKRX#!>_#6PX\<8A*I:M=
M*%1GBP*8HQRX1_2W!Z:"5J$M?9I:+JGECZ0H[9;M]L1Q'U*JI.L;Q"0GXC<1
M+PMBB&^%B%QK?B)*BCU4:]F(8MLCRVY([JUA%X5%!PWXXM"NCJ4K!N'JD*F0
M!I::@GGD]>I'I;\.B&*MORXF<\:3<2%O+:LE*[KB7Q:Y='!VZ5 HUO<L]_1W
MS@SW[R\K5T(XIK "'7?  F$XSKPHWW6,<MJF53"$R%; >HXL24"GN2 ,.,1]
MQ*<BX]D^V);I+54-<"V[BRB(QT:'M(^[I12_?0Y45<6QQI. NF=5XIKVN-9Z
MEY)3H0NX.)46DF][#A?; =]_6^M>>L-(VC<7I=]AQ*&TWGD&)C&0K'B7<CID
M,O%3#?%-F,9J!6Z?GGZ%2WX3XZ"*H>AK+:&T2IEX4[,,BN$U^-X@0T[5""WM
MC34#SWZH*X;SSM--E%B\S)09FJC2>/[10I? A$-N*5Q'&!4[=\ KV-_'&3F"
MK93'> $HWS:,*^,D6'M>(&M 70"R"TG^9EF'W??.292[-/>T>EH 7]W0\[JS
M]B%7(?+LH8D!'Q0+0WQ Y&@/A&V9I &@1JQYS4=PYD4M(]S#4&%[;8OKS/VP
M$:PC/L<;U/L5"4&G)#\^2EZ-.RH=[$B0(Y)NW?62)!-=#%D.F0HIZ#8K#:[\
M8%.W3\I,HK>9[Z?%;?0".2SW0L(RO+/5QF],_-Q<.^>@(;PM#PJG/:+//0SJ
MTJR'M/D-],J(H3(?WVP.]<#@5GDS)O+$I)/-[W+LLO T!5D-3X<P/$15QEMM
ML^56O]"QN\(UJQ&P$0(B%@+T5\:^"YYX[[(Z@*,GI%/>8!/T#_9,+U'AZ\:<
MC%JQ\UKVO;OE<!D>80WMWC))Q>C:=B+U%U&MK S?[BF).>&G^E]-<)R0<Q8N
MB7XW3;!9=G,R>2BFS1F?06?6_"*0'N'I>,.8-/CC#F!G/[XQ_%51?:TI0"/,
MU6IDZDU"WN;F[;M[LE]VQJ^.)8.,GR3K/6C=3%P+AY*(;X^"(A#"FLEA;_G.
M?NI\Q4^2!(>^_OA42?[A<M@W=.$2O3Y[5TZ?RM?OUZUOR0NLD1I&74((%^P:
M[$F(-N)Y;8 6+UL@E<+U>$ZV$ 3C[*1+'] H@J7_+T"B?@4*;?^4K:QD7%GU
M5HSA2@T]QO@O^9#%_YPA68LV,^+D#\K_!^7_E90?[=_T$]R=QLI\2^A]JWHU
M=;7_IY1[;^*.:&!?5JR^W %*JW#)*"(+LIQ.^6+5N*$TFK++6S8LG]%F?)5_
MWL[.]"?Y6>(@D1L- QAUC0W77B4ILJ#\(?:?$W/V52;[TZT_'=*U^3>M0+O_
M[J-G:4V;A,3XC20/FR%-Y?J:F@B27J/M?F7U]TRHY$X!'\K)>N ;)IOZ)08-
MP80G3XW*8XQFG+,+R05U-+^]2[H<^NJ'XV9PN=00N^-/&<=LT^&+EF.SF?N]
MRR'Q\H&P\.?HW?\HWY-VLD(;V8WC8?-B067W\%-!IZ.V/2$>-BC]CKR7^U_8
M[Y_RL%I_QE@.,1L<]O<L^+M1H4"1OM(ES4FGIXM_<.L\4T&L2@P/%V!>Z>#<
MU<16+HLC$A$[Q=;#[EOML^[';W6MO/*N+S9&;PR:?2]-(;L QZKO&'TV?_-M
M1E8=R09OARO4KLBAHQ[\^'XNYC.XNHX#/VN>4?&,AK6%33>O,!6O$=/'?OL6
M<4"IS</N13E-(_OW$MJ%J$@B+IE"EGP'2]W'[.NH0%9#JR=+ SI4$L31)O7H
ME.=PXG$QBWS#60*<!E-T4KH&$ZJM"7"OW>0YMQC0 =1W*BY>==E*K(,C>"^/
M?^\5JXR<46MQTC!5^U3L\073UM/+5Q%^(L>YC)]BQI#:B]<;>U63KB$18LL?
M5>^5N>%**(D&&V5_%GO( \I-6K4G&SAFZ-4N7TQD"C6JLOY**\\+Z\;H?TT4
MLX'FA1_LNE'ER[X%5@IRG?$_'1"I4!1@(EBS*C3:*F'P?O%6KLFJ")0>]_:*
M_ A7J;,^<&9WM?N^;VW>IC'?&$?I0P5:[FB4I<;]?%%#9!J)B.0'P7U*V4D5
M$?)C";TF!;C4(9\R/--P*N#92YH2Y5>+(%R![\H%<4^06*WUFX-\"S$SS"3"
M-N5MNIM@\#D(QZEL]N:YDU%)7J#K#P'&&'6/V?*4!P"D-.Y$JD7V@#>$^CXS
M&5WC%[WQ]3$XU>3@MS>&Y+8:^3M53YW"^4N+=_?3I<;,(F9DT1-:H]M@#0]'
M;\1S+L_RJ66-%2F1<8Z.^S2#U54EQL_#2\Q-^VBG>%6TC&K0P$8A;O@DMF"7
M2O;OS[Z9%CU;,E)!QZD\X7]Z.[]3XTB2HU.B16\?-I/C.V1Z8!*I[QD]M]IC
M-H,LZ:"-9WSMC#'@DV#FPHB8<23[.B.9ZBNX",FM'\YT%WXL]0/4V_5-K2H3
M0N;"H1R2\[#=J![K^,LC'^F:D=PCW41!]V<C#25JW)7.XJ U>].YI?UV0?7,
M!AJNMU^%"KZJARO5$:WV460Y=B:8Z=14U?L3X_:@1HN<ELK8.U!:O'(6#W3W
MH@D^Q0C>GY08G/?A7@=2EY=,;T)-D:IJQ *7(61+34**<RMNO+&.^_*;MP36
M8!WDD4E_CEFT&$ 6- GZ<.&[1,IOQ$^KW5[(X]'A?KJTM,JJ[=/!:/%970;8
MSU4\:Z9L]'0RX:)E8>)=[7-V+ZPUAT9I.A,TPTO%-TXP0$]D&Y*$\Y4>F-NM
MM$8>D30X_BKJ+990A]5FS1E4L(*_HLQ=4@"2\>MGSU^%S-K(@;<?H076G_%I
MQTVY;34+2-NT1?8;E1:77:ZOW?KPE%^/&BBAQD;)TWWZ4*#E0(N7&TO_R!\/
MXOW\X.0<BLWPX?G+ %PND7G,IP?6O:5<4,N:0J%7NJ9:ZOYH"O_4'+8H\+_=
M H=\I]D3_(:,W*(Y(JC]2:]&I70R8:P??G6<XG\8N_@W)FA8"&UJCAL(O7TD
M_B+YQQ$C.4MFX[/]UM_19.A_V0CO"=V'39C42\1M+@A8]1PR=Z!89\).5#_]
M<K[[&_Z4Z>ZW? (LJ+U_W0=W\,BZ?2IW6"R2ED/[LP7_5_X2*'OI]]\<^R%%
MSNH/_[HU?C_P'TSI#XW:K:H]NC2-*8IO:,>?G(8F9\M,T^_1\'L/$*$<=]VP
M&AE<A]X!?'_+ @36N5VZ \QKGXC_4?1'T1]%_PV+=-X@#K(TAD_J'"UD,&E,
MDIH32@V6:&Y":M)5#S]#)5[$B=7]EFCV14'I'6!YS^2\D/SGPE265PJ-K4BX
M-4"UK,27HDTDOHZGR^K!3IK+IO'X(LU[G3-3T=3G0I]<RHY8"%;3R X>%"UA
M K-"":S0H< ]XT<7-KD;+-'U#LD%N-T#[A/5 A-.;-)8M.J1<5)%1!CF3G*$
MN^% N;(.B?_,;)>TEY_S:0&KJ^%0(MVN ^>+T"X,,)59][W1)*]R<;7E2F>\
MY(0D:C_P' M0_E^7'N.]O_!GM.SN4V""=Q$[0[$NAYYJH:&H%6G>*\.M_%*O
M:7VWEQ4H-74EW9R$KCC!?,4\?_(;Q.QBRHQ?$@)S.NG63'4N:-!AG'[&)D_+
MI=>DM%KC'ZQ,,.TJR+'D;(]6*!)PYS&2YY(P7BLRE2FOA"3*T;"(C4$_>I+@
M-%5VN.E4%SB2J@D7DG<D?$HSC4A) E-%.,-P@4\9>6( D=4NZNIR7E+"!"D+
M>+8>.[FQBSH(/@,U<+_%AO?$]W"41:D;5@%1,I$W,:L/CR(_N9:\YE:2>1QH
M>I',D35(=%Q>3V,[W%1+?,";KGCTA/CB"@*JJ:G!VA$I\@*KD(?E@3+C$AJ'
M..MYDPN@B9AS7C';&JEK[?N,$=Y'MB?UZV?AF_%+&%DSW.^!QC^:NX2TVD X
MQ\:G<UWB\<M\X3S;&HWR]O*$CSI50+-VC9BO.$,)YU$;/\_(E7B(AZ^V@S<Y
M:MO]#]!\01#V\,50*[]&4[2B8"K6KOC^>ATO2JJAP!O>S!>6QY1EPE^%BR4I
M^RMM!(+:/D5X4,?U7,3?;MD[;TGRGQ4M )1=TPB"].P9O4\'&I4^&B0-:[Y6
M=(9:Y"8[R2]FC99:&/51F&V"JX;PYK9(WB@R89 Q'':XDB>$$TYL+I0A:CQ(
M]BI9>DH4;J09C!]&:LC3*>28!EMW4?J%VVVI5J^P/*O+RE$R6]P5TC>LM>%-
MJRLUZ*B8G?DR1>^T@C*L7\?JL)XD:QG7PRR&,!QU2,TCZ%V-H<(<P$H K6WA
MY2!9QYZ!9BZHS]'C6L[W#5DU&TB%2T-EQJ,GMI3TAJY S?HU?//8!K,F%//)
M.XN5HP@LQ=0]7)>IKL=66<;&=X#"L%LZ>%[0*;;2AQ574G0QL+;W$@':BI=#
M@N.C:G="\ /$O%K%B-V(LGJ RGQ;6-B88O$U44%7W1IY;]U8-B/I&V"JT8\]
M1,:6!E=<',I>(2C]RS?M<H$D?5W*1873DE?B[.-AJW@%,YV(D)SZ$"U")?QU
M$]4+G>$2/EWM($QMR1S/=/];&M6S]TUC=&SHTA--[@J9%378*6BDP+7E(E8$
M1@)&E2H;^P?M>O*C :]IY8.5&K M2N+@8JU5TNSX#=3B90=3+.LN;!'19/7T
M$%38XTG7,_PTXDO)3_5:VCOCOP G#OFUOG)R<S=+L&U91[?N H862>4>YH14
M/DJ/C1D0!0^OC)KC97&57U),5&*7D[*KB&^/AVE,,/,E3\G5W[ -3R"5E)94
M+DG0TT CD*$W0$6#MF^/A5OX-[07EN"[1@,:WW[2S772"4 !>HZ+2'P<I09?
MT>">[5F#WTK7F;E0M/31!'0ZB253[P-/U-&[0>M[G0E9R5"##\'SJY5&5-*6
M.V=1E0#2"*F"C7^!J,>_#"@8]U^&P0HD$B&2'%A62* S## 8*5LI.Q0=?% T
MW$'Y#..M'$+BG[]L^,/Z_8?U^U\>?_;X?9.^;*3L//_P#K"BW'CE%P[P28?>
M 6B<?_.E'R]X%>U]'L'/OEI[KR$=\X9SS*U 1ZEVI28TWU0$]N#UA(C;8(Y0
MT 3/G@H KGL0W(JY=Q]*7MC(7#KC9)RW.'_/Q@L'H_FY<W?6CU>42(U"HI<X
M6/?6=&(6=R7E:W07:L*X;CD:)Q!$:K3_F0Z?S8S*A\"=MD/$U;^R1HTX-*[>
M!NFWK@#%%I#D@X/.[3'[.J=Z+Z;>1ZBXS!5H/M2)3RA2?>5<3!EWNRFF8T^U
M^79'!PQRLXUFW7I@.^!BC)NX.KHRH_"UI30^^W\4$_]W0YO3#8/C+=X">:AV
MLX&HL\)*!&+YENTP5)K^&86CS_& Z^+!7H$M*Z>-G=?[9N8 IJ\6V;YO0!^X
M']WKB@"M4X0[W'IB^V9*X=N-A^(3FNCUD^5" 2=,#7/&)1G4(_A*-'*ZFX7+
M@['1JD+\F1.O>>R/QKR7:AU1+YK<Y"<P21TE3C<  ;S&%OK.>9PZ B7E_;8B
MW@9U%C2L:UFC^TE3:IB7"FOUD _$'C#J']NQC=40FP_T80<0OAZ1=]X8[Y5J
M7YX4AY;8?XH+P_&:4$U9?;HG*F=;8_&R1K?_4]Y+D)(+>S%4N"N'04U!N)43
MDADJ!Q,S#[H:_[Z;$;GWF:B4F+N$3T/>QEF\R(&%$(BBA14->X8%6RAL6:TW
M3>O/QS1[JZM?FDUQ[I0F0JGFWUMGX?D]3S$(%HV1I*>M9964*>O&[S6D$@^]
M7S"];1!_9<?RSOF>[]96YP>N0D".TW?SAQ_,L-"49(B"?NN(%MO#8O5VF6)[
M4U[@ >K'$;J($!V[_7-XH=&S @T>W-=IS!?VD-)^2X7&!.;HS(8#CP^C[A^S
MZ^(BTZ.4Z@M/&5",5&]HC>GKG\>+"D:123]HHGE^H6"?9\S1CS3VH&EI;6(C
MU2"-YU,#2E&"97R^,E\WO1@337NVD!Y40WQ>X%GXO+O[S3(>KM=DM6HE!@!%
MJ@4HSN@Y#ADLKLNVCJL62P8?Q"=G;Y&(I(SL]3FRM<%ZW[4+7(4'Y=PGD*.T
MH>D%-QE=Y+B),9H9[OBL-8X^3<T:IXUT(NA>$-J1\1I[N:Z:],(YG;TX;'2(
M?U3/J"-_0R%'_MJGPM"L[@Y EW,H$6=%72XJQ]9!<I"_:;AV"'G,+>&[7;AE
MPV=F1?*J1J!B:M TZK6W=I.D:KWW20@]XW=S?-LBRD@G3X*X4,(%EU.X0WQK
MGW)%3=.1FE"@9Q="1K\QWJ@W#XW)V7V.:K3*VZ]JOB]8DEL'^/("J5JMRH1"
M)MWA)$$[L<=/,4G4@#$652-&WC; *)=H;)<'3I!/2S<KM$9"^P0V)NPG 7BG
MO1<=G ;:T3;8I%3-+]) Y)V#9VLO)K-X\?>0$.+0_/E-)M$&JV-ZD]@:#>N*
M/- ,YUJ)V5!1TX495X(1ETJF?( YR/5!^<D0^OS,[*>]5Q[:G@Q("WO.N$7)
M!@9[(5+F)N!:#@FP 2@D.KOA32FA+TO,!>B2-GP2Z58S>G+)\.PX(J#N[:$@
MX2X ;3-EW(1X"U1R\48IW\ Y##52_WCSE05F'KU!=O*+X^2&23B3)X.[?9<0
M<PY8A^UK[$<Y)WFO8>..8F<JM+B-AM%UV&(-SY.>I*YK!O\'%JUI)]?/+6$Z
M.O3W/O/*@]$&Q=DTD$^3Z\=.:0)%*CD+&&$I[2%?X;;HM.0'\^_U+=ILCV:J
MS)^:79H@2[P_+F =<D^<U9-WS&++ ''[2W!P-AH^[!K* !'8!M[;4#E1@]S#
M,;"PQ>(AE+WW'/_#(-&XS>DF;8,-I>_H+7P"<2/J=U;'!#5YXM1-78728.-X
M9F >[&2?12:^Y?4O,,/^4K!1A.;;9W& "G\H Y1E7"H]JB>8V4C<1=^I5A]J
M%^\1A3>O?'OP TBI*<?S(+P-WS;ZG\JI_A3<):C13^TGO0CONEYK>GN[[ OJ
M=3S9[OR2&C_U%#N%4E/*4EWG#E#YQ&]]2K4W<J=O_O(LYBB7+@?H>,US?NN;
M?9-_V]]T!TBWD60#%,@8_/6'Y)\?\6?[!\]_QHK5_O+GZZR_U'/OCSK_J//_
MOCJUX-XZ76<6^S=7/9=:O-;(D3M 7U5ZW*L/[U(%HN;C)P(I7U@)9KR5L;L#
MM$IZWP$DCMYH^?WE2GO-5P-NMOVENLROWTS=0/(@<NX.,-28'D?SUZLGA=H[
M--.ZDFO<^27I%W+[?NMS/__H7R_^>Y5._4TIC]F?UVG8GTU8AR:S;PJ_C^Q+
M=?V\*&K 5-0:79/P$^G4:._EC&F"5?U=<Q55'<#^^RG;'W7^MZ_SMS/ 1>F3
M"5^.=YE7Y:<LSD9O0YE5%0&'\W\V!Q@%AXB)%BN]T1<760P6"RQVO)#E'[I"
MF[D#S ,9Z>E@$W> ]R:&=X#/1D,_#N5NZ*[6?]S;\]N'/3 ?UI\_"-U./\'^
MR<^;6?Y63(J,3Z?FWT4E%TF0DALD+G< '[4'RL"2.P!&\\]GI!K2KY<B+V1.
M__PZ(I08&8A?ZY-2OV^<Z[<76;<$OBZW;Z&2YQV ?_:[<OY_-5(W',CM"_YP
M@4/@-!?"N<;?8\Z*]!Y?2H:9-@4$//WEK.\_@ HQY1P!1(:J*;RLYT8;+@/P
MO ,$W9)LUBM5(6VH^M^O$(J /7$(ICOI0^YE'@ *_C=?5VAK7Z-<Z_B<WZ'B
M=+.Q24 ]Q4%3BAK,EV87>!@VRI*9+RVU+</V8_'T,[[L@1?1Z'R8.5)!]Y8J
MK"NOU/OM[TTIP(H)U(%<O+P>E!2Q$2QCF'2 %:&=D*"NN$F&*R*Y\N:BY,:&
M+45Y]-G*OU2A/W"]V7PS:^>W6O'&U;FY;27!M -(KD29[M3FRZ;X?.JKS&-:
M/%LRA\P0!7;6[.^Z:; UQQNPC76[6&_PMZ2 H<XIGQ$[W@SF'X7([UJ('3!(
M9(H-&Y*_EX5/<0\_YT5_(4\[5N> M4+'Q<1N1D7L'<"5$CR44,,!=3T6U('[
M'3:R.N7UK=:::AV UJ<_D,^Y/,+_!*Y[6T,+;HH"HJ:)CE]3,6U=MLA/.YZ7
M=S@\6[@D-I]_G2K=X2[<X6!&[AS?W;00"@H53E"+UB22]Z(^'3>Y>7Y-81=A
MPDL=5 <'VM),QA?DM;CO22G0*"XDAI:;>O('5VB;\(6O2EKM94VY^H4H\"VH
M3,MZ)^T9[PUIE3]B#TFM QYMF.;1Y\-5#AX@&-N=#7J5[@.P5CM>T64-$&JK
M^%*OOY;%X]60$?N8DD6@S AU78K-78R[*>HE*+(OJ0!0*7F/)R(ZM"\UF>J6
MN%[;L)3M63>7\ I(TVIT%?67Q#/ !C)#,;ZX%"H)M49G-:DSE/=D%] '*.BB
M:5BC^!/3HL087"D'?5VK73GCL[F2?\H0@_Y-IQN @Z4<_EA.D27S8^L_4"V\
M)UW4Y+?(,O=P%[J"3C0/PRGJO-RY8\B3;@\A>$'W?=/\&>LS02O7;T'\T\&=
M(I"XH@P%5FH@4[@O?!-#)CN4![>C_+SHDR,>!*M#^?WD%7A,8,H-D6D7Q%6T
MJ3A!O#<=9L9?[$)"%1_@].+@"YH'UM[9)5/SVZ4PEV#@],690/4PCM-A^=,P
M7] P 3'_5-:]NGV@C>EMQ]M.$#_,C:U R72A)./81X $C&1_')@2OVO$&.F_
MQ^E^6?$I9$?&C>0W_ST]*O4776ND8N.XJ.T)Y*F75BY5@EB0$3<K1H\=Q3RB
M78X>."??'0!3CX&[,]J0(*"M%!)==QB1Q]Z0E?;<\&1 ZY!_+(%\MMN]M^A
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MS26\=F!7;R+">H%=]>_I:/_KP32\P6K]^?Z4.!J%W.><3/]'UB=$]M0!\3"
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M-X]S9EHKC10^!DJH04K5U<#Z!)@B$2-C-46V91=OYG?B_=BS"H#]TDL4DT^
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M>"INNQ>WX&NZM_A,OX=\?=^TB56%N,%2?2WT>V_],*=ZJ R9]34Y'"_*6RQ
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MH6@SWKNK>B3CMK87=X#6.P"0?Y9PD=B@QMONIEL4.6K\\- M/>1D+(G9A M
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M3V-3M*JWWZD>O_1FUYN)1$*ROQ3?ZE<CP#KM%LS/=.M2]V.Q(P5^T9/8:U5
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M.P+^ID(C8<+/%+/&XP=+5CHX)?W='BB%IVR*=TIW.)BD7K-:I\QROR,I$,Z
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MMM9CTDY&E Z,NC&@KW*\M]SG3L_*J!V$2:@R2[J]LZD<\S,B6E2=NX)M5'L
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MN27XSK<O^FD,S_Z!T+^&[HV\*1\!"7:%CX"&!^#IX>R?V'UK!_SI6)3+LH\
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MRQM>K;7^I4Z"5Y1:Q5K#HO6^UXWP!3M",D6J8]?&5$K*UI9B0 XD4+RVPZ/
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M#S%I<IWR@(@XGO)?TQDRM6_!<OG]F#AW75>5UOTS[*E35S;UEM.>_DM^S(^
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MX8E.[UOR\:@3(T["G[.R"/1#W4]5>GV->U8.&>)R/&=#EW\-FSF/#]13;OB
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M\?%J(*_9;&I*<ML-\6<B2I3\F&DM_QKSID1(G/C.Z.*>F]3E$-BS-QXOVS.
M36E</[_!F1J3JL1>XB[*BRA,Q*GX;LJ[G;56XTB]RX%2. @?-7V+G9NZKF5H
M8$AJM6I,0Y7W;]NE(=5))\Z A]!OG3*26BW-4*XKT0GP])IDMZ'O6U/](CEZ
M6[;#02)./X8BVAZS!'IO9V,#Z4V1.)\*%":ABZ(A#4A)PXND-TH*[+7V^;MW
MD_A'$%!%L5IV7B.Z1YZ[W%D1-6$O777.9_"=2HW;L^_E/YF<][UVK@8:;M5?
MP%F'JN:*R;3=<+9_O.9&I&K,?F%9+6M?QPIYZ1  \ISOX&2N=U6)/]8Y%8W+
M^: (R%L14*4+)D%FP/MGL/!_F!!Z[F6G->1.;$Y'*%GN86?ORSBA$(GH<_;C
M0 .1>\^I[LHDS@:AUJC9,/BSV4-!CHEV,J8,MAM%U!G!9Q.3,B>920BNU468
MSI?$S!4X:&-&DC()?A29]^4>E ]KK^^#O<-/+?1M++IM5\/%B1PNH)4<8G72
M+10E_J,/O.#53.,UV4SMW0T><@VRTARLME6%T+;:>[U/U9 =C]$MT/Z@K L,
M%H$$H*-1TD<X09_A5.$A:]9"0VD-_JM5KF\CAJ-,=L^45$1NA2Q(0R8B "=P
M0:1NY"''6*8-^T4?3"_&3.L95Z4?O7QX3!MTBW@ C2SX]9I9:'#E')+Q]4?6
M0BR'2TB;?IL-EU3ZILA[2:-T^&C7^1YA2I,;?;Q\YQ#WC1S F;"W._;5WC72
M^QF3T8%<>8>;&87[]Z34G^J.%5H[]=-.RE=]LDIMKQLKF.)#HIRAAK&K#Z'$
M9DC$.#$!?H+Z5?#$M4PJ1?6-G-%W28^ :,]1?T%V3-%-!@YS\_AO7,X$'+GK
M;4&>'],_7-<J):=0,O[B.%=EO-+864EFJ>?W(@3<#= JN\](_00:Q0?JJYS:
M]:3/!K<_#-;C>.><L>F1=;3HRUFT?UOH^V4S[W112?8*_D;JU.(^*'D4_T:>
M!G&3Q'>-.JQ9UGKF-GFBGPCC)8I0I6/?%A=&B[B77=<C(,03.[C&RM;Y(DXJ
MG\(!"JP3H1RH'!M#M3,Y#>PA=$E23[D>^-;5I&C#CSW2XKL"C7%9?J.W][Q\
MX;DZ$)F9)2;)W6X%&NPBA*6Y-$I<I)6'\=/V<M%==O4A<J7?(E%64H6YTY8G
M!ZNLP1???5[A)#-0UG&^@ =!K0%U5P\X5?1"RXQ$21H:_T!K[7;;%FF+G<H3
M&04H)K%\=AS6RNH>J)*Y]KT!9)>%5SKL%-K]F?K+T5!E]@>.*6\0W(LL[!(Y
M53E$Q"YF'97C^&H9ZP*DV4%)C! CG(.=RG#OM1;-*KS+)]%Y-P >]R8[;3T^
M5!*ID)F@Y>[#AWXX)>L0>*5:G=@?%GYZ=NYO0+^?[F7%.SV=L]X?5](-\.DN
MVF.V3F'1F_]&2WZ$R%/NLK[\C..7BQSKUIP$/4,20G9'2X@?]W'8(^",?O1/
M*3KX'M/-<^K?KF0CK=WPV">3/_0(..(Z@\;D/@+B$GQGC>YW$ \,0I;/Z+KA
MZK[=) 8&8\X\+ICD+M$JB/C]PY;>'(^ >'6FSAOUT?":H)D+Z8J%9_@6%SG8
M7XSAO]9IMDE=SI)))"8?."Y&@RZK():OZ]YWRHP'; OLKPOA[%9;I2].8=4_
M$T6=:!E=$0I/D05'$J6^OT:.4D1M4A(7<^&NA:68[T0F"I,JG3JMO;\.R95B
M3VLNCX,;>ZPU;W<:X-T[0< OYPK/JE/U.HUVL[QF^4XU=&T,>KC,B)BW03?I
MAX*(<&>Y<A()U2$S-%22FQSL?(:TN9G7B<=)RLNZZA9AS>(6?R!ROI9(!2ZR
M!?N!7D\"@&8("H$3(0VOLXE8.TY-8S_3(')U+1->?AT,-YJT8.F0!KP$Q]J]
M=B_;C4I+/A\1)?3MS,2:-#A5*\S<^NC(B<UQR1#JQ\[WPB6&!@%@$H<)\/Z.
M&N.M5MB_10\E\JT):4%L7R:VRV^4<NG7-G,$S+%$7-JXK;H&E\])M4KCKF_V
M$L\.?Z8[$7@(A8R",9NC"8EIU:C\!%O'+R/UK+L9#W7Q/@?R0$'PNO5*M\Y7
MP(DC)#&*DF%%.(%7">5QT:(D72^>!]%4[+9^_)I=Z"U3))EK08S"'34>PEEV
M&+\O%)Z%B%7L6/WNX.FA<E*2&I<BP<)WAIK 2T^VQ4Z*TB>M^M\ZQ#8[Z8M8
MX X[QK>)6B+6P>"]ZT1\FI6Y;4K$8)C$Y.0YU!Q.NZX'[CZUEM2HQ_TB]=P_
MRKGD0B% \%7K./U1480=JV8@)U&+&RG."6/\"JQ>CU;OPS93_?;]10Y65OH
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M[E#$LT6ZG+SB;HL -BS_)JK?N[0C5D-KC .X:&AR*:E-7EX_32W:^9/NTP@
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M'.\]!ICCQ.K1ZE6%LP-U%/O)S!E^ 0: E8PJS"E-8X"!#?",PIGCMQ/P+\?
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M+1IB  K439=[I"$: J*M!R=8[7=LC53JR4WZ*?I" X'>:/K\O@Z-$OFCR)Q
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MS#'MP*@NT7@.)"\7V\I_D5+6ZY?U08@EU=VVT.2DQ+EJ6#?*S^^Y\H7=#XV
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M]6_FUW5O&M;;B $2N#' Q@NT :*V WQ,OXQU6%=Q05$SN^*36#_AX-#E%=9
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MBR]N\GV\4 %ZI8(!SEDT8'VB^Z%R>/_ Y-^NV<, 2.6#F>,],7 ;#794!EY
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M\6HODR!!8U!C#_7NY)/"90'EBW<.!6EXHP27'NQ/JBCF[<NW6TK!96;8=-M
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M:G+RE[#*[,J;O9#&E#]64;Q$?C"CB9)M^H1@%]X=R)6@'4TG9].XMP&MNH'
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MHP6AV%R'.6=;EPXVH1]5B K9F,#NO+L<P^>UIOJ+[9;F2 5D-4,9I$(Y10O
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M/ L@4H;<;":>712S8[T#;VE5[Z/U*UW6[(&4-])$LLN+2*=\%^6WK]UZ6%X
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M SJ:%V)Y/7X_;T2[XN_?Z>;9;#I*QT^^&;-5FSCONV>K;%_/$ C$BZB_3X'
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M;'QB<FIZ9G9Y9?7;VOK&]\VM ]SAT?')Z=GYQ9^Z0  ^Z)_Q/^JBNM:%1T"
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M;?!_[61_05V+6>6O.*VP8+5[8<'D$@?WE<QXX?D'D212>U9H(Z,QU+&-C+O
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MX.U?-:]0\K*V8P'J::I2%IP9?5EWE#4T-TB5=[U]MBVTJ1=*1%6'$G^'WMN
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MP]'S#'T-LUSWDZ?)-\!93PLN.@;.._[ZE3-4P40LN79$1<V(I%D0XSB'_XC
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MF@/:Q5@5'J9@5PR%?]\P%1JW#*MZ!,[#N:DA<.D(.\Z+-,G4 PVCE<.1_,W
MQ>BL9(D:]OSJ&9(=YEU5<$EJI-8B=%9 /$A.V#JET4=T4_G+N6DU6L/O'ROO
M*"O<M68%^45::A6K(5]EH3$Y>U;97F "$3#=%7CT#1VCC%T4V=S$*\.>;CB@
M AN2LX9/MQRF5I;&-B@RQ_"6S9#)S;S>;3QE];P[H3X^,'2'!>3PSE!>&J1Y
M+Q8<F77..*F_RL2[.7EEO))BZ4 *J)72RODI%J4/ENC/V;R?TVD^*K3/@=\X
MN8T+9Y<,4Z&52NAH-I)E-&>L!Q39.ER./,$LBP%EF86I@([0$NL+NEOXIMA4
MC)&'T'!%"/*S2RI^ACKGKEVR Y'R^V8ZWFA&]A%G.G9P-S^*+GU[V,$_LY%%
M6I93];I9="*\%3P>G]S]'&[G_NX$#2@9#8@*FQ078_/#=_; U!HN;27$[L@P
M.?B8@X^Y73[F6[SGK0&0OG PN@^A</R"JL(8^)\,T^NPLPJ*%4BL=&F^&4KK
M0%C<;(%?V7V\C]%EE\HV6F#9%W6S.?>'/VK#AP'^>"/\<8@9#O)\E^7Y&VD!
MJ2&HG_D"O=&;8'J-;+=@9XF ?/"7A!7?7'SQ<:ABVP_7PU)KK,+(OU:IF6\8
M&YRQ  M8:Z!["6*:BZ1DWGW;%:.[D .]VL<=S(,!JOL ]&J#ROS(@_BEN-;Z
ME>C.*L]OOG<=DQ/--4M"('I6(XIDFJ[)+^-G7=51Y$8H,PM4IR61L_W)WT#$
MV@07T!8N2Z5CDR&B-4J-@_OT5[)$F<W-)KN[!8Z#E3I8J;MRT7JC#DN&K+^B
M94@]_MFW3+TF/VN$[:4IR0]^X(CPCH4E;JT+"WPIY/QJ)S[62K;HPTC]88$6
M&I:\N30K>)XP81/7BP=7J5EA[?@NB6#-VMX0H+4X34EC@]C$]'2SZ"$2=-HM
M@XS35/L&5I+$2]YQ?WL$4?!MT\I2"YDOO*/0+=N46/"F)&K0Y&$T)T.:UUP,
M=S'K.P73KYH2BXJ<9BOSW[*Q,4$P $)0YTE8TMXQ,8JEAI!LLD5O\V<_1Z/[
M'<P!W3>C]Y9!;9>K(:.W3;MY?PX-C[QH!B0U1 < ^TEIX"DVE4?KVG#LDB2?
MA/;N2K;BBPH_5?37HESK(=G3MMCT;^QM6OP_"0FEC.D;*D/$7^DA-63RC[D2
M:K %!UOPTT'-)0MOV'%-#K\7605+IP?EULOLL2USIJMYEPHEAXY,;NZLUF[6
MT5X\-$8F>W -Y7X3CI*9O7/+1U HGG 3FM!TFV JS(L0$O$^4,A*LF')%40M
M>&8\U.=-@$@?$6"R2U@RE((IT _Q;_ +WH"D6]V$K-P$N+<X2WOL/J#7#!C8
M6TUD?GZYH4W,;C2'<:]ZJ*XB?12(0Y^5#7U6WO;1_M^+]U\7T!!-NGW=<'(\
M$0!6,G-H]'SV=7T).VU>-C0Y:#=*VC3QH:AC,'<>C;GSKS?6W-G [#AZ=';0
M9VS%X'.);W\K!BA:J4[O&G8X)H4AX)/Z%JDL#FVY@K27SYK$F@*TOA<E/8+4
MR8?G"R:(:GR8T)P>[Q].CNW_#:2\GT%H'A^?'9S0RA^<')Z<'#U>F6D+X9Q$
M6+9P+MYUE@NS[9+0P_0!H++WGR:TUJ&=(WVVN2!=T##H#F6TACL37AI\2O+V
M]D@4+8R!QT)$JX-5I'%O!ML>E+.*2Y(]-9<.M00L;.>>]YI\0[=LST7* ;\D
M00843:O:V$7)KXJL64C'"-TJ^&LB<*ND1"49RL7Z(-J.#,2;G:G%BDU&Q#L+
M/4Z0E%>#/9[_X5F:A@1)W4;,5[Y_8#(5CH>D&_7?:Y:>IG:#"R-9+ZS*#,C$
M6M[N+RH)?=K B &48@!PG!.(3OJ,]V&4W?VCR/\,1[T;0!^"6R$0>$1/DV7"
MH6GV[OVZQY^*,BFXBH\KTB!(%0Z)^:F:T<HU240W5:)4OHMED0NK+2]#N>&(
MT&Q\->N[M)_!:O_D"FBPVK]>J_V%@*=#$;E9*,G6EI$%LY+)N[LD.PYJC<];
M/."VJRCTXZVO"]L/J#<H:6<OJ5JVY=^4R56NQ=QO^$M7X7L.9+%X-"#L6)BP
M_S+9WP]FVL\#<.UB,9.R:!*QU<BK,U8C7]EUN$@7#SC<UX 5WC?5'T8>(P2:
M-;'@ E]M3;I@UDB5>%H:O2EAH<T;9P.!K3&,@]<7EL^HE5)6[0)4IT93Z=W@
M'$*LAHY(R=7:/JF0:F 7W"P3NBJ1*D: ZY-2^X(CX]0L9HZ3I(\_RNO_;=A
M;M&NR,TQ3 #=KA#5U>2^<7U8P5FSPD3K'1 6ZX*6OOYHC&O$SQ#/:]/I$/4F
MM$I,D]4[K0'#^G&W^G# L'XI#.M@GPP8U@>_SW41ARL7[X^;$J;%B 1^48DS
MUVV?@+3.>HK+HJ-&7J\L3]1+",H3]14+>R/?EZ!^,D3I(5? Q<G"$H<! .?Q
MX]E2!?-UR<UH H]UD >:[=4#[+>!.RHM4-\-+D5X6E%B<P<-G"?26;HTU5HK
MDUXZCE911L@,$UFV)X1=A48(/U:CLT^E"#5;N(88HV&<?""%WE-^>)/]^CE
MQ8,,''RT3YY9N8EQAV_+QNHJC?WSK],E'[D/#5U,CL8G9\=;=R^&X/G:O3@[
M.IT>'DZ/#\X.]@^/#H]VN\_Y;:G&\\G#IAJW.W@QMNU\J\_2%3H)HSD''DQ&
M\5/U4WX+]*P^F+UD@UL%G"GY3P-F37Y0:X8&HPJ4?34/U!@P,WW2VVKZJ4*\
MVLO2[5,MQV-.]@IZS  J4UJF+H\X3F(F_RY*K>QHCTZ6D_D]_4[:,*:*G PG
MV]3+;ZP]1J#>?!A+KH6^V&(3)@DJ4,%F>Y#U;0;OECTJH7C#$J$F)?*R49DN
MU922RMX+,9)!(!@EY4P9$)* 3OVU!L+)YEYT'N59IY=9,8,QZ!_0'G-\0U-S
MU)S1V]F0O:$\S"-VS3(D(835>VW=.8&>>+X"C%MN/]BR$LV+@%(#0LDV+6]1
M4T!I<K_<S1VY[]7Z>QO;>'^X37!Z\,%];0>;X$O8!&=GIX<'D^/3LX.3L\.#
MQVT3O/D1-W[3;=([9SS9W0(H?53%SS;NI6G-SL9%4][:GEV9*#Q0^3:V:'\$
M+<YMVK_5R>0NNNW-CY8)Y"';Q@^Z:=!-NZF;_M$;E^%$;[L]>]!NS[[MF?0^
MAK/^&%0(;\!-4TA0@TOT=>@VL6Z8SS1;65XW(&$AB$VW9787R-A&-8P3:A]&
MG&D%E!3 M'=AK[T+JG*\+CY>=>;0 ^?1R*&O)IZ,3E-I+H!MOEWHDU+,:)48
MIYV!E;P1!4^6$]U* "@O"K)Z=D @:8K/XD(=#A)S9B2,;X<QICV9)SD'@VZ9
M?F#B6O0((U.\HI\6!V<+2#B"L%_XO=\,^-3_>J<IF8U-*-E^9<A,^Z@PS,Q+
M+)_PN)D]=<.'O1?6%O H_VX/P9NA3Q?M91,\6&?RGF;+"T</2)"$94/T;5.7
M1? \+1#U6H1"UV8)Z01*FI-%7#7T(NZ'9D:":@@R:-,E@-!:(M<WRCZC6Z,?
M7K.S;&48C0"GLL@NMQ/5R#+\*P=2BZEDD9 _$?N$)#T5E)RBO@HE6+GY:5)5
MQWK&@DI'AA/5UM]WBBJDP80=1%-MSMI\E2B6 1UUQ]4[&M!1G_Y<?9Y);TM0
MB3M4:"[Y$?/9[,3^W9O1BW6QTE[%'\1(8QFG0XLH@(KJ 29TJCO(1O*QQ8PD
MYM1,NN Z':AZTXV@$B!T\CYM<8!5B)!M8*5UO3,L/2U#R;AGG]?G6_)"5;.@
M+437'YF\@I?,C+:-^F9;Y%*_NKM-'$]W71R[::>+RZ JH__^AOYQ?'8\/3W8
M/_W?_?&_EY??!&%6]_[>K!)[F\?3P^7[9SJNZ>&$?H#&-=/?UGE_5=N]S=KW
M1TZW&^+SX"<I'7GRPWOC?K[XY??7+_<F9Y8;_>F@I'=124-K";:BPY<T$N^[
MO=E>Z_%0VP&^Y\P5N<)_.9SXY4@.,-"&*0/Q$7 #VV"R_VWPXOS'?W(TH?VL
MXQ/[K-D*SSH6!?L'$#W!WYA8)OBEO Q-.HF;D__QMU]0]X0H W2]H1'*BWR/
MIV"GR&BFQO 384BH< J4M[*^3A5MS!:(H(9L-DV+9M5V8*!2B':ZUPC[1*A_
M&MMV,#YWO0O=2(=X?O6<+(^B5*@WC;I,JB0W<(T,24B&*EUR;OA)>Y$.SKZ5
MA9Z</C70)MW*]1F;PBLLHJDDL@CFD82I4F:CNK!_GQQ(L9'^.-V7;<=[@!F2
MH669SYZJBV,"* S ,J=AA )?=!EAN!2X%UK3F1Q\BY=OG &7M?4&"+?-8AKD
M3+^<<6#[]JF$B."SKDD3\A#\G/#&8-P/#2*H-%OZDX8]#9X,/%6F6(+/7,F5
MYAA%F.>(OJ+[PRPMN5O%G(2%0:K=\C;; S6)I<DGDYGPRMC,O9QWNBU<E =,
MXV7!51LXP8IV1"R$_SD.7O>\$2V5(C@_&*99+=.!]4H* I7_23+U7%'!U&S@
MKD.73^G*6;CB"OZ<UBEZW*%CWJ>UO:D,D%,Z^8:;RS4X)LOO9Q])9&B3T[?*
MBN4:XP%DS/8U:9B;('%I \;2PE!9E6=H1)JO%(HH+7VE!E6#[+0X&HAM 0M$
M:$.^<&&/@5\*HD.>RU!,Y^Q=="31V?ZW@YS943GS.K?E5'(QI-9G7>"XA '3
M/<H-9=9Q%B+U?*RFK3M4%;ID<3=#!L6L*W"NMLZ*Z\3P"@D?KYY!C(=3&U5=
M%BRCA(;P2C&\/ [P2M+9UC(N&OXU[@=G<NB)$DI1_(PSQIF';K$$ 8;>;6NQ
MH2XC6:31R#)(&K"1W.]#VH[]?;SR5/YU ^R()F+$9[;RHC%[IETO0A[FPDD&
M?$Z3HLNL;'E%4]$O*Q&<F/*\J):<-OPSB5D00MR0I:.EZ#Z;AZXWIU43R\S"
MF3 \S=YF<_%EWXTMRUF4-Q?TGM(UK[[!SODI*:-W_V]%1^!]GC2"_,-G?LS"
M]\7;!3WM?W"GW+/>SFDH9?I>$.W6DF.Q[S@$M7\Z::+NN_V";E?HK[I*% ?
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M9%Z0+R'.K495]BK2:AMB*P"8M.;R,U/>9PQKN-919%QF+?K[P&B':LXHQ#Y
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MXW^>U*C\?'C6Q!VH,MB5G;X_*4I6%4&R6&;%"B(G7*:"=&)!H!1V%L.N&!Y
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M4U)"^*NK\L36T#%ZQPU(\YJS1<Q/VVK8:EMKS.F.P5J^HD-K9" T31D+1Q\
M4'!]:#>XU,"QKUK.U!KCY;.&J[^L!C?GOHUY%7MS++&I"@U,Z Q'M@1%'18_
MZF04EC$(.H=JJ/'=R;-P$S+K>$!F#<BL>U?X'F_"91W?RI-W-'E07-97=J6_
M^?ZUWV9EJE""M/)*$%V3@6S5<6--^S>:V \TE>)BSSRGMUL68X&;646V@[B
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MAT&O#FC5KU,J]T$#3+75!X #;D[N]]X'%CD71=2@_LI+[:_=A74'HV,L,.2
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M?Z#H9J&-G1R+\5K\3\J6G/E@3(56*YW_D-@ P[ETTYEH5$\XW..-XE(?426
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M; W</</O),AX]%EFXM:2HH!![2B8$,K'5JMO2 *U*].3F$J)N.$%\?1>T_&
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MTY#A36R'7B'L>8NWEX=64*U@,0A%#$?3:I824YA8N%AU>!".TC$0F<CIC2J
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MVLBQK'DSX&;A.*%P;!OAS8RL3)@TZ2=&?'./AOS,F,'>]<<XYU 5;J6KKNL
M/>0QE-$Q=3F]Q="V@$^QKYK>-V0#V6-=?/_R@@N4N&C C#*@*HPI2["OZC(+
M[")XU-S'40 H6OB1DR>),@TM&F"4:$A7_3JBH)1EF'X\[O[C[K_?NU^B,&1
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M-C"<_F'4 *_+>>G&C.>K77P/[]JJCV4]P9L;GP]AW)Y&S5XU+T0;(4[Z."A
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M;8=*<U.@@+%!C6%;B3O0*6 TL@EFR7N=>)OS2$4G4M<:$PA+7T>; <@$K:O
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MW\@JQ)%1E6Q!7[D2WK'IX,-8)'_XTW=[R197T:QL&7CC'1#[YI5:O=(H XL
MSIZ7S0$<;E)[I@/]Y'6Y>(U9X=NMR.<'7) \I&YR$)GT4#,P6-6W.O*(N EZ
M<M![9GOJ4_?6]!T7\9L[8"UE=8;5]!=;39=:RZ$S?EW.2P8?3.0,/0 *>2M#
M[?+I#-ED<7,8ZT .%/@!=H(.%51AON/_=NS,LM_ [2R+HKP6WW@S@/I>_$&?
MM,"-Y5\9)VWUUPO]F1T*\B76\EG:)4)(B6TD/A ?Z>26U89=47\!+IO^P"&"
MCDGB=0/6RB!!(E]',6BY1"$7X'L(; 55SIJ<230$P<=4**8Y7PQU36&E68+
MD!FWUS0!; 9UP+9H.W'&%;8=U$J@?<2PC_PZE#>CH'4H15KMKO7HMEZK=-=E
MP_U%HB.@Z""])*9!R#ER_=R12/+#L @+VH25">YNI(H]/F#&B 'YSG?\L7/Y
MF'"YX2K\-[(B!1,U; NZ(EL+N9"9F@.H1&RAB+"+"WUD:I 3D$23$+_E0Z?-
M Z*)W!5*>>&?16R 8C[5P;=9<&$!?2C>:,-*(]E,KK]W*^: @92&)K;Y9C :
MK1!4P660HH:J6 @%K'P.:4-XED/%@1D/\>"P& ZH?3[!&CN0)88,B&[(Q]Q
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MTP9(&4HWS#G%36L!96RTUX3>2&L[B@0'&I4)&QBN+FY)U%]XTSSXKQVCEP_
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M_0L0"V4_$S-OVC9ZLOZ%WO22XM=PM9__$BZ$UXMPF6+W?N"0O]/Q/-T#CPB
M\^-_A/SP)SP9Z4S\_)?Q2/FLL]E[S@3L#+--:!1-&S#%A1YH=33M2BF$BJ9E
MLO2Q9D>BB'\O807HA:IZCF!Q]-V.WT4@7SS'3B?W(OV6_LZMB =Q8A[MZP3Q
MBRWN-TA<?)Q2KH1=1Q_4%?^),G$F:!KMXZ<5>.L99;S)@EZ=*2"(U]8FQEW
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M&1Z?';88"MO??/'L"1U]C_C_6!."__;I1W;-OD'!XJ9IJ^4-S+!PB,Z@3L.
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MR(-VL3PS^;H\MP;SI\OJ6L&84]JJTV0VLB5$*=/)-&7:#J;.GIHW^[MC'11
M[0ELDHZ_: 8KB_&$]YE2 RT7HU4J ,T.,IN"05<#;0=7*$,!F@[@TA@J$M(=
MV$R;<!3R6@&&GJ=>;$QU'P_=1DRLCG]PL3;@TH)%YHJ*S*\2+7D!R$IN4@;M
M$1F.9M*&=>F'[N8?W:$L95Y#4Z9 '@=7XUHG?8"_GLC;ZNQ?!+'A00K?!F(7
M83"AF?L6]#;3XU:B^0Y8#Q-5\M-XY-?[:&<IRKX2V%/X(AW'-4:CM_E#VZF\
M%P^*L!T&QPK7*=9DQ]LD77R_YY_LD;8\(18<2EI2S,Z!]&R9P8X7GF&HA5O[
ML9S<"IZ0S&XQJ/_I53,P0/RA3*._/[=#_S33HU_+5#N*(+,L-LZ<C$(I9K!9
M',\7EW'4,H2.QP=;B0BKF9,4CT<AD4SIDW?Y:7(F<_YS7#C?M5W9&KN!1 RR
M&\$W"7=U('\\=Q Q7F5&. -CF(?LBO8-#"F0V8(*2*X>_ [+Q]3B#\"%P=P^
MB^JY*NQ)R.\YGB>_QBS\=-UOR"'L&8H)7DA<29H^OCI#_##_]4\S/#.DHMQ4
M%"'+\II;FL[IBS;W Z;W# /A(0P1H17%3)!31:$UW^QE]^=3R2 2A2!DIHVK
MC<K'-=Q8II-2N9?1 %!X9A:; #4*4[;DL]N=L0[495[8HQT],XXXA08O[*;H
ML8S6F0(L"FRZ\%WDC[D*8JS+$X:Y =T=&J5D?4TNIF9:?9D0]=AF_V0\%X$+
MAC*_QX>3B*4)41H=M/*)&V7M15>(ZV?^!J.$EA@,K'Y\#6N-322N.?(4=*U
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M)8^)5C+SW!;*V+;AOA.O/X4H0%LOIH]84(41@WN;S>62:_+]Q1W(#3=GIIY
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M^FAUHA1L:^OAQ[(],@K\)U81_^N^\G&<*>.8A$KEB=4SX;?X499CYJ>96:9
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M6C+CVS1CKR\7&IS\O'HA\_KGU<OVP.IV9<F(\6^Y[&V-V%<1>NG%RV]?,5U
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MP%RR*'A9-!(G'9=&-)*I7+^I1,45QICWHT)NV($5<;*0H.L\6ZKGPG:. C'
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MTP"=[&D,JF9;*XJ2QYI:[F=LT#OA]HWP$U#T$PP 68ZKAXUZA\D:DC5<N36
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MJZ_+_L@"2]A!E=C,A^'3MY-=",HQT!GOJ>%VQS&[L+T)3[VJP51=@#"7/'0
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MAZV=@D,RQ@J8!6O#/L"06$CT:PED<IG>C$(94#0_TGI@ZZ.7>OX-'],H 2-
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M) 4OI$HFV*.D&Z97R;6M<QJ*07DI+RIN.CIY<EC* #I$;EDMI&D'Q_*L6/E
M-L)'Y](% $F9GR8>>P NQN"3IA#X(GQ0%[Y=]+:Y5#< Q]AI+Z)=>4G_&7=0
M>@?AAJJ @07I$/N,L:'^?'7-B4&EP)@FOXA:Y+_T_F0O5%Y;F[O[;M@GZ2^<
M#F@ML/%^)>W(35WZV^#?%*JUA;8FQXXZ?L  21RU[=*H6@!^&^][0EH=DP24
M*K7O6OEM=&."90H]'C )E+V@G9QTHG/24B[#/K<$_'P1C0\ PZ)V8U<$K?A
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MJ!K8II901]SRLG$HIIS8:<(CV07$ &6X]]S1GY(J$N36#]8IM?4TXV2;$LZ
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MR.<V3/R C-XD\ ,9I7WIS3I[?V;_1/7]2)H_Q3&E)$8A2ZGD6X95.;1>JP[
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MA[#.L&8"0NQ/ N9G.CUY%XOK3>X7\\KUK!Z8\E_1>J)9<.G"'+RA]]R#*M*
M^W+UG2K9U,$D((883>\HQ>1/MBZ>/4AK!SZA2*T$M$-H$T>NV0AUF)/1'Q_^
MT,6A)+2+!=+T1X3;Z7YFX(#Z=_[ W<LBX@DP6Q+67A)P.)8[@0R F8W>K3FB
M].1[OSO&<5K)Z/,32XC7?-\2_#KT DR;B/E\G,_'\S\?!0SVJN[Z%AT5UTVK
M('4&E:U6#3% R*\$$_;TFV^^A#G]X=7UY>4]@YEC,8OT-\BIE'M'<[O;RSG
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M]8=7D4CVY-1<[MD^,[LW1[LQVI2W69)#KSZC_"XLGN$+"]R>-4P=Y?@B(?F
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M7-H;](&V%A1NY@4C%E93V^-G,@6"P-&IYG=:M@,7^_?..<UQ],?'T;&*OB4
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M"$V;,?] 3HTGKNL0UD=,"["A7<E0Z*GGIBKX@G+;#5MQ5BMJ)PBF'H1/-AO
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MT02ZA+(V^L-LTP8.L9Q*H< 3E-*(]%0<YEQ4%-= OK^G7GZQ>$-V+5(A#&I
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M>Q=*!VFA6.H1H<7'0IDN%G]+ABK$%,SK-R13.3+PX=W>PR1BU BEB0ZPH;
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M^1&(B:'"@=MB#M\IWQ@)(]?RI;ILS.&LD.)D.*'KIBIQQ<3/ZJ_X^(WRJF9
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MS2*$(RWFE$82QFC:Y!@F)\YD0>)GA-]P0 U-8&ZWSZXI(-P(0<</11:L)&A
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MDRL_<?R9!WSC6 X(T9,G+[[LM+(NN.','@Y[9K_3@GQ>-KH9F6#[N@;@A3[
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MH][.(MM9=I+MD(1=1MWH>;E.<L:49$P2NZ_Q<-4]4I\S31!D/\C^G62?&OS
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MI53#?"43'!&5H9E&KHB^GGOL^#G:\K8O]S]!?5IE%<.O=ML0CL@ST^;XEBD
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M_<<:%.@"S&,3 K L%PX!M0EP'$C18/1#.3MU1A5'KXOI*([^KF@>89@__\S
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MZSSYE-4<IMDPQ6('_7.*)<=NX 2'^B@#_>?4KM%!3<%4YQ\)5RHI;-,\,7#
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MLY*\7HJP-ED]2PPMK3S(AA,H!DD#'$7O=92"Z)AZ5<LB:810B4FB<&Y!#AG
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MP./W2:C]#[C&EER;H%"BZ:5WP3 +935]935/0EG-ERJK^6K,C3ZEF((>ZC%
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MDZO DZEM!?1$O!:&Z<'L$61AXO"9;J!9NU^DJ5BEW7)3ZH] 0OW_!PK +9#
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M$:D5YXF5U->"7UL+>C]S"@](J)WQ4B9![*?8J#A%0\T_.R@^/!4:/)&^W-%
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M30/&:!LFJBE$9>6] \1,M^]GRA)@B@0P49FH[2 J8_4NF7/ ZBV#92P!ID@
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MJB BLA#%'O6 .XAW@R9XJFBYB7 #O]0@3"75R4_O(B_,??BP2-5:\SBQLLL
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M/RM8QS]L %L #2^^B&!D@)[X.+>$JPNAO,:&!K' 7X\N;D%_<O>E+^6"@B
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M7ZLHPY6!?J[P+J5.[::D$^=ZWO;&V(@*9Y:E&>OI8L1\75!,A<AA7OCFE(-
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M"7Q)>-/K&^]?K?GKSG0SY4'$*VJ0]W^7B&MD*+R<QIWWP<GVYF@M]'+3&JU
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MG&P$A1HB6EO@J>ZAI[%$SN%U\"JU-UL2'&(%-'D$?^9Q$;"H,+.>%J@CMU)
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M9SI\S?''PW+?XF38X3]FE3QFE<PJN07"RBKY\-PS"5AOJ.0HSF3Z)8N_Y)'
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M/)+(LR22LD1\E))HHZG-,A6E1UE&>!BCM6ZN[$%/PD%D#B$R6"SHO&$0%2W
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MZ EB P(T<<@0H(8%Z"EBHWT!NE@G/%\._%B-%+0&[*!UR+ #]&I !N26[\4
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M PO+QE4Y" 84@$(?G@A8"#H$'<$ L #;)5C(-^0;P0"P -LE6,@WY!O! +
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M%!#QT1L*&.<C74\ ,6E/3  68/L"B^P%V0N"H=M@Z)=U0V31B:'H4/1)!@/
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M%^QZIA)9RF'(:9(OD4A+-?&2!:*IIT%YY3V+7U(@Y=.)REV+I6BAD*I,5CD
M%F#[ HM4!:D*@J';8.B7=4-DT8FAZ%#T208#P )L7V Q^73(R2=:?(J<21)Y
M$D3&'(FWCI*H=([9FN%BPH>NSHO)I\DJQVBU>M\%S%6"J-*[)^T8 M<OXZY*
M;UR=GJZ&1QR*]:[SB=_F]&U8S[Z^Z 97_]RN9MFO3][.\F58ST8H\HN*V6W4
MU0?2T9$BE\6-,L<9 "CCBW[;,5((-X3[J , 2(&T?:20:<CT40< D )I^T@A
MTY#IHPX ( 72]I%"IB'31QT 0 JD[2.%3$.F$0!=!4"/E!MBBHX+Y89R3R
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M3$.FCSH @!1(VT<*F89,'W4  "F0MH\4,@V91@!T%0 ]4FZ(*3HNE!O*/8$
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M[S*"($I "J20:<AT,VW3?0!@@(Y^VYJD8( .Y>\R@B!*0 JDD&G(=#-MTWT
M8(".?MN:I&" #N7O,H):$254W88A "F0'MHB#W94\TN(-N.GMQ^&#,'R$I(@
M5EA+I%*1!&<L44)ZQE5QVJ@;]7F$HDR92$PTA4CN*0E:*L*DBT+3Q"QSUP]#
MOGCEUWGS[&R[V?IE6BQ?OG<@<K/[[M63D#_^],-'3T J-J>&S943(YV"A!RT
M(0= >FQ(FU'(/A)#N-[]78]2K85UCH@2*9%">>*\#R3G+&U((4EYLRK=75QO
MNXK_>+4ZJ>G2YOM_GBVV;S^_#L#'S$_"]*#00-HQTF8$$J9W+*;GBI/<L)K;
M%:.'&C;5P)R.Q!E'=0[:AVBOFYYC,MI2!!&QJ/H>YHC-O! JJ)-:UK>8&W5O
M'LSTY%PHI'N0:2#M&6DS*@GGZV,A<.KUZ(R++-J82!*25X_5C/BD!/&N^K4,
M(CL9K_MRRI32,-2P*ZDFL+Q88H-EI*:SSA8>(Y-Y3%_^G*)TS-FYTDA-.Y"^
M.]8[/Y(M$##]Z?;\/DP?FW^P^0>B!*3=(6U&0/K0>4QKWC]]\C(D46KF9),4
M1%(OB<]&DYR+*$EQ[O2-M3R>3>"%>N)H*41F4XA+-!.3> HI%9:5V=.TII!J
M;B6F-0\DTZ-5U+Y61?TJ1[O[07>JM'V!:\!R\6,:;*!F!.+[-WD=%YL\6Y7Z
M;#5<9ZO70S!M< M+4R,?@&T/+)+5_N[=:JB%)A(,.*^(/CP1L!!T"#J" 6 !
MMDNPD&_(-X(!8 &V2["0;\@W@@%@ ;9+L)!OR#>" 6 !MDNPD&_(-X*AVV#H
MEW5#9-&)H>A0]$D& \ ";%]@(=^0[TD' VIB'[H% !9@IPL69PP/><:0<^I=
MMIP8+S*1C%L2$G.D*&\%5T;'6*Z?,5222Z<B(]:[0F2J[W',#.^)RKE$>3;B
MUC.&/VXV9SD]/5LOEB^?Y_5BE<Z+9^^^^>S\0-/E2:=TSS+:3K Y8V/5;(%P
MM"<<  NP?8%%KHA<$<$ L #;)5AD*@<M\FRB9,YHDDH.1'KKB1=1$9Z38$5+
M5IRYGJDPEJ@TG!$=5<UN%(O$%1M)$%8K3C,U[O9BDC<SE5_]R5G^=*)RYV(I
M<\HXDI7):@?  FQ?8)&L(%E!,'0;#/VR;H@L.C$4'8H^R6  6(#M"RRFGPY:
MC->P:@!.DABT(=*Q1'R)EH0H5%*B&*[H]>FG6-0PT>2)RS81J;(C7D9.LHA.
M&&]CT0733]".<>OUO@N9JP11J7=/ZC&$KE_&7:7>N#H]70V/.!3LW:Z^#>O9
MUQ<]X.J??UTM_Z^?_76;OD)I[$9L&DC;0(J4%1?-'&< H%XO^FW'2"'<$.ZC
M#@ @!=+VD4*F(=-''0! "J3M(X5,0Z:/.@" %$C;1PJ9ADP?=0  *9"VCQ0R
M#9E& '05 #U2;H@I.BZ4&\H]@0  4B!M'RED&C(]N0! '=P^Q =(@;1]I#C,
M=]!:4D53&54AEFM*I*2)>!X8T:D(QP+GP>@'KWI[_O]_6*U?Y/5OBSB4M[U7
MQ5OAW%Q;.M(I/@A%&T(!I$#:/E+8V2'M++%D&&>6A" UD3Y2XFD*A'%5#<L*
M8?Q#VMGN;/K'W>RNY](9W&Q2.@&D0-H^4KC9(=U,TQ(4$YFD0 V106EB+:O/
MJKUF/+MHLWOH0K\/Y&:5)D6"-BVQ %(@;1\IEN2P)(< Z"H >J3<$%-T7"@W
ME'L" 0"D0-H^4LP9'7+.*%A/E="!),XBD5XZXBEG)"6G%)<E)9H?NCKO \X9
M81GD0&(Q6E'>:T61KW+<6VG>?0A-G[5Y%\L/U>:MDK',YTKSK\7VU<QOR?95
MGE4*_\C;#[UI54H>Q&$^6^;M\,L6E[\XKC;;S8??-OO#92><J$XGI6/*E!*F
M)"<R%4JL%I)4>;;9<2EB]#?F]@5/@E5M%[I((O.PSEVD(DI)$8*R4<H;<_N/
MT_^>;;:G-0HVOZP>I[08GL&?//>+]./RB7^]V/J3*UI^V3&>#,TSBFQ+XU!.
MO>UA'L"V!Q:3';BB",& VL_HPQ,!"T&'H",8 !9@NP0+^89\(Q@ %F"[! OY
MAGPC&  68+L$"_F&?",8 !9@NP0+^89\(QBZ#89^63=$%IT8B@Y%GV0P "S
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M%A4Z*G1<# @L CM*8%%]H_K&Q8# (K"C!!;5-ZIO7 P(+ ([2F!1?:/ZQL6
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MOU;\#?S7O9RN8)D"\ZP<W'P5_*F=47A_!B:P:K-Q87*"@['<O9/W#. ;C??
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MGHQQ <@-#G>N!>F-_)LJ?0&&9? +CC_-Q.+"YX8,H9Q+PF'.B=09>!?,.%>
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M:J)S.[>UG/IJ*>T+X[?%5VV.K.VS$ 2H2Y-M"U'"#IJ_GIZ^WY:CA,V2[9:
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MNE128[.]8RR?CT13<$3S##ET."I^"'E=#-I_Y:3>V*.-:>)!VD9/7(F$DS"
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MEOXU/'&W?;+M->$%2%_8'0%KZV3N]>./H2QKV7K)?G[*-ONW\[3?^G*:7RJ
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M##B*,F^5V9A)O]>SN \9&\^AG<S:"QZ$T9X22VQTP<=7+4T)M&(E*+F#C(J
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M _CT9ON:$"G.NS80N/H"<N\^AJ!'&]%3>'N4;<AP^+39@APJCC5 #I: "B>
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MVY#S)X8Y]3YKE7Z=N$S<7HBSO V]V(8!VG:]42OGGD5A);&4^&! 8LW"'Y
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MXQ#[TKD7M??8V0@^0G$5RJ;PN<OB7%V5$4MO]Z$WIR0CENP8_UJ!EG=2&.5
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MJ2C02#K 2BPPTL0HN3$4<:^)-S^[_> \?B$9/75H\HRDUQEKD.Q*ZM%F#.9
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M[U>B,TL8V5E<*\+TJ7&?B_L6\E*Z+DW=YE:C+O]4N]EGUT;]S_X@,*(A)H0
MQ;D-3.U8[/;'@.#<"%T&P2LWFK<^9>3$6C+4^FE8.P3M;\X[":JQP4]>7U*<
M487)\VS]/<]M4:Q4 :184"H5*\5HT PEEP![PZPID2G)AC/XR8?H-W/E['SD
M?O$_C9MS$3C^[VX49=;'R3T84[\;VS654[GZ8_1 /7'*2V_XH#^G>(7Z,4,A
MJ8PVJ^N>*[K[=-,E'1O Q1YPDQB,K(MO;/B'FL9XY7R<7+PQR#BOPTWJ/[U]
MY8>UFTN5QE)U3UJ=L:WFLTDW[RL^.^B7M_#;=#D8J;O)?/8VN>Z__5S9V54@
M3JIL:K]@(N5O:O>V=BEJ[;KW3M/FFGN_V39S_+:JJP;,O>WN\>WVR>/-8[FX
M)%#\,37H>6#\67,AO42\W.$Z=$D$VN4Z<BDPWN%"?$D0V;CND9GK(FWILT:N
M'V1<-]J%\X\_HPUM<'XL0=+3:GMU6H_FGY\G00/YXJ?_^0:_.0!QM[S;3L06
MAZ?U\<I8[XW&$D\LI3GR>1C<ECUR0'8A]^Y#(?LO^(^P#\\04R_?A4S6PY'U
ML$I@?0(MO&0P++JH)Z/*/CQV>1BRIR?J8JV>]Q1CA;=LZN9T^L'M[JDU2VN]
M/D6U8,@O,(6!ZGAQH%JRMG=[KG!<-331"@%[-B.Z/^Z1]ZJ^*FY4U;CDOY)W
M_/R3>V^W#V+VG&@?#S_K^Z#D/:.IZ_TY47_H^U9NU2B]V=SDR+N_NV<5PR.Q
M -=:#R#A&%!+/5#>65 Z&AA 8BXDV<?8^/7PW:]M2/7!6#99BV63K\:R)7XX
M8:)G;+^)\/K$[:=1*OM'=(O3E;'<Z<1-"BJ"B0<Q-Z,-;*U44E3CPGTQ5VK\
MR26P%TOPVIZRVT?:]\BQ<;YG\2B6;X9VIX9VA][$#.I."^HT=&588YS:&GNQ
M81Z;QW,.RM(9(BBS"&]T'[9(LM)*#XP@&E C*) H@#K%7,F-]H0PN)]LV*=@
M.\PO)!-[A'<'8OT,[!X'=AG!]6-?,GHZ)&&/EATP%,TZ6(;.M,[QE]=E4KQO
M:M%SY*6?JN6UDK<_!^0TX90!*J*S,J=+:AW5F@*$8\]?I8-5;*$!%$&#I:6E
MQW3_YO2BX*^5RGNQIX.%RLM^1$OZQ,/],)!SY.,LE,3/DS$PAT12V3SODYFX
M>ZYFWH*3;T&&4J>>GZ%XJ:T+8(A!0*D/B(C$J9X<NQ()Z)#=Z%NT1R@51+/9
M(YI"Z()!WJ_HQ$YYQ7UB^G/!7MF/U1O9\S%U0<Z^JWX<M;ZDFO9])_IS?G+6
M<(9Q7V^W)IR&S @@2A$@&9%E,YR=4,)0B4AIU,9LR3W"N/V M_*"BX>;"?:,
M]3.&R_ZS5Z)]_IF^["Q0@;AQTL?4Q4;52R=:FM#V334NXF2E^D_9D=8[0)<)
MVR?"GCM:>J"SFI1$(&@<D I10#GE 6L@#R BUGAB;(D/X&OJI->[1GC]O9-=
MBQ&$:.L,PBC*>BN1R25_;#)QEA&#!3W9<=6;@[8!?6Q5IRZU:9Y']E_U5"MG
M\O:5O.<.??HCNAYP%"G.(;00E"6" 4]Q!@3!"C@AB72,* ?AP3'8AU:(_CW(
MT%_=U-P/_]W,IV[A0@)XU8?T=1<2OV3]\!_UB:G[K6'_N NN"O^.'6"W@%U;
MW0Z]D>[S)'8@A/N2ILL]S&I??_NV@^\^7_]X'<:>QVR(B(UFQ/]QM8#L-T$V
M-2<<*!]>Y*T:?59W];=OBC\_E\A#9K$_K_+8GKNL6R>PY\0!IW@<FF5T(+E2
M  OA!#5.>KD1L'A.FY-MT^(788MN7'QNIKZGP?6)G.T8XBVS.]/O^SW68;5K
M;3.A.XV57_9WSQW<6_ T[ [N EYB(7?JS%[*71JN[]S!G5V6G.UP(;R4)1UX
M!_<3=9SM24O3_X[1L,*-TYC7$[;#[OENG4-_X,'UA>W)$?EF;3I*;A.?F_GF
M6,:AH&U LWA/X#N2#]#+4LC5_UC<S2>OO;SDCRS]9E)7T97W-LU@JFXCLOL&
MO4!:G+%C;^#A@;Z3MS^G.5>^[QB^Z<^6?7/V TBA9Y X(P!UB@/JA0!::04T
MI+8LH>="ER^)+J79B5]UZ76-C#_,W<_A&1\_N]&M^UMXX%7]LYO]XM/5/RVF
MQ>XG<1GFJ-/ I.>#X"&G,)_E?@?L2WKJ=7G-2#$3MD^$'2"X.ROTY*W#&AH&
MA- (4(XL4)+'FBZIM#;2>&'WD9NS*X"*_NN/GR=[P4CE14GDJ0OS^\3..5DY
M@YS]@QR:[8Z>:N1,WKZ2-\.>$P]'D!)C+R4H.;> *J2 \IP#4D+AJ0^H1ZJC
MPYZKJ7-[ CXBNX?Z(D>R=^=<@0_+ID3O='(F;)\(FV'.:6&.T)Q@0QB0ADE
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M_-T?SM[1X* U-.@$H$L?PTM4 6G*H#6$I8YK;"7:F%[%#*/A2PI0 L,?J)1
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M=-1ZJ("$/GS'<0^DA0YPBZVVUB/'^'/3_>^W&]\Y(/@=IP=,[WJ=8JP_>N<
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M:P%O5K-_S>:?,QYZN\K-0Y9K>&]:B.ENKH5_^"?D*\!M-LL"B>TSMRA\,OH
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M]L@P\ZN=K1+8Y"U%O&^!OQF]6H-MM88&9PV]G8W> A=F5ZE-\!!YZ9NV<W;
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MV]5(\'/6C@,F6)A\NEY.?_AN0"&/7FY";R6H@T\,,I>J#\_\*+AXHT*=URN
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MD17K^ZFX5@6L"4':LE*_BI%3BH#V @-0XCG\^RA8WTO%-2>2#DQO#X']9!U
MO43UC. [YOV6*?\\(%MH:6W@!F%)$^+18*2)YB@$+90 ;Y3XO;&V3P'9>T;.
MA_G23F]X-%?NA,3%5]U5HD_,P)1]!*]/\Y(^#[#6,4G">$")> '^)#'(",J1
MM41:;!QQ?&^PQ5. ];VJ;&[^,E2U_#Y;^0IT?S.T/Y!DQNW.SL*"QS8\=]NG
M[[(H]_GXE_GJ?BH>X71+AFV>["^GFS/[YV KM4E)9!,\R L[_6POFI<_C/[\
M'%7LSW?7L>&FSMQ\&KY7A,6A__GL?#J_B''TOIB/[U8+?PH\,'HWM;/[R$8^
MP+;M=SKRS6ST]]4L=A0P7RU&;@Y<FJWT,%D '<R!.VP .SV&<2&+_)YBO)_"
M(L;\U_/SQ?Q3_G-FFV\NT^B/^6WMB!K_LGW[^W?OVA?"RS^-1_"H_G3DH@>[
M8!13:DEI-.]NE;34A5OW8G.!'-\_FRR;T;G-=0Z3\^RSY9$XY^MO]_.SL_FL
M\SR6IR#_CZ?P[HL%>&- ^V'E6V<$GGUUGC]Y]#9=()3%%#"*1AAP*61"CBJ%
M,+&)$.XEQWN)5P(?2-@K!%:?0IPPBK32%#FAB%)>L$3$O=ETO]HOD[/5V5J?
MWJ]<XQ>38NC]#A[UCAT'ZWSI3"-Z-5GV5S*T*- ?.E]YLAA%@)))KLCQ6_([
MV>RSYE+)+Q-H.^I>$F-7\V#Q?U9V^BP4W?G@:?(289=D;K-)D'-!@;8;ZZ+V
M'ASK/7];!Y649DBG/,G/,X$TYQPQ8K2.CJA X[T5GJTALF0+WJ:?RMH5] 0G
M)EM^-U5U^L-?]5 5?32=?P;E['XIF0 @UW_%91<Z B5N0T> \"/P;N(LK-]\
M9PV^YN1#\HPY$SE*'OQ6;B4'=6 :89.4423ZQ/Q=%*>4"&P6O_BK!T\DY J^
M)LYZ:T<TDR\(-'9Y^HVC"?V\^TOX/"]+T(P^3Y:GD]F#JE;01LL@'6*:65"3
MQ)'Q3"(C= @D)6P#O[-JO07S*1><#5BUEI_G*,<PAJE9\VX!.LTZ&;T"PET"
M[0)P'3WM,L^-L@%4/%D"ZNH2LAXGY!5+5.+(?=BK0;F-?;E%ES_9\PF(M[!L
M\WMLX@)<DU_FBU]62R#--TVSLK,K^?CO+ZZ2 J2)KY^;T%-=O,8V+,54:R\N
MFX,N9VTFRXF=3B]R6+#(L,03)YW\0'S@^VTY?." G8S F;0A3+(H6F=P5FK?
M2C77-6;I)SN9EFZ!W[HZ_'%D5^!AVU+$#C<VF?E%S'94]@R+P3!9-+F*X")_
M3;3@0V8#:1;LHL1 1^&R]/:A,!UL T(%!SO3FX!XE*"\6G.DC$A1,6?)OD/U
MJ';FSU_.)XORY@$S L$#)H1E7)RMK=:BW3DH,H8]]W$RRP=4B^DQ^KN=K>SB
M8K0=IH^E0>Z!OS,,G[^ ]XSL&3SC\EEP"R%1A2#!FZ/<(*ZM098(V$5.:!P<
MD_Y ?>-MM]IM8A>=XV8_@C^WU>"XL%07U_B^^,7 Z&;CU<TO'_X@(^2(X@XK
MP ];B:KU9>#6?"P7V85U((YF!6 _C0TPU7H+V ;DE_?:9 8, ;OC<&SS9/3+
M5IJLRY+U6Z[7-M7MY^V.1W$3I;+^?U8@^6=PM,!3*YB,"E&O*.(L8F2B]$A8
M8B082=[:O;B!H\$P$B7R+&E -.'!\J4&.4J"(R(D@]6]H5-K(*\C#]E"+B_?
MU3"F8[!^!@947X.B0Y;HLS@;DR2G2D<!:AMHKE!*R!D@3:%4,LHE$ZV^JL":
MY:X>PB#,16[TX2*R+'C$ I:>"O@1WU]J8'VNIE7D5VM' A2Y5.3=49')&"L\
M5E^9%M![7=[1XT7I?P+(>W./ZV3T\R;WMFN.TN_V[@XZ=!O_#=CYZ/>3-UY)
M9SRBX",BGB)#-AF'L((?A5.1[H="6 #B<$$C+SV8N))H9!)1B!@GDI?"1[][
MQO&>-M.;;F7>S.Y[6PEP5<#8'NBF @L];Y=ECI%D78Z?XN+C(L;9*,=.)DU>
M[6W/KNRBNU=2#;@HX3:%'L5!0B5R,=I6XT,Z\F@W-=I>QC#Y= "C;G)N_F#0
M"$MLM988)< "<&>U1!9'BKR '\'8EY+OE<'?JAC8G\:PFL9NF^^;A%GPZT$]
M=KIJP0,8XJQ][4,&@@]P#S].X8T_C"+XJN=9F1>K>%UOB%ISLZ\$_P'(T2P!
M$/.)IDVF<U,=OW:7KI3(KYIU\/+'*3P*@M6<3S/IEK^CG-O/;SB;ASB]6>UG
M6T;358 2L_4-:3Z=SC^78-/5HUKV4A]>W-N.O"4L'TN1ZJTZ;JP;D90^).MO
MZFXNW\2+'"U?MW?)WPW+^0*_+&]'4WLQ7RU?I,F7&%Y^GH3E*0BG2*O[@,\G
M5,Z;^**)YW8!FKI^[M*BJ+WV#X=&,V4:=)/I9'GQ8GV-:R8TM5\K\ DC?\@2
MNZ[E37=[)TS>Y&WBA&(VN.M]8]!5I[C?,^EJ VRW[&ZYUN/>],8Z7/[\2+.3
M[E_4?1)M'X92B6\,I;J5D'>;6^$3@7-SJV8^G83K^\(-1//[8J[_5XZ;_[QG
M8=QRI%]%NHITQXET%=V&B&YW&UKY,,MZ^RDV=8O5+=;'+8;[MJQUB_5G+>H6
MNX<MEG,NCV60/_20[:?:8GU9S=QH9E3Z&(RVHO.]GD_PG%&QBK>*MXJWBK>*
MMXIW4.)]ZE#M<[4);Y<-__E+[MX4P^C3?&J7)0-; [V] Z1GDJPXJM)-:BD)
M!.=#?<HC[J5#1GN)E!7)\Q 9\^1)FS5N.H]NN8-K./CG!@URPY1?)[/O.7?T
M]3%&&G1G8)6<?QBAXR\UUMAYS!U#T1.&N-,<N80#"L8I'AQA.NSWK.BIOG[?
M.;EOZ"L_&=P9NDKAE<(KA=]#B_Q &74*&6ESH[/$D192(Z4H(XPSS\7C3)7H
M'X4/K<?X\Z!P9D)R*B%M<[-EDD#W@F#(>,N8D4P(;H:BK_=)X:92>*7P2N'/
MD<*YE8+J&)#6"B#1$ F0"/]',.74AN@X.3"LCPI/!4:1 MESHP72D1.D7"3.
MQJ@5QD.G<*5/AG9(^5E0.'%$)2D42J!EB$>OD);8H2AHE-QY<,8/S$OHI[[>
MJQ>.AZ>OM7;F"/,D8?)I$G(+V8M)G(::8^RIK78'\5:+[4D9T-* A:811:F!
M 2TC2).D41(X2A,BMFR_Z79?XM"O.W3XGC;S]*O$-[A<287$"HD5$N]WNG'B
M/ J;4$XI(\[S[,M ,?BT%GP%*Q/#>UVU>A/7JY!8(;%"8H7$>X[K,4YE4AH%
MSQ/BP5IDM4S9 "3"X1@)[6^<I$+B(\9&:O7H(T1%2GOR/TYF;>NH/]7D5>^H
MKB:O;MQ9C_"$-5,.2184F,[8(B. -@01W$5+J,?L*K=8$Z6142*A/)C;N0&S
M5AI8QHMH(H]>R\/F]FW&,7R-6S[ 3B0'YS/DK=E;)!$G[+(QVY F,]Q#3NJZ
MJ2",$9((1]))@WAB"3E%+-*48LQT,(SMJ:$$O56:"\1<;@9.K4'.*HJ,97 1
MYI2V50V_JH;B&UI8*:U2VO HS4:JB;4!19DKPY3&>2"A0-B1X)VD!(#E*I9@
M;KTCQB#*13[  #!B\\!79@/CEB3FS.&@>L62#DOD(!FMW98/QVLT1.XHC\B&
M/-[->(FT$0&)()RP*42I]PX:!.)YGK:*"#,</F.!TK"R* INI0_:$W78=:^Z
M6!9"GI#*:Y77CH[7, /K-EJ&$J$D#]H%\Y@QB1SP&@O.6'*@";I5,7"FD51$
M(LXD<*'W0(W66J:323[1BB5?XS53>>V0C<6#)DXF)$14B$>ND'8THB09.&)"
MQ:CCGBYR1DP2$6'#\]C2!+SFO$(DQZ)SSD\K5W7Q/GFM%M\-+\S\^Z3Y%TJ+
MF ?, I'$9CG*S>5K6K6G!DQ-JPXUK1H9]3HY8"YE<.8CC$P*"E$1@:D"]<*%
MWA7?97CX!=#A30<.MS@L\:T)5#C'!8>587T.IR68YE33$%$$W4-<4XXT3PJY
M&)5@."@7^##4]?LG^WYU#N$)&YJZ5C*O9%[)_'XKZ:,3B5L.SB7XE9PK0$<)
MOJ8(5DM/, WNP-G')RX;?10R'QPZ/@LRI]9(CP,"4Q/4%2N-G P,"25 57TT
M8G]V<#_5];[)_&A./E8RKV1>R?Q6Z$@!RT@"8)0R@F<>9/;,F4!!1)>P%C+L
M9TV?O.#Y$<B<Y"S[L-#Q.9!YH$$2DQQ2G/ \G5@A:[1!1'MOE'',T_[UW7@$
M,J?'0^;;F13X.4^(/9"%"9-/SW#,[GT/^U;&4@/(GVM!83NI8,&58PFII .G
M0AN2]O+<C@;#2)3(LUP+J@68Q;DNV5$2'!$A&:R^=]CWS]V4Z3+T^]UJX4_A
M'>^F=O:(D[\?1RWZLP&_,?B[R0O5 #R%V$[O+N.Y?W[_[EV?AW_7X=OK;QK>
M\&VN3VXX>UO?Z'T"WLCO\X+RQ)B'O\&G/JHV6+^L#XYP+5Z\O6!]G;X]\,E^
M=?IV1;J*='5NZ7&BVS"F;P]O?>NFZ^&B]&C3U7G<E=?J%JOSN/NSGG4>=[7V
MG[YRHHJWBK>*MXJWBK>*]_'%^]3!V^=J$]9YW$/=,35]<8P5B<3'1(4-R 3-
M$"<J(*T"1TPD(Q/6N<'>O910#6T2F*D5M'W45V5UU-$8)$-,N>65R!VN*1):
M&J*5593=3\G?P":!$2J'=WZK4LVQYI:&)^JC0DG#8B+2192PL8@K3)"Q7.?6
MS8E:DK3='WDL78*W!(,8L#X@:\+(I@0V ;."VVBP-7+HK$ZP.-%#0\GG0.N,
M1^V8\PA'YQ 7/"*C,UDK'$ENTZKP7LN*OBKLO=*ZT,,;*E]=\TKBQY.3OMTF
M^.W/KVI2^@@#D'70[2#PKI[H'ZHE*)3RDD2#C, *<>L8LH$PY*G7F+MHO.IO
M0+*.,'N:)B?#V[,5)"M(WAXDD]%.1.^1),HB'FE .2Z.K.0!"X.EC+*W[G(%
MR=H)JMJ-/8#$_FR(1_66:Z%.'7U:H>ZYA 1O9V]=F6'"-.7&$F0PBV Z*8<L
M300I+;F72C$3]WIP*BRT=D$@DD+IP1F153XA%;@P7B:O-:LS3*Y?"'PBZNC3
M73443BBBB4"2M:$1!08_T2@D);D3U%.VER1ST?F@J436.E!=#::_=8PB*FF>
M"$]YRB,.JQI>>[KL!']#"ROR]CC$\4Q$?1_H0CW!+C"+!,9Y5G<T2*<\>4LK
MQ4D(7.^C2Z*1!:$5\D(!(LD(Q,CA5R65E5()!O!4T>5K),<'R7$//30.BR2-
M"*!(5K(\9-<C(S1%,>@8#+/)X[WZ)<P-T3XPY"Q87=PDB9PV8+,5"E3$65N'
MH0Z!Z?H$M]5YJQ&J6L]Q?'&J.CMQ6'CWK.+R1Y6JU%@'EX1"DN0>W<X(I%4>
M NPU!R./8;=?V?OD]1SW,*'AZW6]^&1P.<OG4(8NN(E).HX<,PEQ3L']-88B
MRC6)(AK+]O/J_536^RQ"'^"8S\HT@PG1/2N!'Q5:)J-5BHH@)1)!/":@=F<!
M R/G45*N++:]JT)Z!&HG0T/+YT#M^2193 HCQ9A"7 F.3"0<84]5XIK9(-DP
ME/5^J?T9G2ZK/GHE\F<;F:RSR!YV%EGPC J3)^TFEDNRI8>?%$-1)V)8Q([R
M>)5?HO8:1V 5)R6XF]H[I"F32$J:O(6]Q-E^RFHSBVR;7WZ:-\M?YHM]9KGD
MG>;5=#KWY=W;<\RN7J7Y\2)/+JM3RNYK2MDB^MP%.HR6\Z6=PBV"/%%)*((V
M7,I^%+_DG^/M)HXMXK0=A#;OAIT1/LK+.+Z<?99_+1_8G88VF947FB5\OJA)
MGIXV/X^+<E=-^81M-:<;M&;/0++P/MMTX\TNYY=M+\(C2GFTO:^?'9(=R?PT
M@4\443<;4,;O=9 9/5$W>B,^,3><\';O]W<3N3SA[1EZL_MC^Q=\ZOK^:N!7
MP3[F=#B"ZWBXIW>U'F$\7!TITL-T1&6;/H%B%>Q#LPVM9#-,LNGCM+X!+^M@
M :U.<ZL8^(PQL'?#$P>\K!4#*P;6S3(X#+Q^NF7%P!YB8(TP] D JV"'&<\>
M'K+TA3#^^"8G].>KQL["H_==&MZR#9$0ZO'0ARXH^3TVT2[\::E^"?%3G,[/
M<W%,K3WM*94?L7C[LRO^[:EK@R\AO#<K5JJ@COJ4#Z916ND58IJK?+;'(9>$
M0U013"5C5/%PM;"5"4F3C0%IX?-YH#*E3P>$F4Z486J<"E<+6U^MBPP/UZ;^
MW)9'[AQ[^,?[UYM3#VS[T /Z^JD'-C:"7WONH:)/!?<JWJ,0;W^PM7+G<^1.
M+2Q6*5*DM>>(!X=S\XN$C#("$QF8=_O3:I/WQF.) O4$<4$CTC%IY%-F5*%=
M,N()N9.,M;S^@&M%GPKN5;Q'(=[^8&OESN?(G<D$ZAA0( G! G=R@C3E$2FC
MA A$8$WV>O$PGIR27*.(B4!< ]\:81-0*:/!!!V(-@_,G7]E\OH)PQ5@!AYZ
M_[ZL2 VZ?\]:_BW.XL).VQ.GX6PRFS3+? KUTQW:,M84;Y]RYS>O+*E+\.1+
M4.V?I[5_)*%<>Y,0C2HB3KE UG"%C K6<Q%QI.2J_4-X2CP(@UCR8#.I/"'$
M,HVX"UK3J&UD>_WX'S%V(,=*7=]*L'<[H$_Z_KQ J!;T]F<MZG;HSQ)43GY:
M3K:"4FE#1$H3A3AAN6&3TD"R2DNB$HM\;SBYL"8PG!2B*7_&2X(<]QXIF@=Q
M*4P]2T^:"Q>*54ZN(%0Y>3AK4;=#?Y:@<O+3<C(0JDM)1.1$"HAG8M;1&Y2K
MS"(+D6,MKG)R$(D%Q25BVB?$(V;(L."0U$Z8E*2W,CYTG@!NM-+N<'"FEO$/
M+Z/P(7?<K+FWGO+R'<2["USTA(H,7&&^RATPAX5<_=DM3U-F\1U+62VMI[6T
M'$X^6A:1( (L+>X,<BE7,W)I3;*),;-G:=VFQ?5C5C/BL:*F'_4:1P1J1T\O
M-1C2NR49S.;H#\Q7QJ^,_U7&-\)'Q61$+%B9:S!AD14)2"7O$G'1*+TWU()0
MJX3!!*5 ,'P&/N@<5L@+[86(1@ORE(POQISUY.S?$6':T;-+)?S>+<E@-D=_
M4+X2?B7\KQ*^HDXYKCPRE K$65#(A: 1K'RD200FO;Y*^ 9C$AR52 <#1H(!
M/]^D@)$'&R'AH#%33UET2,9$WV?18<6TQT^X'/'PNML)"L00O_CI*L3;/GTW
M:^H^'[_ODQ()9WMCL_YRNLGDG=N/L=W)R"9XD!=V^ME>-"]_&/WY.:K8G[^I
M8W7>WYX8_W$.5#I?+49OWKT='_]094)E\)%()+P/B'O@?UU:%T1-@@] O'C/
M7) DD&1I1-Y)CSC1'CEO"$K*>6&TB\+NG=$L5H+[]E!E=W6H\MMVCO(_8P.V
M!K"&BXMN^&6S8UPTW4N75L6;WW[Y>MVDI&/#KC<L^JF?H_.X* \U\[$;0FFS
MG)K1IR*B?/ANG"<[VA'(8S5=CD>?VQ&6'V?P)6'T;T>OT](QJ2-7*&'C$.>4
M(9U40(QZ9D4PEKB]&E^BH@X"<Z0XYXC+0/)9'8<2EU%XQWFR]UU/)'=,8)%'
M>5]?QMM39837IUGP\S3ZYEC4L%I,9A_+ -+EZ2+&T1E<^W0](/7OJUD<,=R.
M106=/9WDYHUE4.EHTHPFL\)C83WMU+KY)[A.&9BY/6_UFG&K^.2; T9[PX4/
M,RRYW\_<'Y5^5<;G'AC7"QJVB*//@*S'CZ!8<>%)2HA9"PBJC44N .$GJHT*
M&AN9]CH&!F*$#"8AKQE\QFN.#/$461&E\BXQ)O:R!C^?G4_G%S&^CXM/$Q\/
MX^AO\UE+;<4>:$I)V-69U[_-E_\5X4[6+'=CT/V:@4#5R>"L@RU 7LVV6/^;
MZ'QE_G3L5J:<Y8?G1Y<OE%58(S1 <[Z"[S[J=DP-@.@%V"'M$\6 +/P.+EHV
M82;SD._QSCOIAVMFN0-I&YP8\BRW[=)8(:!W,%&M4E1@99+>:]OEDV!:"HL,
MF *(BVB0Y:# D7G#E-4^R;UC/@^FP.^*B'Z9+[J7\OO(CK:B)OH7P*F9]7J+
MIO1$7([VOAKYZ?-&*K/;3ZYZTWN!J_]O-/H+_'N?JFLH<28YA41D$7&3%+(X
M:#!F8Q#4!RX"NXOJGOM/7U[\ B(&8VS+__H 5_L1[-E__3"*@)7GV5)8K.)7
MHIB/'IUZ+,/A-DW["3D9=4(=;4GU/BRP 4OR=GOOS0R\@>G%*$_.67NO<?(I
M^[:@]\T2+>+DS*T631%Q=G.[5N\97D=I,3\; ;PZP-:\&+/EQ$WF2]A?O\=F
MTBPM?.1'('/8<G;TXV1^#IA]!D^P*N'^T2OOXQ1H:@E.Q1__]__Z C?A7_[T
MZO<?T7^VOX67?P+_>G2^<M.)1^>+R2?@S=&Y72QG<=&<3LY':55\D/S_F?Y^
MFL_/8]L&9_3J(S@^Y:[+;;YJUG?T/OI%7-K%1?%FWBTB7#"&66R:PL!PZ^=S
MH.D_PPV?Q=#>:?B4@P#ECY>][E]?]KH?O5HM3^>+R?+B\DE^?/7[ZU>;!RF?
M<!?K"$*YI_^(TRE8"''T8;%JEN/1WV(.-ERTGS$OF]$O,90N/[^V_7TN,H__
M'%:^M2>ZNRTW5(SFT3^ O> N_R^L1H#K_VTZ=_GN85W.)GXQ=Q/X;;TT/H[>
MS&;S3^VU\H8J%\R7^1$LF]'_MF?G+T>_1M@,P8[^!I*'^\DZ6SYP A_.R#B+
MK3'[>;(\A<^"C9+:K5FTJ<2XBR<)!LM!C6I6#K7*9#?KU5VK$TN,Q4WX$3X+
MWP-/")9- X)NGWBK]Q$L)KPOOWB^F']<V+.3T0?X99(9/7=**M\"?_HTR2I3
MWC=?PO?E/V9-Z&Y\M#K/YM5#F4O)Z4A,B9@HL-TMI\AY)A#Q.'ELG;5BKU,)
M)HHKY@R\70+G.'B[LRDBFA@&4U]QS\PASFDMF[>I&$,?YIV^=B*TTW]:[P'I
M/LQA#WP"0;R9I78UFX/63\[5-7'66RQ+.91<C(E!FD%9Z;KI&;!55NM%&GUJ
M5RG_^;Q=)U#I]4*-O%UE/P. Y6_P%.>C5Z/W2T"TD>M@=^,\M$&=48;@B]E'
MV!+@5TS ,%Y./LY;SP-@$;#[_^4MD&SC)_D]A[80(-;99+DLV[I]?;USLB=4
M-L_QN^T T$38*%"(1B.>'$-.&HD$\28P1IGS:J^\7S%&O#2(,BQRDR(P-P41
M*#H<+*,N\A1VMO&;5K[=;OYI+?<?+\J&OIGCG4/S?R4G<JC>=4;FO+'_^>H_
MT2NRAO8V] [D\=^P$4:%7%K#H3QYDS\(+X+H8T=I\S:W,7XV"NHU(4I3#(Y)
M3*!L&GA6)(QL3)PZJXCG],X*>HUFOOID)],<+\X9OE?^= *PE9G];=HRF7Z=
M3&.F]"O)I=M&D(@XN;[3=L]U/ ?:<Z1B Z1V+4!0UVSH78HP8^S6C*5\B4Z*
M;0@HZ_H,5O3![!<)CJY4*B&C0\P5RQ$Y&@C8(MAP'G!PTE;[Y1G:+R>C]^>P
M&=,$#(.-GUA"GF&R7,$K(W"S1FOKORAW%Q"%OS3-W$]*4+08_\47"*A3?G#G
M@ ?A;3-XL0U^VM8A*^J^^3+@AD('S>K\?+Y8MF91?@<PQFQ93)DF[MZ2M[.-
M:00;;KX8M_]D;^*B7&@*7PRNQL*"[HVS7N=$;]FCA5DFBX"R0WHQ @T,P%6+
M:Z:AK>^J.$'-O>3(GG&T(N<M\\IVI+_E.^9T_%F;F=SXD5?MU'6N<^87L83I
MBS=^_#9!8L82(S@R,7?7TLDCK1-%BEOKJ33!4+Y7@0+,G[0-*-#H$><8[ @N
M"#+!V0C_LS+B:K1>(?1G86$&*@R+ B-AA4-<*(L<PQQ1[+F1A&G0J*O:9%,N
M?HHF]YPG.>).P8X MTD9:K56Q)EL/3R$-M&3ZSO(]%N;2JAMDR7O:C8R[8%9
MV 6RSNR7R=GJ; V':YR;3D!:7<U&*>S8A<$V-S@N3 6N5!/_9P40.LV\YSH/
M/YLDF[<OYN?S')$ [5Y_T7S+XNQ2C6TL-G]P@\KE"5Z=+R;3+L&_$V@^SS&Y
M+@9W>;%3 .9L[&[<NDLFS?<;OT2_6G:/?Z]QQ6R-OUI]A'>4FST9O8.+KG+@
MN,O7;B[812"O!$5L""6%N!L7.7XX($(ZHDOB-^5Q$H $<,L.)>)IQ%8[3O<B
M(BF/:%(A("HL!N] 801 0#.8!$(YE5[H'3AXM1'NG1 AEX"Q$SI00"@[Y<UO
MKU&<@1E=#)I+&[F8I<69W(IN/[_X'.&26\<]BLF!V6)30,88CZA6.@:'(R=^
MCYQ('GUB&?(2_H\[\&J-4A(QX1D-FLD@^8XVOEM+^,[*2,U@Z6GTQ]:!6A<<
M^M5BD='V^'6,>FJ(C00Y$P"SE(:?E,M*DS0C5GK+[JYC%?%*JK.E\BZ8"Y8$
M(.#Q*Y@A*H#/1I 6N5+:D82L ;94+(&E[:*D^Q,1G\3"+A V7 0KVO6G-M9:
M3+K=>&M:Y6#1.@-Q./I:3-R_V]DJUQ6 W4C':\MU$3]-FG7"V2Y \$LP-#?6
M;EZ]Q<2MEETIX143/JO\Y.Q\6FX&KK*V]#<F?KZ;]FIV.FTC7=FVGIQ/X -P
M6Z^VCR=DJ_P>(LW+4UB_CZ>C=\5()Z/3%0ATY,$4*=42\#R@%244LW[X9Q)@
MX=IC;3A&C.B(.'$::>HQPLP[;5EDBNR[Q$]F=7RU('? !LFS,'!32%H:IY!.
M/KM.R2(GP=1U&CNJK*"8[\7R# 5G+ :%/.&@:D)[9!PHJK(.+N(Y%<$\OJH1
M=G)]4[E^J]K)H=M\S/OH#GS77,)M<@G71J1N6OJ8^?LWVP5[WLR:Y62Y6K9A
MI?\3[71Y>ED,^-N;_[,I!7R4VKFM@!;<SJ]@EDQ+S<2/<%^3L_DBWK1^;J=N
MKK4T]B,+#ULS!_:KB$$$%(C68--Z#3 'N!4$58$ZBK78ZZ6)-<-2XHC ?LY=
MRZE 6HI<JL-THDH$K.57L>YP\OG8<LZY4G:X.>?6F"UV;(XB@VELEW%Z\0SH
MWVLNDI0>89^/@*E\=,%(@X#'G1248Z_VCR[D+K1.<<0B6 O<TI!-!HP\%NS_
M9^_MF]O&E;S1_^^G8&5W]F:J! T! B21[$Z5)S/9)V?G3%*3S)G[_)4" 3#F
M&5G4(:4XWD]_NT%2+Y:<R+9LD3*V]F1LF:3 [D;WKU^A(FEE3M.O;HDSES>]
MS9;8OQ]WL.U?&V6;^Q9KOC\O/MG)1/DZ@+O9;E<U[VRP\WAK;(Y;ZX9K.Y?;
MC%3;#=T4PC85(TT#7KTL6%E5HE18+N!BF& LUZK%U;QSUYMX7-TFNE9/;5=R
MB;VKRQO/%2C8S-II '[_./CSP/,![C_-I#]<O2&0;[6122H(LY:!]68Y2=,D
M(V%J39[PB(;;,; $JQFLDD0I%C<3!C)I#0DYBT.:\3#DFW6,_XVL:Z3J,"[-
M8$L71D_!=N8TL1%/"/P/9["!190LQ=+8F.513#GE6W!2,P/N,<9SLMR"2-$8
M1$HI0E4<<JKC++MF.^\B4MC#.5"Y<8'*TQ>=A O@-..$9CDG/$QRHC(&4J%%
M#$Z*,33>FG<2L0PPF;5$&DT)US8FTN($H"343"54ID(]J#8*AYOW 8>T"6D7
MC<E'*4,#6G4M7$TI']:V!&]Q;$1WX?/6HG\_"J9VW@&">@YVOPMNMZV":,K7
MYJ4X9^B&T2:T&YF"R\ 6/8P*8$<^>%&3JW%PMHJ_V^*SBZH?I/3C]*U\!DZ\
MX*DF(D%WAFDL,,Q!Q^:6QIDR:9AL!<ZM$:D,P8EA>2) C8<X $/EQ,:<"BEA
MFQIQ?8B VUKU[TO^',C:#W9_/0VMG>)!LC&.F)+8K!7BJ!1)*4@*9E*9,49L
M)>K#2#*9Z(C$/ :0$($PICPT1&JA0JXBRK+H8-(UY'E4E9UA;'3JBN)Q$$H;
MH@3WR8(O6: 6=#7O2[^J]9QNK-]>*GB7_%R;1N5ZM8MU;PTN*)W:[ZI.5%W;
MQAS@XS,U<6T"];FU^+>=\X9:;8YZ?4.=[S61HC<3&_H_3Y1OSA/=<YCHW8G<
MCQ%B=YHG>O.LDWTFDNV,H?,HSD4"YC&+*#@P*1=$BBPB.,/:LC@#J[G5MW6G
M,3VJFH(FJ-_9RHWH.<UA)^[N.:C[&G'!B\4,L*16M7W$*2ALO#/?TI<I+;^!
MPOVUK.L !"%PDG"P7.E=EK.1)#WPUHJI8C0!;&"5E+"U, LOA"&I$B:+I15"
M'&1KO<=Z_\7$OLVO;[*?5%WHLZGYN9A@4?P'!!^WW'@^SKS-;4Q_YN5D4EXZ
M[] Y= Y>P*9OTZPXX&TQ5UWU5H:,:%K_&E8X[W."^P T1. FY[;]"P[6U,U'
M=3>$$_XZL9_49'(5E(LYCFEI\L'98K[>[0XX:%%I5WV5706+^L6QZQ"^F<88
MB+6^T\#/;NY^*R#--[6+PT6\4(MYV9UG@-\-+'T1OG27DXFZ DZ_R(LOUKR\
M+,S\'(CCJ-7> &R<J%EM7]0XJ$C-;??>[H"-YMG/=AVV_+FHBZR8%/.K%]TS
M7NX^<KGY6I&,J4R_0Y+==,A#N[XQB^A>UT7I7M>%XUBR/2X,QWM=]@#K2RC?
M;WU\SP6*_:[;?X&1N/,"#W]:]U)9^V.@#WM&E"?LW0D+9,2__M<S/%+O\%3>
M/*\F'(L05AW4Y:0P-Y_;U)&C-_QYO##"75#\_\6QX[]LQ>8?>3]]D]/;Y]\-
MC^6/>V:1-SO'UHZ>L ]M=IBW.L.T.I@D\"9FB";&:S:OV?HH^3W2;*'7;%ZS
M><WF-=NI:38JO68;HF8[?%C@+H=0 TU[Q8U^)TI_ZY*<SUWA5;FHU=34WQ_E
MW/"^<ZT/V, ?R]ZO_?/O?6?E3KO0&^:Z3'A_N?O\Y NLE;34<AD2G4><<)6%
M1%)IB0ASR03-A)!;A]K<I0(*[$S3%X.59<M3!CZ4.)>DG+['@Q?/ 2S:JG85
M43?67T<;]=?P6PUB!#]]O<P_!-(F-T_%Z=G>W4:;?=JR_=;''KEXY-)G3O1G
MIWCDXI'+D)&+M,;D$1YJ(+.4<!JE)$T4(Z&B$<\BS</M(V C&_&(T8S0V!V)
M8+$).-4DU0;^&Z=I&-)>(9=4CACUP.4)J&,/7#QPZ3,G^K-3/'#QP&7(P"65
ML4QRJ8FU3!+.#,>SG"S)=0[R&<DXEN$V<&%"@\@1RV*<HY@*DEI.29)9FBEK
MTR0,>P5<!&RRA'O@<OKJ^$;@<NPJ89\(O T;_W0W6T,4D%%]LEU[XUHS8^!F
M(!;3MG42/YG:^7]F5?!#"[+6_]ULG1QM-UCZ IG>0=T#5$\,&N0^!1X,$)V>
M%/P3<<12:R+"PAC@GY8Q45&*<2L<?I5+F=CM^;]WR+AU"OVLT>>_+;#GZFWN
MI@Z\72GU:P,(-E!@8P+6X5_X==!'1Y(!/ O3 P*_!]H/PX-\@U5.GK#'U_J>
M!\?G@;>\Q[6\-J)Y*GE"0JKP@#7)2*953+1*K1*2<DZW:EWNDC$Z@N5E<B2X
M&*4T]);7*R=O>8\OY=[R]H@'WO(>U_*&)DEI;'+"0\,)S[DD4@JPIU2&@B9A
M:.G6">-W27D<P?)&HT2"'9/>\ Y2-_F>I>&E*G[;&LQXT.R"+Z?QY31/:#?Y
M<AI?3C-D;!G'@D<QRTDL$T,XXQG)\$QEJ[040JLXSK>.B#C$>/2O@<@_X$=K
MWN.9-?7;_,R-G%8_XRC7JG8W+XMKPG6DR5:U-3_2L;SY8(F>;=7A <O^"+6O
M^_5 I<^<Z,].\4#% Y4A Y4TC*.<L90(0!V$<\J)LE(2R47,K$AUE.T(@MT^
M_?3(0"4:AS<?HM:SK>J!B@<J'JAXH.*!B@<J'JC<6"<31CK3>%2RS#+"!8\!
M="A+;!:K+);":KZC3N;VV;K'CJA$L"<\4CE]_;M71Q+\C.UP/^X^(/3.)ZWM
MHO5 #L,Z^.%Z29Q*E8(:L2$C/,DH48:#=,09N#M6T.@PHZ56A^N=3>>%2_\5
MG^U[JQ=5,2]L_4MS8)MY7947KU:'OFV?Q??!'OK<O<>1AO[LO,UC]V;E' \7
M=F?B=6P)ZB5?@DM;V>XX/1/DP)Y=!_-]Y3B^O&S.(H9/BM($[6G&<&UFM5K4
MMCV"N#T@_B*X+!<3$YPK6$9F+9ZAO9(7?Q"?/XAOJPKD#@?Q<;[/>7-[GP\W
M#L-XSW/D4!D=[H%/<('IGD< [GK@L9N=+PIC)K;W(+$/X1)?27V \?K^)+ZA
MSM<?R$E\ ^;T$*M6O5+TUJ9WA/6'N0S=V/3Q +X!LW6P"NT.)^STB1M>!PYP
ML_1(!_;NJ+X!L]7KP"'KP%?PL*PJO.Y[*KJO?X?Y#9BM0XPL^'[8ATX=NE&^
M03G#C&GMJS1[&@CRY.TK>0=8#GE2]8::FC#"">B224-X*E.BM,A)GL9IQD(1
M\UA>+Q2B.N4VLXQ8RQ/".=PC-1<DMCRRF3%<)>IZH= ]RX/.+H"$\_L-R!Q%
M(AE%J>Q'&6*?Q/P$]8HGKR?O<,GKK>)QK:))8Y::/"5<1"%8.!62+&<Y$393
MD8A#HX38+I]-M;0V(X)307B2)T0F>42TI59$6F6YR/IH%6F:CD1$O55\ GK%
MD]>3=[CD]5;QN%:1,ILE2H0D-A:L(LMBDFIJB4FYH7&>ARQA6U91YSRB-B9&
M1HIP)11)X7(2"VK3G(6I9+9_5C$:13$?B?B09REXO=*KT/CM\AL^*'X;7OYN
MC;47KIT$M($C)?X,WY#;JK+(F5+_]<(7]IU>4<L ;70?4)&G=<]IW2?*>N7A
M!=K3>D"T[A-EO?+P NUI/0P?]5K(8)VN[=/NY+RN]_;3->KU3"OUQY]];RN<
MF7'F@S^G%U3VY/4Q^[[JG?_XMR\LI-QOC!/<&)Z\GKS#):]7ZUZM^XWAR>O)
M>U+D':!:/ZD*F\0RF21,$4%Y3#A-&5'61B1E868DES&79JO")@T3:GE*)(\L
MX:D(2<85)8IE6D4L2K-DZYB*XU?8Q"/&Q"BAOANC)WKE 2ML?-SRN''+GWRZ
MJW=&VA.V3X0=(.[ICY:YOSOK-T.?-H,GK"?LL CKU;=7WWXS>,)ZP@Z2L -4
MWR<5=10LBG(3"L)2Q0AGL299;E.2:<G#C*5QJM/K44>5*,%#$1.:R9CP6'*B
MTLP2QE.>Q,I$<2[[&'5,TGB4ROB 44>O2WH2;_35DOU0,FW4\94/Y/?42'OR
M]I6\ T1"_=$[OJSF=#>&)Z\G[W#)Z]6Z5^M^8WCR>O*>%'D'J-9/*FX9BS@U
M7&B29GE&>)C 3PG+B-126F-#)N-LJUHRS#,:)C%1B8%[8FY(JADE6<RMR#07
MD>GAE,YD%"7)B*>AKY;LAU[Q\\B&%)&$[7E1XKKPK(Y+555J.O<!_]Z98D_8
M/A%V@.BF/QK'%]6<UF;PA/6$'19AO?KVZMMO!D]83]A!$G: ZOND8HM<QL8F
MN2%"Z(3P+--$ILJ07.L\LY&5(MPZ%R^+I)2"9R3-THQP&C*2,DE)R-/(IF&6
M)5KW+[88T5$J$E\0>6Q%XD__'5Y@<;^##NX?<O2Q^K[F /<_\=PSHB>,&""T
MZH_&.VHUCM]L0]EL3(A1]S]X%\^1HW/$;XV^,<+;(6^'_&;S=NAI<<1OC;XQ
M8H!VZ*1"S9)2'@*721*'C'!I#$E%SHBTD;6Q$CKB]GJH.4DRDZ8R)(RF*>%<
M"")%%A&A$\5-%&N1IOT+-0LY8LDA>^^]HAIH:'JY^WR7_I%TT8=RKB8^R=,[
MDW\GPFXJ,S9F I69*1>8C?#:K&\\\(CKR ./9)(E*HU)9*D@/+.6*,L2DO P
M9:%5$=-JJW$H%U$:"P6P+#6$"RN)XIH1&VD9P<-T'N<]1%RC2"2C*#WDF'6O
MH4Y60_EP28^8X3=$CWC@3?9Q37:NC%!*4I*))"5<THRD2D>$":-U$FL#QOFZ
MR8YLQ",&5]+8:L*YS8G*4DU2;>"_<9J&80]/1A$CFJ8C$5%OLKV&\B9[4,SP
M&Z)'// F^[@FVRIKE&$Y23+)"5>1)"F."+:QE2R,$\KHUECAR#*A@:?$LAC-
M?"I(:CF%1UB:*6O3) S[9[)9-$JY&"7'GROL5=0=TQKP,Y9Q_]@Q\+?%A:T*
M#;^;XO,-G\*M-Y+PNUM3D#XZ!=E=*(@O[4BR09%VRZ<*D':H-!$RR@F/!2.9
M-!&)A8UBRI(TE?H0@;4W4UU>V _JR\]%K2=EO:CL!WCB3Y-2__4LL+56,V1)
MM6@3I\5T8<W9?-\E?J1?V1Q]X.P^2;5YI:8U*JT7B]G,5EK5]FXV(2LGYK8;
MCT;CH!.:A\Y_W65]C0 %($&VWK7.1UM(L*Z<=HJ<'(.M_+K0M3OYR%+WB(#C
M[:+")ALR5U^"K"S_"D 'U,&EJL%D5P #3)"#V0]*N"Q;U$ 6^&L)F\!! +BP
MF)\7TV!^;H,_P.K#Y>\!'=AZ?#!1N-MK;0@#*-D=L' ?G;U3-<<:T!,SC/#(
M*,(3'>$QL8#&C([SR(+*S;>J3.ZBFM_K<VL6$PM *\^M1E"VU-:_ Y%_M_ =
MNI@4CA<?T.C>I+K]AMA;<LZ":H.N09D[Z;<=#P+<*B#_\$/I!+\&B5_,R^HJ
M^&/\?ASD%G:.FC27%'4 6RDO)Y/RLG[1ITW19Z/\4'"K\19<D^&.8A<%3.Q@
M/WXWN#8OPI?N<C)15^5B_B(OOECS\K(P\W,@CJ-6>P.P<:)FM7U1VYE"UG?O
M[;S3YMG/=E7^?"[J(@-AFU^]Z)YQ0_U/\[5"C*7@WR');O*"VO6-6<3VN"X<
MQZG8XSHY%F*?YT5C1B._O@.OSX])[(.?ZZNY'I*P0$;\ZW\]H^&S!X_H[%G'
MW9&C-_Q9!6#[Z W^7ZNJX!>@C@E^MMI>9+8*(CHZ:NSNM#@]Z!IE;VJ\J>D%
M89>FAGE+,TQ+PT)&O5D9D%DY%E.VRSH\=[Q6/%VM&!XH6X3D(WP<IW+]_P0L
MX;8KC\?)-Q8^*^L"@ZTO*CM1&&2%5WE.O^^;*AFP@#XE_=XG;GB,.\#-TA]M
M3J77YEY 3R((Y&>H/G1^]_TR$8T)2#\CM:=Q.T_>OI+7U[D?N36-Q7FF\H3$
ME&O"C:8D4RHA29+G,K>ACK9'Q=^ELFJ?>JJS^>NFD&>I53<NWJARGRTJ^* &
M>8(O(6R]W#WZ>KD[R$0_AOCT2=#[;66_\_PY/<WOR>L-ZPD;5BZ5C,&HDLB$
ME,!O(9&9E$3#CTFDI(VI.43/]R,:UC>_O?:FU9O6)\"?@>M^3UYO6D_8M&(_
MM9 F 3/),L*58B33-":)B!,6VDCD/#E$;[8WK0/4+?T1WAM-JZ_V'!(;W^,I
M:"13M<7\[L7,3FNW\WT5:>]LNB=LGPCK8=*11_/SB*5)B@/Y,TJXB3E)L7TZ
M9'FN3<IYE&_!I(<*[?]68H/*0KLC)G_Y@DK4N@$V/Z%>?;6F5E^5]?Q D?XQ
M._9$FSX)?+^M[#WB$"?)F<%J?4]8;TY/TIQ&BG)-=4[RU$1H&AE1,DF)2 TW
M49Z&-MR:0?)0 ?UCF--PG'ISZLWI,#DS6*WO">O-:?_4R_-=)?(G9>V5B:(\
M"R-B,BH)3U)PGO.0$V6HH#%+=2IWI.\?)L?P8-:^!E&#C[]A]KDW^T,Q^]\_
M8L[!-Q<\-#=?5=84\]JG^7J*.SQY^TK> 8*[DT)/)N<)-6%(LCS-"<]3392(
M<T)92FEBM+ J?*S4 WS8*M+#Q$'H^)"'VYRP#NF/D/HBQQ/4\9Z\WH2>L FE
M29+9).?$2)/C,:]X $T"BS62AE9E(1C2QTHW'-J$AN-#GC5SPCJD/T+J3>@)
MZGA/7F]"^ZIP3C_%D$5@U#E-B) "K#6-)9$FX22*LAQ<Y)S'R:.E&.YDX?=+
M'PAOZH=EZA\SB> ;%QXP?7"NII]L4$R#7!55\%E-%A:/UL&SU?2Y#6#K-Z>@
M^'1>[U"')VR?"#M ('=22"FD66YSKD@H;4AX)"Q1H3 DYWG(XLS$44KODTZ8
MZ<]?]H))C4I],WT-"O4?J$_?YA\:;?IKITP/%2$Y9+OG26J3_@BM+[8\$3WO
M">L-Z$D:4)F)G*6*$CRZGG 6<:*4DB05G-(P#(7FT7V2"=Z #E";]$=HO0$]
M$3WO">L-Z$D:4*V9CJ/<$IG'G' :69*EJ2)6<0OV4<B=!G3_6'W_#"@=1]Z
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MMXPGMKF>#",&"%%."@-$J4CSW&@BP'03KB0CBIF$Z#!G*HP '0C[6'TS]\
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MN5HM8%:5^.+@\X"=@+L^;W<4.LNPZVN4@\E;$-O1%7X(_:89XJ;YPZG,1@:
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MG7*^DNXWO[W^>@L:':7BY@F)/97UFV4\>+X9MG%_<<HA:.G616F^QY8>%T@
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M=!II3I@&WY-3P0!9Q918:G(IC(2WV!JF=FO!?C3K1?F]JCB/**5K-FQ-NQ[
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M EV5Y4Z[:F#+53,G_-H-H]LMTV_2@VS2OR\-ZLKS:D9ZMYL25?;6]BW]]GU
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M,Z.+2B\ND$H:.R7^Q)*226$_VU6BO:%Q6PU4;U;H9DOLN!:I\NK,>QY['@@
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M)5:+N2B0@9BAS4Z*^=83FB+G&^!?3<JO=M#TLIB06RO:+UW_;&0@\C1W^!J
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M7*( ?P=_9Z]0H;W0WE<0ZG1RI9^\%PC]SV^)X\V3I>'9(8WR+^TU%O[6IJ<
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M23W1'4F!K<?9"^$LF"NJT9Y"Q-AGUA)SQ:%5W#5IT(##?,1W%QR&L^; \65
MJ3NG^/70;!^:2LWG4L,V'!$BE"MQP_W_K?%7BZL!9/D0<1V0J98'\+E*&R7;
MUBD-/89:ND.P>2Y],Q8&=!2D%.?O'NQGY.VB('.4.!6#6?N!7D9SR*FVSJA]
MZ;B^]/:92E40:9._ 3_Y\'#! >=<J$=W0IV7A&ZHK8>P(X5'I'N<M8FSL2?
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M#\#^SJ-6.C?13+=?(H._=6B0URQ1F!(S5Y9:BLDGKSU3NR&<$Y)VF>!&B%0
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ME22O+MBG0Y"+2X.M\)?_!U!+ P04    " !\@%Q4_UMF_T03  "S$@$ %0
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MYY2^YUR2*D(5TTJD/?XR?15/2+OA-?GA:B?/TUWT%JO&=BV6@ 7YK&X9?78
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M:3&?5G6 [BI7U4B91$'6&*#3DK?[CVLBM7/W. G=MDV),%';-M@ 7=; 7:>
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MK_D.\?SH8-"V^U5A)ZML\U3.4!9E_&W>#1S,UE0L%I0ZNN.BIR2:10%*\DG
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MDS_1YXA*5!PJJH/OMSKBNYT$J@OVQG'*(P'HP?,%)<4,!<PBE3S=8_(<!?0
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MRN_K?(>L6,OX'<=5U7:BK660O;UR'9C#:QE&[R]70^<#6\;_.*YF0Z8(6UZ
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M?\];"-MW[^3IB> GE.-!(.X^GV,0'DV2!I 1NQ\<'XRP'W@"LU2I?Y'" ^?
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MT,8DM+W[:@T>P8W2._(<7#FM&&M-KF1O;U'Z,9";+#50S)5I?<*+[7JC-V0
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MU=7(O(5-Z["L(Z*E^P"%0\L[JZ$%U?%H 1 \$I5JTSL4&R4**B0V@Q@<Z4E
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M)_+/U"G'R&SQV+CVZZVSH;7J>M-3@XFC3&1I3VCU7_7U*,W/C4IYTC^!2J^
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MMW*SVCZ%9F@;^Q94_KR 4:"H#Y1M^=)QHP>5PO\- RE5G+I7P$-9]Y J=K_
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M'>Y*,_F.HS%NA+!2_^@]U]R]R(NI3%84M3GW0B.& 76IP-:G'>XL>Z7AG+$
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MX$5$!]:,_..G;S]].B5;1Q57GI!_^?1I]DG\E]I.:98N<6)P#J GC7Q_.B,
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MTYJ^^5.$)<;=0K@I.?*K(MA+*=KQ28]&"_4,)#7V6+_7\Z*Q::X7@L3?!G[
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M@O5)PO]A2RIHB"&W].[RW<52*X@H'0T!*4@11<M2J,T4VWFLSGYXC\+X+_=
MWP"\*(1QH]ASN4[P!5'*+74][LBSW!U(H0<LCJLD]#'1BNOJ5]X[IEQU7^R4
M:MX[. 4Q6%$",&(4R1Y>R"V56:]0/)3>K,M \P^\!&S%%QLN4;=K+JDTR+Z&
MV;XAV4T>!T3W(<@I9WASN]:]4[8706\$S!<!"Z8 YB5^"9*(;UF;2"^696-[
M[Q8+XK(WNRQ]L^+%6LK-X8Q 8PBN?XH_K_V\9F#,A"WJ!5;M/6NB[57%(66B
MIH!,Z$Q0G$6W":<G:"'/*A5XI03F7V90_68M)EQA"9(FF1F'IBALZL4784X
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M8G%_FI$QT715J$FX'A4@ _+IT8<FR2Q'&4Q(DRMWSQ5MS,@_?OKVTZ=3+1E
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M?A46$.@E#JGN3I90*]U/O:)OV2ZJC$$A*GSCJO>?Y9/0H"![8*]Y\"O[B#:
M,7[%@C?P4/._7ONO$#U&!$31C3?79]PLX V>_OA-\L]GE9+&GO9^X)\@KKRG
M.$(5::UXZJ='>]^K(_<U K_#O$1.3-*9T>1*Y]9;K?>$N:/7$6*_J#B&UO1X
M?*8=8Q^W_'IP7SSZBJ]WL=;<Q5\\QD4)_&Z@<<*?MY:5AZYB!!K&8G/8F=8,
M-ME"5]F,'6R_KOFO-RE''VJYY&92U9GI[' !BMLN:U(,'!"-!?!>Z2[^+Q]S
MB2H*64UM)UO9V_])U_R:X!_]C<?YS"( .]!Y'-] RE,Z [FY.9^4%&Q/ $%=
MB\9*^K;5!#OR%;9L)B>3<F8=?ETQCTW/B!."'API< ( XW(A2]-C">>E2\!&
MD<Z "6:(]>6*5 XQ@?4\&=,":I\8M-5AV-E0X63,H$A3"K@2$TQ&,E;UUN1+
MFV<OS=+G)EO]%!K\H#\<="<,/G?7."2BU49A<SLQ6:=X5S,- W%"4NI:)[RG
MO;Y#PLV?TI^0:(73$B6#SZNT9967S6.U30:4&7>T$ 217G)6YW[LX6GDO6J8
MQY?OT'&*KF0_V&TBEGBQWCM7=N4$NL+%ZU1[ 8P:T3JPVB4@BJ>TA[#B"K3Z
MLA.:VP,5I&P!VN,'OWP+EB]!$O%O[XH/BBF5N4FY"&9W9?;SI]-_EHE8A6CE
M! 63[YY/0=0<1$U2+J1M/=>FM(7S&Z2.E=1K);5()X/&A%+J+9_/Y@G.M391
M6R!1W6X\GU['=-/I0 .J)$>6_ J$"5*V>,";$X<-)(F(3Z$9='9/5Y1N$'TQ
MP\O/>VP-A N%R75&LMER\/P%Q_1$)69'"6L]#FE9ZF*(4DD?9M*[FO2%?A6]
MYS?M1^'.*J)P/W/EEJZX/@T)2BYVK8,?::&N^?-SB%C3UWX<>CZWVSI7AJ0D
M24I3E;H(?E#SII(CR!8#'?R_%[$Q ZLLHBG'E8<TY7*#+:=XAVQ$^'$NW%GY
MQGJ$NLLJ-.!N<L)PMPY"D*93+]D2J+N9CC2"UY8^F77WDDW!"ZXF#6R$D^X5
MN-"<4*SR1=:^Q\DUEC.B4/;28:X7#75LJ\P^V@)K#7]..^=$J[I,_O6IJA\(
MD3F]H<AWD8;I@D@:O> ]&P=GRT/%"/(S_:;OKS;<O)AZD7@+07NL$S<I:S46
MN:R #OK(&#8I$=M_9:K;62_9S^"),M&L%/UJ=IJ4FF"5%;BTWYC4Y49S@E"R
M%Y2;Q*X U>!_9U26I<PW 3>9_XX_OPM!'8UWP""4KH*_\"@0ZSW$L(P/HC,R
M(RDK:'#JS,R(8F>&_M)XAD-2GGI$%QMT%7,89%;6L4^\LH&6LM"[Q<(B6C9)
M>U^XTB9G@)#Y1U 9TP5<:<S@DC@:%Q]H.?9Z&)5N(6T'S0L[*-U 8O\(AX]B
M8[R.M:L@7%,OAOS?:U^ ;7?;0K<)8KUPRT/., .+!.:PF58SY#+8\AQJ/&%K
M".2J!W@6A:70O>X_<W[9[]O1F7WY_C*'EGU,B3V7W8]A$'7-44F]=-!QP+'=
MW/;Z;G%<O">/4<C)C)!'W?2X]KW8 VS1Y(EY+EE@_J=-F^EHKN4^N"9W9-$#
M#.%\]==$IF\M@PIT5\TU!/\''?0\B+HE!BI"Q 5*'T,^I7YD4T*LJ ;9-M?-
M/%V1<\LKHG+R^0T%<-KY_GV:[H3'&33_$-V;($)P1KDV %B5W;0,+3=Q1G :
MDLV#H0BK.6F]+D!A;Z0%$7QRQ$_?:VZH:Z^E:T,$$Q#'&:]*5EV]JI /[D+/
M-8!VN5?SJ^@3G""7"=^?)3WJY<L\/P<L7E_NG)&NG''[H+98.O\:["WV+8TA
MNQO1CE90/_;(&;[V4RTZJY0T4;J*B>1K%KQ%HE%<9F#T4I=J7UBY22!S &55
M4\&.@,G@[L\L%*T,M8^4]-J6[E\< "&,=W9P_B1U3U0IYW$^K::?]R SRWQO
MM1WLU6R](@&>,VY"+M:RVGX1WL,YDSL'TU]&\K?1P='?O"VHX 2VG*T76((M
MWB1]]#7N0U@5BX.YH#) B;L("5(LWJ#9D"@=$UD,CA^KW/[H>/[1RFW>TJ[3
M[6&:$:KVG:0WI-H##[VH]L4BFZZM!/9K8ZQ#*>A0C6F>DY)GX2]?Z(_PR5WP
ME3:'P)F5+&:G&?8&?:'D&0^!E94FD;8E9GO"\D-+2]/*WNO")WPB@C.1BTD*
M6XO$V>X-VP(H6+[PWP+B)Y:^+V0]D(*@[@35*&I]9%[9C"1;$ ]KWR<AB]RA
M*5$!3P#;44JF"$]"FF)Y5BH5OA#8;S3WOJPA8N 5A#W+Z2J"LD?E@ERL3;4H
M2]/BG_&ZV\K)A/WG*8\G__1<+5-K4N+*O2FN<T5=%)&F'EU^GMIM8F91OL)N
M_?& ]VBU'KS&L%,?YD5" >1O^19T*X3]_#WF3O"_6("JZTFBMF9JVH8!.K_#
M7(1/9M4G(QI0@6.[2\A: 8.,E=5"8<G->%G5G%BR-YA=9K/6#.4MT?(=Q\PY
MJ J=S/C9E35%4^W./H;4RG>MM:BH[O]66)9>O54!%J.+GG/W7O3;>4A77@Q_
MZY8$KI&%]RS($J K(*2Y?A_B/P6DR2,?'\;<'+?KG#0H+BN3%.739.VK-U0A
M[ (0BU## KM+FEM&,'X=&2M92?HDM/K!VI91OL+BS;P7&E)3B:]53C90%]GN
M>3GWXVJ+VREEY[ZI+:[E&O_T_LA 36],E$1J-X0.EWIC'9S"I$#L \E2,,FD
M3) PF.$!6["]]+[&5WPBAXFDUBO^LZ.+DE5W8T%0ILD2)#ER"?1/I%\QU%&V
MI)MM$#KA3OBCM#2V"^PH)[A Y^DM?</?F,G9PZ9%.02/:0NI_(MJ*N56S.7G
MB>G4JQ6N<3ZC^+7-F)8H 091H4E0]_2$C"!1%/O!Q,NB7ZAQ0_Y,2%_XU9@:
M/V!I<L-SL>X8A-0#;0%J]ZX^F65/@65!V;Z,PH+)S:,,NZ]AJF]F!.$LUG8C
MB[;?<$69V$'26ZL%@\OEDG]6\6Z^6O$QD?P#KOECTPP$/2(II7\BR9%+D(L_
MY<28Y>0@"W_$V80JFR.M*\+-8P[I*4,+$F%'OD<AV)CKI9;U6/M]K9-R6QE+
MN4R9S JRQ&'0'VB3P>Q64:K7R1&=%OOUB8PP^!+LYY"75#U.,U>\RX)D6>$E
MRS'![._CUL+XH:/G>0N6[*T>9L5$]]2EWBOX[;L<#B+))TQI05Y"XH?4VSPE
M?-1J1BCSGCV![!AABW)L%&WQDNHJ'M,DBTA&QY++1[SMQ?J>^O3-809:KF8?
M9BAH6FZW:D8"EF-^L2:2G.4VJV:8+_C:*M^ Q5P'+"X^<]S?Z"K+)>WN>D>R
MY GIDJ@/+'AS<C!-A!,I@@[ ;AF[NY5+2B TV7:\S8@O3%M/+Z@E7WN^5.HL
M=+CL;Q&.<,Q)8"R;GKG^Y"^F"J;K(#,$(QTZ<"7606AS2J7GAY3XO=7N'%DM
MSSGH -T0@(1)Y@I":6<FNW5"G060.U4C-".2E*4-J$48Y_[JB^,G:VBJ"GO@
M@8:OGDNCM$5P/F$U2WKNE!RO,L4\E; Z@[TG*7\@H56H2HOH0H0W-SE1LVNM
MI0NYR>3N(RY.X832%PE"^IO<(D5JD9QTD0JISMH.LGA>W87!VHM-I!P6W,S\
MGRQ9B<A**.S%. Z]IR1&$RH.L#<I]#\.&(-AUS[_I&AD'Z&L@\@E[=?&R*?\
M3 4!RSF+D$\-OD0 $N$[MKLRGA$D2''DK+-RKBTJWGNQB3NNYCKL_WC;\V!U
M[)%>"*\(DH33)$!T[$+415BLBX(7CDQL6OA9I4&+#B.R'K:3N#*CBA^P>O%!
MNVXCJD'X1U@4EE^/A9\K.FG9>\9N!_M>UZ.@CAC9)[;*K^Z"&%IO.4QV4)YO
M("UCL4;_\3*0JM3/CNMZ/ET&?'U>^?AK'S.W.WH2T[G3;N .SHZ8\^B_YKJ*
M[,],7@4+\*.M8();E]"FBC&':_^*GP^R3*RX0JK!M9@8OBOAX5\&*LN3R-GA
M1W)^<OW1UJ58.=MQ!V7[9HS=G_3F&<E&N'@AA_Z*VRU*9X<$["_.N[=)-IU2
MH#G9DS6GRY=$$,9,]AF1M']_JV,L!I?O-:(X%841P&MJ?HED^O$N^'YTLX=F
M8[^#=; :[;6^G'@-W'@NJ#ASSLP*UVGY%G2W1R55DI(E<PNUKX8%8)6\0Q&K
M[:B0.3D*-VV%/".HKN[NY5\G@)!-0(,094W\RV)8^+2U!NE@6TJU#0\IM;9X
MUB9/$?U; BY?T+N6'1(G,E($:9%?D9J%#RH*8_ $KA(7&Y<I[_5%L'$\OY/=
M(XBB;UI2'3GW+,>XZ):6!AM^%30M)NT7PIS8(3 U-G3G-K<PG&,"9_O9>%GJ
MW9/M=+.>I,M2ZV0>W?0%D]MR+S*O9E+6<B[^ >:Q8R<DJL4/4OP3P&#C]G !
M$R[+$P%XMDX0EYP:(EIZ&>;=="7+#AH-V@5A[+B$!22[&4GG/ED'X4GDV&Q-
M6(9I(P']!9Z_@O/OAEP)P:T"L(WL&K 570,"ZUT#K$E:?+EY?*+>NR,<;0"J
MI+X,5%]DV,R3^"4( 4>QRP>MK+@,RA':<6*^Z$S'\9>Y-4XZZ>]BI8P9RUDF
MJ+:F,F]KWL.::HQ&HNNMD_UDR?\6.<(S:2*NR_CD 5@ KS2W0MC#3/NW*&*+
M7QR?Y!Z:[#+([:+/HIKX:O,0?2+K)GJ)Q8<Q;'X( C-=\4(S6P]MV!FBH2GB
M-M%!;0A6;\;JU&U"@=J0K.A?$1(&^9>W_^XL.ES:0]-W35AR 9<^@3/9\TL!
M^*<H),OD.PAWWVZ6C01<O/" %W^5XBU?4)?Q/SII*OG&QBLUQ2S#K>4_E?-,
M2TJ6$U D**3$-2SB"VO2B7,G\/_N(-PK71EPIP,U<O'E83Y:=IG.J:1D_3[N
MS'7Q*$?NF:!H,Z[,)]32:$$-#GS4HSJVR%9>E)3@1&10MH&B2?8$L=]-&YLE
MRIQ[(^UJ9 6"]2Z,1CA7ZC;24J4'5G%=LFS&>_KLP31^#'W3NR5C9K0LM8HW
MQ79)^J5UWE,PPA;H*C(#O<S9:^+K6%3 ZEC\3@:2FND"EZ+,8%<^T#X7"#%3
MGOR?.K_MM\<0[F%-.\N\*L(M;R9?1/E#18N?J<BBKBJ'[0&S:]XG&;^8BE %
M/4BY[74T=LU=*5/UK"I(?$9H:L WCE %;H.89MB'1A"<[6+J6Q<EU9DR^DIM
M@AER )56\9=Q2ZHL4LT%:.(=I<FS&=WQ"\ J>9_8FR@<"TH@S?]J"2=4*$28
M7HFN)7KAQ$ZWTEJI8VDTP>_HV*NR-2U'B<+8GS B9=RGR29P ]=UV'G@_S6!
M:UQFB'=W<NC424I>Y<9/1B361AK;GA'S8A73]W7QW%0\F:AO]52016KG_*^+
M<!F\'9L25:C> WK08A$HCIK]NKH]%"*P)825Q'^HL7)CNOHY8)P,9#9BZK_G
M=RV,4(3):TIY1B3=W^/:*'W15EE$NMX9M[(NPO::MVN!\BYZ670*@;7M>S+#
M7X@)9PJYP7J1ON5UT$TG06*JHK##WJ;V,FTZU)/MEN'GYS )E/CP0FF<V7&1
M$9-*TB9(G%S0V/'81,521YHV!2F(E\W24Q<B/#>?FB^ IT,N@"4--]T@E-7A
MS'^X07BO'75"&^A>XUL'_>)[:G?O/1UQ[2%O=C3'9>B X?VPVSP%[-A4:T&#
M""(CY%/?KK:9S;KY( 3\G1/&.SV3S+"G44Y#<)Y<RMHD16--4O7G>VQ(#A+=
MY'/)049"NY EM&;!6YKH+:?1$J$L!K+L"RO?<&U&5#J=EA%E/S:U? N6+T$2
M.?YJ^<8/9UFA<HV=Z[@J=\>ISN%WZ; K3BNFU"\9V-UI]?G3YT\$2,D6KZ?_
MC/_ZN,*KV^0M(&H.(GA1P8=T$K$N<QR@C58L58RW#;XZ_!(643GYXL1J<6*Q
ME!+6SDN79JNV6*R/7JNE+!T_5(7OHU:->_GN0B.0PX*2/XAU\C%,K$K?8,H_
MDNO--HDQ^U0@+TQ5Q -K??7YB)C0;H2YW?[/?R@MOR<Y;+-EP8Y2#%_><39>
MN,2FSF1Y"L](\7CF_[I\N+O[[T6K/,L;3N>]T_RPLU^-EG+(M DE2=\7P"1>
M4MUM47_^[]\7A]TN:K1Z62(-9*M>EJ4K!NS(FP!Z*[X$/NW4A0/)$*1CK7>&
M"7;SJ=[V>=YO#?@ H#-.N(H>MU"JPD_0/WSZ;*!'P,,CZ,1_./ED ?W%JA1R
M!VF]#E/B1*=N^[1299A9[73'(N6L9Y/%E@V&6&<YGA=KK8)\M#Q7-OS(UKO7
MO+GN&#N11O.?Y-TQ9@D&100QQ7[_D!_=.5=^]OV$Q/[@B?@S76MH]F"*@.CH
M)6 US%NOG7GT0^H&SSXD!R^=]S/JTW7'"/,CW^QA['@^-B9_DA1'+T+)X2/C
MD4Z,K3F?TK-(]NJ$.-Q$Q,H.)4THRBT%+LHDQ&!J;V74,+9_9FU[H5;QQ0E_
M@_H24>[07:T6]"SBR1CCFN485K1L*\TF."_H<84EMZC"Y3V."N2O<[1JZW@K
MA*,IXA3TTB#)C%!R-Q7=I'?6H1Y+BL;N N:Y._%_4]4H6F68]?XC5N1A9:+(
MW"I!6OW13U0XWQ- 0 2))FM=S*)"_X.9PAX2E'MHQ6-,J!RR9:$OH 2I$LWA
MIB -*WT[^9=C!ZSS'O*'.IL=<-5$L0?NOR_\7$M"2]5.G3B6BXS/6S,KLF3Y
MAXW#V%D2>3X]NJ.3S)%'4D31&BW3)=G]MCE//T5YCRZ#N<O-]I : H@L#>>J
MP$B/ )B6Q"L</PJ5.0Z(G&=H],O] U:#F>]J"59=AMH4_;5_MR*K;LRWDC9S
M-TY-X#8*09"1GXQ<]:K!H@^)+N342^==8*RDU0L(><S/ 4@R[E2<HJ9 EX:8
M1*]#(;F)K*NIM@3NLPK%D@RL\GU5OBZ+IGGX[/C>W]'/<1[X$;?/5B)5WU_Q
M#R92/I#%^LKS^6GF.2R%:>J:7ZK/37*38^J(/CV$_U(&2,:!U8S3?"X8>ALB
M@R:_(#@)MIGB&!/5!,E^;/E*&,][_OJMHJ\BV,Z0$*PF),R_N*+K#&88%(O5
MA(BE>*RSHJ.SZGU:=.6FE4R:/1^E/_S)X_QQ(VC7O2V)5IJ44L5\KMOYSQ,5
MC^U)IL]"2B6VW\YDOOIK(@U5;D:FZ.-WCK>Z]L^=K1=+G/2]PK=[2)R(O)C*
MYBMW:%O<BS@4##BN$9NF_LWOKL^E07)2J%_+*MRPQWB(WSX$ \X#:%Z7,6%=
M*QS= N8\</P&DTOGZA6"5+2!_?VLBOSX-+8 ?DY#VP?.H 9(\D:J:BM3]E3/
M(2(8U/><[6Z!BU<:SAD+4!#1HN&XD& ^D^[17]'P+?3BF/K]=;XP)DP^UT**
M8C/9U!CGRG;@]$Y2@K*#HL7(<IJOX[[050+X>WO6(;=9;K)H*C8W,Q8:E"BX
MV$MGSVR<O+3RG:K9P-@KLX[!*-3F)#AI3['$N>N&"=5%-H2X*^CFY.H#?E?)
M=;W9<ET*/\KPPHNV0>2PQ?HFX JZ]TI78N4-&KW9?+"989X3G,CZ5NY#4+8G
MXR(D:C+8U3 =T>7M-R!^3R,*NG+W.T-1&BNO+,]F#Q>#!L?Z<P!VY[WW_-(Q
M<R?7IN$5J9(0R8Y>#I8303C<!3UR;UF"NQ!L_W@'15<QOS,@"7D+7^-C1-<)
MN_'6W="ZH]C;(/)!@O0(X]\S7LV.Y2/,@F!I:$10GF$-GF@OE5*?$4&?P 26
MG$.96RB((G1]7TG7]^7[U@O1G/@S_Y0->?@ <=N%68CRL(.5)^>QE,QJ54Y6
M%!%!Q7$"HF8@V13DS],3L>#G&_AMJF]2Q[2"XCT,G73,!<IC6"FJXY>!U;%O
MO0KA:.A%/>OLVA<>"@-=6/+UM;UEU VZ#,J0ZPPRF4O; U>3X*=?;[;Q)-\*
M=_8$I:KUSP^2[)OAQJ5NR\7Z%\0J[ZB%OV"VH^>3-4C[BM)R;2^D*THWZ()P
M _^5JT\>_'V;3YPA;X*%B0B^_UXSJF# *KJV@*L%5*KS3!?K^V#G,*[LBG-A
MX=_2&%MF+]82R1K]8A$ZD2.N8LQ]KI:SGRA_Z*53YE/* [YEP079RN.)'V(^
MO]4BU;Q;0EYCQ$ Q@[$5!]DA+\C/!ULNMK=2?&M(!M*#?.%C4QO1YIS_7F&?
MZWR ;DH$)^2GC[A21=QT"WO+8@0[CX.[6%?4X5V^NRS!IA.(201-'*%TD_]@
M&5R^.QLN PR_IW$2^M%]P)BT"([VZN3@>?G>JBSI(REO$C )FT!*[B"JI?@3
MX+^"0P(L*K/)UH94R#"=U<T4/F=K244RP"\KL&I+FS/ :O&+S:^NA8]-($_0
MM_,@W$+7;LI/FM7?$B>$EWSEN @!UMUCRV<@Z11$GX.H228E&VLMEG60%BOR
M%9%$FN7L(Y5)1"VDKK]:^/=0U@ Q;V[$>68 RM,H8*"G?%[[41PF(AE!30_U
MYYJFB@D'DAV"_$QW04KT<!$O2F5?[$G;DZ&E(K/<+@J?C2;$IC'?M%(<$I1Z
M2/ V(PHK2"&I]FL&-[I_HBK_CTBAB'Y$^TXY@'ZA$*RAJSFW;[G6>OG.%5B/
M7ZW0LK'+JU9T3R1AHB@3))UUZI[)U(Z(/ -C@WK.AENZ _QJ4;UC3:VFX#7S
MK!'%+BE_(Q:7';M98H00VMXNUAJ4>/?<6-7+TG:;1^-",(W_A>0?^P)CF]B,
MNL6T5Q'.D6=Q=T,E/=6M&BK=^&4%5JT:*MU8+<;#\JMK41D4\8V.>4\R2-)'
MBM-=&+B4KJ*K,-B([[0RD-ZM8E),(WH"I$Z<K9P+8^I4331-:7,H&+JTZI0M
MY!',BHD$UK$QK,G."F)?I6(O,K%E]L1<%[KW%A\WGD^O8[KI%/2H;.Y!?@7Z
M!">PFJEF5C8VK%AZ9UYQVB_6J(\M@POZ2EFP??0]KG?Q4T/ZH)?!74@!PN_:
MQRYE7&?K%'F4O7O%Y8#)2J@.Q@%9"09(HCA(_<[\EUO!!/%2+HCK)*!6/NVX
M#ADD6S+GNDE(M^2)KR2G[GR0U6/YA9-:,O_8A1Z]#(B<FZ23IR$._DLY/\D8
M^"#K4M$4NOO&LN5:59 <B[4L5\'*P\43\YZ=PU:@',E$(7YPT5U9#R.@U8)L
MBM&+5H%BPK>[JO$1%:.+Z<E4=.BW>5\6M6=0$<",ZV[:8KL$(#569EF!SQXJ
M-)=T R[R4'9K.-N=,R>*I&6.]2*=^M(IZJKAQ=F.X 29A?XK3C(I"=EXA-,@
M"RYHY(;>5G1Z[?C>=-P"HA&>E$!L:%GTC6;$R"CNKEXL"R-2L $%2%LBSY/X
M)0C!%=,QWUAK?YS2'#O_K)IU:YG&HH%0_OP]Q]2_"--CRF"KNM7_*-K"D91/
M+(0NOB*GV$(;WSY$K;IW-+'1MU*&VC5-B8O-G%+)94LFM_:%BY?=<UL_:&O,
M5?' []PU=0]@QWD.J<@7AJ[44Q(K?Q47476 -EI.DKKEIATB1_XBR2()F#!P
M2]_P-]UN!DX!:SG 6-*J$4FRY7_U ,&!FT]; 7^@T-$)9"C&)_$+/=GD<=-G
MF-\(B)^*KFLWP&]E@51D#A="5B@(ZLI+)#(V(&5'S& !Q3?>AG\YGW?#A6?>
M.@A]&QZ[(]E3:A69VU0_1.O02X'JTB4&HD@12<MZ?.-8WDL=5RGWUO%M.BXY
M*U]MBVE!"5T&6@0B WOHA,^9H.-3#T$@&K D;1^1TYQ4)8&B+494'$"SF(80
M+'LKR[VWHE[*,#>3^#' 4@O4)#M7.-^+-X'_=^<FMIDL8%7.MC>Q_!44FZBI
M+*:&!B'UGGVQ@UP]>OFCX_E0%'U&^;T+%G"GB)Z8AKAR'A)KT<QG/E-$OH;*
M:"OF81^R:D>GDE7-DXO<PDSD:YCKFQEYPNG 'V#]/+4H.VLK-E;YGZ4R]YT;
MV>6=-B(5W@:^"ZV+^E*N#(DX"D1!,[(P[4V59)U:Q7^'AE7RS<_]U8(;DZ'(
M@#>@LTCRZC5$F*44P!3R-(U[@'(Q+B'+"R=)8S(2$E<5!/95FQ0TKGP;XF<A
M\Y#G_#![]>*=.;2\AV2S 9<:5W<4<8((A])_*)$"(2C9"W!>7VN@/E8-0Z\R
M75Q?B2A;IC[Q]"H3\Y;\Z>ZQ<0U8;LDYQ,I\W/^3DBC]I*O3"V6'5^N!]8J$
MO*XM "H3\NPB^Z.SOZR]@X1C_.+XR9I/C;:$/$D[66$*YG&C$TXOH(D*J$SH
MBD862N;<7.I>FJK,A1!.*CNT*19*@_AK[?NV:&\KAE0Y %;0&2G*2]W[EGWV
M1B0H;LV^*@HOUYC.J-IJ NH!/]\*. JHZF7@VIV":D!KVN+(5Y5.1;28/LQ&
MBG /0IG-)K2>*R)!;Q8A(%=&V*0"TO]_>?'<%P6((WX)6!A8-=<U8TF2Y2=&
M2@ZM%&B4%Q%OLZ$KOAR4R;(20+OC=HR=!B7#K(:*!:D4&[4BBY"(B;%7B:C#
MP+E3;"(U!-$_TOE'B+@F%7"-R=ND,\P#4@#K1U*?_4X6H<%9T1YZ3IE%&D=$
ML&1O]6YI#&VZN:+_ZJWHZFSW& $(GX0_\)^EB>8=H81J+C> 8T*7VE;. T4<
M:S4'<=))IB@HRV3$CN=J"GC9, F4.J?3D'D/LA[]27QQWKU-LKG<;%FPH_0A
M>4JS/.\[=KG* U!MG5T(4$=\F1)I=?&?4N8)@]GMQ=DWEF4R=H!(OHABC.B<
MH4IC%[W;$VK1W%]!!A+?[93O>1I=>)'+ @ /Z6BS:W.@+R(W"\FFZ:6X5QAY
M74Y%#"M8=_@>QZ=<<=N]$5(TFVM_F\31#11N?>X..85TR.=)\*U";AG@CJ!)
M!-$^.LL(Q_5BG=I:N0_+B'.\8$H%U<AYTY-3G=_2_\]-!LV0S)]1_;BXR_).
M.XMGNVEH1;Z&R'?6HQ8*'J8];D5I%EJ)O4(5Y4E*608(KI!TN)0B]R:0-H;5
M'/[^A%6?7G4>CL3SS@>>+OMXT;)3\(V)@J646D^E/MVY9\,PKG6SXAHBOO67
M@*WX4HK"BN[Z&LMFF+6%X@976:3Q\D^R[F)"ZZ!K5_H*W&<K<*ZM0+%X!E;@
M(;<"EQ-; ;8G/-H@.F'K,I7UR^@>LAY#UX].8>JJOA_68].5D?>.AFYMW+T/
MXS8]M@$,(7JY8L%;UX![=A,@MD/T0I!J/[9Z>6O;[H9FH37MB9>VIIV(,*Q4
M#KW%KCW[<T6]OSP DBP_,T\_/RV]^.A@C4:&()UQ<IN#=  "H)B??O[ZZ1NB
M2%OUT'&]Y(7Z41I6O:7\ ^^8(ITCBWG!DQ"!E7$O[79PY0/6I<V\9A%U7JPO
MWUUL\P+>V84/YR+\!Z?]J\/ TWE/^?'HN=QPA5_PJR#_ VUD)TL1V4$GO&2(
M(-ZW^'L$$-<8P $]#O]"LWD_]"*QW/KP7:%X$2D""U_<9?@_;1J2,2!^!W=X
M\6>7?:QAF:OR>U,NUN\GP7>]B_5[RU?<I1_S<_T7RMA_^<&;_T"=*/#I"KT5
MQXHB:!(@>O(;4"6*K/""V&JQF,.2QJZ*_/5 3T5H5[-9OE!(C5BL$>/9B.-J
MBZ#<(LT$.F%!3T5L1;,A\0O%O!,XM)[M=+JR+C,KB"LPR,4DH(3A-% ^MB%\
M(I%XPL^@'R<J;B&'\:BW; NMKRS)*!9.XL5::F=0].DP!ND#ETZ:="3'&O'8
M%M*O;'@H!Y96*5X5Z56Q3'G!,H*4#R(8@? WL++_D$6/[L#K5?AFQ+KQCT&V
M]P/,"^S,3?PTH!%EZ^:*=7O:$0KKMO=0NL]L5N(>W=Y 8(KR.;CV9 Z^4.*H
M<K(?6V9E&__?\KZMN7$<2_-]?P4C=F*F.L(94YFU,[N]LS$1\JW:,T[+(2NK
MMK<?.F@)LCD%D6I>[%3_^L4YN! D 8H2"8)R/71G5@HXP %Q.=?O]*_=4*X8
MRK%CXBKBI)X/!^D\&]?Q%R9QJTKR90A2G]TC2 +NK QH@LIX5??:."5#?"^+
MOL&>N\4M/5MWEUQ7$4!;SFH$%>-RK_[ZIXBD8;IZW:-NT!?@3E,Y%&'4H1]F
MOYP;7TTMBGU4(X-<-QRE[/8I1Z"L!M^_M A";D% (^/B [(ZT DOI^&\G/9=
M#)D*6T0:!V.>!._I!U,I ( B)#G]R5,Y;TE.6C8E05<%"85 7 _KX+5025;_
M=\BA>-C17M*<IQB74?D5W[/4C!J!+($<TO 39JH\/-X_G/DJU M3*GU'?G"E
MS$ HEUB.QF^\;@PLATNL=6M*]M"%*A_U*C]:P9L'/QGG/8,,VQW?3H,G<2O?
M<6#)1\25E*F;(E4<$CA[O2*/\T^IR#IWE,GJA ?UF'#,34ZWS&N5B?1 ^DPX
MJETD=Q8T4?UCC5'B5G-T?![*0?/Y+.;=[J#Y[+J.LE[O(V/+IZZ<_E^A4L0D
M"_[QO_^O+Y^__%O ?G59J,L%5]3(4(61,_M.=<NJ7I.E_%1L F7UO)$QL&6P
MX5[6CKDN"+AB;AFA/KORRX]?_N5\.:'R@C."8*N1 E5P!Z V8;  1G./'Z$0
M0+1842:.]4V@76N('RX3,09F0WPM U:+(R%5B RKE-<^X7_>Q1\*8,<M>TKB
MX\0#.0IXI+U@Z[AEMR$."F[7DNTH]@>KTP4(Y0H#DN[BQLD%68J;"BE-WB%&
MNI<LP^.>V&J\2;I!* E_V!40AZ$S2HQ8)7943/!4:C[!S/W*724IE/G(V;EY
MSDLG]0!2K20< .4S88":YJ['&(R0:=L3JP1\9&0-!A=V\4 <X3*!?YHS52D/
ML1SFKP3<9ZS-&Y.*7D@EF*=77(J@^TD0#FHA2X\ <PE3OPCX)"4\$$X3(+_?
MG)B=SW-E=;?*() Q8LW17B;7?)G@/P<:#X%D(C!_QNE^'PPWR^Z$&^OG-,F.
M?N89Q\^)5A1H3$^]7\X/P#3]'I9@\!/'YP3/O$@TQFFYC" 6\,D+PIXOT'<A
MH:HX.9Z=!Q +FH$B&G"JT^>CX@(<FQE42KJ:.1[(]WSY3N@;^9K$^6N&&2OW
M7(V!$!<F4_:L!/WEQR\.L$[\,6FV6'U$%D\R9<%$ CZ3@$\%,Y;8E7XOM'0Y
MG0^X8C5E7:Q<4BWQIY+T]X TQE=NS58NAI7+^<IM^<J)NG!4*/IR6@XT^O(&
M_"6A!>,@W=]&E.WQ?E>X(A9P:A.>N.'.=C_[WD*(\G,Q%;[8\N=_$66_W:9$
M!>B (>!K% /Z6B^4)$;VTX;193M1A!R!IGH1"-J_O]493&[3?(O:3 .8:@!S
M5:%1W*CC;,'Q FT%QIEO;A.P#<UCZ>KN%2O"\6\B'.P\V9%[P KR<R%1?MA%
MOL'! L08X\.=)].U=XXSS[\B>\I2$8&.S&<MS#NT3+,WG>R_8IW5VR)>#V!6
M1(H!)QD@S:G/GMHF[CBG]%KLC@R,T<*>N;[<+\#B3)@0TS<.2]$/] '@AE5#
M. ['<LIEI<R F=5GC55'-\C/-'D.Z3),7PC3AM](7/0RT7)R08[T@I03G.[4
M:676G%2PF/JL:]>R<<U'#A+A%JEE<O,])W&O9(9&H70>/ O6>W8.R'M(+X(U
M48C"Y\1FNZ(M2G,MDX!3=Q@Y2U)(:^;X5_!L]W\U-9*BY!]*O"YKR W#!&W,
M7\IQ[CUQ-V$:L^\/R6\XYF-"H]5^D ?E 3'(LJSTB9T-&]*R(*B6' 2<\!@A
MV$)MFV_ZE>,Q&DJ5&8W)RNNQR@L-R57MY @-=[X)1JLWY(";VILJN;)_(Y=*
M#<KP &=9!@8L2$@!I5I6U^V'@\UIB4+)[-'9JA&UO/TS8U"+5"SI:Z$5 !,J
M^*X4379<6-<%K[2%S1J7;K'09BMV:@K,4,#"5 9LM 'P#<M!1/FK,>'>G+%(
MNW$G(KW<JO*S8AWE27H;I=N[4\5:02, (L'=M;LO@JL$];&YJU6+#.Z_U_@7
MT$B>#QM4YZ"DJS,S@DS+MVL)W3T80+ X!R6"JWN,X$%YH0?8< ACPL6E-%D1
MLLX@\14LQJ#JS#=0S4;48WY(\C^#26)%H'!P+V50#,6S7",Q&,A2*QQ.I$CG
MKVE2O+P&L^778!.NN*LT3O)@CV8,/H_S7 U:6PC,?I;C(/8P7PAN46=C!7]&
MP],Y\UR7H+MM@OKW=H6L5I8DUQCFFOZ"9"1E0]^R![#(BY3(Q1FP++N6+%WY
M],+6(*> *#Y\$FJ[?)@%H;6UJ!^#^EK<-M=BE"+MGI:G[FS3MDSEQ A/6ZIO
MF0U?)GG*' 6." D/0+=ZRHA PB4R@%#9M8\V*_+7) 6]J-_+5JFIH=R>H:)^
M+ES1.D.5,S@;@9\!:Z9.(.'@W,K,3CJ30"\^ZRU;P)KOIRE4?8Q4*L7O!SG"
M'R"M3>8V5@K<.+91.6'5D)[J+B'5)2>T]KU,F:A.+09EJ(^>BT#6@/O6KZ"7
M 2XR8"V<AISUYX'JTZ_D0D#&T>2G;XRJ,GT%ARX&O?#E,OPNREYF*KOUD<0A
M%66K9%"B2&WN<^?9ZFVR*T[+:%6#8_Z>BHD4XSN_#<=<&Q/ 'Y./=VH%M/4"
M01^0R'>.T0M'Y)\>V!;F73$S[(KAER-+\[^*"-S3#++57#]GP;R]YUF)?N2$
M'!J*>T^7CC73WL"GIZ;U+@@8@M&3'6-5LB*D\-!\'E274:,$VC#X? 8_8*F%
M/_A,HS[+]=85H1Y(M;T3JNV?=@PHMJ],."Y29/,V)7\K2+S:]_?_:%0#1?:L
MN!&[0TL",?+DW!&D0,WG&QF+!-N4$CQF+RF!$X-!-3TC B4TO0RB*?/@0AP%
M)9J5&OK\^*4-5N>;,DVR'"3@H\#AQ7'.C].Z<Z?R<=5G+;^E_,+LL<!/[[*R
MASD'!D_8>,7,SYB_BCIMK%_.;ZO1RY?/WL*(@A'P-DF?0CV "E!SOH:Y^*]?
MH_PUBN<Q!_.3%W>O?(P"(:8HR3*F<H5QD,0$"T)]%&:E/T8.BLXV&%:/)$-L
MHG+D@ \=L+$%DJ%ZR4:+DN$(5D/%^7!J9S%YJL];B^X1D%[NM: '\CY;K9(B
MAI2%QS2)V5]7O&[//)709WJ+*%Y%[#5 IVB_4/;WH*0;5(>&XELEV%FEF1@_
M^ O.X*.L##V319FG+V$<_9T#X['W(J'1FNMQ\?H1?-="EIAO;J,X9+,*J8J)
MRJZC;$43$(T'B;X &2B,]X$^)UX )T2W.7O++XLLBHG+.%+?"R(O$'T-*O/@
M5;6TF8 PJ^921JRQ=T'-9HQ(C"790CYDN@>DY7S/YLRTW Q7JNH2[_WJEZ11
MJJWZ^L^2._'1U2 !'R70. 6-I18$X.A)'X'?FII2\DTXWZNV+XR(HJYB9V2&
M[RR.BY!R=*B>>=$!IR6@IJ8[;5.BL^NY*ZD:Q*,[=OU'*0S+7L7TI9_;'BD&
M)<E T'3NEAJ(%=TMCZQ$)2LK3G/J/-#V+S'!^!L30 U[;K^2_#59)S1YV<^>
M,S34#E3H3QOG=[4<N@7>!50/R$C:-(._R(DZ*S<A] >U9//-@JP)V8+\SE_/
M/&)_K3Z>2\;EZI6<$O1BS%DM4;<WL"[X4,(+FJJIB*<5Y])X6',^'86(YBY*
M9O3EJN$Z*ZU+VS],PBKG$&B3: A>8AXC1!/Y6J=ZN9/!]Y5#0[,+9'M-L# 6
MIS! M3L7-(;DTWB;E$R-@-SO#HW?&[0^/\%)EB](M'TNF   1^JI>.;%E<'S
M,E#AJ 2@Z/1! C;*)U$Q68YS9@S2-MZ"&F_.JTDY8K)^SP*S:879C'W($)D-
MY5"N<J^JV*RGGS9 PJJ<MAI"[22G7RV'-_WY-K!M*U"V#I_7!Y)?A=GK8YJ\
M16N 6/O&I'(FH7 +9/PR@\HG^,8/H2O!4,&&7=$B07$CAPE"-<[_/F=FE:.
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MQV!%O6NP$/CC-=.O!TDI5?@;H0!I0*2G8 V%'JO!;S4HJ-_MZ@TN4S7*I3>
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M2@+<1M]VD&<Y6W.W^75/+5RKJ)>)$8("1PA",03F=7X<[J5_I;VHH/:/:NR
M#Q[(T='N[E! +IXSK*.=W[PA9E[/.C**7,#IC8*.7&/BOJ?SLL[$2,Y+=%J#
M$G&WW:7)&Z\=V#_@4)$-=+IGP09MXV",;'E9PK$_%HND- *"2J])T]'G6XT
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M'\:411=(;6F=AN^?N)PJ+1S@ABIEGD45Z%XX :J0L\IW-1=OAO^FR3OW4&_
M<K$-T]](SDTVOX=E&V@7EBGW"!]5JRTN"Y"[E-G(+HS6(JX78%OPP;CB+R)_
M(ON;<<0H,GR8P[?PETF,)%[C<V246GB<67AT;9?IX$,>*$#18Y2 2R;I,?R-
MX69RR6PC;<-S/ #X\9B6'J9[#:VOK[B,J<K)QM6.''SNFD^3TPNJ6(/.16"5
M9EQ'BX;,\T9! 0U( 1Q@*VPM*JD:,:>S2S02#%@2I=AN89GD-S9@<H]0U_D<
M5DUN+2WMNX&_S=/[3=48](H-Y:15T5\;H#>6=X"YCUJ#!::1Q##7^:;AQF6O
MLPY7UR^0I1P)EL+DQP9A0/=ENPQS:3@M2P/W,&$BMD@DD.JTWQ*]!/E=S/@M
M'.<K#,IQTR^K41UI"U<P.06<645[&1#&M1TM;;;\BH]0!ND9+VFX50B<JN,*
M3OH9K445J]^^&ADO<R'8+2%&<;]+0-) )'R>TP+0&N<<HE9R7M-%6_F:I:L*
M)V&ZDA-A?STP%]'BGZ%L!-GEG_BT1'?X&HXK;/^24$8&ZL] _8JOX?=H6VS5
METE\C(Y?\I^]+;.I'M UR59IA',WK<V!+IX80O5I^9XL7Y,B8\=U^<X^R=Z*
ML\@5<YV]DPAX_WIL-FQ[11SH\YIMJ\_F3]9LYWGJ)Y\P_+]?2)8K1$TCRT/2
M][FE!3ZW"#E&'.Z<W267>YQG8P.W-_?]S<D++/."[*""-UM>4V:I\6-VZ>B9
M.5,^P*]1_OHM3IZA8 SWA^P*3!+0RB:IDF@JYN\NSGF\X4^FM7 QSE26KH(/
MV1)XV;HN78EX9OKJ%6ZBNUA/NX[8Y]I14O[3$Y198P<W^[9;LTL;T5LP2]SR
M-O<FZGM1V(4%3KJ0/H8[@#O)[^(5+=9D#5O<C#K0?,K[4_.\#*5PE629GH*8
MF=BTM_;Y</%ZQ7#:XK7\^U.RR=G$B$7Z.MS%\W=AVR?EXB[_\RXNU[YI8C)]
MJ^,H>&9W2;: (9_N>?T%CA8U*_+7)(W^3M8F_@YT\;DA1=+^8TI6["<("'[*
MBS5;;>&T:VS'0QT\,8,XOKP4P[TPR^I3-_SL^S9#]RL[SREY98*X*FGY+69'
M@,*V^%-"05S].8QBN,/F<1FS.4LCP'#6$?1Y)LXR_&Z\#%T-YGL1Y36A_-HM
MMXRUL6<FI+U\ ;#M/&>_>?8.-IZ*M"I#"5 ,7\]CE9X+!>FSACQ>%<>91@;=
M$7^7!R2W"K4#CS65S<S/)AS#UFU<-O.MP9YJ5> /H30@09W2AO[N:@R/S]0-
M5J.Y84+X"]RX:?+.Q&Y>MK#^9+4T]2[T28C6#I8*:V/O3#128 Z(J;;FGAG1
M72/<*$N95F_BP=S2JP2Z9H\8.\LAO0U7:(NQ*$*VAI[U.>E]^A6!#W*[%F=L
MZ/\$U#0O$<<GY0PA*\EX0?[B=M/ANE#RS+[$KN(V5! 4A%'5R**]];D^P)(C
MH9%J]35^ABTZZ$-\8"R?I[B)B7(O4[8:![FEK>]'@"]VMDQFJ[\544JL"6G&
MAZ%S;Y]?JHPQFZ<O81S]742'Q1D3+-9\*\9@G,AD3.=\HX)PL. ?9Q)V7N/3
M#DE\ B9C\=R@IF0S!.MMO(O$[(%G:YOA2LY3MO_>HGA5F?JAMEZWIKFR(;_N
MC/$J-OQY^$VDYS3WJ(M1?#OL2QNOT4]?_GRN[ZPI &819;_=I@32P0C[=CF$
MOSB/NC$-ZO70(!#?=6?<O^9Y.)* [QW4* J](%!&AX?2/.W8-C?N@</=/#,&
M<-T1FMH %JK%@&EL. $/R-<P+C9,D\=+55J(;=X/8V.?3( A?Y6\Q&#*7X;?
M+TE,-E&>2:4LDUI9MB!90<%Z" : 1_9TI/P!89T>DRPR/SJ#4O<M&8&]5^2F
MV$W,S59>;TE'.A?[<T,B)APP91V_4_-Z'6MDG\MK"BR^30!-;LXD?![?W%B9
M+IV\6J;,Q2CBM59<:[:%R+&_P\?-<O29-.U6)Y'Q:T_\KT),C.FRRF;X&$9L
MSE?A+LI#*B(9YYLC).^!Z'J^_GXN0CA_A,R?:?2"ISD30=?L'4.;MND^[-#-
MM_=L8!<W$T[FFY'<Z7(LSTOX*XE>7MF=/&.B9?A"*E?XO,@!26XMG*LK*"0!
M6%+F@)?3*'D784]00H[N[%6.*/(T49B$;,_:E"ISNX\H JD[>G01J#&RS^65
M3AHIN6#6JHP+59&S&6,/6&!'5BA"5D6I+T&_\B#90-;?6GCJ,@0G81\)OZ1!
M$FQK[I.1>S8/<+E5D48;#)B;^194F)*9AA1VQGH;Q1'XV0&X2VP0^TW<J>,4
MS$!M5EP,5!%%L8U&T>,H3-8NKE>GKKZ6XC =9P _2,[W=Q\.1:PF8JEZLVP)
M,"*E""G44K:G@8T[#>^R';L&(L@W!4W6+,#I+3Z C_/>ZL(>>@#?ATJQ(UQ=
MCV$J$KK8!H3]>KFO_%)W_O8BY-%K>@5^4*9Q7B7KAI=4_VV"9BC=8M35YJ3W
MF<R6LP2=:@:?LCA&Z8:K8MBT[\4A1IA(A+M"G_DYM00WFUMZGOZWIV6*,>;[
MTHICES_MK7U[/DY(@Q3%=XTNDM/)^3Z]AS3ZS*;2BP,GO!< A".5]YH<))5[
M5 5/\NH// ??>P]S[K?"=P#"(=L<A.T6LW;3TMQ_M,)5WVB%[@1\'Q3U")E+
M$MQ\Y_8<\('QU%0A+=Z$*2@!F32"='SJAAK%?U USQ.H)ARIDJR9+ EK6HW.
MG7WOC38]_(&\XT_'FRY43\_LZ>9:P/TJM^,U><[+_S(QV+6OSZNLPQ74GM!P
M+ '/WQ/=TNR&*865KC KW7KZ?E^9KM0"^:!^G?*E8465.OX6L9.:P'>JZ;55
MPQ,3=ZK_H+6T?=J3"?I>#!YD):Z)>;H \55YS=0U>152"F!--^'JM=JV)7+K
M=*+>+96E@<D>G]9LY?M;GJ -WFVW(5:EHS>;#3'G7 Y!U[O?6CAD*G[!;[LD
M/AAD=E3OZ9GYT'A3!L5 )(P1IN)$$I,0\Y4]_'#F<*.I[]?88&,\UAK1P9C>
MD_@4XLH>DCBIPB[(;-8VO)%./7WK.;628D9]QE1VS--%@Z$S?"$;-XCVF^^\
M8I+#/89I:6L0,[YAG ^/F87LT54>O5GUQ^Z]?3_Z/.H5=_1:VB)QDZPOB_PA
MR?],<HB/-0NNW?KZ1ON2=A<=0@[*3YAXLC;V?=&?&L(FZB^%+^ K+N,VN872
M 5!TA_&\(BF;OF^)(/QG$AK DP_WF>(6+ZO-=M[HM0*U_AB2VK]0DK3\T9:\
MM(.=?)_A PYAJ\G#C?^YQW#3#BPT+<:!+KYQ'VQ #4R.,''3UMZW0%&FK>NJ
MK\U%:&@ZD4B'$IZO7;1N:^_[PI':ZGS#96J!/UO+>6G3@(XD,9%OISQP!W )
MVMK[UNIJ'JBJWZD][>]4&K[U]$KI#;3DSC=,<4+EU:B>MW7P&-4GUGA_\WV%
MMD\0J_3YV]IXFG*6YG]=P!R:[J?:3[X12HLT1CV374*WT7?4..TN,WMK_Z:%
M$OA3G=%EHKV' B@"L^LL]H5C2/@M]&%'!H?_MES1Q_;U?7>!I5";3KO,8&_M
M^X2=6(2C"MN+]Z^J2C$OV*T\?-V/CD/Z?L9M'JXO/W[^X^<O]MNK4T??LK[1
MWV,H86AS>W?J[#6/,*3)C.:))8*F^K-O:;]@Y^5O!5O%FS?V?TLVF-W\8VWL
M46RZ%H6<>1C(3;R^KN%I61MY=_CKT1GM5[^M[;0\H;+"@LU,WM+<_X4+2<C=
M+(;6QM,2F,0T=4M\!U')T,O[.3'F9,F$<8@.UE.U0 K0NQR*HCF!Y#07Q';J
M6IK[QG^$"DUZC+\UJ,#<TK<@4[=$MA<#:FGN55C17&^+9!_2?"_L_?-X%L=%
M2)G:B!60YYM?PM4JB@$A>%VL<DA%^5.Q#>,_$=;KM7&Y#$;9=QI8QABXR?((
MHLN,1ZS:PK=2:51V]RT/6GN/"3S-!"\L;GD4.2 @Z2.2",]8WD;%-M.@R6SO
M]O&4IGG9US*2C[S[#;V]JR&['46I,*0@XM[2Y/TNWB3IEHN(;<Z&;EVG$@QJ
MBN"\+2B567OSS3<H//^>1E#[CR?]+1/I:2WQYSC-QJ7K;BC?.T2J#3I$IVW?
M6QO[-0MPI'UMV0$/3KM^,/TQRXPPA$?U]GUGZY")T@!'*N;G96(*=5,O41GJ
MUG;T78SC>^GZI4+:*P(/0MCG\9&Y'!R1A*"LTC@EID;>;WX'('+X?Q[ ZVKC
M3AWO563X*)'V5WCJV%/86*\^Q+PBO<$&%]^O1%@W&Q,[=? =I*6 4]G+MA/0
MX?,-CT0W8EJU]_!N(.7E%F ?6:*R:DU\;B81:5O*$;H&CPDY.OBU;L](:/,*
MZD5M&CA<FAJAJJG4 D9 \*I[E>U1EB[H^PZZQ50[%=,%  :,$6ZL*P 3FXM:
MB3F;MWOOJ50I$G_<1S'Y4G<S61OZ! OC]_HM4Q1""E'G%A>9K9UO(VN?/&<N
MI#2='"#S8@$/'D4%6ZXE$W74&7A_L!JQ,Q!U4NI+1]2!-/6<6KF'WG6YAB#J
MVPW#;BE"JD;@F^]1EA/D1=J%;KZS?S!Z-HXBX!L/I(@0H=\>0U-M,970JE(8
M*.4 0P%TUH#)\FDERDEE9BS)ZC6._E:T.-I<CN<Q4/4*C!<DW8&U&V)FZW9#
M6QO?QB#^$=HL8)46WDVT'2&:->2@=D2E?A3/ OVZ62"ZJ3"<3FL2&]@0GG=X
M3[=TFLJ=/&#LZ5V<)^-&NY8C3E#\4#8VZ?6X+L@#4WB7[X2^D:],/7PUEPP]
MD=94=A3?^OA9OBSYY_FLOIC=MG],?]\W0K4 2'N8G:&E[UB0IY\3=MW&:"\7
ML4C5!*DV@.!N?7UKW.4C\ABF\Q1]J6O<7J92*$=T\_D>-\NWFVN!6]I-)$51
MP6/?Q:AX9@H5%*IIP7%/K(7>CZ4QS< 7=GEC>&9R8HRGL;_O2^5 F=5*=55Q
M#[97;QV6LG>U A#$F2::K$+Z'^RJS-81?DO[57N@BV^&4'#7<$Z,+-0;^74S
MFBP\8,XAW#L!M5X,OL8.O;RZD)=?,?[T4*$L2SO?HI393:T]Q.:8F4.]O%_\
MIM=(Q.9S]%WS?7^PVP2RE"!EJNYYT7_S+6<D6X :6Z$M+-W;+UACP[/Q1(J?
MJLIRFTEB(-+> 6-TE&X4S4W,&II-,Z3]0+KTH4Y^ZVZJ*XI=6%_#N-A T32P
MU<C:?>JQD7:+NQ@<BU5IMS<QWZ)060.BD55W#%C5H=Z^GVI4N-J,'7J#J:0#
M8=0LQA,_%<__Q2[ 9:*#1#1]H=W[^MYVQO!([JC$&O? ![ON$3K>+G.<0,;G
MMSW"K3U99W4%?XY/R2ZE6!M[]0Q!OLK^D,IA;#6%4].C?*BFS'8L'_K%>NK&
MG8;?L)7NQ5FF6X=%9F:!^,7^6F(: \P2EAC5DS&Z.0K[TIR /9H7/,LA,P6W
MJ JXA]RMV>HU8J(=!]+3A+RO$66,)K$A_6L8LCX7YC\(9JJ1[#YB+)0BW1X.
M>Q@;=-(CNOE^O&I)-0BS!08+R,LQ9XT?Z#*]V@\H]QCS<#MW\NZ0!M-XV\53
M;>%;M^B7V,5N"",!6VJEP^&\0GR_)\O7I,B87'";%&E.B%"0*T*\Y?(YIK/O
MS5U'TK@WE0L_W-JK!(T7_67?<IS="4Q![CXEF4_6B687*Y-Q8X"?)RL,1H9_
MTN3@V0M3-%Z@A!*3>Z.8/3%6ZZ"WR?@VC=?=YZ5]$0Z)AH??K<"UO?NT@I&&
M"@%NO6=<C^G[ )<!G,8<1OUWWWI:':7H@)NZK;UO=P=[<TW!WJ;??<MPJU6Q
M+3 @Y9KLV+[F?B/V=TJ$,5$'K;$B^1L%MH%H^SY#/=\=0]UT%\^;89BI.,\D
MO%VKLTPVFMIKBPG#;3I9>P_?:76/<[N56OWH^Q+J@(&@O50RVPT* 9@UQ1[T
M?"]%>PV$\D;M6NER4,)G?A/;[>_2X80E3UW<SAV']@_U/P XTO%4?)LFVI(W
MOH8Y5KXX'!1P AG?,K>I='5E0ZH?,_&K&0OE)$)G>M4"[HN3J[9">&(.@]88
M-4O;J423*!U?3G >+U\) DK5\2B.[>O5</S*1'V(:D''TUP8?F685=-4W-K<
M)R,-2!XCG$&#H6[=IORT:'F!@'NR?$^.?E::)/R+$"4&HD4Z*!OX%BA5&)\Y
MSK8:3'M,6.#Q]'R+ @EZC'@P\2+*?N/% >%O9NN;M?E4K YX4&K"MD0MA8\A
MKOE6HT1'&E-.7+"K_QVZ>2XLP4].&3]S;S+E'VP\@>P+#F[%K7*W[-\J#+0V
M]+RUEF2[2](PW7-QP0((@1+2 WG'7\R%RD^@XUL_4"6M,(#V$"*PM;5_-J2^
M@;A8AG*H\!*S9WF^L2DTQY&8(&#>Y_IYLS;T+9'TM#-)G5OY )9)'E+WSO4N
MXY[YTFHF/(Y5[-A.R ?Q#8N+)IL2K]?$<[W-%+"Z%R0F[R&U91F8F_F^J<%[
M=!FN?B/K+J@>+<V]FB4ZO?3<96\4&4ZGXEO7[U3$;5K5VX[)X*M:C$HK6>/C
M#4'4=PA'FFRBW&;#*'_UKK5OM_#P@G.3Z:SVR\+8<"J"VF/"WCSZ_Z+=5;)N
M)*G;6WK-:.-:\CPNC8X=@CIM.'N]J'DULR<YA!F'5*(7(=+7?(,BS3(1%X&H
ML;9,V/RA?.M=C,8Q(ZIM3X+G*F/J<8C%EHLC8$R[9=>D!.H'@Y/ MA]4]#QR
M['-=XJ:$[5XML@[F%5.'/<#LMIFQR:YQPLMW6\5H>U/?LE9'IT@?AXKOC5ZK
M>6U3OTSM/"(>RTJ:3/*3PEZSKG=KPVF9/#%"7KU$LYR=XN<B1]=-\AC:I/RC
MB?B7=Y4?%6(6V(M;BV(H=4R(9[!(Q4?1F!#+4NZZBR,0/AZ+9QJM9.7"0[RV
M=O9]B?0MQU4OQMA>:MCA<+Z-,R4/&4\""36D3JW":8O!YC@24X/=0Q62=8/9
M&N-FNG3R'YW0,331$KK0L?<$S (B_N4Z@KG&:Q6==4U6E/UQJ%*XM9_7;9G$
M?P]%GKU-8FTT\7T#RXJP0A)@]V(2XQ5PJ(2LJ8/O6U!'BSH,I5]KZ-W>M" O
M$4PESB']RFQIJK;Q'<S2P=WZ""E4[)$U")5M7V@@TE[3L5'(U"ZM4EIH0M9W
MZ^']LBB1ROCQ?TARK1!%>_19U\X3@)_18<ZM]0I;VGJ_2M P%F*('Y-K0H/#
MYU!;KW;;F!3;9)6L5@# &_]7 5GOPJIJ0W@ZV,7[-Q%.@BOVUWFZ3-YC\^=H
M-/-]Z(<TW$IP@U\2RLB 10M-MU$\BMFX=73?*0V=0G*_\T#6(VJ&VBCXWE6
MXX<?,*27(04#Q=,K(7GY'F3MK\D1_7VS>BHN7]L6!O@],V:"L]$\7J#+-(2G
M]FF_?4YH_=JL_.@]UME872/K*",=T7V:IHH2:[!/+F8+E8E@82W?V;'9&\"L
M9O#;,)!90XTQ95_8-R9"\WP%LK[Y#D5W[-6\3B(TD?W2\I&J7[/C1Q?-=!S?
MQR)=O;(EZ8W'YFY"'E\0K'CS^)K$I!D=:_K=MR5+Q>L_@8,>X*^^[=;L;?CR
MX^=__?%+BQ6_2\<IA,":"YQ:FOB6X!JFBVX&#M_3KKG>V6!6JZZYZ30+@)D8
ML#3UN=._ANEO8*GDGE;+E6QJY-NJ6WEA31G;[2W]>Y?J1F->8H#_?ZO\W;6O
M]]@ /="2NZ)Y^+DY&,#6VF,<S@+445.Y<?6#=WO=TS:D]++(HIADC8Q(0Q/?
MFT(<OV4R6['7)R4GA,@<1\(WPX9]?0"5\4"7J8&[*6O=\3"JYJZ^7Y;T)8P%
MGN)5$F?L4EV' FN1?9H,K'D<'EO4*0 @-.%N;K4C#$)X$GHRAU#O\%2U-)]:
M:,Z"K?))X3FFCE-! =9*SF?J'_\4L>DSK7??C"D]B8!O+;0+4J'1WKQ@RD24
M13D1L;,\(6[!171H8(UI=SVF[ROPC:0S2A/D\%"=)FMCWXJE I)IO#M5B.IC
M,&F.(N7[8#3*ZG4).CK4R3<8ZW;'KB'<:NEUE.V2+*3SS7W"+F.F#:WY1^GP
M,IU"Q[O;AF/-'$:CF<3YTR*$?DG@M>20A1:-UM34N^AN =/^EI%-0>^CC:4"
MZ\%N/F6?9NF"6R%WWWS?11R,"F#0&K)/UXZ>OYKN9P=[.0K8%H.BK:WOE^O4
M<!+=;.($)]TTP 1EW<ZFM,Z=I\)D*7B68+"MC)DZ3 54=)'L0ZK2!>?Q \G!
M?I/--R(F#N.VLTAB\\_B:!O2/Q'6Z;5Q/0U%V/LCKT="S3<6EP$OV:6RX2##
M(.?5+Y?)S?=PRWB$Y@N2%VF<+1)*Q65M%AO<CNEUOTG_;N,R-/SLU>5(WJ^2
M%!(><\)VXOIO19CF)&5:]XJ#7YM=,]VZ3>;Z0K':4!,(BP!UNZH[TIB(F?2*
MO9@OG6QE[3VF+I)D![+X.<"5E!D&+QTPW/"^%QJS*U 5@MR9^4:+L+/;ZP[W
M\JIR",>QY0ZN_NP[PAEC(EJAVBLM_.NHM7SQH\I+'='=NUQD##J];RM,=ZC/
M!')X^)ZO8_-\BR-V,V4A/0+UIR]!KT*:<.G.-\)VCHZ5^3.-7D(+QM&A'K[/
MI2A/9[^RJRVFA==QN1?%2/!%L:*F'.XU'6_E-<E6:;13F/$'O)7UYKYMJ=K"
MMEYYQH:^3?8RTT<DBK+'TV*/,[><$!(GQY'+4$LVA6DT[JDC^T_BO%3=VY!5
M ^F^<4M!]4.]?,O4IR*N3QEB/<MWZ5^O9OJTQ3]Y/^X<[DX ,IK/>:6);U6]
M8/*0)BNV8\_:6T]XE_-_AO@X@1)V[&YO$/!M44I2IL/'?.57NG0/%< .5G(\
MHKOOKVJT?'2WD?B6@U.R"Z.U..A,GT3(C JRB5DO/=C-]W=1(2'F=<?#)(Q/
M(D&P0_G#_E2]?V^+^0"2-5J4H</=IFE_: WX/-3'+VAY,Q97Q/Y4P,9-=:=/
M(N#[D1?3E<9&:^%C8T/?1LD.H G\ABSC$HVFRQ/H3$/SK51%S3#&%FR6O[Y&
MJ]=Z451ASK=I^?TH^GYVAJDQ YRX*\#2&&2:,  BROY$Q$)#[W/=&P*47.5%
M%\_*^+6H1<&['LOW;9-LMU$NT47!?,$^,-,0()=(H5NT/?E'$? ='XS/MHD+
M_HMO%4\Z_._B79%G]^#):,DI;VGN^UP6VVV8[N<;]>I6]L4!!*%N?2=H.&QG
MK+V'[R_65BI)U\%DY( YRO)H*M[9%MEF]VTNAF8KWYNOS%4 '/Q., B'^DPP
MB-FN/=M;3]4:T/:$'NPTE5,"ON?L]98F[ZU6@+;VOB4 <^9:"W!+6P>/N? B
MY7O_^<OS,LII Y:X_KM_,;..X-!6.[:E^20,$_/-S??5*TC^(,+/8]CF\#\X
MN6\A)5C9DFWX"%#ZX =VJJO_H+6TVRT&'6:"PNU/QPFW/WD_=1Q>XE="Z7_&
MR7O\Q&2X)&:Z,8@\#>RJUL9^R]!IT9^8RL16&1*9(#-@NWP%O&$RW_QLJ3K7
MO;-/)DU&K[P)87454@HFCIM0&<%$6Z.D.S!IWP_[R4'&/-@.X*CB]>'(+Q?C
M3&'I3L%SQ?_[A>-H<ENKN2:JTX&F\A9<[IL0"WC5V^*ENO4\U[U1II4>R&0<
M@KCWH!D D]UB1"[(=S)"QAP]8VX[!<#$ND6#YXR1K/[OX&IYV-&X\9J<2FBJ
MFFZK$>QP+Y_?U%B+3?BTP2O:^':'.DSEGM6$Z,_'R=R?_4.3ZO'NV7WXK/:,
M)4'P0'O?MKN.=41!I 8TX*ZFY#8:$XE$4($3FBV2J?5M,0F6+GXOB57* ^;Y
MGW?Q45$DQW6?A+6C/7SB"@T4=W'CD\%5PH432I-WL->>&J%QQ!#>[5PB,QF
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M2)\Q.UU?2?Z:K!.:O+1BD(\PK-<85W$%J]G.-PNR)DQ.9O<O/X)YQ/Y:/8$
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MH^G<)_$+K&I;)L#)E'R?I5.5P_8;L#=5KRF]3+V( 7D>8FA4FNI\P\NE)->
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M<:37<F*N2KS@);[U@:#-0VU]FXM$6JB&"&8T$36;^=Y"RM5;ATZ';(H5F!(
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MKD^W=O!^IYM@]"QYM9T[E4S]GW\N>6+R[&___M_DO[#_@Q?PW_\_4$L#!!0
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MS^Z3[)\@PS<+<^&2W<V;PFO$*^_%/^UBLE0[GLT#3'8A.D(7^V\INMSCY19
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M\+GCR80R0>JM.JK*H;".0]@M4KQ1OZ)C^+568+\4P,9(),B )64S^PS-KF^
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MU\/<N3F4O5O"HJ"P%RU7N,;0'7Y[IR@K+'FDN@QE/DFNEM*HPNKE^QLT-Z0
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M#ZH]/0CL4HVDRR0F^.9>]-7+R@MFN:J!.,IR2,[4Y>'+!,<MPV:;,%[&X)_
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M<(-($%,?SHGSZ$5PE?KKBTP["A9I)5D N*%&H#&:]L($'F"R"W$^88IXS[^
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M@0]/ I&%P!-P8LYA5P%CN!)3 K)K1"A$+B$>("CW_OI1UX!R(4?&5:3(!!
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M%[+<+PR[U8-[PV[YR-]_4$L! A0#%     @ ?(!<5%&Q >$2:@, FY8# !$
M             ( !     &EM9S8Y-C(X,S X7S N:G!G4$L! A0#%     @
M?(!<5)LRXM5R%P  )1H  !$              ( !06H# &EM9S8Y-C(X,S X
M7S$N:G!G4$L! A0#%     @ ?(!<5-_<-Z]W$ $ Q5$! !(
M ( !XH$# &EM9S8Y-C(X,S X7S$P+FIP9U!+ 0(4 Q0    ( 'R 7%1"4E:(
M8XT  %/I   2              "  8F2! !I;6<V.38R.#,P.%\Q,2YJ<&=0
M2P$"% ,4    " !\@%Q4/P*VP,;P  !PA0$ $@              @ $<( 4
M:6UG-CDV,C@S,#A?,3(N:G!G4$L! A0#%     @ ?(!<5/+?K*^5YP  )W8!
M !(              ( !$A$& &EM9S8Y-C(X,S X7S$S+FIP9U!+ 0(4 Q0
M   ( 'R 7%0\BEQ)+"\  /]$   2              "  =?X!@!I;6<V.38R
M.#,P.%\Q-"YJ<&=02P$"% ,4    " !\@%Q45B[4A N+   ?[0  $@
M        @ $S* < :6UG-CDV,C@S,#A?,34N:G!G4$L! A0#%     @ ?(!<
M5%L>I=?I[@  0!\! !(              ( !;K,' &EM9S8Y-C(X,S X7S$V
M+FIP9U!+ 0(4 Q0    ( 'R 7%3Q+6C(P_<  *W  0 2              "
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M.%\R,"YJ<&=02P$"% ,4    " !\@%Q4#H1^$]1X  !&F0  $@
M    @ &3<PP :6UG-CDV,C@S,#A?,C$N:G!G4$L! A0#%     @ ?(!<5'Q]
M*.8J2P  !'D  !$              ( !E^P, &EM9S8Y-C(X,S X7S,N:G!G
M4$L! A0#%     @ ?(!<5(Q0JKOR.   XDD  !$              ( !\#<-
M &EM9S8Y-C(X,S X7S0N:G!G4$L! A0#%     @ ?(!<5-FRHL:-*@  G"X
M !$              ( !$7$- &EM9S8Y-C(X,S X7S4N:G!G4$L! A0#%
M  @ ?(!<5$7FX:(Z,P  L3@  !$              ( !S9L- &EM9S8Y-C(X
M,S X7S8N:G!G4$L! A0#%     @ ?(!<5-A2)/FS-0, 5",& !$
M     ( !-L\- &EM9S8Y-C(X,S X7S<N:G!G4$L! A0#%     @ ?(!<5-0A
M^]T$+   :2X  !$              ( !& 41 &EM9S8Y-C(X,S X7S@N:G!G
M4$L! A0#%     @ ?(!<5/O >]S#%@  W1@  !$              ( !2S$1
M &EM9S8Y-C(X,S X7SDN:G!G4$L! A0#%     @ ?(!<5,J^+!ATX00 V4Y$
M !$              ( !/4@1 '!C=G@M,C R,3$R,S$N:'1M4$L! A0#%
M  @ ?(!<5/_'8DO'%P  22(! !$              ( !X"D6 '!C=G@M,C R
M,3$R,S$N>'-D4$L! A0#%     @ ?(!<5/];9O]$$P  LQ(! !4
M     ( !UD$6 '!C=G@M,C R,3$R,S%?8V%L+GAM;%!+ 0(4 Q0    ( 'R
M7%0M;(UVW#4  #XP!  5              "  4U5%@!P8W9X+3(P,C$Q,C,Q
M7V1E9BYX;6Q02P$"% ,4    " !\@%Q4" ^W_^W+  "9/ D %0
M    @ %<BQ8 <&-V>"TR,#(Q,3(S,5]L86(N>&UL4$L! A0#%     @ ?(!<
M5-PTW>H86   B \' !4              ( !?%<7 '!C=G@M,C R,3$R,S%?
M<')E+GAM;%!+ 0(4 Q0    ( 'R 7%3;#&"\P (  $0/   /
M  "  <>O%P!P8W9X+65X,C-?,2YH=&U02P$"% ,4    " !\@%Q4,K78?D,)
M  !N;P  #P              @ &TLA< <&-V>"UE>#,Q7S$N:'1M4$L! A0#
M%     @ ?(!<5#+V,U-("0  >6\   \              ( !)+P7 '!C=G@M
M97@S,5\R+FAT;5!+ 0(4 Q0    ( 'R 7%15G/.2- 4  /@G   /
M      "  9G%%P!P8W9X+65X,S)?,2YH=&U02P$"% ,4    " !\@%Q4#CC9
M#BT%  #Y)P  #P              @ 'ZRA< <&-V>"UE>#,R7S(N:'1M4$L%
3!@     A "$ ,0@  %30%P    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
